Number None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
lymphocytes None None I-cell_type
and None None O
their None None O
sensitivity None None O
to None None O
hormone None None O
action None None O
. None None O

The None None O
study None None O
demonstrated None None O
a None None O
decreased None None O
level None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
( None None O
GR None None I-protein
) None None O
in None None O
peripheral None None I-cell_type
blood None None I-cell_type
lymphocytes None None I-cell_type
from None None O
hypercholesterolemic None None O
subjects None None O
, None None O
and None None O
an None None O
elevated None None O
level None None O
in None None O
patients None None O
with None None O
acute None None O
myocardial None None O
infarction None None O
. None None O

In None None O
the None None O
lymphocytes None None I-cell_type
with None None O
a None None O
high None None O
GR None None I-protein
number None None O
, None None O
dexamethasone None None O
inhibited None None O
[ None None O
3H None None O
] None None O
-thymidine None None O
and None None O
[ None None O
3H None None O
] None None O
-acetate None None O
incorporation None None O
into None None O
DNA None None O
and None None O
cholesterol None None O
, None None O
respectively None None O
, None None O
in None None O
the None None O
same None None O
manner None None O
as None None O
in None None O
the None None O
control None None I-cell_type
cells None None I-cell_type
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
a None None O
decreased None None O
GR None None I-protein
number None None O
resulted None None O
in None None O
a None None O
less None None O
efficient None None O
dexamethasone None None O
inhibition None None O
of None None O
the None None O
incorporation None None O
of None None O
labeled None None O
compounds None None O
. None None O

These None None O
data None None O
showed None None O
that None None O
the None None O
sensitivity None None O
of None None O
lymphocytes None None I-cell_type
to None None O
glucocorticoids None None O
changed None None O
only None None O
with None None O
a None None O
decrease None None O
of None None O
GR None None I-protein
level None None O
. None None O

[ None None O
1 None None I-protein
, None None I-protein
25-Dihydroxyvitamin None None I-protein
D3 None None I-protein
receptors None None I-protein
in None None O
lymphocytes None None I-cell_type
and None None O
T- None None I-cell_type
and None None I-cell_type
B-lymphocyte None None I-cell_type
count None None O
in None None O
patients None None O
with None None O
glomerulonephritis None None O
] None None O

Content None None O
of None None O
receptors None None O
to None None O
hormonal None None O
form None None O
of None None O
vitamin None None O
D3 None None O
, None None O
1.25 None None O
( None None O
OH None None O
) None None O
2D3 None None O
, None None O
constituted None None O
27.3 None None O
fmole/mg None None O
of None None O
protein None None O
in None None O
lymphocytes None None I-cell_type
of None None O
peripheric None None O
blood None None O
of None None O
children None None O
with None None O
glomerulonephritis None None O
. None None O

In None None O
the None None O
patients None None O
concentration None None O
of None None O
total None None O
and None None O
ionized None None O
form None None O
of None None O
Ca2+ None None O
was None None O
decreased None None O
down None None O
to None None O
2.04 None None O
mmole/L None None O
and None None O
1.09 None None O
mmole/L None None O
, None None O
respectively None None O
, None None O
while None None O
an None None O
increase None None O
in None None O
parathormone None None O
( None None O
PTH None None O
) None None O
by None None O
36 None None O
% None None O
and None None O
a None None O
distinct None None O
decrease None None O
in None None O
25 None None O
( None None O
OH None None O
) None None O
D None None O
concentration None None O
( None None O
lower None None O
than None None O
1.25 None None O
ng/ml None None O
) None None O
was None None O
found None None O
in None None O
blood None None O
; None None O
content None None O
of None None O
cAMP None None O
was None None O
also None None O
decreased None None O
in None None O
lymphocytes None None O
by None None O
33 None None O
% None None O
. None None O

At None None O
the None None O
same None None O
time None None O
, None None O
total None None O
content None None O
of None None O
T None None I-cell_type
lymphocytes None None I-cell_type
was None None O
decreased None None O
1.5-fold None None O
in None None O
peripheric None None O
blood None None O
. None None O

Treatment None None O
with None None O
I-hydroxyvitamin None None O
D3 None None O
( None None O
1-1.5 None None O
mg None None O
daily None None O
, None None O
within None None O
4 None None O
weeks None None O
) None None O
led None None O
to None None O
normalization None None O
of None None O
total None None O
and None None O
ionized None None O
form None None O
of None None O
Ca2+ None None O
and None None O
of None None O
25 None None O
( None None O
OH None None O
) None None O
D None None O
, None None O
but None None O
did None None O
not None None O
affect None None O
the None None O
PTH None None O
content None None O
in None None O
blood None None O
. None None O

Concentration None None O
of None None O
the None None O
receptors None None I-protein
to None None O
1.25 None None O
( None None O
OH None None O
) None None O
2D3 None None O
was None None O
elevated None None O
up None None O
to None None O
39.7 None None O
fmole/mg None None O
after None None O
I None None O
week None None O
of None None O
the None None O
treatment None None O
, None None O
whereas None None O
it None None O
was None None O
decreased None None O
to None None O
the None None O
initial None None O
level None None O
24.8 None None O
fmole/mg None None O
within None None O
4 None None O
weeks None None O
; None None O
simultaneous None None O
alteration None None O
in None None O
the None None O
cAMP None None O
content None None O
was None None O
observed None None O
in None None O
lymphocytes None None I-cell_type
. None None O

Treatment None None O
with None None O
1- None None O
( None None O
OH None None O
) None None O
D3 None None O
normalized None None O
also None None O
the None None O
T None None I-cell_type
lymphocytes None None I-cell_type
content None None O
in None None O
peripheric None None O
blood None None O
. None None O

The None None O
data None None O
obtained None None O
suggest None None O
that None None O
under None None O
conditions None None O
of None None O
glomerulonephritis None None O
only None None O
high None None O
content None None O
of None None O
receptors None None I-protein
to None None O
1.25 None None O
( None None O
OH None None O
) None None O
2D3 None None O
in None None O
lymphocytes None None I-cell_type
enabled None None O
to None None O
perform None None O
the None None O
cell None None O
response None None O
to None None O
the None None O
hormone None None O
effect None None O
. None None O

Tumor None None O
and None None O
serum None None O
beta-2-microglobulin None None O
expression None None O
in None None O
women None None O
with None None O
breast None None O
cancer None None O
. None None O

To None None O
investigate None None O
whether None None O
the None None O
tumor None None I-cell_type
expression None None O
of None None O
beta-2-microglobulin None None I-protein
( None None O
beta None None I-protein
2-M None None I-protein
) None None O
could None None O
serve None None O
as None None O
a None None O
marker None None O
of None None O
tumor None None O
biologic None None O
behavior None None O
, None None O
the None None O
authors None None O
studied None None O
specimens None None O
of None None O
breast None None I-cell_type
carcinomas None None I-cell_type
from None None O
60 None None O
consecutive None None O
female None None O
patients None None O
. None None O

Presence None None O
of None None O
beta None None I-protein
2-M None None I-protein
was None None O
analyzed None None O
by None None O
immunohistochemistry None None O
. None None O

No None None O
significant None None O
correlations None None O
were None None O
found None None O
between None None O
tumor None None I-protein
beta None None I-protein
2-M None None I-protein
expression None None O
and None None O
several None None O
histologic None None O
attributes None None O
such None None O
as None None O
type None None O
, None None O
histologic None None O
and None None O
nuclear None None O
grades None None O
, None None O
mitotic None None O
index None None O
, None None O
necrosis None None O
, None None O
vascular None None O
invasion None None O
, None None O
and None None O
lymphocytic None None O
infiltration None None O
. None None O

Likewise None None O
, None None O
beta None None I-protein
2-M None None I-protein
was None None O
not None None O
associated None None O
with None None O
markers None None O
of None None O
disease None None O
extension None None O
such None None O
as None None O
TNM None None O
, None None O
( None None O
UICC None None O
, None None O
classification None None O
of None None O
malignant None None I-cell_type
tumors None None I-cell_type
) None None O
staging None None O
and None None O
axillary None None O
lymph None None O
node None None O
involvement None None O
or None None O
with None None O
estrogen None None O
, None None O
progesterone None None O
, None None O
and None None O
glucocorticoid None None O
receptor None None O
levels None None O
. None None O

However None None O
, None None O
there None None O
was None None O
a None None O
significantly None None O
positive None None O
association None None O
between None None O
tumor None None I-protein
beta None None I-protein
2-M None None I-protein
expression None None O
and None None O
the None None O
degree None None O
of None None O
lymphocytic None None O
infiltration None None O
in None None O
the None None O
tumor None None O
tissue None None O
. None None O

Beta None None I-protein
2-M None None I-protein
serum None None O
levels None None O
were None None O
determined None None O
by None None O
an None None O
enzyme-linked None None O
immunosorbent None None O
assay None None O
in None None O
samples None None O
from None None O
22 None None O
of None None O
the None None O
above None None O
women None None O
. None None O

Although None None O
some None None O
of None None O
the None None O
highest None None O
values None None O
had None None O
been None None O
obtained None None O
in None None O
women None None O
with None None O
larger None None O
( None None O
T4 None None O
) None None O
primary None None O
tumors None None O
, None None O
the None None O
authors None None O
failed None None O
to None None O
detect None None O
any None None O
statistical None None O
relationship None None O
between None None O
beta None None I-protein
2-M None None I-protein
expression None None O
in None None O
the None None O
tumor None None O
with None None O
serum None None O
levels None None O
or None None O
between None None O
serum None None I-protein
beta None None I-protein
2-M None None I-protein
and None None O
the None None O
above None None O
histologic None None O
, None None O
laboratory None None O
, None None O
and None None O
clinical None None O
factors None None O
. None None O

[ None None O
Preliminary None None O
observation None None O
of None None O
level None None O
free-form None None I-protein
E None None I-protein
receptor None None I-protein
levels None None O
in None None O
serum None None O
of None None O
normal None None O
childbearing-aged None None O
and None None O
pregnant None None O
women None None O
] None None O

In None None O
137 None None O
cases None None O
of None None O
childbearing-aged None None O
and None None O
pregnant None None O
women None None O
, None None O
free None None I-protein
form None None I-protein
E None None I-protein
receptor None None I-protein
levels None None O
( None None O
sE None None I-protein
) None None O
in None None O
serum None None O
were None None O
measured None None O
by None None O
ELISA None None O
. None None O

The None None O
level None None O
of None None O
sE None None I-protein
was None None O
significantly None None O
decreased None None O
during None None O
the None None O
first None None O
trimester None None O
, None None O
slightly None None O
higher None None O
in None None O
the None None O
second None None O
trimester None None O
, None None O
and None None O
recovered None None O
to None None O
normal None None O
in None None O
the None None O
third None None O
trimester None None O
. None None O

The None None O
level None None O
remained None None O
lower None None O
in None None O
29 None None O
PIH None None O
women None None O
but None None O
appeared None None O
higher None None O
in None None O
overdue None None O
pregnancies None None O
as None None O
compared None None O
with None None O
the None None O
normal None None O
3rd None None O
trimester None None O
range None None O
. None None O

The None None O
results None None O
indicate None None O
that None None O
there None None O
is None None O
a None None O
relationship None None O
between None None O
a None None O
change None None O
in None None O
T None None I-cell_type
cell None None I-cell_type
function None None O
and None None O
pregnancy None None O
. None None O

Kappa None None I-protein
B-specific None None I-protein
DNA None None I-protein
binding None None I-protein
proteins None None I-protein
: None None O
role None None O
in None None O
the None None O
regulation None None O
of None None O
human None None I-DNA
interleukin-2 None None I-DNA
gene None None I-DNA
expression None None O
. None None O

Transcriptional None None O
activation None None O
of None None O
the None None O
human None None I-DNA
interleukin-2 None None I-DNA
( None None I-DNA
IL-2 None None I-DNA
) None None I-DNA
gene None None I-DNA
, None None O
like None None O
induction None None O
of None None O
the None None O
IL-2 None None I-DNA
receptor None None I-DNA
alpha None None I-DNA
( None None I-DNA
IL-2R None None I-DNA
alpha None None I-DNA
) None None I-DNA
gene None None I-DNA
and None None O
the None None O
type None None O
1 None None O
human None None O
immunodeficiency None None O
virus None None O
( None None O
HIV-1 None None O
) None None O
, None None O
is None None O
shown None None O
to None None O
be None None O
modulated None None O
by None None O
a None None O
kappa None None I-protein
B-like None None I-protein
enhancer None None I-protein
element None None I-protein
. None None O

Mutation None None O
of None None O
a None None O
kappa None None I-DNA
B None None I-DNA
core None None I-DNA
sequence None None I-DNA
identified None None O
in None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
( None None O
-206 None None O
to None None O
-195 None None O
) None None O
partially None None O
inhibits None None O
both None None O
mitogen- None None O
and None None O
HTLV-I None None O
Tax-mediated None None O
activation None None O
of None None O
this None None O
transcription None None I-protein
unit None None I-protein
and None None O
blocks None None O
the None None O
specific None None O
binding None None O
of None None O
two None None O
inducible None None I-protein
cellular None None I-protein
factors None None I-protein
. None None O

These None None O
kappa None None I-protein
B-specific None None I-protein
proteins None None I-protein
( None None O
80 None None O
to None None O
90 None None O
and None None O
50 None None O
to None None O
55 None None O
kilodaltons None None O
) None None O
similarly None None O
interact None None O
with None None O
the None None O
functional None None O
kappa None None I-protein
B None None I-protein
enhancer None None I-protein
present None None O
in None None O
the None None O
IL-2R None None I-DNA
alpha None None I-DNA
promoter None None I-DNA
. None None O

These None None O
data None None O
suggest None None O
that None None O
these None None O
kappa None None I-protein
B-specific None None I-protein
proteins None None I-protein
have None None O
a None None O
role None None O
in None None O
the None None O
coordinate None None O
regulation None None O
of None None O
this None None O
growth None None O
factor-growth None None O
factor None None O
receptor None None O
gene None None O
system None None O
that None None O
controls None None O
T None None I-cell_type
cell None None I-cell_type
proliferation None None O
. None None O

Novel None None O
region None None O
within None None O
the None None O
V None None I-DNA
kappa None None I-DNA
gene None None I-DNA
promoter None None I-DNA
is None None O
responsible None None O
for None None O
tissue None None O
and None None O
stage-specific None None O
expression None None O
of None None O
immunoglobulin None None I-DNA
genes None None I-DNA
in None None O
human None None I-cell_type
lymphoid None None I-cell_type
neoplasms None None I-cell_type
. None None O

Immunoglobulin None None I-protein
gene-specific None None I-protein
transacting None None I-protein
factors None None I-protein
have None None O
been None None O
shown None None O
to None None O
play None None O
a None None O
role None None O
in None None O
lymphoid None None O
tissue-specific None None O
expression None None O
of None None O
immunoglobulin None None I-DNA
genes None None I-DNA
. None None O

The None None O
role None None O
of None None O
these None None O
factors None None O
in None None O
B-cell None None I-cell_type
differentiation None None O
and None None O
stage-specific None None O
expression None None O
of None None O
these None None O
genes None None O
is None None O
, None None O
however None None O
, None None O
not None None O
fully None None O
understood None None O
. None None O

We None None O
have None None O
used None None O
a None None O
model None None O
of None None O
human None None O
lymphoid None None O
neoplasia None None O
to None None O
address None None O
this None None O
question None None O
. None None O

Different None None O
fragments None None O
of None None O
unrearranged None None I-DNA
human None None I-DNA
variable None None I-DNA
region None None I-DNA
of None None O
immunoglobulin None None I-DNA
kappa None None I-DNA
gene None None I-DNA
( None None O
V None None I-DNA
kappa None None I-DNA
) None None O
were None None O
used None None O
for None None O
cell-free None None O
in None None O
vitro None None O
transcription None None O
and None None O
DNA None None O
mobility None None O
shift None None O
assays None None O
. None None O

Previously None None O
described None None O
enhancement None None O
of None None O
in None None O
vitro None None O
transcription None None O
that None None O
was None None O
only None None O
seen None None O
with None None O
nuclear None None O
extracts None None O
derived None None O
from None None O
B-cell None None I-cell_type
neoplasms None None I-cell_type
corresponding None None O
to None None O
the None None O
late None None O
stages None None O
of None None O
B-cell None None I-cell_type
differentiation None None O
was None None O
shown None None O
to None None O
be None None O
dependent None None O
on None None O
the None None O
actions None None O
of None None O
these None None O
factor None None O
( None None O
s None None O
) None None O
on None None O
the None None O
DNA None None O
region None None O
within None None O
the None None O
V None None I-DNA
kappa None None I-DNA
gene None None I-DNA
promoter None None I-DNA
. None None O

This None None O
region None None O
is None None O
located None None O
within None None O
the None None O
920 None None O
bp None None O
fragment None None O
located None None O
210 None None O
bp None None O
upstream None None O
from None None O
the None None O
coding None None O
region None None O
and None None O
this None None O
fragment None None O
represents None None O
a None None O
possible None None O
novel None None O
DNA None None O
region None None O
, None None O
which None None O
plays None None O
a None None O
role None None O
in None None O
the None None O
stage- None None O
and None None O
tissue-specific None None O
expression None None O
of None None O
immunoglobulin None None I-DNA
genes None None I-DNA
. None None O

[ None None O
Determination None None O
of None None O
the None None O
sensitivity None None O
to None None O
glucocorticoids None None I-protein
in None None O
vitro None None O
] None None O

A None None O
modified None None O
method None None O
for None None O
the None None O
determination None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
human None None I-cell_type
lymphocytes None None I-cell_type
is None None O
suggested None None O
. None None O

The None None O
principal None None O
distinction None None O
of None None O
the None None O
method None None O
is None None O
standardization None None O
by None None O
the None None O
lymphocyte None None I-cell_type
count None None O
in None None O
a None None O
sample None None O
( None None O
1 None None O
mln None None O
) None None O
and None None O
the None None O
labeled None None O
hormone None None I-protein
concentration None None O
. None None O

The None None O
modification None None O
saves None None O
time None None O
and None None O
money None None O
, None None O
limits None None O
the None None O
range None None O
of None None O
the None None O
data None None O
variations None None O
, None None O
and None None O
makes None None O
use None None O
of None None O
a None None O
lesser None None O
volume None None O
of None None O
blood None None O
. None None O

Examinations None None O
of None None O
70 None None O
children None None O
aged None None O
4 None None O
to None None O
15 None None O
suffering None None O
from None None O
the None None O
nephrotic None None O
form None None O
of None None O
glomerulonephritis None None O
have None None O
made None None O
it None None O
possible None None O
to None None O
distinguish None None O
two None None O
groups None None O
of None None O
patients None None O
: None None O
with None None O
relatively None None O
high None None O
values None None O
of None None O
specific None None O
binding None None O
X None None O
= None None O
6820.1 None None O
+/- None None O
530.0 None None O
( None None O
n None None O
= None None O
30 None None O
, None None O
p None None O
= None None O
0.95 None None O
, None None O
t None None O
= None None O
2.04 None None O
) None None O
, None None O
this None None O
corresponding None None O
to None None O
a None None O
clinical None None O
form None None O
of None None O
hormone None None I-protein
-sensitive None None O
glomerulonephritis None None O
, None None O
and None None O
with None None O
relatively None None O
low None None O
values None None O
of None None O
specific None None O
binding None None O
X None None O
= None None O
1815.2 None None O
+/- None None O
302.8 None None O
( None None O
n None None O
= None None O
40 None None O
, None None O
p None None O
= None None O
0.95 None None O
, None None O
t None None O
= None None O
1.96 None None O
) None None O
, None None O
that None None O
corresponds None None O
to None None O
hormone None None I-protein
-resistant None None O
glomerulonephritis None None O
. None None O

Dynamic None None O
studies None None O
have None None O
not None None O
shown None None O
any None None O
statistically None None O
significant None None O
changes None None O
in None None O
the None None O
specific None None O
binding None None O
values None None O
. None None O

These None None O
results None None O
permit None None O
regarding None None O
the None None O
specific None None O
binding None None O
value None None O
as None None O
a None None O
prognostic None None O
criterion None None O
in None None O
the None None O
assessment None None O
of None None O
corticosteroid None None I-protein
therapy None None O
; None None O
this None None O
allows None None O
a None None O
wide None None O
employment None None O
of None None O
the None None O
described None None O
method None None O
in None None O
practical None None O
nephrology None None O
. None None O

Octamer-binding None None I-protein
proteins None None I-protein
from None None O
B None None I-cell_line
or None None I-cell_line
HeLa None None I-cell_line
cells None None I-cell_line
stimulate None None O
transcription None None O
of None None O
the None None O
immunoglobulin None None I-DNA
heavy-chain None None I-DNA
promoter None None I-DNA
in None None O
vitro None None O
. None None O

The None None O
B-cell None None I-cell_type
-type None None O
specificity None None O
of None None O
the None None O
immunoglobulin None None I-protein
( None None O
Ig None None I-protein
) None None O
heavy-chain None None O
and None None O
light-chain None None O
promoters None None O
is None None O
mediated None None O
by None None O
an None None O
octanucleotide None None I-DNA
( None None I-DNA
OCTA None None I-DNA
) None None I-DNA
element None None I-DNA
, None None O
ATGCAAAT None None O
, None None O
that None None O
is None None O
also None None O
a None None O
functional None None O
component None None O
of None None O
other None None O
RNA None None I-DNA
polymerase None None I-DNA
II None None I-DNA
promoters None None I-DNA
, None None O
such None None O
as None None O
snRNA None None O
and None None O
histone None None O
H2B None None O
promoters None None O
. None None O

Two None None O
nuclear None None I-protein
proteins None None I-protein
that None None O
bind None None O
specifically None None O
and None None O
with None None O
high None None O
affinity None None O
to None None O
the None None O
OCTA None None I-DNA
element None None I-DNA
have None None O
been None None O
identified None None O
. None None O

NF-A1 None None I-protein
is None None O
present None None O
in None None O
a None None O
variety None None O
of None None O
cell None None O
types None None O
, None None O
whereas None None O
the None None O
presence None None O
of None None O
NF-A2 None None I-protein
is None None O
essentially None None O
confined None None O
to None None O
B None None I-cell_type
cells None None I-cell_type
, None None O
leading None None O
to None None O
the None None O
hypothesis None None O
that None None O
NF-A2 None None I-protein
activates None None O
cell-type-specific None None O
transcription None None O
of None None O
the None None O
Ig None None I-DNA
promoter None None I-DNA
and None None O
NF-A1 None None I-protein
mediates None None O
the None None O
other None None O
responses None None O
of None None O
the None None O
OCTA None None I-DNA
element None None I-DNA
. None None O

Extracts None None O
of None None O
the None None O
B-cell None None I-cell_line
line None None I-cell_line
, None None O
BJA-B None None I-cell_line
, None None O
contain None None O
high None None O
levels None None O
of None None O
NF-A2 None None I-protein
and None None O
specifically None None O
transcribe None None O
Ig None None I-DNA
promoters None None I-DNA
. None None O

In None None O
contrast None None O
, None None O
extracts None None O
from None None O
HeLa None None I-cell_line
cells None None I-cell_line
transcribed None None O
the None None O
Ig None None I-DNA
promoter None None I-DNA
poorly None None O
. None None O

Surprisingly None None O
, None None O
addition None None O
of None None O
either None None O
affinity-enriched None None O
NF-A2 None None O
or None None O
NF-A1 None None O
to None None O
either None None O
a None None O
HeLa None None O
extract None None O
or None None O
a None None O
partially None None O
purified None None O
reaction None None O
system None None O
specifically None None O
stimulates None None O
the None None O
Ig None None I-DNA
promoter None None I-DNA
. None None O

This None None O
suggests None None O
that None None O
the None None O
constitutive None None O
OCTA-binding None None I-protein
factor None None I-protein
NF-A1 None None I-protein
can None None O
activate None None O
transcription None None O
of None None O
the None None O
Ig None None I-DNA
promoter None None I-DNA
and None None O
that None None O
B-cell None None I-cell_type
-specific None None O
transcription None None O
of None None O
this None None O
promoter None None O
, None None O
at None None O
least None None O
in None None O
vitro None None O
, None None O
is None None O
partially None None O
due None None O
to None None O
a None None O
quantitative None None O
difference None None O
in None None O
the None None O
amount None None O
of None None O
OCTA-binding None None I-protein
protein None None I-protein
. None None O

Because None None O
NF-A1 None None I-protein
can None None O
stimulate None None O
Ig None None I-protein
transcription None None O
, None None O
the None None O
inability None None O
of None None O
this None None O
factor None None O
to None None O
activate None None O
in None None O
vivo None None O
the None None O
Ig None None I-DNA
promoter None None I-DNA
to None None O
the None None O
same None None O
degree None None O
as None None O
the None None O
snRNA None None I-DNA
promoters None None I-DNA
probably None None O
reflects None None O
a None None O
difference None None O
in None None O
the None None O
context None None O
of None None O
the None None O
OCTA None None I-DNA
element None None I-DNA
in None None O
these None None O
two None None O
types None None O
of None None O
promoters None None I-DNA
. None None O

Identification None None O
of None None O
a None None O
putative None None O
regulator None None O
of None None O
early None None I-DNA
T None None I-DNA
cell None None I-DNA
activation None None I-DNA
genes None None I-DNA
. None None O

Molecules None None O
involved None None O
in None None O
the None None O
antigen None None O
receptor-dependent None None O
regulation None None O
of None None O
early None None I-DNA
T None None I-DNA
cell None None I-DNA
activation None None I-DNA
genes None None I-DNA
were None None O
investigated None None O
with None None O
the None None O
use None None O
of None None O
functional None None O
sequences None None O
of None None O
the None None O
T None None I-protein
cell None None I-protein
activation-specific None None I-protein
enhancer None None I-protein
of None None O
interleukin-2 None None I-protein
( None None O
IL-2 None None I-protein
) None None O
. None None O

One None None O
of None None O
these None None O
sequences None None O
forms None None O
a None None O
protein None None O
complex None None O
, None None O
NFAT-1 None None I-protein
, None None O
specifically None None O
with None None O
nuclear None None O
extracts None None O
of None None O
activated None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

This None None O
complex None None O
appeared None None O
10 None None O
to None None O
25 None None O
minutes None None O
before None None O
the None None O
activation None None O
of None None O
the None None O
IL-2 None None I-DNA
gene None None I-DNA
. None None O

Studies None None O
with None None O
inhibitors None None O
of None None O
protein None None O
synthesis None None O
indicated None None O
that None None O
the None None O
time None None O
of None None O
synthesis None None O
of None None O
the None None O
activator None None O
of None None O
the None None O
IL-2 None None I-DNA
gene None None I-DNA
in None None O
Jurkat None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
corresponds None None O
to None None O
the None None O
time None None O
of None None O
appearance None None O
of None None O
NFAT-1 None None I-protein
. None None O

NFAT-1 None None I-protein
, None None O
or None None O
a None None O
very None None O
similar None None O
protein None None O
, None None O
bound None None O
functional None None O
sequences None None O
of None None O
the None None O
long None None I-DNA
terminal None None I-DNA
repeat None None I-DNA
( None None O
LTR None None I-DNA
) None None O
of None None O
the None None O
human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
; None None O
the None None O
LTR None None I-DNA
of None None O
this None None O
virus None None O
is None None O
known None None O
to None None O
be None None O
stimulated None None O
during None None O
early None None O
T None None I-cell_type
cell None None I-cell_type
activation None None O
. None None O

The None None O
binding None None I-DNA
site None None I-DNA
for None None O
this None None O
complex None None O
activated None None O
a None None O
linked None None O
promoter None None O
after None None O
transfection None None O
into None None O
antigen None None I-cell_type
receptor-activated None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
but None None O
not None None O
other None None O
cell None None O
types None None O
. None None O

These None None O
characteristics None None O
suggest None None O
that None None O
NFAT-1 None None I-protein
transmits None None O
signals None None O
initiated None None O
at None None O
the None None O
T None None I-protein
cell None None I-protein
antigen None None I-protein
receptor None None I-protein
. None None O

Characterization None None O
of None None O
thyroid None None I-protein
hormone None None I-protein
receptors None None I-protein
in None None O
human None None I-cell_line
IM-9 None None I-cell_line
lymphocytes None None I-cell_line
. None None O

Although None None O
putatively None None O
identified None None O
more None None O
than None None O
10 None None O
years None None O
ago None None O
, None None O
thyroid None None I-protein
hormone None None I-protein
receptors None None I-protein
in None None O
human None None O
tissues None None O
remain None None O
poorly None None O
characterized None None O
. None None O

As None None O
a None None O
first None None O
step None None O
towards None None O
understanding None None O
the None None O
mechanism None None O
of None None O
thyroid None None O
hormone None None O
action None None O
in None None O
man None None O
we None None O
have None None O
characterized None None O
T3 None None I-protein
binding None None I-protein
sites None None I-protein
in None None O
nuclei None None O
of None None O
the None None O
human None None I-cell_line
lymphoblastoid None None I-cell_line
line None None I-cell_line
, None None O
IM-9 None None I-cell_line
cells None None I-cell_line
. None None O

In None None O
whole None None O
cell None None O
experiments None None O
at None None O
37 None None O
degrees None None O
C None None O
, None None O
nuclear None None O
binding None None O
of None None O
[ None None I-protein
125I None None I-protein
] None None I-protein
T3 None None I-protein
was None None O
saturable None None O
( None None O
Kd None None O
34 None None O
+/- None None O
6 None None O
pmol/l None None O
) None None O
and None None O
of None None O
finite None None O
capacity None None O
( None None O
approximately None None O
equal None None O
to None None O
350 None None O
sites/cell None None O
) None None O
. None None O

The None None O
binding None None I-protein
sites None None I-protein
were None None O
extracted None None O
from None None O
a None None O
nuclear None None O
pellet None None O
by None None O
treatment None None O
with None None O
0.4 None None O
mol/l None None O
KCl None None O
and None None O
sonication None None O
. None None O

Separation None None O
of None None O
bound None None O
from None None O
free None None O
[ None None I-protein
125I None None I-protein
] None None I-protein
T3 None None I-protein
in None None O
the None None O
extracts None None O
was None None O
achieved None None O
using None None O
the None None O
calcium None None O
phosphate None None O
matrix None None O
, None None O
hydroxyapatite None None O
at None None O
a None None O
concentration None None O
of None None O
0.3 None None O
ml None None O
of None None O
a None None O
150 None None O
g/l None None O
slurry None None O
. None None O

Rectilinear None None O
Scatchard None None O
plots None None O
were None None O
obtained None None O
only None None O
when None None O
the None None O
hydroxyapatite None None O
was None None O
washed None None O
with None None O
a None None O
buffer None None O
containing None None O
0.5 None None O
% None None O
Triton None None O
X-100 None None O
. None None O

Under None None O
these None None O
conditions None None O
T3 None None I-protein
binding None None I-protein
sites None None I-protein
in None None O
the None None O
nuclear None None O
extracts None None O
were None None O
present None None O
at None None O
a None None O
concentration None None O
of None None O
22.4 None None O
+/- None None O
8.6 None None O
fmol/mg None None O
protein None None O
and None None O
showed None None O
an None None O
affinity None None O
of None None O
( None None O
Kd None None O
, None None O
room None None O
temperature None None O
) None None O
140 None None O
+/- None None O
10 None None O
pmol/l None None O
. None None O

The None None O
same None None O
assay None None O
system None None O
was None None O
used None None O
to None None O
determine None None O
the None None O
hierarchy None None O
of None None O
affinities None None O
for None None O
a None None O
range None None O
of None None O
natural None None O
and None None O
synthetic None None O
analogues None None O
. None None O

Calling None None O
T3 None None O
100 None None O
, None None O
the None None O
order None None O
of None None O
potencies None None O
observed None None O
was None None O
: None None O
Triac None None O
, None None O
500 None None O
; None None O
3 None None O
, None None O
5-diiodo-3'-isopropylthyronine None None O
, None None O
89 None None O
; None None O
T4 None None O
, None None O
32 None None O
; None None O
3 None None O
, None None O
5-dimethyl-3'isopropylthyronine None None O
2 None None O
; None None O
3 None None O
, None None O
5-T2 None None O
, None None O
0.7 None None O
, None None O
rT3 None None O
, None None O
0.4 None None O
; None None O
3'5'-T2 None None O
, None None O
less None None O
than None None O
0.01 None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
T3 None None I-protein
binding None None I-protein
sites None None I-protein
present None None O
in None None O
human None None I-cell_line
IM-9 None None I-cell_line
lymphocyte None None I-cell_line
nuclei None None O
and None None O
extracts None None O
thereof None None O
are None None O
thyroid None None I-protein
hormone None None I-protein
receptors None None I-protein
. None None O

These None None O
cells None None O
may None None O
be None None O
a None None O
useful None None O
tool None None O
to None None O
increase None None O
our None None O
understanding None None O
of None None O
human None None I-protein
T3 None None I-protein
receptors None None I-protein

Definition None None O
of None None O
T-cell None None I-protein
specific None None I-protein
DNA-binding None None I-protein
factors None None I-protein
that None None O
interact None None O
with None None O
a None None O
3'-silencer None None I-DNA
in None None O
the None None O
CD4+ None None I-DNA
T-cell None None I-DNA
gene None None I-DNA
Rpt-1 None None I-DNA
. None None O

Analysis None None O
of None None O
the None None O
region None None O
3 None None O
' None None O
to None None O
the None None O
CD4+ None None I-DNA
T-cell None None I-DNA
gene None None I-DNA
Rpt-1 None None I-DNA
( None None O
encoding None None O
regulatory None None O
protein None None O
T-lymphocyte None None I-protein
1 None None I-protein
) None None O
led None None O
to None None O
the None None O
definition None None O
of None None O
a None None O
silencer None None I-DNA
element None None I-DNA
that None None O
inhibits None None O
heterologous None None I-DNA
gene None None I-DNA
expression None None O
in None None O
certain None None O
CD4+ None None I-cell_type
T-cell None None I-cell_type
lines None None I-cell_type
but None None O
not None None O
in None None O
B-cell None None I-cell_type
or None None O
non-lymphoid None None I-cell_type
cell None None I-cell_type
lines None None I-cell_type
. None None O

Functional None None O
silencer None None I-DNA
activity None None O
in None None O
vivo None None O
was None None O
associated None None O
with None None O
the None None O
presence None None O
of None None O
a None None O
specific None None O
silencer-DNA-protein None None I-protein
complex None None I-protein
in None None O
electrophoretic None None O
mobility None None O
shift None None O
assays None None O
with None None O
T-cell None None I-cell_type
extracts None None O
. None None O

Formation None None O
of None None O
this None None O
complex None None O
was None None O
selectively None None O
inhibited None None O
by None None O
the None None O
region None None O
in None None O
HIV-1 None None I-DNA
containing None None O
a None None O
silencer None None I-DNA
element None None I-DNA
. None None O

We None None O
discuss None None O
the None None O
possibility None None O
that None None O
DNA-binding None None I-protein
factors None None I-protein
may None None O
coregulate None None O
HIV-1 None None O
and None None O
Rpt-1 None None O
gene None None O
expression None None O
through None None O
a None None O
common None None O
transcriptional None None I-DNA
silencer None None I-DNA
element None None I-DNA
. None None O

Congenital None None O
immunodeficiencies None None O
associated None None O
with None None O
absence None None O
of None None O
HLA None None I-protein
class None None I-protein
II None None I-protein
antigens None None I-protein
on None None O
lymphocytes None None I-cell_type
result None None O
from None None O
distinct None None O
mutations None None O
in None None O
trans-acting None None I-protein
factors None None I-protein
. None None O

Coordinate None None O
regulation None None O
of None None O
HLA None None I-DNA
class None None I-DNA
II None None I-DNA
gene None None I-DNA
expression None None O
during None None O
development None None O
and None None O
coinduction None None O
of None None O
class None None I-DNA
II None None I-DNA
genes None None I-DNA
by None None O
soluble None None I-protein
factors None None I-protein
suggests None None O
that None None O
common None None O
trans-acting None None I-protein
factor None None I-protein
( None None O
s None None O
) None None O
control None None O
expression None None O
of None None O
these None None O
genes None None O
. None None O

In None None O
B-lymphoblastoid None None I-cell_type
cell None None I-cell_type
lines None None I-cell_type
derived None None O
from None None O
two None None O
independent None None O
class None None O
II-deficient None None O
bare None None O
lymphocyte None None O
syndrome None None O
patients None None O
, None None O
we None None O
observed None None O
a None None O
drastic None None O
decrease None None O
in None None O
transcription None None O
rates None None O
of None None O
the None None O
class None None I-DNA
II None None I-DNA
genes None None I-DNA
. None None O

When None None O
these None None O
cell None None O
lines None None O
are None None O
fused None None O
, None None O
class None None I-DNA
II None None I-DNA
genes None None I-DNA
are None None O
reexpressed None None O
, None None O
indicating None None O
that None None O
immunodeficiencies None None O
in None None O
bare None None O
lymphocyte None None O
syndrome None None O
patients None None O
are None None O
the None None O
result None None O
of None None O
two None None O
distinct None None O
mutations None None O
. None None O

Further None None O
studies None None O
show None None O
that None None O
genes None None O
governing None None O
the None None O
expression None None O
of None None O
class None None I-protein
II None None I-protein
antigens None None I-protein
fall None None O
into None None O
at None None O
least None None O
three None None O
complementation None None O
groups None None O
; None None O
two None None O
of None None O
these None None O
were None None O
previously None None O
unidentified None None O
in None None O
mutant None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
generated None None O
in None None O
vitro None None O
. None None O

In None None O
addition None None O
, None None O
we None None O
report None None O
the None None O
identification None None O
of None None O
two None None O
discrete None None O
complexes None None O
, None None O
NFX1.1 None None I-protein
and None None O
NFX1.2 None None I-protein
, None None O
that None None O
bind None None O
to None None O
the None None O
DRA None None I-DNA
X None None I-DNA
consensus None None I-DNA
element None None I-DNA
. None None O

Though None None O
the None None O
mutation None None O
in None None O
at None None O
least None None O
one None None O
mutant None None I-cell_line
line None None I-cell_line
generated None None O
in None None O
vitro None None O
( None None O
RJ2.2.5 None None I-cell_line
) None None O
affects None None O
products None None O
functioning None None O
via None None O
interaction None None O
with None None O
the None None O
X None None I-DNA
box None None I-DNA
, None None O
clear None None O
alterations None None O
in None None O
either None None O
NFX1.1 None None I-protein
or None None O
NFX1.2 None None I-protein
are None None O
not None None O
found None None O
in None None O
any None None O
of None None O
the None None O
mutant None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
. None None O

In None None O
vivo None None O
responsiveness None None O
to None None O
glucocorticoid None None O
correlated None None O
with None None O
glucocorticoid None None I-protein
receptor None None I-protein
content None None O
in None None O
peripheral None None I-cell_type
blood None None I-cell_type
leukocytes None None I-cell_type
in None None O
normal None None O
humans None None O
. None None O

Dexamethasone None None O
loading None None O
tests None None O
( None None O
0.1 None None O
mg None None O
dexamethasone/kg None None O
, None None O
iv None None O
) None None O
were None None O
performed None None O
in None None O
18 None None O
normal None None O
males None None O
to None None O
evaluate None None O
the None None O
individual None None O
responsiveness None None O
to None None O
glucocorticoid None None O
. None None O

There None None O
were None None O
inter-individual None None O
differences None None O
in None None O
increase None None O
in None None O
peripheral None None I-cell_type
blood None None I-cell_type
polymorphonuclear None None I-cell_type
leukocyte None None I-cell_type
count None None O
, None None O
decrease None None O
in None None O
peripheral None None I-cell_type
blood None None I-cell_type
lymphocyte None None I-cell_type
count None None O
, None None O
and None None O
increase None None O
in None None O
plasma None None O
free None None O
fatty None None O
acids None None O
levels None None O
after None None O
dexamethasone None None O
injection None None O
. None None O

In None None O
addition None None O
, None None O
there None None O
was None None O
a None None O
significant None None O
correlation None None O
between None None O
the None None O
maximum None None O
increase None None O
in None None O
polymorphonuclear None None I-cell_type
leukocytes None None I-cell_type
and None None O
the None None O
maximum None None O
decrease None None O
in None None O
lymphocytes None None I-cell_type
( None None O
r None None O
= None None O
0.7514 None None O
, None None O
p None None O
less None None O
than None None O
0.0003 None None O
) None None O
. None None O

Simultaneous None None O
measurements None None O
of None None O
glucocorticoid None None I-protein
receptor None None I-protein
content None None O
by None None O
whole-cell None None O
assay None None O
revealed None None O
that None None O
glucocorticoid None None I-protein
receptor None None I-protein
content None None O
in None None O
polymorphonuclear None None I-cell_type
leukocytes None None I-cell_type
linearly None None O
correlated None None O
with None None O
that None None O
in None None O
the None None O
corresponding None None O
lymphocytes None None I-cell_type
( None None O
r None None O
= None None O
0.9482 None None O
, None None O
p None None O
less None None O
than None None O
0.0001 None None O
) None None O
. None None O

There None None O
were None None O
also None None O
significant None None O
correlations None None O
between None None O
the None None O
maximum None None O
increase None None O
in None None O
polymorphonuclear None None I-cell_type
leukocytes None None I-cell_type
and None None O
glucocorticoid None None I-protein
receptor None None I-protein
content None None O
in None None O
polymorphonuclear None None I-cell_type
leukocytes None None I-cell_type
( None None O
r None None O
= None None O
0.7239 None None O
, None None O
p None None O
less None None O
than None None O
0.0007 None None O
) None None O
, None None O
and None None O
between None None O
the None None O
maximum None None O
decrease None None O
in None None O
lymphocytes None None I-cell_type
and None None O
glucocorticoid None None I-protein
receptor None None I-protein
content None None O
in None None O
lymphocytes None None I-cell_type
( None None O
r None None O
= None None O
0.7703 None None O
, None None O
p None None O
less None None O
than None None O
0.0002 None None O
) None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
individual None None O
differences None None O
are None None O
preserved None None O
both None None O
in None None O
glucocorticoid None None O
responsiveness None None O
and None None O
in None None O
glucocorticoid None None I-protein
receptor None None I-protein
content None None O
in None None O
peripheral None None I-cell_type
blood None None I-cell_type
leukocytes None None I-cell_type
in None None O
normal None None O
humans None None O
. None None O

Estradiol None None O
receptors None None O
in None None O
the None None O
cytosol None None O
of None None O
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
in None None O
hepatitis None None O
B None None O
virus None None O
carriers None None O
treated None None O
with None None O
interferon-alpha None None I-protein
. None None O

Estradiol None None I-protein
receptors None None I-protein
in None None O
the None None O
cytosol None None O
of None None O
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
and None None O
the None None O
effects None None O
of None None O
interferon-alpha None None I-protein
( None None O
IFN-alpha None None I-protein
) None None O
on None None O
estradiol None None I-protein
receptors None None I-protein
were None None O
studied None None O
in None None O
asymptomatic None None O
hepatitis None None O
B None None O
virus None None O
( None None O
HBV None None O
) None None O
carriers None None O
, None None O
patients None None O
with None None O
chronic None None O
hepatitis None None O
B None None O
and None None O
normal None None O
controls None None O
. None None O

The None None O
level None None O
of None None O
estradiol None None I-protein
receptors None None I-protein
in None None O
the None None O
cytosol None None O
of None None O
mononuclear None None I-cell_type
cells None None I-cell_type
was None None O
significantly None None O
lower None None O
in None None O
asymptomatic None None O
HBV None None O
carriers None None O
and None None O
patients None None O
with None None O
chronic None None O
hepatitis None None O
B None None O
, None None O
compared None None O
to None None O
normal None None O
controls None None O
. None None O

This None None O
low None None O
level None None O
of None None O
cytosol None None O
estradiol None None I-protein
receptors None None I-protein
in None None O
patients None None O
with None None O
chronic None None O
hepatitis None None O
B None None O
was None None O
increased None None O
by None None O
the None None O
administration None None O
of None None O
IFN-alpha None None I-protein
. None None O

In None None O
addition None None O
, None None O
when None None O
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
from None None O
patients None None O
with None None O
chronic None None O
hepatitis None None O
B None None O
were None None O
incubated None None O
with None None O
IFN-alpha None None I-protein
in None None O
vitro None None O
, None None O
the None None O
level None None O
of None None O
cytosol None None O
estradiol None None I-protein
receptors None None I-protein
also None None O
increased None None O
by None None O
increasing None None O
the None None O
concentration None None O
of None None O
IFN-alpha None None I-protein
. None None O

We None None O
previously None None O
reported None None O
that None None O
the None None O
response None None O
of None None O
mononuclear None None I-cell_type
cells None None I-cell_type
to None None O
estrogen None None O
is None None O
impaired None None O
in None None O
HBV None None O
carriers None None O
, None None O
and None None O
our None None O
present None None O
results None None O
suggested None None O
that None None O
this None None O
may None None O
be None None O
due None None O
to None None O
the None None O
low None None O
level None None O
of None None O
estradiol None None I-protein
receptors None None I-protein
in None None O
the None None O
cytosol None None O
of None None O
mononuclear None None I-cell_type
cells None None I-cell_type
. None None O

Association None None O
of None None O
increased None None O
lytic None None O
effector None None O
cell None None O
function None None O
with None None O
high None None O
estrogen None None I-protein
receptor None None I-protein
levels None None O
in None None O
tumor-bearing None None O
patients None None O
with None None O
breast None None O
cancer None None O
. None None O

Tumor-bearing None None O
patients None None O
with None None O
breast None None O
cancer None None O
were None None O
assayed None None O
for None None O
their None None O
natural None None I-cell_type
killer None None I-cell_type
( None None I-cell_type
NK None None I-cell_type
) None None I-cell_type
cell None None I-cell_type
activity None None O
and None None O
for None None O
the None None O
function None None O
of None None O
activated None None O
cytotoxic None None I-cell_type
T-cells None None I-cell_type
, None None O
as None None O
assessed None None O
by None None O
lectin-dependent None None O
cellular None None O
cytotoxicity None None O
( None None O
LDCC None None O
) None None O
. None None O

Tumor-bearing None None O
patients None None O
with None None O
breast None None O
cancer None None O
had None None O
a None None O
significant None None O
increase None None O
in None None O
NK None None I-cell_type
activity None None O
and None None O
in None None O
LDCC None None O
, None None O
as None None O
compared None None O
with None None O
healthy None None O
control None None O
individuals None None O
. None None O

Although None None O
the None None O
enhanced None None O
NK None None I-cell_type
cell None None I-cell_type
activity None None O
and None None O
LDCC None None O
were None None O
closely None None O
associated None None O
with None None O
high None None O
levels None None O
( None None O
greater None None O
than None None O
31 None None O
fmol/mg None None O
) None None O
of None None O
estrogen None None I-protein
receptor None None I-protein
( None None O
ER None None I-protein
) None None O
content None None O
in None None O
the None None O
primary None None O
tumor None None O
, None None O
no None None O
other None None O
clinical None None O
or None None O
histologic None None O
correlation None None O
between None None O
the None None O
increase None None O
in None None O
either None None O
parameter None None O
of None None O
cytotoxic None None I-cell_type
effector None None I-cell_type
cell None None I-cell_type
function None None O
could None None O
be None None O
found None None O
. None None O

Thus None None O
, None None O
ER None None I-protein
levels None None O
greater None None O
than None None O
31 None None O
fmol/mg None None O
might None None O
be None None O
associated None None O
with None None O
increased None None O
cytotoxic None None I-cell_type
effector None None I-cell_type
cell None None I-cell_type
function None None O
in None None O
tumor-bearing None None O
patients None None O
with None None O
breast None None O
cancer None None O
. None None O

Properties None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
Epstein-Barr None None I-cell_line
virus-transformed None None I-cell_line
lymphocytes None None I-cell_line
from None None O
patients None None O
with None None O
familial None None O
cortisol None None O
resistance None None O
. None None O

In None None O
a None None O
previous None None O
report None None O
of None None O
two None None O
patients None None O
with None None O
familial None None O
glucocorticoid None None O
resistance None None O
due None None O
to None None O
reduced None None O
numbers None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
( None None O
GR None None I-protein
) None None O
, None None O
we None None O
have None None O
shown None None O
decreased None None O
numbers None None O
of None None O
GR None None I-protein
in None None O
peripheral None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
and None None O
cultured None None I-cell_line
fibroblasts None None I-cell_line
but None None O
normal None None O
affinity None None O
of None None O
GR None None I-protein
in None None O
both None None O
patients None None O
. None None O

In None None O
this None None O
study None None O
, None None O
peripheral None None I-cell_type
lymphocytes None None I-cell_type
from None None O
these None None O
patients None None O
, None None O
one None None O
patient None None O
's None None O
son None None O
and None None O
daughter None None O
, None None O
and None None O
normal None None O
subjects None None O
were None None O
transformed None None O
with None None O
Epstein-Barr None None O
virus None None O
. None None O

Reduced None None O
numbers None None O
and None None O
normal None None O
affinity None None O
of None None O
GR None None I-protein
were None None O
found None None O
in None None O
the None None O
Epstein-Barr None None I-cell_line
virus-transformed None None I-cell_line
lymphocytes None None I-cell_line
from None None O
both None None O
patients None None O
while None None O
the None None O
son None None O
and None None O
daughter None None O
had None None O
normal None None O
numbers None None O
and None None O
affinity None None O
of None None O
GR None None I-protein
. None None O

The None None O
thermal None None O
stability None None O
of None None O
GR None None I-protein
and None None O
thermal None None O
activation None None O
of None None O
cytosolic None None I-protein
receptors None None I-protein
in None None O
both None None O
patients None None O
were None None O
found None None O
to None None O
be None None O
normal None None O
. None None O

Although None None O
the None None O
percentages None None O
of None None O
nuclear None None O
bound None None O
GR None None I-protein
were None None O
similar None None O
in None None O
both None None O
patients None None O
and None None O
normal None None O
controls None None O
, None None O
the None None O
absolute None None O
amounts None None O
of None None O
nuclear None None O
bound None None O
GR None None I-protein
of None None O
the None None O
patients None None O
were None None O
about None None O
one-half None None O
that None None O
of None None O
normal None None O
controls None None O
. None None O

These None None O
abnormal None None O
properties None None O
of None None O
GR None None I-protein
( None None O
reduced None None O
numbers None None O
of None None O
GR None None I-protein
) None None O
were None None O
preserved None None O
in None None O
the None None O
transformed None None I-cell_line
cells None None I-cell_line
from None None O
the None None O
patients None None O
. None None O

Octamer None None O
transcription None None O
factors None None O
1 None None O
and None None O
2 None None O
each None None O
bind None None O
to None None O
two None None O
different None None O
functional None None I-DNA
elements None None I-DNA
in None None O
the None None O
immunoglobulin None None I-DNA
heavy-chain None None I-DNA
promoter None None I-DNA
. None None O

Immunoglobulin None None I-DNA
heavy-chain None None I-DNA
genes None None I-DNA
contain None None O
two None None O
conserved None None I-DNA
sequence None None I-DNA
elements None None I-DNA
5 None None O
' None None O
to None None O
the None None O
site None None O
of None None O
transcription None None O
initiation None None O
: None None O
the None None O
octamer None None O
ATGCAAAT None None O
and None None O
the None None O
heptamer None None O
CTCATGA None None O
. None None O

Both None None O
of None None O
these None None O
elements None None O
are None None O
required None None O
for None None O
normal None None I-DNA
cell-specific None None I-DNA
promoter None None I-DNA
function None None O
. None None O

The None None O
present None None O
study None None O
demonstrates None None O
that None None O
both None None O
the None None O
ubiquitous None None I-protein
and None None I-protein
lymphoid-cell-specific None None I-protein
octamer None None I-protein
transcription None None I-protein
factors None None I-protein
( None None O
OTF-1 None None I-protein
and None None O
OTF-2 None None I-protein
, None None O
respectively None None O
) None None O
interact None None O
specifically None None O
with None None O
each None None O
of None None O
the None None O
two None None O
conserved None None I-DNA
sequence None None I-DNA
elements None None I-DNA
, None None O
forming None None O
either None None O
homo- None None I-protein
or None None I-protein
heterodimeric None None I-protein
complexes None None I-protein
. None None O

This None None O
was None None O
surprising None None O
, None None O
since None None O
the None None O
heptamer None None O
and None None O
octamer None None O
sequence None None O
motifs None None O
bear None None O
no None None O
obvious None None O
similarity None None O
to None None O
each None None O
other None None O
. None None O

Binding None None O
of None None O
either None None O
factor None None O
to None None O
the None None O
octamer None None I-DNA
element None None I-DNA
occurred None None O
independently None None O
. None None O

However None None O
, None None O
OTF None None I-protein
interaction None None O
with None None O
the None None O
heptamer None None I-DNA
sequence None None I-DNA
appeared None None O
to None None O
require None None O
the None None O
presence None None O
of None None O
an None None O
intact None None O
octamer None None O
motif None None O
and None None O
occurred None None O
with None None O
a None None O
spacing None None O
of None None O
either None None O
2 None None I-DNA
or None None I-DNA
14 None None I-DNA
base None None I-DNA
pairs None None I-DNA
between None None O
the None None O
two None None O
elements None None O
, None None O
suggesting None None O
coordinate None None O
binding None None O
resulting None None O
from None None O
protein-protein None None O
interactions None None O
. None None O

The None None O
degeneracy None None O
in None None O
sequences None None O
recognized None None O
by None None O
the None None O
OTFs None None I-protein
may None None O
be None None O
important None None O
in None None O
widening None None O
the None None O
range None None O
over None None O
which None None O
gene None None O
expression None None O
can None None O
be None None O
modulated None None O
and None None O
in None None O
establishing None None O
cell None None O
type None None O
specificity None None O
. None None O

Identification None None O
of None None O
a None None O
novel None None O
lymphoid None None I-protein
specific None None I-protein
octamer None None I-protein
binding None None I-protein
protein None None I-protein
( None None O
OTF-2B None None I-protein
) None None O
by None None O
proteolytic None None O
clipping None None O
bandshift None None O
assay None None O
( None None O
PCBA None None O
) None None O
. None None O

The None None O
octamer None None O
sequence None None O
ATGCAAAT None None O
is None None O
found None None O
in None None O
the None None O
promoters None None O
of None None O
immunoglobulin None None I-DNA
( None None I-DNA
Ig None None I-DNA
) None None I-DNA
heavy None None I-DNA
and None None I-DNA
light None None I-DNA
chain None None I-DNA
genes None None I-DNA
and None None O
in None None O
the None None O
heavy None None I-DNA
chain None None I-DNA
enhancer None None I-DNA
and None None O
is None None O
a None None O
major None None O
determinant None None O
of None None O
the None None O
cell None None O
type None None O
specific None None O
expression None None O
of None None O
Ig None None I-DNA
genes None None I-DNA
in None None O
B None None I-cell_type
cells None None I-cell_type
. None None O

An None None O
apparent None None O
paradox None None O
is None None O
that None None O
the None None O
same None None O
sequence None None O
serves None None O
as None None O
an None None O
upstream None None I-DNA
promoter None None I-DNA
or None None I-DNA
enhancer None None I-DNA
element None None I-DNA
in None None O
a None None O
variety None None O
of None None O
housekeeping None None I-DNA
genes None None I-DNA
such None None O
as None None O
the None None O
histone None None I-DNA
H2B None None I-DNA
and None None I-DNA
U None None I-DNA
snRNA None None I-DNA
genes None None I-DNA
. None None O

The None None O
differential None None O
usage None None O
of None None O
this None None O
regulatory None None O
sequence None None O
motif None None O
is None None O
thought None None O
to None None O
be None None O
mediated None None O
by None None O
different None None O
species None None O
of None None O
octamer None None I-protein
binding None None I-protein
proteins None None I-protein
. None None O

One None None O
species None None O
of None None O
100 None None O
kd None None O
, None None O
designated None None O
OTF-1 None None I-protein
, None None O
is None None O
present None None O
in None None O
all None None O
cell None None O
types None None O
and None None O
may None None O
exert None None O
its None None O
activating None None O
function None None O
only None None O
when None None O
it None None O
can None None O
interact None None O
with None None O
additional None None O
adjacent None None O
transcription None None I-protein
factors None None I-protein
. None None O

The None None O
lymphoid None None I-protein
cell None None I-protein
specific None None I-protein
octamer None None I-protein
binding None None I-protein
protein None None I-protein
of None None O
60 None None O
kd None None O
( None None O
OTF-2A None None I-protein
) None None O
specifically None None O
stimulates None None O
Ig None None I-DNA
promoters None None I-DNA
which None None O
consist None None O
essentially None None O
of None None O
a None None O
TATA-box None None I-DNA
and None None O
an None None O
octamer None None I-DNA
sequence None None I-DNA
upstream None None O
of None None O
it None None O
. None None O

Here None None O
we None None O
present None None O
evidence None None O
for None None O
yet None None O
another None None O
B None None I-protein
cell None None I-protein
specific None None I-protein
octamer None None I-protein
binding None None I-protein
protein None None I-protein
of None None O
75 None None O
kd None None O
( None None O
OTF-2B None None I-protein
) None None O
. None None O

From None None O
several None None O
findings None None O
, None None O
including None None O
the None None O
absence None None O
of None None O
OTF-2B None None I-protein
( None None O
but None None O
not None None O
OTF-2A None None I-protein
) None None O
from None None O
a None None O
lymphocyte None None I-cell_line
line None None I-cell_line
that None None O
can None None O
not None None O
respond None None O
to None None O
the None None O
IgH None None I-DNA
enhancer None None I-DNA
, None None O
we None None O
propose None None O
a None None O
role None None O
of None None O
the None None O
novel None None I-protein
octamer None None I-protein
factor None None I-protein
in None None O
the None None O
long None None O
range None None O
activation None None O
by None None O
the None None O
IgH None None I-DNA
enhancer None None I-DNA
. None None O

We None None O
have None None O
used None None O
the None None O
proteolytic None None O
clipping None None O
bandshift None None O
assay None None O
( None None O
PCBA None None O
) None None O
technique None None O
to None None O
distinguish None None O
the None None O
three None None O
different None None O
forms None None O
found None None O
in None None O
B None None I-cell_type
cells None None I-cell_type
. None None O

This None None O
analysis None None O
indicates None None O
that None None O
the None None O
75 None None O
kd-species None None O
OTF-2B None None I-protein
is None None O
closely None None O
related None None O
to None None O
the None None O
60 None None I-protein
kd None None I-protein
species None None I-protein
OTF-2A None None I-protein
. None None O

Inhibition None None O
of None None O
interleukin None None I-protein
2 None None I-protein
-induced None None O
proliferation None None O
of None None O
cloned None None I-cell_line
murine None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
by None None O
glucocorticoids None None O
. None None O

Possible None None O
involvement None None O
of None None O
an None None O
inhibitory None None I-protein
protein None None I-protein
. None None O

The None None O
ability None None O
of None None O
glucocorticoids None None O
to None None O
inhibit None None O
interleukin None None I-protein
2 None None I-protein
( None None O
IL None None I-protein
2 None None I-protein
) None None O
-induced None None O
T None None I-cell_type
cell None None I-cell_type
proliferation None None O
in None None O
two None None O
cytotoxic None None I-cell_line
T None None I-cell_line
cell None None I-cell_line
( None None I-cell_line
CTL None None I-cell_line
) None None I-cell_line
clones None None I-cell_line
has None None O
been None None O
studied None None O
. None None O

A None None O
complete None None O
inhibition None None O
of None None O
DNA None None O
synthesis None None O
by None None O
dexamethasone None None O
( None None O
Dx None None O
) None None O
could None None O
be None None O
observed None None O
when None None O
IL None None I-cell_line
2-depleted None None I-cell_line
cultures None None I-cell_line
of None None O
CTL None None I-cell_line
were None None O
either None None O
incubated None None O
for None None O
6 None None O
h None None O
with None None O
the None None O
hormone None None I-protein
prior None None O
to None None O
the None None O
addition None None O
of None None O
IL None None I-protein
2 None None I-protein
or None None O
treated None None O
simultaneously None None O
with None None O
Dx None None O
and None None O
a None None O
low None None O
concentration None None O
of None None O
IL None None I-protein
2 None None I-protein
. None None O

No None None O
significant None None O
reduction None None O
in None None O
the None None O
number None None O
and None None O
affinity None None O
of None None O
IL None None I-protein
2 None None I-protein
receptors None None I-protein
was None None O
seen None None O
after None None O
6 None None O
h None None O
incubation None None O
with None None O
Dx None None O
. None None O

The None None O
order None None O
of None None O
potency None None O
observed None None O
with None None O
the None None O
different None None O
steroids None None O
indicated None None O
that None None O
this None None O
inhibitory None None O
effect None None O
was None None O
mediated None None O
through None None O
binding None None O
to None None O
a None None O
specific None None O
glucocorticoid None None I-protein
receptor None None I-protein
. None None O

The None None O
action None None O
of None None O
these None None O
hormones None None I-protein
possibly None None O
involves None None O
the None None O
synthesis None None O
of None None O
an None None O
inhibitory None None I-protein
protein None None I-protein
( None None O
s None None O
) None None O
, None None O
since None None O
the None None O
presence None None O
of None None O
cycloheximide None None O
during None None O
the None None O
incubation None None O
with None None O
Dx None None O
prevented None None O
the None None O
inhibition None None O
of None None O
DNA None None O
synthesis None None O
. None None O

Furthermore None None O
, None None O
supernatant None None O
from None None O
Dx-treated None None O
CTL None None I-cell_line
contained None None O
a None None O
nondialyzable None None O
factor None None O
which None None O
inhibited None None O
DNA None None O
synthesis None None O
and None None O
cell None None O
growth None None O
of None None O
CTL None None I-cell_line
clones None None I-cell_line
induced None None O
by None None O
IL None None I-protein
2 None None I-protein
. None None O

Blocking None None O
of None None O
IL None None I-protein
2 None None I-protein
synthesis None None O
and None None O
IL None None I-protein
2 None None I-protein
receptor None None I-protein
formation None None O
have None None O
been None None O
proposed None None O
as None None O
one None None O
of None None O
the None None O
major None None O
mechanisms None None O
of None None O
glucocorticoid-induced None None O
immunosuppression None None O
. None None O

Our None None O
results None None O
indicate None None O
that None None O
these None None O
hormones None None I-protein
may None None O
also None None O
affect None None O
T None None I-cell_type
cell None None I-cell_type
proliferation None None O
by None None O
inhibiting None None O
IL None None I-protein
2 None None I-protein
activity None None O
. None None O

Identification None None O
and None None O
purification None None O
of None None O
a None None O
human None None I-protein
immunoglobulin-enhancer-binding None None I-protein
protein None None I-protein
( None None O
NF-kappa None None I-protein
B None None I-protein
) None None O
that None None O
activates None None O
transcription None None O
from None None O
a None None O
human None None I-DNA
immunodeficiency None None I-DNA
virus None None I-DNA
type None None I-DNA
1 None None I-DNA
promoter None None I-DNA
in None None O
vitro None None O
. None None O

The None None O
enhancer-binding None None I-protein
factor None None I-protein
NF-kappa None None I-protein
B None None I-protein
, None None O
which None None O
is None None O
found None None O
only None None O
in None None O
cells None None O
that None None O
transcribe None None O
immunoglobulin None None I-DNA
light None None I-DNA
chain None None I-DNA
genes None None I-DNA
, None None O
has None None O
been None None O
purified None None O
from None None O
nuclear None None O
extracts None None O
of None None O
Namalwa None None I-cell_line
cells None None I-cell_line
( None None O
human None None I-cell_line
Burkitt None None I-cell_line
lymphoma None None I-cell_line
cells None None I-cell_line
) None None O
by None None O
sequence-specific None None O
DNA None None O
affinity None None O
chromatography None None O
. None None O

The None None O
purified None None O
NF-kappa None None I-protein
B None None I-protein
has None None O
been None None O
identified None None O
as None None O
a None None O
51-kDa None None I-protein
polypeptide None None I-protein
by None None O
UV-crosslinking None None O
analysis None None O
. None None O

`` None None O
Footprint None None O
'' None None O
and None None O
methylation-interference None None O
analyses None None O
have None None O
shown None None O
that None None O
purified None None O
NF-kappa None None I-protein
B None None I-protein
has None None O
a None None O
binding None None O
activity None None O
specific None None O
for None None O
the None None O
kappa None None I-DNA
light None None I-DNA
chain None None I-DNA
enhancer None None I-DNA
sequence None None I-DNA
. None None O

The None None O
purified None None O
factor None None O
activated None None O
in None None O
vitro None None O
transcription None None O
of None None O
the None None O
human None None I-DNA
immunodeficiency None None I-DNA
virus None None I-DNA
type None None I-DNA
I None None I-DNA
promoter None None I-DNA
by None None O
binding None None O
to None None O
an None None O
upstream None None I-DNA
NF-kappa None None I-DNA
B-binding None None I-DNA
site None None I-DNA

Lymphocyte None None I-cell_type
glucocorticoid None None I-protein
receptor None None I-protein
binding None None O
in None None O
depression None None O
: None None O
normal None None O
values None None O
following None None O
recovery None None O
. None None O

The None None O
number None None O
of None None O
glucocorticoid None None I-protein
receptor None None I-protein
sites None None O
in None None O
lymphocytes None None I-cell_type
and None None O
plasma None None O
cortisol None None O
concentrations None None O
were None None O
measured None None O
in None None O
20 None None O
patients None None O
who None None O
had None None O
recovered None None O
from None None O
major None None O
depressive None None O
disorder None None O
and None None O
20 None None O
healthy None None O
control None None O
subjects None None O
. None None O

The None None O
number None None O
of None None O
glucocorticoid None None I-protein
receptor None None I-protein
sites None None O
in None None O
lymphocytes None None I-cell_type
from None None O
the None None O
recovered None None O
depressed None None O
group None None O
was None None O
not None None O
significantly None None O
different None None O
from None None O
that None None O
of None None O
the None None O
control None None O
group None None O
. None None O

Although None None O
the None None O
mean None None O
plasma None None O
cortisol None None O
concentration None None O
in None None O
recovered None None O
depressives None None O
was None None O
higher None None O
than None None O
in None None O
control None None O
subjects None None O
, None None O
the None None O
difference None None O
only None None O
just None None O
reached None None O
significance None None O
. None None O

This None None O
study None None O
shows None None O
that None None O
the None None O
reduction None None O
in None None O
glucocorticoid None None I-protein
receptor None None I-protein
numbers None None O
which None None O
occurs None None O
during None None O
acute None None O
depressive None None O
illness None None O
does None None O
not None None O
persist None None O
on None None O
recovery None None O
and None None O
is None None O
, None None O
therefore None None O
, None None O
state-dependent None None O
. None None O

Identification None None O
and None None O
purification None None O
of None None O
a None None O
human None None I-protein
lymphoid-specific None None I-protein
octamer-binding None None I-protein
protein None None I-protein
( None None O
OTF-2 None None I-protein
) None None O
that None None O
activates None None O
transcription None None O
of None None O
an None None O
immunoglobulin None None I-DNA
promoter None None I-DNA
in None None O
vitro None None O
. None None O

The None None O
octamer None None O
sequence None None O
5'-ATGCAAAT None None O
, None None O
in None None O
either None None O
orientation None None O
, None None O
serves None None O
as None None O
an None None O
upstream None None I-DNA
element None None I-DNA
in None None O
a None None O
variety None None O
of None None O
promoters None None I-DNA
and None None O
also None None O
occurs None None O
as None None O
a None None O
modular None None I-DNA
enhancer None None I-DNA
element None None I-DNA
. None None O

It None None O
is None None O
of None None O
particular None None O
interest None None O
in None None O
immunoglobulin None None I-DNA
genes None None I-DNA
since None None O
it None None O
is None None O
found None None O
in None None O
the None None O
upstream None None I-DNA
regions None None I-DNA
of None None O
all None None O
heavy None None I-DNA
and None None I-DNA
light None None I-DNA
chain None None I-DNA
promoters None None I-DNA
and None None O
in None None O
the None None O
heavy None None I-DNA
chain None None I-DNA
enhancer None None I-DNA
, None None O
both None None O
of None None O
which None None O
are None None O
known None None O
to None None O
be None None O
necessary None None O
for None None O
cell-specific None None O
expression None None O
. None None O

We None None O
report None None O
here None None O
the None None O
chromatographic None None O
separation None None O
of None None O
ubiquitous None None I-protein
and None None I-protein
B None None I-protein
cell-specific None None I-protein
octamer-binding None None I-protein
proteins None None I-protein
. None None O

The None None O
B None None I-protein
cell None None I-protein
factor None None I-protein
was None None O
purified None None O
to None None O
homogeneity None None O
using None None O
affinity None None O
chromatography None None O
and None None O
consists None None O
of None None O
three None None O
peptides None None O
of None None O
62 None None O
, None None O
61 None None O
, None None O
and None None O
58.5 None None O
+/- None None O
1.5 None None O
kd None None O
. None None O

Each None None O
of None None O
the None None O
polypeptides None None O
was None None O
renatured None None O
after None None O
SDS-PAGE None None O
and None None O
shown None None O
to None None O
bind None None O
to None None O
the None None O
octamer None None O
sequence None None O
. None None O

The None None O
specific None None O
DNA None None O
binding None None O
activity None None O
of None None O
the None None O
pure None None O
B None None I-protein
cell-specific None None I-protein
factor None None I-protein
was None None O
indistinguishable None None O
from None None O
that None None O
of None None O
the None None O
affinity-purified None None I-protein
ubiquitous None None I-protein
factor None None I-protein
. None None O

This None None O
B None None I-protein
cell-specific None None I-protein
octamer-binding None None I-protein
factor None None I-protein
, None None O
in None None O
pure None None O
form None None O
, None None O
activated None None O
transcription None None O
from None None O
a None None O
kappa None None I-DNA
light None None I-DNA
chain None None I-DNA
promoter None None I-DNA
in None None O
vitro None None O
, None None O
thus None None O
demonstrating None None O
that None None O
it None None O
is None None O
indeed None None O
a None None O
B None None I-protein
cell-specific None None I-protein
transcription None None I-protein
factor None None I-protein
for None None O
this None None O
gene None None O
. None None O

In None None O
addition None None O
to None None O
the None None O
ubiquitous None None I-protein
and None None I-protein
B None None I-protein
cell-specific None None I-protein
octamer-binding None None I-protein
factors None None I-protein
, None None O
we None None O
identified None None O
several None None O
additional None None O
proteins None None O
, None None O
one None None O
of None None O
which None None O
is None None O
B None None I-cell_type
cell None None I-cell_type
-specific None None O
, None None O
that None None O
interact None None O
with None None O
the None None O
kappa None None I-DNA
promoter None None I-DNA
. None None O

Decreased None None O
deoxyribonucleic None None O
acid None None O
binding None None O
of None None O
glucocorticoid-receptor None None I-protein
complex None None I-protein
in None None O
cultured None None O
skin None None I-cell_line
fibroblasts None None I-cell_line
from None None O
a None None O
patient None None O
with None None O
the None None O
glucocorticoid None None O
resistance None None O
syndrome None None O
. None None O

A None None O
patient None None O
with None None O
the None None O
syndrome None None O
of None None O
glucocorticoid None None O
resistance None None O
was None None O
studied None None O
. None None O

A None None O
27-yr-old None None O
woman None None O
initially None None O
was None None O
diagnosed None None O
as None None O
having None None O
Cushing None None O
's None None O
disease None None O
, None None O
based None None O
on None None O
the None None O
findings None None O
of None None O
high None None O
plasma None None O
ACTH None None O
and None None O
serum None None O
cortisol None None O
levels None None O
, None None O
increased None None O
urinary None None O
cortisol None None O
secretion None None O
, None None O
resistance None None O
to None None O
adrenal None None O
suppression None None O
with None None O
dexamethasone None None O
, None None O
and None None O
bilateral None None O
adrenal None None O
hyperplasia None None O
by None None O
computed None None O
tomography None None O
and None None O
scintigraphy None None O
of None None O
the None None O
adrenal None None O
glands None None O
. None None O

However None None O
, None None O
she None None O
had None None O
no None None O
signs None None O
or None None O
symptoms None None O
of None None O
Cushing None None O
's None None O
syndrome None None O
. None None O

During None None O
a None None O
5-yr None None O
follow-up None None O
, None None O
no None None O
clinical None None O
abnormalities None None O
developed None None O
, None None O
although None None O
hypercortisolism None None O
persisted None None O
. None None O

End-organ None None O
resistance None None O
to None None O
cortisol None None O
was None None O
suspected None None O
. None None O

To None None O
explain None None O
the None None O
end-organ None None O
resistance None None O
to None None O
cortisol None None O
, None None O
the None None O
glucocorticoid None None I-protein
receptors None None I-protein
( None None O
GR None None I-protein
) None None O
in None None O
peripheral None None I-cell_type
mononuclear None None I-cell_type
leukocytes None None I-cell_type
and None None O
cultured None None I-cell_line
skin None None I-cell_line
fibroblasts None None I-cell_line
from None None O
a None None O
forearm None None O
skin None None O
biopsy None None O
were None None O
characterized None None O
and None None O
compared None None O
with None None O
the None None O
results None None O
of None None O
similar None None O
studies None None O
in None None O
normal None None O
subjects None None O
. None None O

The None None O
patient None None O
's None None O
GR None None I-protein
in None None O
whole None None O
cell None None O
assays None None O
had None None O
an None None O
increased None None O
dissociation None None O
constant None None O
( None None O
Kd None None O
) None None O
. None None O

In None None O
the None None O
cytosol None None O
of None None O
cultured None None I-cell_line
skin None None I-cell_line
fibroblasts None None I-cell_line
from None None O
the None None O
patient None None O
, None None O
there None None O
was None None O
also None None O
decreased None None O
binding None None O
capacity None None O
. None None O

The None None O
thermal None None O
stability None None O
and None None O
the None None O
sedimentation None None O
coefficient None None O
in None None O
a None None O
sucrose None None O
density None None O
gradient None None O
of None None O
the None None O
receptors None None O
in None None O
the None None O
cytosol None None O
of None None O
cultured None None I-cell_line
skin None None I-cell_line
fibroblasts None None I-cell_line
from None None O
the None None O
patient None None O
and None None O
normal None None O
subjects None None O
were None None O
similar None None O
. None None O

GR None None I-cell_line
complex None None I-cell_line
activation None None I-cell_line
, None None O
analyzed None None O
by None None O
DEAE-cellulose None None I-cell_line
chromatography None None I-cell_line
, None None O
was None None O
decreased None None O
in None None O
the None None O
patient None None O
. None None O

DNA None None I-DNA
binding None None O
of None None O
the None None O
GR None None I-protein
complex None None I-protein
after None None O
temperature-induced None None O
activation None None O
was None None O
lower None None O
in None None O
the None None O
patient None None O
than None None O
in None None O
normal None None O
subjects None None O
. None None O

Nuclear None None O
translocation None None O
of None None O
GR None None I-protein
complexes None None I-protein
from None None O
the None None O
patient None None O
was None None O
also None None O
slightly None None O
decreased None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
patient None None O
's None None O
glucocorticoid None None O
resistance None None O
was None None O
due None None O
to None None O
a None None O
decrease None None O
in None None O
the None None O
affinity None None O
of None None O
the None None O
receptor None None O
for None None O
glucocorticoids None None O
and None None O
a None None O
decrease None None O
in None None O
the None None O
binding None None O
of None None O
the None None O
GR None None I-protein
complex None None I-protein
to None None O
DNA None None I-DNA
. None None O

Granulocyte-macrophage None None I-protein
colony-stimulating None None I-protein
factor None None I-protein
. None None O

Sensitive None None O
and None None O
receptor-mediated None None O
regulation None None O
by None None O
1 None None O
, None None O
25-dihydroxyvitamin None None O
D3 None None O
in None None O
normal None None O
human None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
lymphocytes None None I-cell_type
. None None O

We None None O
show None None O
that None None O
1 None None O
, None None O
25-dihydroxyvitamin None None O
D3 None None O
( None None O
1 None None O
, None None O
25 None None O
[ None None O
OH None None O
] None None O
2D3 None None O
) None None O
, None None O
the None None O
most None None O
hormonally None None O
active None None O
metabolite None None O
of None None O
vitamin None None O
D3 None None O
, None None O
modulates None None O
sensitively None None O
and None None O
specifically None None O
both None None O
the None None O
protein None None O
and None None O
messenger None None I-RNA
RNA None None I-RNA
accumulation None None O
of None None O
the None None O
multilineage None None I-protein
growth None None I-protein
factor None None I-protein
granulocyte-macrophage None None B-protein
colony-stimulating None None I-protein
factor None None I-protein
( None None O
GM-CSF None None I-protein
) None None O
. None None O

The None None O
regulation None None O
of None None O
GM-CSF None None I-protein
expression None None O
is None None O
seen None None O
in None None O
both None None O
normal None None I-cell_type
human None None I-cell_type
mitogen-activated None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
and None None O
T None None I-cell_line
lymphocytes None None I-cell_line
from None None I-cell_line
a None None I-cell_line
line None None I-cell_line
( None None I-cell_line
S-LB1 None None I-cell_line
) None None I-cell_line
transformed None None I-cell_line
with None None I-cell_line
human None None I-cell_line
T None None I-cell_line
cell None None I-cell_line
lymphotropic None None I-cell_line
virus None None I-cell_line
1 None None I-cell_line
( None None O
HTLV-1 None None O
) None None O
. None None O

In None None O
contrast None None O
, None None O
cells None None O
from None None O
a None None O
HTLV-1 None None I-cell_line
transformed None None I-cell_line
T None None I-cell_line
lymphocyte None None I-cell_line
line None None I-cell_line
( None None O
Ab-VDR None None I-cell_line
) None None O
established None None O
from None None O
a None None O
patient None None O
with None None O
vitamin None None O
D-resistant None None O
rickets None None O
type None None O
II None None O
with None None O
undetectable None None O
1 None None I-protein
, None None I-protein
25 None None I-protein
( None None I-protein
OH None None I-protein
) None None I-protein
2D3 None None I-protein
cellular None None I-protein
receptors None None I-protein
are None None O
resistant None None O
to None None O
the None None O
action None None O
of None None O
1 None None O
, None None O
25 None None O
( None None O
OH None None O
) None None O
2D3 None None O
. None None O

Inhibition None None O
of None None O
GM-CSF None None I-protein
expression None None O
by None None O
1 None None O
, None None O
25 None None O
( None None O
OH None None O
) None None O
2D3 None None O
can None None O
occur None None O
independently None None O
of None None O
interleukin None None I-protein
2 None None I-protein
regulation None None O
and None None O
is None None O
probably None None O
mediated None None O
through None None O
cellular None None I-protein
1 None None I-protein
, None None I-protein
25 None None I-protein
( None None I-protein
OH None None I-protein
) None None I-protein
2D3 None None I-protein
receptors None None I-protein
. None None O

We None None O
conclude None None O
that None None O
1 None None O
, None None O
25 None None O
( None None O
OH None None O
) None None O
2D3 None None O
may None None O
be None None O
important None None O
in None None O
the None None O
physiology None None O
of None None O
hematopoiesis None None O
. None None O

Altered None None O
interaction None None O
between None None O
triiodothyronine None None O
and None None O
its None None O
nuclear None None I-protein
receptors None None I-protein
in None None O
absence None None O
of None None O
cortisol None None O
: None None O
a None None O
proposed None None O
mechanism None None O
for None None O
increased None None O
thyrotropin None None O
secretion None None O
in None None O
corticosteroid None None O
deficiency None None O
states None None O
. None None O

Thyroid None None O
hormones None None O
occasionally None None O
appear None None O
less None None O
effective None None O
when None None O
administered None None O
alone None None O
to None None O
patients None None O
with None None O
panhypopituitarism None None O
, None None O
and None None O
manifestations None None O
suggestive None None O
of None None O
hypothyroidism None None O
have None None O
been None None O
reported None None O
in None None O
patients None None O
suffering None None O
from None None O
untreated None None O
Addison None None O
's None None O
disease None None O
. None None O

In None None O
the None None O
latter None None O
condition None None O
, None None O
thyrotropin None None O
secretion None None O
is None None O
increased None None O
: None None O
this None None O
occurs None None O
already None None O
after None None O
as None None O
little None None O
as None None O
2 None None O
days None None O
of None None O
temporary None None O
withdrawal None None O
of None None O
therapy None None O
with None None O
substitution None None O
doses None None O
of None None O
corticosteroids None None O
while None None O
circulating None None O
levels None None O
of None None O
thyroid None None O
hormones None None O
remain None None O
within None None O
normal None None O
limits None None O
. None None O

Therefore None None O
, None None O
a None None O
possible None None O
role None None O
of None None O
cortisol None None O
in None None O
interaction None None O
between None None O
triiodothyronine None None O
and None None O
its None None O
nuclear None None I-protein
receptors None None I-protein
was None None O
examined None None O
at None None O
the None None O
level None None O
of None None O
circulating None None O
lymphocytes None None O
obtained None None O
from None None O
patients None None O
with None None O
primary None None O
or None None O
secondary None None O
adrenocortical None None O
failure None None O
. None None O

The None None O
affinity None None O
of None None O
these None None O
receptors None None O
was None None O
found None None O
to None None O
be None None O
decreased None None O
, None None O
by None None O
more None None O
than None None O
50 None None O
% None None O
on None None O
average None None O
, None None O
in None None O
the None None O
absence None None O
of None None O
cortisol None None O
treatments None None O
. None None O

This None None O
change None None O
was None None O
promptly None None O
corrected None None O
upon None None O
resumption None None O
of None None O
therapy None None O
. None None O

The None None O
number None None O
of None None O
binding None None O
sites None None O
was None None O
not None None O
significantly None None O
modified None None O
. None None O

The None None O
influence None None O
of None None O
cortisol None None O
on None None O
thyroid None None I-protein
hormone None None I-protein
receptors None None I-protein
discussed None None O
here None None O
might None None O
account None None O
for None None O
the None None O
clinical None None O
observations None None O
mentioned None None O
above None None O
. None None O

Inhibition None None O
by None None O
cortisol None None O
of None None O
human None None I-cell_type
natural None None I-cell_type
killer None None I-cell_type
( None None I-cell_type
NK None None I-cell_type
) None None I-cell_type
cell None None I-cell_type
activity None None O
. None None O

The None None O
effects None None O
of None None O
cortisol None None O
on None None O
the None None O
natural None None I-cell_type
killer None None I-cell_type
( None None O
NK None None O
) None None O
activity None None O
of None None O
human None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
( None None I-cell_type
PBM None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
were None None O
studied None None O
in None None O
vitro None None O
using None None O
a None None O
direct None None O
4-h None None O
51Cr-release None None O
assay None None O
and None None O
K None None I-cell_line
562 None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
as None None O
a None None O
target None None O
. None None O

Preincubation None None O
for None None O
20 None None O
h None None O
of None None O
PBM None None I-cell_type
cells None None I-cell_type
drawn None None O
from None None O
healthy None None O
donors None None O
with None None O
1 None None O
X None None O
10 None None O
( None None O
-8 None None O
) None None O
to None None O
1 None None O
X None None O
10 None None O
( None None O
-5 None None O
) None None O
M None None O
cortisol None None O
resulted None None O
in None None O
a None None O
significant None None O
decrease None None O
of None None O
NK None None I-cell_type
cell None None I-cell_type
activity None None O
. None None O

The None None O
magnitude None None O
of None None O
the None None O
suppression None None O
was None None O
directly None None O
related None None O
to None None O
the None None O
steroid None None O
concentration None None O
and None None O
inversely None None O
related None None O
to None None O
the None None O
number None None O
of None None O
effector None None I-cell_type
cells None None I-cell_type
. None None O

Cortisol None None O
was None None O
able None None O
to None None O
minimize None None O
the None None O
enhancement None None O
of None None O
NK None None O
cytotoxicity None None O
obtainable None None O
in None None O
the None None O
presence None None O
of None None O
immune None None O
interferon None None O
( None None O
IFN-gamma None None O
) None None O
. None None O

A None None O
significantly None None O
higher None None O
suppression None None O
was None None O
achieved None None O
after None None O
sequential None None O
exposure None None O
of None None O
PBM None None I-cell_type
cells None None I-cell_type
to None None O
cortisol None None O
and None None O
equimolar None None O
levels None None O
of None None O
prostaglandin None None O
E2 None None O
( None None O
PgE2 None None O
) None None O
. None None O

The None None O
concomitant None None O
incubation None None O
with None None O
theophylline None None O
and None None O
isobutyl-methylxanthine None None O
failed None None O
to None None O
enhance None None O
the None None O
cortisol-induced None None O
suppression None None O
, None None O
whereas None None O
PgE2-dependent None None O
inhibition None None O
significantly None None O
increased None None O
after None None O
exposure None None O
of None None O
PBM None None I-cell_type
cells None None I-cell_type
to None None O
methyl-xanthines None None O
. None None O

The None None O
inhibitory None None O
effect None None O
of None None O
cortisol None None O
was None None O
partially None None O
or None None O
totally None None O
prevented None None O
by None None O
the None None O
concomitant None None O
incubation None None O
with None None O
equimolar None None O
amounts None None O
of None None O
11-deoxycortisol None None O
and None None O
RU None None O
486 None None O
but None None O
not None None O
of None None O
progesterone None None O
. None None O

Treatment None None O
of None None O
NK None None I-cell_type
effectors None None I-cell_type
with None None O
a None None O
monoclonal None None I-protein
anti-human None None I-protein
corticosteroid-binding None None I-protein
globulin None None I-protein
( None None I-protein
CBG None None I-protein
) None None I-protein
antibody None None I-protein
produced None None O
an None None O
enhancement None None O
of None None O
the None None O
spontaneous None None O
NK None None I-cell_type
activity None None O
and None None O
a None None O
partial None None O
suppression None None O
of None None O
cortisol-mediated None None O
effects None None O
. None None O

Our None None O
results None None O
suggest None None O
that None None O
endogenous None None O
glucocorticoids None None O
play None None O
a None None O
role None None O
in None None O
the None None O
regulation None None O
of None None O
NK None None O
cell-mediated None None O
cytotoxicity None None O
. None None O

Since None None O
the None None O
effect None None O
of None None O
cortisol None None O
was None None O
additive None None O
to None None O
that None None O
of None None O
PgE2 None None O
and None None O
was None None O
not None None O
changed None None O
by None None O
phosphodiesterase None None I-protein
inhibitors None None O
, None None O
it None None O
is None None O
conceivable None None O
that None None O
the None None O
hormone None None O
acts None None O
at None None O
a None None O
level None None O
different None None O
from None None O
the None None O
adenylate None None I-protein
cyclase None None I-protein
- None None O
phosphodiesterase None None I-protein
system None None O
. None None O

Data None None O
obtained None None O
with None None O
the None None O
use None None O
of None None O
antiglucocorticoids None None O
and None None O
the None None O
anti-CBG None None I-protein
antibody None None I-protein
are None None O
compatible None None O
with None None O
a None None O
role None None O
both None None O
of None None O
high-affinity None None O
glucocorticoid None None I-protein
receptors None None I-protein
and None None O
of None None O
CBG None None I-protein
in None None O
mediating None None O
cortisol None None O
action None None O
on None None O
the None None O
human None None I-cell_type
NK None None I-cell_type
cell None None I-cell_type
activity None None O
. None None O

Interaction None None O
of None None O
cell-type-specific None None I-protein
nuclear None None I-protein
proteins None None I-protein
with None None O
immunoglobulin None None I-DNA
VH None None I-DNA
promoter None None I-DNA
region None None I-DNA
sequences None None I-DNA
. None None O

All None None O
human None None I-DNA
and None None I-DNA
murine None None I-DNA
immunoglobulin None None I-DNA
heavy None None I-DNA
chain None None I-DNA
variable None None I-DNA
region None None I-DNA
( None None I-DNA
VH None None I-DNA
) None None I-DNA
genes None None I-DNA
contain None None O
the None None O
sequence None None O
ATGCAAAT None None O
approximately None None O
70 None None O
nucleotides None None O
5 None None O
' None None O
from None None O
the None None O
site None None O
of None None O
transcription None None O
initiation None None O
. None None O

This None None O
octanucleotide None None O
, None None O
in None None O
reverse None None O
orientation None None O
, None None O
is None None O
also None None O
found None None O
in None None O
all None None O
light None None I-DNA
chain None None I-DNA
variable None None I-DNA
region None None I-DNA
( None None I-DNA
VL None None I-DNA
) None None I-DNA
genes None None I-DNA
, None None O
and None None O
in None None O
the None None O
immunoglobulin None None I-DNA
heavy None None I-DNA
chain None None I-DNA
transcriptional None None I-DNA
enhancer None None I-DNA
. None None O

Transfection None None O
studies None None O
have None None O
established None None O
that None None O
this None None O
octamer None None O
is None None O
involved None None O
in None None O
the None None O
lymphoid-specific None None O
transcription None None O
of None None O
immunoglobulin None None I-DNA
genes None None I-DNA
. None None O

Octamer-containing None None I-DNA
fragments None None I-DNA
have None None O
been None None O
reported None None O
to None None O
bind None None O
a None None O
factor None None O
present None None O
in None None O
nuclear None None O
extracts None None O
of None None O
human None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
; None None O
however None None O
, None None O
identical None None O
binding None None O
activity None None O
was None None O
detected None None O
in None None O
both None None O
B None None I-cell_line
lymphoid None None I-cell_line
and None None I-cell_line
non-lymphoid None None I-cell_line
cells None None I-cell_line
. None None O

Here None None O
we None None O
establish None None O
that None None O
nuclear None None O
extracts None None O
from None None O
distinct None None O
cell None None O
types None None O
differ None None O
in None None O
their None None O
ability None None O
to None None O
interact None None O
with None None O
octamer-containing None None I-DNA
fragments None None I-DNA
. None None O

We None None O
have None None O
also None None O
detected None None O
a None None O
DNA-protein None None O
interaction None None O
that None None O
may None None O
be None None O
involved None None O
in None None O
the None None O
cell-type None None O
specificity None None O
of None None O
immunoglobulin None None I-protein
expression None None O
, None None O
and None None O
we None None O
have None None O
determined None None O
that None None O
a None None O
sequence None None O
upstream None None O
of None None O
the None None O
octamer None None O
participates None None O
in None None O
an None None O
interaction None None O
with None None O
a None None O
nuclear None None I-protein
protein None None I-protein
( None None O
s None None O
) None None O
. None None O

Preferential None None O
transcription None None O
of None None O
HTLV-I None None I-DNA
LTR None None I-DNA
in None None O
cell-free None None O
extracts None None O
of None None O
human None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
producing None None O
HTLV-I None None I-protein
viral None None I-protein
proteins None None I-protein
. None None O

The None None O
promoters None None I-DNA
of None None O
the None None O
adenovirus None None I-DNA
2 None None I-DNA
major None None I-DNA
late None None I-DNA
gene None None I-DNA
, None None O
the None None O
mouse None None I-DNA
beta-globin None None I-DNA
gene None None I-DNA
, None None O
the None None O
mouse None None I-DNA
immunoglobulin None None I-DNA
VH None None I-DNA
gene None None I-DNA
and None None O
the None None O
LTR None None I-DNA
of None None O
the None None O
human None None O
T-lymphotropic None None O
retrovirus None None O
type None None O
I None None O
were None None O
tested None None O
for None None O
their None None O
transcription None None O
activities None None O
in None None O
cell-free None None O
extracts None None O
of None None O
four None None O
cell None None O
lines None None O
; None None O
HeLa None None I-cell_line
, None None O
CESS None None I-cell_line
( None None O
Epstein-Barr None None I-cell_line
virus-transformed None None I-cell_line
human None None I-cell_line
B None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
) None None O
, None None O
MT-1 None None I-cell_line
( None None O
HTLV-I-infected None None I-cell_line
human None None I-cell_line
T None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
without None None O
viral None None O
protein None None O
synthesis None None O
) None None O
, None None O
and None None O
MT-2 None None I-cell_line
( None None O
HTLV-I-infected None None I-cell_line
human None None I-cell_line
T None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
producing None None O
viral None None I-protein
proteins None None I-protein
) None None O
. None None O

LTR None None I-DNA
was None None O
preferentially None None O
transcribed None None O
in None None O
the None None O
extracts None None O
of None None O
MT-2 None None I-cell_line
although None None O
the None None O
other None None O
three None None O
genes None None O
were None None O
transcribed None None O
with None None O
relatively None None O
constant None None O
efficiencies None None O
in None None O
different None None O
extracts None None O
. None None O

The None None O
results None None O
agree None None O
well None None O
with None None O
the None None O
previous None None O
in None None O
vivo None None O
studies None None O
on None None O
the None None O
promoter None None O
activity None None O
of None None O
HTLV-I None None I-DNA
LTR None None I-DNA
. None None O

Mixing None None O
of None None O
HeLa None None O
and None None O
MT-2 None None O
extracts None None O
revealed None None O
the None None O
presence None None O
of None None O
a None None O
LTR-specific None None O
stimulating None None O
activity None None O
in None None O
MT-2 None None O
extracts None None O
. None None O

A None None O
nuclear None None I-protein
factor None None I-protein
that None None O
binds None None O
to None None O
a None None O
conserved None None O
sequence None None O
motif None None O
in None None O
transcriptional None None I-DNA
control None None I-DNA
elements None None I-DNA
of None None O
immunoglobulin None None I-DNA
genes None None I-DNA
. None None O

Trans-acting None None I-protein
factors None None I-protein
that None None O
mediate None None O
B-cell None None O
specific None None O
transcription None None O
of None None O
immunoglobulin None None I-DNA
genes None None I-DNA
have None None O
been None None O
postulated None None O
based None None O
on None None O
an None None O
analysis None None O
of None None O
the None None O
expression None None O
of None None O
exogenously None None O
introduced None None O
immunoglobulin None None I-DNA
gene None None I-DNA
recombinants None None I-DNA
in None None O
lymphoid None None I-cell_type
and None None I-cell_type
non-lymphoid None None I-cell_type
cells None None I-cell_type
. None None O

Two None None O
B-cell-specific None None O
, None None O
cis-acting None None I-DNA
transcriptional None None I-DNA
regulatory None None I-DNA
elements None None I-DNA
have None None O
been None None O
identified None None O
. None None O

One None None O
element None None O
is None None O
located None None O
in None None O
the None None O
intron None None O
between None None O
the None None O
variable None None O
( None None O
V None None O
) None None O
and None None O
constant None None O
( None None O
C None None O
) None None O
regions None None O
of None None O
both None None O
heavy None None I-DNA
and None None I-DNA
kappa None None I-DNA
light-chain None None I-DNA
genes None None I-DNA
and None None O
acts None None O
as None None O
a None None O
transcriptional None None O
enhancer None None O
. None None O

The None None O
second None None O
element None None I-DNA
is None None O
found None None O
upstream None None O
of None None O
both None None O
heavy None None I-DNA
and None None I-DNA
kappa None None I-DNA
light-chain None None I-DNA
gene None None I-DNA
promoters None None I-DNA
. None None O

This None None O
element None None O
directs None None O
lymphoid-specific None None O
transcription None None O
even None None O
in None None O
the None None O
presence None None O
of None None O
viral None None I-DNA
enhancers None None I-DNA
. None None O

We None None O
have None None O
sought None None O
nuclear None None O
factors None None O
that None None O
might None None O
bind None None O
specifically None None O
to None None O
these None None O
two None None O
regulatory None None I-DNA
elements None None I-DNA
by None None O
application None None O
of None None O
a None None O
modified None None O
gel None None O
electrophoresis None None O
DNA None None O
binding None None O
assay None None O
. None None O

We None None O
report None None O
here None None O
the None None O
identification None None O
of None None O
a None None O
human None None I-protein
B-cell None None I-protein
nuclear None None I-protein
factor None None I-protein
( None None O
IgNF-A None None I-protein
) None None O
that None None O
binds None None O
to None None O
DNA None None I-DNA
sequences None None I-DNA
in None None O
the None None O
upstream None None I-DNA
regions None None I-DNA
of None None O
both None None O
the None None O
mouse None None I-DNA
heavy None None I-DNA
and None None I-DNA
kappa None None I-DNA
light-chain None None I-DNA
gene None None I-DNA
promoters None None I-DNA
and None None O
also None None O
to None None O
the None None O
mouse None None I-DNA
heavy-chain None None I-DNA
gene None None I-DNA
enhancer None None I-DNA
. None None O

This None None O
sequence-specific None None O
binding None None O
is None None O
probably None None O
mediated None None O
by None None O
a None None O
highly None None O
conserved None None O
sequence None None O
motif None None O
, None None O
ATTTGCAT None None O
, None None O
present None None O
in None None O
all None None O
three None None O
transcriptional None None I-DNA
elements None None I-DNA
. None None O

Interestingly None None O
, None None O
a None None O
factor None None O
showing None None O
similar None None O
binding None None O
specificity None None O
to None None O
IgNF-A None None I-DNA
is None None O
also None None O
present None None O
in None None O
human None None I-cell_line
HeLa None None I-cell_line
cells None None I-cell_line
. None None O

The None None O
new None None O
world None None O
primates None None O
as None None O
animal None None O
models None None O
of None None O
glucocorticoid None None O
resistance None None O
. None None O

Many None None O
New None None O
World None None O
primate None None O
species None None O
have None None O
greatly None None O
increased None None O
plasma None None O
cortisol None None O
concentrations None None O
, None None O
decreased None None O
plasma None None O
cortisol None None O
binding None None O
globulin None None O
capacity None None O
and None None O
affinity None None O
, None None O
marked None None O
resistance None None O
of None None O
the None None O
hypothalamic-pituitary-adrenal None None O
axis None None O
to None None O
suppression None None O
by None None O
dexamethasone None None O
, None None O
and None None O
no None None O
biological None None O
evidence None None O
of None None O
glucocorticoid None None O
excess None None O
. None None O

These None None O
primates None None O
also None None O
have None None O
high None None O
levels None None O
of None None O
circulating None None O
progesterone None None O
, None None O
estrogen None None O
, None None O
mineralocorticoid None None O
, None None O
androgen None None O
and None None O
vitamin None None O
D None None O
. None None O

The None None O
glucocorticoid None None O
target None None O
tissues None None O
that None None O
have None None O
been None None O
examined None None O
( None None O
circulating None None I-cell_type
mononuclear None None I-cell_type
lymphocytes None None I-cell_type
and None None O
cultured None None I-cell_line
skin None None I-cell_line
fibroblasts None None I-cell_line
) None None O
have None None O
normal None None O
concentrations None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
with None None O
decreased None None O
affinity None None O
for None None O
dexamethasone None None O
. None None O

Transformation None None O
of None None O
B-lymphocytes None None I-cell_type
with None None O
the None None O
Epstein-Barr None None O
virus None None O
leads None None O
to None None O
glucocorticoid None None I-protein
receptor None None I-protein
induction None None O
that None None O
is None None O
less None None O
than None None O
that None None O
observed None None O
with None None O
cells None None O
from None None O
Old None None O
World None None O
primates None None O
. None None O

The None None O
receptor None None O
in None None O
these None None O
cells None None O
has None None O
a None None O
low None None O
affinity None None O
for None None O
dexamethasone None None O
. None None O

The None None O
low None None O
affinity None None O
leads None None O
to None None O
an None None O
increased None None O
loss None None O
of None None O
specific None None O
bound None None O
ligand None None O
during None None O
thermal None None O
activation None None O
. None None O

Meroreceptor None None O
generation None None O
is None None O
normal None None O
. None None O

The None None O
molecular None None O
weight None None O
of None None O
the None None O
receptor None None O
, None None O
determined None None O
by None None O
SDS-PAGE None None O
, None None O
is None None O
similar None None O
to None None O
that None None O
of None None O
Old None None O
World None None O
primates None None O
( None None O
approximately None None O
92 None None O
, None None O
000 None None O
) None None O
and None None O
the None None O
activation None None O
pattern None None O
per None None O
se None None O
, None None O
examined None None O
in None None O
vitro None None O
by None None O
heating None None O
cytosol None None O
and None None O
performing None None O
phosphocellulose None None O
chromatography None None O
, None None O
appears None None O
similar None None O
to None None O
that None None O
of None None O
human None None O
controls None None O
. None None O

The None None O
ratios None None O
of None None O
nuclear None None O
to None None O
cytosolic None None I-protein
hormone-receptor-complexes None None I-protein
and None None O
of None None O
cytosolic None None O
activated None None O
to None None O
unactivated None None I-protein
receptor None None I-protein
complexes None None I-protein
in None None O
intact None None O
cells None None O
are None None O
similar None None O
to None None O
Old None None O
World None None O
primates None None O
. None None O

Results None None O
from None None O
mixing None None O
studies None None O
do None None O
not None None O
support None None O
the None None O
hypothesis None None O
that None None O
a None None O
binding None None O
inhibitor None None O
( None None O
s None None O
) None None O
or None None O
a None None O
deficient None None O
cytosolic None None O
positive None None O
modifier None None O
( None None O
s None None O
) None None O
of None None O
binding None None O
underlies None None O
the None None O
findings None None O
in None None O
these None None O
primates None None O
. None None O

The None None O
New None None O
World None None O
primates None None O
, None None O
unlike None None O
men None None O
with None None O
the None None O
syndrome None None O
of None None O
primary None None O
cortisol None None O
resistance None None O
, None None O
have None None O
compensated None None O
for None None O
their None None O
condition None None O
with None None O
intra-adrenal None None O
and None None O
mineralocorticoid None None O
receptor None None O
adaptations None None O
. None None O

Thus None None O
, None None O
unlike None None O
Old None None O
World None None O
primates None None O
, None None O
cortisol None None O
in None None O
New None None O
World None None O
primates None None O
has None None O
only None None O
weak None None O
sodium-retaining None None O
potency None None O
because None None O
the None None O
aldosterone None None I-protein
receptor None None I-protein
has None None O
a None None O
low None None O
affinity None None O
for None None O
cortisol None None O
. None None O

The None None O
common None None O
element None None O
that None None O
would None None O
explain None None O
the None None O
apparent None None O
resistance None None O
to None None O
six None None O
steroid None None O
hormones None None O
in None None O
New None None O
World None None O
primates None None O

Acetylation None None O
and None None O
modulation None None O
of None None O
erythroid None None I-protein
Kruppel-like None None I-protein
factor None None I-protein
( None None O
EKLF None None I-protein
) None None O
activity None None O
by None None O
interaction None None O
with None None O
histone None None I-protein
acetyltransferases None None I-protein
. None None O

Erythroid None None I-protein
Kruppel-like None None I-protein
factor None None I-protein
( None None O
EKLF None None I-protein
) None None O
is None None O
a None None O
red None None I-protein
cell-specific None None I-protein
transcriptional None None I-protein
activator None None I-protein
that None None O
is None None O
crucial None None O
for None None O
consolidating None None O
the None None O
switch None None O
to None None O
high None None O
levels None None O
of None None O
adult None None O
beta-globin None None O
expression None None O
during None None O
erythroid None None O
ontogeny None None O
. None None O

EKLF None None I-protein
is None None O
required None None O
for None None O
integrity None None O
of None None O
the None None O
chromatin None None O
structure None None O
at None None O
the None None O
beta-like None None I-DNA
globin None None I-DNA
locus None None I-DNA
, None None O
and None None O
it None None O
interacts None None O
with None None O
a None None O
positive-acting None None I-protein
factor None None I-protein
in None None O
vivo None None O
. None None O

We None None O
find None None O
that None None O
EKLF None None I-protein
is None None O
an None None O
acetylated None None I-protein
transcription None None I-protein
factor None None I-protein
, None None O
and None None O
that None None O
it None None O
interacts None None O
in None None O
vivo None None O
with None None O
CBP None None I-protein
, None None O
p300 None None I-protein
, None None O
and None None O
P/CAF None None I-protein
. None None O

However None None O
, None None O
its None None O
interactions None None O
with None None O
these None None O
histone None None I-protein
acetyltransferases None None I-protein
are None None O
not None None O
equivalent None None O
, None None O
as None None O
CBP None None I-protein
and None None O
p300 None None I-protein
, None None O
but None None O
not None None O
P/CAF None None I-protein
, None None O
utilize None None O
EKLF None None I-protein
as None None O
a None None O
substrate None None O
for None None O
in None None O
vitro None None O
acetylation None None O
within None None O
its None None O
trans-activation None None O
region None None O
. None None O

The None None O
functional None None O
effects None None O
of None None O
these None None O
interactions None None O
are None None O
that None None O
CBP None None I-protein
and None None O
p300 None None I-protein
, None None O
but None None O
not None None O
P/CAF None None I-protein
, None None O
enhance None None O
EKLF None None I-protein
's None None O
transcriptional None None O
activation None None O
of None None O
the None None O
beta-globin None None I-DNA
promoter None None I-DNA
in None None O
erythroid None None I-cell_type
cells None None I-cell_type
. None None O

These None None O
results None None O
establish None None O
EKLF None None I-protein
as None None O
a None None O
tissue-specific None None I-protein
transcription None None I-protein
factor None None I-protein
that None None O
undergoes None None O
post-translational None None O
acetylation None None O
and None None O
suggest None None O
a None None O
mechanism None None O
by None None O
which None None O
EKLF None None I-protein
is None None O
able None None O
to None None O
alter None None O
chromatin None None O
structure None None O
and None None O
induce None None O
beta-globin None None O
expression None None O
within None None O
the None None O
beta-like None None I-DNA
globin None None I-DNA
cluster None None I-DNA
. None None O

Recognition None None O
of None None O
herpes None None I-protein
simplex None None I-protein
virus None None I-protein
type None None I-protein
2 None None I-protein
tegument None None I-protein
proteins None None I-protein
by None None O
CD4 None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
infiltrating None None O
human None None O
genital None None O
herpes None None O
lesions None None O
. None None O

The None None O
local None None O
cellular None None O
immune None None O
response None None O
to None None O
herpes None None O
simplex None None O
virus None None O
( None None O
HSV None None O
) None None O
is None None O
important None None O
in None None O
the None None O
control None None O
of None None O
recurrent None None O
HSV None None O
infection None None O
. None None O

The None None O
antiviral None None O
functions None None O
of None None O
infiltrating None None I-cell_type
CD4-bearing None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
may None None O
include None None O
cytotoxicity None None O
, None None O
inhibition None None O
of None None O
viral None None O
growth None None O
, None None O
lymphokine None None O
secretion None None O
, None None O
and None None O
support None None O
of None None O
humoral None None O
and None None O
CD8 None None O
responses None None O
. None None O

The None None O
antigens None None O
recognized None None O
by None None O
many None None O
HSV-specific None None I-cell_type
CD4 None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
localizing None None O
to None None O
genital None None O
HSV-2 None None O
lesions None None O
are None None O
unknown None None O
. None None O

T None None I-cell_type
cells None None I-cell_type
recognizing None None O
antigens None None O
encoded None None O
within None None O
map None None O
units None None O
0.67 None None O
to None None O
0.73 None None O
of None None O
HSV None None I-DNA
DNA None None I-DNA
are None None O
frequently None None O
recovered None None O
from None None O
herpetic None None O
lesions None None O
. None None O

Expression None None O
cloning None None O
with None None O
this None None O
region None None O
of None None O
DNA None None O
now None None O
shows None None O
that None None O
tegument None None I-protein
protein None None I-protein
VP22 None None B-protein
and None None O
the None None O
viral None None I-protein
dUTPase None None I-protein
, None None O
encoded None None O
by None None O
genes None None I-DNA
UL49 None None I-DNA
and None None I-DNA
UL50 None None I-DNA
, None None O
respectively None None O
, None None O
are None None O
T-cell None None I-protein
antigens None None I-protein
. None None O

Separate None None O
epitopes None None I-protein
in None None O
VP22 None None I-protein
were None None O
defined None None O
for None None O
T-cell None None I-cell_line
clones None None I-cell_line
from None None O
each None None O
of None None O
three None None O
patients None None O
. None None O

Reactivity None None O
with None None O
the None None O
tegument None None I-protein
protein None None I-protein
encoded None None O
by None None O
UL21 None None I-DNA
was None None O
identified None None O
for None None O
an None None O
additional None None O
patient None None O
. None None O

Three None None O
new None None O
epitopes None None O
were None None O
identified None None O
in None None O
VP16 None None I-protein
, None None O
a None None O
tegument None None I-protein
protein None None I-protein
associated None None O
with None None O
VP22 None None I-protein
. None None O

Some None None O
tegument-specific None None I-cell_line
CD4 None None I-cell_line
T-cell None None I-cell_line
clones None None I-cell_line
exhibited None None O
cytotoxic None None O
activity None None O
against None None O
HSV-infected None None I-cell_type
cells None None I-cell_type
. None None O

These None None O
results None None O
suggest None None O
that None None O
herpes None None I-protein
simplex None None I-protein
tegument None None I-protein
proteins None None I-protein
are None None O
processed None None O
for None None O
antigen None None O
presentation None None O
in None None O
vivo None None O
and None None O
are None None O
possible None None O
candidate None None O
compounds None None O
for None None O
herpes None None O
simplex None None O
vaccines None None O
. None None O

Fibrinogen None None I-protein
activates None None O
NF-kappa None None I-protein
B None None I-protein
transcription None None I-protein
factors None None I-protein
in None None O
mononuclear None None I-cell_type
phagocytes None None I-cell_type
. None None O

Adhesion None None O
to None None O
extracellular None None O
matrices None None O
is None None O
known None None O
to None None O
modulate None None O
leukocyte None None O
activation None None O
, None None O
although None None O
the None None O
mechanisms None None O
are None None O
not None None O
fully None None O
understood None None O
. None None O

Mononuclear None None I-cell_type
phagocytes None None I-cell_type
are None None O
exposed None None O
to None None O
fibrinous None None O
provisional None None O
matrix None None O
throughout None None O
migration None None O
into None None O
inflammatory None None O
foci None None O
, None None O
so None None O
this None None O
study None None O
was None None O
undertaken None None O
to None None O
determine None None O
whether None None O
fibrinogen None None O
triggers None None O
activation None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
transcription None None I-protein
factors None None I-protein
. None None O

U937 None None I-cell_line
cells None None I-cell_line
differentiated None None O
with None None O
PMA None None O
in None None O
nonadherent None None I-cell_line
culture None None I-cell_line
were None None O
shown None None O
to None None O
express None None O
two None None O
fibrinogen-binding None None I-protein
integrins None None I-protein
, None None O
predominately None None O
CD11b/CD18 None None I-protein
, None None O
and None None O
to None None O
a None None O
lesser None None O
extent None None O
, None None O
CD11c/CD18 None None I-protein
. None None O

Cells None None O
stimulated None None O
with None None O
fibrinogen None None I-protein
( None None O
10-100 None None O
microg/ml None None O
) None None O
/Mn2+ None None O
( None None O
50 None None O
microM None None O
) None None O
for None None O
2 None None O
h None None O
were None None O
examined None None O
by None None O
electrophoretic None None O
mobility None None O
shift None None O
assay None None O
. None None O

NF-kappa None None I-protein
B None None I-protein
activation None None O
, None None O
minimal None None O
in None None O
unstimulated None None I-cell_type
cells None None I-cell_type
, None None O
was None None O
substantially None None O
up-regulated None None O
by None None O
fibrinogen None None I-protein
. None None O

Fibrinogen None None I-protein
also None None O
caused None None O
activation None None O
of None None O
AP-1 None None I-protein
, None None O
but None None O
not None None O
SP1 None None I-protein
or None None O
cAMP None None I-protein
response None None I-protein
element-binding None None I-protein
protein None None I-protein
( None None I-protein
CREB None None I-protein
) None None I-protein
factors None None I-protein
. None None O

Blocking None None O
mAbs None None I-protein
against None None O
CD18 None None I-protein
and None None O
CD11b None None I-protein
abrogated None None O
fibrinogen None None I-protein
-induced None None O
NF-kappa None None I-protein
B None None I-protein
activation None None O
. None None O

To None None O
determine None None O
the None None O
effects None None O
on None None O
transcriptional None None O
regulation None None O
, None None O
U937 None None I-cell_line
cells None None I-cell_line
were None None O
transfected None None O
with None None O
a None None O
plasmid None None O
containing None None O
the None None O
HIV-1 None None I-DNA
enhancer None None I-DNA
( None None O
bearing None None O
two None None O
NF-kappa None None I-DNA
B None None I-DNA
sites None None I-DNA
) None None O
coupled None None O
to None None O
a None None O
chloramphenicol None None I-DNA
acetyltransferase None None I-DNA
( None None I-DNA
CAT None None I-DNA
) None None I-DNA
reporter None None I-DNA
. None None O

Cells None None O
were None None O
subsequently None None O
stimulated None None O
with None None O
1 None None O
) None None O
PMA None None O
for None None O
24 None None O
h None None O
, None None O
inducing None None O
CAT None None O
activity None None O
by None None O
2.6-fold None None O
, None None O
2 None None O
) None None O
fibrinogen None None I-protein
/Mn2+ None None O
for None None O
2 None None O
h None None O
, None None O
inducing None None O
CAT None None O
activity None None O
by None None O
3.2-fold None None O
, None None O
or None None O
3 None None O
) None None O
costimulation None None O
with None None O
fibrinogen None None I-protein
and None None O
PMA None None O
, None None O
inducing None None O
5.7-fold None None O
the None None O
CAT None None O
activity None None O
induced None None O
by None None O
PMA None None O
alone None None O
. None None O

We None None O
conclude None None O
that None None O
contact None None O
with None None O
fibrinogen-derived None None I-protein
proteins None None I-protein
may None None O
contribute None None O
to None None O
mononuclear None None O
phagocyte None None O
activation None None O
by None None O
signaling None None O
through None None O
CD11b/CD18 None None I-protein
, None None O
resulting None None O
in None None O
selective None None O
activation None None O
of None None O
transcriptional None None I-protein
regulatory None None I-protein
factors None None I-protein
, None None O
including None None O
NF-kappa None None I-protein
B None None I-protein
. None None O

Peripheral None None I-cell_type
blood None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
and None None I-cell_type
monocytes None None I-cell_type
and None None O
B None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
derived None None O
from None None O
patients None None O
with None None O
lupus None None O
express None None O
estrogen None None O
receptor None None O
transcripts None None O
similar None None O
to None None O
those None None O
of None None O
normal None None I-cell_type
cells None None I-cell_type
. None None O

OBJECTIVE None None O
: None None O
To None None O
identify None None O
and None None O
characterize None None O
estrogen None None I-RNA
receptor None None I-RNA
( None None I-RNA
ER None None I-RNA
) None None I-RNA
transcripts None None I-RNA
expressed None None O
in None None O
immune None None I-cell_type
cells None None I-cell_type
of None None O
patients None None O
with None None O
systemic None None O
lupus None None O
erythematosus None None O
( None None O
SLE None None O
) None None O
and None None O
healthy None None O
donors None None O
. None None O

METHODS None None O
: None None O
Peripheral None None I-cell_type
blood None None I-cell_type
monocytes None None I-cell_type
and None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
were None None O
prepared None None O
from None None O
patients None None O
with None None O
SLE None None O
( None None O
n None None O
= None None O
6 None None O
) None None O
and None None O
healthy None None O
donors None None O
( None None O
n None None O
= None None O
8 None None O
) None None O
. None None O

T None None I-cell_type
cells None None I-cell_type
were None None O
separated None None O
into None None O
CD4 None None I-cell_type
and None None O
CD8 None None I-cell_type
. None None O

Some None None O
monocytes None None I-cell_type
and None None O
T None None I-cell_type
cells None None I-cell_type
were None None O
stimulated None None O
with None None O
estradiol None None O
, None None O
PMA None None O
, None None O
and None None O
ionomycin None None O
. None None O

Epstein-Barr None None O
virus-transformed None None O
B None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
( None None O
n None None O
= None None O
7 None None O
) None None O
and None None O
B None None I-cell_line
cell None None I-cell_line
hybridomas None None I-cell_line
( None None O
n None None O
= None None O
2 None None O
) None None O
established None None O
from None None O
patients None None O
with None None O
SLE None None O
and None None O
a None None O
healthy None None O
individual None None O
were None None O
used None None O
as None None O
a None None O
B None None O
cell None None O
source None None O
. None None O

These None None O
cells None None O
were None None O
examined None None O
for None None O
ER None None I-RNA
mRNA None None I-RNA
by None None O
reverse None None O
transcription None None O
nested None None O
polymerase None None O
chain None None O
reaction None None O
. None None O

Amplified None None O
cDNA None None I-DNA
were None None O
sequenced None None O
by None None O
standard None None O
methods None None O
. None None O

RESULTS None None O
: None None O
In None None O
all None None O
cells None None O
tested None None O
, None None O
ER None None I-RNA
mRNA None None I-RNA
was None None O
expressed None None O
without None None O
prior None None O
in None None O
vitro None None O
stimulation None None O
. None None O

Partial None None O
sequences None None O
from None None O
exons None None I-DNA
1-8 None None I-DNA
were None None O
nearly None None O
identical None None O
to None None O
the None None O
published None None O
sequence None None O
of None None O
the None None O
human None None I-RNA
ER None None I-RNA
mRNA None None I-RNA
. None None O

There None None O
were None None O
no None None O
notable None None O
differences None None O
in None None O
the None None O
ER None None I-RNA
transcripts None None I-RNA
between None None O
patients None None O
and None None O
healthy None None O
controls None None O
. None None O

Variant None None O
receptor None None O
transcripts None None O
lacking None None O
exon None None I-DNA
5 None None I-DNA
or None None O
exon None None I-DNA
7 None None I-DNA
, None None O
which None None O
encodes None None O
the None None O
hormone None None I-protein
binding None None I-protein
domain None None I-protein
, None None O
were None None O
identified None None O
in None None O
the None None O
majority None None O
of None None O
the None None O
cells None None O
. None None O

Precise None None O
deletion None None O
of None None O
the None None O
exons None None O
suggests None None O
that None None O
they None None O
are None None O
alternatively None None O
spliced None None O
transcripts None None O
. None None O

Whether None None O
the None None O
detected None None O
transcripts None None O
are None None O
translated None None O
into None None O
functional None None I-protein
receptor None None I-protein
proteins None None I-protein
remains None None O
to None None O
be None None O
determined None None O
. None None O

In None None O
vitro None None O
stimulation None None O
did None None O
not None None O
affect None None O
ER None None I-RNA
mRNA None None I-RNA
expression None None O
. None None O

The None None O
presence None None O
of None None O
variants None None O
did None None O
not None None O
correlate None None O
with None None O
disease None None O
activity None None O
or None None O
medication None None O
. None None O

CONCLUSION None None O
: None None O
Monocytes None None I-cell_type
, None None O
T None None I-cell_type
cells None None I-cell_type
, None None O
and None None O
B None None I-cell_type
cells None None I-cell_type
in None None O
patients None None O
express None None O
transcripts None None O
of None None O
the None None O
normal None None O
wild None None I-protein
type None None I-protein
ER None None I-protein
and None None O
the None None O
hormone None None I-protein
binding None None I-protein
domain None None I-protein
variants None None I-protein
in None None O
vivo None None O
. None None O

DNA None None O
damaging None None O
agents None None O
induce None None O
expression None None O
of None None O
Fas None None I-protein
ligand None None I-protein
and None None O
subsequent None None O
apoptosis None None O
in None None O
T None None I-cell_type
lymphocytes None None I-cell_type
via None None O
the None None O
activation None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
and None None O
AP-1 None None I-protein
. None None O

Apoptosis None None O
induced None None O
by None None O
DNA None None O
damage None None O
and None None O
other None None O
stresses None None O
can None None O
proceed None None O
via None None O
expression None None O
of None None O
Fas None None I-protein
ligand None None I-protein
( None None O
FasL None None I-protein
) None None O
and None None O
ligation None None O
of None None O
its None None O
receptor None None O
, None None O
Fas None None O
( None None O
CD95 None None O
) None None O
. None None O

We None None O
report None None O
that None None O
activation None None O
of None None O
the None None O
two None None O
transcription None None I-protein
factors None None I-protein
NF-kappa None None I-protein
B None None I-protein
and None None I-protein
AP-1 None None I-protein
is None None O
crucially None None O
involved None None O
in None None O
FasL None None I-protein
expression None None O
induced None None O
by None None O
etoposide None None O
, None None O
teniposide None None O
, None None O
and None None O
UV None None O
irradiation None None O
. None None O

A None None O
nondegradable None None I-protein
mutant None None I-protein
of None None O
I None None I-protein
kappa None None I-protein
B None None I-protein
blocked None None O
both None None O
FasL None None I-protein
expression None None O
and None None O
apoptosis None None O
induced None None O
by None None O
DNA None None O
damage None None O
but None None O
not None None O
Fas None None O
ligation None None O
. None None O

These None None O
stimuli None None O
also None None O
induced None None O
the None None O
stress-activated None None O
kinase None None O
pathway None None O
( None None O
SAPK/JNK None None O
) None None O
, None None O
which None None O
was None None O
required None None O
for None None O
the None None O
maximal None None O
induction None None O
of None None O
apoptosis None None O
. None None O

A None None O
1.2 None None O
kb None None O
FasL None None I-DNA
promoter None None I-DNA
responded None None O
to None None O
DNA None None O
damage None None O
, None None O
as None None O
well None None O
as None None O
coexpression None None O
with None None O
p65 None None I-protein
Rel None None I-protein
or None None O
Fos/Jun None None I-protein
. None None O

Mutations None None O
in None None O
the None None O
relevant None None O
NF-kappa None None I-DNA
B None None I-DNA
and None None I-DNA
AP-1 None None I-DNA
binding None None I-DNA
sites None None I-DNA
eliminated None None O
these None None O
responses None None O
. None None O

Thus None None O
, None None O
activation None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
and None None O
AP-1 None None I-protein
contributes None None O
to None None O
stress-induced None None O
apoptosis None None O
via None None O
the None None O
expression None None O
of None None O
FasL None None I-protein
. None None O

A None None O
small None None O
, None None O
nonpeptidyl None None O
mimic None None O
of None None O
granulocyte-colony-stimulating None None I-protein
factor None None I-protein
[ None None O
see None None O
commetns None None O
] None None O

A None None O
nonpeptidyl None None O
small None None O
molecule None None O
SB None None O
247464 None None O
, None None O
capable None None O
of None None O
activating None None O
granulocyte-colony-stimulating None None I-protein
factor None None I-protein
( None None O
G-CSF None None I-protein
) None None O
signal None None O
transduction None None O
pathways None None O
, None None O
was None None O
identified None None O
in None None O
a None None O
high-throughput None None O
assay None None O
in None None O
cultured None None I-cell_type
cells None None I-cell_type
. None None O

Like None None O
G-CSF None None I-protein
, None None O
SB None None O
247464 None None O
induced None None O
tyrosine None None O
phosphorylation None None O
of None None O
multiple None None I-protein
signaling None None I-protein
proteins None None I-protein
and None None O
stimulated None None O
primary None None I-cell_type
murine None None I-cell_type
bone None None I-cell_type
marrow None None I-cell_type
cells None None I-cell_type
to None None O
form None None O
granulocytic None None I-cell_type
colonies None None I-cell_type
in None None O
vitro None None O
. None None O

It None None O
also None None O
elevated None None O
peripheral None None I-cell_type
blood None None I-cell_type
neutrophil None None I-cell_type
counts None None O
in None None O
mice None None O
. None None O

The None None O
extracellular None None O
domain None None O
of None None O
the None None O
murine None None I-protein
G-CSF None None I-protein
receptor None None I-protein
was None None O
required None None O
for None None O
the None None O
activity None None O
of None None O
SB None None O
247464 None None O
, None None O
suggesting None None O
that None None O
the None None O
compound None None O
acts None None O
by None None O
oligomerizing None None I-protein
receptor None None I-protein
chains None None I-protein
. None None O

The None None O
results None None O
indicate None None O
that None None O
a None None O
small None None O
molecule None None O
can None None O
activate None None O
a None None O
receptor None None O
that None None O
normally None None O
binds None None O
a None None O
relatively None None O
large None None O
protein None None O
ligand None None O
. None None O

Minimal None None O
residual None None O
disease None None O
in None None O
acute None None O
myelogenous None None O
leukemia None None O
with None None O
PML/RAR None None I-protein
alpha None None I-protein
or None None O
AML1/ETO None None I-RNA
mRNA None None I-RNA
and None None O
phenotypic None None O
analysis None None O
of None None O
possible None None O
T None None I-cell_type
and None None I-cell_type
natural None None I-cell_type
killer None None I-cell_type
cells None None I-cell_type
in None None O
bone None None O
marrow None None O
. None None O

Here None None O
we None None O
studied None None O
minimal None None O
residual None None O
disease None None O
( None None O
MRD None None O
) None None O
of None None O
patients None None O
with None None O
acute None None O
myeloid None None O
leukemia None None O
( None None O
AML None None O
) None None O
who None None O
have None None O
PML/RAR None None I-protein
alpha None None I-protein
or None None O
AML1/ETO None None I-protein
as None None O
well None None O
as None None O
the None None O
phenotypic None None O
analysis None None O
of None None O
lymphocyte None None I-cell_type
subsets None None I-cell_type
involved None None O
in None None O
antitumor None None O
immunity None None O
. None None O

Eight None None O
patients None None O
in None None O
long-term None None O
( None None O
LT None None O
; None None O
3 None None O
to None None O
15 None None O
years None None O
) None None O
and None None O
15 None None O
patients None None O
in None None O
short-term None None O
( None None O
ST None None O
; None None O
up None None O
to None None O
3 None None O
years None None O
) None None O
remission None None O
were None None O
studied None None O
. None None O

Using None None O
the None None O
reverse None None O
transcription-polymerase None None O
chain None None O
reaction None None O
( None None O
RT None None O
) None None O
assay None None O
, None None O
the None None O
limit None None O
of None None O
detection None None O
was None None O
10 None None O
( None None O
-5 None None O
) None None O
to None None O
10 None None O
( None None O
-6 None None O
) None None O
for None None O
PML/RAR None None I-RNA
alpha None None I-RNA
transcript None None I-RNA
and None None O
10 None None O
( None None O
-4 None None O
) None None O
to None None O
10 None None O
( None None O
-5 None None O
) None None O
for None None O
the None None O
AML1/ETO None None I-RNA
transcript None None I-RNA
. None None O

Simultaneously None None O
, None None O
T None None I-cell_type
lymphocyte None None I-cell_type
subsets None None I-cell_type
and None None O
NK None None I-cell_type
cells None None I-cell_type
from None None O
the None None O
peripheral None None O
blood None None O
( None None O
PB None None O
) None None O
and None None O
bone None None O
marrow None None O
( None None O
BM None None O
) None None O
were None None O
investigated None None O
by None None O
flow None None O
cytometric None None O
analysis None None O
. None None O

Four None None O
of None None O
the None None O
eight None None O
patients None None O
in None None O
LT None None O
and None None O
7 None None O
of None None O
the None None O
15 None None O
patients None None O
in None None O
ST None None O
remission None None O
were None None O
MRD-positive None None O
. None None O

Although None None O
all None None O
MRD-positive None None O
patients None None O
in None None O
LT None None O
remission None None O
are None None O
still None None O
until None None O
now None None O
event-free None None O
, None None O
3 None None O
of None None O
the None None O
7 None None O
MRD-positive None None O
( None None O
MRD+ None None O
) None None O
patients None None O
in None None O
ST None None O
remission None None O
soon None None O
relapsed None None O
. None None O

The None None O
total None None O
populations None None O
of None None O
CD4 None None I-protein
+ None None O
, None None O
CD8 None None I-protein
+ None None O
and None None O
CD56 None None I-protein
+ None None O
[ None None O
possible None None O
T-cell None None I-cell_type
and None None I-cell_type
natural None None I-cell_type
killer None None I-cell_type
( None None I-cell_type
T/NK None None I-cell_type
) None None I-cell_type
populations None None I-cell_type
] None None O
in None None O
the None None O
BM None None O
of None None O
ST None None O
patients None None O
and None None O
MRD+/LT None None O
patients None None O
were None None O
significantly None None O
( None None O
p None None O
< None None O
.01 None None O
) None None O
low None None O
. None None O

The None None O
CD8+ None None I-cell_type
CD28+ None None I-cell_type
population None None I-cell_type
showed None None O
the None None O
same None None O
tendency None None O
( None None O
p None None O
< None None O
.01-.02 None None O
) None None O
. None None O

The None None O
T/NK None None I-cell_type
subsets None None I-cell_type
in None None O
the None None O
BM None None O
of None None O
MRD-negative None None O
( None None O
MRD- None None O
) None None O
LT None None O
( None None O
MRD-/LT None None O
) None None O
patients None None O
showed None None O
similar None None O
numbers None None O
of None None O
cells None None O
as None None O
normal None None O
volunteers None None O
. None None O

Basically None None O
, None None O
the None None O
total None None O
percentage None None O
of None None O
the None None O
CD4+ None None I-cell_type
, None None I-cell_type
CD8+ None None I-cell_type
and None None I-cell_type
CD56+ None None I-cell_type
cell None None I-cell_type
populations None None I-cell_type
in None None O
the None None O
BM None None O
was None None O
increased None None O
and None None O
in None None O
the None None O
following None None O
order None None O
: None None O
MRD-/LT None None O
patients None None O
, None None O
normal None None O
volunteers None None O
, None None O
MRD+/LT None None O
patients None None O
and None None O
MRD+ None None O
or None None O
-/ST None None O
patients None None O
. None None O

The None None O
percentages None None O
of None None O
the None None O
T/NK-cell None None I-cell_type
subsets None None I-cell_type
in None None O
the None None O
PB None None O
were None None O
not None None O
significantly None None O
different None None O
among None None O
these None None O
groups None None O
. None None O

Thus None None O
, None None O
the None None O
difference None None O
of None None O
the None None O
possible None None O
T/NK-cell None None I-cell_type
phenotype None None O
in None None O
the None None O
BM None None O
may None None O
strongly None None O
influence None None O
clinical None None O
and None None O
molecular None None O
remission None None O
. None None O

These None None O
results None None O
still None None O
remain None None O
to None None O
be None None O
confirmed None None O
by None None O
further None None O
studies None None O
of None None O
the None None O
functional None None O
anti-tumor None None O
immunity None None O
of None None O
T/NK None None I-cell_type
cells None None I-cell_type
of None None O
AML None None I-cell_type
in None None O
remission None None O
. None None O

Mycobacterium None None O
tuberculosis None None O
mannose-capped None None O
lipoarabinomannan None None O
can None None O
induce None None O
NF-kappaB None None I-protein
-dependent None None O
activation None None O
of None None O
human None None I-DNA
immunodeficiency None None I-DNA
virus None None I-DNA
type None None I-DNA
1 None None I-DNA
long None None I-DNA
terminal None None I-DNA
repeat None None I-DNA
in None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

Tuberculosis None None O
has None None O
emerged None None O
as None None O
an None None O
epidemic None None O
, None None O
extended None None O
by None None O
the None None O
large None None O
number None None O
of None None O
individuals None None O
infected None None O
with None None O
human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
( None None O
HIV-1 None None O
) None None O
. None None O

The None None O
major None None O
goal None None O
of None None O
this None None O
study None None O
was None None O
to None None O
determine None None O
whether None None O
the None None O
mycobacterial None None O
cell None None O
wall None None O
component None None O
mannose-capped None None O
lipoarabinomannan None None O
( None None O
ManLAM None None O
) None None O
of None None O
Mycobacterium None None O
tuberculosis None None O
( None None O
M. None None O
tuberculosis None None O
) None None O
could None None O
activate None None O
transcription None None O
of None None O
HIV-1 None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
with None None O
the None None O
use None None O
of None None O
an None None O
in None None O
vitro None None O
cell None None O
culture None None O
system None None O
. None None O

These None None O
experiments None None O
are None None O
of None None O
prime None None O
importance None None O
considering None None O
that None None O
CD4 None None I-protein
-expressing None None O
T None None I-cell_type
lymphocytes None None I-cell_type
represent None None O
the None None O
major None None O
virus None None O
reservoir None None O
in None None O
the None None O
peripheral None None O
blood None None O
of None None O
infected None None O
individuals None None O
. None None O

Using None None O
the None None O
1G5 None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
harbouring None None O
the None None O
luciferase None None O
reporter None None O
gene None None O
under None None O
the None None O
control None None O
of None None O
the None None O
HIV-1 None None I-DNA
LTR None None I-DNA
, None None O
it None None O
was None None O
first None None O
found None None O
that None None O
culture None None O
protein None None O
filtrates None None O
( None None O
CFP None None O
) None None O
from None None O
M. None None O
tuberculosis None None O
or None None O
purified None None O
ManLAM None None O
could None None O
activate None None O
HIV-1 None None I-DNA
LTR-dependent None None I-DNA
gene None None I-DNA
expression None None O
unlike None None O
similarly None None O
prepared None None O
CFP None None O
extracts None None O
devoid None None O
of None None O
ManLAM None None O
. None None O

The None None O
implication None None O
of None None O
protein None None I-protein
tyrosine None None I-protein
kinase None None I-protein
( None None I-protein
s None None I-protein
) None None I-protein
, None None O
protein None None I-protein
kinase None None I-protein
A None None I-protein
and/or None None O
protein None None I-protein
kinase None None I-protein
C None None I-protein
was None None O
highlighted None None O
by None None O
the None None O
abrogation None None O
of None None O
the None None O
ManLAM-mediated None None O
activation None None O
of None None O
HIV-1 None None O
LTR-driven None None O
gene None None O
expression None None O
using None None O
herbimycin None None O
A None None O
and None None O
H7 None None O
. None None O

It None None O
was None None O
also None None O
determined None None O
, None None O
using None None O
electrophoresis None None O
mobility None None O
shift None None O
assays None None O
, None None O
that None None O
M. None None O
tuberculosis None None O
ManLAM None None O
led None None O
to None None O
the None None O
nuclear None None O
translocation None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
NF-kappaB None None I-protein
. None None O

M. None None O
tuberculosis None None O
ManLAM None None O
resulted None None O
in None None O
clear None None O
induction None None O
of None None O
the None None O
luciferase None None I-DNA
gene None None I-DNA
placed None None O
under None None O
the None None O
control None None O
of None None O
the None None O
wild-type None None I-DNA
, None None I-DNA
but None None I-DNA
not None None I-DNA
the None None I-DNA
kappaB-mutated None None I-DNA
, None None I-DNA
HIV-1 None None I-DNA
LTR None None I-DNA
region None None I-DNA
. None None O

Finally None None O
, None None O
the None None O
ManLAM-mediated None None O
activation None None O
of None None O
HIV-1 None None O
LTR None None O
transcription None None O
was None None O
found None None O
to None None O
be None None O
independent None None O
of None None O
the None None O
autocrine None None O
or None None O
paracrine None None O
action None None O
of None None O
endogenous None None I-protein
TNF-alpha None None I-protein
. None None O

The None None O
results None None O
suggest None None O
that None None O
M. None None O
tuberculosis None None O
can None None O
upregulate None None O
HIV-1 None None O
expression None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
and None None O
could None None O
thus None None O
have None None O
the None None O
potential None None O
to None None O
influence None None O
the None None O
pathogenesis None None O
of None None O
HIV-1 None None O
infection None None O
. None None O

Human None None I-DNA
immunodeficiency None None I-DNA
virus None None I-DNA
type None None I-DNA
1 None None I-DNA
long None None I-DNA
terminal None None I-DNA
repeat None None I-DNA
quasispecies None None O
differ None None O
in None None O
basal None None O
transcription None None O
and None None O
nuclear None None O
factor None None O
recruitment None None O
in None None O
human None None I-cell_type
glial None None I-cell_type
cells None None I-cell_type
and None None I-cell_type
lymphocytes None None I-cell_type
. None None O

The None None O
generation None None O
of None None O
genomic None None O
diversity None None O
during None None O
the None None O
course None None O
of None None O
infection None None O
has None None O
the None None O
potential None None O
to None None O
affect None None O
all None None O
aspects None None O
of None None O
HIV-1 None None O
replication None None O
, None None O
including None None O
expression None None O
of None None O
the None None O
proviral None None O
genome None None O
. None None O

To None None O
gain None None O
a None None O
better None None O
understanding None None O
of None None O
the None None O
impact None None O
of None None O
long None None I-DNA
terminal None None I-DNA
repeat None None I-DNA
( None None O
LTR None None I-DNA
) None None O
sequence None None O
diversity None None O
on None None O
LTR-directed None None I-DNA
gene None None I-DNA
expression None None O
in None None O
cells None None O
of None None O
the None None O
central None None O
nervous None None O
system None None O
( None None O
CNS None None O
) None None O
and None None O
immune None None O
system None None O
, None None O
we None None O
amplified None None O
and None None O
cloned None None O
LTRs None None I-DNA
from None None O
proviral None None O
DNA None None O
in None None O
HIV-1-infected None None O
peripheral None None O
blood None None O
. None None O

Sequence None None O
analysis None None O
of None None O
nineteen None None O
LTRs None None I-DNA
cloned None None O
from None None O
2 None None O
adult None None O
and None None O
3 None None O
pediatric None None O
patients None None O
revealed None None O
an None None O
average None None O
of None None O
33 None None O
nucleotide None None O
changes None None O
( None None O
with None None O
respect None None O
to None None O
the None None O
sequence None None O
of None None O
the None None O
LAI None None I-DNA
LTR None None I-DNA
) None None O
within None None O
the None None O
455-bp None None I-DNA
U3 None None I-DNA
region None None I-DNA
. None None O

Transient None None O
expression None None O
analyses None None O
in None None O
cells None None O
of None None O
neuroglial None None O
and None None O
lymphocytic None None O
origin None None O
demonstrated None None O
that None None O
some None None O
of None None O
these None None O
LTRs None None I-DNA
had None None O
activities None None O
which None None O
varied None None O
significantly None None O
from None None O
the None None O
LAI None None I-DNA
LTR None None I-DNA
in None None O
U-373 None None I-cell_line
MG None None I-cell_line
cells None None I-cell_line
( None None O
an None None O
astrocytoma None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
) None None O
as None None O
well None None O
as None None O
in None None O
Jurkat None None I-cell_line
cells None None I-cell_line
( None None O
a None None O
CD4-positive None None I-cell_line
lymphocyte None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
) None None O
. None None O

While None None O
LTRs None None I-DNA
which None None O
demonstrated None None O
the None None O
highest None None O
activities None None O
in None None O
U-373 None None I-cell_line
MG None None I-cell_line
cells None None I-cell_line
also None None O
yielded None None O
high None None O
activities None None O
in None None O
Jurkat None None I-cell_line
cells None None I-cell_line
, None None O
the None None O
LTRs None None I-DNA
were None None O
generally None None O
more None None O
active None None O
in None None O
Jurkat None None I-cell_line
cells None None I-cell_line
when None None O
compared None None O
to None None O
the None None O
LAI None None I-DNA
LTR None None I-DNA
. None None O

Differences None None O
in None None O
LTR None None I-DNA
sequence None None I-DNA
also None None O
resulted None None O
in None None O
differences None None O
in None None O
transcription None None O
factor None None O
recruitment None None O
to None None O
cis-acting None None I-DNA
sites None None I-DNA
within None None O
the None None O
U3 None None I-DNA
region None None I-DNA
of None None O
the None None O
LTR None None I-DNA
, None None O
as None None O
demonstrated None None O
by None None O
electrophoretic None None O
mobility None None O
shift None None O
assays None None O
. None None O

In None None O
particular None None O
, None None O
naturally None None O
occurring None None O
sequence None None O
variation None None O
impacted None None O
transcription None None I-protein
factor None None I-protein
binding None None O
to None None O
an None None O
activating None None I-protein
transcription None None I-protein
factor None None I-protein
/ None None O
cAMP None None I-protein
response None None I-protein
element None None I-protein
binding None None I-protein
( None None O
ATF None None I-protein
/ None None O
CREB None None I-protein
) None None O
binding None None O
site None None O
( None None O
located None None O
between None None O
the None None O
LEF-1 None None I-DNA
and None None I-DNA
distal None None I-DNA
NF-kappaB None None I-DNA
transcription None None I-DNA
factor None None I-DNA
binding None None I-DNA
sites None None I-DNA
) None None O
that None None O
we None None O
identified None None O
in None None O
previous None None O
studies None None O
of None None O
the None None O
HIV-1 None None I-DNA
LTR None None I-DNA
. None None O

These None None O
findings None None O
suggest None None O
that None None O
LTR None None I-DNA
sequence None None I-DNA
changes None None O
can None None O
significantly None None O
affect None None O
basal None None O
LTR None None O
function None None O
and None None O
transcription None None O
factor None None O
recruitment None None O
, None None O
which None None O
may None None O
, None None O
in None None O
turn None None O
, None None O
alter None None O
the None None O
course None None O
of None None O
viral None None O
replication None None O
in None None O
cells None None O
of None None O
CNS None None O
and None None O
immune None None O
system None None O
origin None None O
. None None O

HMG None None I-protein
box None None I-protein
containing None None I-protein
transcription None None I-protein
factors None None I-protein
in None None O
lymphocyte None None I-cell_type
differentiation None None O
. None None O

The None None O
identification None None O
of None None O
the None None O
mammalian None None I-DNA
sex-determining None None I-DNA
gene None None I-DNA
Sry None None I-DNA
has None None O
led None None O
to None None O
the None None O
discovery None None O
of None None O
a None None O
large None None O
family None None O
of None None O
related None None O
( None None O
' None None O
HMG None None I-protein
box None None I-protein
' None None O
) None None O
transcription None None I-protein
factors None None I-protein
that None None O
control None None O
developmental None None O
events None None O
in None None O
yeast None None O
, None None O
C. None None O
elegans None None O
, None None O
Drosophila None None O
and None None O
vertebrates None None O
. None None O

In None None O
lymphocyte None None I-cell_type
differentiation None None O
, None None O
several None None O
HMG None None I-protein
box None None I-protein
proteins None None I-protein
play None None O
a None None O
decisive None None O
role None None O
. None None O

Sox-4 None None I-protein
is None None O
important None None O
for None None O
very None None O
early None None O
B-cell None None O
differentiation None None O
, None None O
while None None O
TCF-1 None None I-protein
/ None None O
LEF-1 None None I-protein
play None None O
a None None O
crucial None None O
role None None O
in None None O
early None None O
thymocyte None None O
development None None O
. None None O

TCF/LEF None None I-protein
proteins None None I-protein
have None None O
recently None None O
been None None O
found None None O
to None None O
constitute None None O
a None None O
downstream None None O
component None None O
of None None O
the None None O
Wingless/Wnt None None O
signal None None O
transduction None None O
pathway None None O
. None None O

In None None O
flies None None O
, None None O
this None None O
pathway None None O
controls None None O
segment None None O
polarity None None O
; None None O
in None None O
Xenopus None None O
it None None O
controls None None O
the None None O
definition None None O
of None None O
the None None O
body None None O
axis None None O
. None None O

Deregulation None None O
of None None O
the None None O
pathway None None O
occurs None None O
in None None O
several None None O
human None None I-cell_type
tumors None None I-cell_type
. None None O

These None None O
insights None None O
in None None O
the None None O
molecular None None O
events None None O
that None None O
are None None O
involved None None O
in None None O
TCF/LEF None None I-protein
function None None O
in None None O
these None None O
organisms None None O
may None None O
eventually None None O
lead None None O
to None None O
the None None O
understanding None None O
of None None O
the None None O
function None None O
of None None O
these None None O
HMG None None I-protein
box None None I-protein
proteins None None I-protein
in None None O
lymphoid None None O
development None None O

Transcriptional None None O
regulation None None O
by None None O
C/EBP None None I-protein
alpha None None I-protein
and None None I-protein
-beta None None I-protein
in None None O
the None None O
expression None None O
of None None O
the None None O
gene None None O
for None None O
the None None O
MRP14 None None I-protein
myeloid None None I-protein
calcium None None I-protein
binding None None I-protein
protein None None I-protein
. None None O

Transcriptional None None O
regulation None None O
of None None O
the None None O
gene None None O
for None None O
the None None O
myeloid None None I-protein
calcium None None I-protein
binding None None I-protein
protein None None I-protein
, None None O
MRP14 None None I-protein
, None None O
was None None O
investigated None None O
in None None O
human None None I-cell_line
monocytic None None I-cell_line
leukemia None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
. None None O

The None None O
MRP14 None None I-DNA
gene None None I-DNA
was None None O
not None None O
expressed None None O
in None None O
monoblastic None None I-cell_line
ML-1 None None I-cell_line
cells None None I-cell_line
, None None O
promonocytic None None I-cell_line
U-937 None None I-cell_line
cells None None I-cell_line
, None None O
or None None O
promyelocytic None None I-cell_line
HL-60 None None I-cell_line
cells None None I-cell_line
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
the None None O
gene None None O
was None None O
expressed None None O
in None None O
monocytic None None I-cell_line
THP-1 None None I-cell_line
cells None None I-cell_line
and None None O
in None None O
the None None O
HL-60 None None I-cell_line
cells None None I-cell_line
treated None None O
with None None O
1 None None O
, None None O
25-dihydroxyvitamin None None O
D3 None None O
( None None O
VD3 None None O
) None None O
. None None O

The None None O
level None None O
of None None O
MRP14 None None I-protein
in None None O
VD3-treated None None O
HL-60 None None I-cell_line
cells None None I-cell_line
was None None O
two-fold None None O
higher None None O
than None None O
that None None O
in None None O
THP-1 None None I-cell_line
cells None None I-cell_line
. None None O

Among None None O
several None None O
known None None O
transcription None None I-DNA
factor None None I-DNA
binding None None I-DNA
motifs None None I-DNA
, None None O
nuclear None None I-protein
protein None None I-protein
( None None I-protein
s None None I-protein
) None None I-protein
of None None O
VD3-treated None None I-cell_line
HL-60 None None I-cell_line
cells None None I-cell_line
and None None I-cell_line
THP-1 None None I-cell_line
cells None None I-cell_line
bound None None O
to None None O
the None None O
CCAAT/enhancer None None I-DNA
binding None None I-DNA
protein None None I-DNA
( None None I-DNA
C/EBP None None I-DNA
) None None I-DNA
-binding None None I-DNA
motif None None I-DNA
that None None O
was None None O
located None None O
in None None O
the None None O
upstream None None I-DNA
region None None I-DNA
of None None O
the None None O
MRP14 None None I-DNA
gene None None I-DNA
( None None O
-81 None None O
) None None O
, None None O
as None None O
evidenced None None O
by None None O
the None None O
competitive None None O
gel None None O
mobility-shift None None O
assay None None O
. None None O

An None None O
antibody None None O
for None None O
C/EBP None None I-protein
alpha None None I-protein
super-shifted None None O
the None None O
nucleoprotein None None I-protein
complex None None I-protein
in None None O
THP-1 None None I-cell_line
cells None None I-cell_line
but None None O
not None None O
in None None O
the None None O
VD3-treated None None I-cell_line
HL-60 None None I-cell_line
cells None None I-cell_line
, None None O
whereas None None O
an None None O
antibody None None O
for None None O
C/EBP None None I-protein
beta None None I-protein
blocked None None O
the None None O
formation None None O
of None None O
the None None O
complex None None O
with None None O
the None None O
nuclear None None I-protein
factor None None I-protein
of None None O
the None None O
HL-60 None None I-cell_line
cells None None I-cell_line
but None None O
not None None O
with None None O
that None None O
of None None O
THP-1 None None I-cell_line
cells None None I-cell_line
. None None O

An None None O
anti-C/EBP None None I-protein
delta None None I-protein
antibody None None I-protein
had None None O
no None None O
effect None None O
on None None O
the None None O
complex None None O
in None None O
either None None O
cell None None O
. None None O

Thus None None O
, None None O
it None None O
was None None O
concluded None None O
that None None O
C/EBP None None I-protein
alpha None None I-protein
and None None I-protein
-beta None None I-protein
were None None O
able None None O
to None None O
bind None None O
to None None O
the None None O
C/EBP None None I-protein
motif None None I-protein
, None None O
and None None O
that None None O
C/EBP None None I-protein
alpha None None I-protein
bound None None O
to None None O
the None None O
motif None None O
in None None O
THP-1 None None I-cell_line
cells None None I-cell_line
and None None O
C/EBP None None I-protein
beta None None I-protein
bound None None O
to None None O
that None None O
in None None O
the None None O
VD3-treated None None I-cell_line
HL-60 None None I-cell_line
cells None None I-cell_line
. None None O

Furthermore None None O
, None None O
to None None O
examine None None O
the None None O
transcriptional None None O
activity None None O
of None None O
the None None O
C/EBP None None I-protein
motif None None I-protein
, None None O
we None None O
transfected None None O
several None None O
constructed None None O
luciferase None None I-DNA
reporter None None I-DNA
DNAs None None I-DNA
into None None O
HL-60 None None I-cell_line
cells None None I-cell_line
and None None O
THP-1 None None I-cell_line
cells None None I-cell_line
. None None O

The None None O
luciferase None None O
activity None None O
of None None O
the None None O
C/EBP None None I-protein
motif None None I-protein
in None None O
HL-60 None None I-cell_line
cells None None I-cell_line
was None None O
increased None None O
by None None O
VD3 None None O
treatment None None O
. None None O

The None None O
C/EBP None None I-protein
motif None None I-protein
in None None O
the None None O
MRP14 None None I-DNA
gene None None I-DNA
was None None O
confirmed None None O
to None None O
function None None O
as None None O
a None None O
regulatory None None O
region None None O
in None None O
VD3-treated None None I-cell_line
HL-60 None None I-cell_line
cells None None I-cell_line
and None None I-cell_line
THP-1 None None I-cell_line
cells None None I-cell_line
by None None O
the None None O
assay None None O
. None None O

Since None None O
C/EBP None None I-protein
beta None None I-protein
was None None O
also None None O
detected None None O
in None None O
VD3-untreated None None I-cell_line
HL-60 None None I-cell_line
cells None None I-cell_line
by None None O
immunoblotting None None O
, None None O
VD3 None None O
activated None None O
C/EBP None None I-protein
beta None None I-protein
to None None O
bind None None O
to None None O
the None None O
motif None None O
, None None O
probably None None O
through None None O
post-translational None None O
modification None None O
. None None O

Patients None None O
with None None O
high-risk None None O
myelodysplastic None None O
syndrome None None O
can None None O
have None None O
polyclonal None None O
or None None O
clonal None None O
haemopoiesis None None O
in None None O
complete None None O
haematological None None O
remission None None O
. None None O

The None None O
clonality None None O
of None None O
mature None None I-cell_type
peripheral None None I-cell_type
blood-derived None None I-cell_type
myeloid None None I-cell_type
and None None I-cell_type
lymphoid None None I-cell_type
cells None None I-cell_type
and None None O
bone None None I-cell_type
marrow None None I-cell_type
haemopoietic None None I-cell_type
progenitors None None I-cell_type
from None None O
18 None None O
females None None O
with None None O
myelodysplasia None None O
( None None O
MDS None None O
) None None O
( None None O
five None None O
refractory None None O
anaemia None None O
, None None O
RA None None O
; None None O
one None None O
RA None None O
with None None O
ringed None None I-cell_type
sideroblasts None None I-cell_type
, None None O
RARS None None O
; None None O
three None None O
chronic None None O
myelomonocytic None None O
leukaemia None None O
, None None O
CMML None None O
; None None O
four None None O
RA None None O
with None None O
excess None None O
of None None O
blasts None None O
, None None O
RAEB None None O
; None None O
five None None O
RAEB None None O
in None None O
transformation None None O
, None None O
RAEB-t None None O
) None None O
was None None O
studied None None O
by None None O
X-chromosome None None I-DNA
inactivation None None O
analysis None None O
. None None O

Using None None O
the None None O
human None None O
androgen-receptor None None O
( None None O
HUMARA None None O
) None None O
assay None None O
, None None O
we None None O
analysed None None O
the None None O
clonal None None O
patterns None None O
of None None O
highly None None I-cell_type
purified None None I-cell_type
immature None None I-cell_type
CD34+ None None I-cell_type
38- None None I-cell_type
and None None I-cell_type
committed None None I-cell_type
CD34+ None None I-cell_type
38+ None None I-cell_type
marrow-derived None None I-cell_type
progenitors None None I-cell_type
, None None O
and None None O
CD16+ None None I-cell_type
14- None None I-cell_type
granulocytes None None I-cell_type
, None None O
CD14+ None None I-cell_type
monocytes None None I-cell_type
, None None O
CD3+ None None I-cell_type
T None None I-cell_type
and None None I-cell_type
CD19+ None None I-cell_type
B None None I-cell_type
lymphocytes None None I-cell_type
from None None O
peripheral None None O
blood None None O
. None None O

In None None O
high-risk None None O
patients None None O
( None None O
RAEB None None O
, None None O
RAEB-t None None O
) None None O
, None None O
clonality None None O
analysis None None O
was None None O
performed None None O
before None None O
and None None O
after None None O
intensive None None O
remission-induction None None O
treatment None None O
. None None O

All None None O
patients None None O
, None None O
except None None O
one None None O
with None None O
RA None None O
, None None O
had None None O
predominance None None O
of None None O
a None None O
single None None O
clone None None O
in None None O
their None None O
granulocytes None None I-cell_type
and None None O
monocytes None None I-cell_type
. None None O

The None None O
same None None O
clonal None None O
pattern None None O
was None None O
found None None O
in None None O
CD34+ None None I-cell_type
progenitor None None I-cell_type
cells None None I-cell_type
. None None O

In None None O
contrast None None O
, None None O
CD3+ None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
were None None O
polyclonal None None O
or None None O
oligoclonal None None O
in None None O
14/18 None None O
patients None None O
. None None O

X-chromosome None None I-DNA
inactivation None None O
patterns None None O
of None None O
CD19+ None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
were None None O
highly None None O
concordant None None O
with None None O
CD3+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
except None None O
for None None O
two None None O
patients None None O
( None None O
one None None O
RA None None O
, None None O
one None None O
CMML None None O
) None None O
with None None O
monoclonal None None I-cell_type
B None None I-cell_type
and None None I-cell_type
polyclonal None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
, None None O
therefore None None O
suggesting None None O
a None None O
clonal None None O
mutation None None O
in None None O
a None None O
progenitor None None I-cell_type
common None None O
to None None O
the None None O
myeloid None None I-cell_type
and None None I-cell_type
B-lymphoid None None I-cell_type
lineages None None I-cell_type
or None None O
the None None O
coexistence None None O
of None None O
MDS None None O
and None None O
a None None O
B-cell None None O
disorder None None O
in None None O
these None None O
particular None None O
patients None None O
. None None O

After None None O
high-dose None None O
non-myeloablative None None O
chemotherapy None None O
, None None O
polyclonal None None O
haemopoiesis None None O
was None None O
reinstalled None None O
in None None O
the None None O
mature None None I-cell_type
myeloid None None I-cell_type
cells None None I-cell_type
and None None O
immature None None O
and None None O
committed None None I-cell_type
marrow None None I-cell_type
progenitors None None I-cell_type
in None None O
three None None O
of None None O
four None None O
patients None None O
achieving None None O
complete None None O
haematological None None O
remission None None O
. None None O

Therefore None None O
we None None O
conclude None None O
that None None O
most None None O
haematological None None O
remissions None None O
in None None O
MDS None None O
are None None O
associated None None O
with None None O
restoration None None O
of None None O
polyclonal None None O
haemopoiesis None None O
. None None O

Prominent None None O
sex None None O
steroid None None O
metabolism None None O
in None None O
human None None I-cell_type
lymphocytes None None I-cell_type
. None None O

Steroid None None O
metabolism None None O
was None None O
investigated None None O
in None None O
cultured None None I-cell_line
human None None I-cell_line
B-lymphoblastoid None None I-cell_line
cells None None I-cell_line
( None None O
B-LCL None None I-cell_line
) None None O
, None None O
and None None O
peripheral None None I-cell_type
blood None None I-cell_type
T None None I-cell_type
and None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
. None None O

Gene None None O
expression None None O
was None None O
examined None None O
by None None O
reverse-transcription None None O
polymerase None None O
chain None None O
reaction None None O
amplification None None O
( None None O
RT-PCR None None O
) None None O
. None None O

Appropriate None None O
sized None None O
transcripts None None I-RNA
were None None O
detected None None O
in None None O
both None None O
cultured None None O
and None None O
fresh None None O
peripheral None None I-cell_type
lymphocytes None None I-cell_type
for None None O
CYP11A None None I-protein
, None None O
CYP17 None None I-protein
, None None O
HSD11L None None I-protein
( None None O
11beta-hydroxysteroid None None I-protein
dehydrogenase None None I-protein
I None None I-protein
) None None O
, None None O
HSD17B1 None None I-protein
( None None O
17beta-hydroxysteroid None None I-protein
dehydrogenase None None I-protein
type None None I-protein
I None None I-protein
) None None O
and None None O
SRD5A1 None None I-protein
( None None O
5alpha-reductase None None I-protein
I None None I-protein
) None None O
. None None O

B-LCL None None O
, None None O
but None None O
not None None O
T None None I-cell_type
and None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
, None None O
expressed None None O
CYP11B None None I-protein
. None None O

There None None O
was None None O
minimal None None O
expression None None O
of None None O
HSD3B1 None None I-protein
and None None O
HSD3B2 None None I-protein
( None None O
3beta-hydroxysteroid None None I-protein
dehydrogenase None None I-protein
I None None I-protein
and None None I-protein
II None None I-protein
) None None O
in None None O
B-LCL None None I-cell_line
and None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

Transcripts None None O
for None None O
CYP19 None None I-protein
and None None O
HSD11K None None I-protein
were None None O
not None None O
detected None None O
. None None O

Corresponding None None O
enzymatic None None O
activity None None O
was None None O
detectable None None O
only None None O
for None None O
17-hydroxysteroid None None I-protein
dehydrogenase None None I-protein
and None None O
5alpha-reductase None None I-protein
, None None O
respectively None None O
producing None None O
testosterone None None O
and None None O
5alpha-dihydrotestosterone None None O
. None None O

Steroid None None O
identities None None O
were None None O
confirmed None None O
by None None O
gas None None O
chromatography/mass None None O
spectrometry None None O
( None None O
GC/MS None None O
) None None O
. None None O

One None None O
metabolite None None O
thought None None O
to None None O
be None None O
deoxycorticosterone None None O
was None None O
identified None None O
by None None O
GC/MS None None O
as None None O
6alpha-hydroxypregnanolone None None O
. None None O

It None None O
was None None O
concluded None None O
that None None O
sex None None O
hormone None None O
metabolism None None O
, None None O
including None None O
androgen None None O
synthesis None None O
, None None O
occurs None None O
in None None O
lymphocytes None None O
, None None O
and None None O
may None None O
modulate None None O
immune None None O
response None None O
. None None O

Human None None I-cell_type
white None None I-cell_type
blood None None I-cell_type
cells None None I-cell_type
and None None O
hair None None O
follicles None None O
are None None O
good None None O
sources None None O
of None None O
mRNA None None I-RNA
for None None O
the None None O
pterin None None I-protein
carbinolamine None None I-protein
dehydratase/dimerization None None I-protein
cofactor None None I-protein
of None None O
HNF1 None None I-protein
for None None O
mutation None None O
detection None None O
. None None O

Pterin None None I-protein
carbinolamine None None I-protein
dehydratase/dimerization None None I-protein
cofactor None None I-protein
of None None O
HNF1 None None I-protein
( None None O
PCD/DCoH None None I-protein
) None None O
is None None O
a None None O
protein None None O
that None None O
has None None O
a None None O
dual None None O
function None None O
. None None O

It None None O
is None None O
a None None O
pterin None None I-protein
4alpha-carbinolamine None None I-protein
dehydratase None None I-protein
that None None O
is None None O
involved None None O
in None None O
the None None O
regeneration None None O
of None None O
the None None O
cofactor None None I-protein
tetrahydrobiopterin None None I-protein
during None None O
the None None O
phenylalanine None None O
hydroxylase- None None O
catalyzed None None O
hydroxylation None None O
of None None O
phenylalanine None None O
. None None O

In None None O
addition None None O
, None None O
it None None O
is None None O
the None None O
dimerization None None O
cofactor None None O
of None None O
HNF1 None None I-protein
that None None O
is None None O
able None None O
to None None O
activate None None O
the None None O
transcriptional None None O
activity None None O
of None None O
HNF1 None None I-protein
. None None O

Deficiencies None None O
in None None O
the None None O
gene None None O
for None None O
this None None O
dual None None I-protein
functional None None I-protein
protein None None I-protein
result None None O
in None None O
hyperphenylalaninemia None None O
. None None O

Here None None O
we None None O
report None None O
for None None O
the None None O
first None None O
time None None O
that None None O
the None None O
PCD/DCoH None None I-RNA
mRNA None None I-RNA
is None None O
present None None O
in None None O
human None None I-cell_type
white None None I-cell_type
blood None None I-cell_type
cells None None I-cell_type
and None None O
hair None None O
follicles None None O
. None None O

Taking None None O
advantage None None O
of None None O
this None None O
finding None None O
, None None O
a None None O
sensitive None None O
, None None O
rapid None None O
and None None O
convenient None None O
method None None O
for None None O
screening None None O
mutations None None O
occurring None None O
in None None O
the None None O
coding None None O
region None None O
of None None O
this None None O
gene None None O
has None None O
been None None O
described None None O
. None None O

Copyright None None O
1998 None None O
Academic None None O
Press None None O
. None None O

Biochemical None None O
characterization None None O
of None None O
the None None O
NF-Y None None I-protein
transcription None None I-protein
factor None None I-protein
complex None None I-protein
during None None O
B None None O
lymphocyte None None O
development None None O
. None None O

The None None O
transcription None None I-protein
factor None None I-protein
, None None O
NF-Y None None I-protein
, None None O
plays None None O
a None None O
critical None None O
role None None O
in None None O
tissue-specific None None O
major None None I-DNA
histocompatibility None None I-DNA
complex None None I-DNA
class None None I-DNA
II None None I-DNA
gene None None I-DNA
transcription None None O
. None None O

In None None O
this None None O
report None None O
the None None O
biochemical None None O
properties None None O
of None None O
the None None O
heterotrimeric None None I-protein
NF-Y None None I-protein
complex None None I-protein
have None None O
been None None O
characterized None None O
during None None O
stage-specific None None O
B-cell None None O
development None None O
, None None O
and None None O
in None None O
several None None O
class None None I-cell_line
II- None None I-cell_line
mutant None None I-cell_line
B-cell None None I-cell_line
lines None None I-cell_line
, None None O
which None None O
represent None None O
distinct None None O
bare None None O
lymphocyte None None O
syndrome None None O
class None None O
II None None O
genetic None None O
complementation None None O
groups None None O
. None None O

The None None O
NF-Y None None I-protein
complex None None I-protein
derived None None O
from None None O
class None None I-cell_type
II+ None None I-cell_type
mature None None I-cell_type
B-cells None None I-cell_type
bound None None O
with None None O
high None None O
affinity None None O
to None None O
anion None None I-protein
exchangers None None I-protein
, None None O
and None None O
eluted None None O
as None None O
an None None O
intact None None O
trimeric None None I-protein
complex None None I-protein
, None None O
whereas None None O
, None None O
NF-Y None None I-protein
derived None None O
from None None O
class None None I-cell_type
II- None None I-cell_type
plasma None None I-cell_type
B-cells None None I-cell_type
, None None O
and None None O
from None None O
bare None None I-cell_line
lymphocyte None None I-cell_line
syndrome None None I-cell_line
group None None I-cell_line
II None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
, None None O
RJ2.2.5 None None I-cell_line
and None None O
RM3 None None I-cell_line
, None None O
dissociated None None O
into None None O
discrete None None O
NF-YA None None I-protein
and None None O
NF-YB None None I-protein
: None None I-protein
C None None I-protein
subunit None None B-protein
fractions None None I-protein
. None None O

Recombination None None O
of None None O
the None None O
MPC11 None None I-protein
plasma None None I-protein
B-cell None None I-protein
derived None None I-protein
NF-Y None None I-protein
A None None I-protein
: None None I-protein
B None None I-protein
: None None I-protein
C None None I-protein
complex None None I-protein
with None None O
the None None O
low None None O
molecular None None O
mass None None O
protein None None O
fraction None None O
, None None O
NF-Y-associated None None I-protein
factors None None I-protein
( None None O
YAFs None None I-protein
) None None O
, None None O
derived None None O
from None None O
mature None None O
A20 None None O
B-cell None None O
nuclei None None O
, None None O
conferred None None O
high None None O
affinity None None O
anion None None O
exchange None None O
binding None None O
to None None O
NF-Y None None I-protein
as None None O
an None None O
intact None None I-protein
trimeric None None I-protein
complex None None I-protein
. None None O

Recombination None None O
of None None O
the None None O
native None None I-protein
NF-YA None None I-protein
: None None I-protein
B None None I-protein
: None None I-protein
C None None I-protein
complex None None I-protein
with None None O
the None None O
transcriptional None None I-protein
cofactor None None I-protein
, None None O
PC4 None None I-protein
, None None O
likewise None None O
conferred None None O
high None None I-protein
affinity None None I-protein
NF-Y None None I-protein
binding None None O
to None None O
anion None None I-protein
exchangers None None I-protein
, None None O
and None None O
stabilized None None O
NF-Y None None I-protein
interaction None None O
with None None O
CCAAT-box None None I-DNA
DNA None None I-DNA
motifs None None I-DNA
in None None O
vitro None None O
. None None O

Interaction None None O
between None None O
PC4 None None I-protein
and None None O
NF-Y None None I-protein
was None None O
mapped None None O
to None None O
the None None O
C-terminal None None I-protein
region None None I-protein
of None None O
PC4 None None I-protein
, None None O
and None None O
the None None O
subunit None None I-protein
interaction None None I-protein
subdomain None None I-protein
of None None O
the None None O
highly None None I-protein
conserved None None I-protein
DNA None None I-protein
binding-subunit None None I-protein
interaction None None I-protein
domain None None I-protein
( None None O
DBD None None I-protein
) None None O
of None None O
NF-YA None None I-protein
. None None O

These None None O
results None None O
suggest None None O
that None None O
in None None O
class None None I-cell_type
II+ None None I-cell_type
mature None None I-cell_type
B-cells None None I-cell_type
NF-Y None None I-protein
is None None O
associated None None O
with None None O
the None None O
protein None None O
cofactor None None O
, None None O
PC4 None None I-protein
, None None O
which None None O
may None None O
play None None O
an None None O
important None None O
role None None O
in None None O
NF-Y-mediated None None O
transcriptional None None O
control None None O
of None None O
class None None I-DNA
II None None I-DNA
genes None None I-DNA
. None None O

Arrest None None O
of None None O
B None None O
lymphocyte None None O
terminal None None O
differentiation None None O
by None None O
CD40 None None O
signaling None None O
: None None O
mechanism None None O
for None None O
lack None None O
of None None O
antibody-secreting None None I-cell_type
cells None None I-cell_type
in None None O
germinal None None O
centers None None O
. None None O

Despite None None O
extensive None None O
research None None O
, None None O
the None None O
role None None O
of None None O
CD40 None None I-protein
signaling None None O
in None None O
B None None O
cell None None O
terminal None None O
differentiation None None O
remains None None O
controversial None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
CD40 None None I-protein
engagement None None O
arrests None None O
B None None O
cell None None O
differentiation None None O
prior None None O
to None None O
plasma None None O
cell None None O
formation None None O
. None None O

This None None O
arrest None None O
is None None O
manifested None None O
at None None O
a None None O
molecular None None O
level None None O
as None None O
a None None O
reduction None None O
in None None O
mRNA None None O
levels None None O
of None None O
secretory None None O
immunoglobulin None None O
gene None None O
products None None O
such None None O
as None None O
mu None None O
( None None O
s None None O
) None None O
and None None O
J None None O
chain None None O
as None None O
well None None O
as None None O
the None None O
loss None None O
of None None O
the None None O
transcriptional None None I-protein
regulator None None I-protein
BLIMP-1 None None B-protein
. None None O

Furthermore None None O
, None None O
the None None O
inhibition None None O
of None None O
B None None O
cell None None O
differentiation None None O
by None None O
CD40 None None I-protein
engagement None None O
could None None O
not None None O
be None None O
overcome None None O
by None None O
either None None O
mitogens None None I-protein
or None None O
cytokines None None I-protein
, None None O
but None None O
could None None O
be None None O
reversed None None O
by None None O
antibodies None None O
that None None O
interfere None None O
with None None O
the None None O
CD40 None None I-protein
/ None None O
gp39 None None I-protein
interaction None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
secretory None None O
immunoglobulin None None O
is None None O
not None None O
produced None None O
by None None O
B None None I-cell_type
cells None None I-cell_type
that None None O
are None None O
actively None None O
engaged None None O
by None None O
gp39-expressing None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

A None None O
positively None None O
charged None None O
alpha-lipoic None None O
acid None None O
analogue None None O
with None None O
increased None None O
cellular None None O
uptake None None O
and None None O
more None None O
potent None None O
immunomodulatory None None O
activity None None O
. None None O

alpha-Lipoic None None O
acid None None O
( None None O
LA None None O
) None None O
is None None O
taken None None O
up None None O
by None None O
cells None None O
and None None O
reduced None None O
to None None O
its None None O
potent None None O
dithiol None None O
form None None O
, None None O
dihydrolipoate None None O
( None None O
DHLA None None O
) None None O
, None None O
much None None O
of None None O
which None None O
is None None O
rapidly None None O
effluxed None None O
out None None O
from None None O
cells None None O
. None None O

To None None O
improve None None O
retention None None O
in None None O
cells None None O
, None None O
the None None O
LA None None O
molecule None None O
was None None O
modified None None O
to None None O
confer None None O
a None None O
positive None None O
charge None None O
at None None O
physiological None None O
pH None None O
. None None O

N None None O
, None None O
N-dimethyl None None O
, None None O
N'-2-amidoethyl-lipoate None None O
was None None O
synthesized None None O
. None None O

The None None O
protonated None None O
form None None O
of None None O
the None None O
new None None O
molecule None None O
is None None O
referred None None O
to None None O
as None None O
LA-Plus None None O
. None None O

The None None O
uptake None None O
of None None O
LA-Plus None None O
by None None O
human None None I-cell_type
Wurzburg None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
was None None O
higher None None O
compared None None O
to None None O
that None None O
of None None O
LA None None O
. None None O

Several-fold None None O
higher None None O
amounts None None O
of None None O
DHLA-Plus None None O
, None None O
the None None O
corresponding None None O
reduced None None O
form None None O
of None None O
LA-Plus None None O
, None None O
were None None O
detected None None O
in None None O
LA-Plus None None O
treated None None O
cells None None O
compared None None O
to None None O
the None None O
amount None None O
of None None O
DHLA None None O
found None None O
in None None O
cells None None O
treated None None O
with None None O
LA None None O
. None None O

At None None O
100 None None O
microM None None O
, None None O
LA None None O
did None None O
not None None O
but None None O
LA-Plus None None O
inhibited None None O
H2O2 None None O
induced None None O
NF-kappaB None None I-protein
activation None None O
and None None O
NF-kappaB None None I-protein
directed None None O
IL-2 None None I-protein
receptor None None I-protein
expression None None O
. None None O

Both None None O
LA None None O
and None None O
LA-Plus None None O
synergised None None O
with None None O
selenium None None O
in None None O
inhibiting None None O
H2O2 None None O
induced None None O
NF-kappaB None None I-protein
activation None None O
. None None O

At None None O
150 None None O
microM None None O
LA-Plus None None O
, None None O
but None None O
not None None O
LA None None O
, None None O
inhibited None None O
TNFalpha None None I-protein
induced None None O
NF-kappaB None None I-protein
activation None None O
. None None O

At None None O
5 None None O
microM None None O
LA-Plus None None O
, None None O
but None None O
not None None O
LA None None O
, None None O
protected None None O
against None None O
both None None O
spontaneous None None O
and None None O
etoposide None None O
induced None None O
apoptosis None None O
in None None O
rat None None I-cell_type
thymocytes None None I-cell_type
. None None O

LA-Plus None None O
is None None O
thus None None O
an None None O
improved None None O
form None None O
of None None O
LA None None O
with None None O
increased None None O
therapeutic None None O
potential None None O
. None None O

Copyright None None O
1998 None None O
Academic None None O
Press None None O
. None None O

Carrier None None O
identification None None O
in None None O
X-linked None None O
immunodeficiency None None O
diseases None None O
. None None O

OBJECTIVE None None O
: None None O
Carrier None None O
identification None None O
in None None O
X-linked None None O
immunodeficiency None None O
disorders None None O
can None None O
be None None O
based None None O
on None None O
the None None O
demonstration None None O
of None None O
non-random None None O
X None None O
inactivation None None O
( None None O
NRXI None None O
) None None O
in None None O
affected None None I-cell_type
blood None None I-cell_type
cell None None I-cell_type
lineages None None I-cell_type
when None None O
growth None None O
is None None O
impaired None None O
in None None O
cells None None O
expressing None None O
the None None O
abnormal None None I-DNA
gene None None I-DNA
. None None O

We None None O
examined None None O
the None None O
utility None None O
of None None O
seeking None None O
evidence None None O
of None None O
NRXI None None O
to None None O
test None None O
the None None O
carrier None None O
status None None O
of None None O
women None None O
in None None O
families None None O
affected None None O
by None None O
X-linked None None O
severe None None O
combined None None O
immunodeficiency None None O
( None None O
XSCID None None O
) None None O
and None None O
X-linked None None O
hypogammaglobulinaemia None None O
( None None O
XLH None None O
) None None O
, None None O
to None None O
identify None None O
as None None O
carriers None None O
the None None O
mothers None None O
of None None O
boys None None O
with None None O
SCID None None O
or None None O
hypogammaglobulinaemia None None O
whose None None O
phenotype None None O
suggested None None O
X-linkage None None O
and None None O
to None None O
infer None None O
X-linkage None None O
in None None O
boys None None O
with None None O
SCID None None O
or None None O
hypogammaglobulinaemia None None O
whose None None O
disease None None O
was None None O
not None None O
clearly None None O
X-linked None None O
on None None O
the None None O
basis None None O
either None None O
of None None O
family None None O
history None None O
or None None O
clinical None None O
and None None O
immunological None None O
characteristics None None O
. None None O

METHODOLOGY None None O
: None None O
A None None O
polymerase None None O
chain None None O
reaction-based None None O
method None None O
was None None O
used None None O
to None None O
amplify None None O
a None None O
polymorphic None None O
CAG None None I-DNA
repeat None None I-DNA
in None None O
the None None O
first None None I-DNA
exon None None I-DNA
of None None O
the None None O
androgen None None I-DNA
receptor None None I-DNA
gene None None I-DNA
after None None O
selective None None O
digestion None None O
of None None O
the None None O
active None None I-DNA
X None None I-DNA
chromosome None None I-DNA
with None None O
a None None O
methylation-sensitive None None I-protein
enzyme None None I-protein
, None None O
HpaII None None I-protein
to None None O
distinguish None None O
between None None O
the None None O
paternal None None I-DNA
and None None I-DNA
maternal None None I-DNA
alleles None None I-DNA
and None None O
to None None O
identify None None O
their None None O
methylation None None O
status None None O
. None None O

RESULTS None None O
: None None O
Heterozygosity None None O
was None None O
found None None O
in None None O
24 None None O
of None None O
31 None None O
female None None O
subjects None None O
( None None O
77 None None O
% None None O
) None None O
. None None O

As None None O
anticipated None None O
, None None O
NRXI None None O
could None None O
be None None O
demonstrated None None O
in None None O
all None None O
lymphoid None None I-cell_type
cells None None I-cell_type
studied None None O
from None None O
obligate None None O
carriers None None O
of None None O
XSCID None None O
and None None O
an None None O
obligate None None O
carrier None None O
of None None O
XLH None None O
but None None O
not None None O
on None None O
a None None O
carrier None None O
of None None O
X-linked None None O
immunodeficiency None None O
with None None O
hyper-IgM None None I-protein
. None None O

The None None O
finding None None O
of None None O
NRXI None None O
in None None O
the None None O
mother None None O
of None None O
a None None O
boy None None O
with None None O
a None None O
SCID None None O
variant None None O
showed None None O
her None None O
to None None O
be None None O
a None None O
carrier None None O
of None None O
XSCID None None O
and None None O
establishes None None O
that None None O
her None None O
son None None O
has None None O
XSCID None None O
, None None O
not None None O
otherwise None None O
evident None None O
from None None O
available None None O
data None None O
. None None O

CONCLUSIONS None None O
: None None O
This None None O
PCR None None O
assay None None O
provides None None O
a None None O
rapid None None O
method None None O
for None None O
carrier None None O
detection None None O
of None None O
X-linked None None O
immunodeficiencies None None O
, None None O
and None None O
has None None O
allowed None None O
us None None O
to None None O
expand None None O
the None None O
phenotype None None O
of None None O
XSCID None None O

Leukocyte-endothelial None None O
interaction None None O
is None None O
augmented None None O
by None None O
high None None O
glucose None None O
concentrations None None O
and None None O
hyperglycemia None None O
in None None O
a None None O
NF-kB-dependent None None O
fashion None None O
. None None O

We None None O
addressed None None O
the None None O
role None None O
of None None O
hyperglycemia None None O
in None None O
leukocyte-endothelium None None O
interaction None None O
under None None O
flow None None O
conditions None None O
by None None O
exposing None None O
human None None I-cell_type
umbilical None None I-cell_type
vein None None I-cell_type
endothelial None None I-cell_type
cells None None I-cell_type
for None None O
24 None None O
h None None O
to None None O
normal None None O
( None None O
5 None None O
mM None None O
) None None O
, None None O
high None None O
concentration None None O
of None None O
glucose None None O
( None None O
30 None None O
mM None None O
) None None O
, None None O
advanced None None O
glycosylation None None O
end None None O
product-albumin None None I-protein
( None None O
100 None None O
microg/ml None None O
) None None O
, None None O
or None None O
hyperglycemic None None O
( None None O
174-316 None None O
mg/dl None None O
) None None O
sera None None O
from None None O
patients None None O
with None None O
diabetes None None O
and None None O
abnormal None None O
hemoglobin None None O
A1c None None O
( None None O
8.1+/-1.4 None None O
% None None O
) None None O
. None None O

At None None O
the None None O
end None None O
of None None O
incubation None None O
endothelial None None I-cell_type
cells None None I-cell_type
were None None O
perfused None None O
with None None O
total None None O
leukocyte None None O
suspension None None O
in None None O
a None None O
parallel None None O
plate None None O
flow None None O
chamber None None O
under None None O
laminar None None O
flow None None O
( None None O
1.5 None None O
dyn/cm2 None None O
) None None O
. None None O

Rolling None None O
and None None O
adherent None None I-cell_type
cells None None I-cell_type
were None None O
evaluated None None O
by None None O
digital None None O
image None None O
processing None None O
. None None O

Results None None O
showed None None O
that None None O
30 None None O
mM None None O
glucose None None O
significantly None None O
( None None O
P None None O
< None None O
0.01 None None O
) None None O
increased None None O
the None None O
number None None O
of None None O
adherent None None I-cell_type
leukocytes None None I-cell_type
to None None O
endothelial None None I-cell_type
cells None None I-cell_type
in None None O
respect None None O
to None None O
control None None O
( None None O
5 None None O
mM None None O
glucose None None O
; None None O
151+/-19 None None O
versus None None O
33+/-8 None None O
cells/mm2 None None O
) None None O
. None None O

A None None O
similar None None O
response None None O
was None None O
induced None None O
by None None O
endothelial None None O
stimulation None None O
with None None O
IL-1beta None None I-protein
, None None O
here None None O
used None None O
as None None O
positive None None O
control None None O
( None None O
195+/-20 None None O
cells/mm2 None None O
) None None O
. None None O

The None None O
number None None O
of None None O
rolling None None I-cell_type
cells None None I-cell_type
on None None O
endothelial None None O
surface None None O
was None None O
not None None O
affected None None O
by None None O
high None None O
glucose None None O
level None None O
. None None O

Stable None None O
adhesion None None O
of None None O
leukocytes None None I-cell_type
to None None O
glucose-treated None None O
as None None O
well None None O
as None None O
to None None O
IL-1beta-stimulated None None I-cell_type
endothelial None None I-cell_type
cells None None I-cell_type
was None None O
preceded None None O
by None None O
short None None O
interaction None None O
of None None O
leukocytes None None I-cell_type
with None None O
the None None O
endothelial None None O
surface None None O
. None None O

The None None O
distance None None O
travelled None None O
by None None O
leukocytes None None I-cell_type
before None None O
arrest None None O
on None None O
30 None None O
mM None None O
glucose None None O
, None None O
or None None O
on None None O
IL-1beta-treated None None I-cell_type
endothelial None None I-cell_type
cells None None I-cell_type
, None None O
was None None O
significantly None None O
( None None O
P None None O
< None None O
0.01 None None O
) None None O
higher None None O
than None None O
that None None O
observed None None O
for None None O
leukocytes None None I-cell_type
adhering None None O
on None None O
control None None O
endothelium None None O
( None None O
30 None None O
mM None None O
glucose None None O
: None None O
76.7+/-3.5 None None O
; None None O
IL1beta None None O
: None None O
69.7+/-4 None None O
versus None None O
5 None None O
mM None None O
glucose None None O
: None None O
21.5+/-5 None None O
microm None None O
) None None O
. None None O

Functional None None O
blocking None None O
of None None O
E-selectin None None I-protein
, None None O
intercellular None None I-protein
cell None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
, None None O
and None None O
vascular None None I-protein
cell None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
on None None O
endothelial None None I-cell_type
cells None None I-cell_type
with None None O
the None None O
corresponding None None O
mouse None None I-protein
mAb None None I-protein
significantly None None O
inhibited None None O
glucose-induced None None O
increase None None O
in None None O
leukocyte None None O
adhesion None None O
( None None O
67+/-16 None None O
, None None O
83+/-12 None None O
, None None O
62+/-8 None None O
versus None None O
144+/-21 None None O
cells/ None None O
mm2 None None O
) None None O
. None None O

Confocal None None O
fluorescence None None O
microscopy None None O
studies None None O
showed None None O
that None None O
30 None None O
mM None None O
glucose None None O
induced None None O
an None None O
increase None None O
in None None O
endothelial None None O
surface None None O
expression None None O
of None None O
E-selectin None None I-protein
, None None O
intercellular None None I-protein
cell None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
, None None O
and None None O
vascular None None I-protein
cell None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
. None None O

Electrophoretic None None O
mobility None None O
shift None None O
assay None None O
of None None O
nuclear None None O
extracts None None O
of None None O
human None None I-cell_type
umbilical None None I-cell_type
vein None None I-cell_type
endothelial None None I-cell_type
cells None None I-cell_type
( None None O
HUVEC None None O
) None None O
exposed None None O
for None None O
1 None None O
h None None O
to None None O
30 None None O
mM None None O
glucose None None O
revealed None None O
an None None O
intense None None O
NF-kB None None I-protein
activation None None O
. None None O

Treatment None None O
of None None O
HUVEC None None O
exposed None None O
to None None O
high None None O
glucose None None O
with None None O
the None None O
NF-kB None None I-protein
inhibitors None None I-protein
pyrrolidinedithiocarbamate None None O
( None None O
100 None None O
microM None None O
) None None O
and None None O
tosyl-phe-chloromethylketone None None O
( None None O
25 None None O
microM None None O
) None None O
significantly None None O
reduced None None O
( None None O
P None None O
< None None O
0.05 None None O
) None None O
leukocyte None None O
adhesion None None O
in None None O
respect None None O
to None None O
HUVEC None None O
treated None None O
with None None O
glucose None None O
alone None None O
. None None O

A None None O
significant None None O
( None None O
P None None O
< None None O
0.01 None None O
) None None O
inhibitory None None O
effect None None O
on None None O
glucose-induced None None O
leukocyte None None O
adhesion None None O
was None None O
observed None None O
after None None O
blocking None None O
protein None None I-protein
kinase None None I-protein
C None None I-protein
activity None None O
with None None O
staurosporine None None O
( None None O
5 None None O
nM None None O
) None None O
. None None O

When None None O
HUVEC None None O
were None None O
treated None None O
with None None O
specific None None O
antisense None None O
oligodesoxynucleotides None None O
against None None O
PKCalpha None None I-protein
and None None I-protein
PKCepsilon None None I-protein
isoforms None None I-protein
before None None O
the None None O
addition None None O
of None None O
30 None None O
mM None None O
glucose None None O
, None None O
a None None O
significant None None O
( None None O
P None None O
< None None O
0.05 None None O
) None None O
reduction None None O
in None None O
the None None O
adhesion None None O
was None None O
also None None O
seen None None O
. None None O

Advanced None None O
glycosylation None None O
end None None O
product-albumin None None I-protein
significantly None None O
increased None None O
the None None O
number None None O
of None None O
adhering None None I-cell_type
leukocytes None None I-cell_type
in None None O
respect None None O
to None None O
native None None I-protein
albumin None None I-protein
used None None O
as None None O
control None None O
( None None O
110+/-16 None None O
versus None None O
66+/-7 None None O
, None None O
P None None O
< None None O
0.01 None None O
) None None O
. None None O

Sera None None O
from None None O
diabetic None None O
patients None None O
significantly None None O
( None None O
P None None O
< None None O
0.01 None None O
) None None O
enhanced None None O
leukocyte None None O
adhesion None None O
as None None O
compared None None O
with None None O
controls None None O
, None None O
despite None None O
normal None None O
levels None None O
of None None O
IL-1beta None None I-protein
and None None O
TNFalpha None None I-protein
in None None O
these None None O
sera None None O
. None None O

These None None O
data None None O
indicate None None O
that None None O
high None None O
glucose None None O
concentration None None O
and None None O
hyperglycemia None None O
promote None None O
leukocyte None None O
adhesion None None O
to None None O
the None None O
endothelium None None O
through None None O
upregulation None None O
of None None O
cell None None O
surface None None O
expression None None O
of None None O
adhesive None None O
proteins None None O
, None None O
possibly None None O
depending None None O
on None None O
NF-kB None None I-protein
activation None None O
. None None O

Ikaros None None I-protein
in None None O
hemopoietic None None O
lineage None None O
determination None None O
and None None O
homeostasis None None O
. None None O

Studies None None O
on None None O
the None None O
molecular None None O
mechanisms None None O
that None None O
control None None O
hemopoietic None None O
differentiation None None O
have None None O
focused None None O
on None None O
signaling None None O
cascades None None O
and None None O
nuclear None None O
effectors None None O
that None None O
drive None None O
this None None O
complex None None O
developmental None None O
system None None O
in None None O
a None None O
regulated None None O
fashion None None O
. None None O

Here None None O
we None None O
review None None O
the None None O
role None None O
of None None O
Ikaros None None I-protein
, None None O
the None None O
founding None None O
member None None O
of None None O
a None None O
unique None None O
family None None O
of None None O
zinc None None I-protein
finger None None I-protein
transcription None None I-protein
factors None None I-protein
in None None O
this None None O
developmental None None O
process None None O
. None None O

Studies None None O
on None None O
an None None O
Ikaros None None I-protein
null None None O
mutation None None O
have None None O
revealed None None O
an None None O
essential None None O
role None None O
for None None O
this None None O
factor None None O
in None None O
lymphoid None None O
cell None None O
fate None None O
determination None None O
and None None O
at None None O
subsequent None None O
branch None None O
points None None O
of None None O
the None None O
T None None O
cell None None O
differentiation None None O
pathway None None O
. None None O

Differences None None O
in None None O
the None None O
phenotypes None None O
of None None O
a None None O
null None None O
and None None O
a None None O
dominant None None I-DNA
negative None None I-DNA
( None None I-DNA
DN None None I-DNA
) None None I-DNA
Ikaros None None I-DNA
mutation None None I-DNA
provide None None O
insight None None O
into None None O
a None None O
regulatory None None O
network None None O
through None None O
which None None O
Ikaros None None I-protein
proteins None None I-protein
exert None None O
their None None O
effects None None O
in None None O
development None None O
. None None O

In None None O
addition None None O
a None None O
comparative None None O
analysis None None O
of None None O
the None None O
hemopoietic None None I-cell_type
stem None None I-cell_type
cell None None I-cell_type
and None None O
precursor None None O
compartment None None O
resulting None None O
from None None O
the None None O
two None None O
Ikaros None None I-DNA
mutations None None I-DNA
reveals None None O
a None None O
profound None None O
yet None None O
not None None O
absolute None None O
requirement None None O
for None None O
Ikaros None None I-protein

Induction None None O
of None None O
early None None I-protein
B None None I-protein
cell None None I-protein
factor None None I-protein
( None None O
EBF None None I-protein
) None None O
and None None O
multiple None None I-DNA
B None None I-DNA
lineage None None I-DNA
genes None None I-DNA
by None None O
the None None O
basic None None I-protein
helix-loop-helix None None I-protein
transcription None None I-protein
factor None None I-protein
E12 None None B-protein
. None None O

The None None O
transcription None None I-protein
factors None None I-protein
encoded None None O
by None None O
the None None O
E2A None None I-protein
and None None O
early None None I-protein
B None None I-protein
cell None None I-protein
factor None None I-protein
( None None O
EBF None None I-protein
) None None O
genes None None O
are None None O
required None None O
for None None O
the None None O
proper None None O
development None None O
of None None O
B None None I-cell_type
lymphocytes None None I-cell_type
. None None O

However None None O
, None None O
the None None O
absence None None O
of None None O
B None None I-cell_type
lineage None None I-cell_type
cells None None I-cell_type
in None None O
E2A- None None O
and None None O
EBF-deficient None None O
mice None None O
has None None O
made None None O
it None None O
difficult None None O
to None None O
determine None None O
the None None O
function None None O
or None None O
relationship None None O
between None None O
these None None O
proteins None None O
. None None O

We None None O
report None None O
the None None O
identification None None O
of None None O
a None None O
novel None None O
model None None O
system None None O
in None None O
which None None O
the None None O
role None None O
of None None O
E2A None None I-protein
and None None O
EBF None None I-protein
in None None O
the None None O
regulation None None O
of None None O
multiple None None O
B None None O
lineage None None O
traits None None O
can None None O
be None None O
studied None None O
. None None O

We None None O
found None None O
that None None O
the None None O
conversion None None O
of None None O
70Z/3 None None I-cell_line
pre-B None None I-cell_line
lymphocytes None None I-cell_line
to None None O
cells None None O
with None None O
a None None O
macrophage-like None None O
phenotype None None O
is None None O
associated None None O
with None None O
the None None O
loss None None O
of None None O
E2A None None I-protein
and None None O
EBF None None I-protein
. None None O

Moreover None None O
, None None O
we None None O
show None None O
that None None O
ectopic None None O
expression None None O
of None None O
the None None O
E2A None None I-protein
protein None None O
E12 None None I-protein
in None None O
this None None O
macrophage None None I-cell_line
line None None I-cell_line
results None None O
in None None O
the None None O
induction None None O
of None None O
many None None I-DNA
B None None I-DNA
lineage None None I-DNA
genes None None I-DNA
, None None O
including None None O
EBF None None I-protein
, None None O
IL7Ralpha None None I-protein
, None None O
lambda5 None None I-protein
, None None O
and None None O
Rag-1 None None O
, None None O
and None None O
the None None O
ability None None O
to None None O
induce None None O
kappa None None I-protein
light None None I-protein
chain None None I-protein
in None None O
response None None O
to None None O
mitogen None None O
. None None O

Activation None None O
of None None O
EBF None None I-protein
may None None O
be None None O
one None None O
of None None O
the None None O
critical None None O
functions None None O
of None None O
E12 None None I-protein
in None None O
regulating None None O
the None None O
B None None O
lineage None None O
phenotype None None O
since None None O
expression None None O
of None None O
EBF None None I-protein
alone None None O
leads None None O
to None None O
the None None O
activation None None O
of None None O
a None None O
subset None None O
of None None O
E12 None None I-protein
-inducible None None O
traits None None O
. None None O

Our None None O
data None None O
demonstrate None None O
that None None O
, None None O
in None None O
the None None O
context None None O
of None None O
this None None O
macrophage None None I-cell_line
line None None I-cell_line
, None None O
E12 None None I-protein
induces None None O
expression None None O
of None None O
EBF None None I-protein
and None None O
together None None O
these None None O
transcription None None I-protein
factors None None I-protein
coordinately None None O
regulate None None O
numerous None None O
B None None I-DNA
lineage-associated None None I-DNA
genes None None I-DNA
. None None O

Activation-induced None None O
down-regulation None None O
of None None O
retinoid None None I-protein
receptor None None I-protein
RXRalpha None None I-protein
expression None None O
in None None O
human None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
. None None O

Role None None O
of None None O
cell None None O
cycle None None O
regulation None None O
. None None O

A None None O
5.4-kilobase None None I-RNA
mRNA None None I-RNA
, None None O
the None None O
expression None None O
of None None O
which None None O
is None None O
down-regulated None None O
after None None O
treatment None None O
of None None O
human None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
( None None O
PBMCs None None I-cell_type
) None None O
with None None O
various None None O
T None None O
cell-activating None None O
agents None None O
, None None O
was None None O
isolated None None O
using None None O
an None None O
mRNA None None O
differential None None O
display None None O
method None None O
. None None O

Nucleotide None None O
sequence None None O
analysis None None O
identified None None O
the None None O
5 None None I-RNA
' None None I-RNA
end None None I-RNA
of None None O
this None None O
RNA None None I-RNA
as None None O
human None None I-RNA
retinoid None None I-RNA
receptor None None I-RNA
RXRalpha None None I-RNA
mRNA None None I-RNA
. None None O

Here None None O
, None None O
we None None O
report None None O
the None None O
nucleotide None None O
sequence None None O
of None None O
3.6 None None I-DNA
kilobases None None I-DNA
of None None O
this None None O
RNA None None O
, None None O
which None None O
represents None None O
the None None O
3 None None I-RNA
' None None I-RNA
end None None I-RNA
of None None O
RXRalpha None None I-RNA
mRNA None None I-RNA
, None None O
the None None O
sequence None None O
of None None O
which None None O
has None None O
not None None O
been None None O
previously None None O
described None None O
. None None O

Activated None None O
PBMCs None None I-cell_type
also None None O
expressed None None O
lower None None O
levels None None O
of None None O
RXRalpha None None I-protein
protein None None O
, None None O
and None None O
a None None O
DNA None None O
binding None None O
assay None None O
showed None None O
that None None O
the None None O
activation-induced None None O
loss None None O
of None None O
RXRalpha None None I-RNA
mRNA None None I-RNA
and None None O
protein None None O
expression None None O
correlated None None O
with None None O
the None None O
loss None None O
of None None O
DNA None None O
binding None None O
activity None None O
of None None O
this None None O
protein None None O
. None None O

We None None O
present None None O
evidence None None O
that None None O
the None None O
transition None None O
from None None O
G0/G1 None None O
to None None O
S None None O
phase None None O
of None None O
the None None O
cell None None O
cycle None None O
results None None O
in None None O
the None None O
down-regulation None None O
of None None O
RXRalpha None None I-protein
expression None None O
and None None O
that None None O
cell None None O
cycle None None O
inhibitors None None O
, None None O
which None None O
block None None O
the None None O
cells None None O
in None None O
G1 None None O
phase None None O
, None None O
prevent None None O
this None None O
down-regulation None None O
. None None O

The None None O
decrease None None O
in None None O
the None None O
levels None None O
of None None O
RXRalpha None None I-RNA
mRNA None None I-RNA
was None None O
found None None O
to None None O
be None None O
regulated None None O
at None None O
the None None O
post-transcriptional None None O
level None None O
and None None O
involved None None O
new None None O
protein None None O
synthesis None None O
. None None O

These None None O
observations None None O
indicate None None O
that None None O
the None None O
levels None None O
of None None O
RXRalpha None None I-protein
expression None None O
in None None O
T None None O
lymphocytes None None O
are None None O
coupled None None O
to None None O
cell None None O
cycle None None O
progression None None O
, None None O
and None None O
there None None O
is None None O
tight None None O
regulatory None None O
control None None O
of None None O
RXRalpha None None I-protein
expression None None O
during None None O
the None None O
transition None None O
from None None O
G0/G1 None None O
to None None O
S None None O
phase None None O
of None None O
the None None O
cell None None O
cycle None None O
. None None O

Epidemiology None None O
and None None O
pathogenesis None None O
of None None O
AIDS-related None None O
lymphomas None None O
. None None O

Among None None O
patients None None O
with None None O
congenital None None O
and None None O
acquired None None O
immunodeficiencies None None O
, None None O
non-Hodgkin None None O
's None None O
lymphoma None None O
( None None O
NHLs None None O
) None None O
are None None O
the None None O
most None None O
common None None O
tumors None None O
of None None O
the None None O
immune None None O
system None None O
. None None O

In None None O
the None None O
setting None None O
of None None O
human None None O
immunodeficiency None None O
virus None None O
( None None O
HIV None None O
) None None O
infection None None O
, None None O
as None None O
many None None O
as None None O
10 None None O
% None None O
to None None O
20 None None O
% None None O
of None None O
people None None O
ultimately None None O
developed None None O
NHLs None None O
. None None O

These None None O
tumors None None O
are None None O
clinically None None O
aggressive None None O
, None None O
frequently None None O
involve None None O
extranodal None None O
sites None None O
, None None O
and None None O
often None None O
exhibit None None O
unique None None O
features None None O
that None None O
distinguish None None O
them None None O
from None None O
NHL None None O
arising None None O
in None None O
individuals None None O
with None None O
other None None O
forms None None O
of None None O
immunosuppression None None O
. None None O

Important None None O
in None None O
the None None O
development None None O
of None None O
HIV-associated None None O
NHL None None O
are None None O
cytokines None None I-protein
and None None O
other None None O
factors None None O
that None None O
induce None None O
B-cell None None O
proliferation None None O
and None None O
increase None None O
the None None O
likelihood None None O
of None None O
mutations None None O
of None None O
c-myc None None I-DNA
, None None O
bcl-6 None None I-DNA
, None None O
and None None O
other None None O
tumor-suppressor None None I-DNA
genes None None I-DNA
with None None O
carcinogenic None None O
potential None None O
. None None O

Specific None None O
forms None None O
of None None O
HIV-associated None None O
NHL None None O
are None None O
linked None None O
to None None O
expression None None O
of None None O
Epstein-Barr None None I-protein
virus None None I-protein
( None None I-protein
EBV None None I-protein
) None None I-protein
-latent None None I-protein
proteins None None I-protein
; None None O
the None None O
newly None None O
described None None O
DNA None None O
virus None None O
, None None O
Karposi None None O
's None None O
sarcoma-associated None None O
herpesvirus/human None None O
herpesvirus-8 None None O
( None None O
KSHV/HHV-8 None None O
) None None O
; None None O
and None None O
perhaps None None O
HIV None None O
. None None O

Elucidation None None O
of None None O
the None None O
factors None None O
that None None O
contribute None None O
to None None O
the None None O
high None None O
incidence None None O
of None None O
NHL None None O
among None None O
patients None None O
infected None None O
with None None O
HIV None None O
provides None None O
insights None None O
into None None O
important None None O
elements None None O
of None None O
lymphomagenesis None None O
. None None O

Matrix None None I-protein
metalloproteinase None None I-protein
expression None None O
in None None O
human None None O
breast None None O
cancer None None O
: None None O
an None None O
immunohistochemical None None O
study None None O
including None None O
correlation None None O
with None None O
cathepsin None None I-protein
D None None I-protein
, None None O
type None None I-protein
IV None None I-protein
collagen None None I-protein
, None None O
laminin None None I-protein
, None None O
fibronectin None None I-protein
, None None O
EGFR None None I-protein
, None None O
c-erbB-2 None None I-protein
oncoprotein None None I-protein
, None None O
p53 None None I-protein
, None None O
steroid None None O
receptors None None O
status None None O
and None None O
proliferative None None O
indices None None O
. None None O

Matrix None None I-protein
metalloproteinase None None I-protein
s None None O
( None None O
MMPs None None I-protein
) None None O
are None None O
a None None O
group None None O
of None None O
enzymes None None O
thought None None O
to None None O
be None None O
responsible None None O
for None None O
both None None O
normal None None O
connective None None O
tissue None None O
matrix None None O
remodelling None None O
and None None O
accelerated None None O
breakdown None None O
associated None None O
with None None O
tumour None None O
development None None O
. None None O

The None None O
current None None O
study None None O
aimed None None O
to None None O
investigate None None O
the None None O
immunohistochemical None None O
expression None None O
of None None O
matrix None None I-protein
metalloproteinase None None I-protein
3 None None I-protein
( None None O
MMP-3 None None I-protein
, None None O
stromelysin-1 None None I-protein
) None None O
in None None O
correlation None None O
with None None O
the None None O
expression None None O
of None None O
Basement None None I-protein
Membrane None None I-protein
( None None I-protein
BM None None I-protein
) None None I-protein
antigen None None I-protein
( None None O
type None None I-protein
IV None None I-protein
collagen None None I-protein
, None None O
laminin None None I-protein
) None None O
, None None O
fibronectin None None I-protein
, None None O
cathepsin None None I-protein
D None None I-protein
, None None O
p53 None None I-protein
, None None O
c-erbB-2 None None I-protein
, None None O
proliferative None None O
activity None None O
( None None O
Ki-67 None None I-protein
, None None O
PCNA None None I-protein
) None None O
, None None O
steroid None None O
receptor None None O
content None None O
as None None O
well None None O
as None None O
to None None O
the None None O
other None None O
conventional None None O
clinicopathological None None O
parameters None None O
in None None O
breast None None O
cancer None None O
. None None O

This None None O
study None None O
was None None O
performed None None O
on None None O
a None None O
series None None O
of None None O
frozen None None O
and None None O
paraffin None None O
sections None None O
from None None O
84 None None O
breast None None O
cancer None None O
specimens None None O
by None None O
immunohistochemistry None None O
using None None O
the None None O
monoclonal None None I-protein
antibody None None I-protein
MMP-3 None None I-protein
( None None O
Ab-1 None None I-protein
) None None O
. None None O

Stromelysin-1 None None I-protein
( None None O
ST1 None None I-protein
) None None O
was None None O
observed None None O
in None None O
about None None O
10 None None O
% None None O
of None None O
epithelial None None I-cell_type
cells None None I-cell_type
in None None O
the None None O
control None None O
groups None None O
( None None O
cases None None O
of None None O
fibrocystic None None O
and None None O
benign None None O
proliferative None None O
breast None None O
disease None None O
) None None O
, None None O
while None None O
expression None None O
( None None O
> None None O
10 None None O
% None None O
of None None O
expression None None O
) None None O
was None None O
detected None None O
in None None O
89.7 None None O
% None None O
of None None O
tumours None None O
. None None O

The None None O
expression None None O
of None None O
ST1 None None I-protein
in None None O
carcinoma None None O
cells None None O
was None None O
strongly None None O
associated None None O
with None None O
its None None O
presence None None O
in None None O
the None None O
stroma None None O
( None None O
p None None O
< None None O
0.001 None None O
) None None O
. None None O

A None None O
significantly None None O
positive None None O
correlation None None O
was None None O
found None None O
between None None O
ST1 None None I-protein
expression None None O
, None None O
and None None O
p53 None None I-protein
tumour None None O
suppressor None None O
gene None None O
product None None O
( None None O
p None None O
= None None O
0.004 None None O
) None None O
, None None O
and None None O
a None None O
relationship None None O
with None None O
c-erbB-2 None None I-protein
protein None None O
and None None O
progesterone None None O
receptor None None O
status None None O
was None None O
also None None O
indicated None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
ST1 None None I-protein
expression None None O
in None None O
breast None None O
cancer None None O
tissue None None O
is None None O
irrespective None None O
of None None O
the None None O
expression None None O
of None None O
the None None O
extracellular None None O
matrix None None O
component None None O
, None None O
the None None O
proteolytic None None I-protein
enzyme None None I-protein
cathepsin None None B-protein
D None None I-protein
and None None O
the None None O
growth None None O
fraction None None O
of None None O
the None None O
tumour None None O
, None None O
and None None O
that None None O
it None None O
could None None O
be None None O
a None None O
potential None None O
new None None O
prognostic None None O
marker None None O
in None None O
breast None None O
cancer None None O
. None None O

Use None None O
of None None O
transfected None None I-cell_line
liver None None I-cell_line
cells None None I-cell_line
to None None O
evaluate None None O
potential None None O
mechanisms None None O
of None None O
alcohol-induced None None O
liver None None O
injury None None O
[ None None O
see None None O
comments None None O
] None None O

There None None O
is None None O
increased None None O
activity None None O
of None None O
the None None O
proinflammatory None None I-protein
cytokine None None I-protein
, None None O
tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
( None None O
TNF None None I-protein
) None None O
in None None O
alcoholic None None O
liver None None O
disease None None O
( None None O
ALD None None O
) None None O
. None None O

Hepatic None None O
neutrophil None None O
infiltration None None O
is None None O
a None None O
principal None None O
injurious None None O
manifestation None None O
of None None O
ALD None None O
. None None O

TNF None None I-protein
can None None O
induce None None O
cellular None None O
oxidative None None O
injury None None O
directly None None O
, None None O
and None None O
indirectly None None O
by None None O
inducing None None O
neutrophil None None O
chemotactic None None O
factor None None O
( None None O
IL-8 None None I-protein
) None None O
production None None O
by None None O
hepatocytes None None O
. None None O

IL-8 None None I-protein
activates None None O
and None None O
chemotactically None None O
attracts None None O
neutrophils None None O
to None None O
the None None O
liver None None O
where None None O
they None None O
release None None O
oxidizing None None O
substances None None O
. None None O

Patients None None O
with None None O
ALD None None O
also None None O
have None None O
decreased None None O
protective None None I-protein
factors None None I-protein
for None None O
cellular None None O
oxidative None None O
injury None None O
. None None O

Manganous None None I-protein
superoxide None None I-protein
dismutase None None I-protein
( None None O
MnSOD None None I-protein
) None None O
is None None O
an None None O
antioxidant None None I-protein
protective None None I-protein
factor None None I-protein
. None None O

The None None O
objectives None None O
of None None O
these None None O
studies None None O
were None None O
to None None O
investigate None None O
mechanisms None None O
for None None O
induction None None O
of None None O
an None None O
injurious None None I-protein
factor None None I-protein
( None None O
IL-8 None None I-protein
) None None O
and None None O
a None None O
protective None None I-protein
factor None None I-protein
( None None O
MnSOD None None I-protein
) None None O
in None None O
the None None O
HepG2 None None I-cell_line
human None None I-cell_line
hepatoma None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
. None None O

In None None O
the None None O
first None None O
set None None O
of None None O
experiments None None O
, None None O
IL-8 None None I-DNA
gene None None I-DNA
reporter None None I-DNA
constructs None None I-DNA
were None None O
used None None O
to None None O
transiently None None O
transfect None None O
a None None O
derivative None None O
( None None O
MVh2E1-9 None None I-cell_line
) None None O
of None None O
the None None O
HepG2 None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
which None None O
expresses None None O
P-4502E1 None None I-protein
and None None O
metabolizes None None O
ethanol None None O
. None None O

Inactivation None None O
of None None O
the None None O
NF-kappaB None None I-DNA
and None None I-DNA
3'NF-IL-6 None None I-DNA
DNA None None I-DNA
binding None None I-DNA
sites None None I-DNA
decreased None None O
IL-8 None None I-DNA
gene None None I-DNA
transcriptional None None O
activation None None O
in None None O
response None None O
to None None O
TNF None None I-protein
while None None O
inactivation None None O
of None None O
the None None O
5'NF-IL-6 None None I-DNA
binding None None I-DNA
site None None I-DNA
increased None None O
IL-8 None None I-DNA
gene None None I-DNA
transcriptional None None O
activity None None O
in None None O
response None None O
to None None O
TNF None None I-protein
. None None O

This None None O
system None None O
may None None O
be None None O
useful None None O
to None None O
assess None None O
the None None O
effects None None O
of None None O
ethanol None None O
on None None O
TNF None None I-protein
-induced None None O
hepatocyte None None O
IL-8 None None I-protein
production None None O
. None None O

In None None O
the None None O
second None None O
set None None O
of None None O
experiments None None O
, None None O
HepG2 None None I-cell_line
cells None None I-cell_line
were None None O
cultured None None O
in None None O
25 None None O
to None None O
100 None None O
mmol None None O
concentrations None None O
of None None O
ethanol None None O
. None None O

Both None None O
TNF None None I-protein
and None None O
ethanol None None O
increased None None O
HepG2 None None I-cell_line
cell None None I-cell_line
MnSOD None None I-protein
activity None None O
in None None O
short-term None None O
( None None O
72 None None O
hr None None O
) None None O
cultures None None O
with None None O
ethanol None None O
. None None O

However None None O
, None None O
after None None O
long-term None None O
( None None O
10 None None O
weeks None None O
) None None O
culture None None O
with None None O
ethanol None None O
, None None O
there None None O
was None None O
no None None O
induction None None O
of None None O
MnSOD None None I-protein
by None None O
ethanol None None O
and None None O
there None None O
was None None O
a None None O
diminished None None O
induction None None O
of None None O
MnSOD None None I-protein
in None None O
response None None O
to None None O
TNF None None I-protein
. None None O

Further None None O
studies None None O
are None None O
needed None None O
to None None O
assess None None O
the None None O
effect None None O
of None None O
this None None O
diminished None None O
induction None None O
of None None O
MnSOD None None I-protein
with None None O
chronic None None O
ethanol None None O
culture None None O
on None None O
HepG2 None None I-cell_line
cell None None I-cell_line
susceptibility None None O
to None None O
TNF None None I-cell_line
cytotoxicity None None I-cell_line
. None None O

We None None O
conclude None None O
that None None O
transfected None None O
liver None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
can None None O
be None None O
used None None O
to None None O
evaluate None None O
mechanisms None None O
for None None O
increased None None O
injurious None None I-protein
factors None None I-protein
and None None O
decreased None None O
protective None None I-protein
factors None None I-protein
in None None O
alcoholic None None O
liver None None O
injury None None O
. None None O

Tissue None None O
factor None None O
transcription None None O
driven None None O
by None None O
Egr-1 None None I-protein
is None None O
a None None O
critical None None O
mechanism None None O
of None None O
murine None None I-protein
pulmonary None None I-protein
fibrin None None I-protein
deposition None None O
in None None O
hypoxia None None O
. None None O

Local None None O
hypoxemia None None O
and None None O
stasis None None O
trigger None None O
thrombosis None None O
. None None O

We None None O
have None None O
demonstrated None None O
previously None None O
that None None O
in None None O
a None None O
murine None None O
model None None O
of None None O
normobaric None None O
hypoxia None None O
pulmonary None None O
fibrin None None I-protein
deposition None None O
is None None O
a None None O
result None None O
of None None O
expression None None O
of None None O
tissue None None I-protein
factor None None I-protein
, None None O
especially None None O
in None None O
oxygen-deprived None None I-protein
mononuclear None None I-protein
phagocytes None None I-protein
( None None O
MPs None None I-protein
) None None O
. None None O

We None None O
now None None O
show None None O
that None None O
transcription None None I-protein
factor None None I-protein
early-growth-response None None I-protein
gene None None I-protein
product None None I-protein
( None None O
Egr-1 None None I-protein
) None None O
is None None O
rapidly None None O
activated None None O
in None None O
hypoxia None None O
, None None O
both None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
, None None O
and None None O
is None None O
responsible None None O
for None None O
transcription None None O
and None None O
expression None None O
of None None O
tissue None None I-protein
factor None None I-protein
in None None O
hypoxic None None O
lung None None O
. None None O

MPs None None I-protein
and None None O
HeLa None None I-cell_line
cells None None I-cell_line
subjected None None O
to None None O
hypoxia None None O
( None None O
pO2 None None O
approximately None None O
13 None None O
torr None None O
) None None O
had None None O
increased None None O
levels None None O
of None None O
tissue None None I-RNA
factor None None I-RNA
transcripts None None I-RNA
( None None O
approximately None None O
18-fold None None O
) None None O
and None None O
an None None O
increased None None O
rate None None O
of None None O
transcription None None O
( None None O
approximately None None O
15-fold None None O
) None None O
, None None O
based None None O
on None None O
nuclear None None O
run-on None None O
analysis None None O
. None None O

Gel-shift None None O
analysis None None O
of None None O
nuclear None None O
extracts None None O
from None None O
hypoxic None None I-protein
MPs None None I-protein
and None None O
HeLa None None I-cell_line
cells None None I-cell_line
demonstrated None None O
increased None None O
DNA-binding None None O
activity None None O
at None None O
the None None O
serum None None I-DNA
response None None I-DNA
region None None I-DNA
( None None O
SRR None None O
; None None O
-111/+14 None None O
bp None None O
) None None O
of None None O
the None None O
tissue None None I-DNA
factor None None I-DNA
promoter None None I-DNA
at None None O
Egr-1 None None I-DNA
motifs None None I-DNA
. None None O

Using None None O
32P-labeled None None O
Egr None None O
consensus None None O
oligonucleotide None None O
, None None O
we None None O
observed None None O
induction None None O
of None None O
DNA-binding None None O
activity None None O
in None None O
nuclear None None O
extracts None None O
from None None O
hypoxic None None O
lung None None O
and None None O
HeLa None None I-cell_line
cells None None I-cell_line
because None None O
of None None O
activation None None O
of None None O
Egr-1 None None I-protein
, None None O
by None None O
means None None O
of None None O
supershift None None O
analysis None None O
. None None O

Transient None None O
transfection None None O
of None None O
HeLa None None I-cell_line
cells None None I-cell_line
with None None O
chimeric None None I-DNA
plasmids None None I-DNA
containing None None O
wild-type None None I-protein
or None None I-protein
mutant None None I-protein
SRR None None I-protein
from None None O
the None None O
tissue None None I-DNA
factor None None I-DNA
promoter None None I-DNA
showed None None O
that None None O
intact None None I-DNA
Sp1 None None I-DNA
sites None None I-DNA
are None None O
necessary None None O
for None None O
basal None None O
promoter None None O
activity None None O
, None None O
whereas None None O
the None None O
integrity None None O
of None None O
Egr-1 None None I-DNA
sites None None I-DNA
was None None O
required None None O
for None None O
hypoxia-enhanced None None O
expression None None O
. None None O

A None None O
central None None O
role None None O
for None None O
Egr-1 None None I-protein
in None None O
hypoxia-mediated None None O
tissue None None O
factor None None O
expression None None O
was None None O
confirmed None None O
by None None O
experiments None None O
with None None O
homozygous None None O
Egr-1 None None I-protein
null None None O
mice None None O
; None None O
wild-type None None O
mice None None O
subjected None None O
to None None O
oxygen None None I-protein
deprivation None None I-protein
expressed None None I-protein
tissue None None I-protein
factor None None I-protein
and None None O
showed None None O
fibrin None None I-protein
deposition None None O
, None None O
but None None O
hypoxic None None O
homozygous None None O
Egr-1 None None I-protein
null None None O
mice None None O
displayed None None O
neither None None O
tissue None None I-protein
factor None None I-protein
nor None None O
fibrin None None I-protein
. None None O

These None None O
data None None O
delineate None None O
a None None O
novel None None O
biology None None O
for None None O
hypoxia-induced None None O
fibrin None None I-protein
deposition None None O
, None None O
in None None O
which None None O
oxygen None None O
deprivation-induced None None O
activation None None O
of None None O
Egr-1 None None I-protein
, None None O
resulting None None O
in None None O
expression None None O
of None None O
tissue None None I-protein
factor None None I-protein
, None None O
has None None O
an None None O
unexpected None None O
and None None O
central None None O
role None None O
. None None O

Kinetics None None O
of None None O
cytokine None None O
and None None O
NFAT None None O
gene None None O
expression None None O
in None None O
human None None I-cell_line
interleukin-2-dependent None None I-cell_line
T None None I-cell_line
lymphoblasts None None I-cell_line
stimulated None None O
via None None O
T-cell None None I-protein
receptor None None I-protein
. None None O

T None None I-cell_type
cells None None I-cell_type
respond None None O
to None None O
mitogenic None None O
or None None O
antigenic None None O
stimulation None None O
by None None O
proliferation None None O
and None None O
by None None O
turning None None O
on None None O
cytokine None None O
gene None None O
expression None None O
. None None O

Here None None O
we None None O
have None None O
analysed None None O
the None None O
kinetics None None O
and None None O
nature None None O
of None None O
cytokine None None O
production None None O
in None None O
human None None I-cell_type
peripheral None None I-cell_type
blood-derived None None I-cell_type
T None None I-cell_type
lymphoblasts None None I-cell_type
stimulated None None O
with None None O
anti-CD3 None None I-protein
antibodies None None I-protein
or None None O
Lens None None I-protein
culinaris None None I-protein
lectin None None I-protein
( None None O
LCL None None I-protein
) None None O
. None None O

T None None I-cell_type
cells None None I-cell_type
were None None O
purified None None O
from None None O
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
( None None O
PBMC None None I-cell_type
) None None O
and None None O
primarily None None O
activated None None O
with None None O
anti-CD3 None None I-protein
antibodies None None I-protein
and None None O
cultured None None O
in None None O
the None None O
presence None None O
of None None O
interleukin-2 None None I-protein
( None None O
IL-2 None None I-protein
) None None O
. None None O

Anti-CD3-restimulated None None O
T None None I-cell_type
cells None None I-cell_type
( None None O
mainly None None O
CD8+ None None O
) None None O
produced None None O
IL-2 None None I-protein
, None None O
interferon-gamma None None I-protein
( None None O
IFN-gamma None None I-protein
) None None O
and None None O
tumour None None I-protein
necrosis None None I-protein
factor-alpha None None I-protein
( None None O
TNF-alpha None None I-protein
) None None O
and None None O
low None None O
levels None None O
of None None O
IL-4 None None I-RNA
and None None I-RNA
IL-10 None None I-RNA
transcripts None None I-RNA
and None None O
proteins None None O
. None None O

No None None O
IL-6 None None I-DNA
gene None None I-DNA
expression None None O
was None None O
observed None None O
. None None O

In None None O
LCL-stimulated None None I-cell_type
cells None None I-cell_type
the None None O
cytokine None None O
production None None O
pattern None None O
was None None O
very None None O
similar None None O
. None None O

Steady-state None None O
mRNA None None O
levels None None O
of None None O
IL-2 None None I-protein
, None None O
IL-10 None None I-protein
and None None O
IFN-gamma None None I-protein
peaked None None O
at None None O
3 None None O
hr None None O
after None None O
anti-CD3 None None O
stimulation None None O
and None None O
declined None None O
rapidly None None O
thereafter None None O
. None None O

The None None O
kinetics None None O
of None None O
TNF-alpha None None I-RNA
mRNA None None I-RNA
expression None None O
was None None O
faster None None O
, None None O
being None None O
at None None O
its None None O
peak None None O
level None None O
1 None None O
hr None None O
after None None O
stimulation None None O
. None None O

Anti-CD3-stimulated None None O
IL-2 None None I-DNA
gene None None I-DNA
expression None None O
was None None O
down-regulated None None O
by None None O
protein None None O
synthesis None None O
inhibitor None None O
, None None O
whereas None None O
IL-10 None None I-DNA
, None None I-DNA
IFN-gamma None None I-DNA
and None None I-DNA
TNF-alpha None None I-DNA
genes None None I-DNA
were None None O
readily None None O
induced None None O
independent None None O
of None None O
ongoing None None O
protein None None O
synthesis None None O
. None None O

T-cell None None I-protein
receptor None None I-protein
stimulation None None O
also None None O
induced None None O
a None None O
very None None O
rapid None None O
expression None None O
of None None O
c-jun None None I-DNA
, None None I-DNA
c-fos None None I-DNA
and None None I-DNA
NFATc1 None None I-DNA
( None None I-DNA
NFATc None None I-DNA
) None None I-DNA
genes None None I-DNA
, None None O
the None None O
gene None None O
products None None O
of None None O
which None None O
are None None O
involved None None O
in None None O
cytokine None None O
gene None None O
expression None None O
. None None O

In None None O
conclusion None None O
, None None O
the None None O
cytokines None None I-protein
synthesized None None O
by None None O
IL-2-dependent None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
were None None O
predominantly None None O
IL-2 None None I-protein
, None None O
IFN-gamma None None I-protein
and None None O
TNF-alpha None None I-protein
. None None O

An None None O
animal None None O
model None None O
to None None O
study None None O
local None None O
oxidation None None O
of None None O
LDL None None O
and None None O
its None None O
biological None None O
effects None None O
in None None O
the None None O
arterial None None O
wall None None O
. None None O

Oxidized None None O
LDL None None O
( None None O
oxLDL None None O
) None None O
is None None O
present None None O
in None None O
atherosclerotic None None O
lesions None None O
and None None O
is None None O
believed None None O
to None None O
play None None O
a None None O
key None None O
role None None O
in None None O
atherogenesis None None O
. None None O

Mainly None None O
on None None O
the None None O
basis None None O
of None None O
cell None None O
culture None None O
studies None None O
, None None O
oxLDL None None O
has None None O
been None None O
shown None None O
to None None O
produce None None O
many None None O
biological None None O
effects None None O
that None None O
influence None None O
the None None O
atherosclerotic None None O
process None None O
. None None O

To None None O
study None None O
LDL None None O
oxidation None None O
in None None O
vivo None None O
, None None O
we None None O
have None None O
established None None O
a None None O
model None None O
in None None O
which None None O
Sprague-Dawley None None O
rats None None O
are None None O
given None None O
a None None O
single None None O
injection None None O
of None None O
unmodified None None O
human None None O
LDL None None O
( None None O
> None None O
or None None O
= None None O
4 None None O
mg/kg None None O
body None None O
weight None None O
) None None O
. None None O

Within None None O
6 None None O
hours None None O
, None None O
an None None O
accumulation None None O
of None None O
apolipoprotein None None O
B None None O
and None None O
epitopes None None I-protein
present None None O
on None None O
oxLDL None None O
are None None O
detected None None O
in None None O
the None None O
arterial None None O
endothelium None None O
and None None O
media None None O
. None None O

The None None O
presence None None O
of None None O
oxLDL None None O
is None None O
associated None None O
with None None O
activation None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
nuclear None None B-protein
factor-kappaB None None I-protein
in None None O
the None None O
endothelium None None O
as None None O
well None None O
as None None O
endothelial None None O
expression None None O
of None None O
intercellular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
. None None O

Injection None None O
of None None O
LDL None None O
enriched None None O
with None None O
the None None O
antioxidant None None O
probucol None None O
resulted None None O
in None None O
arterial None None O
accumulation None None O
of None None O
apolipoprotein None None O
B None None O
, None None O
but None None O
the None None O
expression None None O
of None None O
oxLDL-specific None None O
epitopes None None O
was None None O
reduced None None O
at None None O
24 None None O
hours None None O
. None None O

Thus None None O
, None None O
this None None O
simple None None O
model None None O
has None None O
the None None O
potential None None O
to None None O
analyze None None O
the None None O
mechanisms None None O
behind None None O
and None None O
biological None None O
effects None None O
of None None O
LDL None None O
oxidation None None O
in None None O
vivo None None O
. None None O

Molecular None None O
mechanisms None None O
of None None O
promoter None None O
regulation None None O
of None None O
the None None O
gp34 None None I-DNA
gene None None I-DNA
that None None O
is None None O
trans-activated None None O
by None None O
an None None O
oncoprotein None None I-protein
Tax None None I-protein
of None None O
human None None O
T None None O
cell None None O
leukemia None None O
virus None None O
type None None O
I None None O
. None None O

We None None O
investigated None None O
the None None O
molecular None None O
mechanism None None O
of None None O
transcriptional None None O
activation None None O
of None None O
the None None O
gp34 None None I-DNA
gene None None I-DNA
by None None O
the None None O
Tax None None I-protein
oncoprotein None None I-protein
of None None O
human None None O
T None None O
cell None None O
leukemia None None O
virus None None O
type None None O
I None None O
( None None O
HTLV-I None None O
) None None O
. None None O

gp34 None None I-protein
is None None O
a None None O
type None None I-protein
II None None I-protein
transmembrane None None I-protein
molecule None None I-protein
belonging None None O
to None None O
the None None O
tumor None None O
necrosis None None O
factor None None O
family None None O
and None None O
is None None O
constitutively None None O
expressed None None O
on None None O
HTLV-I-producing None None I-cell_type
cells None None I-cell_type
but None None O
not None None O
normal None None I-cell_type
resting None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
transcriptional None None O
regulatory None None O
region None None O
of None None O
the None None O
gp34 None None I-DNA
gene None None I-DNA
was None None O
activated None None O
by None None O
HTLV-I None None O
Tax None None I-protein
in None None O
the None None O
human None None I-cell_line
T None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
Jurkat None None I-cell_line
, None None O
in None None O
which None None O
endogenous None None O
gp34 None None I-protein
is None None O
induced None None O
by None None O
Tax None None I-protein
. None None O

Sequence None None O
analysis None None O
demonstrated None None O
that None None O
two None None O
NF-kappaB-like None None I-DNA
elements None None I-DNA
( None None O
1 None None O
and None None O
2 None None O
) None None O
were None None O
present None None O
in None None O
the None None O
regulatory None None I-DNA
region None None I-DNA
. None None O

Both None None O
NF-kappaB-like None None I-DNA
elements None None I-DNA
were None None O
able None None O
to None None O
bind None None O
to None None O
NF-kappaB None None I-protein
or None None O
its None None O
related None None O
factor None None O
( None None O
s None None O
) None None O
in None None O
a None None O
Tax None None I-protein
-dependent None None O
manner None None O
. None None O

Chloramphenicol None None I-protein
acetyltransferase None None I-protein
assays None None O
indicated None None O
that None None O
NF-kappaB-like None None I-DNA
element None None I-DNA
1 None None I-DNA
was None None O
Tax None None I-protein
-responsive None None O
, None None O
although None None O
the None None O
activity None None O
was None None O
lower None None O
than None None O
that None None O
the None None O
native None None I-DNA
promoter None None I-DNA
. None None O

NF-kappaB None None I-protein
-like None None O
element None None O
2 None None O
elevated None None O
promoter None None O
activity None None O
when None None O
combined None None O
with None None O
NF-kappaB-like None None I-DNA
element None None I-DNA
1 None None I-DNA
, None None O
indicating None None O
cooperative None None O
function None None O
of None None O
the None None O
elements None None O
for None None O
maximum None None O
promoter None None O
function None None O
. None None O

Unlike None None O
typical None None O
NF-kappaB None None I-DNA
elements None None I-DNA
, None None O
the None None O
NF-kappaB-like None None I-DNA
elements None None I-DNA
in None None O
gp34 None None I-protein
were None None O
not None None O
activated None None O
by None None O
treatment None None O
of None None O
Jurkat None None I-cell_line
cells None None I-cell_line
with None None O
phorbol None None O
ester None None O
despite None None O
induction None None O
of None None O
the None None O
NF-kappaB None None I-protein
-like None None O
binding None None O
activity None None O
. None None O

Chloramphenicol None None I-protein
acetyltransferase None None I-protein
reporter None None O
assays None None O
using None None O
the None None O
region None None O
upstream None None O
of None None O
the None None O
NF-kappaB-like None None I-DNA
elements None None I-DNA
identified None None O
an None None O
upstream None None O
region None None O
that None None O
reduced None None O
transcription None None O
from None None O
cognate None None I-DNA
and None None I-DNA
noncognate None None I-DNA
core None None I-DNA
promoters None None I-DNA
in None None O
a None None O
Tax-independent None None O
manner None None O
. None None O

Our None None O
results None None O
imply None None O
complex None None O
regulation None None O
of None None O
expression None None O
of None None O
the None None O
gp34 None None I-DNA
gene None None I-DNA
and None None O
suggest None None O
implication None None O
of None None O
gp34 None None I-protein
in None None O
proliferation None None O
of None None O
HTLV-I None None O
infected None None O
T None None O
cells None None O
. None None O

beta-Amyloid None None I-protein
fibrils None None I-protein
activate None None O
parallel None None O
mitogen-activated None None I-protein
protein None None I-protein
kinase None None I-protein
pathways None None O
in None None O
microglia None None I-cell_type
and None None O
THP1 None None I-cell_line
monocytes None None I-cell_line
. None None O

The None None O
senile None None O
plaques None None O
of None None O
Alzheimer None None O
's None None O
disease None None O
are None None O
foci None None O
of None None O
local None None O
inflammatory None None O
responses None None O
, None None O
as None None O
evidenced None None O
by None None O
the None None O
presence None None O
of None None O
acute None None I-protein
phase None None I-protein
proteins None None I-protein
and None None O
oxidative None None O
damage None None O
. None None O

Fibrillar None None I-protein
forms None None I-protein
of None None O
beta-amyloid None None I-protein
( None None O
Abeta None None I-protein
) None None O
, None None O
which None None O
are None None O
the None None O
primary None None O
constituents None None O
of None None O
senile None None O
plaques None None O
, None None O
have None None O
been None None O
shown None None O
to None None O
activate None None O
tyrosine None None O
kinase-dependent None None O
signal None None O
transduction None None O
cascades None None O
, None None O
resulting None None O
in None None O
inflammatory None None O
responses None None O
in None None O
microglia None None I-cell_type
. None None O

However None None O
, None None O
the None None O
downstream None None O
signaling None None O
pathways None None O
mediating None None O
Abeta None None I-protein
-induced None None O
inflammatory None None O
events None None O
are None None O
not None None O
well None None O
characterized None None O
. None None O

We None None O
report None None O
that None None O
exposure None None O
of None None O
primary None None I-cell_type
rat None None I-cell_type
microglia None None I-cell_type
and None None O
human None None I-cell_line
THP1 None None I-cell_line
monocytes None None I-cell_line
to None None O
fibrillar None None I-protein
Abeta None None I-protein
results None None O
in None None O
the None None O
tyrosine None None I-protein
kinase None None I-protein
-dependent None None O
activation None None O
of None None O
two None None O
parallel None None O
signal None None O
transduction None None O
cascades None None O
involving None None O
members None None O
of None None O
the None None O
mitogen-activated None None I-protein
protein None None I-protein
kinase None None I-protein
( None None I-protein
MAPK None None I-protein
) None None I-protein
superfamily None None I-protein
. None None O

Abeta None None I-protein
stimulated None None O
the None None O
rapid None None O
, None None O
transient None None O
activation None None O
of None None O
extracellular None None I-protein
signal-regulated None None I-protein
kinase None None I-protein
1 None None I-protein
( None None O
ERK1 None None I-protein
) None None O
and None None O
ERK2 None None I-protein
in None None O
microglia None None I-cell_type
and None None O
ERK2 None None I-protein
in None None O
THP1 None None I-cell_line
monocytes None None I-cell_line
. None None O

A None None O
second None None O
superfamily None None I-protein
member None None I-protein
, None None O
p38 None None I-protein
MAPK None None I-protein
, None None O
was None None O
also None None O
activated None None O
with None None O
similar None None O
kinetics None None O
. None None O

Scavenger None None I-protein
receptor None None I-protein
and None None O
receptor None None I-protein
for None None I-protein
advanced None None I-protein
glycated None None I-protein
end None None I-protein
products None None I-protein
( None None O
RAGE None None I-protein
) None None O
ligands None None O
failed None None O
to None None O
activate None None O
ERK None None I-protein
and None None O
p38 None None I-protein
MAPK None None I-protein
in None None O
the None None O
absence None None O
of None None O
significant None None O
increases None None O
in None None O
protein None None O
tyrosine None None O
phosphorylation None None O
, None None O
demonstrating None None O
that None None O
scavenger None None I-protein
receptors None None I-protein
and None None O
RAGE None None I-protein
are None None O
not None None O
linked None None O
to None None O
these None None O
pathways None None O
. None None O

Importantly None None O
, None None O
the None None O
stress-activated None None I-protein
protein None None I-protein
kinases None None I-protein
( None None O
SAPKs None None I-protein
) None None O
were None None O
not None None O
significantly None None O
activated None None O
in None None O
response None None O
to None None O
Abeta None None I-protein
. None None O

Downstream None None O
effectors None None O
of None None O
the None None O
MAPK None None O
signal None None O
transduction None None O
cascades None None O
include None None O
MAPKAP None None I-protein
kinases None None I-protein
, None None O
such None None O
as None None O
RSK1 None None I-protein
and None None O
RSK2 None None I-protein
, None None O
as None None O
well None None O
as None None O
transcription None None I-protein
factors None None I-protein
. None None O

Exposure None None O
of None None O
microglia None None I-cell_type
and None None O
THP1 None None I-cell_line
monocytes None None I-cell_line
to None None O
Abeta None None I-protein
resulted None None O
in None None O
the None None O
activation None None O
of None None O
RSK1 None None I-protein
and None None O
RSK2 None None I-protein
and None None O
phosphorylation None None O
of None None O
cAMP None None I-protein
response None None I-protein
element-binding None None I-protein
protein None None I-protein
at None None O
Ser133 None None O
, None None O
providing None None O
a None None O
mechanism None None O
for None None O
Abeta None None I-protein
-induced None None O
changes None None O
in None None O
gene None None O
expression None None O

Regulation None None O
of None None O
cellular None None I-protein
retinoic None None I-protein
acid None None I-protein
binding None None I-protein
protein None None I-protein
( None None O
CRABP None None I-protein
II None None I-protein
) None None O
during None None O
human None None I-cell_type
monocyte None None I-cell_type
differentiation None None O
in None None O
vitro None None O
. None None O

Cellular None None I-protein
retinoic None None I-protein
acid None None I-protein
binding None None I-protein
proteins None None I-protein
( None None O
CRABP None None I-protein
) None None O
are None None O
low None None I-protein
molecular None None I-protein
weight None None I-protein
proteins None None I-protein
whose None None O
precise None None O
function None None O
remains None None O
unknown None None O
. None None O

They None None O
bind None None O
retinoids None None O
and None None O
may None None O
thereby None None O
modulate None None O
the None None O
intracellular None None O
steady-state None None O
concentration None None O
of None None O
retinoids None None O
. None None O

Whereas None None O
CRABP None None I-protein
I None None I-protein
is None None O
ubiquitously None None O
expressed None None O
, None None O
CRABP None None I-protein
II None None I-protein
is None None O
mainly None None O
detected None None O
in None None O
various None None O
cell None None O
types None None O
of None None O
the None None O
skin None None O
. None None O

By None None O
representative None None O
difference None None O
analysis None None O
we None None O
found None None O
that None None O
CRABP None None I-protein
II None None I-protein
is None None O
also None None O
strongly None None O
expressed None None O
in None None O
human None None I-cell_type
monocyte-derived None None I-cell_type
macrophages None None I-cell_type
( None None O
MAC None None I-cell_type
) None None O
but None None O
not None None O
in None None O
freshly None None I-cell_type
isolated None None I-cell_type
monocytes None None I-cell_type
( None None O
MO None None I-cell_type
) None None O
. None None O

The None None O
CRABP None None I-RNA
II None None I-RNA
mRNA None None I-RNA
was None None O
gradually None None O
upregulated None None O
during None None O
differentiation None None O
from None None O
MO None None I-cell_type
to None None O
MAC None None I-cell_type
in None None O
the None None O
presence None None O
of None None O
2 None None O
% None None O
serum None None O
. None None O

Adherence None None O
, None None O
which None None O
is None None O
important None None O
for None None O
MO None None I-cell_type
differentiation None None O
, None None O
induced None None O
CRABP None None I-protein
II None None I-protein
expression None None O
, None None O
but None None O
the None None O
addition None None O
of None None O
10 None None O
( None None O
-7 None None O
) None None O
M None None O
retinoic None None O
acid None None O
inhibited None None O
the None None O
upregulation None None O
of None None O
CRABP None None I-protein
II None None I-protein
expression None None O
during None None O
MO/MAC None None O
differentiation None None O
. None None O

As None None O
MO None None I-cell_type
can None None O
differentiate None None O
along None None O
the None None O
classical None None O
pathway None None O
not None None O
only None None O
to None None O
MAC None None I-cell_type
but None None O
also None None O
to None None O
dendritic None None O
cells None None O
we None None O
analyzed None None O
the None None O
expression None None O
of None None O
CRABP None None I-protein
II None None I-protein
in None None O
MO-derived None None I-cell_type
dendritic None None I-cell_type
cells None None I-cell_type
cultured None None O
with None None O
10 None None O
% None None O
FCS None None I-protein
, None None O
IL-4 None None I-protein
, None None O
and None None O
GM-CSF None None I-protein
. None None O

In None None O
contrast None None O
to None None O
MAC None None I-cell_type
, None None O
MO-derived None None I-cell_type
dendritic None None I-cell_type
cells None None I-cell_type
showed None None O
an None None O
extremely None None O
low None None O
expression None None O
of None None O
CRABP None None I-protein
II None None I-protein
. None None O

From None None O
these None None O
results None None O
we None None O
conclude None None O
( None None O
1 None None O
) None None O
that None None O
the None None O
availability None None O
and None None O
the None None O
metabolism None None O
of None None O
retinoids None None O
may None None O
be None None O
different None None O
in None None O
MAC None None I-cell_type
compared None None O
to None None O
MO None None I-cell_type
and None None O
dendritic None None I-cell_type
cells None None I-cell_type
and None None O
( None None O
2 None None O
) None None O
that None None O
this None None O
may None None O
influence None None O
differentiation None None O
and None None O
activation None None O
of None None O
those None None O
cells None None O
. None None O

Transcription None None I-protein
factor None None I-protein
B-cell-specific None None I-protein
activator None None I-protein
protein None None I-protein
( None None O
BSAP None None I-protein
) None None O
is None None O
differentially None None O
expressed None None O
in None None O
B None None I-cell_type
cells None None I-cell_type
and None None O
in None None O
subsets None None O
of None None O
B-cell None None O
lymphomas None None O
. None None O

The None None O
paired None None I-DNA
box None None I-DNA
containing None None I-DNA
gene None None I-DNA
PAX-5 None None B-DNA
encodes None None O
the None None O
transcription None None I-protein
factor None None I-protein
BSAP None None B-protein
( None None O
B-cell-specific None None I-protein
activator None None I-protein
protein None None I-protein
) None None O
, None None O
which None None O
plays None None O
a None None O
key None None O
role None None O
in None None O
B-lymphocyte None None O
development None None O
. None None O

Despite None None O
its None None O
known None None O
involvement None None O
in None None O
a None None O
rare None None O
subtype None None O
of None None O
non-Hodgkin None None O
's None None O
lymphoma None None O
( None None O
NHL None None O
) None None O
, None None O
a None None O
detailed None None O
examination None None O
of None None O
BSAP None None I-protein
expression None None O
in None None O
NHL None None O
has None None O
not None None O
been None None O
previously None None O
reported None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
analyzed None None O
normal None None O
and None None O
malignant None None O
lymphoid None None O
tissues None None O
and None None O
cell None None I-cell_line
lines None None I-cell_line
, None None O
including None None O
102 None None O
cases None None O
of None None O
B-cell None None O
NHL None None O
, None None O
23 None None O
cases None None O
of None None O
T- None None O
and None None O
null-cell None None O
NHL None None O
, None None O
and None None O
18 None None O
cases None None O
of None None O
Hodgkin None None O
's None None O
disease None None O
. None None O

Normal None None O
lymphoid None None O
tissues None None O
showed None None O
strong None None O
nuclear None None O
BSAP None None I-protein
expression None None O
in None None O
mantle None None I-cell_type
zone None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
, None None O
less None None O
intense None None O
reactivity None None O
in None None O
follicular None None I-cell_type
center None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
, None None O
and None None O
no None None O
expression None None O
in None None O
cells None None O
of None None O
the None None O
T-cell-rich None None O
zones None None O
. None None O

Monocytoid None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
showed None None O
weak None None O
expression None None O
, None None O
whereas None None O
plasma None None I-cell_type
cells None None I-cell_type
and None None O
extrafollicular None None I-cell_type
large None None I-cell_type
transformed None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
were None None O
negative None None O
. None None O

Of None None O
the None None O
102 None None O
B-cell None None O
NHLs None None O
, None None O
83 None None O
( None None O
81 None None O
% None None O
) None None O
demonstrated None None O
BSAP None None I-protein
expression None None O
. None None O

All None None O
of None None O
the None None O
13 None None O
( None None O
100 None None O
% None None O
) None None O
B-cell None None O
chronic None None O
lymphocytic None None O
leukemias None None O
( None None O
B-CLLs None None O
) None None O
, None None O
21 None None O
of None None O
( None None O
100 None None O
% None None O
) None None O
mantle None None I-cell_type
cells None None I-cell_type
( None None O
MCLs None None I-cell_type
) None None O
, None None O
and None None O
20 None None O
of None None O
21 None None O
( None None O
95 None None O
% None None O
) None None O
follicular None None O
lymphomas None None O
( None None O
FLs None None O
) None None O
were None None O
positive None None O
. None None O

Moderate None None O
staining None None O
intensities None None O
were None None O
found None None O
in None None O
most None None O
B-CLL None None O
and None None O
FL None None O
cases None None O
, None None O
whereas None None O
most None None O
MCLs None None I-cell_type
showed None None O
strong None None O
reactions None None O
, None None O
paralleling None None O
the None None O
strong None None O
reactivity None None O
of None None O
nonmalignant None None I-cell_type
mantle None None I-cell_type
cells None None I-cell_type
. None None O

Eight None None O
of None None O
12 None None O
( None None O
67 None None O
% None None O
) None None O
marginal None None O
zone None None O
lymphoma None None O
cases None None O
showed None None O
negative None None O
or None None O
low None None O
BSAP None None I-protein
levels None None O
, None None O
and None None O
17 None None O
of None None O
24 None None O
( None None O
71 None None O
% None None O
) None None O
large None None O
B-cell None None O
lymphomas None None O
displayed None None O
moderate None None O
to None None O
strong None None O
expression None None O
. None None O

None None None O
of None None O
the None None O
23 None None O
T- None None O
and None None O
null-cell None None O
lymphomas None None O
reacted None None O
with None None O
the None None O
BSAP None None I-protein
antisera None None O
, None None O
whereas None None O
in None None O
Hodgkin None None O
's None None O
disease None None O
, None None O
2 None None O
of None None O
4 None None O
( None None O
50 None None O
% None None O
) None None O
nodular None None O
lymphocytic None None O
predominance None None O
and None None O
5 None None O
of None None O
14 None None O
( None None O
36 None None O
% None None O
) None None O
classical None None O
cases None None O
showed None None O
weak None None O
nuclear None None O
or None None O
nucleolar None None O
BSAP None None I-protein
reactions None None O
in None None O
a None None O
fraction None None O
of None None O
the None None O
tumor None None I-cell_type
cells None None I-cell_type
. None None O

Western None None O
blot None None O
analysis None None O
showed None None O
a None None O
52-kD None None O
BSAP None None I-protein
band None None O
in None None O
B-cell None None I-cell_line
lines None None I-cell_line
, None None O
but None None O
not None None O
in None None O
non-B-cell None None I-cell_line
or None None I-cell_line
plasma None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
. None None O

We None None O
conclude None None O
that None None O
BSAP None None I-protein
expression None None O
is None None O
largely None None O
restricted None None O
to None None O
lymphomas None None O
of None None O
B-cell None None I-cell_type
lineage None None I-cell_type
and None None O
that None None O
BSAP None None I-protein
expression None None O
varies None None O
in None None O
B-cell None None I-cell_type
subsets None None I-cell_type
and None None O
subtypes None None O
of None None O
B-cell None None O
NHL None None O
. None None O

The None None O
high None None O
levels None None O
of None None O
BSAP None None I-protein
, None None O
especially None None O
those None None O
found None None O
in None None O
large-cell None None I-cell_type
lymphomas None None I-cell_type
and None None O
in None None O
some None None O
follicular None None I-cell_type
lymphomas None None I-cell_type
, None None O
may None None O
be None None O
a None None O
consequence None None O
of None None O
deregulated None None O
gene None None O
expression None None O
and None None O
suggest None None O
a None None O
possible None None O
involvement None None O
of None None O
PAX-5 None None I-DNA
in None None O
certain None None O
B-cell None None O
malignancies None None O
. None None O

This None None O
is None None O
a None None O
US None None O
government None None O
work None None O
. None None O

There None None O
are None None O
no None None O
restrictions None None O
on None None O
its None None O
use None None O
. None None O

Mitogen None None O
and None None O
growth None None O
factor-induced None None O
activation None None O
of None None O
a None None O
STAT-like None None I-protein
molecule None None I-protein
in None None O
channel None None I-cell_type
catfish None None I-cell_type
lymphoid None None I-cell_type
cells None None I-cell_type
. None None O

This None None O
article None None O
describes None None O
the None None O
identification None None O
of None None O
a None None O
putative None None I-protein
STAT None None I-protein
molecule None None I-protein
in None None O
the None None O
channel None None O
catfish None None O
( None None O
Ictalurus None None O
punctatus None None O
) None None O
, None None O
the None None O
first None None O
report None None O
of None None O
such None None O
a None None O
molecule None None O
in None None O
a None None O
'lower None None O
' None None O
vertebrate None None O
. None None O

A None None O
monoclonal None None I-protein
antibody None None I-protein
against None None O
human None None I-protein
STAT6 None None I-protein
recognizes None None O
an None None O
approximately None None O
100 None None I-protein
kDa None None I-protein
molecule None None I-protein
that None None O
becomes None None O
activated None None O
and None None O
translocates None None O
to None None O
the None None O
nucleus None None O
upon None None O
both None None O
growth None None O
factor None None O
and None None O
mitogen None None O
stimulation None None O
of None None O
catfish None None O
leukocytes None None O
. None None O

This None None O
presumed None None O
catfish None None I-protein
STAT None None I-protein
binds None None O
the None None O
mammalian None None I-DNA
interferon-gamma None None I-DNA
activation None None I-DNA
site None None I-DNA
, None None O
a None None O
known None None O
motif None None O
of None None O
mammalian None None O
STAT None None O
binding None None O
, None None O
as None None O
shown None None O
by None None O
electromobility None None O
shift None None O
assays None None O
. None None O

Purification None None O
of None None O
the None None O
proteins None None O
present None None O
in None None O
these None None O
DNA None None I-protein
complexes None None I-protein
confirms None None O
that None None O
the None None O
catfish None None O
reactive None None O
molecule None None O
binds None None O
to None None O
the None None O
interferon-gamma None None I-DNA
activation None None I-DNA
site None None I-DNA
sequence None None I-DNA
. None None O

These None None O
results None None O
suggest None None O
that None None O
STAT None None I-protein
molecules None None I-protein
have None None O
been None None O
highly None None O
conserved None None O
in None None O
vertebrate None None O
evolution None None O
. None None O

Isolation None None O
and None None O
analysis None None O
of None None O
a None None O
T None None I-cell_line
cell None None I-cell_line
clone None None I-cell_line
variant None None I-cell_line
exhibiting None None O
constitutively None None O
phosphorylated None None I-protein
Ser133 None None I-protein
cAMP None None I-protein
response None None I-protein
element-binding None None I-protein
protein None None I-protein
. None None O

In None None O
driving None None O
T None None O
cell None None O
proliferation None None O
, None None O
IL-2 None None I-protein
stimulates None None O
a None None O
new None None O
program None None O
of None None O
gene None None O
expression None None O
that None None O
includes None None O
proliferating None None I-protein
cell None None I-protein
nuclear None None I-protein
antigen None None I-protein
( None None O
PCNA None None I-protein
) None None O
, None None O
a None None O
requisite None None O
processivity None None O
factor None None O
for None None O
DNA None None I-protein
polymerase None None I-protein
delta None None I-protein
. None None O

PCNA None None I-protein
transcription None None O
is None None O
regulated None None O
in None None O
part None None O
through None None O
tandem None None O
CRE None None I-DNA
sequences None None I-DNA
in None None O
the None None O
promoter None None I-protein
and None None I-protein
CRE None None I-protein
binding None None I-protein
proteins None None I-protein
; None None O
IL-2 None None I-protein
stimulates None None O
CREB None None O
phosphorylation None None O
in None None O
the None None O
resting None None I-cell_line
cloned None None I-cell_line
T None None I-cell_line
lymphocyte None None I-cell_line
, None None O
L2 None None I-cell_line
. None None O

After None None O
culturing None None O
L2 None None I-cell_line
cells None None I-cell_line
for None None O
greater None None O
than None None O
91 None None O
days None None O
, None None O
we None None O
consistently None None O
isolate None None O
a None None O
stable None None O
variant None None O
that None None O
exhibits None None O
constitutive None None O
CREB None None O
phosphorylation None None O
. None None O

L2 None None I-cell_line
and None None I-cell_line
L2 None None I-cell_line
variant None None I-cell_line
cells None None I-cell_line
were None None O
tested None None O
for None None O
IL-2 None None I-protein
responsiveness None None O
and None None O
rapamycin None None O
sensitivity None None O
with None None O
respect None None O
to None None O
specific None None O
kinase None None O
activity None None O
, None None O
PCNA None None O
expression None None O
and None None O
proliferation None None O
. None None O

In None None O
L2 None None I-cell_line
cells None None I-cell_line
, None None O
IL-2 None None I-protein
stimulated None None O
and None None O
rapamycin None None O
inhibited None None O
the None None O
following None None O
: None None O
cAMP-independent None None O
CREB None None I-protein
kinase None None I-protein
activity None None O
, None None O
PCNA None None O
expression None None O
and None None O
proliferation None None O
. None None O

In None None O
L2 None None I-cell_line
variant None None I-cell_line
cells None None I-cell_line
, None None O
CREB None None I-protein
kinase None None I-protein
activity None None O
was None None O
constitutively None None O
high None None O
; None None O
IL-2 None None I-protein
stimulated None None O
and None None O
rapamycin None None O
blocked None None O
PCNA None None O
expression None None O
and None None O
proliferation None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
IL-2 None None I-protein
induces None None O
a None None O
rapamycin-sensitive None None O
, None None O
cAMP-independent None None O
CREB None None I-protein
kinase None None I-protein
activity None None O
in None None O
L2 None None I-cell_line
cells None None I-cell_line
. None None O

However None None O
, None None O
phosphorylation None None O
of None None O
CREB None None I-protein
alone None None O
is None None O
not None None O
sufficient None None O
to None None O
drive None None O
PCNA None None I-protein
expression None None O
and None None O
L2 None None O
cell None None O
proliferation None None O
in None None O
the None None O
absence None None O
of None None O
IL-2 None None I-protein
. None None O

Serotonin None None O
derivative None None O
, None None O
N- None None O
( None None O
p-coumaroyl None None O
) None None O
serotonin None None O
, None None O
inhibits None None O
the None None O
production None None O
of None None O
TNF-alpha None None I-protein
, None None O
IL-1alpha None None I-protein
, None None O
IL-1beta None None I-protein
, None None O
and None None O
IL-6 None None I-protein
by None None O
endotoxin-stimulated None None I-cell_type
human None None I-cell_type
blood None None I-cell_type
monocytes None None I-cell_type
. None None O

We None None O
have None None O
reported None None O
that None None O
N- None None O
( None None O
p-coumaroyl None None O
) None None O
serotonin None None O
( None None O
CS None None O
) None None O
and None None O
its None None O
derivatives None None O
with None None O
antioxidative None None O
activity None None O
are None None O
present None None O
in None None O
safflower None None O
seeds None None O
. None None O

As None None O
reactive None None O
oxygen None None O
species None None O
( None None O
ROS None None O
) None None O
are None None O
implicated None None O
in None None O
the None None O
signaling None None O
of None None O
lipopolysaccharide None None O
( None None O
LPS None None O
) None None O
, None None O
we None None O
examined None None O
whether None None O
CS None None O
has None None O
a None None O
suppressive None None O
effect None None O
on None None O
inflammatory None None I-protein
cytokine None None I-protein
generation None None O
from None None O
human None None I-cell_type
monocyte None None I-cell_type
s None None O
in None None O
vitro None None O
. None None O

CS None None O
at None None O
50-200 None None O
microM None None O
reduced None None O
tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
( None None O
TNF None None I-protein
) None None O
, None None O
interleukin-1 None None I-protein
( None None O
IL-1 None None I-protein
) None None O
, None None O
and None None O
IL-6 None None I-protein
activities None None O
in None None O
the None None O
culture None None O
supernatants None None O
from None None O
LPS-stimulated None None I-cell_line
human None None I-cell_line
blood None None I-cell_line
monocytes None None I-cell_line
without None None O
cytotoxicity None None O
. None None O

ELISA None None O
assay None None O
revealed None None O
that None None O
the None None O
production None None O
of None None O
TNF-alpha None None I-protein
, None None O
IL-1alpha None None I-protein
, None None O
IL-1beta None None I-protein
, None None O
and None None O
IL-6 None None I-protein
was None None O
inhibited None None O
by None None O
CS None None O
. None None O

Northern None None O
blot None None O
analysis None None O
showed None None O
that None None O
LPS-induced None None O
expression None None O
of None None O
these None None O
cytokine None None I-RNA
mRNA None None I-RNA
in None None O
monocytes None None I-cell_type
was None None O
suppressed None None O
by None None O
CS None None O
. None None O

NF-kappaB None None O
activation None None O
was None None O
also None None O
inhibited None None O
by None None O
CS None None O
. None None O

These None None O
findings None None O
indicate None None O
that None None O
CS None None O
has None None O
a None None O
suppressive None None O
effect None None O
on None None O
proinflammatory None None O
cytokine None None O
production None None O
from None None O
monocytes None None I-cell_type
, None None O
and None None O
this None None O
effect None None O
is None None O
based None None O
in None None O
part None None O
on None None O
the None None O
suppression None None O
of None None O
cytokine None None I-RNA
mRNA None None I-RNA
expression None None O
through None None O
inhibition None None O
of None None O
NF-kappaB None None I-protein
activation None None O
. None None O

Elevated None None O
expression None None O
of None None O
differentiation None None I-RNA
inhibitory None None I-RNA
factor None None I-RNA
nm23 None None I-RNA
mRNA None None I-RNA
in None None O
monoblastic None None O
crisis None None O
of None None O
a None None O
patient None None O
with None None O
chronic None None O
myelogenous None None O
leukemia None None O
. None None O

Differentiation None None I-protein
inhibitory None None I-protein
factor None None I-protein
nm23 None None I-DNA
gene None None I-DNA
has None None O
been None None O
found None None O
to None None O
be None None O
expressed None None O
in None None O
high None None O
quantities None None O
in None None O
acute None None O
myelogenous None None O
leukemia None None O
( None None O
AML None None O
) None None O
, None None O
especially None None O
in None None O
acute None None O
monocytic None None O
leukemia None None O
( None None O
AML-M5 None None O
) None None O
and None None O
is None None O
suggested None None O
as None None O
a None None O
new None None O
prognostic None None O
factor None None O
in None None O
AML-M5 None None O
. None None O

We None None O
report None None O
an None None O
example None None O
of None None O
elevated None None O
expression None None O
of None None O
nm23 None None I-RNA
mRNA None None I-RNA
in None None O
a None None O
patient None None O
with None None O
chronic None None O
myelogenous None None O
leukemia None None O
( None None O
CML None None O
) None None O
who None None O
developed None None O
monoblastic None None O
crisis None None O
. None None O

Relative None None O
levels None None O
of None None O
nm23-H1 None None I-RNA
and None None I-RNA
-H2 None None I-RNA
mRNA None None I-RNA
extracted None None O
from None None O
the None None O
patient None None O
's None None O
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
and None None O
bone None None I-cell_type
marrow None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
were None None O
measured None None O
by None None O
quantitative None None O
reverse None None O
transcriptase None None O
polymerase None None O
chain None None O
reaction None None O
. None None O

The None None O
level None None O
of None None O
nm23-H1 None None I-RNA
mRNA None None I-RNA
in None None O
CML None None I-cell_line
cells None None I-cell_line
at None None O
the None None O
chronic None None O
phase None None O
was None None O
as None None O
high None None O
as None None O
that None None O
in None None O
bone None None I-cell_type
marrow None None I-cell_type
cells None None I-cell_type
from None None O
healthy None None O
volunteers None None O
. None None O

The None None O
mRNA None None O
level None None O
of None None O
nm23-H2 None None I-protein
was None None O
slightly None None O
below None None O
the None None O
normal None None O
level None None O
. None None O

At None None O
blastic None None O
crisis None None O
, None None O
however None None O
, None None O
expression None None O
of None None O
both None None O
nm23-H1 None None I-RNA
and None None I-RNA
-H2 None None I-RNA
mRNA None None I-RNA
was None None O
elevated None None O
to None None O
about None None O
three None None O
to None None O
nine None None O
times None None O
of None None O
that None None O
at None None O
the None None O
chronic None None O
phase None None O
. None None O

Proliferated None None I-cell_type
blastic None None I-cell_type
cells None None I-cell_type
were None None O
positive None None O
for None None O
non-specific None None I-protein
esterase None None I-protein
, None None O
and None None O
the None None O
serum None None O
lysozyme None None O
level None None O
was None None O
elevated None None O
and None None O
diagnosed None None O
as None None O
monoblastic None None O
crisis None None O
. None None O

The None None O
patient None None O
received None None O
combined None None O
chemotherapy None None O
but None None O
response None None O
was None None O
partial None None O
. None None O

These None None O
findings None None O
are None None O
compatible None None O
with None None O
our None None O
previous None None O
report None None O
that None None O
nm23 None None I-DNA
gene None None I-DNA
is None None O
overexpressed None None O
in None None O
monocytic None None O
leukemia None None O
. None None O

Increased None None O
transcription None None O
decreases None None O
the None None O
spontaneous None None O
mutation None None O
rate None None O
at None None O
the None None O
thymidine None None I-DNA
kinase None None I-DNA
locus None None I-DNA
in None None O
human None None I-cell_type
cells None None I-cell_type
. None None O

Transcription None None O
increases None None O
DNA None None O
repair None None O
efficiency None None O
and None None O
modulates None None O
the None None O
distribution None None O
of None None O
certain None None O
types None None O
of None None O
DNA None None O
damage None None O
. None None O

Furthermore None None O
, None None O
increased None None O
transcription None None O
level None None O
stimulates None None O
spontaneous None None O
mutation None None O
rate None None O
in None None O
yeast None None O
. None None O

We None None O
explored None None O
whether None None O
transcription None None O
level None None O
affects None None O
spontaneous None None O
mutation None None O
rate None None O
in None None O
human None None I-cell_type
cells None None I-cell_type
. None None O

We None None O
first None None O
developed None None O
two None None O
thymidine None None I-cell_line
kinase None None I-cell_line
( None None I-cell_line
tk None None I-cell_line
) None None I-cell_line
inducible None None I-cell_line
human None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
using None None O
the None None O
Gal4-Estrogen None None O
receptor None None O
system None None O
. None None O

In None None O
our None None O
TK6i-G3 None None I-cell_line
and None None I-cell_line
G9 None None I-cell_line
tk None None I-cell_line
heterozygous None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
, None None O
the None None O
active None None O
tk None None I-DNA
allele None None I-DNA
is None None O
linked None None O
to None None O
an None None O
inducible None None O
promoter None None I-DNA
element None None I-DNA
. None None O

Tk None None I-RNA
mRNA None None I-RNA
is None None O
induced None None O
following None None O
treatment None None O
with None None O
estrogen None None O
. None None O

Spontaneous None None O
mutation None None O
rate None None O
was None None O
significantly None None O
decreased None None O
in None None O
human None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
after None None O
induction None None O
in None None O
contrast None None O
to None None O
the None None O
report None None O
in None None O
yeast None None O
. None None O

Thus None None O
, None None O
humans None None O
may None None O
have None None O
evolved None None O
different None None O
or None None O
additional None None O
mechanisms None None O
to None None O
deal None None O
with None None O
transcription None None O
related None None O
spontaneous None None O
mutagenesis None None O
. None None O

Copyright None None O
1998 None None O
Elsevier None None O
Science None None O
B.V None None O
. None None O

All None None O
rights None None O
reserved None None O
. None None O

Mutation None None O
of None None O
BCL-6 None None I-DNA
gene None None I-DNA
in None None O
normal None None O
B None None I-cell_type
cells None None I-cell_type
by None None O
the None None O
process None None O
of None None O
somatic None None O
hypermutation None None O
of None None O
Ig None None I-DNA
genes None None I-DNA
. None None O

Immunoglobulin None None I-DNA
( None None I-DNA
Ig None None I-DNA
) None None I-DNA
genes None None I-DNA
are None None O
hypermutated None None O
in None None O
B None None I-cell_type
lymphocytes None None I-cell_type
that None None O
are None None O
the None None O
precursors None None O
to None None O
memory None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
mutations None None O
are None None O
linked None None O
to None None O
transcription None None O
initiation None None O
, None None O
but None None O
non-Ig None None I-DNA
promoters None None I-DNA
are None None O
permissible None None O
for None None O
the None None O
mutation None None O
process None None O
; None None O
thus None None O
, None None O
other None None O
genes None None O
expressed None None O
in None None O
mutating None None O
B None None I-cell_type
cells None None I-cell_type
may None None O
also None None O
be None None O
subject None None O
to None None O
somatic None None O
hypermutation None None O
. None None O

Significant None None O
mutations None None O
were None None O
not None None O
observed None None O
in None None O
c-MYC None None I-DNA
, None None I-DNA
S14 None None I-DNA
, None None I-DNA
or None None I-DNA
alpha-fetoprotein None None I-DNA
( None None I-DNA
AFP None None I-DNA
) None None I-DNA
genes None None I-DNA
, None None O
but None None O
BCL-6 None None I-protein
was None None O
highly None None O
mutated None None O
in None None O
a None None O
large None None O
proportion None None O
of None None O
memory None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
of None None O
normal None None O
individuals None None O
. None None O

The None None O
mutation None None O
pattern None None O
was None None O
similar None None O
to None None O
that None None O
of None None O
Ig None None I-DNA
genes None None I-DNA
. None None O

CD28-mediated None None O
activation None None O
in None None O
CD45RA+ None None I-cell_type
and None None I-cell_type
CD45RO+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
: None None O
enhanced None None O
levels None None O
of None None O
reactive None None O
oxygen None None O
intermediates None None O
and None None O
c-Rel None None O
nuclear None None O
translocation None None O
in None None O
CD45RA+ None None I-cell_type
cells None None I-cell_type
. None None O

We None None O
have None None O
analyzed None None O
the None None O
effect None None O
of None None O
complete None None O
T None None O
cell None None O
activation None None O
( None None O
anti-CD3 None None O
plus None None O
anti-CD28 None None O
) None None O
on None None O
the None None O
activation None None O
of None None O
NF-kappaB None None I-protein
in None None O
CD45RA+ None None I-cell_type
( None None I-cell_type
naive None None I-cell_type
) None None I-cell_type
and None None I-cell_type
CD45RO+ None None I-cell_type
( None None I-cell_type
memory/effector None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

Long None None O
exposure None None O
( None None O
24 None None O
h None None O
) None None O
induced None None O
stronger None None O
NF-kappaB None None I-protein
DNA None None O
binding None None O
in None None O
CD45RA+ None None I-cell_type
cells None None I-cell_type
than None None O
in None None O
CD45RO+ None None I-cell_type
cells None None I-cell_type
. None None O

Analysis None None O
of None None O
the None None O
nuclear None None I-protein
c-Rel None None I-protein
protein None None I-protein
indicated None None O
that None None O
after None None O
anti-CD3+anti-CD28 None None O
stimulation None None O
the None None O
level None None O
of None None O
c-Rel None None I-protein
was None None O
higher None None O
in None None O
CD45RA+ None None I-cell_type
cells None None I-cell_type
. None None O

Analysis None None O
of None None O
the None None O
cytoplasmic None None I-protein
inhibitor None None I-protein
IkappaBalpha None None B-protein
indicated None None O
that None None O
anti-CD3+anti-CD28 None None O
stimulation None None O
induced None None O
a None None O
long-lasting None None O
degradation None None O
in None None O
CD45RA+ None None I-cell_type
cells None None I-cell_type
but None None O
in None None O
CD45RO+ None None I-cell_type
cells None None I-cell_type
the None None O
degradation None None O
process None None O
was None None O
more None None O
rapid None None O
. None None O

Because None None O
the None None O
CD28 None None I-protein
costimulus None None O
is None None O
known None None O
to None None O
induce None None O
the None None O
production None None O
of None None O
reactive None None O
oxygen None None O
intermediates None None O
( None None O
ROIs None None O
) None None O
, None None O
the None None O
intracellular None None O
ROI None None O
levels None None O
in None None O
CD45RA+ None None I-cell_type
and None None I-cell_type
CD45RO+ None None I-cell_type
cells None None I-cell_type
were None None O
compared None None O
by None None O
flow None None O
cytometry None None O
. None None O

ROIs None None O
were None None O
produced None None O
in None None O
both None None O
cell None None O
types None None O
, None None O
but None None O
more None None O
strongly None None O
in None None O
CD45RA+ None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
data None None O
presented None None O
in None None O
this None None O
study None None O
further None None O
emphasize None None O
the None None O
differences None None O
between None None O
CD45RA+ None None I-cell_type
and None None I-cell_type
CD45RO+ None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
in None None O
ROI-dependent None None O
signaling None None O
pathways None None O
. None None O

Non-Hodgkin None None O
's None None O
lymphoma None None O
involving None None O
bilateral None None O
breasts None None O
[ None None O
see None None O
comments None None O
] None None O

We None None O
describe None None O
here None None O
two None None O
cases None None O
of None None O
diffuse None None O
large None None O
cell None None O
type None None O
non-Hodgkin None None O
's None None O
lymphoma None None O
affecting None None O
the None None O
bilateral None None O
breasts None None O
. None None O

The None None O
contralateral None None O
tumor None None O
in None None O
one None None O
case None None O
appeared None None O
17 None None O
months None None O
after None None O
the None None O
first None None O
mastectomy None None O
, None None O
whereas None None O
the None None O
bilateral None None O
tumors None None O
occurred None None O
concurrently None None O
in None None O
the None None O
other None None O
patient None None O
who None None O
was None None O
pregnant None None O
and None None O
showed None None O
widespread None None O
dissemination None None O
at None None O
initial None None O
presentation None None O
. None None O

Lymphoma None None I-cell_type
cells None None I-cell_type
from None None O
both None None O
cases None None O
showed None None O
the None None O
mature None None O
B-cell None None O
immunophenotype None None O
and None None O
had None None O
rearrangements None None O
of None None O
the None None O
BCL6 None None I-DNA
gene None None I-DNA
. None None O

Both None None O
patients None None O
developed None None O
progressive None None O
disease None None O
despite None None O
chemo-radiotherapy None None O
and None None O
died None None O
of None None O
leukemic None None O
manifestations None None O
. None None O

There None None O
were None None O
no None None O
apparent None None O
pathological None None O
features None None O
of None None O
lymphomas None None O
of None None O
mucosa-associated None None O
lymphoid None None O
tissue None None O
origin None None O

Biochemical None None O
characterization None None O
of None None O
MIP-1 None None I-protein
alpha None None I-protein
nuclear None None I-protein
protein None None I-protein
. None None O

A None None O
family None None O
of None None O
hematopoietic None None I-protein
specific None None I-protein
transcription None None I-protein
factors None None I-protein
, None None O
MIP-1 None None I-protein
alpha None None I-protein
nuclear None None I-protein
protein None None I-protein
( None None I-protein
MNP None None I-protein
) None None I-protein
family None None I-protein
, None None O
has None None O
recently None None O
been None None O
identified None None O
. None None O

They None None O
are None None O
intimately None None O
involved None None O
in None None O
regulating None None O
the None None O
transcription None None O
of None None O
the None None O
huMIP-1 None None I-DNA
alpha None None I-DNA
gene None None I-DNA
in None None O
monocytes None None I-cell_type
, None None O
T-cells None None I-cell_type
, None None O
and None None O
transformed None None I-cell_type
B-cells None None I-cell_type
. None None O

One None None O
member None None O
of None None O
the None None O
family None None O
( None None O
MNP-1 None None I-protein
) None None O
is None None O
essential None None O
for None None O
promoter None None O
activity None None O
in None None O
monocytes None None I-cell_type
and None None O
B-cells None None I-cell_type
, None None O
while None None O
another None None O
( None None O
MNP-2 None None I-protein
) None None O
is None None O
required None None O
for None None O
full None None O
promotor None None O
activity None None O
in None None O
T-cells None None I-cell_type
. None None O

A None None O
third None None O
member None None O
of None None O
the None None O
family None None O
( None None O
MNP-3 None None I-protein
) None None O
is None None O
expressed None None O
in None None O
PMA None None I-cell_line
induced None None I-cell_line
HL60 None None I-cell_line
cells None None I-cell_line
and None None O
probably None None O
has None None O
a None None O
role None None O
in None None O
monocyte None None O
differentiation None None O
. None None O

In None None O
this None None O
communication None None O
we None None O
demonstrate None None O
by None None O
two None None O
techniques None None O
that None None O
MNP-1 None None I-protein
and None None O
MNP-2 None None I-protein
are None None O
distinct None None O
but None None O
related None None O
factors None None O
, None None O
and None None O
we None None O
present None None O
further None None O
evidence None None O
to None None O
show None None O
that None None O
MNP-1 None None I-protein
acts None None O
as None None O
a None None O
heterodimer None None I-protein
. None None O

Bcl-3 None None I-protein
expression None None O
and None None O
nuclear None None O
translocation None None O
are None None O
induced None None O
by None None O
granulocyte-macrophage None None I-protein
colony-stimulating None None I-protein
factor None None I-protein
and None None O
erythropoietin None None I-protein
in None None O
proliferating None None I-cell_type
human None None I-cell_type
erythroid None None I-cell_type
precursors None None I-cell_type
. None None O

Bcl-3 None None I-protein
is None None O
a None None O
proto-oncogene None None I-DNA
involved None None O
in None None O
the None None O
chromosomal None None O
translocation None None O
t None None I-DNA
( None None I-DNA
14 None None I-DNA
; None None I-DNA
19 None None I-DNA
) None None I-DNA
found None None O
in None None O
some None None O
patients None None O
with None None O
chronic None None O
lymphocytic None None O
leukemia None None O
. None None O

It None None O
shares None None O
structural None None O
similarities None None O
with None None O
and None None O
is None None O
a None None O
member None None O
of None None O
the None None O
IkappaB None None I-protein
family None None I-protein
of None None O
proteins None None O
. None None O

In None None O
this None None O
report None None O
, None None O
involvement None None O
of None None O
Bcl-3 None None I-protein
in None None O
hematopoietic None None O
growth None None O
factor-stimulated None None O
erythroid None None O
proliferation None None O
and None None O
differentiation None None O
was None None O
examined None None O
. None None O

In None None O
TF-1 None None I-cell_line
cells None None I-cell_line
, None None O
an None None O
erythroleukemia None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
, None None O
granulocyte-macrophage None None I-protein
colony-stimulating None None I-protein
factor None None I-protein
( None None O
GM-CSF None None I-protein
) None None O
and None None O
erythropoietin None None I-protein
( None None O
Epo None None I-protein
) None None O
greatly None None O
enhanced None None O
Bcl-3 None None I-protein
expression None None O
at None None O
both None None O
the None None O
protein None None O
and None None O
mRNA None None O
levels None None O
in None None O
association None None O
with None None O
stimulation None None O
of None None O
proliferation None None O
. None None O

Bcl-3 None None I-protein
protein None None O
was None None O
also None None O
highly None None O
expressed None None O
in None None O
early None None I-cell_type
burst-forming None None I-cell_type
unit-erythroid None None I-cell_type
( None None I-cell_type
BFU-E None None I-cell_type
) None None I-cell_type
-derived None None I-cell_type
erythroid None None I-cell_type
precursors None None I-cell_type
( None None O
day None None O
7 None None O
) None None O
and None None O
decreased None None O
during None None O
maturation None None O
( None None O
days None None O
10 None None O
and None None O
14 None None O
) None None O
, None None O
suggesting None None O
that None None O
Bcl-3 None None I-protein
is None None O
involved None None O
in None None O
normal None None O
erythroid None None O
proliferation None None O
. None None O

In None None O
these None None O
hematopoietic None None I-cell_type
cells None None I-cell_type
, None None O
Bcl-3 None None I-protein
was None None O
hyperphosphorylated None None O
. None None O

GM-CSF None None I-protein
and None None O
Epo None None I-protein
modulated None None O
the None None O
subcellular None None O
localization None None O
of None None O
Bcl-3 None None I-protein
. None None O

Upon None None O
stimulation None None O
of None None O
TF-1 None None I-cell_line
cells None None I-cell_line
with None None O
GM-CSF None None I-protein
or None None O
Epo None None I-protein
, None None O
the None None O
nuclear None None O
translocation None None O
of None None O
Bcl-3 None None I-protein
was None None O
dramatically None None O
enhanced None None O
. None None O

Overexpression None None O
of None None O
Bcl-3 None None I-protein
in None None O
TF-1 None None I-cell_line
cells None None I-cell_line
by None None O
transient None None O
transfection None None O
along None None O
with None None O
the None None O
NF-kappaB None None I-protein
factors None None I-protein
p50 None None I-protein
or None None I-protein
p52 None None I-protein
resulted None None O
in None None O
significant None None O
induction None None O
of None None O
an None None O
human None None I-DNA
immunodeficiency None None I-DNA
virus-type None None I-DNA
1 None None I-DNA
( None None I-DNA
HIV-1 None None I-DNA
) None None I-DNA
kappaB-TATA-luceriferase None None I-DNA
reporter None None I-DNA
plasmid None None I-DNA
, None None O
demonstrating None None O
that None None O
Bcl-3 None None I-protein
has None None O
a None None O
positive None None O
role None None O
in None None O
transactivation None None O
of None None O
kappaB-containing None None I-DNA
genes None None I-DNA
in None None O
erythroid None None I-cell_type
cells None None I-cell_type
. None None O

Stimulation None None O
with None None O
GM-CSF None None I-protein
enhanced None None O
c-myb None None I-RNA
mRNA None None I-RNA
expression None None O
in None None O
these None None O
cells None None O
. None None O

Bcl-3 None None I-protein
in None None O
nuclear None None O
extracts None None O
of None None O
TF-1 None None I-cell_line
cells None None I-cell_line
bound None None O
to None None O
a None None O
kappaB None None I-DNA
enhancer None None I-DNA
in None None O
the None None O
c-myb None None I-DNA
promoter None None I-DNA
together None None O
with None None O
NF-kappaB2/p52 None None I-protein
and None None O
this None None O
binding None None O
activity None None O
was None None O
enhanced None None O
by None None O
GM-CSF None None I-protein
stimulation None None O
. None None O

Furthermore None None O
, None None O
cotransfection None None O
of None None O
Bcl-3 None None I-protein
with None None O
p52 None None I-protein
or None None O
p50 None None I-protein
in None None O
TF-1 None None I-cell_line
cells None None I-cell_line
resulted None None O
in None None O
significant None None O
activation None None O
of None None O
a None None O
c-myb None None I-DNA
kappaB-TATA-luceriferase None None I-DNA
reporter None None I-DNA
plasmid None None I-DNA
. None None O

These None None O
findings None None O
suggest None None O
that None None O
Bcl-3 None None I-protein
may None None O
participate None None O
in None None O
the None None O
transcriptional None None O
regulation None None O
of None None O
certain None None O
kappaB-containing None None I-DNA
genes None None I-DNA
involved None None O
in None None O
hematopoiesis None None O
, None None O
including None None O
c-myb None None I-DNA
. None None O

Copyright None None O
1998 None None O
by None None O
The None None O
American None None O
Society None None O
of None None O
Hematology None None O
. None None O

5-Lipoxygenase None None I-protein
compartmentalization None None O
in None None O
granulocytic None None O
cells None None O
is None None O
modulated None None O
by None None O
an None None O
internal None None I-protein
bipartite None None I-protein
nuclear None None I-protein
localizing None None I-protein
sequence None None I-protein
and None None O
nuclear None None I-protein
factor None None I-protein
kappa None None I-protein
B None None I-protein
complex None None I-protein
formation None None O
. None None O

A None None O
region None None O
of None None O
basic None None O
amino None None O
acids None None O
spanning None None O
residues None None I-protein
639-656 None None I-protein
in None None O
the None None O
human None None I-protein
5-lipoxygenase None None I-protein
sequence None None I-protein
resembles None None O
a None None O
consensus None None I-protein
bipartite None None I-protein
nuclear None None I-protein
localizing None None I-protein
sequence None None I-protein
. None None O

A None None O
synthetic None None O
peptide None None O
consisting None None O
of None None O
the None None O
Kaposi None None I-protein
fibroblast None None I-protein
growth None None I-protein
factor None None I-protein
signal None None I-protein
sequence None None I-protein
fused None None O
to None None O
the None None O
5-lipoxygenase639-656 None None I-protein
bipartite None None I-protein
nuclear None None I-protein
localizing None None I-protein
sequence None None I-protein
has None None O
a None None O
prominent None None O
inhibitory None None O
effect None None O
on None None O
5-lipoxygenase None None I-protein
catalysis None None O
in None None O
granulocytic None None O
HL-60 None None I-cell_line
cells None None I-cell_line
activated None None O
by None None O
calcium None None O
ionophor None None O
A23187 None None O
. None None O

Recombinant None None O
5-lipoxygenase None None I-protein
was None None O
not None None O
affected None None O
by None None O
the None None O
peptide None None O
. None None O

The None None O
peptide None None O
also None None O
inhibited None None O
redistribution None None O
of None None O
5-lipoxygenase None None I-protein
from None None O
the None None O
cytosol None None O
to None None O
the None None O
nuclear None None O
membrane None None O
of None None O
HL-60 None None I-cell_line
cells None None I-cell_line
stimulated None None O
by None None O
A23187 None None O
. None None O

5-Lipoxygenase None None I-protein
protein None None I-protein
was None None O
detected None None O
in None None O
nuclear None None I-protein
factor None None I-protein
kappaB None None I-protein
( None None I-protein
NF-kappaB None None I-protein
) None None I-protein
p65 None None I-protein
subunit None None I-protein
immunoprecipitate None None O
fractions None None O
prepared None None O
from None None O
HL-60 None None I-cell_line
cell None None I-cell_line
lysates None None O
. None None O

The None None O
amount None None O
of None None O
5-lipoxygenase None None I-protein
protein None None I-protein
coimmunoprecipitated None None O
by None None O
NF-kappaB None None O
antiserum None None O
was None None O
increased None None O
following None None O
A23187 None None O
stimulation None None O
. None None O

In None None O
cells None None O
treated None None O
with None None O
agents None None O
that None None O
block None None O
5-lipoxygenase None None I-protein
translocation None None O
to None None O
the None None O
nucleus None None O
, None None O
5-lipoxygenase None None I-protein
protein None None O
appearing None None O
in None None O
the None None O
NF-kappaB None None I-protein
immunoprecipitate None None O
was None None O
diminished None None O
. None None O

Our None None O
results None None O
implicate None None O
an None None O
internal None None I-protein
bipartite None None I-protein
nuclear None None I-protein
localizing None None I-protein
sequence None None I-protein
as None None O
a None None O
regulatory None None O
domain None None O
that None None O
modulates None None O
5-lipoxygenase None None I-protein
redistribution None None O
and None None O
catalysis None None O
in None None O
granulocytic None None I-cell_type
cells None None I-cell_type
. None None O

Additionally None None O
, None None O
our None None O
results None None O
suggest None None O
that None None O
molecular None None O
determinants None None O
which None None O
govern None None O
5-lipoxygenase None None O
and None None O
NF-kappaB None None O
redistribution None None O
to None None O
the None None O
nucleus None None O
may None None O
be None None O
coordinately None None O
controlled None None O
in None None O
granulocytic None None I-cell_type
cells None None I-cell_type
. None None O

Copyright None None O
1998 None None O
Academic None None O
Press None None O
. None None O

Inhibition None None O
of None None O
CD28/CD3-mediated None None O
costimulation None None O
of None None O
naive None None I-cell_type
and None None I-cell_type
memory None None I-cell_type
human None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
by None None O
intracellular None None O
incorporation None None O
of None None O
polyclonal None None I-protein
antibodies None None I-protein
specific None None O
for None None O
the None None O
activator None None I-protein
protein-1 None None I-protein
transcriptional None None I-protein
complex None None I-protein
. None None O

A None None O
number None None O
of None None O
indirect None None O
methods None None O
have None None O
been None None O
utilized None None O
in None None O
demonstrating None None O
activator None None I-protein
protein-1 None None I-protein
transcription None None O
factor None None O
function None None O
in None None O
IL-2 None None O
promoter None None O
activity None None O
. None None O

However None None O
, None None O
there None None O
has None None O
been None None O
no None None O
direct None None O
demonstration None None O
that None None O
activator None None I-protein
protein-1 None None I-protein
is None None O
involved None None O
in None None O
CD28-dependent None None O
costimulation None None O
of None None O
IL-2 None None I-DNA
gene None None I-DNA
transcription None None O
in None None O
freshly None None O
isolated None None O
naive None None I-cell_type
and None None I-cell_type
memory None None I-cell_type
human None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
. None None O

To None None O
address None None O
this None None O
issue None None O
, None None O
the None None O
method None None O
of None None O
scrape None None O
loading None None O
was None None O
applied None None O
to None None O
purified None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
. None None O

Since None None O
scrape None None O
loading None None O
relies None None O
on None None O
adherent None None I-cell_type
cells None None I-cell_type
, None None O
peripheral None None I-cell_type
blood None None I-cell_type
human None None I-cell_type
T None None I-cell_type
( None None I-cell_type
PB-T None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
were None None O
immobilized None None O
on None None O
the None None O
nonspecific None None O
cell None None O
attachment None None O
factor None None O
poly-L-lysine None None O
. None None O

Cells None None O
scraped None None O
off None None O
poly-L-lysine None None O
in None None O
the None None O
presence None None O
of None None O
Ig None None I-protein
FITC None None I-protein
efficiently None None O
incorporated None None O
Ig None None O
, None None O
with None None O
relatively None None O
uniform None None O
fluorescence None None O
. None None O

T None None O
cells None None O
retained None None O
their None None O
physical None None O
parameters None None O
as None None O
measured None None O
by None None O
forward None None O
and None None O
side None None O
light None None O
scatter None None O
, None None O
and None None O
functional None None O
activity None None O
as None None O
measured None None O
by None None O
costimulation None None O
of None None O
proliferation None None O
and None None O
IL-2 None None I-protein
production None None O
after None None O
being None None O
scraped None None O
off None None O
this None None O
substrate None None O
. None None O

CD28/CD3-costimulated None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
produced None None O
intracellular None None O
IL-2 None None I-protein
from None None O
all None None O
subsets None None O
measured None None O
( None None O
CD4+ None None I-cell_type
, None None O
CD4- None None I-cell_type
, None None O
CD45RO+ None None I-cell_type
, None None O
and None None O
CD45RO- None None I-cell_type
) None None O
. None None O

IL-2 None None I-protein
production None None O
and None None O
intracellular None None O
accumulation None None O
in None None O
nonscraped None None O
PB-T None None I-cell_type
cells None None I-cell_type
activated None None O
with None None O
CD28/CD3 None None O
coligation None None O
were None None O
skewed None None O
favoring None None O
CD45RO+ None None I-cell_type
and None None I-cell_type
CD4+ None None I-cell_type
subsets None None I-cell_type
, None None O
as None None O
was None None O
IL-2 None None I-protein
production None None O
in None None O
scraped None None O
PB-T None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
intracellular None None O
incorporation None None O
of None None O
Abs None None O
specific None None O
for None None O
c-Fos None None I-protein
and None None I-protein
c-Jun None None I-protein
family None None I-protein
members None None I-protein
by None None O
scrape None None O
loading None None O
inhibited None None O
the None None O
production None None O
and None None O
intracellular None None O
accumulation None None O
of None None O
IL-2 None None I-protein
within None None O
6 None None O
h None None O
of None None O
costimulation None None O
with None None O
PMA/ionomycin None None O
, None None O
or None None O
costimulation None None O
by None None O
CD28 None None O
and None None O
CD3 None None O
ligation None None O
. None None O

Scrape None None O
loading None None O
thus None None O
provides None None O
an None None O
efficient None None O
mechanism None None O
for None None O
intracellular None None O
incorporation None None O
of None None O
macromolecules None None O
, None None O
and None None O
the None None O
first None None O
direct None None O
evidence None None O
that None None O
c-Fos None None I-protein
and None None O
c-Jun None None I-protein
are None None O
involved None None O
in None None O
transcription None None O
of None None O
the None None O
IL-2 None None I-DNA
gene None None I-DNA
within None None O
its None None O
correct None None O
chromosomal None None O
context None None O
, None None O
in None None O
resting None None O
human None None O
T None None O
lymphocyte None None O
subpopulations None None O
. None None O

Differential None None O
expression None None O
of None None O
Nur77 None None I-protein
family None None I-protein
members None None I-protein
in None None O
human None None I-cell_type
T-lymphotropic None None I-cell_type
virus None None I-cell_type
type None None I-cell_type
1-infected None None I-cell_type
cells None None I-cell_type
: None None O
transactivation None None O
of None None O
the None None O
TR3/nur77 None None I-DNA
gene None None I-DNA
by None None O
Tax None None I-protein
protein None None I-protein
. None None O

We None None O
analyzed None None O
the None None O
differential None None O
expression None None O
and None None O
regulation None None O
of None None O
three None None O
members None None O
of None None O
the None None O
Nur77 None None I-protein
transcription None None I-protein
factor None None I-protein
family None None I-protein
by None None O
the None None O
human None None O
T-lymphotropic None None O
virus None None O
type None None O
1 None None O
( None None O
HTLV-1 None None O
) None None O
Tax None None I-protein
protein None None I-protein
. None None O

We None None O
have None None O
demonstrated None None O
that None None O
in None None O
both None None O
HTLV-1-infected None None I-cell_type
cells None None I-cell_type
and None None O
Tax-expressing None None I-cell_line
JPX-9 None None I-cell_line
cells None None I-cell_line
, None None O
TR3/nur77 None None I-protein
is None None O
highly None None O
expressed None None O
, None None O
whereas None None O
neither None None O
NOR-1 None None O
nor None None O
NOT None None O
expression None None O
is None None O
detectable None None O
. None None O

Transient None None O
transfection None None O
analysis None None O
further None None O
confirmed None None O
the None None O
Tax None None I-protein
transactivation None None O
of None None O
the None None O
TR3/nur77 None None I-protein
promoter None None O
but None None O
not None None O
the None None O
NOR-1 None None I-DNA
promoter None None I-DNA
in None None O
different None None O
cell None None O
types None None O
. None None O

Furthermore None None O
, None None O
expression None None O
of None None O
a None None O
luciferase None None I-DNA
reporter None None I-DNA
gene None None I-DNA
driven None None O
by None None O
the None None O
NGFI-B None None I-DNA
( None None I-DNA
rat None None I-DNA
homolog None None I-DNA
of None None I-DNA
TR3/Nur77 None None I-DNA
) None None I-DNA
response None None I-DNA
element None None I-DNA
( None None O
NBRE None None I-DNA
) None None O
provided None None O
evidence None None O
that None None O
Tax None None I-protein
-mediated None None O
transactivation None None O
resulted None None O
in None None O
the None None O
induction None None O
of None None O
a None None O
functional None None O
protein None None O
. None None O

Cotransfection None None O
assays None None O
with None None O
the None None O
TR3/nur77 None None I-DNA
promoter None None I-DNA
sequence None None I-DNA
or None None O
the None None O
NBRE None None I-DNA
binding None None O
motif None None O
together None None O
with None None O
a None None O
series None None O
of None None O
Tax None None I-protein
mutants None None O
have None None O
shown None None O
that None None O
Tax None None I-protein
-induced None None O
TR3/nur77 None None I-protein
expression None None O
is None None O
mediated None None O
by None None O
CREB/ATF-related None None I-protein
transcription None None I-protein
factors None None I-protein
. None None O

Negative None None O
regulation None None O
of None None O
the None None O
heat None None O
shock None None O
transcriptional None None O
response None None O
by None None O
HSBP1 None None I-protein
. None None O

In None None O
response None None O
to None None O
stress None None O
, None None O
heat None None I-protein
shock None None I-protein
factor None None I-protein
1 None None I-protein
( None None O
HSF1 None None I-protein
) None None O
acquires None None O
rapid None None O
DNA None None O
binding None None O
and None None O
transient None None O
transcriptional None None O
activity None None O
while None None O
undergoing None None O
conformational None None O
transition None None O
from None None O
an None None O
inert None None O
non-DNA-binding None None I-protein
monomer None None I-protein
to None None O
active None None O
functional None None O
trimers None None O
. None None O

Attenuation None None O
of None None O
the None None O
inducible None None O
transcriptional None None O
response None None O
occurs None None O
during None None O
heat None None O
shock None None O
or None None O
upon None None O
recovery None None O
at None None O
non-stress None None O
conditions None None O
and None None O
involves None None O
dissociation None None O
of None None O
the None None O
HSF1 None None I-protein
trimer None None I-protein
and None None O
loss None None O
of None None O
activity None None O
. None None O

We None None O
have None None O
used None None O
the None None O
hydrophobic None None I-protein
repeats None None I-protein
of None None O
the None None O
HSF1 None None I-protein
trimerization None None O
domain None None O
in None None O
the None None O
yeast None None O
two-hybrid None None O
protein None None O
interaction None None O
assay None None O
to None None O
identify None None O
heat None None I-protein
shock None None I-protein
factor None None I-protein
binding None None I-protein
protein None None I-protein
1 None None I-protein
( None None O
HSBP1 None None I-protein
) None None O
, None None O
a None None O
novel None None O
, None None O
conserved None None O
, None None O
76-amino-acid None None I-protein
protein None None I-protein
that None None O
contains None None O
two None None O
extended None None O
arrays None None O
of None None O
hydrophobic None None I-protein
repeats None None I-protein
that None None O
interact None None O
with None None O
the None None O
HSF1 None None I-protein
heptad None None I-protein
repeats None None I-protein
. None None O

HSBP1 None None I-protein
is None None O
nuclear-localized None None O
and None None O
interacts None None O
in None None O
vivo None None O
with None None O
the None None O
active None None O
trimeric None None O
state None None O
of None None O
HSF1 None None I-protein
that None None O
appears None None O
during None None O
heat None None O
shock None None O
. None None O

During None None O
attenuation None None O
of None None O
HSF1 None None I-protein
to None None O
the None None O
inert None None O
monomer None None O
, None None O
HSBP1 None None I-protein
associates None None O
with None None O
Hsp70 None None O
. None None O

HSBP1 None None I-protein
negatively None None O
affects None None O
HSF1 None None I-protein
DNA-binding None None O
activity None None O
, None None O
and None None O
overexpression None None O
of None None O
HSBP1 None None I-protein
in None None O
mammalian None None I-cell_type
cells None None I-cell_type
represses None None O
the None None O
transactivation None None O
activity None None O
of None None O
HSF1 None None I-protein
. None None O

To None None O
establish None None O
a None None O
biological None None O
role None None O
for None None O
HSBP1 None None I-protein
, None None O
the None None O
homologous None None O
Caenorhabditis None None I-protein
elegans None None I-protein
protein None None I-protein
was None None O
overexpressed None None O
in None None O
body None None I-cell_type
wall None None I-cell_type
muscle None None I-cell_type
cells None None I-cell_type
and None None O
was None None O
shown None None O
to None None O
block None None O
activation None None O
of None None O
the None None O
heat None None O
shock None None O
response None None O
from None None O
a None None O
heat None None I-DNA
shock None None I-DNA
promoter-reporter None None I-DNA
construct None None I-DNA
. None None O

Alteration None None O
in None None O
the None None O
level None None O
of None None O
HSBP1 None None I-protein
expression None None O
in None None O
C. None None O
elegans None None O
has None None O
severe None None O
effects None None O
on None None O
survival None None O
of None None O
the None None O
animals None None O
after None None O
thermal None None O
and None None O
chemical None None O
stress None None O
, None None O
consistent None None O
with None None O
a None None O
role None None O
for None None O
HSBP1 None None I-protein
as None None O
a None None O
negative None None O
regulator None None O
of None None O
the None None O
heat None None O
shock None None O
response None None O
. None None O

Long-range None None O
transcriptional None None O
regulation None None O
of None None O
cytokine None None O
gene None None O
expression None None O
. None None O

Most None None O
studies None None O
on None None O
the None None O
control None None O
of None None O
cytokine None None O
gene None None O
expression None None O
have None None O
involved None None O
the None None O
functional None None O
analysis None None O
of None None O
proximal None None I-DNA
promoters None None I-DNA
. None None O

Recent None None O
work None None O
has None None O
identified None None O
distal None None I-DNA
elements None None I-DNA
that None None O
mediate None None O
long-range None None O
cytokine None None O
gene None None O
regulation None None O
and None None O
has None None O
implicated None None O
chromatin None None O
reorganization None None O
in None None O
regulation None None O
of None None O
cytokine None None I-DNA
gene None None I-DNA
loci None None I-DNA
. None None O

These None None O
studies None None O
have None None O
begun None None O
to None None O
elucidate None None O
the None None O
basis None None O
for None None O
cell-specificity None None O
and None None O
high-level None None O
expression None None O
of None None O
cytokine None None I-DNA
genes None None I-DNA
. None None O

A None None O
signaling None None O
complex None None O
of None None O
Ca2+-calmodulin-dependent None None I-protein
protein None None I-protein
kinase None None I-protein
IV None None I-protein
and None None O
protein None None I-protein
phosphatase None None I-protein
2A None None I-protein
[ None None O
see None None O
comments None None O
] None None O

Stimulation None None O
of None None O
T None None I-cell_type
lymphocytes None None I-cell_type
results None None O
in None None O
a None None O
rapid None None O
increase None None O
in None None O
intracellular None None O
calcium None None O
concentration None None O
( None None O
[ None None O
Ca2+ None None O
] None None O
i None None O
) None None O
that None None O
parallels None None O
the None None O
activation None None O
of None None O
Ca2+-calmodulin-dependent None None I-protein
protein None None I-protein
kinase None None I-protein
IV None None I-protein
( None None O
CaMKIV None None I-protein
) None None O
, None None O
a None None O
nuclear None None I-protein
enzyme None None I-protein
that None None O
can None None O
phosphorylate None None O
and None None O
activate None None O
the None None O
cyclic None None I-protein
adenosine None None I-protein
monophosphate None None I-protein
( None None I-protein
cAMP None None I-protein
) None None I-protein
response None None I-protein
element-binding None None I-protein
protein None None I-protein
( None None O
CREB None None I-protein
) None None O
. None None O

However None None O
, None None O
inactivation None None O
of None None O
CaMKIV None None I-protein
occurs None None O
despite None None O
the None None O
sustained None None O
increase None None O
in None None O
[ None None O
Ca2+ None None O
] None None O
i None None O
that None None O
is None None O
required None None O
for None None O
T None None O
cell None None O
activation None None O
. None None O

A None None O
stable None None O
and None None O
stoichiometric None None O
complex None None O
of None None O
CaMKIV None None I-protein
with None None O
protein None None I-protein
serine-threonine None None I-protein
phosphatase None None I-protein
2A None None I-protein
( None None O
PP2A None None I-protein
) None None O
was None None O
identified None None O
in None None O
which None None O
PP2A None None I-protein
dephosphorylates None None O
CaMKIV None None I-protein
and None None O
functions None None O
as None None O
a None None O
negative None None O
regulator None None O
of None None O
CaMKIV None None I-protein
signaling None None O
. None None O

In None None O
Jurkat None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
, None None O
inhibition None None O
of None None O
PP2A None None I-protein
activity None None O
by None None O
small None None O
t None None O
antigen None None O
enhanced None None O
activation None None O
of None None O
CREB None None I-protein
-mediated None None O
transcription None None O
by None None O
CaMKIV None None I-protein
. None None O

These None None O
findings None None O
reveal None None O
an None None O
intracellular None None O
signaling None None O
mechanism None None O
whereby None None O
a None None O
protein None None I-protein
serine-threonine None None I-protein
kinase None None I-protein
( None None O
CaMKIV None None I-protein
) None None O
is None None O
regulated None None O
by None None O
a None None O
tightly None None O
associated None None O
protein None None I-protein
serine-threonine None None I-protein
phosphatase None None I-protein
( None None O
PP2A None None I-protein
) None None O
. None None O

Hypoxia None None O
down-regulates None None O
MCP-1 None None I-protein
expression None None O
: None None O
implications None None O
for None None O
macrophage None None O
distribution None None O
in None None O
tumors None None O
. None None O

Monocyte None None I-protein
chemoattractant None None I-protein
protein None None I-protein
1 None None I-protein
( None None O
MCP-1 None None I-protein
) None None O
is None None O
likely None None O
to None None O
contribute None None O
to None None O
the None None O
macrophage None None I-cell_type
infiltrate None None I-cell_type
in None None O
human None None O
ovarian None None O
carcinomas None None O
. None None O

Although None None O
MCP-1 None None I-protein
is None None O
predominantly None None O
expressed None None O
by None None O
the None None O
tumor None None O
parenchyma None None O
, None None O
macrophages None None O
accumulate None None O
at None None O
highest None None O
density None None O
in None None O
necrotic None None O
regions None None O
, None None O
which None None O
are None None O
associated None None O
with None None O
low None None O
oxygen None None O
tensions None None O
. None None O

Tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
alpha None None I-protein
( None None O
TNF-alpha None None I-protein
) None None O
can None None O
stimulate None None O
MCP-1 None None I-protein
production None None O
and None None O
is None None O
also None None O
present None None O
within None None O
ovarian None None O
carcinomas None None O
. None None O

We None None O
have None None O
investigated None None O
the None None O
effect None None O
of None None O
hypoxia None None O
both None None O
on None None O
MCP-1 None None I-protein
expression None None O
in None None O
ovarian None None I-cell_line
cancer None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
and None None O
monocyte None None O
migration None None O
. None None O

Hypoxia None None O
down-regulated None None O
TNF-alpha-induced None None I-RNA
MCP-1 None None I-RNA
mRNA None None I-RNA
and None None O
protein None None O
production None None O
by None None O
ovarian None None I-cell_type
cancer None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
effect None None O
was None None O
mimicked None None O
by None None O
cobalt None None O
chloride None None O
and None None O
desferrioxamine None None O
, None None O
consistent None None O
with None None O
a None None O
specific None None O
oxygen-sensing None None O
mechanism None None O
. None None O

Unlike None None O
antioxidants None None O
, None None O
hypoxia None None O
did None None O
not None None O
inhibit None None O
nuclear None None O
factor None None O
KB None None O
mobilization None None O
. None None O

Monocyte None None O
migration None None O
in None None O
response None None O
to None None O
MCP-1 None None I-protein
was None None O
also None None O
diminished None None O
under None None O
hypoxic None None O
conditions None None O
. None None O

Down-regulation None None O
of None None O
MCP-1 None None I-protein
expression None None O
and None None O
the None None O
inhibition None None O
of None None O
monocyte None None O
migration None None O
are None None O
independent None None O
effects None None O
of None None O
hypoxia None None O
that None None O
may None None O
contribute None None O
to None None O
the None None O
distribution None None O
of None None O
macrophages None None I-cell_type
within None None O
ovarian None None O
tumors None None O
. None None O

Activation None None O
of None None O
nuclear None None I-protein
factor None None I-protein
kappa None None I-protein
B None None I-protein
inflammatory None None O
bowel None None O
disease None None O
[ None None O
see None None O
comments None None O
] None None O

BACKGROUND None None O
: None None O
Expression None None O
of None None O
pro-inflammatory None None I-protein
cytokines None None I-protein
is None None O
increased None None O
in None None O
the None None O
intestinal None None O
lamina None None O
propria None None O
of None None O
patients None None O
with None None O
inflammatory None None O
bowel None None O
disease None None O
( None None O
IBD None None O
) None None O
. None None O

Nuclear None None I-protein
factor None None I-protein
kappa None None I-protein
B None None I-protein
( None None O
NF None None I-protein
kappa None None I-protein
B None None I-protein
) None None O
controls None None O
transcription None None O
of None None O
inflammation None None I-DNA
genes None None I-DNA
. None None O

On None None O
activation None None O
, None None O
NF None None I-protein
kappa None None I-protein
B None None I-protein
is None None O
rapidly None None O
released None None O
from None None O
its None None O
cytoplasmic None None I-protein
inhibitor None None I-protein
( None None O
I None None I-protein
kappa None None I-protein
B None None I-protein
) None None O
, None None O
transmigrates None None O
into None None O
the None None O
nucleus None None O
, None None O
and None None O
binds None None O
to None None O
DNA None None I-DNA
response None None I-DNA
elements None None I-DNA
in None None O
gene None None O
promoter None None O
regions None None O
. None None O

AIMS None None O
: None None O
To None None O
investigate None None O
whether None None O
increased None None O
activation None None O
of None None O
NF None None I-protein
kappa None None I-protein
B None None I-protein
is None None O
important None None O
in None None O
IBD None None O
and None None O
may None None O
be None None O
down-regulated None None O
by None None O
anti-inflammatory None None O
treatment None None O
. None None O

METHODS None None O
: None None O
Activation None None O
of None None O
NF None None I-protein
kappa None None I-protein
B None None I-protein
was None None O
determined None None O
by None None O
western None None O
blot None None O
assessment None None O
and None None O
electrophoretic None None O
mobility None None O
shift None None O
assay None None O
in None None O
nuclear None None O
extracts None None O
of None None O
colonic None None O
biopsy None None O
samples None None O
as None None O
well None None O
as None None O
lamina None None I-cell_type
propria None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
. None None O

RESULTS None None O
: None None O
Nuclear None None O
levels None None O
of None None O
NF None None I-protein
kappa None None I-protein
B None None I-protein
p65 None None B-protein
are None None O
increased None None O
in None None O
lamina None None O
propria None None O
biopsy None None O
specimens None None O
from None None O
patients None None O
with None None O
Crohn None None O
's None None O
disease None None O
in None None O
comparison None None O
with None None O
patients None None O
with None None O
ulcerative None None O
colitis None None O
and None None O
controls None None O
. None None O

Increased None None O
activation None None O
of None None O
NF None None I-protein
kappa None None I-protein
B None None I-protein
was None None O
detected None None O
in None None O
lamina None None I-cell_type
propria None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
from None None O
patients None None O
with None None O
active None None O
IBD None None O
. None None O

Corticosteroids None None O
strongly None None O
inhibit None None O
intestinal None None O
NF None None I-protein
kappa None None I-protein
B None None I-protein
activation None None O
in None None O
IBD None None O
in None None O
vivo None None O
and None None O
in None None O
vitro None None O
by None None O
stabilising None None O
the None None O
cytosolic None None I-protein
inhibitor None None I-protein
I None None B-protein
kappa None None I-protein
B None None I-protein
alpha None None O
against None None O
activation None None O
induced None None O
degradation None None O
. None None O

CONCLUSIONS None None O
: None None O
In None None O
both None None O
IBDs None None O
, None None O
but None None O
particularly None None O
Crohn None None O
's None None O
disease None None O
, None None O
increased None None O
activation None None O
of None None O
NF None None I-protein
kappa None None I-protein
B None None I-protein
may None None O
be None None O
involved None None O
in None None O
the None None O
regulation None None O
of None None O
the None None O
inflammatory None None O
response None None O
. None None O

Inhibition None None O
of None None O
NF None None I-protein
kappa None None I-protein
B None None I-protein
activation None None O
may None None O
represent None None O
a None None O
mechanism None None O
by None None O
which None None O
steroids None None O
exert None None O
an None None O
anti-inflammatory None None O
effect None None O
in None None O
IBD None None O

Insufficient None None O
glycemic None None O
control None None O
increases None None O
nuclear None None I-protein
factor-kappa None None I-protein
B None None I-protein
binding None None O
activity None None O
in None None O
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
isolated None None O
from None None O
patients None None O
with None None O
type None None O
1 None None O
diabetes None None O
. None None O

OBJECTIVE None None O
: None None O
The None None O
redox-sensitive None None I-protein
transcription None None I-protein
factor None None I-protein
nuclear None None I-protein
factor-kappa None None I-protein
B None None I-protein
( None None O
NF-kappa None None I-protein
B None None I-protein
) None None O
is None None O
believed None None O
to None None O
contribute None None O
to None None O
late None None O
diabetic None None O
complications None None O
. None None O

It None None O
is None None O
unknown None None O
whether None None O
NF-kappa None None I-protein
B None None I-protein
is None None O
influenced None None O
by None None O
glycemic None None O
control None None O
. None None O

RESEARCH None None O
DESIGN None None O
AND None None O
METHODS None None O
: None None O
To None None O
determine None None O
whether None None O
NF-kappa None None I-protein
B None None I-protein
is None None O
activated None None O
in None None O
patients None None O
with None None O
insufficient None None O
glycemic None None O
control None None O
( None None O
HbA1c None None O
> None None O
10 None None O
% None None O
) None None O
, None None O
we None None O
developed None None O
a None None O
tissue None None O
culture-independent None None O
electrophoretic None None O
mobility None None O
shift None None O
assay None None O
( None None O
EMSA None None O
) None None O
-based None None O
semiquantitative None None O
detection None None O
system None None O
that None None O
allowed None None O
us None None O
to None None O
determine None None O
NF-kappa None None I-protein
B None None I-protein
activation None None O
in None None O
ex None None O
vivo-isolated None None O
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
( None None O
PBMCs None None I-cell_type
) None None O
. None None O

We None None O
included None None O
43 None None O
patients None None O
with None None O
type None None O
1 None None O
diabetes None None O
in None None O
this None None O
cross-sectional None None O
study None None O
. None None O

10 None None O
of None None O
those None None O
received None None O
the None None O
antioxidant None None O
thioctic None None O
acid None None O
( None None O
600 None None O
mg/day None None O
p.o. None None O
) None None O
for None None O
2 None None O
weeks None None O
. None None O

RESULTS None None O
: None None O
Monocytes None None O
of None None O
patients None None O
with None None O
HbA1c None None O
levels None None O
> None None O
10 None None O
% None None O
demonstrated None None O
significantly None None O
higher None None O
NF-kappa None None I-protein
B None None I-protein
binding None None O
activity None None O
in None None O
an None None O
EMSA None None O
and None None O
a None None O
stronger None None O
NF-kappa None None I-protein
B None None I-protein
staining None None O
in None None O
immunohistochemistry None None O
than None None O
monocytes None None I-cell_type
of None None O
patients None None O
with None None O
HbA1c None None O
levels None None O
of None None O
6-8 None None O
% None None O
. None None O

The None None O
increase None None O
in None None O
NF-kappa None None I-protein
B None None I-protein
activation None None O
correlated None None O
with None None O
an None None O
increase None None O
in None None O
plasmatic None None O
markers None None O
of None None O
lipid None None O
peroxidation None None O
. None None O

Treatment None None O
with None None O
the None None O
antioxidant None None O
thioctic None None O
acid None None O
decreased None None O
NF-kappa None None I-protein
B None None I-protein
binding None None O
activity None None O
. None None O

CONCLUSIONS None None O
: None None O
Hyperglycemia None None O
induces None None O
activation None None O
of None None O
the None None O
transcription None None O
factor None None O
NF-kappa None None I-protein
B None None I-protein
in None None O
ex None None O
vivo-isolated None None O
PBMCs None None I-cell_type
of None None O
patients None None O
with None None O
type None None O
1 None None O
diabetes None None O
. None None O

NF-kappa None None I-protein
B None None I-protein
activation None None O
is None None O
at None None O
least None None O
partially None None O
dependent None None O
on None None O
oxidative None None O
stress None None O
, None None O
since None None O
the None None O
antioxidant None None O
thioctic None None O
acid None None O
significantly None None O
lowered None None O
the None None O
extent None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
binding None None O
activity None None O
. None None O

Synergistic None None O
activation None None O
of None None O
MAP None None I-protein
kinase None None I-protein
( None None O
ERK1/2 None None I-protein
) None None O
by None None O
erythropoietin None None I-protein
and None None O
stem None None I-protein
cell None None I-protein
factor None None I-protein
is None None O
essential None None O
for None None O
expanded None None O
erythropoiesis None None O
. None None O

Stem None None I-protein
cell None None I-protein
factor None None I-protein
( None None O
SCF None None I-protein
) None None O
and None None O
erythropoietin None None I-protein
( None None O
EPO None None I-protein
) None None O
work None None O
synergistically None None O
to None None O
support None None O
erythropoiesis None None O
, None None O
but None None O
the None None O
mechanism None None O
for None None O
this None None O
synergism None None O
is None None O
unknown None None O
. None None O

By None None O
using None None O
purified None None I-cell_line
human None None I-cell_line
erythroid None None I-cell_line
colony-forming None None I-cell_line
cells None None I-cell_line
( None None O
ECFC None None I-cell_line
) None None O
, None None O
we None None O
have None None O
found None None O
that None None O
SCF None None I-protein
and None None O
EPO None None I-protein
synergistically None None O
activate None None O
MAP None None I-protein
kinase None None I-protein
( None None O
MAPK None None I-protein
, None None O
ERK1/2 None None I-protein
) None None O
, None None O
which None None O
correlates None None O
with None None O
the None None O
cell None None O
growth None None O
and None None O
thus None None O
may None None O
be None None O
responsible None None O
for None None O
the None None O
synergistic None None O
effects None None O
. None None O

Treatment None None O
of None None O
the None None O
cells None None O
with None None O
PD98059 None None O
and None None O
wortmannin None None O
, None None O
inhibitors None None O
of None None O
MEK None None I-protein
and None None O
PI-3 None None I-protein
kinase None None I-protein
, None None O
respectively None None O
, None None O
inhibited None None O
the None None O
synergistic None None O
activation None None O
of None None O
MAPK None None I-protein
and None None O
also None None O
the None None O
cell None None O
growth None None O
, None None O
further None None O
supporting None None O
this None None O
conclusion None None O
. None None O

Wortmannin None None O
only None None O
inhibits None None O
MAPK None None I-protein
activation None None O
induced None None O
by None None O
EPO None None I-protein
but None None O
not None None O
that None None O
by None None O
SCF None None I-protein
, None None O
suggesting None None O
that None None O
SCF None None I-protein
and None None O
EPO None None I-protein
may None None O
activate None None O
MAPK None None I-protein
through None None O
different None None O
pathways None None O
, None None O
which None None O
would None None O
facilitate None None O
synergy None None O
. None None O

Furthermore None None O
, None None O
EPO None None I-protein
, None None O
but None None O
not None None O
SCF None None I-protein
, None None O
led None None O
to None None O
activation None None O
of None None O
STAT5 None None I-protein
, None None O
whereas None None O
SCF None None I-protein
and None None O
wortmannin None None O
had None None O
no None None O
effect None None O
on None None O
the None None O
EPO None None I-protein
-induced None None O
STAT5 None None I-protein
activation None None O
, None None O
suggesting None None O
that None None O
STAT5 None None I-protein
is None None O
not None None O
involved None None O
in None None O
the None None O
synergistic None None O
action None None O
of None None O
SCF None None I-protein
and None None O
EPO None None I-protein
. None None O

Together None None O
, None None O
the None None O
data None None O
suggest None None O
that None None O
synergistic None None O
activation None None O
of None None O
MAPK None None I-protein
by None None O
SCF None None I-protein
and None None O
EPO None None I-protein
is None None O
essential None None O
for None None O
expanded None None O
erythropoiesis None None O
. None None O

Copyright None None O
1998 None None O
by None None O
The None None O
American None None O
Society None None O
of None None O
Hematology None None O
. None None O

The None None O
molecular None None O
and None None O
phenotypic None None O
profile None None O
of None None O
primary None None O
central None None O
nervous None None O
system None None O
lymphoma None None O
identifies None None O
distinct None None O
categories None None O
of None None O
the None None O
disease None None O
and None None O
is None None O
consistent None None O
with None None O
histogenetic None None O
derivation None None O
from None None O
germinal None None I-cell_type
center-related None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
. None None O

Primary None None O
central None None O
nervous None None O
system None None O
lymphoma None None O
( None None O
PCNSL None None O
) None None O
is None None O
a None None O
major None None O
cause None None O
of None None O
morbidity None None O
and None None O
mortality None None O
among None None O
human None None O
immunodeficiency None None O
virus None None O
( None None O
HIV None None O
) None None O
-infected None None O
individuals None None O
. None None O

The None None O
precise None None O
histogenetic None None O
derivation None None O
and None None O
the None None O
molecular None None O
pathogenesis None None O
of None None O
PCNSL None None O
is None None O
poorly None None O
understood None None O
. None None O

In None None O
an None None O
attempt None None O
to None None O
clarify None None O
the None None O
histogenesis None None O
and None None O
pathogenesis None None O
of None None O
these None None O
lymphomas None None O
, None None O
49 None None O
PCNSL None None O
( None None O
26 None None O
acquired None None O
immunodeficiency None None O
syndrome None None O
[ None None O
AIDS None None O
] None None O
-related None None O
and None None O
23 None None O
AIDS-unrelated None None O
) None None O
were None None O
analyzed None None O
for None None O
multiple None None O
biologic None None O
markers None None O
, None None O
which None None O
are None None O
known None None O
to None None O
bear None None O
histogenetic None None O
and None None O
pathogenetic None None O
significance None None O
for None None O
mature None None O
B-cell None None O
neoplasms None None O
. None None O

PCNSL None None O
associated None None O
frequently None None O
( None None O
50.0 None None O
% None None O
) None None O
with None None O
mutations None None O
of None None O
BCL-6 None None I-DNA
5 None None I-DNA
' None None I-DNA
noncoding None None I-DNA
regions None None I-DNA
, None None O
which None None O
are None None O
regarded None None O
as None None O
a None None O
marker None None O
of None None O
B-cell None None O
transition None None O
through None None O
the None None O
germinal None None O
center None None O
( None None O
GC None None O
) None None O
. None None O

Expression None None O
of None None O
BCL-6 None None I-protein
protein None None I-protein
, None None O
which None None O
is None None O
restricted None None O
to None None O
GC None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
throughout None None O
physiologic None None O
B-cell None None O
maturation None None O
, None None O
was None None O
detected None None O
in None None O
100 None None O
% None None O
AIDS-unrelated None None O
PCNSL None None O
and None None O
in None None O
56.2 None None O
% None None O
AIDS-related None None O
cases None None O
. None None O

Notably None None O
, None None O
among None None O
AIDS-related None None O
PCNSL None None O
, None None O
expression None None O
of None None O
BCL-6 None None I-protein
was None None O
mutually None None O
exclusive None None O
with None None O
expression None None O
of None None O
Epstein-Barr None None I-protein
virus None None I-protein
( None None I-protein
EBV None None I-protein
) None None I-protein
-encoded None None I-protein
latent None None I-protein
membrane None None I-protein
protein None None I-protein
( None None I-protein
LMP None None I-protein
) None None I-protein
-1 None None I-protein
and None None O
, None None O
with None None O
few None None O
exceptions None None O
, None None O
also None None O
of None None O
BCL-2 None None I-protein
. None None O

All None None O
but None None O
one None None O
PCNSL None None O
expressed None None O
hMSH2 None None O
, None None O
which None None O
among None None O
mature None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
selectively None None O
stains None None O
GC None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
. None None O

These None None O
data None None O
suggest None None O
that None None O
PCNSL None None O
may None None O
be None None O
frequently None None O
related None None O
to None None O
GC None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
and None None O
may None None O
be None None O
segregated None None O
into None None O
two None None O
major None None O
biologic None None O
categories None None O
based None None O
on None None O
the None None O
expression None None O
pattern None None O
of None None O
BCL-6 None None I-protein
, None None O
LMP-1 None None I-protein
, None None O
and None None O
BCL-2 None None I-protein
. None None O

BCL-6 None None I-protein
( None None O
+ None None O
) None None O
/ None None O
LMP-1 None None I-protein
( None None O
- None None O
) None None O
/ None None O
BCL-2 None None I-protein
( None None O
- None None O
) None None O
PCNSL None None O
occur None None O
both None None O
in None None O
the None None O
presence None None O
and None None O
in None None O
the None None O
absence None None O
of None None O
HIV None None O
infection None None O
and None None O
consistently None None O
display None None O
a None None O
large None None O
noncleaved None None O
cell None None O
morphology None None O
. None None O

Conversely None None O
, None None O
BCL-6 None None I-protein
( None None O
- None None O
) None None O
/ None None O
LMP-1 None None I-protein
( None None O
+ None None O
) None None O
/ None None O
BCL-2 None None I-protein
( None None O
+ None None O
) None None O
PCNSL None None O
are None None O
restricted None None O
to None None O
HIV-infected None None O
hosts None None O
and None None O
are None None O
represented None None O
by None None O
lymphomas None None O
with None None O
immunoblastic None None O
features None None O
. None None O

These None None O
data None None O
are None None O
relevant None None O
for None None O
the None None O
pathogenesis None None O
and None None O
histogenesis None None O
of None None O
PCNSL None None O
and None None O
may None None O
be None None O
helpful None None O
to None None O
segregate None None O
distinct None None O
biologic None None O
and None None O
prognostic None None O
categories None None O
of None None O
these None None O
lymphomas None None O
. None None O

Copyright None None O
1998 None None O
by None None O
The None None O
American None None O
Society None None O
of None None O
Hematology None None O
. None None O

Antioxidant None None O
regulation None None O
of None None O
phorbol None None O
ester-induced None None O
adhesion None None O
of None None O
human None None I-cell_line
Jurkat None None I-cell_line
T-cells None None I-cell_line
to None None O
endothelial None None I-cell_type
cells None None I-cell_type
. None None O

Regulation None None O
of None None O
adhesion None None O
molecule None None O
expression None None O
and None None O
function None None O
by None None O
reactive None None O
oxygen None None O
species None None O
via None None O
specific None None O
redox None None O
sensitive None None O
mechanisms None None O
have None None O
been None None O
reported None None O
. None None O

The None None O
effects None None O
of None None O
clinically None None O
safe None None O
antioxidants None None O
in None None O
the None None O
regulation None None O
of None None O
adhesion None None O
molecule None None O
expression None None O
in None None O
human None None I-cell_type
endothelial None None I-cell_type
cells None None I-cell_type
( None None O
ECV None None O
) None None O
, None None O
and None None O
adherence None None O
of None None O
human None None I-cell_line
Jurkat None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
to None None O
ECV None None I-cell_type
cells None None I-cell_type
were None None O
investigated None None O
. None None O

The None None O
thiol None None O
antioxidant None None O
, None None O
alpha-lipoate None None O
, None None O
at None None O
clinically None None O
relevant None None O
doses None None O
down-regulated None None O
phorbol None None O
12-myristate None None O
13-acetate None None O
( None None O
PMA None None O
) None None O
-induced None None O
adhesion None None O
molecule None None O
expression None None O
and None None O
cell-cell None None O
adhesion None None O
. None None O

Inhibition None None O
of None None O
PMA-induced None None O
ICAM-1 None None O
and None None O
VCAM-1 None None O
expression None None O
as None None O
well None None O
as None None O
PMA-induced None None O
adhesion None None O
of None None O
Jurkat None None I-cell_line
T-cells None None I-cell_line
to None None O
ECV None None I-cell_type
cells None None I-cell_type
by None None O
alpha-lipoate None None O
was None None O
dose None None O
dependent None None O
( None None O
50-250 None None O
microM None None O
) None None O
. None None O

The None None O
effect None None O
was None None O
significant None None O
for None None O
ICAM-1 None None I-protein
( None None O
p None None O
< None None O
.01 None None O
) None None O
and None None O
VCAM-1 None None I-protein
( None None O
p None None O
< None None O
.01 None None O
) None None O
expression None None O
in None None O
cells None None O
pretreated None None O
with None None O
100 None None O
microM None None O
alpha-lipoate None None O
compared None None O
to None None O
PMA-activated None None I-cell_type
untreated None None I-cell_type
cells None None I-cell_type
. None None O

Inhibition None None O
of None None O
PMA-induced None None O
adhesion None None O
molecule None None O
expression None None O
and None None O
cell-cell None None O
adhesion None None O
was None None O
more None None O
pronounced None None O
when None None O
a None None O
combination None None O
of None None O
antioxidants None None O
, None None O
alpha-lipoate None None O
and None None O
alpha-tocopherol None None O
, None None O
were None None O
used None None O
compared None None O
to None None O
the None None O
use None None O
of None None O
either None None O
of None None O
these None None O
antioxidant None None O
alone None None O
. None None O

The None None O
regulation None None O
of None None O
adhesion None None O
molecule None None O
expression None None O
and None None O
function None None O
by None None O
low None None O
concentration None None O
of None None O
antioxidants None None O
investigated None None O
does None None O
not None None O
appear None None O
to None None O
be None None O
NF-kappaB None None I-protein
regulated None None O
or None None O
transcription None None O
dependent None None O
because None None O
no None None O
change None None O
in None None O
the None None O
mRNA None None O
response None None O
was None None O
observed None None O
. None None O

Protein None None I-protein
kinase None None I-protein
C None None I-protein
( None None O
PKC None None I-protein
) None None O
has None None O
been None None O
suggested None None O
to None None O
regulate None None O
PMA-induced None None O
adhesion None None O
molecule None None O
expression None None O
by None None O
post-transcriptional None None O
stabilization None None O
of None None O
adhesion None None I-RNA
molecule None None I-RNA
mRNA None None I-RNA
. None None O

Alpha-lipoate None None O
pretreatment None None O
did None None O
not None None O
influence None None O
the None None O
response None None O
of None None O
PKC None None I-protein
activity None None O
to None None O
PMA None None O
. None None O

Oxidants None None O
are None None O
known None None O
to None None O
be None None O
involved None None O
in None None O
the None None O
regulation None None O
of None None O
cell None None O
adhesion None None O
processes None None O
. None None O

Treatment None None O
of None None O
ECV None None I-cell_type
cells None None I-cell_type
with None None O
PMA None None O
induced None None O
generation None None O
of None None O
intracellular None None O
oxidants None None O
. None None O

Alpha-lipoate None None O
( None None O
100 None None O
or None None O
250 None None O
microM None None O
) None None O
treatment None None O
decreased None None O
PMA-induced None None O
generation None None O
of None None O
intracellular None None O
oxidants None None O
. None None O

The None None O
inhibitory None None O
effect None None O
of None None O
low None None O
concentration None None O
of None None O
alpha-lipaote None None O
alone None None O
or None None O
in None None O
combination None None O
with None None O
alpha-tocopherol None None O
on None None O
agonist-induced None None O
adhesion None None O
processes None None O
observed None None O
in None None O
this None None O
study None None O
may None None O
be None None O
of None None O
potential None None O
therapeutic None None O
value None None O
. None None O

Binding None None O
of None None O
human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
to None None O
CD4 None None I-protein
and None None I-protein
CXCR4 None None I-protein
receptors None None I-protein
differentially None None O
regulates None None O
expression None None O
of None None O
inflammatory None None I-DNA
genes None None I-DNA
and None None O
activates None None O
the None None O
MEK None None I-protein
/ERK None None O
signaling None None O
pathway None None O
. None None O

We None None O
have None None O
previously None None O
shown None None O
that None None O
binding None None O
of None None O
human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
( None None O
HIV-1 None None O
) None None O
virions None None O
to None None O
CD4 None None I-protein
receptors None None I-protein
stimulates None None O
association None None O
of None None O
Lck None None I-protein
with None None O
Raf-1 None None I-protein
and None None O
results None None O
in None None O
the None None O
activation None None O
of None None O
Raf-1 None None I-protein
kinase None None O
in None None O
a None None O
Ras-independent None None O
manner None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
demonstrate None None O
that None None O
HIV-1 None None I-protein
envelope None None I-protein
glycoproteins None None I-protein
of None None O
both None None O
T-cell-tropic None None O
and None None O
macrophagetropic None None O
strains None None O
rapidly None None O
activate None None O
the None None O
ERK/mitogen-activated None None O
protein None None O
( None None O
MAP None None O
) None None O
kinase None None O
pathway None None O
and None None O
the None None O
binding None None O
of None None O
nuclear None None I-protein
transcription None None I-protein
factors None None I-protein
( None None O
AP-1 None None I-protein
, None None O
NF-kappaB None None I-protein
, None None O
and None None O
C/EBP None None I-protein
) None None O
and None None O
stimulate None None O
expression None None O
of None None O
cytokine None None I-DNA
and None None I-DNA
chemokine None None I-DNA
genes None None I-DNA
. None None O

The None None O
activation None None O
of None None O
this None None O
signaling None None O
pathway None None O
requires None None O
functional None None O
CD4 None None I-protein
receptors None None I-protein
and None None O
is None None O
independent None None O
of None None O
binding None None O
to None None O
CXCR4 None None I-protein
. None None O

Binding None None O
of None None O
the None None O
natural None None O
ligand None None O
stromal None None I-protein
cell-derived None None I-protein
factor None None I-protein
1 None None I-protein
( None None O
SDF-1 None None I-protein
) None None O
to None None O
CXCR4 None None I-protein
, None None O
which None None O
inhibits None None O
entry None None O
of None None O
T-cell-tropic None None O
HIV-1 None None O
, None None O
activates None None O
also None None O
the None None O
ERK/ None None O
MAP None None I-protein
kinase None None I-protein
pathway None None O
. None None O

However None None O
, None None O
SDF-1 None None I-protein
did None None O
not None None O
affect None None O
the None None O
CD4-mediated None None O
expression None None O
of None None O
cytokine None None I-DNA
and None None I-DNA
chemokine None None I-DNA
genes None None I-DNA
. None None O

These None None O
results None None O
provide None None O
firm None None O
molecular None None O
evidence None None O
that None None O
binding None None O
of None None O
HIV-1 None None I-protein
envelope None None I-protein
glycoproteins None None I-protein
to None None O
CD4 None None I-protein
receptor None None I-protein
initiates None None O
a None None O
signaling None None O
pathway None None O
( None None O
s None None O
) None None O
independent None None O
of None None O
the None None O
binding None None O
to None None O
the None None O
chemokine None None I-protein
receptor None None I-protein
that None None O
leads None None O
to None None O
the None None O
aberrant None None O
expression None None O
of None None O
inflammatory None None I-DNA
genes None None I-DNA
and None None O
may None None O
contribute None None O
significantly None None O
to None None O
HIV-1 None None O
replication None None O
as None None O
well None None O
as None None O
to None None O
deregulation None None O
of None None O
the None None O
immune None None O
system None None O
. None None O

Antigen None None O
receptor None None O
signaling None None O
induces None None O
MAP None None O
kinase-mediated None None O
phosphorylation None None O
and None None O
degradation None None O
of None None O
the None None O
BCL-6 None None I-protein
transcription None None B-protein
factor None None I-protein
. None None O

The None None O
bcl-6 None None I-DNA
proto-oncogene None None I-DNA
encodes None None O
a None None O
POZ/zinc None None I-protein
finger None None I-protein
transcriptional None None I-protein
repressor None None I-protein
expressed None None O
in None None O
germinal None None I-cell_type
center None None I-cell_type
( None None I-cell_type
GC None None I-cell_type
) None None I-cell_type
B None None I-cell_type
and None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
and None None O
required None None O
for None None O
GC None None O
formation None None O
and None None O
antibody None None O
affinity None None O
maturation None None O
. None None O

Deregulation None None O
of None None O
bcl-6 None None I-DNA
expression None None O
by None None O
chromosomal None None O
rearrangements None None O
and None None O
point None None O
mutations None None O
of None None O
the None None O
bcl-6 None None I-DNA
promoter None None I-DNA
region None None I-DNA
are None None O
implicated None None O
in None None O
the None None O
pathogenesis None None O
of None None O
B-cell None None O
lymphoma None None O
. None None O

The None None O
signals None None O
regulating None None O
bcl-6 None None I-DNA
expression None None O
are None None O
not None None O
known None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
antigen None None O
receptor None None O
activation None None O
leads None None O
to None None O
BCL-6 None None I-protein
phosphorylation None None O
by None None O
mitogen-activated None None I-protein
protein None None I-protein
kinase None None I-protein
( None None O
MAPK None None I-protein
) None None O
. None None O

Phosphorylation None None O
, None None O
in None None O
turn None None O
, None None O
targets None None O
BCL-6 None None I-protein
for None None O
rapid None None O
degradation None None O
by None None O
the None None O
ubiquitin None None I-protein
/ None None O
proteasome None None I-protein
pathway None None O
. None None O

These None None O
findings None None O
indicate None None O
that None None O
BCL-6 None None I-protein
expression None None O
is None None O
directly None None O
controlled None None O
by None None O
the None None O
antigen None None O
receptor None None O
via None None O
MAPK None None I-protein
activation None None O
. None None O

This None None O
signaling None None O
pathway None None O
may None None O
be None None O
crucial None None O
for None None O
the None None O
control None None O
of None None O
B-cell None None O
differentiation None None O
and None None O
antibody None None O
response None None O
and None None O
has None None O
implications None None O
for None None O
the None None O
regulation None None O
of None None O
other None None O
POZ/zinc None None I-protein
finger None None I-protein
transcription None None I-protein
factors None None I-protein
in None None O
other None None O
tissues None None O
. None None O

Glucocorticoid None None I-protein
receptors None None I-protein
are None None O
differentially None None O
expressed None None O
in None None O
the None None O
cells None None O
and None None O
tissues None None O
of None None O
the None None O
immune None None O
system None None O
. None None O

Cytosolic None None I-protein
glucocorticoid None None I-protein
receptor None None I-protein
( None None O
GR None None I-protein
) None None O
binding None None O
studies None None O
on None None O
immune None None O
tissues None None O
demonstrate None None O
that None None O
the None None O
thymus None None O
exhibits None None O
three None None O
to None None O
four None None O
times None None O
higher None None O
levels None None O
of None None O
GR None None I-protein
protein None None I-protein
than None None O
the None None O
spleen None None O
. None None O

High None None O
levels None None O
of None None O
GR None None I-protein
are None None O
consistent None None O
with None None O
the None None O
exquisite None None O
sensitivity None None O
of None None O
the None None O
thymus None None O
to None None O
glucocorticoid None None O
exposure None None O
. None None O

Nevertheless None None O
, None None O
whole None None O
cell None None O
binding None None O
studies None None O
reveal None None O
similar None None O
levels None None O
of None None O
GR None None I-protein
in None None O
immature None None I-cell_type
thymic None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
and None None O
more None None O
mature None None O
, None None O
splenic None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
. None None O

Moreover None None O
, None None O
whole None None O
cell None None O
binding None None O
techniques None None O
indicate None None O
that None None O
neutrophils None None I-cell_type
( None None O
which None None O
represent None None O
roughly None None O
30 None None O
% None None O
of None None O
splenic None None I-cell_type
leukocytes None None I-cell_type
) None None O
exhibit None None O
higher None None O
GR None None I-protein
than None None O
both None None O
T None None I-cell_type
and None None I-cell_type
B None None I-cell_type
lymphocytes None None I-cell_type
, None None O
further None None O
contradicting None None O
results None None O
from None None O
cytosolic None None O
binding None None O
studies None None O
. None None O

To None None O
address None None O
these None None O
inconsistencies None None O
, None None O
GR None None I-protein
protein None None I-protein
was None None O
assessed None None O
in None None O
immune None None I-cell_type
cells None None I-cell_type
and None None I-cell_type
tissues None None I-cell_type
using None None O
cytosolic None None O
radioligand None None O
binding None None O
. None None O

Western None None O
blot None None O
analysis None None O
, None None O
and None None O
immunocytochemistry None None O
. None None O

Consistent None None O
with None None O
previous None None O
cytosolic None None O
receptor None None O
binding None None O
studies None None O
on None None O
immune None None O
tissue None None O
homogenates None None O
, None None O
thymic None None O
T None None I-cell_type
cells None None I-cell_type
were None None O
found None None O
to None None O
have None None O
higher None None O
levels None None O
of None None O
GR None None I-protein
than None None O
T None None I-cell_type
cells None None I-cell_type
isolated None None O
from None None O
the None None O
spleen None None O
. None None O

In None None O
addition None None O
, None None O
neutrophils None None O
were None None O
found None None O
to None None O
have None None O
fewer None None O
GR None None I-protein
than None None O
lymphocytes None None I-cell_type
and None None O
monocytes None None I-cell_type
. None None O

These None None O
results None None O
indicate None None O
a None None O
meaningful None None O
relationship None None O
between None None O
receptor None None O
expression None None O
and None None O
known None None O
sensitivity None None O
to None None O
glucocorticoids None None O
. None None O

Functional None None O
replacement None None O
of None None O
the None None O
mouse None None I-DNA
E2A None None I-DNA
gene None None I-DNA
with None None O
a None None O
human None None I-DNA
HEB None None I-DNA
cDNA None None I-DNA
. None None O

The None None O
mammalian None None I-DNA
E2A None None I-DNA
, None None I-DNA
HEB None None I-DNA
, None None I-DNA
and None None I-DNA
E2-2 None None I-DNA
genes None None I-DNA
encode None None O
a None None O
unique None None O
class None None O
of None None O
basic None None I-protein
helix-loop-helix None None I-protein
( None None I-protein
bHLH None None I-protein
) None None I-protein
transcription None None I-protein
factors None None I-protein
that None None O
are None None O
evolutionarily None None O
conserved None None O
and None None O
essential None None O
for None None O
embryonic None None O
and None None O
postnatal None None O
development None None O
. None None O

While None None O
the None None O
structural None None O
and None None O
functional None None O
similarities None None O
among None None O
the None None O
gene None None I-protein
products None None I-protein
are None None O
well None None O
demonstrated None None O
, None None O
it None None O
is None None O
not None None O
clear None None O
why None None O
deletion None None O
of None None O
E2A None None I-DNA
, None None O
but None None O
not None None O
HEB None None I-DNA
or None None O
E2-2 None None I-DNA
, None None O
leads None None O
to None None O
a None None O
complete None None O
arrest None None O
in None None O
B-lymphocyte None None O
development None None O
. None None O

To None None O
understand None None O
the None None O
molecular None None O
basis None None O
of None None O
the None None O
functional None None O
specificity None None O
between None None O
E2A None None I-DNA
and None None O
HEB None None I-DNA
/ None None O
E2-2 None None I-DNA
in None None O
mammalian None None O
development None None O
, None None O
we None None O
generated None None O
and None None O
tested None None O
a None None O
panel None None O
of None None O
E2A None None I-DNA
knockin None None O
mutations None None O
including None None O
subtle None None O
mutations None None O
in None None O
the None None O
E12 None None I-DNA
and None None I-DNA
E47 None None I-DNA
exons None None I-DNA
and None None O
substitution None None O
of None None O
both None None O
E12 None None I-DNA
and None None I-DNA
E47 None None I-DNA
exons None None I-DNA
with None None O
a None None O
human None None I-DNA
HEB None None I-DNA
cDNA None None I-DNA
. None None O

We None None O
find None None O
that None None O
the None None O
alternatively None None O
spliced None None O
E12 None None I-protein
and None None I-protein
E47 None None I-protein
bHLH None None I-protein
proteins None None I-protein
of None None O
the None None O
E2A None None I-DNA
gene None None I-DNA
play None None O
similar None None O
and None None O
additive None None O
roles None None O
in None None O
supporting None None O
B None None I-cell_type
lymphopoiesis None None I-cell_type
. None None O

Further None None O
, None None O
we None None O
find None None O
that None None O
HEB None None I-DNA
driven None None O
by None None O
the None None O
endogenous None None I-DNA
E2A None None I-DNA
promoter None None I-DNA
can None None O
functionally None None O
replace None None O
E2A None None I-DNA
in None None O
supporting None None O
B-cell None None O
commitment None None O
and None None O
differentiation None None O
toward None None O
completion None None O
. None None O

Finally None None O
, None None O
the None None O
postnatal None None O
lethality None None O
associated None None O
with None None O
E2A None None I-DNA
disruption None None O
is None None O
fully None None O
rescued None None O
by None None O
the None None O
addition None None O
of None None O
HEB None None I-DNA
. None None O

This None None O
study None None O
suggests None None O
that None None O
the None None O
functional None None O
divergence None None O
among None None O
E12 None None I-DNA
, None None O
E47 None None I-DNA
, None None O
and None None O
HEB None None I-DNA
in None None O
different None None O
cell None None O
types None None O
is None None O
partially None None O
defined None None O
by None None O
the None None O
context None None O
of None None O
gene None None O
expression None None O
. None None O

Biased None None O
dependency None None O
of None None O
CD80 None None I-protein
versus None None O
CD86 None None I-protein
in None None O
the None None O
induction None None O
of None None O
transcription None None I-protein
factors None None I-protein
regulating None None O
the None None O
human None None I-DNA
IL-2 None None I-DNA
promoter None None I-DNA
. None None O

In None None O
addition None None O
to None None O
the None None O
signals None None O
obtained None None O
by None None O
ligation None None O
of None None O
the None None O
TCR None None O
, None None O
T None None I-cell_type
cells None None I-cell_type
need None None O
additional None None O
, None None O
co-stimulatory None None O
signals None None O
to None None O
be None None O
activated None None O
. None None O

One None None O
such None None O
co-stimulatory None None O
signal None None O
is None None O
delivered None None O
when None None O
CD28 None None I-protein
on None None O
T None None I-cell_type
cells None None I-cell_type
binds None None O
to None None O
CD80 None None I-protein
or None None O
CD86 None None I-protein
on None None O
antigen-presenting None None I-cell_type
cells None None I-cell_type
( None None O
APC None None I-cell_type
) None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
analyzed None None O
the None None O
ability None None O
of None None O
CD80 None None I-protein
and None None O
CD86 None None I-protein
to None None O
co-stimulate None None I-cell_type
human None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
activated None None O
by None None O
superantigen None None O
. None None O

Using None None O
the None None O
Raji None None I-cell_line
B None None I-cell_line
cell None None I-cell_line
lymphoma None None I-cell_line
, None None O
which None None O
express None None O
similar None None O
levels None None O
of None None O
CD80 None None I-protein
and None None O
CD86 None None I-protein
, None None O
it None None O
was None None O
found None None O
that None None O
T None None O
cell None None O
proliferation None None O
was None None O
mainly None None O
co-stimulated None None O
by None None O
CD80 None None I-protein
. None None O

To None None O
further None None O
characterize None None O
the None None O
consequences None None O
of None None O
this None None O
biased None None O
co-stimulatory None None O
dependency None None O
, None None O
we None None O
employed None None O
a None None O
well-defined None None O
system None None O
of None None O
transfected None None O
CHO None None I-cell_line
cells None None I-cell_line
expressing None None O
human None None I-protein
MHC None None I-protein
class None None I-protein
II None None I-protein
together None None O
with None None O
CD80 None None I-protein
, None None O
CD86 None None I-protein
or None None O
CD80 None None I-protein
and None None O
CD86 None None I-protein
. None None O

Proliferation None None O
of None None O
freshly None None O
prepared None None O
CD4+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
required None None O
the None None O
presence None None O
of None None O
either None None O
CD80 None None I-protein
or None None O
CD86 None None I-protein
. None None O

However None None O
, None None O
IL-2 None None I-protein
production None None O
reached None None O
only None None O
suboptimal None None O
levels None None O
in None None O
the None None O
presence None None O
of None None O
CD86 None None I-protein
but None None O
optimal None None O
levels None None O
with None None O
CD80 None None I-protein
. None None O

To None None O
analyze None None O
IL-2 None None I-protein
transcriptional None None O
activity None None O
in None None O
CD80 None None I-protein
and None None O
CD86 None None I-protein
co-stimulated None None O
T None None I-cell_type
cells None None I-cell_type
we None None O
used None None O
Jurkat None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
transfected None None O
with None None O
luciferase None None I-DNA
reporter None None I-DNA
gene None None I-DNA
constructs None None I-DNA
. None None O

CD80 None None I-protein
induced None None O
higher None None O
levels None None O
of None None O
IL-2 None None I-DNA
promoter None None I-DNA
-enhancer None None O
activity None None O
compared None None O
to None None O
CD86 None None I-protein
. None None O

Furthermore None None O
, None None O
the None None O
activity None None O
of None None O
transcription None None I-protein
factors None None I-protein
regulating None None O
the None None O
IL-2 None None I-DNA
promoter-enhancer None None I-DNA
region None None I-DNA
including None None O
activation None None I-protein
protein-1 None None I-protein
, None None O
CD28 None None I-DNA
response None None I-DNA
element None None I-DNA
and None None O
nuclear None None I-protein
factor None None I-protein
kappaB None None I-protein
were None None O
4-8 None None O
times None None O
higher None None O
after None None O
CD80 None None I-protein
compared None None O
to None None O
CD86 None None I-protein
ligation None None O
. None None O

Our None None O
results None None O
suggest None None O
that None None O
the None None O
eventual None None O
appearance None None O
of None None O
CD80 None None I-protein
on None None O
recently None None O
activated None None O
CD86+ None None I-cell_type
APC None None I-cell_type
is None None O
important None None O
for None None O
the None None O
superinduction None None O
of None None O
IL-2 None None I-protein
production None None O
and None None O
to None None O
support None None O
vigorous None None O
T None None O
cell None None O
proliferation None None O
. None None O

Duplication None None O
of None None O
the None None O
DR3 None None I-DNA
gene None None I-DNA
on None None O
human None None I-DNA
chromosome None None I-DNA
1p36 None None I-DNA
and None None O
its None None O
deletion None None O
in None None O
human None None I-cell_type
neuroblastoma None None I-cell_type
. None None O

The None None O
human None None I-DNA
DR3 None None I-DNA
gene None None I-DNA
, None None O
whose None None O
product None None O
is None None O
also None None O
known None None O
as None None O
Wsl-1/APO-3/TRAMP/LARD None None I-protein
, None None O
encodes None None O
a None None O
tumor None None I-protein
necrosis None None I-protein
factor-related None None I-protein
receptor None None I-protein
that None None O
is None None O
expressed None None O
primarily None None O
on None None O
the None None O
surface None None O
of None None O
thymocytes None None I-cell_type
and None None O
lymphocytes None None I-cell_type
. None None O

DR3 None None I-protein
is None None O
capable None None O
of None None O
inducing None None O
both None None O
NF-kappa None None I-protein
B None None I-protein
activation None None O
and None None O
apoptosis None None O
when None None O
overexpressed None None O
in None None O
mammalian None None I-cell_type
cells None None I-cell_type
, None None O
although None None O
its None None O
ligand None None O
has None None O
not None None O
yet None None O
been None None O
identified None None O
. None None O

We None None O
report None None O
here None None O
that None None O
the None None O
DR3 None None I-DNA
gene None None I-DNA
locus None None I-DNA
is None None O
tandemly None None O
duplicated None None O
on None None O
human None None I-DNA
chromosome None None I-DNA
band None None I-DNA
1p36.2-p36.3 None None I-DNA
and None None O
that None None O
these None None O
genes None None O
are None None O
hemizygously None None O
deleted None None O
and/or None None O
translocated None None O
to None None O
another None None O
chromosome None None O
in None None O
neuroblastoma None None I-cell_line
( None None I-cell_line
NB None None I-cell_line
) None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
with None None O
amplified None None O
MYCN None None O
. None None O

Duplication None None O
of None None O
at None None O
least None None O
a None None O
portion None None O
of None None O
the None None O
DR3 None None I-DNA
gene None None I-DNA
, None None O
including None None O
the None None O
extracellular None None I-protein
and None None I-protein
transmembrane None None I-protein
regions None None I-protein
but None None O
not None None O
the None None O
cytoplasmic None None I-protein
domain None None I-protein
, None None O
was None None O
demonstrated None None O
by None None O
both None None O
fluorescence None None O
in None None O
situ None None O
hybridization None None O
and None None O
genomic None None O
Southern None None O
blotting None None O
. None None O

In None None O
most None None O
NB None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
, None None O
both None None O
the None None O
DR3 None None I-DNA
and None None I-DNA
the None None I-DNA
DR3L None None I-DNA
sequences None None I-DNA
are None None O
simultaneously None None O
deleted None None O
and/or None None O
translocated None None O
to None None O
another None None O
chromosome None None I-DNA
. None None O

Finally None None O
, None None O
DR3/ None None I-protein
Wsl-1 None None I-protein
protein None None I-protein
expression None None O
is None None O
quite None None O
variable None None O
among None None O
these None None O
NB None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
, None None O
with None None O
very None None O
low None None O
or None None O
undetectable None None O
levels None None O
in None None O
7 None None O
of None None O
17 None None O
NB None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line

Differential None None O
protection None None O
of None None O
normal None None I-cell_type
and None None I-cell_type
malignant None None I-cell_type
human None None I-cell_type
myeloid None None I-cell_type
progenitors None None I-cell_type
( None None O
CFU-GM None None I-cell_type
) None None O
from None None O
Ara-C None None O
toxicity None None O
using None None O
cycloheximide None None O
. None None O

Cycloheximide None None O
, None None O
a None None O
reversible None None O
protein None None O
synthesis None None O
inhibitor None None O
, None None O
is None None O
thought None None O
to None None O
block None None O
DNA None None O
replication None None O
in None None O
normal None None I-cell_type
cells None None I-cell_type
by None None O
preventing None None O
synthesis None None O
of None None O
a None None O
labile None None I-protein
protein None None I-protein
. None None O

In None None O
animal None None O
systems None None O
, None None O
cycloheximide None None O
protects None None O
normal None None I-cell_type
cells None None I-cell_type
from None None O
cytotoxic None None O
S-phase None None O
specific None None O
agents None None O
, None None O
such None None O
as None None O
cytosine None None O
arabinoside None None O
( None None O
Ara-C None None O
) None None O
. None None O

Malignant None None I-cell_type
cells None None I-cell_type
appear None None O
not None None O
to None None O
be None None O
susceptible None None O
to None None O
cycloheximide-induced None None O
cycle None None O
arrest None None O
and None None O
, None None O
subsequently None None O
, None None O
may None None O
not None None O
be None None O
protected None None O
from None None O
Ara-C None None O
cytotoxicity None None O
. None None O

The None None O
effect None None O
of None None O
cycloheximide None None O
on None None O
granulocyte/macrophage None None I-cell_type
progenitors None None I-cell_type
( None None O
CFU-GM None None I-cell_type
) None None O
after None None O
in None None O
vitro None None O
Ara-C None None O
exposure None None O
was None None O
examined None None O
using None None O
normal None None O
human None None O
bone None None O
marrow None None O
, None None O
malignant None None I-cell_type
progenitors None None I-cell_type
from None None O
patients None None O
with None None O
chronic None None O
myelogenous None None O
leukemia None None O
( None None O
CML None None O
) None None O
, None None O
and None None O
clonogenic None None I-cell_line
cells None None I-cell_line
from None None O
the None None O
human None None I-cell_line
acute None None I-cell_line
nonlymphocytic None None I-cell_line
leukemia None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
HL-60 None None I-cell_line
and None None I-cell_line
KG-1 None None I-cell_line
. None None O

Mononuclear None None I-cell_line
or None None I-cell_line
clonogenic None None I-cell_line
cells None None I-cell_line
were None None O
incubated None None O
for None None O
one None None O
hour None None O
with None None O
cycloheximide None None O
, None None O
followed None None O
by None None O
the None None O
addition None None O
, None None O
for None None O
three None None O
or None None O
17 None None O
hours None None O
, None None O
of None None O
Ara-C None None O
before None None O
being None None O
plated None None O
in None None O
a None None O
methylcellulose None None O
culture None None O
system None None O
. None None O

CFU-GM None None O
survival None None O
was None None O
significantly None None O
increase None None O
if None None O
normal None None O
cells None None O
were None None O
treated None None O
with None None O
cycloheximide None None O
before None None O
Ara-C None None O
exposure None None O
. None None O

Similar None None O
cycloheximide None None O
pretreatment None None O
of None None O
CML None None I-cell_type
progenitors None None I-cell_type
and None None O
clonogenic None None I-cell_line
HL-60 None None I-cell_line
and None None I-cell_line
KG-1 None None I-cell_line
cells None None I-cell_line
failed None None O
to None None O
protect None None O
CFU-GM None None I-cell_type
from None None O
Ara-C-induced None None O
cytotoxicity None None O
. None None O

Primary None None O
cortisol None None O
resistance None None O
accompanied None None O
by None None O
a None None O
reduction None None O
in None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
two None None O
members None None O
of None None O
the None None O
same None None O
family None None O
. None None O

This None None O
report None None O
describes None None O
studies None None O
of None None O
a None None O
man None None O
suspected None None O
of None None O
having None None O
primary None None O
cortisol None None O
resistance None None O
. None None O

This None None O
conclusion None None O
is None None O
based None None O
on None None O
his None None O
high None None O
plasma None None O
cortisol None None O
levels None None O
and None None O
high None None O
24-h None None O
urinary None None O
17-hydroxycorticosteroid None None O
and None None O
cortisol None None O
excretion None None O
, None None O
plus None None O
the None None O
fact None None O
that None None O
he None None O
had None None O
no None None O
manifestations None None O
of None None O
Cushing None None O
's None None O
syndrome None None O
. None None O

Among None None O
family None None O
members None None O
tested None None O
, None None O
his None None O
mother None None O
also None None O
had None None O
hypercortisolemia None None O
. None None O

Both None None O
mother None None O
and None None O
son None None O
had None None O
high None None O
levels None None O
of None None O
unbound None None O
plasma None None O
cortisol None None O
, None None O
but None None O
their None None O
plasma None None O
ACTH None None O
concentrations None None O
were None None O
within None None O
the None None O
normal None None O
range None None O
. None None O

Both None None O
were None None O
partially None None O
resistant None None O
to None None O
dexamethasone None None O
adrenal None None O
suppression None None O
, None None O
and None None O
both None None O
had None None O
mild None None O
hypertension None None O
without None None O
hypokalemia None None O
. None None O

To None None O
study None None O
this None None O
apparent None None O
end-organ None None O
resistance None None O
to None None O
cortisol None None O
, None None O
we None None O
examined None None O
the None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
peripheral None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
. None None O

Using None None O
whole None None O
cell None None O
assays None None O
, None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
both None None O
patients None None O
were None None O
found None None O
to None None O
have None None O
reduced None None O
total None None O
binding None None O
capacity None None O
. None None O

We None None O
conclude None None O
that None None O
these None None O
two None None O
patients None None O
, None None O
members None None O
of None None O
the None None O
same None None O
family None None O
, None None O
have None None O
primary None None O
cortisol None None O
resistance None None O
accompanied None None O
by None None O
a None None O
reduced None None O
number None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
. None None O

[ None None O
Glucocorticoid None None I-protein
receptors None None I-protein
and None None O
response None None O
to None None O
polychemotherapy None None O
in None None O
acute None None O
lymphatic None None O
leukemia None None O
] None None O

Glucocorticoid None None I-protein
receptor None None I-protein
( None None O
GR None None I-protein
) None None O
levels None None O
were None None O
quantified None None O
in None None O
leukemic None None I-cell_type
blasts None None I-cell_type
from None None O
peripheral None None O
blood None None O
of None None O
86 None None O
patients None None O
with None None O
acute None None O
lymphoblastic None None O
leukemia None None O
. None None O

The None None O
subsequent None None O
achievement None None O
of None None O
complete None None O
remission None None O
after None None O
combination None None O
chemotherapy None None O
was None None O
correlated None None O
with None None O
high None None O
receptor None None O
levels None None O
. None None O

Forty-seven None None O
of None None O
50 None None O
patients None None O
with None None O
leukemic None None I-cell_type
cells None None I-cell_type
containing None None O
more None None O
than None None O
6 None None O
, None None O
000 None None O
receptor None None O
sites None None O
and None None O
22 None None O
of None None O
36 None None O
patients None None O
with None None O
cells None None O
containing None None O
less None None O
than None None O
6 None None O
, None None O
000 None None O
receptor None None O
sites None None O
achieved None None O
remission None None O
. None None O

The None None O
study None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
leukemic None None I-cell_type
cells None None I-cell_type
may None None O
predict None None O
response None None O
to None None O
combination None None O
chemotherapy None None O
in None None O
patients None None O
with None None O
acute None None O
lymphoblastic None None O
leukemia None None O
. None None O

Specific None None O
uptake None None O
of None None O
1 None None O
, None None O
25-dihydroxycholecalciferol None None O
by None None O
human None None I-cell_type
chronic None None I-cell_type
myeloid None None I-cell_type
leukemia None None I-cell_type
cells None None I-cell_type
. None None O

We None None O
have None None O
examined None None O
mononuclear None None I-cell_line
cell None None I-cell_line
preparations None None I-cell_line
from None None O
patients None None O
with None None O
chronic None None O
myeloid None None O
leukemia None None O
[ None None O
CML None None O
] None None O
for None None O
binding None None O
of None None O
and None None O
response None None O
to None None O
1 None None O
, None None O
25-dihydroxycholecalciferol None None O
[ None None O
1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
] None None O
. None None O

Whole None None O
cells None None O
specifically None None O
took None None O
up None None O
[ None None O
3H None None O
] None None O
-1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
with None None O
high None None O
affinity None None O
( None None O
Kd None None O
3.6 None None O
X None None O
10 None None O
( None None O
-11 None None O
) None None O
M None None O
) None None O
and None None O
low None None O
capacity None None O
. None None O

Subcellular None None O
fractionation None None O
of None None O
labeled None None I-cell_line
cells None None I-cell_line
showed None None O
that None None O
binding None None O
was None None O
restricted None None O
to None None O
cytosols None None O
and None None O
nuclei None None O
. None None O

Sucrose None None O
gradient None None O
centrifugation None None O
of None None O
cells None None O
preincubated None None O
with None None O
[ None None O
3H None None O
] None None O
-1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
revealed None None O
a None None O
single None None O
3.6S None None O
peak None None O
which None None O
was None None O
totally None None O
displaced None None O
with None None O
100-fold None None O
excess None None O
nonradioactive None None O
hormone None None O
. None None O

However None None O
, None None O
we None None O
were None None O
unable None None O
to None None O
demonstrate None None O
specific None None O
binding None None O
of None None O
1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
by None None O
postlabeling None None O
standard None None O
cytosol None None O
preparations None None O
. None None O

In None None O
addition None None O
, None None O
cytosols None None O
prepared None None O
from None None O
a None None O
mixture None None O
of None None O
CML None None I-cell_line
cells None None I-cell_line
and None None O
1 None None I-cell_line
, None None I-cell_line
25- None None I-cell_line
( None None I-cell_line
OH None None I-cell_line
) None None I-cell_line
2D3 None None I-cell_line
receptor-positive None None I-cell_line
T47D None None I-cell_line
( None None O
human None None O
breast None None O
cancer None None O
) None None O
cells None None O
had None None O
less None None O
than None None O
10 None None O
% None None O
of None None O
the None None O
binding None None O
measured None None O
in None None O
T47D None None I-cell_line
cytosol None None O
alone None None O
. None None O

However None None O
, None None O
the None None O
levels None None O
of None None O
binding None None O
in None None O
T47D None None I-cell_line
cytosols None None O
were None None O
not None None O
reduced None None O
if None None O
the None None O
receptors None None O
were None None O
occupied None None O
with None None O
[ None None O
3H None None O
] None None O
-1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
prior None None O
to None None O
the None None O
addition None None O
of None None O
the None None O
CML None None I-cell_line
cytosols None None O
. None None O

Thus None None O
, None None O
CML None None I-cell_line
cells None None I-cell_line
appear None None O
to None None O
contain None None O
both None None O
the None None O
receptor None None O
for None None O
1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
and None None O
an None None O
unknown None None O
substance None None O
which None None O
prevents None None O
its None None O
detection None None O
following None None O
the None None O
preparation None None O
of None None O
cytosol None None O
. None None O

Cells None None O
from None None O
patients None None O
with None None O
CML None None O
in None None O
the None None O
chronic None None O
phase None None O
specifically None None O
bound None None O
more None None O
1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
[ None None O
18.0 None None O
+/- None None O
3.2 None None O
( None None O
S.E. None None O
) None None O
fmol/10 None None O
( None None O
7 None None O
) None None O
cells None None O
] None None O
than None None O
did None None O
those None None O
in None None O
acute None None O
myeloid None None O
transformation None None O
[ None None O
7.2 None None O
+/- None None O
1.5 None None O
] None None O
or None None O
than None None O
did None None O
cells None None O
from None None O
patients None None O
with None None O
acute None None O
myeloid None None O
leukemia None None O
[ None None O
2.6 None None O
+/- None None O
0.8 None None O
] None None O
. None None O

Only None None O
cells None None O
from None None O
the None None O
first None None O
group None None O
of None None O
patients None None O
responded None None O
to None None O
the None None O
addition None None O
of None None O
1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
by None None O
differentiating None None O
along None None O
the None None O
monocyte-macrophage None None O
pathway None None O
. None None O

We None None O
conclude None None O
that None None O
the None None O
differentiation-induction None None O
effect None None O
of None None O
1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
is None None O
likely None None O
to None None O
depend None None O
on None None O
adequate None None O
levels None None O
of None None O
receptor None None O
and None None O
that None None O
intact None None I-cell_type
cells None None I-cell_type
rather None None O
than None None O
cytosol None None O
preparations None None O
should None None O
be None None O
studied None None O
before None None O
cells None None O
of None None O
a None None O
particular None None O
tissue None None O
are None None O
designated None None O
as None None O
receptor None None O
negative None None O
. None None O

Effect None None O
of None None O
cell None None O
cycle None None O
position None None O
on None None O
dexamethasone None None O
binding None None O
by None None O
mouse None None I-cell_line
and None None I-cell_line
human None None I-cell_line
lymphoid None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
: None None O
correlation None None O
between None None O
an None None O
increase None None O
in None None O
dexamethasone None None O
binding None None O
during None None O
S None None O
phase None None O
and None None O
dexamethasone None None O
sensitivity None None O
. None None O

We None None O
determined None None O
the None None O
effect None None O
of None None O
cell None None O
cycle None None O
position None None O
on None None O
the None None O
amount None None O
of None None O
dexamethasone None None O
that None None O
was None None O
specifically None None O
bound None None O
by None None O
mouse None None I-cell_line
and None None I-cell_line
human None None I-cell_line
lymphoid None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
. None None O

Cell None None I-cell_line
lines None None I-cell_line
that None None O
were None None O
either None None O
sensitive None None O
or None None O
resistant None None O
to None None O
growth None None O
inhibition None None O
by None None O
dexamethasone None None O
were None None O
compared None None O
. None None O

Exponentially None None I-cell_type
growing None None I-cell_type
cells None None I-cell_type
were None None O
separated None None O
by None None O
centrifugal None None O
elutriation None None O
into None None O
fractions None None O
that None None O
corresponded None None O
to None None O
different None None O
positions None None O
in None None O
the None None O
cell None None O
cycle None None O
. None None O

The None None O
cell None None O
cycle None None O
phase None None O
distribution None None O
of None None O
each None None O
fraction None None O
was None None O
estimated None None O
by None None O
flow None None O
cytometry None None O
and None None O
autoradiography None None O
. None None O

The None None O
amount None None O
of None None O
dexamethasone None None O
bound None None O
per None None O
cell None None O
in None None O
each None None O
fraction None None O
was None None O
measured None None O
by None None O
a None None O
whole None None O
cell None None O
binding None None O
assay None None O
. None None O

In None None O
three None None O
dexamethasone-sensitive None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
( None None O
two None None O
mouse None None O
and None None O
one None None O
human None None O
) None None O
, None None O
we None None O
found None None O
that None None O
the None None O
amount None None O
of None None O
dexamethasone None None O
bound None None O
per None None O
cell None None O
increased None None O
2-4-fold None None O
between None None O
G1 None None O
phase None None O
and None None O
S None None O
phase None None O
, None None O
and None None O
then None None O
decreased None None O
during None None O
G2/M None None O
phase None None O
. None None O

Results None None O
were None None O
the None None O
same None None O
when None None O
the None None O
amount None None O
of None None O
dexamethasone None None O
bound None None O
per None None O
milligram None None O
of None None O
cell None None I-protein
protein None None I-protein
was None None O
measured None None O
. None None O

Binding None None O
affinity None None O
was None None O
the None None O
same None None O
during None None O
G1 None None O
phase None None O
and None None O
S None None O
phase None None O
, None None O
but None None O
the None None O
proportion None None O
of None None O
bound None None O
dexamethasone None None O
that None None O
translocated None None O
to None None O
the None None O
nucleus None None O
was None None O
greater None None O
during None None O
S None None O
phase None None O
. None None O

In None None O
contrast None None O
, None None O
we None None O
found None None O
that None None O
the None None O
amount None None O
of None None O
dexamethasone None None O
bound None None O
per None None O
cell None None O
by None None O
three None None O
dexamethasone-resistant None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
( None None O
two None None O
mouse None None O
and None None O
one None None O
human None None O
) None None O
did None None O
not None None O
increase None None O
during None None O
S None None O
phase None None O
. None None O

Our None None O
results None None O
indicate None None O
that None None O
cell None None O
cycle None None O
changes None None O
in None None O
dexamethasone None None O
binding None None O
are None None O
not None None O
simply None None O
related None None O
to None None O
changes None None O
in None None O
cell None None I-protein
protein None None I-protein
or None None O
cell None None O
volume None None O
during None None O
the None None O
cell None None O
cycle None None O
. None None O

An None None O
increase None None O
in None None O
dexamethasone None None O
binding None None O
during None None O
S None None O
phase None None O
may None None O
be None None O
required None None O
for None None O
dexamethasone None None O
to None None O
inhibit None None O
cell None None O
growth None None O
, None None O
and None None O
a None None O
failure None None O
of None None O
dexamethasone None None O
binding None None O
to None None O
increase None None O
during None None O
S None None O
phase None None O
might None None O
represent None None O
a None None O
new None None O
mechanism None None O
of None None O
dexamethasone None None O
resistance None None O
in None None O
lymphoid None None I-cell_type
cells None None I-cell_type
. None None O

Presence None None O
and None None O
steroid None None O
inducibility None None O
of None None O
glutamine None None I-protein
synthetase None None I-protein
in None None O
human None None I-cell_type
leukemic None None I-cell_type
cells None None I-cell_type
. None None O

Glutamine None None I-protein
synthetase None None I-protein
( None None O
EC None None O
6.3.1.2 None None O
; None None O
GS None None O
) None None O
is None None O
present None None O
in None None O
lymphoblasts None None I-cell_type
from None None O
patients None None O
with None None O
acute None None O
lymphoblastic None None O
leukemia None None O
( None None O
ALL None None O
) None None O
as None None O
well None None O
as None None O
in None None O
normal None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
lymphocytes None None I-cell_type
. None None O

In None None O
16 None None O
out None None O
of None None O
20 None None O
ALL None None O
patients None None O
studied None None O
exposure None None O
of None None O
the None None O
cells None None O
to None None O
physiological None None O
concentrations None None O
of None None O
dexamethasone None None O
in None None O
vitro None None O
increased None None O
enzyme None None I-protein
activity None None O
above None None O
the None None O
control None None O
levels None None O
. None None O

The None None O
increase None None O
was None None O
specific None None O
for None None O
glucocorticoid None None I-protein
receptor None None I-protein
ligands None None O
. None None O

A None None O
direct None None O
correlation None None O
was None None O
found None None O
between None None O
the None None O
magnitude None None O
of None None O
glucocorticoid-mediated None None O
increase None None O
of None None O
GS None None O
activity None None O
and None None O
the None None O
cellular None None O
levels None None O
of None None O
specific None None O
glucocorticoid None None I-protein
receptors None None I-protein
assayed None None O
in None None O
the None None O
same None None O
cell None None I-cell_type
specimen None None I-cell_type
. None None O

Moreover None None O
, None None O
the None None O
basal None None O
levels None None O
of None None O
the None None O
enzyme None None I-protein
measured None None O
in None None O
cells None None O
prior None None O
to None None O
exposure None None O
to None None O
dexamethasone None None O
correlated None None O
negatively None None O
with None None O
receptor None None O
density None None O
. None None O

It None None O
is None None O
suggested None None O
that None None O
the None None O
presence None None O
of None None O
steroid-inducible None None I-protein
GS None None I-protein
in None None O
ALL None None I-cell_type
cells None None I-cell_type
may None None O
prove None None O
to None None O
be None None O
a None None O
marker None None O
for None None O
functional None None I-protein
receptor None None I-protein
sites None None I-protein
. None None O

Binding None None O
of None None O
progestins None None O
to None None O
the None None O
glucocorticoid None None I-protein
receptor None None I-protein
. None None O

Correlation None None O
to None None O
their None None O
glucocorticoid-like None None O
effects None None O
on None None O
in None None O
vitro None None O
functions None None O
of None None O
human None None I-cell_type
mononuclear None None I-cell_type
leukocytes None None I-cell_type
. None None O

A None None O
number None None O
of None None O
physiological None None O
and None None O
synthetic None None O
progestins None None O
were None None O
tested None None O
for None None O
their None None O
ability None None O
to None None O
compete None None O
with None None O
[ None None O
3H None None O
] None None O
dexamethasone None None O
for None None O
the None None O
binding None None O
to None None O
the None None O
glucocorticoid None None I-protein
receptor None None I-protein
of None None O
human None None I-cell_type
mononuclear None None I-cell_type
leukocytes None None I-cell_type
and None None O
their None None O
ability None None O
to None None O
elicit None None O
glucocorticoid-like None None O
effects None None O
on None None O
the None None O
same None None O
cells None None O
. None None O

As None None O
compared None None O
to None None O
the None None O
reference None None O
compound None None O
dexamethasone None None O
( None None O
relative None None O
receptor None None O
binding None None O
affinity None None O
defined None None O
as None None O
100 None None O
% None None O
) None None O
, None None O
two None None O
potent None None O
synthetic None None O
progestins None None O
with None None O
a None None O
pregnane-type None None O
structure None None O
, None None O
megestrol None None O
acetate None None O
and None None O
medroxyprogesterone None None O
acetate None None O
, None None O
were None None O
found None None O
to None None O
display None None O
a None None O
considerable None None O
binding None None O
affinity None None O
towards None None O
the None None O
receptor None None O
( None None O
46 None None O
and None None O
42 None None O
% None None O
, None None O
respectively None None O
) None None O
. None None O

The None None O
relative None None O
binding None None O
affinity None None O
of None None O
the None None O
naturally None None O
occurring None None O
ligand None None O
, None None O
cortisol None None O
, None None O
to None None O
the None None O
receptor None None O
was None None O
clearly None None O
lower None None O
( None None O
25 None None O
% None None O
) None None O
. None None O

The None None O
effective None None O
binding None None O
of None None O
medroxyprogesterone None None O
acetate None None O
to None None O
the None None O
glucocorticoid None None I-protein
receptor None None I-protein
was None None O
confirmed None None O
by None None O
direct None None O
binding None None O
studies None None O
utilizing None None O
a None None O
tritiated None None O
derivative None None O
of None None O
this None None O
steroid None None O
. None None O

No None None O
evidence None None O
for None None O
the None None O
existence None None O
of None None O
a None None O
specific None None O
progesterone None None I-protein
receptor None None I-protein
in None None O
human None None I-cell_type
mononuclear None None I-cell_type
leukocytes None None I-cell_type
was None None O
obtained None None O
as None None O
judged None None O
by None None O
the None None O
results None None O
of None None O
competition None None O
experiments None None O
where None None O
a None None O
progesterone None None O
receptor-specific None None O
ligand None None O
[ None None O
3H None None O
] None None O
Org None None O
2058 None None O
was None None O
used None None O
. None None O

Medroxyprogesterone None None O
acetate None None O
and None None O
megestrol None None O
acetate None None O
also None None O
induced None None O
glucocorticoid-like None None O
effects None None O
on None None O
the None None O
lymphocyte None None I-cell_type
functions None None O
. None None O

These None None O
included None None O
inhibition None None O
of None None O
the None None O
proliferative None None O
responses None None O
to None None O
the None None O
T-cell None None I-protein
mitogens None None I-protein
concanavalin None None B-protein
A None None I-protein
and None None O
phytohaemagglutinin None None I-protein
and None None O
an None None O
enhanced None None O
accumulation None None O
of None None O
immunoglobulin None None I-cell_type
secreting None None I-cell_type
cells None None I-cell_type
in None None O
pokeweed None None I-cell_line
mitogen-stimulated None None I-cell_line
cultures None None I-cell_line
. None None O

The None None O
progestin None None O
effect None None O
appears None None O
to None None O
be None None O
mediated None None O
through None None O
a None None O
radiosensitive None None O
( None None O
suppressor None None O
) None None O
subpopulation None None O
of None None O
T None None I-cell_type
lymphocytes None None I-cell_type
. None None O

In None None O
contrast None None O
, None None O
the None None O
synthetic None None O
progestins None None O
related None None O
structurally None None O
to None None O
19-nortestosterone None None O
, None None O
norethisterone None None O
and None None O
d-norgestrel None None O
, None None O
were None None O
virtually None None O
devoid None None O
of None None O
binding None None O
affinity None None O
towards None None O
the None None O
glucocorticoid None None I-protein
receptor None None I-protein
nor None None O
did None None O
they None None O
measurably None None O
influence None None O
the None None O
in None None O
vitro None None O
lymphocyte None None I-cell_type
functions None None O
. None None O

These None None O
studies None None O
demonstrate None None O
that None None O
certain None None O
progestins None None O
in None None O
common None None O
clinical None None O
use None None O
probably None None O
possess None None O
inherent None None O
glucocorticoid None None O
activity None None O
and None None O
suggest None None O
that None None O
side None None O
effects None None O
attributable None None O
to None None O
this None None O
character None None O
( None None O
e.g. None None O
suppression None None O
of None None O
the None None O
pituitary-adrenal None None O
axis None None O
) None None O
might None None O
be None None O
expected None None O
when None None O
these None None O
compounds None None O
are None None O
used None None O
in None None O
pharmacological None None O
doses None None O
. None None O

Metabolic None None O
and None None O
ultrastructural None None O
aspects None None O
of None None O
the None None O
in None None O
vitro None None O
lysis None None O
of None None O
chronic None None I-cell_type
lymphocytic None None I-cell_type
leukemia None None I-cell_type
cells None None I-cell_type
by None None O
glucocorticoids None None O
. None None O

Human None None I-cell_type
chronic None None I-cell_type
lymphocytic None None I-cell_type
leukemia None None I-cell_type
( None None I-cell_type
CLL None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
like None None O
prothymocytes None None I-cell_type
and None None O
immunoactivated None None I-cell_type
T-lymphocytes None None I-cell_type
are None None O
readily None None O
lysed None None O
in None None O
vitro None None O
by None None O
pharmacological None None O
concentrations None None O
of None None O
glucocorticoids None None O
such None None O
as None None O
cortisol None None O
, None None O
whereas None None O
peripheral None None I-cell_type
blood None None I-cell_type
lymphocytes None None I-cell_type
and None None O
thymocytes None None I-cell_type
are None None O
unaffected None None O
by None None O
the None None O
hormone None None I-protein
. None None O

In None None O
this None None O
study None None O
, None None O
metabolic None None O
and None None O
ultrastructural None None O
aspects None None O
of None None O
the None None O
cortisol-induced None None O
killing None None O
process None None O
of None None O
CLL None None I-cell_type
cells None None I-cell_type
are None None O
recorded None None O
. None None O

In None None O
vitro None None O
lysis None None O
was None None O
found None None O
to None None O
be None None O
temperature None None O
dependent None None O
and None None O
was None None O
detected None None O
only None None O
after None None O
6 None None O
to None None O
8 None None O
hr None None O
incubation None None O
with None None O
cortisol None None O
by None None O
means None None O
of None None O
the None None O
trypan None None O
blue None None O
exclusion None None O
test None None O
. None None O

However None None O
, None None O
30 None None O
min None None O
of None None O
incubation None None O
with None None O
cortisol None None O
at None None O
either None None O
37 None None O
degrees None None O
or None None O
4 None None O
degrees None None O
followed None None O
by None None O
the None None O
removal None None O
of None None O
the None None O
hormone None None I-protein
was None None O
still None None O
sufficient None None O
to None None O
induce None None O
the None None O
lytic None None O
process None None O
. None None O

Ultrastructural None None O
studies None None O
demonstrated None None O
sequential None None O
changes None None O
in None None O
the None None O
cytoplasm None None O
, None None O
including None None O
swelling None None O
of None None O
mitochondria None None O
and None None O
cytoplasmic None None O
decompartmentalization None None O
, None None O
followed None None O
by None None O
loss None None O
of None None O
surface None None O
microvilli None None O
with None None O
the None None O
appearance None None O
of None None O
`` None None O
holes None None O
'' None None O
in None None O
the None None O
cell None None O
membrane None None O
, None None O
and None None O
subsequent None None O
condensation None None O
of None None O
nuclear None None I-DNA
chromatin None None I-DNA
. None None O

The None None O
large None None O
holes None None O
in None None O
the None None O
membrane None None O
appearing None None O
after None None O
6 None None O
hr None None O
of None None O
incubation None None O
with None None O
the None None O
hormone None None I-protein
may None None O
be None None O
the None None O
cause None None O
for None None O
the None None O
penetration None None O
of None None O
the None None O
viable None None O
stain None None O
into None None O
the None None O
dead None None I-cell_type
cells None None I-cell_type
, None None O
as None None O
seen None None O
by None None O
light None None O
microscopy None None O
. None None O

Addition None None O
of None None O
metabolic None None O
inhibitors None None O
including None None O
actinomycin None None O
D None None O
, None None O
puromycin None None O
, None None O
and None None O
cycloheximide None None O
following None None O
administration None None O
of None None O
cortisol None None O
resulted None None O
in None None O
inhibition None None O
of None None O
the None None O
cell None None O
lysis None None O
. None None O

An None None O
excess None None O
of None None O
an None None O
antagonist None None O
such None None O
as None None O
cortexolone None None O
was None None O
found None None O
to None None O
inhibit None None O
the None None O
cortisol-induced None None O
cytolysis None None O
of None None O
the None None O
CLL None None I-cell_line
cells None None I-cell_line
. None None O

It None None O
is None None O
suggested None None O
that None None O
the None None O
glucocorticoid-induced None None O
lysis None None O
of None None O
human None None I-cell_line
CLL None None I-cell_line
cells None None I-cell_line
is None None O
similar None None O
to None None O
the None None O
phenomenon None None O
observed None None O
in None None O
rat None None I-cell_type
or None None I-cell_type
murine None None I-cell_type
lymphocytes None None I-cell_type
and None None O
is None None O
mediated None None O
by None None O
interaction None None O
of None None O
the None None O
steroid None None O
molecule None None O
with None None O
the None None O
cytoplasmic None None I-protein
receptor None None I-protein
. None None O

The None None O
resulting None None O
complex None None O
appears None None O
to None None O
activate None None O
specific None None O
gene None None I-DNA
( None None O
s None None O
) None None O
the None None O
products None None O
of None None O
which None None O
eventually None None O
cause None None O
cytolysis None None O
. None None O

Glucocorticoid None None I-protein
receptors None None I-protein
in None None O
lymphoid None None O
tumors None None O
. None None O

There None None O
is None None O
a None None O
range None None O
of None None O
levels None None O
of None None O
glucocorticoid None None I-protein
receptor None None I-protein
numbers None None O
seen None None O
in None None O
the None None O
various None None O
subclasses None None O
of None None O
acute None None O
lymphatic None None O
leukemia None None O
( None None O
ALL None None O
) None None O
. None None O

This None None O
variability None None O
can None None O
not None None O
be None None O
explained None None O
by None None O
the None None O
known None None O
correlation None None O
between None None O
active None None O
cell None None O
proliferation None None O
and None None O
an None None O
increase None None O
in None None O
the None None O
number None None O
of None None O
receptors None None O
, None None O
since None None O
the None None O
tumors None None O
with None None O
the None None O
highest None None O
growth None None O
fraction None None O
( None None O
i.e. None None O
, None None O
Burkitt None None O
's None None O
lymphoma None None O
and None None O
T-cell None None O
leukemia None None O
) None None O
tend None None O
to None None O
have None None O
lower None None O
average None None O
receptor None None O
numbers None None O
than None None O
do None None O
tumors None None O
with None None O
lower None None O
growth None None O
fractions None None O
such None None O
as None None O
common None None O
ALL None None O
. None None O

All None None O
clinical None None O
specimens None None O
from None None O
patients None None O
with None None O
lymphatic None None O
leukemia None None O
have None None O
some None None O
measurable None None O
level None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
; None None O
therefore None None O
, None None O
the None None O
resistance None None O
seen None None O
in None None O
vivo None None O
can None None O
not None None O
be None None O
explained None None O
by None None O
the None None O
lack None None O
of None None O
receptors None None O
. None None O

However None None O
, None None O
there None None O
has None None O
been None None O
a None None O
positive None None O
correlation None None O
, None None O
in None None O
our None None O
hands None None O
, None None O
with None None O
receptor None None O
level None None O
and None None O
prognosis None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
in None None O
vitro None None O
models None None O
, None None O
it None None O
is None None O
proposed None None O
that None None O
perhaps None None O
the None None O
high None None I-cell_line
receptor None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
( None None O
i.e. None None O
, None None O
common None None O
ALL None None O
of None None O
childhood None None O
) None None O
have None None O
relative None None O
stability None None O
of None None O
their None None O
genetic None None O
material None None O
making None None O
glucocorticoid-resistant None None O
mutations None None O
less None None O
likely None None O
to None None O
occur None None O
in None None O
patients None None O
with None None O
these None None O
cells None None O
than None None O
in None None O
low-receptor None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
( None None O
i.e. None None O
, None None O
T-cell None None O
leukemia None None O
) None None O
. None None O

This None None O
greater None None O
genetic None None O
variability None None O
in None None O
the None None O
low-receptor None None I-cell_line
lines None None I-cell_line
could None None O
account None None O
for None None O
the None None O
earlier None None O
emergence None None O
of None None O
clinical None None O
glucocorticoid None None O
resistance None None O
in None None O
these None None O
patients None None O
. None None O

[ None None O
Tumor None None O
histology None None O
and None None O
steroid None None I-protein
receptors None None I-protein
in None None O
breast None None O
carcinoma None None O
] None None O

In None None O
Specimens None None O
of None None O
115 None None O
patients None None O
with None None O
breast None None O
cancer None None O
4 None None O
tumorparameters None None O
( None None O
tumorsize None None O
, None None O
tumorboder None None O
, None None O
nucleargrade None None O
, None None O
lymphocytic None None O
stromal None None O
reaction None None O
) None None O
3 None None O
features None None O
of None None O
regional None None O
lymphnodes None None O
( None None O
sinushistiocytosis None None O
, None None O
T-cellreaction None None O
, None None O
lymphnode None None O
metastases None None O
) None None O
and None None O
estrogen None None I-protein
and None None I-protein
progesteron None None I-protein
receptors None None I-protein
were None None O
determined None None O
. None None O

A None None O
strong None None O
sinushistiocytosis None None O
and None None O
T-cellreaction None None O
could None None O
be None None O
verified None None O
mainly None None O
in None None O
metastases None None O
in None None O
free None None O
lymphnodes None None O
. None None O

The None None O
steroid None None I-protein
receptor None None I-protein
content None None O
does None None O
not None None O
correlate None None O
with None None O
histological None None O
parameters None None O

Aldosterone-receptor None None I-protein
deficiency None None O
in None None O
pseudohypoaldosteronism None None O
. None None O

Pseudohypoaldosteronism None None O
, None None O
a None None O
syndrome None None O
characterized None None O
by None None O
salt None None O
wasting None None O
and None None O
failure None None O
to None None O
thrive None None O
, None None O
usually None None O
presents None None O
in None None O
infancy None None O
as None None O
high None None O
urinary None None O
levels None None O
of None None O
sodium None None O
despite None None O
hyponatremia None None O
, None None O
hyperkalemia None None O
, None None O
hyperreninemia None None O
, None None O
and None None O
elevated None None O
aldosterone None None O
levels None None O
. None None O

We None None O
have None None O
investigated None None O
this None None O
syndrome None None O
for None None O
the None None O
possibility None None O
of None None O
abnormal None None I-protein
Type None None I-protein
I None None I-protein
or None None O
`` None None I-protein
mineralocorticoid-like None None I-protein
'' None None I-protein
receptors None None I-protein
, None None O
which None None O
have None None O
intrinsic None None O
steroid None None O
specificity None None O
indistinguishable None None O
from None None O
that None None O
of None None O
renal None None I-protein
mineralocorticoid None None I-protein
receptors None None I-protein
and None None O
are None None O
found None None O
in None None O
many None None O
tissues None None O
and None None O
cells None None I-cell_type
, None None O
including None None O
mononuclear None None I-cell_type
leukocytes None None I-cell_type
. None None O

We None None O
have None None O
studied None None O
three None None O
patients None None O
with None None O
pseudohypoaldosteronism None None O
: None None O
the None None O
28-year-old None None O
index None None O
case None None O
in None None O
Melbourne None None O
( None None O
Patient None None O
1 None None O
) None None O
and None None O
two None None O
siblings None None O
in None None O
Munich None None O
, None None O
eight None None O
and None None O
two None None O
years None None O
of None None O
age None None O
( None None O
Patients None None O
2 None None O
and None None O
3 None None O
) None None O
; None None O
clinically None None O
, None None O
Patient None None O
3 None None O
had None None O
a None None O
less None None O
severe None None O
case None None O
than None None O
his None None O
sister None None O
. None None O

Percoll-separated None None I-cell_type
control None None I-cell_type
monocytes None None I-cell_type
bound None None O
[ None None O
3H None None O
] None None O
aldosterone None None O
with None None O
high None None O
affinity None None O
( None None O
Kd None None O
approximately None None O
3 None None O
nM None None O
) None None O
and None None O
limited None None O
capacity None None O
( None None O
150 None None O
to None None O
600 None None O
sites None None O
per None None O
cell None None O
) None None O
. None None O

On None None O
repeated None None O
examination None None O
, None None O
no None None O
[ None None O
3H None None O
] None None O
aldosterone None None O
binding None None O
was None None O
found None None O
in None None O
monocytes None None I-cell_type
from None None O
Patients None None O
1 None None O
and None None O
2 None None O
; None None O
in None None O
Patient None None O
3 None None O
, None None O
the None None O
levels None None O
were None None O
62 None None O
sites None None O
per None None O
cell None None O
, None None O
more None None O
than None None O
2 None None O
S.D. None None O
below None None O
those None None O
of None None O
the None None O
control None None O
. None None O

Levels None None O
in None None O
the None None O
parents None None O
of None None O
the None None O
Munich None None O
patients None None O
( None None O
first None None O
cousins None None O
) None None O
were None None O
normal None None O
. None None O

It None None O
appears None None O
that None None O
pseudohypoaldosteronism None None O
is None None O
caused None None O
by None None O
a None None O
Type None None O
I None None O
receptor None None O
defect None None O
, None None O
that None None O
the None None O
defect None None O
may None None O
be None None O
complete None None O
or None None O
partial None None O
, None None O
that None None O
transmission None None O
may None None O
be None None O
autosomal None None O
recessive None None O
, None None O
and None None O
that None None O
the None None O
study None None O
of None None O
patients None None O
with None None O
pseudohypoaldosteronism None None O
may None None O
indicate None None O
physiologic None None O
roles None None O
for None None O
Type None None I-protein
I None None I-protein
receptors None None I-protein
in None None O
nonepithelial None None O
tissues None None O
. None None O

Glucocorticoid None None O
inhibition None None O
of None None O
urokinase-like None None I-protein
plasminogen None None I-protein
activators None None I-protein
in None None O
cultured None None I-cell_line
human None None I-cell_line
lymphoblasts None None I-cell_line
. None None O

Two None None O
human None None I-cell_line
lymphoblast None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
, None None O
LICR-LON-HMy2 None None I-cell_line
( None None O
HMy2 None None I-cell_line
cells None None I-cell_line
) None None O
and None None O
GM4672A None None I-cell_line
cells None None I-cell_line
, None None O
are None None O
moderately None None O
growth None None O
inhibited None None O
by None None O
dexamethasone None None O
( None None O
1 None None O
, None None O
4-pregnadien-9-fluoro-16 None None O
alpha-methyl-11 None None O
beta None None O
, None None O
17 None None O
alpha None None O
, None None O
21-triol-3 None None O
, None None O
20-dione None None O
) None None O
( None None O
Dex None None O
) None None O
. None None O

Both None None O
cell None None O
types None None O
secrete None None O
a None None O
urokinase None None I-protein
( None None I-protein
UK None None I-protein
) None None I-protein
-like None None I-protein
plasminogen None None I-protein
activator None None I-protein
( None None O
PA None None I-protein
) None None O
. None None O

Treatment None None O
of None None O
both None None O
HMy2 None None I-cell_line
and None None I-cell_line
GM4672A None None I-cell_line
cells None None I-cell_line
with None None O
Dex None None O
for None None O
1-4 None None O
days None None O
inhibits None None O
extracellular None None O
PA None None I-protein
activity None None O
in None None O
a None None O
concentration-dependent None None O
manner None None O
, None None O
being None None O
half-maximal None None O
at None None O
approximately None None O
1 None None O
X None None O
10 None None O
( None None O
-9 None None O
) None None O
M None None O
. None None O

Inhibition None None O
of None None O
PA None None I-protein
in None None O
both None None O
cell None None O
types None None O
is None None O
specific None None O
for None None O
active None None O
glucocorticoids None None O
, None None O
and None None O
this None None O
specificity None None O
parallels None None O
the None None O
ability None None O
of None None O
various None None O
steroids None None O
to None None O
bind None None O
to None None O
glucocorticoid None None I-protein
receptors None None I-protein
. None None O

HMy2 None None I-cell_line
cell None None I-cell_line
PA None None I-protein
is None None O
fully None None O
suppressible None None O
by None None O
Dex None None O
, None None O
whereas None None O
up None None O
to None None O
one None None O
third None None O
of None None O
the None None O
activator None None O
expressed None None O
by None None O
GM4672A None None I-cell_line
cells None None I-cell_line
is None None O
resistant None None O
to None None O
glucocorticoid None None O
inhibition None None O
. None None O

Mixing None None O
experiments None None O
using None None O
a None None O
UK None None O
standard None None O
and None None O
conditioned None None O
media None None O
from None None O
Dex-treated None None I-cell_line
cells None None I-cell_line
suggest None None O
an None None O
absence None None O
of None None O
glucocorticoid-inducible None None I-protein
inhibitors None None I-protein
to None None O
UK None None I-protein
or None None O
plasmin None None I-protein
in None None O
both None None O
cell None None O
types None None O
. None None O

However None None O
, None None O
conditioned None None O
media None None O
from None None O
Dex-treated None None I-cell_line
GM4672A None None I-cell_line
cells None None I-cell_line
inhibits None None O
a None None O
portion None None O
of None None O
the None None O
homologous None None O
cellular None None O
activator None None O
in None None O
conditioned None None O
media None None O
from None None O
control None None O
GM4672A None None I-cell_line
cells None None I-cell_line
. None None O

Thus None None O
, None None O
low None None O
levels None None O
of None None O
glucocorticoid-inducible None None I-protein
inhibitors None None I-protein
may None None O
contribute None None O
to None None O
, None None O
but None None O
can None None O
not None None O
fully None None O
account None None O
for None None O
, None None O
Dex None None O
inhibition None None O
of None None O
GM4672A None None I-protein
PA None None I-protein
activity None None O
. None None O

Glucocorticoid-inducible None None I-protein
inhibitors None None I-protein
in None None O
HMy2 None None I-cell_line
cells None None I-cell_line
are None None O
either None None O
totally None None O
absent None None O
or None None O
are None None O
present None None O
at None None O
undetectable None None O
levels None None O
. None None O

Thus None None O
, None None O
regulation None None O
of None None O
UK-like None None I-protein
PAs None None I-protein
in None None O
HMy2 None None I-cell_line
and None None I-cell_line
GM4672A None None I-cell_line
cells None None I-cell_line
differs None None O
with None None O
respect None None O
to None None O
the None None O
extent None None O
to None None O
which None None O
glucocorticoids None None O
inhibit None None O
constitutively None None I-protein
expressed None None I-protein
activator None None I-protein
levels None None O
, None None O
as None None O
well None None O
as None None O
the None None O
possible None None O
contribution None None O
of None None O
glucocorticoid-inducible None None I-protein
inhibitors None None I-protein
to None None O
the None None O
regulatory None None O
process None None O
in None None O
GM4672A None None I-cell_line
cells None None I-cell_line
. None None O

Characterization None None O
of None None O
aldosterone None None O
binding None None O
sites None None O
in None None O
circulating None None I-cell_type
human None None I-cell_type
mononuclear None None I-cell_type
leukocytes None None I-cell_type
. None None O

Aldosterone None None O
binding None None O
sites None None O
in None None O
human None None I-cell_line
mononuclear None None I-cell_line
leukocytes None None I-cell_line
were None None O
characterized None None O
after None None O
separation None None O
of None None O
cells None None O
from None None O
blood None None O
by None None O
a None None O
Percoll None None O
gradient None None O
. None None O

After None None O
washing None None O
and None None O
resuspension None None O
in None None O
RPMI-1640 None None O
medium None None O
, None None O
cells None None O
were None None O
incubated None None O
at None None O
37 None None O
degrees None None O
C None None O
for None None O
1 None None O
h None None O
with None None O
different None None O
concentrations None None O
of None None O
[ None None O
3H None None O
] None None O
aldosterone None None O
plus None None O
a None None O
100-fold None None O
concentration None None O
of None None O
RU-26988 None None O
( None None O
11 None None O
alpha None None O
, None None O
17 None None O
alpha-dihydroxy-17 None None O
beta-propynylandrost-1 None None O
, None None O
4 None None O
, None None O
6-trien-3-one None None O
) None None O
, None None O
with None None O
or None None O
without None None O
an None None O
excess None None O
of None None O
unlabeled None None O
aldosterone None None O
. None None O

Aldosterone None None O
binds None None O
to None None O
a None None O
single None None O
class None None O
of None None O
receptors None None O
with None None O
an None None O
affinity None None O
of None None O
2.7 None None O
+/- None None O
0.5 None None O
nM None None O
( None None O
means None None O
+/- None None O
SD None None O
, None None O
n None None O
= None None O
14 None None O
) None None O
and None None O
a None None O
capacity None None O
of None None O
290 None None O
+/- None None O
108 None None O
sites/cell None None O
( None None O
n None None O
= None None O
14 None None O
) None None O
. None None O

The None None O
specificity None None O
data None None O
show None None O
a None None O
hierarchy None None O
of None None O
affinity None None O
of None None O
desoxycorticosterone None None O
= None None O
corticosterone None None O
= None None O
aldosterone None None O
greater None None O
than None None O
hydrocortisone None None O
greater None None O
than None None O
dexamethasone None None O
. None None O

The None None O
results None None O
indicate None None O
that None None O
mononuclear None None I-cell_type
leukocytes None None I-cell_type
could None None O
be None None O
useful None None O
for None None O
studying None None O
the None None O
physiological None None O
significance None None O
of None None O
these None None O
mineralocorticoid None None I-protein
receptors None None I-protein
and None None O
their None None O
regulation None None O
in None None O
humans None None O
. None None O

Mineralocorticoid None None I-protein
and None None I-protein
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
circulating None None I-cell_type
mononuclear None None I-cell_type
leukocytes None None I-cell_type
of None None O
patients None None O
with None None O
primary None None O
hyperaldosteronism None None O
. None None O

Mineralocorticoid None None I-protein
and None None I-protein
glucocorticoid None None I-protein
receptors None None I-protein
were None None O
measured None None O
in None None O
circulating None None I-cell_type
mononuclear None None I-cell_type
leukocytes None None I-cell_type
in None None O
5 None None O
patients None None O
affected None None O
by None None O
Conn None None O
's None None O
syndrome None None O
( None None O
3 None None O
cases None None O
of None None O
bilateral None None O
adrenal None None O
hyperplasia None None O
and None None O
2 None None O
cases None None O
of None None O
adenoma None None O
plus None None O
unilateral None None O
hyperplasia None None O
) None None O
. None None O

The None None O
number None None O
of None None O
the None None O
binding None None O
sites None None O
per None None O
cell None None O
resulted None None O
significantly None None O
lower None None O
( None None O
189 None None O
+/- None None O
114 None None O
, None None O
mean None None O
+/- None None O
SD None None O
) None None O
, None None O
as None None O
compared None None O
with None None O
the None None O
normal None None O
controls None None O
( None None O
298 None None O
+/- None None O
105 None None O
) None None O
. None None O

The None None O
affinity None None O
of None None O
aldosterone None None O
for None None O
the None None O
receptor None None O
was None None O
found None None O
to None None O
be None None O
not None None O
different None None O
than None None O
that None None O
of None None O
healthy None None O
control None None O
subjects None None O
. None None O

The None None O
capacity None None O
and None None O
the None None O
affinity None None O
of None None O
dexamethasone None None O
for None None O
glucocorticoid None None I-protein
receptors None None I-protein
ranged None None O
in None None O
the None None O
normal None None O
values None None O
. None None O

These None None O
data None None O
suggest None None O
a None None O
possible None None O
down-regulation None None O
of None None O
mineralocorticoid None None I-protein
receptors None None I-protein
in None None O
humans None None O
. None None O

Short-term None None O
and None None O
long-term None None O
effects None None O
of None None O
estrogen None None O
on None None O
lymphoid None None O
tissues None None O
and None None O
lymphoid None None I-cell_type
cells None None I-cell_type
with None None O
some None None O
remarks None None O
on None None O
the None None O
significance None None O
for None None O
carcinogenesis None None O
. None None O

Estrogens None None O
have None None O
long None None O
been None None O
thought None None O
to None None O
play None None O
a None None O
role None None O
in None None O
regulating None None O
the None None O
immune None None O
system None None O
. None None O

The None None O
difference None None O
in None None O
some None None O
types None None O
of None None O
immune None None O
responses None None O
between None None O
males None None O
and None None O
females None None O
is None None O
well-known None None O
, None None O
as None None O
is None None O
the None None O
pronounced None None O
thymic None None O
involution None None O
induced None None O
by None None O
exogenous None None O
estrogens None None O
. None None O

Estrogens None None O
stimulate None None O
some None None O
aspects None None O
of None None O
macrophage None None I-cell_type
activity None None O
and None None O
, None None O
depending None None O
on None None O
dose None None O
and None None O
mitogen None None I-protein
, None None O
inhibit None None O
or None None O
stimulate None None O
lymphocyte None None O
proliferative None None O
response None None O
in None None O
vitro None None O
. None None O

Another None None O
example None None O
is None None O
the None None O
estrogen None None O
effect None None O
on None None O
the None None O
delayed None None O
type None None O
hypersensitivity None None O
response None None O
. None None O

A None None O
broad None None O
review None None O
is None None O
given None None O
of None None O
such None None O
estrogen None None O
effects None None O
on None None O
lymphoid None None I-cell_type
tissue None None I-cell_type
and None None O
immune None None O
response None None O
. None None O

Most None None O
of None None O
the None None O
studies None None O
published None None O
so None None O
far None None O
are None None O
phenomenological None None O
. None None O

However None None O
, None None O
the None None O
recent None None O
description None None O
of None None O
estrogen None None I-protein
receptors None None I-protein
in None None O
the None None O
thymus None None O
and None None O
in None None O
some None None O
lymphocyte None None I-cell_line
subpopulations None None I-cell_line
, None None O
as None None O
well None None O
as None None O
a None None O
deeper None None O
understanding None None O
of None None O
regulating None None O
factors None None O
in None None O
the None None O
immune None None O
system None None O
, None None O
open None None O
the None None O
possibility None None O
of None None O
a None None O
more None None O
detailed None None O
understanding None None O
of None None O
the None None O
estrogen None None O
mechanism None None O
of None None O
interference None None O
. None None O

Estrogen None None O
effects None None O
in None None O
adults None None O
are None None O
reversible None None O
. None None O

After None None O
treating None None O
neonatal None None O
mice None None O
with None None O
the None None O
synthetic None None O
estrogen None None O
diethylstilbestrol None None O
( None None O
DES None None O
) None None O
, None None O
disturbances None None O
are None None O
induced None None O
in None None O
lymphocyte None None I-cell_line
populations None None I-cell_line
and None None O
lymphocyte None None I-cell_type
functions None None O
which None None O
are None None O
permanent None None O
and None None O
irreversible None None O
. None None O

Lymphocytes None None I-cell_type
from None None O
adult None None O
, None None O
neonatally None None O
DES-treated None None O
female None None O
mice None None O
have None None O
a None None O
reduced None None O
mitogen None None O
response None None O
to None None O
ConA None None I-protein
and None None O
LPS None None I-protein
( None None O
T None None I-protein
and None None I-protein
B None None I-protein
cell None None I-protein
mitogen None None I-protein
) None None O
and None None O
the None None O
delayed None None O
type None None O
hypersensitivity None None O
response None None O
is None None O
depressed None None O
. None None O

A None None O
detailed None None O
analysis None None O
demonstrated None None O
a None None O
decreased None None O
T None None I-cell_type
helper None None I-cell_type
cell None None I-cell_type
population None None O
. None None O

The None None O
activity None None O
of None None O
Natural None None I-cell_type
Killer None None I-cell_type
cells None None I-cell_type
is None None O
permanently None None O
reduced None None O
and None None O
this None None O
functional None None O
impairment None None O
is None None O
related None None O
to None None O
a None None O
decreased None None O
number None None O
of None None O
these None None O
cells None None O
, None None O
in None None O
turn None None O
determined None None O
at None None O
the None None O
bone None None O
marrow None None O
level None None O
. None None O

The None None O
same None None O
animals None None O
have None None O
an None None O
increased None None O
sensitivity None None O
to None None O
chemical None None O
carcinogens None None O
( None None O
methylcholanthrene None None O
) None None O
and None None O
they None None O
spontaneously None None O
develop None None O
epithelial None None O
changes None None O
in None None O
the None None O
uterine None None O
cervix None None O
which None None O
morphologically None None O
are None None O
similar None None O
to None None O
adenocarcinoma None None O
. None None O

The None None O
association None None O
between None None O
estrogen-associated None None O
malignancy None None O
and None None O
estrogen None None O
effects None None O
in None None O
lymphocyte None None I-cell_type
functions None None O
deserves None None O
further None None O
study None None O
. None None O

Drugs None None O
affecting None None O
the None None O
hormonal None None O
receptors None None O
of None None O
normal None None I-cell_type
and None None I-cell_type
leukaemic None None I-cell_type
peripheral None None I-cell_type
leucocytes None None I-cell_type
. None None O

The None None O
authors None None O
investigated None None O
the None None O
behaviour None None O
of None None O
steroid None None O
hormone None None O
uptake None None O
in None None O
leukaemic None None I-cell_type
cells None None I-cell_type
( None None O
CML None None I-cell_line
, None None O
CLL None None I-cell_line
, None None O
AML None None I-cell_line
, None None O
ALL None None I-cell_line
) None None O
, None None O
in None None O
basal None None O
conditions None None O
and None None O
after None None O
incubation None None O
with None None O
drugs None None O
which None None O
modify None None O
the None None O
cellular None None O
concentration None None O
of None None O
cAMP None None O
, None None O
PGE None None O
and None None O
PGF None None O
. None None O

The None None O
results None None O
demonstrated None None O
the None None O
presence None None O
in None None O
leukaemic None None I-cell_type
cells None None I-cell_type
of None None O
an None None O
alteration None None O
in None None O
the None None O
incorporation None None O
of None None O
steroid None None O
hormones None None O
. None None O

This None None O
alteration None None O
was None None O
scarcely None None O
modified None None O
by None None O
incubation None None O
with None None O
theophylline None None I-protein
, None None O
which None None O
increases None None O
cellular None None O
concentration None None O
of None None O
cAMP None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
it None None O
was None None O
moderately None None O
counteracted None None O
by None None O
thioproline None None O
and None None O
was None None O
evidently None None O
inhibited None None O
by None None O
flurbiprofen None None O
, None None O
which None None O
also None None O
reduced None None O
cellular None None O
concentrations None None O
of None None O
prostaglandins None None O
, None None O
particularly None None O
PGE2 None None O
, None None O
with None None O
the None None O
exception None None O
of None None O
PGF2 None None O
which None None O
showed None None O
a None None O
poor None None O
response None None O
. None None O

Differences None None O
were None None O
observed None None O
in None None O
the None None O
behavior None None O
of None None O
hormonal None None O
uptake None None O
of None None O
CML None None I-cell_line
, None None O
in None None O
contrast None None O
to None None O
that None None O
of None None O
AML None None I-cell_line
, None None I-cell_line
CLL None None I-cell_line
and None None I-cell_line
ALL None None I-cell_line
peripheral None None I-cell_line
leucocytes None None I-cell_line
. None None O

Human None None O
breast None None O
cancer None None O
and None None O
impaired None None O
NK None None I-cell_type
cell None None I-cell_type
function None None O
. None None O

Recent None None O
advances None None O
in None None O
tumor None None O
immunology None None O
have None None O
led None None O
to None None O
the None None O
discovery None None O
of None None O
a None None O
new None None O
lymphoid None None I-cell_type
cell None None I-cell_type
with None None O
unique None None O
antitumor None None O
activity None None O
. None None O

Natural None None I-cell_type
killer None None I-cell_type
( None None I-cell_type
NK None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
form None None O
an None None O
antitumor None None O
surveillance None None O
system None None O
and None None O
appear None None O
to None None O
be None None O
vital None None O
in None None O
preventing None None O
tumor None None O
growth None None O
and None None O
metastasis None None O
in None None O
animal None None O
models None None O
. None None O

We None None O
studied None None O
NK None None I-cell_type
activity None None O
in None None O
patients None None O
with None None O
benign None None O
and None None O
malignant None None O
breast None None O
disease None None O
, None None O
using None None O
a None None O
chromium-51 None None O
release None None O
microtiter None None O
cytotoxicity None None O
assay None None O
with None None O
K562 None None I-cell_line
cells None None I-cell_line
as None None O
targets None None O
. None None O

Compared None None O
with None None O
benign None None O
controls None None O
, None None O
patients None None O
with None None O
malignancies None None O
had None None O
significantly None None O
depressed None None O
NK None None I-cell_type
-mediated None None O
lysis None None O
( None None O
P None None O
less None None O
than None None O
0.01 None None O
) None None O
. None None O

Furthermore None None O
, None None O
lysis None None O
in None None O
those None None O
with None None O
advanced None None O
disease None None O
( None None O
stages None None O
II None None O
, None None O
III None None O
, None None O
and None None O
IV None None O
) None None O
was None None O
significantly None None O
less None None O
than None None O
in None None O
those None None O
with None None O
limited None None O
disease None None O
( None None O
stage None None O
I None None O
) None None O
( None None O
P None None O
less None None O
than None None O
0.01 None None O
) None None O
. None None O

NK None None I-cell_type
activity None None O
was None None O
not None None O
correlated None None O
to None None O
estrogen None None O
or None None O
progesterone None None O
receptor None None O
states None None O
. None None O

Positive None None O
correlation None None O
of None None O
a None None O
depressed None None O
natural None None O
killer None None O
activity None None O
with None None O
the None None O
extent None None O
of None None O
tumor None None O
spread None None O
supports None None O
the None None O
concept None None O
of None None O
an None None O
NK None None I-cell_type
cell None None I-cell_type
immune None None O
surveillance None None O
system None None O
in None None O
breast None None O
cancer None None O
and None None O
emphasizes None None O
its None None O
importance None None O
in None None O
this None None O
malignancy None None O
. None None O

Immunosuppressive None None O
effect None None O
of None None O
serum None None O
progesterone None None O
during None None O
pregnancy None None O
depends None None O
on None None O
the None None O
progesterone None None O
binding None None O
capacity None None O
of None None O
the None None O
lymphocytes None None I-cell_type
. None None O

Cytotoxic None None O
activity None None O
and None None O
progesterone None None O
binding None None O
capacity None None O
of None None O
the None None O
lymphocytes None None I-cell_type
, None None O
together None None O
with None None O
serum None None O
progesterone None None O
concentrations None None O
, None None O
were None None O
determined None None O
in None None O
women None None O
with None None O
normal None None O
pregnancy None None O
or None None O
with None None O
a None None O
clinical None None O
diagnosis None None O
of None None O
threatened None None O
abortion None None O
or None None O
threatened None None O
premature None None O
labour None None O
. None None O

The None None O
lymphocytes None None O
of None None O
women None None O
with None None O
threatened None None O
abortion None None O
or None None O
threatened None None O
premature None None O
labour None None O
showed None None O
significantly None None O
higher None None O
cytotoxic None None O
activity None None O
( None None O
P None None O
less None None O
than None None O
0.001 None None O
) None None O
and None None O
significantly None None O
lower None None O
progesterone None None O
binding None None O
capacity None None O
( None None O
P None None O
less None None O
than None None O
0.001 None None O
) None None O
than None None O
did None None O
lymphocytes None None I-cell_type
obtained None None O
from None None O
the None None O
healthy None None O
pregnant None None O
women None None O
. None None O

Significant None None O
inverse None None O
correlation None None O
was None None O
found None None O
between None None O
progesterone None None O
binding None None O
capacity None None O
and None None O
cytotoxic None None O
activity None None O
of None None O
the None None O
lymphocytes None None I-cell_type
( None None O
P None None O
less None None O
than None None O
0.001 None None O
) None None O
, None None O
but None None O
the None None O
progesterone None None O
concentration None None O
of None None O
the None None O
pregnancy None None O
serum None None O
appeared None None O
to None None O
have None None O
no None None O
influence None None O
on None None O
the None None O
other None None O
two None None O
parameters None None O
. None None O

The None None O
findings None None O
indicate None None O
that None None O
intact None None O
progesterone None None O
binding None None O
capacity None None O
of None None O
the None None O
lymphocytes None None I-cell_type
is None None O
an None None O
essential None None O
factor None None O
for None None O
the None None O
manifestation None None O
of None None O
the None None O
blocking None None O
effect None None O
exerted None None O
by None None O
pregnancy None None O
serum None None O
on None None O
lymphocyte None None I-cell_type
cytotoxicity None None O
in None None O
vitro None None O
. None None O

Serum None None O
sex None None O
steroid None None O
and None None O
peptide None None O
hormone None None O
concentrations None None O
, None None O
and None None O
endometrial None None O
estrogen None None O
and None None O
progestin None None O
receptor None None O
levels None None O
during None None O
administration None None O
of None None O
human None None I-protein
leukocyte None None I-protein
interferon None None I-protein
. None None O

Five None None O
normally None None O
cycling None None O
healthy None None O
women None None O
were None None O
given None None O
daily None None O
subcutaneous None None O
injections None None O
of None None O
human None None I-protein
leukocyte None None I-protein
interferon None None I-protein
( None None O
3 None None O
X None None O
10 None None O
( None None O
6 None None O
) None None O
units/day None None O
) None None O
from None None O
the None None O
3rd None None O
through None None O
23rd None None O
day None None O
of None None O
the None None O
menstrual None None O
cycle None None O
, None None O
and None None O
serum None None O
steroid None None O
and None None O
peptide None None O
hormone None None O
concentrations None None O
monitored None None O
at None None O
3-day None None O
intervals None None O
during None None O
the None None O
treatment None None O
and None None O
the None None O
preceding None None O
control None None O
cycle None None O
. None None O

Concentrations None None O
of None None O
cytosol None None I-protein
and None None I-protein
nuclear None None I-protein
estrogen None None I-protein
receptors None None I-protein
( None None O
ERC None None I-protein
and None None O
ERN None None I-protein
, None None O
respectively None None O
) None None O
and None None O
progestin None None I-protein
receptors None None I-protein
( None None O
PRC None None I-protein
and None None O
PRN None None I-protein
) None None O
were None None O
also None None O
measured None None O
from None None O
endometrial None None O
biopsies None None O
taken None None O
on None None O
the None None O
24th None None O
day None None O
of None None O
the None None O
control None None O
and None None O
treatment None None O
cycle None None O
. None None O

In None None O
addition None None O
, None None O
an None None O
extensive None None O
monitoring None None O
of None None O
clinical None None O
chemical None None O
and None None O
hematological None None O
tests None None O
from None None O
the None None O
blood None None O
samples None None O
were None None O
performed None None O
. None None O

Serum None None O
estradiol None None O
and None None O
progesterone None None O
concentrations None None O
were None None O
significantly None None O
decreased None None O
during None None O
the None None O
treatment None None O
cycle None None O
, None None O
suggesting None None O
that None None O
interferon None None I-protein
interacts None None O
in None None O
vivo None None O
with None None O
the None None O
function None None O
of None None O
both None None O
FSH None None O
and None None O
LH None None O
. None None O

No None None O
significant None None O
changes None None O
were None None O
observed None None O
in None None O
the None None O
serum None None O
peptide None None O
hormone None None O
concentrations None None O
measured None None O
( None None O
FSH None None O
, None None O
LH None None O
, None None O
prolactin None None O
, None None O
insulin None None O
, None None O
growth None None O
hormone None None O
and None None O
TSH None None O
) None None O
; None None O
neither None None O
were None None O
the None None O
levels None None O
of None None O
endometrial None None I-protein
ERC None None I-protein
, None None I-protein
ERN None None I-protein
, None None I-protein
PRC None None I-protein
and None None I-protein
PRN None None I-protein
affected None None O
by None None O
interferon None None I-protein
administration None None O
. None None O

As None None O
expected None None O
, None None O
interferon None None I-protein
administration None None O
resulted None None O
in None None O
decreased None None O
leukocyte None None I-cell_type
counts None None O
. None None O

Moreover None None O
, None None O
an None None O
increasing None None O
tendency None None O
in None None O
the None None O
activities None None O
of None None O
serum None None I-protein
alkaline None None I-protein
phosphatase None None I-protein
and None None O
gamma-glutamyltransferase None None I-protein
during None None O
the None None O
interferon None None I-protein
therapy None None O
shows None None O
that None None O
interferon None None I-protein
may None None O
slightly None None O
interfere None None O
with None None O
the None None O
liver None None O
function None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
one None None O
of None None O
the None None O
mechanisms None None O
by None None O
which None None O
interferon None None I-protein
treatment None None O
may None None O
affect None None O
the None None O
growth None None O
of None None O
hormone-dependent None None O
neoplasms None None O
could None None O
be None None O
the None None O
interaction None None O
with None None O
production None None O
and/or None None O
function None None O
of None None O
circulating None None O
hormonal None None O
compounds None None O
. None None O

[ None None O
Glucocorticoid None None I-protein
receptor None None I-protein
level None None O
in None None O
the None None O
blood None None I-cell_type
leukocytes None None I-cell_type
in None None O
different None None O
acute None None O
diseases None None O
] None None O

Content None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
cytosol None None O
of None None O
blood None None I-cell_type
leukocytes None None I-cell_type
, None None O
concentration None None O
of None None O
cortisol None None O
and None None O
amount None None O
of None None O
leukocytes None None I-cell_type
in None None O
blood None None O
were None None O
studied None None O
in None None O
20 None None O
patients None None O
with None None O
acute None None O
impairments None None O
within None None O
the None None O
second None None O
day None None O
of None None O
the None None O
disease None None O
. None None O

Content None None O
of None None O
receptors None None O
in None None O
cytosol None None O
of None None O
blood None None O
leukocytes None None O
was None None O
studied None None O
using None None O
3H-triamcinolone None None O
acetonide None None O
. None None O

Distinct None None O
increase None None O
in None None O
amount None None O
of None None O
the None None O
leukocyte None None I-protein
glucocorticoid None None I-protein
receptors None None I-protein
was None None O
found None None O
in None None O
patients None None O
with None None O
poisoning None None O
by None None O
dichlorethane None None O
and None None O
hypnotic None None O
drugs None None O
under None None O
conditions None None O
of None None O
acute None None O
myocardial None None O
infarction None None O
. None None O

In None None O
acute None None O
pancreatitis None None O
content None None O
of None None O
the None None O
leukocyte None None I-protein
receptors None None I-protein
was None None O
not None None O
altered None None O
as None None O
compared None None O
with None None O
controls None None O
. None None O

Concentration None None O
of None None O
endogenous None None O
cortisol None None O
was None None O
increased None None O
in None None O
blood None None O
of None None O
all None None O
the None None O
patients None None O
, None None O
except None None O
of None None O
the None None O
cases None None O
of None None O
acetate None None O
intoxication None None O
. None None O

Reverse None None O
correlation None None O
was None None O
observed None None O
between None None O
concentration None None O
of None None O
cortisol None None O
in None None O
blood None None O
and None None O
content None None O
of None None O
glucocorticoid None None O
receptors None None O
in None None O
leukocytes None None I-cell_type
. None None O

But None None O
in None None O
the None None O
patients None None O
with None None O
acute None None O
pancreatitis None None O
the None None O
decrease None None O
in None None O
content None None O
of None None O
leukocyte None None I-protein
glucocorticoid None None I-protein
receptors None None I-protein
was None None O
not None None O
observed None None O
although None None O
there None None O
was None None O
an None None O
increase None None O
in None None O
cortisol None None O
concentration None None O
in None None O
blood None None O
. None None O

The None None O
role None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
immunological None None O
processes None None O
under None None O
conditions None None O
of None None O
purulent None None O
complications None None O
and None None O
possibility None None O
to None None O
regulate None None O
the None None O
metabolism None None O
in None None O
leukocytes None None I-cell_type

Therapeutic None None O
concentrations None None O
of None None O
glucocorticoids None None O
suppress None None O
the None None O
antimicrobial None None O
activity None None O
of None None O
human None None I-cell_type
macrophages None None I-cell_type
without None None O
impairing None None O
their None None O
responsiveness None None O
to None None O
gamma None None I-protein
interferon None None I-protein
. None None O

By None None O
exposing None None O
human None None I-cell_type
blood-derived None None I-cell_type
macrophages None None I-cell_type
and None None I-cell_type
alveolar None None I-cell_type
macrophages None None I-cell_type
in None None O
vitro None None O
to None None O
dexamethasone None None O
, None None O
we None None O
showed None None O
in None None O
these None None O
studies None None O
that None None O
glucocorticoids None None O
markedly None None O
suppress None None O
the None None O
antimicrobial None None O
activity None None O
of None None O
macrophages None None I-cell_type
but None None O
not None None O
macrophage None None I-cell_type
activation None None O
by None None O
lymphokines None None I-cell_type
. None None O

As None None O
little None None O
as None None O
2.5 None None O
X None None O
10 None None O
( None None O
-8 None None O
) None None O
mol/liter None None O
of None None O
dexamethasone None None O
prevented None None O
macrophages None None I-cell_type
from None None O
inhibiting None None O
germination None None O
of None None O
Aspergillus None None O
spores None None O
or None None O
from None None O
eliminating None None O
ingested None None O
bacteria None None O
such None None O
as None None O
Listeria None None O
, None None O
Nocardia None None O
, None None O
or None None O
Salmonella None None O
. None None O

Damage None None O
to None None O
macrophage None None I-cell_type
function None None O
was None None O
inhibited None None O
by None None O
progesterone None None O
and None None O
appeared None None O
to None None O
be None None O
receptor-mediated None None O
. None None O

In None None O
accordance None None O
with None None O
in None None O
vivo None None O
observations None None O
, None None O
dexamethasone None None O
required None None O
24-36 None None O
h None None O
to None None O
suppress None None O
antimicrobial None None O
activity None None O
. None None O

While None None O
glucocorticoids None None O
interfered None None O
with None None O
base-line None None O
activity None None O
of None None O
macrophages None None I-cell_type
, None None O
dexamethasone None None O
concentrations None None O
comparable None None O
to None None O
drug None None O
levels None None O
in None None O
patients None None O
had None None O
no None None O
effect None None O
on None None O
macrophage None None I-cell_type
activation None None O
. None None O

Proliferating None None O
lymphocytes None None I-cell_type
and None None O
gamma-interferon None None I-protein
thus None None O
increased None None O
the None None O
antimicrobial None None O
activity None None O
of None None O
phagocytes None None I-cell_type
exposed None None O
to None None O
glucocorticoids None None O
over None None O
that None None O
of None None O
control None None O
cells None None O
. None None O

Macrophage None None O
activation None None O
and None None O
correction None None O
of None None O
the None None O
dexamethasone None None O
effect None None O
by None None O
gamma-interferon None None I-protein
, None None O
however None None O
, None None O
was None None O
dependent None None O
on None None O
the None None O
pathogen None None O
. None None O

The None None O
lymphokine None None I-protein
enhanced None None O
the None None O
antimicrobial None None O
activity None None O
of None None O
dexamethasone-treated None None I-cell_line
macrophages None None I-cell_line
against None None O
Listeria None None O
and None None O
Salmonella None None O
but None None O
not None None O
against None None O
Aspergillus None None O
or None None O
Nocardia None None O
. None None O

Dexamethasone-induced None None O
damage None None O
to None None O
the None None O
antimicrobial None None O
activity None None O
of None None O
human None None I-cell_type
macrophages None None I-cell_type
in None None O
vitro None None O
parallels None None O
observations None None O
that None None O
glucocorticoids None None O
render None None O
laboratory None None O
animals None None O
susceptible None None O
to None None O
listeriosis None None O
and None None O
aspergillosis None None O
by None None O
damaging None None O
resident None None O
macrophages None None I-cell_line
. None None O

Suppression None None O
of None None O
macrophage None None I-cell_type
antimicrobial None None O
activity None None O
should None None O
thus None None O
be None None O
considered None None O
when None None O
treating None None O
patients None None O
with None None O
glucocorticoids None None O
; None None O
its None None O
prevention None None O
by None None O
gamma-interferon None None I-protein
might None None O
be None None O
beneficial None None O
for None None O
some None None O
but None None O
not None None O
all None None O
pathogens None None O
. None None O

Interleukin None None I-protein
2 None None I-protein
receptor None None I-protein
( None None O
Tac None None I-protein
antigen None None I-protein
) None None O
expression None None O
in None None O
HTLV-I-associated None None O
adult None None O
T-cell None None I-cell_type
leukemia None None O
. None None O

Interleukin-2 None None I-protein
( None None O
IL-2 None None I-protein
) None None O
is None None O
a None None O
lymphokine None None I-protein
synthesized None None O
by None None O
some None None O
T-cells None None I-cell_type
following None None O
activation None None O
. None None O

Resting None None O
T-cells None None I-cell_type
do None None O
not None None O
express None None O
IL-2 None None I-protein
receptors None None I-protein
, None None O
but None None O
receptors None None O
are None None O
rapidly None None O
expressed None None O
on None None O
T-cells None None I-cell_type
following None None O
interaction None None O
of None None O
antigens None None O
, None None O
mitogens None None O
, None None O
or None None O
monoclonal None None I-protein
antibodies None None I-protein
with None None O
the None None O
antigen-specific None None I-protein
T-cell None None I-protein
receptor None None I-protein
complex None None I-protein
. None None O

Using None None O
anti-Tac None None I-protein
, None None O
a None None O
monoclonal None None I-protein
antibody None None I-protein
that None None O
recognizes None None O
the None None O
IL-2 None None I-protein
receptor None None I-protein
, None None O
the None None O
receptor None None O
has None None O
been None None O
purified None None O
and None None O
shown None None O
to None None O
be None None O
a None None O
Mr None None O
33 None None O
, None None O
000 None None O
peptide None None O
that None None O
is None None O
posttranslationally None None O
glycosylated None None O
to None None O
a None None O
Mr None None O
55 None None O
, None None O
000 None None O
mature None None O
form None None O
. None None O

Normal None None O
resting None None O
T-cells None None I-cell_type
and None None O
most None None O
leukemic None None I-cell_line
T-cell None None I-cell_line
populations None None I-cell_line
do None None O
not None None O
express None None O
IL-2 None None I-protein
receptors None None I-protein
; None None O
however None None O
, None None O
the None None O
leukemic None None I-cell_type
cells None None I-cell_type
of None None O
the None None O
11 None None O
patients None None O
examined None None O
who None None O
had None None O
human None None O
T-cell None None O
lymphotropic None None O
virus-associated None None O
adult None None O
T-cell None None O
leukemia None None O
expressed None None O
the None None O
Tac None None I-protein
antigen None None I-protein
. None None O

In None None O
human None None I-cell_type
T-cell None None I-cell_type
lymphotropic None None I-cell_type
virus-I None None I-cell_type
infected None None I-cell_type
cells None None I-cell_type
, None None O
the None None O
Mr None None O
42 None None O
, None None O
000 None None O
long None None O
open None None I-protein
reading None None I-protein
frame None None I-protein
protein None None I-protein
encoded None None O
in None None O
part None None O
by None None O
the None None O
pX None None I-DNA
region None None I-DNA
of None None O
this None None O
virus None None O
may None None O
act None None O
as None None O
a None None O
transacting None None I-protein
transcriptional None None I-protein
activator None None I-protein
that None None O
induces None None O
IL-2 None None I-DNA
receptor None None I-DNA
gene None None I-DNA
transcription None None O
, None None O
thus None None O
providing None None O
an None None O
explanation None None O
for None None O
the None None O
constant None None O
association None None O
of None None O
IL-2 None None I-protein
receptor None None I-protein
expression None None O
with None None O
adult None None O
T-cell None None O
lymphotropic None None O
virus-I None None O
infection None None O
of None None O
lymphoid None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
constant None None O
expression None None O
of None None O
large None None O
numbers None None O
of None None O
IL-2 None None I-protein
receptors None None I-protein
which None None O
may None None O
be None None O
aberrant None None O
may None None O
play None None O
a None None O
role None None O
in None None O
the None None O
uncontrolled None None O
growth None None O
of None None O
adult None None I-cell_type
T-cell None None I-cell_type
leukemia None None I-cell_type
cells None None I-cell_type
. None None O

Two None None O
patients None None O
with None None O
Tac-positive None None O
adult None None O
T-cell None None O
leukemia None None O
have None None O
been None None O
treated None None O
with None None O
the None None O
anti-Tac None None I-protein
. None None O

One None None O
of None None O
the None None O
patients None None O
had None None O
6- None None O
and None None O
3-mo None None O
remissions None None O
of None None O
his None None O
leukemia None None O
following None None O
two None None O
courses None None O
of None None O
therapy None None O
with None None O
this None None O
monoclonal None None I-protein
antibody None None I-protein
directed None None O
toward None None O
this None None O
growth None None I-protein
factor None None I-protein
receptor None None I-protein
. None None O

Lymphocyte None None I-cell_type
glucocorticoid None None I-protein
receptor None None I-protein
binding None None O
in None None O
depressed None None O
patients None None O
with None None O
hypercortisolemia None None O
. None None O

Despite None None O
elevated None None O
levels None None O
of None None O
serum None None O
and None None O
urinary None None O
cortisol None None O
, None None O
patients None None O
with None None O
depressive None None O
illness None None O
manifest None None O
none None None O
of None None O
the None None O
clinical None None O
stigmata None None O
of None None O
glucocorticoid None None O
excess None None O
. None None O

This None None O
hypercortisolemia None None O
in None None O
the None None O
absence None None O
of None None O
clinical None None O
effects None None O
suggests None None O
a None None O
state None None O
of None None O
hormone None None O
resistance None None O
and None None O
could None None O
be None None O
mediated None None O
by None None O
alterations None None O
in None None O
the None None O
glucocorticoid None None I-protein
receptor None None I-protein
. None None O

Earlier None None O
studies None None O
have None None O
shown None None O
that None None O
small None None O
doses None None O
of None None O
glucocorticoids None None O
cause None None O
a None None O
decrease None None O
in None None O
glucocorticoid None None I-protein
receptor None None I-protein
binding None None O
in None None O
normal None None O
human None None I-cell_type
lymphocytes None None I-cell_type
. None None O

White None None O
cells None None O
from None None O
depressed None None O
patients None None O
with None None O
significant None None O
hypercortisolemia None None O
would None None O
be None None O
expected None None O
to None None O
show None None O
a None None O
similar None None O
change None None O
in None None O
receptor None None O
concentration None None O
if None None O
peripheral None None O
tissues None None O
are None None O
adequately None None O
exposed None None O
to None None O
and None None O
sensitive None None O
to None None O
the None None O
hormone None None O
. None None O

In None None O
this None None O
study None None O
we None None O
compared None None O
the None None O
binding None None O
of None None O
[ None None O
3H None None O
] None None O
dexamethasone None None O
to None None O
lymphocytes None None I-cell_type
from None None O
normal None None O
subjects None None O
and None None O
depressed None None O
patients None None O
with None None O
hypercortisolemia None None O
. None None O

Lymphocytes None None I-cell_type
from None None O
normal None None O
subjects None None O
had None None O
a None None O
mean None None O
receptor None None O
concentration None None O
of None None O
10.2 None None O
+/- None None O
0.66 None None O
fm/10 None None O
( None None O
6 None None O
) None None O
cells None None O
( None None O
S.E.M. None None O
) None None O
and None None O
a None None O
dissociation None None O
constant None None O
of None None O
4.8 None None O
+/- None None O
0.47 None None O
nM None None O
. None None O

Lymphocytes None None I-cell_type
from None None O
depressed None None O
patients None None O
with None None O
abnormal None None O
0800 None None O
h None None O
serum None None O
cortisol None None O
after None None O
dexamethasone None None O
had None None O
a None None O
mean None None O
receptor None None O
concentration None None O
of None None O
8.8 None None O
+/- None None O
0.75 None None O
fm/10 None None O
( None None O
6 None None O
) None None O
cells None None O
, None None O
which None None O
was None None O
not None None O
significantly None None O
different None None O
from None None O
that None None O
in None None O
lymphocytes None None I-cell_type
from None None O
normal None None O
subjects None None O
or None None O
from None None O
depressed None None O
subjects None None O
with None None O
normal None None O
post-dexamethasone None None O
cortisol None None O
levels None None O
( None None O
9.4 None None O
+/- None None O
0.95 None None O
fm/10 None None O
( None None O
6 None None O
) None None O
cells None None O
) None None O
. None None O

Lymphocytes None None I-cell_type
from None None O
depressed None None O
patients None None O
with None None O
elevated None None O
urinary None None O
free None None O
cortisol None None O
excretion None None O
( None None O
UFC None None O
) None None O
also None None O
had None None O
normal None None O
receptor None None O
concentration None None O
and None None O
binding None None O
affinity None None O
for None None O
dexamethasone None None O
. None None O

The None None O
lack None None O
of None None O
a None None O
change None None O
in None None O
lymphocyte None None I-cell_type
glucocorticoid None None I-protein
receptor None None I-protein
concentration None None O
in None None O
the None None O
presence None None O
of None None O
cortisol None None O
excess None None O
suggests None None O
the None None O
possibility None None O
that None None O
hypercortisolemia None None O
in None None O
depressive None None O
illness None None O
represents None None O
a None None O
state None None O
of None None O
peripheral None None O
glucocorticoid None None O
resistance None None O
. None None O

Structure None None O
and None None O
regulation None None O
of None None O
the None None O
glucocorticoid None None I-protein
hormone None None I-protein
receptor None None I-protein
. None None O

The None None O
glucocorticoid None None I-protein
receptor None None I-protein
is None None O
an None None O
intracellular None None I-protein
protein None None I-protein
which None None O
possesses None None O
three None None O
distinct None None O
domains None None O
, None None O
one None None O
that None None O
binds None None O
agonist None None O
and None None O
antagonist None None O
steroids None None O
, None None O
one None None O
that None None O
binds None None O
DNA None None O
, None None O
and None None O
one None None O
that None None O
binds None None O
anti-receptor None None I-protein
antibodies None None I-protein
and None None O
is None None O
required None None O
for None None O
glucocorticoid None None O
modulation None None O
of None None O
gene None None O
expression None None O
. None None O

In None None O
intact None None O
cells None None O
, None None O
receptor None None O
number None None O
, None None O
affinity None None O
and None None O
activity None None O
can None None O
change None None O
in None None O
response None None O
to None None O
factors None None O
that None None O
bind None None O
to None None O
the None None O
receptor None None O
, None None O
or None None O
that None None O
act None None O
indirectly None None O
through None None O
ill-defined None None O
mechanisms None None O
which None None O
may None None O
include None None O
resumption None None O
or None None O
arrest None None O
of None None O
cell None None O
cycling None None O
and None None O
variations None None O
in None None O
intracellular None None O
calcium None None O
ion None None O
concentrations None None O
. None None O

Some None None O
of None None O
these None None O
factors None None O
appear None None O
to None None O
exert None None O
their None None O
effect None None O
by None None O
controlling None None O
critical None None O
receptor None None O
properties None None O
such None None O
as None None O
ATP-dependent None None O
phosphorylation None None O
, None None O
integrity None None O
of None None O
thiol None None I-protein
groups None None I-protein
, None None O
and None None O
exposure None None O
of None None O
key None None I-protein
amino None None I-protein
acid None None I-protein
residues None None I-protein
. None None O

Glucocorticoid None None O
agonists None None O
promote None None O
the None None O
'transformation None None O
' None None O
of None None O
the None None O
receptor None None O
into None None O
the None None O
DNA-binding None None O
state None None O
, None None O
which None None O
is None None O
competent None None O
for None None O
modulating None None O
gene None None O
expression None None O
. None None O

Glucocorticoid None None O
antagonists None None O
are None None O
steroids None None O
that None None O
interact None None O
with None None O
the None None O
receptor None None O
but None None O
either None None O
fail None None O
to None None O
produce None None O
a None None O
stable None None I-protein
complex None None I-protein
or None None O
produce None None O
a None None O
stable None None I-protein
but None None I-protein
inefficient None None I-protein
complex None None I-protein
. None None O

Although None None O
substituent None None O
groups None None O
that None None O
confer None None O
agonist None None O
or None None O
antagonist None None O
activity None None O
to None None O
the None None O
steroid None None O
have None None O
been None None O
identified None None O
, None None O
the None None O
molecular None None O
determinants None None O
of None None O
this None None O
difference None None O
at None None O
the None None O
receptor None None O
level None None O
remain None None O
unknown None None O
. None None O

Most None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
data None None O
on None None O
receptor None None O
regulation None None O
can None None O
be None None O
accommodated None None O
by None None O
postulating None None O
the None None O
existence None None O
of None None O
an None None O
intracellular None None O
cycle None None O
that None None O
involves None None O
five None None O
states None None O
of None None O
the None None O
receptor None None O
. None None O

The None None O
active None None O
free None None O
receptor None None O
is None None O
phosphorylated None None O
, None None O
reduced None None O
, None None O
and None None O
presumably None None O
oligomeric None None O
( None None O
state None None O
A None None O
) None None O
. None None O

Following None None O
binding None None O
of None None O
an None None O
agonist None None O
( None None O
state None None O
B None None O
) None None O
, None None O
it None None O
can None None O
become None None O
transformed None None O
by None None O
dissociation None None O
into None None O
its None None O
subunits None None O
and None None O
dephosphorylation None None O
( None None O
state None None O
C None None O
) None None O
. None None O

The None None O
transformed None None I-protein
receptor None None I-protein
then None None O
interacts None None O
with None None O
chromatin None None I-DNA
( None None O
state None None O
D None None O
) None None O
. None None O

Dissociation None None O
of None None O
the None None O
steroid None None O
and None None O
oxidation None None O
of None None O
receptor None None I-protein
thiol None None I-protein
group None None I-protein
( None None O
s None None O
) None None O
lead None None O
to None None O
the None None O
inactive None None O
receptor None None O
form None None O
( None None O
state None None O
E None None O
) None None O
. None None O

Reduction None None O
and None None O
rephosphorylation None None O
of None None O
the None None O
receptor None None O
enable None None O
it None None O
to None None O
bind None None O
steroids None None O
again None None O
so None None O
that None None O
the None None O
cycle None None O
is None None O
closed None None O
. None None O

Thermodynamics None None O
of None None O
steroid None None O
binding None None O
to None None O
the None None O
human None None I-protein
glucocorticoid None None I-protein
receptor None None I-protein
. None None O

The None None O
thermodynamics None None O
of None None O
the None None O
interaction None None O
of None None O
glucocorticoids None None O
with None None O
their None None O
receptor None None O
were None None O
studied None None O
in None None O
cytosol None None O
from None None O
human None None I-cell_type
lymphoblastoid None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
rate None None O
and None None O
affinity None None O
constants None None O
of None None O
dexamethasone None None O
and None None O
cortisol None None O
between None None O
0 None None O
degree None None O
and None None O
25 None None O
degrees None None O
C None None O
were None None O
calculated None None O
by None None O
curve-fitting None None O
from None None O
time-course None None O
and None None O
equilibrium None None O
kinetics None None O
. None None O

The None None O
data None None O
were None None O
consistent None None O
with None None O
a None None O
simple None None O
reversible None None O
bimolecular None None O
interaction None None O
. None None O

Arrhenius None None O
and None None O
Va None None O
n't None None O
Hoff None None O
plots None None O
were None None O
curvilinear None None O
for None None O
both None None O
steroids None None O
. None None O

At None None O
equilibrium None None O
, None None O
the None None O
solution None None O
for None None O
the None None O
equation None None O
delta None None O
G None None O
= None None O
delta None None O
H None None O
- None None O
T None None O
X None None O
delta None None O
S None None O
( None None O
eqn. None None O
1 None None O
) None None O
was None None O
( None None O
in None None O
kJ None None O
X None None O
mol-1 None None O
) None None O
-47 None None O
= None None O
36 None None O
- None None O
83 None None O
( None None O
dexamethasone None None O
) None None O
and None None O
-42 None None O
= None None O
-9 None None O
- None None O
33 None None O
( None None O
cortisol None None O
) None None O
at None None O
0 None None O
degree None None O
C None None O
. None None O

Enthalpy None None O
and None None O
entropy None None O
changes None None O
decreased None None O
quasi-linearly None None O
with None None O
temperature None None O
such None None O
that None None O
, None None O
at None None O
25 None None O
degrees None None O
C None None O
, None None O
the None None O
respective None None O
values None None O
were None None O
-50 None None O
= None None O
-75 None None O
+ None None O
25 None None O
and None None O
-43 None None O
= None None O
-48 None None O
+ None None O
5 None None O
. None None O

Thus None None O
, None None O
for None None O
both None None O
steroids None None O
, None None O
the None None O
interaction None None O
was None None O
entropy-driven None None O
at None None O
low None None O
temperature None None O
and None None O
became None None O
entirely None None O
enthalpy-driven None None O
at None None O
20 None None O
degrees None None O
C None None O
. None None O

Thermodynamic None None O
values None None O
for None None O
the None None O
transition None None O
state None None O
were None None O
calculated None None O
from None None O
the None None O
rate None None O
constants None None O
. None None O

For None None O
the None None O
forward None None O
reaction None None O
, None None O
eqn. None None O
( None None O
1 None None O
) None None O
gave None None O
45 None None O
= None None O
84 None None O
- None None O
39 None None O
( None None O
dexamethasone None None O
) None None O
and None None O
46 None None O
= None None O
60 None None O
- None None O
14 None None O
( None None O
cortisol None None O
) None None O
at None None O
0 None None O
degree None None O
C None None O
, None None O
and None None O
44 None None O
= None None O
24 None None O
+ None None O
20 None None O
( None None O
dexamethasone None None O
) None None O
and None None O
46 None None O
= None None O
28 None None O
+ None None O
18 None None O
( None None O
cortisol None None O
) None None O
at None None O
25 None None O
degrees None None O
C None None O
. None None O

These None None O
data None None O
fit None None O
quite None None O
well None None O
with None None O
a None None O
two-step None None O
model None None O
[ None None O
Ross None None O
& None None O
Subramanian None None O
( None None O
1981 None None O
) None None O
Biochemistry None None O
20 None None O
, None None O
3096-3102 None None O
] None None O
proposed None None O
for None None O
ligand-protein None None O
interactions None None O
, None None O
which None None O
involves None None O
a None None O
partial None None O
immobilization None None O
of None None O
the None None O
reacting None None O
species None None O
governed None None O
by None None O
hydrophobic None None O
forces None None O
, None None O
followed None None O
by None None O
stabilization None None O
of None None O
the None None O
complex None None O
by None None O
short-range None None O
interactions None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
this None None O
model None None O
, None None O
an None None O
analysis None None O
of None None O
the None None O
transition-state None None O
thermodynamics None None O
led None None O
to None None O
the None None O
conclusion None None O
that None None O
no None None O
more None None O
than None None O
half None None O
of None None O
the None None O
steroid None None O
molecular None None O
area None None O
is None None O
engaged None None O
in None None O
the None None O
binding None None O
process None None O
. None None O

Cell None None O
cycle-related None None O
changes None None O
in None None O
number None None O
of None None O
T-lymphocyte None None I-protein
receptors None None I-protein
for None None O
glucocorticoids None None O
and None None O
insulin None None O
. None None O

Enriched None None O
human None None I-cell_type
peripheral None None I-cell_type
T-lymphocytes None None I-cell_type
were None None O
stimulated None None O
with None None O
PHA None None O
and None None O
examined None None O
for None None O
variations None None O
in None None O
insulin None None O
and None None O
glucocorticoid None None O
( None None O
dexamethasone None None O
) None None O
receptor None None O
numbers None None O
during None None O
the None None O
early None None O
phases None None O
of None None O
the None None O
cell None None O
cycle None None O
. None None O

Cells None None O
in None None O
G0 None None O
, None None O
G1a None None O
and None None O
G1b None None O
phases None None O
, None None O
where None None O
the None None O
G1a None None O
- None None O
G1b None None O
transition None None O
is None None O
an None None O
Interleukin None None I-protein
2 None None I-protein
dependent None None O
event None None O
, None None O
were None None O
quantitated None None O
by None None O
flow None None O
cytometry None None O
. None None O

Few None None O
but None None O
significant None None O
numbers None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
( None None O
2700/cell None None O
) None None O
and None None O
no None None O
insulin None None I-protein
receptors None None I-protein
( None None O
-1/cell None None O
) None None O
were None None O
found None None O
in None None O
the None None O
resting None None O
( None None O
G0 None None O
) None None O
phase None None O
. None None O

As None None O
cells None None O
entered None None O
the None None O
G1a None None O
phase None None O
the None None O
specific None None O
binding None None O
of None None O
dexamethasone None None O
increased None None O
and None None O
of None None O
insulin None None O
took None None O
place None None O
. None None O

Although None None O
the None None O
specific None None O
binding None None O
further None None O
increased None None O
as None None O
T-cells None None I-cell_type
entered None None O
the None None O
G1b None None O
phase None None O
( None None O
as None None O
measured None None O
at None None O
44 None None O
h None None O
of None None O
incubation None None O
and None None O
using None None O
hydroxyurea-treated None None I-cell_line
cells None None I-cell_line
) None None O
, None None O
the None None O
major None None O
changes None None O
in None None O
the None None O
specific None None O
binding None None O
of None None O
dexamethasone None None O
took None None O
place None None O
during None None O
the None None O
period None None O
16 None None O
- None None O
20 None None O
h None None O
after None None O
stimulation None None O
. None None O

Based None None O
on None None O
these None None O
findings None None O
, None None O
it None None O
is None None O
concluded None None O
that None None O
both None None O
receptor None None O
types None None O
( None None O
cell None None I-protein
membrane None None I-protein
and None None I-protein
cytoplasmic None None I-protein
receptors None None I-protein
) None None O
are None None O
being None None O
formed None None O
and None None O
increased None None O
at None None O
G1 None None O
phase None None O
prior None None O
to None None O
cell None None O
proliferation None None O
, None None O
indicating None None O
the None None O
importance None None O
of None None O
G1 None None O
phase None None O
in None None O
immunoregulation None None O
. None None O

Glucocorticoid None None I-protein
receptors None None I-protein
and None None O
cortico-sensitivity None None O
in None None O
a None None O
human None None I-cell_line
clonal None None I-cell_line
monocytic None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
, None None O
CM-SM None None I-cell_line
. None None O

CM-SM None None I-cell_line
is None None O
a None None O
clonal None None I-cell_line
line None None I-cell_line
of None None O
human None None I-cell_type
precursor None None I-cell_type
mononuclear None None I-cell_type
phagocytes None None I-cell_type
inducible None None O
to None None O
macrophage None None I-cell_type
differentiation None None O
in None None O
response None None O
to None None O
the None None O
tumor None None O
promoter None None O
phorbol None None O
ester None None O
12-O-tetradecanoyl-phorbol-13-acetate None None O
( None None O
TPA None None O
) None None O
. None None O

Untreated None None O
CM-SM None None O
cells None None O
contain None None O
single None None O
class None None O
, None None O
high-affinity None None O
( None None O
KD None None O
= None None O
4.0 None None O
X None None O
10 None None O
( None None O
-9 None None O
) None None O
M None None O
) None None O
glucocorticoid-specific None None O
receptor None None O
sites None None O
( None None O
approximately None None O
60 None None O
, None None O
000 None None O
per None None O
cell None None O
) None None O
, None None O
as None None O
measured None None O
by None None O
a None None O
whole None None O
cell None None O
assay None None O
, None None O
at None None O
37 None None O
degrees None None O
C None None O
, None None O
using None None O
[ None None O
3H None None O
] None None O
triamcinolone None None O
acetonide None None O
( None None O
TA None None O
) None None O
. None None O

Exposure None None O
of None None O
CM-SM None None I-cell_line
to None None O
dexamethasone None None O
( None None O
DEX None None O
) None None O
produced None None O
a None None O
progressive None None O
, None None O
dose- None None O
and None None O
time-related None None O
series None None O
of None None O
changes None None O
in None None O
CM-SM None None I-cell_line
cell None None O
growth None None O
, None None O
saturation None None O
density None None O
, None None O
morphology None None O
, None None O
and None None O
functional None None O
properties None None O
, None None O
with None None O
half-maximal None None O
effects None None O
at None None O
about None None O
10 None None O
( None None O
-9 None None O
) None None O
M None None O
for None None O
DEX None None O
. None None O

TA-receptor None None O
sites None None O
rapidly None None O
decreased None None O
( None None O
about None None O
70 None None O
% None None O
) None None O
after None None O
DEX None None O
treatment None None O
, None None O
without None None O
any None None O
apparent None None O
change None None O
in None None O
steroid None None O
specificity None None O
and None None O
affinity None None O
. None None O

After None None O
5 None None O
days None None O
in None None O
culture None None O
with None None O
a None None O
saturating None None O
concentration None None O
( None None O
3.6 None None O
X None None O
10 None None O
( None None O
-8 None None O
) None None O
M None None O
) None None O
of None None O
hormone None None O
, None None O
the None None O
cells None None O
reached None None O
a None None O
saturation None None O
density None None O
of None None O
about None None O
9.0 None None O
X None None O
10 None None O
( None None O
6 None None O
) None None O
viable None None O
cells/ml None None O
( None None O
about None None O
4.0 None None O
X None None O
10 None None O
( None None O
6 None None O
) None None O
viable None None O
cells/ml None None O
in None None O
the None None O
controls None None O
) None None O
, None None O
while None None O
the None None O
modal None None O
volume None None O
of None None O
the None None O
resulting None None O
cell None None I-cell_line
population None None I-cell_line
was None None O
approximately None None O
60 None None O
% None None O
, None None O
as None None O
compared None None O
to None None O
the None None O
volume None None O
of None None O
untreated None None I-cell_line
cells None None I-cell_line
. None None O

DEX-treated None None I-cell_line
cells None None I-cell_line
appeared None None O
less None None O
differentiated None None O
than None None O
controls None None O
, None None O
as None None O
assessed None None O
by None None O
combined None None O
morphologic None None O
, None None O
antigenic None None O
, None None O
and None None O
cytoenzymatic None None O
analyses None None O
. None None O

DEX None None O
almost None None O
completely None None O
inhibited None None O
TPA None None O
activation None None O
of None None O
the None None O
following None None O
macrophage None None I-cell_type
functions None None O
: None None O
adherency None None O
to None None O
the None None O
culture None None O
plate None None O
, None None O
expression None None O
of None None O
lysosomal None None I-protein
enzymes None None I-protein
, None None O
Fc None None I-protein
and None None I-protein
C3 None None I-protein
receptors None None I-protein
, None None O
and None None O
stimulation None None O
of None None O
phagocytosis None None O
. None None O

After None None O
removal None None O
of None None O
DEX None None O
, None None O
the None None O
cells None None O
, None None O
within None None O
a None None O
few None None O
passages None None O
, None None O
returned None None O
to None None O
a None None O
state None None O
apparently None None O
identical None None O
to None None O
the None None O
untreated None None O
controls None None O
and None None O
could None None O
be None None O
induced None None O
to None None O
macrophage None None I-cell_type
differentiation None None O
in None None O
response None None O
to None None O
TPA None None O
. None None O

Acute None None O
lymphoblastic None None O
leukemia None None O
in None None O
children None None O
: None None O
current None None O
status None None O
, None None O
controversies None None O
, None None O
and None None O
future None None O
perspective None None O
. None None O

Disease-free None None O
survival None None O
( None None O
DFS None None O
) None None O
in None None O
childhood None None O
ALL None None O
is None None O
60 None None O
% None None O
, None None O
and None None O
survival None None O
in None None O
good None None O
, None None O
average None None O
, None None O
and None None O
poor None None O
prognostic None None O
groups None None O
defined None None O
by None None O
initial None None O
WBC None None O
and None None O
age None None O
is None None O
90 None None O
, None None O
60 None None O
, None None O
and None None O
45 None None O
% None None O
, None None O
respectively None None O
. None None O

Additional None None O
immunological None None O
, None None O
morphological None None O
, None None O
biochemical None None O
, None None O
cytokinetic None None O
, None None O
and None None O
cytogenetic None None O
factors None None O
have None None O
been None None O
identified None None O
, None None O
illustrating None None O
the None None O
heterogeneity None None O
of None None O
ALL None None O
and None None O
its None None O
derivation None None O
from None None O
malignant None None I-cell_line
clones None None I-cell_line
at None None O
various None None O
stages None None O
of None None O
differentiation None None O
and None None O
with None None O
varying None None O
rates None None O
of None None O
proliferation None None O
. None None O

Of None None O
biologic None None O
importance None None O
, None None O
these None None O
factors None None O
may None None O
refine None None O
further None None O
the None None O
characteristic None None O
features None None O
of None None O
clinically-determined None None O
prognostic None None O
groups None None O
. None None O

Multivariate None None O
analysis None None O
of None None O
large None None O
prospective None None O
trials None None O
with None None O
homogeneous None None O
therapy None None O
will None None O
be None None O
required None None O
to None None O
determine None None O
the None None O
independent None None O
prognostic None None O
importance None None O
of None None O
these None None O
factors None None O
. None None O

Current None None O
treatment None None O
strategies None None O
in None None O
ALL None None O
include None None O
( None None O
1 None None O
) None None O
tailoring None None O
therapy None None O
and None None O
its None None O
intensity None None O
to None None O
prognostic None None O
groups None None O
; None None O
( None None O
2 None None O
) None None O
multiple-drug None None O
combinations None None O
in None None O
induction None None O
; None None O
( None None O
3 None None O
) None None O
early None None O
use None None O
of None None O
intrathecal None None O
( None None O
IT None None O
) None None O
methotrexate None None O
( None None O
MTX None None O
) None None O
; None None O
( None None O
4 None None O
) None None O
CNS None None O
prophylaxis None None O
with None None O
IT None None O
MTX None None O
alone None None O
in None None O
good None None O
prognosis None None O
patients None None O
and None None O
combined None None O
cranial None None O
radiation None None O
( None None O
CXRT None None O
) None None O
, None None O
1800 None None O
rads None None O
plus None None O
IT None None O
MTX None None O
, None None O
in None None O
average None None O
and None None O
poor None None O
prognosis None None O
patients None None O
. None None O

Current None None O
studies None None O
show None None O
a None None O
CNS None None O
relapse None None O
rate None None O
of None None O
5 None None O
% None None O
in None None O
all None None O
prognostic None None O
groups None None O
. None None O

Late None None O
neuropsychological None None O
defects None None O
caused None None O
by None None O
cranial None None O
XRT None None O
and None None O
IT None None O
MTX None None O
have None None O
prompted None None O
programs None None O
designed None None O
to None None O
reduce None None O
the None None O
potential None None O
late None None O
toxicity None None O
of None None O
CNS None None O
prophylaxis None None O
. None None O

More None None O
pronounced None None O
in None None O
younger None None O
children None None O
, None None O
these None None O
abnormalities None None O
include None None O
decreased None None O
IQ None None O
, None None O
visual-motor None None O
incoordination None None O
, None None O
poor None None O
performance None None O
in None None O
mathematics None None O
, None None O
and None None O
memory None None O
dysfunction None None O
. None None O

Until None None O
1980 None None O
, None None O
more None None O
intensive None None O
induction None None O
, None None O
consolidation None None O
, None None O
and None None O
maintenance None None O
therapy None None O
had None None O
failed None None O
to None None O
prolong None None O
DFS None None O
in None None O
children None None O
with None None O
a None None O
poor None None O
prognosis None None O
. None None O

In None None O
West None None O
Germany None None O
( None None O
Berlin-Frankfurt-Muenster None None O
protocol None None O
) None None O
a None None O
70 None None O
to None None O
75 None None O
% None None O
DFS None None O
is None None O
seen None None O
in None None O
all None None O
patients None None O
regardless None None O
of None None O
initial None None O
WBC None None O
, None None O
suggesting None None O
that None None O
effective None None O
therapy None None O
will None None O
override None None O
prognostic None None O
factors None None O
. None None O

Ultra-high-dose None None O
MTX None None O
, None None O
without None None O
cranial None None O
radiation None None O
, None None O
is None None O
also None None O
showing None None O
promise None None O
in None None O
poor None None O
prognosis None None O
patients None None O
. None None O

Other None None O
issues None None O
include None None O
the None None O
optimal None None O
duration None None O
of None None O
therapy None None O
, None None O
the None None O
role None None O
of None None O
testicular None None O
biopsies None None O
, None None O
and None None O
prophylactic None None O
testicular None None O
radiation None None O
. None None O

Recent None None O
studies None None O
suggest None None O
that None None O
prognostic None None O
factors None None O
lose None None O
their None None O
significance None None O
after None None O
2 None None O
years None None O
of None None O
continuous None None O
complete None None O
remission None None O
and None None O
that None None O
2 None None O
years None None O
of None None O
maintenance None None O
therapy None None O
is None None O
adequate None None O
. None None O

Bilateral None None O
open-wedge None None O
testicular None None O
biopsies None None O
have None None O
identified None None O
occult None None O
testicular None None O
disease None None O
in None None O
8 None None O
to None None O
10 None None O
% None None O
of None None O
males None None O
. None None O

A None None O
unified None None O
approach None None O
to None None O
children None None O
with None None O
leukemia/lymphoma None None O
, None None O
a None None O
group None None O
with None None O
a None None O
particularly None None O
poor None None O
prognosis None None O
, None None O
utilizing None None O
NHL-type None None O
therapy None None O
may None None O
be None None O
more None None O
effective None None O
than None None O
conventional None None O
ALL None None O
therapy None None O
. None None O

( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
400 None None O
WORDS None None O
) None None O

Glucocorticoid None None I-protein
receptor None None I-protein
and None None O
in None None O
vitro None None O
sensitivity None None O
to None None O
steroid None None O
hormones None None O
in None None O
human None None O
lymphoproliferative None None O
diseases None None O
and None None O
myeloid None None O
leukemia None None O
. None None O

The None None O
glucocorticoid None None I-protein
receptor None None I-protein
( None None O
GR None None I-protein
) None None O
quantitation None None O
by None None O
a None None O
whole-cell None None O
assay None None O
and/or None None O
cytosol None None O
technique None None O
and None None O
the None None O
in None None O
vitro None None O
sensitivity None None O
to None None O
steroids None None O
have None None O
been None None O
assessed None None O
in None None O
peripheral None None I-cell_type
blood None None I-cell_type
cells None None I-cell_type
from None None O
normal None None O
donors None None O
and None None O
patients None None O
with None None O
chronic None None O
lymphatic None None O
leukemia None None O
( None None O
CLL None None O
) None None O
, None None O
acute None None O
lymphoblastic None None O
leukemia None None O
( None None O
ALL None None O
) None None O
, None None O
lymphosarcoma None None O
cell None None O
leukemia None None O
( None None O
LSCL None None O
) None None O
, None None O
acute None None O
nonlymphatic None None O
leukemia None None O
( None None O
ANLL None None O
) None None O
, None None O
and None None O
chronic None None O
myeloid None None O
leukemia None None O
( None None O
CML None None O
) None None O
. None None O

Within None None O
the None None O
lymphoproliferative None None O
diseases None None O
, None None O
ALL None None I-cell_line
cells None None I-cell_line
exhibited None None O
the None None O
highest None None O
GR None None I-protein
concentration None None O
( None None O
regardless None None O
of None None O
the None None O
method None None O
used None None O
) None None O
and None None O
the None None O
highest None None O
in None None O
vitro None None O
inhibition None None O
of None None O
spontaneous None None O
[ None None O
3H None None O
] None None O
thymidine None None O
( None None O
[ None None O
3H None None O
] None None O
TdR None None O
) None None O
uptake None None O
by None None O
glucocorticoids None None O
. None None O

A None None O
significant None None O
relationship None None O
between None None O
GR None None I-protein
concentration None None O
( None None O
whole-cell None None O
assay None None O
) None None O
and None None O
in None None O
vitro None None O
sensitivity None None O
to None None O
dexamethasone None None O
was None None O
also None None O
found None None O
. None None O

On None None O
the None None O
contrary None None O
, None None O
CLL None None I-cell_line
cells None None I-cell_line
presented None None O
the None None O
highest None None O
sensitivity None None O
to None None O
glucocorticoids None None O
in None None O
PHA-stimulated None None I-cell_line
cell None None I-cell_line
cultures None None I-cell_line
. None None O

Cells None None O
from None None O
the None None O
only None None O
two None None O
ALL None None O
patients None None O
who None None O
did None None O
not None None O
undergo None None O
a None None O
remission None None O
after None None O
glucocorticoid-inclusive None None O
chemotherapy None None O
had None None O
both None None O
the None None O
lowest None None O
in None None O
vitro None None O
sensitivity None None O
to None None O
dexamethasone None None O
and None None O
the None None O
lowest None None O
GR None None O
concentration None None O
with None None O
whole-cell None None O
assay None None O
. None None O

Concerning None None O
myeloid None None O
leukemia None None O
, None None O
ANLL None None O
patients None None O
had None None O
GR None None I-protein
concentrations None None O
slightly None None O
higher None None O
than None None O
those None None O
found None None O
in None None O
the None None O
ALL None None O
group None None O
but None None O
exhibited None None O
the None None O
lowest None None O
degree None None O
of None None O
inhibition None None O
of None None O
spontaneous None None O
[ None None O
3H None None O
] None None O
TdR None None O
uptake None None O
by None None O
dexamethasone None None O
( None None O
stimulatory None None O
effects None None O
occurred None None O
in None None O
some None None O
cases None None O
) None None O
. None None O

CML None None I-cell_line
cells None None I-cell_line
exhibited None None O
an None None O
inhibition None None O
degree None None O
by None None O
in None None O
vitro None None O
glucocorticoids None None O
significantly None None O
higher None None O
than None None O
that None None O
of None None O
ANLL None None I-cell_line
cells None None I-cell_line
but None None O
not None None O
different None None O
from None None O
that None None O
of None None O
lymphoproliferative None None O
diseases None None O
. None None O

No None None O
clear None None O
relationship None None O
among None None O
GR None None O
pattern None None O
, None None O
in None None O
vitro None None O
cell None None O
sensitivity None None O
to None None O
glucocorticoids None None O
, None None O
and None None O
clinicohematologic None None O
parameters None None O
was None None O
observed None None O
in None None O
myeloid None None O
leukemia-bearing None None O
patients None None O
. None None O

Glucocorticoid None None I-protein
receptors None None I-protein
and None None O
in None None O
vitro None None O
corticosensitivity None None O
of None None O
peanut-positive None None I-cell_line
and None None I-cell_line
peanut-negative None None I-cell_line
human None None I-cell_line
thymocyte None None I-cell_line
subpopulations None None I-cell_line
. None None O

In None None O
6 None None O
human None None O
thymus None None O
glands None None O
, None None O
the None None O
immature None None O
subset None None O
of None None O
thymocytes None None I-cell_type
was None None O
separated None None O
from None None O
the None None O
more None None O
mature None None O
one None None O
, None None O
by None None O
differential None None O
peanut None None O
lectin None None O
agglutination None None O
. None None O

These None None O
2 None None O
cell None None O
subpopulations None None O
were None None O
analyzed None None O
for None None O
glucocorticoid None None I-protein
receptor None None I-protein
content None None O
by None None O
using None None O
a None None O
whole None None O
cell None None O
assay None None O
, None None O
with None None O
( None None O
3H None None O
) None None O
-triamcinolone None None O
acetonide None None O
as None None O
tracer None None O
. None None O

The None None O
unagglutinated None None I-cell_type
thymocytes None None I-cell_type
( None None O
peanut None None O
negative None None O
) None None O
contained None None O
about None None O
2 None None O
times None None O
more None None O
receptor None None O
sites None None O
per None None O
cell None None O
than None None O
agglutinated None None O
( None None O
peanut None None O
positive None None O
) None None O
ones None None O
( None None O
7650 None None O
+/- None None O
1550 None None O
S.D. None None O
verus None None O
3195 None None O
+/- None None O
896 None None O
S.D. None None O
) None None O
. None None O

The None None O
affinity None None O
for None None O
steroid None None O
was None None O
similar None None O
in None None O
both None None O
cell None None O
subsets None None O
, None None O
as None None O
was None None O
the None None O
stereospecificity None None O
for None None O
glucocorticoids None None O
, None None O
the None None O
time-course None None O
of None None O
steroid-receptor None None O
association None None O
, None None O
and None None O
cytoplasmic None None O
to None None O
nuclear None None O
translocation None None O
. None None O

Despite None None O
the None None O
greater None None O
number None None O
of None None O
glucocorticoid None None I-protein
receptor None None I-protein
sites None None O
, None None O
the None None O
peanut-negative None None I-cell_line
thymocyte None None I-cell_line
subpopulation None None I-cell_line
did None None O
not None None O
differ None None O
from None None O
the None None O
peanut-positive None None I-cell_line
one None None O
in None None O
its None None O
sensitivity None None O
to None None O
the None None O
inhibitory None None O
effects None None O
of None None O
triamcinolone None None O
acetonide None None O
, None None O
as None None O
determined None None O
by None None O
measurements None None O
of None None O
the None None O
incorporation None None O
of None None O
radiolabeled None None O
precursors None None O
of None None O
protein None None O
and None None O
DNA None None O
. None None O

Moreover None None O
, None None O
the None None O
peanut-negative None None I-cell_line
subset None None I-cell_line
appeared None None O
more None None O
resistant None None O
in None None O
vitro None None O
to None None O
the None None O
steroid-induced None None O
cell None None O
lysis None None O
as None None O
compared None None O
to None None O
the None None O
peanut-positive None None I-cell_line
one None None O
. None None O

Thus None None O
, None None O
our None None O
data None None O
suggest None None O
that None None O
glucocorticoid None None O
receptor None None O
density None None O
and None None O
corticosensitivity None None O
are None None O
not None None O
directly None None O
correlated None None O
and None None O
that None None O
the None None O
number None None O
of None None O
glucocorticoid None None I-protein
receptor None None I-protein
sites None None O
may None None O
be None None O
dependent None None O
on None None O
the None None O
degree None None O
of None None O
immunologic None None O
maturation None None O

Defective None None O
binding None None O
and None None O
function None None O
of None None O
1 None None I-protein
, None None I-protein
25-dihydroxyvitamin None None I-protein
D3 None None I-protein
receptors None None I-protein
in None None O
peripheral None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
of None None O
patients None None O
with None None O
end-organ None None O
resistance None None O
to None None O
1 None None O
, None None O
25-dihydroxyvitamin None None O
D None None O
. None None O

Lectin-induced None None O
DNA None None O
synthesis None None O
by None None O
peripheral None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
from None None O
17 None None O
normal None None O
donors None None O
was None None O
inhibited None None O
( None None O
40-60 None None O
% None None O
) None None O
by None None O
1 None None O
, None None O
25-dihydroxyvitamin None None O
D3 None None O
( None None O
1 None None O
, None None O
25 None None O
[ None None O
OH None None O
] None None O
2D3 None None O
) None None O
at None None O
physiological None None O
concentrations None None O
( None None O
10 None None O
( None None O
-10 None None O
) None None O
-10 None None O
( None None O
-9 None None O
) None None O
M None None O
) None None O
. None None O

The None None O
lymphocytes None None I-cell_type
acquire None None O
specific None None O
receptors None None O
for None None O
1 None None O
, None None O
25 None None O
( None None O
OH None None O
) None None O
2D3 None None O
upon None None O
activation None None O
by None None O
the None None O
lectins None None I-protein
. None None O

This None None O
process None None O
precedes None None O
the None None O
inhibitory None None O
effect None None O
of None None O
1 None None O
, None None O
25 None None O
( None None O
OH None None O
) None None O
2D3 None None O
. None None O

We None None O
studied None None O
lymphocytes None None I-cell_type
from None None O
six None None O
patients None None O
from None None O
four None None O
different None None O
kindreds None None O
with None None O
the None None O
syndrome None None O
of None None O
hereditary None None O
end-organ None None O
resistance None None O
to None None O
1 None None O
, None None O
25 None None O
( None None O
OH None None O
) None None O
2D None None O
( None None O
the None None O
so-called None None O
vitamin None None O
D-dependent None None O
rickets None None O
type None None O
II None None O
) None None O
. None None O

In None None O
five None None O
patients None None O
( None None O
three None None O
kindreds None None O
) None None O
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
did None None O
not None None O
acquire None None O
receptors None None O
for None None O
1 None None O
, None None O
25 None None O
( None None O
OH None None O
) None None O
2D3 None None O
upon None None O
phytohemagglutinin-induced None None O
activation None None O
. None None O

Moreover None None O
, None None O
in None None O
contrast None None O
to None None O
normal None None I-cell_type
lymphocytes None None I-cell_type
, None None O
the None None O
mitogenic None None O
stimulation None None O
of None None O
these None None O
patients None None O
' None None O
lymphocytes None None I-cell_type
by None None O
phytohemagglutinin None None I-protein
and None None O
concanavalin None None O
A None None O
was None None O
not None None O
inhibited None None O
by None None O
1 None None O
, None None O
25 None None O
( None None O
OH None None O
) None None O
2D3 None None O
. None None O

Activated None None O
lymphocytes None None I-cell_type
of None None O
the None None O
sixth None None O
patient None None O
from None None O
a None None O
fourth None None O
kindred None None O
exhibited None None O
normal None None O
binding None None O
of None None O
[ None None O
3H None None O
] None None O
1 None None O
, None None O
25 None None O
( None None O
OH None None O
) None None O
2D3 None None O
but None None O
the None None O
hormone None None O
failed None None O
to None None O
inhibit None None O
the None None O
mitogenic None None O
stimulation None None O
. None None O

A None None O
similar None None O
pattern None None O
of None None O
the None None O
vitamin None None O
D None None O
effector None None O
system None None O
was None None O
previously None None O
observed None None O
in None None O
fibroblasts None None O
cultured None None O
from None None O
skin None None O
biopsies None None O
of None None O
the None None O
same None None O
group None None O
of None None O
patients None None O
. None None O

The None None O
conclusions None None O
from None None O
these None None O
findings None None O
are None None O
: None None O
( None None O
a None None O
) None None O
the None None O
inhibition None None O
of None None O
mitogenic None None O
stimulation None None O
by None None O
1 None None O
, None None O
25 None None O
( None None O
OH None None O
) None None O
2D3 None None O
is None None O
mediated None None O
by None None O
specific None None I-protein
functional None None I-protein
receptors None None I-protein
to None None O
the None None O
hormone None None O
; None None O
and None None O
( None None O
b None None O
) None None O
the None None O
receptors None None O
for None None O
1 None None O
, None None O
25 None None O
( None None O
OH None None O
) None None O
2D3 None None O
in None None O
mononuclear None None I-cell_type
cells None None I-cell_type
are None None O
probably None None O
controlled None None O
genetically None None O
by None None O
the None None O
same None None O
mechanisms None None O
as None None O
the None None O
effector None None O
system None None O
in None None O
well-characterized None None O
target None None O
organs None None O
of None None O
the None None O
hormone None None O
, None None O
such None None O
as None None O
intestine None None O
and None None O
kidney None None O
. None None O

Glucocorticoid None None I-protein
receptors None None I-protein
of None None O
mononuclear None None I-cell_type
leukocytes None None I-cell_type
from None None O
myasthenia None None O
gravis None None O
patients None None O
. None None O

The None None O
present None None O
study None None O
was None None O
performed None None O
to None None O
analyse None None O
glucocorticoid None None I-protein
receptor None None I-protein
( None None O
GR None None I-protein
) None None O
binding None None O
in None None O
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
leukocytes None None I-cell_type
( None None O
MNL None None I-cell_type
) None None O
from None None O
39 None None O
myasthenia None None O
gravis None None O
( None None O
MG None None O
) None None O
patients None None O
( None None O
unoperated None None O
patients None None O
( None None O
n None None O
= None None O
13 None None O
) None None O
, None None O
thymectomized None None O
patients None None O
( None None O
n None None O
= None None O
14 None None O
) None None O
and None None O
patients None None O
receiving None None O
glucocorticoids None None O
: None None O
thymectomized None None O
( None None O
n None None O
= None None O
11 None None O
) None None O
and None None O
unoperated None None O
( None None O
n None None O
= None None O
6 None None O
] None None O
. None None O

A None None O
whole None None O
cell None None O
binding None None O
assay None None O
with None None O
3 None None O
( None None O
H None None O
) None None O
dexamethasone None None O
was None None O
used None None O
. None None O

GR None None I-protein
mean None None O
values None None O
were None None O
significantly None None O
higher None None O
in None None O
the None None O
MNL None None I-cell_type
of None None O
MG None None O
patients None None O
( None None O
thymectomized None None O
or None None O
not None None O
) None None O
not None None O
receiving None None O
glucocorticoid None None O
than None None O
in None None O
the None None O
MNL None None I-cell_type
of None None O
healthy None None O
donors None None O
. None None O

Affinity None None O
was None None O
within None None O
the None None O
normal None None O
range None None O
. None None O

Sex None None O
, None None O
age None None O
or None None O
clinical None None O
forms None None O
of None None O
illness None None O
did None None O
not None None O
influence None None O
the None None O
results None None O
. None None O

In None None O
patients None None O
receiving None None O
prednisone None None O
( None None O
Pd None None O
) None None O
the None None O
GR None None I-protein
values None None O
were None None O
significantly None None O
lower None None O
than None None O
in None None O
MG None None O
patients None None O
without None None O
Pd None None O
therapy None None O
, None None O
independent None None O
of None None O
Pd None None O
dose None None O
or None None O
time None None O
of None None O
administration None None O
. None None O

No None None O
differences None None O
in None None O
receptor None None O
binding None None O
between None None O
normal None None O
subjects None None O
and None None O
MG None None O
patients None None O
receiving None None O
Pd None None O
have None None O
been None None O
found None None O
. None None O

Immunological None None O
interference None None O
of None None O
high None None O
dose None None O
corticosteroids None None O
. None None O

High-dose None None O
corticosteroids None None O
( None None O
HDC None None O
) None None O
will None None O
influence None None O
cellular None None O
as None None O
well None None O
as None None O
humoral None None O
participants None None O
of None None O
the None None O
immune None None O
response None None O
. None None O

The None None O
lymphoid None None O
tissue None None O
will None None O
decrease None None O
in None None O
size None None O
and None None O
weight None None O
after None None O
prolonged None None O
treatment None None O
with None None O
HDC None None O
. None None O

Lymphocyte None None O
functions None None O
will None None O
be None None O
impaired None None O
. None None O

Reduced None None O
synthesis None None O
of None None O
B- None None I-cell_type
as None None I-cell_type
well None None I-cell_type
as None None I-cell_type
T-lymphocytes None None I-cell_type
will None None O
be None None O
seen None None O
. None None O

The None None O
inhibitory None None O
effect None None O
on None None O
B-cell None None I-cell_type
function None None O
can None None O
be None None O
observed None None O
both None None O
as None None O
decreased None None O
serum None None O
levels None None O
of None None O
immunoglobulins None None I-protein
and None None O
as None None O
impaired None None O
binding None None O
of None None O
antibodies None None I-protein
and None None O
complement None None O
to None None O
the None None O
cellular None None O
surface None None O
. None None O

Reduced None None O
T-cell None None I-cell_type
function None None O
indicated None None O
by None None O
impaired None None O
stimulation None None O
by None None O
PHA None None I-protein
and None None O
porkweed None None I-protein
as None None O
well None None O
as None None O
by None None O
impaired None None O
lymphokinin None None O
effects None None O
on None None O
leukocyte None None I-cell_type
migration None None O
inhibition None None O
has None None O
been None None O
reported None None O
. None None O

Reduced None None O
lymphocyte None None O
adherence None None O
to None None O
antigen None None O
and None None O
suppressed None None O
lymphocyte None None O
reaction None None O
have None None O
also None None O
been None None O
observed None None O
. None None O

Humoral None None O
factors None None O
involved None None O
in None None O
chemotaxis None None O
, None None O
opsonisation None None O
, None None O
phagocytosis None None O
, None None O
vascular None None O
permeability None None O
leading None None O
to None None O
leakage None None O
of None None O
fluid None None O
and None None O
cells None None O
and None None O
factors None None O
involved None None O
in None None O
lysis None None O
of None None O
antigens None None O
are None None O
impaired None None O
. None None O

This None None O
can None None O
be None None O
explained None None O
partly None None O
by None None O
the None None O
observed None None O
reduced None None O
complement None None O
activation None None O
via None None O
the None None O
alternative None None O
as None None O
well None None O
as None None O
the None None O
classical None None O
pathway None None O
in None None O
association None None O
with None None O
HDC None None O
therapy None None O
. None None O

Acute None None O
processes None None O
with None None O
increased None None O
vascular None None O
permeability None None O
and None None O
accumulation None None O
of None None O
leukocytes None None I-cell_type
as None None O
impairing None None O
factors None None O
could None None O
be None None O
influenced None None O
beneficially None None O
by None None O
HDC None None O
therapy None None O
. None None O

This None None O
positive None None O
effect None None O
can None None O
be None None O
seen None None O
in None None O
treatment None None O
of None None O
septic None None O
shock None None O
or None None O
rejection None None O
of None None O
a None None O
transplant None None O
. None None O

However None None O
, None None O
if None None O
sepsis None None O
or None None O
rejection None None O
is None None O
not None None O
rapidly None None O
reversed None None O
, None None O
complications None None O
such None None O
as None None O
multisystem None None O
organ None None O
failure None None O
and None None O
bacteremia None None O
are None None O
prone None None O
to None None O
appear None None O
. None None O

Identification None None O
of None None O
human None None I-protein
leukemic None None I-protein
glucocorticoid None None I-protein
receptors None None I-protein
using None None O
affinity None None O
labeling None None O
and None None O
anti-human None None I-protein
glucocorticoid None None I-protein
receptor None None I-protein
antibodies None None I-protein
. None None O

Antisera None None O
raised None None O
against None None O
human None None I-protein
lymphoid None None I-protein
glucocorticoid None None I-protein
receptors None None I-protein
were None None O
used None None O
in None None O
combination None None O
with None None O
the None None O
glucocorticoid None None O
receptor None None O
affinity None None O
label None None O
[ None None O
3H None None O
] None None O
dexamethasone None None O
21-mesylate None None O
[ None None O
( None None O
3H None None O
] None None O
DM None None O
) None None O
to None None O
identify None None O
the None None O
glucocorticoid None None I-protein
receptors None None I-protein
of None None O
the None None O
human None None I-cell_line
B-lymphoblastoid None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
IM-9 None None B-cell_line
and None None O
the None None O
human None None I-cell_line
T-cell None None I-cell_line
leukemic None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
CEM-C7 None None B-cell_line
. None None O

Antisera None None O
were None None O
obtained None None O
following None None O
immunization None None O
of None None O
New None None O
Zealand None None O
White None None O
rabbits None None O
with None None O
[ None None I-protein
3H None None I-protein
] None None I-protein
triamcinolone None None I-protein
acetonide None None I-protein
[ None None I-protein
( None None I-protein
3H None None I-protein
] None None I-protein
TA None None I-protein
) None None I-protein
-glucocorticoid None None I-protein
receptor None None I-protein
complexes None None I-protein
partially None None O
purified None None O
by None None O
two-stage None None O
DNA-cellulose None None O
chromatography None None O
. None None O

The None None O
presence None None O
of None None O
anti-human None None I-protein
glucocorticoid None None I-protein
receptor None None I-protein
antibodies None None I-protein
was None None O
verified None None O
by None None O
: None None O
( None None O
a None None O
) None None O
adsorption None None O
of None None O
[ None None I-protein
3H None None I-protein
] None None I-protein
TA-receptor-antibody None None I-protein
complexes None None I-protein
to None None O
Protein None None I-protein
A None None I-protein
; None None O
( None None O
b None None O
) None None O
a None None O
shift None None O
to None None O
higher None None O
apparent None None O
molecular None None O
weight None None O
in None None O
the None None O
elution None None O
position None None O
from None None O
Sephacryl None None O
S300 None None O
of None None O
[ None None I-protein
3H None None I-protein
] None None I-protein
TA-receptor None None I-protein
complexes None None I-protein
incubated None None O
with None None O
immune None None O
serum None None O
; None None O
and None None O
( None None O
c None None O
) None None O
the None None O
ability None None O
of None None O
immune None None O
serum None None O
to None None O
displace None None O
[ None None I-protein
3H None None I-protein
] None None I-protein
TA-receptor None None I-protein
complexes None None I-protein
on None None O
sucrose None None O
gradients None None O
. None None O

These None None O
antibodies None None I-protein
also None None O
recognized None None O
rat None None O
liver None None O
and None None O
murine None None I-protein
S49 None None I-protein
cell None None I-protein
glucocorticoid None None I-protein
receptors None None I-protein
. None None O

Sodium None None O
dodecyl None None O
sulfate-polyacrylamide None None O
gel None None O
electrophoresis None None O
of None None O
[ None None O
3H None None O
] None None O
DM-labeled None None O
IM-9 None None O
cytosol None None O
identified None None O
a None None O
major None None O
competable None None O
band None None O
with None None O
a None None O
molecular None None O
weight None None O
of None None O
approximately None None O
90 None None O
, None None O
000 None None O
, None None O
three None None O
minor None None O
competable None None O
components None None O
with None None O
molecular None None O
weights None None O
of None None O
approximately None None O
78 None None O
, None None O
000 None None O
, None None O
approximately None None O
51 None None O
, None None O
000 None None O
, None None O
and None None O
approximately None None O
38 None None O
, None None O
500 None None O
, None None O
and None None O
at None None O
least None None O
21 None None O
other None None O
noncompetable None None O
components None None O
. None None O

Following None None O
immunoprecipitation None None O
of None None O
[ None None O
3H None None O
] None None O
DM-labeled None None O
cytosol None None O
with None None O
immune None None O
serum None None O
, None None O
only None None O
the None None O
Mr None None O
90 None None O
, None None O
000 None None O
and None None O
78 None None O
, None None O
000 None None O
components None None O
were None None O
seen None None O
. None None O

Sodium None None O
dodecyl None None O
sulfate-polyacrylamide None None O
gel None None O
electrophoresis None None O
of None None O
[ None None O
3H None None O
] None None O
DM-labeled None None O
CEM-C7 None None O
cytosol None None O
revealed None None O
a None None O
larger None None O
number None None O
of None None O
[ None None O
3H None None O
] None None O
DM-labeled None None O
components None None O
. None None O

However None None O
, None None O
after None None O
immunoprecipitation None None O
of None None O
[ None None O
3H None None O
] None None O
DM-labeled None None O
CEM-C7 None None O
cytosol None None O
, None None O
a None None O
predominant None None O
competable None None O
component None None O
with None None O
a None None O
molecular None None O
weight None None O
of None None O
90 None None O
, None None O
000 None None O
was None None O
easily None None O
identified None None O
. None None O

This None None O
component None None O
was None None O
markedly None None O
diminished None None O
when None None O
cytosols None None O
from None None O
the None None O
glucocorticoid None None I-cell_line
receptor-deficient None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
ICR-27 None None B-cell_line
were None None O
used None None O
. None None O

Thus None None O
, None None O
the None None O
combination None None O
of None None O
affinity None None O
labeling None None O
and None None O
anti-human None None I-protein
glucocorticoid None None I-protein
receptor None None I-protein
antibodies None None I-protein
is None None O
capable None None O
of None None O
providing None None O
direct None None O
physical None None O
identification None None O
of None None O
human None None I-protein
lymphoid None None I-protein
glucocorticoid None None I-protein
receptors None None I-protein
. None None O

Effect None None O
of None None O
thymosin None None O
on None None O
glucocorticoid None None I-protein
receptor None None I-protein
activity None None O
and None None O
glucocorticoid None None O
sensitivity None None O
of None None O
human None None I-cell_type
thymocytes None None I-cell_type
. None None O

Incubation None None O
with None None O
thymosin None None O
fraction None None O
5 None None O
, None None O
( None None O
TMS None None O
F5 None None O
at None None O
300 None None O
micrograms/ml None None O
) None None O
a None None O
partially None None O
purified None None O
thymic None None O
factor None None O
, None None O
reduced None None O
the None None O
steroid None None O
binding None None O
activity None None O
of None None O
human None None I-cell_type
infant None None I-cell_type
thymocytes None None I-cell_type
from None None O
9.6 None None O
+/- None None O
2.1 None None O
fmole/ml None None O
to None None O
5.0 None None O
+/- None None O
2.0 None None O
fmole/ml None None O
. None None O

The None None O
glucocorticoid None None I-protein
receptor None None I-protein
activity None None O
in None None O
normal None None O
infant None None O
thymocytes None None O
was None None O
found None None O
to None None O
be None None O
2 None None O
, None None O
146 None None O
+/- None None O
726 None None O
( None None O
s.d. None None O
) None None O
sites None None O
per None None O
cell None None O
with None None O
dissociation None None O
constant None None O
of None None O
1.4 None None O
+/- None None O
0.6 None None O
X None None O
10 None None O
( None None O
-8 None None O
) None None O
M None None O
. None None O

TMS None None O
F5 None None O
also None None O
increased None None O
the None None O
resistance None None O
of None None O
human None None O
thymocytes None None O
to None None O
the None None O
cytolytic None None O
effect None None O
of None None O
dexamethasone None None O
( None None O
2.5 None None O
X None None O
10 None None O
( None None O
-8 None None O
) None None O
M None None O
) None None O
to None None O
168.6 None None O
+/- None None O
30.2 None None O
% None None O
of None None O
control None None O
( None None O
P None None O
less None None O
than None None O
0.01 None None O
) None None O
. None None O

In None None O
animals None None O
, None None O
medullary None None I-cell_type
and None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
are None None O
more None None O
resistant None None O
to None None O
glucocorticoids None None O
than None None O
immature None None I-cell_type
thymic None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
results None None O
show None None O
that None None O
thymosin None None O
can None None O
induce None None O
changes None None O
consistent None None O
with None None O
differentiation None None O
in None None O
human None None I-cell_type
thymocytes None None I-cell_type
. None None O

These None None O
in None None O
vitro None None O
results None None O
are None None O
consistent None None O
with None None O
a None None O
physiological None None O
role None None O
of None None O
thymosin None None O
in None None O
intrathymic None None O
T None None O
cell None None O
maturation None None O
in None None O
man None None O
. None None O

Incubation None None O
of None None O
a None None O
human None None I-cell_line
malignant None None I-cell_line
thymus None None I-cell_line
derived None None I-cell_line
T None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
( None None O
MOLT None None I-cell_line
3 None None I-cell_line
) None None O
with None None O
TMS None None O
F5 None None O
also None None O
resulted None None O
in None None O
a None None O
significant None None O
reduction None None O
of None None O
the None None O
number None None O
of None None O
steroid None None O
binding None None O
sites None None O
to None None O
44.2 None None O
+/- None None O
15.3 None None O
% None None O
of None None O
control None None O
( None None O
P None None O
less None None O
than None None O
0.05 None None O
) None None O
, None None O
but None None O
TMS None None O
F5 None None O
did None None O
not None None O
significantly None None O
reduce None None O
the None None O
glucocorticoid None None O
sensitivity None None O
of None None O
MOLT None None I-cell_line
3 None None I-cell_line
cells None None I-cell_line
. None None O

Specific None None I-protein
high-affinity None None I-protein
receptors None None I-protein
for None None O
1 None None O
, None None O
25-dihydroxyvitamin None None O
D3 None None O
in None None O
human None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
: None None O
presence None None O
in None None O
monocytes None None I-cell_type
and None None O
induction None None O
in None None O
T None None I-cell_type
lymphocytes None None I-cell_type
following None None O
activation None None O
. None None O

Human None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
monocytes None None I-cell_type
have None None O
high None None O
affinity None None O
binding None None O
sites None None O
for None None O
1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
( None None O
Kd None None O
0.14 None None O
nM None None O
, None None O
sedimentation None None O
coefficient None None O
3.7S None None O
) None None O
. None None O

Resting None None I-cell_type
human None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
, None None O
however None None O
, None None O
do None None O
not None None O
have None None O
a None None O
demonstrable None None O
1 None None I-protein
, None None I-protein
25- None None I-protein
( None None I-protein
OH None None I-protein
) None None I-protein
2D3 None None I-protein
receptor None None I-protein
. None None O

After None None O
activation None None O
with None None O
phytohemagglutinin None None I-protein
the None None O
T None None I-cell_type
cells None None I-cell_type
exhibit None None O
the None None O
receptor None None O
within None None O
24 None None O
h None None O
, None None O
and None None O
this None None O
expression None None O
is None None O
blocked None None O
by None None O
cycloheximide None None O
. None None O

The None None O
receptor None None O
in None None O
activated None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
has None None O
a None None O
sedimentation None None O
coefficient None None O
of None None O
3.7S None None O
and None None O
a None None O
high None None O
affinity None None O
( None None O
Kd None None O
0.10 None None O
nM None None O
) None None O
for None None O
the None None O
ligand None None O
. None None O

Effects None None O
of None None O
chronic None None O
glucocorticoid None None O
excess None None O
in None None O
man None None O
on None None O
insulin None None O
binding None None O
to None None O
circulating None None I-cell_type
cells None None I-cell_type
: None None O
differences None None O
between None None O
endogenous None None O
and None None O
exogenous None None O
hypercorticism None None O
. None None O

We None None O
measured None None O
[ None None O
125I None None O
] None None O
insulin None None O
binding None None O
to None None O
circulating None None I-cell_type
monocytes None None I-cell_type
or None None I-cell_type
erythrocytes None None I-cell_type
from None None O
16 None None O
patients None None O
with None None O
chronic None None O
glucocorticoid None None O
excess None None O
, None None O
9 None None O
chronically None None O
treated None None O
with None None O
prednisone None None O
and None None O
7 None None O
with None None O
adrenocortical None None O
hyperfunction None None O
. None None O

With None None O
monocytes None None I-cell_type
, None None O
[ None None O
125I None None O
] None None O
insulin None None O
binding None None O
was None None O
iincreased None None O
in None None O
all None None O
patients None None O
. None None O

Analysis None None O
of None None O
binding None None O
data None None O
indicated None None O
that None None O
increased None None O
binding None None O
in None None O
patients None None O
treated None None O
with None None O
prednisone None None O
was None None O
due None None O
to None None O
an None None O
ncrease None None O
in None None O
receptor None None O
concentration None None O
, None None O
whereas None None O
in None None O
patients None None O
with None None O
adrenocortical None None O
hyperfunction None None O
, None None O
it None None O
was None None O
due None None O
to None None O
an None None O
increase None None O
in None None O
receptor None None O
affinity None None O
. None None O

With None None O
erythrocytes None None O
from None None O
patients None None O
with None None O
adrenocortical None None O
hyperfunction None None O
there None None O
was None None O
an None None O
increase None None O
in None None O
receptor None None O
affinity None None O
and None None O
a None None O
decrease None None O
in None None O
receptor None None O
concentration None None O
, None None O
so None None O
that None None O
the None None O
binding None None O
of None None O
[ None None O
125I None None O
] None None O
insulin None None O
was None None O
normal None None O
. None None O

The None None O
disparity None None O
of None None O
results None None O
between None None O
endogenous None None O
and None None O
exogenous None None O
hypercorticism None None O
, None None O
between None None O
the None None O
two None None O
cell None None O
types None None O
, None None O
and None None O
between None None O
the None None O
present None None O
studies None None O
and None None O
previous None None O
studies None None O
suggest None None O
that None None O
the None None O
effects None None O
of None None O
glucocorticoid None None O
excess None None O
on None None O
the None None O
insulin None None I-protein
receptor None None I-protein
are None None O
extremely None None O
complex None None O
and None None O
wide-ranging None None O
and None None O
that None None O
in None None O
this None None O
condition None None O
, None None O
extrapolations None None O
in None None O
humans None None O
from None None O
data None None O
with None None O
circulating None None I-cell_type
cells None None I-cell_type
to None None O
liver None None O
and None None O
muscle None None O
may None None O
not None None O
be None None O
appropriate None None O
. None None O

Reduced None None O
level None None O
of None None O
cellular None None I-protein
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
patients None None O
with None None O
anorexia None None O
nervosa None None O
. None None O

Specific None None O
glucocorticoid None None I-protein
receptors None None I-protein
were None None O
measured None None O
in None None O
circulating None None O
mononuclear None None I-cell_type
leukocytes None None I-cell_type
from None None O
12 None None O
patients None None O
with None None O
anorexia None None O
nervosa None None O
and None None O
21 None None O
healthy None None O
control None None O
subjects None None O
. None None O

Cells None None O
from None None O
patients None None O
were None None O
found None None O
to None None O
contain None None O
a None None O
significantly None None O
( None None O
p None None O
less None None O
than None None O
0.01 None None O
) None None O
lower None None O
level None None O
of None None O
glucocorticoid None None I-protein
receptor None None I-protein
( None None O
3830 None None O
+/- None None O
210 None None O
sites/cell None None O
, None None O
mean None None O
+/- None None O
SE None None O
) None None O
than None None O
those None None O
from None None O
controls None None O
( None None O
4930 None None O
+/- None None O
250 None None O
sites/cell None None O
) None None O
. None None O

A None None O
partial None None O
glucocorticoid None None I-protein
receptor None None I-protein
defect None None O
may None None O
well None None O
explain None None O
the None None O
abnormal None None O
cortisol None None O
metabolism None None O
and None None O
glucocorticoid None None O
resistance None None O
commonly None None O
found None None O
in None None O
patients None None O
with None None O
anorexia None None O
nervosa None None O
. None None O

Regulation None None O
of None None O
the None None O
glucocorticoid None None I-protein
receptor None None I-protein
in None None O
human None None I-cell_type
lymphocytes None None I-cell_type
. None None O

The None None O
presence None None O
of None None O
a None None O
glucocorticoid None None I-protein
receptor None None I-protein
in None None O
human None None I-cell_type
lymphocytes None None I-cell_type
is None None O
well None None O
established None None O
, None None O
but None None O
factors None None O
affecting None None O
its None None O
regulation None None O
have None None O
not None None O
been None None O
described None None O
. None None O

Using None None O
a None None O
competitive None None O
binding None None O
whole None None O
cell None None O
assay None None O
, None None O
we None None O
have None None O
examined None None O
the None None O
binding None None O
of None None O
[ None None O
3H None None O
] None None O
-dexamethasone None None O
at None None O
24 None None O
and None None O
37 None None O
degrees None None O
C None None O
in None None O
untreated None None O
normal None None O
subjects None None O
and None None O
in None None O
healthy None None O
subjects None None O
taking None None O
various None None O
glucocorticoid None None O
preparations None None O
. None None O

At None None O
24 None None O
degrees None None O
C None None O
normal None None I-cell_type
human None None I-cell_type
lymphocytes None None I-cell_type
had None None O
6000 None None O
binding None None O
sites/cell None None O
and None None O
a None None O
dissociation None None O
constant None None O
of None None O
4 None None O
x None None O
10 None None O
( None None O
-9 None None O
) None None O
M None None O
. None None O

The None None O
administration None None O
of None None O
1 None None O
mg None None O
of None None O
dexamethasone None None O
, None None O
5 None None O
mg None None O
of None None O
prednisone None None O
, None None O
and None None O
37.5 None None O
mg None None O
of None None O
cortisone None None O
acetate None None O
resulted None None O
in None None O
a None None O
30 None None O
% None None O
decrease None None O
in None None O
binding None None O
sites None None O
after None None O
1 None None O
week None None O
with None None O
no None None O
change None None O
in None None O
binding None None O
affinity None None O
. None None O

No None None O
changes None None O
in None None O
the None None O
number None None O
of None None O
binding None None O
sites None None O
was None None O
noted None None O
before None None O
1 None None O
week None None O
and None None O
the None None O
diminished None None O
number None None O
persisted None None O
for None None O
1 None None O
week None None O
after None None O
discontinuation None None O
of None None O
glucocorticoid None None O
treatment None None O
. None None O

Lymphocytes None None I-cell_type
from None None O
hospitalized None None O
patients None None O
taking None None O
40-60 None None O
mg None None O
of None None O
dexamethasone None None O
daily None None O
demonstrated None None O
the None None O
same None None O
change None None O
in None None O
number None None O
of None None O
binding None None O
sites None None O
that None None O
was None None O
seen None None O
in None None O
normal None None O
subjects None None O
taking None None O
1 None None O
mg None None O
of None None O
dexamethasone None None O
. None None O

When None None O
binding None None O
assays None None O
were None None O
carried None None O
out None None O
at None None O
physiologic None None O
temperature None None O
there None None O
was None None O
the None None O
same None None O
decrease None None O
in None None O
number None None O
of None None O
binding None None O
sites None None O
after None None O
dexamethasone None None O
administration None None O
, None None O
and None None O
in None None O
addition None None O
, None None O
there None None O
was None None O
a None None O
two-fold None None O
increase None None O
in None None O
binding None None O
affinity None None O
. None None O

Glucocorticoid None None O
administration None None O
results None None O
in None None O
a None None O
time-dependent None None O
decrease None None O
in None None O
the None None O
number None None O
of None None O
lymphocyte None None O
glucocorticoid None None O
binding None None O
sites None None O
that None None O
is None None O
independent None None O
of None None O
the None None O
type None None O
of None None O
glucocorticoid None None O
administered None None O
. None None O

This None None O
is None None O
the None None O
first None None O
in None None O
vivo None None O
demonstration None None O
that None None O
glucocorticoids None None O
modulate None None O
their None None O
own None None O
receptors None None O
in None None O
man None None O
. None None O

Immunoglobulin None None O
localization None None O
in None None O
benign None None O
and None None O
malignant None None O
lesions None None O
of None None O
the None None O
human None None O
mammary None None O
gland None None O
. None None O

Using None None O
direct None None O
imunofluorescence None None O
, None None O
lesions None None O
from None None O
266 None None O
human None None O
breast None None O
specimens None None O
were None None O
studied None None O
for None None O
the None None O
presence None None O
of None None O
IgA None None O
, None None O
IgM None None O
, None None O
or None None O
IgG None None O
localization None None O
. None None O

The None None O
lesions None None O
included None None O
benign None None O
elements None None O
from None None O
66 None None O
subcutaneous None None O
mastectomy None None O
specimens None None O
in None None O
which None None O
the None None O
absence None None O
of None None O
simultaneous None None O
breast None None O
malignancy None None O
was None None O
documented None None O
, None None O
primary None None O
breast None None O
carcinomas None None O
from None None O
153 None None O
mastectomy None None O
specimens None None O
, None None O
and None None O
47 None None O
biopsies None None O
containing None None O
metastatic None None O
breast None None O
cancer None None O
. None None O

A None None O
statistically None None O
significant None None O
association None None O
of None None O
IgA None None I-protein
and None None O
IgM None None I-protein
with None None O
benign None None O
lesions None None O
was None None O
contrasted None None O
to None None O
the None None O
association None None O
of None None O
IgG None None I-protein
with None None O
malignant None None O
lesions None None O
. None None O

In None None O
both None None O
primary None None O
and None None O
metastatic None None O
lesions None None O
, None None O
IgG None None I-protein
localization None None O
was None None O
associated None None O
with None None O
estrogen-receptor-poor None None O
primary None None O
cancers None None O
as None None O
compared None None O
with None None O
estrogen-receptor-rich None None O
primary None None O
cancers None None O
. None None O

Among None None O
primary None None O
breast None None O
cancer None None O
patients None None O
, None None O
IgG None None I-protein
localization None None O
in None None O
the None None O
tumor None None O
correlated None None O
with None None O
relative None None O
lymphopenia None None O
. None None O

A None None O
shorter None None O
disease-free None None O
interval None None O
was None None O
noted None None O
in None None O
association None None O
with None None O
IgG None None I-protein
localization None None O
among None None O
the None None O
metastatic None None O
breast None None O
lesions None None O
. None None O

No None None O
statistically None None O
significant None None O
association None None O
between None None O
stage None None O
of None None O
disease None None O
and None None O
immunoglobulin None None O
presence None None O
was None None O
demonstrable None None O
. None None O

Moderate-to-severe None None O
intraductal None None O
epithelial None None O
hyperplasias None None O
were None None O
more None None O
often None None O
associated None None O
with None None O
immunoglobulin None None I-protein
G None None I-protein
localization None None O
that None None O
were None None O
other None None O
benign None None O
lesions None None O

Correlation None None O
of None None O
steroid None None I-protein
receptors None None I-protein
with None None O
histologic None None O
differentiation None None O
in None None O
mammary None None O
carcinoma None None O
. None None O

A None None O
Singapore None None O
experience None None O
. None None O

Cancer None None O
of None None O
the None None O
breast None None O
is None None O
the None None O
most None None O
common None None O
tumor None None O
in None None O
females None None O
in None None O
Singapore None None O
, None None O
with None None O
the None None O
rate None None O
of None None O
20.7 None None O
per None None O
100 None None O
, None None O
000 None None O
per None None O
year None None O
( None None O
1977 None None O
estimate None None O
) None None O
, None None O
which None None O
is None None O
predicted None None O
to None None O
increase None None O
to None None O
29.8 None None O
per None None O
100 None None O
, None None O
000 None None O
women None None O
per None None O
year None None O
by None None O
1995 None None O
. None None O

A None None O
detailed None None O
histopathologic None None O
review None None O
of None None O
50 None None O
primary None None O
breast None None O
cancer None None O
tumors None None O
analyzed None None O
for None None O
estrogen None None I-protein
receptor None None I-protein
( None None O
ER None None I-protein
) None None O
level None None O
was None None O
carried None None O
out None None O
and None None O
a None None O
variety None None O
of None None O
morphologic None None O
features None None O
correlated None None O
with None None O
ER None None I-protein
results None None O
to None None O
identify None None O
any None None O
factors None None O
that None None O
will None None O
improve None None O
the None None O
management None None O
and None None O
prognosis None None O
for None None O
breast None None O
cancer None None O
. None None O

Cytosol None None O
was None None O
incubated None None O
with None None O
3H-estradiol None None O
in None None O
the None None O
presence None None O
and None None O
absence None None O
of None None O
cold None None O
diethylstilbestrol None None O
, None None O
and None None O
bound None None O
and None None O
free None None O
hormone None None O
were None None O
separated None None O
by None None O
Dextran-coated None None O
charcoal None None O
method None None O
. None None O

Tumors None None O
binding None None O
more None None O
than None None O
5 None None O
fmol/mg None None O
cytosol None None I-protein
protein None None I-protein
were None None O
classified None None O
as None None O
ER None None I-protein
-positive None None O
. None None O

Progesterone None None I-protein
receptor None None I-protein
( None None O
PR None None I-protein
) None None O
level None None O
was None None O
analyzed None None O
in None None O
some None None O
specimens None None O
with None None O
the None None O
use None None O
of None None O
a None None O
similar None None O
method None None O
. None None O

Most None None O
of None None O
the None None O
patients None None O
were None None O
Chinese None None O
( None None O
90 None None O
% None None O
) None None O
. None None O

Three None None O
patients None None O
were None None O
Malays None None O
, None None O
one None None O
was None None O
Indian None None O
, None None O
and None None O
one None None O
was None None O
European None None O
in None None O
this None None O
series None None O
. None None O

Results None None O
indicated None None O
that None None O
there None None O
was None None O
strong None None O
correlation None None O
between None None O
ER None None I-protein
level None None O
, None None O
age None None O
, None None O
and None None O
histologic None None O
grade None None O
of None None O
the None None O
tumors None None O
. None None O

No None None O
correlation None None O
existed None None O
between None None O
absence None None O
or None None O
presence None None O
of None None O
lymph None None O
node None None O
metastases None None O
and None None O
ER None None I-protein
. None None O

Although None None O
there None None O
was None None O
a None None O
trend None None O
for None None O
ER None None I-protein
-positive None None O
tumors None None O
to None None O
have None None O
a None None O
low-grade None None O
lymphocytic None None O
infiltration None None O
, None None O
the None None O
difference None None O
was None None O
not None None O
statistically None None O
significant None None O
. None None O

Mononuclear None None I-cell_type
cells None None I-cell_type
infiltrating None None O
human None None O
mammary None None O
carcinomas None None O
: None None O
immunohistochemical None None O
analysis None None O
with None None O
monoclonal None None I-protein
antibodies None None I-protein
. None None O

Breast None None O
carcinomas None None O
were None None O
examined None None O
by None None O
the None None O
immunoperoxidase None None O
technique None None O
using None None O
antisera None None O
specific None None O
for None None O
lymphocyte None None I-cell_type
subsets None None I-cell_type
, None None O
monocytes None None I-cell_type
, None None O
NK None None I-cell_type
cells None None I-cell_type
and None None O
major None None I-protein
histocompatibility None None I-protein
antigens None None I-protein
( None None O
HLA-A None None I-protein
, None None O
-B None None I-protein
, None None O
-C None None O
; None None O
Ia-like None None I-protein
) None None O
. None None O

Sixty-four None None O
per None None O
cent None None O
of None None O
the None None O
patients None None O
had None None O
a None None O
moderate None None O
or None None O
strong None None O
mononuclear None None O
cell None None O
infiltration None None O
, None None O
77 None None O
% None None O
of None None O
the None None O
patients None None O
without None None O
mononuclear None None I-cell_type
cell None None I-cell_type
infiltration None None O
had None None O
receptors None None O
for None None O
estrogens None None O
as None None O
compared None None O
to None None O
51 None None O
% None None O
of None None O
the None None O
patients None None O
with None None O
infiltration None None O
. None None O

The None None O
majority None None O
of None None O
the None None O
infiltrating None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
were None None O
T None None I-cell_type
cells None None I-cell_type
; None None O
generally None None O
the None None O
OKT8 None None I-cell_line
cells None None I-cell_line
were None None O
predominant None None O
. None None O

The None None O
Leu None None O
3A/OKT8 None None O
cell None None O
ratio None None O
was None None O
not None None O
related None None O
to None None O
histological None None O
type None None O
, None None O
tumor None None O
size None None O
, None None O
age None None O
of None None O
the None None O
patient None None O
or None None O
presence None None O
of None None O
metastases None None O
. None None O

Some None None O
of None None O
the None None O
T None None O
cells None None O
had None None O
the None None O
Ia None None I-protein
antigen None None I-protein
and None None O
were None None O
thus None None O
probably None None O
activated None None O
. None None O

The None None O
B None None I-cell_type
cells None None I-cell_type
were None None O
either None None O
absent None None O
or None None O
less None None O
numerous None None O
than None None O
the None None O
T None None O
cells None None O
. None None O

There None None O
was None None O
no None None O
relation None None O
between None None O
their None None O
distribution None None O
and None None O
the None None O
various None None O
parameters None None O
studied None None O
. None None O

A None None O
few None None O
monocytes None None I-cell_type
were None None O
heterogeneous None None O
according None None O
to None None O
their None None O
markers None None O
( None None O
OKM None None I-protein
I None None I-protein
and None None O
acid None None O
phosphatase None None O
) None None O
. None None O

In None None O
6 None None O
cases None None O
only None None O
there None None O
was None None O
a None None O
strong None None O
infiltration None None O
of None None O
mononuclear None None I-cell_type
cells None None I-cell_type
positive None None O
for None None O
acid None None I-protein
phosphatase None None I-protein
. None None O

The None None O
number None None O
of None None O
the None None O
natural None None I-cell_type
killer None None I-cell_type
cells None None I-cell_type
was None None O
also None None O
low None None O
. None None O

Only None None O
a None None O
few None None O
mononuclear None None O
infiltrating None None O
cells None None O
had None None O
receptors None None O
for None None O
transferrin None None O
. None None O

There None None O
was None None O
a None None O
positive None None O
correlation None None O
between None None O
the None None O
inflammatory None None O
infiltration None None O
and None None O
the None None O
presence None None O
of None None O
HLA None None I-protein
class-I None None I-protein
antigens None None I-protein
on None None O
tumor None None I-cell_type
cell None None I-cell_type
s None None O
. None None O

Some None None O
of None None O
the None None O
antisera None None O
specific None None O
for None None O
lymphocyte None None I-cell_type
subsets None None I-cell_type
also None None O
stained None None O
the None None O
breast None None I-cell_type
carcinoma None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
great None None O
variations None None O
in None None O
the None None O
subsets None None O
of None None O
mononuclear None None I-cell_type
cells None None I-cell_type
in None None O
breast None None O
carcinomas None None O
may None None O
correspond None None O
to None None O
various None None O
systems None None O
of None None O
defense None None O
against None None O
neoplasm None None O
. None None O

A None None O
case None None O
of None None O
male None None O
pseudohermaphroditism None None O
with None None O
normal None None O
androgen None None I-protein
receptor None None I-protein
binding None None O
and None None O
47 None None O
, None None O
XYY None None O
karyotype None None O
. None None O

A None None O
case None None O
of None None O
male None None O
pseudohermaphroditism None None O
with None None O
47 None None O
, None None O
XYY None None O
karyotype None None O
in None None O
blood None None O
and None None O
cutaneous None None I-cell_type
fibroblasts None None I-cell_type
is None None O
described None None O
. None None O

The None None O
plasma None None O
testosterone None None O
response None None O
to None None O
HCG None None O
stimulation None None O
was None None O
slightly None None O
below None None O
the None None O
normal None None O
range None None O
on None None O
two None None O
occasions None None O
suggesting None None O
a None None O
deficit None None O
of None None O
gonadal None None O
function None None O
. None None O

A None None O
study None None O
of None None O
the None None O
receptors None None O
for None None O
dihydrotestosterone None None O
in None None O
fibroblasts None None I-cell_type
of None None O
genital None None O
and None None O
nongenital None None O
skin None None O
showed None None O
a None None O
normal None None O
concentration None None O
of None None O
receptors None None O
in None None O
genital None None O
skin None None O
; None None O
5-alpha-reductase None None I-protein
activity None None O
in None None O
fibroblasts None None I-cell_type
of None None O
the None None O
genital None None O
skin None None O
was None None O
low None None O
, None None O
but None None O
the None None O
plasma None None O
relationship None None O
testosterone/dihydrotestosterone None None O
under None None O
HCG None None O
stimulation None None O
was None None O
normal None None O
. None None O

The None None O
diagnostic None None O
possibility None None O
of None None O
a None None O
complete None None O
testicular None None O
feminization None None O
syndrome None None O
with None None O
normal None None O
receptors None None O
for None None O
dihydrotestosterone None None O
is None None O
commented None None O
on None None O
. None None O

1 None None O
, None None O
25-Dihydroxyvitamin None None O
D3 None None O
inhibits None None O
antigen-induced None None O
T None None I-cell_type
cell None None I-cell_type
activation None None O
. None None O

The None None O
proliferative None None O
response None None O
of None None O
murine None None I-cell_type
spleen None None I-cell_type
and None None I-cell_type
thymus None None I-cell_type
cells None None I-cell_type
to None None O
antigen None None I-protein
but None None O
not None None O
to None None O
lectin None None I-protein
was None None O
inhibited None None O
by None None O
the None None O
active None None O
metabolite None None O
of None None O
vitamin None None O
D3 None None O
, None None O
1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
. None None O

To None None O
directly None None O
examine None None O
the None None O
effect None None O
of None None O
1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
on None None O
T None None I-cell_type
cell None None I-cell_type
activation None None O
in None None O
the None None O
absence None None O
of None None O
other None None O
complicating None None O
interactions None None O
, None None O
we None None O
utilized None None O
a None None O
panel None None O
of None None O
cloned None None O
Ia-restricted None None I-cell_line
T None None I-cell_line
cell None None I-cell_line
hybridomas None None I-cell_line
that None None O
secrete None None O
IL None None I-protein
2 None None I-protein
on None None O
activation None None O
by None None O
cloned None None O
Ia-bearing None None I-cell_type
stimulator None None I-cell_type
cells None None I-cell_type
( None None O
TA3 None None I-cell_type
) None None O
or None None O
when None None O
stimulated None None O
by None None O
mitogen None None O
. None None O

Physiologic None None O
concentrations None None O
of None None O
1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
( None None O
0.01 None None O
to None None O
0.1 None None O
nm None None O
) None None O
inhibited None None O
the None None O
antigen-induced None None O
secretion None None O
of None None O
IL None None O
2 None None O
by None None O
several None None O
of None None O
these None None O
T None None I-cell_line
cell None None I-cell_line
hybridomas None None I-cell_line
. None None O

This None None O
inhibition None None O
was None None O
dependent None None O
on None None O
the None None O
concentration None None O
of None None O
the None None O
free None None O
hormone None None O
and None None O
could None None O
be None None O
overcome None None O
by None None O
increasing None None O
the None None O
number None None O
of None None O
Ia-bearing None None I-cell_line
stimulator None None I-cell_line
cells None None I-cell_line
used None None O
. None None O

Pretreatment None None O
of None None O
the None None O
T None None I-cell_line
hybridoma None None I-cell_line
but None None O
not None None O
the None None O
TA3 None None I-cell_line
stimulator None None I-cell_line
cell None None I-cell_line
with None None O
1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
resulted None None O
in None None O
inhibition None None O
of None None O
activation None None O
. None None O

These None None O
results None None O
are None None O
consistent None None O
with None None O
the None None O
finding None None O
that None None O
specific None None O
1 None None I-protein
, None None I-protein
25- None None I-protein
( None None I-protein
OH None None I-protein
) None None I-protein
2D3 None None I-protein
receptors None None I-protein
are None None O
present None None O
on None None O
the None None O
T None None O
cell None None O
hybridomas None None O
but None None O
are None None O
lacking None None O
in None None O
TA3 None None I-cell_line
cells None None I-cell_line
. None None O

1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
failed None None O
, None None O
however None None O
, None None O
to None None O
inhibit None None O
the None None O
activation None None O
of None None O
the None None O
T None None I-cell_line
cell None None I-cell_line
hybridomas None None I-cell_line
by None None O
lectin None None I-protein
or None None O
by None None O
an None None O
anti-Thy-1 None None I-protein
antibody None None I-protein
. None None O

These None None O
findings None None O
suggest None None O
that None None O
1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
may None None O
be None None O
interfering None None O
with None None O
early None None O
events None None O
of None None O
antigen-induced None None O
T None None I-cell_type
cell None None I-cell_type
activation None None O
, None None O
perhaps None None O
by None None O
hindering None None O
T None None I-cell_type
cell None None I-cell_type
recognition None None O
of None None O
the None None O
relevant None None O
antigen None None O
on None None O
stimulator None None O
cell None None O
surfaces None None O
. None None O

This None None O
system None None O
should None None O
prove None None O
useful None None O
in None None O
studying None None O
the None None O
molecular None None O
mechanisms None None O
by None None O
which None None O
1 None None O
, None None O
25- None None O
( None None O
OH None None O
) None None O
2D3 None None O
acts None None O
to None None O
inhibit None None O
T None None O
cell None None O
activation None None O
and None None O
subsequent None None O
IL None None I-protein
2 None None I-protein
production None None O
. None None O

Glucocorticoid None None I-protein
receptors None None I-protein
and None None O
steroid None None O
sensitivity None None O
in None None O
normal None None O
and None None O
neoplastic None None O
human None None O
lymphoid None None O
tissues None None O
: None None O
a None None O
review None None O
. None None O

The None None O
determination None None O
of None None O
estrogen None None I-protein
and None None I-protein
progesterone None None I-protein
receptors None None I-protein
in None None O
breast None None O
cancer None None O
has None None O
been None None O
shown None None O
to None None O
be None None O
useful None None O
in None None O
predicting None None O
the None None O
response None None O
to None None O
endocrine None None O
therapy None None O
. None None O

Given None None O
their None None O
well-known None None O
inhibitory None None O
effects None None O
on None None O
lymphoid None None O
tissue None None O
, None None O
glucocorticoids None None O
have None None O
been None None O
used None None O
widely None None O
in None None O
the None None O
treatment None None O
of None None O
leukemia None None O
. None None O

Given None None O
these None None O
facts None None O
, None None O
over None None O
the None None O
last None None O
10 None None O
years None None O
, None None O
several None None O
investigators None None O
have None None O
measured None None O
the None None O
number None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
normal None None O
and None None O
neoplastic None None O
lymphoid None None O
tissue None None O
to None None O
see None None O
whether None None O
their None None O
number None None O
correlated None None O
with None None O
glucocorticoid None None O
responsiveness None None O
in None None O
vitro None None O
or None None O
in None None O
vivo None None O
. None None O

No None None O
clear None None O
correlation None None O
could None None O
be None None O
established None None O
between None None O
the None None O
level None None O
of None None O
glucocorticoid None None I-protein
receptor None None I-protein
and None None O
the None None O
in None None O
vitro None None O
action None None O
of None None O
steroids None None O
in None None O
normal None None O
and None None O
neoplastic None None O
lymphoid None None O
tissue None None O
. None None O

In None None O
contrast None None O
, None None O
attempts None None O
to None None O
correlate None None O
glucocorticoid None None I-protein
receptor None None I-protein
levels None None O
in None None O
acute None None O
lymphocytic None None O
leukemia None None O
to None None O
in None None O
vivo None None O
steroid None None O
responsiveness None None O
and None None O
immunological None None O
type None None O
using None None O
the None None O
whole-cell-binding None None O
assay None None O
for None None O
receptor None None O
determination None None O
and None None O
selecting None None O
the None None O
patients None None O
according None None O
to None None O
age None None O
and None None O
immunological None None O
criteria None None O
have None None O
been None None O
more None None O
successful None None O
. None None O

[ None None O
Glucocorticoid None None I-protein
receptors None None I-protein
in None None O
normal None None I-cell_type
human None None I-cell_type
lymphocytes None None I-cell_type
] None None O

Glucocorticoid None None I-cell_type
( None None I-cell_type
GC None None I-cell_type
) None None I-cell_type
receptors None None I-cell_type
were None None O
studied None None O
in None None O
intact None None O
lymphocytes None None I-cell_type
from None None O
11 None None O
donors None None O
. None None O

GC None None O
binding None None O
parameters None None O
were None None O
found None None O
to None None O
be None None O
highly None None O
reproducible None None O
in None None O
repeated None None O
experiments None None O
with None None O
lymphocytes None None I-cell_type
. None None O

It None None O
was None None O
shown None None O
that None None O
GC None None I-protein
receptors None None I-protein
in None None O
donors None None O
' None None O
lymphocytes None None I-cell_type
could None None O
be None None O
distributed None None O
into None None O
two None None O
different None None O
classes None None O
similarly None None O
to None None O
the None None O
pattern None None O
seen None None O
in None None O
skin None None I-cell_type
fibroblasts None None I-cell_type
. None None O

Human None None I-cell_type
lymphocytes None None I-cell_type
are None None O
an None None O
adequate None None O
object None None O
for None None O
studying None None O
genetically None None O
determined None None O
variability None None O
of None None O
GC None None I-protein
receptors None None I-protein
and None None O
its None None O
clinical None None O
importance None None O
. None None O

Specific None None O
estrogen None None I-protein
binding None None I-protein
sites None None I-protein
in None None O
human None None I-cell_type
lymphoid None None I-cell_type
cells None None I-cell_type
and None None O
thymic None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
binding None None O
of None None O
estrogen None None O
in None None O
preparations None None O
of None None O
human None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
, None None I-cell_type
as None None O
well None None O
as None None O
by None None O
splenic None None I-cell_type
and None None I-cell_type
thymic None None I-cell_type
cells None None I-cell_type
is None None O
demonstrated None None O
by None None O
three None None O
different None None O
approaches None None O
( None None O
Dextran-coated None None O
charcoal None None O
method None None O
, None None O
whole None None O
cell None None O
assay None None O
, None None O
and None None O
gel None None O
filtration None None O
on None None O
a None None O
sepharose None None O
4B None None O
column None None O
) None None O
. None None O

Scatchard None None O
's None None O
analysis None None O
of None None O
[ None None O
3H None None O
] None None O
-moxestrol None None O
( None None O
R2858 None None O
) None None O
and None None O
[ None None O
3H None None O
] None None O
-estradiol None None O
binding None None O
proves None None O
the None None O
existence None None O
of None None O
a None None O
single None None O
class None None O
of None None O
receptor None None I-protein
sites None None I-protein
having None None O
a None None O
dissociation None None O
constant None None O
of None None O
0.18-2.4 None None O
X None None O
10 None None O
( None None O
-9 None None O
) None None O
M None None O
. None None O

Physicochemical None None O
properties None None O
of None None O
the None None O
binder None None O
, None None O
including None None O
binding None None O
capacity None None O
and None None O
steroid None None O
specificity None None O
, None None O
are None None O
quite None None O
similar None None O
to None None O
those None None O
reported None None O
for None None O
the None None O
thymus None None O
of None None O
small None None O
mammalian None None O
species None None O
or None None O
human None None O
thymoma None None O
. None None O

Administration None None O
of None None O
fibroblast None None I-protein
interferon None None I-protein
to None None O
patients None None O
with None None O
advanced None None O
breast None None O
cancer None None O
: None None O
possible None None O
effects None None O
on None None O
skin None None O
metastasis None None O
and None None O
on None None O
hormone None None I-protein
receptors None None I-protein
. None None O

Eleven None None O
patients None None O
with None None O
metastasized None None O
breast None None O
cancer None None O
received None None O
8 None None O
intramuscular None None O
injections None None O
of None None O
6 None None O
x None None O
10 None None O
( None None O
6 None None O
) None None O
units None None O
of None None O
human None None I-protein
fibroblast None None I-protein
interferon None None I-protein
over None None O
a None None O
period None None O
of None None O
40 None None O
days None None O
. None None O

The None None O
injections None None O
did None None O
not None None O
cause None None O
local None None O
irritation None None O
or None None O
inflammation None None O
. None None O

Fever None None O
occurred None None O
in None None O
only None None O
1 None None O
of None None O
the None None O
11 None None O
patients None None O
. None None O

Although None None O
several None None O
types None None O
of None None O
metastases None None O
were None None O
monitored None None O
, None None O
only None None O
skin None None O
nodules None None O
consistently None None O
( None None O
10 None None O
out None None O
of None None O
11 None None O
patients None None O
) None None O
exhibited None None O
changes None None O
that None None O
were None None O
suggestive None None O
of None None O
a None None O
therapeutic None None O
effect None None O
of None None O
the None None O
treatment None None O
regimen None None O
: None None O
either None None O
a None None O
simple None None O
decrease None None O
in None None O
size None None O
of None None O
some None None O
nodules None None O
or None None O
central None None O
necrosis None None O
accompanied None None O
by None None O
an None None O
inflammatory None None O
reaction None None O
. None None O

NK-activity None None O
of None None O
peripheral None None I-cell_type
blood None None I-cell_type
leukocytes None None I-cell_type
was None None O
significantly None None O
increased None None O
after None None O
administration None None O
of None None O
the None None O
first None None O
dose None None O
; None None O
the None None O
effect None None O
of None None O
subsequent None None O
injections None None O
was None None O
less None None O
clear None None O
. None None O

Receptors None None O
for None None O
estrogens None None O
and None None O
progestogens None None O
were None None O
increased None None O
in None None O
the None None O
tumor None None O
biopsies None None O
of None None O
2 None None O
out None None O
of None None O
2 None None O
and None None O
5 None None O
out None None O
of None None O
6 None None O
patients None None O
tested None None O
respectively None None O
. None None O

Decreased None None O
glucocorticoid None None I-protein
receptor None None I-protein
binding None None O
in None None O
adrenal None None O
insufficiency None None O
. None None O

To None None O
examine None None O
the None None O
effect None None O
of None None O
glucocorticoid None None O
deficiency None None O
on None None O
the None None O
glucocorticoid None None I-protein
receptor None None I-protein
, None None O
we None None O
examine None None O
the None None O
binding None None O
of None None O
[ None None O
3H None None O
] None None O
dexamethasone None None O
to None None O
lymphocytes None None I-cell_type
in None None O
normal None None O
subjects None None O
and None None O
patients None None O
with None None O
adrenal None None O
insufficiency None None O
before None None O
and None None O
after None None O
glucocorticoid None None O
replacement None None O
therapy None None O
. None None O

Using None None O
a None None O
whole None None O
cell None None O
competitive None None O
binding None None O
assay None None O
, None None O
normal None None I-cell_type
human None None I-cell_type
lymphocytes None None I-cell_type
had None None O
5977 None None O
+/- None None O
1487 None None O
( None None O
mean None None O
+/- None None O
SD None None O
) None None O
binding None None O
sites/cell None None O
and None None O
a None None O
dissociation None None O
constant None None O
of None None O
10 None None O
+/- None None O
2 None None O
nM None None O
. None None O

Lymphocytes None None I-cell_type
from None None O
patients None None O
with None None O
untreated None None O
adrenal None None O
insufficiency None None O
had None None O
fewer None None O
binding None None I-protein
sites None None I-protein
( None None O
3364 None None O
+/-322 None None O
) None None O
and None None O
a None None O
2-fold None None O
increase None None O
in None None O
binding None None O
affinity None None O
( None None O
5.4 None None O
+/- None None O
0.9 None None O
mM None None O
) None None O
. None None O

The None None O
administration None None O
of None None O
conventional None None O
replacement None None O
doses None None O
of None None O
cortisone None None O
acetate None None O
for None None O
6 None None O
months None None O
caused None None O
no None None O
change None None O
in None None O
receptor None None O
number None None O
, None None O
but None None O
was None None O
associated None None O
with None None O
a None None O
decrease None None O
in None None O
binding None None O
affinity None None O
toward None None O
normal None None O
. None None O

After None None O
long None None O
term None None O
glucocorticoid None None O
replacement None None O
therapy None None O
, None None O
binding None None O
parameters None None O
were None None O
similar None None O
to None None O
those None None O
in None None O
patients None None O
before None None O
treatment None None O
. None None O

The None None O
physiological None None O
implications None None O
of None None O
the None None O
decreased None None O
receptor None None O
number None None O
and None None O
increased None None O
binding None None O
affinity None None O
in None None O
adrenal None None O
insufficiency None None O
remain None None O
to None None O
be None None O
elucidated None None O
. None None O

Glucocorticoid None None I-protein
receptor None None I-protein
concentrations None None O
and None None O
terminal None None O
transferase None None I-protein
activity None None O
as None None O
indicators None None O
of None None O
prognosis None None O
in None None O
acute None None O
non-lymphocytic None None O
leukaemia None None O
. None None O

Activity None None O
of None None O
terminal None None I-protein
deoxynucleotidyl None None I-protein
transferase None None I-protein
( None None O
TdT None None I-protein
) None None O
, None None O
adenosine None None I-protein
deaminase None None I-protein
, None None O
and None None O
5'nucleotidase None None I-protein
and None None O
the None None O
cellular None None O
concentration None None O
of None None O
glucocorticoid None None I-protein
( None None I-protein
dexamethasone None None I-protein
) None None I-protein
receptor None None I-protein
were None None O
determined None None O
in None None O
25 None None O
patients None None O
with None None O
acute None None O
non-lymphocytic None None O
leukaemia None None O
. None None O

All None None O
patients None None O
were None None O
treated None None O
according None None O
to None None O
a None None O
common None None O
protocol None None O
. None None O

Increased None None O
activity None None O
of None None O
TdT None None I-protein
( None None O
greater None None O
than None None O
0.1 None None O
unit/microgram None None O
DNA None None O
) None None O
was None None O
found None None O
in None None O
11 None None O
patients None None O
. None None O

This None None O
group None None O
of None None O
patients None None O
was None None O
shown None None O
to None None O
have None None O
higher None None O
remission None None O
and None None O
survival None None O
rates None None O
( None None O
p None None O
= None None O
0.06 None None O
) None None O
compared None None O
with None None O
patients None None O
with None None O
low None None O
activity None None O
of None None O
TdT None None O
. None None O

The None None O
glucocorticoid None None I-protein
receptor None None I-protein
concentration None None O
of None None O
the None None O
leukaemic None None I-cell_type
blast None None I-cell_type
cells None None I-cell_type
ranged None None O
from None None O
0 None None O
to None None O
0.94 None None O
fmol/microgram None None O
DNA None None O
. None None O

Thirteen None None O
patients None None O
had None None O
blast None None I-cell_type
cells None None I-cell_type
with None None O
a None None O
glucocorticoid None None I-protein
receptor None None I-protein
concentration None None O
over None None O
0.22 None None O
fmol/microgram None None O
DNA None None O
. None None O

These None None O
patients None None O
had None None O
significantly None None O
increased None None O
remission None None O
and None None O
survival None None O
rates None None O
( None None O
p None None O
= None None O
0.006 None None O
) None None O
compared None None O
with None None O
those None None O
with None None O
a None None O
low None None O
receptor None None O
concentration None None O
. None None O

This None None O
finding None None O
can None None O
not None None O
be None None O
explained None None O
by None None O
a None None O
difference None None O
in None None O
sensitivity None None O
to None None O
glucocorticoids None None O
since None None O
these None None O
were None None O
not None None O
used None None O
as None None O
therapeutic None None O
agents None None O
. None None O

Adenosine None None I-protein
deaminase None None I-protein
and None None O
5'nucleotidase None None I-protein
activities None None O
both None None O
varied None None O
within None None O
two None None O
orders None None O
of None None O
magnitude None None O
. None None O

No None None O
correlation None None O
could None None O
be None None O
found None None O
between None None O
activities None None O
of None None O
these None None O
enzymes None None O
and None None O
remission None None O
or None None O
survival None None O
rate None None O
. None None O

These None None O
results None None O
show None None O
that None None O
measurements None None O
of None None O
TdT None None I-protein
activity None None O
and None None O
the None None O
glucocorticoid None None I-protein
receptor None None I-protein
concentration None None O
yield None None O
valuable None None O
prognostic None None O
information None None O
in None None O
acute None None O
non-lymphocytic None None O
leukaemia None None O

[ None None O
3H None None O
] None None O
cortivazol None None O
: None None O
a None None O
unique None None O
high None None O
affinity None None O
ligand None None O
for None None O
the None None O
glucocorticoid None None I-protein
receptor None None I-protein
. None None O

Cortivazol None None O
( None None O
CVZ None None O
) None None O
and None None O
deacylcortivazol None None O
( None None O
DAC None None O
) None None O
are None None O
pyrazolosteroids None None O
with None None O
potent None None O
glucocorticoid None None O
activity None None O
. None None O

In None None O
previous None None O
work None None O
we None None O
showed None None O
that None None O
DAC None None O
is None None O
40-fold None None O
more None None O
potent None None O
than None None O
dexamethasone None None O
( None None O
DEX None None O
) None None O
in None None O
lysing None None O
leukemic None None I-cell_type
lymphoblasts None None I-cell_type
. None None O

To None None O
assess None None O
the None None O
interaction None None O
between None None O
these None None O
atypical None None O
steroids None None O
and None None O
the None None O
glucocorticoid None None I-protein
receptor None None I-protein
, None None O
we None None O
examined None None O
the None None O
binding None None O
of None None O
[ None None O
3H None None O
] None None O
CVZ None None O
to None None O
cytosol None None O
from None None O
glucocorticoid-sensitive None None I-cell_line
and None None I-cell_line
-resistant None None I-cell_line
variants None None I-cell_line
of None None O
the None None O
human None None I-cell_line
leukemic None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
CEM None None B-cell_line
C7 None None I-cell_line
. None None O

In None None O
glucocorticoid-sensitive None None I-cell_line
cells None None I-cell_line
[ None None O
3H None None O
] None None O
CVZ None None O
causes None None O
a None None O
2-fold None None O
induction None None O
of None None O
glutamine None None I-protein
synthetase None None I-protein
and None None O
binds None None O
to None None O
a None None O
protein None None O
in None None O
the None None O
4.6 None None O
S None None O
region None None O
of None None O
high None None O
salt None None O
sucrose None None O
gradients None None O
. None None O

On None None O
DEAE-cellulose None None O
chromatography None None O
, None None O
[ None None I-protein
3H None None I-protein
] None None I-protein
CVZ-receptor None None I-protein
complexes None None I-protein
show None None O
a None None O
shift None None O
from None None O
high None None O
( None None O
0.25 None None O
M None None O
KP None None O
) None None O
to None None O
low None None O
salt None None O
( None None O
0.09 None None O
M None None O
KP None None O
) None None O
eluting None None O
forms None None O
upon None None O
activation None None O
. None None O

CVZ None None O
competes None None O
for None None O
a None None O
97 None None O
, None None O
000-dalton None None O
protein None None O
labeled None None O
by None None O
[ None None O
3H None None O
] None None O
dexamethasone None None O
mesylate None None O
. None None O

Scatchard None None O
analysis None None O
of None None O
the None None O
binding None None O
of None None O
[ None None O
3H None None O
] None None O
CVZ None None O
in None None O
glucocorticoid-sensitive None None I-cell_line
cells None None I-cell_line
revealed None None O
a None None O
curvilinear None None O
plot None None O
which None None O
resolved None None O
into None None O
high None None O
( None None O
0.4 None None O
nM None None O
) None None O
and None None O
low None None O
( None None O
11 None None O
nM None None O
) None None O
affinity None None O
components None None O
. None None O

The None None O
receptor None None O
concentration None None O
of None None O
the None None O
low None None O
affinity None None O
site None None O
( None None O
0.30 None None O
pmol/mg None None O
protein None None O
) None None O
was None None O
approximately None None O
twice None None O
that None None O
of None None O
the None None O
high None None I-protein
affinity None None I-protein
site None None I-protein
( None None O
0.14 None None O
pmol/mg None None O
protein None None O
) None None O
. None None O

Dissociation None None O
experiments None None O
with None None O
dilution None None O
and/or None None O
excess None None O
unlabeled None None O
CVZ None None O
supported None None O
the None None O
presence None None O
of None None O
independent None None O
sites None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
binding None None O
of None None O
[ None None O
3H None None O
] None None O
DEX None None O
to None None O
C7 None None O
cytosol None None O
revealed None None O
a None None O
single None None O
class None None O
of None None O
binding None None O
sites None None O
( None None O
Kd None None O
= None None O
1.9 None None O
nM None None O
; None None O
receptor None None O
concentration None None O
, None None O
0.46 None None O
pmol/mg None None O
protein None None O
) None None O
. None None O

Examination None None O
of None None O
the None None O
binding None None O
of None None O
[ None None O
3H None None O
] None None O
CVZ None None O
using None None O
10 None None O
( None None O
-5 None None O
) None None O
M None None O
DEX None None O
as None None O
the None None O
competing None None O
ligand None None O
showed None None O
that None None O
DEX None None O
binds None None O
only None None O
to None None O
the None None O
low None None O
affinity None None O
site None None O
detected None None O
by None None O
[ None None O
3H None None O
] None None O
CVZ None None O
. None None O

In None None O
cytosol None None O
from None None O
a None None O
glucocorticoid-resistant None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
with None None O
virtually None None O
no None None O
[ None None O
3H None None O
] None None O
DEX None None O
binding None None O
, None None O
[ None None O
3H None None O
] None None O
CVZ None None O
detected None None O
a None None O
single None None O
high None None I-protein
affinity None None I-protein
binding None None I-protein
site None None I-protein
that None None O
was None None O
similar None None O
in None None O
dissociation None None O
constant None None O
( None None O
0.8 None None O
nM None None O
) None None O
and None None O
receptor None None O
concentration None None O
( None None O
0.13 None None O
pmol/mg None None O
protein None None O
) None None O
to None None O
the None None O
high None None I-protein
affinity None None I-protein
site None None I-protein
detected None None O
in None None O
the None None O
glucocorticoid-sensitive None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
C7 None None B-cell_line
. None None O

A None None O
controlled None None O
pore None None O
glass None None O
bead None None O
assay None None O
for None None O
the None None O
measurement None None O
of None None O
cytoplasmic None None I-protein
and None None I-protein
nuclear None None I-protein
glucocorticoid None None I-protein
receptors None None I-protein
. None None O

An None None O
assay None None O
for None None O
the None None O
quantitation None None O
of None None O
cytoplasmic None None I-protein
and None None I-protein
nuclear None None I-protein
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
lymphoid None None O
tissue None None O
has None None O
been None None O
developed None None O
using None None O
controlled None None O
pore None None O
glass None None O
( None None O
CPG None None O
) None None O
beads None None O
. None None O

Soluble None None O
receptor None None I-protein
-- None None I-protein
3H-steroid None None I-protein
complex None None I-protein
( None None O
cytosol None None O
or None None O
nuclear None None O
extract None None O
) None None O
is None None O
adsorbed None None O
quantitatively None None O
within None None O
the None None O
crevasses None None O
of None None O
porous None None O
glass None None O
beads None None O
. None None O

Excess None None O
labeled None None O
steroid None None O
as None None O
well None None O
as None None O
most None None O
non-specifically None None O
bound None None O
steroid None None O
is None None O
easily None None O
washed None None O
away None None O
, None None O
leaving None None O
the None None O
hormone-receptor None None I-protein
complex None None I-protein
retained None None O
by None None O
the None None O
beads None None O
. None None O

Bound None None O
3H-steroid None None O
is None None O
eluted None None O
with None None O
ethanol None None O
and None None O
measured None None O
for None None O
radioactivity None None O
. None None O

This None None O
procedure None None O
which None None O
is None None O
simple None None O
, None None O
rapid None None O
, None None O
and None None O
highly None None O
reproducible None None O
is None None O
carried None None O
out None None O
using None None O
frozen None None O
samples None None O
( None None O
stable None None O
for None None O
many None None O
months None None O
) None None O
containing None None O
as None None O
few None None O
as None None O
1 None None O
X None None O
10 None None O
( None None O
7 None None O
) None None O
cells None None O
. None None O

A None None O
comparison None None O
of None None O
the None None O
CPG None None O
assay None None O
to None None O
dextran None None O
coated None None O
charcoal None None O
and None None O
a None None O
whole None None O
cell None None O
assay None None O
demonstrates None None O
that None None O
CPG None None O
and None None O
dextran None None O
coated None None O
charcoal None None O
give None None O
equivalent None None O
measurements None None O
of None None O
cytosolic None None I-protein
receptor None None I-protein
concentration None None O
, None None O
while None None O
the None None O
CPG None None O
and None None O
whole None None O
cell None None O
assays None None O
provide None None O
equivalent None None O
values None None O
for None None O
total None None O
receptor None None O
content None None O
. None None O

Plasmacytoid None None O
blast None None O
crisis None None O
in None None O
B-cell None None I-cell_type
chronic None None O
lymphocytic None None O
leukemia None None O
: None None O
effect None None O
of None None O
estradiol None None O
on None None O
growth None None O
and None None O
differentiation None None O
in None None O
vitro None None O
. None None O

Evolution None None O
of None None O
a None None O
case None None O
of None None O
chronic None None O
lymphocytic None None O
leukemia None None O
( None None O
CLL None None O
) None None O
into None None O
blast None None O
crisis None None O
was None None O
found None None O
to None None O
be None None O
characterized None None O
by None None O
three None None O
unusual None None O
features None None O
( None None O
1 None None O
) None None O
the None None O
phenotype None None O
of None None O
the None None O
emerging None None I-cell_type
blast None None I-cell_type
cells None None I-cell_type
was None None O
that None None O
of None None O
pre-plasmacytoid None None I-cell_type
cells None None I-cell_type
as None None O
shown None None O
by None None O
plasma None None O
cell None None O
morphology None None O
and None None O
an None None O
immunological None None O
phenotype None None O
corresponding None None O
partially None None O
with None None O
CLL- None None I-cell_type
or None None I-cell_type
intermediate None None I-cell_type
B-cells None None I-cell_type
, None None O
partially None None O
with None None O
plasma None None I-cell_type
cells None None I-cell_type
( None None O
terminal None None I-protein
transferase None None I-protein
- None None O
, None None O
common None None O
acute None None I-protein
lymphocytic None None I-protein
leukemia None None I-protein
antigen None None I-protein
- None None O
, None None O
Ia+ None None I-protein
, None None O
surface None None I-protein
immunoglobulin None None I-protein
heavy None None I-protein
chains None None I-protein
- None None O
, None None O
surface None None I-protein
kappa None None I-protein
light None None I-protein
chains None None I-protein
+ None None O
, None None O
intracytoplasmic None None I-protein
immunoglobulin None None I-protein
A+ None None I-protein
and None None I-protein
G+ None None I-protein
, None None O
BA-1+ None None I-protein
, None None O
polyclonal None None O
gammaglobulin None None O
production None None O
) None None O
; None None O
( None None O
2 None None O
) None None O
cytogenetic None None O
analysis None None O
of None None O
spontaneous None None O
metaphases None None O
revealed None None O
that None None O
in None None O
addition None None O
to None None O
the None None O
typical None None O
CLL None None O
abnormality None None O
, None None O
trisomy None None O
12 None None O
, None None O
in None None O
all None None O
of None None O
the None None O
cells None None O
, None None O
an None None O
additional None None O
translocation None None O
between None None O
chromosomes None None I-DNA
14 None None I-DNA
and None None I-DNA
17 None None I-DNA
was None None O
present None None O
in None None O
40 None None O
% None None O
with None None O
a None None O
presumptive None None O
breakpoint None None O
on None None O
chromosome None None I-DNA
14 None None I-DNA
( None None O
q12-3 None None O
) None None O
never None None O
described None None O
before None None O
( None None O
commonly None None O
q32 None None O
) None None O
and None None O
( None None O
3 None None O
) None None O
the None None O
progression None None O
of None None O
the None None O
disease None None O
was None None O
associated None None O
with None None O
a None None O
striking None None O
increase None None O
in None None O
the None None O
expression None None O
by None None O
the None None O
transformed None None I-cell_type
cells None None I-cell_type
of None None O
specific None None O
binding None None O
sites None None O
for None None O
estradiol None None O
( None None O
E2 None None O
) None None O
due None None O
to None None O
an None None O
actual None None O
increase None None O
in None None O
total None None O
cellular None None I-protein
receptor None None I-protein
proteins None None I-protein
and None None O
not None None O
to None None O
a None None O
change None None O
in None None O
receptor None None O
affinity None None O
for None None O
E2 None None O
. None None O

The None None O
functional None None O
status None None O
of None None O
the None None O
steroid None None I-protein
receptors None None I-protein
was None None O
confirmed None None O
by None None O
nuclear None None O
transfer None None O
of None None O
the None None O
cytoplasmic None None I-protein
hormone-receptor None None I-protein
complex None None I-protein
upon None None O
temperature None None O
activation None None O
. None None O

Since None None O
the None None O
rise None None O
in None None O
E2-receptor None None I-protein
display None None O
paralleled None None O
a None None O
large None None O
increase None None O
in None None O
the None None O
proliferative None None O
activity None None O
of None None O
the None None O
cells None None O
as None None O
well None None O
as None None O
a None None O
change None None O
in None None O
their None None O
maturation None None O
status None None O
the None None O
question None None O
was None None O
raised None None O
as None None O
to None None O
whether None None O
the None None O
E2-receptor None None I-protein
should None None O
be None None O
considered None None O
as None None O
a None None O
physiological None None O
marker None None O
of None None O
growth None None O
rate None None O
or None None O
of None None O
cellular None None O
differentiation None None O
. None None O

Exposure None None O
of None None O
the None None O
patient None None O
's None None O
blast None None I-cell_type
cells None None I-cell_type
to None None O
E2 None None O
in None None O
vitro None None O
resulted None None O
in None None O
cessation None None O
of None None O
cell None None O
growth None None O
following None None O
at None None O
least None None O
one None None O
mitosis None None O
after None None O
addition None None O
of None None O
the None None O
inducer None None O
as None None O
seen None None O
from None None O
the None None O
replacement None None O
of None None O
the None None O
large None None I-cell_type
blasts None None I-cell_type
by None None O
small None None O
CLL-like None None I-cell_type
cells None None I-cell_type
without None None O
definite None None O
signs None None O
of None None O
alteration None None O
of None None O
the None None O
differentiation None None O
status None None O
. None None O

This None None O
suggests None None O
the None None O
association None None O
of None None O
E2-receptor None None I-protein
expression None None O
with None None O
control None None O
of None None O
growth None None O
rather None None O
than None None O
cell None None O
maturation None None O
. None None O

Multiple None None O
forms None None O
and None None O
fragments None None O
of None None O
cytosolic None None I-protein
glucocorticoid None None I-protein
receptors None None I-protein
from None None O
human None None I-cell_type
leukemic None None I-cell_type
cells None None I-cell_type
and None None O
normal None None I-cell_type
lymphocytes None None I-cell_type
. None None O

Therapy None None O
with None None O
glucocorticoids None None O
is None None O
generally None None O
more None None O
effective None None O
in None None O
acute None None O
lymphoblastic None None O
leukemia None None O
than None None O
in None None O
other None None O
types None None O
of None None O
human None None O
leukemia None None O
. None None O

Previous None None O
studies None None O
, None None O
however None None O
, None None O
have None None O
not None None O
revealed None None O
any None None O
consistent None None O
relationship None None O
between None None O
clinical None None O
responsiveness None None O
and None None O
the None None O
cellular None None O
or None None O
cytosolic None None O
concentration None None O
of None None O
glucocorticoid-binding None None I-protein
sites None None I-protein
. None None O

The None None O
objectives None None O
of None None O
this None None O
study None None O
were None None O
to None None O
determine None None O
whether None None O
there None None O
are None None O
intrinsic None None O
structural None None O
differences None None O
among None None O
the None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
various None None O
types None None O
of None None O
leukemic None None I-cell_type
cells None None I-cell_type
and None None O
normal None None I-cell_type
lymphocytes None None I-cell_type
and None None O
to None None O
investigate None None O
the None None O
role None None O
of None None O
endogenous None None I-protein
peptidases None None I-protein
in None None O
receptor None None O
degradation None None O
. None None O

Cytosols None None O
were None None O
prepared None None O
from None None O
fresh None None I-cell_type
or None None I-cell_type
rapidly None None I-cell_type
frozen None None I-cell_type
leukocytes None None I-cell_type
from None None O
6 None None O
healthy None None O
adults None None O
and None None O
35 None None O
high-risk None None O
leukemia None None O
patients None None O
( None None O
median None None O
white None None O
blood None None O
cell None None O
count None None O
, None None O
150 None None O
, None None O
000 None None O
cells/microliter None None O
; None None O
median None None O
age None None O
, None None O
13 None None O
years None None O
) None None O
. None None O

Receptors None None O
were None None O
labeled None None O
with None None O
[ None None O
3H None None O
] None None O
triamcinolone None None O
acetonide None None O
and None None O
quantitated None None O
by None None O
charcoal-dextran None None O
treatment None None O
or None None O
Sephadex None None O
LH-20 None None O
chromatography None None O
. None None O

Mean None None O
and None None O
median None None O
cytosolic None None O
receptor None None O
concentrations None None O
in None None O
12 None None O
acute None None O
lymphoblastic None None O
leukemia None None O
specimens None None O
lacking None None O
the None None O
standard None None O
B-cell None None O
or None None O
T-cell None None O
markers None None O
( None None O
`` None None O
null None None O
cells None None O
'' None None O
) None None O
were None None O
approximately None None O
4-fold None None O
higher None None O
than None None O
in None None O
23 None None O
other None None O
leukemic None None I-cell_type
cell None None I-cell_type
specimens None None I-cell_type
. None None O

No None None O
other None None O
consistent None None O
differences None None O
in None None O
receptor None None O
content None None O
were None None O
observed None None O
. None None O

Agarose None None O
filtration None None O
and None None O
ultracentrifugation None None O
in None None O
hypotonic None None O
buffers None None O
containing None None O
20 None None O
mM None None O
Na2MoO4 None None O
revealed None None O
complexes None None O
of None None O
similar None None O
size None None O
and None None O
shape None None O
in None None O
all None None O
clinical None None O
specimens None None O
tested None None O
and None None O
two None None O
established None None O
leukemic None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
. None None O

They None None O
had None None O
Stokes None None O
radii None None O
( None None O
Rs None None O
) None None O
of None None O
8.1 None None O
+/- None None O
0.5 None None O
( None None O
S.D. None None O
) None None O
nm None None O
( None None O
n None None O
= None None O
50 None None O
) None None O
, None None O
sedimentation None None O
coefficients None None O
of None None O
9.5 None None O
+/- None None O
0.3S None None O
( None None O
n None None O
= None None O
40 None None O
) None None O
, None None O
molecular None None O
weights None None O
of None None O
approximately None None O
330 None None O
, None None O
000 None None O
, None None O
and None None O
axial None None O
ratios None None O
( None None O
a/b None None O
) None None O
of None None O
approximately None None O
12 None None O
. None None O

In None None O
hypertonic None None O
, None None O
molybdate-free None None O
buffer None None O
, None None O
these None None O
oligomeric None None I-protein
complexes None None I-protein
were None None O
dissociated None None O
into None None O
subunits None None O
with None None O
Rs None None O
of None None O
5.9 None None O
+/- None None O
0.3 None None O
nm None None O
( None None O
n None None O
= None None O
12 None None O
) None None O
and None None O
a/b None None O
of None None O
11 None None O
to None None O
12 None None O
, None None O
as None None O
observed None None O
previously None None O
for None None O
other None None O
receptors None None O
. None None O

Fragmentation None None O
of None None O
the None None O
oligomer None None I-protein
and None None O
the None None O
subunit None None I-protein
was None None O
evident None None O
in None None O
some None None O
cytosols None None O
. None None O

High None None O
activities None None O
of None None O
peptidases None None I-protein
of None None O
various None None O
specificities None None O
were None None O
detected None None O
in None None O
leukemic None None O
cell None None O
cytosols None None O
, None None O
as None None O
in None None O
other None None O
cytosols None None O
, None None O
by None None O
fluorometric None None O
assays None None O
with None None O
derivatives None None O
of None None O
7-amino-4-methylcoumarin None None O
. None None O

Receptor None None O
cleavage None None O
by None None O
these None None O
and None None O
other None None O
endogenous None None I-protein
enzymes None None I-protein
may None None O
account None None O
for None None O
previous None None O
observations None None O
of None None O
`` None None O
abnormal None None O
'' None None O
receptors None None O
in None None O
cytosols None None O
from None None O
some None None O
leukemic None None I-cell_type
specimens None None I-cell_type
. None None O

We None None O
conclude None None O
that None None O
intrinsic None None O
structural None None O
defects None None O
in None None O
the None None O
receptors None None O
are None None O
unlikely None None O
explanations None None O
for None None O
the None None O
unresponsiveness None None O
of None None O
some None None O
types None None O
of None None O
leukemia None None O
to None None O
steroid None None O
therapy None None O
. None None O

Glucocorticoid None None I-protein
receptor None None I-protein
number None None O
and None None O
intracellular None None O
water None None O
space None None O
. None None O

In None None O
order None None O
to None None O
elucidate None None O
the None None O
relationship None None O
between None None O
cell None None O
water None None O
content None None O
and None None O
number None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
, None None O
eleven None None O
normal None None O
and None None O
malignant None None I-cell_type
lymphoid None None I-cell_type
or None None I-cell_type
myelomonocytic None None I-cell_type
cell None None I-cell_type
types None None I-cell_type
originating None None O
from None None O
mouse None None O
, None None O
rat None None O
and None None O
man None None O
were None None O
investigated None None O
. None None O

The None None O
cellular None None O
water None None O
space None None O
was None None O
measured None None O
with None None O
3H2O None None O
, None None O
and None None O
glucocorticoid None None I-protein
receptor None None I-protein
number None None O
was None None O
measured None None O
in None None O
a None None O
whole-cell None None O
binding None None O
assay None None O
with None None O
[ None None O
3H None None O
] None None O
dexamethasone None None O
at None None O
30 None None O
and None None O
37 None None O
degrees None None O
C None None O
. None None O

The None None O
intracellular None None O
water None None O
phase None None O
concentration None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
( None None O
around None None O
40 None None O
nmol/l None None O
cell None None O
water None None O
) None None O
, None None O
and None None O
the None None O
dependence None None O
of None None O
receptor None None O
affinity None None O
on None None O
temperature None None O
were None None O
similar None None O
in None None O
normal None None I-cell_type
and None None I-cell_type
malignant None None I-cell_type
rodent None None I-cell_type
and None None I-cell_type
human None None I-cell_type
cells None None I-cell_type
. None None O

It None None O
is None None O
concluded None None O
that None None O
comparisons None None O
of None None O
glucocorticoid None None I-protein
receptor None None I-protein
levels None None O
are None None O
best None None O
made None None O
on None None O
the None None O
basis None None O
of None None O
intracellular None None I-protein
receptor None None I-protein
concentrations None None O
. None None O

Covalent None None O
labeling None None O
of None None O
rat None None I-cell_type
thymocyte None None I-cell_type
and None None O
human None None I-protein
lymphoid None None I-protein
glucocorticoid None None I-protein
receptor None None I-protein
. None None O

Lymphoid None None I-cell_type
cells None None I-cell_type
contain None None O
specific None None O
receptors None None I-protein
for None None O
glucocorticoids None None O
. None None O

We None None O
have None None O
used None None O
[ None None O
3H None None O
] None None O
dexamethasone-21-mesylate None None O
to None None O
label None None O
covalently None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
rat None None I-cell_type
thymic None None I-cell_type
lymphocytes None None I-cell_type
and None None O
in None None O
neoplastic None None I-cell_type
cells None None I-cell_type
obtained None None O
from None None O
patients None None O
with None None O
acute None None O
lymphoblastic None None O
leukemia None None O
and None None O
malignant None None O
lymphoma None None O
. None None O

The None None O
covalently None None O
labeled None None O
glucocorticoid None None I-protein
receptors None None I-protein
were None None O
identified None None O
by None None O
polyacrylamide None None O
gel None None O
electrophoresis None None O
( None None O
in None None O
the None None O
presence None None O
of None None O
0.1 None None O
% None None O
sodium None None O
dodecyl None None O
sulfate None None O
) None None O
. None None O

In None None O
cytosolic None None O
fractions None None O
prepared None None O
from None None O
rat None None I-cell_type
thymic None None I-cell_type
lymphocytes None None I-cell_type
, None None O
[ None None O
3H None None O
] None None O
-dexamethasone-21-mesylate None None O
labels None None O
a None None O
protein None None O
( None None O
Mr None None O
approximately None None O
equal None None O
to None None O
95 None None O
, None None O
000 None None O
) None None O
which None None O
was None None O
identified None None O
as None None O
the None None O
glucocorticoid None None I-protein
receptor None None I-protein
by None None O
the None None O
following None None O
criteria None None O
: None None O
( None None O
a None None O
) None None O
labeling None None O
of None None O
this None None O
moiety None None O
is None None O
inhibited None None O
by None None O
treatment None None O
with None None O
a None None O
100-fold None None O
molar None None O
excess None None O
of None None O
glucocorticoids None None O
, None None O
such None None O
as None None O
dexamethasone None None O
and None None O
triamcinolone None None O
acetonide None None O
; None None O
and None None O
( None None O
b None None O
) None None O
the None None O
covalently None None O
labeled None None O
Mr None None O
approximately None None O
equal None None O
to None None O
95 None None O
, None None O
000 None None O
protein None None O
is None None O
activated None None O
( None None O
by None None O
heating None None O
at None None O
20 None None O
degrees None None O
for None None O
30 None None O
min None None O
) None None O
to None None O
a None None O
form None None O
that None None O
binds None None O
to None None O
DNA-cellulose None None O
. None None O

When None None O
intact None None I-cell_type
thymocytes None None I-cell_type
are None None O
treated None None O
with None None O
[ None None O
3H None None O
] None None O
dexamethasone-21-mesylate None None O
, None None O
an None None O
Mr None None O
approximately None None O
equal None None O
to None None O
95 None None O
, None None O
000 None None O
moiety None None O
is None None O
also None None O
labeled None None O
covalently None None O
. None None O

Approximately None None O
35 None None O
% None None O
of None None O
the None None O
glucocorticoid None None I-protein
receptors None None I-protein
can None None O
be None None O
labeled None None O
covalently None None O
when None None O
intact None None O
thymocytes None None I-cell_type
are None None O
treated None None O
with None None O
100 None None O
nM None None O
[ None None O
3H None None O
] None None O
dexamethasone-21-mesylate None None O
for None None O
30 None None O
min None None O
at None None O
4 None None O
degrees None None O
. None None O

Neoplastic None None I-cell_type
cells None None I-cell_type
from None None O
acute None None O
lymphoblastic None None O
leukemia None None O
and None None O
malignant None None O
lymphoma None None O
were None None O
treated None None O
with None None O
[ None None O
3H None None O
] None None O
dexamethasone-21-mesylate None None O
. None None O

In None None O
all None None O
samples None None O
, None None O
an None None O
Mr None None O
approximately None None O
equal None None O
to None None O
95 None None O
, None None O
000 None None O
moiety None None O
was None None O
labeled None None O
covalently None None O
; None None O
labeling None None O
was None None O
inhibited None None O
by None None O
excess None None O
glucocorticoid None None O
. None None O

Smaller None None I-protein
moieties None None I-protein
were None None O
also None None O
identified None None O
by None None O
competition None None O
experiments None None O
; None None O
these None None O
may None None O
represent None None O
proteolytic None None I-protein
fragments None None I-protein
of None None O
the None None O
Mr None None O
approximately None None O
equal None None O
to None None O
95 None None O
, None None O
000 None None O
receptor None None O
. None None O

Thus None None O
, None None O
in None None O
rat None None I-cell_type
and None None I-cell_type
human None None I-cell_type
lymphoid None None I-cell_type
cells None None I-cell_type
, None None O
[ None None O
3H None None O
] None None O
dexamethasone-21-mesylate None None O
can None None O
be None None O
used None None O
to None None O
label None None O
covalently None None O
the None None O
glucocorticoid None None I-protein
receptor None None I-protein
. None None O

The None None O
association None None O
of None None O
cytosol None None O
oestrogen None None I-protein
and None None I-protein
progesterone None None I-protein
receptors None None I-protein
with None None O
histological None None O
features None None O
of None None O
breast None None O
cancer None None O
and None None O
early None None O
recurrence None None O
of None None O
disease None None O
. None None O

Two None None O
hundred None None O
and None None O
eighty-eight None None O
primary None None O
breast None None O
tumours None None O
were None None O
examined None None O
for None None O
the None None O
presence None None O
or None None O
absence None None O
of None None O
oestrogen None None I-protein
( None None I-protein
REc None None I-protein
) None None I-protein
and None None I-protein
progesterone None None I-protein
( None None I-protein
RPc None None I-protein
) None None I-protein
receptors None None I-protein
. None None O

Analysis None None O
has None None O
shown None None O
a None None O
relative None None O
interdependence None None O
between None None O
the None None O
steroid None None I-protein
receptor None None I-protein
status None None O
of None None O
primary None None O
breast None None O
cancer None None O
and None None O
other None None O
prognostic None None O
variables None None O
such None None O
as None None O
histological None None O
grade None None O
, None None O
lymphocytic None None O
infiltration None None O
and None None O
tumour None None O
elastosis None None O
. None None O

There None None O
were None None O
significant None None O
associations None None O
between None None O
epithelial None None O
cellularity None None O
, None None O
stromal None None O
fibrosis None None O
and None None O
the None None O
value None None O
of None None O
REc None None I-protein
in None None O
those None None O
tumours None None O
in None None O
which None None O
the None None O
receptor None None O
was None None O
present None None O
. None None O

Cellularity None None O
and None None O
fibrosis None None O
were None None O
unrelated None None O
to None None O
the None None O
presence None None O
or None None O
absence None None O
of None None O
oestrogen None None I-protein
receptor None None I-protein
. None None O

By None None O
contrast None None O
, None None O
neither None None O
the None None O
presence None None O
or None None O
absence None None O
nor None None O
the None None O
value None None O
of None None O
RPc None None I-protein
could None None O
be None None O
related None None O
to None None O
cellularity None None O
or None None O
fibrosis None None O
. None None O

The None None O
value None None O
of None None O
REc None None I-protein
and None None O
RPc None None I-protein
analysis None None O
as None None O
an None None O
indicator None None O
of None None O
prognosis None None O
was None None O
examined None None O
in None None O
a None None O
sub-group None None O
of None None O
175 None None O
patients None None O
receiving None None O
no None None O
additional None None O
treatment None None O
following None None O
mastectomy None None O
. None None O

Overall None None O
relapse-free None None O
survival None None O
( None None O
RFS None None O
) None None O
was None None O
no None None O
different None None O
for None None O
those None None O
patients None None O
with None None O
receptors None None O
compared None None O
to None None O
those None None O
without None None O
them None None O
( None None O
REc None None I-protein
P None None O
= None None O
0.11 None None O
, None None O
RPc None None O
P None None O
= None None O
0.7 None None O
) None None O
. None None O

There None None O
was None None O
no None None O
difference None None O
in None None O
RFS None None O
of None None O
receptor None None O
positive None None O
and None None O
negative None None O
tumours None None O
when None None O
the None None O
axillary None None O
node None None O
status None None O
was None None O
taken None None O
into None None O
account None None O
. None None O

Clinical None None O
implications None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
human None None O
leukemia None None O
. None None O

Normal None None I-cell_type
lymphoid None None I-cell_type
cells None None I-cell_type
contain None None O
glucocorticoid None None I-protein
receptor None None I-protein
. None None O

A None None O
variety None None O
of None None O
stimuli None None O
that None None O
activate None None O
these None None O
cells None None O
also None None O
induce None None O
increases None None O
in None None O
receptor None None O
concentration None None O
. None None O

Similar None None O
glucocorticoid None None I-protein
receptors None None I-protein
can None None O
be None None O
detected None None O
in None None O
lymphoid None None I-cell_type
cells None None I-cell_type
from None None O
patients None None O
with None None O
acute None None O
lymphoblastic None None O
leukemia None None O
( None None O
ALL None None O
) None None O
. None None O

Absence None None O
of None None O
the None None O
glucocorticoid None None I-protein
receptor None None I-protein
( None None O
usually None None O
found None None O
in None None O
treated None None O
patients None None O
) None None O
predicts None None O
lack None None O
of None None O
glucocorticoid None None O
responsiveness None None O
. None None O

Furthermore None None O
, None None O
in None None O
our None None O
hands None None O
, None None O
glucocorticoid None None I-protein
receptor None None I-protein
levels None None O
correlate None None O
with None None O
the None None O
duration None None O
of None None O
complete None None O
remission None None O
in None None O
ALL None None O
( None None O
though None None O
not None None O
in None None O
other None None O
forms None None O
of None None O
leukemia None None O
) None None O
. None None O

This None None O
association None None O
is None None O
independent None None O
of None None O
cell None None O
type None None O
, None None O
age None None O
, None None O
sex None None O
, None None O
or None None O
initial None None O
leukocyte None None I-cell_type
count None None O
. None None O

The None None O
level None None O
of None None O
receptor None None O
shows None None O
a None None O
negative None None O
correlation None None O
with None None O
increasing None None O
aggressiveness None None O
of None None O
the None None O
tumor None None O
( None None O
null-cell None None O
leukemia None None O
greater None None O
than None None O
T-cell None None O
leukemia None None O
greater None None O
than None None O
Burkitt None None O
's None None O
lymphoma None None O
) None None O
. None None O

Corticosteroid-mediated None None O
immunoregulation None None O
in None None O
man None None O
. None None O

Glucocorticoids None None O
have None None O
profound None None O
and None None O
complex None None O
effects None None O
on None None O
the None None O
human None None O
immune None None O
response None None O
. None None O

However None None O
, None None O
the None None O
precise None None O
mechanisms None None O
of None None O
the None None O
corticosteroid-induced None None O
immunoregulation None None O
in None None O
man None None O
have None None O
not None None O
been None None O
precisely None None O
defined None None O
. None None O

Intracytoplasmic None None I-protein
corticosteroid-specific None None I-protein
receptors None None I-protein
appear None None O
to None None O
be None None O
an None None O
important None None O
common None None O
pathway None None O
for None None O
steroid-induced None None O
changes None None O
, None None O
but None None O
variations None None O
of None None O
receptor None None O
parameters None None O
do None None O
not None None O
account None None O
for None None O
the None None O
multifaceted None None O
effects None None O
on None None O
the None None O
immune None None O
system None None O
. None None O

Human None None I-cell_type
circulating None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
redistribute None None O
out None None O
of None None O
the None None O
intravascular None None O
compartment None None O
following None None O
treatment None None O
with None None O
corticosteroids None None O
. None None O

Although None None O
certain None None O
components None None O
at None None O
this None None O
redistribution None None O
phenomenon None None O
have None None O
been None None O
well-characterized None None O
, None None O
the None None O
importance None None O
of None None O
this None None O
compartmental None None O
cellular None None O
shift None None O
with None None O
respect None None O
to None None O
the None None O
mechanisms None None O
of None None O
corticosteroid-induced None None O
immunoregulation None None O
are None None O
less None None O
well-defined None None O
. None None O

Recent None None O
observations None None O
that None None O
activated None None I-cell_type
lymphocytes None None I-cell_type
may None None O
be None None O
sensitive None None O
to None None O
the None None O
lytic None None O
effects None None O
of None None O
glucocorticoids None None O
suggest None None O
that None None O
under None None O
certain None None O
situations None None O
the None None O
elimination None None O
of None None O
selected None None O
subsets None None O
of None None O
cells None None O
may None None O
be None None O
a None None O
relevant None None O
mechanism None None O
of None None O
corticosteroid-mediated None None O
immunoregulation None None O
in None None O
man None None O
. None None O

Corticosteroid-mediated None None O
effects None None O
on None None O
monocyte None None I-cell_type
function None None O
may None None O
be None None O
an None None O
important None None O
mechanism None None O
of None None O
drug-induced None None I-cell_type
immunoregulation None None I-cell_type
in None None O
monocyte-dependent None None I-cell_type
responses None None I-cell_type
. None None O

In None None O
some None None O
experimental None None O
conditions None None O
, None None O
corticosteroids None None O
inhibit None None O
Interleukin None None I-protein
1 None None I-protein
production None None O
by None None O
monocytes None None I-cell_type
. None None O

The None None O
immunoregulatory None None O
effects None None O
of None None O
corticosteroids None None O
on None None O
lymphocyte None None I-cell_type
immune None None O
responses None None O
are None None O
complex None None O
. None None O

In None None O
vitro None None O
corticosteroids None None O
appear None None O
to None None O
selectively None None O
affect None None O
early None None O
immunoregulatory None None O
events None None O
as None None O
opposed None None O
to None None O
altering None None O
an None None O
established None None O
response None None O
. None None O

Multiple None None O
sites None None O
of None None O
steroid-induced None None O
modulations None None O
of None None O
human None None I-cell_type
B None None I-cell_type
cell None None I-cell_type
responses None None O
have None None O
been None None O
defined None None O
. None None O

Human None None I-cell_line
lymphoid None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
and None None O
glucocorticoids None None O
: None None O
II None None O
. None None O

Whole None None O
cell None None O
and None None O
cytoplasmic None None O
binding None None O
properties None None O
of None None O
lymphoblastoid None None I-cell_line
, None None I-cell_line
leukaemia None None I-cell_line
and None None I-cell_line
lymphoma None None I-cell_line
lines None None I-cell_line
. None None O

The None None O
glucocorticoid None None O
binding None None O
properties None None O
of None None O
18 None None O
human None None I-cell_line
lymphoid None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
( None None O
HLCL None None I-cell_line
) None None O
have None None O
been None None O
investigated None None O
. None None O

The None None O
specificity None None O
of None None O
steroid None None O
binding None None O
was None None O
confirmed None None O
with None None O
various None None O
glucocorticoid None None O
agonists None None O
and None None O
antagonists None None O
. None None O

A None None O
gradation None None O
in None None O
whole None None O
cell None None O
and None None O
cytoplasmic None None O
glucocorticoid None None O
binding None None O
capacity None None O
was None None O
observed None None O
in None None O
the None None O
different None None O
cell None None O
line None None O
types None None O
: None None O
lymphoblastoid None None I-cell_line
greater None None O
than None None O
lymphoma None None I-cell_line
greater None None O
than None None O
leukaemia None None I-cell_line
. None None O

The None None O
cytoplasmic None None I-protein
receptors None None I-protein
of None None O
leukaemia None None I-cell_line
and None None I-cell_line
lymphoblastoid None None I-cell_line
lines None None I-cell_line
appeared None None O
to None None O
contain None None O
both None None O
proteinaceous None None O
and None None O
phospholipid None None O
components None None O
. None None O

Cytoplasmic None None I-protein
steroid-receptor None None I-protein
complexes None None I-protein
exhibited None None O
a None None O
wide None None O
range None None O
of None None O
sedimentation None None O
coefficients None None O
( None None O
8.5-11.3S None None O
) None None O
in None None O
low None None O
ionic None None O
strength None None O
buffer None None O
but None None O
there None None O
was None None O
no None None O
correlation None None O
with None None O
cell None None O
line None None O
type None None O
or None None O
glucocorticoid None None O
sensitivity None None O
. None None O

Activation None None O
of None None O
these None None O
complexes None None O
by None None O
heat None None O
( None None O
37 None None O
degrees None None O
C None None O
) None None O
or None None O
exposure None None O
to None None O
high None None O
ionic None None O
strength None None O
buffer None None O
( None None O
0.3 None None O
M None None O
NaCl None None O
) None None O
induced None None O
nuclear None None O
binding None None O
of None None O
steroid None None O
but None None O
only None None O
complexes None None O
in None None O
high None None O
ionic None None O
strength None None O
buffer None None O
manifested None None O
changes None None O
in None None O
sedimentation None None O
coefficient None None O
. None None O

No None None O
correlation None None O
was None None O
observed None None O
between None None O
the None None O
level None None O
or None None O
nature None None O
of None None O
glucocorticoid None None O
binding None None O
and None None O
the None None O
cytolethal None None O
or None None O
cytostatic None None O
responsiveness None None O
of None None O
HLCL None None I-cell_line
to None None O
glucocorticoid None None O
treatment None None O
in None None O
vitro None None O
. None None O

The None None O
resistance None None O
to None None O
cytolethal None None O
effects None None O
can None None O
not None None O
be None None O
ascribed None None O
to None None O
a None None O
failure None None O
of None None O
cells None None O
to None None O
take None None O
up None None O
and None None O
bind None None O
steroid None None O
or None None O
to None None O
significant None None O
differences None None O
in None None O
the None None O
molecular None None O
species None None O
of None None O
cytoplasmic None None I-protein
receptors None None I-protein
present None None O
. None None O

The None None O
molecular None None O
mechanisms None None O
by None None O
which None None O
glucocorticoids None None O
achieve None None O
cytolethal None None O
responses None None O
in None None O
human None None I-cell_type
lymphoid None None I-cell_type
cells None None I-cell_type

CD28 None None I-protein
-mediated None None O
activation None None O
in None None O
CD45RA+ None None I-cell_type
and None None I-cell_type
CD45RO+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
: None None O
enhanced None None O
levels None None O
of None None O
reactive None None O
oxygen None None O
intermediates None None O
and None None O
c-Rel None None I-protein
nuclear None None O
translocation None None O
in None None O
CD45RA+ None None I-cell_type
cells None None I-cell_type
. None None O

We None None O
have None None O
analyzed None None O
the None None O
effect None None O
of None None O
complete None None O
T None None O
cell None None O
activation None None O
( None None O
anti-CD3 None None I-protein
plus None None O
anti-CD28 None None I-protein
) None None O
on None None O
the None None O
activation None None O
of None None O
NF-kappaB None None I-protein
in None None O
CD45RA+ None None I-cell_type
( None None I-cell_type
naive None None I-cell_type
) None None I-cell_type
and None None I-cell_type
CD45RO+ None None I-cell_type
( None None I-cell_type
memory/effector None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

Long None None O
exposure None None O
( None None O
24 None None O
h None None O
) None None O
induced None None O
stronger None None O
NF-kappaB None None I-protein
DNA None None O
binding None None O
in None None O
CD45RA+ None None I-cell_type
cells None None I-cell_type
than None None O
in None None O
CD45RO+ None None I-cell_type
cells None None I-cell_type
. None None O

Analysis None None O
of None None O
the None None O
nuclear None None I-protein
c-Rel None None I-protein
protein None None I-protein
indicated None None O
that None None O
after None None O
anti-CD3+anti-CD28 None None O
stimulation None None O
the None None O
level None None O
of None None O
c-Rel None None I-protein
was None None O
higher None None O
in None None O
CD45RA+ None None I-cell_type
cells None None I-cell_type
. None None O

Analysis None None O
of None None O
the None None O
cytoplasmic None None O
inhibitor None None O
IkappaBalpha None None I-protein
indicated None None O
that None None O
anti-CD3+anti-CD28 None None O
stimulation None None O
induced None None O
a None None O
long-lasting None None O
degradation None None O
in None None O
CD45RA+ None None I-cell_type
cells None None I-cell_type
but None None O
in None None O
CD45RO+ None None I-cell_type
cells None None I-cell_type
the None None O
degradation None None O
process None None O
was None None O
more None None O
rapid None None O
. None None O

Because None None O
the None None O
CD28 None None O
costimulus None None O
is None None O
known None None O
to None None O
induce None None O
the None None O
production None None O
of None None O
reactive None None O
oxygen None None O
intermediates None None O
( None None O
ROIs None None O
) None None O
, None None O
the None None O
intracellular None None O
ROI None None O
levels None None O
in None None O
CD45RA+ None None I-cell_type
and None None I-cell_type
CD45RO+ None None I-cell_type
cells None None I-cell_type
were None None O
compared None None O
by None None O
flow None None O
cytometry None None O
. None None O

ROIs None None O
were None None O
produced None None O
in None None O
both None None O
cell None None O
types None None O
, None None O
but None None O
more None None O
strongly None None O
in None None O
CD45RA+ None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
data None None O
presented None None O
in None None O
this None None O
study None None O
further None None O
emphasize None None O
the None None O
differences None None O
between None None O
CD45RA+ None None I-cell_type
and None None I-cell_type
CD45RO+ None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
in None None O
ROI-dependent None None O
signaling None None O
pathways None None O
. None None O

Ikaros None None I-protein
in None None O
hemopoietic None None I-cell_line
lineage None None I-cell_line
determination None None O
and None None O
homeostasis None None O
. None None O

Studies None None O
on None None O
the None None O
molecular None None O
mechanisms None None O
that None None O
control None None O
hemopoietic None None O
differentiation None None O
have None None O
focused None None O
on None None O
signaling None None O
cascades None None O
and None None O
nuclear None None O
effectors None None O
that None None O
drive None None O
this None None O
complex None None O
developmental None None O
system None None O
in None None O
a None None O
regulated None None O
fashion None None O
. None None O

Here None None O
we None None O
review None None O
the None None O
role None None O
of None None O
Ikaros None None I-protein
, None None O
the None None O
founding None None O
member None None O
of None None O
a None None O
unique None None O
family None None O
of None None O
zinc None None I-protein
finger None None I-protein
transcription None None I-protein
factors None None I-protein
in None None O
this None None O
developmental None None O
process None None O
. None None O

Studies None None O
on None None O
an None None O
Ikaros None None I-protein
null None None O
mutation None None O
have None None O
revealed None None O
an None None O
essential None None O
role None None O
for None None O
this None None O
factor None None O
in None None O
lymphoid None None I-cell_type
cell None None I-cell_type
fate None None O
determination None None O
and None None O
at None None O
subsequent None None O
branch None None O
points None None O
of None None O
the None None O
T None None I-cell_type
cell None None I-cell_type
differentiation None None O
pathway None None O
. None None O

Differences None None O
in None None O
the None None O
phenotypes None None O
of None None O
a None None O
null None None O
and None None O
a None None O
dominant None None O
negative None None O
( None None O
DN None None O
) None None O
Ikaros None None O
mutation None None O
provide None None O
insight None None O
into None None O
a None None O
regulatory None None O
network None None O
through None None O
which None None O
Ikaros None None I-protein
proteins None None I-protein
exert None None O
their None None O
effects None None O
in None None O
development None None O
. None None O

In None None O
addition None None O
a None None O
comparative None None O
analysis None None O
of None None O
the None None O
hemopoietic None None I-cell_type
stem None None I-cell_type
cell None None I-cell_type
and None None O
precursor None None O
compartment None None O
resulting None None O
from None None O
the None None O
two None None O
Ikaros None None I-protein
mutations None None O
reveals None None O
a None None O
profound None None O
yet None None O
not None None O
absolute None None O
requirement None None O
for None None O
Ikaros None None I-protein
in None None O
the None None O
production None None O
and None None O
differentiation None None O
of None None O
these None None O
populations None None O
. None None O

Overexpression None None O
of None None O
p65 None None O
and None None O
c-Jun None None O
substitutes None None O
for None None O
B7-1 None None O
costimulation None None O
by None None O
targeting None None O
the None None O
CD28RE None None I-DNA
within None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
. None None O

The None None O
role None None O
of None None O
Rel None None I-protein
and None None O
activation None None I-protein
protein-1 None None I-protein
( None None O
AP-1 None None I-protein
) None None O
in None None O
IL-2 None None I-DNA
promoter None None I-DNA
activity None None O
in None None O
B7-1- None None I-cell_type
and None None I-cell_type
leukocyte None None I-cell_type
function-associated None None I-cell_type
Ag-3 None None I-cell_type
( None None I-cell_type
LFA. None None I-cell_type
3 None None I-cell_type
) None None I-cell_type
-costimulated None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
has None None O
been None None O
evaluated None None O
. None None O

We None None O
demonstrate None None O
that None None O
overexpression None None O
of None None O
c-Jun None None I-protein
but None None O
not None None O
c-Fos None None I-protein
increases None None O
IL-2 None None I-DNA
promoter None None I-DNA
activity None None O
in None None O
both None None O
B7-1- None None I-cell_type
and None None I-cell_type
LFA-3-costimulated None None I-cell_type
Jurkat None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

Cotransfection None None O
of None None O
both None None O
c-Jun None None O
and None None O
c-Fos None None O
substitutes None None O
for None None O
B7-1 None None O
costimulation None None O
in None None O
driving None None O
an None None O
activation None None I-DNA
protein-1 None None I-DNA
response None None I-DNA
element None None I-DNA
but None None O
not None None O
for None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
. None None O

Overexpression None None O
of None None O
Rel None None I-protein
proteins None None I-protein
demonstrated None None O
that None None O
p65-expressing None None I-cell_line
Jurkat None None I-cell_line
cells None None I-cell_line
transcribed None None O
equally None None O
well None None O
a None None O
nuclear None None I-DNA
factor None None I-DNA
kappabeta None None I-DNA
reporter None None I-DNA
construct None None I-DNA
when None None O
costimulated None None O
with None None O
B7-1 None None I-protein
or None None O
LFA-3 None None I-protein
, None None O
but None None O
transcription None None O
of None None O
IL-2 None None I-DNA
promoter None None I-DNA
or None None O
CD28 None None I-DNA
response None None I-DNA
element None None I-DNA
( None None I-DNA
CD28RE None None I-DNA
) None None I-DNA
-driven None None I-DNA
reporters None None I-DNA
was None None O
superior None None O
in None None O
B7-1-costimulated None None I-cell_line
cells None None I-cell_line
. None None O

Combined None None O
expression None None O
of None None O
c-Jun None None I-protein
and None None O
p65 None None I-protein
induced None None O
vigorous None None O
transcription None None O
of None None O
IL-2 None None I-DNA
promoter- None None I-DNA
and None None I-DNA
CD28RE-driven None None I-DNA
reporter None None I-DNA
constructs None None I-DNA
in None None O
both None None O
LFA-3- None None I-cell_type
and None None I-cell_type
B7-1-costimulated None None I-cell_type
Jurkat None None I-cell_type
cells None None I-cell_type
. None None O

Mutating None None O
the None None O
CD28RE None None I-DNA
but None None O
not None None O
the None None O
upstream None None I-DNA
nuclear None None I-DNA
factor None None I-DNA
kappabeta-binding None None I-DNA
site None None I-DNA
in None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
reduced None None O
B7-1 None None I-protein
-driven None None O
transcription None None O
> None None O
90 None None O
% None None O
. None None O

The None None O
results None None O
implicates None None O
a None None O
major None None O
role None None O
of None None O
the None None O
CD28RE None None I-DNA
in None None O
the None None O
integration None None O
of None None O
p65 None None I-protein
/ None None O
c-Jun None None I-protein
-mediated None None O
transcription None None O
within None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
. None None O

We None None O
suggest None None O
that None None O
the None None O
transition None None O
from None None O
an None None O
autocrine None None O
LFA-3 None None I-protein
-driven None None O
immune None None O
response None None O
to None None O
a None None O
B7 None None O
-- None None O
induced None None O
paracrine None None O
immune None None O
response None None O
involves None None O
the None None O
activation None None O
of None None O
c-Jun None None I-protein
and None None O
p65 None None I-protein
, None None O
which None None O
target None None O
the None None O
CD28RE None None I-DNA
region None None O
of None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
. None None O

Defects None None O
in None None O
actin-cap None None O
formation None None O
in None None O
Vav-deficient None None O
mice None None O
implicate None None O
an None None O
actin None None O
requirement None None O
for None None O
lymphocyte None None O
signal None None O
transduction None None O
. None None O

BACKGROUND None None O
: None None O
Antigen-receptor None None O
interactions None None O
on None None O
lymphocytes None None I-cell_type
result None None O
in None None O
local None None O
clustering None None O
of None None O
actin None None I-protein
, None None O
receptors None None O
and None None O
signaling None None O
molecules None None O
into None None O
an None None O
asymmetric None None O
membrane None None O
structure None None O
termed None None O
a None None O
cap None None O
. None None O

Although None None O
actin None None O
polymerization None None O
is None None O
known None None O
to None None O
be None None O
required None None O
, None None O
the None None O
mechanisms None None O
underlying None None O
cap None None O
formation None None O
are None None O
unclear None None O
. None None O

We None None O
have None None O
studied None None O
the None None O
events None None O
underlying None None O
cap None None O
formation None None O
using None None O
mice None None O
bearing None None O
a None None O
null None None O
mutation None None O
in None None O
vav None None I-DNA
( None None O
vav None None I-DNA
-/- None None O
) None None O
, None None O
a None None O
gene None None O
that None None O
encodes None None O
a None None O
guanine-nucleotide None None I-protein
exchange None None I-protein
factor None None I-protein
for None None O
the None None O
GTPase None None I-protein
Rac None None I-protein
. None None O

RESULTS None None O
: None None O
Lymphocytes None None I-cell_type
from None None O
vav None None I-DNA
-/- None None O
mice None None O
failed None None O
to None None O
form None None O
T-cell None None O
receptor None None O
caps None None O
following None None O
activation None None O
and None None O
had None None O
a None None O
defective None None O
actin None None O
cytoskeleton None None O
. None None O

The None None O
vav-/- None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
were None None O
deficient None None O
in None None O
interleukin-2 None None O
( None None O
IL-2 None None O
) None None O
production None None O
and None None O
proliferation None None O
, None None O
and None None O
the None None O
peak None None O
of None None O
Ca2+ None None O
mobilization None None O
was None None O
reduced None None O
although None None O
of None None O
normal None None O
duration None None O
. None None O

Activation None None O
of None None O
Jun None None I-protein
N-terminal None None I-protein
kinase None None I-protein
or None None O
stress-activated None None I-protein
kinase None None I-protein
( None None O
JNK None None I-protein
or None None O
SAPK None None I-protein
) None None O
and None None O
mitogen-activated None None I-protein
protein None None I-protein
kinase None None I-protein
( None None O
MAPK None None I-protein
) None None O
and None None O
the None None O
induction None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
NF-ATc1 None None I-DNA
and None None I-DNA
egr-1 None None I-DNA
genes None None I-DNA
was None None O
normal None None O
. None None O

Despite None None O
the None None O
reduced None None O
Ca2+ None None O
mobilization None None O
, None None O
translocation None None O
of None None O
cytoplasmic None None I-protein
NF-ATc None None I-protein
to None None O
the None None O
nucleus None None O
was None None O
normal None None O
, None None O
reflecting None None O
that None None O
the None None O
lower None None O
levels None None O
of None None O
Ca2+ None None O
in None None O
vav-/- None None I-cell_type
cells None None I-cell_type
were None None O
still None None O
sufficient None None O
to None None O
activate None None O
calcineurin None None I-protein
. None None O

Treatment None None O
of None None O
lymphocytes None None I-cell_type
with None None O
cytochalasin None None O
D None None O
, None None O
which None None O
blocks None None O
actin None None O
polymerization None None O
, None None O
inhibited None None O
cap None None O
formation None None O
and None None O
produced None None O
defects None None O
in None None O
signaling None None O
and None None O
IL-2 None None O
transcriptional None None O
induction None None O
in None None O
response None None O
to None None O
antigen-receptor None None O
signaling None None O
that None None O
were None None O
nearly None None O
identical None None O
to None None O
those None None O
seen None None O
in None None O
vav-/- None None I-cell_type
cells None None I-cell_type
. None None O

In None None O
transfection None None O
studies None None O
, None None O
either None None O
constitutively None None O
active None None O
Vav None None I-protein
or None None O
Rac None None I-protein
could None None O
complement None None O
constitutively None None O
active None None O
calcineurin None None I-protein
to None None O
activate None None O
NF-AT-dependent None None O
transcription None None O
. None None O

CONCLUSIONS None None O
: None None O
These None None O
results None None O
indicate None None O
that None None O
Vav None None I-protein
is None None O
required None None O
for None None O
cap None None O
formation None None O
in None None O
lymphocytes None None I-cell_type
. None None O

Furthermore None None O
, None None O
the None None O
correlation None None O
between None None O
cap None None O
formation None None O
, None None O
IL-2 None None O
production None None O
and None None O
proliferation None None O
supports None None O
the None None O
hypothesis None None O
that None None O
an None None O
actin-dependent None None O
pathway None None O
is None None O
a None None O
source None None O
of None None O
specialized None None O
growth None None O
regulatory None None O
signals None None O
. None None O

CD14 None None I-protein
-dependent None None O
activation None None O
of None None O
human None None I-cell_type
endothelial None None I-cell_type
cells None None I-cell_type
by None None O
Bacteroides None None O
fragilis None None O
outer None None O
membrane None None O
. None None O

We None None O
studied None None O
the None None O
capacity None None O
of None None O
isolated None None O
Bacteriodes None None O
fragilis None None O
outer None None O
membrane None None O
, None None O
B. None None O
fragilis None None O
NCTC9343 None None O
lipopolysaccharide None None O
( None None O
LPS None None O
; None None O
endotoxin None None O
) None None O
, None None O
and None None O
B. None None O
fragilis None None O
NCTC9343 None None O
capsular None None O
polysaccharides None None O
to None None O
activate None None O
human None None O
umbilical None None O
vein None None O
endothelial None None O
cell None None O
( None None O
HUVEC None None O
) None None O
monolayers None None O
. None None O

To None None O
assess None None O
HUVEC None None O
activation None None O
, None None O
E-selectin None None I-protein
expression None None O
was None None O
measured None None O
by None None O
enzyme-linked None None O
immunosorbent None None O
assay None None O
( None None O
ELISA None None O
) None None O
, None None O
Northern None None O
blot None None O
analysis None None O
for None None O
E-selectin-specific None None I-RNA
mRNA None None I-RNA
, None None O
and None None O
electrophoretic None None O
gel None None O
mobility None None O
shift None None O
assay None None O
( None None O
EMSA None None O
) None None O
for None None O
NF-kappa None None I-protein
B None None I-protein
, None None O
a None None O
transcription None None I-protein
factor None None I-protein
necessary None None O
for None None O
E-selectin None None I-DNA
gene None None I-DNA
activation None None O
. None None O

Exposure None None O
of None None O
HUVECs None None I-cell_type
to None None O
B. None None O
fragilis None None O
outer None None O
membrane None None O
fractions None None O
, None None O
separated None None O
from None None O
other None None O
components None None O
of None None O
the None None O
B. None None O
fragilis None None O
cell None None O
wall None None O
by None None O
isopycnic None None O
, None None O
sucrose None None O
gradient None None O
centrifugation None None O
, None None O
significantly None None O
increased None None O
surface None None O
expression None None O
of None None O
E-selectin None None I-protein
and None None O
induced None None O
functional None None O
endothelial None None I-cell_type
cell None None I-cell_type
-dependent None None O
leukocyte None None O
adhesion None None O
. None None O

B. None None O
fragilis None None O
outer None None O
membranes None None O
induced None None O
translocation None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
to None None O
HUVEC None None O
nuclei None None O
and None None O
accumulation None None O
of None None O
E-selectin None None I-RNA
mRNA None None I-RNA
in None None O
HUVEC None None O
cytoplasm None None O
. None None O

E-selectin None None O
expression None None O
induced None None O
by None None O
B. None None O
fragilis None None O
outer None None O
membranes None None O
was None None O
not None None O
blocked None None O
by None None O
polymixin None None O
B None None O
. None None O

In None None O
contrast None None O
, None None O
E-selectin None None O
expression None None O
induced None None O
by None None O
outer None None O
membrane None None O
fractions None None O
purified None None O
from None None O
E. None None O
coli None None O
was None None O
competitively None None O
inhibited None None O
by None None O
polymixin None None O
B None None O
. None None O

Neither None None O
purified None None O
B. None None O
fragilis None None O
LPS None None O
, None None O
a None None O
prominent None None O
constituent None None O
of None None O
the None None O
outer None None O
membrane None None O
, None None O
nor None None O
purified None None O
B. None None O
fragilis None None O
capsular None None O
polysaccharides None None O
induced None None O
HUVEC None None O
activation None None O
. None None O

Two None None O
different None None O
monoclonal None None I-protein
antibodies None None I-protein
directed None None O
against None None O
human None None I-protein
CD14 None None I-protein
completely None None O
inhibited None None O
B. None None O
fragilis None None O
outer None None O
membrane-induced None None O
NF-kappa None None I-protein
B None None I-protein
activation None None O
, None None O
E-selectin None None O
transcription None None O
, None None O
and None None O
E-selectin None None O
surface None None O
expression None None O
. None None O

We None None O
conclude None None O
that None None O
the None None O
outer None None O
membrane None None O
component None None O
of None None O
the None None O
B. None None O
fragilis None None O
cell None None O
wall None None O
contains None None O
a None None O
proinflammatory None None O
factor None None O
( None None O
s None None O
) None None O
, None None O
that None None O
is None None O
not None None O
LPS None None O
, None None O
which None None O
induces None None O
human None None I-cell_type
endothelial None None I-cell_type
cell None None I-cell_type
activation None None O
by None None O
a None None O
soluble None None O
CD14 None None I-protein
-dependent None None O
mechanism None None O
. None None O

NF-kappaB None None I-protein
protects None None O
HIV-1-infected None None O
myeloid None None I-cell_type
cells None None I-cell_type
from None None O
apoptosis None None O
. None None O

HIV-1 None None O
infection None None O
of None None O
primary None None I-cell_type
monocytic None None I-cell_type
cells None None I-cell_type
and None None O
myeloid None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
results None None O
in None None O
sustained None None O
NF-kappaB None None O
activation None None O
. None None O

Recently None None O
, None None O
NF-kappaB None None O
induction None None O
has None None O
been None None O
shown None None O
to None None O
play None None O
a None None O
role None None O
in None None O
protecting None None O
cells None None O
from None None O
programmed None None O
cell None None O
death None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
sought None None O
to None None O
investigate None None O
whether None None O
constitutive None None O
NF-kappaB None None I-protein
activity None None O
in None None O
chronically None None O
HIV-1-infected None None O
promonocytic None None I-cell_line
U937 None None I-cell_line
( None None I-cell_line
U9-IIIB None None I-cell_line
) None None I-cell_line
and None None I-cell_line
myeloblastic None None I-cell_line
PLB-985 None None I-cell_line
( None None I-cell_line
PLB-IIIB None None I-cell_line
) None None I-cell_line
cells None None I-cell_line
affects None None O
apoptotic None None O
signaling None None O
. None None O

TNFalpha None None I-protein
and None None O
cycloheximide None None O
caused None None O
infected None None O
cells None None O
to None None O
undergo None None O
apoptosis None None O
more None None O
rapidly None None O
than None None O
parental None None I-cell_line
U937 None None I-cell_line
and None None O
PLB-985 None None I-cell_line
cells None None I-cell_line
. None None O

Inhibition None None O
of None None O
TNFalpha None None I-protein
-induced None None O
NF-kappaB None None O
activation None None O
using None None O
the None None O
antioxidant None None O
N-acetylcysteine None None O
( None None O
NAC None None O
) None None O
resulted None None O
in None None O
increased None None O
apoptosis None None O
in None None O
both None None O
U937 None None I-cell_line
and None None I-cell_line
U9-IIIB None None I-cell_line
cells None None I-cell_line
, None None O
while None None O
preactivation None None O
of None None O
NF-kappaB None None I-protein
with None None O
the None None O
non-apoptotic None None I-protein
inducer None None I-protein
IL-1beta None None I-protein
caused None None O
a None None O
relative None None O
decrease None None O
in None None O
apoptosis None None O
. None None O

Inhibition None None O
of None None O
constitutive None None O
NF-kappaB None None I-protein
activity None None O
in None None O
U9-IIIB None None I-cell_line
and None None I-cell_line
PLB-IIIB None None I-cell_line
cells None None I-cell_line
also None None O
induced None None O
apoptosis None None O
, None None O
suggesting None None O
that None None O
NF-kappaB None None I-cell_type
protects None None I-cell_type
cells None None I-cell_type
from None None O
a None None O
persistent None None O
apoptotic None None O
signal None None O
. None None O

TNFalpha None None I-protein
plus None None O
NAC None None O
treatment None None O
resulted None None O
in None None O
a None None O
marked None None O
decrease None None O
in None None O
Bcl-2 None None I-protein
protein None None I-protein
levels None None O
in None None O
HIV-1-infected None None I-cell_type
cells None None I-cell_type
, None None O
coupled None None O
with None None O
an None None O
increase None None O
in None None O
Bax None None I-protein
protein None None I-protein
compared None None O
to None None O
uninfected None None O
cells None None O
, None None O
suggesting None None O
that None None O
the None None O
difference None None O
in None None O
susceptibility None None O
to None None O
TNFalpha None None I-protein
-induced None None O
apoptosis None None O
may None None O
relate None None O
to None None O
the None None O
differences None None O
in None None O
relative None None O
levels None None O
of None None O
Bcl-2 None None I-protein
and None None O
Bax None None I-protein
. None None O

The None None O
protective None None O
role None None O
of None None O
NF-kappaB None None I-protein
in None None O
blocking None None O
TNFalpha- None None O
and None None O
HIV-1-induced None None O
apoptosis None None O
was None None O
supported None None O
by None None O
studies None None O
in None None O
Jurkat None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
engineered None None O
to None None O
express None None O
IkappaB None None I-protein
alpha None None I-protein
repressor None None I-protein
mutants None None I-protein
( None None O
TD-IkappaB None None I-protein
) None None O
under None None O
the None None O
control None None O
of None None O
a None None O
tetracycline-responsive None None I-DNA
promoter None None I-DNA
. None None O

Cells None None O
underwent None None O
apoptosis None None O
in None None O
response None None O
to None None O
TNFalpha None None I-protein
only None None O
when None None O
NF-kappaB None None O
activation None None O
was None None O
inhibited None None O
by None None O
TD-IkappaB None None I-protein
expression None None O
. None None O

As None None O
was None None O
observed None None O
for None None O
the None None O
U9-IIIB None None I-cell_line
cells None None I-cell_line
, None None O
TNFalpha None None I-protein
treatment None None O
also None None O
induced None None O
a None None O
marked None None O
decrease None None O
in None None O
Bcl-2 None None I-protein
protein None None I-protein
levels None None O
in None None O
TD-IkappaB None None I-cell_type
expressing None None I-cell_type
cells None None I-cell_type
. None None O

These None None O
experiments None None O
demonstrate None None O
that None None O
apoptotic None None O
signaling None None O
is None None O
perturbed None None O
in None None O
HIV-1-infected None None O
U9-IIIB None None I-cell_line
cells None None I-cell_line
and None None O
indicate None None O
that None None O
NF-kappaB None None O
activation None None O
may None None O
play None None O
an None None O
additional None None O
protective None None O
role None None O
against None None O
HIV-1-induced None None O
apoptosis None None O
in None None O
myeloid None None I-cell_type
cells None None I-cell_type
. None None O

Human None None I-cell_type
normal None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
B-lymphocytes None None I-cell_type
are None None O
deficient None None O
in None None O
DNA-dependent None None O
protein None None O
kinase None None O
activity None None O
due None None O
to None None O
the None None O
expression None None O
of None None O
a None None O
variant None None O
form None None O
of None None O
the None None O
Ku86 None None I-protein
protein None None I-protein
. None None O

The None None O
heterodimeric None None O
Ku None None I-protein
protein None None I-protein
, None None O
which None None O
comprises None None O
a None None O
86 None None I-protein
kDa None None I-protein
( None None I-protein
Ku86 None None I-protein
) None None I-protein
amd None None O
a None None O
70 None None I-protein
kDa None None I-protein
( None None I-protein
Ku70 None None I-protein
) None None I-protein
subunits None None I-protein
, None None O
is None None O
an None None O
abundant None None O
nuclear None None I-protein
DNA-binding None None I-protein
protein None None I-protein
which None None O
binds None None O
in None None O
vitro None None O
to None None O
DNA None None I-DNA
termini None None I-DNA
without None None O
sequence None None O
specificity None None O
. None None O

Ku None None I-protein
is None None O
the None None O
DNA-targeting None None I-protein
component None None I-protein
of None None O
the None None O
large None None O
catalytic None None I-protein
sub-unit None None I-protein
of None None O
the None None O
DNA-dependent None None I-protein
protein None None I-protein
kinase None None I-protein
complex None None I-protein
( None None O
DNA-PK None None I-protein
[ None None I-protein
CS None None I-protein
] None None I-protein
) None None O
, None None O
that None None O
plays None None O
a None None O
critical None None O
role None None O
in None None O
mammalian None None O
double-strand None None O
break None None O
repair None None O
and None None O
lymphoid None None O
V None None O
( None None O
D None None O
) None None O
J None None O
recombination None None O
. None None O

By None None O
using None None O
electrophoretic None None O
mobility None None O
shift None None O
assays None None O
, None None O
we None None O
demonstrated None None O
that None None O
in None None O
addition None None O
to None None O
the None None O
major None None I-protein
Ku None None I-protein
x None None I-protein
DNA None None I-protein
complex None None I-protein
usually None None O
detected None None O
in None None O
cell None None O
line None None O
extracts None None O
, None None O
a None None O
second None None O
complex None None O
with None None O
faster None None O
electrophoretic None None O
mobility None None O
was None None O
observed None None O
in None None O
normal None None O
peripheral None None I-cell_type
blood None None I-cell_type
lymphocytes None None I-cell_type
( None None O
PBL None None I-cell_type
) None None O
extracts None None O
. None None O

The None None O
presence None None O
of None None O
this None None O
faster None None I-protein
migrating None None I-protein
complex None None I-protein
was None None O
restricted None None O
to None None O
B None None I-cell_type
cells None None I-cell_type
among None None O
the None None O
circulating None None I-cell_type
lymphocyte None None I-cell_type
population None None I-cell_type
. None None O

Western None None O
blot None None O
analysis None None O
revealed None None O
that None None O
B None None I-cell_type
cells None None I-cell_type
express None None O
a None None O
variant None None O
form None None O
of None None O
the None None O
Ku86 None None I-protein
protein None None I-protein
with None None O
an None None O
apparent None None O
molecular None None O
weight None None O
of None None O
69 None None O
kDa None None O
, None None O
and None None O
not None None O
the None None O
86 None None I-protein
kDa- None None I-protein
full-length None None I-protein
protein None None I-protein
. None None O

Although None None O
the None None O
heterodimer None None I-protein
Ku70/variant-Ku86 None None I-protein
binds None None O
to None None O
DNA-ends None None I-DNA
, None None O
this None None O
altered None None O
form None None O
of None None O
the None None O
Ku None None I-protein
heterodimer None None I-protein
has None None O
a None None O
decreased None None O
ability None None O
to None None O
recruit None None O
the None None O
catalytic None None I-protein
component None None I-protein
of None None O
the None None O
complex None None O
, None None O
DNA-PK None None I-protein
( None None I-protein
CS None None I-protein
) None None I-protein
, None None O
which None None O
contributes None None O
to None None O
an None None O
absence None None O
of None None O
detectable None None O
DNA-PK None None O
activity None None O
in None None O
B None None I-cell_type
cells None None I-cell_type
. None None O

These None None O
data None None O
provide None None O
a None None O
molecular None None O
basis None None O
for None None O
the None None O
increased None None O
sensitivity None None O
of None None O
B None None I-cell_type
cells None None I-cell_type
to None None O
ionizing None None O
radiation None None O
and None None O
identify None None O
a None None O
new None None O
mechanism None None O
of None None O
regulation None None O
of None None O
DNA-PK None None O
activity None None O
that None None O
operates None None O
in None None O
vivo None None O
. None None O

Co-stimulation None None O
of None None O
human None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
with None None O
IL-2 None None I-protein
and None None O
anti-CD3 None None I-protein
monoclonal None None I-protein
antibodies None None I-protein
induces None None O
phosphorylation None None O
of None None O
CREB None None I-protein
. None None O

Phosphorylation None None O
of None None O
the None None O
cAMP-response None None I-protein
element None None I-protein
binding None None I-protein
protein None None I-protein
CREB None None I-protein
within None None O
1 None None O
h None None O
of None None O
CD2 None None I-protein
but None None O
not None None O
CD3 None None I-protein
cross-linking None None O
of None None O
human None None I-cell_type
PBMC None None I-cell_type
was None None O
recently None None O
demonstrated None None O
. None None O

The None None O
absence None None O
of None None O
P-CREB None None I-protein
following None None O
CD3 None None O
cross-linking None None O
was None None O
unexpected None None O
, None None O
as None None O
other None None O
laboratories None None O
reported None None O
increased None None O
phosphorylation None None O
of None None O
CREB None None I-protein
following None None O
CD3 None None O
cross-linking None None O
of None None O
the None None O
Jurkat None None I-cell_line
lymphocyte None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
. None None O

Due None None O
to None None O
Jurkat None None I-cell_line
T-cells None None I-cell_line
being None None O
IL-2-independent None None O
, None None O
it None None O
was None None O
postulated None None O
that None None O
IL-2 None None I-protein
might None None O
provide None None O
a None None O
necessary None None O
co-stimulus None None O
for None None O
phosphorylation None None O
of None None O
CREB None None I-protein
in None None O
primary None None I-cell_type
lymphocytes None None I-cell_type
. None None O

Therefore None None O
, None None O
P-CREB None None I-protein
was None None O
evaluated None None O
following None None O
co-stimulation None None O
of None None O
human None None I-cell_type
PBMC None None I-cell_type
through None None O
the None None O
IL-2 None None I-protein
and None None I-protein
CD2 None None I-protein
or None None I-protein
CD3 None None I-protein
receptors None None I-protein
. None None O

IL-2 None None I-protein
did None None O
not None None O
further None None O
augment None None O
phosphorylation None None O
of None None O
CREB None None I-protein
following None None O
CD2 None None O
cross-linking None None O
. None None O

However None None O
, None None O
while None None O
neither None None O
IL-2 None None I-protein
nor None None O
CD3 None None O
cross-linking None None O
alone None None O
induced None None O
P-CREB None None I-protein
, None None O
a None None O
4.5-fold None None O
increase None None O
in None None O
phosphorylation None None O
of None None O
CREB None None I-protein
within None None O
1 None None O
h None None O
of None None O
IL-2/CD3 None None O
co-stimulation None None O
was None None O
observed None None O
. None None O

Phosphorylation None None O
was None None O
not None None O
associated None None O
with None None O
the None None O
induction None None O
of None None O
cAMP None None O
, None None O
and None None O
inhibition None None O
of None None O
PKA None None O
signaling None None O
had None None O
no None None O
effect None None O
on None None O
P-CREB None None I-protein
. None None O

Consistent None None O
with None None O
signal None None O
transduction None None O
through None None O
p56lck None None I-protein
or None None O
p59fyn None None I-protein
, None None O
inhibition None None O
of None None O
PTK None None O
signaling None None O
reduced None None O
phosphorylation None None O
50 None None O
% None None O
. None None O

Interestingly None None O
, None None O
inhibiting None None O
PKC None None O
signaling None None O
with None None O
calphostin None None O
C None None O
further None None O
increased None None O
P-CREB None None O
levels None None O
3-fold None None O
over None None O
that None None O
observed None None O
in None None O
IL-2/CD3 None None I-cell_type
co-stimulated None None I-cell_type
cells None None I-cell_type
not None None O
pretreated None None O
with None None O
a None None O
PKC None None O
inhibitor None None O
. None None O

In None None O
contrast None None O
to None None O
previous None None O
studies None None O
performed None None O
in None None O
the None None O
absence None None O
of None None O
exogenous None None I-protein
IL-2 None None I-protein
, None None O
no None None O
increase None None O
in None None O
binding None None O
of None None O
CREB None None I-protein
to None None O
a None None O
32P-labeled None None O
oligonucleotide None None O
probe None None O
was None None O
observed None None O
by None None O
electrophoretic None None O
mobility None None O
shift None None O
assay None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
the None None O
IL-2 None None I-protein
and None None O
CD3 None None I-protein
signaling None None O
pathways None None O
provide None None O
a None None O
necessary None None O
and None None O
co-operative None None O
stimulus None None O
promoting None None O
phosphorylation None None O
of None None O
CREB None None I-protein
following None None O
receptor None None O
cross-linking None None O
. None None O

HIV-1 None None O
infection None None O
induces None None O
a None None O
selective None None O
reduction None None O
in None None O
STAT5 None None O
protein None None O
expression None None O
. None None O

HIV-1 None None O
infection None None O
is None None O
accompanied None None O
by None None O
qualitative None None O
and None None O
quantitative None None O
defects None None O
in None None O
CD4+ None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
. None None O

Loss None None O
of None None O
immune None None O
function None None O
in None None O
HIV None None O
patients None None O
is None None O
usually None None O
associated None None O
with None None O
a None None O
profound None None O
dysregulation None None O
of None None O
cytokine None None I-protein
production None None O
. None None O

To None None O
investigate None None O
whether None None O
cytokine None None I-protein
signaling None None O
defects None None O
occur None None O
during None None O
HIV None None O
infection None None O
, None None O
PHA None None I-cell_type
blasts None None I-cell_type
from None None O
healthy None None O
human None None O
donors None None O
were None None O
infected None None O
with None None O
two None None O
strains None None O
of None None O
HIV-1 None None O
and None None O
screened None None O
for None None O
the None None O
expression None None O
of None None O
STAT None None I-protein
proteins None None I-protein
used None None O
in None None O
cytokine None None I-protein
signaling None None O
. None None O

A None None O
selective None None O
decrease None None O
in None None O
STAT5B None None I-protein
was None None O
seen None None O
8 None None O
days None None O
after None None O
infection None None O
with None None O
the None None O
BZ167 None None O
dual-tropic None None O
HIV None None O
isolate None None O
, None None O
but None None O
not None None O
with None None O
the None None O
Ba-L None None O
, None None O
M-tropic None None O
strain None None O
. None None O

Based None None O
on None None O
these None None O
findings None None O
, None None O
purified None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
from None None O
HIV-infected None None O
patients None None O
in None None O
different None None O
stages None None O
of None None O
disease None None O
were None None O
also None None O
tested None None O
for None None O
STAT None None O
expression None None O
; None None O
decreases None None O
in None None O
STAT5A None None I-protein
, None None O
STAT5B None None I-protein
, None None O
and None None O
STAT1alpha None None I-protein
were None None O
observed None None O
in None None O
all None None O
patients None None O
. None None O

The None None O
reduction None None O
in None None O
STATs None None I-protein
seen None None O
in None None O
vivo None None O
and None None O
in None None O
vitro None None O
after None None O
HIV None None O
infection None None O
may None None O
contribute None None O
to None None O
the None None O
loss None None O
of None None O
T None None I-cell_type
cell None None I-cell_type
function None None O
in None None O
HIV None None O
disease None None O
. None None O

Transcription None None I-protein
factors None None I-protein
that None None O
regulate None None O
monocyte None None I-cell_type
/ None None O
macrophage None None I-cell_type
differentiation None None O
. None None O

Although None None O
all None None O
the None None O
cells None None O
in None None O
an None None O
organism None None O
contain None None O
the None None O
same None None O
genetic None None O
information None None O
, None None O
differences None None O
in None None O
the None None O
cell None None O
phenotype None None O
arise None None O
from None None O
the None None O
expression None None O
of None None O
lineage-specific None None I-DNA
genes None None I-DNA
. None None O

During None None O
myelopoiesis None None O
, None None O
external None None O
differentiating None None O
signals None None O
regulate None None O
the None None O
expression None None O
of None None O
a None None O
set None None O
of None None O
transcription None None I-protein
factors None None I-protein
. None None O

The None None O
combined None None O
action None None O
of None None O
these None None O
transcription None None I-protein
factors None None I-protein
subsequently None None O
determines None None O
the None None O
expression None None O
of None None O
myeloid-specific None None I-DNA
genes None None I-DNA
and None None O
the None None O
generation None None O
of None None O
monocytes None None I-cell_type
and None None O
macrophages None None I-cell_type
. None None O

In None None O
particular None None O
, None None O
the None None O
transcription None None I-protein
factor None None I-protein
PU.1 None None I-protein
has None None O
a None None O
critical None None O
role None None O
in None None O
this None None O
process None None O
. None None O

We None None O
review None None O
the None None O
contribution None None O
of None None O
several None None O
transcription None None I-protein
factors None None I-protein
to None None O
the None None O
control None None O
of None None O
macrophage None None I-cell_type
development None None O

Transcription None None I-protein
factor None None I-protein
LKLF None None I-protein
is None None O
sufficient None None O
to None None O
program None None O
T None None O
cell None None O
quiescence None None O
via None None O
a None None O
c-Myc None None O
-- None None O
dependent None None O
pathway None None O
. None None O

T None None I-cell_type
lymphocytes None None I-cell_type
circulate None None O
in None None O
a None None O
quiescent None None O
state None None O
until None None O
they None None O
encounter None None O
cognate None None I-protein
antigen None None I-protein
bound None None O
to None None O
the None None O
surface None None O
of None None O
an None None O
antigen-presenting None None I-cell_type
cell None None I-cell_type
. None None O

The None None O
molecular None None O
pathways None None O
that None None O
regulate None None O
T None None O
cell None None O
quiescence None None O
remain None None O
largely None None O
unknown None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
forced None None O
expression None None O
of None None O
the None None O
lung None None I-protein
Kruppel-like None None I-protein
transcription None None I-protein
factor None None I-protein
( None None O
LKLF None None I-protein
) None None O
in None None O
Jurkat None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
is None None O
sufficient None None O
to None None O
program None None O
a None None O
quiescent None None O
phenotype None None O
characterized None None O
by None None O
decreased None None O
proliferation None None O
, None None O
reduced None None O
cell None None O
size None None O
and None None O
protein None None O
synthesis None None O
and None None O
decreased None None O
surface None None O
expression None None O
of None None O
activation None None O
markers None None O
. None None O

Conversely None None O
, None None O
LKLF-deficient None None I-cell_type
peripheral None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
produced None None O
by None None O
gene None None O
targeting None None O
showed None None O
increased None None O
proliferation None None O
, None None O
increased None None O
cell None None O
size None None O
and None None O
enhanced None None O
expression None None O
of None None O
surface None None O
activation None None O
markers None None O
in None None O
vivo None None O
. None None O

LKLF None None I-protein
appeared None None O
to None None O
function None None O
, None None O
at None None O
least None None O
in None None O
part None None O
, None None O
by None None O
decreasing None None O
expression None None O
of None None O
the None None O
proto-oncogene None None I-DNA
encoding None None O
c-Myc None None I-protein
. None None O

Forced None None O
expression None None O
of None None O
LKLF None None I-protein
was None None O
associated None None O
with None None O
markedly None None O
decreased None None O
c-Myc None None I-protein
expression None None O
. None None O

In None None O
addition None None O
, None None O
many None None O
effects None None O
of None None O
LKLF None None I-protein
expression None None O
were None None O
mimicked None None O
by None None O
expression None None O
of None None O
the None None O
dominant-negative None None I-protein
MadMyc None None I-protein
protein None None I-protein
and None None O
rescued None None O
by None None O
overexpression None None O
of None None O
c-Myc None None I-protein
. None None O

Thus None None O
, None None O
LKLF None None I-protein
is None None O
both None None O
necessary None None O
and None None O
sufficient None None O
to None None O
program None None O
quiescence None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
and None None O
functions None None O
, None None O
in None None O
part None None O
, None None O
by None None O
negatively None None O
regulating None None O
a None None O
c-Myc None None O
-- None None O
dependent None None O
pathway None None O
. None None O

HTLV-1 None None I-protein
p12 None None I-protein
( None None I-protein
I None None I-protein
) None None I-protein
protein None None I-protein
enhances None None O
STAT5 None None O
activation None None O
and None None O
decreases None None O
the None None O
interleukin-2 None None I-protein
requirement None None O
for None None O
proliferation None None O
of None None O
primary None None I-cell_type
human None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
p12 None None I-protein
( None None I-protein
I None None I-protein
) None None I-protein
protein None None I-protein
, None None O
encoded None None O
by None None O
the None None O
pX None None I-DNA
open None None I-DNA
reading None None I-DNA
frame None None I-DNA
I None None I-DNA
of None None O
the None None O
human None None O
T-lymphotropic None None O
virus None None O
type None None O
1 None None O
( None None O
HTLV-1 None None O
) None None O
, None None O
is None None O
a None None O
hydrophobic None None I-protein
protein None None I-protein
that None None O
localizes None None O
to None None O
the None None O
endoplasmic None None O
reticulum None None O
and None None O
the None None O
Golgi None None O
. None None O

Although None None O
p12 None None I-protein
( None None I-protein
I None None I-protein
) None None I-protein
contains None None O
4 None None O
minimal None None O
proline-rich None None O
, None None O
src None None I-protein
homology None None I-protein
3-binding None None I-protein
motifs None None I-protein
( None None O
PXXP None None I-protein
) None None O
, None None O
a None None O
characteristic None None O
commonly None None O
found None None O
in None None O
proteins None None O
involved None None O
in None None O
signaling None None O
pathways None None O
, None None O
it None None O
has None None O
not None None O
been None None O
known None None O
whether None None O
p12 None None I-protein
( None None I-protein
I None None I-protein
) None None I-protein
has None None O
a None None O
role None None O
in None None O
modulating None None O
intracellular None None O
signaling None None O
pathways None None O
. None None O

This None None O
study None None O
demonstrated None None O
that None None O
p12 None None I-protein
( None None I-protein
I None None I-protein
) None None I-protein
binds None None O
to None None O
the None None O
cytoplasmic None None I-protein
domain None None I-protein
of None None O
the None None O
interleukin-2 None None I-protein
receptor None None I-protein
( None None I-protein
IL-2R None None I-protein
) None None I-protein
beta None None I-protein
chain None None I-protein
that None None O
is None None O
involved None None O
in None None O
the None None O
recruitment None None O
of None None O
the None None O
Jak1 None None I-protein
and None None I-protein
Jak3 None None I-protein
kinases None None I-protein
. None None O

As None None O
a None None O
result None None O
of None None O
this None None O
interaction None None O
, None None O
p12 None None I-protein
( None None I-protein
I None None I-protein
) None None I-protein
increases None None O
signal None None I-protein
transducers None None I-protein
and None None I-protein
activators None None I-protein
of None None I-protein
transcription None None I-protein
5 None None I-protein
( None None O
STAT5 None None I-protein
) None None O
DNA None None O
binding None None O
and None None O
transcriptional None None O
activity None None O
and None None O
this None None O
effect None None O
depends None None O
on None None O
the None None O
presence None None O
of None None O
both None None O
IL-2R None None I-protein
beta None None I-protein
and None None I-protein
gamma None None I-protein
( None None I-protein
c None None I-protein
) None None I-protein
chains None None I-protein
and None None O
Jak3 None None I-protein
. None None O

Transduction None None O
of None None O
primary None None I-cell_line
human None None I-cell_line
peripheral None None I-cell_line
blood None None I-cell_line
mononuclear None None I-cell_line
cells None None I-cell_line
( None None O
PBMCs None None I-cell_type
) None None O
with None None O
a None None O
human None None I-DNA
immunodeficiency None None I-DNA
virus None None I-DNA
type None None I-DNA
1-based None None I-DNA
retroviral None None I-DNA
vector None None I-DNA
expressing None None O
p12 None None I-protein
( None None I-protein
I None None I-protein
) None None I-protein
also None None O
resulted None None O
in None None O
increased None None O
STAT5 None None I-protein
phosphorylation None None O
and None None O
DNA None None O
binding None None O
. None None O

However None None O
, None None O
p12 None None I-protein
( None None I-protein
I None None I-protein
) None None I-protein
could None None O
increase None None O
proliferation None None O
of None None O
human None None I-cell_type
PBMCs None None I-cell_type
only None None O
after None None O
stimulation None None O
of None None O
T-cell None None I-protein
receptors None None I-protein
by None None O
treatment None None O
of None None O
cells None None O
with None None O
low None None O
concentrations None None O
of None None O
alphaCD3 None None I-protein
and None None I-protein
alphaCD28 None None I-protein
antibodies None None I-protein
. None None O

In None None O
addition None None O
, None None O
the None None O
proliferative None None O
advantage None None O
of None None O
p12 None None I-cell_type
( None None I-cell_type
I None None I-cell_type
) None None I-cell_type
-transduced None None I-cell_type
PBMCs None None I-cell_type
was None None O
evident None None O
mainly None None O
at None None O
low None None O
concentrations None None O
of None None O
IL-2 None None I-protein
. None None O

Together None None O
, None None O
these None None O
data None None O
indicate None None O
that None None O
p12 None None I-protein
( None None I-protein
I None None I-protein
) None None I-protein
may None None O
confer None None O
a None None O
proliferative None None O
advantage None None O
on None None O
HTLV-1-infected None None I-cell_type
cells None None I-cell_type
in None None O
the None None O
presence None None O
of None None O
suboptimal None None O
antigen None None O
stimulation None None O
and None None O
that None None O
this None None O
event None None O
may None None O
account None None O
for None None O
the None None O
clonal None None O
proliferation None None O
of None None O
infected None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
in None None O
vivo None None O
. None None O

( None None O
Blood. None None O
2001 None None O
; None None O
98 None None O
: None None O
823-829 None None O
) None None O

Single None None O
dose None None O
intranasal None None O
administration None None O
of None None O
retinal None None I-protein
autoantigen None None I-protein
generates None None O
a None None O
rapid None None O
accumulation None None O
and None None O
cell None None O
activation None None O
in None None O
draining None None O
lymph None None O
node None None O
and None None O
spleen None None O
: None None O
implications None None O
for None None O
tolerance None None O
therapy None None O
. None None O

BACKGROUND/AIMS None None O
: None None O
A None None O
single None None O
intranasal None None O
delivery None None O
of None None O
retinal None None I-protein
autoantigen None None I-protein
suppresses None None O
effectively None None O
experimental None None O
autoimmune None None O
uveoretinitis None None O
( None None O
EAU None None O
) None None O
. None None O

To None None O
further None None O
unravel None None O
underlying None None O
mechanisms None None O
the None None O
authors None None O
wished None None O
to None None O
determine None None O
, None None O
firstly None None O
, None None O
the None None O
kinetics None None O
of None None O
antigen None None O
delivery None None O
and None None O
, None None O
secondly None None O
, None None O
the None None O
early None None O
cellular None None O
responses None None O
involved None None O
in None None O
the None None O
initial None None O
stages None None O
of None None O
nasal None None O
mucosal None None O
tolerance None None O
induction None None O
. None None O

METHODS None None O
: None None O
Flow None None O
cytometry None None O
, None None O
cell None None O
proliferation None None O
assays None None O
, None None O
and None None O
microscopy None None O
were None None O
used None None O
to None None O
track None None O
antigen None None I-protein
following None None O
a None None O
single None None O
, None None O
intranasal None None O
dose None None O
of None None O
Alexa-488 None None I-protein
labelled None None I-protein
retinal None None I-protein
antigen None None I-protein
. None None O

RESULTS None None O
: None None O
A None None O
rapid None None O
accumulation None None O
of None None O
antigen None None I-protein
within None None O
both None None O
superficial None None O
cervical None None O
lymph None None O
nodes None None O
( None None O
SCLN None None O
) None None O
and None None O
spleen None None O
was None None O
observed None None O
after None None O
30 None None O
minutes None None O
. None None O

Significant None None O
proliferative None None O
responses None None O
to None None O
IRBP None None O
were None None O
elicited None None O
by None None O
48 None None O
hours None None O
indicating None None O
that None None O
systemic None None O
priming None None O
of None None O
naive None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
to None None O
retinal None None I-protein
antigen None None I-protein
had None None O
occurred None None O
. None None O

Cell None None O
activation None None O
was None None O
further None None O
confirmed None None O
by None None O
immunoprecipitation None None O
studies None None O
, None None O
which None None O
demonstrated None None O
phosphorylation None None O
of None None O
STAT4 None None I-protein
but None None O
not None None O
STAT6 None None I-protein
in None None O
both None None O
lymph None None O
nodes None None O
and None None O
spleen None None O
. None None O

However None None O
, None None O
at None None O
24 None None O
hours None None O
, None None O
STAT4 None None O
heterodimerisation None None O
with None None O
STAT None None I-protein
3 None None I-protein
was None None O
only None None O
observed None None O
in None None O
spleen None None O
. None None O

CONCLUSIONS None None O
: None None O
The None None O
results None None O
provide None None O
novel None None O
evidence None None O
that None None O
following None None O
a None None O
single None None O
intranasal None None O
application None None O
rapid None None O
transfer None None O
of None None O
antigen None None I-protein
occurs None None O
. None None O

Resulting None None O
T None None O
cell None None O
proliferation None None O
develops None None O
consequent None None O
to None None O
differential None None O
cell None None O
signalling None None O
in None None O
SCLN None None O
and None None O
spleen None None O
. None None O

Further None None O
understanding None None O
of None None O
these None None O
underlying None None O
cellular None None O
mechanisms None None O
, None None O
in None None O
particular None None O
as None None O
is None None O
inferred None None O
by None None O
the None None O
results None None O
the None None O
contribution None None O
of None None O
local None None O
versus None None O
systemic None None O
tolerance None None O
induction None None O
, None None O
may None None O
assist None None O
in None None O
strategies None None O
to None None O
clinically None None O
apply None None O
mucosal None None O
tolerance None None O
therapy None None O
successfully None None O
. None None O

Regulation None None O
of None None O
interleukin None None I-protein
( None None I-protein
IL None None I-protein
) None None I-protein
-18 None None I-protein
receptor None None I-protein
alpha None None I-protein
chain None None I-protein
expression None None O
on None None O
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
during None None O
T None None O
helper None None O
( None None O
Th None None O
) None None O
1/Th2 None None O
differentiation None None O
. None None O

Critical None None O
downregulatory None None O
role None None O
of None None O
IL-4 None None I-protein
. None None O

Interleukin None None I-protein
( None None I-protein
IL None None I-protein
) None None I-protein
-18 None None I-protein
has None None O
been None None O
well None None O
characterized None None O
as None None O
a None None O
costimulatory None None I-protein
factor None None I-protein
for None None O
the None None O
induction None None O
of None None O
IL-12-mediated None None I-protein
interferon None None I-protein
( None None I-protein
IFN None None I-protein
) None None I-protein
-gamma None None I-protein
production None None O
by None None O
T None None I-cell_type
helper None None I-cell_type
( None None I-cell_type
Th None None I-cell_type
) None None I-cell_type
1 None None I-cell_type
cells None None I-cell_type
, None None O
but None None O
also None None O
can None None O
induce None None O
IL-4 None None O
production None None O
and None None O
thus None None O
facilitate None None O
the None None O
differentiation None None O
of None None O
Th2 None None I-cell_type
cells None None I-cell_type
. None None O

To None None O
determine None None O
the None None O
mechanisms None None O
by None None O
which None None O
IL-18 None None I-protein
might None None O
regulate None None O
these None None O
diametrically None None O
distinct None None O
immune None None O
responses None None O
, None None O
we None None O
have None None O
analyzed None None O
the None None O
role None None O
of None None O
cytokines None None I-protein
in None None O
the None None O
regulation None None O
of None None O
IL-18 None None I-protein
receptor None None I-protein
alpha None None I-protein
chain None None I-protein
( None None O
IL-18Ralpha None None I-protein
) None None O
expression None None O
. None None O

The None None O
majority None None O
of None None O
peripheral None None I-cell_type
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
constitutively None None O
expressed None None O
the None None O
IL-18Ralpha None None I-protein
. None None O

Upon None None O
antigen None None O
stimulation None None O
in None None O
the None None O
presence None None O
of None None O
IL-12 None None I-protein
, None None O
marked None None O
enhancement None None O
of None None O
IL-18Ralpha None None I-protein
expression None None O
was None None O
observed None None O
. None None O

IL-12 None None I-protein
-mediated None None O
upregulation None None O
of None None O
IL-18Ralpha None None I-protein
required None None O
IFN-gamma None None I-protein
. None None O

Activated None None I-cell_type
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
that None None O
expressed None None O
low None None O
levels None None O
of None None O
IL-18Ralpha None None I-protein
could None None O
produce None None O
IFN-gamma None None I-protein
when None None O
stimulated None None O
with None None O
the None None O
combination None None O
of None None O
IL-12 None None I-protein
and None None O
IL-18 None None I-protein
, None None O
while None None O
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
which None None O
expressed None None O
high None None O
levels None None O
of None None O
IL-18Ralpha None None I-protein
could None None O
respond None None O
to None None O
IL-18 None None I-protein
alone None None O
. None None O

In None None O
contrast None None O
, None None O
T None None O
cell None None O
stimulation None None O
in None None O
the None None O
presence None None O
of None None O
IL-4 None None I-protein
resulted None None O
in None None O
a None None O
downregulation None None O
of None None O
IL-18Ralpha None None I-protein
expression None None O
. None None O

Both None None O
IL-4 None None I-cell_type
( None None I-cell_type
-/ None None I-cell_type
) None None I-cell_type
- None None I-cell_type
and None None I-cell_type
signal None None I-cell_type
transducer None None I-cell_type
and None None I-cell_type
activator None None I-cell_type
of None None I-cell_type
transcription None None I-cell_type
( None None I-cell_type
Stat None None I-cell_type
) None None I-cell_type
6 None None I-cell_type
( None None I-cell_type
-/ None None I-cell_type
) None None I-cell_type
- None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
expressed None None O
higher None None O
levels None None O
of None None O
IL-18Ralpha None None I-protein
after None None O
TCR None None O
stimulation None None O
. None None O

Furthermore None None O
, None None O
activated None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
from None None O
Stat6 None None O
( None None O
-/ None None O
) None None O
- None None O
mice None None O
produced None None O
more None None O
IFN-gamma None None I-protein
in None None O
response None None O
to None None O
IL-18 None None I-protein
than None None O
wild-type None None O
controls None None O
. None None O

Thus None None O
, None None O
positive/negative None None O
regulation None None O
of None None O
the None None O
IL-18Ralpha None None I-protein
by None None O
the None None O
major None None O
inductive None None O
cytokines None None I-protein
( None None O
IL-12 None None I-protein
and None None O
IL-4 None None I-protein
) None None O
determines None None O
the None None O
capacity None None O
of None None O
IL-18 None None I-protein
to None None O
polarize None None O
an None None O
immune None None O
response None None O
. None None O

Glucocorticoid-regulated None None I-protein
transcription None None I-protein
factors None None I-protein
. None None O

Glucocorticoids None None O
are None None O
the None None O
most None None O
effective None None O
antiinflammatory None None O
drugs None None O
used None None O
in None None O
the None None O
treatment None None O
of None None O
asthma None None O
. None None O

They None None O
act None None O
by None None O
binding None None O
to None None O
a None None O
specific None None O
receptor None None O
( None None O
GR None None I-protein
) None None O
that None None O
, None None O
upon None None O
activation None None O
, None None O
translocates None None O
to None None O
the None None O
nucleus None None O
and None None O
either None None O
increases None None O
( None None O
transactivates None None O
) None None O
or None None O
decreases None None O
( None None O
transrepresses None None O
) None None O
gene None None O
expression None None O
. None None O

Inhibition None None O
of None None O
pro-inflammatory None None I-protein
transcription None None I-protein
factors None None I-protein
such None None O
as None None O
activator None None I-protein
protein None None I-protein
( None None I-protein
AP None None I-protein
) None None I-protein
-1 None None I-protein
, None None O
signal None None I-protein
transducers None None I-protein
and None None I-protein
activators None None I-protein
of None None I-protein
transcription None None I-protein
( None None O
STATs None None I-protein
) None None O
, None None O
nuclear None None I-protein
factor None None I-protein
of None None I-protein
activated None None I-protein
T None None I-protein
cells None None I-protein
( None None O
NFAT None None I-protein
) None None O
and None None O
nuclear None None I-protein
factor None None I-protein
( None None I-protein
NF None None I-protein
) None None I-protein
-kappa None None I-protein
B None None I-protein
is None None O
thought None None O
to None None O
be None None O
a None None O
major None None O
action None None O
of None None O
glucocorticoids None None O
. None None O

Acetylation None None O
of None None O
histones None None I-protein
allows None None O
unwinding None None O
of None None O
the None None O
local None None I-DNA
DNA None None I-DNA
structure None None I-DNA
and None None O
enables None None O
RNA None None I-protein
polymerase None None I-protein
II None None I-protein
to None None O
enhance None None O
gene None None O
transcription None None O
. None None O

Histone None None O
acetylation None None O
is None None O
regulated None None O
by None None O
a None None O
balance None None O
between None None O
the None None O
activity None None O
of None None O
histone None None I-protein
acetyltransferases None None I-protein
( None None O
HATs None None I-protein
) None None O
and None None O
histone None None I-protein
deacetylases None None I-protein
( None None O
HDACs None None I-protein
) None None O
. None None O

GR None None I-protein
acts None None O
as None None O
a None None O
direct None None O
inhibitor None None O
of None None O
NF-kappa None None O
B-induced None None O
HAT None None O
activity None None O
and None None O
also None None O
by None None O
recruiting None None O
HDAC2 None None I-protein
to None None O
the None None O
NF-kappa None None I-protein
B/HAT None None I-protein
complex None None I-protein
. None None O

A None None O
sub-group None None O
of None None O
patients None None O
with None None O
glucocorticoid-insensitive None None O
asthma None None O
have None None O
an None None O
inability None None O
to None None O
induce None None O
histone None None O
acetylation None None O
in None None O
response None None O
to None None O
dexamethasone None None O
suggesting None None O
reduced None None O
expression None None O
of None None O
a None None O
GR-specific None None I-protein
HAT None None I-protein
. None None O

This None None O
suggests None None O
that None None O
pharmacological None None O
manipulation None None O
of None None O
specific None None O
histone None None O
acetylation None None O
status None None O
is None None O
a None None O
potentially None None O
useful None None O
approach None None O
for None None O
the None None O
treatment None None O
of None None O
inflammatory None None O
diseases None None O
. None None O

Identification None None O
of None None O
the None None O
precise None None O
mechanism None None O
by None None O
which None None O
activated None None I-protein
GR None None I-protein
recruits None None O
HDAC2 None None I-protein
may None None O
reveal None None O
new None None O
targets None None O
for None None O
the None None O
development None None O
of None None O
drugs None None O
that None None O
may None None O
dissociate None None O
the None None O
antiinflammatory None None O
actions None None O
of None None O
glucocorticoids None None O
from None None O
their None None O
side None None O
effects None None O
that None None O
are None None O
largely None None O
due None None O
to None None O
gene None None O
induction None None O
. None None O

Copyright None None O
Academic None None O
Press None None O
. None None O

Differential None None O
ultraviolet-B-induced None None O
immunomodulation None None O
in None None O
XPA None None O
, None None O
XPC None None O
, None None O
and None None O
CSB None None O
DNA None None O
repair-deficient None None O
mice None None O
. None None O

Ultraviolet None None O
B None None O
irradiation None None O
has None None O
serious None None O
consequences None None O
for None None O
cellular None None O
immunity None None O
and None None O
can None None O
suppress None None O
the None None O
rejection None None O
of None None O
skin None None O
tumors None None O
and None None O
the None None O
resistance None None O
to None None O
infectious None None O
diseases None None O
. None None O

DNA None None O
damage None None O
plays None None O
a None None O
crucial None None O
role None None O
in None None O
these None None O
immunomodulatory None None O
effects None None O
of None None O
ultraviolet None None O
B None None O
, None None O
as None None O
impaired None None O
repair None None O
of None None O
ultraviolet-B-induced None None O
DNA None None O
damage None None O
has None None O
been None None O
shown None None O
to None None O
cause None None O
suppression None None O
of None None O
cellular None None O
immunity None None O
. None None O

Ultraviolet-B-induced None None O
DNA None None O
damage None None O
is None None O
repaired None None O
by None None O
the None None O
nucleotide None None O
excision None None O
repair None None O
mechanism None None O
very None None O
efficiently None None O
. None None O

Nucleotide None None O
excision None None O
repair None None O
comprises None None O
two None None O
subpathways None None O
: None None O
transcription-coupled None None O
and None None O
global None None O
genome None None O
repair None None O
. None None O

In None None O
this None None O
study None None O
the None None O
immunologic None None O
consequences None None O
of None None O
specific None None O
nucleotide None None O
excision None None O
repair None None O
defects None None O
in None None O
three None None O
mouse None None O
models None None O
, None None O
XPA None None O
, None None O
XPC None None O
, None None O
and None None O
CSB None None O
mutant None None O
mice None None O
, None None O
were None None O
investigated None None O
. None None O

XPA None None O
mice None None O
carry None None O
a None None O
total None None O
nucleotide None None O
excision None None O
repair None None O
defect None None O
, None None O
whereas None None O
XPC None None O
and None None O
CSB None None O
mice None None O
only None None O
lack None None O
global None None O
genome None None O
and None None O
transcription-coupled None None O
nucleotide None None O
excision None None O
repair None None O
, None None O
respectively None None O
. None None O

Our None None O
data None None O
demonstrate None None O
that None None O
cellular None None O
immune None None O
parameters None None O
in None None O
XPA None None O
, None None O
XPC None None O
, None None O
and None None O
CSB None None O
mice None None O
are None None O
normal None None O
compared None None O
with None None O
their None None O
wild-type None None O
( None None O
control None None O
) None None O
littermates None None O
. None None O

This None None O
may None None O
indicate None None O
that None None O
the None None O
reported None None O
altered None None O
cellular None None O
responses None None O
in None None O
xeroderma None None O
pigmentosum None None O
patients None None O
are None None O
not None None O
constitutive None None O
but None None O
could None None O
be None None O
due None None O
to None None O
external None None O
factors None None O
, None None O
such None None O
as None None O
ultraviolet None None O
B None None O
. None None O

Upon None None O
exposure None None O
to None None O
ultraviolet None None O
B None None O
, None None O
only None None O
XPA None None O
mice None None O
are None None O
very None None O
sensitive None None O
to None None O
ultraviolet-B-induced None None O
inhibition None None O
of None None O
Th1-mediated None None O
contact None None O
hypersensitivity None None O
responses None None O
and None None O
interferon-gamma None None I-protein
production None None O
in None None O
skin None None O
draining None None O
lymph None None O
nodes None None O
. None None O

Lipopolysaccharide-stimulated None None O
tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
alpha None None I-protein
and None None O
interleukin-10 None None I-protein
production None None O
are None None O
significantly None None O
augmented None None O
in None None O
both None None O
XPA None None O
and None None O
CSB None None O
mice None None O
after None None O
ultraviolet None None O
B None None O
exposure None None O
. None None O

Lymph None None O
node None None O
cell None None O
numbers None None O
were None None O
increased None None O
very None None O
significantly None None O
in None None O
XPA None None O
, None None O
mildly None None O
increased None None O
in None None O
CSB None None O
, None None O
and None None O
not None None O
in None None O
XPC None None O
mice None None O
. None None O

In None None O
general None None O
XPC None None O
mice None None O
do None None O
not None None O
exhibit None None O
any None None O
indication None None O
of None None O
enhanced None None O
ultraviolet None None O
B None None O
susceptibility None None O
with None None O
regard None None O
to None None O
the None None O
immune None None O
parameters None None O
analyzed None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
both None None O
global None None O
genome None None O
repair None None O
and None None O
transcription-coupled None None O
repair None None O
are None None O
needed None None O
to None None O
prevent None None O
immunomodulation None None O
by None None O
ultraviolet None None O
B None None O
, None None O
whereas None None O
transcription-coupled None None O
repair None None O
is None None O
the None None O
major None None O
DNA None None O
repair None None O
subpathway None None O
of None None O
nucleotide None None O
excision None None O
repair None None O
that None None O
prevents None None O
the None None O
acute None None O
ultraviolet-B-induced None None O
effects None None O
such None None O
as None None O
erythema None None O
. None None O

Biomechanical None None O
strain None None O
induces None None O
class None None O
a None None O
scavenger None None I-protein
receptor None None I-protein
expression None None O
in None None O
human None None I-cell_type
monocyte/macrophages None None I-cell_type
and None None O
THP-1 None None I-cell_type
cells None None I-cell_type
: None None O
a None None O
potential None None O
mechanism None None O
of None None O
increased None None O
atherosclerosis None None O
in None None O
hypertension None None O
. None None O

BACKGROUND None None O
: None None O
Although None None O
hypertension None None O
is None None O
an None None O
important None None O
risk None None O
factor None None O
for None None O
the None None O
development None None O
of None None O
atherosclerosis None None O
, None None O
the None None O
mechanisms None None O
for None None O
this None None O
interaction None None O
are None None O
incompletely None None O
described None None O
. None None O

Previous None None O
studies None None O
have None None O
suggested None None O
that None None O
biomechanical None None O
strain None None O
regulates None None O
macrophage None None O
phenotype None None O
. None None O

We None None O
tested None None O
the None None O
hypothesis None None O
that None None O
biomechanical None None O
strain None None O
can None None O
induce None None O
expression None None O
of None None O
the None None O
class None None I-protein
A None None I-protein
scavenger None None I-protein
receptor None None I-protein
( None None O
SRA None None I-protein
) None None O
, None None O
an None None O
important None None O
lipoprotein None None I-protein
receptor None None I-protein
in None None O
atherogenesis None None O
. None None O

METHODS None None O
AND None None O
RESULTS None None O
: None None O
Human None None I-cell_type
monocyte/macrophages None None I-cell_type
or None None O
THP-1 None None I-cell_type
cells None None I-cell_type
were None None O
cultured None None O
in None None O
a None None O
device None None O
that None None O
imposes None None O
uniform None None O
biaxial None None O
cyclic None None O
1-Hz None None O
strains None None O
of None None O
0 None None O
% None None O
, None None O
1 None None O
% None None O
, None None O
2 None None O
% None None O
, None None O
or None None O
3 None None O
% None None O
, None None O
and None None O
SRA None None I-protein
expression None None O
was None None O
analyzed None None O
. None None O

Mechanical None None O
strains None None O
induced None None O
SRA None None I-RNA
mRNA None None I-RNA
( None None O
3.5+/-0.6-fold None None O
at None None O
3 None None O
% None None O
strain None None O
for None None O
48 None None O
hours None None O
, None None O
P None None O
< None None O
0.01 None None O
) None None O
and None None O
SRA None None I-protein
protein None None I-protein
in None None O
THP-1 None None I-cell_type
cells None None I-cell_type
in None None O
an None None O
amplitude-dependent None None O
manner None None O
. None None O

This None None O
induction None None O
was None None O
accompanied None None O
by None None O
augmented None None O
expression None None O
of None None O
the None None O
class None None I-protein
B None None I-protein
scavenger None None I-protein
receptor None None I-protein
CD36 None None I-protein
( None None O
2.8+/-0.3-fold None None O
, None None O
P None None O
< None None O
0.001 None None O
) None None O
but None None O
not None None O
by None None O
increased None None O
peroxisome None None I-protein
proliferator-activated None None I-protein
receptor-gamma None None I-protein
expression None None O
. None None O

To None None O
evaluate None None O
this None None O
effect None None O
in None None O
vivo None None O
, None None O
apolipoprotein None None O
E None None O
( None None O
-/- None None O
) None None O
mice None None O
were None None O
randomly None None O
assigned None None O
to None None O
receive None None O
standard None None O
chow None None O
, None None O
a None None O
high-cholesterol None None O
diet None None O
, None None O
or None None O
a None None O
high-cholesterol None None O
diet None None O
with None None O
hypertension None None O
induced None None O
by None None O
angiotensin None None O
II None None O
infusion None None O
for None None O
8 None None O
weeks None None O
. None None O

Immunohistochemistry None None O
revealed None None O
that None None O
among None None O
macrophages None None I-cell_type
in None None O
atherosclerotic None None O
lesions None None O
of None None O
the None None O
aorta None None O
, None None O
the None None O
proportion None None O
of None None O
macrophages None None I-cell_type
with None None O
SRA None None I-protein
expression None None O
was None None O
highest None None O
in None None O
hypertensive None None O
animals None None O
on None None O
a None None O
high-cholesterol None None O
diet None None O
( None None O
43.9+/-0.7 None None O
% None None O
, None None O
versus None None O
12.0+/-2.0 None None O
% None None O
for None None O
normotensive None None O
animals None None O
on None None O
a None None O
high-cholesterol None None O
diet None None O
and None None O
4.7+/-4.7 None None O
% None None O
for None None O
animals None None O
on None None O
standard None None O
chow None None O
; None None O
P None None O
< None None O
0.001 None None O
) None None O
. None None O

CONCLUSIONS None None O
: None None O
Biomechanical None None O
strain None None O
induces None None O
SRA None None I-protein
expression None None O
by None None O
monocyte/macrophages None None I-cell_type
, None None O
suggesting None None O
a None None O
novel None None O
mechanism None None O
for None None O
promotion None None O
of None None O
atherosclerosis None None O
in None None O
hypertensive None None O
patients None None O
. None None O

High None None O
glucose None None O
induces None None O
MCP-1 None None O
expression None None O
partly None None O
via None None O
tyrosine None None O
kinase-AP-1 None None O
pathway None None O
in None None O
peritoneal None None I-cell_type
mesothelial None None I-cell_type
cells None None I-cell_type
. None None O

BACKGROUND None None O
: None None O
High None None O
glucose None None O
in None None O
peritoneal None None O
dialysis None None O
solutions None None O
has None None O
been None None O
implicated None None O
in None None O
the None None O
pathogenesis None None O
of None None O
peritoneal None None O
fibrosis None None O
in None None O
chronic None None O
ambulatory None None O
peritoneal None None O
dialysis None None O
( None None O
CAPD None None O
) None None O
patients None None O
. None None O

However None None O
, None None O
the None None O
mechanisms None None O
are None None O
not None None O
very None None O
clear None None O
. None None O

Peritoneal None None I-cell_type
macrophages None None I-cell_type
seem None None O
to None None O
participate None None O
in None None O
the None None O
process None None O
of None None O
peritoneal None None O
fibrosis None None O
and None None O
monocyte None None I-protein
chemoattractant None None I-protein
protein-1 None None I-protein
( None None O
MCP-1 None None I-protein
) None None O
plays None None O
a None None O
key None None O
role None None O
in None None O
the None None O
recruitment None None O
of None None O
monocytes None None I-cell_type
toward None None O
the None None O
peritoneal None None O
cavity None None O
. None None O

However None None O
, None None O
little None None O
is None None O
known None None O
about None None O
the None None O
effect None None O
of None None O
high None None O
glucose None None O
on None None O
MCP-1 None None I-protein
expression None None O
and None None O
its None None O
signal None None O
transduction None None O
pathway None None O
in None None O
human None None I-cell_type
peritoneal None None I-cell_type
mesothelial None None I-cell_type
cells None None I-cell_type
. None None O

METHODS None None O
: None None O
Mesothelial None None I-cell_type
cells None None I-cell_type
were None None O
cultured None None O
with None None O
glucose None None O
( None None O
5 None None O
to None None O
100 None None O
mmol/L None None O
) None None O
or None None O
mannitol None None O
chronically None None O
for None None O
up None None O
to None None O
seven None None O
days None None O
. None None O

MCP-1 None None I-protein
expression None None O
of None None O
mRNA None None O
and None None O
protein None None O
was None None O
measured None None O
by None None O
Northern None None O
blot None None O
analysis None None O
and None None O
enzyme-linked None None O
immunosorbent None None O
assay None None O
( None None O
ELISA None None O
) None None O
. None None O

Chemotactic None None O
activity None None O
of None None O
high-glucose-conditioned None None O
culture None None O
supernatant None None O
was None None O
measured None None O
by None None O
chemotactic None None O
assay None None O
. None None O

To None None O
examine None None O
the None None O
roles None None O
of None None O
the None None O
transcription None None I-protein
factors None None I-protein
activator None None B-protein
protein-1 None None I-protein
( None None O
AP-1 None None I-protein
) None None O
and None None O
nuclear None None I-protein
factor-kappaB None None I-protein
( None None O
NF-kappaB None None I-protein
) None None O
, None None O
electrophoretic None None O
mobility None None O
shift None None O
assay None None O
( None None O
EMSA None None O
) None None O
was None None O
performed None None O
. None None O

RESULTS None None O
: None None O
Glucose None None O
induced None None O
MCP-1 None None I-RNA
mRNA None None I-RNA
expression None None O
in None None O
a None None O
time- None None O
and None None O
dose-dependent None None O
manner None None O
. None None O

MCP-1 None None I-protein
protein None None I-protein
in None None O
cell None None O
culture None None O
supernant None None O
was None None O
also None None O
increased None None O
. None None O

Equivalent None None O
concentrations None None O
of None None O
mannitol None None O
had None None O
no None None O
significant None None O
effect None None O
. None None O

High-glucose-conditioned None None O
supernatant None None O
possessed None None O
an None None O
increased None None O
chemotactic None None O
activity None None O
for None None O
monocytes None None I-cell_type
, None None O
which None None O
was None None O
neutralized None None O
by None None O
anti-MCP-1 None None I-protein
antibody None None I-protein
. None None O

EMSA None None O
revealed None None O
that None None O
glucose None None O
increased None None O
the None None O
AP-1 None None I-protein
binding None None O
activity None None O
in None None O
a None None O
time- None None O
and None None O
dose-dependent None None O
manner None None O
, None None O
but None None O
not None None O
NF-kappaB None None I-protein
. None None O

Curcumin None None O
, None None O
an None None O
inhibitor None None O
of None None O
AP-1 None None I-protein
, None None O
dose-dependently None None O
suppressed None None O
the None None O
induction None None O
of None None O
MCP-1 None None I-RNA
mRNA None None I-RNA
by None None O
high None None O
glucose None None O
. None None O

Tyrosine None None O
kinase None None O
inhibitors None None O
such None None O
as None None O
genistein None None O
( None None O
12.5 None None O
to None None O
50 None None O
micromol/L None None O
) None None O
and None None O
herbimycin None None O
A None None O
( None None O
0.1 None None O
to None None O
1 None None O
micromol/L None None O
) None None O
inhibited None None O
the None None O
high-glucose-induced None None O
MCP-1 None None I-RNA
mRNA None None I-RNA
expression None None O
in None None O
a None None O
dose-dependent None None O
manner None None O
, None None O
and None None O
also None None O
suppressed None None O
the None None O
high-glucose-induced None None O
AP-1 None None I-protein
binding None None O
activity None None O
. None None O

CONCLUSIONS None None O
: None None O
: None None O
High None None O
glucose None None O
induced None None O
mesothelial None None O
MCP-1 None None I-protein
expression None None O
partly None None O
via None None O
the None None O
tyrosine None None O
kinase- None None O
AP-1 None None I-protein
pathway None None O
. None None O

Signal None None O
thresholds None None O
and None None O
modular None None O
synergy None None O
during None None O
expression None None O
of None None O
costimulatory None None O
molecules None None O
in None None O
B None None I-cell_type
lymphocytes None None I-cell_type
. None None O

We None None O
analyzed None None O
intracellular None None O
pathways None None O
modulating None None O
surface None None O
densities None None O
of None None O
CD80 None None I-protein
and None None O
CD86 None None I-protein
in None None O
B None None I-cell_type
cells None None I-cell_type
activated None None O
through None None O
ligation None None O
of None None O
the None None O
Ag None None I-protein
receptor None None I-protein
, None None O
and None None O
the None None O
adhesion None None I-protein
molecule None None I-protein
CD54 None None B-protein
. None None O

Whereas None None O
B None None I-protein
cell None None I-protein
Ag None None I-protein
receptor None None I-protein
( None None O
BCR None None I-protein
) None None O
cross-linking None None O
alone None None O
stimulated None None O
increased None None O
expression None None O
of None None O
CD86 None None I-protein
, None None O
up-regulation None None O
of None None O
CD80 None None I-protein
required None None O
dual None None O
stimulation None None O
with None None O
anti-IgM None None I-protein
and None None O
anti-CD54 None None I-protein
. None None O

The None None O
principal None None O
downstream None None O
component None None O
contributed None None O
by None None O
BCR None None I-protein
signaling None None O
, None None O
toward None None O
both None None O
CD80 None None I-protein
and None None O
CD86 None None I-protein
induction None None O
, None None O
was None None O
the None None O
elevated None None O
concentration None None O
of None None O
free None None O
cytoplasmic None None O
Ca None None O
( None None O
2+ None None O
) None None O
, None None O
recruited None None O
by None None O
way None None O
of None None O
capacitative None None O
influx None None O
. None None O

This None None O
alone None None O
was None None O
sufficient None None O
to None None O
generate None None O
an None None O
increase None None O
in None None O
CD86 None None I-protein
levels None None O
. None None O

However None None O
, None None O
CD80 None None I-protein
enhancement None None O
required None None O
the None None O
concerted None None O
action None None O
of None None O
both None None O
intracellular None None O
Ca None None O
( None None O
2+ None None O
) None None O
concentration None None O
and None None O
CD54-initiated None None O
pathways None None O
. None None O

The None None O
nexus None None O
between None None O
anti-IgM None None O
and None None O
anti-CD54 None None O
stimulation None None O
, None None O
in None None O
the None None O
context None None O
of None None O
CD80 None None I-protein
regulation None None O
, None None O
was None None O
identified None None O
to None None O
involve None None O
a None None O
self-propagating None None O
process None None O
of None None O
sequential None None O
synergy None None O
. None None O

The None None O
first None None O
step None None O
involved None None O
amplified None None O
accumulation None None O
of None None O
intracellular None None O
cAMP None None O
, None None O
as None None O
a None None O
result None None O
of None None O
cross-talk None None O
between None None O
BCR None None I-protein
-mobilized None None O
Ca None None O
( None None O
2+ None None O
) None None O
and None None O
CD54-derived None None O
signals None None O
. None None O

This None None O
then None None O
facilitated None None O
a None None O
second None None O
synergistic None None O
interaction None None O
between None None O
Ca None None O
( None None O
2+ None None O
) None None O
and None None O
cAMP None None O
, None None O
culminating None None O
in None None O
CD80 None None I-protein
expression None None O
. None None O

Our None None O
findings None None O
of None None O
distinct None None O
signal None None O
transducer None None O
requirements None None O
, None None O
with None None O
the None None O
added None None O
consequences None None O
of None None O
cross-talk None None O
, None None O
offers None None O
an None None O
explanation None None O
for None None O
variable None None O
modulation None None O
of None None O
costimulatory None None O
molecule None None O
expression None None O
in None None O
response None None O
to None None O
diverse None None O
physiological None None O
stimuli None None O
. None None O

Importantly None None O
, None None O
these None None O
results None None O
also None None O
reveal None None O
how None None O
concentration None None O
threshold None None O
barriers None None O
for None None O
recruitment None None O
of None None O
individual None None O
second None None O
messengers None None O
can None None O
be None None O
overcome None None O
by None None O
constructive None None O
convergence None None O
of None None O
signaling None None O
modules None None O
. None None O

The None None O
role None None O
of None None O
Epstein-Barr None None O
virus None None O
in None None O
neoplastic None None O
transformation None None O
. None None O

In None None O
this None None O
review None None O
, None None O
we None None O
focus None None O
on None None O
new None None O
data None None O
from None None O
basic None None O
, None None O
translational None None O
and None None O
clinical None None O
research None None O
relating None None O
to None None O
the None None O
Epstein-Barr None None O
virus None None O
( None None O
EBV None None O
) None None O
. None None O

Beside None None O
its None None O
well-known None None O
tropism None None O
for None None O
B None None I-cell_type
lymphocytes None None I-cell_type
and None None O
epithelial None None I-cell_type
cells None None I-cell_type
, None None O
EBV None None O
also None None O
infects None None O
T None None I-cell_type
lymphocytes None None I-cell_type
, None None O
monocytes None None I-cell_type
and None None O
granulocytes None None I-cell_type
. None None O

After None None O
primary None None O
infection None None O
, None None O
EBV None None O
persists None None O
throughout None None O
the None None O
life None None O
span None None O
in None None O
resting None None I-cell_type
memory None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
, None None O
from None None O
where None None O
it None None O
is None None O
reactivated None None O
upon None None O
breakdown None None O
of None None O
cellular None None O
immunity None None O
. None None O

In None None O
the None None O
process None None O
of None None O
neoplastic None None O
transformation None None O
, None None O
the None None O
EBV-encoded None None I-DNA
latent None None I-DNA
membrane None None I-DNA
protein None None I-DNA
1 None None I-DNA
( None None I-DNA
LMP1 None None I-DNA
) None None I-DNA
oncogene None None I-DNA
represents None None O
the None None O
major None None O
driving None None O
force None None O
. None None O

LMP1 None None I-protein
acts None None O
like None None O
a None None O
constitutively None None I-protein
activated None None I-protein
receptor None None I-protein
of None None O
the None None O
tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
receptor None None I-protein
family None None I-protein
and None None O
allows None None O
the None None O
amplification None None O
or None None O
bypassing None None O
of None None O
physiological None None O
regulatory None None O
signals None None O
through None None O
direct None None O
and None None O
indirect None None O
interactions None None O
with None None O
proteins None None O
of None None O
the None None O
tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
receptor-associated None None I-protein
factor None None I-protein
( None None I-protein
TRAF None None I-protein
) None None I-protein
family None None I-protein
. None None O

TRAF2 None None I-protein
-mediated None None O
NF-kappaB None None I-protein
activation None None O
, None None O
AP-1 None None I-protein
induction None None O
and None None O
JAK3 None None I-protein
/ None None O
STAT None None I-protein
activation None None O
may None None O
result None None O
in None None O
sustained None None O
proliferation None None O
leading None None O
to None None O
lymphoma None None I-cell_line
. None None O

The None None O
ability None None O
of None None O
LMP1 None None I-protein
to None None O
suppress None None O
germinal None None O
center None None O
formation None None O
and None None O
its None None O
capacity None None O
to None None O
mediate None None O
its None None O
own None None O
transcriptional None None O
activation None None O
shed None None O
new None None O
light None None O
on None None O
the None None O
pathogenesis None None O
of None None O
EBV-associated None None O
latency None None O
type None None O
II None None O
lymphoproliferations None None O
like None None O
Hodgkin None None O
's None None O
disease None None O
and None None O
angioimmunoblastic None None O
lymphadenopathy None None O
. None None O

The None None O
carboxy None None I-protein
terminus None None I-protein
of None None O
LMP1 None None I-protein
is None None O
also None None O
a None None O
reliable None None O
marker None None O
for None None O
individual None None O
EBV None None O
strain None None O
identification None None O
and None None O
thus None None O
offers None None O
new None None O
possibilities None None O
in None None O
tracing None None O
the None None O
molecular None None O
events None None O
leading None None O
to None None O
posttransplant None None O
lymphoproliferative None None O
disorders None None O
( None None O
PTLDs None None O
) None None O
. None None O

Cytotoxic None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
directed None None O
against None None O
well-characterized None None O
epitopes None None O
of None None O
EBV None None I-DNA
latency None None I-DNA
genes None None I-DNA
represent None None O
an None None O
already None None O
successful None None O
and None None O
promising None None O
therapeutic None None O
approach None None O
to None None O
EBV-associated None None I-cell_line
lymphomas None None I-cell_line
, None None O
in None None O
particular None None O
PTLDs None None O

Interferon-alpha None None I-protein
drives None None O
T None None O
cell-mediated None None O
immunopathology None None O
in None None O
the None None O
intestine None None O
. None None O

The None None O
ability None None O
of None None O
interferon None None I-protein
( None None I-protein
IFN None None I-protein
) None None I-protein
-alpha None None I-protein
to None None O
induce None None O
autoimmunity None None O
and None None O
exacerbate None None O
Th1 None None O
diseases None None O
is None None O
well None None O
known None None O
. None None O

We None None O
have None None O
recently None None O
described None None O
enhanced None None O
expression None None O
of None None O
IFN-alpha None None I-protein
in None None O
the None None O
mucosa None None O
of None None O
patients None None O
with None None O
celiac None None O
disease None None O
( None None O
CD None None O
) None None O
, None None O
a None None O
gluten-sensitive None None O
Th1-mediated None None O
enteropathy None None O
, None None O
characterized None None O
by None None O
villous None None O
atrophy None None O
and None None O
crypt None None O
cell None None O
hyperplasia None None O
. None None O

Previous None None O
studies None None O
from None None O
this None None O
laboratory None None O
have None None O
shown None None O
that None None O
T None None I-cell_type
cell None None I-cell_type
activation None None O
in None None O
explant None None O
cultures None None O
of None None O
human None None O
fetal None None O
gut None None O
can None None O
also None None O
result None None O
in None None O
villous None None O
atrophy None None O
and None None O
crypt None None O
cell None None O
hyperplasia None None O
. None None O

We None None O
have None None O
, None None O
therefore None None O
, None None O
examined None None O
changes None None O
that None None O
take None None O
place None None O
in None None O
explant None None O
cultures None None O
of None None O
human None None O
fetal None None O
gut None None O
after None None O
activation None None O
of None None O
T None None I-cell_type
cells None None I-cell_type
with None None O
anti-CD3 None None I-protein
and/or None None O
IFN-alpha None None I-protein
. None None O

We None None O
show None None O
that None None O
activation None None O
of None None O
T None None I-cell_type
cells None None I-cell_type
with None None O
anti-CD3 None None I-protein
alone None None O
elicits None None O
a None None O
small None None O
IFN-gamma None None I-protein
and None None O
TNF-alpha None None I-protein
response None None O
with None None O
no None None O
tissue None None O
injury None None O
. None None O

Similarly None None O
, None None O
no None None O
changes None None O
are None None O
seen None None O
in None None O
explants None None O
cultured None None O
with None None O
IFN-alpha None None I-protein
alone None None O
. None None O

However None None O
, None None O
addition None None O
of None None O
IFN-alpha None None I-protein
with None None O
anti-CD3 None None I-protein
results None None O
in None None O
enhanced None None O
Th1 None None O
response None None O
and None None O
crypt None None O
cell None None O
hyperplasia None None O
. None None O

This None None O
is None None O
associated None None O
with None None O
enhanced None None O
phosphorylation None None O
of None None O
STAT1 None None I-protein
, None None O
STAT3 None None I-protein
, None None O
and None None O
Fyn None None I-protein
, None None I-protein
a None None I-protein
Src None None I-protein
homology None None I-protein
tyrosine None None I-protein
kinase None None I-protein
, None None O
which None None O
interacts None None O
with None None O
both None None O
TCR None None O
and None None O
IFN-alpha None None O
signal None None O
components None None O
. None None O

Together None None O
these None None O
data None None O
indicate None None O
that None None O
IFN-alpha None None I-protein
can None None O
facilitate None None O
activation None None O
of None None O
Th1-reactive None None I-cell_type
cells None None I-cell_type
in None None O
the None None O
gut None None O
and None None O
drive None None O
immunopathology None None O
. None None O

Suppression None None O
of None None O
tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
alpha None None I-protein
production None None O
by None None O
cAMP None None O
in None None O
human None None I-cell_type
monocytes None None I-cell_type
: None None O
dissociation None None O
with None None O
mRNA None None O
level None None O
and None None O
independent None None O
of None None O
interleukin-10 None None I-protein
. None None O

BACKGROUND None None O
: None None O
Elevation None None O
of None None O
cellular None None O
cAMP None None O
inhibits None None O
lipopolysaccharide None None O
( None None O
LPS None None O
) None None O
-stimulated None None O
tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
alpha None None I-protein
( None None O
TNF-alpha None None I-protein
) None None O
production None None O
and None None O
increases None None O
the None None O
expression None None O
of None None O
interleukin None None I-protein
( None None I-protein
IL None None I-protein
) None None I-protein
-10 None None I-protein
in None None O
mononuclear None None I-cell_type
cells None None I-cell_type
. None None O

TNF-alpha None None I-DNA
gene None None I-DNA
expression None None O
obligates None None O
activation None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
nuclear None None B-protein
factor None None I-protein
kappaB None None I-protein
( None None O
NF-kappaB None None I-protein
) None None O
. None None O

Exogenous None None O
IL-10 None None I-protein
inhibits None None O
NF-kappaB None None I-protein
in None None O
monocytes None None I-cell_type
and None None O
thus None None O
attenuates None None O
TNF-alpha None None I-protein
production None None O
. None None O

We None None O
examined None None O
the None None O
role None None O
of None None O
endogenous None None O
IL-10 None None I-protein
in None None O
the None None O
regulation None None O
of None None O
NF-kappaB None None I-protein
activation None None O
and None None O
TNF-alpha None None I-protein
production None None O
in None None O
human None None I-cell_type
monocytes None None I-cell_type
by None None O
cAMP None None O
. None None O

METHODS None None O
: None None O
Human None None I-cell_type
monocytes None None I-cell_type
were None None O
stimulated None None O
with None None O
Escherichia None None O
coli None None O
LPS None None O
( None None O
100 None None O
ng/ml None None O
) None None O
with None None O
and None None O
without None None O
forskolin None None O
( None None O
FSK None None O
, None None O
50 None None O
microM None None O
) None None O
or None None O
dibutyryl None None O
cyclic None None O
AMP None None O
( None None O
dbcAMP None None O
, None None O
100 None None O
microM None None O
) None None O
. None None O

Cytokine None None I-protein
( None None O
TNF-alpha None None I-protein
and None None O
IL-10 None None I-protein
) None None O
release None None O
was None None O
measured None None O
by None None O
immunoassay None None O
. None None O

TNF-alpha None None I-RNA
mRNA None None I-RNA
was None None O
measured None None O
by None None O
reverse None None O
transcription None None O
polymerase None None O
chain None None O
reaction None None O
, None None O
and None None O
NF-kappaB None None I-protein
DNA None None O
binding None None O
activity None None O
was None None O
assessed None None O
by None None O
gel None None O
mobility None None O
shift None None O
assay None None O
. None None O

RESULTS None None O
: None None O
cAMP-elevating None None O
agents None None O
inhibited None None O
LPS-stimulated None None O
TNF-alpha None None I-protein
release None None O
( None None O
0.77 None None O
+/- None None O
0.13 None None O
ng/10 None None O
( None None O
6 None None O
) None None O
cells None None O
in None None O
LPS None None O
+ None None O
dbcAMP None None O
and None None O
0.68 None None O
+/- None None O
0.19 None None O
ng/10 None None O
( None None O
6 None None O
) None None O
cells None None O
in None None O
LPS None None O
+ None None O
FSK None None O
, None None O
both None None O
P None None O
< None None O
0.05 None None O
vs None None O
1.61 None None O
+/- None None O
0.34 None None O
ng/10 None None O
( None None O
6 None None O
) None None O
cells None None O
in None None O
LPS None None O
alone None None O
) None None O
. None None O

Conversely None None O
, None None O
cAMP None None O
enhanced None None O
LPS-stimulated None None O
IL-10 None None I-protein
release None None O
( None None O
100 None None O
+/- None None O
21.5 None None O
pg/10 None None O
( None None O
6 None None O
) None None O
cells None None O
in None None O
LPS None None O
+ None None O
dbcAMP None None O
and None None O
110 None None O
+/- None None O
25.2 None None O
pg/10 None None O
( None None O
6 None None O
) None None O
cells None None O
in None None O
LPS None None O
+ None None O
FSK None None O
, None None O
both None None O
P None None O
< None None O
0.05 None None O
vs None None O
53.3 None None O
+/- None None O
12.8 None None O
pg/10 None None O
( None None O
6 None None O
) None None O
cells None None O
in None None O
LPS None None O
alone None None O
) None None O
. None None O

Neither None None O
TNF-alpha None None I-RNA
mRNA None None I-RNA
expression None None O
nor None None O
NF-kappaB None None I-protein
activation None None O
stimulated None None O
by None None O
LPS None None O
was None None O
inhibited None None O
by None None O
the None None O
cAMP-elevating None None O
agents None None O
. None None O

Neutralization None None O
of None None O
IL-10 None None I-protein
with None None O
a None None O
specific None None O
antibody None None I-protein
did None None O
not None None O
attenuate None None O
the None None O
effect None None O
of None None O
cAMP-elevating None None O
agents None None O
on None None O
TNF-alpha None None I-protein
production None None O
. None None O

CONCLUSION None None O
: None None O
The None None O
results None None O
indicate None None O
that None None O
cAMP None None O
inhibits None None O
LPS-stimulated None None O
TNF-alpha None None I-protein
production None None O
through None None O
a None None O
posttranscriptional None None O
mechanism None None O
that None None O
is None None O
independent None None O
of None None O
endogenous None None O
IL-10 None None I-protein
. None None O

Copyright None None O
2001 None None O
Academic None None O
Press None None O
. None None O

Activation None None O
of None None O
the None None O
p21 None None I-DNA
( None None I-DNA
CIP1/WAF1 None None I-DNA
) None None I-DNA
promoter None None I-DNA
by None None O
bone None None I-protein
morphogenetic None None I-protein
protein-2 None None I-protein
in None None O
mouse None None O
B None None I-cell_line
lineage None None I-cell_line
cells None None I-cell_line
. None None O

BMPs None None I-protein
exert None None O
a None None O
negative None None O
growth None None O
effect None None O
on None None O
various None None O
types None None O
of None None O
cells None None O
. None None O

We None None O
have None None O
previously None None O
reported None None O
that None None O
BMP-2 None None I-protein
inhibited None None O
the None None O
growth None None O
of None None O
HS-72 None None I-cell_line
mouse None None I-cell_line
hybridoma None None I-cell_line
cells None None I-cell_line
by None None O
inducing None None O
p21 None None O
( None None O
CIP1/WAF1 None None O
) None None O
expression None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
demonstrated None None O
that None None O
BMP-2 None None I-protein
activated None None O
the None None O
mouse None None O
p21 None None I-DNA
( None None I-DNA
CIP1/WAF1 None None I-DNA
) None None I-DNA
promoter None None I-DNA
in None None O
HS-72 None None I-cell_line
cells None None I-cell_line
, None None O
and None None O
that None None O
a None None O
29-base None None I-DNA
pair None None I-DNA
( None None I-DNA
b None None I-DNA
) None None I-DNA
region None None I-DNA
of None None O
the None None O
promoter None None O
( None None O
-1928/-1900 None None O
relative None None O
to None None O
the None None O
TATA None None I-DNA
box None None I-DNA
) None None O
, None None O
conserved None None O
between None None O
mice None None O
and None None O
humans None None O
, None None O
was None None O
responsive None None O
to None None O
BMP-2 None None I-protein
as None None O
well None None O
as None None O
expression None None O
of None None O
Smad1 None None I-protein
, None None O
Smad4 None None I-protein
, None None O
and None None O
constitutively None None O
active None None O
mutants None None O
of None None O
BMP None None I-protein
type None None I-protein
I None None I-protein
receptors None None I-protein
. None None O

Furthermore None None O
, None None O
an None None O
oligonucleotide None None O
containing None None O
the None None O
29-b None None I-DNA
region None None I-DNA
was None None O
found None None O
to None None O
be None None O
associated None None O
with None None O
Smad4 None None I-protein
and None None O
phosphorylated None None I-protein
Smad1 None None I-protein
in None None O
the None None O
nuclear None None O
extract None None O
of None None O
BMP-2 None None I-protein
-stimulated None None O
HS-72 None None I-cell_line
cells None None I-cell_line
. None None O

These None None O
results None None O
suggested None None O
that None None O
BMP-2 None None I-protein
might None None O
activate None None O
p21 None None O
( None None O
CIP1/WAF1 None None O
) None None O
transcription None None O
by None None O
inducing None None O
a None None O
binding None None O
of None None O
Smad4 None None I-protein
and None None O
Smad1 None None I-protein
to None None O
the None None O
29-b None None I-DNA
region None None I-DNA
in None None O
HS-72 None None I-cell_line
cells None None I-cell_line
. None None O

Dendritic None None I-cell_type
cell None None I-cell_type
development None None O
from None None O
common None None O
myeloid None None I-cell_type
progenitors None None I-cell_type
. None None O

Dendritic None None I-cell_type
cells None None I-cell_type
( None None O
DCs None None I-cell_type
) None None O
are None None O
professional None None O
antigen-presenting None None I-cell_type
cells None None I-cell_type
which None None O
both None None O
initiate None None O
adaptive None None O
immune None None O
responses None None O
and None None O
control None None O
tolerance None None O
to None None O
self-antigens None None I-protein
. None None O

It None None O
has None None O
been None None O
suggested None None O
that None None O
these None None O
different None None O
effects None None O
on None None O
responder None None O
cells None None O
depend None None O
on None None O
subsets None None O
of None None O
DCs None None I-cell_type
arising None None O
from None None O
either None None O
myeloid None None O
or None None O
lymphoid None None O
hematopoietic None None O
origins None None O
. None None O

In None None O
this None None O
model None None O
, None None O
CD8 None None I-cell_type
alpha+ None None I-cell_type
Mac-1- None None I-cell_type
DCs None None I-cell_type
are None None O
supposed None None O
to None None O
be None None O
of None None O
lymphoid None None O
while None None O
CD8 None None I-cell_type
alpha- None None I-cell_type
Mac-1+ None None I-cell_type
DCs None None I-cell_type
are None None O
supposed None None O
to None None O
be None None O
of None None O
myeloid None None O
origin None None O
. None None O

Here None None O
we None None O
summarize None None O
our None None O
findings None None O
that None None O
both None None O
CD8 None None I-cell_type
alpha+ None None I-cell_type
and None None I-cell_type
CD8 None None I-cell_type
alpha- None None I-cell_type
DCs None None I-cell_type
can None None O
arise None None O
from None None O
clonogenic None None I-cell_type
common None None I-cell_type
myeloid None None I-cell_type
progenitors None None I-cell_type
( None None O
CMPs None None I-cell_type
) None None O
in None None O
both None None O
thymus None None O
and None None O
spleen None None O
. None None O

Therefore None None O
CD8 None None I-protein
alpha None None I-protein
expression None None O
DCs None None I-cell_type
does None None O
not None None O
indicate None None O
a None None O
lymphoid None None O
origin None None O
and None None O
differences None None O
among None None O
CD8 None None I-cell_type
alpha+ None None I-cell_type
and None None I-cell_type
CD8 None None I-cell_type
alpha- None None I-cell_type
DCs None None I-cell_type
might None None O
rather None None O
reflect None None O
maturation None None O
status None None O
than None None O
ontogeny None None O
. None None O

On None None O
the None None O
basis None None O
of None None O
transplantation None None O
studies None None O
, None None O
it None None O
seems None None O
likely None None O
that None None O
most None None O
of None None O
the None None O
DCs None None I-cell_type
in None None O
secondary None None O
lymphoid None None O
organs None None O
and None None O
a None None O
substantial None None O
fraction None None O
of None None O
thymic None None I-cell_type
DCs None None I-cell_type
are None None O
myeloid-derived None None O
. None None O

Macrophage None None O
stimulation None None O
with None None O
Murabutide None None O
, None None O
an None None O
HIV-suppressive None None O
muramyl None None O
peptide None None O
derivative None None O
, None None O
selectively None None O
activates None None O
extracellular None None I-protein
signal-regulated None None I-protein
kinases None None I-protein
1 None None I-protein
and None None I-protein
2 None None I-protein
, None None O
C/EBPbeta None None I-protein
and None None O
STAT1 None None I-protein
: None None O
role None None O
of None None O
CD14 None None I-protein
and None None O
Toll-like None None I-protein
receptors None None I-protein
2 None None I-protein
and None None I-protein
4 None None I-protein
. None None O

The None None O
smallest None None O
unit None None O
of None None O
bacterial None None O
peptidoglycans None None O
known None None O
to None None O
be None None O
endowed None None O
with None None O
biological None None O
activities None None O
is None None O
muramyl None None O
dipeptide None None O
( None None O
MDP None None O
) None None O
. None None O

A None None O
clinically None None O
acceptable None None O
synthetic None None O
derivative None None O
of None None O
MDP None None O
, None None O
namely None None O
murabutide None None O
( None None O
MB None None O
) None None O
, None None O
has None None O
been None None O
found None None O
to None None O
present None None O
interesting None None O
pharmacological None None O
properties None None O
and None None O
to None None O
suppress None None O
HIV-1 None None O
replication None None O
in None None O
monocyte-derived None None I-cell_type
macrophages None None I-cell_type
( None None O
MDM None None I-cell_type
) None None O
. None None O

We None None O
have None None O
addressed None None O
the None None O
signaling None None O
events None None O
activated None None O
in None None O
MDM None None I-cell_type
following None None O
stimulation None None O
with None None O
either None None O
MB None None O
or None None O
the None None O
potent None None O
immunostimulant None None O
LPS None None O
. None None O

We None None O
also None None O
examined None None O
whether None None O
signaling None None O
by None None O
muramyl None None O
peptides None None O
involves None None O
the None None O
use None None O
of None None O
cell None None I-protein
surface None None I-protein
receptors None None I-protein
, None None O
including None None O
CD14 None None I-protein
and None None O
Toll-like None None I-protein
receptor None None I-protein
2 None None I-protein
( None None O
TLR2 None None I-protein
) None None O
or None None O
TLR4 None None I-protein
that None None O
are None None O
known None None O
to None None O
be None None O
signal-transducing None None I-protein
receptors None None I-protein
for None None O
other None None O
bacterial None None O
cell None None O
wall None None O
components None None O
. None None O

We None None O
demonstrate None None O
that None None O
, None None O
unlike None None O
LPS None None O
, None None O
the None None O
safe None None O
immunomodulator None None O
MB None None O
selectively None None O
activates None None O
extracellular None None I-protein
signal-regulated None None I-protein
kinases None None I-protein
( None None I-protein
Erk None None I-protein
) None None I-protein
1/2 None None I-protein
, None None O
in None None O
the None None O
absence None None O
of None None O
detectable None None O
Jun None None I-protein
N-terminal None None I-protein
kinase None None I-protein
( None None O
JNK None None I-protein
) None None O
or None None O
p38 None None I-protein
mitogen-activated None None I-protein
kinase None None I-protein
activation None None O
. None None O

Furthermore None None O
, None None O
STAT1 None None I-protein
activation None None O
but None None O
weak None None O
or None None O
no None None O
activation None None O
of None None O
STAT3 None None I-protein
or None None O
STAT5 None None I-protein
respectively None None O
, None None O
could None None O
be None None O
detected None None O
in None None O
MB-stimulated None None I-cell_type
MDM None None I-cell_type
. None None O

Using None None O
MonoMac6 None None I-cell_line
cells None None I-cell_line
, None None O
we None None O
observed None None O
high None None O
C/EBPbeta None None I-protein
and None None O
AP-1 None None I-protein
but None None O
weaker None None O
and None None O
transient None None O
NF-kappaB None None I-protein
activation None None O
by None None O
MB None None O
. None None O

Moreover None None O
, None None O
the None None O
truncated None None O
form None None O
of None None O
C/EBPbeta None None I-protein
, None None O
known None None O
to None None O
repress None None O
HIV-1 None None O
transcription None None O
, None None O
was None None O
detected None None O
in None None O
extracts None None O
from None None O
MB-treated None None I-cell_line
THP-1 None None I-cell_line
cells None None I-cell_line
. None None O

Surprisingly None None O
, None None O
neither None None O
MB None None O
nor None None O
MDP None None O
were None None O
able None None O
to None None O
transduce None None O
signals None None O
via None None O
CD14 None None I-protein
and None None O
TLR2 None None I-protein
or None None I-protein
4 None None I-protein
. None None O

These None None O
findings None None O
present None None O
major None None O
differences None None O
in None None O
the None None O
early None None O
cell None None O
activation None None O
process None None O
between None None O
LPS None None O
and None None O
muramyl None None O
peptides None None O
, None None O
and None None O
strongly None None O
argue None None O
for None None O
the None None O
implication None None O
of None None O
co-receptors None None I-protein
other None None O
than None None O
TLR2 None None I-protein
and None None O
TLR4 None None I-protein
in None None O
mediating None None O
the None None O
signaling None None O
events None None O
induced None None O
by None None O
defined None None O
subunits None None O
of None None O
bacterial None None O
peptidoglycans None None O
. None None O

Nuclear None None I-protein
peroxisome None None I-protein
proliferator-activated None None I-protein
receptors None None I-protein
alpha None None I-protein
and None None I-protein
gamma None None I-protein
have None None O
opposing None None O
effects None None O
on None None O
monocyte None None O
chemotaxis None None O
in None None O
endometriosis None None O
. None None O

The None None O
peroxisome None None I-protein
proliferator-activated None None I-protein
receptors None None I-protein
( None None I-protein
PPARs None None I-protein
) None None I-protein
alpha None None I-protein
and None None I-protein
gamma None None I-protein
are None None O
nuclear None None I-protein
receptors None None I-protein
that None None O
play None None O
important None None O
roles None None O
in None None O
inflammatory None None O
diseases None None O
like None None O
ulcerative None None O
colitis None None O
and None None O
arthritis None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
examined None None O
the None None O
possible None None O
role None None O
of None None O
PPARs None None I-protein
in None None O
macrophage None None O
attraction None None O
into None None O
the None None O
peritoneal None None O
cavity None None O
of None None O
patients None None O
with None None O
endometriosis None None O
. None None O

We None None O
identified None None O
PPAR-alpha None None I-RNA
and None None I-RNA
-gamma None None I-RNA
messenger None None O
RNA None None O
by None None O
RT-PCR None None O
and None None O
protein None None O
by None None O
immunoblotting None None O
of None None O
lysates None None O
of None None O
peritoneal None None I-cell_type
macrophages None None I-cell_type
and None None O
monocytic None None I-cell_line
U937 None None I-cell_line
cells None None I-cell_line
. None None O

Using None None O
immunocytochemistry None None O
, None None O
we None None O
localized None None O
PPAR-alpha None None I-protein
and None None I-protein
-gamma None None I-protein
within None None O
the None None O
nuclei None None O
of None None O
both None None O
cell None None O
types None None O
. None None O

Monocyte None None O
chemotactic None None O
activity None None O
of None None O
peritoneal None None O
fluid None None O
from None None O
patients None None O
with None None O
endometriosis None None O
was None None O
quantified None None O
in None None O
Boyden None None O
chambers None None O
. None None O

Migration None None O
of None None O
U937 None None I-cell_line
cells None None I-cell_line
was None None O
increased None None O
by None None O
WY None None O
14643 None None O
and None None O
reduced None None O
by None None O
rosiglitazone None None O
. None None O

Peritoneal None None O
fluid None None O
from None None O
patients None None O
with None None O
endometriosis None None O
activated None None O
U937 None None I-cell_line
cells None None I-cell_line
transiently None None O
transfected None None O
with None None O
a None None O
PPAR-alpha/GAL4 None None I-DNA
luciferase None None I-DNA
reporter None None I-DNA
. None None O

By None None O
contrast None None O
, None None O
peritoneal None None O
fluid None None O
did None None O
not None None O
cause None None O
significant None None O
activation None None O
of None None O
PPAR-gamma/GAL4 None None I-DNA
constructs None None I-DNA
. None None O

The None None O
U937 None None I-cell_line
cells None None I-cell_line
transiently None None O
transfected None None O
with None None O
a None None O
PPAR None None I-DNA
response None None I-DNA
element None None I-DNA
luciferase None None I-DNA
reporter None None I-DNA
showed None None O
disease None None O
stage-dependent None None O
up-regulation None None O
when None None O
treated None None O
with None None O
peritoneal None None O
fluid None None O
from None None O
patients None None O
with None None O
endometriosis None None O
. None None O

Treatment None None O
with None None O
peritoneal None None O
fluid None None O
from None None O
healthy None None O
controls None None O
down-regulated None None O
PPAR None None O
response None None O
element None None O
transactivation None None O
. None None O

We None None O
conclude None None O
that None None O
peritoneal None None O
fluid None None O
of None None O
endometriosis None None O
patients None None O
contains None None O
activators None None O
of None None O
PPAR-alpha None None I-protein
that None None O
stimulate None None O
macrophage None None O
chemotaxis None None O
. None None O

Inhibitors None None O
of None None O
PPAR-alpha None None I-protein
or None None O
activators None None O
of None None O
PPAR-gamma None None I-protein
could None None O
be None None O
developed None None O
for None None O
the None None O
treatment None None O
of None None O
inflammation None None O
associated None None O
with None None O
endometriosis None None O
. None None O

Long-term-impaired None None O
expression None None O
of None None O
nuclear None None I-protein
factor-kappa None None I-protein
B None None I-protein
and None None O
I None None I-protein
kappa None None I-protein
B None None I-protein
alpha None None I-protein
in None None O
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
of None None O
trauma None None O
patients None None O
. None None O

Nuclear None None I-protein
factor None None I-protein
( None None I-protein
NF None None I-protein
) None None I-protein
-kappa None None I-protein
B None None I-protein
expression None None O
and None None O
dimer None None O
characteristics None None O
were None None O
studied None None O
in None None O
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
( None None O
PBMCs None None I-cell_type
) None None O
of None None O
major-trauma None None O
patients None None O
and None None O
healthy None None O
controls None None O
. None None O

Analysis None None O
of None None O
PBMCs None None I-cell_type
on None None O
days None None O
1 None None O
, None None O
3 None None O
, None None O
5 None None O
, None None O
and None None O
10 None None O
after None None O
trauma None None O
revealed None None O
that None None O
expression None None O
of None None O
both None None O
p65p50 None None I-protein
heterodimers None None I-protein
and None None O
p50p50 None None I-protein
homodimers None None I-protein
was None None O
significantly None None O
reduced None None O
compared None None O
with None None O
that None None O
in None None O
controls None None O
. None None O

In None None O
vitro None None O
lipopolysaccharide None None O
( None None O
LPS None None O
) None None O
stimulation None None O
of None None O
PBMCs None None I-cell_type
induced None None O
NF-kappa None None O
B None None O
translocation None None O
. None None O

However None None O
, None None O
throughout None None O
the None None O
survey None None O
, None None O
p65p50 None None O
activation None None O
remained None None O
significantly None None O
lower None None O
in None None O
trauma None None O
patients None None O
than None None O
in None None O
controls None None O
. None None O

After None None O
LPS None None O
stimulation None None O
in None None O
vitro None None O
, None None O
the None None O
p65p50/p50p50 None None O
ratio None None O
was None None O
significantly None None O
lower None None O
in None None O
PBMCs None None I-cell_type
from None None O
trauma None None O
patients None None O
than None None O
from None None O
healthy None None O
controls None None O
. None None O

The None None O
ex None None O
vivo None None O
expression None None O
of None None O
I None None I-protein
kappa None None I-protein
B None None I-protein
alpha None None I-protein
was None None O
higher None None O
in None None O
PBMCs None None I-cell_type
of None None O
controls None None O
than None None O
of None None O
trauma None None O
patients None None O
. None None O

LPS None None O
did None None O
not None None O
induce None None O
I None None O
kappa None None O
B None None O
expression None None O
in None None O
PBMCs None None I-cell_type
from None None O
trauma None None O
patients None None O
, None None O
but None None O
strong None None O
induction None None O
was None None O
obtained None None O
with None None O
staphylococci None None O
, None None O
suggesting None None O
that None None O
this None None O
defect None None O
is None None O
not None None O
universal None None O
and None None O
depends None None O
on None None O
the None None O
nature None None O
of None None O
the None None O
activating None None O
signal None None O
. None None O

Although None None O
no None None O
direct None None O
correlation None None O
was None None O
found None None O
between None None O
levels None None O
of None None O
interleukin-10 None None I-protein
or None None O
transforming None None I-protein
growth None None I-protein
factor-beta None None I-protein
and None None O
NF-kappa None None I-protein
B None None I-protein
, None None O
these None None O
immunosuppressive None None I-protein
cytokines None None I-protein
were None None O
significantly None None O
elevated None None O
in None None O
trauma None None O
patients None None O
by None None O
10 None None O
days None None O
after None None O
admission None None O
. None None O

The None None O
long-term None None O
low-basal None None O
and None None O
LPS-induced None None O
nuclear None None O
translocation None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
recalled None None O
long-term None None O
immunoparalysis None None O
observed None None O
in None None O
patients None None O
with None None O
severe None None O
inflammatory None None O
stress None None O
such None None O
as None None O
trauma None None O
. None None O

Hepatic None None O
ischemia-reperfusion None None O
injury None None O
. None None O

BACKGROUND None None O
: None None O
The None None O
morbidity None None O
associated None None O
with None None O
liver None None O
transplantation None None O
and None None O
major None None O
hepatic None None O
resections None None O
is None None O
partly None None O
a None None O
result None None O
of None None O
ischemia-reperfusion None None O
injury None None O
. None None O

DATA None None O
SOURCES None None O
: None None O
The None None O
entire None None O
world None None O
literature None None O
on None None O
the None None O
subject None None O
was None None O
searched None None O
via None None O
Medline None None O
. None None O

Keywords None None O
included None None O
reperfusion None None O
injury None None O
, None None O
transplantation None None O
, None None O
liver None None O
resection None None O
, None None O
nitric None None O
oxide None None O
, None None O
endothelin None None O
, None None O
cytokines None None I-protein
, None None O
Kupffer None None I-cell_type
cells None None I-cell_type
, None None O
ischemic/ischaemic None None O
preconditioning None None O
, None None O
and None None O
nuclear None None I-protein
factor-kappa None None I-protein
B None None I-protein
. None None O

CONCLUSIONS None None O
: None None O
An None None O
imbalance None None O
between None None O
endothelin None None O
and None None O
nitric None None O
oxide None None O
levels None None O
results None None O
in None None O
failure None None O
of None None O
the None None O
hepatic None None O
microcirculation None None O
at None None O
the None None O
onset None None O
of None None O
reperfusion None None O
. None None O

Activation None None O
of None None O
nuclear None None I-protein
factor-kappa None None I-protein
B None None I-protein
in None None O
the None None O
liver None None O
promotes None None O
proinflammatory None None I-protein
cytokine None None I-protein
and None None O
adhesion None None I-protein
molecule None None I-protein
synthesis None None O
. None None O

These None None O
result None None O
in None None O
oxygen-derived None None O
free None None O
radical None None O
production None None O
and None None O
neutrophil None None O
recruitment None None O
, None None O
further None None O
contributing None None O
to None None O
cellular None None O
injury None None O
. None None O

Various None None O
therapeutic None None O
modalities None None O
acting None None O
on None None O
the None None O
above None None O
mediators None None O
have None None O
been None None O
successfully None None O
used None None O
to None None O
attenuate None None O
reperfusion None None O
injury None None O
in None None O
animal None None O
models None None O
of None None O
hepatic None None O
transplantation None None O
and None None O
resection None None O
. None None O

Application None None O
of None None O
the None None O
knowledge None None O
gained None None O
from None None O
animal None None O
models None None O
of None None O
hepatic None None O
ischemia-reperfusion None None O
to None None O
the None None O
clinical None None O
setting None None O
will None None O
improve None None O
the None None O
outcome None None O
of None None O
hepatic None None O
surgery None None O
. None None O

Down-regulation None None O
of None None O
IL-12 None None I-DNA
p40 None None I-DNA
gene None None I-DNA
in None None O
Plasmodium None None O
berghei-infected None None O
mice None None O
. None None O

We None None O
analyzed None None O
the None None O
mechanism None None O
that None None O
causes None None O
suppression None None O
of None None O
IL-12 None None I-DNA
p40 None None I-DNA
gene None None I-DNA
induction None None O
during None None O
Plasmodium None None O
berghei None None O
infection None None O
. None None O

Although None None O
IL-12 None None I-protein
together None None O
with None None O
IFN-gamma None None I-protein
plays None None O
an None None O
important None None O
role None None O
in None None O
protection None None O
against None None O
pathogenic None None O
infection None None O
, None None O
the None None O
IL-12 None None I-protein
p70 None None I-protein
protein None None I-protein
production None None O
of None None O
infected None None I-cell_type
macrophages None None I-cell_type
is None None O
lower None None O
than None None O
that None None O
by None None O
the None None O
uninfected None None I-cell_type
macrophages None None I-cell_type
. None None O

We None None O
showed None None O
in None None O
the None None O
present None None O
study None None O
that None None O
the None None O
induction None None O
of None None O
IL-12 None None I-DNA
p40 None None I-DNA
gene None None I-DNA
but None None O
not None None O
IL-12 None None I-DNA
p35 None None I-DNA
gene None None I-DNA
in None None O
macrophages None None I-cell_type
of None None O
P. None None O
berghei-infected None None O
mice None None O
was None None O
profoundly None None O
inhibited None None O
. None None O

The None None O
inhibition None None O
was None None O
induced None None O
by None None O
interaction None None O
with None None O
macrophages None None I-cell_type
that None None O
had None None O
contacted None None O
with None None O
P. None None I-cell_type
berghei-infected None None I-cell_type
erythrocytes None None I-cell_type
and None None O
was None None O
mediated None None O
by None None O
a None None O
soluble None None O
factor None None O
, None None O
IL-10 None None I-protein
. None None O

There None None O
was None None O
comparable None None O
activation None None O
of None None O
NF-kappaB None None I-protein
in None None O
uninfected None None I-cell_type
and None None I-cell_type
infected None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
induction None None O
of None None O
IFN-regulatory None None I-DNA
factor-1 None None I-DNA
gene None None I-DNA
was None None O
comparable None None O
in None None O
transcription None None O
level None None O
in None None O
uninfected None None I-cell_type
and None None I-cell_type
infected None None I-cell_type
cells None None I-cell_type
, None None O
while None None O
the None None O
unidentified None None O
complex None None O
formation None None O
of None None O
IFN-regulatory None None I-protein
factor-1 None None I-protein
was None None O
observed None None O
in None None O
infected None None I-cell_type
cells None None I-cell_type
. None None O

Therefore None None O
, None None O
the None None O
inhibition None None O
of None None O
the None None O
IL-12 None None I-DNA
p40 None None I-DNA
gene None None I-DNA
induction None None O
appeared None None O
to None None O
be None None O
regulated None None O
at None None O
transcriptional None None O
regulation None None O
level None None O
of None None O
the None None O
gene None None O
. None None O

The None None O
Friend None None I-protein
of None None I-protein
GATA None None I-protein
proteins None None I-protein
U-shaped None None O
, None None O
FOG-1 None None I-protein
, None None O
and None None O
FOG-2 None None I-protein
function None None O
as None None O
negative None None O
regulators None None O
of None None O
blood None None O
, None None O
heart None None O
, None None O
and None None O
eye None None O
development None None O
in None None O
Drosophila None None O
. None None O

Friend None None I-protein
of None None I-protein
GATA None None I-protein
( None None I-protein
FOG None None I-protein
) None None I-protein
proteins None None I-protein
regulate None None O
GATA None None O
factor-activated None None O
gene None None O
transcription None None O
. None None O

During None None O
vertebrate None None O
hematopoiesis None None O
, None None O
FOG None None I-protein
and None None I-protein
GATA None None I-protein
proteins None None I-protein
cooperate None None O
to None None O
promote None None O
erythrocyte None None O
and None None O
megakaryocyte None None O
differentiation None None O
. None None O

The None None O
Drosophila None None I-protein
FOG None None I-protein
homologue None None I-protein
U-shaped None None I-protein
( None None O
Ush None None I-protein
) None None O
is None None O
expressed None None O
similarly None None O
in None None O
the None None O
blood None None O
cell None None O
anlage None None O
during None None O
embryogenesis None None O
. None None O

During None None O
hematopoiesis None None O
, None None O
the None None O
acute None None O
myeloid None None O
leukemia None None O
1 None None O
homologue None None O
Lozenge None None I-cell_type
and None None I-cell_type
Glial None None I-cell_type
cells None None I-cell_type
missing None None O
are None None O
required None None O
for None None O
the None None O
production None None O
of None None O
crystal None None I-cell_type
cells None None I-cell_type
and None None O
plasmatocytes None None I-cell_type
, None None O
respectively None None O
. None None O

However None None O
, None None O
additional None None O
factors None None O
have None None O
been None None O
predicted None None O
to None None O
control None None O
crystal None None O
cell None None O
proliferation None None O
. None None O

In None None O
this None None O
report None None O
, None None O
we None None O
show None None O
that None None O
Ush None None I-protein
is None None O
expressed None None O
in None None O
hemocyte None None I-cell_type
precursors None None I-cell_type
and None None O
plasmatocytes None None I-cell_type
throughout None None O
embryogenesis None None O
and None None O
larval None None O
development None None O
, None None O
and None None O
the None None O
GATA None None I-protein
factor None None I-protein
Serpent None None I-protein
is None None O
essential None None O
for None None O
Ush None None I-protein
embryonic None None O
expression None None O
. None None O

Furthermore None None O
, None None O
loss None None O
of None None O
ush None None O
function None None O
results None None O
in None None O
an None None O
overproduction None None O
of None None O
crystal None None I-cell_type
cells None None I-cell_type
, None None O
whereas None None O
forced None None O
expression None None O
of None None O
Ush None None I-protein
reduces None None O
this None None O
cell None None O
population None None O
. None None O

Murine None None I-protein
FOG-1 None None I-protein
and None None I-protein
FOG-2 None None I-protein
also None None O
can None None O
repress None None O
crystal None None O
cell None None O
production None None O
, None None O
but None None O
a None None O
mutant None None O
version None None O
of None None O
FOG-2 None None I-protein
lacking None None O
a None None O
conserved None None O
motif None None O
that None None O
binds None None O
the None None O
corepressor None None I-protein
C-terminal None None I-protein
binding None None I-protein
protein None None I-protein
fails None None O
to None None O
affect None None O
the None None O
cell None None O
lineage None None O
. None None O

The None None O
GATA None None I-protein
factor None None I-protein
Pannier None None I-protein
( None None O
Pnr None None I-protein
) None None O
is None None O
required None None O
for None None O
eye None None O
and None None O
heart None None O
development None None O
in None None O
Drosophila None None O
. None None O

When None None O
Ush None None I-protein
, None None O
FOG-1 None None I-protein
, None None O
FOG-2 None None I-protein
, None None O
or None None O
mutant None None I-protein
FOG-2 None None I-protein
is None None O
coexpressed None None O
with None None O
Pnr None None I-protein
during None None O
these None None O
developmental None None O
processes None None O
, None None O
severe None None O
eye None None O
and None None O
heart None None O
phenotypes None None O
result None None O
, None None O
consistent None None O
with None None O
a None None O
conserved None None O
negative None None O
regulation None None O
of None None O
Pnr None None I-protein
function None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
the None None O
fly None None O
and None None O
mouse None None O
FOG None None I-protein
proteins None None I-protein
function None None O
similarly None None O
in None None O
three None None O
distinct None None O
cellular None None O
contexts None None O
in None None O
Drosophila None None O
, None None O
but None None O
may None None O
use None None O
different None None O
mechanisms None None O
to None None O
regulate None None O
genetic None None O
events None None O
in None None O
blood None None O
vs None None O
. None None O
cardial None None I-cell_line
or None None I-cell_line
eye None None I-cell_line
cell None None I-cell_line
lineages None None I-cell_line

The None None O
RING None None I-protein
finger None None I-protein
protein None None I-protein
Siah-1 None None B-protein
regulates None None O
the None None O
level None None O
of None None O
the None None O
transcriptional None None I-protein
coactivator None None I-protein
OBF-1 None None B-protein
. None None O

The None None O
transcriptional None None I-protein
coactivator None None I-protein
OBF-1 None None B-protein
, None None O
which None None O
interacts None None O
with None None O
Oct-1 None None I-protein
and None None O
Oct-2 None None I-protein
and None None O
the None None O
octamer None None I-DNA
site None None I-DNA
DNA None None I-DNA
, None None O
has None None O
been None None O
shown None None O
to None None O
be None None O
critical None None O
for None None O
development None None O
of None None O
a None None O
normal None None O
immune None None O
response None None O
and None None O
the None None O
formation None None O
of None None O
germinal None None O
centers None None O
in None None O
secondary None None O
lymphoid None None O
organs None None O
. None None O

Here None None O
we None None O
have None None O
identified None None O
the None None O
RING None None I-protein
finger None None I-protein
protein None None I-protein
Siah-1 None None B-protein
as None None O
a None None O
protein None None O
interacting None None O
specifically None None O
with None None O
OBF-1 None None I-protein
. None None O

This None None O
interaction None None O
is None None O
mediated None None O
by None None O
the None None O
C-terminal None None I-protein
part None None O
of None None O
Siah-1 None None I-protein
and None None O
by None None O
residues None None O
in None None O
the None None O
N-terminus None None I-protein
of None None O
OBF-1 None None I-protein
, None None O
partly None None O
distinct None None O
from None None O
the None None O
residues None None O
required None None O
for None None O
formation None None O
of None None O
a None None O
complex None None O
with None None O
the None None O
Oct None None I-protein
POU None None I-protein
domains None None I-protein
and None None O
the None None O
DNA None None O
. None None O

Interaction None None O
between None None O
Siah-1 None None I-protein
and None None O
OBF-1 None None I-protein
leads None None O
to None None O
downregulation None None O
of None None O
OBF-1 None None O
protein None None O
level None None O
but None None O
not None None O
mRNA None None O
, None None O
and None None O
to None None O
a None None O
corresponding None None O
reduction None None O
in None None O
octamer None None O
site-dependent None None O
transcription None None O
activation None None O
. None None O

Inhibition None None O
of None None O
the None None O
ubiquitin-proteasome None None O
pathway None None O
in None None O
B None None I-cell_type
cells None None I-cell_type
leads None None O
to None None O
elevated None None O
levels None None O
of None None O
OBF-1 None None I-protein
protein None None I-protein
. None None O

Furthermore None None O
, None None O
in None None O
immunized None None O
mice None None O
, None None O
OBF-1 None None I-protein
protein None None I-protein
amounts None None O
are None None O
dramatically None None O
increased None None O
in None None O
primary None None I-cell_type
activated None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
, None None O
without None None O
concomitant None None O
increase None None O
in None None O
OBF-1 None None I-RNA
mRNA None None I-RNA
. None None O

These None None O
data None None O
suggest None None O
that None None O
Siah-1 None None I-protein
is None None O
part None None O
of None None O
a None None O
novel None None O
regulatory None None O
loop None None O
controlling None None O
the None None O
level None None O
of None None O
OBF-1 None None I-protein
protein None None I-protein
in None None O
B None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
beta-catenin None None O
-- None None O
TCF-1 None None O
pathway None None O
ensures None None O
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
CD8 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
thymocyte None None I-cell_type
survival None None O
. None None O

The None None O
association None None O
of None None O
trans-acting None None I-protein
T None None I-protein
cell None None I-protein
factors None None I-protein
( None None O
TCFs None None I-protein
) None None O
or None None O
lymphoid None None I-protein
enhancer None None I-protein
factor None None I-protein
1 None None I-protein
( None None O
LEF-1 None None I-protein
) None None O
with None None O
their None None O
coactivator None None O
beta-catenin None None O
mediates None None O
transient None None O
transcriptional None None O
responses None None O
to None None O
extracellular None None O
Wnt None None O
signals None None O
. None None O

We None None O
show None None O
here None None O
that None None O
T None None O
cell None None O
maturation None None O
depends None None O
on None None O
the None None O
presence None None O
of None None O
the None None O
beta-catenin None None I-protein
-- None None I-protein
binding None None I-protein
domain None None I-protein
in None None O
TCF-1 None None I-protein
. None None O

This None None O
domain None None O
is None None O
necessary None None O
to None None O
mediate None None O
the None None O
survival None None O
of None None O
immature None None O
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
CD8 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
double-positive None None I-cell_type
( None None I-cell_type
DP None None I-cell_type
) None None I-cell_type
thymocytes None None I-cell_type
. None None O

Accelerated None None O
spontaneous None None O
thymocyte None None O
death None None O
in None None O
the None None O
absence None None O
of None None O
TCF-1 None None I-protein
correlates None None O
with None None O
aberrantly None None O
low None None O
expression None None O
of None None O
the None None O
anti-apoptotic None None I-protein
protein None None I-protein
Bcl-x None None B-protein
( None None I-protein
L None None I-protein
) None None I-protein
. None None O

Increasing None None O
anti-apoptotic None None O
effectors None None O
in None None O
thymocytes None None I-cell_type
by None None O
the None None O
use None None O
of None None O
a None None O
Bcl-2 None None I-DNA
transgene None None I-DNA
rescued None None O
TCF-1-deficient None None I-cell_type
DP None None I-cell_type
thymocytes None None I-cell_type
from None None O
apoptosis None None O
. None None O

Thus None None O
, None None O
TCF-1 None None I-protein
, None None O
upon None None O
association None None O
with None None O
beta-catenin None None O
, None None O
transiently None None O
ensures None None O
the None None O
survival None None O
of None None O
immature None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
, None None O
which None None O
enables None None O
them None None O
to None None O
generate None None O
and None None O
edit None None O
T None None I-protein
cell None None I-protein
receptor None None I-protein
( None None I-protein
TCR None None I-protein
) None None I-protein
alpha None None I-protein
chains None None I-protein
and None None O
attempt None None O
TCR None None I-protein
-mediated None None O
positive None None O
selection None None O
. None None O

TRAIL/Apo2L None None I-protein
ligand None None I-protein
selectively None None O
induces None None O
apoptosis None None O
and None None O
overcomes None None O
drug None None O
resistance None None O
in None None O
multiple None None O
myeloma None None O
: None None O
therapeutic None None O
applications None None O
. None None O

Multiple None None O
myeloma None None O
( None None O
MM None None O
) None None O
remains None None O
incurable None None O
and None None O
novel None None O
treatments None None O
are None None O
urgently None None O
needed None None O
. None None O

Preclinical None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
evaluations None None O
were None None O
performed None None O
to None None O
assess None None O
the None None O
potential None None O
therapeutic None None O
applications None None O
of None None O
human None None O
recombinant None None O
tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
( None None I-protein
TNF None None I-protein
) None None I-protein
-related None None I-protein
apoptosis-inducing None None I-protein
ligand/Apo2 None None I-protein
ligand None None I-protein
( None None O
TRAIL/Apo2L None None I-protein
) None None O
in None None O
MM None None O
. None None O

TRAIL/Apo2L None None I-protein
potently None None O
induced None None O
apoptosis None None O
of None None O
MM None None I-cell_type
cells None None I-cell_type
from None None O
patients None None O
and None None O
the None None O
majority None None O
of None None O
MM None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
, None None O
including None None O
cells None None O
sensitive None None O
or None None O
resistant None None O
to None None O
dexamethasone None None O
( None None O
Dex None None O
) None None O
, None None O
doxorubicin None None O
( None None O
Dox None None O
) None None O
, None None O
melphalan None None O
, None None O
and None None O
mitoxantrone None None O
. None None O

TRAIL/Apo2L None None I-protein
also None None O
overcame None None O
the None None O
survival None None O
effect None None O
of None None O
interleukin None None I-protein
6 None None I-protein
on None None O
MM None None I-cell_type
cells None None I-cell_type
and None None O
did None None O
not None None O
affect None None O
the None None O
survival None None O
of None None O
peripheral None None I-cell_type
blood None None I-cell_type
and None None I-cell_type
bone None None I-cell_type
marrow None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
and None None O
purified None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
from None None O
healthy None None O
donors None None O
. None None O

The None None O
status None None O
of None None O
the None None O
TRAIL None None I-protein
receptors None None I-protein
( None None O
assessed None None O
by None None O
immunoblotting None None O
and None None O
flow None None O
cytometry None None O
) None None O
could None None O
not None None O
predict None None O
TRAIL None None O
sensitivity None None O
of None None O
MM None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
anti-MM None None O
activity None None O
of None None O
TRAIL/Apo2L None None I-protein
was None None O
confirmed None None O
in None None O
nu/xid/bg None None O
mice None None O
xenografted None None O
with None None O
human None None I-cell_type
MM None None I-cell_type
cells None None I-cell_type
; None None O
TRAIL None None I-protein
( None None O
500 None None O
microg None None O
intraperitoneally None None O
daily None None O
for None None O
14 None None O
days None None O
) None None O
was None None O
well None None O
tolerated None None O
and None None O
significantly None None O
suppressed None None O
the None None O
growth None None O
of None None O
plasmacytomas None None I-cell_type
. None None O

Dox None None O
up-regulated None None O
the None None O
expression None None O
of None None O
the None None O
TRAIL None None I-protein
receptor None None I-protein
death None None B-protein
receptor None None I-protein
5 None None I-protein
( None None O
DR5 None None I-protein
) None None O
and None None O
synergistically None None O
enhanced None None O
the None None O
effect None None O
of None None O
TRAIL None None I-protein
not None None O
only None None O
against None None O
MM None None I-cell_type
cells None None I-cell_type
sensitive None None O
to None None O
, None None O
but None None O
also None None O
against None None O
those None None O
resistant None None O
to None None O
, None None O
Dex- None None O
or None None O
Dox-induced None None O
apoptosis None None O
. None None O

Nuclear None None O
factor None None O
( None None O
NF None None O
) None None O
-kappaB None None O
inhibitors None None O
, None None O
such None None O
as None None O
SN50 None None O
( None None O
a None None O
cell-permeable None None O
inhibitor None None O
of None None O
the None None O
nuclear None None O
translocation None None O
and None None O
transcriptional None None O
activity None None O
of None None O
NF-kappaB None None I-protein
) None None O
or None None O
the None None O
proteasome None None O
inhibitor None None O
PS-341 None None O
, None None O
enhanced None None O
the None None O
proapoptotic None None O
activity None None O
of None None O
TRAIL/Apo2L None None I-protein
against None None O
TRAIL-sensitive None None I-cell_type
MM None None I-cell_type
cells None None I-cell_type
, None None O
whereas None None O
SN50 None None O
reversed None None O
the None None O
TRAIL None None O
resistance None None O
of None None O
ARH-77 None None I-cell_type
and None None I-cell_type
IM-9 None None I-cell_type
MM None None I-cell_type
cells None None I-cell_type
. None None O

Importantly None None O
, None None O
normal None None I-cell_type
B None None I-cell_type
lymphocytes None None I-cell_type
were None None O
not None None O
sensitized None None O
to None None O
TRAIL None None I-protein
by None None O
either None None O
Dox None None O
, None None O
SN50 None None O
, None None O
or None None O
PS-341 None None O
. None None O

These None None O
preclinical None None O
studies None None O
suggest None None O
that None None O
TRAIL/Apo2L None None I-protein
can None None O
overcome None None O
conventional None None O
drug None None O
resistance None None O
and None None O
provide None None O
the None None O
basis None None O
for None None O
clinical None None O
trials None None O
of None None O
TRAIL None None I-protein
-based None None O
treatment None None O
regimens None None O
to None None O
improve None None O
outcome None None O
in None None O
patients None None O
with None None O
MM None None O
. None None O

( None None O
Blood. None None O
2001 None None O
; None None O
98 None None O
: None None O
795-804 None None O
) None None O

CD28 None None I-protein
costimulation None None O
is None None O
required None None O
not None None O
only None None O
to None None O
induce None None O
IL-12 None None I-protein
receptor None None I-protein
but None None O
also None None O
to None None O
render None None O
janus None None I-protein
kinases/STAT4 None None I-protein
responsive None None O
to None None O
IL-12 None None I-protein
stimulation None None O
in None None O
TCR-triggered None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
activation None None O
of None None O
resting None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
for None None O
the None None O
acquisition None None O
of None None O
various None None O
functions None None O
depends None None O
on None None O
whether None None O
CD28 None None O
costimulatory None None O
signals None None O
are None None O
provided None None O
upon None None O
T None None O
cell None None O
receptor None None O
stimulation None None O
. None None O

Here None None O
, None None O
we None None O
investigated None None O
how None None O
CD28 None None O
costimulation None None O
functions None None O
to None None O
allow None None O
TCR None None I-protein
-triggered None None O
resting None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
to None None O
acquire None None O
IL-12 None None I-protein
responsiveness None None O
. None None O

When None None O
T None None I-cell_type
cells None None I-cell_type
are None None O
stimulated None None O
with None None O
low None None O
doses None None O
of None None O
anti-CD3 None None I-protein
mAb None None I-protein
, None None O
CD28 None None O
costimulation None None O
was None None O
required None None O
for None None O
the None None O
optimal None None O
levels None None O
of None None O
IL-12 None None I-protein
receptor None None I-protein
( None None O
IL-12R None None I-protein
) None None O
expression None None O
. None None O

However None None O
, None None O
stimulation None None O
of None None O
T None None I-cell_type
cells None None I-cell_type
with None None O
high None None O
doses None None O
of None None O
anti-CD3 None None I-protein
alone None None O
induced None None O
comparable None None O
levels None None O
of None None O
IL-12R None None I-protein
expression None None O
to None None O
those None None O
induced None None O
upon None None O
CD28 None None O
costimulation None None O
. None None O

Nevertheless None None O
, None None O
there None None O
was None None O
a None None O
substantial None None O
difference None None O
in None None O
IL-12 None None I-protein
responsiveness None None O
between None None O
these None None O
two None None O
groups None None O
of None None O
T None None I-cell_type
cells None None I-cell_type
: None None O
compared None None O
to None None O
anti-CD28-costimulated None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
, None None O
T None None I-cell_type
cells None None I-cell_type
that None None O
were None None O
not None None O
costimulated None None O
with None None O
anti-CD28 None None I-protein
exhibited None None O
decreased None None O
levels None None O
of None None O
Janus None None I-protein
kinases None None I-protein
( None None O
JAK None None I-protein
) None None O
JAK2/TYK2 None None I-protein
and None None O
STAT4 None None I-protein
phosphorylation None None O
and None None O
IFN-y None None O
production None None O
following None None O
IL-12 None None I-protein
stimulation None None O
. None None O

Importantly None None O
, None None O
STAT6 None None O
phosphorylation None None O
following None None O
IL-4 None None O
stimulation None None O
was None None O
not None None O
decreased None None O
in None None O
anti-CD28-uncostimulated None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

These None None O
resutls None None O
indicate None None O
that None None O
CD28 None None O
costimulation None None O
not None None O
only None None O
contributes None None O
to None None O
up-regulating None None O
IL-12R None None I-protein
expression None None O
but None None O
is None None O
also None None O
required None None O
to None None O
render None None O
JAKs/STAT4 None None I-protein
responsive None None O
to None None O
IL-12 None None I-protein
stimulation None None O
. None None O

Constitutively None None O
activated None None O
Akt-1 None None I-protein
is None None O
vital None None O
for None None O
the None None O
survival None None O
of None None O
human None None I-cell_type
monocyte-differentiated None None I-cell_type
macrophages None None I-cell_type
. None None O

Role None None O
of None None O
Mcl-1 None None I-protein
, None None O
independent None None O
of None None O
nuclear None None I-protein
factor None None I-protein
( None None I-protein
NF None None I-protein
) None None I-protein
-kappaB None None I-protein
, None None O
Bad None None I-protein
, None None O
or None None O
caspase None None O
activation None None O
. None None O

Recent None None O
data None None O
from None None O
mice None None O
deficient None None O
for None None O
phosphatase None None I-protein
and None None O
tensin None None I-DNA
homologue None None I-DNA
deleted None None O
from None None O
chromosome None None I-DNA
10 None None I-DNA
or None None O
src None None I-protein
homology None None I-protein
2 None None I-protein
domain-containing None None I-protein
5 None None I-protein
' None None I-protein
inositol None None I-protein
phosphatase None None I-protein
, None None O
phosphatases None None I-protein
that None None O
negatively None None O
regulate None None O
the None None O
phosphatidylinositol None None I-protein
3-kinase None None I-protein
( None None O
PI3K None None I-protein
) None None O
pathway None None O
, None None O
revealed None None O
an None None O
increased None None O
number None None O
of None None O
macrophages None None I-cell_type
in None None O
these None None O
animals None None O
, None None O
suggesting None None O
an None None O
essential None None O
role None None O
for None None O
the None None O
PI3K None None I-protein
pathway None None O
for None None O
macro-phage None None I-cell_type
survival None None O
. None None O

Here None None O
, None None O
we None None O
focused None None O
on None None O
the None None O
role None None O
of None None O
the None None O
PI3K-regulated None None I-protein
serine/threonine None None I-protein
kinase None None I-protein
Akt-1 None None B-protein
in None None O
modulating None None O
macrophage None None I-cell_type
survival None None O
. None None O

Akt-1 None None I-protein
was None None O
constitutively None None O
activated None None O
in None None O
human None None I-cell_type
macrophages None None I-cell_type
and None None O
addition None None O
of None None O
the None None O
PI3K None None I-protein
inhibitor None None O
, None None O
LY294002 None None O
, None None O
suppressed None None O
the None None O
activation None None O
of None None O
Akt-1 None None I-protein
and None None O
induced None None O
cell None None O
death None None O
. None None O

Furthermore None None O
, None None O
suppression None None O
of None None O
Akt-1 None None I-protein
by None None O
inhibition None None O
of None None O
PI3K None None I-protein
or None None O
a None None O
dominant None None I-protein
negative None None I-protein
( None None I-protein
DN None None I-protein
) None None I-protein
Akt-1 None None I-protein
resulted None None O
in None None O
loss None None O
of None None O
mitochondrial None None O
transmembrane None None O
potential None None O
, None None O
activation None None O
of None None O
caspases-9 None None I-protein
and None None I-protein
-3 None None I-protein
, None None O
and None None O
DNA None None O
fragmentation None None O
. None None O

The None None O
effects None None O
of None None O
PI3K None None I-protein
inhibition None None O
were None None O
reversed None None O
by None None O
the None None O
ectopic None None O
expression None None O
of None None O
constitutively None None O
activated None None O
Akt-1 None None I-protein
or None None O
Bcl-x None None I-protein
( None None I-protein
L None None I-protein
) None None I-protein
. None None O

Inhibition None None O
of None None O
PI3K None None I-protein
/Akt-1 None None O
pathway None None O
either None None O
by None None O
LY294002 None None O
or None None O
DN None None I-protein
Akt-1 None None I-protein
had None None O
no None None O
effect None None O
on None None O
the None None O
constitutive None None O
or None None O
inducible None None O
activation None None O
of None None O
nuclear None None I-protein
factor None None I-protein
( None None I-protein
NF None None I-protein
) None None I-protein
-kappaB None None I-protein
in None None O
human None None I-cell_type
macrophages None None I-cell_type
. None None O

However None None O
, None None O
after None None O
inhibition None None O
of None None O
the None None O
PI3K None None I-protein
/ None None O
Akt-1 None None I-protein
pathway None None O
, None None O
a None None O
marked None None O
decrease None None O
in None None O
the None None O
expression None None O
of None None O
the None None O
antiapoptotic None None I-protein
molecule None None I-protein
Mcl-1 None None B-protein
, None None O
but None None O
not None None O
other None None O
Bcl-2 None None I-protein
family None None I-protein
members None None I-protein
was None None O
observed None None O
, None None O
and None None O
Mcl-1 None None I-protein
rescued None None O
macrophages None None I-cell_type
from None None O
LY294002-induced None None O
cell None None O
death None None O
. None None O

Further None None O
, None None O
inhibition None None O
of None None O
Mcl-1 None None I-protein
by None None O
antisense None None O
oligonucleotides None None O
, None None O
also None None O
resulted None None O
in None None O
macrophage None None I-cell_type
apoptosis None None O
. None None O

Thus None None O
, None None O
our None None O
findings None None O
demonstrate None None O
that None None O
the None None O
constitutive None None O
activation None None O
of None None O
Akt-1 None None I-protein
regulates None None O
macrophage None None I-cell_type
survival None None O
through None None O
Mcl-1 None None I-protein
, None None O
which None None O
is None None O
independent None None O
of None None O
caspases None None I-protein
, None None O
NF-kappaB None None I-protein
, None None O
or None None O
Bad None None I-protein
. None None O

GRbeta None None O
expression None None O
in None None O
nasal None None I-cell_type
polyp None None I-cell_type
inflammatory None None I-cell_type
cells None None I-cell_type
and None None O
its None None O
relationship None None O
to None None O
the None None O
anti-inflammatory None None O
effects None None O
of None None O
intranasal None None O
fluticasone None None O
. None None O

BACKGROUND None None O
: None None O
Nasal None None O
polyposis None None O
disease None None O
is None None O
an None None O
inflammatory None None O
disorder None None O
with None None O
intense None None O
eosinophilic None None O
infiltration None None O
of None None O
respiratory None None O
mucosa None None O
that None None O
is None None O
often None None O
difficult None None O
to None None O
control None None O
with None None O
topical None None O
steroids None None O
. None None O

Recent None None O
evidence None None O
suggests None None O
that None None O
overexpression None None O
of None None O
the None None O
glucocorticoid None None I-protein
receptor None None I-protein
splice None None I-protein
variant None None I-protein
GRbeta None None B-protein
in None None O
inflammatory None None I-cell_type
cells None None I-cell_type
might None None O
contribute None None O
to None None O
steroid None None O
insensitivity None None O
in None None O
diseases None None O
such None None O
as None None O
asthma None None O
. None None O

OBJECTIVE None None O
: None None O
The None None O
purposes None None O
of None None O
this None None O
investigation None None O
were None None O
to None None O
determine None None O
whether None None O
nasal None None I-cell_type
polyp None None I-cell_type
( None None I-cell_type
NP None None I-cell_type
) None None I-cell_type
inflammatory None None I-cell_type
cells None None I-cell_type
overexpress None None O
GRbeta None None I-protein
and None None O
to None None O
examine None None O
whether None None O
GRbeta None None I-protein
overexpression None None O
is None None O
associated None None O
with None None O
insensitivity None None O
to None None O
the None None O
potent None None O
topical None None O
steroid None None O
fluticasone None None O
propionate None None O
( None None O
FP None None O
) None None O
. None None O

METHODS None None O
: None None O
Biopsies None None O
were None None O
obtained None None O
from None None O
10 None None O
subjects None None O
with None None O
NPs None None O
before None None O
and None None O
4 None None O
weeks None None O
after None None O
treatment None None O
with None None O
intranasal None None O
FP None None O
. None None O

Middle None None O
turbinates None None O
biopsies None None O
from None None O
6 None None O
healthy None None O
, None None O
nonallergic None None O
subjects None None O
served None None O
as None None O
normal None None O
controls None None O
. None None O

Biopsies None None O
were None None O
immunostained None None O
for None None O
inflammatory None None O
cell None None O
markers None None O
as None None O
well None None O
as None None O
GRbeta None None I-protein
and None None O
probed None None O
for None None O
various None None O
cytokine None None I-RNA
mRNA None None I-RNA
. None None O

The None None O
anti-inflammatory None None O
response None None O
to None None O
FP None None O
was None None O
examined None None O
in None None O
relation None None O
to None None O
pretreatment None None O
levels None None O
of None None O
GRbeta None None O
expression None None O
. None None O

RESULTS None None O
: None None O
The None None O
total None None O
numbers None None O
of None None O
inflammatory None None I-cell_type
cells None None I-cell_type
were None None O
increased None None O
in None None O
NPs None None I-cell_type
. None None O

The None None O
percentage None None O
of None None O
inflammatory None None I-cell_type
cells None None I-cell_type
expressing None None O
GRbeta None None I-protein
was None None O
also None None O
increased None None O
( None None O
40.5 None None O
% None None O
+/- None None O
19.2 None None O
% None None O
vs None None O
16.1 None None O
% None None O
+/- None None O
4.0 None None O
% None None O
, None None O
P None None O
=.009 None None O
) None None O
. None None O

GRbeta None None I-protein
expression None None O
in None None O
NPs None None I-cell_type
was None None O
almost None None O
exclusive None None O
to None None O
T None None I-cell_type
lymphocytes None None I-cell_type
, None None O
eosinophils None None I-cell_type
, None None O
and None None O
macrophages None None I-cell_type
. None None O

An None None O
inverse None None O
correlation None None O
was None None O
observed None None O
between None None O
the None None O
baseline None None O
inflammatory None None O
cell None None O
GRbeta None None I-protein
expression None None O
and None None O
the None None O
reduction None None O
after None None O
FP None None O
treatment None None O
in None None O
EG2-positive None None I-cell_type
eosinophils None None I-cell_type
, None None O
CD4-positive None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
, None None O
endothelial None None O
VCAM-1 None None I-protein
expression None None O
, None None O
and None None O
IL-4 None None I-cell_type
mRNA-positive None None I-cell_type
cells None None I-cell_type
. None None O

NPs None None I-cell_type
that None None O
were None None O
`` None None O
FP-insensitive None None O
'' None None O
in None None O
terms None None O
of None None O
suppression None None O
of None None O
eosinophil None None I-cell_type
numbers None None O
( None None O
major None None I-protein
basic None None I-protein
protein None None I-protein
-positive None None O
) None None O
had None None O
a None None O
significantly None None O
greater None None O
percentage None None O
of None None O
GRbeta-positive None None I-cell_type
inflammatory None None I-cell_type
cells None None I-cell_type
, None None O
a None None O
higher None None O
ratio None None O
of None None O
GRbeta-positive/GRalpha-positive None None I-cell_type
cells None None I-cell_type
, None None O
and None None O
increased None None O
numbers None None O
of None None O
GRbeta-positive None None I-cell_type
eosinophils None None I-cell_type
and None None O
macrophages None None I-cell_type
in None None O
comparison None None O
with None None O
those None None O
that None None O
were None None O
`` None None O
FP-sensitive. None None O
'' None None O

`` None None I-cell_type
FP-insensitive None None I-cell_type
'' None None I-cell_type
NPs None None I-cell_type
also None None O
demonstrated None None O
a None None O
higher None None O
percentage None None O
of None None O
IL-5-positive None None I-cell_type
inflammatory None None I-cell_type
cells None None I-cell_type
expressing None None O
GRbeta None None I-protein
before None None O
and None None O
after None None O
FP None None O
treatment None None O
. None None O

CONCLUSION None None O
: None None O
GRbeta None None I-protein
expression None None O
appears None None O
to None None O
be None None O
a None None O
marker None None O
of None None O
steroid None None O
insensitivity None None O
in None None O
NPs None None I-cell_type
. None None O

Expression None None O
of None None O
GRbeta None None I-protein
by None None O
NP None None I-cell_type
inflammatory None None I-cell_type
cells None None I-cell_type
, None None O
particularly None None O
T None None I-cell_type
cells None None I-cell_type
and None None O
eosinophils None None I-cell_type
, None None O
might None None O
render None None O
them None None O
resistant None None O
to None None O
suppression None None O
by None None O
topical None None O
steroids None None O
and None None O
thereby None None O
contribute None None O
to None None O
persistent None None O
NP None None I-cell_type
inflammation None None O
. None None O

Transcriptional None None O
regulation None None O
of None None O
galectin-10 None None I-protein
( None None O
eosinophil None None I-protein
Charcot-Leyden None None I-protein
crystal None None I-protein
protein None None I-protein
) None None O
: None None O
a None None O
GC None None I-DNA
box None None I-DNA
( None None O
-44 None None O
to None None O
-50 None None O
) None None O
controls None None O
butyric None None O
acid None None O
induction None None O
of None None O
gene None None O
expression None None O
. None None O

Galectin-10 None None I-protein
( None None O
gal-10 None None I-protein
, None None O
also None None O
known None None O
as None None O
Charcot-Leyden None None I-protein
crystal None None I-protein
protein None None I-protein
) None None O
is None None O
a None None O
member None None O
of None None O
the None None O
galectin None None I-protein
family None None I-protein
of None None O
beta-galactoside None None I-protein
binding None None I-protein
proteins None None I-protein
that None None O
is None None O
expressed None None O
uniquely None None O
in None None O
eosinophilic None None I-cell_type
and None None I-cell_type
basophilic None None I-cell_type
leukocytes None None I-cell_type
. None None O

To None None O
gain None None O
a None None O
better None None O
understanding None None O
of None None O
galectin None None O
gene None None O
expression None None O
, None None O
we None None O
present None None O
an None None O
analysis None None O
of None None O
the None None O
transcriptional None None O
regulation None None O
of None None O
the None None O
gene None None O
encoding None None O
gal-10 None None I-protein
. None None O

Analysis None None O
of None None O
the None None O
minimal None None I-DNA
promoter None None I-DNA
revealed None None O
nine None None O
consensus-binding None None I-DNA
sites None None I-DNA
for None None O
transcription None None I-protein
factors None None I-protein
, None None O
including None None O
several None None O
that None None O
are None None O
also None None O
found None None O
in None None O
the None None O
minimal None None I-DNA
promoters None None I-DNA
of None None O
galectins None None I-DNA
-1 None None I-DNA
, None None I-DNA
-2 None None I-DNA
, None None I-DNA
and None None I-DNA
-3 None None I-DNA
. None None O

The None None O
decrease None None O
in None None O
gal-10 None None O
promoter None None O
activity None None O
after None None O
disruption None None O
of None None O
either None None O
the None None O
GC None None I-DNA
box None None I-DNA
( None None O
-44 None None O
to None None O
-50 None None O
) None None O
or None None O
the None None O
Oct None None I-DNA
site None None I-DNA
( None None O
-255 None None O
to None None O
-261 None None O
) None None O
suggests None None O
that None None O
these None None O
sites None None O
, None None O
along None None O
with None None O
the None None O
previously None None O
characterized None None O
GATA None None I-DNA
and None None I-DNA
EoTF None None I-DNA
sites None None I-DNA
, None None O
are None None O
necessary None None O
for None None O
full None None O
promoter None None O
activity None None O
. None None O

By None None O
supershift None None O
analysis None None O
, None None O
we None None O
demonstrate None None O
binding None None O
of None None O
the None None O
transcription None None I-protein
factors None None I-protein
Sp1 None None B-protein
and None None O
Oct1 None None I-protein
to None None O
the None None O
consensus None None I-DNA
GC None None I-DNA
box None None I-DNA
and None None O
the None None O
Oct None None I-DNA
site None None I-DNA
, None None O
respectively None None O
. None None O

Similar None None O
to None None O
gal-1 None None I-DNA
, None None O
gal-10 None None O
expression None None O
is None None O
induced None None O
by None None O
butyric None None O
acid None None O
, None None O
an None None O
effect None None O
that None None O
is None None O
lost None None O
upon None None O
ablation None None O
of None None O
the None None O
GC None None I-DNA
box None None I-DNA
. None None O

Additionally None None O
, None None O
we None None O
demonstrate None None O
AML3 None None O
binding None None O
to None None O
the None None O
consensus None None I-DNA
AML None None I-DNA
site None None I-DNA
and None None O
YY1 None None I-protein
binding None None I-protein
to None None O
the None None O
Inr None None I-DNA
sequence None None I-DNA
, None None O
both None None O
elements None None O
functioning None None O
as None None O
silencers None None O
in None None O
the None None O
gal-10 None None I-DNA
promoter None None I-DNA
. None None O

Tumour-stromal None None O
interactions None None O
. None None O

Role None None O
of None None O
the None None O
stroma None None O
in None None O
mammary None None O
development None None O
. None None O

Mammary None None O
development None None O
depends None None O
on None None O
branching None None O
morphogenesis None None O
, None None O
namely None None O
the None None O
bifurcation None None O
and None None O
extension None None O
of None None O
ductal None None O
growth None None O
points None None O
( None None O
end None None O
buds None None O
) None None O
and None None O
secretory None None O
lobules None None O
into None None O
a None None O
more None None O
or None None O
less None None O
fatty None None O
stroma None None O
. None None O

Because None None O
breast None None O
carcinomas None None O
are None None O
overwhelmingly None None O
ductal None None O
in None None O
origin None None O
, None None O
this None None O
review None None O
focuses None None O
on None None O
stromal None None O
influences None None O
guiding None None O
postnatal None None O
ductal None None O
development None None O
and None None O
there None None O
is None None O
only None None O
the None None O
briefest None None O
account None None O
of None None O
the None None O
role None None O
of None None O
embryonic None None O
stroma None None O
( None None O
mesenchyme None None O
) None None O
. None None O

The None None O
stroma None None O
as None None O
the None None O
necessary None None O
target None None O
for None None O
endocrine None None O
mammogens None None O
and None None O
the None None O
source None None O
of None None O
stimulatory None None O
growth None None O
factors None None O
is None None O
described None None O
and None None O
the None None O
importance None None O
of None None O
mammary None None O
epithelium-induced None None O
modifications None None O
of None None O
the None None O
periductal None None O
stroma None None O
is None None O
emphasized None None O
. None None O

Evidence None None O
is None None O
presented None None O
that None None O
if None None O
they None None O
are None None O
to None None O
grow None None O
, None None O
end None None O
buds None None O
must None None O
condition None None O
proximal None None O
fatty None None O
stroma None None O
by None None O
recruiting None None O
white None None I-cell_type
blood None None I-cell_type
cells None None I-cell_type
as None None O
well None None O
as None None O
inducing None None O
stromal None None O
cell None None O
division None None O
and None None O
, None None O
possibly None None O
, None None O
estrogen None None I-protein
receptors None None I-protein
. None None O

The None None O
induction None None O
of None None O
a None None O
fibrous None None O
stromal None None O
tunic None None O
around None None O
the None None O
end None None O
bud None None O
is None None O
described None None O
and None None O
its None None O
likely None None O
role None None O
as None None O
a None None O
complex None None O
ductal None None O
morphogen None None O
is None None O
discussed None None O
; None None O
a None None O
possible None None O
role None None O
in None None O
growth None None O
inhibition None None O
is None None O
also None None O
considered None None O
. None None O

Although None None O
the None None O
signals None None O
governing None None O
fibrotic None None O
induction None None O
, None None O
ductal None None O
morphogenesis None None O
, None None O
and None None O
growth None None O
inhibition None None O
are None None O
unknown None None O
, None None O
a None None O
role None None O
for None None O
transforming None None O
growth None None I-protein
factor-beta None None I-protein
is None None O
highly None None O
likely None None O
and None None O
is None None O
discussed None None O
. None None O

Finally None None O
, None None O
a None None O
need None None O
for None None O
new None None O
conceptual None None O
and None None O
experimental None None O
approaches None None O
to None None O
understanding None None O
stromal-epithelial None None O
signaling None None O
is None None O
discussed None None O
. None None O

Adipophilin None None I-protein
is None None O
a None None O
sensitive None None O
marker None None O
for None None O
lipid None None O
loading None None O
in None None O
human None None I-cell_type
blood None None I-cell_type
monocytes None None I-cell_type
. None None O

Adipophilin None None I-protein
, None None O
a None None O
marker None None O
of None None O
lipid None None O
accumulation None None O
initially None None O
described None None O
in None None O
adipocytes None None I-cell_type
, None None O
was None None O
recently None None O
shown None None O
to None None O
be None None O
induced None None O
in None None O
macrophage None None I-cell_type
foam None None I-cell_type
cells None None I-cell_type
. None None O

We None None O
found None None O
that None None O
even None None O
freshly None None I-cell_type
isolated None None I-cell_type
blood None None I-cell_type
monocytes None None I-cell_type
express None None O
adipophilin None None I-protein
and None None O
that None None O
the None None O
amount None None O
of None None O
adipophilin None None I-protein
protein None None I-protein
is None None O
variable None None O
in None None O
monocytes None None I-cell_type
from None None O
different None None O
healthy None None O
individuals None None O
. None None O

However None None O
, None None O
the None None O
physiological None None O
expression None None O
of None None O
adipophilin None None I-protein
does None None O
not None None O
correlate None None O
with None None O
the None None O
levels None None O
of None None O
free None None O
fatty None None O
acids None None O
, None None O
cholesterylesters None None O
or None None O
free None None O
cholesterol None None O
. None None O

Enzymatically None None I-protein
modified None None I-protein
low-density None None I-protein
lipoprotein None None I-protein
( None None O
E-LDL None None I-protein
) None None O
induces None None O
rapid None None O
foam None None O
cell None None O
formation None None O
in None None O
monocytes None None I-cell_type
and None None O
upregulates None None O
adipophilin None None I-protein
mRNA None None O
and None None O
protein None None O
within None None O
2 None None O
h None None O
of None None O
incubation None None O
. None None O

This None None O
rapid None None O
induction None None O
of None None O
adipophilin None None I-protein
is None None O
accompanied None None O
by None None O
a None None O
significant None None O
increase None None O
of None None O
free None None O
fatty None None O
acids None None O
in None None O
monocytes None None I-cell_type
incubated None None O
with None None O
E-LDL None None I-protein
. None None O

Adipophilin None None I-protein
facilitates None None O
the None None O
uptake None None O
of None None O
free None None O
fatty None None O
acids None None O
, None None O
and None None O
here None None O
we None None O
demonstrate None None O
that None None O
free None None O
fatty None None O
acids None None O
increase None None O
is None None O
related None None O
to None None O
the None None O
early None None O
upregulation None None O
of None None O
adipophilin None None O
expression None None O
in None None O
blood None None I-cell_type
monocytes None None I-cell_type
. None None O

Fatty None None O
acids None None O
are None None O
ligands None None O
for None None O
peroxisome None None I-protein
proliferator-activated None None I-protein
receptor-gamma None None I-protein
( None None O
PPARgamma None None I-protein
) None None O
, None None O
and None None O
the None None O
upregulation None None O
of None None O
adipophilin None None I-RNA
mRNA None None I-RNA
by None None O
PPARgamma None None I-protein
agonists None None O
like None None O
15d-PGJ None None O
( None None O
2 None None O
) None None O
and None None O
ciglitazone None None O
indicates None None O
that None None O
PPARgamma None None I-protein
may None None O
mediate None None O
the None None O
induction None None O
of None None O
adipophilin None None O
expression None None O
in None None O
human None None I-cell_type
blood None None I-cell_type
monocytes None None I-cell_type
. None None O

Constitutive None None O
expression None None O
of None None O
MHC None None I-DNA
class None None I-DNA
II None None I-DNA
genes None None I-DNA
in None None O
melanoma None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
results None None O
from None None O
the None None O
transcription None None O
of None None O
class None None I-DNA
II None None I-DNA
transactivator None None I-DNA
abnormally None None O
initiated None None O
from None None O
its None None O
B None None I-DNA
cell-specific None None I-DNA
promoter None None I-DNA
. None None O

In None None O
melanoma None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
, None None O
two None None O
different None None O
patterns None None O
of None None O
MHC None None O
class None None O
II None None O
expression None None O
have None None O
been None None O
described None None O
, None None O
either None None O
an None None O
IFN None None O
gamma-inducible None None O
expression None None O
of None None O
HLA-DR None None I-DNA
and None None O
HLA-DP None None I-DNA
, None None O
with None None O
a None None O
faint None None O
or None None O
null None None O
expression None None O
of None None O
HLA-DQ None None I-DNA
, None None O
resembling None None O
that None None O
described None None O
for None None O
melanocytes None None I-cell_type
, None None O
or None None O
a None None O
constitutive None None O
expression None None O
, None None O
i.e. None None O
, None None O
IFN-gamma None None O
independent None None O
, None None O
of None None O
all None None O
three None None O
HLA-D None None I-DNA
isotypes None None I-DNA
. None None O

As None None O
this None None O
latter None None O
phenotype None None O
has None None O
been None None O
associated None None O
with None None O
a None None O
more None None O
rapid None None O
progression None None O
of None None O
melanoma None None O
tumors None None O
, None None O
we None None O
have None None O
analyzed None None O
in None None O
different None None O
melanoma None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
the None None O
molecular None None O
mechanisms None None O
leading None None O
to None None O
this None None O
abnormal None None O
pattern None None O
of None None O
MHC None None O
class None None O
II None None O
expression None None O
. None None O

In None None O
agreement None None O
with None None O
the None None O
evidence None None O
of None None O
a None None O
coordinate None None O
transcription None None O
of None None O
the None None O
HLA-D None None I-DNA
genes None None I-DNA
in None None O
these None None O
cell None None O
lines None None O
, None None O
we None None O
have None None O
shown None None O
the None None O
constitutive None None O
expression None None O
of None None O
CIITA None None I-RNA
( None None I-RNA
class None None I-RNA
II None None I-RNA
transactivator None None I-RNA
) None None I-RNA
transcripts None None I-RNA
, None None O
CIITA None None I-protein
being None None O
known None None O
as None None O
the None None O
master None None O
switch None None O
of None None O
MHC None None O
class None None O
II None None O
expression None None O
. None None O

Unexpectedly None None O
, None None O
these None None O
transcripts None None O
initiate None None O
from None None O
promoter None None I-DNA
III None None I-DNA
of None None O
the None None O
CIITA None None I-DNA
gene None None I-DNA
, None None O
a None None O
promoter None None O
that None None O
is None None O
mainly None None O
used None None O
constitutively None None O
in None None O
B None None I-cell_type
lymphocytes None None I-cell_type
. None None O

This None None O
expression None None O
was None None O
further None None O
shown None None O
to None None O
occur None None O
through None None O
factor None None O
( None None O
s None None O
) None None O
acting None None O
on None None O
the None None O
enhancer None None O
located None None O
upstream None None O
of None None O
CIITA None None I-DNA
promoter None None I-DNA
III None None I-DNA
, None None O
which None None O
was None None O
previously None None O
described None None O
in None None O
epithelioid None None I-cell_type
cells None None I-cell_type
as None None O
an None None O
IFN-gamma-response None None O
sequence None None O
. None None O

The None None O
hypothesis None None O
of None None O
a None None O
general None None O
abnormality None None O
of None None O
the None None O
IFN-gamma None None O
transduction None None O
pathway None None O
was None None O
dismissed None None O
. None None O

Constitutive None None O
transcription None None O
of None None O
CIITA None None I-DNA
from None None O
promoter None None I-DNA
III None None I-DNA
having None None O
been None None O
observed None None O
in None None O
unrelated None None O
melanoma None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
, None None O
we None None O
propose None None O
the None None O
hypothesis None None O
that None None O
this None None O
phenomenon None None O
might None None O
not None None O
be None None O
a None None O
random None None O
event None None O
, None None O
but None None O
could None None O
be None None O
linked None None O
to None None O
the None None O
neoplasic None None O
state None None O
of None None O
the None None O
melanoma None None I-cell_type
cells None None I-cell_type

Caspase None None I-protein
-mediated None None O
calcineurin None None O
activation None None O
contributes None None O
to None None O
IL-2 None None I-protein
release None None O
during None None O
T None None O
cell None None O
activation None None O
. None None O

Calcineurin None None I-protein
, None None O
a None None O
Ca None None I-protein
( None None I-protein
2+ None None I-protein
) None None I-protein
/calmodulin-dependent None None I-protein
Ser/Thr None None I-protein
phosphatase None None I-protein
( None None I-protein
protein None None I-protein
phosphatase None None I-protein
2B None None I-protein
) None None I-protein
, None None O
plays None None O
a None None O
critical None None O
role None None O
in None None O
IL-2 None None O
production None None O
during None None O
T None None O
cell None None O
activation None None O
. None None O

It None None O
has None None O
been None None O
previously None None O
reported None None O
that None None O
IL-2 None None I-protein
release None None O
in None None O
activated None None O
Jurkat None None I-cell_line
T None None I-cell_line
requires None None O
caspase-like None None O
activity None None O
( None None O
Posmantur None None O
et None None O
al. None None O
( None None O
1998 None None O
) None None O
Exp. None None O
Cell. None None O
Res. None None O
244 None None O
, None None O
302-309 None None O
) None None O
. None None O

We None None O
report None None O
here None None O
that None None O
the None None O
60-kDa None None I-protein
catalytic None None I-protein
subunit None None I-protein
of None None O
calcineurin None None I-protein
A None None I-protein
( None None O
Cn None None I-protein
A None None I-protein
) None None O
was None None O
partially None None O
cleaved None None O
to None None O
a None None O
45-kDa None None I-protein
form None None O
in None None O
phytohemagglutinin None None O
A None None O
( None None O
PHA None None O
) None None O
or None None O
phorbol None None O
ester None None O
+ None None O
ionomycin None None O
( None None O
P None None O
+ None None O
I None None O
) None None O
-activated None None O
Jurkat None None I-cell_line
cells None None I-cell_line
. None None O

In None None O
parallel None None O
, None None O
proteolytic None None O
activation None None O
of None None O
upstream None None O
caspases None None I-protein
( None None O
caspase-8 None None O
and None None O
-9 None None O
) None None O
as None None O
well None None O
as None None O
effector None None I-protein
caspase-3 None None I-protein
was None None O
also None None O
observed None None O
. None None O

Cn None None I-protein
A None None I-protein
cleavage None None O
was None None O
caspase None None O
mediated None None O
, None None O
since None None O
it None None O
was None None O
inhibitable None None O
by None None O
pan-caspase None None O
inhibitor None None O
Cbz-Asp-CH None None O
( None None O
2 None None O
) None None O
OC None None O
( None None O
O None None O
) None None O
-2 None None O
, None None O
6-dichlorobenzene None None O
( None None O
Z-D-DCB None None O
) None None O
. None None O

Cn None None I-protein
A None None I-protein
cleavage None None O
was None None O
also None None O
observed None None O
when None None O
purified None None O
calcineurin None None I-protein
was None None O
digested None None O
in None None O
vitro None None O
with None None O
caspase-3 None None I-protein
. None None O

Truncated None None I-protein
Cn None None I-protein
A None None I-protein
was None None O
associated None None O
with None None O
enhanced None None O
phosphatase None None O
activity None None O
and None None O
reduced None None O
calmodulin None None O
sensitivity None None O
. None None O

Furthermore None None O
, None None O
in None None O
PHA None None O
or None None O
P None None O
+ None None O
I-activated None None O
Jurkat None None I-cell_line
cells None None I-cell_line
, None None O
dephosphorylation None None O
of None None O
calcineurin None None I-protein
substrate None None O
NFATc None None I-protein
( None None O
a None None O
transcription None None I-protein
factor None None I-protein
known None None O
to None None O
be None None O
involved None None O
in None None O
transactivation None None O
of None None O
the None None O
IL-2 None None I-DNA
gene None None I-DNA
) None None O
, None None O
was None None O
also None None O
suppressed None None O
by None None O
Z-D-DCB None None O
. None None O

Taken None None O
together None None O
, None None O
our None None O
results None None O
suggest None None O
that None None O
caspase-mediated None None O
cleavage None None O
of None None O
Cn None None I-protein
A None None I-protein
contributes None None O
to None None O
IL-2 None None O
production None None O
during None None O
T None None O
cell None None O
activation None None O
. None None O

Copyright None None O
2001 None None O
Academic None None O
Press None None O
. None None O

Maturation None None O
of None None O
human None None I-cell_type
dendritic None None I-cell_type
cells None None I-cell_type
as None None O
sulfasalazine None None O
target None None O
. None None O

AIM None None O
: None None O
Sulfasalazine None None O
, None None O
a None None O
nonsteroidal None None O
anti-inflammatory None None O
drug None None O
, None None O
is None None O
effective None None O
in None None O
treating None None O
some None None O
autoimmune None None O
diseases None None O
, None None O
but None None O
its None None O
mechanism None None O
of None None O
action None None O
is None None O
unclear None None O
. None None O

To None None O
determine None None O
whether None None O
dendritic None None I-cell_type
cells None None I-cell_type
could None None O
be None None O
a None None O
possible None None O
target None None O
of None None O
the None None O
drug None None O
, None None O
we None None O
studied None None O
the None None O
effects None None O
of None None O
sulfasalazine None None O
and None None O
its None None O
metabolites None None O
, None None O
aminosalicylate None None O
and None None O
sulfapyridine None None O
, None None O
on None None O
in None None O
vitro None None O
maturation None None O
( None None O
terminal None None O
differentiation None None O
) None None O
of None None O
human None None I-cell_type
myeloid None None I-cell_type
dendritic None None I-cell_type
cells None None I-cell_type
. None None O

METHODS None None O
: None None O
We None None O
prepared None None O
immature None None I-cell_type
dendritic None None I-cell_type
cells None None I-cell_type
by None None O
incubating None None O
CD14-positive None None I-cell_type
cells None None I-cell_type
in None None O
the None None O
presence None None O
of None None O
granulocyte- None None I-protein
macrophage None None I-protein
colony-stimulating None None I-protein
factor None None I-protein
and None None O
interleukin None None I-protein
( None None I-protein
IL None None I-protein
) None None I-protein
-4 None None I-protein
. None None O

The None None O
cells None None O
were None None O
matured None None O
by None None O
addition None None O
of None None O
tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
( None None I-protein
TNF None None I-protein
) None None I-protein
-a None None I-protein
, None None O
IL-1 None None I-protein
beta None None I-protein
, None None O
and None None O
prostaglandin None None I-protein
E2 None None I-protein
in None None O
the None None O
presence None None O
of None None O
sulfasalazine None None O
or None None O
its None None O
metabolites None None O
-- None None O
aminosalicylate None None O
and None None O
sulfapyridine None None O
, None None O
or None None O
their None None O
combinations None None O
. None None O

We None None O
quantified None None O
the None None O
effect None None O
of None None O
drugs None None O
on None None O
the None None O
dendritic None None O
cell None None O
characteristics None None O
, None None O
such None None O
as None None O
stimulation None None O
of None None O
autologous None None O
and None None O
allogeneic None None O
pan-T None None O
cell None None O
proliferation None None O
, None None O
surface None None O
marker None None O
phenotype None None O
, None None O
IL-12 None None O
p40 None None O
subunit None None O
secretion None None O
, None None O
and None None O
activation None None O
of None None O
nuclear None None I-protein
transcription None None I-protein
factor None None I-protein
( None None I-protein
NF None None I-protein
) None None I-protein
-kappa None None I-protein
B None None I-protein
. None None O

RESULTS None None O
: None None O
Dendritic None None I-cell_type
cells None None I-cell_type
treated None None O
with None None O
sulfasalazine None None O
( None None O
1.25 None None O
micromol/L None None O
or None None O
2.5 None None O
micromol/L None None O
) None None O
could None None O
not None None O
stimulate None None O
T None None I-cell_type
cells None None I-cell_type
( None None O
p None None O
< None None O
0.028 None None O
, None None O
two-sided None None O
paired None None O
t-test None None O
) None None O
. None None O

In None None O
distinction None None O
to None None O
drug-free None None O
maturing None None O
dendritic None None I-cell_type
cells None None I-cell_type
, None None O
2.5 None None O
micromol/L None None O
sulfasalazine None None O
upregulated None None O
the None None O
levels None None O
of None None O
CD14 None None I-protein
and None None O
CD68 None None I-protein
and None None O
downregulated None None O
the None None O
levels None None O
of None None O
CD40 None None I-protein
, None None O
CD80 None None I-protein
, None None O
and None None O
CD83 None None I-protein
( None None O
for None None O
all None None O
CD None None O
markers None None O
, None None O
p None None O
< None None O
0.03 None None O
for None None O
difference None None O
between None None O
measurements None None O
in None None O
the None None O
absence None None O
and None None O
the None None O
presence None None O
of None None O
sulfasalazine None None O
) None None O
. None None O

From None None O
concentration-dependent None None O
changes None None O
in None None O
CD83 None None O
expression None None O
, None None O
we None None O
found None None O
an None None O
apparent None None O
ID50 None None O
> None None O
> None None O
1.5 None None O
micromol/L None None O
sulfasalazine None None O
. None None O

The None None O
apparent None None O
ID50 None None O
value None None O
for None None O
aminosalicylate-inhibited None None O
maturation None None O
was None None O
4 None None O
micromol/L None None O
. None None O

Sulfapyridine None None O
had None None O
no None None O
effect None None O
. None None O

At None None O
1.25 None None O
micromol/L None None O
, None None O
sulfasalazine None None O
largely None None O
inhibited None None O
NF-kB None None O
activation None None O
in None None O
dendritic None None I-cell_type
cells None None I-cell_type
. None None O

CONCLUSION None None O
: None None O
Maturing None None I-cell_type
human None None I-cell_type
dendritic None None I-cell_type
cells None None I-cell_type
are None None O
hundred-fold None None O
more None None O
sensitive None None O
to None None O
sulfasalazine None None O
than None None O
T None None I-cell_type
cells None None I-cell_type
and None None O
NK None None I-cell_type
cells None None I-cell_type
and None None O
the None None O
most None None O
sensitive None None O
human None None O
cells None None O
described None None O
so None None O
far None None O
. None None O

Thus None None O
, None None O
dendritic None None O
cell None None O
maturation None None O
is None None O
an None None O
important None None O
target None None O
of None None O
sulfasalazine None None O
. None None O

Because None None O
of None None O
the None None O
role None None O
of None None O
dendritic None None I-cell_type
cells None None I-cell_type
in None None O
( None None O
auto None None O
) None None O
immunity None None O
, None None O
inhibition None None O
of None None O
their None None O
maturation None None O
might None None O
provide None None O
a None None O
target None None O
for None None O
further None None O
optimization None None O
of None None O
sulfasalazine None None O
therapy None None O
. None None O

Defective None None O
function None None O
of None None O
the None None O
proteasome None None I-protein
in None None O
autoimmunity None None O
: None None O
involvement None None O
of None None O
impaired None None O
NF-kappaB None None O
activation None None O
. None None O

Type None None O
1 None None O
diabetes None None O
( None None O
also None None O
known None None O
as None None O
insulin-dependent None None O
diabetes None None O
mellitus None None O
or None None O
juvenile-onset None None O
diabetes None None O
) None None O
is None None O
usually None None O
caused None None O
by None None O
T None None O
cell-mediated None None O
autoimmunity None None O
, None None O
with None None O
a None None O
prediabetic None None O
state None None O
characterized None None O
by None None O
the None None O
production None None O
of None None O
autoantibodies None None I-protein
specific None None O
for None None O
proteins None None O
expressed None None O
by None None O
pancreatic None None I-cell_type
beta None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
nonobese None None O
patient None None O
with None None O
diabetes None None O
( None None O
NOD None None O
) None None O
mouse None None O
is None None O
a None None O
spontaneous None None O
model None None O
of None None O
type None None O
1 None None O
diabetes None None O
with None None O
a None None O
strong None None O
genetic None None O
component None None O
that None None O
maps None None O
to None None O
the None None O
major None None I-DNA
histocompatibility None None I-DNA
complex None None I-DNA
( None None I-DNA
MHC None None I-DNA
) None None I-DNA
region None None I-DNA
of None None O
the None None O
genome None None I-DNA
. None None O

A None None O
specific None None O
proteasome None None I-protein
defect None None O
has None None O
been None None O
identified None None O
in None None O
NOD None None O
mouse None None O
in None None O
select None None O
lymphocytic None None I-cell_line
and None None I-cell_line
monocytic None None I-cell_line
lineages None None I-cell_line
that None None O
results None None O
from None None O
down-regulation None None O
of None None O
expression None None O
of None None O
the None None O
proteasome None None I-protein
subunit None None I-protein
LMP2 None None I-protein
, None None O
which None None O
is None None O
encoded None None O
by None None O
a None None O
gene None None O
in None None O
the None None O
MHC None None I-DNA
genomic None None I-DNA
region None None I-DNA
. None None O

This None None O
defect None None O
prevents None None O
the None None O
proteolytic None None O
processing None None O
required None None O
for None None O
the None None O
production None None O
and None None O
activation None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
nuclear None None I-protein
factor-kappaB None None I-protein
( None None O
NF-kappaB None None I-protein
) None None O
, None None O
which None None O
plays None None O
important None None O
roles None None O
in None None O
immune None None O
and None None O
inflammatory None None O
responses None None O
, None None O
as None None O
well None None O
as None None O
increases None None O
the None None O
susceptibility None None O
of None None O
the None None O
affected None None O
cells None None O
to None None O
apoptosis None None O
induced None None O
by None None O
tumor None None I-protein
necrosis None None I-protein
factor-alpha None None I-protein
( None None O
TNF-alpha None None I-protein
) None None O
. None None O

The None None O
novel None None O
role None None O
of None None O
the None None O
proteasome None None I-protein
in None None O
dysfunction None None O
in None None O
autoimmunity None None O
is None None O
presented None None O
and None None O
documented None None O
to None None O
be None None O
both None None O
tissue None None O
and None None O
developmental None None O
stage None None O
specific None None O
. None None O

We None None O
propose None None O
a None None O
role None None O
of None None O
the None None O
proteasome None None I-protein
as None None O
a None None O
step None None O
in None None O
disease None None O
pathogenesis None None O
and None None O
tissue None None O
targeting None None O
. None None O

Down-regulation None None O
of None None O
TDT None None O
transcription None None O
in None None O
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
CD8 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
thymocytes None None I-cell_type
by None None O
Ikaros None None I-protein
proteins None None I-protein
in None None O
direct None None O
competition None None O
with None None O
an None None O
Ets None None I-protein
activator None None I-protein
. None None O

Ikaros None None I-protein
is None None O
a None None O
unique None None O
regulator None None O
of None None O
lymphopoiesis None None O
that None None O
associates None None O
with None None O
pericentromeric None None I-DNA
heterochromatin None None I-DNA
and None None O
has None None O
been None None O
implicated None None O
in None None O
heritable None None O
gene None None O
inactivation None None O
. None None O

Binding None None O
and None None O
competition None None O
experiments None None O
demonstrate None None O
that None None O
Ikaros None None I-protein
dimers None None I-protein
compete None None O
with None None O
an None None O
Ets None None I-protein
activator None None I-protein
for None None O
occupancy None None O
of None None O
the None None O
lymphocyte-specific None None I-DNA
TdT None None I-DNA
promoter None None I-DNA
. None None O

Mutations None None O
that None None O
selectively None None O
disrupt None None O
Ikaros None None O
binding None None O
to None None O
an None None O
integrated None None I-DNA
TdT None None I-DNA
promoter None None I-DNA
had None None O
no None None O
effect None None O
on None None O
promoter None None O
function None None O
in None None O
a None None O
CD4 None None I-cell_line
( None None I-cell_line
+ None None I-cell_line
) None None I-cell_line
CD8 None None I-cell_line
( None None I-cell_line
+ None None I-cell_line
) None None I-cell_line
thymocyte None None I-cell_line
line None None I-cell_line
. None None O

However None None O
, None None O
these None None O
mutations None None O
abolished None None O
down-regulation None None O
on None None O
differentiation None None O
, None None O
providing None None O
evidence None None O
that None None O
Ikaros None None I-protein
plays None None O
a None None O
direct None None O
role None None O
in None None O
repression None None O
. None None O

Reduced None None O
access None None O
to None None O
restriction None None O
enzyme None None O
cleavage None None O
suggested None None O
that None None O
chromatin None None O
alterations None None O
accompany None None O
down-regulation None None O
. None None O

The None None O
Ikaros-dependent None None O
down-regulation None None O
event None None O
and None None O
the None None O
observed None None O
chromatin None None O
alterations None None O
appear None None O
to None None O
precede None None O
pericentromeric None None O
repositioning None None O
. None None O

Current None None O
models None None O
propose None None O
that None None O
the None None O
functions None None O
of None None O
Ikaros None None I-protein
should None None O
be None None O
disrupted None None O
by None None O
a None None O
small None None O
isoform None None I-protein
that None None O
retains None None O
the None None O
dimerization None None I-protein
domain None None I-protein
and None None O
lacks None None O
the None None O
DNA-binding None None I-protein
domain None None I-protein
. None None O

Surprisingly None None O
, None None O
in None None O
the None None O
CD4 None None I-cell_line
( None None I-cell_line
+ None None I-cell_line
) None None I-cell_line
CD8 None None I-cell_line
( None None I-cell_line
+ None None I-cell_line
) None None I-cell_line
thymocyte None None I-cell_line
line None None I-cell_line
, None None O
overexpression None None O
of None None O
a None None O
small None None I-protein
Ikaros None None I-protein
isoform None None I-protein
had None None O
no None None O
effect None None O
on None None O
differentiation None None O
or None None O
on None None O
the None None O
pericentromeric None None O
targeting None None O
and None None O
DNA-binding None None O
properties None None O
of None None O
Ikaros None None I-protein
. None None O

Rather None None O
, None None O
the None None O
small None None O
isoform None None I-protein
assembled None None O
into None None O
multimeric None None I-protein
complexes None None I-protein
with None None O
DNA-bound None None I-protein
Ikaros None None I-protein
at None None O
the None None O
pericentromeric None None O
foci None None O
. None None O

The None None O
capacity None None O
for None None O
in None None O
vivo None None O
multimer None None O
formation None None O
suggests None None O
that None None O
interactions None None O
between None None O
Ikaros None None I-protein
dimers None None I-protein
bound None None O
to None None O
the None None O
TdT None None I-DNA
promoter None None I-DNA
and None None O
those None None O
bound None None O
to None None O
pericentromeric None None I-DNA
repeat None None I-DNA
sequences None None I-DNA
may None None O
contribute None None O
to None None O
the None None O
pericentromeric None None O
repositioning None None O
of None None O
the None None O
inactive None None I-DNA
gene None None I-DNA
. None None O

Type None None I-protein
I None None I-protein
interferons None None I-protein
and None None O
IL-12 None None I-protein
: None None O
convergence None None O
and None None O
cross-regulation None None O
among None None O
mediators None None O
of None None O
cellular None None O
immunity None None O
. None None O

Therapeutic None None O
use None None O
of None None O
type None None I-protein
I None None I-protein
IFN None None I-protein
( None None O
IFN-alpha/beta None None I-protein
) None None O
has None None O
become None None O
common None None O
. None None O

Many None None O
of None None O
the None None O
diverse None None O
diseases None None O
targeted None None O
are None None O
marked None None O
by None None O
pathogenetic None None O
abnormalities None None O
in None None O
cell-mediated None None O
immunity None None O
( None None O
CMI None None O
) None None O
, None None O
these None None O
cellular None None O
immune None None O
responses None None O
either None None O
causing None None O
injury None None O
to None None O
the None None O
host None None O
, None None O
lacking None None O
sufficient None None O
vigor None None O
for None None O
virus None None O
or None None O
tumor None None O
clearance None None O
, None None O
or None None O
both None None O
. None None O

In None None O
general None None O
, None None O
therapeutic None None O
efficacy None None O
is None None O
limited None None O
. None None O

It None None O
is None None O
thus None None O
notable None None O
that None None O
the None None O
pleiotropic None None O
effects None None O
of None None O
type None None I-protein
I None None I-protein
IFN None None I-protein
on None None O
CMI None None O
remain None None O
poorly None None O
understood None None O
. None None O

We None None O
characterized None None O
the None None O
effects None None O
of None None O
type None None I-protein
I None None I-protein
IFN None None I-protein
on None None O
the None None O
production None None O
of None None O
IL-12 None None I-protein
, None None O
the None None O
central None None I-protein
immunoregulatory None None I-protein
cytokine None None I-protein
of None None O
the None None O
CD4 None None I-protein
( None None I-protein
+ None None I-protein
) None None I-protein
T None None I-protein
cell None None I-protein
arm None None I-protein
of None None O
CMI None None O
. None None O

We None None O
show None None O
that None None O
type None None I-protein
I None None I-protein
IFN None None I-protein
are None None O
potent None None O
inhibitors None None O
of None None O
IL-12 None None O
production None None O
by None None O
human None None I-cell_type
monocytes/macrophages None None I-cell_type
. None None O

The None None O
underlying None None O
mechanism None None O
involves None None O
transcriptional None None O
inhibition None None O
of None None O
the None None O
IL-12p40 None None I-DNA
gene None None I-DNA
, None None O
marked None None O
by None None O
down-regulation None None O
of None None O
PU.1 None None O
binding None None O
activity None None O
at None None O
the None None O
upstream None None I-DNA
Ets None None I-DNA
site None None I-DNA
of None None O
the None None O
IL-12p40 None None I-DNA
promoter None None I-DNA
. None None O

Type None None I-protein
I None None I-protein
IFN None None I-protein
have None None O
previously None None O
been None None O
shown None None O
to None None O
be None None O
able None None O
to None None O
substitute None None O
for None None O
IL-12 None None I-protein
in None None O
driving None None O
IFN-gamma None None O
production None None O
from None None O
T None None I-cell_type
and None None I-cell_type
NK None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
ability None None O
of None None O
IFN-alpha/beta None None I-protein
to None None O
suppress None None O
IL-12 None None O
production None None O
while None None O
up-regulating None None O
IFN-gamma None None O
production None None O
suggests None None O
a None None O
possible None None O
mechanistic None None O
basis None None O
for None None O
the None None O
difficulties None None O
of None None O
employing None None O
these None None O
cytokines None None I-protein
in None None O
diseases None None O
involving None None O
abnormalities None None O
of None None O
CMI None None O
. None None O

Nuclear None None I-protein
factor-kappaB None None I-protein
suppressive None None O
and None None O
inhibitor-kappaB None None I-protein
stimulatory None None O
effects None None O
of None None O
troglitazone None None O
in None None O
obese None None O
patients None None O
with None None O
type None None O
2 None None O
diabetes None None O
: None None O
evidence None None O
of None None O
an None None O
antiinflammatory None None O
action None None O
? None None O

It None None O
has None None O
been None None O
shown None None O
recently None None O
that None None O
troglitazone None None O
exerts None None O
an None None O
anti-inflammatory None None O
effect None None O
, None None O
in None None O
vitro None None O
, None None O
and None None O
in None None O
experimental None None O
animals None None O
. None None O

To None None O
test None None O
these None None O
properties None None O
in None None O
humans None None O
, None None O
we None None O
investigated None None O
the None None O
effect None None O
of None None O
troglitazone None None O
on None None O
the None None O
proinflammatory None None I-protein
transcription None None I-protein
factor None None I-protein
nuclear None None I-protein
factor-kappaB None None I-protein
and None None O
its None None O
inhibitory None None I-protein
protein None None I-protein
IkappaB None None I-protein
in None None O
mononuclear None None I-cell_type
cells None None I-cell_type
( None None O
MNC None None I-cell_type
) None None O
and None None O
plasma None None I-protein
soluble None None I-protein
intracellular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
, None None O
monocyte None None I-protein
chemoattractant None None I-protein
protein-1 None None I-protein
, None None O
plasminogen None None I-protein
activator None None I-protein
inhibitor-1 None None I-protein
, None None O
and None None O
C-reactive None None I-protein
protein None None I-protein
. None None O

We None None O
also None None O
examined None None O
the None None O
effect None None O
of None None O
troglitazone None None O
on None None O
reactive None None O
oxygen None None O
species None None O
generation None None O
, None None O
p47 None None O
( None None O
phox None None O
) None None O
subunit None None O
expression None None O
, None None O
9-hydroxyoctadecadienoic None None O
acid None None O
( None None O
9-HODE None None O
) None None O
, None None O
13-HODE None None O
, None None O
o-tyrosine None None O
, None None O
and None None O
m-tyrosine None None O
in None None O
obese None None O
patients None None O
with None None O
type None None O
2 None None O
diabetes None None O
. None None O

Seven None None O
obese None None O
patients None None O
with None None O
type None None O
2 None None O
diabetes None None O
were None None O
treated None None O
with None None O
troglitazone None None O
( None None O
400 None None O
mg/day None None O
) None None O
for None None O
4 None None O
weeks None None O
. None None O

Blood None None O
samples None None O
were None None O
obtained None None O
at None None O
weekly None None O
intervals None None O
. None None O

Nuclear None None I-protein
factor-kappaB None None I-protein
binding None None O
activity None None O
in None None O
MNC None None I-cell_type
nuclear None None O
extracts None None O
was None None O
significantly None None O
inhibited None None O
after None None O
troglitazone None None O
treatment None None O
at None None O
week None None O
1 None None O
and None None O
continued None None O
to None None O
be None None O
inhibited None None O
up None None O
to None None O
week None None O
4 None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
IkappaB None None O
protein None None O
levels None None O
increased None None O
significantly None None O
after None None O
troglitazone None None O
treatment None None O
at None None O
week None None O
1 None None O
, None None O
and None None O
this None None O
increase None None O
persisted None None O
throughout None None O
the None None O
study None None O
. None None O

Plasma None None I-protein
monocyte None None I-protein
chemoattractant None None I-protein
protein-1 None None I-protein
and None None O
soluble None None I-protein
intracellular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
concentrations None None O
did None None O
not None None O
decrease None None O
significantly None None O
after None None O
troglitazone None None O
treatment None None O
, None None O
although None None O
there None None O
was None None O
a None None O
trend None None O
toward None None O
inhibition None None O
. None None O

Reactive None None O
oxygen None None O
species None None O
generation None None O
by None None O
polymorphonuclear None None I-cell_type
cells None None I-cell_type
and None None O
MNC None None I-cell_type
, None None O
p47 None None I-protein
( None None I-protein
phox None None I-protein
) None None I-protein
subunit None None I-protein
protein None None I-protein
quantities None None O
, None None O
plasminogen None None I-protein
activator None None I-protein
inhibitor-1 None None I-protein
, None None O
and None None O
C-reactive None None I-protein
protein None None I-protein
levels None None O
decreased None None O
significantly None None O
after None None O
troglitazone None None O
intake None None O
. None None O

13-HODE/linoleic None None O
acid None None O
and None None O
9-HODE/linoleic None None O
acid None None O
ratios None None O
also None None O
decreased None None O
after None None O
troglitazone None None O
intake None None O
. None None O

However None None O
, None None O
o-tyrosine/phenylalanine None None O
and None None O
m-tyrosine/phenylalanine None None O
ratios None None O
did None None O
not None None O
change None None O
significantly None None O
. None None O

These None None O
data None None O
show None None O
that None None O
troglitazone None None O
has None None O
profound None None O
antiinflammatory None None O
effects None None O
in None None O
addition None None O
to None None O
antioxidant None None O
effects None None O
in None None O
obese None None O
type None None O
2 None None O
diabetics None None O
; None None O
these None None O
effects None None O
may None None O
be None None O
relevant None None O
to None None O
the None None O
recently None None O
described None None O
beneficial None None O
antiatherosclerotic None None O
effects None None O
of None None O
troglitazone None None O
at None None O
the None None O
vascular None None O
level None None O
. None None O

OX40 None None O
stimulation None None O
by None None O
gp34/OX40 None None I-protein
ligand None None I-protein
enhances None None O
productive None None O
human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
infection None None O
. None None O

OX40 None None I-protein
is None None O
a None None O
member None None O
of None None O
the None None O
tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
( None None I-protein
TNF None None I-protein
) None None I-protein
receptor None None I-protein
superfamily None None I-protein
and None None O
known None None O
to None None O
be None None O
an None None O
important None None O
costimulatory None None I-protein
molecule None None I-protein
expressed None None O
on None None O
activated None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

To None None O
investigate None None O
the None None O
role None None O
of None None O
costimulation None None O
of None None O
OX40 None None I-protein
in None None O
human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
( None None O
HIV-1 None None O
) None None O
infection None None O
by None None O
its None None O
natural None None O
ligand None None O
, None None O
gp34 None None I-protein
, None None O
the None None O
OX40-transfected None None I-cell_line
ACH-2 None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
, None None I-cell_line
ACH-2/OX40 None None I-cell_line
, None None O
chronically None None O
infected None None O
with None None O
HIV-1 None None O
, None None O
was None None O
cocultured None None O
with None None O
paraformaldehyde None None O
( None None O
PFA None None O
) None None O
-fixed None None O
gp34-transfected None None I-cell_line
mouse None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
, None None I-cell_line
SV-T2/gp34 None None I-cell_line
. None None O

The None None O
results None None O
showed None None O
that None None O
HIV-1 None None O
production None None O
was None None O
strongly None None O
induced None None O
. None None O

This None None O
was None None O
followed None None O
by None None O
apparent None None O
apoptosis None None O
, None None O
and None None O
both None None O
processes None None O
were None None O
specifically None None O
inhibited None None O
by None None O
the None None O
gp34 None None I-protein
-specific None None O
neutralizing None None I-protein
monoclonal None None I-protein
antibody None None I-protein
5A8 None None I-protein
. None None O

Endogenous None None O
TNF None None I-protein
alpha None None I-protein
( None None O
TNF-alpha None None I-protein
) None None O
and None None O
TNF-beta None None I-protein
production None None O
were None None O
not None None O
involved None None O
in None None O
the None None O
enhanced None None O
HIV-1 None None O
production None None O
. None None O

Furthermore None None O
, None None O
enhanced None None O
HIV-1 None None O
transcription None None O
in None None O
gp34 None None I-protein
-stimulated None None O
ACH-2/OX40 None None I-cell_line
cells None None I-cell_line
was None None O
dependent None None O
on None None O
the None None O
kappa None None I-DNA
B None None I-DNA
site None None I-DNA
of None None O
the None None O
HIV-1 None None I-DNA
long None None I-DNA
terminal None None I-DNA
repeat None None I-DNA
, None None O
and None None O
the None None O
OX40-gp34 None None O
interaction None None O
activated None None O
NF-kappa None None I-protein
B None None I-protein
consisting None None O
of None None O
p50 None None I-protein
and None None I-protein
p65 None None I-protein
subunits None None I-protein
. None None O

When None None O
primary None None O
activated None None O
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
acutely None None O
infected None None O
with None None O
HIV-1 None None O
( None None O
NL4-3 None None O
) None None O
( None None O
CXCR4-using None None I-cell_line
T-cell-line-tropic None None I-cell_line
) None None O
were None None O
cocultured None None O
with None None O
PFA-fixed None None O
gp34 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
human None None I-cell_type
T-cell None None I-cell_type
leukemia None None O
virus None None O
type None None O
1-bearing None None O
MT-2 None None I-cell_line
cells None None I-cell_line
or None None O
SV-T2/gp34 None None I-cell_line
cells None None I-cell_line
, None None O
HIV-1 None None O
production None None O
was None None O
also None None O
markedly None None O
enhanced None None O
. None None O

The None None O
enhancement None None O
was None None O
again None None O
significantly None None O
inhibited None None O
by None None O
5A8 None None I-protein
. None None O

The None None O
present None None O
study None None O
first None None O
shows None None O
that None None O
OX40-gp34 None None O
interaction None None O
stimulates None None O
HIV-1 None None O
expression None None O
and None None O
suggests None None O
that None None O
OX40 None None O
triggering None None O
by None None O
gp34 None None I-protein
may None None O
play None None O
an None None O
important None None O
role None None O
in None None O
enhancing None None O
HIV-1 None None O
production None None O
in None None O
both None None O
acutely None None O
and None None O
latently None None O
infected None None O
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
in None None O
vivo None None O
. None None O

Troglitazone None None O
, None None O
a None None O
PPARgamma None None O
ligand None None O
, None None O
inhibits None None O
osteopontin None None O
gene None None O
expression None None O
in None None O
human None None I-cell_type
monocytes/macrophage None None I-cell_type
THP-1 None None I-cell_type
cells None None I-cell_type
. None None O

Peroxizome None None I-protein
proliferator-activated None None I-protein
receptor-gamma None None I-protein
( None None O
PPARgamma None None I-protein
) None None O
is None None O
a None None O
member None None O
of None None O
the None None O
nuclear None None I-protein
receptor None None I-protein
family None None I-protein
of None None O
transcription None None I-protein
factors None None I-protein
that None None O
regulate None None O
adipocyte None None O
differentiation None None O
. None None O

Recent None None O
studies None None O
indicate None None O
that None None O
liganded None None I-protein
PPARgamma None None I-protein
not None None O
only None None O
promotes None None O
differentiation None None O
but None None O
also None None O
inhibits None None O
the None None O
activation None None O
of None None O
macrophages None None I-cell_type
. None None O

Osteopontin None None I-protein
, None None O
a None None O
component None None O
of None None O
extracellular None None O
matrix None None O
, None None O
is None None O
synthesized None None O
by None None O
macrophages None None I-cell_type
in None None O
atherosclerotic None None O
plaques None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
examined None None O
whether None None O
PPARgamma None None I-protein
ligand None None O
regulates None None O
osteopontin None None O
gene None None O
expression None None O
in None None O
THP-1 None None I-cell_line
cells None None I-cell_line
, None None O
a None None O
cell None None O
line None None O
derived None None O
from None None O
human None None I-cell_type
monocytic None None I-cell_type
leukemia None None I-cell_type
cells None None I-cell_type
which None None O
can None None O
differentiate None None O
to None None O
macrophage None None I-cell_type
upon None None O
stimulation None None O
with None None O
phorbol None None O
ester None None O
PMA None None O
. None None O

Northern None None O
blot None None O
analysis None None O
showed None None O
that None None O
osteopontin None None O
expression None None O
is None None O
markedly None None O
induced None None O
in None None O
response None None O
to None None O
PMA None None O
. None None O

Troglitazone None None O
, None None O
a None None O
PPARgamma None None I-protein
ligand None None O
, None None O
dramatically None None O
attenuated None None O
the None None O
PMA-induced None None O
osteopontin None None O
expression None None O
. None None O

Transient None None O
transfection None None O
assays None None O
of None None O
the None None O
human None None I-DNA
osteopontin None None I-DNA
promoter/luciferase None None I-DNA
construct None None I-DNA
which None None O
contains None None O
a None None O
5'-flanking None None I-DNA
region None None I-DNA
between None None O
-1500 None None O
and None None O
+87 None None O
relative None None O
to None None O
the None None O
transcription None None I-DNA
start None None I-DNA
site None None I-DNA
demonstrate None None O
that None None O
either None None O
treatment None None O
with None None O
troglitazone None None O
or None None O
cotransfection None None O
of None None O
PPARgamma None None I-DNA
expression None None I-DNA
vector None None I-DNA
inhibits None None O
osteopontin None None O
promoter None None O
activity None None O
. None None O

These None None O
data None None O
indicate None None O
that None None O
troglitazone None None O
reduces None None O
osteopontin None None O
gene None None O
expression None None O
at None None O
transcriptional None None O
level None None O
through None None O
PPARgamma None None I-protein
activation None None O
, None None O
and None None O
suggest None None O
the None None O
role None None O
of None None O
troglitazone None None O
in None None O
inhibiting None None O
the None None O
ability None None O
of None None O
macrophages None None I-cell_type
to None None O
produce None None O
extracellular None None O
matrix None None O
, None None O
which None None O
is None None O
particularly None None O
relevant None None O
to None None O
atherosclerotic None None O
plaque None None O
formation None None O
. None None O

Transcription None None I-protein
factor None None I-protein
NF-kappa None None I-protein
B None None I-protein
regulates None None O
Ig None None I-protein
lambda None None I-protein
light None None O
chain None None O
gene None None O
rearrangement None None O
. None None O

The None None O
tissue- None None O
and None None O
stage-specific None None O
assembly None None O
of None None O
Ig None None I-DNA
and None None I-DNA
TCR None None I-DNA
genes None None I-DNA
is None None O
mediated None None O
by None None O
a None None O
common None None O
V None None I-protein
( None None I-protein
D None None I-protein
) None None I-protein
J None None I-protein
recombinase None None I-protein
complex None None I-protein
in None None O
precursor None None I-cell_type
lymphocytes None None I-cell_type
. None None O

Directed None None O
alterations None None O
in None None O
the None None O
accessibility None None O
of None None O
V None None I-DNA
, None None I-DNA
D None None I-DNA
, None None I-DNA
and None None I-DNA
J None None I-DNA
gene None None I-DNA
segments None None I-DNA
target None None O
the None None O
recombinase None None I-protein
to None None O
specific None None O
Ag None None I-DNA
receptor None None I-DNA
loci None None I-DNA
. None None O

Accessibility None None O
within None None O
a None None O
given None None O
locus None None I-DNA
is None None O
regulated None None O
by None None O
the None None O
functional None None O
interaction None None O
of None None O
transcription None None I-protein
factors None None I-protein
with None None O
cognate None None I-DNA
enhancer None None I-DNA
elements None None I-DNA
and None None O
correlates None None O
with None None O
the None None O
transcriptional None None O
activity None None O
of None None O
unrearranged None None O
gene None None I-DNA
segments None None I-DNA
. None None O

As None None O
demonstrated None None O
in None None O
our None None O
prior None None O
studies None None O
, None None O
rearrangement None None O
of None None O
the None None O
Igkappa None None I-DNA
locus None None I-DNA
is None None O
regulated None None O
by None None O
the None None O
inducible None None I-protein
transcription None None I-protein
factor None None I-protein
NF-kappaB None None B-protein
. None None O

In None None O
contrast None None O
to None None O
the None None O
Igkappa None None I-DNA
locus None None I-DNA
, None None O
known None None O
transcriptional None None I-DNA
control None None I-DNA
elements None None I-DNA
in None None O
the None None O
Iglambda None None I-DNA
locus None None I-DNA
lack None None O
functional None None O
NF-kappaB None None I-DNA
binding None None I-DNA
sites None None I-DNA
. None None O

Consistent None None O
with None None O
this None None O
observation None None O
, None None O
the None None O
expression None None O
of None None O
assembled None None O
Iglambda None None I-DNA
genes None None I-DNA
in None None O
mature None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
has None None O
been None None O
shown None None O
to None None O
be None None O
NF-kappaB None None I-protein
independent None None O
. None None O

Nonetheless None None O
, None None O
we None None O
now None None O
show None None O
that None None O
specific None None O
repression None None O
of None None O
NF-kappaB None None I-protein
inhibits None None O
germline None None O
transcription None None O
and None None O
recombination None None O
of None None O
Iglambda None None I-DNA
gene None None I-DNA
segments None None I-DNA
in None None O
precursor None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
. None None O

Molecular None None O
analyses None None O
indicate None None O
that None None O
the None None O
block None None O
in None None O
NF-kappaB None None I-protein
impairs None None O
Iglambda None None O
rearrangement None None O
at None None O
the None None O
level None None O
of None None O
recombinase None None I-protein
accessibility None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
activities None None O
of None None O
known None None O
Iglambda None None I-DNA
promoter None None I-DNA
and None None O
enhancer None None I-DNA
elements None None I-DNA
are None None O
unaffected None None O
in None None O
the None None O
same None None O
cellular None None O
background None None O
. None None O

These None None O
findings None None O
expand None None O
the None None O
range None None O
of None None O
NF-kappaB None None I-protein
action None None O
in None None O
precursor None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
beyond None None O
Igkappa None None I-protein
to None None O
include None None O
the None None O
control None None O
of None None O
recombinational None None O
accessibility None None O
at None None O
both None None O
L None None I-DNA
chain None None I-DNA
loci None None I-DNA
. None None O

Moreover None None O
, None None O
our None None O
results None None O
strongly None None O
suggest None None O
the None None O
existence None None O
of None None O
a None None O
novel None None O
Iglambda None None I-DNA
regulatory None None I-DNA
element None None I-DNA
that None None O
is None None O
either None None O
directly None None O
or None None O
indirectly None None O
activated None None O
by None None O
NF-kappaB None None I-protein
during None None O
the None None O
early None None O
stages None None O
of None None O
B None None O
cell None None O
development None None O
. None None O

Transcription None None I-protein
factor None None I-protein
STAT5A None None B-protein
is None None O
a None None O
substrate None None O
of None None O
Bruton None None I-protein
's None None I-protein
tyrosine None None I-protein
kinase None None I-protein
in None None O
B None None I-cell_type
cells None None I-cell_type
. None None O

STAT5A None None I-protein
is None None O
a None None O
molecular None None O
regulator None None O
of None None O
proliferation None None O
, None None O
differentiation None None O
, None None O
and None None O
apoptosis None None O
in None None O
lymphohematopoietic None None I-cell_type
cells None None I-cell_type
. None None O

Here None None O
we None None O
show None None O
that None None O
STAT5A None None I-protein
can None None O
serve None None O
as None None O
a None None O
functional None None O
substrate None None O
of None None O
Bruton None None I-protein
's None None I-protein
tyrosine None None I-protein
kinase None None I-protein
( None None O
BTK None None I-protein
) None None O
. None None O

Purified None None I-protein
recombinant None None I-protein
BTK None None I-protein
was None None O
capable None None O
of None None O
directly None None O
binding None None O
purified None None I-protein
recombinant None None I-protein
STAT5A None None I-protein
with None None O
high None None O
affinity None None O
( None None O
K None None O
( None None O
d None None O
) None None O
= None None O
44 None None O
nm None None O
) None None O
, None None O
as None None O
determined None None O
by None None O
surface None None O
plasmon None None O
resonance None None O
using None None O
a None None O
BIAcore None None O
biosensor None None O
system None None O
. None None O

BTK None None I-protein
was None None O
also None None O
capable None None O
of None None O
tyrosine-phosphorylating None None O
ectopically None None O
expressed None None O
recombinant None None I-protein
STAT5A None None I-protein
on None None O
Tyr None None O
( None None O
694 None None O
) None None O
both None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
in None None O
a None None O
Janus None None I-protein
kinase None None I-protein
3 None None I-protein
-independent None None O
fashion None None O
. None None O

BTK None None I-protein
phosphorylated None None O
the None None O
Y665F None None I-protein
, None None I-protein
Y668F None None I-protein
, None None I-protein
and None None I-protein
Y682F None None I-protein
, None None I-protein
Y683F None None I-protein
mutants None None I-protein
but None None O
not None None O
the None None O
Y694F None None I-protein
mutant None None I-protein
of None None O
STAT5A None None I-protein
. None None O

STAT5A None None O
mutations None None O
in None None O
the None None O
Src None None I-protein
homology None None I-protein
2 None None I-protein
( None None I-protein
SH2 None None I-protein
) None None I-protein
and None None I-protein
SH3 None None I-protein
domains None None I-protein
did None None O
not None None O
alter None None O
the None None O
BTK None None I-protein
-mediated None None O
tyrosine None None O
phosphorylation None None O
. None None O

Recombinant None None I-protein
BTK None None I-protein
proteins None None I-protein
with None None O
mutant None None O
pleckstrin None None O
homology None None O
, None None O
SH2 None None I-protein
, None None I-protein
or None None I-protein
SH3 None None I-protein
domains None None I-protein
were None None O
capable None None O
of None None O
phosphorylating None None O
STAT5A None None I-protein
, None None O
whereas None None O
recombinant None None I-protein
BTK None None I-protein
proteins None None I-protein
with None None O
SH1/kinase None None O
domain None None O
mutations None None O
were None None O
not None None O
. None None O

In None None O
pull-down None None O
experiments None None O
, None None O
only None None O
full-length None None I-protein
BTK None None I-protein
and None None O
its None None O
SH1/kinase None None I-protein
domain None None I-protein
( None None O
but None None O
not None None O
the None None O
pleckstrin None None O
homology None None O
, None None O
SH2 None None I-protein
, None None I-protein
or None None I-protein
SH3 None None I-protein
domains None None I-protein
) None None O
were None None O
capable None None O
of None None O
binding None None O
STAT5A None None I-protein
. None None O

Ectopically None None O
expressed None None O
BTK None None I-protein
kinase None None I-protein
domain None None I-protein
was None None O
capable None None O
of None None O
tyrosine-phosphorylating None None O
STAT5A None None I-protein
both None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
. None None O

BTK None None I-protein
-mediated None None O
tyrosine None None O
phosphorylation None None O
of None None O
ectopically None None O
expressed None None O
wild None None O
type None None O
( None None O
but None None O
not None None O
Tyr None None I-protein
( None None I-protein
694 None None I-protein
) None None I-protein
mutant None None I-protein
) None None O
STAT5A None None I-protein
enhanced None None O
its None None O
DNA None None O
binding None None O
activity None None O
. None None O

In None None O
BTK None None I-protein
-competent None None O
chicken None None O
B None None I-cell_type
cells None None I-cell_type
, None None O
anti-IgM-stimulated None None O
tyrosine None None O
phosphorylation None None O
of None None O
STAT5 None None I-protein
protein None None I-protein
was None None O
prevented None None O
by None None O
pretreatment None None O
with None None O
the None None O
BTK None None I-protein
inhibitor None None O
LFM-A13 None None O
but None None O
not None None O
by None None O
pretreatment None None O
with None None O
the None None O
JAK3 None None O
inhibitor None None O
HI-P131 None None O
. None None O

B None None O
cell None None O
antigen None None O
receptor None None O
ligation None None O
resulted None None O
in None None O
enhanced None None O
tyrosine None None O
phosphorylation None None O
of None None O
STAT5 None None I-protein
in None None O
BTK None None I-protein
-deficient None None O
chicken None None O
B None None I-cell_type
cells None None I-cell_type
reconstituted None None O
with None None O
wild None None I-protein
type None None I-protein
human None None I-protein
BTK None None I-protein
but None None O
not None None O
in None None O
BTK None None I-protein
-deficient None None O
chicken None None O
B None None I-cell_type
cells None None I-cell_type
reconstituted None None O
with None None O
kinase-inactive None None I-protein
mutant None None I-protein
BTK None None I-protein
. None None O

Similarly None None O
, None None O
anti-IgM None None O
stimulation None None O
resulted None None O
in None None O
enhanced None None O
tyrosine None None O
phosphorylation None None O
of None None O
STAT5A None None I-protein
in None None O
BTK None None I-protein
-competent None None O
B None None I-cell_type
cells None None I-cell_type
from None None O
wild None None O
type None None O
mice None None O
but None None O
not None None O
in None None O
BTK None None I-protein
-deficient None None O
B None None I-cell_type
cells None None I-cell_type
from None None O
XID None None O
mice None None O
. None None O

In None None O
contrast None None O
to None None O
B None None I-cell_type
cells None None I-cell_type
from None None O
XID None None O
mice None None O
, None None O
B None None I-cell_type
cells None None I-cell_type
from None None O
JAK3 None None O
knockout None None O
mice None None O
showed None None O
a None None O
normal None None O
STAT5A None None O
phosphorylation None None O
response None None O
to None None O
anti-IgM None None O
stimulation None None O
. None None O

These None None O
findings None None O
provide None None O
unprecedented None None O
experimental None None O
evidence None None O
that None None O
BTK None None I-protein
plays None None O
a None None O
nonredundant None None O
and None None O
pivotal None None O
role None None O
in None None O
B None None O
cell None None O
antigen None None O
receptor-mediated None None O
STAT5A None None O
activation None None O
in None None O
B None None I-cell_type
cells None None I-cell_type

Role None None O
of None None O
T-bet None None I-protein
in None None O
commitment None None O
of None None O
TH1 None None I-cell_type
cells None None I-cell_type
before None None O
IL-12 None None I-protein
-dependent None None O
selection None None O
. None None O

How None None O
cytokines None None I-protein
control None None O
differentiation None None O
of None None O
helper None None I-cell_type
T None None I-cell_type
( None None I-cell_type
TH None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
is None None O
controversial None None O
. None None O

We None None O
show None None O
that None None O
T-bet None None I-protein
, None None O
without None None O
apparent None None O
assistance None None O
from None None O
interleukin None None I-protein
12 None None I-protein
( None None I-protein
IL-12 None None I-protein
) None None I-protein
/ None None O
STAT4 None None I-protein
, None None O
specifies None None O
TH1 None None I-cell_type
effector None None O
fate None None O
by None None O
targeting None None O
chromatin None None O
remodeling None None O
to None None O
individual None None O
interferon-gamma None None I-DNA
( None None I-DNA
IFN-gamma None None I-DNA
) None None I-DNA
alleles None None I-DNA
and None None O
by None None O
inducing None None O
IL-12 None None I-DNA
receptor None None I-DNA
beta2 None None I-DNA
expression None None O
. None None O

Subsequently None None O
, None None O
it None None O
appears None None O
that None None O
IL-12 None None I-protein
/ None None O
STAT4 None None I-protein
serves None None O
two None None O
essential None None O
functions None None O
in None None O
the None None O
development None None O
of None None O
TH1 None None I-cell_type
cells None None I-cell_type
: None None O
as None None O
growth None None I-protein
signal None None I-protein
, None None O
inducing None None O
survival None None O
and None None O
cell None None O
division None None O
; None None O
and None None O
as None None O
trans-activator None None I-protein
, None None O
prolonging None None O
IFN-gamma None None I-protein
synthesis None None O
through None None O
a None None O
genetic None None O
interaction None None O
with None None O
the None None O
coactivator None None I-protein
, None None O
CREB-binding None None I-protein
protein None None I-protein
. None None O

These None None O
results None None O
suggest None None O
that None None O
a None None O
cytokine None None I-protein
does None None O
not None None O
simply None None O
induce None None O
TH None None O
fate None None O
choice None None O
but None None O
instead None None O
may None None O
act None None O
as None None O
an None None O
essential None None O
secondary None None O
stimulus None None O
that None None O
mediates None None O
selective None None O
survival None None O
of None None O
a None None O
lineage None None O
. None None O

Stat6 None None I-protein
is None None O
necessary None None O
and None None O
sufficient None None O
for None None O
IL-4 None None O
's None None O
role None None O
in None None O
Th2 None None O
differentiation None None O
and None None O
cell None None O
expansion None None O
. None None O

IL-4 None None I-protein
plays None None O
a None None O
critical None None O
role None None O
in None None O
the None None O
differentiation None None O
of None None O
T None None O
CR-stimulated None None I-cell_type
naive None None I-cell_type
CD4 None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
to None None O
the None None O
Th2 None None O
phenotype None None O
. None None O

In None None O
response None None O
to None None O
IL-4 None None I-protein
, None None O
the None None O
IL-4R None None I-protein
activates None None O
a None None O
set None None O
of None None O
phosphotyrosine None None I-protein
binding None None I-protein
domain-containing None None I-protein
proteins None None I-protein
, None None O
including None None O
insulin None None I-protein
receptor None None I-protein
substrate None None I-protein
1/2 None None I-protein
, None None O
Shc None None I-protein
, None None O
and None None O
IL-4R None None I-protein
interacting None None I-protein
protein None None I-protein
, None None O
as None None O
well None None O
as None None O
Stat6 None None I-protein
. None None O

Stat6 None None I-protein
has None None O
been None None O
shown None None O
to None None O
be None None O
required None None O
for None None O
Th2 None None O
differentiation None None O
. None None O

To None None O
determine None None O
the None None O
roles None None O
of None None O
the None None O
phosphotyrosine None None I-protein
binding None None I-protein
adaptors None None I-protein
in None None O
Th2 None None O
differentiation None None O
, None None O
we None None O
prepared None None O
a None None O
retrovirus None None O
containing None None O
a None None O
mutant None None O
of None None O
the None None O
human None None I-protein
( None None I-protein
h None None I-protein
) None None I-protein
IL-4R None None I-protein
alpha-chain None None I-protein
, None None O
Y497F None None I-protein
, None None O
which None None O
is None None O
unable None None O
to None None O
recruit None None O
these None None O
adaptors None None O
. None None O

The None None O
mutant None None I-protein
hIL-4Ralpha None None I-protein
, None None O
as None None O
well None None O
as None None O
the None None O
wild-type None None I-protein
( None None I-protein
WT None None I-protein
) None None I-protein
hIL-4Ralpha None None I-protein
, None None O
was None None O
introduced None None O
into None None O
naive None None I-cell_type
CD4 None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

Upon None None O
hIL-4 None None O
stimulation None None O
, None None O
Y497F None None I-protein
worked None None O
as None None O
well None None O
as None None O
the None None O
WT None None I-protein
hIL-4Ralpha None None I-protein
in None None O
driving None None O
Th2 None None O
differentiation None None O
, None None O
as None None O
measured None None O
by None None O
Gata3 None None O
up-regulation None None O
and None None O
IL-4 None None O
production None None O
. None None O

Furthermore None None O
, None None O
IL-4-driven None None O
cell None None O
expansion None None O
was None None O
also None None O
normal None None O
in None None O
the None None O
cells None None O
infected None None O
with None None O
Y497F None None I-protein
, None None O
although None None O
cells None None O
infected None None O
with None None O
Y497F None None I-protein
were None None O
not None None O
capable None None O
of None None O
phosphorylating None None O
insulin None None I-protein
receptor None None I-protein
substrate None None I-protein
2 None None I-protein
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
signal None None O
pathway None None O
mediated None None O
by None None O
Y497 None None I-protein
is None None O
dispensable None None O
for None None O
both None None O
IL-4 None None I-protein
-driven None None O
Th2 None None O
differentiation None None O
and None None O
cell None None O
expansion None None O
. None None O

Both None None O
WT None None I-protein
and None None I-protein
Y497F None None I-protein
hIL-4Ralpha None None I-protein
lose None None O
the None None O
ability None None O
to None None O
drive None None O
Th2 None None O
differentiation None None O
and None None O
cell None None O
expansion None None O
in None None O
Stat6-knockout None None I-cell_type
CD4 None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

A None None O
constitutively None None O
activated None None O
form None None O
of None None O
Stat6 None None I-protein
introduced None None O
into None None O
CD4 None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
resulted None None O
in None None O
both None None O
Th2 None None O
differentiation None None O
and None None O
enhanced None None O
cell None None O
expansion None None O
. None None O

Thus None None O
, None None O
activated None None I-protein
Stat6 None None I-protein
is None None O
necessary None None O
and None None O
sufficient None None O
to None None O
mediate None None O
both None None O
IL-4 None None I-protein
-driven None None O
Th2 None None O
differentiation None None O
and None None O
cell None None O
expansion None None O
in None None O
CD4 None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
effect None None O
of None None O
HIV-1 None None I-protein
regulatory None None I-protein
proteins None None I-protein
on None None O
cellular None None O
genes None None O
: None None O
derepression None None O
of None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
by None None O
Tat None None I-protein
. None None O

In None None O
HIV-infected None None O
individuals None None O
dysregulation None None O
of None None O
the None None O
immune None None O
system None None O
is None None O
characterized None None O
by None None O
severe None None O
disorders None None O
of None None O
the None None O
cytokine None None O
network None None O
. None None O

Increase None None O
secretion None None O
of None None O
IL-2 None None I-protein
, None None O
the None None O
major None None O
T None None I-cell_type
cell None None I-cell_type
growth None None O
and None None O
differentiation None None O
cytokine None None I-protein
, None None O
may None None O
play None None O
a None None O
decisive None None O
role None None O
in None None O
sensitization None None O
of None None O
T None None I-cell_type
cells None None I-cell_type
for None None O
activation None None O
induced None None O
apoptosis None None O
and None None O
indirect None None O
death None None O
of None None O
activated None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
through None None O
augmented None None O
virus None None O
replication None None O
. None None O

We None None O
investigated None None O
the None None O
cause None None O
of None None O
enhanced None None O
IL-2 None None O
secretion None None O
and None None O
found None None O
that None None O
the None None O
HIV None None I-protein
Tat None None I-protein
induces None None O
this None None O
effect None None O
. None None O

We None None O
demonstrate None None O
that None None O
increased None None O
IL-2 None None O
secretion None None O
is None None O
due None None O
to None None O
Tat None None I-protein
-enhanced None None O
IL-2 None None I-DNA
promoter None None I-DNA
activation None None O
. None None O

Tat None None I-protein
derepresses None None O
and None None O
activates None None O
the None None O
distal None None I-DNA
AP-1 None None I-DNA
site None None I-DNA
( None None O
position None None I-DNA
-185 None None I-DNA
to None None I-DNA
-177 None None I-DNA
) None None O
in None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
. None None O

In None None O
nonstimulated None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
a None None O
repressor None None O
complex None None O
containing None None O
NF-IL6 None None I-protein
, None None O
JunB None None I-protein
, None None O
c-Fos None None I-protein
and None None O
Fra-1 None None I-protein
is None None O
formed None None O
on None None O
the None None O
AP-1 None None I-DNA
( None None I-DNA
IL-2/d None None I-DNA
) None None I-DNA
site None None I-DNA
and None None O
represses None None O
IL-2 None None I-DNA
promoter None None I-DNA
activity None None O
. None None O

After None None O
T None None O
cell None None O
activation None None O
, None None O
a None None O
heterodimeric None None I-protein
activator None None I-protein
containing None None O
p65 None None I-protein
and None None O
c-Jun None None I-protein
binds None None O
to None None O
the None None O
AP-1 None None I-DNA
( None None I-DNA
IL-2/d None None I-DNA
) None None I-DNA
site None None I-DNA
. None None O

HIV None None I-protein
Tat None None I-protein
enhances None None O
activation None None O
of None None O
NF-kappaB None None I-protein
and None None O
consequently None None O
, None None O
activates None None O
the None None O
AP-1 None None I-DNA
( None None I-DNA
IL-2/d None None I-DNA
) None None I-DNA
site None None I-DNA
. None None O

Our None None O
data None None O
provide None None O
evidence None None O
for None None O
a None None O
novel None None O
mechanism None None O
by None None O
which None None O
HIV None None I-protein
Tat None None I-protein
dysregulates None None O
IL-2 None None O
production None None O
and None None O
therefore None None O
may None None O
contribute None None O
to None None O
the None None O
HIV-1 None None O
infection None None O
in None None O
a None None O
way None None O
yet None None O
to None None O
be None None O
clarified None None O
. None None O

Transforming None None I-protein
growth None None I-protein
factor-beta1 None None I-protein
interferes None None O
with None None O
thrombopoietin-induced None None O
signal None None O
transduction None None O
in None None O
megakaryoblastic None None I-cell_type
and None None I-cell_type
erythroleukemic None None I-cell_type
cells None None I-cell_type
. None None O

OBJECTIVE None None O
: None None O
Thrombopoietin None None I-protein
( None None O
TPO None None I-protein
) None None O
and None None O
transforming None None I-protein
growth None None I-protein
factor-beta None None I-protein
( None None I-protein
1 None None I-protein
) None None I-protein
( None None O
TGF-beta None None I-protein
( None None I-protein
1 None None I-protein
) None None I-protein
) None None O
have None None O
been None None O
shown None None O
to None None O
exert None None O
opposite None None O
effects None None O
on None None O
proliferation None None O
and None None O
megakaryocytic None None O
differentiation None None O
of None None O
hematopoietic None None I-cell_type
cells None None I-cell_type
. None None O

To None None O
determine None None O
whether None None O
TGF-beta None None I-protein
( None None I-protein
1 None None I-protein
) None None I-protein
interferes None None O
directly None None O
with None None O
TPO None None I-protein
-induced None None O
signal None None O
transduction None None O
in None None O
hematopoietic None None I-cell_type
cells None None I-cell_type
, None None O
we None None O
compared None None O
the None None O
regulatory None None O
effects None None O
in None None O
the None None O
TPO None None I-protein
-responsive None None O
cell None None O
lines None None O
Mo-7e None None O
and None None O
HEL None None O
. None None O

MATERIALS None None O
AND None None O
METHODS None None O
: None None O
The None None O
cells None None O
were None None O
stimulated None None O
by None None O
100 None None O
ng/mL None None O
TPO None None I-protein
and/or None None O
100 None None O
ng/mL None None O
TGF-beta1 None None I-protein
and None None O
analyzed None None O
for None None O
proliferation None None O
( None None O
3H None None O
thymidine None None O
incorporation None None O
) None None O
, None None O
viability None None O
( None None O
trypan None None O
blue None None O
exclusion None None O
) None None O
, None None O
and None None O
protein None None O
expression None None O
and None None O
phosphorylation None None O
( None None O
Western None None O
blot None None O
) None None O
. None None O

RESULTS None None O
: None None O
TPO None None I-protein
enhanced None None O
the None None O
proliferation None None O
of None None O
Mo-7e None None I-cell_line
cells None None I-cell_line
as None None O
determined None None O
by None None O
3H-thymidine None None O
incorporation None None O
, None None O
whereas None None O
TGF-beta1 None None I-protein
suppressed None None O
baseline None None O
cell None None O
growth None None O
and None None O
antagonized None None O
the None None O
proliferative None None O
effect None None O
of None None O
TPO None None I-protein
. None None O

TPO None None I-protein
-induced None None O
proliferation None None O
also None None O
was None None O
reduced None None O
by None None O
a None None O
specific None None O
inhibitor None None O
of None None O
the None None O
mitogen-activated None None I-protein
protein None None I-protein
kinase None None I-protein
( None None O
MAPK None None I-protein
) None None O
pathway None None O
( None None O
PD098059 None None O
) None None O
, None None O
which None None O
inhibits None None O
activation None None O
of None None O
the None None O
MAPK None None I-protein
extracellular None None I-protein
signal-regulated None None I-protein
kinases None None I-protein
( None None O
ERK None None I-protein
) None None O
ERK1 None None I-protein
and None None O
ERK2 None None I-protein
, None None O
and None None O
AG490 None None O
, None None O
an None None O
inhibitor None None O
of None None O
Janus None None I-protein
kinase-2 None None I-protein
, None None O
which None None O
completely None None O
blocked None None O
TPO None None I-protein
-induced None None O
proliferation None None O
. None None O

As None None O
demonstrated None None O
by None None O
Western None None O
blotting None None O
, None None O
TGF-beta1 None None I-protein
reduced None None O
the None None O
TPO None None I-protein
-stimulated None None O
ERK1 None None I-protein
/ None None O
ERK2 None None I-protein
and None None O
STAT5 None None O
phosphorylation None None O
in None None O
Mo-7e None None I-cell_line
and None None I-cell_line
HEL None None I-cell_line
cells None None I-cell_line
. None None O

This None None O
effect None None O
was None None O
completely None None O
reversed None None O
by None None O
preincubation None None O
with None None O
a None None O
tyrosine None None O
phosphatase None None O
inhibitor None None O
( None None O
Na3VO4 None None O
) None None O
, None None O
which None None O
suggests None None O
that None None O
TGF-beta1 None None I-protein
activated None None O
a None None O
phosphatase None None I-protein
. None None O

Although None None O
STAT3 None None I-protein
also None None O
was None None O
activated None None O
by None None O
TPO None None I-protein
, None None O
STAT3 None None I-protein
activation None None O
remained None None O
unaltered None None O
by None None O
TGF-beta1 None None I-protein
. None None O

CONCLUSION None None O
: None None O
Taken None None O
together None None O
, None None O
these None None O
data None None O
suggest None None O
that None None O
TGF-beta1 None None I-protein
modulates None None O
TPO None None I-protein
-mediated None None O
effects None None O
on None None O
megakaryocytic None None O
proliferation None None O
by None None O
interfering None None O
with None None O
TPO None None I-protein
-induced None None O
signal None None O
transduction None None O
, None None O
particularly None None O
by None None O
reducing None None O
the None None O
activities None None O
of None None O
MAPK None None I-protein
ERK1/ERK2 None None I-protein
and None None I-protein
STAT5 None None I-protein
. None None O

Invariant None None I-protein
chain None None I-protein
induces None None O
B None None O
cell None None O
maturation None None O
by None None O
activating None None O
a None None O
TAF None None I-protein
( None None I-protein
II None None I-protein
) None None I-protein
105-NF-kappaB None None I-protein
-dependent None None O
transcription None None O
program None None O
. None None O

Early None None O
stages None None O
of None None O
B None None O
cell None None O
development None None O
occur None None O
in None None O
the None None O
bone None None O
marrow None None O
, None None O
resulting None None O
in None None O
formation None None O
of None None O
immature None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
. None None O

From None None O
there None None O
these None None O
immature None None I-cell_type
cells None None I-cell_type
migrate None None O
to None None O
the None None O
spleen None None O
where None None O
they None None O
differentiate None None O
to None None O
mature None None I-cell_type
cells None None I-cell_type
. None None O

This None None O
final None None O
maturation None None O
step None None O
is None None O
crucial None None O
for None None O
the None None O
B None None I-cell_type
cells None None I-cell_type
to None None O
become None None O
responsive None None O
to None None O
antigens None None I-protein
and None None O
to None None O
participate None None O
in None None O
the None None O
immune None None O
response None None O
. None None O

Recently None None O
, None None O
invariant None None I-protein
chain None None I-protein
( None None O
Ii None None I-protein
) None None O
, None None O
a None None O
major None None I-protein
histocompatibility None None I-protein
complex None None I-protein
class None None I-protein
II None None I-protein
chaperone None None I-protein
, None None O
as None None O
well None None O
as None None O
the None None O
transcription None None I-protein
factors None None I-protein
c-Rel None None B-protein
and None None O
p65/RelA None None I-protein
, None None O
were None None O
found None None O
to None None O
play None None O
a None None O
role None None O
in None None O
the None None O
final None None O
antigen-independent None None O
differentiation None None O
stage None None O
of None None O
B None None I-cell_type
cells None None I-cell_type
in None None O
the None None O
spleen None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
investigated None None O
a None None O
possible None None O
link None None O
between None None O
Ii None None I-protein
-dependent None None O
B None None O
cell None None O
maturation None None O
and None None O
the None None O
NF-kappaB None None O
pathway None None O
. None None O

Our None None O
studies None None O
indicate None None O
that None None O
Ii None None I-protein
-induced None None O
B None None O
cell None None O
maturation None None O
involves None None O
activation None None O
of None None O
transcription None None O
mediated None None O
by None None O
the None None O
NF-kappaB None None I-protein
p65/RelA None None I-protein
homodimer None None I-protein
and None None O
requires None None O
the None None O
B None None I-protein
cell-enriched None None I-protein
coactivator None None I-protein
TBP-associated None None B-protein
factor None None I-protein
( None None I-protein
II None None I-protein
) None None I-protein
105 None None I-protein
. None None O

Androgens None None O
indirectly None None O
accelerate None None O
thymocyte None None I-cell_type
apoptosis None None O
. None None O

Apoptotic None None O
processes None None O
, None None O
or None None O
the None None O
disturbance None None O
of None None O
the None None O
natural None None O
regulation None None O
of None None O
these None None O
processes None None O
, None None O
may None None O
be None None O
involved None None O
in None None O
the None None O
pathogenesis None None O
of None None O
autoimmune None None O
diseases None None O
( None None O
AID None None O
) None None O
. None None O

Women None None O
are None None O
, None None O
in None None O
general None None O
, None None O
more None None O
susceptible None None O
than None None O
men None None O
to None None O
develop None None O
AID None None O
like None None O
rheumatoid None None O
arthritis None None O
. None None O

Androgens None None O
and None None O
glucocorticoids None None O
, None None O
in None None O
contrast None None O
to None None O
oestrogens None None O
, None None O
have None None O
favourable None None O
effects None None O
in None None O
AID None None O
models None None O
as None None O
well None None O
as None None O
in None None O
human None None O
AID None None O
. None None O

It None None O
is None None O
known None None O
that None None O
glucocorticoids None None O
( None None O
GC None None O
) None None O
, None None O
used None None O
for None None O
treatment None None O
of None None O
AID None None O
, None None O
increase None None O
apoptosis None None O
in None None O
the None None O
thymus None None O
resulting None None O
in None None O
decreased None None O
numbers None None O
of None None O
CD4+ None None I-cell_type
CD8+ None None I-cell_type
thymocytes None None I-cell_type
. None None O

It None None O
was None None O
asked None None O
whether None None O
androgens None None O
, None None O
in None None O
contrast None None O
to None None O
oestrogens None None O
, None None O
exert None None O
their None None O
favourable None None O
effects None None O
in None None O
the None None O
treatment None None O
of None None O
AID None None O
by None None O
a None None O
mechanism None None O
comparable None None O
to None None O
that None None O
described None None O
for None None O
GC None None O
by None None O
eliminating None None O
the None None O
apoptosis None None O
prone None None O
CD4+ None None I-cell_type
CD8+ None None I-cell_type
population None None I-cell_type
in None None O
the None None O
thymus None None O
. None None O

Although None None O
both None None O
androgens None None O
and None None O
oestrogens None None O
proved None None O
thymolytic None None O
, None None O
a None None O
significantly None None O
decreased None None O
percentage None None O
of None None O
CD4+ None None I-cell_type
CD8+ None None I-cell_type
thymocytes None None I-cell_type
was None None O
observed None None O
by None None O
flow None None O
cytometry None None O
after None None O
treatment None None O
of None None O
mice None None O
with None None O
the None None O
androgen None None O
methyltestosterone None None O
, None None O
but None None O
not None None O
with None None O
the None None O
oestrogen None None O
ethinylestradiol None None O
. None None O

To None None O
investigate None None O
whether None None O
the None None O
observed None None O
thymolytic None None O
effects None None O
were None None O
due None None O
to None None O
the None None O
presence None None O
of None None O
hormone None None I-protein
receptors None None I-protein
on None None O
thymocytes None None I-cell_type
, None None O
cells None None O
were None None O
isolated None None O
from None None O
the None None O
thymus None None O
and None None O
incubated None None O
with None None O
androgens None None O
or None None O
oestrogens None None O
to None None O
measure None None O
apoptosis None None O
. None None O

Several None None O
techniques None None O
were None None O
used None None O
to None None O
determine None None O
thymocyte None None I-cell_type
apoptosis None None O
in None None O
vitro None None O
, None None O
but None None O
no None None O
enhanced None None O
apoptotic None None O
signal None None O
was None None O
observed None None O
. None None O

Using None None O
the None None O
very None None O
sensitive None None O
TUNEL None None O
assay None None O
, None None O
no None None O
direct None None O
effect None None O
of None None O
androgens None None O
on None None O
thymocytes None None I-cell_type
in None None O
vitro None None O
could None None O
be None None O
observed None None O
. None None O

This None None O
is None None O
in None None O
sharp None None O
contrast None None O
to None None O
the None None O
high None None O
signal None None O
observed None None O
with None None O
GC None None O
. None None O

Therefore None None O
, None None O
upon None None O
in None None O
vivo None None O
androgen None None O
treatment None None O
, None None O
other None None O
cells None None O
containing None None O
androgen None None I-protein
receptors None None I-protein
than None None O
thymocytes None None I-cell_type
are None None O
probably None None O
involved None None O
in None None O
inducing None None O
the None None O
increase None None O
in None None O
thymic None None O
apoptosis None None O
. None None O

To None None O
study None None O
the None None O
role None None O
of None None O
the None None O
androgen None None I-protein
receptor None None I-protein
on None None O
thymocyte None None I-cell_type
apoptosis None None O
, None None O
androgen None None I-protein
receptor None None I-protein
mutant None None O
( None None O
Tfm/Y None None O
) None None O
mice None None O
were None None O
treated None None O
with None None O
androgens None None O
. None None O

No None None O
alterations None None O
of None None O
thymocyte None None I-cell_type
subpopulations None None I-cell_type
were None None O
seen None None O
, None None O
suggesting None None O
that None None O
changes None None O
in None None O
the None None O
percentage None None O
of None None O
CD4+ None None I-cell_type
CD8+ None None I-cell_type
thymocytes None None I-cell_type
after None None O
administration None None O
of None None O
androgens None None O
depend None None O
on None None O
the None None O
presence None None O
of None None O
functional None None O
androgen None None I-protein
receptors None None I-protein
. None None O

Thus None None O
, None None O
it None None O
is None None O
concluded None None O
that None None O
androgens None None O
indirectly None None O
accelerate None None O
thymocyte None None I-cell_type
apoptosis None None O
in None None O
vivo None None O
. None None O

Inhibition None None O
of None None O
the None None O
transcription None None I-protein
factors None None I-protein
AP-1 None None B-protein
and None None O
NF-kappaB None None I-protein
in None None O
CD4 None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
by None None O
peroxisome None None I-protein
proliferator-activated None None I-protein
receptor None None I-protein
gamma None None I-protein
ligands None None I-protein
. None None O

The None None O
peroxisome None None I-protein
proliferator-activated None None I-protein
receptor None None I-protein
gamma None None I-protein
( None None O
PPARgamma None None I-protein
) None None O
, None None O
a None None O
member None None O
of None None O
the None None O
nuclear None None I-protein
hormone None None I-protein
receptor None None I-protein
superfamily None None I-protein
, None None O
is None None O
essential None None O
for None None O
adipocyte None None O
differentiation None None O
and None None O
glucose None None O
homeostasis None None O
. None None O

PPARgamma None None I-protein
has None None O
been None None O
found None None O
recently None None O
to None None O
regulate None None O
macrophage None None O
activation None None O
in None None O
response None None O
to None None O
mitogens None None I-protein
and None None O
inflammation None None O
. None None O

Our None None O
study None None O
shows None None O
PPARgamma None None I-protein
to None None O
be None None O
preferentially None None O
expressed None None O
in None None O
the None None O
nuclei None None O
of None None O
resting None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
and None None O
to None None O
increase None None O
upon None None O
activation None None O
of None None O
T None None I-cell_type
cells None None I-cell_type
by None None O
either None None O
anti-CD3 None None I-protein
and None None O
anti-CD28 None None I-protein
or None None O
phorbol None None O
myristyl None None O
acetate None None O
( None None O
PMA None None O
) None None O
. None None O

We None None O
also None None O
found None None O
the None None O
PPARgamma None None I-protein
ligand None None I-protein
ciglitizone None None O
to None None O
attenuate None None O
the None None O
activation None None O
of None None O
T None None I-cell_type
cells None None I-cell_type
by None None O
inhibiting None None O
cytokine None None O
gene None None O
expression None None O
and None None O
anti-CD3 None None I-protein
and None None O
anti-CD28 None None I-protein
or None None O
PMA-induced None None O
proliferative None None O
responses None None O
. None None O

Inhibition None None O
of None None O
both None None O
the None None O
proliferative None None O
response None None O
and None None O
inflammatory None None O
cytokine None None O
expression None None O
in None None O
CD4 None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
was None None O
correlated None None O
with None None O
suppression None None O
of None None O
the None None O
activated None None O
transcription None None I-protein
factors None None I-protein
AP1 None None B-protein
and None None O
NF-kappaB None None I-protein
. None None O

PPARgamma None None I-protein
ligands None None I-protein
also None None O
strongly None None O
inhibited None None O
SEA-induced None None O
Vbeta3 None None O
T None None O
cell None None O
activation None None O
in None None O
vivo None None O
. None None O

These None None O
results None None O
, None None O
together None None O
with None None O
previous None None O
findings None None O
of None None O
the None None O
inhibitory None None O
effect None None O
of None None O
PPARgamma None None I-protein
ligands None None I-protein
on None None O
activated None None I-cell_type
macrophages None None I-cell_type
, None None O
provide None None O
clear None None O
evidence None None O
for None None O
PPARgamma None None I-protein
as None None O
a None None O
negative None None I-protein
regulator None None I-protein
of None None O
the None None O
inflammatory None None O
activation None None O
of None None O
both None None O
macrophage None None I-cell_type
and None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

PPARgamma None None I-protein
may None None O
thus None None O
be None None O
a None None O
potential None None O
therapeutic None None O
target None None O
for None None O
the None None O
treatment None None O
of None None O
autoimmunity None None O
. None None O

A None None O
prominent None None O
role None None O
for None None O
activator None None I-protein
protein-1 None None I-protein
in None None O
the None None O
transcription None None O
of None None O
the None None O
human None None I-DNA
2B4 None None I-DNA
( None None I-DNA
CD244 None None I-DNA
) None None I-DNA
gene None None I-DNA
in None None O
NK None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
cell None None I-protein
surface None None I-protein
glycoprotein None None I-protein
2B4 None None I-protein
( None None O
CD244 None None I-protein
) None None O
of None None O
the None None O
Ig None None I-protein
superfamily None None I-protein
is None None O
involved None None O
in None None O
the None None O
regulation None None O
of None None O
NK None None I-cell_type
and None None O
T None None I-cell_type
lymphocyte None None I-cell_type
functions None None O
. None None O

We None None O
have None None O
recently None None O
identified None None O
CD48 None None I-protein
as None None O
the None None O
high None None I-protein
affinity None None I-protein
counterreceptor None None I-protein
for None None O
2B4 None None I-protein
in None None O
both None None O
mice None None O
and None None O
humans None None O
. None None O

The None None O
cytoplasmic None None I-protein
domain None None I-protein
of None None O
2B4 None None I-protein
associates None None O
with None None O
src None None I-protein
homology None None I-protein
2 None None I-protein
domain-containing None None I-protein
protein None None I-protein
or None None O
signaling None None I-protein
lymphocyte None None I-protein
activation None None I-protein
molecule-associated None None I-protein
protein None None I-protein
, None None O
whose None None O
mutation None None O
is None None O
the None None O
underlying None None O
genetic None None O
defect None None O
in None None O
the None None O
X-linked None None O
lymphoproliferative None None O
syndrome None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
report None None O
the None None O
molecular None None O
cloning None None O
and None None O
characterization None None O
of None None O
the None None O
human None None I-DNA
2B4 None None I-DNA
( None None I-DNA
h2B4 None None I-DNA
) None None I-DNA
promoter None None I-DNA
. None None O

Through None None O
primer None None O
extension None None O
analysis None None O
, None None O
we None None O
found None None O
that None None O
the None None O
transcription None None O
of None None O
the None None O
h2B4 None None I-DNA
gene None None I-DNA
initiates None None O
at None None O
multiple None None O
start None None O
sites None None O
. None None O

We None None O
isolated None None O
h2B4 None None I-DNA
genomic None None I-DNA
clones None None I-DNA
and None None O
PCR None None O
amplified None None O
the None None O
5 None None I-DNA
' None None I-DNA
untranslated None None I-DNA
region None None I-DNA
containing None None O
the None None O
promoter None None I-DNA
elements None None I-DNA
. None None O

We None None O
have None None O
identified None None O
a None None O
functional None None O
AP-1 None None I-DNA
site None None I-DNA
that None None O
lies None None O
between None None O
( None None O
-106 None None O
to None None O
-100 None None O
) None None O
through None None O
transient None None O
transfection None None O
analysis None None O
in None None O
YT None None I-cell_line
cells None None I-cell_line
, None None O
a None None O
human None None I-cell_line
NK None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
. None None O

EMSAs None None O
with None None O
Abs None None I-protein
specific None None O
for None None O
various None None O
protein None None I-protein
factors None None I-protein
of None None O
the None None O
AP-1 None None I-protein
family None None I-protein
revealed None None O
that None None O
multiple None None O
members None None O
of None None O
the None None O
Jun None None I-protein
family None None I-protein
are None None O
involved None None O
in None None O
the None None O
regulation None None O
of None None O
the None None O
h2B4 None None I-DNA
gene None None I-DNA
. None None O

Mutation None None O
of None None O
the None None O
AP-1 None None I-DNA
site None None I-DNA
not None None O
only None None O
abolishes None None O
protein/DNA None None O
interactions None None O
but None None O
also None None O
promoter None None O
activity None None O
. None None O

These None None O
results None None O
demonstrate None None O
a None None O
significant None None O
role None None O
for None None O
AP-1 None None I-protein
in None None O
the None None O
transcriptional None None O
regulation None None O
of None None O
the None None O
h2B4 None None I-DNA
gene None None I-DNA
. None None O

Functional None None O
correction None None O
of None None O
FA-C None None I-cell_type
cells None None I-cell_type
with None None O
FANCC None None I-protein
suppresses None None O
the None None O
expression None None O
of None None O
interferon None None I-DNA
gamma-inducible None None I-DNA
genes None None I-DNA
. None None O

Because None None O
hematopoietic None None I-cell_type
cells None None I-cell_type
derived None None O
from None None O
Fanconi None None O
anemia None None O
( None None O
FA None None O
) None None O
patients None None O
of None None O
the None None O
C-complementation None None O
group None None O
( None None O
FA-C None None O
) None None O
are None None O
hypersensitive None None O
to None None O
the None None O
inhibitory None None O
effects None None O
of None None O
interferon None None I-protein
gamma None None I-protein
( None None O
IFNgamma None None I-protein
) None None O
, None None O
the None None O
products None None O
of None None O
certain None None O
IFNgamma-inducible None None I-DNA
genes None None I-DNA
known None None O
to None None O
influence None None O
hematopoietic None None O
cell None None O
survival None None O
were None None O
quantified None None O
. None None O

High None None O
constitutive None None O
expression None None O
of None None O
the None None O
IFNgamma-inducible None None I-DNA
genes None None I-DNA
, None None O
IFN-stimulated None None I-protein
gene None None I-protein
factor None None I-protein
3 None None I-protein
gamma None None I-protein
subunit None None I-protein
( None None O
ISGF3gamma None None I-protein
) None None O
, None None O
IFN None None I-protein
regulatory None None I-protein
factor-1 None None I-protein
( None None O
IRF-1 None None I-protein
) None None O
, None None O
and None None O
the None None O
cyclin-dependent None None I-protein
kinase None None I-protein
inhibitor None None I-protein
p21 None None I-protein
( None None O
WAF1 None None I-protein
) None None O
was None None O
found None None O
in None None O
FANCC None None I-protein
mutant None None O
B None None I-cell_type
lymphoblasts None None I-cell_type
, None None O
low-density None None I-cell_type
bone None None I-cell_type
marrow None None I-cell_type
cells None None I-cell_type
, None None O
and None None O
murine None None I-cell_type
embryonic None None I-cell_type
fibroblasts None None I-cell_type
. None None O

Paradoxically None None O
, None None O
these None None O
cells None None O
do None None O
not None None O
activate None None I-protein
signal None None I-protein
transducer None None I-protein
and None None I-protein
activator None None I-protein
of None None I-protein
transcription None None I-protein
( None None I-protein
STAT None None I-protein
) None None I-protein
1 None None I-protein
properly None None O
. None None O

In None None O
an None None O
attempt None None O
to None None O
clarify None None O
mechanisms None None O
by None None O
which None None O
FA-C None None I-cell_type
cells None None I-cell_type
overexpress None None O
IFNgamma-inducible None None I-DNA
genes None None I-DNA
in None None O
the None None O
face None None O
of None None O
defective None None O
STAT1 None None O
phosphorylation None None O
, None None O
it None None O
was None None O
reasoned None None O
that None None O
decreased None None O
levels None None O
of None None O
activated None None I-protein
STAT1 None None I-protein
might None None O
result None None O
in None None O
reduced None None O
expression None None O
of None None O
a None None O
hematopoietic None None I-protein
IFNgamma-responsive None None I-protein
protein None None I-protein
that None None O
normally None None O
modulates None None O
expression None None O
of None None O
other None None O
IFNgamma-responsive None None I-DNA
genes None None I-DNA
. None None O

Levels None None O
of None None O
the None None O
IFNgamma None None I-protein
-inducible None None O
factor None None O
IFN None None I-protein
consensus None None I-protein
sequence None None I-protein
binding None None I-protein
protein None None I-protein
( None None O
ICSBP None None I-protein
) None None O
, None None O
a None None O
negative None None I-protein
trans-acting None None I-protein
regulator None None I-protein
of None None O
some None None O
IFNgamma-inducible None None I-DNA
genes None None I-DNA
, None None O
were None None O
quantified None None O
. None None O

ICSBP None None I-protein
levels None None O
were None None O
reduced None None O
in None None O
FA-C None None I-cell_type
B None None I-cell_type
lymphoblasts None None I-cell_type
and None None O
MEFs None None I-cell_type
. None None O

However None None O
, None None O
enforced None None O
expression None None O
of None None O
ICSBP None None I-protein
failed None None O
to None None O
down-regulate None None O
IRF-1 None None I-protein
, None None O
ISGF3gamma None None I-protein
, None None O
and None None O
p21 None None I-protein
( None None I-protein
WAF1 None None I-protein
) None None I-protein
. None None O

Thus None None O
, None None O
the None None O
FANCC None None I-protein
protein None None I-protein
functions None None O
to None None O
modulate None None O
expression None None O
of None None O
a None None O
family None None O
of None None O
genes None None O
that None None O
in None None O
normal None None O
cells None None O
are None None O
inducible None None O
only None None O
by None None O
specific None None O
environmental None None O
cues None None O
for None None O
apoptosis None None O
or None None O
mitogenic None None O
inhibition None None O
, None None O
but None None O
it None None O
does None None O
so None None O
independently None None O
of None None O
the None None O
classic None None O
IFN-STAT1 None None O
pathway None None O
and None None O
is None None O
not None None O
the None None O
direct None None O
result None None O
of None None O
reduced None None O
ICSBP None None I-protein
expression None None O
. None None O

A None None O
genetic None None O
investigation None None O
of None None O
E2A None None O
function None None O
in None None O
lymphocyte None None O
development None None O
. None None O

Lymphocytes None None I-cell_type
are None None O
derived None None O
from None None O
hematopoietic None None I-cell_type
stem None None I-cell_type
cells None None I-cell_type
( None None O
HSC None None I-cell_type
) None None O
following None None O
a None None O
series None None O
of None None O
regulated None None O
differentiation None None O
events None None O
. None None O

Multipotent None None I-cell_type
HSCs None None I-cell_type
become None None O
committed None None O
to None None O
the None None O
B None None I-cell_line
cell None None I-cell_line
lineage None None I-cell_line
in None None O
bone None None O
marrow None None O
and None None O
the None None O
T None None I-cell_line
cell None None I-cell_line
lineage None None I-cell_line
in None None O
the None None O
thymus None None O
after None None O
receiving None None O
appropriate None None O
signals None None O
from None None O
the None None O
corresponding None None O
microenvironment None None O
. None None O

These None None O
committed None None O
lymphoid None None I-cell_type
cells None None I-cell_type
must None None O
then None None O
undergo None None O
V None None O
( None None O
D None None O
) None None O
J None None O
recombination None None O
at None None O
the None None O
immunoglobulin None None I-DNA
gene None None I-DNA
or None None O
T None None I-DNA
cell None None I-DNA
receptor None None I-DNA
gene None None I-DNA
locus None None I-DNA
resulting None None O
in None None O
clonal None None O
production None None O
of None None O
functional None None O
B None None I-cell_type
or None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
, None None O
respectively None None O
. None None O

Lymphocyte None None O
commitment None None O
and None None O
differentiation None None O
are None None O
accompanied None None O
by None None O
programmed None None O
gene None None O
expression None None O
or None None O
repression None None O
events None None O
which None None O
are None None O
driven None None O
by None None O
lineage None None I-protein
and None None I-protein
stage None None I-protein
specific None None I-protein
transcription None None I-protein
factors None None I-protein
. None None O

The None None O
basic-helix-loop-helix None None I-protein
( None None I-protein
bHLH None None I-protein
) None None I-protein
transcription None None I-protein
factors None None I-protein
encoded None None O
by None None O
the None None O
E2A None None I-DNA
gene None None I-DNA
are None None O
involved None None O
in None None O
several None None O
differentiation None None O
events None None O
during None None O
B None None O
and None None O
T None None O
cell None None O
development None None O
, None None O
including None None O
lineage None None O
commitment None None O
, None None O
initiation None None O
of None None O
V None None O
( None None O
D None None O
) None None O
J None None O
recombination None None O
, None None O
and None None O
antigen None None O
receptor None None O
mediated None None O
proliferation None None O
and None None O
differentiation None None O
. None None O

Several None None O
recent None None O
reviews None None O
have None None O
provided None None O
a None None O
comprehensive None None O
discussion None None O
of None None O
biochemical None None O
, None None O
cellular None None O
, None None O
and None None O
genetic None None O
research None None O
on None None O
E2A None None O
function None None O
in None None O
lymphocyte None None O
development None None O
( None None O
1 None None O
, None None O
2 None None O
) None None O
. None None O

Here None None O
, None None O
we None None O
only None None O
discuss None None O
some None None O
of None None O
the None None O
genetic None None O
approaches None None O
our None None O
laboratory None None O
( None None O
except None None O
where None None O
it None None O
is None None O
noted None None O
) None None O
has None None O
undertaken None None O
to None None O
investigate None None O
the None None O
molecular None None O
pathways None None O
mediated None None O
by None None O
E2A None None I-protein
transcription None None I-protein
factors None None I-protein
in None None O
lymphocyte None None O
development None None O

D609 None None O
inhibits None None O
ionizing None None O
radiation-induced None None O
oxidative None None O
damage None None O
by None None O
acting None None O
as None None O
a None None O
potent None None O
antioxidant None None O
. None None O

Tricyclodecan-9-yl-xanthogenate None None O
( None None O
D609 None None O
) None None O
has None None O
been None None O
extensively None None O
studied None None O
in None None O
biological None None O
systems None None O
and None None O
exhibits None None O
a None None O
variety None None O
of None None O
biological None None O
functions None None O
, None None O
including None None O
antiviral None None O
, None None O
antitumor None None O
, None None O
and None None O
anti-inflammatory None None O
activities None None O
. None None O

Most None None O
of None None O
these None None O
activities None None O
have None None O
been None None O
largely None None O
attributed None None O
to None None O
the None None O
inhibitory None None O
effect None None O
of None None O
D609 None None O
on None None O
phosphatidylcholine-specific None None O
phospholipase None None I-protein
C None None I-protein
. None None O

However None None O
, None None O
as None None O
a None None O
xanthate None None O
derivative None None O
, None None O
D609 None None O
is None None O
a None None O
strong None None O
electrolyte None None O
and None None O
readily None None O
dissociates None None O
to None None O
xanthate None None O
anions None None O
and None None O
cations None None O
of None None O
alkali None None O
metals None None O
in None None O
solution None None O
. None None O

Xanthate None None O
anions None None O
and None None O
protonated None None O
xanthic None None O
acid None None O
contain None None O
a None None O
free None None O
thiol None None O
moiety None None O
and None None O
are None None O
highly None None O
reductive None None O
. None None O

This None None O
implies None None O
that None None O
D609 None None O
and None None O
other None None O
xanthate None None O
derivatives None None O
may None None O
function None None O
as None None O
potent None None O
antioxidants None None O
. None None O

Indeed None None O
, None None O
we None None O
found None None O
that None None O
D609 None None O
inhibited None None O
the None None O
Fenton None None O
reaction-induced None None O
oxidation None None O
of None None O
dihydrorhodamine None None O
123 None None O
in None None O
a None None O
dose-dependent None None O
manner None None O
similar None None O
to None None O
that None None O
of None None O
pyrrolidinedithiocarbamate None None O
, None None O
a None None O
well None None O
known None None O
antioxidant None None O
. None None O

In None None O
addition None None O
, None None O
D609 None None O
inhibited None None O
the None None O
formation None None O
of None None O
the None None O
alpha-phenyl-tert-butylnitrone-free None None O
radical None None O
spin None None O
adducts None None O
and None None O
lipid None None O
peroxidation None None O
of None None O
synaptosomal None None O
membranes None None O
by None None O
the None None O
Fenton None None O
reagents None None O
. None None O

Furthermore None None O
, None None O
preincubation None None O
of None None O
lymphocytes None None I-cell_type
with None None O
D609 None None O
resulted None None O
in None None O
a None None O
significant None None O
diminution None None O
of None None O
ionizing None None O
radiation None None O
( None None O
IR None None O
) None None O
-induced None None O
1 None None O
) None None O
production None None O
of None None O
reactive None None O
oxygen None None O
species None None O
; None None O
2 None None O
) None None O
decrease None None O
in None None O
intracellular None None O
reduced None None O
glutathione None None O
; None None O
3 None None O
) None None O
oxidative None None O
damage None None O
to None None O
proteins None None O
and None None O
lipids None None O
; None None O
and None None O
4 None None O
) None None O
activation None None O
of None None O
nuclear None None I-protein
factor-kappaB None None I-protein
. None None O

Moreover None None O
, None None O
when None None O
D609 None None O
( None None O
50 None None O
mg/kg None None O
i.v. None None O
) None None O
was None None O
administered None None O
to None None O
mice None None O
10 None None O
min None None O
prior None None O
to None None O
total None None O
body None None O
IR None None O
( None None O
6.5 None None O
and None None O
8.5 None None O
Gy None None O
) None None O
, None None O
it None None O
protected None None O
the None None O
mice None None O
from None None O
IR-induced None None O
lethality None None O
. None None O

Thus None None O
, None None O
these None None O
results None None O
indicate None None O
that None None O
D609 None None O
is None None O
a None None O
potent None None O
antioxidant None None O
and None None O
has None None O
the None None O
ability None None O
to None None O
inhibit None None O
IR-induced None None O
cellular None None O
oxidative None None O
stress None None O
. None None O

Inhibition None None O
of None None O
AP-1 None None I-protein
by None None O
the None None O
glucocorticoid-inducible None None O
protein None None I-protein
GILZ None None I-protein
. None None O

The None None O
immunosuppressive None None O
effects None None O
of None None O
glucocorticoids None None O
arise None None O
largely None None O
by None None O
inhibition None None O
of None None O
cytokine None None O
gene None None O
expression None None O
, None None O
which None None O
has None None O
been None None O
ascribed None None O
to None None O
interference None None O
between None None O
the None None O
glucocorticoid None None I-protein
receptor None None I-protein
and None None O
transcription None None I-protein
factors None None I-protein
such None None O
as None None O
AP-1 None None I-protein
and None None O
NF-kappa None None I-protein
B None None I-protein
as None None O
well None None O
as None None O
by None None O
competition None None O
for None None O
common None None O
coactivators None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
glucocorticoid-induced None None O
inhibition None None O
of None None O
interleukin-2 None None O
mRNA None None O
expression None None O
in None None O
activated None None I-cell_type
normal None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
required None None O
new None None O
protein None None O
synthesis None None O
, None None O
suggesting None None O
that None None O
this None None O
phenomenon None None O
is None None O
secondary None None O
to None None O
expression None None O
of None None O
glucocorticoid-regulated None None O
genes None None I-DNA
. None None O

One None None O
of None None O
the None None O
most None None O
prominent None None O
glucocorticoid-induced None None O
genes None None I-DNA
is None None O
glucocorticoid-induced None None I-DNA
leucine None None I-DNA
zipper None None I-DNA
( None None O
GILZ None None I-DNA
) None None O
, None None O
which None None O
has None None O
been None None O
reported None None O
to None None O
inhibit None None O
activation-induced None None O
up-regulation None None O
of None None O
Fas None None I-RNA
ligand None None I-RNA
( None None I-RNA
FasL None None I-RNA
) None None I-RNA
mRNA None None I-RNA
. None None O

Indeed None None O
, None None O
transient None None O
expression None None O
of None None O
GILZ None None I-DNA
in None None O
Jurkat None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
blocked None None O
induction None None O
of None None O
a None None O
reporter None None I-DNA
construct None None I-DNA
driven None None O
by None None O
the None None O
FasL None None I-DNA
promoter None None I-DNA
. None None O

This None None O
could None None O
be None None O
accounted None None O
for None None O
by None None O
GILZ None None I-protein
-mediated None None O
inhibition None None O
of None None O
Egr-2 None None I-protein
and None None O
Egr-3 None None I-protein
, None None O
NFAT/AP-1 None None I-protein
-inducible None None O
transcription None None I-protein
factors None None I-protein
that None None O
bind None None O
a None None O
regulatory None None I-DNA
element None None I-DNA
in None None O
the None None O
FasL None None I-DNA
promoter None None I-DNA
and None None O
up-regulate None None O
FasL None None O
expression None None O
. None None O

GILZ None None I-protein
also None None O
potently None None O
inhibited None None O
AP-1-driven None None I-DNA
and None None I-DNA
IL-2 None None I-DNA
promoter-driven None None I-DNA
reporter None None I-DNA
constructs None None I-DNA
, None None O
and None None O
recombinant None None O
GILZ None None I-protein
specifically None None O
interacted None None O
with None None O
c-Fos None None I-protein
and None None O
c-Jun None None I-protein
in None None O
vitro None None O
and None None O
inhibited None None O
the None None O
binding None None O
of None None O
active None None I-protein
AP-1 None None I-protein
to None None O
its None None O
target None None O
DNA None None O
. None None O

Whereas None None O
homodimerization None None O
of None None O
GILZ None None I-protein
required None None O
the None None O
presence None None O
of None None O
its None None O
leucine None None I-protein
zipper None None I-protein
, None None O
the None None O
interaction None None O
with None None O
c-Fos None None I-protein
and None None O
c-Jun None None I-protein
occurred None None O
through None None O
the None None O
N-terminal None None I-protein
60-amino None None B-protein
acid None None I-protein
region None None I-protein
of None None O
GILZ None None I-protein
. None None O

Thus None None O
, None None O
GILZ None None I-protein
represents None None O
a None None O
glucocorticoid-induced None None O
gene None None O
product None None O
that None None O
can None None O
inhibit None None O
a None None O
variety None None O
of None None O
activation-induced None None O
events None None O
, None None O
at None None O
least None None O
in None None O
part None None O
by None None O
direct None None O
interference None None O
with None None O
AP-1 None None I-protein
, None None O
and None None O
is None None O
therefore None None O
a None None O
candidate None None O
for None None O
a None None O
mediator None None O
of None None O
glucocorticoid-induced None None O
immunosuppression None None O
. None None O

Pharmacokinetic None None O
differences None None O
between None None O
a None None O
T None None O
cell-tolerizing None None O
and None None O
a None None O
T None None O
cell-activating None None O
peptide None None O
. None None O

Vaccination None None O
with None None O
a None None O
peptide None None O
representing None None O
a None None O
CTL None None O
epitope None None O
from None None O
the None None O
human None None O
papillomavirus None None O
( None None O
HPV None None O
) None None O
16 None None O
E7 None None I-protein
protein None None I-protein
induces None None O
a None None O
specific None None O
CTL None None O
response None None O
that None None O
prevents None None O
the None None O
outgrowth None None O
of None None O
HPV16 None None O
E7-expressing None None O
tumors None None O
. None None O

In None None O
contrast None None O
, None None O
vaccination None None O
with None None O
a None None O
peptide None None O
encoding None None O
an None None O
adenovirus None None O
type None None O
5 None None O
( None None O
Ad5 None None O
) None None O
E1A None None O
CTL None None O
epitope None None O
results None None O
in None None O
CTL None None O
tolerance None None O
and None None O
enhanced None None O
growth None None O
of None None O
an None None O
Ad5 None None O
E1A-expressing None None O
tumor None None O
. None None O

It None None O
is None None O
unclear None None O
why None None O
these None None O
peptides None None O
induce None None O
such None None O
opposite None None O
effects None None O
. None None O

To None None O
determine None None O
whether None None O
a None None O
difference None None O
in None None O
pharmacokinetics None None O
can None None O
explain None None O
the None None O
functional None None O
contrasts None None O
, None None O
tritiated None None O
Ad5 None None O
E1A None None O
and None None O
HPV16 None None O
E7 None None O
peptides None None O
were None None O
injected None None O
into None None O
mice None None O
. None None O

Results None None O
show None None O
that None None O
the None None O
tolerizing None None O
peptide None None O
spread None None O
through None None O
the None None O
body None None O
16 None None O
times None None O
faster None None O
than None None O
the None None O
activating None None O
peptide None None O
and None None O
was None None O
cleared None None O
at None None O
least None None O
2 None None O
times None None O
faster None None O
. None None O

The None None O
HPV16 None None O
E7 None None O
peptide None None O
kinetics None None O
correlated None None O
with None None O
the None None O
kinetics None None O
of None None O
HPV16 None None I-protein
E7 None None I-protein
-specific None None O
CTL None None O
induction None None O
. None None O

In None None O
contrast None None O
, None None O
Ad5 None None O
E1A None None O
peptide None None O
injection None None O
resulted None None O
in None None O
physical None None O
deletion None None O
of None None O
preexisting None None O
Ad5 None None I-protein
E1A None None I-protein
-specific None None O
CTLs None None I-protein
within None None O
24 None None O
h None None O
after None None O
injection None None O
. None None O

This None None O
tolerization None None O
occurred None None O
at None None O
the None None O
time None None O
when None None O
the None None O
peptide None None O
reached None None O
its None None O
maximum None None O
peptide None None O
concentration None None O
in None None O
the None None O
organs None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
ubiquitous None None O
expression None None O
of None None O
the None None O
tolerizing None None O
Ad5 None None O
E1A None None O
peptide None None O
within None None O
a None None O
short None None O
period None None O
of None None O
time None None O
causes None None O
activation-induced None None O
cell None None O
death None None O
of None None O
Ad5 None None I-protein
E1A None None I-protein
-specific None None O
CTLs None None I-protein
. None None O

Therefore None None O
, None None O
information None None O
on None None O
the None None O
pharmacokinetics None None O
of None None O
peptides None None O
is None None O
vital None None O
for None None O
the None None O
safety None None O
and None None O
efficacy None None O
of None None O
peptide-based None None O
vaccines None None O
. None None O

Smad3 None None I-protein
and None None O
Smad4 None None I-protein
mediate None None O
transforming None None I-protein
growth None None I-protein
factor-beta1 None None I-protein
-induced None None O
IgA None None O
expression None None O
in None None O
murine None None I-cell_type
B None None I-cell_type
lymphocytes None None I-cell_type
. None None O

Transforming None None I-protein
growth None None I-protein
factor None None I-protein
( None None I-protein
TGF None None I-protein
) None None I-protein
-beta1 None None I-protein
is None None O
well None None O
established None None O
as None None O
a None None O
critical None None O
IgA None None I-protein
isotype None None I-protein
switching None None I-protein
factor None None I-protein
and None None O
Smad None None I-protein
molecules None None I-protein
have None None O
been None None O
reported None None O
to None None O
act None None O
as None None O
transducers None None I-protein
and None None O
transcriptional None None I-protein
factors None None I-protein
in None None O
the None None O
expression None None O
of None None O
TGF-beta1 None None I-protein
-targeted None None O
genes None None I-DNA
. None None O

We None None O
examined None None O
the None None O
involvement None None O
of None None O
Smad None None I-protein
proteins None None I-protein
in None None O
TGF-beta1 None None I-protein
-induced None None O
IgA None None O
expression None None O
. None None O

First None None O
, None None O
we None None O
found None None O
that None None O
TGF-beta1 None None I-protein
significantly None None O
increases None None O
endogenous None None I-RNA
germ-line None None I-RNA
( None None I-RNA
GL None None I-RNA
) None None I-RNA
alpha None None I-RNA
transcripts None None I-RNA
by None None O
LPS-stimulated None None O
CH12.LX.4933 None None I-cell_line
( None None I-cell_line
mu None None I-cell_line
( None None I-cell_line
+ None None I-cell_line
) None None I-cell_line
) None None I-cell_line
B None None I-cell_line
lymphoma None None I-cell_line
cells None None I-cell_line
. None None O

To None None O
investigate None None O
its None None O
signaling None None O
mechanisms None None O
, None None O
the None None O
lymphoma None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
was None None O
transfected None None O
with None None O
pFL3 None None I-DNA
that None None O
contains None None O
the None None O
TGF-beta-responsive None None I-DNA
element None None I-DNA
of None None O
the None None O
GLalpha None None I-DNA
promoter None None I-DNA
, None None O
and None None O
stimulated None None O
with None None O
TGF-beta1 None None I-protein
. None None O

Similar None None O
to None None O
endogenous None None I-RNA
GLalpha None None I-RNA
transcripts None None I-RNA
, None None O
TGF-beta1 None None I-protein
induces None None O
GLalpha None None I-DNA
promoter None None I-DNA
activity None None O
and None None O
overexpression None None O
of None None O
Smad3 None None I-protein
markedly None None O
enhances None None O
the None None O
promoter None None O
activity None None O
. None None O

This None None O
activity None None O
is None None O
further None None O
augmented None None O
by None None O
cotransfected None None I-protein
Smad4 None None I-protein
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
Smad7 None None I-protein
substantially None None O
abrogates None None O
the None None O
synergistic None None O
effect None None O
of None None O
Smad3/4 None None I-protein
on None None O
GLalpha None None I-DNA
promoter None None I-DNA
activity None None O
. None None O

In None None O
addition None None O
, None None O
overexpression None None O
of None None O
Smad3/4 None None I-protein
enhances None None O
TGF-beta1 None None I-protein
-induced None None O
endogenous None None I-RNA
GLalpha None None I-RNA
transcripts None None I-RNA
in None None O
normal None None I-cell_type
spleen None None I-cell_type
B None None I-cell_type
cell None None I-cell_type
s None None O
. None None O

Finally None None O
, None None O
in None None O
the None None O
presence None None O
of None None O
TGF-beta1 None None I-protein
, None None O
overexpression None None O
of None None O
Smad3/4 None None I-protein
selectively None None O
increases None None O
both None None O
surface None None O
IgA None None O
expression None None O
and None None O
IgA None None O
production None None O
. None None O

The None None O
results None None O
from None None O
the None None O
present None None O
study None None O
indicate None None O
that None None O
Smad3 None None I-protein
, None None O
Smad4 None None I-protein
, None None O
and None None O
Smad7 None None I-protein
, None None O
at None None O
least None None O
in None None O
part None None O
, None None O
serve None None O
as None None O
mediators None None O
linking None None O
TGF-beta1 None None I-protein
to None None O
transcriptional None None O
regulation None None O
of None None O
IgA None None I-DNA
switching None None I-DNA
related None None I-DNA
gene None None I-DNA
and None None O
regulation None None O
of None None O
IgA None None O
class None None O
switching None None O
. None None O

The None None O
translesion None None I-protein
DNA None None I-protein
polymerase None None I-protein
zeta None None I-protein
plays None None O
a None None O
major None None O
role None None O
in None None O
Ig None None O
and None None O
bcl-6 None None O
somatic None None O
hypermutation None None O
. None None O

Ig None None O
somatic None None O
mutations None None O
would None None O
be None None O
introduced None None O
by None None O
a None None O
polymerase None None I-protein
( None None O
pol None None I-protein
) None None O
while None None O
repairing None None O
DNA None None O
outside None None O
main None None O
DNA None None O
replication None None O
. None None O

We None None O
show None None O
that None None O
human None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
constitutively None None O
express None None O
the None None O
translesion None None I-protein
pol None None I-protein
zeta None None I-protein
, None None O
which None None O
effectively None None O
extends None None O
DNA None None O
past None None O
mismatched None None O
bases None None O
( None None O
mispair None None O
extender None None O
) None None O
, None None O
and None None O
pol None None I-protein
eta None None I-protein
, None None O
which None None O
bypasses None None O
DNA None None O
lesions None None O
in None None O
an None None O
error-free None None O
fashion None None O
. None None O

Upon None None O
B None None I-protein
cell None None I-protein
receptor None None I-protein
( None None O
BCR None None I-protein
) None None O
engagement None None O
and None None O
coculture None None O
with None None O
activated None None I-cell_type
CD4+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
, None None O
these None None O
lymphocytes None None I-cell_type
upregulated None None O
pol None None I-protein
zeta None None I-protein
, None None O
downregulated None None O
pol None None I-protein
eta None None I-protein
, None None O
and None None O
mutated None None O
the None None O
Ig None None I-DNA
and None None I-DNA
bcl-6 None None I-DNA
genes None None I-DNA
. None None O

Inhibition None None O
of None None O
the None None O
pol None None I-protein
zeta None None I-protein
REV3 None None B-protein
catalytic None None I-protein
subunit None None I-protein
by None None O
specific None None O
phosphorothioate-modified None None O
oligonucleotides None None O
impaired None None O
Ig None None O
and None None O
bcl-6 None None O
hypermutation None None O
and None None O
UV None None O
damage-induced None None O
DNA None None O
mutagenesis None None O
, None None O
without None None O
affecting None None O
cell None None O
cycle None None O
or None None O
viability None None O
. None None O

Thus None None O
, None None O
pol None None I-protein
zeta None None I-protein
plays None None O
a None None O
critical None None O
role None None O
in None None O
Ig None None O
and None None O
bcl-6 None None O
hypermutation None None O
, None None O
perhaps None None O
facilitated None None O
by None None O
the None None O
downregulation None None O
of None None O
pol None None I-protein
eta None None I-protein
. None None O

Molecular None None O
mechanism None None O
of None None O
cell None None O
cycle None None O
progression None None O
induced None None O
by None None O
the None None O
oncogene None None I-protein
product None None I-protein
Tax None None I-protein
of None None O
human None None O
T-cell None None O
leukemia None None O
virus None None O
type None None O
I None None O
. None None O

The None None O
trans-activator None None I-protein
protein None None I-protein
Tax None None I-protein
of None None O
human None None O
T-cell None None O
leukemia None None O
virus None None O
type None None O
I None None O
( None None O
HTLV-I None None O
) None None O
plays None None O
an None None O
important None None O
role None None O
in None None O
the None None O
development None None O
of None None O
adult None None O
T-cell None None O
leukemia None None O
through None None O
, None None O
at None None O
least None None O
in None None O
part None None O
, None None O
its None None O
ability None None O
to None None O
stimulate None None O
cell None None O
growth None None O
. None None O

We None None O
previously None None O
reported None None O
that None None O
Tax None None I-protein
induced None None O
cell None None O
cycle None None O
progression None None O
from None None O
G0/G1 None None O
phase None None O
to None None O
S None None O
and None None O
G2/M None None O
phases None None O
in None None O
human None None I-cell_line
T-cell None None I-cell_line
line None None I-cell_line
Kit None None I-cell_line
225 None None I-cell_line
cells None None I-cell_line
. None None O

To None None O
elucidate None None O
molecular None None O
mechanism None None O
of None None O
Tax None None I-protein
-induced None None O
cell None None O
cycle None None O
progression None None O
, None None O
we None None O
systematically None None O
examined None None O
the None None O
effects None None O
of None None O
Tax None None I-protein
on None None O
biochemical None None O
events None None O
associated None None O
with None None O
cell None None O
cycle None None O
progression None None O
. None None O

Introduction None None O
of None None O
Tax None None I-protein
into None None O
resting None None I-cell_line
Kit None None I-cell_line
225 None None I-cell_line
cells None None I-cell_line
induced None None O
activation None None O
of None None O
the None None O
G1/S None None O
transition None None O
regulation None None O
cascade None None O
consisting None None O
of None None O
activation None None O
of None None O
cyclin None None I-protein
dependent None None I-protein
kinase None None I-protein
2 None None I-protein
( None None O
CDK2 None None I-protein
) None None O
and None None O
CDK4 None None I-protein
, None None O
phosphorylation None None O
of None None O
the None None O
Rb None None I-protein
family None None I-protein
proteins None None I-protein
and None None O
an None None O
increase None None O
in None None O
free None None O
E2F None None I-protein
. None None O

The None None O
kinase None None O
activation None None O
was None None O
found None None O
to None None O
result None None O
from None None O
Tax None None I-protein
-induced None None O
expression None None O
of None None O
genes None None O
for None None O
cell None None I-protein
cycle None None I-protein
regulatory None None I-protein
molecules None None I-protein
including None None O
cyclin None None I-protein
D2 None None I-protein
, None None O
cyclin None None I-protein
E None None I-protein
, None None O
E2F1 None None I-protein
, None None O
CDK2 None None I-protein
, None None O
CDK4 None None I-protein
and None None O
CDK6 None None I-protein
, None None O
and None None O
Tax None None I-protein
-induced None None O
reduction None None O
of None None O
CDK None None I-protein
inhibitors None None I-protein
p19 None None I-protein
( None None O
INK4d None None I-protein
) None None O
and None None O
p27 None None I-protein
( None None I-protein
Kip1 None None I-protein
) None None I-protein
. None None O

These None None O
modulations None None O
by None None O
Tax None None I-protein
always None None O
paralleled None None O
the None None O
ability None None O
of None None O
Tax None None I-protein
to None None O
activate None None O
the None None O
NF-kappaB None None O
transcription None None O
pathway None None O
. None None O

These None None O
results None None O
indicate None None O
the None None O
important None None O
role None None O
of None None O
Tax None None I-protein
-mediated None None O
trans-activation None None O
of None None O
the None None O
genes None None O
for None None O
cell None None I-protein
cycle None None I-protein
regulatory None None I-protein
molecules None None I-protein
in None None O
Tax None None I-protein
-induced None None O
cell None None O
cycle None None O
progression None None O
. None None O

Cot None None I-protein
kinase None None I-protein
induces None None O
cyclooxygenase-2 None None O
expression None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
through None None O
activation None None O
of None None O
the None None O
nuclear None None I-protein
factor None None I-protein
of None None I-protein
activated None None I-protein
T None None I-protein
cells None None I-protein
. None None O

Cyclooxygenase-2 None None I-protein
( None None O
COX-2 None None I-protein
) None None O
is None None O
induced None None O
in None None O
human None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
upon None None O
T None None I-protein
cell None None I-protein
receptor None None I-protein
triggering None None O
. None None O

Here None None O
we None None O
report None None O
that None None O
Cot None None I-protein
kinase None None I-protein
, None None O
a None None O
mitogen-activated None None I-protein
protein None None I-protein
kinase None None I-protein
kinase None None I-protein
kinase None None I-protein
involved None None O
in None None O
T None None O
cell None None O
activation None None O
, None None O
up-regulates None None O
COX-2 None None I-DNA
gene None None I-DNA
expression None None O
in None None O
Jurkat None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
. None None O

Induction None None O
of None None O
COX-2 None None O
promoter None None O
activity None None O
by None None O
Cot None None I-protein
kinase None None I-protein
occurred None None O
mainly None None O
through None None O
activation None None O
of None None O
the None None O
nuclear None None I-protein
factor None None I-protein
of None None I-protein
activated None None I-protein
T None None I-protein
cells None None I-protein
( None None O
NFAT None None I-protein
) None None O
. None None O

Mutation None None O
of None None O
the None None O
distal None None I-DNA
( None None I-DNA
-105/-97 None None I-DNA
) None None I-DNA
and None None O
proximal None None I-DNA
( None None I-DNA
-76/-61 None None I-DNA
) None None I-DNA
NFAT None None B-DNA
response None None I-DNA
elements None None I-DNA
in None None O
the None None O
COX-2 None None I-DNA
promoter None None I-DNA
abolished None None O
the None None O
activation None None O
induced None None O
by None None O
Cot None None I-protein
kinase None None I-protein
. None None O

Even None None O
more None None O
, None None O
coexpression None None O
of None None O
a None None O
dominant None None O
negative None None O
version None None O
of None None O
NFAT None None I-protein
inhibited None None O
Cot None None I-protein
kinase None None I-protein
-mediated None None O
COX-2 None None I-DNA
promoter None None I-DNA
activation None None O
, None None O
whereas None None O
cotransfection None None O
of None None O
a None None O
constitutively None None O
active None None O
version None None O
of None None O
the None None O
calcium-dependent None None I-protein
phosphatase None None I-protein
calcineurin None None I-protein
synergizes None None O
with None None O
Cot None None I-protein
kinase None None I-protein
in None None O
the None None O
up-regulation None None O
of None None O
COX-2 None None I-DNA
promoter None None I-DNA
-driven None None O
transcription None None O
. None None O

Strikingly None None O
, None None O
Cot None None I-protein
kinase None None I-protein
increased None None O
transactivation None None O
mediated None None O
by None None O
a None None O
GAL4-NFAT None None I-protein
fusion None None I-protein
protein None None I-protein
containing None None O
the None None O
N-terminal None None I-protein
transactivation None None I-protein
domain None None I-protein
of None None O
NFATp None None I-protein
. None None O

In None None O
contrast None None O
to None None O
phorbol None None O
ester None None O
plus None None O
calcium None None O
ionophore None None O
A23187 None None O
, None None O
Cot None None I-protein
kinase None None I-protein
increases None None O
both None None O
COX-2 None None I-DNA
promoter None None I-DNA
activity None None O
and None None O
NFAT None None I-protein
-mediated None None O
transactivation None None O
in None None O
a None None O
cyclosporin None None O
A-independent None None O
manner None None O
. None None O

These None None O
data None None O
indicate None None O
that None None O
Cot None None I-protein
kinase None None I-protein
up-regulates None None O
COX-2 None None I-DNA
promoter None None I-DNA
-driven None None O
transcription None None O
through None None O
the None None O
NFAT None None I-DNA
response None None I-DNA
elements None None I-DNA
, None None O
being None None O
the None None O
Cot None None I-protein
kinase None None I-protein
-induced None None O
NFAT None None I-protein
-dependent None None O
transactivation None None O
presumably None None O
implicated None None O
in None None O
this None None O
up-regulation None None O
. None None O

Positive None None O
and None None O
negative None None O
roles None None O
of None None O
the None None O
trans-acting None None I-protein
T None None I-protein
cell None None I-protein
factor-1 None None I-protein
for None None O
the None None O
acquisition None None O
of None None O
distinct None None O
Ly-49 None None I-protein
MHC None None I-protein
class None None I-protein
I None None I-protein
receptors None None I-protein
by None None O
NK None None I-cell_type
cells None None I-cell_type
. None None O

Members None None O
of None None O
the None None O
Ly-49 None None I-DNA
gene None None I-DNA
family None None I-DNA
code None None O
for None None O
class None None I-protein
I None None I-protein
MHC-specific None None I-protein
receptors None None I-protein
that None None O
regulate None None O
NK None None O
cell None None O
function None None O
. None None O

Due None None O
to None None O
a None None O
combinatorial None None O
distribution None None O
of None None O
Ly-49 None None I-protein
receptors None None I-protein
, None None O
NK None None I-cell_type
cells None None I-cell_type
display None None O
considerable None None O
clonal None None O
heterogeneity None None O
. None None O

The None None O
acquisition None None O
of None None O
one None None O
Ly-49 None None I-protein
receptor None None I-protein
, None None O
Ly-49A None None I-protein
is None None O
strictly None None O
dependent None None O
on None None O
the None None O
transcriptional None None I-protein
trans-acting None None I-protein
factor None None I-protein
T None None B-protein
cell-specific None None I-protein
factor-1 None None I-protein
( None None O
TCF-1 None None I-protein
) None None O
. None None O

Indeed None None O
, None None O
TCF-1 None None I-protein
binds None None O
to None None O
two None None O
sites None None O
in None None O
the None None O
Ly-49a None None I-DNA
promoter None None I-DNA
and None None O
regulates None None O
its None None O
activity None None O
, None None O
suggesting None None O
that None None O
the None None O
Ly-49a None None I-DNA
gene None None I-DNA
is None None O
a None None O
direct None None O
TCF-1 None None I-protein
target None None O
. None None O

TCF-1 None None I-protein
deficiency None None O
resulted None None O
in None None O
the None None O
altered None None O
usage None None O
of None None O
additional None None O
Ly-49 None None I-protein
receptors None None I-protein
. None None O

We None None O
show None None O
in None None O
this None None O
study None None O
, None None O
using None None O
TCF-1 None None I-protein
beta None None I-protein
( None None I-protein
2 None None I-protein
) None None I-protein
-microglobulin None None I-protein
double-deficient None None O
mice None None O
, None None O
that None None O
these None None O
repertoire None None O
alterations None None O
are None None O
not None None O
due None None O
to None None O
Ly-49/MHC None None O
class None None O
I None None O
interactions None None O
. None None O

Our None None O
findings None None O
rather None None O
suggest None None O
a None None O
TCF-1 None None I-protein
-dependent None None O
, None None O
cell None None O
autonomous None None O
effect None None O
on None None O
the None None O
acquisition None None O
of None None O
multiple None None O
Ly-49 None None I-protein
receptors None None I-protein
. None None O

Besides None None O
reduced None None O
receptor None None O
usage None None O
( None None O
Ly-49A None None I-protein
and None None I-protein
D None None I-protein
) None None O
, None None O
we None None O
also None None O
observed None None O
no None None O
effect None None O
( None None O
Ly-49C None None I-protein
) None None O
and None None O
significantly None None O
expanded None None O
( None None O
Ly-49G None None I-protein
and None None I-protein
I None None I-protein
) None None O
receptor None None O
usage None None O
in None None O
the None None O
absence None None O
of None None O
TCF-1 None None I-protein
. None None O

These None None O
effects None None O
did None None O
not None None O
in None None O
all None None O
cases None None O
correlate None None O
with None None O
the None None O
presence None None O
of None None O
TCF None None I-DNA
binding None None I-DNA
sites None None I-DNA
in None None O
the None None O
respective None None O
proximal None None I-DNA
promoter None None I-DNA
. None None O

Therefore None None O
, None None O
besides None None O
TCF-1 None None I-protein
binding None None O
to None None O
the None None O
proximal None None I-DNA
promoter None None I-DNA
, None None O
Ly-49 None None O
acquisition None None O
may None None O
also None None O
be None None O
regulated None None O
by None None O
TCF-1 None None I-protein
binding None None O
to None None O
more None None O
distant None None O
cis-acting None None I-DNA
elements None None I-DNA
and/or None None O
by None None O
regulating None None O
the None None O
expression None None O
of None None O
additional None None O
trans-acting None None I-DNA
factors None None I-DNA
. None None O

Consistent None None O
with None None O
the None None O
observed None None O
differential None None O
, None None O
positive None None O
or None None O
negative None None O
role None None O
of None None O
TCF-1 None None I-protein
for None None O
Ly-49 None None I-protein
receptor None None I-protein
acquisition None None O
, None None O
reporter None None O
gene None None O
assays None None O
revealed None None O
the None None O
presence None None O
of None None O
an None None O
inducing None None O
as None None O
well None None O
as None None O
a None None O
repressing None None O
TCF None None I-DNA
site None None I-DNA
in None None O
certain None None O
proximal None None O
Ly-49 None None I-DNA
promoters None None I-DNA
. None None O

These None None O
findings None None O
reveal None None O
an None None O
important None None O
role None None O
of None None O
TCF-1 None None I-protein
for None None O
the None None O
formation None None O
of None None O
the None None O
NK None None I-protein
cell None None I-protein
receptor None None I-protein
repertoire None None O
. None None O

Ligation None None O
of None None O
CD11b None None I-protein
and None None O
CD11c None None I-protein
beta None None I-protein
( None None I-protein
2 None None I-protein
) None None I-protein
integrins None None B-protein
by None None O
antibodies None None I-protein
or None None O
soluble None None I-protein
CD23 None None I-protein
induces None None O
macrophage None None I-protein
inflammatory None None I-protein
protein None None I-protein
1alpha None None I-protein
( None None O
MIP-1alpha None None I-protein
) None None O
and None None O
MIP-1beta None None I-protein
production None None O
in None None O
primary None None I-cell_type
human None None I-cell_type
monocytes None None I-cell_type
through None None O
a None None O
pathway None None O
dependent None None O
on None None O
nuclear None None I-protein
factor-kappaB None None I-protein
. None None O

Chemokines None None I-protein
and None None O
adhesion None None I-protein
molecules None None I-protein
such None None O
as None None O
integrins None None I-protein
play None None O
a None None O
major None None O
part None None O
in None None O
the None None O
trafficking None None O
, None None O
extravasation None None O
, None None O
and None None O
recruitment None None O
of None None O
leukocytes None None I-cell_type
to None None O
inflammatory None None O
sites None None O
. None None O

This None None O
study None None O
investigated None None O
the None None O
effects None None O
of None None O
beta None None O
( None None O
2 None None O
) None None O
integrin None None O
engagement None None O
on None None O
chemokine None None O
production None None O
by None None O
freshly None None I-cell_type
isolated None None I-cell_type
human None None I-cell_type
monocytes None None I-cell_type
. None None O

We None None O
found None None O
that None None O
ligation None None O
of None None O
CD11b None None I-protein
or None None O
CD11c None None I-protein
but None None O
not None None O
CD11a None None I-protein
alpha None None I-protein
chains None None I-protein
of None None O
beta None None I-protein
( None None I-protein
2 None None I-protein
) None None I-protein
integrins None None I-protein
by None None O
antibodies None None I-protein
or None None O
soluble None None I-protein
CD23 None None I-protein
( None None I-protein
sCD23 None None I-protein
) None None I-protein
fusion None None I-protein
proteins None None I-protein
rapidly None None O
induced None None O
transcription None None O
and None None O
secretion None None O
of None None O
interleukin None None I-protein
8 None None I-protein
, None None O
macrophage None None I-protein
inflammatory None None I-protein
protein None None I-protein
( None None I-protein
MIP None None I-protein
) None None I-protein
1alpha None None I-protein
, None None O
and None None O
MIP-1beta None None I-protein
. None None O

Because None None O
the None None O
promoters None None I-DNA
of None None O
these None None O
chemokine None None I-DNA
genes None None I-DNA
contain None None O
kappaB None None I-DNA
binding None None I-DNA
sites None None I-DNA
, None None O
we None None O
assessed None None O
the None None O
possible None None O
role None None O
of None None O
nuclear None None I-protein
factor-kappaB None None I-protein
( None None O
NF-kappaB None None I-protein
) None None O
in None None O
controlling None None O
induction None None O
of None None O
the None None O
genes None None O
through None None O
beta None None O
( None None O
2 None None O
) None None O
integrin None None O
engagement None None O
. None None O

Electrophoretic None None O
mobility None None O
shift None None O
assays None None O
showed None None O
that None None O
sCD23 None None I-protein
or None None O
antibodies None None I-protein
to None None O
CD11b None None I-protein
or None None O
to None None O
CD11c None None I-protein
up-regulated None None O
DNA-binding None None O
activity None None O
of None None O
NF-kappaB None None I-protein
. None None O

Activation None None O
of None None O
NF-kappaB None None I-protein
was None None O
accompanied None None O
by None None O
degradation None None O
of None None O
its None None O
cytosolic None None I-protein
inhibitor None None I-protein
IkappaB-alpha None None I-protein
. None None O

Blockade None None O
of None None O
depletion None None O
of None None O
IkappaB-alpha None None I-protein
by None None O
proteasome None None O
inhibitors None None O
( None None O
proteasome None None O
inhibitor None None O
I None None O
or None None O
acetyl-leucinyl-leucinyl-norleucinal None None O
) None None O
led None None O
to None None O
concomitant None None O
inhibition None None O
of None None O
NF-kappaB None None O
DNA-binding None None O
activity None None O
and None None O
expression None None O
of None None O
MIP-1alpha None None I-RNA
and None None I-RNA
MIP-1beta None None I-RNA
messenger None None I-RNA
RNA None None I-RNA
induced None None O
by None None O
beta None None O
( None None O
2 None None O
) None None O
integrin None None O
ligation None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
triggering None None O
of None None O
CD11b None None I-protein
or None None O
CD11c None None I-protein
beta None None I-protein
( None None I-protein
2 None None I-protein
) None None I-protein
integrin None None O
on None None O
primary None None I-cell_type
human None None I-cell_type
monocytes None None I-cell_type
provides None None O
activation None None O
signals None None O
leading None None O
to None None O
nuclear None None O
translocation None None O
of None None O
NF-kappaB None None I-protein
and None None O
subsequent None None O
secretion None None O
of None None O
MIP-1alpha None None I-protein
and None None O
MIP-1beta None None I-protein
that None None O
may None None O
have None None O
an None None O
important None None O
role None None O
in None None O
recruitment None None O
of None None O
other None None O
inflammatory None None I-cell_type
cells None None I-cell_type
during None None O
initiation None None O
of None None O
an None None O
inflammatory None None O
response None None O

Synergistic None None O
transcriptional None None O
activation None None O
of None None O
human None None I-DNA
Acyl-coenzyme None None I-DNA
A None None I-DNA
: None None I-DNA
cholesterol None None I-DNA
acyltransterase-1 None None I-DNA
gene None None I-DNA
by None None O
interferon-gamma None None I-protein
and None None O
all-trans-retinoic None None O
acid None None O
THP-1 None None I-cell_type
cells None None I-cell_type
. None None O

Acyl-coenzyme None None I-protein
A None None I-protein
: None None I-protein
cholesterol None None I-protein
acyltransferase None None I-protein
( None None O
ACAT None None I-protein
) None None O
is None None O
an None None O
intracellular None None I-protein
enzyme None None I-protein
involved None None O
in None None O
cellular None None O
cholesterol None None O
homeostasis None None O
and None None O
in None None O
atherosclerotic None None O
foam None None O
cell None None O
formation None None O
. None None O

Human None None I-DNA
ACAT-1 None None I-DNA
gene None None I-DNA
contains None None O
two None None O
promoters None None I-DNA
( None None O
P1 None None I-DNA
and None None O
P7 None None I-DNA
) None None O
, None None O
each None None O
located None None O
in None None O
a None None O
different None None O
chromosome None None I-DNA
( None None I-DNA
1 None None I-DNA
and None None I-DNA
7 None None I-DNA
) None None I-DNA
( None None O
Li None None O
, None None O
B. None None O
L. None None O
, None None O
Li None None O
, None None O
X. None None O
L. None None O
, None None O
Duan None None O
, None None O
Z. None None O
J. None None O
, None None O
Lee None None O
, None None O
O. None None O
, None None O
Lin None None O
, None None O
S. None None O
, None None O
Ma None None O
, None None O
Z. None None O
M. None None O
, None None O
Chang None None O
, None None O
C. None None O
C. None None O
, None None O
Yang None None O
, None None O
X. None None O
Y. None None O
, None None O
Park None None O
, None None O
J. None None O
P. None None O
, None None O
Mohandas None None O
, None None O
T. None None O
K. None None O
, None None O
Noll None None O
, None None O
W. None None O
, None None O
Chan None None O
, None None O
L. None None O
, None None O
and None None O
Chang None None O
, None None O
T. None None O
Y. None None O
( None None O
1999 None None O
) None None O
J. None None O
Biol None None O
Chem. None None O
274 None None O
, None None O
11060-11071 None None O
) None None O
. None None O

Interferon-gamma None None I-protein
( None None O
IFN-gamma None None I-protein
) None None O
, None None O
a None None O
cytokine None None I-protein
that None None O
exerts None None O
many None None O
pro-atherosclerotic None None O
effects None None O
in None None O
vivo None None O
, None None O
causes None None O
up-regulation None None O
of None None O
ACAT-1 None None I-RNA
mRNA None None I-RNA
in None None O
human None None I-cell_type
blood None None I-cell_type
monocyte-derived None None I-cell_type
macrophages None None I-cell_type
and None None O
macrophage-like None None I-cell_type
cells None None I-cell_type
but None None O
not None None O
in None None O
other None None O
cell None None O
types None None O
. None None O

To None None O
examine None None O
the None None O
molecular None None O
nature None None O
of None None O
this None None O
observation None None O
, None None O
we None None O
identified None None O
within None None O
the None None O
ACAT-1 None None I-DNA
P1 None None I-DNA
promoter None None I-DNA
a None None O
159-base None None I-DNA
pair None None I-DNA
core None None I-DNA
region None None I-DNA
. None None O

This None None O
region None None O
contains None None O
4 None None O
Sp1 None None I-DNA
elements None None I-DNA
and None None O
an None None O
IFN-gamma None None I-DNA
activated None None I-DNA
sequence None None I-DNA
( None None O
GAS None None I-DNA
) None None O
that None None O
overlaps None None O
with None None O
the None None O
second None None O
Sp1 None None I-DNA
element None None I-DNA
. None None O

In None None O
the None None O
monocytic None None I-cell_type
cell None None I-cell_type
line None None I-cell_type
THP-1 None None I-cell_type
cell None None I-cell_type
, None None O
the None None O
combination None None O
of None None O
IFN-gamma None None I-protein
and None None O
all-trans-retinoic None None O
acid None None O
( None None O
a None None O
known None None O
differentiation None None O
agent None None O
) None None O
enhances None None O
the None None O
ACAT-1 None None I-DNA
P1 None None I-DNA
promoter None None I-DNA
but None None O
not None None O
the None None O
P7 None None I-DNA
promoter None None I-DNA
. None None O

Additional None None O
experiments None None O
showed None None O
that None None O
all-trans-retinoic None None O
acid None None O
causes None None O
large None None O
induction None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
STAT1 None None I-protein
, None None O
while None None O
IFN-gamma None None I-protein
causes None None O
activation None None O
of None None O
STAT1 None None I-protein
such None None O
that None None O
it None None O
binds None None O
to None None O
the None None O
GAS/Sp1 None None I-DNA
site None None I-DNA
in None None O
the None None O
ACAT-1 None None I-DNA
P1 None None I-DNA
promoter None None I-DNA
. None None O

Our None None O
work None None O
provides None None O
a None None O
molecular None None O
mechanism None None O
to None None O
account None None O
for None None O
the None None O
effect None None O
of None None O
IFN-gamma None None I-protein
in None None O
causing None None O
transcriptional None None O
activation None None O
of None None O
ACAT-1 None None I-protein
in None None O
macrophage-like None None I-cell_type
cells None None I-cell_type
. None None O

Inhaled None None O
nitric None None O
oxide None None O
down-regulates None None O
intrapulmonary None None O
nitric None None O
oxide None None O
production None None O
in None None O
lipopolysaccharide-induced None None O
acute None None O
lung None None O
injury None None O
. None None O

OBJECTIVE None None O
: None None O
To None None O
examine None None O
whether None None O
inhaled None None O
nitric None None O
oxide None None O
( None None O
NO None None O
) None None O
affected None None O
the None None O
intrapulmonary None None O
production None None O
of None None O
NO None None O
, None None O
reactive None None O
oxygen None None O
species None None O
, None None O
and None None O
nuclear None None I-protein
factor-kappaB None None I-protein
in None None O
a None None O
lipopolysaccharide None None O
( None None O
LPS None None O
) None None O
-induced None None O
model None None O
of None None O
acute None None O
lung None None O
injury None None O
. None None O

DESIGN None None O
: None None O
Prospective None None O
, None None O
randomized None None O
, None None O
laboratory None None O
study None None O
. None None O

SETTING None None O
: None None O
Experimental None None O
laboratory None None O
at None None O
a None None O
biomedical None None O
institute None None O
. None None O

SUBJECTS None None O
: None None O
Twenty None None O
male None None O
rabbits None None O
weighing None None O
2.5-3.5 None None O
kg None None O
. None None O

INTERVENTIONS None None O
: None None O
Saline None None O
or None None O
LPS None None O
( None None O
5 None None O
mg/kg None None O
of None None O
body None None O
weight None None O
) None None O
was None None O
administered None None O
intravenously None None O
with None None O
or None None O
without None None O
NO None None O
inhalation None None O
( None None O
10 None None O
ppm None None O
) None None O
in None None O
each None None O
group None None O
of None None O
five None None O
rabbits None None O
. None None O

MEASUREMENTS None None O
AND None None O
MAIN None None O
RESULTS None None O
: None None O
LPS None None O
increased None None O
the None None O
lung None None O
leak None None O
index None None O
, None None O
the None None O
neutrophils None None I-cell_type
and None None O
NO None None O
levels None None O
in None None O
bronchoalveolar None None O
lavage None None O
fluid None None O
, None None O
and None None O
NO None None O
levels None None O
produced None None O
by None None O
resting None None O
and None None O
stimulated None None O
alveolar None None I-cell_type
macrophages None None I-cell_type
. None None O

Inhaled None None O
NO None None O
decreased None None O
the None None O
lung None None O
leak None None O
index None None O
, None None O
the None None O
neutrophils None None I-cell_type
and None None O
NO None None O
levels None None O
as None None O
measured None None O
by None None O
nitrite None None O
levels None None O
in None None O
the None None O
lavage None None O
fluid None None O
, None None O
and None None O
NO None None O
produced None None O
by None None O
the None None O
resting None None O
and None None O
stimulated None None O
alveolar None None I-cell_type
macrophages None None I-cell_type
. None None O

Inhaled None None O
NO None None O
also None None O
blocked None None O
the None None O
activities None None O
of None None O
reactive None None O
oxygen None None O
species None None O
and None None O
nuclear None None I-protein
factor-kappaB None None I-protein
binding None None O
to None None O
DNA None None O
in None None O
lavage None None I-cell_type
cells None None I-cell_type
and None None O
in None None O
alveolar None None I-cell_type
macrophages None None I-cell_type
. None None O

CONCLUSION None None O
: None None O
Inhaled None None O
NO None None O
attenuates None None O
LPS-induced None None O
acute None None O
lung None None O
injury None None O
, None None O
possibly None None O
by None None O
decreasing None None O
NO None None O
production None None O
in None None O
the None None O
lungs None None O
. None None O

The None None O
mechanism None None O
of None None O
reducing None None O
NO None None O
production None None O
resulting None None O
from None None O
inhaled None None O
NO None None O
may None None O
involve None None O
, None None O
in None None O
part None None O
, None None O
the None None O
activities None None O
of None None O
reactive None None O
oxygen None None O
species None None O
and/or None None O
nuclear None None I-protein
factor-kappaB None None I-protein
. None None O

Treatment None None O
of None None O
allergic None None O
airway None None O
inflammation None None O
and None None O
hyperresponsiveness None None O
by None None O
antisense-induced None None O
local None None O
blockade None None O
of None None O
GATA-3 None None I-DNA
expression None None O
. None None O

Recent None None O
studies None None O
in None None O
transgenic None None O
mice None None O
have None None O
revealed None None O
that None None O
expression None None O
of None None O
a None None O
dominant None None O
negative None None O
form None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
GATA-3 None None I-protein
in None None O
T None None I-cell_type
cells None None I-cell_type
can None None O
prevent None None O
T None None I-cell_type
helper None None I-cell_type
cell None None I-cell_type
type None None I-cell_type
2 None None I-cell_type
( None None O
Th2 None None I-cell_type
) None None O
-mediated None None O
allergic None None O
airway None None O
inflammation None None O
in None None O
mice None None O
. None None O

However None None O
, None None O
it None None O
remains None None O
unclear None None O
whether None None O
GATA-3 None None I-protein
plays None None O
a None None O
role None None O
in None None O
the None None O
effector None None O
phase None None O
of None None O
allergic None None O
airway None None O
inflammation None None O
and None None O
whether None None O
antagonizing None None O
the None None O
expression None None O
and/or None None O
function None None O
of None None O
GATA-3 None None I-DNA
can None None O
be None None O
used None None O
for None None O
the None None O
therapy None None O
of None None O
allergic None None O
airway None None O
inflammation None None O
and None None O
hyperresponsiveness None None O
. None None O

Here None None O
, None None O
we None None O
analyzed None None O
the None None O
effects None None O
of None None O
locally None None O
antagonizing None None O
GATA-3 None None I-protein
function None None O
in None None O
a None None O
murine None None O
model None None O
of None None O
asthma None None O
. None None O

We None None O
could None None O
suppress None None O
GATA-3 None None O
expression None None O
in None None O
interleukin None None I-protein
( None None I-protein
IL None None I-protein
) None None I-protein
-4 None None I-protein
-producing None None O
T None None I-cell_type
cells None None I-cell_type
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
by None None O
an None None O
antisense None None O
phosphorothioate None None O
oligonucleotide None None O
overlapping None None O
the None None O
translation None None I-DNA
start None None I-DNA
site None None I-DNA
of None None O
GATA-3 None None I-DNA
, None None O
whereas None None O
nonsense None None O
control None None O
oligonucleotides None None O
were None None O
virtually None None O
inactive None None O
. None None O

In None None O
a None None O
murine None None O
model None None O
of None None O
asthma None None O
associated None None O
with None None O
allergic None None O
pulmonary None None O
inflammation None None O
and None None O
hyperresponsiveness None None O
in None None O
ovalbumin None None O
( None None O
OVA None None O
) None None O
-sensitized None None O
mice None None O
, None None O
local None None O
intranasal None None O
administration None None O
of None None O
fluorescein None None O
isothiocyanate-labeled None None O
GATA-3 None None O
antisense None None O
oligonucleotides None None O
led None None O
to None None O
DNA None None O
uptake None None O
in None None O
lung None None I-cell_type
cells None None I-cell_type
associated None None O
with None None O
a None None O
reduction None None O
of None None O
intracellular None None O
GATA-3 None None O
expression None None O
. None None O

Such None None O
intrapulmonary None None O
blockade None None O
of None None O
GATA-3 None None O
expression None None O
caused None None O
an None None O
abrogation None None O
of None None O
signs None None O
of None None O
lung None None O
inflammation None None O
including None None O
infiltration None None O
of None None O
eosinophils None None I-cell_type
and None None O
Th2 None None I-cell_type
cytokine None None O
production None None O
. None None O

Furthermore None None O
, None None O
treatment None None O
with None None O
antisense None None O
but None None O
not None None O
nonsense None None O
oligonucleotides None None O
induced None None O
a None None O
significant None None O
reduction None None O
of None None O
airway None None O
hyperresponsiveness None None O
in None None O
OVA-sensitized None None O
mice None None O
to None None O
levels None None O
comparable None None O
to None None O
saline-treated None None O
control None None O
mice None None O
, None None O
as None None O
assessed None None O
by None None O
both None None O
enhanced None None O
pause None None O
( None None O
PenH None None O
) None None O
responses None None O
and None None O
pulmonary None None O
resistance None None O
determined None None O
by None None O
body None None O
plethysmography None None O
. None None O

These None None O
data None None O
indicate None None O
a None None O
critical None None O
role None None O
for None None O
GATA-3 None None I-DNA
in None None O
the None None O
effector None None O
phase None None O
of None None O
a None None O
murine None None O
asthma None None O
model None None O
and None None O
suggest None None O
that None None O
local None None O
delivery None None O
of None None O
GATA-3 None None O
antisense None None O
oligonucleotides None None O
may None None O
be None None O
a None None O
novel None None O
approach None None O
for None None O
the None None O
treatment None None O
of None None O
airway None None O
hyperresponsiveness None None O
such None None O
as None None O
in None None O
asthma None None O
. None None O

This None None O
approach None None O
has None None O
the None None O
potential None None O
advantage None None O
of None None O
suppressing None None O
the None None O
expression None None O
of None None O
various None None O
proinflammatory None None I-protein
Th2 None None I-protein
cytokines None None I-protein
simultaneously None None O
rather None None O
than None None O
suppressing None None O
the None None O
activity None None O
of None None O
a None None O
single None None O
cytokine None None I-protein
. None None O

T None None O
helper-cell None None O
phenotype None None O
regulates None None O
atherosclerosis None None O
in None None O
mice None None O
under None None O
conditions None None O
of None None O
mild None None O
hypercholesterolemia None None O
. None None O

BACKGROUND None None O
: None None O
T None None I-cell_type
cells None None I-cell_type
are None None O
implicated None None O
in None None O
atherosclerosis None None O
, None None O
but None None O
little None None O
is None None O
known None None O
about None None O
the None None O
genetic None None O
control None None O
or None None O
molecular None None O
pathways None None O
, None None O
especially None None O
under None None O
conditions None None O
of None None O
mild None None O
hypercholesterolemia None None O
. None None O

METHODS None None O
AND None None O
RESULTS None None O
: None None O
BALB/c None None O
mice None None O
, None None O
making None None O
a None None O
CD4+ None None O
Th2 None None O
( None None O
IL-4+ None None O
) None None O
cell None None O
response None None O
, None None O
express None None O
both None None O
MHC None None I-protein
class None None I-protein
II None None I-protein
antigens None None I-protein
( None None O
IA None None I-protein
( None None I-protein
d None None I-protein
) None None I-protein
, None None O
IE None None I-protein
( None None I-protein
d None None I-protein
) None None I-protein
) None None O
and None None O
are None None O
atherosclerosis-resistant None None O
. None None O

C57Bl/6 None None O
mice None None O
produce None None O
a None None O
CD4+ None None O
Th1 None None O
( None None O
interferon None None O
[ None None O
IFN None None O
] None None O
gamma+ None None O
) None None O
response None None O
, None None O
express None None O
IA None None I-protein
( None None I-protein
b None None I-protein
) None None I-protein
but None None O
no None None O
IE None None I-protein
, None None O
and None None O
are None None O
atherosclerosis-prone None None O
. None None O

To None None O
evaluate None None O
T None None O
helper-cell None None O
phenotype None None O
in None None O
fatty None None O
streak None None O
formation None None O
, None None O
wild-type None None O
C57Bl/6 None None O
mice None None O
( None None O
IA None None O
( None None O
b None None O
) None None O
+IE- None None O
) None None O
and None None O
transgenic None None O
mice None None O
, None None O
either None None O
AB None None O
( None None O
o None None O
) None None O
, None None O
IA None None O
( None None O
b None None O
) None None O
-IE- None None O
; None None O
ABEalpha None None O
, None None O
IA-IE None None O
( None None O
k None None O
) None None O
+ None None O
; None None O
or None None O
BL None None O
: None None O
TG None None O
: None None O
Ealpha None None O
, None None O
IA None None O
( None None O
b None None O
) None None O
+IE None None O
( None None O
k None None O
) None None O
+ None None O
, None None O
were None None O
fed None None O
a None None O
high-cholesterol None None O
diet None None O
for None None O
16 None None O
weeks None None O
and None None O
evaluated None None O
histomorphometrically None None O
for None None O
aortic None None O
lesions None None O
. None None O

Lesion None None O
size None None O
in None None O
AB None None O
( None None O
o None None O
) None None O
, None None O
ABEalpha None None O
, None None O
and None None O
BL None None O
: None None O
TG None None O
: None None O
Ealpha None None O
strains None None O
was None None O
decreased None None O
by None None O
54 None None O
% None None O
, None None O
79 None None O
% None None O
, None None O
and None None O
82 None None O
% None None O
, None None O
respectively None None O
, None None O
compared None None O
with None None O
wild-type None None O
, None None O
correlating None None O
with None None O
decreased None None O
Th1 None None I-cell_type
and None None O
increased None None O
Th2 None None I-cell_type
expression None None O
and None None O
suggesting None None O
that None None O
T None None O
helper-cell None None O
phenotype None None O
is None None O
important None None O
in None None O
fatty None None O
lesion None None O
development None None O
. None None O

Decreasing None None O
Th1 None None I-cell_type
cells None None I-cell_type
by None None O
antibodies None None I-protein
( None None O
alpha-CD4 None None I-protein
) None None O
or None None O
cytokines None None I-protein
( None None O
IL-4 None None I-protein
) None None O
also None None O
caused None None O
> None None O
/=80 None None O
% None None O
reductions None None O
in None None O
lesion None None O
size None None O
. None None O

Immunohistology None None O
revealed None None O
IFN-gamma None None I-protein
, None None O
but None None O
not None None O
IL-4 None None I-protein
, None None O
colocalized None None O
with None None O
activated None None O
macrophages None None I-cell_type
. None None O

Confirming None None O
these None None O
findings None None O
in None None O
a None None O
different None None O
mouse None None O
strain None None O
, None None O
BALB/c None None O
Stat None None O
6 None None O
knockout None None O
mice None None O
( None None O
Th2 None None O
cell-deficient None None O
) None None O
developed None None O
aortic None None O
lesions None None O
comparable None None O
to None None O
C57Bl/6 None None O
mice None None O
on None None O
the None None O
same None None O
diet None None O
. None None O

CONCLUSIONS None None O
: None None O
In None None O
mildly None None O
hypercholesterolemic None None O
C57Bl/6 None None O
mice None None O
, None None O
presence None None O
of None None O
IA None None I-protein
( None None I-protein
b None None I-protein
) None None I-protein
and None None O
absence None None O
of None None O
IE None None I-protein
regulated None None O
CD4+ None None O
T None None O
helper-cell None None O
phenotype None None O
; None None O
fatty None None O
lesions None None O
were None None O
proportional None None O
to None None O
IFNgamma+ None None I-cell_type
Th1 None None I-cell_type
cells None None I-cell_type
in None None O
both None None O
C57Bl/6 None None O
and None None O
BALB/c None None O
strains None None O
. None None O

IFN-gamma None None I-protein
may None None O
participate None None O
through None None O
macrophage None None O
activation None None O
, None None O
whereas None None O
IL-4 None None I-protein
may None None O
act None None O
to None None O
limit None None O
Th1-cell None None O
response None None O
. None None O

Requirement None None O
for None None O
p38 None None I-protein
and None None O
p44/p42 None None I-protein
mitogen-activated None None B-protein
protein None None I-protein
kinases None None I-protein
in None None O
RAGE None None I-protein
-mediated None None O
nuclear None None I-protein
factor-kappaB None None I-protein
transcriptional None None O
activation None None O
and None None O
cytokine None None O
secretion None None O
. None None O

Advanced None None O
glycation None None O
end None None O
product None None O
( None None O
AGE None None O
) None None O
activation None None O
of None None O
the None None O
signal-transducing None None I-protein
receptor None None I-protein
for None None I-protein
AGE None None I-protein
( None None O
RAGE None None I-protein
) None None O
has None None O
been None None O
linked None None O
to None None O
a None None O
proinflammatory None None O
phenotypic None None O
change None None O
within None None O
cells None None O
. None None O

However None None O
, None None O
the None None O
precise None None O
intracellular None None O
signaling None None O
pathways None None O
involved None None O
have None None O
not None None O
been None None O
elucidated None None O
. None None O

We None None O
demonstrate None None O
here None None O
that None None O
human None None O
serum None None O
albumin None None O
modified None None O
with None None O
N None None O
( None None O
varepsilon None None O
) None None O
- None None O
( None None O
carboxymethyl None None O
) None None O
lysine None None O
( None None O
CML None None O
) None None O
, None None O
a None None O
major None None O
AGE None None O
adduct None None O
that None None O
progressively None None O
accumulates None None O
with None None O
aging None None O
, None None O
diabetes None None O
, None None O
and None None O
renal None None O
failure None None O
, None None O
induced None None O
nuclear None None I-protein
factor None None I-protein
( None None I-protein
NF None None I-protein
) None None I-protein
-kappaB None None I-protein
-driven None None O
reporter None None O
gene None None O
expression None None O
in None None O
human None None I-cell_type
monocytic None None I-cell_type
THP-1 None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
NF-kappaB None None O
response None None O
was None None O
blocked None None O
with None None O
a None None O
synthetic None None O
peptide None None O
corresponding None None O
to None None O
the None None O
putative None None I-protein
ligand-binding None None I-protein
domain None None I-protein
of None None O
RAGE None None I-protein
, None None O
with None None O
anti- None None O
RAGE None None I-protein
antiserum None None O
, None None O
and None None O
by None None O
coexpression None None O
of None None O
truncated None None I-protein
receptors None None I-protein
lacking None None O
the None None O
intracellular None None I-protein
domain None None I-protein
. None None O

Signal None None O
transduction None None O
from None None O
RAGE None None I-protein
to None None O
NF-kappaB None None I-protein
involved None None O
the None None O
generation None None O
of None None O
reactive None None O
oxygen None None O
species None None O
, None None O
since None None O
reporter None None O
gene None None O
expression None None O
was None None O
blocked None None O
with None None O
the None None O
antioxidant None None O
N-acetyl-L-cysteine None None O
. None None O

CML-modified None None I-protein
albumin None None I-protein
produced None None O
rapid None None O
transient None None O
activation None None O
of None None O
tyrosine None None O
phosphorylation None None O
, None None O
extracellular None None I-protein
signal-regulated None None I-protein
kinase None None I-protein
1 None None I-protein
and None None I-protein
2 None None I-protein
, None None O
and None None O
p38 None None I-protein
mitogen-activated None None I-protein
protein None None I-protein
kinase None None I-protein
( None None O
MAPK None None I-protein
) None None O
, None None O
but None None O
not None None O
c-Jun None None I-protein
NH None None I-protein
( None None I-protein
2 None None I-protein
) None None I-protein
-terminal None None I-protein
kinase None None I-protein
. None None O

RAGE None None I-protein
-mediated None None O
NF-kappaB None None O
activation None None O
was None None O
suppressed None None O
by None None O
the None None O
selective None None O
p38 None None I-protein
MAPK None None I-protein
inhibitor None None O
SB203580 None None O
and None None O
by None None O
coexpression None None O
of None None O
a None None O
kinase-dead None None O
p38 None None O
dominant-negative None None O
mutant None None O
. None None O

Activation None None O
of None None O
NF-kappaB None None I-protein
by None None O
CML-modified None None I-protein
albumin None None I-protein
increased None None O
secretion None None O
of None None O
proinflammatory None None I-protein
cytokines None None I-protein
( None None O
tumor None None I-protein
necrosis None None I-protein
factor-alpha None None I-protein
, None None O
interleukin-1beta None None I-protein
, None None O
and None None O
monocyte None None I-protein
chemoattractant None None I-protein
protein-1 None None I-protein
) None None O
severalfold None None O
, None None O
and None None O
inhibition None None O
of None None O
p38 None None I-protein
MAPK None None I-protein
blocked None None O
these None None O
increases None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
p38 None None I-protein
MAPK None None I-protein
activation None None O
mediates None None O
RAGE None None I-protein
-induced None None O
NF-kappaB None None I-protein
-dependent None None O
secretion None None O
of None None O
proinflammatory None None I-protein
cytokines None None I-protein
and None None O
suggest None None O
that None None O
accelerated None None O
inflammation None None O
may None None O
be None None O
a None None O
consequence None None O
of None None O
cellular None None O
activation None None O
induced None None O
by None None O
this None None O
receptor None None O
. None None O

Antigen-receptor None None O
cross-linking None None O
and None None O
lipopolysaccharide None None O
trigger None None O
distinct None None O
phosphoinositide None None I-protein
3-kinase None None I-protein
-dependent None None O
pathways None None O
to None None O
NF-kappa None None O
B None None O
activation None None O
in None None O
primary None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
NF-kappaB/Rel None None I-protein
transcription None None I-protein
factors None None I-protein
play None None O
an None None O
important None None O
role None None O
in None None O
the None None O
expression None None O
of None None O
genes None None O
involved None None O
in None None O
B None None O
cell None None O
development None None O
, None None O
differentiation None None O
and None None O
function None None O
. None None O

Nuclear None None I-protein
NF-kappaB None None I-protein
is None None O
induced None None O
in None None O
B None None I-cell_type
cells None None I-cell_type
by None None O
engagement None None O
of None None O
either None None O
the None None O
BCR None None I-protein
or None None O
CD40 None None I-protein
or None None O
by None None O
stimulation None None O
with None None O
lipopolysaccharide None None O
( None None O
LPS None None O
) None None O
. None None O

Despite None None O
the None None O
importance None None O
of None None O
NF-kappaB None None I-protein
to None None O
B None None O
cell None None O
function None None O
, None None O
little None None O
is None None O
known None None O
about None None O
the None None O
signaling None None O
pathways None None O
leading None None O
to None None O
NF-kappaB None None O
activation None None O
. None None O

In None None O
this None None O
report None None O
we None None O
address None None O
the None None O
role None None O
of None None O
phosphoinositide None None I-protein
3'-kinase None None I-protein
( None None O
PI None None I-protein
3-kinase None None I-protein
) None None O
in None None O
BCR None None I-protein
- None None O
and None None O
LPS-induced None None O
NF-kappaB None None O
activation None None O
using None None O
populations None None O
of None None O
primary None None I-cell_type
murine None None I-cell_type
resting None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
. None None O

Using None None O
the None None O
specific None None O
pharmacological None None O
inhibitors None None O
of None None O
PI None None I-protein
3-kinase None None I-protein
, None None O
Wortmannin None None O
and None None O
LY294002 None None O
, None None O
we None None O
demonstrate None None O
that None None O
PI None None I-protein
3-kinase None None I-protein
activity None None O
is None None O
vital None None O
for None None O
BCR None None I-protein
-induced None None O
NF-kappaB None None I-protein
DNA-binding None None O
activity None None O
. None None O

Furthermore None None O
, None None O
we None None O
show None None O
that None None O
this None None O
is None None O
achieved None None O
via None None O
protein None None I-protein
kinase None None I-protein
C None None I-protein
-dependent None None O
degradation None None O
of None None O
IkappaBalpha None None I-protein
. None None O

Similar None None O
analyses None None O
reveal None None O
that None None O
PI None None I-protein
3-kinase None None I-protein
is None None O
also None None O
critical None None O
in None None O
triggering None None O
NF-kappaB None None I-protein
DNA-binding None None O
activity None None O
and None None O
IkappaBalpha None None I-protein
degradation None None O
following None None O
LPS None None O
stimulation None None O
. None None O

Interestingly None None O
, None None O
a None None O
PKC None None O
inhibitor None None O
which None None O
blocked None None O
the None None O
BCR None None I-protein
-induced None None O
IkappaBalpha None None I-protein
degradation None None O
had None None O
no None None O
effect None None O
on None None O
the None None O
degradation None None O
of None None O
IkappaBalpha None None I-protein
after None None O
LPS None None O
stimulation None None O
. None None O

Taken None None O
together None None O
, None None O
our None None O
results None None O
indicate None None O
the None None O
involvement None None O
of None None O
PI None None I-protein
3-kinase None None I-protein
in None None O
at None None O
least None None O
two None None O
distinct None None O
signaling None None O
pathways None None O
leading None None O
to None None O
activation None None O
of None None O
NF-kappaB None None I-protein
in None None O
B None None I-cell_type
cells None None I-cell_type
. None None O

Tetramer-guided None None O
epitope None None O
mapping None None O
: None None O
rapid None None O
identification None None O
and None None O
characterization None None O
of None None O
immunodominant None None I-cell_type
CD4+ None None I-cell_type
T None None I-cell_type
cell None None I-cell_type
epitopes None None I-cell_type
from None None O
complex None None O
antigens None None I-protein
. None None O

T None None O
cell None None O
responses None None O
to None None O
Ags None None I-protein
involve None None O
recognition None None O
of None None O
selected None None O
peptide None None I-protein
epitopes None None I-protein
contained None None O
within None None O
the None None O
antigenic None None I-protein
protein None None I-protein
. None None O

In None None O
this None None O
report None None O
, None None O
we None None O
describe None None O
a None None O
new None None O
approach None None O
for None None O
direct None None O
identification None None O
of None None O
CD4+ None None I-cell_type
T None None I-cell_type
cell None None I-cell_type
epitopes None None I-cell_type
of None None O
complex None None O
Ags None None I-protein
that None None O
uses None None O
human None None I-protein
class None None I-protein
II None None I-protein
tetramers None None I-protein
to None None O
identify None None O
reactive None None O
cells None None O
. None None O

With None None O
a None None O
panel None None O
of None None O
60 None None O
overlapping None None O
peptides None None O
covering None None O
the None None O
entire None None O
sequence None None O
of None None O
the None None O
VP16 None None I-protein
protein None None I-protein
, None None O
a None None O
major None None O
Ag None None I-protein
for None None O
HSV-2 None None O
, None None O
we None None O
generated None None O
a None None O
panel None None O
of None None O
class None None I-protein
II None None I-protein
MHC None None I-protein
tetramers None None I-protein
loaded None None O
with None None O
peptide None None O
pools None None O
that None None O
were None None O
used None None O
to None None O
stain None None O
peripheral None None I-cell_type
lymphocytes None None I-cell_type
of None None O
an None None O
HSV-2 None None O
infected None None O
individual None None O
. None None O

With None None O
this None None O
approach None None O
, None None O
we None None O
identified None None O
four None None O
new None None O
DRA1*0101/DRB1*0401- None None O
and None None O
two None None O
DRA1*0101/DRB1*0404-restricted None None O
, None None O
VP16-specific None None I-protein
epitopes None None I-protein
. None None O

By None None O
using None None O
tetramers None None I-protein
to None None O
sort None None O
individual None None O
cells None None O
, None None O
we None None O
easily None None O
obtained None None O
a None None O
large None None O
number None None O
of None None O
clones None None O
specific None None O
to None None O
these None None O
epitopes None None I-protein
. None None O

Although None None O
DRA1*0101/DRB1*0401 None None O
and None None O
DRA1*0101/DRB1*0404 None None O
are None None O
structurally None None O
very None None O
similar None None O
, None None O
nonoverlapping None None O
VP16 None None I-protein
epitopes None None I-protein
were None None O
identified None None O
, None None O
illustrating None None O
high None None O
selectivity None None O
of None None O
individual None None O
allele None None O
polymorphisms None None O
within None None O
common None None O
MHC None None O
variants None None O
. None None O

This None None O
rapid None None O
approach None None O
to None None O
detecting None None O
CD4+ None None I-cell_type
T None None I-cell_type
cell None None I-cell_type
epitopes None None I-cell_type
from None None O
complex None None O
Ags None None I-protein
can None None O
be None None O
applied None None O
to None None O
any None None O
known None None O
Ag None None I-protein
that None None O
gives None None O
a None None O
T None None O
cell None None O
response None None O
. None None O

Localized None None O
pancreatic None None O
NF-kappaB None None O
activation None None O
and None None O
inflammatory None None O
response None None O
in None None O
taurocholate-induced None None O
pancreatitis None None O
. None None O

Transcription None None I-protein
factor None None I-protein
nuclear None None I-protein
factor-kappaB None None I-protein
( None None O
NF-kappaB None None I-protein
) None None O
is None None O
activated None None O
in None None O
cerulein None None O
pancreatitis None None O
and None None O
mediates None None O
cytokine None None O
expression None None O
. None None O

The None None O
role None None O
of None None O
transcription None None O
factor None None O
activation None None O
in None None O
other None None O
models None None O
of None None O
pancreatitis None None O
has None None O
not None None O
been None None O
established None None O
. None None O

Here None None O
we None None O
report None None O
upregulation None None O
of None None O
NF-kappaB None None I-protein
and None None O
inflammatory None None I-protein
molecules None None I-protein
, None None O
and None None O
their None None O
correlation None None O
with None None O
local None None O
pancreatic None None O
injury None None O
, None None O
in None None O
a None None O
model None None O
of None None O
severe None None O
pancreatitis None None O
. None None O

Rats None None O
received None None O
intraductal None None O
infusion None None O
of None None O
taurocholate None None O
or None None O
saline None None O
, None None O
and None None O
the None None O
pancreatic None None O
head None None O
and None None O
tail None None O
were None None O
analyzed None None O
separately None None O
. None None O

NF-kappaB None None I-protein
and None None O
activator None None I-protein
protein-1 None None I-protein
( None None O
AP-1 None None I-protein
) None None O
activation None None O
were None None O
assessed None None O
by None None O
gel None None O
shift None None O
assay None None O
, None None O
and None None O
mRNA None None O
expression None None O
of None None O
interleukin-6 None None I-RNA
, None None O
tumor None None I-protein
necrosis None None I-protein
factor-alpha None None I-protein
, None None O
KC None None O
, None None O
monocyte None None I-protein
chemoattractant None None I-protein
protein-1 None None I-protein
, None None O
and None None O
inducible None None I-protein
nitric None None I-protein
oxide None None I-protein
synthase None None I-protein
was None None O
assessed None None O
by None None O
semiquantitative None None O
RT-PCR None None O
. None None O

Morphological None None O
damage None None O
and None None O
trypsin None None O
activation None None O
were None None O
much None None O
greater None None O
in None None O
the None None O
pancreatic None None O
head None None O
than None None O
tail None None O
, None None O
in None None O
parallel None None O
with None None O
a None None O
stronger None None O
activation None None O
of None None O
NF-kappaB None None I-RNA
and None None I-RNA
cytokine None None I-RNA
mRNA None None I-RNA
. None None O

Saline None None O
infusion None None O
mildly None None O
affected None None O
these None None O
parameters None None O
. None None O

AP-1 None None I-protein
was None None O
strongly None None O
activated None None O
in None None O
both None None O
pancreatic None None O
segments None None O
after None None O
either None None O
taurocholate None None O
or None None O
saline None None O
infusion None None O
. None None O

NF-kappaB None None I-protein
inhibition None None O
with None None O
N-acetylcysteine None None O
ameliorated None None O
the None None O
local None None O
inflammatory None None O
response None None O
. None None O

Correlation None None O
between None None O
localized None None O
NF-kappaB None None I-protein
activation None None O
, None None O
cytokine None None O
upregulation None None O
, None None O
and None None O
tissue None None O
damage None None O
suggests None None O
a None None O
key None None O
role None None O
for None None O
NF-kappaB None None I-protein
in None None O
the None None O
development None None O
of None None O
the None None O
inflammatory None None O
response None None O
of None None O
acute None None O
pancreatitis None None O
. None None O

CD45 None None I-protein
tyrosine None None I-protein
phosphatase None None I-protein
controls None None O
common None None O
gamma-chain None None I-protein
cytokine None None I-protein
-mediated None None O
STAT None None I-protein
and None None O
extracellular None None O
signal-related None None O
kinase None None O
phosphorylation None None O
in None None O
activated None None I-cell_type
human None None I-cell_type
lymphoblasts None None I-cell_type
: None None O
inhibition None None O
of None None O
proliferation None None O
without None None O
induction None None O
of None None O
apoptosis None None O
. None None O

The None None O
objective None None O
of None None O
this None None O
study None None O
was None None O
to None None O
test None None O
whether None None O
CD45 None None O
signals None None O
can None None O
influence None None O
signaling None None O
processes None None O
in None None O
activated None None I-cell_type
human None None I-cell_type
lymphoblasts None None I-cell_type
. None None O

To None None O
this None None O
end None None O
, None None O
we None None O
generated None None O
lymphoblasts None None I-cell_type
which None None O
proliferate None None O
in None None O
response None None O
to None None O
common None None O
gamma-chain None None I-protein
cytokines None None I-protein
, None None O
but None None O
readily None None O
undergo None None O
apoptosis None None O
after None None O
cytokine None None O
withdrawal None None O
. None None O

In None None O
experiments None None O
with None None O
the None None O
CD45R0 None None I-protein
mAb None None I-protein
UCHL-1 None None I-protein
, None None O
but None None O
not None None O
control None None I-protein
CD45 None None I-protein
mAbs None None I-protein
, None None O
we None None O
found None None O
significant None None O
inhibition None None O
of None None O
proliferation None None O
. None None O

Interestingly None None O
, None None O
the None None O
pan-CD45 None None I-protein
mAb None None I-protein
GAP8.3 None None I-protein
, None None O
which None None O
is None None O
most None None O
effective None None O
in None None O
inhibition None None O
of None None O
OKT-3-mediated None None O
proliferation None None O
in None None O
quiescent None None I-cell_type
lymphocytes None None I-cell_type
, None None O
was None None O
ineffective None None O
in None None O
lymphoblasts None None I-cell_type
. None None O

Addition None None O
of None None O
CD3 None None I-protein
mAb None None I-protein
OKT-3 None None I-protein
had None None O
no None None O
influence None None O
on None None O
IL-2-mediated None None O
proliferation None None O
( None None O
with None None O
or None None O
without None None O
UCHL-1 None None I-protein
) None None O
. None None O

In None None O
contrast None None O
, None None O
after None None O
addition None None O
of None None O
OKT-3 None None I-protein
to None None O
IL-4 None None I-protein
- None None O
and None None O
IL-7 None None I-protein
-stimulated None None O
proliferation None None O
assays None None O
, None None O
UCHL-1 None None I-protein
signals None None O
could None None O
not None None O
significantly None None O
alter None None O
cellular None None O
proliferation None None O
. None None O

We None None O
did None None O
not None None O
find None None O
induction None None O
of None None O
apoptosis None None O
following None None O
CD45R0 None None O
signaling None None O
. None None O

In None None O
Western None None O
blots None None O
using None None O
mAbs None None I-protein
detecting None None O
phosphorylated None None I-protein
STAT-3 None None I-protein
, None None I-protein
STAT-5 None None I-protein
, None None I-protein
STAT-6 None None I-protein
, None None O
or None None O
extracellular None None I-protein
signal-related None None I-protein
kinase None None I-protein
1/2 None None I-protein
, None None O
we None None O
found None None O
that None None O
CD45R0 None None O
signaling None None O
could None None O
effectively None None O
diminish None None O
phosphorylation None None O
of None None O
these None None O
intracellular None None O
signaling None None O
components None None O
. None None O

Using None None O
RT-PCR None None O
, None None O
we None None O
found None None O
that None None O
CD45R0 None None O
signaling None None O
inhibited None None O
IL-2 None None O
mRNA None None O
production None None O
without None None O
major None None O
influence None None O
on None None O
IL-13 None None I-protein
, None None O
IL-5 None None I-protein
, None None O
or None None O
IFN-gamma None None I-RNA
mRNA None None I-RNA
levels None None O
. None None O

Costimulation None None O
with None None O
OKT-3 None None I-protein
and None None O
IL-2 None None I-protein
optimally None None O
induced None None O
secretion None None O
of None None O
IFN-gamma None None I-protein
, None None O
TNF-alpha None None I-protein
, None None O
and None None O
IL-5 None None I-protein
, None None O
which None None O
was None None O
not None None O
decreased None None O
by None None O
CD45 None None O
signals None None O
. None None O

In None None O
conclusion None None O
, None None O
we None None O
illustrate None None O
that None None O
CD45R0 None None O
signals None None O
control None None O
early None None O
cytokine None None O
receptor-associated None None O
signaling None None O
processes None None O
and None None O
mRNA None None O
and None None O
DNA None None O
synthesis None None O
in None None O
activated None None I-cell_type
human None None I-cell_type
lymphoblasts None None I-cell_type
. None None O

Furthermore None None O
, None None O
we None None O
show None None O
the None None O
existence None None O
of None None O
CD45 None None I-protein
epitopes None None I-protein
( None None O
GAP8.3 None None I-protein
) None None O
, None None O
which None None O
are None None O
active None None O
and None None O
critical None None O
for None None O
signaling None None O
in None None O
quiescent None None I-cell_type
lymphocytes None None I-cell_type
, None None O
but None None O
are None None O
nonfunctional None None O
in None None O
activated None None I-cell_type
human None None I-cell_type
lymphoblasts None None I-cell_type
. None None O

Pax5 None None I-DNA
determines None None O
the None None O
identity None None O
of None None O
B None None I-cell_type
cells None None I-cell_type
from None None O
the None None O
beginning None None O
to None None O
the None None O
end None None O
of None None O
B-lymphopoiesis None None O
. None None O

Despite None None O
being None None O
one None None O
of None None O
the None None O
most None None O
intensively None None O
studied None None O
cell None None O
types None None O
, None None O
the None None O
molecular None None O
basis None None O
of None None O
B None None O
cell None None O
specification None None O
is None None O
largely None None O
unknown None None O
. None None O

The None None O
Pax5 None None I-DNA
gene None None I-DNA
encoding None None O
the None None O
transcription None None I-protein
factor None None I-protein
BSAP None None I-protein
is None None O
required None None O
for None None O
progression None None O
of None None O
B-lymphopoiesis None None O
beyond None None O
the None None O
pro-B None None O
cell None None O
stage None None O
. None None O

Pax5-deficient None None I-cell_type
pro-B None None I-cell_type
cells None None I-cell_type
are None None O
, None None O
however None None O
, None None O
not None None O
yet None None O
committed None None O
to None None O
the None None O
B-lymphoid None None I-cell_type
lineage None None I-cell_type
, None None O
but None None O
instead None None O
have None None O
a None None O
broad None None O
lymphomyeloid None None O
developmental None None O
potential None None O
. None None O

Pax5 None None I-DNA
appears None None O
to None None O
mediate None None O
B-lineage None None O
commitment None None O
by None None O
repressing None None O
the None None O
transcription None None O
of None None O
non-B-lymphoid None None I-DNA
genes None None I-DNA
and None None O
by None None O
simultaneously None None O
activating None None O
the None None O
expression None None O
of None None O
B-lineage-specific None None I-DNA
genes None None I-DNA
. None None O

Pax5 None None I-DNA
thus None None O
functions None None O
both None None O
as None None O
a None None O
transcriptional None None O
repressor None None O
and None None O
activator None None O
, None None O
depending None None O
on None None O
its None None O
interactions None None O
with None None O
corepressors None None I-protein
of None None O
the None None O
Groucho None None I-protein
protein None None I-protein
family None None I-protein
or None None O
with None None O
positive None None O
regulators None None O
such None None O
as None None O
the None None O
TATA-binding None None I-protein
protein None None I-protein
. None None O

Once None None O
committed None None O
to None None O
the None None O
B-lineage None None I-cell_type
, None None O
B None None I-cell_type
cells None None I-cell_type
require None None O
Pax5 None None I-DNA
function None None O
to None None O
maintain None None O
their None None O
B-lymphoid None None O
identity None None O
throughout None None O
B None None O
cell None None O
development None None O

Partners None None O
in None None O
transcription None None O
: None None O
NFAT None None I-protein
and None None O
AP-1 None None I-protein
. None None O

Combinatorial None None O
regulation None None O
is None None O
a None None O
powerful None None O
mechanism None None O
that None None O
enables None None O
tight None None O
control None None O
of None None O
gene None None O
expression None None O
, None None O
via None None O
integration None None O
of None None O
multiple None None O
signaling None None O
pathways None None O
that None None O
induce None None O
different None None O
transcription None None I-protein
factors None None I-protein
required None None O
for None None O
enhanceosome None None O
assembly None None O
. None None O

The None None O
four None None O
calcium-regulated None None O
transcription None None I-protein
factors None None I-protein
of None None O
the None None O
NFAT None None I-protein
family None None I-protein
act None None O
synergistically None None O
with None None O
AP-1 None None I-protein
( None None I-protein
Fos/Jun None None I-protein
) None None I-protein
proteins None None I-protein
on None None O
composite None None O
DNA None None O
elements None None O
which None None O
contain None None O
adjacent None None O
NFAT None None I-DNA
and None None I-DNA
AP-1 None None I-DNA
binding None None I-DNA
sites None None I-DNA
, None None O
where None None O
they None None O
form None None O
highly None None O
stable None None O
ternary None None O
complexes None None O
to None None O
regulate None None O
the None None O
expression None None O
of None None O
diverse None None O
inducible None None O
genes None None O
. None None O

Concomitant None None O
induction None None O
of None None O
NFAT None None I-protein
and None None O
AP-1 None None I-protein
requires None None O
concerted None None O
activation None None O
of None None O
two None None O
different None None O
signaling None None O
pathways None None O
: None None O
calcium/calcineurin None None O
, None None O
which None None O
promotes None None O
NFAT None None O
dephosphorylation None None O
, None None O
nuclear None None O
translocation None None O
and None None O
activation None None O
; None None O
and None None O
protein None None I-protein
kinase None None I-protein
C None None I-protein
( None None I-protein
PKC None None I-protein
) None None I-protein
/Ras None None I-protein
, None None O
which None None O
promotes None None O
the None None O
synthesis None None O
, None None O
phosphorylation None None O
and None None O
activation None None O
of None None O
members None None O
of None None O
the None None O
Fos None None I-protein
and None None I-protein
Jun None None I-protein
families None None I-protein
of None None O
transcription None None I-protein
factors None None I-protein
. None None O

A None None O
fifth None None O
member None None O
of None None O
the None None O
NFAT None None I-protein
family None None I-protein
, None None O
NFAT5 None None I-protein
, None None O
controls None None O
the None None O
cellular None None O
response None None O
to None None O
osmotic None None O
stress None None O
, None None O
by None None O
a None None O
mechanism None None O
that None None O
requires None None O
dimer None None O
formation None None O
and None None O
is None None O
independent None None O
of None None O
calcineurin None None I-protein
or None None O
of None None O
interaction None None O
with None None O
AP-1 None None I-protein
. None None O

Pharmacological None None O
interference None None O
with None None O
theNFAT None None O
: None None O
AP-1 None None O
interaction None None O
may None None O
be None None O
useful None None O
in None None O
selective None None O
manipulation None None O
of None None O
the None None O
immune None None O
response None None O
. None None O

Balanced None None O
activation None None O
of None None O
NFAT None None I-protein
and None None O
AP-1 None None I-protein
is None None O
known None None O
to None None O
be None None O
required None None O
for None None O
productive None None O
immune None None O
responses None None O
, None None O
but None None O
the None None O
role None None O
of None None O
NFAT None None O
: None None O
AP-1 None None O
interactions None None O
in None None O
other None None O
cell None None O
types None None O
and None None O
biological None None O
processes None None O
remains None None O
to None None O
be None None O
understood None None O
. None None O

Cytokine None None O
production None None O
by None None O
Vgamma None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
-T-cell None None I-cell_type
subsets None None I-cell_type
is None None O
an None None O
important None None O
factor None None O
determining None None O
CD4 None None O
( None None O
+ None None O
) None None O
-Th-cell None None O
phenotype None None O
and None None O
susceptibility None None O
of None None O
BALB/c None None O
mice None None O
to None None O
coxsackievirus None None O
B3-induced None None O
myocarditis None None O
. None None O

Two None None O
coxsackievirus None None O
B3 None None O
( None None O
CVB3 None None O
) None None O
variants None None O
( None None O
H3 None None O
and None None O
H310A1 None None O
) None None O
differ None None O
by None None O
a None None O
single None None O
amino None None O
acid None None O
mutation None None O
in None None O
the None None O
VP2 None None I-protein
capsid None None I-protein
protein None None I-protein
. None None O

H3 None None O
induces None None O
severe None None O
myocarditis None None O
in None None O
BALB/c None None O
mice None None O
, None None O
but None None O
H310A1 None None O
is None None O
amyocarditic None None O
. None None O

Infection None None O
with None None O
H3 None None O
, None None O
but None None O
not None None O
H310A1 None None O
, None None O
preferentially None None O
activates None None O
Vgamma4 None None I-cell_type
Vdelta4 None None I-cell_type
cells None None I-cell_type
, None None O
which None None O
are None None O
strongly None None O
positive None None O
for None None O
gamma None None I-protein
interferon None None I-protein
( None None O
IFN-gamma None None I-protein
) None None O
, None None O
whereas None None O
Vgamma1 None None I-cell_type
Vdelta4 None None I-cell_type
cells None None I-cell_type
are None None O
increased None None O
in None None O
both None None O
H3 None None O
and None None O
H310A1 None None O
virus-infected None None O
animals None None O
. None None O

Depletion None None O
of None None O
Vgamma1 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
using None None O
monoclonal None None I-protein
anti-Vgamma1 None None I-protein
antibody None None I-protein
enhanced None None O
myocarditis None None O
and None None O
CD4 None None O
( None None O
+ None None O
) None None O
- None None O
, None None O
IFN-gamma None None I-protein
( None None O
+ None None O
) None None O
-cell None None O
responses None None O
in None None O
both None None O
H3- None None O
and None None O
H310A1-infected None None O
mice None None O
yet None None O
decreased None None O
the None None O
CD4 None None O
( None None O
+ None None O
) None None O
- None None O
, None None O
IL-4 None None O
( None None O
+ None None O
) None None O
-cell None None O
response None None O
. None None O

Depleting None None O
Vgamma4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
suppressed None None O
myocarditis None None O
and None None O
reduced None None O
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
IFN-gamma None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
but None None O
increased None None O
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
IL-4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
role None None O
of None None O
cytokine None None O
production None None O
by None None O
Vgamma1 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
and None None I-cell_type
Vgamma4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
was None None O
investigated None None O
by None None O
adoptively None None O
transferring None None O
these None None O
cells None None O
isolated None None O
from None None O
H3-infected None None O
BALB/c None None O
Stat4 None None O
knockout None None O
( None None O
Stat4ko None None O
) None None O
( None None O
defective None None O
in None None O
IFN-gamma None None I-protein
expression None None O
) None None O
or None None O
BALB/c None None O
Stat6ko None None O
( None None O
defective None None O
in None None O
IL-4 None None O
expression None None O
) None None O
mice None None O
into None None O
H3 None None O
virus-infected None None O
wild-type None None O
BALB/c None None O
recipients None None O
. None None O

Vgamma4 None None I-cell_type
and None None I-cell_type
Vgamma1 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
from None None O
Stat4ko None None O
mice None None O
expressed None None O
IL-4 None None I-protein
but None None O
no None None O
or None None O
minimal None None O
IFN-gamma None None I-protein
, None None O
whereas None None O
these None None O
cell None None O
populations None None O
derived None None O
from None None O
Stat6ko None None O
mice None None O
expressed None None O
IFN-gamma None None I-protein
but None None O
no None None O
IL-4 None None I-protein
. None None O

Stat4ko None None I-cell_type
Vgamma1 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
( None None I-cell_type
IL-4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
) None None O
suppress None None O
myocarditis None None O
. None None O

Stat6ko None None I-cell_type
Vgamma1 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
( None None I-cell_type
IFN-gamma None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
) None None I-cell_type
were None None O
not None None O
inhibitory None None O
. None None O

Stat6ko None None I-cell_type
Vgamma4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
( None None I-cell_type
IFN-gamma None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
) None None I-cell_type
significantly None None O
enhanced None None O
myocarditis None None O
. None None O

Stat4ko None None I-cell_type
Vgamma4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
( None None I-cell_type
IL-4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
) None None I-cell_type
neither None None O
inhibited None None O
nor None None O
enhanced None None O
disease None None O
. None None O

These None None O
results None None O
show None None O
that None None O
distinct None None O
gammadelta-T-cell None None I-cell_type
subsets None None I-cell_type
control None None O
myocarditis None None O
susceptibility None None O
and None None O
bias None None O
the None None O
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
-Th-cell None None I-cell_type
response None None O
. None None O

The None None O
cytokines None None I-protein
produced None None O
by None None O
the None None O
Vgamma None None I-cell_type
subpopulation None None I-cell_type
have None None O
a None None O
significant None None O
influence None None O
on None None O
the None None O
CD4 None None I-protein
( None None O
+ None None O
) None None O
-Th-cell None None O
phenotype None None O
. None None O

Plasmin None None I-protein
-induced None None O
expression None None O
of None None O
cytokines None None I-protein
and None None O
tissue None None I-protein
factor None None I-protein
in None None O
human None None I-cell_type
monocytes None None I-cell_type
involves None None O
AP-1 None None I-protein
and None None O
IKKbeta None None I-protein
-mediated None None O
NF-kappaB None None O
activation None None O
. None None O

It None None O
was None None O
previously None None O
shown None None O
that None None O
plasmin None None I-protein
activates None None O
human None None I-cell_type
peripheral None None I-cell_type
monocytes None None I-cell_type
in None None O
terms None None O
of None None O
lipid None None O
mediator None None O
release None None O
and None None O
chemotactic None None O
migration None None O
. None None O

Here None None O
it None None O
is None None O
demonstrated None None O
that None None O
plasmin None None I-protein
induces None None O
proinflammatory None None I-protein
cytokine None None I-protein
release None None O
and None None O
tissue None None I-protein
factor None None I-protein
( None None O
TF None None I-protein
) None None O
expression None None O
by None None O
monocytes None None I-cell_type
. None None O

Plasmin None None I-protein
0.043 None None O
to None None O
1.43 None None O
CTA None None O
U/mL None None O
, None None O
but None None O
not None None O
active None None I-protein
site-blocked None None I-protein
plasmin None None I-protein
, None None O
triggered None None O
concentration-dependent None None O
expression None None O
of None None O
mRNA None None O
for None None O
interleukin-1alpha None None I-protein
( None None O
IL-1alpha None None I-protein
) None None O
, None None O
IL-1beta None None I-protein
, None None O
tumor None None I-protein
necrosis None None I-protein
factor-alpha None None I-protein
( None None O
TNF-alpha None None I-protein
) None None O
, None None O
and None None O
TF None None I-protein
with None None O
maximum None None O
responses None None O
after None None O
4 None None O
hours None None O
. None None O

Plasmin None None I-protein
-mediated None None O
mRNA None None O
expression None None O
was None None O
inhibited None None O
in None None O
a None None O
concentration-dependent None None O
manner None None O
by None None O
the None None O
lysine None None O
analogue None None O
trans-4- None None O
( None None O
aminomethyl None None O
) None None O
cyclohexane-1-carboxylic None None O
acid None None O
( None None O
t-AMCA None None O
) None None O
. None None O

Increases None None O
in None None O
mRNA None None O
levels None None O
were None None O
followed None None O
by None None O
concentration- None None O
and None None O
time-dependent None None O
release None None O
of None None O
IL-1alpha None None I-protein
, None None O
IL-1beta None None I-protein
and None None O
TNF-alpha None None I-protein
and None None O
by None None O
TF None None I-protein
expression None None O
on None None O
monocyte None None O
surfaces None None O
. None None O

Neither None None O
cytokines None None I-protein
nor None None O
TF None None I-protein
could None None O
be None None O
detected None None O
when None None O
monocytes None None I-cell_type
were None None O
preincubated None None O
with None None O
actinomycin None None O
D None None O
or None None O
cycloheximide None None O
. None None O

Electrophoretic None None O
mobility None None O
shift None None O
assays None None O
indicated None None O
plasmin None None I-protein
-induced None None O
activation None None O
of None None O
NF-kappaB None None I-protein
; None None O
DNA-binding None None I-protein
complexes None None I-protein
were None None O
composed None None O
of None None O
p50 None None I-protein
, None None O
p65 None None I-protein
, None None O
and None None O
c-Rel None None I-protein
, None None O
as None None O
shown None None O
by None None O
supershift None None O
experiments None None O
. None None O

Nuclear None None O
translocation None None O
of None None O
NF-kappaB/Rel None None I-protein
proteins None None I-protein
coincided None None O
with None None O
IkappaBalpha None None O
degradation None None O
. None None O

At None None O
variance None None O
with None None O
endotoxic None None O
lipopolysaccharide None None O
, None None O
plasmin None None I-protein
elicited None None O
the None None O
rapid None None O
degradation None None O
of None None O
another None None O
cytoplasmic None None I-protein
NF-kappaB None None I-protein
inhibitor None None I-protein
, None None I-protein
p105 None None I-protein
. None None O

Proteolysis None None O
of None None O
NF-kappaB None None O
inhibitors None None O
was None None O
apparently None None O
due None None O
to None None O
transient None None O
activation None None O
of None None O
IkappaB None None I-protein
kinase None None I-protein
( None None I-protein
IKK None None I-protein
) None None I-protein
beta None None I-protein
that None None O
reached None None O
maximum None None O
activity None None O
at None None O
1 None None O
hour None None O
after None None O
plasmin None None I-protein
stimulation None None O
. None None O

In None None O
addition None None O
, None None O
AP-1 None None O
binding None None O
was None None O
increased None None O
in None None O
plasmin None None I-protein
-treated None None O
monocytes None None I-cell_type
, None None O
with None None O
most None None O
complexes None None O
composed None None O
of None None O
JunD None None I-protein
, None None O
c-Fos None None I-protein
, None None O
and None None O
FosB None None I-protein
. None None O

These None None O
findings None None O
further None None O
substantiate None None O
the None None O
role None None O
of None None O
plasmin None None I-protein
as None None O
a None None O
proinflammatory None None O
activator None None O
of None None O
human None None I-cell_type
monocytes None None I-cell_type
and None None O
reveal None None O
an None None O
important None None O
new None None O
link None None O
between None None O
the None None O
plasminogen-plasmin None None O
system None None O
and None None O
inflammation None None O
. None None O

( None None O
Blood. None None O
2001 None None O
; None None O
97 None None O
: None None O
3941-3950 None None O
) None None O

STAT3 None None I-protein
is None None O
constitutively None None O
active None None O
in None None O
some None None O
patients None None O
with None None O
Polycythemia None None O
rubra None None O
vera None None O
. None None O

OBJECTIVE None None O
: None None O
Polycythemia None None O
vera None None O
is None None O
a None None O
clonal None None O
stem None None O
cell None None O
disorder None None O
characterized None None O
by None None O
hyperproliferation None None O
of None None O
the None None O
erythroid None None I-cell_type
, None None I-cell_type
myeloid None None I-cell_type
, None None I-cell_type
and None None I-cell_type
megakaryocytic None None I-cell_type
lineages None None I-cell_type
. None None O

While None None O
it None None O
has None None O
been None None O
shown None None O
that None None O
progenitor None None I-cell_type
cells None None I-cell_type
of None None O
P. None None O
vera None None O
patients None None O
are None None O
hypersensitive None None O
to None None O
several None None O
growth None None O
factors None None O
including None None O
erythropoietin None None I-protein
, None None O
insulin-like None None I-protein
growth None None I-protein
factor-1 None None I-protein
, None None O
thrombopoietin None None I-protein
, None None O
interleukin-3 None None I-protein
, None None O
and None None O
granulocyte/monocyte None None I-protein
colony-stimulating None None I-protein
factor None None I-protein
, None None O
the None None O
molecular None None O
pathogenesis None None O
of None None O
this None None O
disease None None O
remains None None O
unknown None None O
. None None O

Growth None None O
factor None None O
hypersensitivity None None O
could None None O
be None None O
mediated None None O
by None None O
changes None None O
in None None O
signal None None O
transduction None None O
pathways None None O
. None None O

We None None O
therefore None None O
investigated None None O
a None None O
common None None O
downstream None None O
effector None None O
of None None O
cytokines None None I-protein
, None None O
the None None O
signal None None I-protein
transducers None None I-protein
and None None I-protein
activators None None I-protein
of None None I-protein
transcription None None I-protein
( None None O
STATs None None I-protein
) None None O
. None None O

A None None O
constitutive None None O
activation None None O
of None None O
STAT None None I-protein
factors None None I-protein
could None None O
explain None None O
the None None O
increased None None O
proliferation None None O
of None None O
P. None None I-cell_type
vera None None I-cell_type
cells None None I-cell_type
even None None O
in None None O
the None None O
absence None None O
of None None O
growth None None O
factor None None O
stimulation None None O
. None None O

METHODS None None O
: None None O
Peripheral None None I-cell_type
granulocytes None None I-cell_type
from None None O
patients None None O
with None None O
P. None None O
vera None None O
and None None O
from None None O
healthy None None O
volunteers None None O
were None None O
assayed None None O
for None None O
STAT1 None None I-protein
, None None I-protein
3 None None I-protein
, None None I-protein
and None None I-protein
5 None None I-protein
DNA None None O
binding None None O
by None None O
electrophoretic None None O
mobility None None O
shift None None O
assay None None O
. None None O

RESULTS None None O
: None None O
Four None None O
of None None O
14 None None O
P. None None O
vera None None O
patients None None O
analyzed None None O
showed None None O
constitutive None None O
STAT3 None None O
DNA None None O
binding None None O
in None None O
unstimulated None None I-cell_type
peripheral None None I-cell_type
granulocytes None None I-cell_type
, None None O
while None None O
none None None O
of None None O
the None None O
17 None None O
healthy None None O
volunteers None None O
tested None None O
did None None O
. None None O

None None None O
of None None O
the None None O
subjects None None O
showed None None O
constitutive None None O
STAT1 None None I-protein
or None None O
STAT5 None None I-protein
activity None None O
. None None O

Western None None O
blotting None None O
demonstrated None None O
that None None O
, None None O
in None None O
the None None O
three None None O
patients None None O
, None None O
STAT3 None None I-protein
is None None O
constitutively None None O
phosphorylated None None O
on None None O
Tyr None None O
705 None None O
, None None O
whereas None None O
it None None O
is None None O
unphosphorylated None None O
in None None O
the None None O
other None None O
patients None None O
and None None O
in None None O
controls None None O
. None None O

Interestingly None None O
, None None O
constitutive None None O
STAT3 None None I-protein
activity None None O
did None None O
not None None O
correlate None None O
with None None O
the None None O
duration None None O
of None None O
disease None None O
or None None O
the None None O
treatment None None O
regimen None None O
. None None O

It None None O
was None None O
observed None None O
in None None O
a None None O
recently None None O
diagnosed None None O
patient None None O
and None None O
in None None O
two None None O
patients None None O
treated None None O
only None None O
with None None O
phlebotomy None None O
. None None O

CONCLUSION None None O
: None None O
Our None None O
data None None O
suggest None None O
that None None O
constitutive None None O
phosphorylation None None O
and None None O
activation None None O
of None None O
STAT3 None None I-protein
is None None O
not None None O
a None None O
secondary None None O
event None None O
induced None None O
by None None O
mutagenizing None None O
agents None None O
or None None O
by None None O
prolonged None None O
hyperproliferation None None O
of None None O
hematopoietic None None I-cell_type
cells None None I-cell_type
, None None O
but None None O
rather None None O
represents None None O
a None None O
primary None None O
molecular None None O
aberration None None O
. None None O

Constitutively None None I-protein
active None None I-protein
STAT3 None None I-protein
may None None O
contribute None None O
to None None O
the None None O
growth None None O
factor None None O
hypersensitivity None None O
of None None O
P. None None I-cell_type
vera None None I-cell_type
cells None None I-cell_type
. None None O

Identification None None O
of None None O
phosphorylation None None I-protein
sites None None I-protein
for None None O
Bruton None None I-protein
's None None I-protein
tyrosine None None I-protein
kinase None None I-protein
within None None O
the None None O
transcriptional None None I-protein
regulator None None I-protein
BAP/TFII-I None None I-protein
. None None O

Bruton None None I-protein
's None None I-protein
tyrosine None None I-protein
kinase None None I-protein
( None None O
Btk None None I-protein
) None None O
, None None O
a None None O
member None None O
of None None O
the None None O
Tec None None I-protein
family None None I-protein
of None None I-protein
cytosolic None None I-protein
kinases None None I-protein
, None None O
is None None O
essential None None O
for None None O
B None None I-cell_type
cell None None I-cell_type
development None None O
and None None O
function None None O
. None None O

BAP/TFII-I None None I-protein
, None None O
a None None O
protein None None O
implicated None None O
in None None O
transcriptional None None O
regulation None None O
, None None O
is None None O
associated None None O
with None None O
Btk None None I-protein
in None None O
B None None I-cell_type
cells None None I-cell_type
and None None O
is None None O
transiently None None O
phosphorylated None None O
on None None O
tyrosine None None O
following None None O
B None None I-cell_type
cell None None I-cell_type
receptor None None O
engagement None None O
. None None O

BAP/TFII-I None None I-protein
is None None O
a None None O
substrate None None O
for None None O
Btk None None I-protein
in None None O
vitro None None O
and None None O
is None None O
hyperphosphorylated None None O
on None None O
tyrosine None None O
upon None None O
coexpression None None O
with None None O
Btk None None I-protein
in None None O
mammalian None None I-cell_type
cells None None I-cell_type
. None None O

In None None O
an None None O
effort None None O
to None None O
understand None None O
the None None O
physiologic None None O
consequences None None O
of None None O
BAP/TFII-I None None I-protein
tyrosine None None O
phosphorylation None None O
following None None O
B None None O
cell None None O
receptor None None O
stimulation None None O
, None None O
site-directed None None O
mutagenesis None None O
and None None O
phosphopeptide None None O
mapping None None O
were None None O
used None None O
to None None O
locate None None O
the None None O
predominant None None O
sites None None O
of None None O
BAP/TFII-I None None I-protein
phosphorylation None None O
by None None O
Btk None None I-protein
in None None O
vitro None None O
. None None O

These None None O
residues None None O
, None None O
Tyr248 None None O
, None None O
Tyr357 None None O
, None None O
and None None O
Tyr462 None None O
, None None O
were None None O
also None None O
found None None O
to None None O
be None None O
the None None O
major None None O
sites None None O
for None None O
Btk None None I-protein
-dependent None None O
phosphorylation None None O
of None None O
BAP/TFII-I None None I-protein
in None None O
vivo None None O
. None None O

Residues None None O
Tyr357 None None O
and None None O
Tyr462 None None O
are None None O
contained None None O
within None None O
the None None O
loop None None I-protein
regions None None I-protein
of None None O
adjacent None None O
helix-loop-helix-like None None I-protein
repeats None None I-protein
within None None O
BAP/TFII-I None None I-protein
. None None O

Mutation None None O
of None None O
either None None O
Tyr248 None None O
, None None O
Tyr357 None None O
, None None O
or None None O
Tyr462 None None O
to None None O
phenylalanine None None O
reduced None None O
transcription None None O
from None None O
a None None O
c-fos None None I-DNA
promoter None None I-DNA
relative None None O
to None None O
wild-type None None I-DNA
BAP/TFII-I None None I-DNA
in None None O
transfected None None O
COS-7 None None I-cell_line
cells None None I-cell_line
, None None O
consistent None None O
with None None O
the None None O
interpretation None None O
that None None O
phosphorylation None None O
at None None O
these None None O
sites None None O
contributes None None O
to None None O
transcriptional None None O
activation None None O
. None None O

Phosphorylation None None O
of None None O
BAP/TFII-I None None I-protein
by None None O
Btk None None I-protein
may None None O
link None None O
engagement None None O
of None None O
receptors None None O
such None None O
as None None O
surface None None O
immunoglobulin None None I-protein
to None None O
modulation None None O
of None None O
gene None None O
expression None None O
. None None O

Expression None None O
of None None O
interferon None None I-protein
consensus None None I-protein
sequence None None I-protein
binding None None I-protein
protein None None I-protein
induces None None O
potent None None O
immunity None None O
against None None O
BCR/ABL-induced None None O
leukemia None None O
. None None O

Mice None None O
deficient None None O
in None None O
the None None O
interferon None None I-protein
consensus None None I-protein
sequence None None I-protein
binding None None I-protein
protein None None I-protein
( None None O
ICSBP None None I-protein
) None None O
develop None None O
a None None O
disease None None O
resembling None None O
chronic None None O
myeloid None None O
leukemia None None O
( None None O
CML None None O
) None None O
, None None O
which None None O
in None None O
humans None None O
is None None O
caused None None O
by None None O
the None None O
BCR/ABL None None I-protein
oncoprotein None None I-protein
. None None O

Interferon-alpha None None I-protein
( None None O
IFN-alpha None None I-protein
) None None O
induces None None O
ICSBP None None I-protein
expression None None O
and None None O
is None None O
an None None O
effective None None O
therapy None None O
for None None O
CML None None O
. None None O

This None None O
study None None O
examined None None O
whether None None O
enforced None None O
expression None None O
of None None O
ICSBP None None I-protein
might None None O
antagonize None None O
BCR/ABL-induced None None O
leukemia None None O
; None None O
results None None O
demonstrated None None O
that None None O
ICSBP-modified None None I-cell_type
cells None None I-cell_type
generated None None O
a None None O
protective None None O
CD8 None None O
( None None O
+ None None O
) None None O
cytotoxic None None O
T-cell None None O
response None None O
against None None O
BCR/ABL-transformed None None I-cell_type
BaF3 None None I-cell_type
cells None None I-cell_type
in None None O
a None None O
murine None None O
leukemia None None O
model None None O
. None None O

ICSBP None None I-protein
expression None None O
represents None None O
a None None O
novel None None O
means None None O
of None None O
stimulating None None O
a None None O
host None None O
immune None None O
response None None O
to None None O
BCR/ABL None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
leukemia None None I-cell_type
cells None None I-cell_type
and None None O
a None None O
potential None None O
strategy None None O
for None None O
immunotherapy None None O
of None None O
CML None None O
. None None O

( None None O
Blood. None None O
2001 None None O
; None None O
97 None None O
: None None O
3491-3497 None None O
) None None O

A None None O
transcriptional None None O
block None None O
in None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
at None None O
the None None O
-150 None None I-DNA
AP-1 None None I-DNA
site None None I-DNA
in None None O
effector None None I-cell_type
CD8+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

Both None None O
CD4+ None None I-cell_type
and None None I-cell_type
CD8+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
that None None O
produce None None O
IL-2 None None I-protein
in None None O
response None None O
to None None O
Ag None None O
recognition None None O
have None None O
been None None O
isolated None None O
. None None O

However None None O
, None None O
most None None O
effector None None I-cell_type
CD8+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
recovered None None O
after None None O
exposure None None O
to None None O
Ag None None I-protein
do None None O
not None None O
produce None None O
sufficient None None O
IL-2 None None I-protein
to None None O
sustain None None O
growth None None O
, None None O
and None None O
depend None None O
on None None O
CD4+ None None I-cell_type
T None None I-cell_type
helper None None I-cell_type
cells None None I-cell_type
for None None O
this None None O
obligate None None O
growth None None O
factor None None O
. None None O

IL-2 None None O
expression None None O
in None None O
CD4+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
is None None O
primarily None None O
controlled None None O
at None None O
the None None O
level None None O
of None None O
transcription None None O
, None None O
but None None O
mechanisms None None O
restricting None None O
IL-2 None None O
production None None O
in None None O
CD8+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
have None None O
not None None O
been None None O
elucidated None None O
. None None O

To None None O
evaluate None None O
transcriptional None None O
regulation None None O
of None None O
the None None O
IL-2 None None I-DNA
gene None None I-DNA
in None None O
CD8+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
, None None O
we None None O
stably None None O
transfected None None O
reporter None None I-DNA
genes None None I-DNA
into None None O
Ag None None I-protein
-specific None None O
CD8+ None None I-cell_line
T None None I-cell_line
cell None None I-cell_line
clones None None I-cell_line
. None None O

CD28+ None None I-cell_type
CD8 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
unable None None O
to None None O
transcribe None None O
the None None O
IL-2 None None I-DNA
gene None None I-DNA
in None None O
response None None O
to None None O
antigenic None None O
stimulation None None O
had None None O
a None None O
block None None O
in None None O
transactivation None None O
of None None O
the None None O
-150 None None I-DNA
CD28 None None I-DNA
response None None I-DNA
element None None I-DNA
( None None I-DNA
CD28RE None None I-DNA
) None None I-DNA
/AP-1 None None I-DNA
site None None I-DNA
of None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
, None None O
but None None O
did None None O
transactivate None None O
the None None O
composite None None O
NFAT/AP-1 None None I-DNA
and None None I-DNA
OCT/AP-1 None None I-DNA
sites None None I-DNA
, None None O
and None None O
a None None O
consensus None None I-DNA
AP-1 None None I-DNA
motif None None I-DNA
. None None O

Mutation None None O
of None None O
the None None O
nonconsensus None None I-DNA
-150 None None I-DNA
AP-1 None None I-DNA
site None None I-DNA
to None None O
a None None O
consensus None None I-DNA
AP-1 None None I-DNA
site None None I-DNA
, None None O
or None None O
insertion None None O
of None None O
a None None O
CD28RE/AP-1 None None I-DNA
consensus None None I-DNA
site None None I-DNA
upstream None None O
of None None O
the None None O
native None None O
-150 None None I-DNA
CD28RE/AP-1 None None I-DNA
site None None I-DNA
restored None None O
transactivation None None O
of None None O
the None None O
altered None None O
promoter None None I-DNA
. None None O

These None None O
results None None O
suggest None None O
that None None O
the None None O
defect None None O
at None None O
the None None O
-150 None None I-DNA
site None None I-DNA
may None None O
reflect None None O
the None None O
absence None None O
or None None O
inactivity None None O
of None None O
a None None O
required None None O
factor None None O
rather None None O
than None None O
repression None None O
of None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
. None None O

Stem None None I-protein
cell None None I-protein
factor None None I-protein
and None None O
interleukin-3 None None I-protein
induce None None O
stepwise None None O
generation None None O
of None None O
erythroid None None I-cell_type
precursor None None I-cell_type
cells None None I-cell_type
from None None O
a None None O
basic None None O
fibroblast None None I-protein
growth None None I-protein
factor None None I-protein
-dependent None None O
hematopoietic None None I-cell_line
stem None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
, None None I-cell_line
A-6 None None I-cell_line
. None None O

A None None O
m None None O
ultipotent None None I-cell_type
immature None None I-cell_type
myeloid None None I-cell_type
cell None None I-cell_type
population None None I-cell_type
was None None O
produced None None O
from None None O
a None None O
basic None None I-protein
fibroblast None None I-protein
growth None None I-protein
factor None None I-protein
( None None O
bFGF None None I-protein
) None None O
-dependent None None O
hematopoietic None None I-cell_line
stem None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
, None None I-cell_line
A-6 None None I-cell_line
, None None O
when None None O
cultured None None O
with None None O
stem None None I-protein
cell None None I-protein
factor None None I-protein
( None None O
SCF None None I-protein
) None None O
replacing None None O
bFGF None None I-protein
. None None O

Those None None O
cells None None O
were None None O
positive None None O
for None None O
stem None None I-protein
cell None None I-protein
markers None None I-protein
, None None O
c-kit None None I-protein
and None None O
CD34 None None I-protein
, None None O
and None None O
a None None O
myeloid None None I-protein
cell None None I-protein
marker None None I-protein
, None None I-protein
F4/80 None None I-protein
. None None O

Some None None O
cell None None O
fractions None None O
were None None O
also None None O
positive None None O
for None None O
Mac-1 None None I-protein
, None None I-protein
a None None I-protein
macrophage None None I-protein
marker None None I-protein
or None None O
Gr-1 None None I-protein
, None None I-protein
a None None I-protein
granulocytic None None I-protein
maker None None I-protein
, None None O
but None None O
negative None None O
for None None O
an None None O
erythroid None None I-protein
marker None None I-protein
TER119 None None I-protein
. None None O

They None None O
also None None O
showed None None O
the None None O
expression None None O
of None None O
mRNA None None O
for None None O
the None None O
myeloid-specific None None I-protein
PU.1 None None I-protein
but None None O
did None None O
not None None O
that None None O
for None None O
the None None O
erythroid-specific None None I-protein
GATA-1 None None I-protein
. None None O

Among None None O
various None None O
cytokines None None I-protein
, None None O
interleukin-3 None None I-protein
( None None O
IL-3 None None I-protein
) None None O
induced None None O
erythroid None None I-cell_type
precursor None None I-cell_type
cells None None I-cell_type
that None None O
expressed None None O
the None None O
erythroid-specific None None I-protein
GATA-1 None None I-protein
and None None O
beta-major None None I-protein
globin None None I-protein
. None None O

The None None O
quantitative None None O
analysis None None O
showed None None O
that None None O
erythroid None None I-cell_type
precursor None None I-cell_type
cells None None I-cell_type
were None None O
newly None None O
produced None None O
from None None O
the None None O
immature None None I-cell_type
myeloid None None I-cell_type
cells None None I-cell_type
by None None O
cultivation None None O
with None None O
IL-3 None None I-protein
. None None O

SCF None None I-protein
and None None O
IL-3 None None I-protein
induced None None O
stepwise None None O
generation None None O
of None None O
erythroid None None I-cell_type
precursor None None I-cell_type
cells None None I-cell_type
from None None O
an None None O
A-6 None None I-cell_line
hematopoietic None None I-cell_line
stem None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
. None None O

Copyright None None O
2001 None None O
Academic None None O
Press None None O
. None None O

Distinct None None O
BMI-1 None None I-protein
and None None O
EZH2 None None I-protein
expression None None O
patterns None None O
in None None O
thymocytes None None I-cell_type
and None None O
mature None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
suggest None None O
a None None O
role None None O
for None None O
Polycomb None None I-DNA
genes None None I-DNA
in None None O
human None None O
T None None O
cell None None O
differentiation None None O
. None None O

BMI-1 None None I-protein
and None None O
EZH2 None None I-protein
Polycomb-group None None B-protein
( None None I-protein
PcG None None I-protein
) None None I-protein
proteins None None I-protein
belong None None O
to None None O
two None None O
distinct None None O
protein None None O
complexes None None O
involved None None O
in None None O
the None None O
regulation None None O
of None None O
hematopoiesis None None O
. None None O

Using None None O
unique None None O
PcG-specific None None O
antisera None None O
and None None O
triple None None O
immunofluorescence None None O
, None None O
we None None O
found None None O
that None None O
mature None None I-cell_type
resting None None I-cell_type
peripheral None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
expressed None None O
BMI-1 None None I-protein
, None None O
whereas None None O
dividing None None I-cell_type
blasts None None I-cell_type
were None None O
EZH2 None None O
( None None O
+ None None O
) None None O
. None None O

By None None O
contrast None None O
, None None O
subcapsular None None I-cell_type
immature None None I-cell_type
double-negative None None I-cell_type
( None None I-cell_type
DN None None I-cell_type
) None None I-cell_type
( None None I-cell_type
CD4 None None I-cell_type
( None None I-cell_type
- None None I-cell_type
) None None I-cell_type
/CD8 None None I-cell_type
( None None I-cell_type
- None None I-cell_type
) None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
in None None O
the None None O
thymus None None O
coexpressed None None O
BMI-1 None None I-protein
and None None O
EZH2 None None I-protein
or None None O
were None None O
BMI-1 None None O
single None None O
positive None None O
. None None O

Their None None O
descendants None None O
, None None O
double-positive None None I-cell_type
( None None I-cell_type
DP None None I-cell_type
; None None I-cell_type
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
/CD8 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
) None None I-cell_type
cortical None None I-cell_type
thymocytes None None I-cell_type
, None None O
expressed None None O
EZH2 None None I-protein
without None None O
BMI-1 None None I-protein
. None None O

Most None None O
EZH2 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
DN None None I-cell_type
and None None I-cell_type
DP None None I-cell_type
thymocytes None None I-cell_type
were None None O
dividing None None O
, None None O
while None None O
DN None None I-cell_type
BMI-1 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
/EZH2 None None I-cell_type
( None None I-cell_type
- None None I-cell_type
) None None I-cell_type
thymocytes None None I-cell_type
were None None O
resting None None O
and None None O
proliferation None None O
was None None O
occasionally None None O
noted None None O
in None None O
DN None None I-cell_type
BMI-1 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
/EZH2 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
. None None O

Maturation None None O
of None None O
DP None None I-cell_type
cortical None None I-cell_type
thymocytes None None I-cell_type
to None None O
single-positive None None I-cell_type
( None None I-cell_type
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
/CD8 None None I-cell_type
( None None I-cell_type
- None None I-cell_type
) None None I-cell_type
or None None O
CD8 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
/CD4 None None I-cell_type
( None None I-cell_type
- None None I-cell_type
) None None I-cell_type
) None None I-cell_type
medullar None None I-cell_type
thymocytes None None I-cell_type
correlated None None O
with None None O
decreased None None O
detectability None None O
of None None O
EZH2 None None I-protein
and None None O
continued None None O
relative None None O
absence None None O
of None None O
BMI-1 None None I-protein
. None None O

Our None None O
data None None O
show None None O
that None None O
BMI-1 None None I-protein
and None None O
EZH2 None None I-protein
expression None None O
in None None O
mature None None I-cell_type
peripheral None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
is None None O
mutually None None O
exclusive None None O
and None None O
linked None None O
to None None O
proliferation None None O
status None None O
, None None O
and None None O
that None None O
this None None O
pattern None None O
is None None O
not None None O
yet None None O
established None None O
in None None O
thymocytes None None I-cell_type
of None None O
the None None O
cortex None None O
and None None O
medulla None None O
. None None O

T None None I-cell_type
cell None None I-cell_type
stage-specific None None O
PcG None None O
expression None None O
profiles None None O
suggest None None O
that None None O
PcG None None I-DNA
genes None None I-DNA
contribute None None O
to None None O
regulation None None O
of None None O
T None None O
cell None None O
differentiation None None O
. None None O

They None None O
probably None None O
reflect None None O
stabilization None None O
of None None O
cell None None O
type-specific None None O
gene None None O
expression None None O
and None None O
irreversibility None None O
of None None O
lineage None None O
choice None None O
. None None O

The None None O
difference None None O
in None None O
PcG None None O
expression None None O
between None None O
medullar None None I-cell_type
thymocytes None None I-cell_type
and None None O
mature None None I-cell_type
interfollicular None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
indicates None None O
that None None O
additional None None O
maturation None None O
processes None None O
occur None None O
after None None O
thymocyte None None O
transportation None None O
from None None O
the None None O
thymus None None O
. None None O

Stepwise None None O
lineage None None O
restriction None None O
of None None O
progenitors None None I-cell_type
in None None O
lympho-myelopoiesis None None O
. None None O

It None None O
has None None O
long None None O
been None None O
controversial None None O
whether None None O
hematopoiesis None None O
progresses None None O
through None None O
ordered None None O
stages None None O
of None None O
determination None None O
as None None O
in None None O
embryonic None None O
development None None O
. None None O

This None None O
is None None O
due None None O
to None None O
the None None O
absence None None O
of None None O
a None None O
methodology None None O
capable None None O
of None None O
exactly None None O
determining None None O
the None None O
developmental None None O
potential None None O
of None None O
hematopoietic None None I-cell_type
stem/progenitor None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
multilineage None None O
progenitor None None O
( None None O
MLP None None O
) None None O
assay None None O
enabled None None O
us None None O
to None None O
discriminate None None O
among None None O
seven None None O
types None None O
of None None O
hematopoietic None None O
progenitors None None O
, None None O
which None None O
are None None O
multipotent None None O
progenitor None None O
p-MTB None None O
( None None O
capable None None O
of None None O
generating None None O
myeloid None None I-cell_type
, None None I-cell_type
T None None I-cell_type
and None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
) None None O
, None None O
bipotent None None O
progenitors None None O
p-MT None None O
, None None O
p-MB None None O
and None None O
p-TB None None O
, None None O
and None None O
unipotent None None O
progenitors None None O
p-M None None O
, None None O
p-T None None O
and None None O
p-B None None O
. None None O

Among None None O
these None None O
seven None None O
types None None O
, None None O
the None None O
p-TB None None O
type None None O
progenitor None None O
was None None O
found None None O
to None None O
be None None O
absent None None O
. None None O

These None None O
findings None None O
indicate None None O
that None None O
the None None O
process None None O
of None None O
lineage None None O
commitment None None O
proceeds None None O
through None None O
an None None O
ordered None None O
but None None O
not None None O
random None None O
process None None O
. None None O

By None None O
extending None None O
the None None O
area None None O
of None None O
investigation None None O
to None None O
include None None O
the None None O
erythroid None None I-cell_type
lineage None None I-cell_type
, None None O
more None None O
convincing None None O
evidence None None O
for None None O
the None None O
ordered None None O
process None None O
was None None O
obtained None None O
. None None O

Detailed None None O
and None None O
exact None None O
illustration None None O
of None None O
the None None O
process None None O
of None None O
hematopoiesis None None O
will None None O
provide None None O
an None None O
opportunity None None O
to None None O
revive None None O
hematopoiesis None None O
as None None O
one None None O
of None None O
the None None O
most None None O
fascinating None None O
targets None None O
of None None O
research None None O
in None None O
developmental None None O
biology None None O

Epstein-Barr None None O
Virus None None O
and None None O
its None None O
glycoprotein-350 None None I-protein
upregulate None None O
IL-6 None None I-protein
in None None O
human None None I-cell_type
B-lymphocytes None None I-cell_type
via None None O
CD21 None None I-protein
, None None O
involving None None O
activation None None O
of None None O
NF-kappaB None None I-protein
and None None O
different None None O
signaling None None O
pathways None None O
. None None O

Epstein-Barr None None O
virus None None O
( None None O
EBV None None O
) None None O
is None None O
a None None O
ubiquitous None None O
and None None O
highly None None O
immunotropic None None O
gamma None None O
herpesvirus None None O
that None None O
infects None None O
more None None O
than None None O
90 None None O
% None None O
of None None O
humans None None O
worldwide None None O
. None None O

Its None None O
pathogenicity None None O
leads None None O
to None None O
a None None O
number None None O
of None None O
diseases None None O
including None None O
tumors None None O
that None None O
result None None O
from None None O
EBV None None O
's None None O
ability None None O
to None None O
readily None None O
transform None None O
B-lymphocytes None None I-cell_type
and None None O
, None None O
to None None O
a None None O
lesser None None O
extent None None O
, None None O
epithelial None None I-cell_type
cells None None I-cell_type
. None None O

EBV None None O
utilizes None None O
CD21/CR2 None None I-protein
as None None O
its None None O
receptor None None O
on None None O
B None None I-cell_type
cells None None I-cell_type
to None None O
initiate None None O
the None None O
infection None None O
process None None O
. None None O

EBV None None O
binds None None O
to None None O
CR2 None None I-protein
through None None O
its None None O
major None None I-protein
envelope None None I-protein
glycoprotein-350 None None I-protein
( None None O
gp350 None None I-protein
) None None O
and None None O
is None None O
also None None O
a None None O
remarkable None None O
immunomodulating None None O
agent None None O
. None None O

We None None O
had None None O
previously None None O
shown None None O
that None None O
EBV None None O
is None None O
capable None None O
of None None O
modulating None None O
the None None O
synthesis None None O
of None None O
a None None O
number None None O
of None None O
cytokines None None I-protein
. None None O

We None None O
now None None O
show None None O
that None None O
while None None O
both None None O
purified None None O
recombinant None None I-protein
gp350 None None I-protein
( None None O
rgp350 None None I-protein
) None None O
and None None O
EBV None None O
upregulate None None O
IL-6 None None I-RNA
mRNA None None I-RNA
synthesis None None O
in None None O
B None None I-cell_type
cells None None I-cell_type
, None None O
EBV-induced None None O
IL-6 None None O
gene None None O
activation None None O
occurs None None O
for None None O
a None None O
significantly None None O
longer None None O
period None None O
of None None O
time None None O
( None None O
i.e. None None O
12 None None O
hours None None O
for None None O
EBV None None O
as None None O
compared None None O
to None None O
6 None None O
hours None None O
for None None O
rgp350 None None I-protein
) None None O
. None None O

Moreover None None O
, None None O
the None None O
half-life None None O
of None None O
EBV-induced None None O
IL-6 None None I-RNA
mRNA None None I-RNA
was None None O
also None None O
significantly None None O
longer None None O
( None None O
10 None None O
hours None None O
) None None O
than None None O
that None None O
of None None O
mRNA None None O
induced None None O
by None None O
rgp350 None None I-protein
( None None O
about None None O
6 None None O
hours None None O
) None None O
. None None O

Both None None O
EBV None None O
and None None O
gp350 None None I-protein
enhance None None O
the None None O
binding None None O
of None None O
the None None O
NF-kappaB None None I-protein
transcription None None I-protein
factor None None I-protein
, None None O
as None None O
determined None None O
by None None O
band-shift None None O
and None None O
augment None None O
NF-kappaB None None I-protein
-mediated None None O
activation None None O
of None None O
a None None O
CAT None None I-DNA
reporter None None I-DNA
plasmid None None I-DNA
. None None O

Furthermore None None O
, None None O
we None None O
demonstrate None None O
that None None O
while None None O
the None None O
activation None None O
of None None O
IL-6 None None O
gene None None O
expression None None O
by None None O
gp350 None None I-protein
is None None O
mediated None None O
primarily None None O
by None None O
the None None O
protein None None O
kinase None None O
C None None O
pathway None None O
, None None O
EBV None None O
can None None O
mediate None None O
its None None O
effects None None O
through None None O
multiple None None O
signaling None None O
pathways None None O
. None None O

To None None O
our None None O
knowledge None None O
this None None O
is None None O
the None None O
first None None O
report None None O
showing None None O
that None None O
the None None O
binding None None O
of None None O
a None None O
herpesvirus None None I-protein
envelope None None I-protein
glycoprotein None None I-protein
to None None O
CR2 None None I-protein
on None None O
human None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
results None None O
in None None O
the None None O
activation None None O
of None None O
the None None O
NF-kappaB None None I-protein
transcription None None I-protein
factor None None I-protein
leading None None O
to None None O
the None None O
upregulation None None O
of None None O
IL-6 None None O
gene None None O
expression None None O
in None None O
these None None O
lymphocytes None None I-cell_type
. None None O

Copyright None None O
2001 None None O
Academic None None O
Press None None O
. None None O

Gene- None None O
and None None O
tissue-specificity None None O
of None None O
mutation None None O
in None None O
Big None None O
Blue None None O
rats None None O
treated None None O
with None None O
the None None O
hepatocarcinogen None None O
N-hydroxy-2-acetylaminofluorene None None O
. None None O

In None None O
a None None O
previous None None O
study None None O
, None None O
we None None O
found None None O
that None None O
treating None None O
transgenic None None O
Big None None O
Blue None None O
rats None None O
with None None O
the None None O
hepatocarcinogen None None O
N-hydroxy-2-acetylaminofluorene None None O
( None None O
N-OH-AAF None None O
) None None O
produced None None O
the None None O
same None None O
major None None O
DNA None None O
adduct None None O
in None None O
the None None O
target None None O
liver None None O
and None None O
the None None O
nontarget None None I-cell_type
spleen None None I-cell_type
lymphocytes None None I-cell_type
and None None O
bone None None I-cell_type
marrow None None I-cell_type
cells None None I-cell_type
, None None O
induced None None O
lacI None None I-cell_type
mutants None None I-cell_type
in None None O
the None None O
liver None None O
, None None O
and None None O
induced None None O
much None None O
lower None None O
frequencies None None O
of None None O
l None None O
acI None None I-cell_type
and None None I-cell_type
hprt None None I-cell_type
mutants None None I-cell_type
in None None O
spleen None None I-cell_type
lymphocytes None None I-cell_type
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
sequence None None O
analysis None None O
was None None O
conducted None None O
on None None O
lacI None None I-DNA
DNA None None I-DNA
and None None O
hprt None None I-DNA
cDNA None None I-DNA
from None None O
the None None O
mutants None None O
, None None O
to None None O
determine None None O
the None None O
mutational None None O
specificity None None O
of None None O
N-OH-AAF None None O
in None None O
the None None O
rat None None O
. None None O

All None None O
the None None O
mutation None None O
spectra None None O
from None None O
N-OH-AAF-treated None None O
rats None None O
differed None None O
significantly None None O
from None None O
corresponding None None O
mutation None None O
profiles None None O
from None None O
untreated None None O
animals None None O
( None None O
P None None O
= None None O
0.02 None None O
to None None O
P None None O
< None None O
0.0001 None None O
) None None O
. None None O

Although None None O
there None None O
were None None O
similarities None None O
among None None O
the None None O
mutational None None O
patterns None None O
derived None None O
from None None O
N-OH-AAF-treated None None O
rats None None O
( None None O
e.g. None None O
, None None O
G None None O
: None None O
C None None O
-- None None O
> None None O
T None None O
: None None O
A None None O
transversion None None O
was None None O
the None None O
most None None O
common None None O
mutation None None O
in None None O
all None None O
mutation None None O
sets None None O
) None None O
, None None O
there None None O
were None None O
significant None None O
differences None None O
in None None O
the None None O
patterns None None O
of None None O
basepair None None O
substitution None None O
and None None O
frameshift None None O
mutation None None O
between None None O
the None None O
liver None None O
and None None O
spleen None None I-cell_type
lymphocyte None None I-cell_type
lacI None None I-cell_type
mutants None None I-cell_type
( None None O
P None None O
= None None O
0.02 None None O
) None None O
and None None O
between None None O
the None None O
spleen None None I-cell_type
lymphocyte None None I-cell_type
lacI None None B-cell_type
and None None I-cell_type
hprt None None I-cell_type
mutants None None I-cell_type
( None None O
P None None O
= None None O
0.04 None None O
) None None O
. None None O

Also None None O
, None None O
multiplex None None O
PCR None None O
analysis None None O
of None None O
genomic None None I-DNA
DNA None None I-DNA
from None None O
the None None O
hprt None None I-cell_type
mutants None None I-cell_type
indicated None None O
that None None O
12 None None O
% None None O
of None None O
mutants None None O
from None None O
treated None None O
rats None None O
had None None O
major None None O
deletions None None O
in None None O
the None None O
hprt None None I-DNA
gene None None I-DNA
; None None O
no None None O
corresponding None None O
incidence None None O
of None None O
large None None O
deletions None None O
was None None O
evident None None O
among None None O
lacI None None O
mutations None None O
. None None O

All None None O
the None None O
mutation None None O
profiles None None O
reflect None None O
the None None O
general None None O
mutational None None O
specificity None None O
of None None O
the None None O
major None None O
DNA None None O
adduct None None O
formed None None O
by None None O
N-OH-AAF None None O
. None None O

The None None O
differences None None O
between None None O
N-OH-AAF None None O
mutation None None O
in None None O
the None None O
endogenous None None I-DNA
gene None None I-DNA
and None None O
transgene None None I-DNA
can None None O
be None None O
partially None None O
explained None None O
by None None O
the None None O
structures None None O
of None None O
the None None O
two None None O
genes None None O
. None None O

The None None O
tissue-specificity None None O
of None None O
the None None O
mutation None None O
spectra None None O
may None None O
contribute None None O
to None None O
targeting None None O
tumor None None O
formation None None O
to None None O
the None None O
liver None None O
. None None O

Environ. None None O
Mol. None None O
Mutagen. None None O
37 None None O
: None None O
203-214 None None O
, None None O
2001 None None O
. None None O

Published None None O
2001 None None O
Wiley-Liss None None O
, None None O
Inc None None O
. None None O

Caspase None None I-protein
-dependent None None O
cleavage None None O
of None None O
the None None O
hematopoietic None None I-protein
specific None None I-protein
adaptor None None I-protein
protein None None I-protein
Gads None None I-protein
alters None None O
signalling None None O
from None None O
the None None O
T None None I-protein
cell None None I-protein
receptor None None I-protein
. None None O

Gads None None I-protein
is None None O
a None None O
SH2 None None I-protein
and None None I-protein
SH3 None None I-protein
domain None None I-protein
-containing None None O
, None None O
hematopoietic-specific None None I-protein
adaptor None None I-protein
protein None None I-protein
that None None O
functions None None O
in None None O
signalling None None O
from None None O
the None None O
T None None I-protein
cell None None I-protein
receptor None None I-protein
. None None O

Gads None None I-protein
acts None None O
by None None O
linking None None O
SLP-76 None None I-protein
, None None O
bound None None O
by None None O
the None None O
carboxy-terminal None None I-protein
Gads None None I-protein
SH3 None None I-protein
domain None None I-protein
, None None O
to None None O
tyrosine None None I-protein
phosphorylated None None I-protein
LAT None None I-protein
which None None O
contains None None O
binding None None O
sites None None O
for None None O
the None None O
Gads None None I-protein
SH2 None None I-protein
domain None None I-protein
. None None O

Gads None None I-protein
is None None O
distinguished None None O
from None None O
Grb2 None None I-protein
and None None O
the None None O
closely None None O
related None None O
Grap None None I-protein
protein None None I-protein
by None None O
the None None O
presence None None O
of None None O
a None None O
120 None None I-protein
amino None None I-protein
acid None None I-protein
unique None None I-protein
region None None I-protein
between None None O
the None None O
SH2 None None I-protein
domain None None I-protein
and None None O
the None None O
carboxy None None I-protein
terminal None None I-protein
SH3 None None I-protein
domain None None I-protein
. None None O

Here None None O
we None None O
demonstrate None None O
that None None O
the None None O
unique None None O
region None None O
of None None O
Gads None None I-protein
contains None None O
a None None O
capase None None I-protein
cleavage None None I-protein
site None None I-protein
. None None O

Induction None None O
of None None O
apoptosis None None O
in None None O
lymphocytes None None I-cell_type
results None None O
in None None O
detectable None None O
Gads None None I-protein
cleavage None None O
by None None O
60 None None O
min None None O
. None None O

Gads None None I-protein
cleavage None None O
is None None O
blocked None None O
in None None O
vivo None None O
by None None O
treating None None O
cells None None O
with None None O
a None None O
caspase None None O
3 None None O
inhibitor None None O
. None None O

A None None O
putative None None I-protein
caspase None None I-protein
3 None None I-protein
cleavage None None I-protein
site None None I-protein
was None None O
identified None None O
within None None O
the None None O
unique None None O
region None None O
and None None O
mutation None None O
of None None O
this None None O
site None None O
prevented None None O
Gads None None I-protein
cleavage None None O
in None None O
vitro None None O
, None None O
and None None O
in None None O
vivo None None O
. None None O

The None None O
Gads None None I-protein
cleavage None None O
products None None O
retained None None O
the None None O
predicted None None O
binding None None O
specificity None None O
for None None O
SLP-76 None None I-protein
and None None O
LAT None None I-protein
. None None O

Expression None None O
of None None O
the None None O
Gads None None I-protein
cleavage None None O
products None None O
in None None O
Jurkat None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
inhibited None None O
NFAT None None O
activation None None O
following None None O
TCR None None O
cross None None O
linking None None O
. None None O

These None None O
findings None None O
indicate None None O
that None None O
cleavage None None O
of None None O
Gads None None I-protein
in None None O
vivo None None O
could None None O
function None None O
to None None O
alter None None O
signalling None None O
downstream None None O
of None None O
the None None O
T None None I-protein
cell None None I-protein
receptor None None I-protein
by None None O
disrupting None None O
cross None None O
talk None None O
between None None O
SLP-76 None None I-protein
and None None O
LAT None None I-protein
. None None O

Targeting None None O
of None None O
p300 None None I-protein
to None None O
the None None O
interleukin-2 None None I-DNA
promoter None None I-DNA
via None None O
CREB-Rel None None O
cross-talk None None O
during None None O
mitogen None None I-protein
and None None O
oncogenic None None O
molecular None None O
signaling None None O
in None None O
activated None None I-cell_type
T-cells None None I-cell_type
. None None O

In None None O
this None None O
report None None O
, None None O
we None None O
explore None None O
the None None O
mechanisms None None O
of None None O
targeting None None O
of None None O
p300 None None I-protein
to None None O
the None None O
interleukin-2 None None I-DNA
( None None I-DNA
IL-2 None None I-DNA
) None None I-DNA
promoter None None I-DNA
in None None O
response None None O
to None None O
mitogenic None None O
and None None O
oncogenic None None O
molecular None None O
signals None None O
. None None O

Recruitment None None O
of None None O
p300 None None I-protein
by None None O
cAMP-responsive None None I-protein
element-binding None None I-protein
protein-Rel None None I-protein
cross-talk None None O
at None None O
the None None O
composite None None I-protein
CD28 None None I-protein
response None None I-protein
element None None I-protein
( None None O
CD28RE None None I-protein
) None None O
- None None O
TRE None None I-DNA
element None None I-DNA
of None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
is None None O
essential None None O
for None None O
promoter None None O
inducibility None None O
during None None O
T-cell None None O
activation None None O
, None None O
and None None O
CD28RE-TRE None None I-DNA
is None None O
the None None O
exclusive None None O
target None None O
of None None O
the None None O
human None None I-cell_type
T-cell None None I-cell_type
lymphotropic None None O
virus None None O
type None None O
I None None O
oncoprotein None None I-protein
Tax None None I-protein
. None None O

The None None O
intrinsic None None O
histone None None O
acetyltransferase None None O
activity None None O
of None None O
p300 None None I-protein
is None None O
dispensable None None O
for None None O
activation None None O
of None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
, None None O
and None None O
the None None O
N-terminal None None I-protein
743 None None I-protein
residues None None I-protein
contain None None O
the None None O
minimal None None O
structural None None O
requirements None None O
for None None O
synergistic None None O
transactivation None None O
of None None O
the None None O
CD28RE-TRE None None I-DNA
, None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
, None None O
and None None O
endogenous None None O
IL-2 None None I-DNA
gene None None I-DNA
expression None None O
. None None O

Mutational None None O
analysis None None O
of None None O
p300 None None I-protein
reveals None None O
differential None None O
structural None None O
requirements None None O
for None None O
the None None O
N-terminal None None O
p300 None None O
module None None O
by None None O
individual None None O
cis-elements None None I-DNA
within None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
. None None O

These None None O
findings None None O
provide None None O
evidence None None O
that None None O
p300 None None I-protein
assembles None None O
at None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
to None None O
form None None O
an None None O
enhanceosome-like None None O
signal None None O
transduction None None O
target None None O
that None None O
is None None O
centrally None None O
integrated None None O
at None None O
the None None O
CD28RE-TRE None None I-DNA
element None None I-DNA
of None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
through None None O
specific None None O
protein None None O
module-targeted None None O
associations None None O
in None None O
activated None None I-cell_type
T-cells None None I-cell_type
. None None O

Regulation None None O
of None None O
cytokine None None O
production None None O
in None None O
T-cell None None I-cell_type
responses None None O
to None None O
inhalant None None O
allergen None None O
: None None O
GATA-3 None None I-protein
expression None None O
distinguishes None None O
between None None O
Th1- None None O
and None None O
Th2-polarized None None O
immunity None None O
. None None O

BACKGROUND None None O
: None None O
The None None O
precise None None O
nature None None O
of None None O
allergen-specific None None O
cytokine None None O
responses None None O
in None None O
atopics None None O
versus None None O
non-atopics None None O
, None None O
in None None O
particular None None O
the None None O
'Th1 None None O
polarity None None O
' None None O
of None None O
responses None None O
in None None O
non-atopics None None O
, None None O
remains None None O
controversial None None O
. None None O

This None None O
is None None O
due None None O
in None None O
part None None O
to None None O
the None None O
relative None None O
insensitivity None None O
of None None O
cytokine None None O
detection None None O
systems None None O
, None None O
and None None O
associated None None O
variations None None O
in None None O
kinetics None None O
of None None O
cytokine None None O
production None None O
and None None O
catabolism None None O
in None None O
in None None O
vitro None None O
culture None None O
systems None None O
. None None O

As None None O
an None None O
alternative None None O
to None None O
cytokine None None O
measurement None None O
, None None O
this None None O
study None None O
focuses None None O
on None None O
expression None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
GATA-3 None None I-protein
for None None O
analysis None None O
of None None O
allergen-specific None None O
Th None None O
cell None None O
responses None None O
. None None O

METHODS None None O
: None None O
Cord None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
were None None O
Th1- None None O
or None None O
Th2-polarized None None O
by None None O
culture None None O
in None None O
IL-12- None None O
or None None O
IL-4-employing None None O
established None None O
methods None None O
; None None O
PBMC None None I-cell_type
from None None O
house None None O
dust None None O
mite None None O
( None None O
HDM None None O
) None None O
-sensitive None None O
atopics None None O
and None None O
controls None None O
were None None O
stimulated None None O
overnight None None O
with None None O
HDM None None O
; None None O
cytokine None None O
production None None O
was None None O
measured None None O
by None None O
ELISA None None O
and None None O
GATA-3 None None I-RNA
mRNA None None I-RNA
expression None None O
by None None O
PCR None None O
. None None O

RESULTS None None O
: None None O
Cytokine None None I-protein
-driven None None O
Th2 None None O
polarization None None O
of None None O
naive None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
is None None O
associated None None O
with None None O
marked None None O
upregulation None None O
of None None O
GATA-3 None None I-protein
expression None None O
, None None O
whereas None None O
a None None O
reciprocal None None O
expression None None O
pattern None None O
accompanies None None O
differentiation None None O
towards None None O
the None None O
Th1 None None O
cytokine None None O
phenotype None None O
. None None O

In None None O
T None None I-cell_type
cells None None I-cell_type
from None None O
HDM None None O
skin None None O
prick None None O
test-positive None None O
( None None O
HDM-SPT+/HDM-IgE+ None None O
) None None O
volunteers None None O
, None None O
overnight None None O
stimulation None None O
results None None O
in None None O
marked None None O
upregulation None None O
of None None O
GATA-3 None None I-protein
expression None None O
, None None O
compared None None O
to None None O
an None None O
equally None None O
marked None None O
downregulation None None O
of None None O
expression None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
from None None O
SPT-/IgE- None None O
subjects None None O
. None None O

In None None O
subjects None None O
who None None O
are None None O
HDM-SPT+ None None O
but None None O
IgE- None None O
, None None O
GATA-3 None None I-protein
expression None None O
levels None None O
remained None None O
relatively None None O
stable None None O
during None None O
culture None None O
with None None O
HDM None None O
. None None O

CONCLUSIONS None None O
: None None O
Upregulation None None O
of None None O
GATA-3 None None I-protein
expression None None O
in None None O
PBMC None None I-cell_type
is None None O
a None None O
hallmark None None O
of None None O
the None None O
early None None O
phase None None O
of None None O
Th2 None None O
recall None None O
responses None None O
to None None O
specific None None O
allergen None None O
in None None O
atopics None None O
. None None O

The None None O
reciprocal None None O
expression None None O
pattern None None O
observed None None O
in None None O
HDM-specific None None O
recall None None O
responses None None O
of None None O
non-atopics None None O
provides None None O
independent None None O
confirmation None None O
of None None O
the None None O
presence None None O
of None None O
underlying None None O
Th1-like None None O
immunity None None O
in None None O
these None None O
subjects None None O
. None None O

The None None O
parallel None None O
findings None None O
in None None O
neonatal None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
suggest None None O
that None None O
the None None O
same None None O
approach None None O
may None None O
be None None O
utilized None None O
for None None O
monitoring None None O
the None None O
progress None None O
of None None O
allergen-specific None None O
Th1/Th2 None None O
memory None None O
development None None O
during None None O
early None None O
childhood None None O
, None None O
and None None O
hence None None O
in None None O
assessment None None O
of None None O
risk None None O
for None None O
future None None O
allergic None None O
disease None None O
. None None O

Copyright None None O
2001 None None O
S. None None O
Karger None None O
AG None None O
, None None O
Basel None None O

The None None O
heat None None O
shock None None O
response None None O
reduces None None O
myelin None None I-protein
oligodendrocyte None None I-protein
glycoprotein None None I-protein
-induced None None O
experimental None None O
autoimmune None None O
encephalomyelitis None None O
in None None O
mice None None O
. None None O

The None None O
stress None None O
response None None O
( None None O
SR None None O
) None None O
can None None O
block None None O
inflammatory None None O
gene None None O
expression None None O
by None None O
preventing None None O
activation None None O
of None None O
transcription None None I-protein
factor None None I-protein
nuclear None None B-protein
factor-kappa None None I-protein
B None None I-protein
( None None O
NF-kappaB None None I-protein
) None None O
. None None O

As None None O
inflammatory None None O
gene None None O
expression None None O
contributes None None O
to None None O
the None None O
pathogenesis None None O
of None None O
demyelinating None None O
diseases None None O
, None None O
we None None O
tested None None O
the None None O
effects None None O
of None None O
the None None O
SR None None O
on None None O
the None None O
progression None None O
of None None O
the None None O
demyelinating None None O
disease None None O
experimental None None O
autoimmune None None O
encephalomyelitis None None O
( None None O
EAE None None O
) None None O
. None None O

EAE None None O
was None None O
actively None None O
induced None None O
in None None O
C57BL/6 None None O
mice None None O
using None None O
an None None O
encephalitogenic None None O
myelin None None I-protein
oligodendrocyte None None I-protein
glycoprotein None None I-protein
( None None O
MOG None None I-protein
( None None I-protein
35-55 None None I-protein
) None None I-protein
) None None O
peptide None None O
. None None O

Whole None None O
body None None O
hyperthermia None None O
was None None O
used None None O
to None None O
induce None None O
a None None O
heat None None O
shock None None O
response None None O
( None None O
HSR None None O
) None None O
in None None O
immunized None None O
mice None None O
2 None None O
days None None O
after None None O
the None None O
booster None None O
MOG None None O
( None None O
35-55 None None O
) None None O
peptide None None O
injection None None O
. None None O

The None None O
HSR None None O
reduced None None O
the None None O
incidence None None O
of None None O
EAE None None O
by None None O
70 None None O
% None None O
, None None O
delayed None None O
disease None None O
onset None None O
by None None O
6 None None O
days None None O
, None None O
and None None O
attenuated None None O
disease None None O
severity None None O
. None None O

The None None O
HSR None None O
attenuated None None O
leukocyte None None I-cell_type
infiltration None None O
into None None O
CNS None None O
assessed None None O
by None None O
quantitation None None O
of None None O
perivascular None None O
infiltrates None None O
, None None O
and None None O
by None None O
reduced None None O
staining None None O
for None None O
CD4 None None I-protein
and None None O
CD25 None None I-protein
immunopositive None None O
T-cells None None I-cell_type
. None None O

T-cell None None O
activation None None O
, None None O
assessed None None O
by None None O
the None None O
production None None O
of None None O
interferon None None I-protein
gamma None None I-protein
( None None O
IFNgamma None None I-protein
) None None O
in None None O
response None None O
to None None O
MOG None None I-protein
( None None I-protein
35-55 None None I-protein
) None None I-protein
, None None O
was None None O
also None None O
decreased None None O
by None None O
the None None O
HSR None None O
. None None O

The None None O
HSR None None O
reduced None None O
inflammatory None None O
gene None None O
expression None None O
in None None O
the None None O
brain None None O
that None None O
normally None None O
occurs None None O
during None None O
EAE None None O
, None None O
including None None O
the None None O
early None None O
increase None None O
in None None O
RANTES None None I-protein
( None None O
regulated None None I-protein
on None None I-protein
activation None None I-protein
of None None I-protein
normal None None I-protein
T-cell None None I-protein
expressed None None I-protein
and None None I-protein
secreted None None I-protein
) None None O
expression None None O
, None None O
and None None O
the None None O
later None None O
expression None None O
of None None O
the None None O
inducible None None O
form None None O
of None None O
nitric None None I-protein
oxide None None I-protein
synthase None None I-protein
. None None O

The None None O
early None None O
activation None None O
of None None O
transcription None None I-protein
factor None None I-protein
NF-kappaB None None B-protein
was None None O
also None None O
blocked None None O
by None None O
the None None O
HSR None None O
. None None O

The None None O
finding None None O
that None None O
the None None O
SR None None O
reduces None None O
inflammation None None O
in None None O
the None None O
brain None None O
and None None O
the None None O
clinical None None O
severity None None O
of None None O
EAE None None O
opens None None O
a None None O
novel None None O
therapeutic None None O
approach None None O
for None None O
prevention None None O
of None None O
autoimmune None None O
diseases None None O
. None None O

In None None O
vivo None None O
detection None None O
of None None O
intracellular None None O
signaling None None O
pathways None None O
in None None O
developing None None O
thymocytes None None I-cell_type
. None None O

Information None None O
regarding None None O
the None None O
intracellular None None O
signaling None None O
processes None None O
that None None O
occur None None O
during None None O
the None None O
development None None O
of None None O
T None None I-cell_type
cells None None I-cell_type
has None None O
largely None None O
been None None O
obtained None None O
with None None O
the None None O
use None None O
of None None O
transgenic None None O
mouse None None O
models None None O
, None None O
which None None O
although None None O
providing None None O
invaluable None None O
information None None O
are None None O
time None None O
consuming None None O
and None None O
costly None None O
. None None O

To None None O
this None None O
end None None O
, None None O
we None None O
have None None O
developed None None O
a None None O
novel None None O
system None None O
that None None O
facilitates None None O
the None None O
in None None O
vivo None None O
analysis None None O
of None None O
signal None None O
transduction None None O
pathways None None O
during None None O
T-lymphocyte None None I-cell_type
development None None O
. None None O

This None None O
approach None None O
uses None None O
reporter-plasmids None None I-DNA
for None None O
the None None O
detection None None O
of None None O
intracellular None None O
signals None None O
mediated None None O
by None None O
the None None O
mitogen-activated None None I-protein
protein None None I-protein
kinase None None I-protein
or None None O
cyclic None None I-protein
AMP-dependent None None I-protein
protein None None I-protein
kinase None None I-protein
. None None O

Reporter-plasmids None None I-DNA
are None None O
transfected None None O
into None None O
thymocytes None None I-cell_type
in None None O
fetal None None O
thymic None None O
organ None None O
culture None None O
by None None O
accelerated None None O
DNA/particle None None O
bombardment None None O
( None None O
gene None None O
gun None None O
) None None O
, None None O
and None None O
the None None O
activation None None O
of None None O
a None None O
signaling None None O
pathway None None O
is None None O
determined None None O
in None None O
the None None O
form None None O
of None None O
a None None O
standard None None O
luciferase None None O
assay None None O
. None None O

Importantly None None O
, None None O
this None None O
powerful None None O
technique None None O
preserves None None O
the None None O
structural None None O
integrity None None O
of None None O
the None None O
thymus None None O
, None None O
and None None O
will None None O
provide None None O
an None None O
invaluable None None O
tool None None O
to None None O
study None None O
how None None O
thymocytes None None I-cell_type
respond None None O
to None None O
normal None None O
environmental None None O
stimuli None None O
encountered None None O
during None None O
differentiation None None O
within None None O
the None None O
thymic None None O
milieu None None O
. None None O

Thus None None O
, None None O
this None None O
method None None O
allows None None O
for None None O
the None None O
monitoring None None O
of None None O
signals None None O
that None None O
occur None None O
in None None O
a None None O
biological None None O
time None None O
frame None None O
, None None O
such None None O
as None None O
during None None O
differentiation None None O
, None None O
and None None O
within None None O
the None None O
natural None None O
environment None None O
of None None O
differentiating None None I-cell_type
cells None None I-cell_type
. None None O

Core-binding None None I-protein
factor None None I-protein
beta None None I-protein
( None None O
CBFbeta None None I-protein
) None None O
, None None O
but None None O
not None None O
CBFbeta-smooth None None I-protein
muscle None None I-protein
myosin None None I-protein
heavy None None I-protein
chain None None I-protein
, None None O
rescues None None O
definitive None None O
hematopoiesis None None O
in None None O
CBFbeta None None I-protein
-deficient None None O
embryonic None None I-cell_type
stem None None I-cell_type
cells None None I-cell_type
. None None O

Core-binding None None I-protein
factor None None I-protein
beta None None I-protein
( None None O
CBFbeta None None I-protein
) None None O
is None None O
the None None O
non-DNA-binding None None I-protein
subunit None None I-protein
of None None O
the None None O
heterodimeric None None I-protein
CBFs None None I-protein
. None None O

Genes None None I-DNA
encoding None None I-DNA
CBFbeta None None I-DNA
( None None O
CBFB None None I-DNA
) None None O
, None None O
and None None O
one None None O
of None None O
the None None O
DNA-binding None None I-protein
CBFalpha None None I-protein
subunits None None I-protein
, None None I-protein
Runx1 None None I-protein
( None None O
also None None O
known None None O
as None None O
CBFalpha2 None None I-protein
, None None O
AML1 None None I-protein
, None None O
and None None O
PEBP2alphaB None None I-protein
) None None O
, None None O
are None None O
required None None O
for None None O
normal None None O
hematopoiesis None None O
and None None O
are None None O
also None None O
frequent None None O
targets None None O
of None None O
chromosomal None None O
translocations None None O
in None None O
acute None None O
leukemias None None O
in None None O
humans None None O
. None None O

Homozygous None None O
disruption None None O
of None None O
either None None O
the None None O
Runx1 None None I-DNA
or None None I-DNA
Cbfb None None I-DNA
gene None None I-DNA
in None None O
mice None None O
results None None O
in None None O
embryonic None None O
lethality None None O
at None None O
midgestation None None O
due None None O
to None None O
hemorrhaging None None O
in None None O
the None None O
central None None O
nervous None None O
system None None O
, None None O
and None None O
severely None None O
impairs None None O
fetal None None O
liver None None O
hematopoiesis None None O
. None None O

Results None None O
of None None O
this None None O
study None None O
show None None O
that None None O
Cbfb-deficient None None O
mouse None None O
embryonic None None I-cell_type
stem None None I-cell_type
( None None I-cell_type
ES None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
can None None O
differentiate None None O
into None None O
primitive None None I-cell_type
erythroid None None I-cell_type
colonies None None I-cell_type
in None None O
vitro None None O
, None None O
but None None O
are None None O
impaired None None O
in None None O
their None None O
ability None None O
to None None O
produce None None O
definitive None None O
erythroid None None I-cell_type
and None None I-cell_type
myeloid None None I-cell_type
colonies None None I-cell_type
, None None O
mimicking None None O
the None None O
in None None O
vivo None None O
defect None None O
. None None O

Definitive None None O
hematopoiesis None None O
is None None O
restored None None O
by None None O
ectopic None None O
expression None None O
of None None O
full-length None None I-DNA
Cbfb None None I-DNA
transgenes None None I-DNA
, None None O
as None None O
well None None O
as None None O
by None None O
a None None O
transgene None None O
encoding None None O
only None None O
the None None O
heterodimerization None None I-protein
domain None None I-protein
of None None O
CBFbeta None None I-protein
. None None O

In None None O
contrast None None O
, None None O
the None None O
CBFbeta None None I-protein
- None None O
smooth None None I-protein
muscle None None I-protein
myosin None None I-protein
heavy None None I-protein
chain None None I-protein
( None None I-protein
SMMHC None None I-protein
) None None I-protein
fusion None None I-protein
protein None None I-protein
generated None None O
by None None O
the None None O
inv None None I-protein
( None None I-protein
16 None None I-protein
) None None I-protein
associated None None O
with None None O
acute None None I-cell_line
myeloid None None I-cell_line
leukemias None None I-cell_line
( None None O
M4Eo None None I-cell_line
) None None O
can None None O
not None None O
rescue None None O
definitive None None O
hematopoiesis None None O
by None None O
Cbfb-deficient None None I-cell_type
ES None None I-cell_type
cells None None I-cell_type
. None None O

Sequences None None O
responsible None None O
for None None O
the None None O
inability None None O
of None None O
CBFbeta None None I-protein
-SMMHC None None O
to None None O
rescue None None O
definitive None None O
hematopoiesis None None O
reside None None O
in None None O
the None None O
SMMHC None None I-protein
portion None None I-protein
of None None O
the None None O
fusion None None I-protein
protein None None I-protein
. None None O

Results None None O
also None None O
show None None O
that None None O
the None None O
CBFbeta-SMMHC None None I-protein
fusion None None I-protein
protein None None I-protein
transdominantly None None O
inhibits None None O
definitive None None O
hematopoiesis None None O
, None None O
but None None O
not None None O
to None None O
the None None O
same None None O
extent None None O
as None None O
homozygous None None O
loss None None O
of None None O
Runx1 None None I-protein
or None None O
Cbfb None None I-protein
. None None O

CBFbeta-SMMHC None None I-protein
preferentially None None O
inhibits None None O
the None None O
differentiation None None O
of None None O
myeloid None None I-cell_type
lineage None None I-cell_type
cells None None I-cell_type
, None None O
while None None O
increasing None None O
the None None O
number None None O
of None None O
blastlike None None I-cell_type
cells None None I-cell_type
in None None O
culture None None O
. None None O

The None None O
latency None None O
pattern None None O
of None None O
Epstein-Barr None None O
virus None None O
infection None None O
and None None O
viral None None O
IL-10 None None I-protein
expression None None O
in None None O
cutaneous None None I-cell_type
natural None None I-cell_type
killer/T-cell None None I-cell_type
lymphomas None None I-cell_type
. None None O

The None None O
nasal None None I-cell_type
type None None I-cell_type
, None None I-cell_type
extranodal None None I-cell_type
natural None None I-cell_type
killer None None I-cell_type
or None None I-cell_type
T None None I-cell_type
( None None I-cell_type
NK/T None None I-cell_type
) None None I-cell_type
-cell None None I-cell_type
lymphoma None None I-cell_type
is None None O
usually None None O
associated None None O
with None None O
latent None None O
Epstein-Barr None None O
virus None None O
( None None O
EBV None None O
) None None O
infection None None O
. None None O

In None None O
order None None O
to None None O
elucidate None None O
the None None O
EBV None None O
gene None None O
expression None None O
patterns None None O
in None None O
vivo None None O
, None None O
we None None O
examined None None O
eight None None O
patients None None O
with None None O
cutaneous None None O
EBV-related None None O
NK/T-cell None None O
lymphomas None None O
, None None O
including None None O
six None None O
patients None None O
with None None O
a None None O
NK-cell None None O
phenotype None None O
and None None O
two None None O
patients None None O
with None None O
a None None O
T-cell None None O
phenotype None None O
. None None O

The None None O
implication None None O
of None None O
EBV None None O
in None None O
the None None O
skin None None O
lesions None None O
was None None O
determined None None O
by None None O
the None None O
presence None None O
of None None O
EBV-DNA None None I-DNA
, None None O
EBV-encoded None None I-RNA
nuclear None None I-RNA
RNA None None I-RNA
( None None O
EBER None None I-RNA
) None None O
and None None O
a None None O
clonality None None O
of None None O
EBV-DNA None None I-DNA
fragments None None I-DNA
containing None None O
the None None O
terminal None None I-DNA
repeats None None I-DNA
. None None O

Transcripts None None O
of None None O
EBV-encoded None None I-DNA
genes None None I-DNA
were None None O
screened None None O
by None None O
reverse None None O
transcription- None None O
polymerase None None O
chain None None O
reaction None None O
( None None O
RT-PCR None None O
) None None O
, None None O
and None None O
confirmed None None O
by None None O
Southern None None O
blot None None O
hybridization None None O
. None None O

The None None O
expression None None O
of None None O
EBV-related None None I-protein
antigens None None I-protein
was None None O
examined None None O
by None None O
immunostaining None None O
using None None O
paraffin-embedded None None O
tissue None None O
sections None None O
and None None O
cell None None O
pellets None None O
of None None O
EBV-positive None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
. None None O

Our None None O
study None None O
demonstrated None None O
that None None O
all None None O
samples None None O
from None None O
the None None O
patients None None O
contained None None O
EBV None None I-RNA
nuclear None None I-RNA
antigen None None I-RNA
( None None I-RNA
EBNA None None I-RNA
) None None I-RNA
-1 None None I-RNA
mRNA None None I-RNA
which None None O
was None None O
transcribed None None O
using None None O
the None None O
Q None None I-DNA
promoter None None I-DNA
, None None O
whereas None None O
both None None O
the None None O
Q None None I-DNA
promoter None None I-DNA
and None None O
another None None O
upstream None None I-DNA
promoter None None I-DNA
( None None O
Cp/Wp None None I-DNA
) None None O
were None None O
used None None O
in None None O
EBV-positive None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
, None None O
B95.8 None None I-cell_line
, None None O
Raji None None I-cell_line
and None None O
Jiyoye None None I-cell_line
. None None O

Latent None None I-RNA
membrane None None I-RNA
protein-1 None None I-RNA
( None None I-RNA
LMP-1 None None I-RNA
) None None I-RNA
mRNA None None I-RNA
was None None O
detected None None O
in None None O
seven None None O
of None None O
eight None None O
patients None None O
and None None O
all None None O
cell None None I-cell_line
lines None None I-cell_line
, None None O
whereas None None O
EBNA-2 None None I-RNA
transcripts None None I-RNA
were None None O
found None None O
only None None O
in None None O
the None None O
cell None None I-cell_line
lines None None I-cell_line
. None None O

Immunostaining None None O
showed None None O
no None None O
LMP-1 None None I-protein
, None None I-protein
EBNA-2 None None I-protein
or None None I-protein
ZEBRA None None I-protein
antigens None None I-protein
in None None O
the None None O
paraffin-embedded None None O
tissue None None O
sections None None O
, None None O
although None None O
they None None O
were None None O
positive None None O
in None None O
the None None O
cell None None I-cell_line
line None None I-cell_line
cells None None I-cell_line
. None None O

Latent None None I-RNA
BHRF1 None None I-RNA
transcripts None None I-RNA
encoding None None O
bcl-2 None None I-RNA
homologue None None I-RNA
and None None O
BCRF1 None None I-RNA
transcripts None None I-RNA
encoding None None O
viral None None I-protein
interleukin None None I-protein
( None None I-protein
vIL None None I-protein
) None None I-protein
-10 None None I-protein
were None None O
detected None None O
in None None O
one None None O
and None None O
two None None O
of None None O
eight None None O
patients None None O
, None None O
respectively None None O
. None None O

A None None O
patient None None O
with None None O
NK-cell None None O
lymphoma None None O
expressing None None O
both None None O
transcripts None None O
died None None O
of None None O
rapid None None O
progression None None O
of None None O
the None None O
illness None None O
. None None O

Our None None O
results None None O
indicate None None O
that None None O
the None None O
restricted None None O
expression None None O
of None None O
the None None O
latency-associated None None I-DNA
EBV None None I-DNA
genes None None I-DNA
and None None O
the None None O
production None None O
of None None O
vIL-10 None None I-RNA
and None None I-RNA
bcl-2 None None I-RNA
homologue None None I-RNA
may None None O
favour None None O
tumour None None O
growth None None O
, None None O
evading None None O
the None None O
host None None O
immune None None O
surveillance None None O
. None None O

Copyright None None O
2001 None None O
Cancer None None O
Research None None O
Campaign None None O
. None None O

Oxidized None None O
alkyl None None O
phospholipids None None O
are None None O
specific None None O
, None None O
high None None O
affinity None None O
peroxisome None None O
proliferator-activated None None O
receptor None None O
gamma None None O
ligands None None O
and None None O
agonists None None O
. None None O

Synthetic None None O
high None None O
affinity None None O
peroxisome None None O
proliferator-activated None None O
receptor None None O
( None None O
PPAR None None O
) None None O
agonists None None O
are None None O
known None None O
, None None O
but None None O
biologic None None O
ligands None None O
are None None O
of None None O
low None None O
affinity None None O
. None None O

Oxidized None None I-protein
low None None I-protein
density None None I-protein
lipoprotein None None I-protein
( None None O
oxLDL None None I-protein
) None None O
is None None O
inflammatory None None O
and None None O
signals None None O
through None None O
PPARs None None I-protein
. None None O

We None None O
showed None None O
, None None O
by None None O
phospholipase None None O
A None None O
( None None O
1 None None O
) None None O
digestion None None O
, None None O
that None None O
PPARgamma None None O
agonists None None O
in None None O
oxLDL None None I-protein
arise None None O
from None None O
the None None O
small None None O
pool None None O
of None None O
alkyl None None O
phosphatidylcholines None None O
in None None O
LDL None None I-protein
. None None O

We None None O
identified None None O
an None None O
abundant None None O
oxidatively None None O
fragmented None None O
alkyl None None O
phospholipid None None O
in None None O
oxLDL None None I-protein
, None None O
hexadecyl None None O
azelaoyl None None O
phosphatidylcholine None None O
( None None O
azPC None None O
) None None O
, None None O
as None None O
a None None O
high None None O
affinity None None O
ligand None None O
and None None O
agonist None None O
for None None O
PPARgamma None None I-protein
. None None O

[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
azPC None None O
bound None None O
recombinant None None I-protein
PPARgamma None None I-protein
with None None O
an None None O
affinity None None O
( None None O
K None None O
( None None O
d None None O
) None None O
( None None O
( None None O
app None None O
) None None O
) None None O
approximately None None O
40 None None O
nm None None O
) None None O
that None None O
was None None O
equivalent None None O
to None None O
rosiglitazone None None O
( None None O
BRL49653 None None O
) None None O
, None None O
and None None O
competition None None O
with None None O
rosiglitazone None None O
showed None None O
that None None O
binding None None O
occurred None None O
in None None O
the None None O
ligand-binding None None I-protein
pocket None None I-protein
. None None O

azPC None None O
induced None None O
PPRE None None O
reporter None None O
gene None None O
expression None None O
, None None O
as None None O
did None None O
rosiglitazone None None O
, None None O
with None None O
a None None O
half-maximal None None O
effect None None O
at None None O
100 None None O
nm None None O
. None None O

Overexpression None None O
of None None O
PPARalpha None None I-protein
or None None O
PPARgamma None None I-protein
revealed None None O
that None None O
azPC None None O
was None None O
a None None O
specific None None O
PPARgamma None None O
agonist None None O
. None None O

The None None O
scavenger None None I-protein
receptor None None I-protein
CD36 None None I-protein
is None None O
encoded None None O
by None None O
a None None O
PPRE-responsive None None I-DNA
gene None None I-DNA
, None None O
and None None O
azPC None None O
enhanced None None O
expression None None O
of None None O
CD36 None None I-protein
in None None O
primary None None I-cell_type
human None None I-cell_type
monocytes None None I-cell_type
. None None O

We None None O
found None None O
that None None O
anti-CD36 None None I-protein
inhibited None None O
azPC None None O
uptake None None O
, None None O
and None None O
it None None O
inhibited None None O
PPRE None None O
reporter None None O
induction None None O
. None None O

Results None None O
with None None O
a None None O
small None None O
molecule None None O
phospholipid None None I-protein
flippase None None I-protein
mimetic None None I-protein
suggest None None O
azPC None None O
acts None None O
intracellularly None None O
and None None O
that None None O
cellular None None O
azPC None None O
accumulation None None O
was None None O
efficient None None O
. None None O

Thus None None O
, None None O
certain None None O
alkyl None None O
phospholipid None None O
oxidation None None O
products None None O
in None None O
oxLDL None None I-protein
are None None O
specific None None O
, None None O
high None None O
affinity None None O
extracellular None None O
ligands None None O
and None None O
agonists None None O
for None None O
PPARgamma None None I-protein
that None None O
induce None None O
PPAR-responsive None None I-DNA
genes None None I-DNA

Regulation None None O
of None None O
the None None O
human None None I-DNA
MAT2B None None I-DNA
gene None None I-DNA
encoding None None O
the None None O
regulatory None None I-protein
beta None None I-protein
subunit None None I-protein
of None None O
methionine None None I-protein
adenosyltransferase None None I-protein
, None None O
MAT None None I-protein
II None None I-protein
. None None O

Methionine None None I-protein
adenosyltransferase None None I-protein
( None None O
MAT None None I-protein
) None None O
catalyzes None None O
the None None O
biosynthesis None None O
of None None O
S-adenosylmethionine None None I-protein
( None None O
AdoMet None None I-protein
) None None O
, None None O
a None None O
key None None O
molecule None None O
in None None O
transmethylation None None O
reactions None None O
and None None O
polyamine None None O
biosynthesis None None O
. None None O

The None None O
MAT None None I-protein
II None None I-protein
isozyme None None I-protein
consists None None O
of None None O
a None None O
catalytic None None I-protein
alpha2 None None I-protein
and None None I-protein
a None None I-protein
regulatory None None I-protein
beta None None I-protein
subunit None None I-protein
. None None O

Down-regulation None None O
of None None O
the None None O
MAT None None I-protein
II None None I-protein
beta None None I-protein
subunit None None I-protein
expression None None O
causes None None O
a None None O
6-10-fold None None O
increase None None O
in None None O
intracellular None None O
AdoMet None None I-protein
levels None None O
. None None O

To None None O
understand None None O
the None None O
mechanism None None O
by None None O
which None None O
the None None O
beta None None I-protein
subunit None None I-protein
expression None None O
is None None O
regulated None None O
, None None O
we None None O
cloned None None O
the None None O
MAT2B None None I-DNA
gene None None I-DNA
, None None O
determined None None O
its None None O
organization None None O
, None None O
characterized None None O
its None None O
5'-flanking None None I-DNA
sequences None None I-DNA
, None None O
and None None O
elucidated None None O
the None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
regulation None None O
of None None O
its None None O
promoter None None I-DNA
. None None O

Transcription None None O
of None None O
the None None O
MAT2B None None I-DNA
gene None None I-DNA
initiates None None O
at None None O
position None None O
-203 None None O
relative None None O
to None None O
the None None O
translation None None I-DNA
start None None I-DNA
site None None I-DNA
. None None O

Promoter None None I-DNA
deletion None None I-DNA
analysis None None I-DNA
defined None None O
a None None O
minimal None None I-DNA
promoter None None I-DNA
between None None O
positions None None I-DNA
+52 None None I-DNA
and None None I-DNA
+93 None None I-DNA
base None None O
pairs None None O
, None None O
a None None O
GC-rich None None I-DNA
region None None I-DNA
. None None O

Inclusion None None O
of None None O
the None None O
sequences None None O
between None None O
-4 None None O
and None None O
+52 None None O
enhanced None None O
promoter None None O
activity None None O
; None None O
this None None O
was None None O
primarily None None O
because None None O
of None None O
an None None O
Sp1 None None I-DNA
recognition None None I-DNA
site None None I-DNA
at None None O
+9/+15 None None O
. None None O

The None None O
inclusion None None O
of None None O
sequences None None O
up None None O
to None None O
position None None O
-115 None None O
provided None None O
full None None O
activity None None O
; None None O
this None None O
was None None O
attributed None None O
to None None O
a None None O
TATA None None I-DNA
at None None O
-32 None None O
. None None O

The None None O
Sp1 None None I-DNA
site None None I-DNA
at None None O
position None None O
+9 None None O
was None None O
key None None O
for None None O
the None None O
formation None None O
of None None O
protein.DNA None None O
complexes None None O
. None None O

Mutation None None O
of None None O
both None None O
the None None O
Sp1 None None I-DNA
site None None I-DNA
at None None O
+9 None None O
and None None O
the None None O
TATA None None I-DNA
at None None O
-32 None None O
reduced None None O
promoter None None O
activity None None O
to None None O
its None None O
minimal None None O
level None None O
. None None O

Supershift None None O
assays None None O
showed None None O
no None None O
effect None None O
of None None O
the None None O
anti-Sp1 None None I-protein
antibody None None I-protein
on None None O
complex None None O
formation None None O
, None None O
whereas None None O
the None None O
anti-Sp3 None None I-protein
antibody None None I-protein
had None None O
a None None O
strong None None O
effect None None O
on None None O
protein.DNA None None O
complex None None O
formation None None O
, None None O
suggesting None None O
that None None O
Sp3 None None I-protein
is None None O
one None None O
of None None O
the None None O
main None None O
factors None None O
binding None None O
to None None O
this None None O
Sp1 None None I-DNA
site None None I-DNA
. None None O

Chromatin None None O
immunoprecipitation None None O
assays None None O
supported None None O
the None None O
involvement None None O
of None None O
both None None O
Sp1 None None I-protein
and None None O
Sp3 None None I-protein
in None None O
complexes None None O
formed None None O
on None None O
the None None O
MAT2B None None I-DNA
promoter None None I-DNA
. None None O

The None None O
data None None O
show None None O
that None None O
the None None O
5'-untranslated None None I-DNA
sequences None None I-DNA
play None None O
an None None O
important None None O
role None None O
in None None O
regulating None None O
the None None O
MAT2B None None I-DNA
gene None None I-DNA
and None None O
identifies None None O
the None None O
Sp1 None None I-DNA
site None None I-DNA
at None None O
+9 None None O
as None None O
a None None O
potential None None O
target None None O
for None None O
modulating None None O
MAT2B None None O
expression None None O
, None None O
a None None O
process None None O
that None None O
can None None O
have None None O
a None None O
major None None O
effect None None O
on None None O
intracellular None None O
AdoMet None None I-protein
levels None None O
. None None O

Molecular None None O
pathogenesis None None O
of None None O
influenza None None O
A None None O
virus None None O
infection None None O
and None None O
virus-induced None None O
regulation None None O
of None None O
cytokine None None I-DNA
gene None None I-DNA
expression None None O
. None None O

Despite None None O
vaccines None None O
and None None O
antiviral None None O
substances None None O
influenza None None O
still None None O
causes None None O
significant None None O
morbidity None None O
and None None O
mortality None None O
world None None O
wide None None O
. None None O

Better None None O
understanding None None O
of None None O
the None None O
molecular None None O
mechanisms None None O
of None None O
influenza None None O
virus None None O
replication None None O
, None None O
pathogenesis None None O
and None None O
host None None O
immune None None O
responses None None O
is None None O
required None None O
for None None O
the None None O
development None None O
of None None O
more None None O
efficient None None O
means None None O
of None None O
prevention None None O
and None None O
treatment None None O
of None None O
influenza None None O
. None None O

Influenza None None O
A None None O
virus None None O
, None None O
which None None O
replicates None None O
in None None O
epithelial None None I-cell_type
cells None None I-cell_type
and None None O
leukocytes None None I-cell_type
, None None O
regulates None None O
host None None O
cell None None O
transcriptional None None O
and None None O
translational None None O
systems None None O
and None None O
activates None None O
, None None O
as None None O
well None None O
as None None O
downregulates None None O
apoptotic None None O
pathways None None O
. None None O

Influenza None None O
A None None O
virus None None O
infection None None O
results None None O
in None None O
the None None O
production None None O
of None None O
chemotactic None None O
( None None O
RANTES None None I-protein
, None None O
MIP-1 None None I-protein
alpha None None I-protein
, None None O
MCP-1 None None I-protein
, None None O
MCP-3 None None I-protein
, None None O
and None None O
IP-10 None None I-protein
) None None O
, None None O
pro-inflammatory None None O
( None None O
IL-1 None None I-protein
beta None None I-protein
, None None O
IL-6 None None I-protein
, None None O
IL-18 None None I-protein
, None None O
and None None O
TNF-alpha None None I-protein
) None None O
, None None O
and None None O
antiviral None None I-protein
( None None I-protein
IFN-alpha/beta None None I-protein
) None None I-protein
cytokines None None I-protein
. None None O

Cytokine None None O
gene None None O
expression None None O
is None None O
associated None None O
with None None O
the None None O
activation None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
, None None O
AP-1 None None I-protein
, None None O
STAT None None I-protein
and None None O
IRF None None I-protein
signal None None I-protein
transducing None None I-protein
molecules None None I-protein
in None None O
influenza None None O
A None None O
virus-infected None None O
cells None None O
. None None O

In None None O
addition None None O
of None None O
upregulating None None O
cytokine None None I-DNA
gene None None I-DNA
expression None None O
, None None O
influenza None None O
A None None O
virus None None O
infection None None O
activates None None O
caspase-1 None None I-protein
enzyme None None I-protein
, None None O
which None None O
is None None O
involved None None O
in None None O
the None None O
proteolytic None None O
processing None None O
of None None O
proIL-1 None None I-protein
beta None None I-protein
and None None O
proIL-18 None None I-protein
into None None O
their None None O
biologically None None O
active None None O
forms None None O
. None None O

Influenza None None O
A None None O
virus-induced None None O
IFN-alpha/beta None None I-protein
is None None O
essential None None O
in None None O
host None None O
's None None O
antiviral None None O
defence None None O
by None None O
activating None None O
the None None O
expression None None O
of None None O
antiviral None None I-DNA
Mx None None I-DNA
, None None O
PKR None None I-DNA
and None None I-DNA
oligoadenylate None None I-DNA
synthetase None None I-DNA
genes None None I-DNA
. None None O

IFN-alpha/beta None None I-protein
also None None O
prolongs None None O
T None None O
cell None None O
survival None None O
, None None O
upregulates None None O
IL-12 None None O
and None None O
IL-18 None None O
receptor None None O
gene None None O
expression None None O
and None None O
together None None O
with None None O
IL-18 None None I-protein
stimulates None None O
NK None None I-cell_type
and None None I-cell_type
T None None I-cell_type
cell None None I-cell_type
IFN-gamma None None O
production None None O
and None None O
the None None O
development None None O
of None None O
Th1-type None None O
immune None None O
response None None O
. None None O

Comparison None None O
of None None O
hprt None None O
and None None O
lacI None None O
mutant None None O
frequency None None O
with None None O
DNA None None O
adduct None None O
formation None None O
in None None O
N-hydroxy-2-acetylaminofluorene-treated None None O
Big None None O
Blue None None O
rats None None O
. None None O

N-Hydroxy-2-acetylaminofluorene None None O
( None None O
N-OH-AAF None None O
) None None O
is None None O
the None None O
proximate None None O
carcinogenic None None O
metabolite None None O
of None None O
the None None O
powerful None None O
rat None None O
liver None None O
carcinogen None None O
2-acetylaminofluorene None None O
. None None O

In None None O
this None None O
study None None O
, None None O
transgenic None None O
Big None None O
Blue None None O
( None None O
R None None O
) None None O
rats None None O
were None None O
used None None O
to None None O
examine None None O
the None None O
relationship None None O
between None None O
in None None O
vivo None None O
mutagenicity None None O
and None None O
DNA None None O
adduct None None O
formation None None O
by None None O
N-OH-AAF None None O
in None None O
the None None O
target None None O
liver None None O
compared None None O
with None None O
that None None O
in None None O
nontarget None None O
tissues None None O
. None None O

Male None None O
rats None None O
were None None O
given None None O
one None None O
, None None O
two None None O
, None None O
or None None O
four None None O
doses None None O
of None None O
25 None None O
mg None None O
N-OH-AAF/kg None None O
body None None O
weight None None O
by None None O
i.p. None None O
injection None None O
at None None O
4-day None None O
intervals None None O
, None None O
and None None O
groups None None O
of None None O
treated None None O
and None None O
control None None O
rats None None O
were None None O
euthanized None None O
up None None O
to None None O
10 None None O
weeks None None O
after None None O
beginning None None O
the None None O
dosing None None O
. None None O

Mutant None None O
frequencies None None O
were None None O
measured None None O
in None None O
the None None O
spleen None None I-DNA
lymphocyte None None I-DNA
hprt None None I-DNA
gene None None I-DNA
, None None O
and None None O
lacI None None O
mutant None None O
frequencies None None O
were None None O
determined None None O
in None None O
the None None O
liver None None O
and None None O
spleen None None O
lymphocytes None None I-cell_type
. None None O

At None None O
6 None None O
weeks None None O
after None None O
beginning None None O
the None None O
dosing None None O
, None None O
the None None O
hprt None None O
mutant None None O
frequency None None O
in None None O
spleen None None I-cell_type
lymphocytes None None I-cell_type
from None None O
the None None O
four-dose None None O
group None None O
was None None O
16.5 None None O
x None None O
10 None None O
( None None O
-6 None None O
) None None O
compared None None O
with None None O
3.2 None None O
x None None O
10 None None O
( None None O
-6 None None O
) None None O
in None None O
control None None O
animals None None O
. None None O

Also None None O
at None None O
6 None None O
weeks None None O
, None None O
rats None None O
given None None O
one None None O
, None None O
two None None O
, None None O
or None None O
four None None O
doses None None O
of None None O
N-OH-AAF None None O
had None None O
lacI None None O
mutant None None O
frequencies None None O
in None None O
the None None O
liver None None O
of None None O
97.6 None None O
, None None O
155.6 None None O
, None None O
and None None O
406.8 None None O
x None None O
10 None None O
( None None O
-6 None None O
) None None O
, None None O
respectively None None O
, None None O
compared None None O
with None None O
a None None O
control None None O
frequency None None O
of None None O
25.7 None None O
x None None O
10 None None O
( None None O
-6 None None O
) None None O
; None None O
rats None None O
given None None O
four None None O
doses None None O
had None None O
lacI None None O
mutant None None O
frequencies None None O
in None None O
spleen None None I-cell_type
lymphocytes None None I-cell_type
of None None O
55.8 None None O
x None None O
10 None None O
( None None O
-6 None None O
) None None O
compared None None O
with None None O
a None None O
control None None O
frequency None None O
of None None O
20.4 None None O
x None None O
10 None None O
( None None O
-6 None None O
) None None O
. None None O

Additional None None O
rats None None O
were None None O
evaluated None None O
for None None O
DNA None None O
adduct None None O
formation None None O
in None None O
the None None O
liver None None O
, None None O
spleen None None I-cell_type
lymphocytes None None I-cell_type
, None None O
and None None O
bone None None O
marrow None None O
by None None O
( None None O
32 None None O
) None None O
P-postlabeling None None O
. None None O

Adduct None None O
analysis None None O
was None None O
conducted None None O
1 None None O
day None None O
after None None O
one None None O
, None None O
two None None O
, None None O
and None None O
four None None O
treatments None None O
with None None O
N-OH-AAF None None O
, None None O
5 None None O
days None None O
after None None O
one None None O
treatment None None O
, None None O
and None None O
9 None None O
days None None O
after None None O
two None None O
treatments None None O
. None None O

N- None None O
( None None O
Deoxyguanosin-8-yl None None O
) None None O
-2-aminofluorene None None O
was None None O
the None None O
major None None O
DNA None None O
adduct None None O
identified None None O
in None None O
all None None O
the None None O
tissues None None O
examined None None O
. None None O

Adduct None None O
concentrations None None O
increased None None O
with None None O
total None None O
dose None None O
to None None O
maximum None None O
values None None O
in None None O
samples None None O
taken None None O
1 None None O
day None None O
after None None O
two None None O
doses None None O
, None None O
and None None O
remained None None O
essentially None None O
the None None O
same None None O
after None None O
four None None O
doses None None O
. None None O

In None None O
samples None None O
taken None None O
after None None O
four None None O
doses None None O
, None None O
adduct None None O
levels None None O
were None None O
103 None None O
, None None O
28 None None O
, None None O
and None None O
7 None None O
fmol/microg None None O
of None None O
DNA None None O
in None None O
liver None None O
, None None O
spleen None None I-cell_type
lymphocytes None None I-cell_type
, None None O
and None None O
bone None None O
marrow None None O
, None None O
respectively None None O
. None None O

The None None O
results None None O
indicate None None O
that None None O
the None None O
extent None None O
of None None O
both None None O
DNA None None O
adduct None None O
formation None None O
and None None O
mutant None None O
induction None None O
correlates None None O
with None None O
the None None O
organ None None O
specificity None None O
for None None O
N-OH-AAF None None O
carcinogenesis None None O
in None None O
the None None O
rat None None O
. None None O

Environ. None None O
Mol. None None O
Mutagen. None None O
37 None None O
: None None O
195-202 None None O
, None None O
2001 None None O
. None None O

Published None None O
2001 None None O
Wiley-Liss None None O
, None None O
Inc None None O
. None None O

Expression None None O
of None None O
Mad1 None None I-protein
in None None O
T None None I-cell_type
cells None None I-cell_type
leads None None O
to None None O
reduced None None O
thymic None None O
cellularity None None O
and None None O
impaired None None O
mitogen-induced None None O
proliferation None None O
. None None O

To None None O
investigate None None O
Mad1 None None I-protein
function None None O
in None None O
vivo None None O
, None None O
transgenic None None O
mice None None O
were None None O
generated None None O
that None None O
express None None O
a None None O
Mad1 None None I-DNA
transgene None None I-DNA
in None None O
T None None I-cell_type
lineage None None I-cell_type
cells None None I-cell_type
under None None O
the None None O
control None None O
of None None O
the None None O
proximal None None I-DNA
lck None None I-DNA
promoter None None I-DNA
. None None O

Thymus None None O
size None None O
in None None O
lck-Mad1 None None O
transgenic None None O
mice None None O
is None None O
drastically None None O
reduced None None O
although None None O
representation None None O
of None None O
the None None O
various None None O
thymocyte None None I-cell_type
sub None None I-cell_type
populations None None I-cell_type
appears None None O
normal None None O
. None None O

To None None O
investigate None None O
more None None O
closely None None O
any None None O
effects None None O
of None None O
Mad1 None None O
expression None None O
on None None O
thymocytes None None I-cell_type
, None None O
we None None O
examined None None O
thymic None None O
selection None None O
using None None O
MHC None None O
class None None O
I-restricted None None O
H-Y-TCR None None O
transgenic None None O
mice None None O
. None None O

Mad1 None None O
expression None None O
in None None O
vivo None None O
reduces None None O
the None None O
efficiency None None O
of None None O
positive None None O
selection None None O
. None None O

Furthermore None None O
, None None O
thymocytes None None I-cell_type
and None None O
splenic None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
from None None O
lck-Mad1 None None O
transgenic None None O
mice None None O
display None None O
a None None O
profound None None O
proliferative None None O
defect None None O
in None None O
response None None O
to None None O
activation None None O
with None None O
either None None O
PMA/Ionomycin None None O
or None None O
immobilized None None I-protein
anti-CD3/CD28 None None I-protein
antibody None None I-protein
. None None O

This None None O
proliferative None None O
defect None None O
is None None O
not None None O
reversed None None O
by None None O
addition None None O
of None None O
exogenous None None I-protein
IL-2 None None I-protein
and None None O
is None None O
p53-independent None None O
. None None O

The None None O
growth None None O
inhibition None None O
caused None None O
by None None O
Mad1 None None I-protein
is None None O
overcome None None O
by None None O
expression None None O
of None None O
active None None I-protein
c-Myc None None I-protein
. None None O

Differential None None O
requirement None None O
for None None O
the None None O
transcription None None I-protein
factor None None I-protein
PU.1 None None I-protein
in None None O
the None None O
generation None None O
of None None O
natural None None I-cell_type
killer None None I-cell_type
cells None None I-cell_type
versus None None O
B None None I-cell_type
and None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

PU.1 None None I-protein
is None None O
a None None O
member None None O
of None None O
the None None O
Ets None None I-protein
family None None I-protein
of None None I-protein
transcription None None I-protein
factors None None I-protein
required None None O
for None None O
the None None O
development None None O
of None None O
various None None O
lymphoid None None I-cell_line
and None None I-cell_line
myeloid None None I-cell_line
cell None None I-cell_line
lineages None None I-cell_line
, None None O
but None None O
its None None O
role None None O
in None None O
natural None None I-cell_type
killer None None I-cell_type
( None None I-cell_type
NK None None I-cell_type
) None None I-cell_type
cell None None I-cell_type
development None None O
is None None O
not None None O
known None None O
. None None O

The None None O
study None None O
shows None None O
that None None O
PU.1 None None I-protein
is None None O
expressed None None O
in None None O
NK None None I-cell_type
cells None None I-cell_type
and None None O
that None None O
, None None O
on None None O
cell None None O
transfer None None O
into None None O
alymphoid None None O
Rag2/gammac None None O
( None None O
-/- None None O
) None None O
mice None None O
, None None O
hematopoietic None None I-cell_type
progenitors None None I-cell_type
of None None O
PU.1 None None I-cell_type
( None None I-cell_type
-/- None None I-cell_type
) None None I-cell_type
fetal None None I-cell_type
liver None None I-cell_type
cells None None I-cell_type
could None None O
generate None None O
functional None None O
NK None None I-cell_type
cells None None I-cell_type
but None None O
not None None O
B None None I-cell_type
or None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

Nevertheless None None O
, None None O
the None None O
numbers None None O
of None None O
bone None None I-cell_type
marrow None None I-cell_type
NK None None I-cell_type
cell None None I-cell_type
precursors None None I-cell_type
and None None O
splenic None None I-cell_type
mature None None I-cell_type
NK None None I-cell_type
cells None None I-cell_type
were None None O
reduced None None O
compared None None O
to None None O
controls None None O
. None None O

Moreover None None O
, None None O
PU.1 None None I-cell_type
( None None I-cell_type
-/- None None I-cell_type
) None None I-cell_type
NK None None I-cell_type
cells None None I-cell_type
displayed None None O
reduced None None O
expression None None O
of None None O
the None None O
receptors None None O
for None None O
stem None None I-protein
cell None None I-protein
factor None None I-protein
and None None O
interleukin None None I-protein
( None None I-protein
IL None None I-protein
) None None I-protein
-7 None None I-protein
, None None O
suggesting None None O
a None None O
nonredundant None None O
role None None O
for None None O
PU.1 None None I-protein
in None None O
regulating None None O
the None None O
expression None None O
of None None O
these None None O
cytokine None None I-DNA
receptor None None I-DNA
genes None None I-DNA
during None None O
NK None None O
cell None None O
development None None O
. None None O

PU.1 None None I-cell_type
( None None I-cell_type
-/- None None I-cell_type
) None None I-cell_type
NK None None I-cell_type
cells None None I-cell_type
also None None O
showed None None O
defective None None O
expression None None O
of None None O
inhibitory None None O
and None None O
activating None None O
members None None O
of None None O
the None None O
Ly49 None None I-protein
family None None I-protein
and None None O
failed None None O
to None None O
proliferate None None O
in None None O
response None None O
to None None O
IL-2 None None I-protein
and None None O
IL-12 None None I-protein
. None None O

Thus None None O
, None None O
despite None None O
the None None O
less None None O
stringent None None O
requirement None None O
for None None O
PU.1 None None I-protein
in None None O
NK None None O
cell None None O
development None None O
compared None None O
to None None O
B None None I-cell_type
and None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
, None None O
PU.1 None None I-protein
regulates None None O
NK None None O
cell None None O
differentiation None None O
and None None O
homeostasis None None O
. None None O

Benzene-extracted None None O
components None None O
are None None O
important None None O
for None None O
the None None O
major None None O
activity None None O
of None None O
diesel None None O
exhaust None None O
particles None None O
: None None O
effect None None O
on None None O
interleukin-8 None None I-DNA
gene None None I-DNA
expression None None O
in None None O
human None None I-cell_type
bronchial None None I-cell_type
epithelial None None I-cell_type
cells None None I-cell_type
. None None O

Epidemiologic None None O
and None None O
experimental None None O
studies None None O
suggest None None O
that None None O
diesel None None O
exhaust None None O
particles None None O
( None None O
DEPs None None O
) None None O
may None None O
be None None O
related None None O
to None None O
increasing None None O
respiratory None None O
mortality None None O
and None None O
morbidity None None O
. None None O

We None None O
have None None O
shown None None O
that None None O
DEPs None None O
augmented None None O
the None None O
production None None O
of None None O
inflammatory None None I-protein
cytokines None None I-protein
by None None O
human None None I-cell_type
airway None None I-cell_type
epithelial None None I-cell_type
cells None None I-cell_type
in None None O
vitro None None O
. None None O

To None None O
better None None O
understand None None O
the None None O
mechanisms None None O
of None None O
their None None O
proinflammatory None None O
activities None None O
, None None O
we None None O
studied None None O
the None None O
effects None None O
of None None O
several None None O
components None None O
extracted None None O
from None None O
DEPs None None O
on None None O
interleukin None None O
( None None O
IL None None O
) None None O
-8 None None O
expression None None O
in None None O
human None None I-cell_line
bronchial None None I-cell_line
epithelial None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
BEAS-2B None None I-cell_line
and None None O
normal None None I-cell_type
human None None I-cell_type
airway None None I-cell_type
epithelial None None I-cell_type
cells None None I-cell_type
obtained None None O
from None None O
very None None O
peripheral None None O
airways None None O
by None None O
an None None O
ultrathin None None O
bronchoscope None None O
. None None O

We None None O
used None None O
several None None O
agents None None O
active None None O
on None None O
signal None None O
transduction None None O
pathways None None O
in None None O
cytokine None None O
expression None None O
, None None O
such None None O
as None None O
the None None O
protein None None O
kinase None None O
C None None O
inhibitor None None O
staurosporin None None O
, None None O
antioxidant None None O
agents None None O
including None None O
N-acetyl None None O
cysteine None None O
( None None O
NAC None None O
) None None O
and None None O
pyrrolidine None None O
dithiocarbamate None None O
( None None O
PDTC None None O
) None None O
, None None O
and None None O
p38 None None I-protein
mitogen-activated None None I-protein
protein None None I-protein
kinase None None I-protein
( None None O
MAPK None None I-protein
) None None O
inhibitor None None O
SB203580 None None O
. None None O

Benzene-extracted None None O
components None None O
showed None None O
effects None None O
mimicking None None O
DEPs None None O
on None None O
IL-8 None None O
gene None None O
expression None None O
, None None O
release None None O
of None None O
several None None O
cytokines None None I-protein
( None None O
IL-8 None None I-protein
; None None O
granulocyte None None I-protein
macrophage None None I-protein
colony-stimulating None None I-protein
factor None None I-protein
; None None O
and None None O
regulated None None O
on None None O
activation None None O
, None None O
normal None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
expressed None None O
and None None O
secreted None None O
) None None O
and None None O
nuclear None None O
factor None None O
( None None O
NF None None O
) None None O
-kappa None None O
B None None O
activation None None O
. None None O

We None None O
also None None O
found None None O
that None None O
NAC None None O
, None None O
PDTC None None O
, None None O
and None None O
SB203580 None None O
suppressed None None O
the None None O
activities None None O
of None None O
DEPs None None O
and None None O
their None None O
benzene None None O
extracts None None O
, None None O
suggesting None None O
the None None O
roles None None O
of None None O
oxidants-mediated None None O
NF-kappa None None O
B None None O
activation None None O
and None None O
p38MAPK None None I-protein
pathways None None O
. None None O

Finally None None O
, None None O
benzo None None O
[ None None O
a None None O
] None None O
pyrene None None O
, None None O
one None None O
of None None O
the None None O
important None None O
compounds None None O
included None None O
in None None O
the None None O
benzene None None O
component None None O
, None None O
replicated None None O
the None None O
activities None None O
shown None None O
by None None O
DEPs None None O
. None None O

The None None O
nuclear None None I-protein
receptor None None I-protein
PPAR None None I-protein
gamma None None I-protein
is None None O
expressed None None O
by None None O
mouse None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
and None None O
PPAR None None O
gamma None None O
agonists None None O
induce None None O
apoptosis None None O
. None None O

Peroxisome None None I-protein
proliferator-activated None None I-protein
receptor None None I-protein
( None None I-protein
PPAR None None I-protein
) None None I-protein
-gamma None None I-protein
is None None O
a None None O
nuclear None None I-protein
hormone None None I-protein
receptor None None I-protein
that None None O
serves None None O
as None None O
a None None O
trans None None O
factor None None O
to None None O
regulate None None O
lipid None None O
metabolism None None O
. None None O

Intense None None O
interest None None O
is None None O
focused None None O
on None None O
PPAR-gamma None None I-protein
and None None O
its None None O
ligands None None O
owing None None O
to None None O
its None None O
putative None None O
role None None O
in None None O
adipocyte None None O
differentiation None None O
. None None O

Little None None O
is None None O
known None None O
, None None O
however None None O
, None None O
about None None O
the None None O
functions None None O
of None None O
PPAR-gamma None None I-protein
in None None O
the None None O
immune None None O
system None None O
, None None O
especially None None O
in None None O
T None None I-cell_type
lymphocytes None None I-cell_type
. None None O

We None None O
demonstrate None None O
that None None O
both None None O
naive None None I-cell_type
and None None I-cell_type
activated None None I-cell_type
ovalbumin-specific None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
from None None O
DO11.10-transgenic None None O
mice None None O
express None None O
PPAR-gamma None None I-RNA
mRNA None None O
and None None O
protein None None O
. None None O

In None None O
order None None O
to None None O
determine None None O
the None None O
function None None O
of None None O
PPAR-gamma None None I-protein
, None None O
T None None I-cell_type
cells None None I-cell_type
were None None O
stimulated None None O
with None None O
phorbol None None O
12-myristate None None O
13-acetate None None O
and None None O
ionomycin None None O
or None None O
antigen None None O
and None None O
antigen-presenting None None I-cell_type
cells None None I-cell_type
. None None O

Simultaneous None None O
exposure None None O
to None None O
PPAR-gamma None None O
ligands None None O
( None None O
e.g. None None O
15-deoxy-Delta None None O
( None None O
12 None None O
, None None O
14 None None O
) None None O
-prostaglandin None None O
J None None O
( None None O
2 None None O
) None None O
, None None O
troglitazone None None O
) None None O
showed None None O
drastic None None O
inhibition None None O
of None None O
proliferation None None O
and None None O
significant None None O
decreases None None O
in None None O
cell None None O
viability None None O
. None None O

The None None O
decrease None None O
in None None O
cell None None O
viability None None O
was None None O
due None None O
to None None O
apoptosis None None O
of None None O
the None None O
T None None I-cell_type
lymphocytes None None I-cell_type
, None None O
and None None O
occurred None None O
only None None O
when None None O
cells None None O
were None None O
treated None None O
with None None O
PPAR-gamma None None I-protein
, None None O
and None None O
not None None O
PPAR-alpha None None O
agonists None None O
, None None O
revealing None None O
specificity None None O
of None None O
this None None O
response None None O
for None None O
PPAR-gamma None None I-protein
. None None O

These None None O
observations None None O
suggest None None O
that None None O
PPAR-gamma None None O
agonists None None O
play None None O
an None None O
important None None O
role None None O
in None None O
regulating None None O
T None None O
cell-mediated None None O
immune None None O
responses None None O
by None None O
inducing None None O
apoptosis None None O
. None None O

T None None O
cell None None O
death None None O
via None None O
PPAR-gamma None None O
ligation None None O
may None None O
act None None O
as None None O
a None None O
potent None None O
anti-inflammatory None None O
signal None None O
in None None O
the None None O
immune None None O
system None None O
, None None O
and None None O
ligands None None O
could None None O
possibly None None O
be None None O
used None None O
to None None O
control None None O
disorders None None O
in None None O
which None None O
excessive None None O
inflammation None None O
occurs None None O
. None None O

Suppression None None O
of None None O
lung None None O
inflammation None None O
in None None O
rats None None O
by None None O
prevention None None O
of None None O
NF-kappaB None None O
activation None None O
in None None O
the None None O
liver None None O
. None None O

Activation None None O
of None None O
NF-kappaB None None I-protein
and None None O
production None None O
of None None O
NF-kappaB None None I-protein
-dependent None None O
chemokines None None I-protein
are None None O
thought None None O
to None None O
be None None O
involved None None O
in None None O
the None None O
pathogenesis None None O
of None None O
neutrophilic None None O
lung None None O
inflammation None None O
. None None O

Calpain-1 None None O
inhibitor None None O
( None None O
CI-1 None None O
) None None O
blocks None None O
activation None None O
of None None O
NF-kappaB None None I-protein
by None None O
preventing None None O
proteolysis None None O
of None None O
the None None O
inhibitory None None O
protein None None O
IkappaB-alpha None None I-protein
by None None O
the None None O
ubiquitin/proteasome None None O
pathway None None O
. None None O

We None None O
hypothesized None None O
that None None O
inhibition None None O
of None None O
proteasome None None O
function None None O
with None None O
CI-1 None None O
would None None O
block None None O
NF-kappaB None None O
activation None None O
in None None O
vivo None None O
after None None O
intraperitoneal None None O
( None None O
i.p. None None O
) None None O
treatment None None O
with None None O
bacterial None None O
lipopolysaccharide None None O
( None None O
LPS None None O
) None None O
, None None O
and None None O
that None None O
NF-kappaB None None O
inhibition None None O
would None None O
be None None O
associated None None O
with None None O
suppression None None O
of None None O
chemokine None None O
gene None None O
expression None None O
and None None O
attenuation None None O
of None None O
neutrophilic None None O
alveolitis None None O
. None None O

We None None O
treated None None O
rats None None O
with None None O
a None None O
single None None O
i.p. None None O
injection None None O
of None None O
CI-1 None None O
( None None O
10 None None O
mg/kg None None O
) None None O
two None None O
hours None None O
prior None None O
to None None O
i.p. None None O
LPS None None O
( None None O
7 None None O
mg/kg None None O
) None None O
. None None O

Treatment None None O
with None None O
Cl-1 None None O
prevented None None O
degradation None None O
of None None O
IkappaB-alpha None None I-protein
and None None O
activation None None O
of None None O
NF-kappaB None None I-protein
in None None O
the None None O
liver None None O
in None None O
response None None O
to None None O
LPS None None O
; None None O
however None None O
, None None O
Cl-1 None None O
treatment None None O
had None None O
no None None O
detected None None O
effect None None O
on None None O
NF-kappaB None None O
activation None None O
in None None O
lung None None O
tissue None None O
. None None O

CI-1 None None O
treatment None None O
prior None None O
to None None O
LPS None None O
resulted None None O
in None None O
40 None None O
% None None O
lower None None O
MIP-2 None None O
concentration None None O
in None None O
lung None None O
lavage None None O
fluid None None O
compared None None O
to None None O
rats None None O
treated None None O
with None None O
vehicle None None O
prior None None O
to None None O
LPS None None O
( None None O
502 None None O
+/- None None O
112 None None O
pg/ml None None O
vs. None None O
859 None None O
+/-144 None None O
pg/ml None None O
, None None O
P None None O
< None None O
0.05 None None O
) None None O
. None None O

In None None O
addition None None O
, None None O
CI-1 None None O
treatment None None O
substantially None None O
inhibited None None O
LPS-induced None None O
neutrophilic None None O
alveolitis None None O
( None None O
2.7+ None None O
/- None None O
1.2 None None O
x None None O
10 None None O
( None None O
5 None None O
) None None O
vs. None None O
43.7 None None O
+/- None None O
12.2 None None O
x None None O
10 None None O
( None None O
5 None None O
) None None O
lung None None I-cell_type
lavage None None I-cell_type
neutrophils None None I-cell_type
, None None O
P None None O
< None None O
0.01 None None O
) None None O
. None None O

These None None O
data None None O
indicate None None O
that None None O
NF-kappaB None None O
inhibition None None O
in None None O
the None None O
liver None None O
can None None O
alter None None O
lung None None O
inflammation None None O
induced None None O
by None None O
systemic None None O
LPS None None O
treatment None None O
and None None O
suggest None None O
that None None O
a None None O
liver-lung None None O
interaction None None O
contributes None None O
to None None O
the None None O
inflammatory None None O
response None None O
of None None O
the None None O
lung None None O
. None None O

Notch1 None None I-protein
regulates None None O
maturation None None O
of None None O
CD4+ None None I-cell_type
and None None I-cell_type
CD8+ None None I-cell_type
thymocytes None None I-cell_type
by None None O
modulating None None O
TCR None None O
signal None None O
strength None None O
. None None O

Notch None None O
signaling None None O
regulates None None O
cell None None O
fate None None O
decisions None None O
in None None O
multiple None None O
lineages None None O
. None None O

We None None O
demonstrate None None O
in None None O
this None None O
report None None O
that None None O
retroviral None None O
expression None None O
of None None O
activated None None O
Notch1 None None I-protein
in None None O
mouse None None I-cell_type
thymocytes None None I-cell_type
abrogates None None O
differentiation None None O
of None None O
immature None None I-cell_type
CD4+CD8+ None None I-cell_type
thymocytes None None I-cell_type
into None None O
both None None O
CD4 None None I-cell_type
and None None I-cell_type
CD8 None None I-cell_type
mature None None I-cell_type
single-positive None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
ability None None O
of None None O
Notch1 None None I-protein
to None None O
inhibit None None O
T None None O
cell None None O
development None None O
was None None O
observed None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
with None None O
both None None O
normal None None I-cell_type
and None None I-cell_type
TCR None None I-cell_type
transgenic None None I-cell_type
thymocytes None None I-cell_type
. None None O

Notch1 None None I-protein
-mediated None None O
developmental None None O
arrest None None O
was None None O
dose None None O
dependent None None O
and None None O
was None None O
associated None None O
with None None O
impaired None None O
thymocyte None None O
responses None None O
to None None O
TCR None None O
stimulation None None O
. None None O

Notch1 None None I-protein
also None None O
inhibited None None O
TCR-mediated None None O
signaling None None O
in None None O
Jurkat None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
. None None O

These None None O
data None None O
indicate None None O
that None None O
constitutively None None O
active None None O
Notch1 None None I-protein
abrogates None None O
CD4+ None None O
and None None O
CD8+ None None O
maturation None None O
by None None O
interfering None None O
with None None O
TCR None None O
signal None None O
strength None None O
and None None O
provide None None O
an None None O
explanation None None O
for None None O
the None None O
physiological None None O
regulation None None O
of None None O
Notch None None O
expression None None O
during None None O
thymocyte None None O
development None None O
. None None O

Expression None None O
of None None O
SART3 None None I-protein
antigen None None I-protein
and None None O
induction None None O
of None None O
CTLs None None I-cell_type
by None None O
SART3-derived None None O
peptides None None O
in None None O
breast None None O
cancer None None O
patients None None O
. None None O

We None None O
recently None None O
reported None None O
the None None O
SART3 None None I-protein
tumour-rejection None None I-protein
antigen None None I-protein
as None None O
possessing None None O
tumour None None O
epitopes None None O
capable None None O
of None None O
inducing None None O
HLA-class None None I-cell_type
I-restricted None None I-cell_type
cytotoxic None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
( None None O
CTLs None None I-cell_type
) None None O
. None None O

This None None O
study None None O
investigated None None O
expression None None O
of None None O
the None None O
SART3 None None I-protein
antigen None None I-protein
in None None O
breast None None O
cancer None None O
to None None O
explore None None O
an None None O
appropriate None None O
molecule None None O
for None None O
use None None O
in None None O
specific None None O
immunotherapy None None O
of None None O
breast None None O
cancer None None O
patients None None O
. None None O

The None None O
SART3 None None I-protein
antigen None None I-protein
was None None O
detected None None O
in None None O
all None None O
of None None O
the None None O
breast None None I-cell_line
cancer None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
tested None None O
, None None O
30 None None O
of None None O
40 None None O
( None None O
75 None None O
% None None O
) None None O
breast None None O
cancer None None O
tissue None None O
samples None None O
, None None O
and None None O
0 None None O
of None None O
3 None None O
non-tumourous None None O
breast None None O
tissue None None O
samples None None O
. None None O

SART3 None None O
derived None None O
peptides None None O
at None None O
positions None None I-DNA
109-118 None None I-DNA
and None None I-DNA
315-323 None None I-DNA
induced None None O
HLA-A24 None None O
restricted None None O
CTLs None None I-cell_type
that None None O
reacted None None O
to None None O
breast None None I-cell_type
cancer None None I-cell_type
cells None None I-cell_type
from None None O
the None None O
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
( None None O
PBMCs None None I-cell_type
) None None O
of None None O
breast None None O
cancer None None O
patients None None O
. None None O

Therefore None None O
, None None O
the None None O
SART3 None None I-protein
antigen None None I-protein
and None None O
its None None O
peptides None None O
could None None O
be None None O
an None None O
appropriate None None O
molecule None None O
for None None O
use None None O
in None None O
specific None None O
immunotherapy None None O
of None None O
the None None O
majority None None O
of None None O
HLA-A24-positive None None O
breast None None O
cancer None None O
patients None None O

Autostimulation None None O
of None None O
the None None O
Epstein-Barr None None O
virus None None O
BRLF1 None None I-DNA
promoter None None I-DNA
is None None O
mediated None None O
through None None O
consensus None None O
Sp1 None None I-DNA
and None None I-DNA
Sp3 None None I-DNA
binding None None I-DNA
sites None None I-DNA
. None None O

As None None O
an None None O
essential None None O
step None None O
in None None O
the None None O
lytic None None O
cascade None None O
, None None O
the None None O
Rta None None O
homologues None None O
of None None O
gammaherpesviruses None None O
all None None O
activate None None O
their None None O
own None None O
expression None None O
. None None O

Consistent None None O
with None None O
this None None O
biologic None None O
function None None O
, None None O
the None None O
Epstein-Barr None None O
virus None None O
( None None O
EBV None None O
) None None O
Rta None None I-protein
protein None None I-protein
powerfully None None O
stimulates None None O
the None None O
promoter None None I-DNA
of None None O
its None None O
own None None O
gene None None O
, None None O
Rp None None I-DNA
, None None O
in None None O
EBV-positive None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
in None None O
transient-transfection None None O
reporter-based None None O
assays None None O
. None None O

We None None O
analyzed None None O
the None None O
activity None None O
of None None O
RpCAT None None I-DNA
in None None O
response None None O
to None None O
Rta None None I-protein
by None None O
deletional None None O
and None None O
site-directed None None O
mutagenesis None None O
. None None O

Two None None O
cognate None None I-DNA
Sp1 None None I-DNA
binding None None I-DNA
sites None None I-DNA
located None None O
at None None O
-279 None None O
and None None O
-45 None None O
relative None None O
to None None O
the None None O
transcriptional None None I-DNA
start None None I-DNA
site None None I-DNA
proved None None O
crucial None None O
for None None O
Rta-mediated None None O
activation None None O
. None None O

Previously None None O
described None None O
binding None None O
sites None None O
for None None O
the None None O
cellular None None O
transcription None None I-protein
factor None None I-protein
Zif268 None None I-protein
and None None O
the None None O
viral None None I-protein
transactivator None None I-protein
ZEBRA None None I-protein
were None None O
found None None O
to None None O
be None None O
dispensable None None O
for None None O
activation None None O
of None None O
RpCAT None None I-DNA
by None None O
Rta None None I-protein
. None None O

Gel None None O
shift None None O
analysis None None O
, None None O
using None None O
extracts None None O
of None None O
B None None I-cell_type
cells None None I-cell_type
in None None O
latency None None O
or None None O
induced None None O
into None None O
the None None O
lytic None None O
cycle None None O
, None None O
identified None None O
Sp1 None None I-protein
and None None O
Sp3 None None I-protein
as None None O
the None None O
predominant None None O
cellular None None I-protein
proteins None None I-protein
bound None None O
to None None O
Rp None None I-DNA
near None None O
-45 None None O
. None None O

During None None O
the None None O
lytic None None O
cycle None None O
, None None O
ZEBRA None None I-protein
bound None None O
Rp None None I-DNA
near None None O
the None None O
Sp1/Sp3 None None I-DNA
site None None I-DNA
. None None O

The None None O
binding None None O
of None None O
Sp1 None None I-protein
and None None O
Sp3 None None I-protein
to None None O
Rp None None I-DNA
correlated None None O
with None None O
the None None O
reporter None None O
activities None None O
in None None O
the None None O
mutagenesis None None O
study None None O
, None None O
establishing None None O
a None None O
direct None None O
link None None O
between None None O
transcriptional None None O
activation None None O
of None None O
Rp None None I-DNA
by None None O
Rta None None I-protein
and None None O
DNA None None O
binding None None O
by None None O
Sp1 None None I-protein
and/or None None O
Sp3 None None I-protein
. None None O

The None None O
relative None None O
abundance None None O
or None None O
functional None None O
state None None O
of None None O
the None None O
cellular None None O
Sp1 None None I-protein
and None None O
Sp3 None None I-protein
transcription None None B-protein
factors None None I-protein
may None None O
be None None O
altered None None O
in None None O
response None None O
to None None O
stimuli None None O
that None None O
induce None None O
the None None O
BRLF1 None None I-DNA
promoter None None I-DNA
and None None O
thereby None None O
contribute None None O
to None None O
the None None O
activation None None O
of None None O
the None None O
viral None None O
lytic None None O
cycle None None O
. None None O

Gene None None O
transfer None None O
of None None O
antisense None None O
hypoxia None None I-protein
inducible None None I-protein
factor-1 None None I-protein
alpha None None I-protein
enhances None None O
the None None O
therapeutic None None O
efficacy None None O
of None None O
cancer None None O
immunotherapy None None O
. None None O

Solid None None O
tumors None None O
meet None None O
their None None O
demands None None O
for None None O
nascent None None O
blood None None O
vessels None None O
and None None O
increased None None O
glycolysis None None O
, None None O
to None None O
combat None None O
hypoxia None None O
, None None O
by None None O
activating None None O
multiple None None O
genes None None O
involved None None O
in None None O
angiogenesis None None O
and None None O
glucose None None O
metabolism None None O
. None None O

Hypoxia None None I-protein
inducible None None I-protein
factor-1 None None I-protein
( None None O
HIF-1 None None I-protein
) None None O
is None None O
a None None O
constitutively None None O
expressed None None O
basic None None O
helix-loop-helix None None I-protein
transcription None None I-protein
factor None None I-protein
, None None O
formed None None O
by None None O
the None None O
assembly None None O
of None None O
HIF-1alpha None None I-protein
and None None O
HIF-1beta None None I-protein
( None None O
Arnt None None I-protein
) None None O
, None None O
that None None O
is None None O
stablized None None O
in None None O
response None None O
to None None O
hypoxia None None O
, None None O
and None None O
rapidly None None O
degraded None None O
under None None O
normoxic None None O
conditions None None O
. None None O

It None None O
activates None None O
the None None O
transcription None None O
of None None O
genes None None O
important None None O
for None None O
maintaining None None O
oxygen None None O
homeostasis None None O
. None None O

Here None None O
, None None O
we None None O
demonstrate None None O
that None None O
engineered None None O
down-regulation None None O
of None None O
HIF-1alpha None None I-protein
by None None O
intratumoral None None O
gene None None O
transfer None None O
of None None O
an None None O
antisense None None I-DNA
HIF-1alpha None None I-DNA
plasmid None None I-DNA
leads None None O
to None None O
the None None O
down-regulation None None O
of None None O
VEGF None None I-DNA
, None None O
and None None O
decreased None None O
tumor None None O
microvessel None None O
density None None O
. None None O

Antisense None None O
HIF-1alpha None None O
monotherapy None None O
resulted None None O
in None None O
the None None O
complete None None O
and None None O
permanent None None O
rejection None None O
of None None O
small None None O
( None None O
0.1 None None O
cm None None O
in None None O
diameter None None O
) None None O
EL-4 None None O
tumors None None O
, None None O
which None None O
is None None O
unusual None None O
for None None O
an None None O
anti-angiogenic None None O
agent None None O
where None None O
transient None None O
suppression None None O
of None None O
tumor None None O
growth None None O
is None None O
the None None O
norm None None O
. None None O

It None None O
induced None None O
NK None None I-cell_type
cell None None I-cell_type
-dependent None None O
rejection None None O
of None None O
tumors None None O
, None None O
but None None O
failed None None O
to None None O
stimulate None None O
systemic None None O
T None None I-cell_type
cell None None I-cell_type
-mediated None None O
anti-tumor None None O
immunity None None O
, None None O
and None None O
synergized None None O
with None None O
B7-1-mediated None None O
immunotherapy None None O
to None None O
cause None None O
the None None O
NK None None I-cell_type
cell None None I-cell_type
and None None O
CD8 None None I-cell_type
T None None I-cell_type
cell None None I-cell_type
-dependent None None O
rejection None None O
of None None O
larger None None O
EL-4 None None O
tumors None None O
( None None O
0.4 None None O
cm None None O
in None None O
diameter None None O
) None None O
that None None O
were None None O
refractory None None O
to None None O
monotherapies None None O
. None None O

Mice None None O
cured None None O
of None None O
their None None O
tumors None None O
by None None O
combination None None O
therapy None None O
resisted None None O
a None None O
rechallenge None None O
with None None O
parental None None I-cell_type
tumor None None I-cell_type
cells None None I-cell_type
, None None O
indicating None None O
systemic None None O
antitumor None None O
immunity None None O
had None None O
been None None O
achieved None None O
. None None O

In None None O
summary None None O
, None None O
whilst None None O
intensive None None O
investigations None None O
are None None O
in None None O
progress None None O
to None None O
target None None O
the None None O
many None None O
HIF-1 None None I-protein
effectors None None O
, None None O
the None None O
results None None O
herein None None O
indicate None None O
that None None O
blocking None None O
hypoxia-inducible None None O
pathways None None O
and None None O
enhancing None None O
NK-mediated None None O
antitumor None None O
immunity None None O
by None None O
targeting None None O
HIF-1 None None I-protein
itself None None O
may None None O
be None None O
advantageous None None O
, None None O
especially None None O
when None None O
combined None None O
with None None O
cancer None None O
immunotherapy None None O
. None None O

Runx2 None None I-DNA
: None None O
a None None O
novel None None O
oncogenic None None O
effector None None O
revealed None None O
by None None O
in None None O
vivo None None O
complementation None None O
and None None O
retroviral None None O
tagging None None O
. None None O

The None None O
Runx2 None None I-DNA
( None None O
Cbfa1 None None I-DNA
, None None O
Pebp2alphaA None None I-DNA
, None None O
Aml3 None None I-DNA
) None None O
gene None None O
was None None O
previously None None O
identified None None O
as None None O
a None None O
frequent None None O
target None None O
for None None O
transcriptional None None O
activation None None O
by None None O
proviral None None O
insertion None None O
in None None O
T-cell None None O
lymphomas None None O
of None None O
CD2-MYC None None O
transgenic None None O
mice None None O
. None None O

We None None O
have None None O
recently None None O
shown None None O
that None None O
over-expression None None O
of None None O
the None None O
full-length None None O
, None None O
most None None O
highly None None O
expressed None None O
Runx2 None None I-DNA
isoform None None O
in None None O
the None None O
thymus None None O
perturbs None None O
T-cell None None O
development None None O
, None None O
leads None None O
to None None O
development None None O
of None None O
spontaneous None None O
lymphomas None None O
at None None O
low None None O
frequency None None O
and None None O
is None None O
strongly None None O
synergistic None None O
with None None O
Myc None None I-protein
. None None O

To None None O
gain None None O
further None None O
insight None None O
into None None O
the None None O
relationship None None O
of None None O
Runx2 None None I-DNA
to None None O
other None None O
lymphomagenic None None O
pathways None None O
, None None O
we None None O
tested None None O
the None None O
effect None None O
of None None O
combining None None O
the None None O
CD2-Runx2 None None I-DNA
transgene None None I-DNA
either None None O
with None None O
a None None O
Pim1 None None I-DNA
transgene None None I-DNA
( None None O
E None None I-DNA
( None None I-DNA
mu None None I-DNA
) None None I-DNA
-Pim1 None None I-DNA
) None None O
or None None O
with None None O
the None None O
p53 None None I-DNA
null None None O
genotype None None O
, None None O
as None None O
each None None O
of None None O
these None None O
displays None None O
independent None None O
synergy None None O
with None None O
Myc None None I-protein
. None None O

In None None O
both None None O
cases None None O
we None None O
observed None None O
synergistic None None O
tumour None None O
development None None O
. None None O

However None None O
, None None O
Runx2 None None I-protein
appeared None None O
to None None O
have None None O
a None None O
dominant None None O
effect None None O
on None None O
the None None O
tumour None None O
phenotype None None O
in None None O
each None None O
case None None O
, None None O
with None None O
most None None O
tumours None None O
conforming None None O
to None None O
the None None O
CD3 None None O
( None None O
+ None None O
) None None O
, None None O
CD8 None None O
( None None O
+ None None O
) None None O
, None None O
CD4 None None O
( None None O
+/- None None O
) None None O
phenotype None None O
seen None None O
in None None O
CD2-Runx2 None None O
mice None None O
. None None O

Neonatal None None O
infection None None O
of None None O
CD2-Runx2 None None O
mice None None O
with None None O
Moloney None None O
murine None None O
leukaemia None None O
virus None None O
( None None O
Moloney None None O
MLV None None O
) None None O
also None None O
led None None O
to None None O
a None None O
dramatic None None O
acceleration None None O
of None None O
tumour None None O
onset None None O
. None None O

Analysis None None O
of None None O
known None None O
Moloney None None I-DNA
MLV None None I-DNA
target None None I-DNA
genes None None I-DNA
in None None O
these None None O
lymphomas None None O
showed None None O
a None None O
high None None O
frequency None None O
of None None O
rearrangement None None O
at None None O
c-Myc None None I-DNA
or None None O
N-Myc None None I-DNA
( None None O
82 None None O
% None None O
) None None O
, None None O
and None None O
a None None O
significant None None O
number None None O
at None None O
Pim1 None None I-DNA
or None None O
Pim2 None None I-DNA
( None None O
23 None None O
% None None O
) None None O
, None None O
and None None O
at None None O
Pal1/Gfi1 None None I-DNA
( None None O
18 None None O
% None None O
) None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
Runx2 None None I-protein
makes None None O
a None None O
distinct None None O
contribution None None O
to None None O
T-cell None None O
lymphoma None None O
development None None O
which None None O
does None None O
not None None O
coincide None None O
with None None O
any None None O
of None None O
the None None O
oncogene None None O
complementation None None O
groups None None O
previously None None O
identified None None O
by None None O
retroviral None None O
tagging None None O
. None None O

The None None O
involvement None None O
of None None O
TNF-alpha None None I-protein
-related None None O
apoptosis-inducing None None O
ligand None None O
in None None O
the None None O
enhanced None None O
cytotoxicity None None O
of None None O
IFN-beta None None I-protein
-stimulated None None O
human None None I-cell_type
dendritic None None I-cell_type
cells None None I-cell_type
to None None O
tumor None None I-cell_type
cells None None I-cell_type
. None None O

TNF-alpha None None I-protein
-related None None O
apoptosis-inducing None None O
ligand None None O
( None None O
TRAIL None None O
) None None O
is None None O
characterized None None O
by None None O
its None None O
preferential None None O
induction None None O
of None None O
apoptosis None None O
of None None O
tumor None None I-cell_type
cells None None I-cell_type
but None None O
not None None O
normal None None I-cell_type
cells None None I-cell_type
. None None O

Dendritic None None I-cell_type
cells None None I-cell_type
( None None O
DCs None None I-cell_type
) None None O
, None None O
besides None None O
their None None O
role None None O
as None None O
APCs None None O
, None None O
now None None O
have None None O
been None None O
demonstrated None None O
to None None O
exert None None O
cytotoxicity None None O
or None None O
cytostasis None None O
on None None O
some None None O
tumor None None I-cell_type
cells None None I-cell_type
. None None O

Here None None O
, None None O
we None None O
report None None O
that None None O
both None None O
human None None I-cell_type
CD34 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
stem None None I-cell_type
cell None None I-cell_type
-derived None None O
DCs None None I-cell_type
( None None O
CD34DCs None None I-cell_type
) None None O
and None None O
human None None I-cell_type
CD14 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
monocyte None None I-cell_type
-derived None None O
DCs None None I-cell_type
( None None O
MoDCs None None I-cell_type
) None None O
express None None O
TRAIL None None O
and None None O
exhibit None None O
cytotoxicity None None O
to None None O
some None None O
types None None O
of None None O
tumor None None I-cell_type
cells None None I-cell_type
partially None None O
through None None O
TRAIL None None O
. None None O

Moderate None None O
expression None None O
of None None O
TRAIL None None O
appeared None None O
on None None O
CD34DCs None None I-cell_type
from None None O
the None None O
8th None None O
day None None O
of None None O
culture None None O
and None None O
was None None O
also None None O
seen None None O
on None None O
freshly None None I-cell_type
isolated None None I-cell_type
monocytes None None I-cell_type
. None None O

The None None O
level None None O
of None None O
TRAIL None None O
expression None None O
remained None None O
constant None None O
until None None O
DC None None O
maturation None None O
. None None O

TRAIL None None O
expression None None O
on None None O
immature None None I-cell_type
CD34DCs None None I-cell_type
or None None O
MoDCs None None I-cell_type
was None None O
greatly None None O
up-regulated None None O
after None None O
IFN-beta None None I-protein
stimulation None None O
. None None O

Moreover None None O
, None None O
IFN-beta None None I-protein
could None None O
strikingly None None O
enhance None None O
the None None O
ability None None O
of None None O
CD34DCs None None I-cell_type
or None None O
MoDCs None None I-cell_type
to None None O
kill None None O
TRAIL-sensitive None None O
tumor None None I-cell_type
cells None None I-cell_type
, None None O
but None None O
LPS None None O
did None None O
not None None O
have None None O
such None None O
an None None O
effect None None O
. None None O

The None None O
up-regulation None None O
of None None O
TRAIL None None O
on None None O
IFN-beta None None I-protein
-stimulated None None O
DCs None None I-cell_type
partially None None O
contributed None None O
to None None O
the None None O
increased None None O
cytotoxicity None None O
of None None O
DCS None None I-cell_type
: None None O
Pretreatment None None O
of None None O
TRAIL-sensitive None None O
tumor None None I-cell_type
cells None None I-cell_type
with None None O
caspase-3 None None O
inhibitor None None O
could None None O
significantly None None O
increase None None O
their None None O
resistance None None O
to None None O
the None None O
cytotoxicity None None O
of None None O
IFN-beta None None I-protein
-stimulated None None O
DCS None None I-cell_type
: None None O
In None None O
contrast None None O
, None None O
NF-kappaB None None O
inhibitor None None O
could None None O
significantly None None O
increase None None O
the None None O
sensitivity None None O
of None None O
tumor None None I-cell_type
cells None None I-cell_type
to None None O
the None None O
killing None None O
by None None O
nonstimulated None None O
or None None O
LPS-stimulated None None O
DCS None None I-cell_type
: None None O
Our None None O
studies None None O
demonstrate None None O
that None None O
IFN-beta None None I-protein
-stimulated None None O
DCs None None I-cell_type
are None None O
functionally None None O
cytotoxic None None O
. None None O

Thus None None O
, None None O
an None None O
innate None None O
mechanism None None O
of None None O
DC-mediated None None O
antitumor None None O
immunity None None O
might None None O
exist None None O
in None None O
vivo None None O
in None None O
which None None O
DCs None None I-cell_type
act None None O
as None None O
effectors None None O
to None None O
directly None None O
kill None None O
tumor None None I-cell_type
cells None None I-cell_type
partially None None O
via None None O
TRAIL None None O
. None None O

Subsequently None None O
, None None O
DCs None None I-cell_type
act None None O
as None None O
APCs None None O
involved None None O
in None None O
the None None O
uptake None None O
, None None O
processing None None O
, None None O
and None None O
presentation None None O
of None None O
apoptotic None None I-protein
tumor None None I-protein
Ags None None I-protein
to None None O
cross-prime None None O
CD8 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
CTL None None I-cell_type
cells None None I-cell_type
. None None O

Tumor None None I-cell_type
cells None None I-cell_type
regulate None None O
the None None O
lytic None None O
activity None None O
of None None O
tumor-specific None None I-cell_type
cytotoxic None None I-cell_type
t None None I-cell_type
lymphocytes None None I-cell_type
by None None O
modulating None None O
the None None O
inhibitory None None O
natural None None O
killer None None O
receptor None None O
function None None O
. None None O

Tumor-infiltrating None None I-cell_type
p58+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
from None None O
a None None O
renal None None O
tumor None None O
were None None O
specifically None None O
expanded None None O
in None None O
response None None O
to None None O
tumor None None O
cell None None O
stimulation None None O
and None None O
cloned None None O
. None None O

These None None O
p58+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
were None None O
found None None O
to None None O
express None None O
a None None O
memory None None I-cell_type
phenotype None None I-cell_type
and None None O
corresponded None None O
to None None O
clonal None None O
TCRBV3 None None O
T-cell None None O
expansion None None O
. None None O

Functionally None None O
, None None O
p58 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
CTLs None None I-cell_type
displayed None None O
a None None O
low None None O
lytic None None O
activity None None O
for None None O
HLA-A2 None None I-cell_type
tumor None None I-cell_type
and None None I-cell_type
normal None None I-cell_type
cells None None I-cell_type
. None None O

However None None O
, None None O
this None None O
lytic None None O
activity None None O
was None None O
significantly None None O
increased None None O
after None None O
blockade None None O
of None None O
p58 None None I-protein
with None None O
specific None None O
monoclonal None None I-protein
antibodies None None I-protein
. None None O

Interestingly None None O
, None None O
we None None O
demonstrated None None O
that None None O
stimulation None None O
by None None O
tumor None None I-cell_type
cells None None I-cell_type
was None None O
required None None O
to None None O
trigger None None O
the None None O
inhibitory None None O
effect None None O
of None None O
p58 None None I-protein
on None None O
the None None O
lytic None None O
activity None None O
of None None O
antigen-specific None None I-cell_type
CTLs None None I-cell_type
and None None O
that None None O
stimulation None None O
of None None O
the None None O
inhibitory None None O
function None None O
of None None O
p58 None None I-protein
by None None O
tumor None None I-cell_type
cells None None I-cell_type
correlated None None O
with None None O
an None None O
inhibition None None O
of None None O
nuclear None None O
factor-kappaB None None O
activation None None O
in None None O
p58+ None None I-cell_type
tumor-specific None None I-cell_type
CTLS None None I-cell_type
. None None O

T-cell None None I-protein
factor-1 None None I-protein
expression None None O
during None None O
human None None I-cell_type
natural None None I-cell_type
killer None None I-cell_type
cell None None I-cell_type
development None None O
and None None O
in None None O
circulating None None O
CD56 None None I-protein
( None None I-protein
+ None None I-protein
) None None I-protein
bright None None O
natural None None I-cell_type
killer None None I-cell_type
cells None None I-cell_type
. None None O

Transcription None None I-protein
factors None None I-protein
are None None O
essential None None O
to None None O
govern None None O
differentiation None None O
along None None O
the None None O
lymphoid None None I-cell_type
lineage None None I-cell_type
from None None O
uncommitted None None I-cell_type
hematopoietic None None I-cell_type
stem None None I-cell_type
cells None None I-cell_type
. None None O

Although None None O
many None None O
of None None O
these None None O
transcription None None I-protein
factors None None I-protein
have None None O
putative None None O
roles None None O
based None None O
on None None O
murine None None O
knockout None None O
experiments None None O
, None None O
their None None O
function None None O
in None None O
human None None O
lymphoid None None O
development None None O
is None None O
less None None O
known None None O
and None None O
was None None O
studied None None O
further None None O
. None None O

Transcription None None O
factor None None O
expression None None O
in None None O
fresh None None O
and None None O
cultured None None O
adult None None I-cell_type
human None None I-cell_type
bone None None I-cell_type
marrow None None I-cell_type
and None None I-cell_type
umbilical None None I-cell_type
cord None None I-cell_type
blood None None I-cell_type
progenitors None None I-cell_type
was None None O
evaluated None None O
. None None O

We None None O
found None None O
that None None O
fresh None None I-cell_type
CD34 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
Lin None None I-cell_type
( None None I-cell_type
- None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
that None None O
are None None O
human None None O
leukocyte None None O
antigen None None O
( None None O
HLA None None O
) None None O
-DR None None O
( None None O
- None None O
) None None O
or None None O
CD38 None None O
( None None O
- None None O
) None None O
constitutively None None O
express None None O
GATA-3 None None I-protein
but None None O
not None None O
T-cell None None I-protein
factor-1 None None I-protein
( None None O
TCF-1 None None I-protein
) None None O
or None None O
Id-3 None None I-protein
. None None O

Culture None None O
with None None O
the None None O
murine None None I-cell_line
fetal None None I-cell_line
liver None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
AFT024 None None I-cell_line
and None None O
defined None None O
cytokines None None I-protein
was None None O
capable None None O
of None None O
inducing None None O
TCF-1 None None I-RNA
mRNA None None I-RNA
. None None O

However None None O
, None None O
no None None O
T-cell None None I-DNA
receptor None None I-DNA
gene None None I-DNA
rearrangement None None O
was None None O
identified None None O
in None None O
cultured None None O
progeny None None O
. None None O

Id-3 None None I-protein
, None None O
a None None O
basic None None I-protein
helix None None I-protein
loop None None I-protein
helix None None I-protein
factor None None I-protein
with None None O
dominant None None O
negative None None O
function None None O
for None None O
T-cell None None O
differentiation None None O
transcription None None I-protein
factors None None I-protein
, None None O
also None None O
was None None O
upregulated None None O
and None None O
may None None O
explain None None O
unsuccessful None None O
T-cell None None O
maturation None None O
. None None O

To None None O
better None None O
understand None None O
the None None O
developmental None None O
link None None O
between None None O
natural None None I-cell_type
killer None None I-cell_type
( None None I-cell_type
NK None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
derived None None O
from None None O
progenitors None None I-cell_type
, None None O
we None None O
studied None None O
NK None None I-cell_type
cell None None I-cell_type
subsets None None I-cell_type
circulating None None O
in None None O
blood None None O
. None None O

CD56 None None I-cell_type
( None None I-cell_type
+bright None None I-cell_type
) None None I-cell_type
, None None O
but None None O
not None None O
CD56 None None I-cell_type
( None None I-cell_type
+dim None None I-cell_type
) None None I-cell_type
, None None O
NK None None I-cell_type
cells None None I-cell_type
constitutively None None O
express None None O
TCF-1 None None I-protein
by None None O
reverse None None O
transcriptase None None O
polymerase None None O
chain None None O
reaction None None O
and None None O
Western None None O
blot None None O
analysis None None O
. None None O

The None None O
TCF-1 None None I-protein
isoform None None I-protein
found None None O
in None None O
CD56 None None I-cell_type
( None None I-cell_type
+bright None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
, None None O
which None None O
express None None O
lectin None None I-protein
but None None O
not None None O
immunoglobulin None None I-protein
class None None I-protein
I None None I-protein
recognizing None None O
inhibitory None None I-protein
receptors None None I-protein
, None None O
was None None O
identical None None O
to None None O
that None None O
induced None None O
in None None O
NK None None O
cell None None O
differentiation None None O
culture None None O
and None None O
was None None O
distinctly None None O
different None None O
from None None O
isoforms None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

These None None O
results None None O
suggest None None O
that None None O
TCF-1 None None I-protein
does None None O
not None None O
target None None O
human None None I-DNA
killer None None I-DNA
immunoglobulin None None I-DNA
receptor None None I-DNA
genes None None I-DNA
, None None O
TCF-1 None None I-protein
is None None O
uniquely None None O
expressed None None O
in None None O
circulating None None O
CD56 None None I-cell_type
( None None I-cell_type
+bright None None I-cell_type
) None None I-cell_type
NK None None I-cell_type
cells None None I-cell_type
, None None O
and None None O
specific None None O
TCF-1 None None I-protein
isoforms None None I-protein
may None None O
play None None O
an None None O
important None None O
role None None O
in None None O
regulating None None O
NK None None O
differentiation None None O
from None None O
a None None O
common None None O
NK/T-cell None None I-cell_type
progenitor None None I-cell_type
. None None O

Transcriptional None None O
activation None None O
by None None O
a None None O
matrix None None I-protein
associating None None I-protein
region-binding None None I-protein
protein None None I-protein
. None None O

contextual None None O
requirements None None O
for None None O
the None None O
function None None O
of None None O
bright None None I-protein
. None None O

Bright None None I-protein
( None None O
B None None I-protein
cell None None I-protein
regulator None None I-protein
of None None I-protein
IgH None None I-protein
transcription None None I-protein
) None None O
is None None O
a None None O
B None None I-cell_type
cell None None I-cell_type
-specific None None O
, None None O
matrix None None I-protein
associating None None I-protein
region-binding None None I-protein
protein None None I-protein
that None None O
transactivates None None O
gene None None O
expression None None O
from None None O
the None None O
IgH None None I-DNA
intronic None None I-DNA
enhancer None None I-DNA
( None None O
E None None I-DNA
mu None None I-DNA
) None None O
. None None O

We None None O
show None None O
here None None O
that None None O
Bright None None I-protein
has None None O
multiple None None O
contextual None None O
requirements None None O
to None None O
function None None O
as None None O
a None None O
transcriptional None None I-protein
activator None None I-protein
. None None O

Bright None None I-protein
can None None O
not None None O
transactivate None None O
via None None O
out None None O
of None None O
context None None O
, None None O
concatenated None None I-protein
binding None None I-protein
sites None None I-protein
. None None O

Transactivation None None O
is None None O
maximal None None O
on None None O
integrated None None O
substrates None None O
. None None O

Two None None O
of None None O
the None None O
three None None O
previously None None O
identified None None O
binding None None I-DNA
sites None None I-DNA
in None None O
E None None I-DNA
mu None None I-DNA
are None None O
required None None O
for None None O
full None None O
Bright None None I-protein
transactivation None None O
. None None O

The None None O
Bright None None I-protein
DNA None None I-protein
binding None None I-protein
domain None None I-protein
defined None None O
a None None O
new None None O
family None None O
, None None O
which None None O
includes None None O
SWI1 None None I-protein
, None None O
a None None O
component None None O
of None None O
the None None O
SWI.SNF None None I-protein
complex None None I-protein
shown None None O
to None None O
have None None O
high None None O
mobility None None O
group-like None None O
DNA None None O
binding None None O
characteristics None None O
. None None O

Similar None None O
to None None O
one None None O
group None None O
of None None O
high None None I-protein
mobility None None I-protein
group None None I-protein
box None None I-protein
proteins None None I-protein
, None None O
Bright None None I-protein
distorts None None O
E None None I-DNA
mu None None I-DNA
binding None None I-DNA
site None None I-DNA
-containing None None O
DNA None None O
on None None O
binding None None O
, None None O
supporting None None O
the None None O
concept None None O
that None None O
it None None O
mediates None None O
E None None I-DNA
mu None None I-DNA
remodeling None None O
. None None O

Transfection None None O
studies None None O
further None None O
implicate None None O
Bright None None I-protein
in None None O
facilitating None None O
spatially None None O
separated None None O
promoter-enhancer None None O
interactions None None O
in None None O
both None None O
transient None None O
and None None O
stable None None O
assays None None O
. None None O

Finally None None O
, None None O
we None None O
show None None O
that None None O
overexpression None None O
of None None O
Bright None None I-protein
leads None None O
to None None O
enhanced None None O
DNase None None O
I None None O
sensitivity None None O
of None None O
the None None O
endogenous None None O
E None None I-DNA
mu None None I-DNA
matrix None None O
associating None None O
regions None None O
. None None O

These None None O
data None None O
further None None O
suggest None None O
that None None O
Bright None None I-protein
may None None O
contribute None None O
to None None O
increased None None O
gene None None O
expression None None O
by None None O
remodeling None None O
the None None O
immunoglobulin None None I-DNA
locus None None I-DNA
during None None O
B None None I-cell_type
cell None None I-cell_type
development None None O
. None None O

Analysis None None O
of None None O
BCL-6 None None O
mutations None None O
in None None O
classic None None O
Hodgkin None None O
disease None None O
of None None O
the None None O
B- None None I-cell_type
and None None I-cell_type
T-cell None None I-cell_type
type None None I-cell_type
. None None O

BCL-6 None None I-DNA
is None None O
essential None None O
for None None O
germinal None None O
center None None O
formation None None O
and None None O
thus None None O
for None None O
affinity None None O
maturation None None O
of None None O
immunoglobulin None None I-DNA
( None None I-DNA
Ig None None I-DNA
) None None I-DNA
genes None None I-DNA
by None None O
somatic None None O
mutations None None O
. None None O

The None None O
5'-noncoding None None I-DNA
region None None I-DNA
of None None O
the None None O
BCL-6 None None I-DNA
gene None None I-DNA
is None None O
even None None O
a None None O
target None None O
for None None O
the None None O
mutation None None O
machinery None None O
. None None O

Translocations None None O
of None None O
the None None O
BCL-6 None None I-DNA
gene None None I-DNA
to None None O
heterologous None None I-DNA
promoters None None I-DNA
and None None O
mutations None None O
of None None O
its None None O
5'-noncoding None None I-DNA
regulatory None None I-DNA
region None None I-DNA
were None None O
reported None None O
to None None O
be None None O
potential None None O
mechanisms None None O
for None None O
deregulating None None O
BCL-6 None None I-DNA
expression None None O
and None None O
for None None O
playing None None O
a None None O
role None None O
in None None O
the None None O
genesis None None O
of None None O
non-Hodgkin None None O
lymphoma None None O
. None None O

In None None O
line None None O
with None None O
this None None O
hypothesis None None O
is None None O
the None None O
observation None None O
that None None O
B-cell None None O
lymphoma None None O
with None None O
somatic None None O
mutations None None O
, None None O
such None None O
as None None O
diffuse None None O
large None None O
B-cell None None O
lymphoma None None O
and None None O
follicular None None O
lymphoma None None O
, None None O
also None None O
carry None None O
BCL-6 None None O
mutations None None O
, None None O
some None None O
of None None O
which None None O
are None None O
recurrently None None O
detectable None None O
. None None O

Classic None None O
Hodgkin None None O
disease None None O
( None None O
cHD None None O
) None None O
is None None O
also None None O
derived None None O
from None None O
B None None I-cell_type
cells None None I-cell_type
with None None O
high None None O
loads None None O
of None None O
somatic None None O
mutations None None O
and None None O
thus None None O
a None None O
further None None O
candidate None None O
for None None O
BCL-6 None None O
mutations None None O
. None None O

To None None O
determine None None O
the None None O
presence None None O
and None None O
potential None None O
role None None O
of None None O
BCL-6 None None O
mutations None None O
in None None O
cHD None None O
, None None O
the None None O
5'-noncoding None None I-DNA
BCL-6 None None I-DNA
proportion None None O
of None None O
single None None I-cell_type
Hodgkin None None I-cell_type
and None None I-cell_type
Reed-Sternberg None None I-cell_type
( None None I-cell_type
HRS None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
from None None O
6 None None O
cases None None O
of None None O
cHD None None O
and None None O
6 None None O
cases None None O
of None None O
HD-derived None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
was None None O
analyzed None None O
. None None O

All None None O
B-cell-derived None None O
HD None None O
cases None None O
and None None O
cell None None O
lines None None O
harbored None None O
BCL-6 None None O
mutations None None O
. None None O

In None None O
contrast None None O
, None None O
both None None O
T-cell-derived None None O
HD None None O
cases None None O
and None None O
cell None None O
lines None None O
were None None O
devoid None None O
of None None O
BCL-6 None None O
mutations None None O
. None None O

With None None O
only None None O
one None None O
exception None None O
, None None O
there None None O
were None None O
no None None O
lymphoma-specific None None O
recurrent None None O
BCL-6 None None O
mutations None None O
detected None None O
, None None O
and None None O
BCL-6 None None I-protein
protein None None I-protein
was None None O
absent None None O
from None None O
the None None O
HRS None None I-cell_type
cells None None I-cell_type
of None None O
most None None O
cases None None O
. None None O

In None None O
conclusion None None O
, None None O
( None None O
1 None None O
) None None O
somatic None None O
BCL-6 None None O
mutations None None O
are None None O
restricted None None O
to None None O
cHD None None O
cases None None O
of None None O
B-cell None None I-cell_type
origin None None O
, None None O
and None None O
( None None O
2 None None O
) None None O
the None None O
BCL-6 None None O
mutations None None O
represent None None O
mostly None None O
irrelevant None None O
somatic None None O
base None None O
substitutions None None O
without None None O
consequences None None O
for None None O
BCL-6 None None I-protein
protein None None I-protein
expression None None O
and None None O
the None None O
pathogenesis None None O
of None None O
cHD None None O
. None None O

Gadd45gamma None None I-DNA
is None None O
dispensable None None O
for None None O
normal None None O
mouse None None O
development None None O
and None None O
T-cell None None O
proliferation None None O
. None None O

Gadd45gamma None None I-DNA
, None None O
a None None O
family None None O
member None None O
of None None O
the None None O
growth None None I-DNA
arrest None None I-DNA
and None None I-DNA
DNA None None I-DNA
damage-inducible None None I-DNA
gene None None I-DNA
family None None I-DNA
45 None None I-DNA
( None None O
Gadd45 None None I-DNA
) None None O
, None None O
is None None O
strongly None None O
induced None None O
by None None O
interleukin-2 None None I-protein
( None None O
IL-2 None None I-protein
) None None O
in None None O
peripheral None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

While None None O
in None None O
most None None O
tissues None None O
all None None O
Gadd45 None None I-DNA
family None None I-DNA
members None None I-DNA
are None None O
expressed None None O
, None None O
Gadd45gamma None None I-DNA
is None None O
the None None O
only None None O
member None None O
that None None O
is None None O
induced None None O
by None None O
IL-2 None None I-protein
. None None O

Here None None O
we None None O
show None None O
that None None O
the None None O
IL-2 None None I-protein
-induced None None O
expression None None O
of None None O
Gadd45gamma None None I-DNA
is None None O
dependent None None O
on None None O
a None None O
signaling None None O
pathway None None O
mediated None None O
by None None O
the None None O
tyrosine None None I-protein
kinase None None I-protein
Jak3 None None I-protein
and None None O
the None None O
transcription None None I-protein
factors None None I-protein
Stat5a None None B-protein
and None None O
Stat5b None None I-protein
( None None O
signal None None I-protein
transducer None None I-protein
and None None I-protein
activator None None I-protein
of None None I-protein
transcription None None I-protein
) None None O
. None None O

Previous None None O
studies None None O
with None None O
ectopically None None O
overexpressed None None O
Gadd45gamma None None I-DNA
in None None O
various None None O
cell None None O
lines None None O
implicated None None O
its None None O
function None None O
in None None O
negative None None O
growth None None O
control None None O
. None None O

To None None O
analyze None None O
the None None O
physiological None None O
role None None O
of None None O
Gadd45gamma None None I-DNA
we None None O
used None None O
homologous None None O
recombination None None O
to None None O
generate None None O
mice None None O
lacking None None O
Gadd45gamma None None I-DNA
. None None O

Gadd45gamma None None I-DNA
-deficient None None O
mice None None O
develop None None O
normally None None O
, None None O
are None None O
indistinguishable None None O
from None None O
their None None O
littermates None None O
, None None O
and None None O
are None None O
fertile None None O
. None None O

Furthermore None None O
, None None O
hematopoiesis None None O
in None None O
mice None None O
lacking None None O
Gadd45gamma None None I-DNA
is None None O
not None None O
impaired None None O
and None None O
Gadd45gamma None None I-DNA
-deficient None None O
T None None I-cell_type
lymphocytes None None I-cell_type
show None None O
normal None None O
responses None None O
to None None O
IL-2 None None I-protein
. None None O

These None None O
data None None O
demonstrate None None O
that None None O
Gadd45gamma None None I-DNA
is None None O
not None None O
essential None None O
for None None O
normal None None O
mouse None None O
development None None O
and None None O
hematopoiesis None None O
, None None O
possibly None None O
due None None O
to None None O
functional None None O
redundancy None None O
among None None O
the None None O
Gadd45 None None I-DNA
family None None I-DNA
members None None I-DNA
. None None O

Gadd45gamma None None I-DNA
is None None O
also None None O
dispensable None None O
for None None O
IL-2 None None I-protein
-induced None None O
T-cell None None O
proliferation None None O
. None None O

Decreased None None O
expression None None O
of None None O
c-myc None None I-DNA
family None None I-DNA
genes None None I-DNA
in None None O
thymuses None None O
from None None O
myasthenia None None O
gravis None None O
patients None None O
. None None O

The None None O
thymus None None O
is None None O
a None None O
critical None None O
organ None None O
for None None O
the None None O
elimination None None O
of None None O
autoreactive None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
by None None O
apoptosis None None O
. None None O

We None None O
studied None None O
the None None O
expression None None O
of None None O
apoptosis-associated None None O
genes None None O
, None None O
bcl-xL None None I-DNA
, None None O
bad None None I-DNA
, None None O
caspase-3 None None I-DNA
, None None O
and None None O
c-myc None None I-DNA
family None None I-DNA
genes None None I-DNA
in None None O
myasthenia None None O
gravis None None O
( None None O
MG None None O
) None None O
thymuses None None O
. None None O

We None None O
observed None None O
that None None O
the None None O
mRNA None None O
levels None None O
of None None O
myc None None I-DNA
family None None I-DNA
genes None None I-DNA
, None None O
c-myc None None I-DNA
and None None O
max None None I-DNA
, None None O
were None None O
markedly None None O
reduced None None O
in None None O
MG None None O
thymuses None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
c-myc None None I-DNA
-mediated None None O
signaling None None O
is None None O
abnormal None None O
in None None O
MG None None O
thymuses None None O
. None None O

The None None O
levels None None O
of None None O
molecules None None O
whose None None O
expressions None None O
are None None O
associated None None O
with None None O
myc None None I-DNA
, None None O
such None None O
as None None O
STAM None None I-protein
, None None O
prothymosin-alpha None None I-protein
, None None O
and None None O
NFkappaB None None I-protein

Immunohistochemical None None O
detection None None O
of None None O
interferon-gamma-producing None None I-cell_type
cells None None I-cell_type
in None None O
dermatophytosis None None O
. None None O

Skin None None O
lesions None None O
of None None O
dermatophytosis None None O
are None None O
thought None None O
to None None O
be None None O
a None None O
result None None O
of None None O
a None None O
T None None I-cell_type
cell None None I-cell_type
-dependent None None O
inflammatory None None O
response None None O
that None None O
is None None O
mediated None None O
by None None O
various None None O
cytokines None None I-protein
. None None O

We None None O
examined None None O
whether None None O
IFN-gamma-positive None None I-cell_type
cells None None I-cell_type
( None None O
as None None O
expression None None O
of None None O
Th1 None None I-cell_type
response None None O
) None None O
were None None O
present None None O
in None None O
the None None O
skin None None O
lesions None None O
of None None O
dermatophytosis None None O
in None None O
situ None None O
by None None O
immunohistochemical None None O
techniques None None O
. None None O

Mixtures None None O
of None None O
CD4-positive None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
and None None O
CD8-positive None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
were None None O
found None None O
to None None O
be None None O
present None None O
in None None O
the None None O
dermal None None O
infiltrates None None O
of None None O
the None None O
lesions None None O
. None None O

Considerable None None O
numbers None None O
of None None O
CD1a-positive None None I-cell_type
cells None None I-cell_type
were None None O
detected None None O
in None None O
the None None O
upper None None O
dermis None None O
and None None O
epidermis None None O
. None None O

A None None O
marked None None O
accumulation None None O
of None None O
CD68-positive None None I-cell_type
cells None None I-cell_type
was None None O
found None None O
in None None O
the None None O
upper None None O
dermis None None O
. None None O

IFN-gamma-positive None None I-cell_type
cells None None I-cell_type
were None None O
present None None O
in None None O
the None None O
upper None None O
dermis None None O
of None None O
the None None O
lesions None None O
. None None O

The None None O
pattern None None O
of None None O
IFN-gamma None None I-protein
staining None None O
appeared None None O
to None None O
be None None O
intracellular None None O
in None None O
mononuclear None None I-cell_type
lymphoid None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
staining None None O
was None None O
considered None None O
to None None O
be None None O
highly None None O
specific None None O
because None None O
it None None O
could None None O
be None None O
completely None None O
blocked None None O
by None None O
preabsorption None None O
with None None O
recombinant None None I-protein
IFN-gamma None None I-protein
. None None O

Our None None O
data None None O
support None None O
the None None O
hypothesis None None O
that None None O
the None None O
skin None None O
lesions None None O
of None None O
dermatophytosis None None O
may None None O
be None None O
associated None None O
with None None O
a None None O
Th1 None None I-cell_type
response None None O
. None None O

Th1 None None I-cell_type
response None None O
, None None O
which None None O
is None None O
characterized None None O
by None None O
IFN-gamma None None I-protein
release None None O
, None None O
is None None O
thought None None O
to None None O
be None None O
involved None None O
in None None O
the None None O
host None None O
defense None None O
against None None O
dermatophytes None None O
and None None O
to None None O
reflect None None O
cutaneous None None O
reaction None None O
in None None O
dermatophytosis None None O
. None None O

Regulation None None O
of None None O
the None None O
helix-loop-helix None None I-protein
proteins None None I-protein
, None None O
E2A None None I-protein
and None None O
Id3 None None I-protein
, None None O
by None None O
the None None O
Ras None None I-protein
- None None O
ERK None None I-protein
MAPK None None B-protein
cascade None None O
. None None O

Activation None None O
of None None O
mitogen-activated None None I-protein
protein None None I-protein
kinase None None I-protein
( None None O
MAPK None None I-protein
) None None O
pathways None None O
leads None None O
to None None O
cellular None None O
differentiation None None O
and/or None None O
proliferation None None O
in None None O
a None None O
wide None None O
variety None None O
of None None O
cell None None O
types None None O
, None None O
including None None O
developing None None I-cell_type
thymocytes None None I-cell_type
. None None O

The None None O
basic None None I-protein
helix-loop-helix None None I-protein
( None None I-protein
bHLH None None I-protein
) None None I-protein
proteins None None I-protein
E12 None None B-protein
and None None O
E47 None None I-protein
and None None O
an None None O
inhibitor None None I-protein
HLH None None I-protein
protein None None I-protein
, None None O
Id3 None None I-protein
, None None O
play None None O
key None None O
roles None None O
in None None O
thymocyte None None O
differentiation None None O
. None None O

We None None O
show None None O
here None None O
that None None O
E2A None None I-protein
DNA None None O
binding None None O
is None None O
lowered None None O
in None None O
primary None None I-cell_type
immature None None I-cell_type
thymocytes None None I-cell_type
consequent None None O
to None None O
T None None O
cell None None O
receptor None None O
( None None O
TCR None None O
) None None O
-mediated None None O
ligation None None O
. None None O

Whereas None None O
expression None None O
of None None O
E2A None None O
mRNA None None O
and None None O
protein None None O
are None None O
unaltered None None O
, None None O
Id3 None None I-RNA
transcripts None None I-RNA
are None None O
rapidly None None O
induced None None O
upon None None O
signaling None None O
from None None O
the None None O
TCR None None I-protein
. None None O

Activation None None O
of None None O
Id3 None None O
transcription None None O
is None None O
regulated None None O
in None None O
a None None O
dose-dependent None None O
manner None None O
by None None O
the None None O
extracellular None None O
signal-regulated None None O
kinase None None O
( None None O
ERK None None I-protein
) None None O
MAPK None None I-protein
module None None O
. None None O

These None None O
observations None None O
directly None None O
connect None None O
the None None O
ERK None None I-protein
MAPK None None B-protein
cascade None None O
and None None O
HLH None None I-protein
proteins None None I-protein
in None None O
a None None O
linear None None O
pathway None None O
. None None O

Retinoic None None O
acid None None O
up-regulates None None O
myeloid None None O
ICAM-3 None None O
expression None None O
and None None O
function None None O
in None None O
a None None O
cell-specific None None O
fashion None None O
-- None None O
evidence None None O
for None None O
retinoid None None O
signaling None None O
pathways None None O
in None None O
the None None O
mast None None I-cell_type
cell None None I-cell_type
lineage None None I-cell_type
. None None O

Investigation None None O
of None None O
mast None None O
cell None None O
responsiveness None None O
toward None None O
retinoic None None O
acid None None O
( None None O
RA None None O
) None None O
revealed None None O
selective None None O
promotion None None O
of None None O
ICAM-3 None None I-protein
expression None None O
in None None O
the None None O
human None None I-cell_line
mast None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
HMC-1 None None I-cell_line
. None None O

This None None O
process None None O
was None None O
dose- None None O
and None None O
time-dependent None None O
and None None O
detectable None None O
by None None O
flow None None O
cytometry None None O
, None None O
Western None None O
blot None None O
analysis None None O
, None None O
ELISA None None O
, None None O
and None None O
Northern None None O
blot None None O
analysis None None O
. None None O

ICAM-3 None None I-protein
modulation None None O
was None None O
found None None O
to None None O
be None None O
cell-type None None O
dependent None None O
, None None O
detectable None None O
also None None O
for None None O
HL-60 None None I-cell_line
cells None None I-cell_line
and None None O
monocytes None None I-cell_type
but None None O
not None None O
U-937 None None I-cell_line
and None None O
only None None O
weakly None None O
for None None O
KU812 None None I-cell_line
cells None None I-cell_line
. None None O

Terminally None None I-cell_type
differentiated None None I-cell_type
skin None None I-cell_type
mast None None I-cell_type
cells None None I-cell_type
also None None O
failed None None O
to None None O
up-modulate None None O
their None None O
ICAM-3 None None I-protein
, None None O
suggesting None None O
the None None O
requirement None None O
for None None O
some None None O
degree None None O
of None None O
immaturity None None O
for None None O
the None None O
process None None O
. None None O

RA-mediated None None O
effects None None O
on None None O
ICAM-1 None None I-protein
expression None None O
, None None O
studied None None O
in None None O
parallel None None O
, None None O
were None None O
clearly None None O
distinct None None O
from None None O
those None None O
on None None O
ICAM-3 None None I-protein
. None None O

Investigation None None O
of None None O
retinoid None None I-protein
receptor None None I-protein
expression None None O
, None None O
known None None O
to None None O
mediate None None O
intracellular None None O
RA None None O
signaling None None O
, None None O
revealed None None O
presence None None O
of None None O
RAR None None I-RNA
alpha None None I-RNA
, None None I-RNA
RAR None None I-RNA
gamma None None I-RNA
, None None I-RNA
RXR None None I-RNA
beta None None I-RNA
, None None I-RNA
and None None I-RNA
RXR None None I-RNA
gamma None None I-RNA
transcripts None None I-RNA
in None None O
all None None O
cell None None O
lines None None O
studied None None O
, None None O
and None None O
HMC-1 None None I-cell_line
cells None None I-cell_line
were None None O
the None None O
only None None O
line None None O
lacking None None O
RXR None None I-protein
alpha None None I-protein
. None None O

RAR None None I-protein
beta None None I-protein
, None None O
not None None O
expressed None None O
at None None O
baseline None None O
, None None O
was None None O
induced None None O
by None None O
RA None None O
in None None O
a None None O
fashion None None O
obviously None None O
correlating None None O
with None None O
ICAM-3 None None I-protein
up-regulation None None O
. None None O

Increased None None O
ICAM-3 None None I-protein
expression None None O
was None None O
of None None O
functional None None O
significance None None O
, None None O
such None None O
that None None O
processes None None O
stimulated None None O
or None None O
co-stimulated None None O
via None None O
ICAM-3 None None I-protein
( None None O
homotypic None None O
aggregation None None O
, None None O
IL-8 None None O
secretion None None O
) None None O
were None None O
clearly None None O
enhanced None None O
upon None None O
RA None None O
pretreatment None None O
, None None O
suggesting None None O
that None None O
RA None None O
may None None O
contribute None None O
via None None O
hitherto None None O
unrecognized None None O
pathways None None O
to None None O
immune None None O
function None None O
and None None O
host None None O
defense None None O
. None None O

CD28 None None I-protein
and None None O
T None None I-cell_type
cell None None I-cell_type
co-stimulation None None O
. None None O

Over None None O
the None None O
last None None O
decade None None O
the None None O
concept None None O
of None None O
T None None I-cell_type
cell None None I-cell_type
co-stimulation None None O
has None None O
emerged None None O
to None None O
take None None O
a None None O
central None None O
role None None O
in None None O
the None None O
process None None O
of None None O
T None None O
cell None None O
activation None None O
. None None O

However None None O
, None None O
the None None O
exact None None O
definition None None O
of None None O
co-stimulation None None O
is None None O
still None None O
unclear None None O
. None None O

In None None O
this None None O
review None None O
, None None O
we None None O
re-examine None None O
the None None O
concept None None O
of None None O
co-stimulation None None O
. None None O

We None None O
suggest None None O
that None None O
while None None O
co-stimulation None None O
is None None O
important None None O
, None None O
there None None O
is None None O
little None None O
evidence None None O
to None None O
link None None O
co-stimulation None None O
with None None O
T None None I-cell_type
cell None None I-cell_type
anergy None None O
. None None O

We None None O
then None None O
suggest None None O
a None None O
framework None None O
for None None O
studying None None O
co-stimulation None None O
. None None O

Focusing None None O
on None None O
recent None None O
advances None None O
in None None O
our None None O
understanding None None O
of None None O
CD28 None None I-protein
, None None O
we None None O
discuss None None O
four None None O
areas None None O
of None None O
T None None I-cell_type
cell None None I-cell_type
activation None None O
where None None O
co-stimulation None None O
may None None O
play None None O
a None None O
role None None O
. None None O

Regulation None None O
of None None O
activator None None I-protein
protein-1 None None I-protein
and None None O
NF-kappa None None I-protein
B None None I-protein
in None None O
CD8+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
exposed None None O
to None None O
peripheral None None I-protein
self-antigens None None I-protein
. None None O

The None None O
transcriptional None None O
events None None O
that None None O
control None None O
T None None I-cell_type
cell None None I-cell_type
tolerance None None O
to None None O
peripheral None None I-protein
self None None I-protein
Ags None None I-protein
are None None O
still None None O
unknown None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
analyzed None None O
the None None O
regulation None None O
of None None O
AP-1 None None I-protein
- None None O
and None None O
NF-kappa None None I-protein
B None None I-protein
-mediated None None O
transcription None None O
during None None O
in None None O
vivo None None O
induction None None O
of None None O
tolerance None None O
to None None O
a None None O
self None None I-protein
Ag None None I-protein
expressed None None O
exclusively None None O
on None None O
hepatocytes None None I-cell_type
. None None O

Naive None None I-cell_type
CD8 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
Desire None None I-cell_type
( None None I-cell_type
Des None None I-cell_type
) None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
isolated None None O
from None None O
the None None O
Des None None O
TCR-transgenic None None O
mice None None O
that None None O
are None None O
specific None None O
for None None O
the None None O
H-2K None None I-protein
( None None I-protein
b None None I-protein
) None None I-protein
class None None I-protein
I None None I-protein
Ag None None I-protein
were None None O
transferred None None O
into None None O
Alb-K None None O
( None None O
b None None O
) None None O
-transgenic None None O
mice None None O
that None None O
express None None O
the None None O
H-2K None None I-protein
( None None I-protein
b None None I-protein
) None None I-protein
Ag None None I-protein
on None None O
hepatocytes None None I-cell_type
only None None O
. None None O

Tolerance None None O
develops None None O
in None None O
these None None O
mice None None O
. None None O

We None None O
found None None O
that None None O
the None None O
self-reactive None None I-cell_type
CD8 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
Des None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
were None None O
transiently None None O
activated None None O
, None None O
then None None O
became None None O
unresponsive None None O
and None None O
were None None O
further None None O
deleted None None O
. None None O

In None None O
contrast None None O
to None None O
CD8 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
Des None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
activated None None O
in None None O
vivo None None O
with None None O
APCs None None O
, None None O
which None None O
express None None O
high None None O
AP-1 None None I-protein
and None None O
high None None O
NF-kappa None None I-protein
B None None I-protein
transcriptional None None O
activity None None O
, None None O
the None None O
unresponsive None None O
CD8 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
Des None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
expressed None None O
no None None O
AP-1 None None I-protein
and None None O
only None None O
weak None None O
NF-kappa None None I-protein
B None None I-protein
transcriptional None None O
activity None None O
. None None O

The None None O
differences None None O
in None None O
NF-kappa None None I-protein
B None None I-protein
transcriptional None None O
activity None None O
correlated None None O
with None None O
the None None O
generation None None O
of None None O
distinct None None O
NF-kappa None None I-protein
B None None I-protein
complexes None None I-protein
. None None O

Indeed None None O
, None None O
in None None O
vivo None None O
primed None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
predominantly None None O
express None None O
p50/p50 None None I-protein
and None None I-protein
p65/p50 None None I-protein
dimers None None I-protein
, None None O
whereas None None O
these None None O
p50-containing None None I-protein
complexes None None I-protein
are None None O
barely None None O
detectable None None O
in None None O
tolerant None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
that None None O
express None None O
p65- None None I-protein
and None None I-protein
c-Rel-containing None None I-protein
complexes None None I-protein
. None None O

These None None O
observations None None O
suggest None None O
that None None O
fine None None O
regulation None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
complex None None I-protein
formation None None O
may None None O
determine None None O
T None None I-cell_type
cell None None I-cell_type
fate None None O
. None None O

Transcriptional None None O
regulation None None O
in None None O
lymphocytes None None I-cell_type
. None None O

Lymphocytes None None I-cell_type
have None None O
been None None O
used None None O
to None None O
investigate None None O
many None None O
cellular None None O
processes None None O
, None None O
including None None O
lineage None None O
commitment None None O
, None None O
differentiation None None O
, None None O
proliferation None None O
and None None O
apoptosis None None O
. None None O

The None None O
transcription None None I-protein
factors None None I-protein
that None None O
mediate None None O
these None None O
processes None None O
are None None O
often None None O
expressed None None O
broadly None None O
in None None O
many None None O
cell None None O
types None None O
. None None O

The None None O
emerging None None O
theme None None O
is None None O
one None None O
of None None O
cell-type-specific None None O
regulation None None O
, None None O
affecting None None O
not None None O
only None None O
the None None O
functional None None O
activation None None O
of None None O
transcription None None I-protein
factors None None I-protein
but None None O
also None None O
their None None O
access None None O
to None None O
appropriate None None O
regions None None O
of None None O
DNA None None O
. None None O

Existence None None O
of None None O
retinoic None None I-protein
acid-receptor None None I-protein
-independent None None O
retinoid None None I-protein
X-receptor None None I-protein
-dependent None None O
pathway None None O
in None None O
myeloid None None I-cell_type
cell None None I-cell_type
function None None O
. None None O

We None None O
previously None None O
reported None None O
that None None O
ER-27191 None None O
( None None O
4- None None O
[ None None O
4 None None O
, None None O
5 None None O
, None None O
7 None None O
, None None O
8 None None O
, None None O
9 None None O
, None None O
10-hexahydro-7 None None O
, None None O
7 None None O
, None None O
10 None None O
, None None O
10-tetramethyl-1- None None O
( None None O
3-pyridylmethyl None None O
) None None O
anthra None None O
[ None None O
1 None None O
, None None O
2-b None None O
] None None O
pyrrol-3-yl None None O
] None None O
benzoic None None O
acid None None O
) None None O
is None None O
a None None O
potent None None O
antagonist None None O
of None None O
retinoic None None I-protein
acid None None I-protein
receptor None None I-protein
( None None O
RAR None None I-protein
) None None O
, None None O
and None None O
ER-35795 None None O
( None None O
( None None O
2E None None O
, None None O
4E None None O
, None None O
6E None None O
) None None O
-7- None None O
[ None None O
1- None None O
( None None O
1-methylethyl None None O
) None None O
-8-chloro-1 None None O
, None None O
2 None None O
, None None O
3 None None O
, None None O
4-tetrahydroquinolin-6-yl None None O
] None None O
-6-fluoro-3-methyl-2 None None O
, None None O
4 None None O
, None None O
6-nonatrienoic None None O
acid None None O
) None None O
is None None O
a None None O
novel None None O
retinoid None None I-protein
X None None I-protein
receptor None None I-protein
( None None O
RXR None None I-protein
) None None O
-specific None None O
agonist None None O
. None None O

By None None O
using None None O
these None None O
compounds None None O
, None None O
we None None O
investigated None None O
whether None None O
distinct None None O
RAR None None I-protein
-dependent None None O
and None None O
RXR None None I-protein
-dependent None None O
pathways None None O
operate None None O
to None None O
mediate None None O
the None None O
diverse None None O
activities None None O
of None None O
retinoids None None O
, None None O
particularly None None O
, None None O
the None None O
effects None None O
of None None O
the None None O
RXR None None I-protein
pathway None None O
on None None O
cellular None None O
function None None O
. None None O

ER-27191 None None O
completely None None O
antagonized None None O
HL60 None None I-cell_line
cell None None I-cell_line
differentiation None None O
induced None None O
by None None O
all-trans-retinoic None None O
acid None None O
( None None O
atRA None None O
) None None O
. None None O

However None None O
, None None O
the None None O
differentiation None None O
induced None None O
by None None O
the None None O
ER-35795 None None O
was None None O
not None None O
antagonized None None O
at None None O
all None None O
by None None O
the None None O
RAR None None I-protein
antagonist None None O
, None None O
but None None O
was None None O
inhibited None None O
by None None O
an None None O
RXR None None I-protein
homodimer None None I-protein
antagonist None None O
( None None O
LGD100754 None None O
, None None O
( None None O
2E None None O
, None None O
4E None None O
, None None O
6Z None None O
) None None O
-7- None None O
( None None O
3-n-propoxy-5 None None O
, None None O
6 None None O
, None None O
7 None None O
, None None O
8-tetrahydro-5 None None O
, None None O
5 None None O
, None None O
8 None None O
, None None O
8-tetramethylnaphthalen-2-yl None None O
) None None O
-3-methylocta-2 None None O
, None None O
4 None None O
, None None O
6-trienoic None None O
acid None None O
) None None O
. None None O

Its None None O
agonistic None None O
action None None O
on None None O
RXR/RAR None None I-protein
heterodimer None None I-protein
, None None O
on None None O
the None None O
other None None O
hand None None O
, None None O
was None None O
neutralized None None O
by None None O
the None None O
RAR None None I-protein
antagonist None None O
. None None O

During None None O
HL60 None None I-cell_line
cell None None I-cell_line
differentiation None None O
, None None O
atRA None None O
induced None None O
RARbeta None None I-RNA
mRNA None None I-RNA
, None None O
while None None O
the None None O
RXR None None I-protein
had None None O
no None None O
effect None None O
. None None O

Interestingly None None O
, None None O
a None None O
functional None None O
RXR None None I-protein
-pathway None None O
was None None O
also None None O
seen None None O
in None None O
lipopolysaccharide-induced None None O
inhibition None None O
of None None O
mouse None None I-cell_type
splenocyte None None I-cell_type
proliferation None None O
. None None O

These None None O
results None None O
strongly None None O
suggest None None O
the None None O
existence None None O
of None None O
a None None O
pharmacological None None O
RXR None None I-protein
-dependent None None O
pathway None None O
that None None O
is None None O
activated None None O
by None None O
a None None O
ligand None None O
that None None O
can None None O
bind None None O
to None None O
RXR None None I-protein
. None None O

Targeting None None O
Src None None I-protein
homology None None I-protein
2 None None I-protein
domain-containing None None I-protein
tyrosine None None I-protein
phosphatase None None I-protein
( None None O
SHP-1 None None I-protein
) None None O
into None None O
lipid None None O
rafts None None O
inhibits None None O
CD3 None None I-protein
-induced None None O
T None None I-cell_type
cell None None I-cell_type
activation None None O
. None None O

To None None O
study None None O
the None None O
mechanism None None O
by None None O
which None None O
protein None None I-protein
tyrosine None None I-protein
phosphatases None None I-protein
( None None O
PTPs None None I-protein
) None None O
regulate None None O
CD3 None None I-protein
-induced None None O
tyrosine None None O
phosphorylation None None O
, None None O
we None None O
investigated None None O
the None None O
distribution None None O
of None None O
PTPs None None I-protein
in None None O
subdomains None None O
of None None O
plasma None None O
membrane None None O
. None None O

We None None O
report None None O
here None None O
that None None O
the None None O
bulk None None O
PTP None None I-protein
activity None None O
associated None None O
with None None O
T None None I-cell_type
cell None None I-cell_type
membrane None None O
is None None O
present None None O
outside None None O
the None None O
lipid None None O
rafts None None O
, None None O
as None None O
determined None None O
by None None O
sucrose None None O
density None None O
gradient None None O
sedimentation None None O
. None None O

In None None O
Jurkat None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
, None None O
approximately None None O
5 None None O
-- None None O
10 None None O
% None None O
of None None O
Src None None I-protein
homology None None I-protein
2 None None I-protein
domain-containing None None I-protein
tyrosine None None I-protein
phosphatase None None I-protein
( None None O
SHP-1 None None I-protein
) None None O
is None None O
constitutively None None O
associated None None O
with None None O
plasma None None O
membrane None None O
, None None O
and None None O
nearly None None O
50 None None O
% None None O
of None None O
SHP-2 None None I-protein
is None None O
translocated None None O
to None None O
plasma None None O
membrane None None O
after None None O
vanadate None None O
treatment None None O
. None None O

Similar None None O
to None None O
transmembrane None None I-protein
PTP None None I-protein
, None None O
CD45 None None I-protein
, None None O
the None None O
membrane-associated None None O
populations None None O
of None None O
SHP-1 None None I-protein
and None None O
SHP-2 None None I-protein
are None None O
essentially None None O
excluded None None O
from None None O
lipid None None O
rafts None None O
, None None O
where None None O
other None None O
signaling None None I-protein
molecules None None I-protein
such None None O
as None None O
Lck None None I-protein
, None None I-protein
linker None None I-protein
for None None I-protein
activation None None I-protein
of None None I-protein
T None None I-protein
cells None None I-protein
, None None O
and None None O
CD3 None None I-protein
zeta None None I-protein
are None None O
enriched None None O
. None None O

We None None O
further None None O
demonstrated None None O
that None None O
CD3 None None I-protein
-induced None None O
tyrosine None None O
phosphorylation None None O
of None None O
these None None O
substrates None None O
is None None O
largely None None O
restricted None None O
to None None O
lipid None None O
rafts None None O
, None None O
unless None None O
PTPs None None I-protein
are None None O
inhibited None None O
. None None O

It None None O
suggests None None O
that None None O
a None None O
restricted None None O
partition None None O
of None None O
PTPs None None I-protein
among None None O
membrane None None O
subdomains None None O
may None None O
regulate None None O
protein None None O
tyrosine None None O
phosphorylation None None O
in None None O
T None None I-cell_type
cell None None I-cell_type
membrane None None O
. None None O

To None None O
test None None O
this None None O
hypothesis None None O
, None None O
we None None O
targeted None None O
SHP-1 None None I-protein
into None None O
lipid None None O
rafts None None O
by None None O
using None None O
the None None O
N-terminal None None I-protein
region None None I-protein
of None None I-protein
Lck None None I-protein
( None None O
residues None None I-protein
1 None None I-protein
-- None None I-protein
14 None None I-protein
) None None O
. None None O

The None None O
results None None O
indicate None None O
that None None O
the None None O
expression None None O
of None None O
Lck/SHP-1 None None I-protein
chimera None None I-protein
inside None None O
lipid None None O
rafts None None O
profoundly None None O
inhibits None None O
CD3 None None I-protein
-induced None None O
tyrosine None None O
phosphorylation None None O
of None None O
CD3 None None I-protein
zeta/epsilon None None I-protein
, None None O
IL-2 None None O
generation None None O
, None None O
and None None O
nuclear None None O
mobilization None None O
of None None O
NF-AT None None I-protein
. None None O

Collectively None None O
, None None O
these None None O
results None None O
suggest None None O
that None None O
the None None O
exclusion None None O
of None None O
PTPs None None I-protein
from None None O
lipid None None O
rafts None None O
may None None O
be None None O
a None None O
mechanism None None O
that None None O
potentiates None None O
TCR None None I-protein
/ None None O
CD3 None None I-protein
activation None None O

An None None O
instructive None None O
component None None O
in None None O
T None None I-cell_type
helper None None I-cell_type
cell None None I-cell_type
type None None I-cell_type
2 None None I-cell_type
( None None O
Th2 None None I-cell_type
) None None O
development None None O
mediated None None O
by None None O
GATA-3 None None I-protein
. None None O

Although None None O
interleukin None None I-protein
( None None I-protein
IL None None I-protein
) None None I-protein
-12 None None I-protein
and None None O
IL-4 None None I-protein
polarize None None O
naive None None I-cell_type
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
toward None None O
T None None O
helper None None O
cell None None O
type None None O
1 None None O
( None None O
Th1 None None O
) None None O
or None None O
Th2 None None O
phenotypes None None O
, None None O
it None None O
is None None O
not None None O
known None None O
whether None None O
cytokines None None I-protein
instruct None None O
the None None O
developmental None None O
fate None None O
in None None O
uncommitted None None I-cell_type
progenitors None None I-cell_type
or None None O
select None None O
for None None O
outgrowth None None O
of None None O
cells None None O
that None None O
have None None O
stochastically None None O
committed None None O
to None None O
a None None O
particular None None O
fate None None O
. None None O

To None None O
distinguish None None O
these None None O
instructive None None O
and None None O
selective None None O
models None None O
, None None O
we None None O
used None None O
surface None None O
affinity None None O
matrix None None O
technology None None O
to None None O
isolate None None O
committed None None I-cell_type
progenitors None None I-cell_type
based None None O
on None None O
cytokine None None O
secretion None None O
phenotype None None O
and None None O
developed None None O
retroviral-based None None O
tagging None None O
approaches None None O
to None None O
directly None None O
monitor None None O
individual None None O
progenitor None None O
fate None None O
decisions None None O
at None None O
the None None O
clonal None None O
and None None O
population None None O
levels None None O
. None None O

We None None O
observe None None O
IL-4 None None I-protein
-dependent None None O
redirection None None O
of None None O
phenotype None None O
in None None O
cells None None O
that None None O
have None None O
already None None O
committed None None O
to None None O
a None None O
non-IL-4-producing None None O
fate None None O
, None None O
inconsistent None None O
with None None O
predictions None None O
of None None O
the None None O
selective None None O
model None None O
. None None O

Further None None O
, None None O
retroviral None None O
tagging None None O
of None None O
naive None None I-cell_type
progenitors None None I-cell_type
with None None O
the None None O
Th2-specific None None I-protein
transcription None None I-protein
factor None None I-protein
GATA-3 None None I-protein
provided None None O
direct None None O
evidence None None O
for None None O
instructive None None O
differentiation None None O
, None None O
and None None O
no None None O
evidence None None O
for None None O
the None None O
selective None None O
outgrowth None None O
of None None O
cells None None O
committed None None O
to None None O
either None None O
the None None O
Th1 None None O
or None None O
Th2 None None O
fate None None O
. None None O

These None None O
data None None O
would None None O
seem None None O
to None None O
exclude None None O
selection None None O
as None None O
an None None O
exclusive None None O
mechanism None None O
in None None O
Th1 None None I-cell_type
/ None None O
Th2 None None I-cell_type
differentiation None None O
, None None O
and None None O
support None None O
an None None O
instructive None None O
model None None O
of None None O
cytokine-driven None None O
transcriptional None None O
programming None None O
of None None O
cell None None O
fate None None O
decisions None None O
. None None O

In None None O
vitro-activated None None O
human None None I-cell_type
lupus None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
express None None O
normal None None O
estrogen None None I-protein
receptor None None I-protein
proteins None None I-protein
which None None O
bind None None O
to None None O
the None None O
estrogen None None I-protein
response None None I-protein
element None None I-protein
. None None O

We None None O
have None None O
shown None None O
that None None O
estrogen None None I-protein
receptor None None I-protein
( None None O
ERalpha None None I-protein
, None None O
ERbeta None None I-protein
) None None O
transcripts None None O
are None None O
expressed None None O
in None None O
SLE None None I-cell_type
and None None I-cell_type
normal None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

In None None O
this None None O
study None None O
, None None O
T None None O
cell None None O
nuclear None None O
extracts None None O
from None None O
female None None O
lupus None None O
patients None None O
and None None O
normal None None O
donors None None O
were None None O
tested None None O
for None None O
biologically None None O
active None None O
ER None None I-protein
proteins None None I-protein
capable None None O
of None None O
binding None None O
to None None O
the None None O
human None None I-DNA
estrogen None None I-DNA
response None None I-DNA
element None None I-DNA
( None None O
hERE None None I-DNA
) None None O
by None None O
electrophoretic None None O
mobility None None O
shift None None O
assays None None O
. None None O

When None None O
peripheral None None I-cell_type
blood None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
were None None O
stimulated None None O
with None None O
17beta-estradiol None None O
( None None O
E2 None None O
) None None O
, None None O
PMA None None O
and None None O
ionomycin None None O
, None None O
two None None O
major None None O
retarded None None O
bands None None O
in None None O
T None None O
cell None None O
nuclear None None O
extracts None None O
exhibited None None O
a None None O
migration None None O
pattern None None O
similar None None O
to None None O
slow None None O
migrating None None O
protein-ERE None None I-protein
complexes None None I-protein
in None None O
human None None O
breast None None O
cancer None None O
cell None None O
extracts None None O
. None None O

T None None I-cell_type
cells None None I-cell_type
cultured None None O
only None None O
with None None O
E2 None None O
did None None O
not None None O
have None None O
these None None O
complexes None None O
. None None O

The None None O
formation None None O
of None None O
the None None O
complexes None None O
was None None O
inhibited None None O
by None None O
competition None None O
with None None O
the None None O
hERE None None O
cold None None O
oligonucleotide None None O
and None None O
partially None None O
with None None O
anti-ERalpha None None I-protein
antibodies None None I-protein
. None None O

There None None O
was None None O
no None None O
notable None None O
difference None None O
in None None O
the None None O
migration None None O
pattern None None O
of None None O
ERE-binding None None I-protein
proteins None None I-protein
between None None O
the None None O
SLE None None O
and None None O
normal None None O
T None None O
cell None None O
extracts None None O
. None None O

Together None None O
, None None O
these None None O
results None None O
suggest None None O
that None None O
activated None None I-cell_type
human None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
, None None O
whether None None O
lupus-derived None None O
or None None O
normal-derived None None O
, None None O
contain None None O
biologically None None O
active None None O
ERalpha None None I-protein
proteins None None I-protein
. None None O

Other None None O
factors None None O
may None None O
be None None O
responsible None None O
for None None O
differential None None O
sensitivity None None O
of None None O
lupus None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
to None None O
estrogen None None O
. None None O

Mechanism None None O
of None None O
the None None O
inhibitory None None O
effect None None O
of None None O
protease None None O
inhibitor None None O
on None None O
tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
alpha None None I-protein
production None None O
of None None O
monocytes None None I-cell_type
. None None O

If None None O
the None None O
inflammatory None None O
response None None O
becomes None None O
excessive None None O
or None None O
uncontrolled None None O
by None None O
some None None O
stimuli None None O
, None None O
inappropriate None None O
inflammatory None None O
responses None None O
occur None None O
. None None O

Monocytes None None I-cell_type
are None None O
extremely None None O
important None None O
cells None None O
for None None O
regulating None None O
the None None O
cytokine None None O
network None None O
and None None O
tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
alpha None None I-protein
( None None O
TNFalpha None None I-protein
) None None O
and None None O
interleukin- None None I-protein
( None None I-protein
IL None None I-protein
) None None I-protein
10 None None I-protein
, None None O
which None None O
are None None O
mainly None None O
synthesized None None O
by None None O
monocytes None None I-cell_type
, None None O
are None None O
representative None None O
cytokines None None I-protein
that None None O
play None None O
a None None O
central None None O
role None None O
in None None O
the None None O
cytokine None None O
network None None O
. None None O

Protease None None O
inhibitors None None O
such None None O
as None None O
gabexate None None O
mesilate None None O
( None None O
GM None None O
) None None O
and None None O
ulinastatin None None O
( None None O
UTI None None O
) None None O
have None None O
been None None O
shown None None O
to None None O
have None None O
various None None O
beneficial None None O
effects None None O
by None None O
inhibiting None None O
the None None O
activation None None O
of None None O
leukocytes None None I-cell_type
, None None O
but None None O
the None None O
mechanism None None O
for None None O
this None None O
has None None O
yet None None O
to None None O
be None None O
fully None None O
elucidated None None O
. None None O

In None None O
this None None O
study None None O
we None None O
investigated None None O
the None None O
mechanism None None O
of None None O
the None None O
inhibitory None None O
effect None None O
of None None O
protease None None O
inhibitors None None O
on None None O
the None None O
proinflammatory None None O
cytokine None None O
production None None O
of None None O
lipopolysaccharide- None None O
( None None O
LPS None None O
) None None O
stimulated None None O
monocytes None None I-cell_type
. None None O

LPS-stimulated None None O
monocytes None None I-cell_type
were None None O
treated None None O
with None None O
GM None None O
or None None O
UTI None None O
. None None O

The None None O
value None None O
of None None O
TNFalpha None None I-protein
and None None O
IL-10 None None I-protein
in None None O
the None None O
culture None None O
medium None None O
of None None O
monocytes None None I-cell_type
was None None O
measured None None O
and None None O
each None None O
mRNA None None O
expression None None O
was None None O
assayed None None O
. None None O

The None None O
inhibitory None None O
effect None None O
of None None O
protease None None O
inhibitors None None O
on None None O
the None None O
activity None None O
of None None O
intracellular None None O
signal None None O
transduction None None O
pathways None None O
such None None O
as None None O
protein None None I-protein
kinase None None I-protein
C None None I-protein
( None None O
PKC None None I-protein
) None None O
and None None O
nuclear None None I-protein
factor None None I-protein
kappa None None I-protein
B None None I-protein
( None None O
NFkappaB None None I-protein
) None None O
were None None O
also None None O
evaluated None None O
. None None O

GM None None O
decreased None None O
the None None O
TNFalpha None None I-protein
production None None O
of None None O
LPS-stimulated None None O
monocytes None None I-cell_type
as None None O
shown None None O
by None None O
the None None O
inhibition None None O
of None None O
mRNA None None O
expression None None O
and None None O
increased None None O
the None None O
IL-10 None None I-protein
production None None O
of None None O
LPS-stimulated None None O
monocytes None None I-cell_type
. None None O

GM None None O
also None None O
suppressed None None O
the None None O
NFkappaB None None I-protein
activity None None O
of None None O
LPS-stimulated None None O
monocytes None None I-cell_type
. None None O

UTI None None O
decreased None None O
the None None O
TNFalpha None None I-protein
production None None O
of None None O
LPS-stimulated None None O
monocytes None None I-cell_type
, None None O
but None None O
did None None O
not None None O
inhibit None None O
the None None O
TNFalpha None None I-RNA
mRNA None None I-RNA
expression None None O
. None None O

The None None O
present None None O
study None None O
shows None None O
that None None O
the None None O
inhibitory None None O
effect None None O
of None None O
GM None None O
on None None O
the None None O
TNFalpha None None I-protein
production None None O
of None None O
activated None None O
human None None I-cell_type
monocytes None None I-cell_type
is None None O
mediated None None O
by None None O
the None None O
suppression None None O
of None None O
NFkappaB None None I-protein
activation None None O
, None None O
while None None O
the None None O
mechanism None None O
of None None O
UTI None None O
inhibiting None None O
TNFalpha None None I-protein
production None None O
of None None O
human None None I-cell_type
monocytes None None I-cell_type
may None None O
be None None O
due None None O
to None None O
the None None O
inhibition None None O
of None None O
either None None O
the None None O
translation None None O
or None None O
secretion None None O
of None None O
TNFalpha None None I-protein
. None None O

Homocysteine None None O
stimulates None None O
the None None O
expression None None O
of None None O
monocyte None None I-protein
chemoattractant None None I-protein
protein-1 None None I-protein
in None None O
endothelial None None I-cell_type
cells None None I-cell_type
leading None None O
to None None O
enhanced None None O
monocyte None None O
chemotaxis None None O
. None None O

Hyperhomocysteinemia None None O
has None None O
been None None O
identified None None O
as None None O
an None None O
independent None None O
risk None None O
factor None None O
for None None O
atherosclerosis None None O
. None None O

The None None O
infiltration None None O
of None None O
monocytes None None I-cell_type
into None None O
the None None O
arterial None None O
wall None None O
is None None O
one None None O
of None None O
the None None O
key None None O
events None None O
during None None O
atherogenesis None None O
. None None O

Monocyte None None I-protein
chemoattractant None None I-protein
protein-1 None None I-protein
( None None O
MCP-1 None None I-protein
) None None O
is None None O
a None None O
potent None None O
chemokine None None I-protein
that None None O
stimulates None None O
the None None O
migration None None O
of None None O
monocytes None None I-cell_type
into None None O
the None None O
intima None None O
of None None O
the None None O
arterial None None O
wall None None O
. None None O

The None None O
mechanism None None O
by None None O
which None None O
increased None None O
monocyte None None O
infiltration None None O
occurs None None O
in None None O
atherosclerotic None None O
lesions None None O
in None None O
patients None None O
with None None O
hyperhomocysteinemia None None O
has None None O
not None None O
been None None O
delineated None None O
. None None O

The None None O
objective None None O
of None None O
the None None O
present None None O
study None None O
was None None O
to None None O
investigate None None O
the None None O
effect None None O
of None None O
homocysteine None None O
on None None O
MCP-1 None None I-protein
production None None O
in None None O
endothelial None None I-cell_type
cells None None I-cell_type
. None None O

Cells None None O
were None None O
incubated None None O
with None None O
homocysteine None None O
. None None O

The None None O
secretion None None O
of None None O
MCP-1 None None I-protein
protein None None I-protein
was None None O
significantly None None O
increased None None O
( None None O
195 None None O
% None None O
as None None O
compared None None O
to None None O
the None None O
control None None O
) None None O
in None None O
cells None None O
treated None None O
with None None O
pathological None None O
concentrations None None O
of None None O
homocysteine None None O
. None None O

Such None None O
effect None None O
was None None O
accompanied None None O
by None None O
an None None O
increased None None O
expression None None O
of None None O
MCP-1 None None I-RNA
mRNA None None I-RNA
( None None O
176 None None O
% None None O
as None None O
compared None None O
to None None O
the None None O
control None None O
) None None O
in None None O
endothelial None None I-cell_type
cells None None I-cell_type
which None None O
resulted None None O
in None None O
enhanced None None O
monocyte None None O
chemotaxis None None O
. None None O

The None None O
p38 None None I-protein
MAP None None I-protein
kinase None None I-protein
as None None O
well None None O
as None None O
other None None O
members None None O
of None None O
the None None O
p38 None None O
MAP None None O
kinase None None O
pathway None None O
, None None O
including None None O
MKK3 None None I-protein
, None None O
MKK6 None None I-protein
, None None O
ATF-2 None None I-protein
and None None O
Elk-1 None None I-protein
, None None O
were None None O
activated None None O
in None None O
homocysteine-treated None None I-cell_type
cells None None I-cell_type
. None None O

Homocysteine-induced None None O
MCP-1 None None I-protein
expression None None O
and None None O
subsequent None None O
monocyte None None O
chemotaxis None None O
were None None O
blocked None None O
by None None O
a None None O
p38 None None I-protein
MAP None None I-protein
kinase None None I-protein
inhibitor None None O
( None None O
SB203580 None None O
) None None O
suggesting None None O
that None None O
the None None O
p38 None None I-protein
MAP None None I-protein
kinase None None I-protein
pathway None None O
might None None O
be None None O
involved None None O
in None None O
homocysteine-induced None None O
MCP-1 None None I-protein
expression None None O
in None None O
endothelial None None I-cell_type
cells None None I-cell_type
. None None O

In None None O
contrast None None O
, None None O
staurosporine None None O
, None None O
a None None O
protein None None I-protein
kinase None None I-protein
C None None I-protein
inhibitor None None O
, None None O
had None None O
no None None O
effect None None O
on None None O
homocysteine-induced None None O
MCP-1 None None I-protein
expression None None O
. None None O

In None None O
conclusion None None O
, None None O
our None None O
results None None O
indicate None None O
that None None O
homocysteine None None O
stimulates None None O
MCP-1 None None I-protein
expression None None O
in None None O
endothelial None None I-cell_type
cells None None I-cell_type
leading None None O
to None None O
enhanced None None O
monocyte None None O
chemotaxis None None O
. None None O

Inducible None None O
resistance None None O
to None None O
Fas-mediated None None O
apoptosis None None O
in None None O
B None None I-cell_type
cells None None I-cell_type
. None None O

Apoptosis None None O
produced None None O
in None None O
B None None I-cell_type
cells None None I-cell_type
through None None O
Fas None None I-protein
( None None O
APO-1 None None I-protein
, None None O
CD95 None None I-protein
) None None O
triggering None None O
is None None O
regulated None None O
by None None O
signals None None O
derived None None O
from None None O
other None None O
surface None None O
receptors None None O
: None None O
CD40 None None O
engagement None None O
produces None None O
upregulation None None O
of None None O
Fas None None I-protein
expression None None O
and None None O
marked None None O
susceptibility None None O
to None None O
Fas None None I-protein
-induced None None O
cell None None O
death None None O
, None None O
whereas None None O
antigen None None O
receptor None None O
engagement None None O
, None None O
or None None O
IL-4R None None O
engagement None None O
, None None O
inhibits None None O
Fas None None I-protein
killing None None O
and None None O
in None None O
so None None O
doing None None O
induces None None O
a None None O
state None None O
of None None O
Fas None None I-protein
-resistance None None O
, None None O
even None None O
in None None O
otherwise None None O
sensitive None None O
, None None O
CD40 None None I-protein
-stimulated None None O
targets None None O
. None None O

Surface None None I-protein
immunoglobulin None None I-protein
and None None O
IL-4R None None I-protein
utilize None None O
at None None O
least None None O
partially None None O
distinct None None O
pathways None None O
to None None O
produce None None O
Fas None None I-protein
-resistance None None O
that None None O
differentially None None O
depend None None O
on None None O
PKC None None I-protein
and None None O
STAT6 None None I-protein
, None None O
respectively None None O
. None None O

Further None None O
, None None O
surface None None O
immunoglobulin None None O
signaling None None O
for None None O
inducible None None O
Fas None None I-protein
-resistance None None O
bypasses None None O
Btk None None I-protein
, None None O
requires None None O
NF-kappaB None None I-protein
, None None O
and None None O
entails None None O
new None None O
macromolecular None None O
synthesis None None O
. None None O

Terminal None None O
effectors None None O
of None None O
B None None I-cell_type
cell None None I-cell_type
Fas None None I-protein
-resistance None None O
include None None O
the None None O
known None None O
anti-apoptotic None None I-protein
gene None None I-protein
products None None I-protein
, None None O
Bcl-xL None None I-protein
and None None O
FLIP None None I-protein
, None None O
and None None O
a None None O
novel None None O
anti-apoptotic None None I-DNA
gene None None I-DNA
that None None O
encodes None None O
FAIM None None I-protein
( None None O
Fas None None I-protein
Apoptosis None None I-protein
Inhibitory None None I-protein
Molecule None None I-protein
) None None O
. None None O

faim None None I-protein
was None None O
identified None None O
by None None O
differential None None O
display None None O
and None None O
exists None None O
in None None O
two None None O
alternatively None None O
spliced None None O
forms None None O
; None None O
faim-S None None I-protein
is None None O
broadly None None O
expressed None None O
, None None O
but None None O
faim-L None None O
expression None None O
is None None O
tissue-specific None None O
. None None O

The None None O
FAIM None None I-DNA
sequence None None I-DNA
is None None O
highly None None O
evolu- None None O
tionarily None None O
conserved None None O
, None None O
suggesting None None O
an None None O
important None None O
role None None O
for None None O
this None None O
molecule None None O
throughout None None O
phylogeny None None O
. None None O

Inducible None None O
resistance None None O
to None None O
Fas None None I-protein
killing None None O
is None None O
hypothesized None None O
to None None O
protect None None O
foreign None None O
antigen-specific None None O
B None None I-cell_type
cells None None I-cell_type
during None None O
potentially None None O
hazardous None None O
interactions None None O
with None None O
FasL-bearing None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
, None None O
whereas None None O
autoreactive None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
fail None None O
to None None O
become None None O
Fas None None I-protein
-resistant None None O
and None None O
are None None O
deleted None None O
via None None O
Fas None None I-protein
-dependent None None O
cytotoxicity None None O
. None None O

Inadvertent None None O
or None None O
aberrant None None O
acquisition None None O
of None None O
Fas None None I-protein
-resistance None None O
may None None O
permit None None O
autoreactive None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
to None None O
escape None None O
Fas None None I-protein
deletion None None O
, None None O
and None None O
malignant None None I-cell_type
lymphocytes None None I-cell_type
to None None O
impede None None O
anti-tumor None None O
immunity None None O
. None None O

Stromal None None I-protein
cell-derived None None I-protein
factor None None I-protein
1 None None I-protein
alpha None None I-protein
-induced None None O
chemotaxis None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
is None None O
mediated None None O
by None None O
nitric None None O
oxide None None O
signaling None None O
pathways None None O
. None None O

Stromal None None I-protein
cell-derived None None I-protein
factor None None I-protein
1 None None I-protein
alpha None None I-protein
( None None O
SDF1 None None I-protein
alpha None None I-protein
) None None O
and None None O
its None None O
cognate None None O
chemokine None None I-protein
receptor None None I-protein
CXCR4 None None I-protein
act None None O
as None None O
potent None None O
chemoattractants None None O
and None None O
regulate None None O
trafficking None None O
and None None O
homing None None O
of None None O
hematopoietic None None I-cell_type
progenitor None None I-cell_type
cells None None I-cell_type
and None None O
lymphocytes None None I-cell_type
. None None O

However None None O
, None None O
the None None O
molecular None None O
mechanisms None None O
regulating None None O
SDF1 None None I-protein
alpha None None I-protein
-driven None None O
cell None None O
migration None None O
are None None O
not None None O
well None None O
defined None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
have None None O
explored None None O
the None None O
roles None None O
of None None O
the None None O
second None None O
messenger None None O
NO None None O
and None None O
the None None O
transcription None None I-protein
factor None None I-protein
NF-kappa None None I-protein
B None None I-protein
in None None O
SDF1 None None I-protein
alpha None None I-protein
-induced None None O
T None None O
cell None None O
migration None None O
. None None O

SDF1 None None I-protein
alpha None None I-protein
treatment None None O
of None None O
Jurkat None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
increased None None O
the None None O
activity None None O
of None None O
NO None None I-protein
synthase None None I-protein
, None None O
which None None O
catalyzes None None O
the None None O
generation None None O
of None None O
NO None None O
. None None O

We None None O
observed None None O
that None None O
pretreatment None None O
of None None O
Jurkat None None I-cell_line
cells None None I-cell_line
or None None O
activated None None O
PBLs None None I-cell_type
with None None O
several None None O
NO None None O
donors None None O
significantly None None O
enhanced None None O
the None None O
SDF1 None None I-protein
alpha None None I-protein
-induced None None O
migration None None O
, None None O
whereas None None O
various None None O
inhibitors None None O
of None None O
NO None None I-protein
synthase None None I-protein
markedly None None O
abrogated None None O
the None None O
chemotactic None None O
response None None O
in None None O
a None None O
concentration-dependent None None O
manner None None O
. None None O

Furthermore None None O
, None None O
we None None O
observed None None O
that None None O
inhibitors None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
NF-kappa None None I-protein
B None None I-protein
, None None O
which None None O
is None None O
linked None None O
to None None O
NO None None O
signaling None None O
pathways None None O
, None None O
also None None O
significantly None None O
blocked None None O
the None None O
SDF1 None None I-protein
alpha None None I-protein
-induced None None O
chemotactic None None O
response None None O
. None None O

However None None O
, None None O
these None None O
compounds None None O
did None None O
not None None O
have None None O
a None None O
significant None None O
effect None None O
on None None O
SDF1 None None I-protein
alpha None None I-protein
-induced None None O
mitogen-activated None None O
protein None None O
kinase None None O
activity None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
MAP/Erk None None O
kinase None None O
kinase None None O
inhibitor None None O
PD98059 None None O
did None None O
not None None O
abrogate None None O
SDF1 None None I-protein
alpha None None I-protein
-induced None None O
chemotaxis None None O
. None None O

AKT None None I-protein
, None None O
which None None O
has None None O
been None None O
shown None None O
to None None O
mediate None None O
NO None None O
production None None O
, None None O
was None None O
also None None O
phosphorylated None None O
upon None None O
SDF1 None None I-protein
alpha None None I-protein
stimulation None None O
. None None O

These None None O
studies None None O
suggest None None O
that None None O
NO-related None None O
signaling None None O
pathways None None O
may None None O
mediate None None O
SDF1 None None I-protein
alpha None None I-protein
-induced None None O
chemotaxis None None O
, None None O
but None None O
not None None O
mitogen-activated None None I-protein
protein None None I-protein
kinase None None I-protein
activation None None O
. None None O

The None None O
lack None None O
of None None O
NF-kappa None None O
B None None O
transactivation None None O
and None None O
PKC None None O
epsilon None None O
expression None None O
in None None O
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
CD8 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
thymocytes None None I-cell_type
correlates None None O
with None None O
negative None None O
selection None None O
. None None O

Deletion None None O
of None None O
autoreactive None None I-cell_type
thymocytes None None I-cell_type
at None None O
the None None O
DP None None O
stage None None O
is None None O
the None None O
basis None None O
for None None O
tolerance None None O
to None None O
thymus-expressed None None I-protein
self None None I-protein
antigens None None I-protein
. None None O

In None None O
this None None O
study None None O
we None None O
investigated None None O
whether None None O
distinct None None O
signalling None None O
pathways None None O
are None None O
induced None None O
in None None O
DP None None I-cell_type
thymocytes None None I-cell_type
as None None O
compared None None O
to None None O
mature None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
upon None None O
stimulation None None O
with None None O
antigen None None O
. None None O

Using None None O
triple None None O
transgenic None None O
mice None None O
expressing None None O
a None None O
TCR None None I-DNA
transgene None None I-DNA
, None None O
dominant None None I-protein
negative None None I-protein
ras/Mek None None I-protein
proteins None None I-protein
and None None O
a None None O
reporter None None I-DNA
gene None None I-DNA
construct None None I-DNA
with None None O
AP-1 None None I-DNA
or None None I-DNA
NF-kappa None None I-DNA
B None None I-DNA
binding None None I-DNA
sites None None I-DNA
, None None O
we None None O
showed None None O
a None None O
complete None None O
lack None None O
of None None O
transcriptional None None O
activity None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
but None None O
not None None O
AP-1 None None I-protein
in None None O
DP None None I-cell_type
thymocytes None None I-cell_type
, None None O
whereas None None O
both None None O
were None None O
transcriptionally None None O
active None None O
in None None O
mature None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
after None None O
antigenic None None O
stimulation None None O
. None None O

Lack None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
induction None None O
correlated None None O
with None None O
increased None None O
death None None O
in None None O
response None None O
to None None O
antigen None None I-protein
. None None O

AP-1 None None I-protein
induction None None O
was None None O
dependent None None O
on None None O
the None None O
integrity None None O
of None None O
the None None O
ras/Mek None None O
pathway None None O
indicating None None O
that None None O
this None None O
pathway None None O
was None None O
activated None None O
in None None O
the None None O
DP None None I-cell_type
thymocytes None None I-cell_type
. None None O

In None None O
contrast None None O
, None None O
we None None O
found None None O
a None None O
complete None None O
lack None None O
of None None O
constitutive None None O
expression None None O
of None None O
the None None O
epsilon None None I-protein
isoform None None I-protein
of None None I-protein
Protein None None I-protein
Kinase None None I-protein
C None None I-protein
( None None O
PKC None None I-protein
) None None O
in None None O
DP None None I-cell_type
thymocytes None None I-cell_type
, None None O
although None None O
it None None O
was None None O
present None None O
in None None O
mature None None I-cell_type
thymocytes None None I-cell_type
and None None O
peripheral None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

Taken None None O
together None None O
the None None O
results None None O
suggest None None O
that None None O
the None None O
lack None None O
of None None O
PKC None None I-protein
epsilon None None I-protein
in None None O
DP None None I-cell_type
thymocytes None None I-cell_type
could None None O
lead None None O
to None None O
the None None O
absence None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
activity None None O
after None None O
antigenic None None O
stimulation None None O
contributing None None O
to None None O
negative None None O
selection None None O
. None None O

Cell None None O
Death None None O
and None None O
Differentiation None None O
( None None O
2000 None None O
) None None O
7 None None O
, None None O
1253 None None O
- None None O
1262 None None O
. None None O

CD2 None None O
stimulation None None O
leads None None O
to None None O
the None None O
delayed None None O
and None None O
prolonged None None O
activation None None O
of None None O
STAT1 None None I-protein
in None None O
T None None I-cell_type
cells None None I-cell_type
but None None O
not None None O
NK None None I-cell_type
cells None None I-cell_type
. None None O

OBJECTIVE None None O
: None None O
T None None I-cell_type
lymphocytes None None I-cell_type
can None None O
be None None O
activated None None O
by None None O
soluble None None O
factors None None O
such None None O
as None None O
cytokines None None I-protein
or None None O
through None None O
direct None None O
cell-cell None None O
interactions None None O
. None None O

Although None None O
cytokine None None I-protein
receptors None None I-protein
are None None O
known None None O
to None None O
signal None None O
through None None O
STAT None None I-protein
family None None I-protein
transcription None None I-protein
factors None None I-protein
, None None O
the None None O
mechanisms None None O
by None None O
which None None O
other None None O
cell-surface None None I-protein
molecules None None I-protein
, None None O
such None None O
as None None O
CD2 None None I-protein
, None None O
transduce None None O
signals None None O
is None None O
unclear None None O
. None None O

The None None O
goal None None O
of None None O
this None None O
study None None O
was None None O
to None None O
determine None None O
whether None None O
stimulation None None O
of None None O
T None None I-cell_type
cells None None I-cell_type
through None None O
CD2 None None I-protein
recapitulates None None O
aspects None None O
of None None O
cytokine None None I-protein
-induced None None O
T-cell None None O
activation None None O
by None None O
use None None O
of None None O
STAT None None I-protein
transcription None None I-protein
factors None None I-protein
. None None O

MATERIALS None None O
AND None None O
METHODS None None O
: None None O
T None None I-cell_type
cells None None I-cell_type
were None None O
treated None None O
with None None O
anti-CD2 None None I-protein
antibodies None None I-protein
or None None O
cells None None O
bearing None None O
the None None O
natural None None O
CD2 None None I-protein
ligand None None I-protein
CD58 None None I-protein
, None None O
after None None O
which None None O
signaling None None O
through None None O
STAT None None I-protein
transcription None None I-protein
factors None None I-protein
was None None O
assessed None None O
. None None O

RESULTS None None O
: None None O
Stimulation None None O
of None None O
CD2 None None I-protein
on None None O
primary None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
leads None None O
to None None O
the None None O
tyrosine None None O
phosphorylation None None O
, None None O
nuclear None None O
translocation None None O
, None None O
and None None O
DNA None None O
binding None None O
of None None O
STAT1 None None I-protein
. None None O

In None None O
contrast None None O
to None None O
stimulation None None O
by None None O
cytokines None None I-protein
, None None O
the None None O
activation None None O
of None None O
STAT1 None None I-protein
in None None O
response None None O
to None None O
CD2 None None O
ligation None None O
is None None O
delayed None None O
and None None O
does None None O
not None None O
involve None None O
Jak None None I-protein
kinases None None I-protein
. None None O

Furthermore None None O
, None None O
while None None O
STAT None None O
phosphorylation None None O
induced None None O
by None None O
cytokines None None I-protein
is None None O
generally None None O
transient None None O
, None None O
STAT1 None None O
phosphorylation None None O
following None None O
CD2 None None O
stimulation None None O
persists None None O
for None None O
a None None O
period None None O
of None None O
days None None O
. None None O

Transcription None None O
of None None O
key None None O
target None None O
genes None None O
such None None O
as None None O
IRF1 None None I-DNA
and None None O
c-fos None None I-DNA
proceeds None None O
with None None O
delayed None None O
kinetics None None O
following None None O
CD2 None None O
stimulation None None O
, None None O
suggesting None None O
that None None O
this None None O
unique None None O
pattern None None O
of None None O
STAT None None O
activation None None O
may None None O
lead None None O
to None None O
a None None O
distinct None None O
cellular None None O
response None None O
following None None O
CD2 None None O
ligation None None O
. None None O

This None None O
pathway None None O
appears None None O
to None None O
be None None O
restricted None None O
to None None O
T None None I-cell_type
cells None None I-cell_type
, None None O
as None None O
stimulation None None O
of None None O
CD2 None None I-protein
on None None O
NK None None I-cell_type
cells None None I-cell_type
does None None O
not None None O
lead None None O
to None None O
STAT1 None None O
activation None None O
. None None O

CONCLUSION None None O
: None None O
Stimulation None None O
of None None O
T None None I-cell_type
cells None None I-cell_type
through None None O
cell-surface None None I-protein
molecules None None I-protein
such None None O
as None None O
CD2 None None I-protein
involves None None O
activation None None O
of None None O
STAT None None I-protein
transcription None None I-protein
factors None None I-protein
, None None O
thus None None O
recapitulating None None O
elements None None O
of None None O
cytokine None None O
signaling None None O
. None None O

NFATc1 None None I-protein
and None None O
NFATc2 None None I-protein
together None None O
control None None O
both None None O
T None None O
and None None O
B None None O
cell None None O
activation None None O
and None None O
differentiation None None O
. None None O

NFAT None None I-protein
transcription None None I-protein
factors None None I-protein
play None None O
critical None None O
roles None None O
in None None O
gene None None O
transcription None None O
during None None O
immune None None O
responses None None O
. None None O

To None None O
investigate None None O
further None None O
the None None O
two None None O
most None None O
prominent None None O
NFAT None None I-protein
family None None I-protein
members None None I-protein
, None None O
NFATc1 None None I-protein
and None None O
NFATc2 None None I-protein
, None None O
we None None O
generated None None O
mice None None O
bearing None None O
lymphoid None None O
systems None None O
devoid None None O
of None None O
both None None O
. None None O

Doubly None None O
deficient None None O
T None None I-cell_type
cells None None I-cell_type
displayed None None O
cell None None O
surface None None O
markers None None O
of None None O
activation None None O
yet None None O
were None None O
significantly None None O
deficient None None O
in None None O
the None None O
development None None O
of None None O
multiple None None O
effector None None O
functions None None O
, None None O
including None None O
Th None None I-protein
cytokine None None I-protein
production None None O
, None None O
surface None None I-protein
effector None None I-protein
molecule None None I-protein
expression None None O
, None None O
and None None O
cytolytic None None O
activity None None O
. None None O

Nevertheless None None O
, None None O
doubly None None I-cell_type
deficient None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
were None None O
hyperactivated None None O
, None None O
as None None O
evidenced None None O
by None None O
extremely None None O
elevated None None O
serum None None O
IgG1 None None I-protein
and None None O
IgE None None I-protein
, None None O
as None None O
well None None O
as None None O
plasma None None I-cell_type
cell None None I-cell_type
expansion None None O
and None None O
infiltration None None O
of None None O
end None None O
organs None None O
. None None O

Thus None None O
, None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
, None None O
NFATc1 None None I-protein
and None None O
NFATc2 None None I-protein
are None None O
dispensable None None O
for None None O
inflammatory None None O
reactivity None None O
but None None O
are None None O
required None None O
for None None O
effector None None O
differentiation None None O
, None None O
while None None O
in None None O
B None None I-cell_type
cells None None I-cell_type
, None None O
NFATs None None I-protein
regulate None None O
both None None O
normal None None O
homeostasis None None O
and None None O
differentiation None None O
. None None O

Epstein-barr None None O
virus None None O
immediate-early None None I-protein
protein None None I-protein
BZLF1 None None I-protein
is None None O
SUMO-1 None None O
modified None None O
and None None O
disrupts None None O
promyelocytic None None O
leukemia None None O
bodies None None O
. None None O

Although None None O
the None None O
immediate-early None None I-protein
proteins None None I-protein
of None None O
both None None O
herpes None None O
simplex None None O
virus None None O
( None None O
HSV None None O
) None None O
and None None O
cytomegalovirus None None O
( None None O
CMV None None O
) None None O
are None None O
known None None O
to None None O
modify None None O
promyelocytic None None O
leukemia None None O
( None None O
PML None None O
) None None O
( None None O
ND10 None None O
) None None O
bodies None None O
in None None O
the None None O
nucleus None None O
of None None O
the None None O
host None None O
cell None None O
, None None O
it None None O
has None None O
been None None O
unclear None None O
whether None None O
lytic None None O
infection None None O
with None None O
gamma None None O
herpesviruses None None O
induces None None O
a None None O
similar None None O
effect None None O
. None None O

The None None O
PML None None I-protein
protein None None I-protein
is None None O
induced None None O
by None None O
interferon None None I-protein
, None None O
involved None None O
in None None O
major None None I-protein
histocompatibility None None I-protein
complex None None I-protein
class None None I-protein
I None None I-protein
presentation None None O
, None None O
and None None O
necessary None None O
for None None O
certain None None O
types None None O
of None None O
apoptosis None None O
. None None O

Therefore None None O
, None None O
it None None O
is None None O
likely None None O
that None None O
PML None None O
bodies None None O
function None None O
in None None O
an None None O
antiviral None None O
capacity None None O
. None None O

SUMO-1 None None O
modification None None O
of None None O
PML None None I-protein
is None None O
known None None O
to None None O
be None None O
required None None O
for None None O
the None None O
formation None None O
of None None O
PML None None O
bodies None None O
. None None O

To None None O
examine None None O
whether None None O
Epstein-Barr None None O
virus None None O
( None None O
EBV None None O
) None None O
lytic None None O
replication None None O
interferes None None O
with None None O
PML None None O
bodies None None O
, None None O
we None None O
expressed None None O
the None None O
EBV None None I-DNA
immediate-early None None I-DNA
genes None None I-DNA
BZLF1 None None B-DNA
( None None I-DNA
Z None None I-DNA
) None None I-DNA
and None None O
BRLF1 None None I-DNA
( None None I-DNA
R None None I-DNA
) None None I-DNA
in None None O
EBV-positive None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
and None None O
examined None None O
PML None None I-protein
localization None None O
. None None O

Both None None O
Z None None O
and None None O
R None None O
expression None None O
resulted None None O
in None None O
PML None None I-protein
dispersion None None O
in None None O
EBV-positive None None I-cell_type
cells None None I-cell_type
. None None O

Z None None O
but None None O
not None None O
R None None O
expression None None O
is None None O
sufficient None None O
to None None O
disrupt None None O
PML None None O
bodies None None O
in None None O
EBV-negative None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
. None None O

We None None O
show None None O
that None None O
dispersion None None O
of None None O
PML None None O
bodies None None O
by None None O
Z None None I-DNA
requires None None O
a None None O
portion None None O
of None None O
the None None O
transcriptional None None I-DNA
activation None None I-DNA
domain None None I-DNA
of None None O
Z None None I-DNA
but None None O
not None None O
the None None O
DNA-binding None None O
function None None O
. None None O

As None None O
was None None O
previously None None O
reported None None O
for None None O
the None None O
HSV-1 None None I-protein
ICP0 None None I-protein
and None None I-protein
CMV None None I-protein
IE1 None None I-protein
proteins None None I-protein
, None None O
Z None None I-DNA
reduces None None O
the None None O
amount None None O
of None None O
SUMO-1-modified None None I-protein
PML None None I-protein
. None None O

We None None O
also None None O
found None None O
that None None O
Z None None I-DNA
itself None None O
is None None O
SUMO-1 None None O
modified None None O
( None None O
through None None O
amino None None O
acid None None O
12 None None O
) None None O
and None None O
that None None O
Z None None I-DNA
competes None None O
with None None O
PML None None I-protein
for None None O
limiting None None O
amounts None None O
of None None O
SUMO-1 None None I-protein
. None None O

These None None O
results None None O
suggest None None O
that None None O
disruption None None O
of None None O
PML None None O
bodies None None O
is None None O
important None None O
for None None O
efficient None None O
lytic None None O
replication None None O
of None None O
EBV None None O
. None None O

Furthermore None None O
, None None O
Z None None I-DNA
may None None O
potentially None None O
alter None None O
the None None O
function None None O
of None None O
a None None O
variety None None O
of None None O
cellular None None O
proteins None None O
by None None O
inhibiting None None O
SUMO-1 None None O
modification None None O

Suppression None None O
of None None O
nuclear None None I-protein
factor-kappaB None None I-protein
and None None O
stimulation None None O
of None None O
inhibitor None None I-protein
kappaB None None I-protein
by None None O
troglitazone None None O
: None None O
evidence None None O
for None None O
an None None O
anti-inflammatory None None O
effect None None O
and None None O
a None None O
potential None None O
antiatherosclerotic None None O
effect None None O
in None None O
the None None O
obese None None O
. None None O

To None None O
elucidate None None O
whether None None O
troglitazone None None O
exerts None None O
an None None O
antiinflammatory None None O
effect None None O
in None None O
humans None None O
, None None O
in None None O
vivo None None O
, None None O
we None None O
investigated None None O
the None None O
suppression None None O
of None None O
nuclear None None I-protein
factor None None I-protein
kappaB None None I-protein
( None None O
NFkappaB None None I-protein
) None None O
in None None O
mononuclear None None I-cell_type
cells None None I-cell_type
( None None I-cell_type
MNC None None I-cell_type
) None None I-cell_type
by None None O
this None None O
drug None None O
. None None O

We None None O
measured None None O
intranuclear None None I-protein
NFkappaB None None I-protein
, None None O
total None None O
cellular None None I-protein
NFkappaB None None I-protein
, None None O
inhibitor None None I-protein
kappaB None None I-protein
( None None I-protein
IkappaB None None I-protein
) None None I-protein
alpha None None I-protein
, None None O
reactive None None O
oxygen None None O
species None None O
( None None O
ROS None None O
) None None O
generation None None O
, None None O
and None None O
p47 None None I-protein
( None None I-protein
phox None None I-protein
) None None I-protein
subunit None None I-protein
( None None O
a None None O
key None None O
component None None O
protein None None O
of None None O
nicotinamide None None I-protein
adenine None None I-protein
dinucleotide None None I-protein
phosphate None None I-protein
oxidase None None I-protein
) None None O
in None None O
MNC None None I-cell_type
. None None O

Plasma None None I-protein
tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
( None None I-protein
TNF None None I-protein
) None None I-protein
-alpha None None I-protein
, None None O
soluble None None I-protein
intercellular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
( None None O
sICAM-1 None None I-protein
) None None O
, None None O
monocyte None None I-protein
chemoattractant None None I-protein
protein-1 None None I-protein
( None None I-protein
MCP-1 None None I-protein
) None None I-protein
, None None O
plasminogen None None I-protein
activator None None I-protein
inhibitor None None I-protein
type None None I-protein
1 None None I-protein
( None None O
PAI-1 None None I-protein
) None None O
, None None O
C-reactive None None I-protein
protein None None I-protein
( None None I-protein
CRP None None I-protein
) None None I-protein
, None None O
and None None O
interleukin None None I-protein
( None None I-protein
IL None None I-protein
) None None I-protein
-10 None None I-protein
( None None O
antiinflammatory None None I-protein
cytokine None None I-protein
) None None O
concentrations None None O
were None None O
also None None O
measured None None O
as None None O
mediators None None O
of None None O
inflammatory None None O
activity None None O
that None None O
are None None O
regulated None None O
by None None O
the None None O
proinflammatory None None I-protein
transcription None None I-protein
factor None None I-protein
NFkappaB None None I-protein
. None None O

Seven None None O
nondiabetic None None O
obese None None O
patients None None O
were None None O
given None None O
400 None None O
mg None None O
troglitazone None None O
daily None None O
for None None O
4 None None O
weeks None None O
. None None O

Blood None None O
samples None None O
were None None O
collected None None O
before None None O
and None None O
at None None O
weekly None None O
intervals None None O
thereafter None None O
. None None O

MNC None None I-cell_type
were None None O
separated None None O
; None None O
and None None O
the None None O
levels None None O
of None None O
intranuclear None None I-protein
NFkappaB None None I-protein
, None None O
total None None O
cellular None None I-protein
NFkappaB None None I-protein
, None None O
IkappaBalpha None None I-protein
, None None O
and None None O
p47 None None I-protein
( None None I-protein
phox None None I-protein
) None None I-protein
subunit None None I-protein
and None None O
ROS None None O
generation None None O
were None None O
determined None None O
. None None O

Plasma None None O
was None None O
used None None O
to None None O
measure None None O
insulin None None O
glucose None None O
, None None O
TNFalpha None None I-protein
, None None O
sICAM None None I-protein
, None None O
MCP-1 None None I-protein
, None None O
PAI-1 None None I-protein
, None None O
CRP None None I-protein
, None None O
and None None O
IL-10 None None I-protein
. None None O

Plasma None None O
insulin None None O
concentrations None None O
fell None None O
significantly None None O
at None None O
week None None O
1 None None O
, None None O
from None None O
31.2 None None O
+/- None None O
29.1 None None O
to None None O
14.2 None None O
+/- None None O
11.4 None None O
mU/L None None O
( None None O
P None None O
< None None O
0.01 None None O
) None None O
and None None O
remained None None O
low None None O
throughout None None O
4 None None O
weeks None None O
. None None O

Plasma None None O
glucose None None O
concentrations None None O
did None None O
not None None O
alter None None O
significantly None None O
. None None O

There None None O
was None None O
a None None O
fall None None O
in None None O
intranuclear None None I-protein
NFkappaB None None I-protein
, None None O
total None None O
cellular None None I-protein
NFkappaB None None I-protein
, None None O
and None None O
p47 None None I-protein
( None None I-protein
phox None None I-protein
) None None I-protein
subunit None None I-protein
, None None O
with None None O
an None None O
increase None None O
in None None O
cellular None None O
IkappaBalpha None None I-protein
at None None O
week None None O
2 None None O
, None None O
which None None O
persisted None None O
until None None O
week None None O
4 None None O
. None None O

There None None O
was None None O
a None None O
parallel None None O
fall None None O
in None None O
ROS None None O
generation None None O
by None None O
MNC None None I-cell_type
at None None O
week None None O
1 None None O
; None None O
this None None O
progressed None None O
and None None O
persisted None None O
until None None O
week None None O
4 None None O
( None None O
P None None O
< None None O
0.001 None None O
) None None O
. None None O

Plasma None None O
TNF-alpha None None I-protein
, None None O
sICAM-1 None None I-protein
, None None O
MCP-1 None None I-protein
, None None O
and None None O
PAI-1 None None I-protein
concentrations None None O
fell None None O
significantly None None O
at None None O
week None None O
4 None None O
. None None O

Plasma None None O
IL-10 None None I-protein
concentration None None O
increased None None O
significantly None None O
, None None O
whereas None None O
plasma None None I-protein
CRP None None I-protein
concentrations None None O
decreased None None O
. None None O

We None None O
conclude None None O
that None None O
troglitazone None None O
has None None O
an None None O
antiinflammatory None None O
action None None O
that None None O
may None None O
contribute None None O
to None None O
its None None O
putative None None O
antiatherosclerotic None None O
effects None None O
. None None O

Tyrosine None None O
phosphorylation-dependent None None O
activation None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
. None None O

Requirement None None O
for None None O
p56 None None I-protein
LCK None None I-protein
and None None I-protein
ZAP-70 None None I-protein
protein None None I-protein
tyrosine None None I-protein
kinases None None I-protein
. None None O

Phosphorylation None None O
of None None O
the None None O
N-terminal None None I-protein
domain None None I-protein
of None None O
I None None I-protein
kappa None None I-protein
B None None I-protein
inhibitory None None I-protein
subunits None None I-protein
induces None None O
activation None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
NF-kappa None None I-protein
B None None I-protein
. None None O

Although None None O
serine None None O
phosphorylation None None O
has None None O
been None None O
shown None None O
to None None O
induce None None O
ubiquitination None None O
and None None O
subsequent None None O
proteasome-mediated None None O
degradation None None O
of None None O
I None None I-protein
kappa None None I-protein
B-alpha None None I-protein
, None None O
little None None O
is None None O
known None None O
about None None O
the None None O
mechanisms None None O
that None None O
lead None None O
to None None O
release None None O
of None None O
active None None O
NF-kappa None None I-protein
B None None I-protein
in None None O
T None None I-cell_type
cells None None I-cell_type
as None None O
a None None O
consequence None None O
of None None O
tyrosine None None O
phosphorylation None None O
of None None O
I None None I-protein
kappa None None I-protein
B-alpha None None I-protein
[ None None O
Imbert None None O
, None None O
V. None None O
, None None O
Rupec None None O
, None None O
R.A. None None O
, None None O
Livolsi None None O
, None None O
A. None None O
, None None O
Pahl None None O
, None None O
H.L. None None O
, None None O
Traenckner None None O
, None None O
B.M. None None O
, None None O
Mueller-Dieckmann None None O
, None None O
C. None None O
, None None O
Farahifar None None O
, None None O
D. None None O
, None None O
Rossi None None O
, None None O
B. None None O
, None None O
Auberger None None O
, None None O
P. None None O
, None None O
Baeuerle None None O
, None None O
P. None None O
& None None O
Peyron None None O
, None None O
J.F. None None O
( None None O
1996 None None O
) None None O
Cell None None O
86 None None O
, None None O
787 None None O
-- None None O
798 None None O
] None None O
. None None O

The None None O
involvement None None O
of None None O
the None None O
tyrosine None None I-protein
kinases None None I-protein
p56 None None B-protein
( None None I-protein
lck None None I-protein
) None None I-protein
and None None O
ZAP-70 None None I-protein
in None None O
this None None O
reaction None None O
is None None O
demonstrated None None O
here None None O
using None None O
specific None None O
pharmacological None None O
inhibitors None None O
and None None O
Jurkat None None I-cell_line
mutants None None I-cell_line
unable None None O
to None None O
express None None O
these None None O
kinases None None I-protein
. None None O

Although None None O
the None None O
inhibitors None None O
prevented None None O
both None None O
pervanadate-induced None None O
phosphorylation None None O
of None None O
I None None I-protein
kappa None None I-protein
B-alpha None None I-protein
on None None O
Tyr42 None None O
and None None O
NF-kappa None None I-protein
B None None I-protein
activation None None O
, None None O
we None None O
observed None None O
that None None O
, None None O
in None None O
p56 None None I-cell_line
( None None I-cell_line
lck None None I-cell_line
) None None I-cell_line
-deficient None None I-cell_line
Jurkat None None I-cell_line
mutants None None I-cell_line
, None None O
NF-kappa None None I-protein
B None None I-protein
could None None O
still None None O
associate None None O
with None None O
I None None I-protein
kappa None None I-protein
B-alpha None None I-protein
despite None None O
phosphorylation None None O
on None None O
Tyr42 None None O
. None None O

Furthermore None None O
, None None O
the None None O
SH2 None None I-protein
domain None None I-protein
of None None O
p56 None None I-protein
( None None I-protein
lck None None I-protein
) None None I-protein
appeared None None O
to None None O
be None None O
required None None O
for None None O
pervanadate-induced None None O
NF-kappa None None I-protein
B None None I-protein
activation None None O
but None None O
not None None O
for None None O
Tyr42 None None O
phosphorylation None None O
. None None O

These None None O
results None None O
show None None O
that None None O
p56 None None I-protein
( None None I-protein
lck None None I-protein
) None None I-protein
and None None O
ZAP-70 None None I-protein
are None None O
key None None O
components None None O
of None None O
the None None O
signaling None None O
pathway None None O
that None None O
leads None None O
to None None O
phosphotyrosine-dependent None None O
NF-kappa None None I-protein
B None None I-protein
activation None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
and None None O
confirm None None O
that None None O
tyrosine None None I-protein
kinases None None I-protein
must None None O
control None None O
at None None O
least None None O
two None None O
different None None O
steps None None O
to None None O
induce None None O
activation None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
. None None O

Finally None None O
, None None O
we None None O
show None None O
that None None O
H None None O
( None None O
2 None None O
) None None O
O None None O
( None None O
2 None None O
) None None O
, None None O
which None None O
stimulates None None O
p56 None None I-protein
( None None I-protein
lck None None I-protein
) None None I-protein
and None None O
ZAP-70 None None I-protein
in None None O
T None None I-cell_type
cells None None I-cell_type
, None None O
is None None O
an None None O
activator None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
through None None O
tyrosine None None O
phosphorylation None None O
of None None O
I None None I-protein
kappa None None I-protein
B-alpha None None I-protein
. None None O

Specific None None O
missense None None O
mutations None None O
in None None O
NEMO None None I-DNA
result None None O
in None None O
hyper-IgM None None O
syndrome None None O
with None None O
hypohydrotic None None O
ectodermal None None O
dysplasia None None O
. None None O

The None None O
gene None None O
that None None O
encodes None None O
nuclear None None I-DNA
factor None None I-DNA
kappaB None None I-DNA
( None None I-DNA
NF-kappaB None None I-DNA
) None None I-DNA
essential None None I-DNA
modulator None None I-DNA
( None None O
or None None O
NEMO None None I-DNA
, None None O
also None None O
known None None O
as None None O
IKKgamma None None I-DNA
) None None O
is None None O
required None None O
for None None O
activation None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
NF-kappaB None None I-protein
. None None O

We None None O
describe None None O
mutations None None O
in None None O
the None None O
putative None None I-protein
zinc-finger None None I-protein
domain None None I-protein
of None None O
NEMO None None I-protein
that None None O
result None None O
in None None O
an None None O
X-linked None None O
primary None None O
immunodeficiency None None O
characterized None None O
by None None O
hyper-IgM None None O
syndrome None None O
and None None O
hypohydrotic None None O
ectodermal None None O
dysplasia None None O
( None None O
XHM-ED None None O
) None None O
. None None O

These None None O
mutations None None O
prevent None None O
CD40 None None I-protein
ligand None None I-protein
( None None O
CD40L None None I-protein
) None None O
-mediated None None O
degradation None None O
of None None O
inhibitor None None O
of None None O
NF-kappaB None None I-protein
alpha None None I-protein
( None None O
IkappaB-alpha None None I-protein
) None None O
and None None O
account None None O
for None None O
the None None O
following None None O
observations None None O
: None None O
B None None I-cell_type
cells None None I-cell_type
from None None O
XHM-ED None None O
patients None None O
are None None O
unable None None O
to None None O
undergo None None O
immunoglobulin None None O
class-switch None None O
recombination None None O
and None None O
antigen-presenting None None I-cell_type
cells None None I-cell_type
( None None O
APCs None None I-cell_type
) None None O
are None None O
unable None None O
to None None O
synthesize None None O
the None None O
NF-kappaB-regulated None None I-protein
cytokines None None I-protein
interleukin None None B-protein
12 None None I-protein
( None None O
IL-12 None None I-protein
) None None O
or None None O
tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
alpha None None I-protein
( None None O
TNF-alpha None None I-protein
) None None O
when None None O
stimulated None None O
with None None O
CD40L None None I-protein
. None None O

Nevertheless None None O
, None None O
innate None None O
immunity None None O
is None None O
preserved None None O
in None None O
XHM-ED None None O
patients None None O
because None None O
APCs None None I-cell_type
retain None None O
the None None O
capacity None None O
to None None O
respond None None O
to None None O
stimulation None None O
by None None O
lipopolysaccharide None None O
or None None O
Staphylococcus None None I-protein
aureus None None I-protein
Cowan None None I-protein
's None None I-protein
antigen None None I-protein
( None None O
SAC None None I-protein
) None None O
. None None O

Overall None None O
, None None O
the None None O
phenotype None None O
observed None None O
in None None O
XHM-ED None None O
patients None None O
shows None None O
that None None O
the None None O
putative None None I-protein
zinc-finger None None I-protein
domain None None I-protein
of None None O
NEMO None None I-protein
has None None O
a None None O
regulatory None None O
function None None O
and None None O
demonstrates None None O
the None None O
definite None None O
requirement None None O
of None None O
CD40 None None I-protein
-mediated None None O
NF-kappaB None None O
activation None None O
for None None O
B None None I-cell_type
cell None None I-cell_type
immunoglobulin None None O
class-switching None None O
. None None O

Granulocytic None None O
differentiation None None O
of None None O
human None None I-cell_type
NB4 None None I-cell_type
promyelocytic None None I-cell_type
leukemia None None I-cell_type
cells None None I-cell_type
induced None None O
by None None O
all-trans None None O
retinoic None None O
acid None None O
metabolites None None O
. None None O

The None None O
metabolism None None O
of None None O
all-trans None None O
retinoic None None O
acid None None O
( None None O
ATRA None None O
) None None O
has None None O
been None None O
reported None None O
to None None O
be None None O
partly None None O
responsible None None O
for None None O
the None None O
in None None O
vivo None None O
resistance None None O
to None None O
ATRA None None O
seen None None O
in None None O
the None None O
treatment None None O
of None None O
human None None O
acute None None O
promyelocytic None None O
leukemia None None O
( None None O
APL None None O
) None None O
. None None O

However None None O
, None None O
ATRA None None O
metabolism None None O
appears None None O
to None None O
be None None O
involved None None O
in None None O
the None None O
growth None None O
inhibition None None O
of None None O
several None None O
cancer None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
in None None O
vitro None None O
. None None O

The None None O
purpose None None O
of None None O
this None None O
study None None O
was None None O
to None None O
evaluate None None O
the None None O
in None None O
vitro None None O
activity None None O
of None None O
the None None O
principal None None O
metabolites None None O
of None None O
ATRA None None O
[ None None O
4-hydroxy-retinoic None None O
acid None None O
( None None O
4-OH-RA None None O
) None None O
, None None O
18-hydroxy-retinoic None None O
acid None None O
( None None O
18-OH-RA None None O
) None None O
, None None O
4-oxo-retinoic None None O
acid None None O
( None None O
4-oxo-RA None None O
) None None O
, None None O
and None None O
5 None None O
, None None O
6-epoxy-retinoic None None O
acid None None O
( None None O
5 None None O
, None None O
6-epoxy-RA None None O
) None None O
] None None O
in None None O
NB4 None None I-cell_line
, None None I-cell_line
a None None I-cell_line
human None None I-cell_line
promyelocytic None None I-cell_line
leukemia None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
that None None O
exhibits None None O
the None None O
APL None None O
diagnostic None None O
t None None O
( None None O
15 None None O
; None None O
17 None None O
) None None O
chromosomal None None O
translocation None None O
and None None O
expresses None None O
the None None O
PML-RAR None None I-protein
alpha None None I-protein
fusion None None I-protein
protein None None I-protein
. None None O

We None None O
established None None O
that None None O
the None None O
four None None O
ATRA None None O
metabolites None None O
were None None O
indeed None None O
formed None None O
by None None O
the None None O
NB4 None None I-cell_line
cells None None I-cell_line
in None None O
vitro None None O
. None None O

NB4 None None O
cell None None O
growth None None O
was None None O
inhibited None None O
( None None O
69-78 None None O
% None None O
at None None O
120 None None O
h None None O
) None None O
and None None O
cell None None O
cycle None None O
progression None None O
in None None O
the None None O
G1 None None O
phase None None O
( None None O
82-85 None None O
% None None O
at None None O
120 None None O
h None None O
) None None O
was None None O
blocked None None O
by None None O
ATRA None None O
and None None O
all None None O
of None None O
the None None O
metabolites None None O
at None None O
1 None None O
microM None None O
concentration None None O
. None None O

ATRA None None O
and None None O
its None None O
metabolites None None O
could None None O
induce None None O
NB4 None None I-cell_line
cells None None I-cell_line
differentiation None None O
with None None O
similar None None O
activity None None O
, None None O
as None None O
evaluated None None O
by None None O
cell None None O
morphology None None O
, None None O
by None None O
the None None O
nitroblue None None O
tetrazolium None None O
reduction None None O
test None None O
( None None O
82-88 None None O
% None None O
at None None O
120 None None O
h None None O
) None None O
or None None O
by None None O
the None None O
expression None None O
of None None O
the None None O
maturation None None I-protein
specific None None I-protein
cell None None I-protein
surface None None I-protein
marker None None I-protein
CD11c None None I-protein
. None None O

In None None O
addition None None O
, None None O
nuclear None None O
body None None O
reorganization None None O
to None None O
macropunctated None None O
structures None None O
, None None O
as None None O
well None None O
as None None O
the None None O
degradation None None O
of None None O
PML-RAR None None I-protein
alpha None None I-protein
, None None O
was None None O
found None None O
to None None O
be None None O
similar None None O
for None None O
ATRA None None O
and None None O
all None None O
of None None O
its None None O
metabolites None None O
. None None O

Comparison None None O
of None None O
the None None O
relative None None O
potency None None O
of None None O
the None None O
retinoids None None O
using None None O
the None None O
nitroblue None None O
tetrazolium None None O
reduction None None O
test None None O
showed None None O
effective None None O
concentrations None None O
required None None O
to None None O
differentiate None None O
50 None None O
% None None O
of None None O
cells None None O
in None None O
72 None None O
h None None O
as None None O
follows None None O
: None None O
ATRA None None O
, None None O
15.8 None None O
+/- None None O
1.7 None None O
nM None None O
; None None O
4-oxo-RA None None O
, None None O
38.3 None None O
+/- None None O
1.3 None None O
nM None None O
; None None O
18-OH-RA None None O
, None None O
55.5 None None O
+/- None None O
1.8 None None O
nM None None O
; None None O
4-OH-RA None None O
, None None O
79.8 None None O
+/- None None O
1.8 None None O
nM None None O
; None None O
and None None O
5 None None O
, None None O
6-epoxy-RA None None O
, None None O
99.5 None None O
+/- None None O
1.5 None None O
nM None None O
. None None O

The None None O
ATRA None None O
metabolites None None O
were None None O
found None None O
to None None O
exert None None O
their None None O
differentiation None None O
effects None None O
via None None O
the None None O
RAR None None I-protein
alpha None None I-protein
nuclear None None I-protein
receptors None None I-protein
, None None O
because None None O
the None None O
RAR None None O
alpha-specific None None O
antagonist None None O
BMS614 None None O
blocked None None O
metabolite-induced None None O
CD11c None None O
expression None None O
in None None O
NB4 None None I-cell_line
cells None None I-cell_line
. None None O

These None None O
data None None O
demonstrate None None O
that None None O
the None None O
principal None None O
ATRA None None O
Phase None None O
1 None None O
metabolites None None O
can None None O
elicit None None O
leukemia None None I-cell_type
cell None None I-cell_type
growth None None O
inhibition None None O
and None None O
differentiation None None O
in None None O
vitro None None O
through None None O
the None None O
RAR None None O
alpha None None O
signaling None None O
pathway None None O
, None None O
and None None O
they None None O
suggest None None O
that None None O
these None None O
metabolites None None O
may None None O
play None None O
a None None O
role None None O
in None None O
ATRA None None O
antileukemic None None O
activity None None O
in None None O
vivo None None O
. None None O

Expression None None O
of None None O
oestrogen None None I-protein
and None None I-protein
progesterone None None I-protein
receptors None None I-protein
by None None O
mast None None I-cell_type
cells None None I-cell_type
alone None None O
, None None O
but None None O
not None None O
lymphocytes None None I-cell_type
, None None O
macrophages None None I-cell_type
or None None O
other None None O
immune None None I-cell_type
cells None None I-cell_type
in None None O
human None None O
upper None None O
airways None None O
. None None O

BACKGROUND None None O
: None None O
Nasal None None O
polyposis None None O
often None None O
coexists None None O
with None None O
asthma None None O
in None None O
airway None None O
inflammatory None None O
conditions None None O
characterised None None O
by None None O
the None None O
infiltration None None O
of None None O
a None None O
range None None O
of None None O
immune None None I-cell_type
cells None None I-cell_type
. None None O

A None None O
potentially None None O
important None None O
role None None O
for None None O
ovarian None None O
hormones None None O
has None None O
been None None O
implicated None None O
in None None O
airway None None O
inflammation None None O
but None None O
the None None O
cellular None None O
target None None O
for None None O
such None None O
action None None O
is None None O
not None None O
known None None O
. None None O

METHODS None None O
: None None O
Expression None None O
of None None O
oestrogen None None I-protein
receptors None None I-protein
( None None O
ER None None I-protein
) None None O
and None None O
progesterone None None I-protein
receptors None None I-protein
( None None O
PR None None I-protein
) None None O
was None None O
examined None None O
using None None O
immunohistochemistry None None O
in None None O
formalin None None O
fixed None None O
nasal None None O
polyp None None O
tissues None None O
from None None O
47 None None O
subjects None None O
. None None O

The None None O
cells None None O
positive None None O
for None None O
ER None None I-protein
or None None O
PR None None I-protein
were None None O
confirmed None None O
by None None O
spatial None None O
location None None O
, None None O
dual None None O
immunolabelling None None O
, None None O
and None None O
histochemical None None O
staining None None O
. None None O

RESULTS None None O
: None None O
Consistent None None O
with None None O
the None None O
known None None O
features None None O
of None None O
nasal None None O
polyps None None O
, None None O
CD4+ None None I-cell_type
( None None I-cell_type
T None None I-cell_type
helper/inducer None None I-cell_type
) None None I-cell_type
, None None O
CD8+ None None I-cell_type
( None None I-cell_type
cytotoxic/suppressor None None I-cell_type
) None None I-cell_type
, None None O
CD68+ None None I-cell_type
( None None O
macrophages None None I-cell_type
) None None O
, None None O
mast None None I-cell_type
cells None None I-cell_type
, None None O
eosinophils None None I-cell_type
and None None O
neutrophils None None I-cell_type
were None None O
all None None O
clearly None None O
detected None None O
by None None O
their None None O
relevant None None O
monoclonal None None I-protein
antibodies None None I-protein
or None None O
appropriate None None O
histochemical None None O
staining None None O
, None None O
but None None O
only None None O
mast None None I-cell_type
cells None None I-cell_type
tested None None O
positive None None O
for None None O
ER None None I-protein
/PR None None O
labelling None None O
with None None O
their None None O
polyclonal None None I-protein
and None None I-protein
monoclonal None None I-protein
antibodies None None I-protein
. None None O

The None None O
frequencies None None O
for None None O
expression None None O
were None None O
61.7 None None O
% None None O
for None None O
ER None None I-cell_type
positive None None I-cell_type
and None None O
59.6 None None O
% None None O
for None None O
PR None None I-cell_type
positive None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
expression None None O
of None None O
ER None None I-protein
/ None None O
PR None None I-protein
was None None O
independent None None O
of None None O
patient None None O
sex None None O
and None None O
age None None O
but None None O
was None None O
highly None None O
correlated None None O
with None None O
the None None O
numbers None None O
of None None O
mast None None I-cell_type
cells None None I-cell_type
( None None O
r None None O
= None None O
0.973 None None O
, None None O
p None None O
< None None O
0.001 None None O
for None None O
ER None None I-protein
; None None O
r None None O
= None None O
0.955 None None O
, None None O
p None None O
< None None O
0.001 None None O
for None None O
PR None None I-protein
) None None O
. None None O

Fewer None None O
than None None O
5 None None O
% None None O
of None None O
mast None None I-cell_type
cells None None I-cell_type
were None None O
found None None O
to None None O
be None None O
negative None None O
for None None O
ER None None I-protein
/ None None O
PR None None I-protein
expression None None O
. None None O

CONCLUSIONS None None O
: None None O
Mast None None I-cell_type
cells None None I-cell_type
alone None None O
, None None O
but None None O
not None None O
lymphocytes None None I-cell_type
, None None O
macrophages None None I-cell_type
, None None O
or None None O
other None None O
immune None None I-cell_type
cells None None I-cell_type
, None None O
express None None O
ER None None I-protein
/ None None O
PR None None I-protein
in None None O
human None None O
upper None None O
airways None None O
. None None O

Numerous None None O
ER/PR None None I-cell_type
positive None None I-cell_type
mast None None I-cell_type
cells None None I-cell_type
exist None None O
in None None O
nasal None None O
polyps None None O
, None None O
indicating None None O
that None None O
this None None O
may None None O
be None None O
a None None O
major None None O
route None None O
for None None O
the None None O
involvement None None O
of None None O
sex None None O
hormones None None O
in None None O
airway None None O
inflammation None None O
when None None O
exposed None None O
to None None O
the None None O
higher None None O
and None None O
varying None None O
concentration None None O
of None None O
oestrogen None None O
and None None O
progesterone None None O
characteristic None None O
of None None O
females None None O
. None None O

NF None None O
kappa None None O
b None None O
signaling None None O
in None None O
posthypoxic None None I-cell_type
endothelial None None I-cell_type
cells None None I-cell_type
: None None O
relevance None None O
to None None O
E-selectin None None O
expression None None O
and None None O
neutrophil None None O
adhesion None None O
. None None O

Our None None O
previous None None O
studies None None O
have None None O
implicated None None O
the None None O
nuclear None None O
transcription None None O
factor None None O
kappa None None O
B None None O
( None None O
NF None None I-protein
kappa None None I-protein
B None None I-protein
) None None O
in None None O
the None None O
regulation None None O
of None None O
adhesion None None I-protein
molecule None None I-protein
expression None None O
in None None O
endothelial None None I-cell_type
cells None None I-cell_type
exposed None None O
to None None O
anoxia-reoxygenation None None O
( None None O
A/R None None O
) None None O
or None None O
a None None O
redox None None O
imbalance None None O
. None None O

The None None O
objectives None None O
of None None O
this None None O
study None None O
were None None O
( None None O
1 None None O
) None None O
to None None O
define None None O
the None None O
kinetics None None O
of None None O
NF None None I-protein
kappa None None I-protein
B None None I-protein
activation None None O
by None None O
examining None None O
I None None O
kappa None None O
B None None O
alpha None None O
degradation None None O
and None None O
the None None O
nuclear None None O
translocation None None O
of None None O
p65 None None I-protein
in None None O
response None None O
to None None O
A/R None None O
or None None O
redox None None O
imbalance None None O
( None None O
induced None None O
by None None O
treatment None None O
of None None O
cells None None O
with None None O
diamide None None O
and None None O
buthionine None None O
sulfoximine None None O
) None None O
and None None O
( None None O
2 None None O
) None None O
to None None O
determine None None O
whether None None O
the None None O
signal None None O
for None None O
I None None O
kappa None None O
B None None O
alpha None None O
degradation None None O
, None None O
nuclear None None O
translocation None None O
of None None O
p65 None None I-protein
, None None O
and None None O
E-selectin None None I-protein
-mediated None None O
neutrophil None None O
adhesion None None O
is None None O
related None None O
to None None O
the None None O
activity None None O
of None None O
protein None None I-protein
tyrosine None None I-protein
kinase None None I-protein
( None None O
PTK None None I-protein
) None None O
, None None O
protein None None I-protein
tyrosine None None I-protein
phosphatase None None I-protein
( None None O
PTPase None None I-protein
) None None O
and/or None None O
protein None None I-protein
kinase None None I-protein
C None None I-protein
( None None O
PKC None None I-protein
) None None O
. None None O

The None None O
results None None O
demonstrate None None O
that None None O
both None None O
A/R None None O
and None None O
redox None None O
imbalance None None O
led None None O
to None None O
I None None O
kappa None None O
B None None O
alpha None None O
degradation None None O
within None None O
30 None None O
min None None O
and None None O
the None None O
concomitant None None O
appearance None None O
of None None O
p65 None None I-protein
in None None O
the None None O
nucleus None None O
, None None O
consistent None None O
with None None O
rapid None None O
cytosolic None None O
activation None None O
of None None O
NF None None I-protein
kappa None None I-protein
B None None I-protein
and None None O
subsequent None None O
nuclear None None O
translocation None None O
of None None O
the None None O
activated None None I-protein
p65 None None I-protein
subunit None None I-protein
. None None O

Inhibition None None O
of None None O
PKC None None I-protein
blocked None None O
I None None I-protein
kappa None None I-protein
B None None I-protein
alpha None None I-protein
degradation None None O
and None None O
p65 None None I-protein
translocation None None O
in None None O
A/R-challenged None None O
, None None O
but None None O
not None None O
redox-altered None None O
, None None O
endothelial None None I-cell_type
cells None None I-cell_type
. None None O

However None None O
, None None O
both None None O
A/R- None None O
and None None O
redox-induced None None O
NF None None O
kappa None None O
B None None O
activation None None O
was None None O
blocked None None O
by None None O
inhibition None None O
of None None O
PTK None None I-protein
. None None O

Similarly None None O
, None None O
A/R-induced None None O
E-selectin None None O
expression None None O
and None None O
neutrophil-endothelial None None O
cell None None O
adhesion None None O
were None None O
blocked None None O
by None None O
inhibition None None O
of None None O
PKC None None I-protein
or None None O
PTK None None I-protein
, None None O
while None None O
only None None O
PTK None None I-protein
inhibited None None O
the None None O
redox-induced None None O
adhesion None None O
response None None O
. None None O

Pretreatment None None O
of None None O
cells None None O
with None None O
N-acetyl None None O
cysteine None None O
effectively None None O
blocked None None O
A/R- None None O
or None None O
redox-induced None None O
I None None O
kappa None None O
B None None O
degradation None None O
and None None O
significantly None None O
attenuated None None O
the None None O
respective None None O
neutrophil None None O
adhesion None None O
responses None None O
. None None O

Collectively None None O
, None None O
these None None O
findings None None O
indicate None None O
that None None O
A/R-induced None None O
E-selectin None None O
expression None None O
and None None O
neutrophil-endothelial None None O
cell None None O
adhesion None None O
are None None O
mediated None None O
by None None O
both None None O
PKC None None I-protein
and None None O
PTK None None I-protein
, None None O
which None None O
signal None None O
rapid None None O
activation None None O
of None None O
NF None None I-protein
kappa None None I-protein
B None None I-protein
. None None O

This None None O
A/R-induced None None O
NF None None I-protein
kappa None None I-protein
B None None I-protein
signaling None None O
response None None O
appears None None O
to None None O
be None None O
mediated None None O
, None None O
at None None O
least None None O
in None None O
part None None O
, None None O
by None None O
intracellular None None O
redox None None O
imbalance None None O
. None None O

Copyright None None O
2001 None None O
S. None None O
Karger None None O
AG None None O
, None None O
Basel None None O

Induction None None O
of None None O
apoptosis None None O
in None None O
human None None I-cell_type
lymphocytes None None I-cell_type
by None None O
the None None O
herbicide None None O
2 None None O
, None None O
4-dichlorophenoxyacetic None None O
acid None None O
. None None O

Dimethylammonium None None O
salt None None O
of None None O
2 None None O
, None None O
4-dichlorophenoxyacetic None None O
acid None None O
( None None O
DMA-2 None None O
, None None O
4-D None None O
) None None O
is None None O
a None None O
widely None None O
used None None O
herbicide None None O
that None None O
is None None O
considered None None O
moderately None None O
toxic None None O
. None None O

In None None O
the None None O
present None None O
study None None O
we None None O
found None None O
that None None O
DMA-2 None None O
, None None O
4-D None None O
is None None O
able None None O
to None None O
cause None None O
apoptosis None None O
in None None O
peripheral None None I-cell_type
blood None None I-cell_type
lymphocytes None None I-cell_type
of None None O
healthy None None O
individuals None None O
and None None O
Jurkat None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
. None None O

Apoptosis None None O
induced None None O
by None None O
DMA-2 None None O
, None None O
4-D None None O
was None None O
dose None None O
and None None O
time None None O
dependent None None O
, None None O
independent None None O
of None None O
Fas None None I-protein
, None None O
TNF None None I-protein
receptor None None I-protein
1 None None I-protein
or None None O
the None None O
aromatic None None I-protein
hydrocarbon None None I-protein
receptor None None I-protein
, None None O
and None None O
involved None None O
disruption None None O
of None None O
the None None O
mitochondrial None None O
transmembrane None None O
potential None None O
and None None O
activation None None O
of None None O
caspase-9 None None I-protein
. None None O

ZVAD-FMK None None O
, None None O
a None None O
broad-spectrum None None O
inhibitor None None O
of None None O
caspases None None I-protein
, None None O
blocked None None O
DMA-2 None None O
, None None O
4-D-induced None None O
apoptosis None None O
completely None None O
. None None O

While None None O
an None None O
inhibitor None None O
of None None O
caspase-9 None None I-protein
, None None O
as None None O
well None None O
as None None O
caspase-9 None None I-protein
and None None O
caspase-3 None None O
inhibitors None None O
in None None O
combination None None O
, None None O
strongly None None O
blocked None None O
DMA-2 None None O
, None None O
4-D-induced None None O
apoptosis None None O
, None None O
an None None O
inhibitor None None O
of None None O
caspase-3 None None I-protein
had None None O
a None None O
moderate None None O
inhibitory None None O
effect None None O
. None None O

Unlike None None O
Fas None None I-protein
-mediated None None O
apoptosis None None O
, None None O
the None None O
initiator None None I-protein
caspase None None I-protein
, None None O
caspase-8 None None I-protein
, None None O
was None None O
not None None O
involved None None O
in None None O
DMA-2 None None O
, None None O
4-D-induced None None O
apoptosis None None O
. None None O

Transfection None None O
of None None O
Jurkat None None I-cell_line
cells None None I-cell_line
with None None O
Bcl-2 None None I-protein
prevented None None O
DMA-2 None None O
, None None O
4-D-induced None None O
disruption None None O
of None None O
the None None O
mitochondrial None None O
transmembrane None None O
potential None None O
and None None O
led None None O
to None None O
a None None O
complete None None O
blockage None None O
of None None O
apoptosis None None O
. None None O

Our None None O
data None None O
indicate None None O
that None None O
DMA-2 None None O
, None None O
4-D None None O
kills None None O
human None None I-cell_type
lymphocytes None None I-cell_type
by None None O
initiating None None O
apoptosis None None O
via None None O
a None None O
direct None None O
effect None None O
on None None O
mitochondria None None O
. None None O

The None None O
activation None None O
of None None O
caspases None None I-protein
occurs None None O
downstream None None O
of None None O
mitochondrial None None O
damage None None O
, None None O
and None None O
the None None O
dysfunction None None O
of None None O
mitochondria None None O
appears None None O
to None None O
be None None O
sufficient None None O
for None None O
triggering None None O
all None None O
downstream None None O
events None None O
leading None None O
to None None O
apoptosis None None O
. None None O

Inhibition None None O
of None None O
Th1 None None O
differentiation None None O
by None None O
IL-6 None None I-protein
is None None O
mediated None None O
by None None O
SOCS1 None None I-protein
. None None O

Interleukin None None I-protein
6 None None I-protein
( None None O
IL-6 None None I-protein
) None None O
is None None O
a None None O
cytokine None None I-protein
produced None None O
by None None O
immune None None I-cell_type
and None None I-cell_type
nonimmune None None I-cell_type
cells None None I-cell_type
and None None O
exhibits None None O
functional None None O
pleiotropy None None O
and None None O
redundancy None None O
. None None O

IL-6 None None I-protein
plays None None O
an None None O
important None None O
role None None O
in None None O
the None None O
differentiation None None O
of None None O
several None None O
cell None None O
types None None O
. None None O

Here None None O
, None None O
we None None O
describe None None O
a None None O
novel None None O
function None None O
of None None O
IL-6 None None I-protein
: None None O
the None None O
negative None None O
regulation None None O
of None None O
CD4 None None I-protein
+ None None O
Th1 None None O
cell None None O
differentiation None None O
. None None O

While None None O
IL-6 None None I-protein
-directed None None O
CD4 None None I-protein
+ None None O
Th2 None None O
differentiation None None O
is None None O
mediated None None O
by None None O
IL-4 None None I-protein
, None None O
inhibition None None O
of None None O
Th1 None None O
differentiation None None O
by None None O
IL-6 None None I-protein
is None None O
independent None None O
of None None O
IL-4 None None I-protein
. None None O

IL-6 None None I-protein
upregulates None None O
suppressor None None I-protein
of None None I-protein
cytokine None None I-protein
signaling None None I-protein
1 None None I-protein
( None None O
SOCS1 None None I-protein
) None None O
expression None None O
in None None O
activated None None I-cell_type
CD4+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
, None None O
thereby None None O
interfering None None O
with None None O
signal None None I-protein
transducer None None I-protein
and None None I-protein
activator None None I-protein
of None None I-protein
transcription None None I-protein
1 None None I-protein
( None None O
STAT1 None None I-protein
) None None O
phosphorylation None None O
induced None None O
by None None O
interferon None None I-protein
gamma None None I-protein
( None None O
IFNgamma None None I-protein
) None None O
. None None O

Inhibition None None O
of None None O
IFNgamma None None I-protein
receptor-mediated None None O
signals None None O
by None None O
IL-6 None None I-protein
prevents None None O
autoregulation None None O
of None None O
IFNgamma None None I-DNA
gene None None I-DNA
expression None None O
by None None O
IFNgamma None None I-protein
during None None O
CD4+ None None I-cell_type
T None None I-cell_type
cell None None I-cell_type
activation None None O
, None None O
thereby None None O
preventing None None O
Th1 None None O
differentiation None None O
. None None O

Thus None None O
, None None O
IL-6 None None I-protein
promotes None None O
CD4 None None I-protein
+ None None O
Th2 None None O
differentiation None None O
and None None O
inhibits None None O
Th1 None None O
differentiation None None O
by None None O
two None None O
independent None None O
molecular None None O
mechanisms None None O
. None None O

Interaction None None O
between None None O
CCAAT/enhancer None None I-protein
binding None None I-protein
protein None None I-protein
and None None O
cyclic None None I-protein
AMP None None I-protein
response None None I-protein
element None None I-protein
binding None None I-protein
protein None None I-protein
1 None None I-protein
regulates None None O
human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
transcription None None O
in None None O
cells None None O
of None None O
the None None O
monocyte/macrophage None None I-cell_type
lineage None None I-cell_type
. None None O

Recent None None O
observations None None O
have None None O
shown None None O
two None None O
CCAAT/enhancer None None I-DNA
binding None None I-DNA
protein None None I-DNA
( None None I-DNA
C/EBP None None I-DNA
) None None I-DNA
binding None None I-DNA
sites None None I-DNA
to None None O
be None None O
critically None None O
important None None O
for None None O
efficient None None O
human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
( None None O
HIV-1 None None O
) None None O
replication None None O
within None None O
cells None None O
of None None O
the None None O
monocyte/macrophage None None I-cell_type
lineage None None I-cell_type
, None None O
a None None O
cell None None O
type None None O
likely None None O
involved None None O
in None None O
transport None None O
of None None O
the None None O
virus None None O
to None None O
the None None O
brain None None O
. None None O

Additionally None None O
, None None O
sequence None None O
variation None None O
at None None O
C/EBP None None I-DNA
site None None I-DNA
I None None I-DNA
, None None O
which None None O
lies None None O
immediately None None O
upstream None None O
of None None O
the None None O
distal None None I-DNA
nuclear None None I-DNA
factor None None I-DNA
kappa None None I-DNA
B None None I-DNA
site None None I-DNA
and None None O
immediately None None O
downstream None None O
of None None O
a None None O
binding None None O
site None None O
for None None O
activating None None I-protein
transcription None None I-protein
factor None None I-protein
( None None O
ATF None None I-protein
) None None O
/ None None O
cyclic None None I-protein
AMP None None I-protein
response None None I-protein
element None None I-protein
binding None None I-protein
protein None None I-protein
( None None O
CREB None None I-protein
) None None O
, None None O
has None None O
been None None O
shown None None O
to None None O
affect None None O
HIV-1 None None I-DNA
long None None I-DNA
terminal None None I-DNA
repeat None None I-DNA
( None None O
LTR None None I-DNA
) None None O
activity None None O
. None None O

Given None None O
that None None O
C/EBP None None I-protein
proteins None None I-protein
have None None O
been None None O
shown None None O
to None None O
interact None None O
with None None O
many None None O
other None None O
transcription None None I-protein
factors None None I-protein
including None None O
members None None O
of None None O
the None None O
ATF/CREB None None I-protein
family None None I-protein
, None None O
we None None O
proceeded None None O
to None None O
determine None None O
whether None None O
an None None O
adjacent None None O
ATF/CREB None None I-DNA
binding None None I-DNA
site None None I-DNA
could None None O
affect None None O
C/EBP None None I-protein
protein None None I-protein
binding None None O
to None None O
C/EBP None None I-DNA
site None None I-DNA
I None None I-DNA
. None None O

Electrophoretic None None O
mobility None None O
shift None None O
analyses None None O
indicated None None O
that None None O
selected None None O
ATF/CREB None None I-DNA
site None None I-DNA
variants None None I-DNA
assisted None None O
in None None O
the None None O
recruitment None None O
of None None O
C/EBP None None I-protein
proteins None None I-protein
to None None O
an None None O
adjacent None None O
, None None O
naturally None None O
occurring None None O
, None None O
low-affinity None None O
C/EBP None None I-DNA
site None None I-DNA
. None None O

This None None O
biophysical None None O
interaction None None O
appears None None O
to None None O
occur None None O
via None None O
at None None O
least None None O
two None None O
mechanisms None None O
. None None O

First None None O
, None None O
low None None O
amounts None None O
of None None O
CREB-1 None None I-protein
and None None O
C/EBP None None I-protein
appear None None O
to None None O
heterodimerize None None O
and None None O
bind None None O
to None None O
a None None O
site None None O
consisting None None O
of None None O
a None None O
half None None O
site None None O
from None None O
both None None O
the None None O
ATF/CREB None None I-DNA
and None None I-DNA
C/EBP None None I-DNA
binding None None I-DNA
sites None None I-DNA
. None None O

In None None O
addition None None O
, None None O
CREB-1 None None I-protein
homodimers None None I-protein
bind None None O
to None None O
the None None O
ATF/CREB None None I-DNA
site None None I-DNA
and None None O
recruit None None O
C/EBP None None I-protein
dimers None None I-protein
to None None O
their None None O
cognate None None O
weak None None I-DNA
binding None None I-DNA
sites None None I-DNA
. None None O

This None None O
interaction None None O
is None None O
reciprocal None None O
, None None O
since None None O
C/EBP None None I-protein
dimer None None I-protein
binding None None O
to None None O
a None None O
strong None None O
C/EBP None None I-DNA
site None None I-DNA
leads None None O
to None None O
enhanced None None O
CREB-1 None None I-protein
recruitment None None O
to None None O
ATF/CREB None None I-DNA
sites None None I-DNA
that None None O
are None None O
weakly None None O
bound None None O
by None None O
CREB None None I-protein
. None None O

Sequence None None O
variation None None O
at None None O
both None None O
C/EBP None None I-DNA
and None None I-DNA
ATF/CREB None None I-DNA
sites None None I-DNA
affects None None O
the None None O
molecular None None O
interactions None None O
involved None None O
in None None O
mediating None None O
both None None O
of None None O
these None None O
mechanisms None None O
. None None O

Most None None O
importantly None None O
, None None O
sequence None None O
variation None None O
at None None O
the None None O
ATF/CREB None None I-DNA
binding None None I-DNA
site None None I-DNA
affected None None O
basal None None O
LTR None None I-DNA
activity None None O
as None None O
well None None O
as None None O
LTR None None I-DNA
function None None O
following None None O
interleukin-6 None None I-protein
stimulation None None O
, None None O
a None None O
treatment None None O
that None None O
leads None None O
to None None O
increases None None O
in None None O
C/EBP None None O
activation None None O
. None None O

Thus None None O
, None None O
HIV-1 None None I-DNA
LTR None None I-DNA
ATF/CREB None None B-DNA
binding None None I-DNA
site None None I-DNA
sequence None None O
variation None None O
may None None O
modulate None None O
cellular None None O
signaling None None O
at None None O
the None None O
viral None None I-DNA
promoter None None I-DNA
through None None O
the None None O
C/EBP None None O
pathway None None O

Selective None None O
inhibition None None O
of None None O
interleukin-4 None None O
gene None None O
expression None None O
in None None O
human None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
by None None O
aspirin None None O
. None None O

Previous None None O
studies None None O
indicated None None O
that None None O
aspirin None None O
( None None O
acetylsalicylic None None O
acid None None O
[ None None O
ASA None None O
] None None O
) None None O
can None None O
have None None O
profound None None O
immunomodulatory None None O
effects None None O
by None None O
regulating None None O
cytokine None None O
gene None None O
expression None None O
in None None O
several None None O
types None None O
of None None O
cells None None O
. None None O

This None None O
study None None O
is None None O
the None None O
first None None O
in None None O
which None None O
concentrations None None O
of None None O
ASA None None O
in None None O
the None None O
therapeutic None None O
range None None O
were None None O
found None None O
to None None O
significantly None None O
reduce None None O
interleukin None None I-protein
( None None I-protein
IL None None I-protein
) None None I-protein
-4 None None I-protein
secretion None None O
and None None O
RNA None None O
expression None None O
in None None O
freshly None None I-cell_type
isolated None None I-cell_type
and None None I-cell_type
mitogen-primed None None I-cell_type
human None None I-cell_type
CD4+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

In None None O
contrast None None O
, None None O
ASA None None O
did None None O
not None None O
affect None None O
IL-13 None None I-protein
, None None O
interferon-gamma None None I-protein
, None None O
and None None O
IL-2 None None I-protein
expression None None O
. None None O

ASA None None O
inhibited None None O
IL-4 None None I-protein
, None None O
but None None O
not None None O
IL-2 None None I-protein
, None None O
promoter-driven None None O
chloramphenicol None None O
acetyltransferase None None O
expression None None O
in None None O
transiently None None O
transfected None None O
Jurkat None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
. None None O

The None None O
structurally None None O
unrelated None None O
nonsteroidal None None O
anti-inflammatory None None O
drugs None None O
indomethacin None None O
and None None O
flurbiprofen None None O
did None None O
not None None O
affect None None O
cytokine None None O
gene None None O
expression None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
, None None O
whereas None None O
the None None O
weak None None O
cyclo-oxygenase None None O
inhibitor None None O
salicylic None None O
acid None None O
was None None O
at None None O
least None None O
as None None O
effective None None O
as None None O
ASA None None O
in None None O
inhibiting None None O
IL-4 None None I-protein
expression None None O
and None None O
promoter None None O
activity None None O
. None None O

The None None O
inhibitory None None O
effect None None O
of None None O
ASA None None O
on None None O
IL-4 None None O
transcription None None O
was None None O
not None None O
mediated None None O
by None None O
decreased None None O
nuclear None None O
expression None None O
of None None O
the None None O
known None None O
salicylate None None I-protein
target None None I-protein
nuclear None None I-protein
factor None None I-protein
( None None I-protein
NF None None I-protein
) None None I-protein
-kappaB None None I-protein
and None None O
was None None O
accompanied None None O
by None None O
reduced None None O
binding None None O
of None None O
an None None O
inducible None None O
factor None None O
to None None O
an None None O
IL-4 None None I-DNA
promoter None None I-DNA
region None None I-DNA
upstream None None O
of None None O
, None None O
but None None O
not None None O
overlapping None None O
, None None O
the None None O
NF None None I-DNA
of None None I-DNA
activated None None I-DNA
T None None I-DNA
cells- None None I-DNA
and None None I-DNA
NF-kappaB-binding None None I-DNA
P1 None None I-DNA
element None None I-DNA
. None None O

It None None O
is None None O
concluded None None O
that None None O
anti-inflammatory None None O
salicylates None None O
, None None O
by None None O
means None None O
of None None O
a None None O
previously None None O
unrecognized None None O
mechanism None None O
of None None O
action None None O
, None None O
can None None O
influence None None O
the None None O
nature None None O
of None None O
adaptive None None O
immune None None O
responses None None O
by None None O
selectively None None O
inhibiting None None O
the None None O
expression None None O
of None None O
IL-4 None None I-protein
, None None O
a None None O
critical None None O
effector None None O
of None None O
these None None O
responses None None O
, None None O
in None None O
CD4+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

Molecular None None O
and None None O
cellular None None O
mediators None None O
of None None O
interleukin-1 None None I-protein
-dependent None None O
acute None None O
inflammatory None None O
arthritis None None O
. None None O

OBJECTIVE None None O
: None None O
To None None O
examine None None O
the None None O
molecular None None O
and None None O
cellular None None O
mechanisms None None O
in None None O
a None None O
model None None O
of None None O
acute None None O
inflammatory None None O
monarticular None None O
arthritis None None O
induced None None O
by None None O
methylated None None I-protein
bovine None None I-protein
serum None None I-protein
albumin None None I-protein
( None None O
mBSA None None I-protein
) None None O
and None None O
interleukin-1 None None I-protein
( None None O
IL-1 None None I-protein
) None None O
. None None O

METHODS None None O
: None None O
Mice None None O
were None None O
injected None None O
intraarticularly None None O
with None None O
mBSA None None I-protein
on None None O
day None None O
0 None None O
and None None O
subcutaneously None None O
with None None O
recombinant None None I-protein
human None None I-protein
IL-1beta None None I-protein
on None None O
days None None O
0-2 None None O
. None None O

At None None O
day None None O
7 None None O
, None None O
knee None None O
joints None None O
were None None O
removed None None O
and None None O
assessed None None O
histologically None None O
. None None O

Flow None None O
cytometry None None O
and None None O
RNase None None O
protection None None O
were None None O
used None None O
to None None O
analyze None None O
IL-1 None None I-protein
-dependent None None O
events None None O
. None None O

RESULTS None None O
: None None O
C57BL/6 None None O
( None None O
B6 None None O
) None None O
, None None O
129/Sv None None O
, None None O
and None None O
( None None O
B6 None None O
x None None O
129/ None None O
Sv None None O
) None None O
F1 None None O
hybrid None None O
mice None None O
, None None O
all None None O
H-2b None None O
strains None None O
, None None O
were None None O
susceptible None None O
to None None O
mBSA None None I-protein
/IL-1-induced None None O
arthritis None None O
, None None O
whereas None None O
C3H/HeJ None None O
( None None O
H-2k None None O
) None None O
mice None None O
were None None O
not None None O
. None None O

B6 None None O
mice None None O
lacking None None O
T None None I-cell_type
and None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
( None None O
RAG1-/- None None O
) None None O
or None None O
major None None I-protein
histocompatibility None None I-protein
complex None None I-protein
( None None I-protein
MHC None None I-protein
) None None I-protein
class None None I-protein
II None None I-protein
antigens None None I-protein
( None None O
MHCII-/- None None O
) None None O
, None None O
and None None O
B6 None None O
mice None None O
treated None None O
with None None O
a None None O
CD4+ None None I-protein
T None None I-protein
cell-depleting None None I-protein
monoclonal None None I-protein
antibody None None I-protein
, None None O
were None None O
resistant None None O
to None None O
disease None None O
. None None O

In None None O
contrast None None O
, None None O
B None None O
cell-deficient None None O
( None None O
muMT/ None None O
muMT None None O
) None None O
mice None None O
developed None None O
arthritis None None O
at None None O
an None None O
incidence None None O
and None None O
severity None None O
similar None None O
to None None O
that None None O
of None None O
controls None None O
. None None O

RelB-deficient None None O
( None None O
RelB-/- None None O
) None None O
bone None None O
marrow None None O
chimeric None None O
mice None None O
had None None O
arthritis None None O
that None None O
was None None O
significantly None None O
reduced None None O
in None None O
incidence None None O
and None None O
severity None None O
. None None O

In None None O
B6 None None O
mice None None O
, None None O
flow None None O
cytometry None None O
demonstrated None None O
an None None O
IL-1-dependent None None I-cell_type
leukocyte None None I-cell_type
infiltration None None O
into None None O
the None None O
synovial None None O
compartment None None O
and None None O
RNase None None O
protection None None O
assays None None O
revealed None None O
induction None None O
of None None O
messenger None None I-RNA
RNA None None I-RNA
( None None O
mRNA None None I-RNA
) None None O
for None None O
the None None O
chemokines None None I-protein
monocyte None None B-protein
chemoattractant None None I-protein
protein None None I-protein
1 None None I-protein
, None None O
macrophage None None I-protein
inhibitory None None I-protein
protein None None I-protein
2 None None I-protein
( None None O
MIP-2 None None I-protein
) None None O
, None None O
RANTES None None I-protein
, None None O
MIP-1alpha None None I-protein
, None None O
and None None O
MIP-1beta None None I-protein
, None None O
in None None O
vivo None None O
and None None O
in None None O
vitro None None O
. None None O

CONCLUSION None None O
: None None O
Arthritis None None O
induced None None O
by None None O
mBSA None None I-protein
/ None None O
IL-1 None None I-protein
is None None O
strain None None O
specific None None O
and None None O
dependent None None O
on None None O
CD4+ None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
and None None O
at None None O
least None None O
partially None None O
on None None O
RelB None None I-protein
, None None O
but None None O
not None None O
on None None O
B None None I-cell_type
lymphocytes None None I-cell_type
or None None O
antibody None None I-protein
. None None O

IL-1 None None I-protein
contributes None None O
to None None O
leukocyte None None O
recruitment None None O
to None None O
the None None O
synovium None None O
and None None O
directly None None O
induces None None O
chemokine None None O
mRNA None None O
production None None O
by None None O
synovial None None I-cell_type
cells None None I-cell_type
. None None O

This None None O
model None None O
of None None O
acute None None O
monarticular None None O
arthritis None None O
is None None O
particularly None None O
suitable None None O
for None None O
further None None O
investigations None None O
into None None O
cell-mediated None None O
immunity None None O
in None None O
arthritis None None O
and None None O
the None None O
role None None O
of None None O
IL-1 None None I-protein
. None None O

Positive None None O
and None None O
negative None None O
regulation None None O
of None None O
granulopoiesis None None O
by None None O
endogenous None None I-protein
RARalpha None None I-protein
. None None O

Acute None None O
promyelocytic None None O
leukemia None None O
( None None O
APL None None O
) None None O
is None None O
always None None O
associated None None O
with None None O
chromosomal None None O
translocations None None O
that None None O
disrupt None None O
the None None O
retinoic None None I-DNA
acid None None I-DNA
receptor None None I-DNA
alpha None None I-DNA
( None None I-DNA
RARalpha None None I-DNA
) None None I-DNA
gene None None I-DNA
. None None O

Whether None None O
these None None O
translocations None None O
relate None None O
to None None O
a None None O
role None None O
for None None O
endogenous None None I-protein
RARalpha None None I-protein
in None None O
normal None None O
granulopoiesis None None O
remains None None O
uncertain None None O
because None None O
most None None O
studies None None O
addressing None None O
this None None O
question None None O
have None None O
used None None O
non-physiological None None O
overexpression None None O
systems None None O
. None None O

Granulocyte None None O
differentiation None None O
in None None O
cells None None O
derived None None O
from None None O
RARalpha-deficient None None O
( None None O
RARalpha None None O
( None None O
-/- None None O
) None None O
) None None O
mice None None O
was None None O
studied None None O
and None None O
evaluated None None O
in None None O
the None None O
context None None O
of None None O
agonist-bound None None I-protein
and None None I-protein
ligand-free None None I-protein
RARalpha None None I-protein
. None None O

Our None None O
results None None O
demonstrate None None O
that None None O
RARalpha None None I-protein
is None None O
dispensable None None O
for None None O
granulopoiesis None None O
, None None O
as None None O
RARalpha None None O
( None None O
-/- None None O
) None None O
mice None None O
have None None O
a None None O
normal None None I-cell_type
granulocyte None None I-cell_type
population None None I-cell_type
despite None None O
an None None O
impaired None None O
ability None None O
to None None O
respond None None O
to None None O
retinoids None None O
. None None O

However None None O
, None None O
although None None O
it None None O
is None None O
not None None O
absolutely None None O
required None None O
, None None O
RARalpha None None I-protein
can None None O
bidirectionally None None O
modulate None None O
granulopoiesis None None O
. None None O

RARalpha None None I-protein
stimulates None None O
differentiation None None O
in None None O
response None None O
to None None O
exogenous None None O
retinoic None None O
acid None None O
. None None O

Furthermore None None O
, None None O
endogenous None None O
retinoids None None O
control None None O
granulopoiesis None None O
in None None O
vivo None None O
, None None O
as None None O
either None None O
vitamin None None O
A-deficient None None O
mice None None O
or None None O
animals None None O
treated None None O
with None None O
an None None O
RAR None None O
antagonist None None O
accumulate None None O
more None None O
immature None None I-cell_type
granulocytes None None I-cell_type
in None None O
their None None O
bone None None O
marrow None None O
. None None O

Conversely None None O
, None None O
RARalpha None None I-protein
acts None None O
to None None O
limit None None O
differentiation None None O
in None None O
the None None O
absence None None O
of None None O
ligand None None I-protein
because None None O
granulocyte None None I-cell_type
precursors None None I-cell_type
from None None O
RARalpha None None O
( None None O
-/- None None O
) None None O
mice None None O
differentiate None None O
earlier None None O
in None None O
culture None None O
. None None O

Thus None None O
, None None O
the None None O
block None None O
in None None O
granulopoiesis None None O
exerted None None O
by None None O
RARalpha None None I-protein
fusion None None B-protein
proteins None None I-protein
expressed None None O
in None None O
APL None None I-cell_type
cells None None I-cell_type
may None None O
correspond None None O
to None None O
an None None O
amplification None None O
of None None O
a None None O
normal None None O
function None None O
of None None O
unliganded None None I-protein
RARalpha None None I-protein
. None None O

Expression None None O
and None None O
function None None O
of None None O
a None None O
stem None None I-DNA
cell None None I-DNA
promoter None None I-DNA
for None None O
the None None O
murine None None I-DNA
CBFalpha2 None None I-DNA
gene None None I-DNA
: None None O
distinct None None O
roles None None O
and None None O
regulation None None O
in None None O
natural None None I-cell_type
killer None None I-cell_type
and None None I-cell_type
T None None I-cell_type
cell None None I-cell_type
development None None O
. None None O

The None None O
Runt None None I-protein
family None None I-protein
transcription None None I-protein
factor None None I-protein
CBFalpha2 None None B-protein
( None None O
AML1 None None I-protein
, None None O
PEBP2alphaB None None I-protein
, None None O
or None None O
Runx1 None None I-protein
) None None O
is None None O
required None None O
by None None O
hematopoietic None None I-cell_type
stem None None I-cell_type
cells None None I-cell_type
and None None O
expressed None None O
at None None O
high None None O
levels None None O
in None None O
T-lineage None None I-cell_type
cells None None I-cell_type
. None None O

In None None O
human None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
CBFalpha2 None None I-protein
is None None O
usually None None O
transcribed None None O
from None None O
a None None O
different None None I-DNA
promoter None None I-DNA
( None None O
distal None None I-DNA
promoter None None I-DNA
) None None O
than None None O
in None None O
myeloid None None I-cell_type
cells None None I-cell_type
( None None O
proximal None None I-DNA
promoter None None I-DNA
) None None O
, None None O
but None None O
the None None O
developmental None None O
and None None O
functional None None O
significance None None O
of None None O
this None None O
promoter None None O
switch None None O
has None None O
not None None O
been None None O
known None None O
. None None O

Here None None O
, None None O
we None None O
report None None O
that None None O
both None None O
coding None None I-DNA
and None None I-DNA
noncoding None None I-DNA
sequences None None I-DNA
of None None O
the None None O
distal None None I-DNA
5 None None I-DNA
' None None I-DNA
end None None I-DNA
are None None O
highly None None O
conserved None None O
between None None O
the None None O
human None None I-DNA
and None None I-DNA
the None None I-DNA
murine None None I-DNA
genes None None I-DNA
, None None O
and None None O
the None None O
distal None None I-DNA
promoter None None I-DNA
is None None O
responsible None None O
for None None O
the None None O
overwhelming None None O
majority None None O
of None None O
CBFalpha2 None None O
expression None None O
in None None O
murine None None O
hematopoietic None None I-cell_type
stem None None I-cell_type
cells None None I-cell_type
as None None O
well None None O
as None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

Distal None None O
promoter None None O
activity None None O
is None None O
maintained None None O
throughout None None O
T None None O
cell None None O
development None None O
and None None O
at None None O
lower None None O
levels None None O
in None None O
B None None O
cell None None O
development None None O
, None None O
but None None O
downregulated None None O
in None None O
natural None None O
killer None None O
cell None None O
development None None O
. None None O

The None None O
distal None None I-DNA
N-terminal None None I-DNA
isoform None None I-DNA
binds None None O
to None None O
functionally None None O
important None None O
regulatory None None I-DNA
sites None None I-DNA
from None None O
known None None O
target None None I-DNA
genes None None I-DNA
with None None O
two- None None O
to None None O
threefold None None O
higher None None O
affinity None None O
than None None O
the None None O
proximal None None I-DNA
N-terminal None None I-DNA
isoform None None I-DNA
. None None O

Neither None None O
full-length None None I-DNA
isoform None None I-DNA
alters None None O
growth None None O
of None None O
a None None O
myeloid None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
under None None O
nondifferentiating None None O
conditions None None O
, None None O
but None None O
the None None O
proximal None None I-DNA
isoform None None I-DNA
selectively None None O
delays None None O
mitotic None None O
arrest None None O
of None None O
the None None O
cell None None O
line None None O
under None None O
differentiating None None O
conditions None None O
, None None O
resulting None None O
in None None O
the None None O
generation None None O
of None None O
greater None None O
numbers None None O
of None None O
neutrophils None None I-cell_type
. None None O

Constitutive None None O
PI3-K None None O
activity None None O
is None None O
essential None None O
for None None O
proliferation None None O
, None None O
but None None O
not None None O
survival None None O
, None None O
of None None O
Theileria None None I-cell_type
parva-transformed None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
. None None O

Theileria None None O
is None None O
an None None O
intracellular None None O
parasite None None O
that None None O
causes None None O
lymphoproliferative None None O
disorders None None O
in None None O
cattle None None O
, None None O
and None None O
infection None None O
of None None O
leucocytes None None I-cell_type
induces None None O
a None None O
transformed None None O
phenotype None None O
similar None None O
to None None O
tumour None None I-cell_type
cells None None I-cell_type
, None None O
but None None O
the None None O
mechanisms None None O
by None None O
which None None O
the None None O
parasite None None O
induces None None O
this None None O
phenotype None None O
are None None O
not None None O
understood None None O
. None None O

Here None None O
, None None O
we None None O
show None None O
that None None O
infected None None I-cell_type
B None None I-cell_type
lymphocytes None None I-cell_type
display None None O
constitutive None None O
phosphoinositide None None O
3-kinase None None O
( None None O
PI3-K None None O
) None None O
activity None None O
, None None O
which None None O
appears None None O
to None None O
be None None O
necessary None None O
for None None O
proliferation None None O
, None None O
but None None O
not None None O
survival None None O
. None None O

Importantly None None O
, None None O
we None None O
demonstrate None None O
that None None O
one None None O
mechanism None None O
by None None O
which None None O
PI3-K None None I-protein
mediates None None O
the None None O
proliferation None None O
of None None O
infected None None I-cell_type
B None None I-cell_type
lymphocytes None None I-cell_type
is None None O
through None None O
the None None O
induction None None O
of None None O
a None None O
granulocyte-monocyte None None I-protein
colony-stimulating None None I-protein
factor None None I-protein
( None None O
GM-CSF None None I-protein
) None None O
-dependent None None O
autocrine None None O
loop None None O
. None None O

PI3-K None None I-protein
induction None None O
of None None O
GM-CSF None None I-protein
appears None None O
to None None O
be None None O
at None None O
the None None O
transcriptional None None O
level None None O
and None None O
, None None O
consistently None None O
, None None O
we None None O
demonstrate None None O
that None None O
PI3-K None None I-protein
is None None O
also None None O
involved None None O
in None None O
the None None O
constitutive None None O
induction None None O
of None None O
AP-1 None None I-protein
and None None O
NF-kappaB None None I-protein
, None None O
which None None O
characterizes None None O
Theileria-infected None None O
leucocytes None None I-cell_type
. None None O

Taken None None O
together None None O
, None None O
our None None O
results None None O
highlight None None O
a None None O
novel None None O
strategy None None O
exploited None None O
by None None O
the None None O
intracellular None None O
parasite None None O
Theileria None None O
to None None O
induce None None O
continued None None O
proliferation None None O
of None None O
its None None O
host None None I-cell_type
leucocyte None None I-cell_type
. None None O

Lymphokine None None I-protein
dependence None None O
of None None O
STAT3 None None O
activation None None O
produced None None O
by None None O
surface None None O
immunoglobulin None None O
cross-linking None None O
and None None O
by None None O
phorbol None None O
ester None None O
plus None None O
calcium None None O
ionophore None None O
treatment None None O
in None None O
B None None I-cell_type
cells None None I-cell_type
. None None O

Stimulation None None O
of None None O
B None None I-cell_type
cells None None I-cell_type
by None None O
surface None None I-protein
immunoglobulin None None I-protein
( None None O
sIg None None I-protein
) None None O
triggering None None O
, None None O
or None None O
through None None O
the None None O
mitogenic None None O
combination None None O
of None None O
phorbol None None O
ester None None O
and None None O
calcium None None O
ionophore None None O
, None None O
is None None O
accompanied None None O
by None None O
activation None None O
of None None O
STAT None None I-protein
transcription None None I-protein
factors None None I-protein
. None None O

The None None O
mechanism None None O
responsible None None O
for None None O
the None None O
delayed None None O
nuclear None None O
accumulation None None O
of None None O
phosphorylated None None I-protein
STAT3 None None I-protein
was None None O
examined None None O
in None None O
detail None None O
, None None O
focusing None None O
on None None O
the None None O
role None None O
of None None O
B None None I-protein
cell-derived None None I-protein
lymphokines None None I-protein
. None None O

sIg None None I-protein
-induced None None O
activation None None O
of None None O
STAT3 None None I-protein
was None None O
partially None None O
inhibited None None O
in None None O
B None None I-cell_type
cells None None I-cell_type
obtained None None O
from None None O
IL-6- None None O
or None None O
IL-10-deficient None None O
mice None None O
, None None O
and None None O
was None None O
partially None None O
blocked None None O
by None None O
neutralizing None None I-protein
antibodies None None I-protein
directed None None O
against None None O
either None None O
of None None O
these None None O
lymphokines None None I-protein
. None None O

sIg None None I-protein
-induced None None O
STAT3 None None O
activation None None O
was None None O
completely None None O
inhibited None None O
by None None O
combining None None O
IL-6- None None I-protein
and None None I-protein
IL-10-specific None None I-protein
neutralizing None None I-protein
antibodies None None I-protein
, None None O
or None None O
by None None O
adding None None O
individual None None O
neutralizing None None I-protein
antibodies None None I-protein
to None None O
B None None I-cell_type
cells None None I-cell_type
obtained None None O
from None None O
lymphokine-deficient None None O
animals None None O
. None None O

In None None O
contrast None None O
, None None O
IL-10 None None I-protein
alone None None O
appeared None None O
to None None O
account None None O
for None None O
STAT3 None None O
activation None None O
resulting None None O
from None None O
B None None O
cell None None O
stimulation None None O
with None None O
phorbol None None O
ester None None O
and None None O
calcium None None O
ionophore None None O
. None None O

In None None O
keeping None None O
with None None O
these None None O
results None None O
, None None O
soluble None None O
IL-6 None None I-protein
and None None O
IL-10 None None I-protein
were None None O
found None None O
in None None O
supernatant None None O
fluid None None O
obtained None None O
from None None O
stimulated None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
. None None O

This None None O
work None None O
indicates None None O
that None None O
a None None O
lymphokine None None O
pathway None None O
is None None O
responsible None None O
for None None O
STAT3 None None O
activation None None O
that None None O
occurs None None O
late None None O
after None None O
B None None O
cell None None O
stimulation None None O
, None None O
and None None O
points None None O
out None None O
differences None None O
in None None O
B None None O
cell None None O
activation None None O
that None None O
result None None O
from None None O
stimulation None None O
through None None O
the None None O
antigen None None I-protein
receptor None None I-protein
and None None O
through None None O
pharmacological None None O
mimicry None None O
of None None O
signaling None None I-protein
mediators None None I-protein
. None None O

Transcription None None I-protein
factor None None I-protein
AP-4 None None I-protein
is None None O
a None None O
ligand None None I-protein
for None None O
immunoglobulin-kappa None None I-DNA
promoter None None I-DNA
E-box None None I-DNA
elements None None I-DNA
. None None O

Immunoglobulin None None I-DNA
( None None I-DNA
Ig None None I-DNA
) None None I-DNA
-kappa None None I-DNA
promoters None None I-DNA
from None None O
humans None None O
and None None O
mice None None O
share None None O
conserved None None I-DNA
sequences None None I-DNA
. None None O

The None None O
octamer None None I-DNA
element None None I-DNA
is None None O
common None None O
to None None O
all None None O
Ig None None I-DNA
promoters None None I-DNA
and None None O
pivotal None None O
for None None O
their None None O
function None None O
. None None O

However None None O
, None None O
other None None O
conserved None None I-DNA
sequence None None I-DNA
motifs None None I-DNA
, None None O
that None None O
differ None None O
between None None O
Ig None None I-DNA
variable None None I-DNA
gene None None I-DNA
families None None I-DNA
, None None O
are None None O
required None None O
for None None O
normal None None O
promoter None None O
function None None O
. None None O

These None None O
conserved None None O
motifs None None O
do None None O
not None None O
stimulate None None O
transcription None None O
in None None O
the None None O
absence None None O
of None None O
an None None O
octamer None None I-DNA
. None None O

One None None O
example None None O
is None None O
an None None O
E-box None None I-DNA
of None None O
the None None O
E47/E12 None None I-DNA
type None None I-DNA
( None None I-DNA
5'-CAGCTG-3 None None I-DNA
' None None I-DNA
) None None I-DNA
, None None O
which None None O
is None None O
found None None O
in None None O
all None None O
promoters None None O
of None None O
the None None O
human None None I-DNA
and None None I-DNA
murine None None I-DNA
Ig-kappa None None I-DNA
gene None None I-DNA
subgroups/families None None I-DNA
, None None O
with None None O
the None None O
exception None None O
of None None O
subgroups None None O
II None None O
and None None O
VI None None O
and None None O
their None None O
related None None O
murine None None I-DNA
families None None I-DNA
. None None O

In None None O
the None None O
present None None O
study None None O
we None None O
show None None O
that None None O
the None None O
ubiquitously None None O
expressed None None O
transcription None None I-protein
factor None None I-protein
AP-4 None None I-protein
, None None O
and None None O
not None None O
E47 None None I-protein
, None None O
interacts None None O
specifically None None O
with None None O
the None None O
kappa None None I-DNA
promoter None None I-DNA
E-boxes None None I-DNA
when None None O
tested None None O
in None None O
electrophoretic None None O
mobility-shift None None O
assays None None O
using None None O
nuclear None None O
extracts None None O
derived None None O
from None None O
human None None I-cell_line
and None None I-cell_line
murine None None I-cell_line
B-cell None None I-cell_line
lines None None I-cell_line
. None None O

Furthermore None None O
, None None O
AP-4 None None I-protein
, None None O
unlike None None O
E47 None None I-protein
, None None O
did None None O
not None None O
act None None O
as None None O
a None None O
transactivator None None I-protein
, None None O
which None None O
is None None O
in None None O
agreement None None O
with None None O
previous None None O
studies None None O
on None None O
intact None None O
kappa None None I-DNA
promoters None None I-DNA
, None None O
showing None None O
that None None O
transcription None None O
is None None O
absent None None O
when None None O
the None None O
octamer None None I-DNA
element None None I-DNA
has None None O
been None None O
mutated None None O
. None None O

Based None None O
on None None O
these None None O
data None None O
, None None O
and None None O
the None None O
conservation None None O
of None None O
the None None O
5'-CAGCTG-3 None None I-DNA
' None None I-DNA
motif None None I-DNA
among None None O
human None None I-DNA
and None None I-DNA
murine None None I-DNA
kappa None None I-DNA
promoters None None I-DNA
, None None O
we None None O
propose None None O
that None None O
AP-4 None None I-protein
is None None O
the None None O
major None None I-protein
ligand None None I-protein
for None None O
Ig-kappa None None I-DNA
promoter None None I-DNA
E-boxes None None I-DNA
. None None O

A None None O
16-mer None None O
peptide None None O
( None None O
RQIKIWFQNRRMKWKK None None O
) None None O
from None None O
antennapedia None None O
preferentially None None O
targets None None O
the None None O
Class None None O
I None None O
pathway None None O
. None None O

Translocation None None O
of None None O
antigenic None None O
peptides None None O
into None None O
the None None O
cytosol None None O
of None None O
antigen None None I-cell_type
presenting None None I-cell_type
cells None None I-cell_type
facilitates None None O
proteosomal None None O
processing None None O
and None None O
loading None None O
into None None O
Class None None I-protein
I None None I-protein
molecules None None I-protein
for None None O
MHC None None O
presentation None None O
on None None O
the None None O
cell None None O
surface None None O
. None None O

The None None O
DNA None None I-protein
binding None None I-protein
domain None None I-protein
of None None O
the None None O
Drosophila None None I-protein
transcription None None I-protein
factor None None I-protein
( None None O
Antennapedia None None I-protein
) None None O
, None None O
a None None O
60 None None I-protein
amino None None I-protein
acid None None I-protein
protein None None I-protein
, None None O
is None None O
rapidly None None O
taken None None O
up None None O
by None None O
cells None None O
and None None O
has None None O
been None None O
fused None None O
to None None O
selected None None O
antigens None None I-protein
to None None O
enhance None None O
their None None O
immunogenicity None None O
. None None O

We None None O
now None None O
demonstrate None None O
that None None O
a None None O
16 None None O
amino None None O
acid None None O
peptide None None O
from None None O
antennapedia None None O
can None None O
facilitate None None O
the None None O
cytoplasmic None None O
uptake None None O
of None None O
CTL None None O
epitope None None O
9-mer None None O
peptides None None O
. None None O

Synthetic None None O
peptides None None O
were None None O
made None None O
containing None None O
the None None O
16-mer None None O
antennapedia None None O
peptide None None O
linked None None O
in None None O
tandem None None O
to None None O
the None None O
ovalbumin None None O
SIINFEKL None None O
CTL None None O
peptide None None O
. None None O

The None None O
peptide None None O
complex None None O
was None None O
shown None None O
to None None O
rapidly None None O
internalise None None O
into None None O
APCs None None I-cell_type
by None None O
confocal None None O
microscopy None None O
. None None O

This None None O
peptide None None O
induced None None O
CTL None None I-cell_type
in None None O
C57BL/6 None None O
mice None None O
and None None O
protected None None O
them None None O
against None None O
growth None None O
of None None O
an None None O
ovalbumin None None I-cell_line
expressing None None I-cell_line
tumour None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
( None None O
E.G7-OVA None None I-cell_line
) None None O
. None None O

The None None O
ability None None O
of None None O
the None None O
hybrid None None O
peptide None None O
to None None O
be None None O
processed None None O
and None None O
presented None None O
by None None O
APCs None None I-cell_type
was None None O
similar None None O
, None None O
whether None None O
the None None O
SIINFEKL None None O
sequence None None O
was None None O
appended None None O
at None None O
the None None O
C-terminus None None I-protein
or None None O
N-terminus None None I-protein
of None None O
the None None O
Antennapedia None None O
peptide None None O
. None None O

The None None O
production None None O
of None None O
synthetic None None O
peptides None None O
containing None None O
other None None O
CTL None None O
peptide None None O
epitopes None None O
may None None O
be None None O
useful None None O
for None None O
priming None None O
CTLs None None I-cell_type
in None None O
vitro None None O
and None None O
in None None O
vivo None None O

Bone None None I-cell_type
marrow None None I-cell_type
cells None None I-cell_type
promote None None O
TH2 None None O
polarization None None O
and None None O
inhibit None None O
virus-specific None None O
CTL None None O
generation None None O
. None None O

This None None O
laboratory None None O
recently None None O
reported None None O
that None None O
human None None I-cell_type
bone None None I-cell_type
marrow None None I-cell_type
cells None None I-cell_type
( None None O
BMC None None I-cell_type
) None None O
inhibit None None O
the None None O
generation None None O
of None None O
virus-specific None None I-cell_type
CTL None None I-cell_type
in None None O
culture None None O
. None None O

The None None O
culture None None O
supernatants None None O
contained None None O
increased None None O
levels None None O
of None None O
prostaglandin None None I-protein
E None None I-protein
( None None I-protein
2 None None I-protein
) None None I-protein
( None None I-protein
PGE None None I-protein
( None None I-protein
2 None None I-protein
) None None I-protein
) None None I-protein
( None None O
shown None None O
to None None O
favor None None O
TH2 None None O
cell None None O
development None None O
) None None O
and None None O
also None None O
inhibited None None O
EBV-CTL None None O
effector None None O
cell None None O
development None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
obtained None None O
PBL None None I-cell_type
from None None O
Epstein-Barr None None O
virus None None O
( None None O
EBV None None O
) None None O
IgG None None I-protein
antibody None None I-protein
positive None None O
kidney None None O
transplant None None O
recipients None None O
( None None O
R None None O
) None None O
and None None O
their None None O
living-related None None O
donors None None O
( None None O
LRD None None O
) None None O
one None None O
year None None O
after None None O
renal None None O
transplantation None None O
. None None O

EBV-specific None None I-cell_type
CTL None None I-cell_type
were None None O
then None None O
generated None None O
in None None O
vitro None None O
by None None O
stimulating None None O
PBL None None I-cell_type
with None None O
autologous None None O
EBV-transformed None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
( None None O
EBV-B None None I-cell_type
) None None O
in None None O
the None None O
presence None None O
or None None O
absence None None O
of None None O
autologous None None I-cell_type
BMC None None I-cell_type
. None None O

The None None O
addition None None O
of None None O
BMC None None I-cell_type
to None None O
the None None O
EBV-CTL None None I-cell_type
generation None None I-cell_type
cultures None None I-cell_type
increased None None O
the None None O
intracellular None None O
expression None None O
in None None O
CD3+ None None I-cell_type
cells None None I-cell_type
of None None O
IL-4 None None I-protein
, None None I-protein
-5 None None I-protein
, None None I-protein
-6 None None I-protein
, None None I-protein
-10 None None I-protein
, None None I-protein
and None None I-protein
-13 None None I-protein
. None None O

These None None O
CD3+ None None I-cell_type
cells None None I-cell_type
also None None O
expressed None None O
increased None None O
levels None None O
of None None O
the None None O
TH2 None None I-protein
associated None None I-protein
receptor None None I-protein
CCR3 None None I-protein
. None None O

Inhibition None None O
was None None O
even None None O
observed None None O
by None None O
preparing None None O
EBV-CTL None None I-cell_type
generating None None I-cell_type
cultures None None I-cell_type
in None None O
trans-wells None None O
that None None O
separated None None O
the None None O
autologous None None I-cell_type
BMC None None I-cell_type
from None None O
the None None O
PBL None None I-cell_type
+ None None O
EBV-B None None I-cell_type
. None None O

It None None O
was None None O
then None None O
observed None None O
that None None O
CD3+ None None I-cell_type
cells None None I-cell_type
obtained None None O
after None None O
7 None None O
days None None O
of None None O
culture None None O
in None None O
the None None O
presence None None O
of None None O
autologous None None I-cell_type
BMC None None I-cell_type
could None None O
be None None O
used None None O
as None None O
inhibitors None None O
of None None O
EBV-CTL None None O
generation None None O
. None None O

Protein None None I-protein
Kinase None None I-protein
A None None I-protein
( None None O
PKA None None I-protein
) None None O
, None None O
a None None O
cAMP None None I-protein
kinase None None I-protein
that None None O
is None None O
involved None None O
in None None O
the None None O
upregulation None None O
of None None O
TH2 None None I-protein
cytokine None None I-protein
activity None None O
, None None O
was None None O
increased None None O
in None None O
EBV-CTL None None I-cell_type
cultures None None I-cell_type
by None None O
the None None O
presence None None O
of None None O
BMC None None I-cell_type
. None None O

Additionally None None O
, None None O
IL-4-mediated None None O
signal None None O
transduction None None O
and None None O
activation None None O
of None None O
transcription None None O
( None None O
STAT-6 None None I-protein
) None None O
phosphorylation None None O
was None None O
slightly None None O
increased None None O
. None None O

These None None O
results None None O
show None None O
that None None O
the None None O
BMC None None I-cell_type
inhibition None None O
is None None O
mediated None None O
by None None O
soluble None None I-protein
factors None None I-protein
( None None O
cytokines None None I-protein
) None None O
and None None O
that None None O
cell-cell None None O
contact None None O
in None None O
this None None O
autologous None None O
system None None O
is None None O
not None None O
required None None O
, None None O
so None None O
that None None O
BMC None None I-cell_type
( None None O
at None None O
least None None O
partially None None O
, None None O
via None None O
cytokine None None O
production None None O
) None None O
promote None None O
TH2 None None O
polarization None None O
in None None O
culture None None O
. None None O

Moreover None None O
, None None O
TH2 None None I-cell_type
cells None None I-cell_type
induced None None O
by None None O
culturing None None O
with None None O
autologous None None I-cell_type
BMC None None I-cell_type
directly None None O
inhibit None None O
EBV-CTL None None O
generation None None O
, None None O
and None None O
TH2 None None I-protein
associated None None O
PKA None None I-protein
, None None O
CCR3 None None I-protein
, None None O
and None None O
STAT-6 None None I-protein
phosphorylation None None O
are None None O
enhanced None None O
by None None O
BMC None None I-cell_type
. None None O

Reduction None None O
in None None O
DNA None None O
binding None None O
activity None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
Pax-5a None None B-protein
in None None O
B None None I-cell_type
lymphocytes None None I-cell_type
of None None O
aged None None O
mice None None O
. None None O

Aging None None O
has None None O
been None None O
associated None None O
with None None O
intrinsic None None O
changes None None O
of None None O
the None None O
humoral None None O
immune None None O
response None None O
, None None O
which None None O
may None None O
lead None None O
to None None O
an None None O
increased None None O
occurrence None None O
of None None O
autoimmune None None O
disorders None None O
and None None O
pathogenic None None O
susceptibility None None O
. None None O

The None None O
transcription None None I-protein
factor None None I-protein
Pax-5 None None B-protein
is None None O
a None None O
key None None O
regulator None None O
of None None O
B None None O
cell None None O
development None None O
. None None O

Pax-5a/B None None I-protein
cell-specific None None I-protein
activator None None I-protein
protein None None I-protein
and None None O
an None None O
alternatively None None I-protein
spliced None None I-protein
isoform None None I-protein
, None None I-protein
Pax-5d None None I-protein
, None None O
may None None O
have None None O
opposing None None O
functions None None O
in None None O
transcriptional None None O
regulation None None O
due None None O
to None None O
the None None O
lack None None O
of None None O
a None None O
transactivation None None I-protein
domain None None I-protein
in None None O
Pax-5d None None I-protein
. None None O

To None None O
study None None O
B None None I-cell_type
cell None None I-cell_type
-specific None None O
changes None None O
that None None O
occur None None O
during None None O
the None None O
aging None None O
process None None O
, None None O
we None None O
investigated None None O
expression None None O
patterns None None O
of None None O
Pax-5a None None I-protein
and None None I-protein
5d None None I-protein
in None None O
mature None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
of None None O
young None None O
and None None O
aged None None O
mice None None O
. None None O

RNase None None O
protection None None O
assays None None O
showed None None O
a None None O
similar None None O
transcriptional None None O
pattern None None O
for None None O
both None None O
age None None O
groups None None O
that None None O
indicates None None O
that None None O
aging None None O
has None None O
no None None O
affect None None O
on None None O
transcription None None O
initiation None None O
or None None O
alternative None None O
splicing None None O
for None None O
either None None O
isoform None None I-protein
. None None O

In None None O
contrast None None O
, None None O
a None None O
significant None None O
reduction None None O
in None None O
the None None O
DNA None None O
binding None None O
activity None None O
of None None O
Pax-5a None None I-protein
but None None O
not None None O
Pax-5d None None I-protein
protein None None O
was None None O
observed None None O
in None None O
aged None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
in None None O
vitro None None O
, None None O
while None None O
Western None None O
blot None None O
analyses None None O
showed None None O
that None None O
similar None None O
levels None None O
of None None O
Pax-5a None None I-protein
and None None I-protein
5d None None I-protein
proteins None None O
were None None O
present None None O
in None None O
both None None O
age None None O
groups None None O
. None None O

The None None O
observed None None O
decrease None None O
in None None O
Pax-5a None None I-protein
binding None None O
activity None None O
correlated None None O
with None None O
changes None None O
in None None O
expression None None O
of None None O
two None None O
Pax-5 None None I-DNA
target None None I-DNA
genes None None I-DNA
in None None O
aged None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
. None None O

Expression None None O
of None None O
the None None O
Ig None None I-protein
J None None I-protein
chain None None I-protein
and None None O
the None None O
secreted None None O
form None None O
of None None O
Ig None None I-protein
mu None None I-protein
, None None O
which None None O
are None None O
both None None O
known None None O
to None None O
be None None O
suppressed None None O
by None None O
Pax-5a None None I-protein
in None None O
mature None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
, None None O
were None None O
increased None None O
in None None O
B None None I-cell_type
cells None None I-cell_type
of None None O
aged None None O
mice None None O
. None None O

Together None None O
, None None O
our None None O
studies None None O
suggest None None O
that None None O
changes None None O
associated None None O
with None None O
the None None O
aging None None O
phenotype None None O
cause None None O
posttranslational None None O
modification None None O
( None None O
s None None O
) None None O
of None None O
Pax-5a None None I-protein
but None None O
not None None O
Pax-5d None None I-protein
, None None O
which None None O
may None None O
lead None None O
to None None O
an None None O
abnormal None None O
B None None O
cell None None O
phenotype None None O
in None None O
aged None None O
mice None None O
, None None O
associated None None O
with None None O
elevated None None O
levels None None O
of None None O
J None None I-protein
chain None None I-protein
, None None O
and None None O
secretion None None O
of None None O
IgM None None I-protein

NF-kappa None None I-protein
B/Rel None None I-protein
participation None None O
in None None O
the None None O
lymphokine-dependent None None O
proliferation None None O
of None None O
T None None I-cell_type
lymphoid None None I-cell_type
cells None None I-cell_type
. None None O

Proliferative None None O
responses None None O
of None None O
lymphoid None None I-cell_type
cells None None I-cell_type
to None None O
IL-2 None None I-protein
and None None O
IL-4 None None I-protein
depend None None O
on None None O
activation None None O
of None None O
the None None O
cells None None O
, None None O
but None None O
the None None O
mechanism None None O
( None None O
s None None O
) None None O
by None None O
which None None O
activation None None O
enhances None None O
cellular None None O
competence None None O
to None None O
respond None None O
to None None O
cytokines None None I-protein
is None None O
not None None O
fully None None O
understood None None O
. None None O

The None None O
NF-kappaB/Rel None None I-protein
family None None I-protein
represents None None O
one None None O
signal None None O
transduction None None O
pathway None None O
induced None None O
during None None O
such None None O
activation None None O
. None None O

We None None O
show None None O
in None None O
this None None O
study None None O
that None None O
inhibition None None O
of None None O
NF-kappaB None None I-protein
through None None O
the None None O
expression None None O
of None None O
an None None O
IkappaBalpha None None I-protein
( None None O
inhibitory None None I-protein
protein None None I-protein
that None None O
dissociates None None O
from None None O
NF-kappaB None None I-protein
) None None O
mutant None None O
refractory None None O
to None None O
signal-induced None None O
degradation None None O
( None None O
IkappaBalpha None None I-protein
( None None I-protein
DeltaN None None I-protein
) None None I-protein
) None None O
interfered None None O
with None None O
the None None O
acquisition None None O
of None None O
competence None None O
to None None O
proliferate None None O
in None None O
response None None O
to None None O
IL-4 None None I-protein
as None None O
well None None O
as None None O
IL-2 None None I-protein
. None None O

Thymocytes None None I-cell_type
and None None O
T None None I-cell_type
cells None None I-cell_type
from None None O
IkappaBalpha None None I-protein
( None None I-protein
DeltaN None None I-protein
) None None I-protein
transgenic None None O
mice None None O
expressed None None O
normal None None O
levels None None O
of None None O
IL-2R None None I-protein
subunits None None I-protein
. None None O

However None None O
, None None O
transgenic None None I-cell_type
cells None None I-cell_type
exhibited None None O
a None None O
dramatic None None O
defect None None O
in None None O
Stat5A None None O
activation None None O
treatment None None O
with None None O
IL-2 None None I-protein
, None None O
and None None O
a None None O
similar None None O
defect None None O
was None None O
observed None None O
for None None O
IL-4 None None I-protein
-induced None None O
Stat5 None None I-protein
. None None O

In None None O
contrast None None O
, None None O
T None None I-cell_type
lymphoid None None I-cell_type
cells None None I-cell_type
with None None O
inhibition None None O
of None None O
NF-kappaB None None I-protein
showed None None O
normal None None O
insulin None None O
receptor None None O
substrate-2 None None O
phosphorylation None None O
and None None O
only None None O
a None None O
modest None None O
decrease None None O
in None None O
Stat6 None None O
activation None None O
and None None O
insulin None None O
receptor None None O
substrate-1 None None O
phosphorylation None None O
after None None O
IL-4 None None O
stimulation None None O
. None None O

These None None O
results None None O
indicate None None O
that None None O
the None None O
NF-kappaB/Rel/IkappaBalpha None None O
system None None O
can None None O
regulate None None O
cytokine None None I-protein
receptor None None I-protein
capacitation None None O
through None None O
effects None None O
on None None O
the None None O
induction None None O
of None None O
downstream None None O
signaling None None O
by None None O
the None None O
Stat None None I-protein
transcription None None I-protein
factor None None I-protein
family None None I-protein
. None None O

BMS-189453 None None O
, None None O
a None None O
novel None None O
retinoid None None O
receptor None None O
antagonist None None O
, None None O
is None None O
a None None O
potent None None O
testicular None None O
toxin None None O
. None None O

BMS-189453 None None O
is None None O
a None None O
synthetic None None O
retinoid None None O
that None None O
acts None None O
as None None O
an None None O
antagonist None None O
at None None O
retinoic None None I-protein
acid None None I-protein
receptors None None I-protein
alpha None None I-protein
, None None I-protein
beta None None I-protein
, None None I-protein
and None None I-protein
gamma None None I-protein
. None None O

In None None O
Sprague None None O
Dawley None None O
rats None None O
at None None O
daily None None O
oral None None O
doses None None O
of None None O
15 None None O
, None None O
60 None None O
, None None O
or None None O
240 None None O
mg/kg None None O
for None None O
1 None None O
month None None O
, None None O
BMS-189453 None None O
produced None None O
increases None None O
in None None O
leukocyte None None I-cell_type
counts None None O
, None None O
alkaline None None I-protein
phosphatase None None I-protein
and None None O
alanine None None I-protein
aminotransferase None None I-protein
levels None None O
, None None O
and None None O
marked None None O
testicular None None O
degeneration None None O
and None None O
atrophy None None O
at None None O
all None None O
doses None None O
. None None O

Significant None None O
overt None None O
signs None None O
of None None O
toxicity None None O
and None None O
deaths None None O
occurred None None O
at None None O
240 None None O
mg/kg None None O
, None None O
whereas None None O
body-weight None None O
and None None O
food-consumption None None O
decreases None None O
occurred None None O
at None None O
60 None None O
and None None O
240 None None O
mg/kg None None O
. None None O

When None None O
BMS-189453 None None O
was None None O
administered None None O
to None None O
male None None O
rats None None O
at None None O
daily None None O
doses None None O
ranging None None O
from None None O
12.5 None None O
to None None O
100 None None O
mg/kg None None O
for None None O
1 None None O
week None None O
, None None O
only None None O
minimal None None O
testicular None None O
changes None None O
occurred None None O
at None None O
all None None O
doses None None O
, None None O
shortly None None O
after None None O
the None None O
dosing None None O
period None None O
. None None O

However None None O
, None None O
after None None O
a None None O
1-month None None O
drug-free None None O
observation None None O
period None None O
, None None O
marked None None O
testicular None None O
atrophy None None O
was None None O
evident None None O
at None None O
all None None O
doses None None O
. None None O

BMS-189453 None None O
was None None O
then None None O
administered None None O
at None None O
doses None None O
of None None O
2 None None O
, None None O
10 None None O
, None None O
or None None O
50 None None O
mg/kg None None O
to None None O
male None None O
rats None None O
for None None O
1 None None O
, None None O
3 None None O
, None None O
or None None O
7 None None O
consecutive None None O
days None None O
. None None O

Dose- None None O
and None None O
duration-dependent None None O
testicular None None O
toxicity None None O
that None None O
occurred None None O
after None None O
a None None O
1-month None None O
observation None None O
period None None O
did None None O
not None None O
recover None None O
, None None O
and None None O
, None None O
in None None O
some None None O
cases None None O
, None None O
was None None O
more None None O
severe None None O
4 None None O
months None None O
after None None O
the None None O
last None None O
dose None None O
. None None O

In None None O
rabbits None None O
administered None None O
BMS-189453 None None O
at None None O
oral None None O
doses None None O
of None None O
2 None None O
, None None O
10 None None O
, None None O
or None None O
50 None None O
mg/kg None None O
for None None O
1 None None O
week None None O
, None None O
testicular None None O
degeneration None None O
and None None O
atrophy None None O
were None None O
evident None None O
in None None O
the None None O
high-dose None None O
group None None O
at None None O
1 None None O
month None None O
following None None O
treatment None None O
. None None O

These None None O
studies None None O
indicate None None O
that None None O
retinoid None None O
antagonists None None O
can None None O
selectively None None O
produce None None O
progressive None None O
and None None O
prolonged None None O
testicular None None O
toxicity None None O
after None None O
single None None O
or None None O
repeated None None O
oral None None O
doses None None O
that None None O
are None None O
otherwise None None O
well None None O
tolerated None None O
. None None O

Sequential None None O
involvement None None O
of None None O
NFAT None None I-protein
and None None O
Egr None None I-protein
transcription None None B-protein
factors None None I-protein
in None None O
FasL None None O
regulation None None O
. None None O

The None None O
critical None None O
function None None O
of None None O
NFAT None None I-protein
proteins None None I-protein
in None None O
maintaining None None O
lymphoid None None O
homeostasis None None O
was None None O
revealed None None O
in None None O
mice None None O
lacking None None O
both None None O
NFATp None None I-protein
and None None O
NFAT4 None None I-protein
( None None O
DKO None None O
) None None O
. None None O

DKO None None O
mice None None O
exhibit None None O
increased None None O
lymphoproliferation None None O
, None None O
decreased None None O
activation-induced None None O
cell None None O
death None None O
, None None O
and None None O
impaired None None O
induction None None O
of None None O
FasL None None I-protein
. None None O

The None None O
transcription None None I-protein
factors None None I-protein
Egr2 None None B-protein
and None None O
Egr3 None None I-protein
are None None O
potent None None O
activators None None O
of None None O
FasL None None O
expression None None O
. None None O

Here None None O
we None None O
find None None O
that None None O
Egr2 None None I-DNA
and None None O
Egr3 None None I-DNA
are None None O
NFAT None None I-DNA
target None None I-DNA
genes None None I-DNA
. None None O

Activation None None O
of None None O
FasL None None I-protein
occurs None None O
via None None O
the None None O
NFAT None None I-protein
-dependent None None O
induction None None O
of None None O
Egr3 None None I-DNA
, None None O
as None None O
demonstrated None None O
by None None O
the None None O
ability None None O
of None None O
exogenously None None O
provided None None O
NFATp None None I-protein
to None None O
restore None None O
Egr None None I-protein
-dependent None None O
FasL None None O
promoter None None O
activity None None O
in None None O
DKO None None I-cell_type
lymph None None I-cell_type
node None None I-cell_type
cells None None I-cell_type
. None None O

Further None None O
, None None O
Egr3 None None I-DNA
expression None None O
is None None O
enriched None None O
in None None O
Th1 None None I-cell_type
cells None None I-cell_type
, None None O
suggesting None None O
a None None O
molecular None None O
basis None None O
for None None O
the None None O
known None None O
preferential None None O
expression None None O
of None None O
FasL None None I-protein
in None None O
the None None O
Th1 None None O
versus None None O
Th2 None None O
subset None None O
. None None O

Mechanisms None None O
and None None O
clinical None None O
relevance None None O
of None None O
nongenomic None None O
glucocorticoid None None O
actions None None O
. None None O

Glucocorticoids None None O
have None None O
profound None None O
anti-inflammatory None None O
and None None O
immunosuppressive None None O
actions None None O
when None None O
used None None O
therapeutically None None O
. None None O

The None None O
therapeutic None None O
dose None None O
is None None O
quite None None O
variable None None O
and None None O
depends None None O
on None None O
the None None O
disease None None O
, None None O
but None None O
ranges None None O
from None None O
very None None O
low None None O
to None None O
extremely None None O
high None None O
. None None O

The None None O
rationale None None O
for None None O
the None None O
use None None O
of None None O
various None None O
dosage None None O
regimens None None O
for None None O
specific None None O
clinical None None O
indications None None O
is None None O
the None None O
existence None None O
of None None O
three None None O
distinct None None O
, None None O
therapeutically None None O
relevant None None O
effects None None O
: None None O
genomic None None O
, None None O
specific None None O
nongenomic None None O
and None None O
unspecific None None O
nongenomic None None O
. None None O

Genomic None None O
effects None None O
are None None O
mediated None None O
by None None O
cytosolic None None I-protein
receptors None None I-protein
that None None O
alter None None O
expression None None O
of None None O
specific None None O
genes None None O
. None None O

Specific None None O
nongenomic None None O
effects None None O
occur None None O
within None None O
a None None O
few None None O
minutes None None O
and None None O
are None None O
mediated None None O
by None None O
steroid-selective None None I-protein
membrane None None I-protein
receptors None None I-protein
. None None O

Unspecific None None O
nongenomic None None O
effects None None O
occur None None O
within None None O
seconds None None O
, None None O
but None None O
only None None O
at None None O
high None None O
glucocorticoid None None O
dosages None None O
, None None O
and None None O
seem None None O
to None None O
result None None O
from None None O
direct None None O
interactions None None O
with None None O
biological None None O
membranes None None O
. None None O

For None None O
unspecific None None O
nongenomic None None O
effects None None O
, None None O
methylprednisolone None None O
and None None O
other None None O
glucocorticoids None None O
have None None O
been None None O
shown None None O
to None None O
inhibit None None O
cation None None O
cycling None None O
across None None O
the None None O
plasma None None O
membrane None None O
, None None O
but None None O
to None None O
have None None O
little None None O
effect None None O
on None None O
protein None None O
synthesis None None O
. None None O

Thus None None O
, None None O
glucocorticoids None None O
could None None O
diminish None None O
or None None O
prevent None None O
the None None O
acute None None O
immune None None O
response None None O
by None None O
interfering None None O
with None None O
processes None None O
such None None O
as None None O
the None None O
rise None None O
in None None O
intracellular None None O
Ca2+ None None O
concentration None None O
. None None O

It None None O
is None None O
proposed None None O
that None None O
the None None O
additional None None O
therapeutic None None O
benefit None None O
of None None O
higher None None O
doses None None O
is None None O
obtained None None O
via None None O
these None None O
nongenomic None None O
effects None None O
. None None O

High None None O
glucose-induced None None O
intercellular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
( None None O
ICAM-1 None None I-protein
) None None O
expression None None O
through None None O
an None None O
osmotic None None O
effect None None O
in None None O
rat None None I-cell_type
mesangial None None I-cell_type
cells None None I-cell_type
is None None O
PKC-NF-kappa None None O
B-dependent None None O
. None None O

AIMS/HYPOTHESIS None None O
: None None O
Infiltration None None O
of None None O
mononuclear None None I-cell_type
cells None None I-cell_type
and None None O
glomerular None None O
enlargement None None O
accompanied None None O
by None None O
glomerular None None I-cell_type
cell None None I-cell_type
proliferation None None O
are None None O
very None None O
early None None O
characteristics None None O
of None None O
the None None O
pathophysiology None None O
of None None O
diabetes None None O
. None None O

To None None O
clarify None None O
the None None O
mechanism None None O
of None None O
early None None O
diabetic None None O
nephropathy None None O
, None None O
we None None O
measured None None O
[ None None O
3H None None O
] None None O
-thymidine None None O
incorporation None None O
and None None O
cell None None O
numbers None None O
to None None O
show None None O
the None None O
influence None None O
of None None O
a None None O
high None None O
ambient None None O
glucose None None O
concentration None None O
and None None O
the None None O
osmotic None None O
effect None None O
on None None O
rat None None I-cell_type
mesangial None None I-cell_type
cell None None I-cell_type
proliferation None None O
. None None O

We None None O
also None None O
measured None None O
the None None O
effect None None O
of None None O
high None None O
glucose None None O
on None None O
the None None O
expression None None O
of None None O
intercellular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
and None None O
vascular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
by None None O
flow None None O
cytometry None None O
and None None O
semiquantitative None None O
RT-PCR None None O
in None None O
mesangial None None I-cell_type
cells None None I-cell_type
and None None O
the None None O
adhesion None None O
of None None O
leukocytes None None I-cell_type
to None None O
mesangial None None I-cell_type
cells None None I-cell_type
. None None O

METHODS/RESULTS None None O
: None None O
Cells None None O
exposed None None O
to None None O
high None None O
D-glucose None None O
( None None O
30 None None O
mmol/l None None O
) None None O
caused None None O
an None None O
increase None None O
in None None O
[ None None O
3H None None O
] None None O
-thymidine None None O
incorporation None None O
and None None O
cell None None O
numbers None None O
at None None O
24 None None O
and None None O
48 None None O
h None None O
and None None O
normalized None None O
at None None O
72 None None O
h None None O
( None None O
p None None O
< None None O
0.05 None None O
) None None O
, None None O
whereas None None O
these None None O
changes None None O
were None None O
not None None O
found None None O
in None None O
high None None O
mannitol None None O
( None None O
30 None None O
mmol/l None None O
) None None O
, None None O
IL-1 None None I-protein
beta None None I-protein
, None None O
or None None O
TNF None None I-protein
alpha None None I-protein
-stimulated None None O
mesangial None None I-cell_type
cells None None I-cell_type
. None None O

Cells None None O
exposed None None O
to None None O
high-glucose None None O
( None None O
15 None None O
, None None O
30 None None O
, None None O
or None None O
60 None None O
mmol/l None None O
) None None O
or None None O
osmotic None None O
agents None None O
( None None O
L-glucose None None O
, None None O
raffinose None None O
and None None O
mannitol None None O
) None None O
showed None None O
that None None O
intercellular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
expression None None O
began None None O
to None None O
increase None None O
after None None O
24 None None O
h None None O
, None None O
reached None None O
its None None O
maximum None None O
at None None O
24 None None O
and None None O
48 None None O
h None None O
and None None O
gradually None None O
decreased None None O
afterwards None None O
. None None O

The None None O
stimulatory None None O
effects None None O
of None None O
high None None O
glucose None None O
and None None O
high None None O
mannitol None None O
on None None O
mRNA None None O
expression None None O
were None None O
observed None None O
as None None O
early None None O
as None None O
6 None None O
h None None O
and None None O
reached None None O
its None None O
maximum None None O
at None None O
12 None None O
h None None O
. None None O

Up-regulation None None O
of None None O
ICAM-1 None None I-protein
protein None None O
and None None O
mRNA None None O
was None None O
also None None O
found None None O
in None None O
IL-1-beta None None I-protein
and None None O
TNF-alpha None None I-protein
-stimulated None None O
mesangial None None I-cell_type
cells None None I-cell_type
. None None O

Neither None None O
vascular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
protein None None O
nor None None O
mRNA None None O
expression None None O
was None None O
, None None O
however None None O
, None None O
affected None None O
by None None O
high None None O
glucose None None O
and None None O
high None None O
mannitol None None O
. None None O

Notably None None O
, None None O
the None None O
protein None None O
kinase None None O
C None None O
inhibitors None None O
calphostin None None O
C None None O
and None None O
staurosporine None None O
reduced None None O
high None None O
glucose- None None O
or None None O
high None None O
mannitol-induced None None O
intercellular None None I-RNA
adhesion None None I-RNA
molecule-1 None None I-RNA
mRNA None None O
expression None None O
and None None O
high None None O
glucose-induced None None O
proliferation None None O
. None None O

Furthermore None None O
, None None O
the None None O
NF-kappa None None O
B None None O
inhibitor None None O
N-tosyl-L-phenylalanine None None O
chloromethyl None None O
ketone None None O
reduced None None O
high None None O
glucose- None None O
or None None O
high None None O
mannitol-induced None None O
intercellular None None I-RNA
adhesion None None I-RNA
molecule-1 None None I-RNA
mRNA None None O
expression None None O
and None None O
high None None O
glucose-induced None None O
proliferation None None O
. None None O

Results None None O
showed None None O
that None None O
high None None O
glucose None None O
( None None O
15 None None O
, None None O
30 None None O
mmol/l None None O
) None None O
or None None O
high None None O
concentrations None None O
of None None O
osmotic None None O
agents None None O
remarkably None None O
increased None None O
the None None O
number None None O
of None None O
adherent None None O
leukocytes None None I-cell_type
to None None O
mesangial None None I-cell_type
cells None None I-cell_type
( None None O
p None None O
< None None O
0.01 None None O
) None None O
compared None None O
with None None O
control None None I-cell_type
cells None None I-cell_type
( None None O
5 None None O
mmol/l None None O
D-glucose None None O
) None None O
. None None O

Functional None None O
blocking None None O
of None None O
intercellular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
on None None O
mesangial None None I-cell_type
cells None None I-cell_type
with None None O
rat None None I-protein
intercellular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
monoclonal None None I-protein
antibody None None I-protein
, None None O
calphostin None None O
C None None O
, None None O
staurosporine None None O
, None None O
or None None O
N-tosyl-L-phenylalanine None None O
chloromethyl None None O
ketone None None O
significantly None None O
inhibited None None O
high None None O
glucose- None None O
or None None O
high None None O
mannitol-induced None None O
increase None None O
in None None O
leukocyte None None O
adhesion None None O
( None None O
p None None O
< None None O
< None None O
0.05 None None O
) None None O
. None None O

CONCLUSION/INTERPRETATION None None O
: None None O
These None None O
results None None O
suggest None None O
that None None O
high None None O
glucose None None O
can None None O
upregulate None None O
intercellular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
protein None None O
and None None O
mRNA None None O
expression None None O
but None None O
not None None O
vascular None None O
adhesion None None O
molecule-1 None None O
expression None None O
in None None O
mesangial None None I-cell_type
cells None None I-cell_type
and None None O
promote None None O
leukocyte None None O
adhesion None None O
through None None O
up-regulation None None O
of None None O
intercellular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
through None None O
osmotic None None O
effect None None O
, None None O
possibly None None O
depending None None O
on None None O
the None None O
protein None None I-protein
kinase None None I-protein
C None None I-protein
nuclear None None B-protein
factor-kappa None None I-protein
B None None I-protein
( None None O
PKC None None I-protein
- None None O
NF-kappa None None I-protein
B None None I-protein
) None None O
pathway None None O
. None None O

High None None O
glucose None None O
itself None None O
can None None O
also None None O
promote None None O
mesangial None None O
cell None None O
proliferation None None O
through None None O
the None None O
PKC-NF-kappa None None O
B None None O
pathways None None O
. None None O

We None None O
conclude None None O
that None None O
hyperglycaemia None None O
in None None O
itself None None O
seems None None O
to None None O
be None None O
an None None O
important None None O
factor None None O
in None None O
the None None O
development None None O
of None None O
early None None O
diabetic None None O
nephropathy None None O
. None None O

Combined None None O
corticosteroid/ None None O
granulocyte None None I-protein
colony-stimulating None None I-protein
factor None None I-protein
( None None O
G-CSF None None I-protein
) None None O
therapy None None O
in None None O
the None None O
treatment None None O
of None None O
severe None None O
congenital None None O
neutropenia None None O
unresponsive None None O
to None None O
G-CSF None None I-protein
: None None O
Activated None None O
glucocorticoid None None I-protein
receptors None None I-protein
synergize None None O
with None None O
G-CSF None None I-protein
signals None None O
. None None O

More None None O
than None None O
90 None None O
% None None O
of None None O
patients None None O
with None None O
severe None None O
congenital None None O
neutropenia None None O
( None None O
SCN None None O
) None None O
respond None None O
to None None O
granulocyte None None I-protein
colony-stimulating None None I-protein
factor None None I-protein
( None None O
G-CSF None None I-protein
) None None O
therapy None None O
. None None O

The None None O
basis None None O
for None None O
the None None O
refractory None None O
state None None O
in None None O
the None None O
remaining None None O
patients None None O
is None None O
unknown None None O
. None None O

To None None O
address None None O
this None None O
issue None None O
, None None O
we None None O
studied None None O
a None None O
child None None O
with None None O
SCN None None O
who None None O
was None None O
totally None None O
unresponsive None None O
to None None O
G-CSF None None I-protein
and None None O
had None None O
a None None O
novel None None O
point None None O
mutation None None O
in None None O
the None None O
extracellular None None I-protein
domain None None I-protein
of None None O
the None None O
G-CSF None None I-protein
receptor None None I-protein
( None None O
GCSF-R None None I-protein
) None None O
. None None O

Marrow None None O
stromal None None O
support None None O
of None None O
granulopoiesis None None O
was None None O
evaluated None None O
by None None O
plating None None O
CD34 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
on None None O
preformed None None O
stromal None None O
layers None None O
. None None O

Nonadherent None None I-cell_type
cells None None I-cell_type
were None None O
harvested None None O
and None None O
assayed None None O
in None None O
clonogenic None None O
assays None None O
for None None O
granulocytic None None O
colony None None O
production None None O
. None None O

The None None O
in None None O
vitro None None O
effect None None O
of None None O
G-CSF None None I-protein
and None None O
corticosteroids None None O
on None None O
granulopoiesis None None O
was None None O
evaluated None None O
in None None O
clonogenic None None O
assays None None O
of None None O
marrow None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
, None None O
by None None O
proliferation None None O
studies None None O
of None None O
the None None O
murine None None I-cell_line
myeloid None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
32D None None I-cell_line
expressing None None O
the None None O
patient None None O
's None None O
mutated None None I-protein
G-CSFR None None I-protein
, None None O
and None None O
by None None O
measuring None None O
STAT5 None None O
activation None None O
in None None O
nuclear None None O
extracts None None O
from None None O
stimulated None None I-cell_type
cells None None I-cell_type
. None None O

Patient None None O
's None None O
stroma None None O
supported None None O
granulopoiesis None None O
derived None None O
from None None O
control None None O
marrow None None I-cell_type
CD34 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
in None None O
a None None O
normal None None O
manner None None O
. None None O

Normal None None O
stroma None None O
, None None O
however None None O
, None None O
failed None None O
to None None O
induce None None O
granulopoiesis None None O
from None None O
patient None None O
's None None O
CD34 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
. None None O

Clonogenic None None O
assays None None O
of None None O
the None None O
patient None None O
's None None O
marrow None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
incorporating None None O
either None None O
G-CSF None None I-protein
or None None O
hydrocortisone None None O
produced None None O
little None None O
neutrophil None None O
growth None None O
. None None O

In None None O
contrast None None O
, None None O
inclusion None None O
of None None O
both None None O
G-CSF None None I-protein
and None None O
hydrocortisone None None O
in None None O
the None None O
cytokine None None I-protein
`` None None I-protein
cocktail None None I-protein
'' None None I-protein
markedly None None O
increased None None O
the None None O
neutrophil None None O
numbers None None O
. None None O

Proliferation None None O
of None None O
32D None None I-cell_line
cells None None I-cell_line
expressing None None O
the None None O
mutated None None I-protein
receptor None None I-protein
and None None O
STAT5 None None O
activation None None O
were None None O
improved None None O
by None None O
a None None O
combination None None O
of None None O
G-CSF None None I-protein
and None None O
dexamethasone None None O
. None None O

When None None O
small None None O
daily None None O
doses None None O
of None None O
oral None None O
prednisone None None O
were None None O
then None None O
administered None None O
to None None O
the None None O
patient None None O
with None None O
conventional None None O
doses None None O
of None None O
subcutaneous None None I-protein
G-CSF None None I-protein
, None None O
the None None O
patient None None O
responded None None O
with None None O
increased None None O
neutrophil None None O
numbers None None O
and None None O
with None None O
a None None O
complete None None O
reversal None None O
of None None O
the None None O
infectious None None O
problems None None O
. None None O

These None None O
data None None O
provide None None O
insight None None O
into None None O
SCN None None O
unresponsive None None O
to None None O
standard None None O
G-CSF None None I-protein
treatment None None O
and None None O
to None None O
the None None O
potential None None O
corrective None None O
action None None O
of None None O
combined None None O
treatment None None O
with None None O
G-CSF None None I-protein
and None None O
corticosteroids None None O
through None None O
synergistic None None O
activation None None O
of None None O
STAT5 None None I-protein
. None None O

Human None None I-cell_type
renal None None I-cell_type
mesangial None None I-cell_type
cells None None I-cell_type
are None None O
a None None O
target None None O
for None None O
the None None O
anti-inflammatory None None O
action None None O
of None None O
9-cis None None O
retinoic None None O
acid None None O
. None None O

Mesangial None None I-cell_type
cells None None I-cell_type
play None None O
an None None O
active None None O
role None None O
in None None O
the None None O
inflammatory None None O
response None None O
to None None O
glomerular None None O
injury None None O
. None None O

We None None O
have None None O
studied None None O
in None None O
cultured None None I-cell_line
human None None I-cell_line
mesangial None None I-cell_line
cells None None I-cell_line
( None None O
CHMC None None I-cell_line
) None None O
several None None O
effects None None O
of None None O
9-cis None None O
retinoic None None O
acid None None O
( None None O
9-cRA None None O
) None None O
, None None O
an None None O
activator None None O
of None None O
both None None O
retinoic None None I-protein
acid None None I-protein
receptors None None I-protein
( None None O
RARs None None I-protein
) None None O
and None None O
retinoid None None I-protein
X None None I-protein
receptors None None I-protein
( None None O
RXRs None None I-protein
) None None O
. None None O

9-cRA None None O
inhibited None None O
foetal None None O
calf None None O
serum-induced None None O
CHMC None None I-cell_line
proliferation None None O
. None None O

It None None O
also None None O
prevented None None O
CHMC None None I-cell_line
death None None O
induced None None O
by None None O
the None None O
inflammatory None None O
mediator None None O
H None None O
( None None O
2 None None O
) None None O
O None None O
( None None O
2 None None O
) None None O
. None None O

This None None O
preventive None None O
effect None None O
was None None O
not None None O
due None None O
to None None O
any None None O
increase None None O
in None None O
H None None O
( None None O
2 None None O
) None None O
O None None O
( None None O
2 None None O
) None None O
catabolism None None O
and None None O
it None None O
persisted None None O
even None None O
when None None O
both None None O
catalase None None O
and None None O
glutathione None None O
synthesis None None O
were None None O
inhibited None None O
. None None O

Finally None None O
, None None O
9-cRA None None O
diminished None None O
monocyte None None O
adhesion None None O
to None None O
FCS-stimulated None None I-cell_line
CHMC None None I-cell_line
. None None O

Interestingly None None O
, None None O
the None None O
retinoid None None O
also None None O
inhibited None None O
in None None O
FCS-stimulated None None I-cell_type
cells None None I-cell_type
the None None O
protein None None O
expression None None O
of None None O
two None None O
mesangial None None I-protein
adhesion None None I-protein
molecules None None I-protein
, None None O
fibronectin None None I-protein
and None None O
osteopontin None None I-protein
, None None O
but None None O
it None None O
did None None O
not None None O
modify None None O
the None None O
protein None None O
expression None None O
of None None O
intercellular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
and None None O
vascular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
. None None O

All None None O
major None None O
RARs None None I-protein
and None None I-protein
RXRs None None I-protein
isotypes None None I-protein
were None None O
expressed None None O
in None None O
CHMC None None I-cell_line
regardless None None O
of None None O
the None None O
presence None None O
or None None O
absence None None O
of None None O
9-cRA None None O
. None None O

Transcripts None None O
to None None O
RAR-alpha None None I-RNA
, None None O
RAR-beta None None I-RNA
and None None O
RXR-alpha None None I-RNA
increased None None O
after None None O
incubation None None O
with None None O
9-cRA None None O
whereas None None O
RXR-gamma None None I-RNA
was None None O
inhibited None None O
, None None O
suggesting None None O
a None None O
major None None O
role None None O
for None None O
RARs None None I-protein
and None None O
RXRs None None I-protein
in None None O
9-cRA-anti-inflammatory None None O
effects None None O
. None None O

9-cRA None None O
was None None O
toxic None None O
only None None O
at None None O
50 None None O
microM None None O
( None None O
a None None O
concentration None None O
50 None None O
- None None O
5000 None None O
times None None O
higher None None O
than None None O
required None None O
for None None O
the None None O
effects None None O
above None None O
) None None O
. None None O

Cell None None O
death None None O
occurred None None O
by None None O
apoptosis None None O
, None None O
whose None None O
onset None None O
was None None O
associated None None O
with None None O
a None None O
pronounced None None O
increase None None O
in None None O
catalase None None O
activity None None O
and None None O
reduced None None O
glutathione None None O
content None None O
, None None O
being None None O
more None None O
effectively None None O
induced None None O
by None None O
all-trans None None O
retinoic None None O
acid None None O
. None None O

Modulation None None O
of None None O
the None None O
oxidant/antioxidant None None O
balance None None O
failed None None O
to None None O
inhibit None None O
apoptosis None None O
. None None O

We None None O
conclude None None O
that None None O
mesangial None None I-cell_type
cells None None I-cell_type
might None None O
be None None O
a None None O
target None None O
for None None O
the None None O
treatment None None O
of None None O
inflammatory None None O
glomerulopathies None None O
with None None O
9-cRA None None O
. None None O

Expression None None O
of None None O
mammalian None None I-DNA
defensin None None I-DNA
genes None None I-DNA
. None None O

Antimicrobial None None O
peptides None None O
are None None O
a None None O
prevalent None None O
mechanism None None O
of None None O
host None None O
defense None None O
found None None O
throughout None None O
nature None None O
. None None O

In None None O
mammals None None O
, None None O
defensins None None I-protein
are None None O
among None None O
the None None O
most None None O
abundant None None O
of None None O
these None None O
broad-spectrum None None O
antibiotics None None O
, None None O
and None None O
are None None O
expressed None None O
in None None O
epithelial None None I-cell_type
and None None I-cell_type
hematopoietic None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
defensin None None O
peptides None None O
are None None O
especially None None O
abundant None None O
in None None O
neutrophils None None I-cell_type
; None None O
however None None O
, None None O
gene None None O
expression None None O
is None None O
limited None None O
to None None O
the None None O
promyelocyte None None O
stage None None O
. None None O

In None None O
epithelial None None I-cell_type
cells None None I-cell_type
, None None O
defensin None None I-DNA
genes None None I-DNA
are None None O
found None None O
as None None O
both None None O
constitutively None None O
expressed None None O
and None None O
inducible None None O
. None None O

Induction None None O
has None None O
been None None O
observed None None O
in None None O
vitro None None O
by None None O
stimulation None None O
with None None O
bacterial None None O
lipopolysaccharide None None O
as None None O
well None None O
as None None O
inflammatory None None O
mediators None None O
. None None O

In None None O
vivo None None O
, None None O
up-regulation None None O
of None None O
several None None O
defensin None None I-DNA
genes None None I-DNA
occurs None None O
in None None O
both None None O
infectious None None O
and None None O
inflammatory None None O
states None None O
. None None O

Gene None None O
regulation None None O
occurs None None O
via None None O
signal None None O
transduction None None O
pathways None None O
common None None O
to None None O
other None None O
innate None None O
immune None None O
responses None None O
, None None O
utilizing None None O
transcription None None I-protein
factors None None I-protein
such None None O
as None None O
nuclear None None I-protein
factor None None I-protein
( None None I-protein
NF None None I-protein
) None None I-protein
-kappaB None None I-protein
and None None O
NF None None I-protein
interleukin-6 None None I-protein
. None None O

Together None None O
, None None O
the None None O
data None None O
suggest None None O
a None None O
broad-based None None O
innate None None O
host None None O
defense None None O
whereby None None O
potent None None O
antimicrobial None None O
peptides None None O
are None None O
present None None O
to None None O
prevent None None O
initial None None O
colonization None None O
by None None O
pathogenic None None O
microorganisms None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
recognition None None O
of None None O
bacteria None None O
coupled None None O
with None None O
a None None O
nascent None None O
inflammatory None None O
response None None O
can None None O
bolster None None O
this None None O
defense None None O
by None None O
a None None O
coordinated None None O
up-regulation None None O
of None None O
the None None O
peptides None None O
. None None O

Multiple None None O
signals None None O
required None None O
for None None O
cyclic None None I-protein
AMP-responsive None None I-protein
element None None I-protein
binding None None I-protein
protein None None I-protein
( None None O
CREB None None I-protein
) None None O
binding None None O
protein None None O
interaction None None O
induced None None O
by None None O
CD3/CD28 None None O
costimulation None None O
. None None O

The None None O
optimal None None O
activation None None O
of None None O
cAMP-responsive None None I-protein
element None None I-protein
binding None None I-protein
protein None None I-protein
( None None O
CREB None None I-protein
) None None O
, None None O
similar None None O
to None None O
the None None O
full None None O
activation None None O
of None None O
T None None I-cell_type
lymphocytes None None I-cell_type
, None None O
requires None None O
the None None O
stimulation None None O
of None None O
both None None O
CD3 None None I-protein
and None None O
CD28 None None I-protein
. None None O

Using None None O
a None None O
reporter None None O
system None None O
to None None O
detect None None O
interaction None None O
of None None O
CREB None None I-protein
and None None O
CREB-binding None None I-protein
protein None None I-protein
( None None O
CBP None None I-protein
) None None O
, None None O
in None None O
this None None O
study None None O
we None None O
found None None O
that None None O
CREB None None I-protein
binds None None O
to None None O
CBP None None I-protein
only None None O
by None None O
engagement None None O
of None None O
both None None O
CD3 None None I-protein
and None None O
CD28 None None I-protein
. None None O

CD3/CD28 None None I-protein
-promoted None None O
CREB None None I-protein
- None None O
CBP None None I-protein
interaction None None O
was None None O
dependent None None O
on None None O
p38 None None I-protein
mitogen-activated None None I-protein
protein None None I-protein
kinase None None I-protein
( None None O
MAPK None None I-protein
) None None O
and None None O
calcium/calmodulin-dependent None None I-protein
protein None None I-protein
kinase None None I-protein
( None None I-protein
CaMK None None I-protein
) None None I-protein
IV None None I-protein
in None None O
addition None None O
to None None O
the None None O
previously None None O
identified None None O
extracellular None None O
signal-regulated None None O
kinase None None O
pathway None None O
. None None O

Extracellular None None I-protein
signal-regulated None None I-protein
kinase None None I-protein
, None None I-protein
CaMKIV None None I-protein
, None None O
and None None O
p38 None None I-protein
MAPK None None I-protein
were None None O
also None None O
the None None O
kinases None None O
involved None None O
in None None O
CREB None None I-protein
Ser None None O
( None None O
133 None None O
) None None O
phosphorylation None None O
induced None None O
by None None O
CD3/CD28 None None I-protein
. None None O

A None None O
reconstitution None None O
experiment None None O
illustrated None None O
that None None O
optimum None None O
CREB None None I-protein
- None None O
CBP None None I-protein
interaction None None O
and None None O
CREB None None I-protein
trans-activation None None O
were None None O
attained None None O
when None None O
these None None O
three None None O
kinase None None O
pathways None None O
were None None O
simultaneously None None O
activated None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

Our None None O
results None None O
demonstrate None None O
that None None O
coordinated None None O
activation None None O
of None None O
different None None O
kinases None None I-protein
leads None None O
to None None O
full None None O
activation None None O
of None None O
CREB None None I-protein
. None None O

Notably None None O
, None None O
CD28 None None O
ligation None None O
activated None None O
p38 None None I-protein
MAPK None None I-protein
and None None O
CaMKIV None None I-protein
, None None O
the None None O
kinases None None I-protein
stimulated None None O
by None None O
CD3 None None O
engagement None None O
, None None O
suggesting None None O
that None None O
CD28 None None I-protein
acts None None O
by None None O
increasing None None O
the None None O
activation None None O
extent None None O
of None None O
p38 None None I-protein
MAPK None None I-protein
and None None O
CaMKIV None None I-protein
. None None O

These None None O
results None None O
support None None O
the None None O
model None None O
of None None O
a None None O
minimum None None O
activation None None O
threshold None None O
for None None O
CREB None None I-protein
- None None O
CBP None None I-protein
interaction None None O
that None None O
can None None O
be None None O
reached None None O
only None None O
when None None O
both None None O
CD3 None None I-protein
and None None O
CD28 None None I-protein
are None None O
stimulated None None O
. None None O

The None None O
murine None None I-DNA
IL-2 None None I-DNA
promoter None None I-DNA
contains None None O
distal None None I-DNA
regulatory None None I-DNA
elements None None I-DNA
responsive None None O
to None None O
the None None O
Ah None None I-protein
receptor None None I-protein
, None None O
a None None O
member None None O
of None None O
the None None O
evolutionarily None None O
conserved None None O
bHLH-PAS None None I-protein
transcription None None I-protein
factor None None I-protein
family None None I-protein
. None None O

Signaling None None O
through None None O
the None None O
TCR None None I-protein
and None None O
costimulatory None None O
signals None None O
primarily None None O
control None None O
transcription None None O
of None None O
the None None O
IL-2 None None I-DNA
gene None None I-DNA
in None None O
naive None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
minimal None None I-DNA
promoter None None I-DNA
necessary None None O
for None None O
this None None O
expression None None O
lies None None O
proximal None None O
, None None O
between None None O
-300 None None O
and None None O
the None None O
transcription None None I-DNA
start None None I-DNA
site None None I-DNA
. None None O

We None None O
had None None O
previously None None O
shown None None O
that None None O
activation None None O
of None None O
the None None O
arylhydrocarbon None None I-protein
receptor None None I-protein
( None None O
AHR None None I-protein
) None None O
, None None O
a None None O
member None None O
of None None O
the None None O
bHLH-PAS None None I-protein
family None None I-protein
of None None I-protein
transcription None None I-protein
factors None None I-protein
, None None O
leads None None O
to None None O
increased None None O
mRNA None None O
expression None None O
of None None O
IL-2 None None I-RNA
in None None O
murine None None I-cell_type
fetal None None I-cell_type
thymocytes None None I-cell_type
. None None O

The None None O
AHR None None I-protein
is None None O
abundant None None O
in None None O
the None None O
thymus None None O
and None None O
may None None O
play None None O
a None None O
role None None O
for None None O
the None None O
development None None O
of None None O
the None None O
immune None None O
system None None O
. None None O

Moreover None None O
, None None O
its None None O
overactivation None None O
by None None O
chemicals None None O
such None None O
as None None O
dioxins None None O
leads None None O
to None None O
immunosuppression None None O
and None None O
thymic None None O
involution None None O
. None None O

Binding None None O
motifs None None O
for None None O
the None None O
liganded None None I-protein
AHR None None I-protein
can None None O
be None None O
identified None None O
in None None O
the None None O
distal None None I-DNA
region None None I-DNA
-1300 None None I-DNA
to None None I-DNA
-800 None None I-DNA
of None None O
the None None O
mouse None None I-DNA
IL-2 None None I-DNA
promoter None None I-DNA
. None None O

We None None O
show None None O
here None None O
that None None O
these None None O
DNA None None I-DNA
motifs None None I-DNA
, None None O
the None None O
so-called None None O
dioxin None None I-DNA
response None None I-DNA
elements None None I-DNA
, None None O
after None None O
binding None None O
to None None O
the None None O
liganded None None I-protein
AHR None None I-protein
are None None O
sufficient None None O
to None None O
transactivate None None O
luciferase None None O
expression None None O
in None None O
a None None O
reporter None None O
gene None None O
system None None O
. None None O

The None None O
IL-2 None None I-DNA
gene None None I-DNA
can None None O
be None None O
induced None None O
by None None O
the None None O
AHR None None I-protein
also None None O
in None None O
thymocytes None None I-cell_type
in None None O
vivo None None O
after None None O
injection None None O
of None None O
2 None None O
, None None O
3 None None O
, None None O
7 None None O
, None None O
8-tetrachlorodibenzo-p-dioxin None None O
, None None O
a None None O
potent None None O
ligand None None O
of None None O
the None None O
AHR None None I-protein
. None None O

The None None O
AHR None None I-protein
mediates None None O
the None None O
IL-2 None None O
induction None None O
as None None O
shown None None O
with None None O
AHR None None I-protein
-deficient None None O
mice None None O
. None None O

However None None O
, None None O
in None None O
spleen None None I-cell_type
cells None None I-cell_type
in None None O
vitro None None O
costimulation None None O
via None None O
the None None O
TCR None None I-protein
is None None O
necessary None None O
for None None O
optimal None None O
IL-2 None None I-DNA
gene None None I-DNA
induction None None O
. None None O

Thus None None O
, None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
region None None I-DNA
contains None None O
novel None None O
distal None None I-DNA
regulatory None None I-DNA
elements None None I-DNA
that None None O
can None None O
be None None O
addressed None None O
by None None O
the None None O
AHR None None I-protein
to None None O
induce None None O
IL-2 None None I-DNA
and None None O
can None None O
cooperate None None O
with None None O
the None None O
proximal None None I-DNA
promoter None None I-DNA

Visualization None None O
of None None O
Syk-antigen None None I-protein
receptor None None I-protein
interactions None None O
using None None O
green None None I-protein
fluorescent None None I-protein
protein None None I-protein
: None None O
differential None None O
roles None None O
for None None O
Syk None None I-protein
and None None O
Lyn None None I-protein
in None None O
the None None O
regulation None None O
of None None O
receptor None None O
capping None None O
and None None O
internalization None None O
. None None O

The None None O
cross-linking None None O
of None None O
the None None O
B None None I-protein
cell None None I-protein
Ag None None I-protein
receptor None None I-protein
( None None O
BCR None None I-protein
) None None O
is None None O
coupled None None O
to None None O
the None None O
stimulation None None O
of None None O
multiple None None O
intracellular None None O
signal None None O
transduction None None O
cascades None None O
via None None O
receptor-associated None None O
, None None O
protein None None I-protein
tyrosine None None I-protein
kinases None None I-protein
of None None O
both None None O
the None None O
Src None None I-protein
and None None I-protein
Syk None None I-protein
families None None I-protein
. None None O

To None None O
monitor None None O
changes None None O
in None None O
the None None O
subcellular None None O
distribution None None O
of None None O
Syk None None I-protein
in None None O
B None None I-cell_type
cells None None I-cell_type
responding None None O
to None None O
BCR None None I-protein
cross-linking None None O
, None None O
we None None O
expressed None None O
in None None O
Syk None None I-protein
-deficient None None O
DT40 None None I-cell_line
B None None I-cell_line
cells None None I-cell_line
a None None O
fusion None None I-protein
protein None None I-protein
consisting None None O
of None None O
Syk None None I-protein
coupled None None O
to None None O
green None None I-protein
fluorescent None None I-protein
protein None None I-protein
. None None O

Treatment None None O
of None None O
these None None O
cells None None O
with None None O
anti-IgM None None I-protein
Abs None None I-protein
leads None None O
to None None O
the None None O
recruitment None None O
of None None O
the None None O
kinase None None I-protein
from None None O
cytoplasmic None None O
and None None O
nuclear None None O
compartments None None O
to None None O
the None None O
site None None O
of None None O
the None None O
cross-linked None None I-protein
receptor None None I-protein
at None None O
the None None O
plasma None None O
membrane None None O
. None None O

The None None O
Syk-receptor None None I-protein
complexes None None I-protein
aggregate None None O
into None None O
membrane None None O
patches None None O
that None None O
redistribute None None O
to None None O
form None None O
a None None O
cap None None O
at None None O
one None None O
pole None None O
of None None O
the None None O
cell None None O
. None None O

Syk None None I-protein
is None None O
not None None O
demonstrably None None O
associated None None O
with None None O
the None None O
internalized None None I-protein
receptor None None I-protein
. None None O

Catalytically None None O
active None None O
Syk None None I-protein
promotes None None O
and None None O
stabilizes None None O
the None None O
formation None None O
of None None O
tightly None None I-protein
capped None None I-protein
BCR None None I-protein
complexes None None I-protein
at None None O
the None None O
plasma None None O
membrane None None O
. None None O

Lyn None None I-protein
is None None O
not None None O
required None None O
for None None O
the None None O
recruitment None None O
of None None O
Syk None None I-protein
to None None O
the None None O
cross-linked None None I-protein
receptor None None I-protein
, None None O
but None None O
is None None O
required None None O
for None None O
the None None O
internalization None None O
of None None O
the None None O
clustered None None O
BCR None None I-protein
complexes None None I-protein
. None None O

In None None O
the None None O
absence None None O
of None None O
Lyn None None I-protein
, None None O
receptor-Syk None None I-protein
complexes None None I-protein
at None None O
the None None O
plasma None None O
membrane None None O
are None None O
long None None O
lived None None O
, None None O
and None None O
the None None O
receptor-mediated None None O
activation None None O
of None None O
the None None O
NF-AT None None I-protein
transcription None None I-protein
factor None None I-protein
is None None O
enhanced None None O
. None None O

Thus None None O
, None None O
Lyn None None I-protein
appears None None O
to None None O
function None None O
to None None O
negatively None None O
regulate None None O
aspects None None O
of None None O
BCR None None I-protein
-dependent None None O
signaling None None O
by None None O
stimulating None None O
receptor None None O
internalization None None O
and None None O
down-regulation None None O
. None None O

Renal None None O
interstitial None None O
fibrosis None None O
is None None O
reduced None None O
in None None O
angiotensin None None I-protein
II None None I-protein
type None None I-protein
1a None None I-protein
receptor None None I-protein
-deficient None None O
mice None None O
. None None O

Unilateral None None O
ureteral None None O
obstruction None None O
( None None O
UUO None None O
) None None O
results None None O
in None None O
tubulointerstitial None None O
fibrosis None None O
of None None O
the None None O
affected None None O
kidney None None O
by None None O
stimulating None None O
the None None O
renin-angiotensin None None O
system None None O
. None None O

This None None O
study None None O
established None None O
a None None O
UUO None None O
model None None O
in None None O
angiotensin None None I-protein
type None None I-protein
1a None None I-protein
receptor None None I-protein
( None None O
AT1a None None I-protein
) None None O
deficient None None O
( None None O
mutant None None O
) None None O
mice None None O
to None None O
elucidate None None O
the None None O
role None None O
of None None O
angiotensin None None I-protein
II None None I-protein
through None None O
AT1a None None I-protein
on None None O
the None None O
fibrosis None None O
of None None O
the None None O
obstructed None None O
kidney None None O
( None None O
OBK None None O
) None None O
. None None O

The None None O
relative None None O
volume None None O
of None None O
the None None O
tubulointerstitium None None O
was None None O
measured None None O
by None None O
an None None O
image None None O
analyzer None None O
; None None O
deposition None None O
of None None O
collagen None None I-protein
types None None I-protein
III None None I-protein
and None None I-protein
IV None None I-protein
and None None O
monocyte None None I-cell_type
/ None None O
macrophage None None I-cell_type
infiltration None None O
were None None O
histologically None None O
examined None None O
using None None O
specific None None I-protein
antibodies None None I-protein
. None None O

Also None None O
determined None None O
were None None O
the None None O
mRNA None None O
levels None None O
of None None O
transforming None None I-protein
growth None None I-protein
factor-beta None None I-protein
by None None O
Northern None None O
blot None None O
analysis None None O
. None None O

Nuclear None None I-protein
factor-kappaB None None I-protein
activity None None O
was None None O
assessed None None O
by None None O
gel None None O
shift None None O
assay None None O
. None None O

UUO None None O
in None None O
wild None None O
mice None None O
resulted None None O
in None None O
a None None O
marked None None O
expansion None None O
of None None O
relative None None O
volume None None O
of None None O
the None None O
tubulointerstitium None None O
, None None O
together None None O
with None None O
increased None None O
deposition None None O
of None None O
collagen None None I-protein
types None None I-protein
III None None I-protein
and None None I-protein
IV None None I-protein
and None None O
number None None O
of None None O
infiltrated None None O
monocytes None None I-cell_type
/ None None O
macrophages None None I-cell_type
in None None O
the None None O
interstitium None None O
, None None O
relative None None O
to None None O
sham-operated None None O
mice None None O
. None None O

In None None O
comparison None None O
, None None O
these None None O
changes None None O
were None None O
significantly None None O
lower None None O
in None None O
mutant None None O
mice None None O
with None None O
UUO None None O
. None None O

The None None O
mRNA None None O
level None None O
of None None O
transforming None None I-protein
growth None None I-protein
factor-beta None None I-protein
was None None O
significantly None None O
higher None None O
in None None O
the None None O
OBK None None O
of None None O
wild None None O
mice None None O
with None None O
UUO None None O
compared None None O
with None None O
sham-operated None None O
mice None None O
. None None O

In None None O
contrast None None O
, None None O
the None None O
increase None None O
in None None O
mRNA None None O
level None None O
in None None O
the None None O
OBK None None O
of None None O
mutant None None O
mice None None O
was None None O
significantly None None O
less None None O
than None None O
in None None O
wild None None O
mice None None O
. None None O

Finally None None O
, None None O
UUO None None O
resulted None None O
in None None O
activation None None O
of None None O
nuclear None None I-protein
factor-kappaB None None I-protein
in None None O
wild None None O
mice None None O
but None None O
was None None O
inhibited None None O
in None None O
the None None O
OBK None None O
of None None O
mutant None None O
mice None None O
. None None O

The None None O
results None None O
provide None None O
direct None None O
evidence None None O
that None None O
angiotensin None None I-protein
II None None I-protein
acting None None O
via None None O
the None None O
AT1a None None I-protein
plays None None O
a None None O
pivotal None None O
role None None O
in None None O
the None None O
development None None O
of None None O
tubulointerstitial None None O
fibrosis None None O
in None None O
UUO None None O
. None None O

HLA-DQ None None I-protein
tetramers None None I-protein
identify None None O
epitope-specific None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
in None None O
peripheral None None O
blood None None O
of None None O
herpes None None O
simplex None None O
virus None None O
type None None O
2-infected None None O
individuals None None O
: None None O
direct None None O
detection None None O
of None None O
immunodominant None None I-cell_type
antigen-responsive None None I-cell_type
cells None None I-cell_type
. None None O

Ag-specific None None I-cell_type
CD4+ None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
are None None O
present None None O
in None None O
peripheral None None O
blood None None O
in None None O
low None None O
frequency None None O
, None None O
where None None O
they None None O
undergo None None O
recruitment None None O
and None None O
expansion None None O
during None None O
immune None None O
responses None None O
and None None O
in None None O
the None None O
pathogenesis None None O
of None None O
numerous None None O
autoimmune None None O
diseases None None O
. None None O

MHC None None I-protein
tetramers None None I-protein
, None None O
which None None O
constitute None None O
a None None O
labeled None None I-protein
MHC-peptide None None I-protein
ligand None None I-protein
suitable None None O
for None None O
binding None None O
to None None O
the None None O
Ag-specific None None I-protein
receptor None None I-protein
on None None O
T None None I-cell_type
cells None None I-cell_type
, None None O
provide None None O
a None None O
novel None None O
approach None None O
for None None O
the None None O
detection None None O
and None None O
characterization None None O
of None None O
such None None O
rare None None I-cell_type
cells None None I-cell_type
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
utilized None None O
this None None O
technology None None O
to None None O
identify None None O
HLA None None I-protein
DQ None None I-protein
-restricted None None O
Ag-specific None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
in None None O
the None None O
peripheral None None O
blood None None O
of None None O
human None None O
subjects None None O
and None None O
to None None O
identify None None O
immunodominant None None O
epitopes None None O
associated None None O
with None None O
viral None None O
infection None None O
. None None O

Peptides None None O
representing None None O
potential None None O
epitope None None I-protein
regions None None I-protein
of None None O
the None None O
VP16 None None I-protein
protein None None I-protein
from None None O
HSV-2 None None O
were None None O
loaded None None O
onto None None O
recombinant None None I-protein
DQ0602 None None I-protein
molecules None None I-protein
to None None O
generate None None O
a None None O
panel None None O
of None None O
Ag-specific None None I-protein
DQ0602 None None I-protein
tetramers None None I-protein
. None None O

VP16 None None I-protein
Ag None None I-protein
-specific None None O
DQ-restricted None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
were None None O
identified None None O
and None None O
expanded None None O
from None None O
the None None O
peripheral None None O
blood None None O
of None None O
HSV-2-infected None None O
individuals None None O
, None None O
representing None None O
two None None O
predominant None None O
epitope None None O
specificities None None O
. None None O

Although None None O
the None None O
VP16 None None O
369-380 None None O
peptide None None O
has None None O
a None None O
lower None None O
binding None None O
affinity None None O
for None None O
DQ0602 None None I-protein
molecules None None I-protein
than None None O
the None None O
VP16 None None O
33-52 None None O
peptide None None O
, None None O
T None None I-cell_type
cells None None I-cell_type
that None None O
recognized None None O
the None None O
VP16 None None O
369-380 None None O
peptide None None O
occurred None None O
at None None O
a None None O
much None None O
higher None None O
frequency None None O
than None None O
those None None O
that None None O
were None None O
specific None None O
for None None O
the None None O
VP16 None None O
33-52 None None O
peptide None None O
. None None O

Down-regulation None None O
of None None O
BOB.1/OBF.1 None None I-protein
and None None O
Oct2 None None I-protein
in None None O
classical None None O
Hodgkin None None O
disease None None O
but None None O
not None None O
in None None O
lymphocyte None None O
predominant None None O
Hodgkin None None O
disease None None O
correlates None None O
with None None O
immunoglobulin None None O
transcription None None O
. None None O

In None None O
contrast None None O
to None None O
the None None O
tumor None None I-cell_type
cells None None I-cell_type
( None None O
L None None I-cell_type
& None None I-cell_type
H None None I-cell_type
cells None None I-cell_type
) None None O
of None None O
lymphocyte None None O
predominant None None O
Hodgkin None None O
disease None None O
( None None O
LPHD None None O
) None None O
, None None O
Hodgkin None None I-cell_type
and None None I-cell_type
Reed-Sternberg None None I-cell_type
( None None I-cell_type
HRS None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
of None None O
classical None None O
Hodgkin None None O
disease None None O
( None None O
cHD None None O
) None None O
are None None O
unable None None O
to None None O
transcribe None None O
immunoglobulin None None I-protein
, None None O
despite None None O
the None None O
presence None None O
of None None O
rearranged None None I-DNA
immunoglobulin None None I-DNA
genes None None I-DNA
. None None O

Although None None O
initial None None O
studies None None O
have None None O
suggested None None O
crippling None None O
immunoglobulin None None O
gene None None O
mutations None None O
to None None O
be None None O
the None None O
cause None None O
of None None O
absent None None O
immunoglobulin None None O
expression None None O
in None None O
cHD None None O
, None None O
recent None None O
work None None O
of None None O
our None None O
group None None O
has None None O
demonstrated None None O
an None None O
impaired None None O
activation None None O
of None None O
the None None O
immunoglobulin None None I-DNA
promoter None None I-DNA
as None None O
a None None O
superior None None O
mechanism None None O
. None None O

As None None O
immunoglobulin None None O
transcription None None O
is None None O
mainly None None O
regulated None None O
by None None O
the None None O
B-cell None None I-protein
transcription None None I-protein
factors None None I-protein
Oct2 None None B-protein
and None None O
BOB.1/OBF.1 None None I-protein
, None None O
we None None O
analyzed None None O
35 None None O
cases None None O
of None None O
LPHD None None O
, None None O
32 None None O
cases None None O
of None None O
cHD None None O
, None None O
and None None O
2 None None O
Hodgkin None None I-cell_line
disease None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
for None None O
the None None O
expression None None O
of None None O
these None None O
transcription None None I-protein
factors None None I-protein
and None None O
also None None O
in None None O
parallel None None O
for None None O
immunoglobulin None None O
expression None None O
. None None O

Our None None O
results None None O
demonstrate None None O
an None None O
absence None None O
of None None O
Oct2 None None I-protein
and/or None None O
BOB.1/OBF.1 None None I-protein
in None None O
cHD None None O
and None None O
a None None O
striking None None O
overexpression None None O
of None None O
Oct2 None None I-protein
in None None O
LPHD None None O
. None None O

Immunoglobulin None None O
expression None None O
was None None O
lacking None None O
in None None O
cHD None None O
but None None O
present None None O
in None None O
LPHD None None O
. None None O

Furthermore None None O
, None None O
the None None O
reintroduction None None O
of None None O
BOB.1/OBF.1 None None I-protein
and None None O
Oct2 None None I-protein
into None None O
cultured None None O
HRS None None I-cell_type
cells None None I-cell_type
restored None None O
the None None O
activity None None O
of None None O
cotransduced None None O
immunoglobulin None None I-DNA
promoter None None I-DNA
constructs None None I-DNA
. None None O

Our None None O
findings None None O
dismiss None None O
the None None O
concept None None O
that None None O
the None None O
different None None O
immunoglobulin None None O
expression None None O
in None None O
cHD None None O
and None None O
LPHD None None O
is None None O
due None None O
to None None O
disrupting None None O
mutations None None O
of None None O
immunoglobulin None None I-DNA
V None None I-DNA
genes None None I-DNA
in None None O
cHD None None O
but None None O
is None None O
most None None O
likely None None O
due None None O
to None None O
a None None O
down-regulation None None O
of None None O
Oct2 None None I-protein
and/or None None O
BOB.1/OBF.1 None None I-protein
. None None O

This None None O
study None None O
further None None O
revealed None None O
Oct2 None None I-protein
as None None O
a None None O
new None None O
and None None O
valuable None None O
marker None None O
for None None O
the None None O
identification None None O
of None None O
L None None I-cell_type
& None None I-cell_type
H None None I-cell_type
cells None None I-cell_type
and None None O
their None None O
distinction None None O
from None None O
HRS None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
impairment None None O
of None None O
immunoglobulin None None O
transcription None None O
with None None O
a None None O
down-regulated None None O
synthesis None None O
of None None O
Oct2 None None I-protein
and None None O
BOB.1/OBF.1 None None I-protein
is None None O
the None None O
first None None O
established None None O
general None None O
recurrent None None O
defect None None O
found None None O
in None None O
HRS None None I-cell_type
cells None None I-cell_type
. None None O

Constitutive None None O
expression None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
is None None O
a None None O
characteristic None None O
feature None None O
of None None O
mycosis None None O
fungoides None None O
: None None O
implications None None O
for None None O
apoptosis None None O
resistance None None O
and None None O
pathogenesis None None O
. None None O

The None None O
NF-kappa None None I-protein
B None None I-protein
family None None I-protein
of None None I-protein
transcription None None I-protein
factors None None I-protein
is None None O
an None None O
important None None O
regulator None None O
of None None O
genes None None O
expressed None None O
during None None O
inflammatory None None O
responses None None O
, None None O
immunoglobulin None None O
( None None O
Ig None None O
) None None O
class None None O
switching None None O
, None None O
cellular None None O
differentiation None None O
, None None O
and None None O
apoptosis None None O
. None None O

Recently None None O
, None None O
members None None O
of None None O
the None None O
NF-kappaB None None I-protein
family None None I-protein
, None None O
including None None O
p65 None None I-protein
( None None I-protein
Rel None None I-protein
A None None I-protein
) None None I-protein
, None None O
have None None O
been None None O
implicated None None O
in None None O
promoting None None O
survival None None O
of None None O
various None None O
hematopoeitic None None O
neoplasms None None O
, None None O
including None None O
T None None O
cell None None O
malignancies None None O
such None None O
as None None O
adult None None O
T None None O
cell None None O
leukemia-lymphoma None None O
. None None O

We None None O
investigated None None O
the None None O
expression None None O
of None None O
active None None I-protein
NF-kappa None None I-protein
B None None I-protein
p65 None None I-protein
( None None I-protein
Rel None None I-protein
A None None I-protein
) None None I-protein
in None None O
cases None None O
of None None O
mycosis None None O
fungoides None None O
( None None O
MF None None O
) None None O
and None None O
the None None O
effect None None O
of None None O
chemical None None O
inhibitors None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
on None None O
apoptosis None None O
in None None O
cutaneous None None I-cell_line
T None None I-cell_line
cell None None I-cell_line
lymphoma None None I-cell_line
( None None I-cell_line
CTCL None None I-cell_line
) None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
. None None O

Paraffin-embedded None None O
tissues None None O
from None None O
23 None None O
cutaneous None None O
lesions None None O
and None None O
a None None O
single None None O
lymph None None O
node None None O
biopsy None None O
from None None O
patients None None O
diagnosed None None O
with None None O
MF None None O
were None None O
evaluated None None O
for None None O
p65 None None O
( None None O
Rel None None O
A None None O
) None None O
expression None None O
by None None O
using None None O
a None None O
monoclonal None None I-protein
mouse None None I-protein
antibody None None I-protein
that None None O
detects None None O
the None None O
activated None None O
form None None O
of None None O
p65 None None I-protein
( None None I-protein
Rel None None I-protein
A None None I-protein
) None None I-protein
. None None O

Apoptosis None None O
after None None O
treatment None None O
with None None O
the None None O
NF-kappa None None O
B None None O
inhibitors None None O
gliotoxin None None O
, None None O
MG132 None None O
, None None O
BAY None None O
11-7082 None None O
, None None O
and None None O
BAY None None O
11-7085 None None O
was None None O
quantitatively None None O
measured None None O
in None None O
the None None O
CTCL None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
HuT-78 None None I-cell_line
and None None I-cell_line
HH None None I-cell_line
by None None O
propidium None None O
iodide None None O
( None None O
PI None None O
) None None O
/cell None None O
cycle None None O
analysis None None O
for None None O
detection None None O
of None None O
a None None O
hypodiploid None None O
( None None O
sub-G None None O
( None None O
0 None None O
) None None O
) None None O
population None None O
and None None O
by None None O
determination None None O
of None None O
increased None None O
Annexin None None O
V/7-amino-actinomycin None None O
D None None O
( None None O
7-AAD None None O
) None None O
expression None None O
. None None O

Nuclear None None O
extracts None None O
from None None O
CTCL None None I-cell_type
cells None None I-cell_type
before None None O
and None None O
after None None O
chemical None None O
inhibition None None O
were None None O
analyzed None None O
for None None O
NF-kappa None None O
B None None O
nuclear None None O
DNA-binding None None O
activity None None O
by None None O
electrophoretic None None O
mobility None None O
shift None None O
assay None None O
( None None O
EMSA None None O
) None None O
with None None O
quantitative None None O
densitometry None None O
. None None O

Nuclear None None O
expression None None O
of None None O
p65 None None I-protein
( None None I-protein
Rel None None I-protein
A None None I-protein
) None None I-protein
before None None O
and None None O
after None None O
treatment None None O
with None None O
the None None O
various None None O
inhibitory None None O
compounds None None O
was None None O
measured None None O
by None None O
immunofluorescence None None O
staining None None O
in None None O
each None None O
CTCL None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
. None None O

Neoplastic None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
from None None O
22 None None O
of None None O
24 None None O
cases None None O
of None None O
MF None None O
showed None None O
strong None None O
nuclear None None O
and None None O
cytoplasmic None None O
expression None None O
of None None O
active None None I-protein
p65 None None I-protein
( None None I-protein
Rel None None I-protein
A None None I-protein
) None None I-protein
. None None O

Compared None None O
with None None O
untreated None None O
control None None I-cell_type
cells None None I-cell_type
, None None O
a None None O
marked None None O
increase None None O
in None None O
apoptosis None None O
, None None O
a None None O
significant None None O
decrease None None O
in None None O
NF-kappa None None O
B None None O
DNA-binding None None O
activity None None O
, None None O
and None None O
a None None O
marked None None O
decrease None None O
in None None O
nuclear None None O
p65 None None O
( None None O
Rel None None O
A None None O
) None None O
expression None None O
were None None O
seen None None O
in None None O
cells None None O
from None None O
both None None O
CTCL None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
after None None O
chemical None None O
NF-kappa None None O
B None None O
inhibition None None O
. None None O

These None None O
data None None O
show None None O
that None None O
the None None O
active None None O
form None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
p65 None None I-protein
( None None I-protein
Rel None None I-protein
A None None I-protein
) None None I-protein
is None None O
commonly None None O
expressed None None O
in None None O
neoplastic None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
in None None O
patients None None O
with None None O
MF None None O
. None None O

In None None O
CTCL None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
, None None O
the None None O
significant None None O
decrease None None O
in None None O
nuclear None None O
NF-kappa None None O
B None None O
expression None None O
and None None O
the None None O
marked None None O
increase None None O
in None None O
spontaneous None None O
apoptosis None None O
caused None None O
by None None O
chemical None None O
NF-kappa None None O
B None None O
inhibition None None O
suggest None None O
a None None O
critical None None O
role None None O
for None None O
NF-kappa None None I-protein
B None None I-protein
in None None O
the None None O
pathogenesis None None O
and None None O
tumor None None O
cell None None O
maintenance None None O
of None None O
CTCLs None None O
. None None O

HUM None None O
PATHOL None None O
31 None None O
: None None O
1482-1490 None None O
. None None O

Human None None O
T-cell None None O
leukemia None None O
virus None None O
type None None O
1 None None O
tax None None I-protein
protein None None I-protein
activates None None O
transcription None None O
through None None O
AP-1 None None I-DNA
site None None I-DNA
by None None O
inducing None None O
DNA None None O
binding None None O
activity None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

Human None None O
T-cell None None O
leukemia None None O
virus None None O
type None None O
1 None None O
( None None O
HTLV-1 None None O
) None None O
Tax None None I-protein
protein None None I-protein
induces None None O
the None None O
expression None None O
of None None O
various None None O
family None None O
members None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
AP-1 None None I-protein
, None None O
such None None O
as None None O
c-Jun None None I-protein
, None None O
JunD None None I-protein
, None None O
c-Fos None None I-protein
, None None O
and None None O
Fra-1 None None I-protein
, None None O
at None None O
the None None O
level None None O
of None None O
RNA None None O
expression None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

We None None O
examined None None O
the None None O
activity None None O
of None None O
Tax None None I-protein
in None None O
transcription None None O
through None None O
AP-1-binding None None I-DNA
sites None None I-DNA
( None None O
AP-1 None None I-DNA
site None None I-DNA
) None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

Transient None None O
transfection None None O
studies None None O
showed None None O
that None None O
Tax None None I-protein
activated None None O
the None None O
expression None None O
of None None O
a None None O
luciferase None None I-DNA
gene None None I-DNA
regulated None None O
by None None O
two None None O
copies None None O
of None None O
an None None O
AP-1 None None I-DNA
site None None I-DNA
in None None O
the None None O
human None None I-cell_line
Jurkat None None I-cell_line
T-cell None None I-cell_line
line None None I-cell_line
. None None O

Tax None None I-protein
activates None None O
the None None O
expression None None O
of None None O
viral None None I-DNA
and None None I-DNA
cellular None None I-DNA
genes None None I-DNA
through None None O
two None None O
different None None O
enhancers None None O
: None None O
a None None O
cAMP-responsive None None I-DNA
( None None I-DNA
CRE None None I-DNA
) None None I-DNA
-like None None I-DNA
element None None I-DNA
and None None O
a None None O
kappaB None None I-DNA
element None None I-DNA
. None None O

Two None None O
Tax None None I-protein
mutants None None I-protein
differentially None None O
activated None None O
expression None None O
of None None O
these None None O
two None None O
elements None None O
. None None O

Tax703 None None I-protein
preferentially None None O
activated None None O
the None None O
kappaB None None I-DNA
element None None I-DNA
but None None O
not None None O
the None None O
CRE-like None None O
one None None O
, None None O
whereas None None O
TaxM22 None None I-protein
showed None None O
the None None O
reverse None None O
. None None O

In None None O
addition None None O
, None None O
Tax703 None None I-protein
and None None O
Tax None None I-protein
, None None O
but None None O
not None None O
TaxM22 None None I-protein
, None None O
converted None None O
cell None None O
growth None None O
of None None O
a None None O
mouse None None I-cell_line
T-cell None None I-cell_line
line None None I-cell_line
from None None O
being None None O
interleukin None None O
( None None O
IL None None O
) None None O
-2-dependent None None O
to None None O
being None None O
IL-2-independent None None O
. None None O

Unlike None None O
the None None O
wild-type None None I-protein
Tax None None I-protein
, None None O
Tax703 None None I-protein
and None None O
TaxM22 None None I-protein
only None None O
weakly None None O
activated None None O
the None None O
AP-1 None None I-DNA
site None None I-DNA
in None None O
the None None O
T-cell None None I-cell_line
line None None I-cell_line
. None None O

Thus None None O
, None None O
Tax None None I-protein
seems None None O
to None None O
activate None None O
the None None O
AP-1 None None I-DNA
site None None I-DNA
via None None O
mechanisms None None O
distinct None None O
from None None O
those None None O
of None None O
kappaB None None I-DNA
or None None I-DNA
CRE-like None None I-DNA
elements None None I-DNA
, None None O
and None None O
the None None O
activation None None O
of None None O
the None None O
AP-1 None None I-DNA
site None None I-DNA
is None None O
dispensable None None O
for None None O
IL-2-independent None None O
growth None None O
of None None O
CTLL-2 None None O
. None None O

Electrophoretic None None O
mobility None None O
shift None None O
assays None None O
showed None None O
that None None O
Tax None None I-protein
induced None None O
strong None None O
binding None None O
activity None None O
to None None O
an None None O
AP-1 None None I-DNA
site None None I-DNA
in None None O
CTLL-2 None None O
, None None O
whereas None None O
Tax703 None None I-protein
did None None O
not None None O
, None None O
indicating None None O
that None None O
the None None O
induction None None O
of None None O
binding None None O
activity None None O
to None None O
the None None O
AP-1 None None I-DNA
site None None I-DNA
is None None O
essential None None O
for None None O
the None None O
transcriptional None None O
activation None None O
by None None O
Tax None None I-protein
. None None O

The None None O
binding None None I-protein
complex None None I-protein
induced None None O
by None None O
Tax None None I-protein
in None None O
CTLL-2 None None O
contained None None O
JunD None None I-protein
and None None O
Fra-2 None None I-protein
. None None O

Other None None O
AP-1 None None I-protein
proteins None None I-protein
were None None O
undetectable None None O
. None None O

Activation None None O
of None None O
transcription None None O
through None None O
the None None O
AP-1 None None I-DNA
site None None I-DNA
in None None O
Jurkat None None I-cell_line
cells None None I-cell_line
by None None O
JunD None None I-protein
and/or None None O
Fra-2 None None I-protein
was None None O
weak None None O
. None None O

c-Jun None None I-protein
, None None O
JunB None None I-protein
, None None O
and None None O
c-Fos None None I-protein
activation None None O
was None None O
greater None None O
, None None O
although None None O
the None None O
level None None O
was None None O
still None None O
less None None O
than None None O
that None None O
with None None O
Tax None None I-protein
. None None O

Thus None None O
, None None O
the None None O
induction None None O
of None None O
AP-1 None None I-RNA
mRNA None None I-RNA
by None None O
Tax None None I-protein
may None None O
not None None O
be None None O
sufficient None None O
for None None O
a None None O
complete None None O
activation None None O
of None None O
AP-1 None None I-DNA
site None None I-DNA
by None None O
Tax None None I-protein
. None None O

Our None None O
results None None O
suggest None None O
that None None O
Tax None None I-protein
activates None None O
the None None O
transcription None None O
of None None O
cellular None None I-DNA
genes None None I-DNA
with None None O
AP-1 None None I-DNA
sites None None I-DNA
by None None O
inducing None None O
the None None O
DNA-binding None None O
activity None None O
of None None O
AP-1 None None I-protein
proteins None None I-protein
in None None O
T None None I-cell_type
cells None None I-cell_type
, None None O
a None None O
mechanism None None O
distinct None None O
from None None O
those None None O
of None None O
CRE-like None None I-DNA
and None None I-DNA
kappaB None None I-DNA
elements None None I-DNA
. None None O

Copyright None None O
2001 None None O
Academic None None O
Press None None O
. None None O

Strict None None O
control None None O
of None None O
human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
replication None None O
by None None O
a None None O
genetic None None O
switch None None O
: None None O
Tet None None O
for None None O
Tat None None O
. None None O

Live-attenuated None None O
human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
( None None O
HIV-1 None None O
) None None O
variants None None O
have None None O
shown None None O
great None None O
promise None None O
as None None O
AIDS None None O
vaccines None None O
, None None O
but None None O
continued None None O
replication None None O
can None None O
lead None None O
to None None O
the None None O
selection None None O
of None None O
faster-replicating None None O
variants None None O
that None None O
are None None O
pathogenic None None O
. None None O

We None None O
therefore None None O
designed None None O
HIV-1 None None I-DNA
genomes None None I-DNA
that None None O
replicate None None O
exclusively None None O
upon None None O
addition None None O
of None None O
the None None O
nontoxic None None O
effector None None O
doxycycline None None O
( None None O
dox None None O
) None None O
. None None O

This None None O
was None None O
achieved None None O
by None None O
replacement None None O
of None None O
the None None O
viral None None O
TAR-Tat None None O
system None None O
for None None O
transcriptional None None O
activation None None O
by None None O
the None None O
Escherichia None None O
coli-derived None None O
Tet None None O
system None None O
for None None O
inducible None None O
gene None None O
expression None None O
. None None O

These None None O
designer None None O
`` None None O
HIV-rtTA None None O
'' None None O
viruses None None O
replicate None None O
in None None O
a None None O
strictly None None O
dox-dependent None None O
manner None None O
both None None O
in None None O
a None None O
T-cell None None I-cell_line
line None None I-cell_line
and None None O
in None None O
primary None None I-cell_type
blood None None I-cell_type
cells None None I-cell_type
, None None O
and None None O
the None None O
rate None None O
of None None O
replication None None O
can None None O
be None None O
fine-tuned None None O
by None None O
simple None None O
variation None None O
of None None O
the None None O
dox None None O
concentration None None O
. None None O

These None None O
HIV-rtTA None None O
viruses None None O
provide None None O
a None None O
tool None None O
to None None O
perform None None O
genetics None None O
, None None O
e.g. None None O
, None None O
selection None None O
and None None O
optimization None None O
experiments None None O
, None None O
with None None O
the None None O
E. None None O
coli-derived None None O
Tet None None O
reagents None None O
in None None O
a None None O
eukaryotic None None O
background None None O
. None None O

Furthermore None None O
, None None O
such None None O
viruses None None O
may None None O
represent None None O
improved None None O
vaccine None None O
candidates None None O
because None None O
their None None O
replication None None O
can None None O
be None None O
turned None None O
on None None O
and None None O
off None None O
at None None O
will None None O
. None None O

Synovial None None O
fluid None None O
induced None None O
nuclear None None I-protein
factor-kappaB None None I-protein
DNA None None O
binding None None O
in None None O
a None None O
monocytic None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
. None None O

OBJECTIVE None None O
: None None O
To None None O
determine None None O
the None None O
effects None None O
of None None O
synovial None None O
fluids None None O
( None None O
SF None None O
) None None O
on None None O
DNA None None O
binding None None O
activity None None O
of None None O
transcription None None I-protein
factor None None I-protein
nuclear None None B-protein
factor-kappaB None None I-protein
( None None O
NF-kappaB None None I-protein
) None None O
in None None O
the None None O
Mono None None I-cell_line
Mac None None I-cell_line
6 None None I-cell_line
monocytic/macrophage None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
as None None O
a None None O
model None None O
for None None O
the None None O
interaction None None O
between None None O
SF None None O
and None None O
synovial None None I-cell_type
tissue None None I-cell_type
macrophages None None I-cell_type
in None None O
arthritis None None O
. None None O

METHODS None None O
: None None O
Mono None None I-cell_line
Mac None None I-cell_line
6 None None I-cell_line
cells None None I-cell_line
were None None O
incubated None None O
with None None O
SF None None O
from None None O
the None None O
knee None None O
joints None None O
of None None O
human None None O
subjects None None O
with None None O
rheumatoid None None O
arthritis None None O
( None None O
RA None None O
) None None O
, None None O
undifferentiated None None O
seronegative None None O
oligoarthritis None None O
, None None O
and None None O
osteoarthritis None None O
( None None O
OA None None O
) None None O
. None None O

Nuclear None None O
extracts None None O
prepared None None O
from None None O
the None None O
Mono None None I-cell_line
Mac None None I-cell_line
6 None None I-cell_line
cells None None I-cell_line
and None None O
RA None None O
synovial None None O
tissue None None O
were None None O
analyzed None None O
by None None O
electrophoretic None None O
mobility None None O
shift None None O
analysis None None O
( None None O
EMSA None None O
) None None O
for None None O
NF-kappaB None None I-protein
DNA None None I-protein
binding None None I-protein
proteins None None I-protein
. None None O

RESULTS None None O
: None None O
Induction None None O
of None None O
NF-kappaB None None I-protein
DNA None None O
binding None None O
by None None O
the None None O
p65 None None I-protein
( None None I-protein
RelA None None I-protein
) None None I-protein
/p50 None None I-protein
heterodimer None None I-protein
was None None O
observed None None O
in None None O
response None None O
to None None O
incubation None None O
of None None O
Mono None None I-cell_line
Mac None None I-cell_line
6 None None I-cell_line
cells None None I-cell_line
with None None O
SF None None O
( None None O
20 None None O
% None None O
in None None O
culture None None O
medium None None O
) None None O
from None None O
5 None None O
of None None O
8 None None O
subjects None None O
with None None O
RA None None O
, None None O
4 None None O
of None None O
5 None None O
with None None O
OA None None O
, None None O
and None None O
none None None O
of None None O
3 None None O
with None None O
undifferentiated None None O
seronegative None None O
oligoarthritis None None O
. None None O

Incubation None None O
of None None O
SF None None O
with None None O
neutralizing None None I-protein
antibodies None None I-protein
against None None O
tumor None None I-protein
necrosis None None I-protein
factor-alpha None None I-protein
( None None I-protein
TNF-alpha None None I-protein
) None None I-protein
, None None O
but None None O
not None None O
antibodies None None I-protein
against None None O
interleukin None None I-protein
6 None None I-protein
( None None I-protein
IL-6 None None I-protein
) None None I-protein
, None None O
significantly None None O
reduced None None O
the None None O
induction None None O
of None None O
p65/p50 None None O
binding None None O
activity None None O
in None None O
SF None None O
from None None O
subjects None None O
with None None O
RA None None O
and None None O
OA None None O
. None None O

Unexpectedly None None O
, None None O
a None None O
slowly None None O
migrating None None O
SF None None O
inducible None None O
NF-kappaB None None I-protein
-binding None None O
complex None None O
was None None O
observed None None O
in None None O
EMSA None None O
of None None O
Mono None None I-cell_line
Mac None None I-cell_line
6 None None I-cell_line
cells None None I-cell_line
after None None O
incubation None None O
with None None O
SF None None O
from None None O
5 None None O
of None None O
8 None None O
RA None None O
and None None O
2 None None O
of None None O
5 None None O
OA None None O
subjects None None O
. None None O

The None None O
induction None None O
of None None O
this None None O
complex None None O
by None None O
SF None None O
was None None O
not None None O
affected None None O
by None None O
neutralization None None O
of None None O
TNF-alpha None None I-protein
or None None O
IL-6 None None I-protein
in None None O
SF None None O
, None None O
and None None O
the None None O
complex None None O
was None None O
not None None O
inducible None None O
by None None O
TNF-alpha None None I-protein
, None None O
IL-1beta None None O
, None None O
TNF-alpha None None I-protein
/ None None O
IL-1beta None None I-protein
, None None O
IL-6 None None I-protein
, None None O
platelet None None I-protein
derived None None I-protein
growth None None I-protein
factor None None I-protein
, None None O
lipopolysaccharide None None O
, None None O
or None None O
tetradecanoyl None None O
phorbol None None O
acetate None None O
. None None O

The None None O
slowly None None O
migrating None None I-protein
complex None None I-protein
could None None O
not None None O
be None None O
supershifted None None O
with None None O
antibodies None None I-protein
against None None O
NF-kappaB None None I-protein
, None None O
Jun None None I-protein
, None None O
or None None O
the None None O
transcriptional None None O
coactivators None None O
p300 None None I-protein
or None None O
CBP None None I-protein
. None None O

A None None O
NF-kappaB-binding None None I-protein
complex None None I-protein
with None None O
similar None None O
slow None None O
mobility None None O
was None None O
observed None None O
in None None O
nuclear None None O
extracts None None O
prepared None None O
from None None O
fresh None None O
human None None O
RA None None O
synovial None None O
tissue None None O
. None None O

CONCLUSION None None O
: None None O
Biological None None O
activity None None O
of None None O
TNF-alpha None None I-protein
in None None O
SF None None O
from None None O
RA None None O
and None None O
OA None None O
subjects None None O
is None None O
capable None None O
of None None O
inducing None None O
p65/p50 None None I-protein
NF-kappaB None None I-protein
DNA None None O
binding None None O
activity None None O
in None None O
macrophages None None I-cell_type
. None None O

A None None O
property None None O
of None None O
SF None None O
that None None O
is None None O
independent None None O
of None None O
TNF-alpha None None I-protein
and None None O
other None None O
cytokines None None I-protein
is None None O
responsible None None O
for None None O
the None None O
induction None None O
of None None O
a None None O
novel None None O
slowly None None O
migrating None None O
NF-kappaB-binding None None I-protein
complex None None I-protein
. None None O

Soluble None None O
mediators None None O
in None None O
SF None None O
of None None O
subjects None None O
with None None O
RA None None O
and None None O
OA None None O
can None None O
therefore None None O
modulate None None O
binding None None O
of None None O
nuclear None None I-protein
proteins None None I-protein
to None None O
the None None O
NF-kappaB None None I-protein
binding None None I-protein
site None None I-protein
in None None O
macrophages None None I-cell_type
and None None O
may None None O
play None None O
a None None O
role None None O
in None None O
inflammatory None None O
gene None None O
expression None None O
in None None O
arthritis None None O
. None None O

Peroxisome None None I-protein
proliferator None None I-protein
activator None None I-protein
receptor-gamma None None I-protein
agonists None None O
and None None O
15-deoxy-Delta None None O
( None None O
12 None None O
, None None O
14 None None O
) None None O
( None None O
12 None None O
, None None O
14 None None O
) None None O
-PGJ None None O
( None None O
2 None None O
) None None O
induce None None O
apoptosis None None O
in None None O
normal None None O
and None None O
malignant None None O
B-lineage None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
research None None O
described None None O
herein None None O
evaluates None None O
the None None O
expression None None O
and None None O
functional None None O
significance None None O
of None None O
peroxisome None None I-protein
proliferator None None I-protein
activator None None I-protein
receptor-gamma None None I-protein
( None None I-protein
PPAR-gamma None None I-protein
) None None I-protein
on None None O
B-lineage None None I-cell_type
cells None None I-cell_type
. None None O

Normal None None I-cell_type
mouse None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
and None None O
a None None O
variety None None O
of None None O
B None None I-cell_type
lymphoma None None I-cell_type
cells None None I-cell_type
reflective None None O
of None None O
stages None None O
of None None O
B None None O
cell None None O
differentiation None None O
( None None O
e.g. None None O
, None None O
70Z/3 None None O
, None None O
CH31 None None O
, None None O
WEHI-231 None None O
, None None O
CH12 None None O
, None None O
and None None O
J558 None None O
) None None O
express None None O
PPAR-gamma None None I-RNA
mRNA None None I-RNA
and None None O
, None None O
by None None O
Western None None O
blot None None O
analysis None None O
, None None O
the None None O
67-kDa None None I-protein
PPAR-gamma None None I-protein
protein None None I-protein
. None None O

15-Deoxy-Delta None None O
( None None O
12 None None O
, None None O
14 None None O
) None None O
-PGJ None None O
( None None O
2 None None O
) None None O
( None None O
15d-PGJ None None O
( None None O
2 None None O
) None None O
) None None O
, None None O
a None None O
PPAR-gamma None None O
agonist None None O
, None None O
has None None O
a None None O
dose-dependent None None O
antiproliferative None None O
and None None O
cytotoxic None None O
effect None None O
on None None O
normal None None I-cell_type
and None None I-cell_type
malignant None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
as None None O
shown None None O
by None None O
[ None None O
( None None O
3 None None O
) None None O
H None None O
] None None O
thymidine None None O
and None None O
3- None None O
[ None None O
4 None None O
, None None O
5-dimethylthiazol-2-yl None None O
] None None O
-2 None None O
, None None O
5-diphenyltetrazolium None None O
bromide None None O
assays None None O
. None None O

Only None None O
PPAR-gamma None None O
agonists None None O
( None None O
thiazolidinediones None None O
) None None O
, None None O
and None None O
not None None O
PPAR-alpha None None O
agonists None None O
, None None O
mimicked None None O
the None None O
effect None None O
of None None O
15d-PGJ None None O
( None None O
2 None None O
) None None O
on None None O
B-lineage None None I-cell_type
cells None None I-cell_type
, None None O
indicating None None O
that None None O
the None None O
mechanism None None O
by None None O
which None None O
15d-PGJ None None O
( None None O
2 None None O
) None None O
negatively None None O
affects None None O
B-lineage None None I-cell_type
cells None None I-cell_type
involves None None O
in None None O
part None None O
PPAR-gamma None None I-protein
. None None O

The None None O
mechanism None None O
by None None O
which None None O
PPAR-gamma None None O
agonists None None O
induce None None O
cytotoxicity None None O
is None None O
via None None O
apoptosis None None O
, None None O
as None None O
shown None None O
by None None O
annexin None None O
V None None O
staining None None O
and None None O
as None None O
confirmed None None O
by None None O
DNA None None O
fragmentation None None O
detected None None O
using None None O
the None None O
TUNEL None None O
assay None None O
. None None O

Interestingly None None O
, None None O
addition None None O
of None None O
PGF None None O
( None None O
2alpha None None O
) None None O
, None None O
which None None O
was None None O
not None None O
known None None O
to None None O
affect None None O
lymphocytes None None I-cell_type
, None None O
dramatically None None O
attenuated None None O
the None None O
deleterious None None O
effects None None O
of None None O
PPAR-gamma None None O
agonists None None O
on None None O
B None None I-cell_type
lymphomas None None I-cell_type
. None None O

Surprisingly None None O
, None None O
15d-PGJ None None O
( None None O
2 None None O
) None None O
induced None None O
a None None O
massive None None O
increase None None O
in None None O
nuclear None None O
mitogen-activated None None O
protein None None O
kinase None None O
activation None None O
, None None O
and None None O
pretreatment None None O
with None None O
PGF None None O
( None None O
2alpha None None O
) None None O
blunted None None O
the None None O
mitogen-activated None None O
protein None None O
kinase None None O
activation None None O
. None None O

This None None O
is None None O
the None None O
first None None O
study None None O
evaluating None None O
PPAR-gamma None None O
expression None None O
and None None O
its None None O
significance None None O
on None None O
B None None I-cell_type
lymphocytes None None I-cell_type
. None None O

PPAR-gamma None None O
agonists None None O
may None None O
serve None None O
as None None O
a None None O
counterbalance None None O
to None None O
the None None O
stimulating None None O
effects None None O
of None None O
other None None O
PGs None None O
, None None O
namely None None O
PGE None None O
( None None O
2 None None O
) None None O
, None None O
which None None O
promotes None None O
B None None O
cell None None O
differentiation None None O
. None None O

Finally None None O
, None None O
the None None O
use None None O
of None None O
PGs None None O
, None None O
such None None O
as None None O
15d-PGJ None None O
( None None O
2 None None O
) None None O
, None None O
and None None O
synthetic None None O
PPAR-gamma None None O
agonists None None O
to None None O
induce None None O
apoptosis None None O
in None None O
B-lineage None None I-cell_type
cells None None I-cell_type
may None None O
lead None None O
to None None O
the None None O
development None None O
of None None O
novel None None O
therapies None None O
for None None O
fatal None None I-cell_type
B None None I-cell_type
lymphomas None None I-cell_type

Inhibition None None O
of None None O
STAT3 None None O
signaling None None O
leads None None O
to None None O
apoptosis None None O
of None None O
leukemic None None I-cell_type
large None None I-cell_type
granular None None I-cell_type
lymphocytes None None I-cell_type
and None None O
decreased None None O
Mcl-1 None None O
expression None None O
. None None O

Large None None O
granular None None O
lymphocyte None None O
( None None O
LGL None None O
) None None O
leukemia None None O
is None None O
characterized None None O
by None None O
the None None O
expansion None None O
of None None O
antigen-activated None None I-cell_type
cytotoxic None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
. None None O

These None None O
leukemic None None I-cell_type
cells None None I-cell_type
are None None O
resistant None None O
to None None O
Fas-mediated None None O
apoptosis None None O
despite None None O
expressing None None O
high None None O
levels None None O
of None None O
Fas None None I-protein
. None None O

We None None O
found None None O
that None None O
leukemic None None I-cell_type
LGL None None I-cell_type
from None None O
19 None None O
patients None None O
displayed None None O
high None None O
levels None None O
of None None O
activated None None I-protein
STAT3 None None I-protein
. None None O

Treatment None None O
of None None O
leukemic None None I-cell_type
LGL None None I-cell_type
with None None O
the None None O
JAK-selective None None O
tyrosine None None O
kinase None None O
inhibitor None None O
AG-490 None None O
induced None None O
apoptosis None None O
with None None O
a None None O
corresponding None None O
decrease None None O
in None None O
STAT None None I-protein
-DNA None None O
binding None None O
activity None None O
. None None O

Moreover None None O
, None None O
using None None O
an None None O
antisense None None O
oligonucleotide None None O
approach None None O
to None None O
diminish None None O
STAT3 None None O
expression None None O
, None None O
we None None O
found None None O
that None None O
Fas None None O
sensitivity None None O
was None None O
restored None None O
in None None O
leukemic None None I-cell_type
LGL None None I-cell_type
. None None O

AG-490-induced None None O
apoptosis None None O
in None None O
leukemic None None I-cell_type
LGL None None I-cell_type
was None None O
independent None None O
of None None O
Bcl-xL None None O
or None None O
Bcl-2 None None O
expression None None O
. None None O

However None None O
, None None O
we None None O
found None None O
that None None O
the None None O
Bcl-2-family None None I-protein
protein None None I-protein
Mcl-1 None None I-protein
was None None O
significantly None None O
reduced None None O
by None None O
AG-490 None None O
treatment None None O
. None None O

Activated None None I-protein
STAT3 None None I-protein
was None None O
shown None None O
to None None O
bind None None O
an None None O
SIE-related None None I-DNA
element None None I-DNA
in None None O
the None None O
murine None None I-DNA
mcl-1 None None I-DNA
promoter None None I-DNA
. None None O

Using None None O
a None None O
luciferase None None O
reporter None None O
assay None None O
, None None O
we None None O
demonstrated None None O
that None None O
v-src None None O
overexpression None None O
in None None O
NIH3T3 None None O
induced None None O
STAT3 None None I-protein
-dependent None None O
transcriptional None None O
activity None None O
from None None O
the None None O
mcl-1 None None I-DNA
promoter None None I-DNA
and None None O
increased None None O
endogenous None None O
Mcl-1 None None O
protein None None O
levels None None O
. None None O

We None None O
conclude None None O
that None None O
STAT3 None None I-protein
activation None None O
contributed None None O
to None None O
accumulation None None O
of None None O
the None None O
leukemic None None I-cell_type
LGL None None I-cell_type
clones None None I-cell_type
. None None O

These None None O
findings None None O
suggest None None O
that None None O
investigation None None O
should None None O
focus None None O
on None None O
novel None None O
strategies None None O
targeting None None O
STAT3 None None I-protein
in None None O
the None None O
treatment None None O
of None None O
LGL None None O
leukemia None None O
. None None O

Decreased None None O
immediate None None O
inflammatory None None I-DNA
gene None None I-DNA
induction None None O
in None None O
activating None None I-protein
transcription None None I-protein
factor-2 None None I-protein
mutant None None O
mice None None O
. None None O

Transcription None None I-protein
factor None None I-protein
activating None None I-protein
transcription None None I-protein
factor None None I-protein
( None None I-protein
ATF None None I-protein
) None None I-protein
-2 None None I-protein
is None None O
activated None None O
by None None O
inflammatory None None O
signals None None O
transduced None None O
by None None O
the None None O
JNK None None O
and None None O
p38 None None O
MAP None None O
kinase None None O
pathways None None O
. None None O

To None None O
better None None O
define None None O
the None None O
role None None O
of None None O
ATF-2 None None I-protein
in None None O
inflammation None None O
, None None O
adult None None O
mice None None O
expressing None None O
small None None O
amounts None None O
of None None O
a None None O
mutant None None I-protein
ATF-2 None None I-protein
protein None None I-protein
were None None O
challenged None None O
with None None O
lipopolysaccharide None None O
( None None O
LPS None None O
) None None O
, None None O
anti-CD3 None None I-protein
antibody None None I-protein
or None None O
virus None None O
. None None O

Within None None O
3 None None O
h None None O
of None None O
challenge None None O
by None None O
LPS None None O
, None None O
ATF-2 None None O
mutant None None O
mice None None O
had None None O
decreased None None O
induction None None O
of None None O
the None None O
adhesion None None I-protein
molecules None None I-protein
E-selectin None None B-protein
, None None O
P-selectin None None I-protein
and None None O
VCAM-1 None None I-protein
as None None O
well None None O
as None None O
the None None O
cytokines None None I-protein
tumor None None B-protein
necrosis None None I-protein
factor-alpha None None I-protein
, None None O
IL-1beta None None I-protein
and None None O
IL-6 None None I-protein
compared None None O
with None None O
control None None O
mice None None O
. None None O

Stimulation None None O
of None None O
T None None I-cell_type
lymphocytes None None I-cell_type
by None None O
anti-CD3 None None I-protein
antibody None None I-protein
also None None O
showed None None O
less None None O
induction None None O
of None None O
IL-1 None None I-protein
and None None O
IL-6 None None I-protein
in None None O
ATF-2 None None O
mutant None None O
tissues None None O
. None None O

ATF-2 None None I-cell_type
mutant None None I-cell_type
thymocytes None None I-cell_type
treated None None O
with None None O
anti-CD3 None None I-protein
antibody None None I-protein
in None None O
vitro None None O
demonstrated None None O
reduced None None O
induction None None O
of None None O
c-Jun None None I-protein
, None None O
JunB None None I-protein
, None None O
JunD None None I-protein
and None None O
Fra-2 None None I-protein
. None None O

However None None O
, None None O
similar None None O
to None None O
what None None O
was None None O
observed None None O
after None None O
p38 None None O
kinase None None O
inhibition None None O
in None None O
normal None None O
mice None None O
, None None O
relative None None O
ATF-2 None None O
deficiency None None O
did None None O
not None None O
prevent None None O
the None None O
development None None O
of None None O
a None None O
mononuclear None None I-cell_type
cell None None I-cell_type
infiltrate None None O
in None None O
the None None O
week None None O
following None None O
an None None O
inflammatory None None O
stimulus None None O
. None None O

ATF-2 None None O
mutant None None O
mice None None O
proved None None O
more None None O
susceptible None None O
to None None O
death None None O
than None None O
control None None O
mice None None O
from None None O
LPS None None O
plus None None O
D-galactosamine None None O
injection None None O
or None None O
Coxsackievirus None None O
B3 None None O
infection None None O
and None None O
had None None O
a None None O
higher None None O
incidence None None O
of None None O
mononuclear None None O
pulmonary None None O
infiltrates None None O
after None None O
exposure None None O
to None None O
Herpes None None O
simplex None None O
virus-1 None None O
. None None O

ATF-2 None None I-protein
is None None O
essential None None O
for None None O
maximal None None O
immediate None None O
induction None None O
of None None O
adhesion None None I-protein
molecules None None I-protein
and None None O
cytokine None None I-DNA
genes None None I-DNA
, None None O
but None None O
at None None O
later None None O
time None None O
points None None O
may None None O
even None None O
protect None None O
against None None O
overactive None None O
immune None None O
responses None None O
. None None O

LIGHT None None I-protein
, None None O
a None None O
TNF-like None None I-protein
molecule None None I-protein
, None None O
costimulates None None O
T None None O
cell None None O
proliferation None None O
and None None O
is None None O
required None None O
for None None O
dendritic None None I-cell_type
cell None None I-cell_type
-mediated None None O
allogeneic None None O
T None None O
cell None None O
response None None O
. None None O

LIGHT None None I-protein
is None None O
a None None O
recently None None O
identified None None O
member None None O
of None None O
the None None O
TNF None None I-protein
superfamily None None I-protein
and None None O
its None None O
receptors None None O
, None None O
herpesvirus None None I-protein
entry None None I-protein
mediator None None I-protein
and None None O
lymphotoxin None None I-protein
beta None None I-protein
receptor None None I-protein
, None None O
are None None O
found None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
and None None O
stromal None None I-cell_type
cells None None I-cell_type
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
demonstrate None None O
that None None O
LIGHT None None I-protein
is None None O
selectively None None O
expressed None None O
on None None O
immature None None I-cell_type
dendritic None None I-cell_type
cells None None I-cell_type
( None None O
DCs None None I-cell_type
) None None O
generated None None O
from None None O
human None None I-cell_type
PBMCs None None I-cell_type
. None None O

In None None O
contrast None None O
, None None O
LIGHT None None I-protein
is None None O
not None None O
detectable None None O
in None None O
DCs None None I-cell_type
either None None O
freshly None None O
isolated None None O
from None None O
PBMCs None None I-cell_type
or None None O
rendered None None O
mature None None O
in None None O
vitro None None O
by None None O
LPS None None O
treatment None None O
. None None O

Blockade None None O
of None None O
LIGHT None None I-protein
by None None O
its None None O
soluble None None I-protein
receptors None None I-protein
, None None O
lymphotoxin None None I-protein
beta None None I-protein
receptor-Ig None None I-protein
or None None O
HVEM-Ig None None I-protein
, None None O
inhibits None None O
the None None O
induction None None O
of None None O
DC None None I-cell_type
-mediated None None O
primary None None O
allogeneic None None O
T None None O
cell None None O
response None None O
. None None O

Furthermore None None O
, None None O
engagement None None O
of None None O
LIGHT None None I-protein
costimulates None None O
human None None O
T None None O
cell None None O
proliferation None None O
, None None O
amplifies None None O
the None None O
NF-kappaB None None O
signaling None None O
pathway None None O
, None None O
and None None O
preferentially None None O
induces None None O
the None None O
production None None O
of None None O
IFN-gamma None None I-protein
, None None O
but None None O
not None None O
IL-4 None None I-protein
, None None O
in None None O
the None None O
presence None None O
of None None O
an None None O
antigenic None None O
signal None None O
. None None O

Our None None O
results None None O
suggest None None O
that None None O
LIGHT None None I-protein
is None None O
a None None O
costimulatory None None I-protein
molecule None None I-protein
involved None None O
in None None O
DC None None I-cell_type
-mediated None None O
cellular None None O
immune None None O
responses None None O
. None None O

Suppression None None O
of None None O
HIV None None O
type None None O
1 None None O
replication None None O
by None None O
a None None O
dominant-negative None None I-protein
Ets-1 None None I-protein
mutant None None I-protein
. None None O

Activity None None O
of None None O
the None None O
distal None None I-DNA
region None None I-DNA
of None None O
the None None O
human None None O
immunodeficiency None None O
virus None None O
( None None O
HIV-1 None None O
) None None O
long None None I-DNA
terminal None None I-DNA
repeat None None I-DNA
( None None O
LTR None None I-DNA
) None None O
, None None O
which None None O
contains None None O
binding None None I-DNA
sites None None I-DNA
for None None O
the None None O
Ets-1 None None I-protein
and None None I-protein
USF-1 None None I-protein
proteins None None I-protein
, None None O
is None None O
integral None None O
for None None O
HIV-1 None None O
replication None None O
. None None O

The None None O
Ets-1 None None I-protein
and None None I-protein
USF-1 None None I-protein
proteins None None I-protein
play None None O
a None None O
critical None None O
role None None O
in None None O
the None None O
activity None None O
of None None O
the None None O
HIV-1 None None I-DNA
LTR None None I-DNA
distal None None I-DNA
enhancer None None I-DNA
region None None I-DNA
, None None O
as None None O
indicated None None O
by None None O
the None None O
potent None None O
dominant None None O
negative None None O
effect None None O
of None None O
a None None O
mutant None None I-DNA
Ets-1 None None I-DNA
lacking None None I-DNA
trans-activation None None I-DNA
domains None None I-DNA
on None None O
the None None O
transcriptional None None O
activity None None O
of None None O
the None None O
LTR None None I-DNA
. None None O

To None None O
determine None None O
the None None O
biological None None O
relevance None None O
of None None O
the None None O
Ets-1 None None I-protein
and None None I-protein
USF-1 None None I-protein
proteins None None I-protein
in None None O
HIV-1 None None O
replication None None O
, None None O
we None None O
examined None None O
the None None O
effect None None O
of None None O
expression None None O
of None None O
the None None O
dominant-negative None None O
mutant None None O
of None None O
Ets-1 None None I-DNA
( None None O
dnEts-1 None None I-DNA
) None None O
on None None O
HIV-1 None None O
infection None None O
of None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

We None None O
demonstrated None None O
that None None O
expression None None O
of None None O
dnEts None None I-DNA
markedly None None O
suppressed None None O
HIV-1 None None O
infection None None O
of None None O
a None None O
T None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
. None None O

This None None O
finding None None O
indicates None None O
that None None O
formation None None O
of None None O
a None None O
transcriptionaly None None I-protein
active None None I-protein
USF-1/Ets-1 None None I-protein
complex None None I-protein
is None None O
important None None O
in None None O
the None None O
productive None None O
infection None None O
of None None O
cells None None O
by None None O
HIV-1 None None O
, None None O
and None None O
suggests None None O
that None None O
inhibition None None O
of None None O
the None None O
interaction None None O
between None None O
USF-1 None None I-protein
and None None O
Ets-1 None None I-protein
with None None O
the None None O
HIV-1 None None I-DNA
LTR None None I-DNA
may None None O
provide None None O
a None None O
new None None O
target None None O
for None None O
anti-HIV-1 None None O
gene None None O
therapy None None O
. None None O

Human None None I-cell_type
eosinophils None None I-cell_type
constitutively None None O
express None None O
nuclear None None I-protein
factor None None I-protein
of None None I-protein
activated None None I-protein
T None None I-protein
cells None None I-protein
p None None I-protein
and None None I-protein
c None None I-protein
. None None O

BACKGROUND None None O
: None None O
Eosinophils None None I-cell_type
are None None O
now None None O
known None None O
to None None O
produce None None O
a None None O
variety None None O
of None None O
proinflammatory None None I-protein
cytokines None None I-protein
, None None O
although None None O
the None None O
molecular None None O
factors None None O
that None None O
regulate None None O
their None None O
production None None O
are None None O
poorly None None O
understood None None O
. None None O

The None None O
expression None None O
of None None O
almost None None O
all None None O
of None None O
the None None O
cytokines None None I-protein
produced None None O
by None None O
eosinophils None None I-cell_type
, None None O
including None None O
the None None O
proallergic None None I-protein
cytokine None None I-protein
IL-4 None None I-protein
, None None O
is None None O
now None None O
known None None O
to None None O
be None None O
regulated None None O
at None None O
the None None O
level None None O
of None None O
transcription None None O
by None None O
members None None O
of None None O
the None None O
nuclear None None I-protein
factor None None I-protein
of None None I-protein
activated None None I-protein
T None None I-protein
cells None None I-protein
( None None O
NFAT None None I-protein
) None None O
family None None O
of None None O
transcription None None O
factors None None O
. None None O

OBJECTIVE None None O
: None None O
We None None O
sought None None O
to None None O
characterize None None O
the None None O
expression None None O
of None None O
different None None O
NFAT None None I-protein
proteins None None I-protein
in None None O
resting None None I-cell_type
and None None I-cell_type
activated None None I-cell_type
eosinophils None None I-cell_type
. None None O

METHODS None None O
: None None O
Nuclear None None O
and None None O
whole None None O
cell None None O
extracts None None O
were None None O
obtained None None O
from None None O
both None None O
peripheral None None I-cell_type
blood None None I-cell_type
eosinophils None None I-cell_type
and None None O
those None None O
obtained None None O
from None None O
bronchoalveolar None None O
lavage None None O
fluid None None O
of None None O
asthmatic None None O
subjects None None O
after None None O
endobronchial None None O
allergen None None O
challenge None None O
. None None O

NFAT None None I-protein
expression None None O
was None None O
determined None None O
by None None O
using None None O
immunoprecipitation None None O
and None None O
Western None None O
blot None None O
analysis None None O
, None None O
DNA-binding None None O
assays None None O
, None None O
and None None O
RT-PCR None None O
analysis None None O
of None None O
eosinophil None None I-RNA
mRNA None None I-RNA
. None None O

RESULTS None None O
: None None O
Both None None O
peripheral None None I-cell_type
blood None None I-cell_type
and None None I-cell_type
bronchoalveolar None None I-cell_type
lavage None None I-cell_type
fluid None None I-cell_type
eosinophils None None I-cell_type
expressed None None O
NFATp None None I-protein
and None None I-protein
NFATc None None I-protein
protein None None I-protein
. None None O

Unlike None None O
activated None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
, None None O
which None None O
express None None O
multiple None None O
NFATc None None O
isoforms None None O
, None None O
eosinophils None None I-cell_type
preferentially None None O
express None None O
the None None O
approximately None None O
85-kd None None O
isoform None None O
. None None O

In None None O
addition None None O
, None None O
eosinophils None None I-cell_type
were None None O
found None None O
to None None O
constitutively None None O
express None None O
NFATc None None I-RNA
mRNA None None I-RNA
. None None O

A None None O
brief None None O
incubation None None O
with None None O
the None None O
T None None I-protein
( None None I-protein
H None None I-protein
) None None I-protein
2 None None I-protein
cytokines None None I-protein
IL-4 None None B-protein
and None None O
IL-5 None None I-protein
was None None O
sufficient None None O
to None None O
induce None None O
the None None O
nuclear None None O
translocation None None O
of None None O
NFATc None None I-protein
. None None O

Eosinophil None None O
nuclear None None O
extracts None None O
contain None None O
multiple None None O
factors None None O
that None None O
can None None O
specifically None None O
recognize None None O
the None None O
IL-4 None None I-DNA
promoter None None I-DNA
P1 None None I-DNA
NFAT None None I-DNA
site None None I-DNA
in None None O
DNA-binding None None O
assays None None O
, None None O
including None None O
NFATp None None I-protein
. None None O

CONCLUSION None None O
: None None O
NFATp None None I-protein
and None None O
NFATc None None I-protein
can None None O
regulate None None O
the None None O
expression None None O
of None None O
cytokines None None I-protein
and None None O
other None None O
genes None None O
in None None O
eosinophils None None I-cell_type
but None None O
appear None None O
to None None O
be None None O
regulated None None O
by None None O
a None None O
novel None None O
signal None None O
transduction None None O
mechanism None None O
in None None O
these None None O
cells None None O
. None None O

BLyS None None I-protein
BINDS None None O
TO None None O
B None None I-cell_type
CELLS None None I-cell_type
WITH None None O
HIGH None None O
AFFINITY None None O
AND None None O
INDUCES None None O
ACTIVATION None None O
OF None None O
THE None None O
TRANSCRIPTION None None I-protein
FACTORS None None I-protein
NF-kappaB None None B-protein
AND None None O
ELF-1 None None I-protein
. None None O

B None None I-protein
lymphocyte None None I-protein
stimulator None None I-protein
( None None O
BLyS None None I-protein
) None None O
is None None O
a None None O
novel None None O
member None None O
of None None O
the None None O
TNF None None I-protein
family None None I-protein
of None None I-protein
proteins None None I-protein
expressed None None O
by None None O
myeloid None None I-cell_type
cells None None I-cell_type
as None None O
membrane-bound None None O
and None None O
soluble None None O
forms None None O
. None None O

BLyS None None I-protein
was None None O
shown None None O
to None None O
act None None O
specifically None None O
on None None O
B None None I-cell_type
cells None None I-cell_type
, None None O
inducing None None O
proliferation None None O
and None None O
immunoglobulin None None O
production None None O
both None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
. None None O

The None None O
present None None O
study None None O
was None None O
undertaken None None O
to None None O
characterize None None O
binding None None O
of None None O
radiolabeled None None I-protein
BLyS None None I-protein
to None None O
its None None O
cognate None None I-protein
receptor None None I-protein
on None None O
human None None I-cell_type
B None None I-cell_type
lymphocytes None None I-cell_type
and None None O
examine None None O
intracellular None None O
events None None O
initiated None None O
by None None O
BLyS None None I-protein
binding None None O
. None None O

Similar None None O
to None None O
other None None O
TNF None None I-protein
family None None I-protein
members None None I-protein
, None None O
BLyS None None I-protein
is None None O
present None None O
in None None O
solution None None O
as None None O
a None None O
homotrimer None None I-protein
as None None O
determined None None O
by None None O
gel None None O
filtration None None O
chromatography None None O
and None None O
light None None O
scattering None None O
analysis None None O
. None None O

BLyS None None I-protein
binding None None O
to None None O
B None None I-cell_type
cells None None I-cell_type
is None None O
specific None None O
as None None O
other None None O
TNF None None I-protein
family None None I-protein
members None None I-protein
tested None None O
did None None O
not None None O
compete None None O
for None None O
( None None O
125 None None O
) None None O
I- None None O
BLyS None None I-protein
binding None None O
. None None O

Analysis None None O
of None None O
equilibrium None None O
binding None None O
of None None O
( None None I-protein
125 None None I-protein
) None None I-protein
I-labeled None None I-protein
BLyS None None I-protein
to None None O
purified None None O
human None None I-cell_type
tonsillar None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
demonstrated None None O
saturable None None O
binding None None O
. None None O

Scatchard None None O
analysis None None O
of None None O
the None None O
binding None None O
data None None O
revealed None None O
a None None O
single None None O
class None None O
of None None O
high-affinity None None O
binding None None O
on None None O
human None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
with None None O
approximately None None O
2600 None None O
binding None None O
sites None None O
per None None O
cell None None O
and None None O
an None None O
apparent None None O
dissociation None None O
constant None None O
( None None O
K None None O
( None None O
D None None O
) None None O
) None None O
of None None O
about None None O
0.1 None None O
nM None None O
. None None O

In None None O
addition None None O
we None None O
report None None O
that None None O
BLyS None None I-protein
binding None None O
to None None O
B None None I-cell_type
cells None None I-cell_type
results None None O
in None None O
the None None O
activation None None O
of None None O
NF-kappaB None None I-protein
and None None O
the None None O
Ets None None I-protein
family None None I-protein
transcription None None I-protein
factor None None I-protein
, None None O
ELF-1 None None I-protein
, None None O
and None None O
in None None O
the None None O
induction None None O
of None None O
mRNA None None O
for None None O
Polo-like None None I-protein
kinase None None I-protein
( None None O
PLK None None I-protein
) None None O
. None None O

Copyright None None O
2001 None None O
Academic None None O
Press None None O
. None None O

Design None None O
and None None O
use None None O
of None None O
an None None O
inducibly None None O
activated None None O
human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
Nef None None I-protein
to None None O
study None None O
immune None None O
modulation None None O
. None None O

The None None O
Nef None None I-protein
protein None None I-protein
of None None O
the None None O
human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
( None None O
HIV-1 None None O
) None None O
has None None O
been None None O
shown None None O
to None None O
enhance None None O
the None None O
infectivity None None O
of None None O
virus None None O
particles None None O
, None None O
downmodulate None None O
cell None None I-protein
surface None None I-protein
proteins None None I-protein
, None None O
and None None O
associate None None O
with None None O
many None None O
intracellular None None I-protein
proteins None None I-protein
that None None O
are None None O
thought None None O
to None None O
facilitate None None O
HIV None None O
infection None None O
. None None O

One None None O
of None None O
the None None O
challenges None None O
in None None O
defining None None O
the None None O
molecular None None O
events None None O
regulated None None O
by None None O
Nef None None I-protein
has None None O
been None None O
obtaining None None O
good None None O
expression None None O
of None None O
Nef None None I-protein
protein None None I-protein
in None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

This None None O
has None None O
been None None O
attributed None None O
to None None O
effects None None O
of None None O
Nef None None I-protein
on None None O
cell None None O
proliferation None None O
and None None O
apoptosis None None O
. None None O

We None None O
have None None O
designed None None O
a None None O
Nef None None I-protein
protein None None I-protein
that None None O
is None None O
readily None None O
expressed None None O
in None None O
T-cell None None I-cell_line
lines None None I-cell_line
and None None O
whose None None O
function None None O
is None None O
inducibly None None O
activated None None O
. None None O

It None None O
is None None O
composed None None O
of None None O
a None None O
fusion None None O
between None None O
full-length None None I-protein
Nef None None I-protein
and None None O
the None None O
estrogen None None I-protein
receptor None None I-protein
hormone-binding None None I-protein
domain None None I-protein
( None None O
Nef-ER None None I-protein
) None None O
. None None O

The None None O
Nef-ER None None I-protein
is None None O
kept None None O
in None None O
an None None O
inactive None None O
state None None O
due None None O
to None None O
steric None None O
hindrance None None O
, None None O
and None None O
addition None None O
of None None O
the None None O
membrane-permeable None None O
drug None None O
4-hydroxytamoxifen None None O
( None None O
4-HT None None O
) None None O
, None None O
which None None O
binds None None O
to None None O
the None None O
ER None None I-protein
domain None None I-protein
, None None O
leads None None O
to None None O
inducible None None O
activation None None O
of None None O
Nef-ER None None I-protein
within None None O
cells None None O
. None None O

We None None O
demonstrate None None O
that None None O
Nef-ER None None I-protein
inducibly None None O
associates None None O
with None None O
the None None O
62-kDa None None I-protein
Ser/Thr None None I-protein
kinase None None I-protein
and None None O
is None None O
localized None None O
to None None O
specific None None O
membrane None None O
microdomains None None O
( None None O
lipid None None O
rafts None None O
) None None O
only None None O
after None None O
activation None None O
. None None O

Using None None O
this None None O
inducible None None O
Nef None None I-protein
, None None O
we None None O
also None None O
compared None None O
the None None O
specific None None O
requirements None None O
for None None O
CD4 None None I-protein
and None None O
HLA-A2 None None I-protein
downmodulation None None O
in None None O
a None None O
SupT1 None None I-cell_line
T-cell None None I-cell_line
line None None I-cell_line
. None None O

Half-maximal None None O
downmodulation None None O
of None None O
cell None None I-protein
surface None None I-protein
CD4 None None I-protein
required None None O
very None None O
little None None O
active None None O
Nef-ER None None I-protein
and None None O
occurred None None O
as None None O
early None None O
as None None O
4 None None O
h None None O
after None None O
addition None None O
of None None O
4-HT None None O
. None None O

In None None O
contrast None None O
, None None O
50 None None O
% None None O
downmodulation None None O
of None None O
HLA-A2 None None I-protein
by None None O
Nef None None I-protein
required None None O
16 None None O
to None None O
24 None None O
h None None O
and None None O
about None None O
50- None None O
to None None O
100-fold-greater None None O
concentrations None None O
of None None O
4-HT None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
HLA-A2 None None I-protein
downmodulation None None O
may None None O
require None None O
certain None None O
threshold None None O
levels None None O
of None None O
active None None O
Nef None None I-protein
. None None O

The None None O
differential None None O
timing None None O
of None None O
CD4 None None I-protein
and None None O
HLA-A2 None None I-protein
downmodulation None None O
may None None O
have None None O
implications None None O
for None None O
HIV None None O
pathogenesis None None O
and None None O
immune None None O
evasion None None O
. None None O

Regulation None None O
of None None O
chemokine None None O
mRNA None None O
expression None None O
in None None O
a None None O
rat None None O
model None None O
of None None O
vanadium-induced None None O
pulmonary None None O
inflammation None None O
. None None O

Environmental None None O
and None None O
occupational None None O
exposure None None O
to None None O
vanadium None None O
dusts None None O
results None None O
in None None O
toxic None None O
effects None None O
mainly None None O
confined None None O
to None None O
the None None O
respiratory None None O
system None None O
. None None O

Using None None O
a None None O
rat None None O
model None None O
of None None O
acute None None O
lung None None O
inflammation None None O
induced None None O
by None None O
intratracheal None None O
instillation None None O
of None None O
sodium None None O
metavanadate None None O
( None None O
NaVO3 None None O
) None None O
at None None O
the None None O
dose None None O
of None None O
200 None None O
microg None None O
V/kg None None O
, None None O
we None None O
investigated None None O
the None None O
relationship None None O
between None None O
the None None O
cytologic None None O
characterization None None O
of None None O
pulmonary None None O
inflammation None None O
and None None O
the None None O
expression None None O
of None None O
chemokine None None I-RNA
mRNA None None I-RNA
. None None O

Significant None None O
polymorphonuclear None None I-cell_type
leukocyte None None I-cell_type
( None None O
PMN None None I-cell_type
) None None O
influx None None O
( None None O
P None None O
< None None O
0.01 None None O
) None None O
into None None O
the None None O
lung None None O
was None None O
noted None None O
4 None None O
h None None O
after None None O
NaVO3 None None O
instillation None None O
, None None O
whereas None None O
alveolar None None I-cell_type
macrophages None None I-cell_type
( None None O
AMs None None I-cell_type
) None None O
in None None O
bronchoalveolar None None I-cell_type
lavage None None I-cell_type
( None None I-cell_type
BAL None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
appeared None None O
to None None O
decrease None None O
significantly None None O
. None None O

In None None O
contrast None None O
, None None O
neither None None O
PMNs None None I-cell_type
nor None None O
AMs None None I-cell_type
changed None None O
substantially None None O
1 None None O
h None None O
after None None O
NaVO3 None None O
instillation None None O
. None None O

By None None O
Northern None None O
analysis None None O
, None None O
macrophage None None I-RNA
inflammatory None None I-RNA
protein None None I-RNA
( None None I-RNA
MIP None None I-RNA
) None None I-RNA
-2 None None I-RNA
mRNA None None I-RNA
in None None O
BAL None None I-cell_type
cells None None I-cell_type
increased None None O
markedly None None O
1 None None O
h None None O
after None None O
NaVO3 None None O
instillation None None O
and None None O
reduced None None O
a None None O
little None None O
bit None None O
at None None O
4 None None O
h None None O
, None None O
whereas None None O
MIP-1alpha None None I-RNA
mRNA None None I-RNA
in None None O
BAL None None I-cell_type
cells None None I-cell_type
was None None O
expressed None None O
relatively None None O
high None None O
1 None None O
h None None O
after None None O
NaVO3 None None O
instillation None None O
, None None O
although None None O
a None None O
basal None None O
expression None None O
was None None O
detected None None O
in None None O
control None None O
group None None O
, None None O
and None None O
returned None None O
rapidly None None O
nearly None None O
to None None O
control None None O
level None None O
at None None O
4 None None O
h None None O
. None None O

Since None None O
MIP-2 None None I-protein
is None None O
a None None O
potent None None O
PMN None None I-cell_type
chemoattractant None None O
and None None O
MIP-1alpha None None I-protein
is None None O
a None None O
potent None None O
macrophage/monocyte None None O
chemoattractant None None O
has None None O
been None None O
well None None O
known None None O
. None None O

The None None O
facts None None O
that None None O
PMN None None I-cell_type
influx None None O
was None None O
preceded None None O
by None None O
increased None None O
MIP-2 None None O
mRNA None None O
expression None None O
, None None O
suggesting None None O
that None None O
MIP-2 None None I-protein
is None None O
involved None None O
in None None O
the None None O
development None None O
of None None O
NaVO3-induced None None O
pulmonary None None O
inflammation None None O
, None None O
whereas None None O
increased None None O
MIP-1alpha None None I-RNA
mRNA None None I-RNA
expression None None O
was None None O
followed None None O
by None None O
decreased None None O
AMs None None I-cell_type
in None None O
BAL None None I-cell_type
cells None None I-cell_type
, None None O
suggesting None None O
AMs None None I-cell_type
might None None O
be None None O
activated None None O
by None None O
MIP-1alpha None None I-protein
, None None O
adherent None None O
to None None O
the None None O
lining None None O
surface None None O
of None None O
the None None O
airways None None O
and None None O
then None None O
resistant None None O
to None None O
be None None O
washed None None O
out None None O
. None None O

To None None O
delineate None None O
the None None O
mechanisms None None O
of None None O
transcriptional None None O
activation None None O
, None None O
we None None O
recently None None O
cloned None None O
the None None O
5'-flanking None None I-DNA
region None None I-DNA
of None None O
the None None O
MIP-2 None None I-DNA
gene None None I-DNA
. None None O

The None None O
promotor None None I-DNA
region None None I-DNA
contains None None O
consensus None None I-DNA
binding None None I-DNA
sites None None I-DNA
for None None O
transcription None None I-protein
factor None None I-protein
nuclear None None I-protein
factor None None I-protein
kappaB None None I-protein
( None None O
NF-kappaB None None I-protein
) None None O
and None None O
activator None None I-protein
protein-1 None None I-protein
( None None O
AP-1 None None I-protein
) None None O
. None None O

Using None None O
electrophoretic None None O
mobility None None O
shift None None O
assay None None O
, None None O
increased None None O
nuclear None None O
NF-kappaB None None I-protein
, None None O
not None None O
AP-1 None None I-protein
, None None O
binding None None O
activity None None O
was None None O
detected None None O
1 None None O
h None None O
after None None O
NaVO3 None None O
instillation None None O
, None None O
which None None O
correlated None None O
with None None O
the None None O
induction None None O
of None None O
MIP-2 None None I-RNA
mRNA None None I-RNA
. None None O

p65 None None I-protein
( None None I-protein
Rel None None I-protein
A None None I-protein
) None None I-protein
and None None O
p50 None None I-protein
protein None None I-protein
appears None None O
to None None O
be None None O
involved None None O
in None None O
MIP-2 None None O
NF-kappaB None None I-protein
binding None None O
. None None O

Taken None None O
together None None O
, None None O
our None None O
studies None None O
suggest None None O
that None None O
MIP-2 None None I-protein
is None None O
an None None O
important None None O
mediator None None O
of None None O
NaVO3-induced None None O
pulmonary None None O
inflammation None None O
in None None O
the None None O
rat None None O
model None None O
. None None O

In None None O
addition None None O
, None None O
elevated None None O
MIP-2 None None I-RNA
mRNA None None I-RNA
levels None None O
are None None O
accompanied None None O
by None None O
increased None None O
NF-kappaB None None I-protein
binding None None O
activity None None O
in None None O
BAL None None I-cell_type
cells None None I-cell_type
, None None O
suggesting None None O
possible None None O
MIP-2 None None I-protein
transcriptional None None O
regulation None None O
through None None O
NF-kappaB None None I-protein
. None None O

Activation None None O
of None None O
signal None None O
transduction None None O
and None None O
apoptosis None None O
in None None O
healthy None None I-cell_type
lymphomonocytes None None I-cell_type
exposed None None O
to None None O
bystander None None O
HIV-1-infected None None I-cell_type
cells None None I-cell_type
. None None O

Persistent None None O
activation None None O
of None None O
the None None O
immune None None O
system None None O
is None None O
one None None O
of None None O
the None None O
hallmarks None None O
of None None O
HIV-1 None None O
infection None None O
. None None O

In None None O
this None None O
study None None O
we None None O
analysed None None O
the None None O
induction None None O
of None None O
factors None None O
involved None None O
in None None O
cytokine None None O
signal None None O
transduction None None O
, None None O
such None None O
as None None O
STAT None None I-protein
1 None None I-protein
proteins None None I-protein
and None None O
IRF-1 None None I-RNA
mRNA None None I-RNA
, None None O
in None None O
normal None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
( None None O
PBMC None None I-cell_type
) None None O
exposed None None O
to None None O
HIV-infected None None I-cell_type
cells None None I-cell_type
, None None O
and None None O
the None None O
induction None None O
of None None O
apoptosis None None O
. None None O

Western None None O
blot None None O
analyses None None O
and None None O
reverse None None O
transcriptase-polymerase None None O
chain None None O
reaction None None O
results None None O
indicate None None O
that None None O
both None None O
cells None None O
infected None None O
with None None O
a None None O
X4 None None O
strain None None O
and None None O
cells None None O
infected None None O
with None None O
a None None O
R5 None None O
strain None None O
are None None O
able None None O
to None None O
increase None None O
intracellular None None O
levels None None O
of None None O
STAT None None I-protein
1alpha None None I-protein
and None None I-protein
beta None None I-protein
proteins None None O
as None None O
well None None O
as None None O
IRF-1 None None I-RNA
mRNA None None I-RNA
. None None O

This None None O
effect None None O
was None None O
prevented None None O
by None None O
neutralizing None None O
antibodies None None O
against None None O
interferon-alpha None None I-protein
( None None O
IFN-alpha None None I-protein
) None None O
. None None O

HIV-1-infected None None I-cell_type
cells None None I-cell_type
dose-dependently None None O
induced None None O
apoptotic None None O
commitment None None O
in None None O
normal None None I-cell_type
PBMC None None I-cell_type
, None None O
as None None O
revealed None None O
by None None O
DNA None None O
fragmentation None None O
analysis None None O
, None None O
but None None O
this None None O
was None None O
not None None O
accompanied None None O
by None None O
an None None O
increase None None O
of None None O
caspase-3 None None O
activity None None O
, None None O
even None None O
if None None O
a None None O
slight None None O
up-regulation None None O
of None None O
IL-1beta-converting None None I-RNA
enzyme None None I-RNA
mRNA None None I-RNA
was None None O
detected None None O
. None None O

Apoptosis None None O
induction None None O
could None None O
be None None O
abrogated None None O
mainly None None O
by None None O
antibodies None None I-protein
against None None O
tumour None None I-protein
necrosis None None I-protein
factor-alpha None None I-protein
( None None O
TNF-alpha None None I-protein
) None None O
and None None O
, None None O
to None None O
a None None O
lesser None None O
extent None None O
, None None O
by None None O
antibodies None None I-protein
against None None O
IFN-gamma None None I-protein
. None None O

All None None O
these None None O
findings None None O
suggest None None O
that None None O
uninfected None None I-cell_type
PBMC None None I-cell_type
can None None O
undergo None None O
activation None None O
of None None O
signal None None O
transduction None None O
and None None O
apoptosis None None O
after None None O
exposure None None O
to None None O
bystander None None O
HIV-infected None None I-cell_type
cells None None I-cell_type
, None None O
subsequent None None O
to None None O
the None None O
induction None None O
of None None O
cytokines None None I-protein
such None None O
as None None O
IFNs None None I-protein
and None None O
TNF-alpha None None I-protein
. None None O

The None None O
physical None None O
association None None O
of None None O
protein None None I-protein
kinase None None I-protein
C None None I-protein
theta None None I-protein
with None None O
a None None O
lipid None None O
raft-associated None None O
inhibitor None None O
of None None O
kappa None None I-protein
B None None I-protein
factor None None I-protein
kinase None None I-protein
( None None I-protein
IKK None None I-protein
) None None I-protein
complex None None I-protein
plays None None O
a None None O
role None None O
in None None O
the None None O
activation None None O
of None None O
the None None O
NF-kappa None None O
B None None O
cascade None None O
by None None O
TCR None None I-protein
and None None O
CD28 None None I-protein
. None None O

We None None O
investigated None None O
the None None O
role None None O
of None None O
protein None None I-protein
kinase None None I-protein
C None None I-protein
theta None None I-protein
( None None O
PKCtheta None None I-protein
) None None O
in None None O
the None None O
activation None None O
of None None O
the None None O
NF-kappaB None None I-protein
cascade None None O
in None None O
primary None None I-cell_type
human None None I-cell_type
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
lymphocytes None None I-cell_type
. None None O

Among None None O
six None None O
or None None O
so None None O
PKC None None I-protein
isoforms None None I-protein
expressed None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
, None None O
only None None O
PKCtheta None None I-protein
participates None None O
in None None O
the None None O
assembly None None O
of None None O
the None None O
supramolecular None None O
activation None None O
clusters None None O
at None None O
the None None O
contact None None O
site None None O
of None None O
the None None O
TCR None None I-protein
with None None O
Ag None None I-protein
. None None O

Signaling None None O
via None None O
both None None O
the None None O
TCR None None I-protein
and None None O
CD28 None None I-protein
is None None O
required None None O
for None None O
optimal None None O
activation None None O
of None None O
the None None O
multisubunit None None I-protein
IkappaB None None I-protein
kinase None None I-protein
( None None I-protein
IKK None None I-protein
) None None I-protein
complex None None I-protein
in None None O
primary None None I-cell_type
human None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
; None None O
this None None O
activation None None O
could None None O
be None None O
inhibited None None O
by None None O
a None None O
Ca None None O
( None None O
2+ None None O
) None None O
-independent None None O
PKC None None O
isoform None None O
inhibitor None None O
, None None O
rottlerin None None O
. None None O

Moreover None None O
, None None O
endogenous None None O
PKCtheta None None I-protein
physically None None O
associates None None O
with None None O
activated None None O
IKK None None I-protein
complexes None None I-protein
in None None O
CD3/CD28-costimulated None None I-cell_type
primary None None I-cell_type
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
same None None O
set None None O
of None None O
stimuli None None O
also None None O
induced None None O
relocation None None O
of None None O
endogenous None None O
PKCtheta None None I-protein
and None None O
IKKs None None I-protein
to None None O
a None None O
GM1 None None O
ganglioside-enriched None None O
, None None O
detergent-insoluble None None O
membrane None None O
compartment None None O
in None None O
primary None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

IKKs None None I-protein
recruited None None O
to None None O
these None None O
lipid None None O
rafts None None O
were None None O
capable None None O
of None None O
phosphorylating None None O
a None None O
recombinant None None O
IkappaBalpha None None O
sustrate None None O
. None None O

Confocal None None O
microscopy None None O
further None None O
demonstrated None None O
that None None O
exogenously None None O
expressed None None O
PKCtheta None None I-protein
and None None O
IKKss None None I-protein
colocalize None None O
in None None O
the None None O
membrane None None O
of None None O
CD3/CD28-costimulated None None I-cell_line
Jurkat None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
. None None O

Constitutively None None O
active None None O
but None None O
not None None O
kinase-inactive None None I-protein
PKCtheta None None I-protein
activated None None O
IKKbeta None None I-protein
in None None O
Jurkat None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
. None None O

Expression None None O
of None None O
dominant-active None None I-protein
PKCtheta None None I-protein
also None None O
had None None O
stimulatory None None O
effects None None O
on None None O
the None None O
CD28 None None I-DNA
response None None I-DNA
element None None I-DNA
of None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
. None None O

Taken None None O
together None None O
, None None O
these None None O
data None None O
show None None O
that None None O
the None None O
activation None None O
of None None O
PKCtheta None None I-protein
by None None O
the None None O
TCR None None I-protein
and None None O
CD28 None None I-protein
plays None None O
an None None O
important None None O
role None None O
in None None O
the None None O
assembly None None O
and None None O
activation None None O
of None None O
IKK None None I-protein
complexes None None I-protein
in None None O
the None None O
T None None O
cell None None O
membrane None None O

T-cell None None I-cell_type
-mediated None None O
regulation None None O
of None None O
osteoclastogenesis None None O
by None None O
signalling None None O
cross-talk None None O
between None None O
RANKL None None I-protein
and None None O
IFN-gamma None None I-protein
. None None O

Bone None None O
resorption None None O
is None None O
regulated None None O
by None None O
the None None O
immune None None O
system None None O
, None None O
where None None O
T-cell None None I-cell_type
expression None None O
of None None O
RANKL None None I-protein
( None None O
receptor None None I-protein
activator None None I-protein
of None None I-protein
nuclear None None I-protein
factor None None I-protein
( None None I-protein
NF None None I-protein
) None None I-protein
-kappaB None None I-protein
ligand None None I-protein
) None None O
, None None O
a None None O
member None None O
of None None O
the None None O
tumour-necrosis None None I-protein
factor None None I-protein
family None None I-protein
that None None O
is None None O
essential None None O
for None None O
osteoclastogenesis None None O
, None None O
may None None O
contribute None None O
to None None O
pathological None None O
conditions None None O
, None None O
such None None O
as None None O
autoimmune None None O
arthritis None None O
. None None O

However None None O
, None None O
whether None None O
activated None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
maintain None None O
bone None None O
homeostasis None None O
by None None O
counterbalancing None None O
the None None O
action None None O
of None None O
RANKL None None I-protein
remains None None O
unknown None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
T-cell None None I-cell_type
production None None O
of None None O
interferon None None I-protein
( None None I-protein
IFN None None I-protein
) None None I-protein
-gamma None None I-protein
strongly None None O
suppresses None None O
osteoclastogenesis None None O
by None None O
interfering None None O
with None None O
the None None O
RANKL None None I-protein
-RANK None None O
signalling None None O
pathway None None O
. None None O

IFN-gamma None None I-protein
induces None None O
rapid None None O
degradation None None O
of None None O
the None None O
RANK None None I-protein
adapter None None I-protein
protein None None I-protein
, None None O
TRAF6 None None I-protein
( None None O
tumour None None I-protein
necrosis None None I-protein
factor None None I-protein
receptor-associated None None I-protein
factor None None I-protein
6 None None I-protein
) None None O
, None None O
which None None O
results None None O
in None None O
strong None None O
inhibition None None O
of None None O
the None None O
RANKL None None I-protein
-induced None None O
activation None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
NF-kappaB None None B-protein
and None None O
JNK None None I-protein
. None None O

This None None O
inhibition None None O
of None None O
osteoclastogenesis None None O
is None None O
rescued None None O
by None None O
overexpressing None None O
TRAF6 None None I-protein
in None None O
precursor None None I-cell_type
cells None None I-cell_type
, None None O
which None None O
indicates None None O
that None None O
TRAF6 None None I-protein
is None None O
the None None O
target None None O
critical None None O
for None None O
the None None O
IFN-gamma None None I-protein
action None None O
. None None O

Furthermore None None O
, None None O
we None None O
provide None None O
evidence None None O
that None None O
the None None O
accelerated None None O
degradation None None O
of None None O
TRAF6 None None I-protein
requires None None O
both None None O
its None None O
ubiquitination None None O
, None None O
which None None O
is None None O
initiated None None O
by None None O
RANKL None None I-protein
, None None O
and None None O
IFN-gamma None None I-protein
-induced None None O
activation None None O
of None None O
the None None O
ubiquitin-proteasome None None O
system None None O
. None None O

Our None None O
study None None O
shows None None O
that None None O
there None None O
is None None O
cross-talk None None O
between None None O
the None None O
tumour None None I-protein
necrosis None None I-protein
factor None None I-protein
and None None O
IFN None None I-protein
families None None I-protein
of None None O
cytokines None None I-protein
, None None O
through None None O
which None None O
IFN-gamma None None I-protein
provides None None O
a None None O
negative None None O
link None None O
between None None O
T-cell None None I-cell_type
activation None None O
and None None O
bone None None O
resorption None None O
. None None O

Our None None O
results None None O
may None None O
offer None None O
a None None O
therapeutic None None O
approach None None O
to None None O
treat None None O
the None None O
inflammation-induced None None O
tissue None None O
breakdown None None O
. None None O

Stromal-derived None None I-protein
factor None None I-protein
1 None None I-protein
and None None O
thrombopoietin None None I-protein
regulate None None O
distinct None None O
aspects None None O
of None None O
human None None O
megakaryopoiesis None None O
. None None O

The None None O
role None None O
of None None O
the None None O
chemokine None None I-protein
binding None None O
stromal-derived None None I-protein
factor None None I-protein
1 None None I-protein
( None None O
SDF-1 None None I-protein
) None None O
in None None O
normal None None O
human None None O
megakaryopoiesis None None O
at None None O
the None None O
cellular None None O
and None None O
molecular None None O
levels None None O
and None None O
its None None O
comparison None None O
with None None O
that None None O
of None None O
thrombopoietin None None I-protein
( None None O
TPO None None I-protein
) None None O
have None None O
not None None O
been None None O
determined None None O
. None None O

In None None O
this None None O
study None None O
it None None O
was None None O
found None None O
that None None O
SDF-1 None None I-protein
, None None O
unlike None None O
TPO None None I-protein
, None None O
does None None O
not None None O
stimulate None None O
alpha None None O
( None None O
IIb None None O
) None None O
beta None None O
( None None O
3 None None O
) None None O
( None None O
+ None None O
) None None O
cell None None O
proliferation None None O
or None None O
differentiation None None O
or None None O
have None None O
an None None O
antiapoptotic None None O
effect None None O
. None None O

However None None O
, None None O
it None None O
does None None O
induce None None O
chemotaxis None None O
, None None O
trans-Matrigel None None O
migration None None O
, None None O
and None None O
secretion None None O
of None None O
matrix None None O
metalloproteinase None None I-protein
9 None None I-protein
( None None O
MMP-9 None None I-protein
) None None O
and None None O
vascular None None I-protein
endothelial None None I-protein
growth None None I-protein
factor None None I-protein
( None None O
VEGF None None I-protein
) None None O
by None None O
these None None O
cells None None O
, None None O
and None None O
both None None O
SDF-1 None None I-protein
and None None O
TPO None None I-protein
increase None None O
the None None O
adhesion None None O
of None None O
alpha None None I-cell_type
( None None I-cell_type
IIb None None I-cell_type
) None None I-cell_type
beta None None I-cell_type
( None None I-cell_type
3 None None I-cell_type
) None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
to None None O
fibrinogen None None I-protein
and None None O
vitronectin None None I-protein
. None None O

Investigating None None O
the None None O
intracellular None None O
signaling None None O
pathways None None O
induced None None O
by None None O
SDF-1 None None I-protein
and None None O
TPO None None I-protein
revealed None None O
some None None O
overlapping None None O
patterns None None O
of None None O
protein None None O
phosphorylation/activation None None O
( None None O
mitogen-activated None None I-protein
protein None None I-protein
kinase None None I-protein
[ None None I-protein
MAPK None None I-protein
] None None I-protein
p42/44 None None I-protein
, None None O
MAPK None None I-protein
p38 None None I-protein
, None None O
and None None O
AKT None None I-protein
[ None None I-protein
protein None None I-protein
kinase None None I-protein
B None None I-protein
] None None I-protein
) None None O
and None None O
some None None O
that None None O
were None None O
distinct None None O
for None None O
TPO None None I-protein
( None None O
eg None None O
, None None O
JAK-STAT None None I-protein
) None None O
and None None O
for None None O
SDF-1 None None I-protein
( None None O
eg None None O
, None None O
NF-kappa None None I-protein
B None None I-protein
) None None O
. None None O

It None None O
was None None O
also None None O
found None None O
that None None O
though None None O
inhibition None None O
of None None O
phosphatidyl-inositol None None I-protein
3-kinase None None I-protein
( None None O
PI-3K None None I-protein
) None None O
by None None O
LY294002 None None O
in None None O
alpha None None I-cell_type
( None None I-cell_type
IIb None None I-cell_type
) None None I-cell_type
beta None None I-cell_type
( None None I-cell_type
3 None None I-cell_type
) None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
induced None None O
apoptosis None None O
and None None O
inhibited None None O
chemotaxis None None O
adhesion None None O
and None None O
the None None O
secretion None None O
of None None O
MMP-9 None None I-protein
and None None O
VEGF None None I-protein
, None None O
the None None O
inhibition None None O
of None None O
MAPK None None I-protein
p42/44 None None I-protein
( None None O
by None None O
the None None O
MEK None None O
inhibitor None None O
U0126 None None O
) None None O
had None None O
no None None O
effect None None O
on None None O
the None None O
survival None None O
, None None O
proliferation None None O
, None None O
and None None O
migration None None O
of None None O
these None None O
cells None None O
. None None O

Hence None None O
, None None O
it None None O
is None None O
suggested None None O
that None None O
the None None O
proliferative None None O
effect None None O
of None None O
TPO None None I-protein
is None None O
more None None O
related None None O
to None None O
activation None None O
of None None O
the None None O
JAK-STAT None None O
pathway None None O
( None None O
unique None None O
to None None O
TPO None None I-protein
) None None O
, None None O
and None None O
the None None O
PI-3K-AKT None None O
axis None None O
is None None O
differentially None None O
involved None None O
in None None O
TPO- None None O
and None None O
SDF-1-dependent None None O
signaling None None O
. None None O

Accordingly None None O
, None None O
PI-3K None None I-protein
is None None O
involved None None O
in None None O
TPO None None I-protein
-mediated None None O
inhibition None None O
of None None O
apoptosis None None O
, None None O
TPO- None None O
and None None O
SDF-1-regulated None None O
adhesion None None O
to None None O
fibrinogen None None I-protein
and None None O
vitronectin None None I-protein
, None None O
and None None O
SDF-1 None None I-protein
-mediated None None O
migration None None O
. None None O

This None None O
study None None O
expands None None O
the None None O
understanding None None O
of None None O
the None None O
role None None O
of None None O
SDF-1 None None I-protein
and None None O
TPO None None I-protein
in None None O
normal None None O
human None None O
megakaryopoiesis None None O
and None None O
indicates None None O
the None None O
molecular None None O
basis None None O
of None None O
the None None O
observed None None O
differences None None O
in None None O
cellular None None O
responses None None O
. None None O

( None None O
Blood. None None O
2000 None None O
; None None O
96 None None O
: None None O
4142-4151 None None O
) None None O

Adhesion None None O
of None None O
immature None None I-cell_type
and None None I-cell_type
mature None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
induces None None O
in None None O
human None None I-cell_type
thymic None None I-cell_type
epithelial None None I-cell_type
cells None None I-cell_type
( None None O
TEC None None I-cell_type
) None None O
activation None None O
of None None O
IL-6 None None I-protein
gene None None I-protein
trascription None None I-protein
factors None None I-protein
( None None O
NF-kappaB None None I-protein
and None None O
NF-IL6 None None I-protein
) None None O
and None None O
IL-6 None None O
gene None None O
expression None None O
: None None O
role None None O
of None None O
alpha3beta1 None None I-protein
and None None I-protein
alpha6beta4 None None I-protein
integrins None None I-protein
. None None O

T None None I-cell_type
cell None None I-cell_type
precursors None None I-cell_type
homed None None O
to None None O
thymus None None O
develop None None O
in None None O
close None None O
contact None None O
with None None O
stromal None None I-cell_type
cells None None I-cell_type
. None None O

Among None None O
them None None O
, None None O
thymic None None I-cell_type
epithelial None None I-cell_type
cells None None I-cell_type
( None None O
TEC None None I-cell_type
) None None O
are None None O
known None None O
to None None O
exert None None O
dominant None None O
roles None None O
in None None O
their None None O
survival None None O
and None None O
functional None None O
shaping None None O
. None None O

Key None None O
molecules None None O
mediating None None O
TEC None None I-cell_type
/ None None O
thymocytes None None I-cell_type
interactions None None O
include None None O
cytokines None None I-protein
and None None O
growth None None I-protein
factors None None I-protein
secreted None None O
by None None O
the None None O
two None None O
cell None None O
types None None O
and None None O
adhesion None None I-protein
receptors None None I-protein
mediating None None O
cell None None O
contact None None O
. None None O

Signaling None None O
events None None O
triggered None None O
in None None O
thymocytes None None I-cell_type
by None None O
adhesion None None O
to None None O
epithelial None None I-cell_type
cells None None I-cell_type
have None None O
been None None O
extensively None None O
investigated None None O
, None None O
whereas None None O
little None None O
is None None O
known None None O
on None None O
the None None O
opposite None None O
phenomenon None None O
. None None O

We None None O
have None None O
previously None None O
investigated None None O
this None None O
issue None None O
in None None O
a None None O
co-culture None None O
system None None O
composed None None O
of None None O
TEC None None I-cell_type
cultures None None I-cell_type
derived None None O
from None None O
human None None O
normal None None O
thymus None None O
and None None O
heterologous None None I-cell_type
thymocytes None None I-cell_type
. None None O

We None None O
demonstrated None None O
that None None O
thymocytes None None I-cell_type
adhere None None O
to None None O
TEC None None I-cell_type
involving None None O
beta1 None None I-protein
and None None I-protein
beta4 None None I-protein
integrins None None I-protein
and None None O
induce None None O
the None None O
clustering None None O
of None None O
alpha3beta1 None None I-protein
and None None I-protein
alpha6beta4 None None I-protein
heterodimers None None I-protein
at None None O
the None None O
TEC None None O
surface None None O
. None None O

In None None O
addition None None O
thymocyte None None O
adhesion None None O
was None None O
followed None None O
by None None O
activation None None O
of None None O
NF-kappaB None None I-protein
and None None O
NF-IL6 None None I-protein
gene None None B-protein
transcription None None I-protein
factors None None I-protein
and None None O
enhanced None None O
IL-6 None None O
production None None O
. None None O

The None None O
two None None O
latter None None O
phenomena None None O
were None None O
reproduced None None O
by None None O
the None None O
cross-linking None None O
of None None O
the None None O
alpha3 None None I-protein
, None None O
alpha6 None None I-protein
, None None O
beta1 None None I-protein
and None None I-protein
beta4 None None I-protein
integrins None None I-protein
, None None O
thus None None O
implying None None O
that None None O
the None None O
alpha3beta1 None None I-protein
and None None I-protein
alpha6beta4 None None I-protein
heterodimers None None I-protein
can None None O
signal None None O
during None None O
thymocyte None None O
adhesion None None O
. None None O

We None None O
have None None O
extended None None O
our None None O
previous None None O
work None None O
investigating None None O
in None None O
the None None O
same None None O
experimental None None O
setting None None O
the None None O
inducing None None O
activity None None O
of None None O
non None None O
stimulated None None O
or None None O
activated None None O
policlonal None None I-cell_type
or None None I-cell_type
clonal None None I-cell_type
mature None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
as None None O
representative None None O
of None None O
the None None O
more None None O
mature None None I-cell_type
thymocyte None None I-cell_type
subset None None I-cell_type
. None None O

We None None O
found None None O
that None None O
adhesion None None O
of None None O
unstimulated None None I-cell_type
T None None I-cell_type
cell None None I-cell_type
i None None O
) None None O
involved None None O
beta1 None None O
, None None O
but None None O
not None None O
beta4 None None O
integrin None None O
functions None None O
at None None O
the None None O
surface None None O
ii None None O
) None None O
induced None None O
the None None O
clustering None None O
of None None O
alpha3beta1 None None I-protein
, None None O
but None None O
not None None O
alpha2beta1 None None I-protein
heterodimers None None I-protein
at None None O
the None None O
TEC None None O
surface None None O
and None None O
iii None None O
) None None O
up-regulated None None O
the None None O
nuclear None None O
binding None None O
activity None None O
of None None O
NF-kappaB None None I-protein
transcription None None I-protein
factor None None I-protein
and None None O
the None None O
IL-6 None None O
secretion None None O
. None None O

We None None O
propose None None O
that None None O
alpha3beta1 None None I-protein
and None None I-protein
alpha6beta4 None None I-protein
heterodimers None None I-protein
are None None O
induced None None O
to None None O
cluster None None O
at None None O
the None None O
TEC None None O
surface None None O
recognizing None None O
yet None None O
unknown None None O
cellular None None I-protein
ligands None None I-protein
differentially None None O
expressed None None O
during None None O
T None None O
cell None None O
development None None O
. None None O

Identification None None O
and None None O
characterization None None O
of None None O
SKAT-2 None None I-DNA
, None None O
a None None O
novel None None O
Th2-specific None None I-DNA
zinc None None I-DNA
finger None None I-DNA
gene None None I-DNA
. None None O

We None None O
have None None O
identified None None O
a None None O
novel None None O
Kruppel-type None None I-DNA
zinc None None I-DNA
finger None None I-DNA
( None None I-DNA
ZF None None I-DNA
) None None I-DNA
gene None None I-DNA
, None None O
SKAT-2 None None I-DNA
, None None O
which None None O
is None None O
selectively None None O
expressed None None O
by None None O
murine None None I-cell_type
Th2 None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
protein None None O
encoded None None O
by None None O
this None None O
gene None None O
has None None O
14 None None O
C2H2-type None None O
ZF None None O
tandemly None None O
arrayed None None O
at None None O
its None None O
C None None I-DNA
terminus None None I-DNA
and None None O
N-terminal None None I-DNA
SCAN None None B-DNA
box None None I-DNA
and None None O
KRAB None None I-DNA
domains None None I-DNA
. None None O

SKAT-2 None None I-DNA
is None None O
tissue None None O
restricted None None O
in None None O
expression None None O
at None None O
the None None O
RNA None None O
level None None O
, None None O
detectable None None O
only None None O
in None None O
brain None None O
and None None O
at None None O
low None None O
levels None None O
in None None O
kidney None None O
and None None O
spleen None None O
and None None O
few None None O
hematopoietic None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
. None None O

By None None O
in None None O
situ None None O
hybridization None None O
, None None O
SKAT-2 None None I-DNA
expression None None O
was None None O
found None None O
to None None O
peak None None O
in None None O
antigen-stimulated None None O
CD4 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
after None None O
2-3 None None O
days None None O
of None None O
culture None None O
under None None O
Th2 None None O
but None None O
not None None O
Th1 None None O
biasing None None O
conditions None None O
. None None O

This None None O
pattern None None O
of None None O
expression None None O
closely None None O
mirrored None None O
that None None O
of None None O
GATA-3 None None I-protein
in None None O
the None None O
same None None O
cells None None O
. None None O

In None None O
transient None None O
transfection None None O
experiments None None O
in None None O
phorbol None None O
12-myristate None None O
13-acetate/ionomycin-stimulated None None O
EL4 None None I-cell_line
cells None None I-cell_line
, None None O
SKAT-2 None None I-DNA
was None None O
found None None O
to None None O
up-regulate None None O
the None None O
activity None None O
of None None O
the None None O
IL-4 None None I-DNA
but None None I-DNA
not None None I-DNA
the None None I-DNA
IL-5 None None I-DNA
promoter None None I-DNA
, None None O
contrasting None None O
with None None O
the None None O
ability None None O
of None None O
GATA-3 None None I-protein
to None None O
activate None None O
both None None O
promoters None None I-DNA
. None None O

This None None O
result None None O
was None None O
confirmed None None O
using None None O
clones None None O
of None None O
EL4 None None I-cell_line
cells None None I-cell_line
stably None None O
expressing None None O
an None None O
inducible None None O
form None None O
of None None O
SKAT-2 None None I-DNA
, None None O
thus None None O
SKAT-2 None None I-DNA
is None None O
a None None O
novel None None O
Th2-specific None None I-DNA
gene None None I-DNA
that None None O
may None None O
play None None O
a None None O
role None None O
in None None O
selective None None O
regulation None None O
of None None O
cytokine None None I-DNA
genes None None I-DNA
in None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

hsp70 None None I-protein
interacting None None I-protein
protein None None I-protein
Hip None None I-protein
does None None O
not None None O
affect None None O
glucocorticoid None None I-protein
receptor None None I-protein
folding None None O
by None None O
the None None O
hsp90-based None None O
chaperone None None O
machinery None None O
except None None O
to None None O
oppose None None O
the None None O
effect None None O
of None None O
BAG-1 None None I-protein
. None None O

Reticulocyte None None O
lysate None None O
contains None None O
a None None O
chaperone None None O
system None None O
that None None O
assembles None None O
glucocorticoid None None I-protein
receptor None None I-protein
( None None I-protein
GR None None I-protein
) None None I-protein
.hsp90 None None I-protein
heterocomplexes None None I-protein
. None None O

Using None None O
purified None None I-protein
proteins None None I-protein
, None None O
we None None O
have None None O
prepared None None O
a None None O
five-protein None None O
heterocomplex None None O
assembly None None O
system None None O
consisting None None O
of None None O
two None None O
proteins None None O
essential None None O
for None None O
heterocomplex None None O
assembly- None None O
hsp90 None None I-protein
and None None O
hsp70 None None I-protein
-and None None O
three None None O
proteins None None O
that None None O
act None None O
as None None O
co-chaperones None None O
to None None O
enhance None None O
assembly- None None O
Hop None None I-protein
, None None O
hsp40 None None I-protein
, None None O
p23 None None I-protein
[ None None O
Morishima None None O
, None None O
Y. None None O
, None None O
Kanelakis None None O
, None None O
K. None None O
C. None None O
, None None O
Silverstein None None O
, None None O
A. None None O
M. None None O
, None None O
Dittmar None None O
, None None O
K. None None O
D. None None O
, None None O
Estrada None None O
, None None O
L. None None O
, None None O
and None None O
Pratt None None O
, None None O
W. None None O
B. None None O
( None None O
2000 None None O
) None None O
J. None None O
Biol. None None O
Chem. None None O
275 None None O
, None None O
6894-6900 None None O
] None None O
. None None O

The None None O
hsp70 None None I-protein
co-chaperone None None I-protein
Hip None None I-protein
has None None O
been None None O
recovered None None O
in None None O
receptor.hsp90 None None I-protein
heterocomplexes None None I-protein
at None None O
an None None O
intermediate None None O
stage None None O
of None None O
assembly None None O
in None None O
reticulocyte None None O
lysate None None O
, None None O
and None None O
Hip None None I-protein
is None None O
also None None O
thought None None O
to None None O
be None None O
an None None O
intrinsic None None O
component None None O
of None None O
the None None O
assembly None None O
machinery None None O
. None None O

Here None None O
we None None O
show None None O
that None None O
immunodepletion None None O
of None None O
Hip None None I-protein
from None None O
reticulocyte None None O
lysate None None O
or None None O
addition None None O
of None None O
high None None O
levels None None O
of None None O
Hip None None I-protein
to None None O
the None None O
purified None None O
five-protein None None O
system None None O
does None None O
not None None O
affect None None O
GR.hsp90 None None O
heterocomplex None None O
assembly None None O
or None None O
the None None O
activation None None O
of None None O
steroid None None O
binding None None O
activity None None O
that None None O
occurs None None O
with None None O
assembly None None O
. None None O

Despite None None O
the None None O
fact None None O
that None None O
Hip None None I-protein
does None None O
not None None O
affect None None O
assembly None None O
, None None O
it None None O
is None None O
recovered None None O
in None None O
GR.hsp90 None None I-protein
heterocomplexes None None I-protein
assembled None None O
by None None O
both None None O
systems None None O
. None None O

In None None O
the None None O
five-protein None None O
system None None O
, None None O
Hip None None I-protein
prevents None None O
inhibition None None O
of None None O
assembly None None O
by None None O
the None None O
hsp70 None None I-protein
co-chaperone None None I-protein
BAG-1 None None I-protein
, None None O
and None None O
cotransfection None None O
of None None O
Hip None None I-protein
with None None O
BAG-1 None None I-protein
opposes None None O
BAG-1 None None I-protein
reduction None None O
of None None O
steroid None None O
binding None None O
activity None None O
in None None O
COS None None I-cell_line
cells None None I-cell_line
. None None O

We None None O
conclude None None O
that None None O
Hip None None I-protein
is None None O
not None None O
a None None O
component None None O
of None None O
the None None O
assembly None None O
machinery None None O
but None None O
that None None O
it None None O
could None None O
play None None O
a None None O
regulatory None None O
role None None O
in None None O
opposition None None O
to None None O
BAG-1 None None I-protein
. None None O

Cutting None None O
edge None None O
: None None O
STAT6-deficient None None O
mice None None O
have None None O
enhanced None None O
tumor None None O
immunity None None O
to None None O
primary None None O
and None None O
metastatic None None O
mammary None None O
carcinoma None None O
. None None O

STAT4 None None I-protein
and None None O
STAT6 None None I-protein
are None None O
essential None None O
for None None O
the None None O
development None None O
of None None O
CD4 None None O
( None None O
+ None None O
) None None O
Th1 None None O
and None None O
Th2 None None O
development None None O
, None None O
respectively None None O
. None None O

Tumor None None O
immunologists None None O
have None None O
hypothesized None None O
that None None O
Th1 None None I-cell_type
cells None None I-cell_type
are None None O
critical None None O
in None None O
tumor None None O
immunity None None O
because None None O
they None None O
facilitate None None O
differentiation None None O
of None None O
CD8 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
, None None O
which None None O
are None None O
potent None None O
anti-tumor None None I-cell_type
effectors None None I-cell_type
. None None O

We None None O
have None None O
used None None O
STAT4 None None O
( None None O
-/- None None O
) None None O
and None None O
STAT6 None None O
( None None O
-/- None None O
) None None O
mice None None O
to None None O
test None None O
this None None O
hypothesis None None O
. None None O

BALB/c None None O
and None None O
knockout None None O
mice None None O
were None None O
challenged None None O
in None None O
the None None O
mammary None None O
gland None None O
with None None O
the None None O
highly None None O
malignant None None O
and None None O
spontaneously None None O
metastatic None None O
BALB/c-derived None None O
4T1 None None O
mammary None None O
carcinoma None None O
. None None O

Primary None None O
tumor None None O
growth None None O
and None None O
metastatic None None O
disease None None O
are None None O
reduced None None O
in None None O
STAT6 None None O
( None None O
-/- None None O
) None None O
mice None None O
relative None None O
to None None O
BALB/c None None O
and None None O
STAT4 None None O
( None None O
-/- None None O
) None None O
mice None None O
. None None O

Ab None None O
depletions None None O
demonstrate None None O
that None None O
the None None O
effect None None O
is None None O
mediated None None O
by None None O
CD8 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
, None None O
and None None O
immunized None None O
STAT6 None None O
( None None O
-/- None None O
) None None O
mice None None O
have None None O
higher None None O
levels None None O
of None None O
4T1-specific None None I-cell_type
CTL None None I-cell_type
than None None O
BALB/c None None O
or None None O
STAT4 None None O
( None None O
-/- None None O
) None None O
mice None None O
. None None O

Surprisingly None None O
, None None O
Th1 None None I-cell_type
or None None I-cell_type
Th2 None None I-cell_type
cells None None I-cell_type
are None None O
not None None O
involved None None O
, None None O
because None None O
CD4 None None O
depletion None None O
does None None O
not None None O
diminish None None O
the None None O
anti-tumor None None O
effect None None O
. None None O

Therefore None None O
, None None O
deletion None None O
of None None O
the None None O
STAT6 None None I-DNA
gene None None I-DNA
facilitates None None O
development None None O
of None None O
potent None None O
anti-tumor None None O
immunity None None O
via None None O
a None None O
CD4 None None O
( None None O
+ None None O
) None None O
-independent None None O
pathway None None O
. None None O

Activation None None O
of None None O
oncogenic None None I-protein
transcription None None I-protein
factor None None I-protein
AP-1 None None I-protein
in None None O
T None None I-cell_type
cells None None I-cell_type
infected None None O
with None None O
human None None O
T None None O
cell None None O
leukemia None None O
virus None None O
type None None O
1 None None O
. None None O

Human None None O
T None None O
cell None None O
leukemia None None O
virus None None O
type None None O
1 None None O
( None None O
HTLV-1 None None O
) None None O
Tax None None I-protein
protein None None I-protein
transforms None None O
primary None None I-cell_type
human None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
in None None O
vitro None None O
. None None O

We None None O
previously None None O
showed None None O
that None None O
Tax None None I-protein
induces None None O
the None None O
expression None None O
of None None O
various None None O
family None None O
members None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
AP-1 None None I-protein
such None None O
as None None O
c-Jun None None I-protein
, None None O
JunD None None I-protein
, None None O
c-Fos None None I-protein
, None None O
and None None O
Fra-1 None None I-protein
at None None O
the None None O
mRNA None None O
level None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
have None None O
examined None None O
the None None O
ability None None O
of None None O
Tax None None I-protein
to None None O
activate None None O
transcription None None O
through None None O
the None None O
AP-1-binding None None I-DNA
site None None I-DNA
( None None O
AP-1 None None I-DNA
site None None I-DNA
) None None O
. None None O

A None None O
transient None None O
transfection None None O
study None None O
showed None None O
that None None O
Tax None None I-protein
can None None O
activate None None O
transcription None None O
through None None O
the None None O
AP-1-binding None None I-DNA
site None None I-DNA
in None None O
a None None O
human None None I-cell_line
T None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
, None None O
whereas None None O
any None None O
combination None None O
of None None O
AP-1 None None I-protein
proteins None None I-protein
did None None O
so None None O
much None None O
less None None O
than None None O
Tax None None I-protein
, None None O
indicating None None O
that None None O
the None None O
activation None None O
of None None O
the None None O
AP-1 None None I-DNA
site None None I-DNA
by None None O
Tax None None I-protein
may None None O
require None None O
a None None O
mechanism None None O
other None None O
than None None O
the None None O
induction None None O
of None None O
AP-1 None None I-RNA
mRNA None None I-RNA
. None None O

Fresh None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
leukemia None None I-cell_type
cells None None I-cell_type
of None None O
all None None O
surveyed None None O
ATL None None O
patients None None O
displayed None None O
constitutive None None O
AP-1 None None O
DNA-binding None None O
activity None None O
, None None O
whereas None None O
no None None O
normal None None O
individuals None None O
did None None O
. None None O

However None None O
, None None O
the None None O
HTLV-1 None None I-DNA
genes None None I-DNA
, None None O
including None None O
tax None None I-DNA
, None None O
are None None O
not None None O
significantly None None O
expressed None None O
in None None O
fresh None None O
leukemia None None I-cell_type
cells None None I-cell_type
from None None O
ATL None None O
patients None None O
. None None O

Our None None O
present None None O
results None None O
suggest None None O
that None None O
activation None None O
of None None O
AP-1 None None I-protein
occurs None None O
through None None O
Tax-dependent None None O
and None None O
-independent None None O
mechanisms None None O
in None None O
HTLV-1-infected None None O
T None None I-cell_type
cells None None I-cell_type
, None None O
which None None O
may None None O
play None None O
some None None O
roles None None O
in None None O
dysregulated None None O
phenotypes None None O
of None None O
HTLV-1-infected None None I-cell_type
cells None None I-cell_type
. None None O

2 None None O
, None None O
2 None None O
' None None O
, None None O
4 None None O
, None None O
6 None None O
, None None O
6'-pentachlorobiphenyl None None O
induces None None O
apoptosis None None O
in None None O
human None None I-cell_type
monocytic None None I-cell_type
cells None None I-cell_type
. None None O

Polychlorinatedbiphenyls None None O
( None None O
PCBs None None O
) None None O
are None None O
a None None O
group None None O
of None None O
persistent None None O
and None None O
widely None None O
dispersed None None O
environmental None None O
pollutants None None O
, None None O
some None None O
of None None O
which None None O
may None None O
be None None O
immunotoxic None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
investigated None None O
the None None O
effect None None O
of None None O
PCBs None None O
on None None O
immune None None O
system None None O
by None None O
assessing None None O
apoptotic None None O
cell None None O
death None None O
in None None O
human None None I-cell_line
monocytic None None I-cell_line
U937 None None I-cell_line
cells None None I-cell_line
. None None O

Among None None O
the None None O
various None None O
congeners None None O
tested None None O
, None None O
2 None None O
, None None O
2 None None O
' None None O
, None None O
4 None None O
, None None O
6 None None O
, None None O
6'-pentachlorobiphenyl None None O
( None None O
PeCB None None O
) None None O
, None None O
a None None O
highly None None O
ortho-substituted None None O
congener None None O
, None None O
specifically None None O
induced None None O
DNA None None O
fragmentation None None O
, None None O
a None None O
hallmark None None O
of None None O
apoptosis None None O
, None None O
while None None O
the None None O
other None None O
examined None None O
di- None None O
, None None O
tri- None None O
, None None O
tetra- None None O
, None None O
and None None O
pentachlorobiphenyls None None O
did None None O
not None None O
. None None O

To None None O
further None None O
study None None O
the None None O
2 None None O
, None None O
2 None None O
' None None O
, None None O
4 None None O
, None None O
6 None None O
, None None O
6'-PeCB-induced None None O
cell None None O
death None None O
, None None O
various None None O
features None None O
of None None O
apoptosis None None O
were None None O
examined None None O
. None None O

2 None None O
, None None O
2 None None O
' None None O
, None None O
4 None None O
, None None O
6 None None O
, None None O
6'-PeCB None None O
caused None None O
a None None O
decrease None None O
in None None O
cell None None O
viability None None O
and None None O
induced None None O
cellular None None O
morphologic None None O
features None None O
characteristic None None O
of None None O
apoptosis None None O
such None None O
as None None O
chromatin None None O
aggregation None None O
and None None O
apoptotic None None O
bodies None None O
. None None O

In None None O
addition None None O
, None None O
caspase-3 None None I-protein
, None None O
an None None O
executioner None None O
of None None O
apoptosis None None O
, None None O
was None None O
activated None None O
and None None O
its None None O
substrate None None O
, None None O
poly None None I-protein
( None None I-protein
ADP-ribose None None I-protein
) None None I-protein
polymerase None None I-protein
( None None O
PARP None None I-protein
) None None O
, None None O
was None None O
cleaved None None O
during None None O
2 None None O
, None None O
2 None None O
' None None O
, None None O
4 None None O
, None None O
6 None None O
, None None O
6'-PeCB-induced None None O
apoptosis None None O
. None None O

In None None O
contrast None None O
, None None O
3 None None O
, None None O
3 None None O
' None None O
, None None O
4 None None O
, None None O
4 None None O
' None None O
, None None O
5-PeCB None None O
, None None O
a None None O
congener None None O
of None None O
coplanar None None O
structure None None O
, None None O
as None None O
well None None O
as None None O
2 None None O
, None None O
3 None None O
, None None O
7 None None O
, None None O
8-TCDD None None O
did None None O
not None None O
induce None None O
apoptosis None None O
in None None O
these None None O
human None None I-cell_type
monocytic None None I-cell_type
cells None None I-cell_type
, None None O
although None None O
they None None O
potently None None O
induced None None O
CYP None None I-protein
1A1 None None I-protein
in None None O
human None None I-cell_line
hepatoma None None I-cell_line
Hep None None I-cell_line
G2 None None I-cell_line
cells None None I-cell_line
. None None O

Taken None None O
together None None O
, None None O
the None None O
data None None O
indicate None None O
that None None O
2 None None O
, None None O
2 None None O
' None None O
, None None O
4 None None O
, None None O
6 None None O
, None None O
6'-PeCB None None O
induces None None O
apoptosis None None O
in None None O
human None None I-cell_type
monocytic None None I-cell_type
cells None None I-cell_type
through None None O
a None None O
mechanism None None O
that None None O
is None None O
independent None None O
of None None O
the None None O
arylhydrocarbon None None I-protein
receptor None None I-protein
. None None O

This None None O
suggests None None O
a None None O
possibly None None O
separate None None O
mechanism None None O
by None None O
which None None O
PCBs None None O
cause None None O
immunosuppression None None O
. None None O

Effects None None O
of None None O
deregulated None None O
Raf None None O
activation None None O
on None None O
integrin None None I-protein
, None None O
cytokine-receptor None None O
expression None None O
and None None O
the None None O
induction None None O
of None None O
apoptosis None None O
in None None O
hematopoietic None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
effects None None O
of None None O
deregulated None None O
Raf None None O
activation None None O
on None None O
the None None O
growth None None O
and None None O
differentiation None None O
of None None O
hematopoietic None None I-cell_type
cells None None I-cell_type
were None None O
investigated None None O
. None None O

The None None O
cytokine-dependent None None I-cell_line
murine None None I-cell_line
myeloid None None I-cell_line
FDC-P1 None None I-cell_line
and None None O
human None None I-cell_line
erythroleukemic None None I-cell_line
TF-1 None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
were None None O
transformed None None O
to None None O
grow None None O
in None None O
response None None O
to None None O
deregulated None None O
Raf None None O
expression None None O
in None None O
the None None O
absence None None O
of None None O
exogenous None None I-protein
cytokines None None I-protein
. None None O

The None None O
conditionally None None O
active None None O
Raf None None I-protein
proteins None None I-protein
were None None O
regulated None None O
by None None O
beta-estradiol None None O
as None None O
cDNAs None None I-DNA
containing None None O
the None None O
Raf None None I-protein
catalytic None None I-protein
, None None O
but None None O
lacking None None O
negative-regulatory None None I-protein
domains None None I-protein
, None None O
were None None O
ligated None None O
to None None O
the None None O
hormone None None I-protein
binding None None I-protein
domain None None I-protein
of None None O
the None None O
estrogen None None I-protein
receptor None None I-protein
( None None O
deltaRaf None None I-protein
: None None I-protein
ER None None I-protein
) None None O
. None None O

Continuous None None O
deltaRaf None None I-protein
expression None None O
prevented None None O
apoptosis None None O
in None None O
the None None O
absence None None O
of None None O
exogenous None None I-protein
cytokines None None I-protein
and None None O
altered None None O
the None None O
morphology None None O
of None None O
the None None O
FD/deltaRaf None None I-cell_type
: None None I-cell_type
ER None None I-cell_type
cells None None I-cell_type
as None None O
they None None O
grew None None O
in None None O
large None None O
aggregated None None O
masses None None O
( None None O
> None None O
100 None None O
cells None None O
) None None O
whereas None None O
the None None O
parental None None I-cell_line
cytokine-dependent None None I-cell_line
FDC-P1 None None I-cell_line
cells None None I-cell_line
grew None None O
in None None O
smaller None None O
grape-like None None O
clusters None None O
( None None O
< None None O
10 None None O
cells None None O
) None None O
. None None O

FD/deltaRaf-1 None None I-cell_line
: None None I-cell_line
ER None None I-cell_line
cells None None I-cell_line
growing None None O
in None None O
response None None O
to None None O
Raf None None O
activation None None O
displayed None None O
decreased None None O
levels None None O
of None None O
the None None O
Mac-2 None None I-protein
and None None I-protein
Mac-3 None None I-protein
molecules None None I-protein
on None None O
their None None O
cell None None I-cell_type
surface None None I-cell_type
. None None O

In None None O
contrast None None O
, None None O
when None None O
these None None O
cells None None O
were None None O
cultured None None O
in None None O
IL-3 None None I-protein
, None None O
higher None None O
levels None None O
of None None O
these None None O
adhesion None None I-protein
molecules None None I-protein
were None None O
detected None None O
. None None O

Expression None None O
of None None O
activated None None O
Raf None None I-protein
oncoproteins None None I-protein
also None None O
abrogated None None O
cytokine None None O
dependency None None O
and None None O
prevented None None O
apoptosis None None O
of None None O
TF-1 None None I-cell_line
cells None None I-cell_line
. None None O

Moreover None None O
, None None O
the None None O
differentiation None None O
status None None O
of None None O
these None None O
Raf-responsive None None I-cell_type
cells None None I-cell_type
was None None O
more None None O
immature None None O
upon None None O
Raf None None O
activation None None O
as None None O
culture None None O
with None None O
the None None O
differentiation-inducing None None O
agent None None O
phorbol None None O
12 None None O
myristate None None O
13-acetate None None O
( None None O
PMA None None O
) None None O
and None None O
beta-estradiol None None O
resulted None None O
in None None O
decreased None None O
levels None None O
of None None O
the None None O
CD11b None None I-protein
and None None I-protein
CD18 None None I-protein
integrin None None I-protein
molecules None None I-protein
on None None O
the None None O
cell None None I-cell_type
surface None None I-cell_type
. None None O

In None None O
contrast None None O
when None None O
the None None O
Raf-responsive None None I-cell_type
cells None None I-cell_type
were None None O
induced None None O
to None None O
differentiate None None O
with None None O
PMA None None O
and None None O
GM-CSF None None I-protein
, None None O
in None None O
the None None O
absence None None O
of None None O
deltaRaf None None I-protein
: None None I-protein
ER None None I-protein
activation None None O
, None None O
increased None None O
levels None None O
of None None O
the None None O
CD11b None None I-protein
and None None I-protein
CD18 None None I-protein
molecules None None I-protein
were None None O
detected None None O
. None None O

Retinoic None None O
acid None None O
( None None O
RA None None O
) None None O
inhibited None None O
3H-thymidine None None O
incorporation None None O
in None None O
response None None O
to None None O
GM-CSF None None I-protein
. None None O

Interestingly None None O
, None None O
Raf None None O
activation None None O
counterbalanced None None O
the None None O
inhibition None None O
of None None O
DNA None None O
synthesis None None O
caused None None O
by None None O
RA None None O
but None None O
not None None O
PMA None None O
. None None O

Thus None None O
deregulated None None O
Raf None None O
expression None None O
can None None O
alter None None O
cytokine None None O
dependency None None O
, None None O
integrin None None O
expression None None O
and None None O
the None None O
stage None None O
of None None O
differentiation None None O
. None None O

These None None O
Raf-responsive None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
will None None O
be None None O
useful None None O
in None None O
elucidating None None O
the None None O
roles None None O
of None None O
the None None O
MAP None None O
kinase None None O
cascade None None O
on None None O
hematopoietic None None I-cell_type
cell None None I-cell_type
differentiation None None O
and None None O
malignant None None O
transformation None None O

Cyclic None None O
AMP None None O
activates None None O
p38 None None I-protein
mitogen-activated None None I-protein
protein None None I-protein
kinase None None I-protein
in None None O
Th2 None None I-cell_type
cells None None I-cell_type
: None None O
phosphorylation None None O
of None None O
GATA-3 None None I-protein
and None None O
stimulation None None O
of None None O
Th2 None None I-cell_type
cytokine None None O
gene None None O
expression None None O
. None None O

cAMP None None O
is None None O
an None None O
important None None O
second None None O
messenger None None O
with None None O
immunomodulatory None None O
properties None None O
. None None O

Elevation None None O
of None None O
intracellular None None O
cAMP None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
, None None O
induced None None O
by None None O
agents None None O
such None None O
as None None O
IL-1alpha None None I-protein
or None None O
PGs None None I-protein
, None None O
inhibits None None O
T None None O
cell None None O
activation None None O
. None None O

In None None O
effector None None O
T None None I-cell_type
cells None None I-cell_type
, None None O
an None None O
increase None None O
in None None O
the None None O
level None None O
of None None O
intracellular None None O
cAMP None None O
inhibits None None O
cytokine None None I-protein
production None None O
in None None O
Th1 None None I-cell_type
cells None None I-cell_type
but None None O
stimulates None None O
cytokine None None I-protein
production None None O
in None None O
Th2 None None I-cell_type
cells None None I-cell_type
. None None O

Here None None O
we None None O
report None None O
that None None O
cAMP-induced None None O
effects None None O
in None None O
Th2 None None I-cell_type
cells None None I-cell_type
occur None None O
independently None None O
of None None O
the None None O
protein None None I-protein
kinase None None I-protein
A None None I-protein
pathway None None O
, None None O
which None None O
is None None O
the None None O
major None None O
mediator None None O
of None None O
cAMP-induced None None O
signaling None None O
events None None O
in None None O
most None None O
cell None None O
types None None O
. None None O

Instead None None O
, None None O
cAMP None None O
stimulates None None O
activation None None O
of None None O
p38 None None I-protein
mitogen-activated None None I-protein
protein None None I-protein
kinase None None I-protein
in None None O
Th2 None None I-cell_type
cells None None I-cell_type
. None None O

This None None O
appears None None O
to None None O
be None None O
a None None O
Th2 None None I-cell_type
-selective None None O
event None None O
because None None O
cAMP None None O
barely None None O
increased None None O
p38 None None I-protein
phosphorylation None None O
in None None O
Th1 None None I-cell_type
cells None None I-cell_type
. None None O

We None None O
show None None O
that None None O
in None None O
Th2 None None I-cell_type
cells None None I-cell_type
, None None O
cAMP None None O
promotes None None O
the None None O
production None None O
of None None O
both None None O
IL-5 None None I-protein
and None None O
IL-13 None None I-protein
, None None O
which None None O
play None None O
distinct None None O
but None None O
critical None None O
roles None None O
in None None O
asthma None None O
pathogenesis None None O
. None None O

Our None None O
data None None O
also None None O
show None None O
that None None O
cAMP None None O
causes None None O
increased None None O
phosphorylation None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
GATA-3 None None I-protein
, None None O
which None None O
we None None O
have None None O
shown None None O
is None None O
a None None O
critical None None O
regulator None None O
of None None O
Th2 None None I-cell_type
cytokine None None O
gene None None O
expression None None O
and None None O
, None None O
in None None O
turn None None O
, None None O
of None None O
airway None None O
inflammation None None O
in None None O
mice None None O
. None None O

Thus None None O
, None None O
Th2 None None I-cell_type
-specific None None O
GATA-3 None None I-protein
expression None None O
and None None O
p38 None None I-protein
mitogen-activated None None I-protein
protein None None I-protein
kinase None None I-protein
activation None None O
together None None O
provide None None O
a None None O
molecular None None O
basis None None O
for None None O
the None None O
differential None None O
effects None None O
of None None O
cAMP None None O
in None None O
the None None O
two None None O
T None None I-cell_type
helper None None I-cell_type
cell None None I-cell_type
subsets None None I-cell_type
. None None O

Characterization None None O
of None None O
IL-4 None None I-protein
and None None O
IL-13 None None I-protein
signals None None O
dependent None None O
on None None O
the None None O
human None None I-protein
IL-13 None None I-protein
receptor None None I-protein
alpha None None I-protein
chain None None I-protein
1 None None I-protein
: None None O
redundancy None None O
of None None O
requirement None None O
of None None O
tyrosine None None O
residue None None O
for None None O
STAT3 None None O
activation None None O
. None None O

IL-4 None None I-protein
and None None O
IL-13 None None I-protein
are None None O
pleiotropic None None I-protein
cytokines None None I-protein
whose None None O
biological None None O
activities None None O
overlap None None O
with None None O
each None None O
other None None O
. None None O

IL-13 None None I-protein
receptor None None I-protein
alpha None None I-protein
chain None None I-protein
1 None None I-protein
( None None O
IL-13R None None I-protein
alpha None None I-protein
1 None None I-protein
) None None O
is None None O
necessary None None O
for None None O
binding None None O
to None None O
IL-13 None None I-protein
, None None O
and None None O
the None None O
heterodimer None None O
composed None None O
of None None O
IL-13R None None I-protein
alpha None None I-protein
1 None None I-protein
and None None O
IL-4R None None I-protein
alpha None None I-protein
chain None None I-protein
transduces None None O
IL-13 None None I-protein
and None None O
IL-4 None None I-protein
signals None None O
; None None O
however None None O
, None None O
the None None O
functional None None O
mapping None None O
of None None O
the None None O
intracellular None None I-protein
domain None None I-protein
of None None O
IL-13R None None I-protein
alpha None None I-protein
1 None None I-protein
is None None O
not None None O
fully None None O
understood None None O
. None None O

In None None O
this None None O
study None None O
, None None O
we None None O
constructed None None O
wild None None O
and None None O
mutated None None O
types None None O
of None None O
human None None I-protein
IL-13R None None I-protein
alpha None None I-protein
1 None None I-protein
, None None O
and None None O
analyzed None None O
IL-4 None None I-protein
and None None O
IL-13 None None I-protein
signals None None O
using None None O
an None None O
IL-13R None None I-protein
alpha None None I-protein
1 None None I-protein
-transfected None None O
human None None I-cell_line
B None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
. None None O

Expression None None O
of None None O
IL-13R None None I-protein
alpha None None I-protein
1 None None I-protein
evoked None None O
STAT3 None None I-protein
activation None None O
by None None O
IL-4 None None I-protein
and None None O
IL-13 None None I-protein
, None None O
and None None O
in None None O
stimulated None None O
human None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
, None None O
on None None O
which None None O
IL-13R None None I-protein
alpha None None I-protein
1 None None I-protein
was None None O
highly None None O
expressed None None O
, None None O
IL-4 None None I-protein
and None None O
IL-13 None None I-protein
induced None None O
STAT3 None None I-protein
activation None None O
. None None O

Replacement None None O
of None None O
the None None O
two None None O
tyrosine None None O
residues None None O
completely None None O
abolished None None O
STAT3 None None I-protein
activation None None O
, None None O
although None None O
replacing None None O
either None None O
tyrosine None None O
residue None None O
alone None None O
retained None None O
it None None O
. None None O

Furthermore None None O
, None None O
we None None O
found None None O
that None None O
the None None O
Box1 None None I-protein
region None None I-protein
and None None O
the None None O
C-terminal None None I-protein
tail None None I-protein
of None None O
IL-13R None None I-protein
alpha None None I-protein
1 None None I-protein
were None None O
critical None None O
for None None O
binding None None O
to None None O
Tyk2 None None I-protein
, None None O
and None None O
activation None None O
of None None O
Jak1 None None I-protein
, None None O
Tyk2 None None I-protein
, None None O
the None None O
insulin None None I-protein
receptor None None I-protein
substrate-1 None None I-protein
and None None O
STAT6 None None I-protein
respectively None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
STAT3 None None I-protein
activation None None O
is None None O
involved None None O
with None None O
IL-4 None None I-protein
and None None O
IL-13 None None I-protein
signals None None O
in None None O
human None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
along None None O
with None None O
the None None O
activation None None O
of None None O
STAT6 None None I-protein
, None None O
and None None O
that None None O
there None None O
is None None O
a None None O
unique None None O
sequence None None O
in None None O
IL-13R None None I-protein
alpha None None I-protein
1 None None I-protein
to None None O
activate None None O
STAT3 None None I-protein
. None None O

Functional None None O
uncoupling None None O
of None None O
the None None O
Janus None None O
kinase None None O
3-Stat5 None None O
pathway None None O
in None None O
malignant None None O
growth None None O
of None None O
human None None O
T None None O
cell None None O
leukemia None None O
virus None None O
type None None O
1-transformed None None O
human None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

Human None None O
T None None O
cell None None O
leukemia None None O
virus None None O
type None None O
1 None None O
( None None O
HTLV-1 None None O
) None None O
transforms None None O
cytokine None None I-protein
-dependent None None O
T None None I-cell_type
lymphocytes None None I-cell_type
and None None O
causes None None O
adult None None O
T None None O
cell None None O
leukemia None None O
. None None O

Janus None None I-protein
tyrosine None None I-protein
kinase None None I-protein
( None None I-protein
Jak None None I-protein
) None None I-protein
3 None None I-protein
and None None O
transcription None None I-protein
factors None None I-protein
Stat5a None None B-protein
and None None O
Stat5b None None I-protein
are None None O
essential None None O
for None None O
the None None O
proliferation None None O
of None None O
normal None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
and None None O
are None None O
constitutively None None O
hyperactivated None None O
in None None O
both None None O
HTLV-1-transformed None None I-cell_line
human None None I-cell_line
T None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
and None None O
lymphocytes None None I-cell_type
isolated None None O
from None None O
HTLV-1-infected None None O
patients None None O
; None None O
therefore None None O
, None None O
a None None O
critical None None O
role None None O
for None None O
the None None O
Jak3-Stat5 None None O
pathway None None O
in None None O
the None None O
progression None None O
of None None O
this None None O
disease None None O
has None None O
been None None O
postulated None None O
. None None O

We None None O
recently None None O
reported None None O
that None None O
tyrphostin None None O
AG-490 None None O
selectively None None O
blocked None None O
IL-2 None None O
activation None None O
of None None O
Jak3/Stat5 None None I-protein
and None None O
growth None None O
of None None O
murine None None I-cell_line
T None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
. None None O

Here None None O
we None None O
demonstrate None None O
that None None O
disruption None None O
of None None O
Jak3/Stat5a/b None None O
signaling None None O
with None None O
AG-490 None None O
( None None O
50 None None O
& None None O
mgr None None O
; None None O
M None None O
) None None O
blocked None None O
the None None O
proliferation None None O
of None None O
primary None None I-cell_type
human None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
, None None O
but None None O
paradoxically None None O
failed None None O
to None None O
inhibit None None O
the None None O
proliferation None None O
of None None O
HTLV-1-transformed None None I-cell_line
human None None I-cell_line
T None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
, None None O
HuT-102 None None I-cell_line
and None None O
MT-2 None None I-cell_line
. None None O

Structural None None O
homologues None None O
of None None O
AG-490 None None O
also None None O
inhibited None None O
the None None O
proliferation None None O
of None None O
primary None None I-cell_type
human None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
, None None O
but None None O
not None None O
HTLV-1-infected None None I-cell_type
cells None None I-cell_type
. None None O

Disruption None None O
of None None O
constitutive None None O
Jak3/Stat5 None None O
activation None None O
by None None O
AG-490 None None O
was None None O
demonstrated None None O
by None None O
inhibition None None O
of None None O
1 None None O
) None None O
tyrosine None None O
phosphorylation None None O
of None None O
Jak3 None None I-protein
, None None O
Stat5a None None I-protein
( None None O
Tyr None None O
( None None O
694 None None O
) None None O
) None None O
, None None O
and None None O
Stat5b None None I-protein
( None None O
Tyr None None O
( None None O
699 None None O
) None None O
) None None O
; None None O
2 None None O
) None None O
serine None None O
phosphorylation None None O
of None None O
Stat5a None None I-protein
( None None O
Ser None None O
( None None O
726 None None O
) None None O
) None None O
as None None O
determined None None O
by None None O
a None None O
novel None None O
phosphospecific None None I-protein
Ab None None I-protein
; None None O
and None None O
3 None None O
) None None O
Stat5a/b None None O
DNA None None O
binding None None O
to None None O
the None None O
Stat5-responsive None None I-DNA
beta-casein None None I-DNA
promoter None None I-DNA
. None None O

In None None O
contrast None None O
, None None O
AG-490 None None O
had None None O
no None None O
effect None None O
on None None O
DNA None None O
binding None None O
by None None O
p50/p65 None None I-protein
components None None I-protein
of None None O
NF-kappaB None None I-protein
, None None O
a None None O
transcription None None I-protein
factor None None I-protein
activated None None O
by None None O
the None None O
HTLV-1-encoded None None I-protein
phosphoprotein None None I-protein
, None None I-protein
Tax None None I-protein
. None None O

Collectively None None O
, None None O
these None None O
data None None O
suggest None None O
that None None O
the None None O
Jak3-Stat5 None None O
pathway None None O
in None None O
HTLV-1-transformed None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
has None None O
become None None O
functionally None None O
redundant None None O
for None None O
proliferation None None O
. None None O

Reversal None None O
of None None O
this None None O
functional None None O
uncoupling None None O
may None None O
be None None O
required None None O
before None None O
Jak3/Stat5 None None O
inhibitors None None O
will None None O
be None None O
useful None None O
in None None O
the None None O
treatment None None O
of None None O
this None None O
malignancy None None O
. None None O

The None None O
Epstein-Barr None None I-DNA
virus None None I-DNA
promoter None None I-DNA
initiating None None O
B-cell None None O
transformation None None O
is None None O
activated None None O
by None None O
RFX None None I-protein
proteins None None I-protein
and None None O
the None None O
B-cell-specific None None I-protein
activator None None I-protein
protein None None I-protein
BSAP/Pax5 None None I-protein
. None None O

Epstein-Barr None None O
virus None None O
( None None O
EBV None None O
) None None O
-induced None None O
B-cell None None I-cell_type
growth None None O
transformation None None O
, None None O
a None None O
central None None O
feature None None O
of None None O
the None None O
virus None None O
' None None O
strategy None None O
for None None O
colonizing None None O
the None None O
human None None O
B-cell None None O
system None None O
, None None O
requires None None O
full None None O
virus None None O
latent None None O
gene None None O
expression None None O
and None None O
is None None O
initiated None None O
by None None O
transcription None None O
from None None O
the None None O
viral None None I-DNA
promoter None None I-DNA
Wp None None I-DNA
. None None O

Interestingly None None O
, None None O
when None None O
EBV None None O
accesses None None O
other None None O
cell None None O
types None None O
, None None O
this None None O
growth-transforming None None O
program None None O
is None None O
not None None O
activated None None O
. None None O

The None None O
present None None O
work None None O
focuses None None O
on None None O
a None None O
region None None O
of None None O
Wp None None I-DNA
which None None O
in None None O
reporter None None O
assays None None O
confers None None O
B-cell None None I-cell_type
-specific None None O
activity None None O
. None None O

Bandshift None None O
studies None None O
indicate None None O
that None None O
this None None O
region None None O
contains None None O
three None None O
factor None None O
binding None None O
sites None None O
, None None O
termed None None O
sites None None I-DNA
B None None I-DNA
, None None I-DNA
C None None I-DNA
, None None I-DNA
and None None I-DNA
D None None I-DNA
, None None O
in None None O
addition None None O
to None None O
a None None O
previously None None O
characterized None None O
CREB None None I-DNA
site None None I-DNA
. None None O

Here None None O
we None None O
show None None O
that None None O
site None None I-DNA
C None None I-DNA
binds None None O
members None None O
of None None O
the None None O
ubiquitously None None O
expressed None None O
RFX None None I-protein
family None None I-protein
of None None I-protein
proteins None None I-protein
, None None O
notably None None O
RFX1 None None I-protein
, None None O
RFX3 None None I-protein
, None None O
and None None O
the None None O
associated None None O
factor None None O
MIBP1 None None I-protein
, None None O
whereas None None O
sites None None I-DNA
B None None I-DNA
and None None I-DNA
D None None I-DNA
both None None O
bind None None O
the None None O
B-cell-specific None None I-protein
activator None None I-protein
protein None None I-protein
BSAP/Pax5 None None I-protein
. None None O

In None None O
reporter None None O
assays None None O
with None None O
mutant None None I-DNA
Wp None None I-DNA
constructs None None I-DNA
, None None O
the None None O
loss None None O
of None None O
factor None None O
binding None None O
to None None O
any None None O
one None None O
of None None O
these None None O
sites None None O
severely None None O
impaired None None O
promoter None None O
activity None None O
in None None O
B None None I-cell_type
cells None None I-cell_type
, None None O
while None None O
the None None O
wild-type None None I-DNA
promoter None None I-DNA
could None None O
be None None O
activated None None O
in None None O
non-B None None I-cell_type
cells None None I-cell_type
by None None O
ectopic None None O
BSAP None None O
expression None None O
. None None O

We None None O
suggest None None O
that None None O
Wp None None I-DNA
regulation None None O
by None None O
BSAP None None I-protein
helps None None O
to None None O
ensure None None O
the None None O
B-cell None None I-cell_type
specificity None None O
of None None O
EBV None None O
's None None O
growth-transforming None None O
function None None O
. None None O

Activation None None O
of None None O
the None None O
Lck None None I-protein
tyrosine None None I-protein
protein None None I-protein
kinase None None I-protein
by None None O
the None None O
Herpesvirus None None O
saimiri None None O
tip None None I-protein
protein None None I-protein
involves None None O
two None None O
binding None None O
interactions None None O
. None None O

The None None O
Tip None None I-protein
protein None None I-protein
of None None O
Herpesvirus None None O
saimiri None None O
strain None None O
484C None None O
binds None None O
to None None O
and None None O
activates None None O
the None None O
Lck None None I-protein
tyrosine None None I-protein
protein None None I-protein
kinase None None I-protein
. None None O

Two None None O
sequences None None O
in None None O
the None None O
Tip None None I-protein
protein None None I-protein
were None None O
previously None None O
shown None None O
to None None O
be None None O
involved None None O
in None None O
binding None None O
to None None O
Lck None None I-protein
. None None O

A None None O
proline-rich None None I-protein
region None None I-protein
, None None O
residues None None O
132-141 None None O
, None None O
binds None None O
to None None O
the None None O
SH3 None None I-protein
domain None None I-protein
of None None O
the None None O
Lck None None I-protein
protein None None I-protein
. None None O

We None None O
show None None O
here None None O
that None None O
the None None O
other None None O
Lck-binding None None I-protein
domain None None I-protein
, None None O
residues None None O
104-113 None None O
, None None O
binds None None O
to None None O
the None None O
carboxyl-terminal None None I-protein
half None None I-protein
of None None O
Lck None None I-protein
and None None O
that None None O
this None None O
binding None None O
does None None O
not None None O
require None None O
the None None O
Lck None None I-protein
SH3 None None I-protein
domain None None I-protein
. None None O

Mutated None None O
Tip None None I-protein
containing None None O
only None None O
one None None O
functional None None O
Lck-binding None None I-protein
domain None None I-protein
can None None O
bind None None O
stably None None O
to None None O
Lck None None I-protein
, None None O
although None None O
not None None O
as None None O
strongly None None O
as None None O
wild-type None None I-protein
Tip None None I-protein
. None None O

Interaction None None O
of None None O
Tip None None I-protein
with None None O
Lck None None I-protein
through None None O
either None None O
Lck-binding None None I-protein
domain None None I-protein
increases None None O
the None None O
activity None None O
of None None O
Lck None None I-protein
in None None O
vivo None None O
. None None O

Simultaneous None None O
binding None None O
of None None O
both None None O
domains None None O
is None None O
required None None O
for None None O
maximal None None O
activation None None O
of None None O
Lck None None I-protein
. None None O

The None None O
transient None None O
expression None None O
of None None O
Tip None None I-protein
in None None O
T None None I-cell_type
cells None None I-cell_type
was None None O
found None None O
to None None O
stimulate None None O
both None None O
Stat3 None None I-protein
-dependent None None O
and None None O
NF-AT None None I-protein
-dependent None None O
transcription None None O
. None None O

Mutant None None O
forms None None O
of None None O
Tip None None I-protein
lacking None None O
one None None O
or None None O
the None None O
other None None O
of None None O
the None None O
two None None O
Lck-binding None None I-protein
domains None None I-protein
retained None None O
the None None O
ability None None O
to None None O
stimulate None None O
Stat3 None None I-protein
-dependent None None O
transcription None None O
. None None O

Tip None None I-protein
lacking None None O
the None None O
proline-rich None None O
Lck-binding None None I-protein
domain None None I-protein
exhibited None None O
almost None None O
wild-type None None O
activity None None O
in None None O
this None None O
assay None None O
. None None O

In None None O
contrast None None O
, None None O
ablation None None O
of None None O
either None None O
Lck-binding None None I-protein
domain None None I-protein
abolished None None O
the None None O
ability None None O
of None None O
Tip None None I-protein
to None None O
stimulate None None O
NF-AT None None I-protein
-dependent None None O
transcription None None O
. None None O

Full None None O
biological None None O
activity None None O
of None None O
Tip None None I-protein
, None None O
therefore None None O
, None None O
appears None None O
to None None O
require None None O
both None None O
Lck-binding None None I-protein
domains None None I-protein
. None None O

Accumulation None None O
of None None O
RXR None None I-protein
alpha None None I-protein
during None None O
activation None None O
of None None O
cycling None None O
human None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
: None None O
modulation None None O
of None None O
RXRE None None O
transactivation None None O
function None None O
by None None O
mitogen-activated None None O
protein None None O
kinase None None O
pathways None None O
. None None O

We None None O
have None None O
previously None None O
reported None None O
that None None O
the None None O
activation None None O
of None None O
resting None None O
human None None I-cell_type
immature None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
T None None I-cell_type
( None None I-cell_type
PBT None None I-cell_type
) None None I-cell_type
lymphocytes None None I-cell_type
is None None O
associated None None O
with None None O
the None None O
loss None None O
of None None O
retinoid None None I-protein
X None None I-protein
receptor None None I-protein
alpha None None I-protein
( None None O
RXRalpha None None I-protein
) None None O
expression None None O
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
have None None O
demonstrated None None O
that None None O
, None None O
unlike None None O
resting None None O
cells None None O
, None None O
activation None None O
of None None O
cycling None None I-cell_type
human None None I-cell_type
mature None None I-cell_type
PBT None None I-cell_type
lymphocytes None None I-cell_type
, None None O
and None None O
T None None I-cell_line
lymphocyte None None I-cell_line
leukemia None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
is None None O
accompanied None None O
by None None O
the None None O
accumulation None None O
of None None O
RXRalpha None None I-protein
mRNA None None O
and None None O
protein None None O
. None None O

Interestingly None None O
, None None O
cyclosporin None None O
A None None O
further None None O
augmented None None O
RXRalpha None None I-protein
expression None None O
, None None O
indicating None None O
the None None O
involvement None None O
of None None O
calcineurin None None O
pathways None None O
in None None O
the None None O
process None None O
. None None O

9-cis None None O
retinoic None None O
acid None None O
inhibited None None O
the None None O
accumulation None None O
, None None O
suggesting None None O
that None None O
retinoids None None O
can None None O
regulate None None O
the None None O
synthesis None None O
of None None O
their None None O
own None None O
receptors None None O
during None None O
T None None O
cell None None O
activation None None O
. None None O

Transfection None None O
analysis None None O
in None None O
Jurkat None None I-cell_line
cells None None I-cell_line
, None None O
using None None O
RXRE-dependent None None O
reporter None None O
assays None None O
, None None O
showed None None O
that None None O
RXRalpha None None I-protein
accumulated None None O
during None None O
T None None O
cell None None O
activation None None O
was None None O
transcriptionally None None O
inactive None None O
. None None O

To None None O
investigate None None O
the None None O
mechanism None None O
of None None O
such None None O
inhibition None None O
, None None O
the None None O
role None None O
of None None O
two None None O
mitogen-activated None None O
protein None None O
kinase None None O
pathways None None O
, None None O
c-Jun None None I-protein
N-terminal None None I-protein
kinase None None I-protein
( None None O
JNK None None I-protein
) None None O
and None None O
extracellular None None I-protein
signal-regulated None None I-protein
kinase None None I-protein
( None None O
ERK None None I-protein
) None None O
, None None O
in None None O
modulating None None O
RXRE-dependent None None O
transcription None None O
, None None O
was None None O
explored None None O
. None None O

The None None O
expression None None O
of None None O
constitutively None None O
active None None O
MAP/ERK None None I-protein
kinase None None I-protein
kinase None None I-protein
1 None None I-protein
( None None O
MEKK1 None None I-protein
) None None O
inhibited None None O
RXRE-dependent None None O
transcription None None O
, None None O
whereas None None O
dominant None None I-protein
negative None None I-protein
MEKK1 None None I-protein
increased None None O
the None None O
transcription None None O
, None None O
indicating None None O
the None None O
involvement None None O
of None None O
JNK None None I-protein
signaling None None O
pathways None None O
in None None O
the None None O
process None None O
. None None O

In None None O
contrast None None O
, None None O
expression None None O
of None None O
constitutively None None I-protein
active None None I-protein
MEK1 None None I-protein
, None None O
which None None O
activates None None O
ERK None None I-protein
pathway None None O
, None None O
enhanced None None O
RXRE-dependent None None O
activation None None O
. None None O

When None None O
both None None O
were None None O
activated None None O
simultaneously None None O
, None None O
JNK None None I-protein
pathway None None O
was None None O
dominant None None O
over None None O
ERK None None I-protein
pathway None None O
and None None O
resulted None None O
in None None O
inhibition None None O
of None None O
RXRE-mediated None None O
transcription None None O
. None None O

These None None O
data None None O
demonstrate None None O
a None None O
dual None None O
regulatory None None O
control None None O
of None None O
RXRalpha None None I-protein
expression None None O
during None None O
the None None O
activation None None O
of None None O
resting None None I-cell_type
and None None I-cell_type
cycling None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
and None None O
indicate None None O
a None None O
dynamic None None O
balance None None O
between None None O
JNK None None O
and None None O
ERK None None O
pathways None None O
in None None O
modulating None None O
RXRE-mediated None None O
transactivation None None O
. None None O

The None None O
proteasome None None I-protein
regulates None None O
receptor-mediated None None O
endocytosis None None O
of None None O
interleukin-2 None None I-protein
. None None O

Recent None None O
studies None None O
have None None O
increasingly None None O
implicated None None O
the None None O
proteasome None None I-protein
in None None O
the None None O
regulation None None O
of None None O
cell None None I-protein
surface None None I-protein
receptors None None I-protein
. None None O

In None None O
the None None O
present None None O
study None None O
, None None O
we None None O
investigated None None O
the None None O
role None None O
of None None O
the None None O
proteasome None None I-protein
for None None O
ligand-dependent None None O
endocytosis None None O
and None None O
degradation None None O
of None None O
the None None O
interleukin-2 None None I-protein
( None None I-protein
IL-2 None None I-protein
) None None I-protein
-interleukin-2 None None I-protein
receptor None None I-protein
( None None I-protein
IL-2R None None I-protein
) None None I-protein
complex None None I-protein
. None None O

Proteasome None None O
inhibitors None None O
impaired None None O
internalization None None O
of None None O
IL-2.IL-2R None None I-protein
and None None O
prevented None None O
the None None O
lysosomal None None O
degradation None None O
of None None O
this None None O
cytokine None None I-protein
. None None O

Based None None O
on None None O
time-course None None O
studies None None O
, None None O
proteasome None None I-protein
activity None None O
is None None O
primarily None None O
required None None O
after None None O
initial None None O
endocytosis None None O
of None None O
the None None O
IL-2.IL-2R None None I-protein
. None None O

Proteasome None None O
function None None O
was None None O
also None None O
necessary None None O
for None None O
the None None O
lysosomal None None O
degradation None None O
of None None O
IL-2 None None I-protein
internalized None None O
by None None O
IL-2R None None I-protein
that None None O
were None None O
comprised None None O
of None None O
cytoplasmic None None I-protein
tailless None None I-protein
beta- None None B-protein
or None None I-protein
gamma None None I-protein
c-subunits None None I-protein
, None None O
suggesting None None O
that None None O
the None None O
target None None O
protein None None O
for None None O
the None None O
proteasome None None I-protein
is None None O
independent None None O
of None None O
either None None O
the None None O
cytoplasmic None None I-protein
tail None None I-protein
of None None O
the None None O
IL-2R None None I-protein
beta- None None B-protein
or None None I-protein
gamma None None I-protein
c-subunits None None I-protein
and None None O
their None None O
associated None None O
signaling None None O
components None None O
. None None O

Therefore None None O
, None None O
a None None O
functional None None O
proteasome None None I-protein
is None None O
required None None O
for None None O
optimal None None O
endocytosis None None O
of None None O
the None None O
IL-2R/ligand None None I-protein
complex None None I-protein
and None None O
is None None O
essential None None O
for None None O
the None None O
subsequent None None O
lysosomal None None O
degradation None None O
of None None O
IL-2 None None I-protein
, None None O
possibly None None O
by None None O
regulating None None O
trafficking None None O
to None None O
the None None O
lysosome None None O
. None None O

Functional None None O
characterization None None O
of None None O
the None None O
two None None O
alternative None None O
promoters None None O
of None None O
human None None I-DNA
p45 None None I-DNA
NF-E2 None None I-DNA
gene None None I-DNA
. None None O

OBJECTIVE None None O
: None None O
The None None O
transcription None None I-protein
factor None None I-protein
NF-E2 None None I-protein
, None None O
a None None O
heterodimeric None None I-protein
protein None None I-protein
complex None None I-protein
composed None None O
of None None O
p45 None None I-protein
and None None O
small None None O
Maf None None I-protein
family None None I-protein
proteins None None I-protein
, None None O
is None None O
considered None None O
crucial None None O
for None None O
the None None O
proper None None O
differentiation None None O
of None None O
erythrocytes None None I-cell_type
and None None O
megakaryocytes None None I-cell_type
in None None O
vivo None None O
. None None O

We None None O
report None None O
the None None O
results None None O
of None None O
studies None None O
aimed None None O
at None None O
understanding None None O
the None None O
regulatory None None O
mechanisms None None O
controlling None None O
p45 None None I-DNA
gene None None I-DNA
expression None None O
in None None O
erythroid None None I-cell_type
cells None None I-cell_type
. None None O

MATERIALS None None O
AND None None O
METHODS None None O
: None None O
Human None None I-RNA
p45 None None I-RNA
mRNAs None None I-RNA
have None None O
two None None O
alternative None None O
isoforms None None O
, None None O
aNF-E2 None None I-RNA
and None None O
fNF-E2 None None I-RNA
, None None O
and None None O
these None None O
isoforms None None O
are None None O
transcribed None None O
from None None O
the None None O
alternative None None I-DNA
promoters None None I-DNA
. None None O

We None None O
investigated None None O
lineage-specific None None O
expression None None O
of None None O
both None None O
isomers None None O
in None None O
human None None O
erythroid None None I-cell_type
and None None I-cell_type
megakaryocytic None None I-cell_type
cells None None I-cell_type
by None None O
reverse None None O
transcriptase None None O
polymerase None None O
chain None None O
reaction None None O
or None None O
Northern None None O
blot None None O
analysis None None O
. None None O

For None None O
functional None None O
characterization None None O
of None None O
both None None O
promoters None None O
, None None O
plasmids None None O
in None None O
which None None O
reporter None None I-DNA
genes None None I-DNA
were None None O
placed None None O
under None None O
the None None O
control None None O
of None None O
a None None O
series None None O
of None None O
truncated None None O
or None None O
mutated None None O
promoter None None I-DNA
fragments None None I-DNA
were None None O
transfected None None O
to None None O
human None None I-cell_line
hematopoietic None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
. None None O

RESULTS None None O
: None None O
When None None O
CD34 None None I-cell_type
( None None I-cell_type
+ None None I-cell_type
) None None I-cell_type
cells None None I-cell_type
isolated None None O
from None None O
human None None O
cord None None O
blood None None O
were None None O
induced None None O
to None None O
unilineage None None O
erythroid None None O
or None None O
megakaryocytic None None O
differentiation None None O
in None None O
liquid None None O
suspension None None O
culture None None O
, None None O
both None None O
transcripts None None O
, None None O
although None None O
barely None None O
detected None None O
at None None O
day None None O
0 None None O
, None None O
were None None O
induced None None O
in None None O
both None None O
erythroid None None O
and None None O
megakaryocytic None None O
cultures None None O
. None None O

fNF-E2 None None I-RNA
mRNA None None I-RNA
was None None O
found None None O
to None None O
be None None O
more None None O
abundant None None O
in None None O
erythroid None None I-cell_type
cells None None I-cell_type
than None None O
megakaryocytic None None I-cell_type
cells None None I-cell_type
at None None O
day None None O
7 None None O
of None None O
culture None None O
. None None O

Although None None O
both None None O
isomers None None O
were None None O
expressed None None O
in None None O
human None None I-cell_line
erythroid-megakaryocytic None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
, None None O
megakaryocytic None None O
maturation None None O
with None None O
loss None None O
of None None O
erythroid None None O
phenotype None None O
induced None None O
by None None O
phorbol None None O
12-myristate None None O
13-acetate None None O
( None None O
PMA None None O
) None None O
resulted None None O
in None None O
exclusive None None O
downregulation None None O
of None None O
fNF-E2 None None I-RNA
, None None O
suggesting None None O
that None None O
fNF-E2 None None I-DNA
promoter None None I-DNA
is None None O
more None None O
erythroid None None O
specific None None O
. None None O

Functional None None O
analysis None None O
of None None O
fNF-E2 None None I-DNA
promoter None None I-DNA
showed None None O
that None None O
the None None O
promoter None None O
is None None O
active None None O
only None None O
in None None O
erythroid-megakaryocytic None None I-cell_type
cells None None I-cell_type
and None None O
that None None O
the None None O
double None None I-DNA
GATA None None I-DNA
sit None None I-DNA
e None None O
in None None O
the None None O
proximal None None O
region None None O
is None None O
necessary None None O
for None None O
its None None O
efficient None None O
activity None None O
. None None O

CONCLUSION None None O
: None None O
These None None O
results None None O
suggest None None O
that None None O
GATA None None I-protein
proteins None None I-protein
, None None O
which None None O
govern None None O
the None None O
differentiation None None O
of None None O
erythroid None None I-cell_type
lineage None None I-cell_type
cells None None I-cell_type
, None None O
are None None O
required None None O
for None None O
full None None O
promoter None None O
activity None None O
of None None O
the None None O
p45 None None I-DNA
gene None None I-DNA
. None None O

Transcriptional None None O
activation None None O
of None None O
heme None None I-DNA
oxygenase-1 None None I-DNA
and None None O
its None None O
functional None None O
significance None None O
in None None O
acetaminophen-induced None None O
hepatitis None None O
and None None O
hepatocellular None None O
injury None None O
in None None O
the None None O
rat None None O
. None None O

BACKGROUND/AIM None None O
: None None O
Glutathione None None O
depletion None None O
contributes None None O
to None None O
acetaminophen None None O
hepatotoxicity None None O
and None None O
is None None O
known None None O
to None None O
induce None None O
the None None O
oxidative None None O
stress None None O
reactant None None O
heme None None I-protein
oxygenase-1 None None I-protein
. None None O

The None None O
metabolites None None O
of None None O
the None None O
heme None None O
oxygenase None None O
pathway None None O
, None None O
biliverdin None None O
, None None O
carbon None None O
monoxide None None O
, None None O
and None None O
iron None None O
may None None O
modulate None None O
acetaminophen None None O
toxicity None None O
. None None O

The None None O
aim None None O
of None None O
this None None O
study None None O
was None None O
to None None O
assess None None O
cell-type None None O
specific None None O
expression None None O
of None None O
heme None None I-DNA
oxygenase-1 None None I-DNA
and None None O
its None None O
impact None None O
on None None O
liver None None O
injury None None O
and None None O
microcirculatory None None O
disturbances None None O
in None None O
a None None O
model None None O
of None None O
acetaminophen-induced None None O
hepatitis None None O
. None None O

METHODS None None O
: None None O
Gene None None O
expression None None O
of None None O
heme None None I-DNA
oxygenase-1 None None I-DNA
was None None O
studied None None O
by None None O
Northern- None None O
and None None O
Western None None O
analysis None None O
as None None O
well None None O
as None None O
immunohistochemistry None None O
. None None O

The None None O
time None None O
course None None O
of None None O
heme None None I-protein
oxygenase-1 None None I-protein
and None None I-protein
-2 None None I-protein
, None None O
cytokine-induced None None I-protein
neutrophil None None I-protein
chemoattractant-1 None None I-protein
, None None O
and None None O
intercellular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
was None None O
studied None None O
by None None O
Northern None None O
analysis None None O
. None None O

DNA-binding None None O
activity None None O
of None None O
nuclear None None I-protein
factor-kappaB None None I-protein
was None None O
determined None None O
by None None O
electrophoretic None None O
mobility None None O
shift None None O
assay None None O
. None None O

Sinusoidal None None O
perfusion None None O
and None None O
leukocyte-endothelial None None O
interactions None None O
were None None O
assessed None None O
by None None O
intravital None None O
microscopy None None O
. None None O

RESULTS None None O
: None None O
Acetaminophen None None O
caused None None O
a None None O
moderate None None O
sinusoidal None None O
perfusion None None O
failure None None O
( None None O
-15 None None O
% None None O
) None None O
and None None O
infiltration None None O
of None None O
neutrophils None None I-cell_type
along None None O
with None None O
activation None None O
of None None O
nuclear None None I-protein
factor-kappaB None None I-protein
and None None O
intercellular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
and None None O
cytokine-induced None None I-protein
neutrophil None None I-protein
chemoattractant-1 None None I-protein
mRNAs None None O
. None None O

Induction None None O
of None None O
heme None None I-protein
oxygenase-1 None None I-protein
mRNA None None O
and None None O
protein None None O
( None None O
approximately None None O
30-fold None None O
) None None O
in None None O
hepatocytes None None I-cell_type
and None None O
non-parenchymal None None I-cell_type
cells None None I-cell_type
paralleled None None O
the None None O
inflammatory None None O
response None None O
. None None O

Blockade None None O
of None None O
heme None None O
oxygenase None None O
activity None None O
with None None O
tin-protoporphyrin-IX None None O
abrogated None None O
acetaminophen-induced None None O
hepatic None None I-cell_type
neutrophil None None I-cell_type
accumulation None None O
and None None O
nuclear None None I-protein
factor-kappaB None None I-protein
activation None None O
, None None O
but None None O
failed None None O
to None None O
affect None None O
sinusoidal None None O
perfusion None None O
and None None O
liver None None O
injury None None O
. None None O

CONCLUSIONS None None O
: None None O
The None None O
inflammatory None None O
response None None O
associated None None O
with None None O
acetaminophen None None O
hepatotoxicity None None O
is None None O
modulated None None O
by None None O
the None None O
parallel None None O
induction None None O
of None None O
the None None O
heme None None I-DNA
oxygenase-1 None None I-DNA
gene None None I-DNA
. None None O

However None None O
, None None O
heme None None I-DNA
oxygenase-1 None None I-DNA
has None None O
no None None O
permissive None None O
effect None None O
on None None O
sinusoidal None None O
perfusion None None O
and None None O
does None None O
not None None O
affect None None O
liver None None O
injury None None O
in None None O
this None None O
model None None O
. None None O

These None None O
data None None O
argue None None O
against None None O
a None None O
central None None O
role None None O
of None None O
nuclear None None I-protein
factor-kappaB None None I-protein
activation None None O
and None None O
neutrophil None None O
infiltration None None O
as None None O
perpetuating None None O
factors None None O
of None None O
liver None None O
injury None None O
in None None O
acetaminophen None None O
toxicity None None O
. None None O

Tumor None None I-protein
necrosis None None I-protein
factor-alpha None None I-protein
-induced None None O
proliferation None None O
requires None None O
synthesis None None O
of None None O
granulocyte-macrophage None None I-protein
colony-stimulating None None I-protein
factor None None I-protein
. None None O

OBJECTIVE None None O
: None None O
Tumor None None I-protein
necrosis None None I-protein
factor- None None I-protein
alpha None None I-protein
( None None O
TNF-alpha None None I-protein
) None None O
induces None None O
a None None O
variety None None O
of None None O
cellular None None O
responses None None O
, None None O
some None None O
of None None O
them None None O
being None None O
at None None O
least None None O
seemingly None None O
contradictory None None O
. None None O

Thus None None O
, None None O
we None None O
set None None O
out None None O
to None None O
find None None O
differences None None O
in None None O
the None None O
modes None None O
of None None O
proliferative None None O
and None None O
apoptotic None None O
responses None None O
to None None O
TNF- None None I-protein
alpha None None I-protein
. None None O

MATERIALS None None O
AND None None O
METHODS None None O
: None None O
We None None O
screened None None O
a None None O
panel None None O
of None None O
acute None None I-cell_line
myeloid None None I-cell_line
leukemia-derived None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
for None None O
TNF- None None I-protein
alpha None None I-protein
-responsiveness None None O
. None None O

In None None O
two None None O
lines None None O
( None None O
OCI-AML-1 None None I-cell_line
, None None O
OCI-AML-11 None None I-cell_line
) None None O
, None None O
TNF- None None I-protein
alpha None None I-protein
acted None None O
as None None O
an None None O
apoptotic None None O
agent None None O
; None None O
in None None O
others None None O
( None None O
HU-3 None None I-cell_line
, None None O
M-07e None None I-cell_line
, None None O
TF-1 None None I-cell_line
) None None O
, None None O
it None None O
had None None O
the None None O
opposite None None O
effect None None O
, None None O
preventing None None O
apoptosis None None O
and None None O
inducing None None O
proliferation None None O
. None None O

Direct None None O
and None None O
indirect None None O
signaling None None O
mechanisms None None O
, None None O
including None None O
NF-kappaB None None I-protein
activation None None O
and None None O
cytokine None None O
synthesis None None O
, None None O
were None None O
analyzed None None O
. None None O

RESULTS None None O
: None None O
All None None O
cell None None O
lines None None O
tested None None O
expressed None None O
TNF- None None I-protein
alpha None None I-protein
receptors None None I-protein
I None None I-protein
and None None I-protein
II None None I-protein
and None None O
responded None None O
to None None O
TNF- None None I-protein
alpha None None I-protein
by None None O
upregulation None None O
of None None O
intercellular None None I-protein
adhesion None None I-protein
molecule-1 None None I-protein
. None None O

In None None O
contrast None None O
to None None O
granulocyte-macrophage None None I-protein
colony-stimulating None None I-protein
factor None None I-protein
( None None O
GM-CSF None None I-protein
) None None O
, None None O
TNF- None None I-protein
alpha None None I-protein
did None None O
not None None O
activate None None O
the None None O
MAP None None I-protein
kinase None None I-protein
and None None O
p70S6 None None O
kinase None None O
pathways None None O
. None None O

Nevertheless None None O
, None None O
inhibitors None None O
of None None O
these None None O
pathways None None O
clearly None None O
reduced None None O
the None None O
TNF-alpha None None I-protein
-induced None None O
cell None None O
growth None None O
, None None O
indicating None None O
that None None O
TNF- None None I-cell_type
alpha-proliferative None None I-cell_type
cells None None I-cell_type
produced None None O
a None None O
growth None None O
factor None None O
that None None O
induced None None O
proliferation None None O
upon None None O
stimulation None None O
of None None O
the None None O
above None None O
pathways None None O
. None None O

Anti-GM-CSF None None I-protein
antibodies None None I-protein
inhibited None None O
the None None O
TNF-alpha None None I-protein
-induced None None O
growth None None O
, None None O
suggesting None None O
the None None O
presence None None O
of None None O
an None None O
autocrine None None O
loop None None O
for None None O
cell None None O
proliferation None None O
mediated None None O
by None None O
GM-CSF None None I-protein
. None None O

Supporting None None O
this None None O
notion None None O
, None None O
TNF-alpha None None I-protein
-induced None None O
upregulation None None O
of None None O
GM-CSF None None I-RNA
mRNA None None I-RNA
levels None None O
and None None O
protein None None O
secretion None None O
in None None O
the None None O
TNF-alpha None None I-protein
-proliferative None None O
, None None O
but None None O
not None None O
in None None O
the None None O
TNF-alpha-apoptotic None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
. None None O

CONCLUSION None None O
: None None O
These None None O
data None None O
identify None None O
GM-CSF None None I-protein
synthesis None None O
as None None O
an None None O
early None None O
and None None O
essential None None O
step None None O
in None None O
TNF- None None O
alpha-induced None None O
proliferation None None O
. None None O

We None None O
show None None O
for None None O
the None None O
first None None O
time None None O
that None None O
TNF-alpha-treated None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
producing None None O
no None None O
or None None O
only None None O
minimal None None O
amounts None None O
of None None O
GM-CSF None None I-protein
demonstrate None None O
an None None O
apoptotic None None O
phenotype None None O
, None None O
while None None O
cell None None O
lines None None O
with None None O
high None None O
GM-CSF None None I-protein
expression None None O
rates None None O
can None None O
escape None None O
from None None O
growth None None O
arrest None None O
or None None O
even None None O
apoptosis None None O
. None None O

In None None O
this None None O
context None None O
, None None O
we None None O
discuss None None O
arguments None None O
pointing None None O
at None None O
NF-kappaB None None I-protein
as None None O
regulator None None O
of None None O
GM-CSF None None I-protein
synthesis None None O
and None None O
thus None None O
indirectly None None O
as None None O
regulator None None O
for None None O
the None None O
escape None None O
of None None O
TNF-alpha None None I-protein
-induced None None O
apoptosis None None O

Glucocorticoid None None I-protein
receptor None None I-protein
content None None O
of None None O
T None None I-cell_type
lymphocytes None None I-cell_type
: None None O
evidence None None O
for None None O
heterogeneity None None O
. None None O

Glucocorticoid None None I-protein
receptors None None I-protein
were None None O
measured None None O
in None None O
T None None I-cell_type
lymphocytes None None I-cell_type
that None None O
were None None O
isolated None None O
from None None O
peripheral None None O
blood None None O
by None None O
either None None O
nylon None None O
wool None None O
filtration None None O
or None None O
E-rosette None None O
sedimentation None None O
. None None O

T None None I-cell_type
cells None None I-cell_type
isolated None None O
by None None O
nylon None None O
wool None None O
filtration None None O
specifically None None O
bind None None O
6.7 None None O
+/- None None O
0.2 None None O
fmol None None O
of None None O
dexamethasone None None O
per None None O
million None None O
cells None None O
( None None O
equivalent None None O
to None None O
4000 None None O
+/- None None O
200 None None O
receptors None None O
per None None O
cell None None O
) None None O
, None None O
whereas None None O
T None None I-cell_type
cells None None I-cell_type
isolated None None O
by None None O
E-rosette None None O
sedimentation None None O
bind None None O
12.0 None None O
+/- None None O
0.7 None None O
fmol None None O
of None None O
dexamethasone None None O
per None None O
million None None O
cells None None O
( None None O
equivalent None None O
to None None O
7200 None None O
+/- None None O
400 None None O
receptors None None O
per None None O
cell None None O
) None None O
. None None O

This None None O
difference None None O
in None None O
the None None O
amount None None O
of None None O
dexamethasone None None O
bound None None O
by None None O
the None None O
two None None O
T None None O
cell None None O
preparations None None O
was None None O
significant None None O
( None None O
p None None O
less None None O
than None None O
.001 None None O
) None None O
and None None O
was None None O
present None None O
immediately None None O
after None None O
cell None None O
isolation None None O
. None None O

The None None O
binding None None O
affinities None None O
of None None O
the None None O
different None None O
T None None I-cell_line
cell None None I-cell_line
preparations None None I-cell_line
for None None O
dexamethasone None None O
were None None O
similar None None O
. None None O

T None None O
cells None None O
that None None O
are None None O
isolated None None O
by None None O
a None None O
combination None None O
of None None O
nylon None None O
wool None None O
filtration None None O
followed None None O
by None None O
E-rosette None None O
sedimentation None None O
bind None None O
the None None O
same None None O
amount None None O
of None None O
dexamethasone None None O
as None None O
T None None I-cell_type
cells None None I-cell_type
isolated None None O
by None None O
nylon None None O
wool None None O
filtration None None O
alone None None O
. None None O

T None None I-cell_type
cells None None I-cell_type
isolated None None O
by None None O
a None None O
combination None None O
of None None O
E-rosette None None O
sedimentation None None O
following None None O
by None None O
nylon None None O
wool None None O
filtration None None O
bind None None O
less None None O
dexamethasone None None O
than None None O
do None None O
T None None I-cell_type
cells None None I-cell_type
isolated None None O
by None None O
E-rosette None None O
sedimentation None None O
alone None None O
. None None O

These None None O
findings None None O
suggest None None O
that None None O
T None None I-cell_type
cells None None I-cell_type
are None None O
heterogeneous None None O
with None None O
respect None None O
to None None O
their None None O
quantity None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
. None None O

Isolation None None O
of None None O
T None None I-cell_type
cells None None I-cell_type
by None None O
E-rosette None None O
sedimentation None None O
enriches None None O
for None None O
T None None I-cell_type
cells None None I-cell_type
that None None O
have None None O
a None None O
greater None None O
number None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
, None None O
and None None O
isolation None None O
of None None O
T None None I-cell_type
cells None None I-cell_type
by None None O
nylon None None O
wool None None O
filtration None None O
enriches None None O
for None None O
T None None I-cell_type
cells None None I-cell_type
that None None O
have None None O
a None None O
lesser None None O
number None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
. None None O

Glucocorticoid None None I-protein
receptors None None I-protein
and None None O
glucocorticoid None None O
sensitivity None None O
of None None O
human None None I-cell_type
leukemic None None I-cell_type
cells None None I-cell_type
. None None O

We None None O
have None None O
established None None O
optimal None None O
conditions None None O
for None None O
the None None O
measurement None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
( None None O
GR None None I-protein
) None None O
in None None O
human None None I-cell_type
white None None I-cell_type
cells None None I-cell_type
using None None O
a None None O
whole-cell None None O
binding None None O
assay None None O
with None None O
[ None None O
3H None None O
] None None O
dexamethasone None None O
as None None O
the None None O
ligand None None O
, None None O
and None None O
the None None O
subsequent None None O
determination None None O
of None None O
the None None O
GR None None I-protein
content None None O
in None None O
normal None None I-cell_type
human None None I-cell_type
lymphocytes None None I-cell_type
and None None O
in None None O
leukemic None None I-cell_type
cells None None I-cell_type
of None None O
patients None None O
with None None O
various None None O
forms None None O
of None None O
acute None None O
and None None O
chronic None None O
leukemia None None O
. None None O

A None None O
number None None O
of None None O
leukemia None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
in None None O
continuous None None O
culture None None O
were None None O
also None None O
subjected None None O
to None None O
the None None O
GR None None I-protein
assay None None O
, None None O
and None None O
the None None O
results None None O
were None None O
correlated None None O
with None None O
the None None O
sensitivity None None O
of None None O
these None None O
cell None None I-cell_line
lines None None I-cell_line
to None None O
glucocorticoid None None O
steroids None None O
in None None O
vitro None None O
. None None O

The None None O
GR None None I-protein
content None None O
of None None O
normal None None I-cell_type
human None None I-cell_type
lymphocytes None None I-cell_type
amounted None None O
to None None O
4 None None O
, None None O
850 None None O
+/- None None O
1 None None O
, None None O
340 None None O
( None None O
mean None None O
+/- None None O
SD None None O
) None None O
receptors/cell None None O
. None None O

The None None O
mean None None O
equilibrium None None O
dissociation None None O
constant None None O
( None None O
KD None None O
) None None O
of None None O
the None None O
interaction None None O
of None None O
[ None None O
3H None None O
] None None O
dexamethasone None None O
with None None O
the None None O
GR None None I-protein
was None None O
1.2 None None O
x None None O
10 None None O
( None None O
-8 None None O
) None None O
M None None O
. None None O

Steroidal None None O
compounds None None O
with None None O
a None None O
known None None O
glucocorticoid None None O
potency None None O
effectively None None O
competed None None O
for None None O
the None None O
binding None None O
, None None O
whereas None None O
steroids None None O
devoid None None O
of None None O
glucocorticoid None None O
activity None None O
( None None O
e.g. None None O
estradiol-17 None None O
beta None None O
and None None O
testosterone None None O
) None None O
were None None O
ineffective None None O
. None None O

The None None O
GR None None I-protein
content None None O
of None None O
the None None O
blast None None I-cell_type
cells None None I-cell_type
obtained None None O
from None None O
eight None None O
patients None None O
suffering None None O
from None None O
acute None None O
leukemia None None O
and None None O
four None None O
patients None None O
with None None O
a None None O
blast None None O
crisis None None O
of None None O
chronic None None O
myelocytic None None O
leukemia None None O
was None None O
found None None O
to None None O
be None None O
highly None None O
variable None None O
( None None O
3 None None O
, None None O
230-29 None None O
, None None O
900 None None O
receptors/cell None None O
) None None O
, None None O
while None None O
the None None O
lymphocytes None None I-cell_type
of None None O
six None None O
patients None None O
with None None O
chronic None None O
lymphatic None None O
leukemia None None O
contained None None O
a None None O
rather None None O
stable None None O
GR None None I-protein
content None None O
( None None O
2 None None O
, None None O
930-5 None None O
, None None O
120 None None O
receptors/cell None None O
) None None O
, None None O
which None None O
was None None O
comparable None None O
with None None O
that None None O
of None None O
normal None None I-cell_type
lymphocytes None None I-cell_type
. None None O

GR None None I-protein
was None None O
identified None None O
in None None O
all None None O
the None None O
12 None None O
malignant None None I-cell_line
continuous None None I-cell_line
white None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
studied None None O
. None None O

Large None None O
cells None None O
contained None None O
more None None O
GR None None I-protein
than None None O
the None None O
smaller None None O
ones None None O
. None None O

There None None O
was None None O
no None None O
apparent None None O
correlation None None O
between None None O
the None None O
GR None None I-protein
concentration None None O
and None None O
the None None O
sensitivity None None O
of None None O
the None None O
cells None None O
in None None O
vitro None None O
to None None O
glucocorticoids None None O
as None None O
judged None None O
by None None O
[ None None O
3H None None O
] None None O
thymidine None None O
incorporation None None O
studies None None O
. None None O

Distribution None None O
of None None O
the None None O
surface None None O
markers None None O
in None None O
the None None O
leukemic None None I-cell_line
cell None None I-cell_line
lines None None I-cell_line
did None None O
not None None O
relate None None O
to None None O
the None None O
GR None None I-protein
concentration None None O
. None None O

We None None O
conclude None None O
that None None O
the None None O
presence None None O
of None None O
GR None None I-protein
is None None O
probably None None O
a None None O
universal None None O
feature None None O
of None None O
the None None O
leukemic None None I-cell_type
cells None None I-cell_type
, None None O
and None None O
, None None O
from None None O
a None None O
clinical None None O
standpoint None None O
, None None O
probably None None O
does None None O
not None None O
alone None None O
imply None None O
steroid None None O
responsiveness None None O
. None None O

Evidence None None O
for None None O
a None None O
steroid None None I-protein
receptor None None I-protein
in None None O
rheumatoid None None I-cell_type
synovial None None I-cell_type
tissue None None I-cell_type
cells None None I-cell_type
. None None O

One None None O
mechanism None None O
by None None O
which None None O
glucocorticoids None None O
could None None O
exert None None O
their None None O
anti-inflammatory None None O
action None None O
is None None O
via None None O
rapidly None None O
saturable None None O
, None None O
stereo-specific None None I-protein
cytoplasmic None None I-protein
protein None None I-protein
receptors None None I-protein
. None None O

This None None O
report None None O
is None None O
of None None O
an None None O
investigation None None O
into None None O
such None None O
a None None O
possibility None None O
in None None O
synovial None None I-cell_type
cells None None I-cell_type
. None None O

Synovium None None O
, None None O
obtained None None O
from None None O
knee None None O
joints None None O
of None None O
rheumatoid None None O
patients None None O
undergoing None None O
surgery None None O
, None None O
was None None O
incubated None None O
with None None O
clostridiopeptidase None None I-protein
A None None I-protein
and None None O
trypsin-EDTA None None I-protein
to None None O
obtain None None O
cell None None O
suspensions None None O
. None None O

These None None O
, None None O
together None None O
with None None O
cells None None O
obtained None None O
from None None O
synovial None None O
fluid None None O
aspirated None None O
from None None O
patients None None O
with None None O
rheumatoid None None O
arthritis None None O
, None None O
were None None O
identified None None O
by None None O
electron None None O
microscopy None None O
. None None O

Duplicate None None O
samples None None O
of None None O
these None None O
cell None None O
suspensions None None O
were None None O
incubated None None O
with None None O
increasing None None O
concentrations None None O
of None None O
H3Dexamethasone None None O
( None None O
1 None None O
x None None O
10 None None O
( None None O
-10 None None O
) None None O
M-1 None None O
x None None O
10 None None O
( None None O
-9 None None O
) None None O
M None None O
) None None O
for None None O
30 None None O
minutes None None O
at None None O
37 None None O
degrees None None O
C None None O
. None None O

Analysis None None O
of None None O
the None None O
proportion None None O
of None None O
steroid None None O
bound None None O
to None None O
whole None None I-cell_type
cells None None I-cell_type
showed None None O
evidence None None O
for None None O
specific None None O
, None None O
rapidly None None O
saturable None None O
, None None O
receptors None None O
in None None O
the None None O
cells None None O
obtained None None O
from None None O
synovial None None O
tissue None None O
, None None O
but None None O
this None None O
was None None O
not None None O
found None None O
in None None O
synovial None None I-cell_type
fluid None None I-cell_type
cells None None I-cell_type
. None None O

Electron None None O
micrographs None None O
showed None None O
that None None O
cells None None O
obtained None None O
from None None O
synovial None None O
tissue None None O
consisted None None O
of None None O
synovial None None I-cell_type
fibroblast None None I-cell_type
- None None O
and None None O
macrophage-types None None I-cell_type
, None None O
lymphocytes None None I-cell_type
, None None O
monocytes None None I-cell_type
and None None O
macrophages None None I-cell_type
. None None O

Polymorphonuclear None None I-cell_type
leucocytes None None I-cell_type
appeared None None O
to None None O
be None None O
absent None None O
. None None O

However None None O
, None None O
in None None O
synovial None None I-cell_type
fluid None None I-cell_type
cell None None I-cell_type
type None None I-cell_type
polymorphonuclear None None I-cell_type
leucocytes None None I-cell_type
were None None O
the None None O
predominant None None O
cell None None O
type None None O
. None None O

We None None O
concluded None None O
from None None O
this None None O
, None None O
that None None O
one None None O
or None None O
more None None O
of None None O
the None None O
cell None None O
types None None O
present None None O
in None None O
synovial None None O
tissue None None O
contain None None O
a None None O
specific None None I-protein
steroid None None I-protein
receptor None None I-protein
, None None O
but None None O
that None None O
this None None O
is None None O
lacking None None O
in None None O
synovial None None I-cell_type
fluid None None I-cell_type
polymorphonuclear None None I-cell_type
leucocytes None None I-cell_type
. None None O

Clinical None None O
implications None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
human None None O
leukemia None None O
. None None O

Glucorticoid None None I-protein
receptors None None I-protein
were None None O
studied None None O
in None None O
various None None O
populations None None O
of None None O
normal None None O
human None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
lymphocytes None None I-cell_type
and None None O
leukemic None None I-cell_type
lymphoblasts None None I-cell_type
. None None O

Normal None None I-cell_type
lymphocytes None None I-cell_type
contain None None O
low None None O
levels None None O
of None None O
glucocorticoid None None I-protein
receptor None None I-protein
( None None O
approximately None None O
2 None None O
, None None O
500 None None O
sites/cell None None O
) None None O
which None None O
are None None O
identical None None O
in None None O
T- None None O
and None None O
non-T-fractions None None O
. None None O

Phytohemagglutinin None None I-protein
treatment None None O
increases None None O
levels None None O
about None None O
3-fold None None O
. None None O

Leukemic None None I-cell_type
lymphoblasts None None I-cell_type
contain None None O
larger None None O
numbers None None O
of None None O
receptor None None O
sites None None O
. None None O

Presence None None O
of None None O
receptor None None O
is None None O
correlated None None O
with None None O
in None None O
vitro None None O
sensitivitiy None None O
to None None O
glucocorticoids None None O
and None None O
in None None O
vivo None None O
response None None O
to None None O
therapy None None O
. None None O

Quantity None None O
of None None O
receptor None None O
is None None O
also None None O
correlated None None O
with None None O
complete None None O
remission None None O
duration None None O
independently None None O
of None None O
leukemic None None I-cell_type
cell None None I-cell_type
type None None I-cell_type
( None None O
T None None O
or None None O
null None None O
) None None O
, None None O
initial None None O
WBC None None I-cell_type
, None None O
or None None O
age None None O
of None None O
patient None None O
. None None O

Quantitative None None O
determination None None O
of None None O
glucocorticoid None None I-protein
receptor None None I-protein
levels None None O
in None None O
acute None None O
lymphoblastic None None O
leukemia None None O
may None None O
be None None O
of None None O
value None None O
both None None O
as None None O
an None None O
independent None None O
prognostic None None O
variable None None O
and None None O
in None None O
suggesting None None O
which None None O
patients None None O
should None None O
receive None None O
glucocorticoid None None O
therapy None None O
. None None O

Functional None None O
and None None O
physical None None O
interaction None None O
of None None O
protein-tyrosine None None I-protein
kinases None None I-protein
Fyn None None I-protein
and None None I-protein
Csk None None I-protein
in None None O
the None None O
T-cell None None O
signaling None None O
system None None O
. None None O

The None None O
Src-like None None I-protein
protein-tyrosine None None I-protein
kinase None None I-protein
Fyn None None B-protein
is None None O
associated None None O
with None None O
T-cell None None I-protein
antigen None None I-protein
receptor None None I-protein
. None None O

Transient None None O
expression None None O
of None None O
actively None None O
mutated None None O
Fyn None None I-protein
, None None O
having None None O
Phe-528 None None O
instead None None O
of None None O
Tyr-528 None None O
or None None O
Thr-338 None None O
instead None None O
of None None O
Ile-338 None None O
, None None O
in None None O
Jurkat None None I-cell_type
T-cells None None I-cell_type
stimulated None None I-DNA
the None None I-DNA
serum None None I-DNA
response None None I-DNA
element None None I-DNA
( None None O
SRE None None I-DNA
) None None O
, None None O
12-O-tetradecanoyl-phorbol-13-acetate None None I-DNA
response None None I-DNA
element None None I-DNA
, None None O
cyclic None None I-DNA
AMP None None I-DNA
response None None I-DNA
element None None I-DNA
, None None O
and None None O
c-fos None None I-DNA
promoter None None I-DNA
. None None O

The None None O
stimulation None None O
of None None O
SRE None None I-DNA
was None None O
particularly None None O
prominent None None O
not None None O
only None None O
with None None O
active None None O
Fyn None None I-protein
but None None O
also None None O
with None None O
normal None None I-protein
( None None I-protein
wild-type None None I-protein
) None None I-protein
Fyn None None I-protein
. None None O

SRE None None I-DNA
was None None O
also None None O
stimulated None None O
by None None O
both None None O
normal None None I-protein
and None None I-protein
active None None I-protein
Lck None None I-protein
. None None O

Furthermore None None O
, None None O
normal None None I-protein
and None None I-protein
active None None I-protein
Fyn None None I-protein
stimulated None None O
transcription None None O
from None None O
the None None O
IL-2 None None I-DNA
gene None None I-DNA
promoter None None I-DNA
when None None O
transfected None None O
cells None None O
were None None O
stimulated None None O
by None None O
concanavalin None None I-protein
A None None I-protein
plus None None O
12-O-tetradecanoylphorbol-13-acetate None None O
. None None O

Under None None O
the None None O
same None None O
conditions None None O
, None None O
Lck None None I-protein
did None None O
not None None O
stimulate None None O
IL-2 None None I-DNA
promoter None None I-DNA
unless None None O
it None None O
was None None O
activated None None O
by None None O
mutation None None O
. None None O

Interestingly None None O
, None None O
a None None O
mutant None None I-protein
Fyn None None I-protein
, None None O
which None None O
has None None O
deletions None None O
within None None O
the None None O
SH2 None None I-protein
region None None I-protein
and None None O
so None None O
is None None O
able None None O
to None None O
transform None None O
chicken None None I-cell_type
embryo None None I-cell_type
fibroblasts None None I-cell_type
, None None O
did None None O
not None None O
stimulate None None O
either None None O
the None None O
c-fos None None I-DNA
or None None I-DNA
IL-2 None None I-DNA
promoter None None I-DNA
, None None O
suggesting None None O
the None None O
importance None None O
of None None O
this None None O
region None None O
in None None O
T-cell None None I-cell_type
signaling None None O
. None None O

Csk None None I-protein
, None None O
which None None O
phosphorylates None None O
tyrosine None None O
residues None None O
in None None O
the None None O
negative None None O
regulatory None None O
sites None None O
of None None O
Src None None I-protein
family None None I-protein
kinases None None I-protein
, None None O
down-regulated None None O
Fyn- None None O
and None None O
Lck-mediated None None O
stimulation None None O
of None None O
the None None O
serum None None I-DNA
response None None I-DNA
element None None I-DNA
and None None O
Fyn-mediated None None O
enhancement None None O
of None None O
IL-2 None None I-DNA
promoter None None I-DNA
activity None None O
. None None O

These None None O
data None None O
suggest None None O
that None None O
Fyn None None I-protein
and None None O
Lck None None I-protein
, None None O
whose None None O
activities None None O
are None None O
regulated None None O
by None None O
Csk None None I-protein
, None None O
are None None O
involved None None O
in None None O
different None None O
phases None None O
of None None O
T-cell None None I-cell_type
activation None None O
. None None O

A None None O
novel None None O
NF-kappa None None I-protein
B None None I-protein
complex None None I-protein
containing None None O
p65 None None I-protein
homodimers None None I-protein
: None None O
implications None None O
for None None O
transcriptional None None O
control None None O
at None None O
the None None O
level None None O
of None None O
subunit None None O
dimerization None None O
. None None O

The None None O
predominant None None O
inducible None None O
form None None O
of None None O
the None None O
NF-kappa None None I-protein
B None None I-protein
transcription None None I-protein
factor None None I-protein
is None None O
a None None O
heteromeric None None I-protein
complex None None I-protein
containing None None O
two None None O
Rel-related None None I-protein
DNA-binding None None I-protein
subunits None None I-protein
, None None O
termed None None I-protein
p65 None None I-protein
and None None O
p50 None None I-protein
. None None O

Prior None None O
transfection None None O
studies None None O
have None None O
shown None None O
that None None O
when None None O
these None None O
p65 None None I-protein
and None None I-protein
p50 None None I-protein
subunits None None I-protein
are None None O
expressed None None O
independently None None O
as None None O
stable None None I-protein
homodimers None None I-protein
, None None O
p65 None None I-protein
stimulates None None O
kappa None None O
B-directed None None O
transcription None None O
, None None O
whereas None None O
p50 None None I-protein
functions None None O
as None None O
a None None O
kappa None None O
B-specific None None O
repressor None None O
. None None O

While None None O
authentic None None O
p50 None None I-protein
homodimers None None I-protein
( None None O
previously None None O
termed None None O
KBF1 None None I-protein
) None None O
have None None O
been None None O
detected None None O
in None None O
nuclear None None O
extracts None None O
from None None O
nontransfected None None O
cells None None O
, None None O
experimental None None O
evidence None None O
supporting None None O
the None None O
existence None None O
of None None O
p65 None None I-protein
homodimers None None I-protein
in None None O
vivo None None O
was None None O
lacking None None O
. None None O

We None None O
now None None O
provide None None O
direct None None O
biochemical None None O
evidence None None O
for None None O
the None None O
presence None None O
of None None O
an None None O
endogenous None None O
pool None None O
of None None O
inducible None None O
p65 None None I-protein
homodimers None None I-protein
in None None O
intact None None O
human None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

As None None O
with None None O
the None None O
prototypical None None O
NF-kappa None None I-protein
B None None I-protein
p50-p65 None None I-protein
heterodimer None None I-protein
, None None O
this None None O
novel None None O
p65 None None I-protein
homodimeric None None I-protein
form None None I-protein
of None None O
NF-kappa None None I-protein
B None None I-protein
is None None O
functionally None None O
sequestered None None O
in None None O
the None None O
cytoplasm None None O
but None None O
rapidly None None O
appears None None O
in None None O
the None None O
nuclear None None O
compartment None None O
following None None O
cellular None None O
stimulation None None O
. None None O

Site-directed None None O
mutagenesis None None O
studies None None O
indicate None None O
that None None O
the None None O
homodimerization None None O
function None None O
of None None O
p65 None None I-protein
is None None O
dependent None None O
upon None None O
the None None O
presence None None O
of None None O
cysteine None None O
216 None None O
and None None O
a None None O
conserved None None O
recognition None None O
motif None None O
for None None O
protein None None I-protein
kinase None None I-protein
A None None I-protein
( None None O
RRPS None None I-protein
; None None O
amino None None O
acids None None O
273 None None O
to None None O
276 None None O
) None None O
, None None O
both None None O
of None None O
which None None O
reside None None O
within None None O
a None None O
91-amino-acid None None O
segment None None O
of None None O
the None None O
Rel None None I-protein
homology None None I-protein
domain None None I-protein
that None None O
mediates None None O
self-association None None O
. None None O

In None None O
contrast None None O
, None None O
mutations None None O
at None None O
these None None O
two None None O
sites None None O
do None None O
not None None O
affect None None O
heterodimerization None None O
of None None O
p65 None None I-protein
with None None O
p50 None None I-protein
or None None O
its None None O
functional None None O
interaction None None O
with None None O
I None None O
kappa None None O
B None None O
alpha None None O
. None None O

These None None O
later None None O
findings None None O
indicate None None O
that None None O
neither None None O
homo- None None O
nor None None O
heterodimer None None O
formation None None O
is None None O
an None None O
absolute None None O
prerequisite None None O
for None None O
I None None I-protein
kappa None None I-protein
B None None I-protein
alpha None None I-protein
recognition None None O
of None None O
p65 None None I-protein
. None None O

Taken None None O
together None None O
with None None O
prior None None O
in None None O
vivo None None O
transcription None None O
studies None None O
, None None O
these None None O
results None None O
suggest None None O
that None None O
the None None O
biological None None O
activities None None O
of None None O
p65 None None I-protein
and None None I-protein
p50 None None I-protein
homodimers None None I-protein
are None None O
independently None None O
regulated None None O
, None None O
thereby None None O
providing None None O
an None None O
integrated None None O
and None None O
flexible None None O
control None None O
mechanism None None O
for None None O
the None None O
rapid None None O
activation None None O
and None None O
repression None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
/ None None O
Rel None None I-protein
-directed None None O
gene None None O
expression None None O
. None None O

Carrier None None O
determination None None O
for None None O
X-linked None None O
agammaglobulinemia None None O
using None None O
X None None O
inactivation None None O
analysis None None O
of None None O
purified None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
. None None O

We None None O
report None None O
the None None O
development None None O
of None None O
a None None O
relatively None None O
quick None None O
and None None O
simple None None O
method None None O
for None None O
the None None O
assessment None None O
of None None O
X None None O
inactivation None None O
status None None O
for None None O
carrier None None O
determination None None O
in None None O
families None None O
affected None None O
by None None O
X-linked None None O
agammaglobulinemia None None O
( None None O
XLA None None O
) None None O
. None None O

This None None O
method None None O
utilises None None O
an None None O
immunomagnetic None None O
separation None None O
technique None None O
for None None O
B None None I-cell_type
cell None None I-cell_type
purification None None O
and None None O
a None None O
polymerase None None O
chain None None O
reaction None None O
( None None O
PCR None None O
) None None O
based None None O
assay None None O
for None None O
the None None O
determination None None O
of None None O
methylation None None O
status None None O
at None None O
the None None O
androgen None None I-DNA
receptor None None I-DNA
( None None I-DNA
AR None None I-DNA
) None None I-DNA
gene None None I-DNA
locus None None I-DNA
to None None O
assess None None O
whether None None O
X None None O
inactivation None None O
is None None O
random None None O
or None None O
non-random None None O
at None None O
this None None O
locus None None O
. None None O

We None None O
report None None O
the None None O
results None None O
we None None O
have None None O
obtained None None O
using None None O
this None None O
assay None None O
to None None O
investigate None None O
females None None O
known None None O
to None None O
be None None O
carriers None None O
of None None O
various None None O
X-linked None None O
immunodeficiency None None O
disorders None None O
. None None O

In None None O
addition None None O
, None None O
we None None O
investigated None None O
four None None O
females None None O
from None None O
different None None O
families None None O
affected None None O
by None None O
XLA None None O
, None None O
two None None O
of None None O
whom None None O
were None None O
of None None O
unknown None None O
carrier None None O
status None None O
, None None O
and None None O
we None None O
discuss None None O
the None None O
results None None O
obtained None None O
with None None O
this None None O
and None None O
other None None O
X-inactivation None None O
assays None None O
. None None O

A None None O
similar None None O
assay None None O
has None None O
recently None None O
been None None O
described None None O
by None None O
Allen None None O
et None None O
al. None None O
( None None O
1992 None None O
) None None O
and None None O
applied None None O
to None None O
members None None O
of None None O
one None None O
family None None O
affected None None O
by None None O
XLA None None O
. None None O

Effects None None O
of None None O
IL-4 None None I-protein
and None None O
Fc None None I-protein
gamma None None I-protein
receptor None None I-protein
II None None I-protein
engagement None None O
on None None O
Egr-1 None None I-protein
expression None None O
during None None O
stimulation None None O
of None None O
B None None I-cell_type
lymphocytes None None I-cell_type
by None None O
membrane None None O
immunoglobulin None None O
crosslinking None None O
. None None O

Egr-1 None None I-DNA
is None None O
an None None O
immediate None None I-DNA
early None None I-DNA
gene None None I-DNA
that None None O
is None None O
rapidly None None O
upregulated None None O
in None None O
response None None O
to None None O
mitogenic None None O
signals None None O
induced None None O
by None None O
antigen None None O
receptor None None O
crosslinking None None O
on None None O
murine None None I-cell_type
B None None I-cell_type
lymphocytes None None I-cell_type
. None None O

It None None O
has None None O
been None None O
shown None None O
that None None O
levels None None O
of None None O
Egr-1 None None I-DNA
expression None None O
are None None O
closely None None O
correlated None None O
with None None O
B None None I-cell_type
cell None None I-cell_type
proliferation None None O
in None None O
several None None O
models None None O
of None None O
B None None O
cell None None O
activation None None O
and None None O
tolerance None None O
. None None O

We None None O
compared None None O
the None None O
expression None None O
of None None O
Egr-1 None None I-DNA
during None None O
B None None O
cell None None O
stimulation None None O
with None None O
Fab'2 None None I-protein
and None None O
IgG None None I-protein
anti-immunoglobulin None None I-protein
( None None O
anti-Ig None None I-protein
) None None O
, None None O
since None None O
it None None O
is None None O
known None None O
that None None O
Fab'2 None None I-protein
anti-Ig None None I-protein
is None None O
mitogenic None None O
while None None O
IgG None None I-protein
anti-Ig None None I-protein
is None None O
not None None O
, None None O
owing None None O
to None None O
a None None O
dominant None None O
inhibitory None None O
effect None None O
of None None O
crosslinking None None O
the None None O
B None None I-protein
cell None None I-protein
Fc None None I-protein
gamma None None I-protein
RII None None I-protein
to None None O
membrane None None I-protein
Ig None None I-protein
. None None O

While None None O
mitogenic None None O
doses None None O
of None None O
Fab'2 None None I-protein
anti-Ig None None I-protein
induce None None O
large None None O
and None None O
rapid None None O
increases None None O
in None None O
Egr-1 None None O
expression None None O
, None None O
IgG None None I-protein
anti-Ig None None I-protein
results None None O
in None None O
smaller None None O
increases None None O
in None None O
Egr-1 None None I-RNA
mRNA None None I-RNA
, None None O
comparable None None O
to None None O
that None None O
seen None None O
with None None O
submitogenic None None O
concentrations None None O
of None None O
Fab'2 None None I-protein
anti-Ig None None I-protein
. None None O

However None None O
, None None O
the None None O
correlation None None O
between None None O
Egr-1 None None O
expression None None O
and None None O
B None None O
cell None None O
proliferation None None O
breaks None None O
down None None O
when None None O
IL-4 None None I-protein
is None None O
added None None O
as None None O
a None None O
co-mitogen None None O
to None None O
induce None None O
B None None O
cell None None O
proliferation None None O
with None None O
IgG None None I-protein
anti-Ig None None I-protein
or None None O
submitogenic None None O
concentrations None None O
of None None O
Fab'2 None None I-protein
anti-Ig None None I-protein
. None None O

No None None O
corresponding None None O
increases None None O
in None None O
Egr-1 None None I-RNA
mRNA None None I-RNA
levels None None O
are None None O
observed None None O
when None None O
IL-4 None None I-protein
is None None O
added None None O
. None None O

Therefore None None O
, None None O
IL-4 None None I-protein
overcomes None None O
Fc None None O
receptor-mediated None None O
inhibition None None O
of None None O
B None None I-cell_type
cell None None I-cell_type
proliferation None None O
without None None O
affecting None None O
inhibition None None O
of None None O
Egr-1 None None I-RNA
mRNA None None I-RNA
induction None None O
, None None O
as None None O
demonstrated None None O
earlier None None O
for None None O
c-myc None None I-RNA
mRNA None None I-RNA
in None None O
this None None O
system None None O
. None None O

Identification None None O
of None None O
a None None O
novel None None O
cyclosporin-sensitive None None I-DNA
element None None I-DNA
in None None O
the None None O
human None None I-DNA
tumor None None I-DNA
necrosis None None I-DNA
factor None None I-DNA
alpha None None I-DNA
gene None None I-DNA
promoter None None I-DNA
. None None O

Tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
alpha None None I-protein
( None None O
TNF-alpha None None I-protein
) None None O
, None None O
a None None O
cytokine None None I-protein
with None None O
pleiotropic None None O
biological None None O
effects None None O
, None None O
is None None O
produced None None O
by None None O
a None None O
variety None None O
of None None O
cell None None O
types None None O
in None None O
response None None O
to None None O
induction None None O
by None None O
diverse None None O
stimuli None None O
. None None O

In None None O
this None None O
paper None None O
, None None O
TNF-alpha None None I-RNA
mRNA None None I-RNA
is None None O
shown None None O
to None None O
be None None O
highly None None O
induced None None O
in None None O
a None None O
murine None None I-cell_line
T None None I-cell_line
cell None None I-cell_line
clone None None I-cell_line
by None None O
stimulation None None O
with None None O
T None None I-protein
cell None None I-protein
receptor None None I-protein
( None None O
TCR None None I-protein
) None None O
ligands None None O
or None None O
by None None O
calcium None None O
ionophores None None O
alone None None O
. None None O

Induction None None O
is None None O
rapid None None O
, None None O
does None None O
not None None O
require None None O
de None None O
novo None None O
protein None None O
synthesis None None O
, None None O
and None None O
is None None O
completely None None O
blocked None None O
by None None O
the None None O
immunosuppressant None None O
cyclosporin None None O
A None None O
( None None O
CsA None None O
) None None O
. None None O

We None None O
have None None O
identified None None O
a None None O
human None None I-DNA
TNF-alpha None None I-DNA
promoter None None I-DNA
element None None I-DNA
, None None O
kappa None None I-DNA
3 None None I-DNA
, None None O
which None None O
plays None None O
a None None O
key None None O
role None None O
in None None O
the None None O
calcium-mediated None None O
inducibility None None O
and None None O
CsA None None O
sensitivity None None O
of None None O
the None None O
gene None None O
. None None O

In None None O
electrophoretic None None O
mobility None None O
shift None None O
assays None None O
, None None O
an None None O
oligonucleotide None None O
containing None None O
kappa None None I-DNA
3 None None I-DNA
forms None None O
two None None O
DNA None None O
protein None None O
complexes None None O
with None None O
proteins None None O
that None None O
are None None O
present None None O
in None None O
extracts None None O
from None None O
unstimulated None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

These None None O
complexes None None O
appear None None O
in None None O
nuclear None None O
extracts None None O
only None None O
after None None O
T None None O
cell None None O
stimulation None None O
. None None O

Induction None None O
of None None O
the None None O
inducible None None O
nuclear None None I-protein
complexes None None I-protein
is None None O
rapid None None O
, None None O
independent None None O
of None None O
protein None None O
synthesis None None O
, None None O
and None None O
blocked None None O
by None None O
CsA None None O
, None None O
and None None O
thus None None O
, None None O
exactly None None O
parallels None None O
the None None O
induction None None O
of None None O
TNF-alpha None None I-RNA
mRNA None None I-RNA
by None None O
TCR None None O
ligands None None O
or None None O
by None None O
calcium None None O
ionophore None None O
. None None O

Our None None O
studies None None O
indicate None None O
that None None O
the None None O
kappa None None I-protein
3 None None I-protein
binding None None I-protein
factor None None I-protein
resembles None None O
the None None O
preexisting None None O
component None None O
of None None O
nuclear None None I-protein
factor None None I-protein
of None None O
activated None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

Thus None None O
, None None O
the None None O
TNF-alpha None None I-DNA
gene None None I-DNA
is None None O
an None None O
immediate None None O
early None None O
gene None None O
in None None O
activated None None O
T None None I-cell_type
cells None None I-cell_type
and None None O
provides None None O
a None None O
new None None O
model None None O
system None None O
in None None O
which None None O
to None None O
study None None O
CsA-sensitive None None I-DNA
gene None None I-DNA
induction None None O
in None None O
activated None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
. None None O

Differences None None O
in None None O
expression None None O
of None None O
transcription None None I-protein
factor None None I-protein
AP-1 None None I-protein
in None None O
human None None I-cell_line
promyelocytic None None I-cell_line
HL-60 None None I-cell_line
cells None None I-cell_line
during None None O
differentiation None None O
towards None None O
macrophages None None I-cell_type
versus None None O
granulocytes None None I-cell_type
. None None O

Commitment None None O
of None None O
HL-60 None None I-cell_line
cells None None I-cell_line
to None None O
macrophage None None O
or None None O
granulocytic None None O
differentiation None None O
was None None O
achieved None None O
by None None O
incubation None None O
with None None O
4 None None O
beta-phorbol None None O
12-myristate None None O
13-acetate None None O
( None None O
PMA None None O
) None None O
for None None O
30-60 None None O
min None None O
or None None O
with None None O
dimethyl None None O
sulphoxide None None O
( None None O
DMSO None None O
) None None O
for None None O
24 None None O
h None None O
respectively None None O
. None None O

The None None O
commitment None None O
stage None None O
towards None None O
PMA-induced None None O
macrophage None None O
differentiation None None O
was None None O
associated None None O
with None None O
increases None None O
in None None O
jun None None O
B None None O
and None None O
c-fos None None O
mRNA None None O
levels None None O
, None None O
as None None O
well None None O
as None None O
with None None O
an None None O
increase None None O
in None None O
the None None O
binding None None O
activity None None O
of None None O
transcription None None I-protein
factor None None I-protein
AP-1 None None I-protein
. None None O

Nevertheless None None O
, None None O
gel None None O
retardation None None O
analysis None None O
indicated None None O
that None None O
the None None O
AP-1 None None I-protein
activity None None O
detected None None O
in None None O
untreated None None O
cells None None O
was None None O
drastically None None O
reduced None None O
during None None O
the None None O
commitment None None O
stage None None O
of None None O
DMSO-induced None None O
HL-60 None None O
differentiation None None O
towards None None O
granulocytes None None I-cell_type
. None None O

When None None O
HL-60 None None I-cell_line
cells None None I-cell_line
were None None O
treated None None O
with None None O
sodium None None O
butyrate None None O
, None None O
which None None O
induced None None O
monocytic None None O
differentiation None None O
, None None O
a None None O
remarkable None None O
increase None None O
in None None O
AP-1 None None O
binding None None O
activity None None O
was None None O
detected None None O
. None None O

Treatment None None O
of None None O
HL-60 None None I-cell_line
cells None None I-cell_line
with None None O
1 None None O
alpha None None O
, None None O
25-dihydroxyvitamin None None O
D3 None None O
, None None O
another None None O
monocytic None None O
differentiation None None O
agent None None O
, None None O
induced None None O
a None None O
weak None None O
, None None O
but None None O
appreciable None None O
, None None O
increase None None O
in None None O
AP-1 None None I-protein
activity None None O
. None None O

Furthermore None None O
, None None O
addition None None O
of None None O
sodium None None O
butyrate None None O
or None None O
1 None None O
alpha None None O
, None None O
25-dihydroxyvitamin None None O
D3 None None O
to None None O
HL-60 None None I-cell_line
cells None None I-cell_line
induced None None O
the None None O
expression None None O
of None None O
c-fos None None I-DNA
, None None I-DNA
c-jun None None I-DNA
, None None I-DNA
jun None None I-DNA
B None None I-DNA
and None None I-DNA
jun None None I-DNA
D None None I-DNA
proto-oncogenes None None I-DNA
. None None O

In None None O
contrast None None O
, None None O
when None None O
HL-60 None None I-cell_line
cells None None I-cell_line
were None None O
treated None None O
with None None O
retinoic None None O
acid None None O
, None None O
a None None O
granulocytic None None O
differentiation None None O
inducer None None O
, None None O
no None None O
enhanced None None O
AP-1 None None O
binding None None O
activity None None O
was None None O
observed None None O
, None None O
and None None O
only None None O
a None None O
weak None None O
increase None None O
in None None O
jun None None I-RNA
D None None I-RNA
mRNA None None I-RNA
level None None O
was None None O
detected None None O
. None None O

These None None O
data None None O
indicate None None O
that None None O
formation None None O
of None None O
AP-1 None None I-protein
is None None O
not None None O
required None None O
for None None O
the None None O
induction None None O
of None None O
HL-60 None None I-cell_line
differentiation None None O
towards None None O
granulocytes None None I-cell_type
, None None O
whereas None None O
induction None None O
of None None O
monocytic None None O
differentiation None None O
is None None O
correlated None None O
with None None O
an None None O
increase None None O
in None None O
AP-1 None None I-protein
activity None None O
. None None O

The None None O
differential None None O
expression None None O
of None None O
AP-1 None None I-protein
activity None None O
may None None O
be None None O
critical None None O
in None None O
the None None O
differentiation None None O
of None None O
HL-60 None None I-cell_line
cells None None I-cell_line
towards None None O
monocytic None None I-cell_type
or None None I-cell_type
granulocytic None None I-cell_type
lineages None None I-cell_type

Glucocorticoid None None I-protein
receptors None None I-protein
and None None O
sensitivity None None O
in None None O
leukemias None None O
. None None O

In None None O
an None None O
attempt None None O
to None None O
investigate None None O
the None None O
utility None None O
of None None O
glucocorticoid None None I-protein
receptor None None I-protein
determination None None O
to None None O
predict None None O
clinical None None O
responsiveness None None O
in None None O
human None None O
leukemias None None O
we None None O
have None None O
studied None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
the None None O
leukemic None None I-cell_type
cells None None I-cell_type
from None None O
46 None None O
patients None None O
and None None O
in None None O
the None None O
lymphocytes None None I-cell_type
from None None O
18 None None O
normal None None O
donors None None O
. None None O

In None None O
the None None O
normal None None I-cell_type
lymphocytes None None I-cell_type
there None None O
were None None O
3 None None O
, None None O
875 None None O
( None None O
Median None None O
) None None O
specific None None O
binding None None O
sites None None O
per None None O
cell None None O
. None None O

The None None O
blasts None None I-cell_type
from None None O
17 None None O
patients None None O
with None None O
ANLL None None O
had None None O
on None None O
average None None O
higher None None O
levels None None O
of None None O
binding None None I-protein
sites None None I-protein
per None None O
cell None None O
( None None O
Median None None O
= None None O
7 None None O
, None None O
250 None None O
, None None O
range None None O
: None None O
0 None None O
to None None O
15 None None O
, None None O
295 None None O
) None None O
than None None O
the None None O
other None None O
leukemias None None O
. None None O

Of None None O
the None None O
15 None None O
patients None None O
with None None O
CLL None None O
, None None O
six None None O
had None None O
received None None O
glucocorticoid None None O
treatment None None O
for None None O
3 None None O
to None None O
5 None None O
years None None O
. None None O

Their None None O
lymphocytes None None I-cell_type
had None None O
lower None None O
number None None O
of None None O
receptors None None O
( None None O
Median None None O
= None None O
2 None None O
, None None O
000 None None O
) None None O
than None None O
the None None O
other None None O
cases None None O
which None None O
were None None O
newly None None O
diagnosed None None O
( None None O
Median None None O
= None None O
4 None None O
, None None O
500 None None O
) None None O
. None None O

Four None None O
patients None None O
had None None O
ALL/AUL None None O
, None None O
three None None O
patients None None O
had None None O
blast None None O
crisis None None O
as None None O
terminal None None O
phase None None O
of None None O
CML None None O
, None None O
and None None O
seven None None O
had None None O
leukemic None None O
Non-Hodgkin None None O
lymphomas None None O
( None None O
Median None None O
= None None O
3 None None O
, None None O
500 None None O
sites/cell None None O
) None None O
. None None O

In None None O
24 None None O
patients None None O
we None None O
have None None O
also None None O
studied None None O
the None None O
in None None O
vitro None None O
sensitivity None None O
of None None O
the None None O
leukemic None None I-cell_type
cells None None I-cell_type
to None None O
dexamethasone None None O
. None None O

There None None O
was None None O
no None None O
marked None None O
correlation None None O
between None None O
glucocorticoid None None I-protein
receptor None None I-protein
levels None None O
and None None O
in None None O
vitro None None O
sensitivity None None O
. None None O

An None None O
attempt None None O
to None None O
correlate None None O
receptor None None O
levels None None O
with None None O
clinical None None O
responsiveness None None O
demonstrated None None O
that None None O
glucocorticoid None None I-protein
receptor None None I-protein
determination None None O
might None None O
be None None O
of None None O
value None None O
in None None O
patients None None O
with None None O
lymphoid None None O
malignancies None None O
but None None O
probably None None O
not None None O
in None None O
patients None None O
with None None O
other None None O
leukemias None None O
. None None O

'Activation-labile None None I-protein
' None None I-protein
glucocorticoid-receptor None None I-protein
complexes None None I-protein
of None None O
a None None O
steroid-resistant None None O
variant None None O
of None None O
CEM-C7 None None I-cell_line
human None None I-cell_line
lymphoid None None I-cell_line
cells None None I-cell_line
. None None O

For None None O
cytoplasmic None None I-protein
glucocorticoid-receptor None None I-protein
complexes None None I-protein
to None None O
enter None None O
and None None O
accumulate None None O
in None None O
the None None O
nucleus None None O
a None None O
temperature-dependent None None O
event None None O
, None None O
'activation None None O
' None None O
is None None O
required None None O
. None None O

Activation None None O
can None None O
be None None O
achieved None None O
in None None O
vitro None None O
by None None O
increased None None O
ionic None None O
strength None None O
, None None O
dilution None None O
or None None O
gel None None O
filtration None None O
and None None O
is None None O
manifested None None O
by None None O
an None None O
increased None None O
affinity None None O
of None None O
steroid-receptor None None I-protein
complex None None I-protein
for None None O
DNA None None I-DNA
and None None O
an None None O
altered None None O
elution None None O
profile None None O
from None None O
ion-exchange None None O
resins None None O
. None None O

Munck None None O
and None None O
Foley None None O
have None None O
shown None None O
that None None O
activated None None I-protein
complexes None None I-protein
isolated None None O
from None None O
thymocytes None None O
elute None None O
from None None O
DEAE-cellulose None None O
in None None O
a None None O
manner None None O
identical None None O
to None None O
complexes None None O
activated None None O
in None None O
vitro None None O
. None None O

We None None O
report None None O
here None None O
that None None O
DEAE-cellulose None None O
chromatography None None O
of None None O
steroid-receptor None None I-protein
complexes None None I-protein
from None None O
CEM-C7 None None I-cell_line
, None None O
a None None O
cloned None None I-cell_line
human None None I-cell_line
leukaemic None None I-cell_line
T-cell None None I-cell_line
line None None I-cell_line
sensitive None None O
to None None O
the None None O
cytolytic None None O
action None None O
of None None O
glucocorticoids None None O
, None None O
and None None O
its None None O
steroid-resistant None None I-cell_line
subclone None None I-cell_line
4R4 None None I-cell_line
demonstrated None None O
that None None O
steroid None None I-protein
receptors None None I-protein
of None None O
clone None None I-cell_line
4R4 None None I-cell_line
can None None O
not None None O
form None None O
stable None None O
activated None None O
complexes None None O
. None None O

This None None O
defines None None O
a None None O
new None None O
defect None None O
in None None O
receptor None None O
action None None O
, None None O
activation None None O
lability None None O
( None None O
r+act1 None None O
) None None O
, None None O
which None None O
is None None O
unlike None None O
either None None O
the None None O
r- None None I-cell_line
, None None I-cell_line
r+nt- None None I-cell_line
, None None I-cell_line
or None None I-cell_line
r+nti None None I-cell_line
phenotypes None None I-cell_line
previously None None O
described None None O
for None None O
mouse None None I-cell_line
lymphoid None None I-cell_line
variants None None I-cell_line
. None None O

Granulocytes None None I-cell_type
in None None O
the None None O
endometrium None None O
of None None O
post-partum None None O
women None None O
. None None O

Endometrial None None O
samples None None O
of None None O
women None None O
at None None O
various None None O
stages None None O
of None None O
gonadal None None O
activity None None O
after None None O
parturition None None O
were None None O
examined None None O
for None None O
the None None O
presence None None O
and None None O
numbers None None O
of None None O
endometrial None None I-cell_type
granulocytes None None I-cell_type
. None None O

Although None None O
samples None None O
at None None O
all None None O
the None None O
stages None None O
contained None None O
significant None None O
numbers None None O
of None None O
the None None O
granulocytes None None I-cell_type
( None None O
i.e. None None O
greater None None O
than None None O
7/high-power None None O
field None None O
) None None O
, None None O
the None None O
100 None None O
% None None O
values None None O
for None None O
late-proliferative None None O
and None None O
adaptation None None O
hyperplasia None None O
were None None O
significantly None None O
higher None None O
than None None O
the None None O
values None None O
for None None O
the None None O
resting None None O
( None None O
81.8 None None O
% None None O
) None None O
, None None O
early None None O
( None None O
82.4 None None O
% None None O
) None None O
and None None O
mid- None None O
( None None O
87.9 None None O
% None None O
) None None O
proliferative None None O
and None None O
secretory None None O
( None None O
83.3 None None O
% None None O
) None None O
phases None None O
. None None O

We None None O
suggest None None O
that None None O
this None None O
correlates None None O
with None None O
the None None O
suggestion None None O
that None None O
the None None O
granulocytes None None I-cell_type
constitute None None O
a None None O
receptor None None O
system None None O
for None None O
oestrogens None None O
. None None O

Interaction None None O
of None None O
glucocorticoids None None O
with None None O
macrophages None None I-cell_type
. None None O

Identification None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
monocytes None None I-cell_type
and None None O
macrophages None None I-cell_type
. None None O

Glucocorticoid None None O
binding None None O
was None None O
measured None None O
in None None O
resident None None O
and None None O
thioglycollate-elicited None None I-cell_type
mouse None None I-cell_type
peritoneal None None I-cell_type
macrophages None None I-cell_type
, None None O
rabbit None None I-cell_type
alveolar None None I-cell_type
macrophages None None I-cell_type
, None None O
and None None O
human None None I-cell_type
monocytes None None I-cell_type
. None None O

Two None None O
assays None None O
of None None O
binding None None O
were None None O
used None None O
-- None None O
an None None O
assay None None O
with None None O
intact None None I-cell_type
cells None None I-cell_type
in None None O
suspension None None O
or None None O
monolayers None None O
, None None O
and None None O
an None None O
assay None None O
of None None O
cytosol None None O
and None None O
nuclear None None O
forms None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
. None None O

The None None O
mononuclear None None I-cell_type
phagocytes None None I-cell_type
contained None None O
approximately None None O
equal None None O
to None None O
4 None None O
-- None None O
10 None None O
X None None O
10 None None O
( None None O
3 None None O
) None None O
high None None I-protein
affinity None None I-protein
receptor None None I-protein
sites None None I-protein
per None None O
cell None None O
, None None O
with None None O
dissociation None None O
constants None None O
of None None O
approximately None None O
equal None None O
to None None O
2 None None O
-- None None O
8 None None O
nM None None O
dexamethasone None None O
. None None O

The None None O
binding None None O
to None None O
the None None O
saturable None None I-protein
sites None None I-protein
was None None O
specific None None O
for None None O
steroids None None O
with None None O
glucocorticoid None None O
or None None O
antiglucocorticoid None None O
activity None None O
. None None O

Cortisol None None O
, None None O
corticosterone None None O
, None None O
and None None O
progesterone None None O
competed None None O
with None None O
dexamethasone None None O
for None None O
binding None None O
, None None O
whereas None None O
estradiol None None O
, None None O
dihydrotestosterone None None O
, None None O
and None None O
11-epicortisol None None O
competed None None O
very None None O
little None None O
. None None O

Binding None None O
of None None O
dexamethasone None None O
to None None O
cytosol None None O
and None None O
nuclear None None O
forms None None O
of None None O
the None None O
receptor None None I-protein
complex None None I-protein
and None None O
temperature-sensitive None None O
translocation None None O
of None None O
cytosol None None O
forms None None O
to None None O
nuclear None None O
forms None None O
were None None O
shown None None O
. None None O

At None None O
37 None None O
degrees None None O
C None None O
the None None O
predominant None None O
form None None O
of None None O
the None None O
hormone-receptor None None I-protein
complex None None I-protein
was None None O
nuclear None None O
. None None O

These None None O
results None None O
demonstrate None None O
that None None O
corticosteroids None None O
interact None None O
with None None O
macrophages None None I-cell_type
at None None O
physiological None None O
concentrations None None O
. None None O

Nitric None None O
oxide None None O
signaling None None O
: None None O
a None None O
possible None None O
role None None O
for None None O
G None None I-protein
proteins None None I-protein
. None None O

We None None O
have None None O
previously None None O
reported None None O
various None None O
inductive None None O
effects None None O
of None None O
nitric None None O
oxide None None O
on None None O
human None None I-cell_type
PBMC None None I-cell_type
. None None O

We None None O
describe None None O
a None None O
novel None None O
and None None O
potentially None None O
important None None O
mechanism None None O
of None None O
nitric None None O
oxide None None O
signaling-through None None O
direct None None O
activation None None O
of None None O
guanine None None I-protein
nucleotide-binding None None I-protein
proteins None None I-protein
( None None O
G None None I-protein
proteins None None I-protein
) None None O
. None None O

We None None O
have None None O
found None None O
that None None O
nitric None None O
oxide None None O
treatment None None O
of None None O
membranes None None O
isolated None None O
from None None O
fresh None None I-cell_type
human None None I-cell_type
PBMC None None I-cell_type
enhances None None O
the None None O
ability None None O
of None None O
these None None O
membranes None None O
to None None O
hydrolyze None None O
[ None None O
gamma-32P None None O
] None None O
GTP None None O
and None None O
bind None None O
[ None None O
gamma-35S None None O
] None None O
GTP None None O
. None None O

In None None O
addition None None O
, None None O
treatment None None O
of None None O
whole None None O
cells None None O
with None None O
nitric None None O
oxide None None O
yielded None None O
membranes None None O
with None None O
enhanced None None O
GTPase None None O
activity None None O
. None None O

Furthermore None None O
, None None O
the None None O
GTPase None None O
activity None None O
of None None O
pure None None O
, None None O
recombinant None None O
Gs None None I-protein
alpha None None I-protein
, None None O
Gi None None I-protein
alpha None None I-protein
1 None None I-protein
, None None O
and None None O
p21ras None None I-protein
was None None O
greatly None None O
enhanced None None O
by None None O
nitric None None O
oxide None None O
. None None O

In None None O
support None None O
of None None O
the None None O
existence None None O
of None None O
this None None O
pathway None None O
in None None O
whole None None O
cells None None O
, None None O
we None None O
found None None O
that None None O
the None None O
G None None O
protein None None O
inhibitor None None O
, None None O
GDP-beta-S None None O
, None None O
blocked None None O
NF-kappa None None I-protein
B None None I-protein
translocation None None O
induced None None O
by None None O
nitric None None O
oxide None None O
or None None O
LPS None None O
in None None O
permeabilized None None I-cell_type
cells None None I-cell_type
. None None O

In None None O
addition None None O
, None None O
nitric None None O
oxide None None O
greatly None None O
reduced None None O
the None None O
pertussis None None O
toxin-mediated None None O
ADP-ribosylation None None O
of None None O
45- None None I-protein
and None None I-protein
41-kDa None None I-protein
proteins None None I-protein
in None None O
membranes None None O
of None None O
these None None O
cells None None O
. None None O

Because None None O
G None None I-protein
proteins None None I-protein
play None None O
a None None O
central None None O
role None None O
in None None O
many None None O
diverse None None O
signaling None None O
systems None None O
, None None O
activation None None O
by None None O
an None None O
endogenous None None O
and None None O
inducible None None O
oxidant None None O
may None None O
represent None None O
a None None O
novel None None O
signaling None None O
pathway None None O
. None None O

The None None O
granulocyte-macrophage None None I-DNA
colony-stimulating None None I-DNA
factor None None I-DNA
promoter None None I-DNA
cis-acting None None I-DNA
element None None I-DNA
CLE0 None None B-DNA
mediates None None O
induction None None O
signals None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
and None None O
is None None O
recognized None None O
by None None O
factors None None O
related None None O
to None None O
AP1 None None I-protein
and None None O
NFAT None None I-protein
. None None O

Expression None None O
of None None O
the None None O
granulocyte-macrophage None None I-DNA
colony-stimulating None None I-DNA
factor None None I-DNA
( None None I-DNA
GM-CSF None None I-DNA
) None None I-DNA
gene None None I-DNA
in None None O
T None None O
cells None None O
is None None O
activated None None O
by None None O
the None None O
combination None None O
of None None O
phorbol None None O
ester None None O
( None None O
phorbol None None O
myristate None None O
acetate None None O
) None None O
and None None O
calcium None None O
ionophore None None O
( None None O
A23187 None None O
) None None O
, None None O
which None None O
mimic None None O
antigen None None O
stimulation None None O
through None None O
the None None O
T-cell None None I-protein
receptor None None I-protein
. None None O

We None None O
have None None O
previously None None O
shown None None O
that None None O
a None None O
fragment None None O
containing None None O
bp None None I-DNA
-95 None None I-DNA
to None None I-DNA
+27 None None I-DNA
of None None O
the None None O
mouse None None I-DNA
GM-CSF None None I-DNA
promoter None None I-DNA
can None None O
confer None None O
inducibility None None O
to None None O
reporter None None I-DNA
genes None None I-DNA
in None None O
the None None O
human None None I-cell_line
Jurkat None None I-cell_line
T-cell None None I-cell_line
line None None I-cell_line
. None None O

Here None None O
we None None O
use None None O
an None None O
in None None O
vitro None None O
transcription None None O
system None None O
to None None O
demonstrate None None O
that None None O
a None None O
cis-acting None None I-DNA
element None None I-DNA
( None None O
positions None None I-DNA
-54 None None I-DNA
to None None I-DNA
-40 None None I-DNA
) None None O
, None None O
referred None None O
to None None O
as None None O
CLE0 None None I-DNA
, None None O
is None None O
a None None O
target None None O
for None None O
the None None O
induction None None O
signals None None O
. None None O

We None None O
observed None None O
induction None None O
with None None O
templates None None O
containing None None O
intact None None O
CLE0 None None I-DNA
but None None O
not None None O
with None None O
templates None None O
with None None O
deleted None None I-DNA
or None None I-DNA
mutated None None I-DNA
CLE0 None None I-DNA
. None None O

We None None O
also None None O
observed None None O
that None None O
two None None O
distinct None None O
signals None None O
were None None O
required None None O
for None None O
the None None O
stimulation None None O
through None None O
CLE0 None None I-DNA
, None None O
since None None O
only None None O
extracts None None O
from None None O
cells None None O
treated None None O
with None None O
both None None O
phorbol None None O
myristate None None O
acetate None None O
and None None O
A23187 None None O
supported None None O
optimal None None O
induction None None O
. None None O

Stimulation None None O
probably None None O
was None None O
mediated None None O
by None None O
CLE0-binding None None I-protein
proteins None None I-protein
because None None O
depletion None None O
of None None O
these None None O
proteins None None O
specifically None None O
reduced None None O
GM-CSF None None I-protein
transcription None None O
. None None O

One None None O
of None None O
the None None O
binding None None I-protein
factors None None I-protein
possessed None None O
biochemical None None O
and None None O
immunological None None O
features None None O
identical None None O
to None None O
those None None O
of None None O
the None None O
transcription None None I-protein
factor None None I-protein
AP1 None None I-protein
. None None O

Another None None O
factor None None O
resembled None None O
the None None O
T-cell-specific None None I-protein
factor None None I-protein
NFAT None None I-protein
. None None O

The None None O
characteristics None None O
of None None O
these None None O
two None None O
factors None None O
are None None O
consistent None None O
with None None O
their None None O
involvement None None O
in None None O
GM-CSF None None O
induction None None O
. None None O

The None None O
presence None None O
of None None O
CLE0-like None None I-DNA
elements None None I-DNA
in None None O
the None None O
promoters None None I-DNA
of None None O
interleukin-3 None None I-DNA
( None None I-DNA
IL-3 None None I-DNA
) None None I-DNA
, None None I-DNA
IL-4 None None I-DNA
, None None I-DNA
IL-5 None None I-DNA
, None None I-DNA
GM-CSF None None I-DNA
, None None I-DNA
and None None I-DNA
NFAT None None I-DNA
sites None None I-DNA
in None None O
the None None O
IL-2 None None I-DNA
promoter None None I-DNA
suggests None None O
that None None O
the None None O
factors None None O
we None None O
detected None None O
, None None O
or None None O
related None None O
factors None None O
that None None O
recognize None None O
these None None O
sites None None O
, None None O
may None None O
account None None O
for None None O
the None None O
coordinate None None O
induction None None O
of None None O
these None None O
genes None None O
during None None O
T-cell None None I-cell_type
activation None None O
. None None O

Identification None None O
and None None O
characterization None None O
of None None O
an None None O
Alu-containing None None I-DNA
, None None I-DNA
T-cell-specific None None I-DNA
enhancer None None I-DNA
located None None O
in None None O
the None None O
last None None O
intron None None I-DNA
of None None O
the None None O
human None None I-DNA
CD8 None None I-DNA
alpha None None I-DNA
gene None None I-DNA
. None None O

Expression None None O
of None None O
the None None O
human None None I-DNA
CD8 None None I-DNA
alpha None None I-DNA
gene None None I-DNA
is None None O
restricted None None O
to None None O
cells None None O
of None None O
the None None O
lymphoid None None I-cell_type
lineage None None I-cell_type
and None None O
developmentally None None O
regulated None None O
during None None O
thymopoiesis None None O
. None None O

As None None O
an None None O
initial None None O
step None None O
towards None None O
understanding None None O
the None None O
molecular None None O
basis None None O
for None None O
tissue-specific None None O
expression None None O
of None None O
this None None O
gene None None O
, None None O
we None None O
surveyed None None O
the None None O
surrounding None None O
chromatin None None O
structure None None O
for None None O
potential None None O
cis-acting None None I-DNA
regulatory None None I-DNA
regions None None I-DNA
by None None O
DNase None None I-protein
I None None I-protein
hypersensitivity None None O
mapping None None O
and None None O
found None None O
four None None O
hypersensitive None None O
sites None None O
, None None O
three None None O
of None None O
which None None O
were None None O
T None None O
cell None None O
restricted None None O
. None None O

By None None O
using None None O
a None None O
reporter-based None None O
expression None None O
approach None None O
, None None O
a None None O
T-cell-specific None None I-DNA
enhancer None None I-DNA
was None None O
identified None None O
by None None O
its None None O
close None None O
association None None O
with None None O
a None None O
prominent None None O
T-cell-restricted None None I-DNA
hypersensitive None None I-DNA
sites None None I-DNA
in None None O
the None None O
last None None O
intron None None O
of None None O
the None None O
CD8 None None I-DNA
alpha None None I-DNA
gene None None I-DNA
. None None O

Deletion None None O
studies None None O
demonstrated None None O
that None None O
the None None O
minimal None None O
enhancer None None O
is None None O
adjacent None None O
to None None O
a None None O
negative None None O
regulatory None None O
element None None O
. None None O

DNA None None O
sequence None None O
analysis None None O
of None None O
the None None O
minimal None None I-DNA
enhancer None None I-DNA
revealed None None O
a None None O
striking None None O
cluster None None O
of None None O
consensus None None I-DNA
binding None None I-DNA
sites None None I-DNA
for None None O
Ets-1 None None I-protein
, None None I-protein
TCF-1 None None I-protein
, None None I-protein
CRE None None I-protein
, None None I-protein
GATA-3 None None I-protein
, None None I-protein
LyF-1 None None I-protein
, None None I-protein
and None None I-protein
bHLH None None I-protein
proteins None None I-protein
which None None O
were None None O
verified None None O
by None None O
electrophoretic None None O
mobility None None O
shift None None O
assays None None O
. None None O

In None None O
addition None None O
, None None O
the None None O
5 None None I-DNA
' None None I-DNA
end None None I-DNA
of None None O
the None None O
enhancer None None I-DNA
was None None O
composed None None O
of None None O
an None None O
Alu None None O
repeat None None O
which None None O
contained None None O
the None None O
GATA-3 None None I-DNA
, None None I-DNA
bHLH None None I-DNA
, None None I-DNA
and None None I-DNA
LyF-1 None None I-DNA
binding None None I-DNA
sites None None I-DNA
. None None O

Site-directed None None O
mutation None None O
of None None O
the None None O
Ets-1 None None I-DNA
and None None I-DNA
GATA-3 None None I-DNA
sites None None I-DNA
dramatically None None O
reduced None None O
enhancer None None O
activity None None O
. None None O

The None None O
functional None None O
importance None None O
of None None O
the None None O
other None None O
binding None None O
sites None None O
only None None O
became None None O
apparent None None O
when None None O
combinations None None O
of None None O
mutations None None O
were None None O
analyzed None None O
. None None O

Taken None None O
together None None O
, None None O
these None None O
results None None O
suggest None None O
that None None O
the None None O
human None None I-DNA
CD8 None None I-DNA
alpha None None I-DNA
gene None None I-DNA
is None None O
regulated None None O
by None None O
the None None O
interaction None None O
of None None O
multiple None None O
T-cell None None I-protein
nuclear None None I-protein
proteins None None I-protein
with None None O
a None None O
transcriptional None None O
enhancer None None O
located None None O
in None None O
the None None O
last None None O
intron None None I-DNA
of None None O
the None None O
gene None None O
. None None O

Comparison None None O
of None None O
the None None O
CD8 None None I-DNA
alpha None None I-DNA
enhancer None None I-DNA
with None None O
other None None O
recently None None O
identified None None O
T-cell-specific None None I-DNA
regulatory None None I-DNA
elements None None I-DNA
suggests None None O
that None None O
a None None O
common None None O
set None None O
of None None O
transcription None None I-protein
factors None None I-protein
regulates None None O
several None None O
T-cell None None I-DNA
genes None None I-DNA
. None None O

Molecular None None O
regulation None None O
of None None O
the None None O
human None None I-DNA
IL-3 None None I-DNA
gene None None I-DNA
: None None O
inducible None None O
T None None O
cell-restricted None None O
expression None None O
requires None None O
intact None None O
AP-1 None None I-DNA
and None None I-DNA
Elf-1 None None I-DNA
nuclear None None I-DNA
protein None None I-DNA
binding None None I-DNA
sites None None I-DNA
. None None O

Interleukin None None I-protein
3 None None I-protein
( None None O
IL-3 None None I-protein
) None None O
is None None O
a None None O
hematopoietic None None I-protein
stem-cell None None I-protein
growth None None I-protein
and None None I-protein
differentiation None None I-protein
factor None None I-protein
that None None O
is None None O
expressed None None O
solely None None O
in None None O
activated None None O
T None None I-cell_type
and None None I-cell_type
NK None None I-cell_type
cells None None I-cell_type
. None None O

Studies None None O
to None None O
date None None O
have None None O
identified None None O
elements None None O
5 None None O
' None None O
to None None O
the None None O
IL-3 None None I-DNA
coding None None I-DNA
sequences None None I-DNA
that None None O
regulate None None O
its None None O
transcription None None O
, None None O
but None None O
the None None O
sequences None None O
that None None O
confer None None O
T None None O
cell-specific None None O
expression None None O
remain None None O
to None None O
be None None O
clearly None None O
defined None None O
. None None O

We None None O
have None None O
now None None O
identified None None O
DNA None None I-DNA
sequences None None I-DNA
that None None O
are None None O
required None None O
for None None O
T None None O
cell-restricted None None O
IL-3 None None I-DNA
gene None None I-DNA
transcription None None O
. None None O

A None None O
series None None O
of None None O
transient None None O
transfections None None O
performed None None O
with None None O
human None None I-DNA
IL-3-chloramphenicol None None I-DNA
acetyltransferase None None I-DNA
( None None I-DNA
CAT None None I-DNA
) None None I-DNA
reporter None None I-DNA
plasmids None None I-DNA
in None None O
T None None I-cell_type
and None None I-cell_type
non-T None None I-cell_type
cells None None I-cell_type
revealed None None O
that None None O
a None None O
plasmid None None I-DNA
containing None None O
319 None None O
bp None None O
of None None O
5 None None I-DNA
' None None I-DNA
flanking None None I-DNA
sequences None None I-DNA
was None None O
active None None O
exclusively None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

Deletion None None O
analysis None None O
revealed None None O
that None None O
T None None I-cell_type
cell None None I-cell_type
specificity None None O
was None None O
conferred None None O
by None None O
a None None O
49-bp None None I-DNA
fragment None None I-DNA
( None None O
bp None None I-DNA
-319 None None I-DNA
to None None I-DNA
-270 None None I-DNA
) None None O
that None None O
included None None O
a None None O
potential None None I-DNA
binding None None I-DNA
site None None I-DNA
for None None O
AP-1 None None I-protein
transcription None None I-protein
factors None None I-protein
6 None None O
bp None None O
upstream None None O
of None None O
a None None O
binding None None I-DNA
site None None I-DNA
for None None I-DNA
Elf-1 None None I-DNA
, None None O
a None None O
member None None O
of None None O
the None None O
Ets None None I-protein
family None None I-protein
of None None O
transcription None None I-protein
factors None None I-protein
. None None O

DNaseI None None I-protein
footprint None None O
and None None O
electrophoretic None None O
mobility None None O
shift None None O
assay None None O
analyses None None O
performed None None O
with None None O
MLA-144 None None I-cell_line
T None None I-cell_line
cell None None I-cell_line
nuclear None None O
extracts None None O
demonstrated None None O
that None None O
this None None O
49-bp None None I-DNA
region None None I-DNA
contains None None O
a None None O
nuclear None None I-DNA
protein None None I-DNA
binding None None I-DNA
region None None I-DNA
that None None O
includes None None O
consensus None None I-DNA
AP-1 None None I-DNA
and None None I-DNA
Elf-1 None None I-DNA
binding None None I-DNA
sites None None I-DNA
. None None O

In None None O
addition None None O
, None None O
extracts None None O
prepared None None O
from None None O
purified None None I-cell_type
human None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
contained None None O
proteins None None O
that None None O
bound None None O
to None None O
synthetic None None O
oligonucleotides None None O
corresponding None None O
to None None O
the None None O
AP-1 None None I-DNA
and None None I-DNA
Elf-1 None None I-DNA
binding None None I-DNA
sites None None I-DNA
. None None O

In None None O
vitro-transcribed None None O
and None None O
-translated None None O
Elf-1 None None I-protein
protein None None I-protein
bound None None O
specifically None None O
to None None O
the None None O
Elf-1 None None I-DNA
site None None I-DNA
, None None O
and None None O
Elf-1 None None O
antisera None None O
competed None None O
and None None O
super None None O
shifted None None O
nuclear None None O
protein None None O
complexes None None O
present None None O
in None None O
MLA-144 None None I-cell_line
nuclear None None O
extracts None None O
. None None O

Moreover None None O
, None None O
addition None None O
of None None O
anti-Jun None None O
family None None O
antiserum None None O
in None None O
electrophoretic None None O
mobility None None O
shift None None O
assay None None O
reactions None None O
completely None None O
blocked None None O
formation None None O
of None None O
the None None O
AP-1-related None None I-protein
complexes None None I-protein
. None None O

Transient None None O
transfection None None O
studies None None O
in None None O
MLA-144 None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
revealed None None O
that None None O
constructs None None O
containing None None O
mutations None None O
in None None O
the None None O
AP-1 None None I-DNA
site None None I-DNA
almost None None O
completely None None O
abolished None None O
CAT None None O
activity None None O
while None None O
mutation None None O
of None None O
the None None O
Elf-1 None None I-DNA
site None None I-DNA
or None None O
the None None O
NF-IL-3 None None I-DNA
site None None I-DNA
, None None O
a None None O
previously None None O
described None None O
nuclear None None I-DNA
protein None None I-DNA
binding None None I-DNA
site None None I-DNA
( None None O
bp. None None I-DNA
-155 None None I-DNA
to None None I-DNA
-148 None None I-DNA
) None None O
in None None O
the None None O
IL-3 None None I-DNA
promoter None None I-DNA
, None None O
reduced None None O
CAT None None O
activity None None O
to None None O
< None None O
25 None None O
% None None O
of None None O
the None None O
activity None None O
given None None O
by None None O
wild-type None None O
constructs None None O
. None None O

We None None O
conclude None None O
that None None O
expression None None O
of None None O
the None None O
human None None I-DNA
IL-3 None None I-DNA
gene None None I-DNA
requires None None O
the None None O
AP-1 None None I-DNA
and None None I-DNA
Elf-1 None None I-DNA
binding None None I-DNA
sites None None I-DNA
; None None O
however None None O
, None None O
unlike None None O
other None None O
previously None None O
characterized None None O
cytokine None None I-DNA
genes None None I-DNA
such None None O
as None None O
IL-2 None None I-protein
, None None O
the None None O
AP-1 None None I-protein
and None None I-protein
Elf-1 None None I-protein
factors None None I-protein
can None None O
bind None None O
independently None None O
in None None O
the None None O
IL-3 None None I-DNA
gene None None I-DNA
. None None O

( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
400 None None O
WORDS None None O
) None None O

Combination None None O
IL-2 None None I-protein
and None None O
IL-4 None None I-protein
reduces None None O
glucocorticoid None None O
receptor-binding None None O
affinity None None O
and None None O
T None None I-cell_type
cell None None I-cell_type
response None None O
to None None O
glucocorticoids None None O
. None None O

The None None O
mechanisms None None O
contributing None None O
to None None O
persistent None None O
T None None I-cell_type
cell None None I-cell_type
activation None None O
and None None O
poor None None O
response None None O
to None None O
glucocorticoids None None O
in None None O
chronic None None O
inflammatory None None O
illnesses None None O
such None None O
as None None O
steroid None None O
resistant None None O
( None None O
SR None None O
) None None O
asthma None None O
are None None O
poorly None None O
defined None None O
. None None O

We None None O
examined None None O
the None None O
possibility None None O
that None None O
certain None None O
cytokines None None O
, None None O
specifically None None O
IL-2 None None I-protein
and None None O
IL-4 None None I-protein
, None None O
could None None O
affect None None O
T None None O
cell None None O
response None None O
to None None O
glucocorticoids None None O
. None None O

A None None O
[ None None O
3H None None O
] None None O
dexamethasone None None O
radioligand-binding None None O
assay None None O
was None None O
used None None O
to None None O
measure None None O
the None None O
number None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
( None None O
GR None None I-protein
) None None O
and None None O
dissociation None None O
constant None None O
( None None O
Kd None None O
) None None O
in None None O
PBMC None None I-cell_type
from None None O
normal None None O
donors None None O
and None None O
patients None None O
with None None O
SR None None O
asthma None None O
, None None O
cultured None None O
in None None O
the None None O
absence None None O
and None None O
presence None None O
of None None O
these None None O
cytokines None None I-protein
. None None O

PBMC None None O
from None None O
normal None None O
donors None None O
incubated None None O
for None None O
48 None None O
h None None O
in None None O
the None None O
presence None None O
of None None O
combination None None O
IL-2 None None I-protein
+ None None O
IL-4 None None I-protein
had None None O
nuclear None None O
GR None None O
with None None O
significantly None None O
reduced None None O
binding None None O
affinity None None O
( None None O
GR None None O
Kd None None O
= None None O
36.1 None None O
+/- None None O
1.63 None None O
nM None None O
, None None O
mean None None O
+/- None None O
SEM None None O
; None None O
p None None O
= None None O
0.0001 None None O
) None None O
as None None O
compared None None O
with None None O
PBMC None None I-cell_type
incubated None None O
with None None O
medium None None O
alone None None O
( None None O
GR None None O
Kd None None O
= None None O
6.74 None None O
+/- None None O
0.46 None None O
nM None None O
) None None O
. None None O

The None None O
cytosolic None None O
GR None None O
Kd None None O
remained None None O
unchanged None None O
. None None O

However None None O
, None None O
when None None O
PBMC None None I-cell_type
were None None O
incubated None None O
with None None O
IL-2 None None I-protein
alone None None O
or None None O
IL-4 None None I-protein
alone None None O
, None None O
no None None O
change None None O
in None None O
GR-binding None None O
affinity None None O
was None None O
observed None None O
. None None O

Furthermore None None O
, None None O
when None None O
T None None I-cell_type
cells None None I-cell_type
and None None O
non-T None None I-cell_type
cells None None I-cell_type
were None None O
individually None None O
stimulated None None O
with None None O
combination None None O
IL-2 None None O
+ None None O
IL-4 None None O
, None None O
a None None O
significant None None O
reduction None None O
in None None O
GR-binding None None O
affinity None None O
was None None O
observed None None O
only None None O
in None None O
the None None O
T None None I-cell_type
cell None None I-cell_type
population None None I-cell_type
( None None O
p None None O
= None None O
0.0001 None None O
) None None O
. None None O

The None None O
IL-2 None None O
+ None None O
IL-4-induced None None O
alteration None None O
in None None O
PBMC None None O
GR None None O
Kd None None O
was None None O
associated None None O
with None None O
an None None O
increase None None O
in None None O
GR None None O
number None None O
( None None O
8348 None None O
+/- None None O
964 None None O
vs None None O
1710 None None O
+/- None None O
228 None None O
sites/cell None None O
; None None O
p None None O
= None None O
0.0003 None None O
) None None O
. None None O

More None None O
importantly None None O
, None None O
the None None O
alteration None None O
in None None O
PBMC None None O
GR-binding None None O
affinity None None O
with None None O
IL-2 None None I-protein
+ None None O
IL-4 None None I-protein
was None None O
associated None None O
with None None O
a None None O
functional None None O
change None None O
in None None O
T None None O
cell None None O
response None None O
to None None O
methylprednisolone None None O
MPN None None O
, None None O
i.e. None None O
, None None O
a None None O
reduced None None O
inhibitory None None O
effect None None O
of None None O
MPN None None O
on None None O
PMA/ionomycin-induced None None O
T None None I-cell_type
cell None None I-cell_type
proliferation None None O
. None None O

These None None O
effects None None O
of None None O
IL-2 None None I-protein
+ None None O
IL-4 None None I-protein
on None None O
PBMC None None I-cell_type
GR None None I-protein
affinity None None O
and None None O
response None None O
to None None O
MPN None None O
were None None O
blocked None None O
by None None O
co-incubation None None O
with None None O
IFN-gamma None None I-protein
. None None O

Freshly None None O
isolated None None O
PBMC None None I-cell_type
from None None O
four None None O
patients None None O
with None None O
SR None None O
asthma None None O
had None None O
a None None O
significantly None None O
reduced None None O
GR-binding None None O
affinity None None O
( None None O
Kd None None O
= None None O
40.0 None None O
+/- None None O
2.68 None None O
nM None None O
; None None O
p None None O
= None None O
0.0001 None None O
) None None O
when None None O
compared None None O
with None None O
seven None None O
normal None None O
subjects None None O
( None None O
7.15 None None O
+/- None None O
0.41 None None O
nM None None O
) None None O
. None None O

The None None O
altered None None O
PBMC None None O
GR None None O
binding None None O
from None None O
patients None None O
with None None O
SR None None O
asthma None None O
reversed None None O
to None None O
normal None None O
when None None O
incubated None None O
with None None O
medium None None O
alone None None O
, None None O
but None None O
was None None O
sustained None None O
with None None O
IL-2 None None I-protein
+ None None O
IL-4 None None I-protein
. None None O

These None None O
observations None None O
suggest None None O
that None None O
with None None O
persistent None None O
inflammation None None O
certain None None O
cytokines None None I-protein
may None None O
contribute None None O
to None None O
an None None O
impaired None None O
response None None O
to None None O
glucocorticoids None None O
. None None O

Furthermore None None O
, None None O
the None None O
effects None None O
of None None O
IL-2 None None I-protein
and None None O
IL-4 None None I-protein
were None None O
blocked None None O
by None None O
IFN-gamma None None I-protein
. None None O

Characterization None None O
of None None O
the None None O
human None None I-DNA
CD4 None None I-DNA
gene None None I-DNA
promoter None None I-DNA
: None None O
transcription None None O
from None None O
the None None O
CD4 None None I-DNA
gene None None I-DNA
core None None I-DNA
promoter None None I-DNA
is None None O
tissue-specific None None O
and None None O
is None None O
activated None None O
by None None O
Ets None None I-protein
proteins None None I-protein
. None None O

We None None O
analyzed None None O
the None None O
5 None None I-DNA
' None None I-DNA
transcription None None I-DNA
control None None I-DNA
sequences None None I-DNA
of None None O
the None None O
human None None I-DNA
CD4 None None I-DNA
gene None None I-DNA
. None None O

We None None O
located None None O
the None None O
transcription None None I-DNA
initiation None None I-DNA
site None None I-DNA
and None None O
showed None None O
that None None O
the None None O
CD4 None None I-DNA
core None None I-DNA
promoter None None I-DNA
( None None O
positions None None I-DNA
-40 None None I-DNA
to None None I-DNA
+16 None None I-DNA
) None None O
lacks None None O
a None None O
classical None None O
`` None None O
TATA None None O
'' None None O
or None None O
initiator None None I-DNA
positioning None None I-DNA
consensus None None I-DNA
sequence None None I-DNA
but None None O
directs None None O
precise None None O
and None None O
efficient None None O
transcription None None O
when None None O
coupled None None O
to None None O
the None None O
ubiquitously None None O
active None None O
simian None None I-DNA
virus None None I-DNA
40 None None I-DNA
enhancer None None I-DNA
. None None O

The None None O
transcriptional None None O
activity None None O
of None None O
the None None O
CD4 None None I-DNA
gene None None I-DNA
promoter None None I-DNA
correlated None None O
with None None O
CD4 None None O
expression None None O
in None None O
various None None O
cell None None O
types None None O
. None None O

Interestingly None None O
, None None O
the None None O
CD4 None None I-DNA
core None None I-DNA
promoter None None I-DNA
also None None O
displayed None None O
a None None O
tissue-specific None None O
transcriptional None None O
activity None None O
. None None O

Within None None O
this None None O
fragment None None O
, None None O
three None None O
nucleic None None O
acid None None O
sequences None None O
are None None O
completely None None O
conserved None None O
in None None O
the None None O
murine None None I-DNA
CD4 None None I-DNA
gene None None I-DNA
. None None O

One None None O
of None None O
these None None O
sequences None None O
contains None None O
a None None O
perfect None None I-DNA
ETS None None I-DNA
consensus None None I-DNA
sequence None None I-DNA
. None None O

Another None None O
ETS None None I-DNA
consensus None None I-DNA
sequence None None I-DNA
is None None O
located None None O
1060 None None O
nt None None O
upstream None None O
. None None O

Electrophoretic-mobility-shift None None O
assays None None O
showed None None O
that None None O
the None None O
core None None O
promoter None None O
ETS None None O
motif None None O
binds None None O
an None None O
Ets-related None None I-protein
protein None None I-protein
specifically None None O
expressed None None O
at None None O
high None None O
levels None None O
in None None O
CD4+ None None I-cell_type
cells None None I-cell_type
. None None O

Moreover None None O
, None None O
in None None O
CD4- None None I-cell_type
cells None None I-cell_type
, None None O
overexpression None None O
of None None O
Ets-1 None None I-protein
or None None O
Ets-2 None None I-protein
efficiently None None O
and None None O
specifically None None O
activated None None O
transcription None None O
from None None O
the None None O
CD4 None None I-DNA
promoter None None I-DNA
and None None O
core None None I-DNA
promoter None None I-DNA
. None None O

These None None O
data None None O
indicate None None O
that None None O
Ets None None I-protein
transcription None None I-protein
factors None None I-protein
play None None O
a None None O
central None None O
role None None O
in None None O
controlling None None O
CD4 None None O
gene None None O
expression None None O
, None None O
by None None O
binding None None O
to None None O
both None None O
a None None O
classical None None I-DNA
remote None None I-DNA
site None None I-DNA
and None None O
an None None O
unusual None None O
proximal None None I-DNA
activator None None I-DNA
sequence None None I-DNA

Glucocorticoid None None O
receptor None None O
activation None None O
and None None O
inactivation None None O
in None None O
c None None O
ultured None None I-cell_line
human None None I-cell_line
lymphocytes None None I-cell_line
. None None O

Although None None O
glucocorticoids None None O
are None None O
not None None O
cytolytic None None O
for None None O
and None None O
do None None O
not None None O
inhibit None None O
the None None O
growth None None O
of None None O
the None None O
IM-9 None None I-cell_line
line None None I-cell_line
of None None O
cultured None None I-cell_line
human None None I-cell_line
lymphoblasts None None I-cell_line
, None None O
these None None O
cells None None O
have None None O
a None None O
high None None O
steroid-binding None None O
capacity None None O
. None None O

We None None O
have None None O
used None None O
IM-9 None None I-cell_type
cells None None I-cell_type
in None None O
order None None O
to None None O
examine None None O
whether None None O
unoccupied None None I-protein
glucocorticoid None None I-protein
receptors None None I-protein
are None None O
inactivated None None O
and None None O
activated None None O
in None None O
intact None None I-cell_type
cells None None I-cell_type
. None None O

when None None O
IM-9 None None I-cell_type
cells None None I-cell_type
are None None O
incubated None None O
in None None O
glucose-free None None O
medium None None O
in None None O
a None None O
nitrogen None None O
atmosphere None None O
, None None O
both None None O
their None None O
ability None None O
to None None O
bind None None O
triamcinolone None None O
acetonide None None O
and None None O
their None None O
ATP None None O
levels None None O
decline None None O
and None None O
, None None O
when None None O
glucose None None O
and None None O
oxygen None None O
are None None O
reintroduced None None O
, None None O
ATP None None O
levels None None O
and None None O
receptor None None O
activity None None O
return None None O
. None None O

The None None O
specific None None O
glucocorticoid-binding None None O
activity None None O
of None None O
cytosol None None O
prepared None None O
from None None O
cells None None O
exposed None None O
to None None O
various None None O
degrees None None O
of None None O
energy None None O
limitation None None O
is None None O
directly None None O
correlated None None O
with None None O
the None None O
ATP None None O
content None None O
. None None O

Receptor None None O
activation None None O
in None None O
intact None None I-cell_type
cells None None I-cell_type
is None None O
rapid None None O
and None None O
independent None None O
of None None O
protein None None O
synthesis None None O
. None None O

Cytosol None None O
prepared None None O
from None None O
inactivated None None O
cells None None O
can None None O
not None None O
be None None O
activated None None O
by None None O
addition None None O
of None None O
ATP None None O
. None None O

The None None O
inactivation None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
that None None O
occurs None None O
when None None O
cytosol None None O
from None None O
normal None None O
IM-9 None None I-cell_line
cells None None I-cell_line
is None None O
incubated None None O
at None None O
25 None None O
degrees None None O
C None None O
is None None O
inhibited None None O
by None None O
molybdate None None O
, None None O
vanadate None None O
, None None O
fluoride None None O
, None None O
ATP None None O
, None None O
and None None O
several None None O
other None None O
nucleotides None None O
. None None O

The None None O
experiments None None O
with None None O
intact None None I-cell_type
human None None I-cell_type
lymphoblasts None None I-cell_type
suggest None None O
that None None O
assays None None O
of None None O
specific None None O
glucocorticoid-binding None None O
capacity None None O
do None None O
not None None O
necessarily None None O
reflect None None O
the None None O
cellular None None O
content None None O
of None None O
receptor None None I-protein
protein None None I-protein
. None None O

Glucocorticoids None None O
and None None O
lymphocytes None None I-cell_type
. None None O

II None None O
. None None O

Cell None None O
cycle-dependent None None O
changes None None O
in None None O
glucocorticoid None None I-protein
receptor None None I-protein
content None None O
. None None O

To None None O
study None None O
variations None None O
in None None O
glucocorticoid None None I-protein
receptor None None I-protein
levels None None O
during None None O
the None None O
cell None None O
cycle None None O
, None None O
we None None O
have None None O
separated None None O
mitogen-stimulated None None I-cell_line
human None None I-cell_line
peripheral None None I-cell_line
lymphocytes None None I-cell_line
and None None O
rat None None I-cell_type
lymph None None I-cell_type
node None None I-cell_type
cells None None I-cell_type
by None None O
unit None None O
gravity None None O
sedimentation None None O
and None None O
measured None None O
glucocorticoid None None O
binding None None O
in None None O
the None None O
resultant None None O
fractions None None O
. None None O

By None None O
morphologic None None O
criteria None None O
and None None O
thymidine None None O
incorporation None None O
, None None O
the None None O
fractions None None O
were None None O
separated None None O
into None None O
populations None None O
of None None O
G0 None None I-cell_type
and None None I-cell_type
G1 None None I-cell_type
phase None None I-cell_type
and None None I-cell_type
S None None I-cell_type
and None None I-cell_type
post-S None None I-cell_type
phase None None I-cell_type
cells None None I-cell_type
. None None O

A None None O
2- None None O
to None None O
3-fold None None O
increase None None O
in None None O
glucocorticoid None None O
receptor None None O
sites None None O
per None None O
cell None None O
, None None O
for None None O
cells None None O
in None None O
the None None O
S None None O
and None None O
post-S None None O
phase None None O
over None None O
those None None O
in None None O
G0 None None O
and None None O
G1 None None O
, None None O
was None None O
observed None None O
with None None O
both None None O
nonstimulated None None I-cell_type
rat None None I-cell_type
lymph None None I-cell_type
node None None I-cell_type
cell None None I-cell_type
suspensions None None I-cell_type
and None None O
concanavalin None None I-cell_line
A-stimulated None None I-cell_line
human None None I-cell_line
peripheral None None I-cell_line
lymphocytes None None I-cell_line
. None None O

These None None O
observations None None O
together None None O
with None None O
those None None O
from None None O
other None None O
studies None None O
indicate None None O
that None None O
formation None None O
of None None O
new None None O
glucocorticoid None None I-protein
receptors None None I-protein
near None None O
the None None O
S None None O
phase None None O
may None None O
be None None O
a None None O
general None None O
phenomenon None None O
in None None O
proliferating None None I-cell_type
cells None None I-cell_type
. None None O

We None None O
propose None None O
that None None O
this None None O
increase None None O
in None None O
glucocorticoid None None I-protein
receptors None None I-protein
during None None O
the None None O
cell None None O
cycle None None O
may None None O
explain None None O
the None None O
increase None None O
in None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
mitogen-stimulated None None I-cell_type
lymphocytes None None I-cell_type
. None None O

The None None O
leukocyte None None I-cell_type
migration None None O
inhibition None None O
response None None O
to None None O
certain None None O
breast None None I-protein
cancer-related None None I-protein
antigens None None I-protein
( None None O
MCF-7 None None I-protein
and None None O
MuMTV None None I-protein
) None None O
: None None O
their None None O
potential None None O
as None None O
discriminants None None O
. None None O

Certain None None O
oncogenic None None O
viruses None None O
have None None O
been None None O
implicated None None O
in None None O
human None None O
breast None None O
cancer None None O
, None None O
including None None O
the None None O
murine None None O
mammary None None O
tumor None None O
virus None None O
( None None O
MuMTV None None O
) None None O
and None None O
the None None O
Mason-Pfizer None None O
monkey None None O
virus None None O
( None None O
MPMV None None O
) None None O
. None None O

We None None O
have None None O
used None None O
the None None O
leukocyte None None O
migration None None O
inhibition None None O
( None None O
LMI None None O
) None None O
response None None O
to None None O
assay None None O
the None None O
response None None O
to None None O
several None None O
potential None None O
breast None None O
cancer-related None None O
antigens None None O
, None None O
including None None O
MuMTV None None I-protein
, None None O
MPMV None None I-protein
, None None O
and None None O
a None None O
breast None None I-cell_line
cancer None None I-cell_line
cultured None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
, None None O
MCF-7 None None I-cell_line
, None None O
in None None O
96 None None O
breast None None O
cancer None None O
patients None None O
, None None O
in None None O
32 None None O
women None None O
with None None O
benign None None O
breast None None O
disease None None O
, None None O
and None None O
in None None O
67 None None O
normal None None O
women None None O
. None None O

The None None O
lowest None None O
tenth None None O
percentile None None O
of None None O
control None None O
( None None O
LMI None None O
) None None O
responses None None O
was None None O
used None None O
as None None O
the None None O
cutoff None None O
point None None O
to None None O
designate None None O
responders None None O
. None None O

Breast None None O
cancer None None O
patients None None O
showed None None O
significant None None O
responses None None O
to None None O
MuMTV None None I-protein
( None None O
49 None None O
% None None O
and None None O
to None None O
MCF-7 None None O
( None None O
50 None None O
% None None O
) None None O
, None None O
but None None O
not None None O
to None None O
MPMV None None I-protein
( None None O
29 None None O
% None None O
) None None O
. None None O

In None None O
a None None O
paired-antigen None None O
study None None O
using None None O
MuMTV None None I-protein
and None None O
MCF-7 None None I-protein
, None None O
75 None None O
% None None O
of None None O
the None None O
breast None None O
cancer None None O
patients None None O
responded None None O
, None None O
versus None None O
18 None None O
% None None O
of None None O
the None None O
normal None None O
women None None O
( None None O
P None None O
less None None O
than None None O
0.0050 None None O
) None None O
. None None O

The None None O
potential None None O
for None None O
this None None O
assay None None O
to None None O
distinguish None None O
`` None None O
normal None None O
'' None None O
from None None O
`` None None O
breast None None O
cancer None None O
'' None None O
was None None O
analyzed None None O
using None None O
a None None O
migration None None O
index None None O
derived None None O
from None None O
discriminant None None O
analysis None None O
. None None O

The None None O
ability None None O
of None None O
the None None O
assay None None O
to None None O
discriminate None None O
`` None None O
normal None None O
'' None None O
from None None O
`` None None O
cancer None None O
'' None None O
was None None O
significant None None O
( None None O
P None None O
less None None O
than None None O
0.001 None None O
) None None O
and None None O
showed None None O
a None None O
sensitivity None None O
of None None O
detecting None None O
`` None None O
cancer None None O
'' None None O
of None None O
75 None None O
% None None O
. None None O

The None None O
overall None None O
responses None None O
to None None O
MuMTV None None I-protein
and None None O
MCF-7 None None I-protein
were None None O
analyzed None None O
with None None O
reference None None O
to None None O
certain None None O
prognostic None None O
factors None None O
, None None O
but None None O
showed None None O
no None None O
relation None None O
to None None O
age None None O
, None None O
menstrual None None O
status None None O
, None None O
estrogen None None O
receptor None None O
status None None O
, None None O
or None None O
stage None None O
of None None O
disease None None O
. None None O

The None None O
above None None O
reactions None None O
suggest None None O
that None None O
a None None O
large None None O
proportion None None O
of None None O
breast None None O
cancer None None O
patients None None O
exhibit None None O
presensitization None None O
to None None O
antigenfs None None O
found None None O
in None None O
MuMTV None None I-protein
and None None O
MCF-7 None None I-protein
, None None O
which None None O
may None None O
be None None O
cross-reactive None None O
with None None O
antigens None None O
in None None O
the None None O
primary None None O
cancer None None O
. None None O

These None None O
responses None None O
appear None None O
to None None O
be None None O
independent None None O
of None None O
major None None O
prognostic None None O
variables None None O
. None None O

Further None None O
refinement None None O
of None None O
this None None O
assay None None O
may None None O
yield None None O
one None None O
which None None O
is None None O
more None None O
highly None None O
discriminating None None O
for None None O
breast None None O
cancer None None O
. None None O

Chronic None None O
lymphatic None None O
leukaemia None None O
: None None O
cellular None None O
effects None None O
of None None O
glucocorticoids None None O
in None None O
vitro None None O
. None None O

Glucocorticoid None None I-protein
receptor None None I-protein
levels None None O
and None None O
steroid None None O
induced None None O
inhibition None None O
of None None O
nucleic None None O
acid None None O
precursors None None O
have None None O
been None None O
examined None None O
in None None O
lymphocytes None None I-cell_type
from None None O
27 None None O
patients None None O
at None None O
different None None O
stages None None O
of None None O
chronic None None O
lymphatic None None O
leukaemia None None O
. None None O

No None None O
correlation None None O
can None None O
be None None O
found None None O
between None None O
the None None O
level None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
and None None O
the None None O
stage None None O
of None None O
the None None O
disease None None O
. None None O

On None None O
the None None O
other None None O
hand None None O
, None None O
a None None O
significant None None O
difference None None O
( None None O
P None None O
less None None O
than None None O
0.02 None None O
) None None O
was None None O
found None None O
between None None O
stage None None O
O None None O
and None None O
stage None None O
III/IV None None O
patients None None O
, None None O
in None None O
terms None None O
of None None O
the None None O
in None None O
vitro None None O
effect None None O
of None None O
dexamethasone None None O
on None None O
[ None None O
3H None None O
] None None O
uridine None None O
incorporation None None O
. None None O

Pyrrolidine None None O
dithiocarbamate None None O
inhibits None None O
NF-kappa None None I-protein
B None None I-protein
mobilization None None O
and None None O
TNF None None O
production None None O
in None None O
human None None I-cell_type
monocytes None None I-cell_type
. None None O

The None None O
human None None I-DNA
TNF None None I-DNA
promoter None None I-DNA
contains None None O
four None None O
potential None None O
nuclear None None I-DNA
factor-kappa None None I-DNA
B None None I-DNA
( None None I-DNA
NF-kappa None None I-DNA
B None None I-DNA
) None None I-DNA
-binding None None I-DNA
sites None None I-DNA
, None None O
with None None O
the None None O
strongest None None O
binding None None O
seen None None O
for None None O
the None None O
-605 None None O
motif None None O
. None None O

Nuclear None None O
extracts None None O
from None None O
unstimulated None None I-cell_line
cells None None I-cell_line
of None None O
the None None O
human None None I-cell_line
monocytic None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
, None None O
Mono None None I-cell_line
Mac None None I-cell_line
6 None None I-cell_line
, None None O
contain None None O
one None None O
specific None None I-protein
binding None None I-protein
protein None None I-protein
( None None O
complex None None I-protein
II None None I-protein
) None None O
, None None O
consistent None None O
with None None O
a None None O
constitutive None None I-protein
p50 None None I-protein
homodimer None None I-protein
. None None O

Stimulation None None O
of None None O
Mono None None I-cell_line
Mac None None I-cell_line
6 None None I-cell_line
cells None None I-cell_line
with None None O
LPS None None O
will None None O
increase None None O
complex None None I-protein
II None None I-protein
and None None O
will None None O
strongly None None O
induce None None O
a None None O
second None None O
specific None None O
complex None None O
( None None O
complex None None I-protein
I None None I-protein
) None None O
, None None O
which None None O
represents None None O
the None None O
p50/65 None None I-protein
heterodimer None None I-protein
. None None O

Treatment None None O
of None None O
Mono None None I-cell_type
Mac None None I-cell_type
6 None None I-cell_type
cells None None I-cell_type
with None None O
pyrrolidine-dithiocarbamate None None O
( None None O
PDTC None None O
) None None O
at None None O
300 None None O
microM None None O
will None None O
block None None O
the None None O
LPS-induced None None I-protein
complex None None I-protein
I None None I-protein
almost None None O
completely None None O
and None None O
will None None O
reduce None None O
complex None None I-protein
II None None I-protein
to None None O
the None None O
constitutive None None O
level None None O
. None None O

Binding None None O
activity None None O
of None None O
other None None O
nuclear None None I-protein
factors None None I-protein
that None None O
recognize None None O
the None None O
SP-1 None None O
and None None O
c/EBP None None O
motifs None None O
of None None O
the None None O
human None None I-DNA
TNF None None I-DNA
promoter None None I-DNA
is None None O
not None None O
affected None None O
by None None O
such None None O
treatment None None O
. None None O

Northern None None O
blot None None O
analysis None None O
demonstrates None None O
that None None O
PDTC None None O
treatment None None O
will None None O
strongly None None O
reduce None None O
LPS-induced None None I-protein
TNF None None I-protein
transcripts None None I-protein
. None None O

Secreted None None O
TNF None None I-protein
protein None None I-protein
as None None O
detected None None O
in None None O
the None None O
Wehi None None O
164S/ActD None None O
bioassay None None O
and None None O
in None None O
a None None O
sandwich None None O
immunoassay None None O
was None None O
similarly None None O
reduced None None O
by None None O
PDTC None None O
. None None O

Kinetic None None O
analyses None None O
show None None O
that None None O
after None None O
LPS None None O
stimulation None None O
, None None O
NF-kappa None None I-protein
B None None I-protein
will None None O
peak None None O
at None None O
1 None None O
h None None O
, None None O
TNF None None O
transcript None None O
prevalence None None O
at None None O
2 None None O
h None None O
, None None O
and None None O
TNF None None I-protein
protein None None I-protein
at None None O
4 None None O
h None None O
. None None O

PDTC None None O
did None None O
not None None O
shift None None O
this None None O
response None None O
to None None O
LPS None None O
to None None O
a None None O
later None None O
time None None O
, None None O
but None None O
suppressed None None O
NF-kappa None None O
B None None O
mobilization None None O
, None None O
TNF None None I-protein
transcripts None None I-protein
, None None O
and None None O
TNF None None I-protein
protein None None I-protein
over None None O
the None None O
entire None None O
8-h None None O
observation None None O
period None None O
. None None O

Analysis None None O
of None None O
freshly None None O
isolated None None O
, None None O
LPS-stimulated None None I-cell_type
blood None None I-cell_type
monocytes None None I-cell_type
showed None None O
a None None O
similar None None O
blockade None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
. None None O

Furthermore None None O
, None None O
in None None O
these None None O
primary None None O
cells None None O
, None None O
induction None None O
of None None O
TNF None None I-protein
transcripts None None I-protein
, None None O
as None None O
determined None None O
by None None O
Northern None None O
blot None None O
analysis None None O
and None None O
by None None O
quantitative None None O
polymerase None None O
chain None None O
reaction None None O
, None None O
was None None O
prevented None None O
by None None O
PDTC None None O
as None None O
was None None O
TNF None None I-protein
protein None None I-protein
production None None O
. None None O

These None None O
data None None O
show None None O
that None None O
dithiocarbamates None None O
can None None O
profoundly None None O
affect None None O
cytokine None None O
expression None None O
and None None O
suggest None None O
that None None O
NF-kappa None None I-protein
B None None I-protein
is None None O
involved None None O
in None None O
LPS-induced None None O
TNF None None O
gene None None O
expression None None O
in None None O
human None None I-cell_type
monocytes None None I-cell_type
. None None O

Comparing None None O
regions None None O
of None None O
the None None O
Epstein-Barr None None I-protein
virus None None I-protein
ZEBRA None None I-protein
protein None None I-protein
which None None O
function None None O
as None None O
transcriptional None None I-DNA
activating None None I-DNA
sequences None None I-DNA
in None None O
Saccharomyces None None O
cerevisiae None None O
and None None O
in None None O
B None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
ZEBRA None None I-protein
protein None None I-protein
activates None None O
expression None None O
of None None O
Epstein-Barr None None O
virus None None O
early-lytic-cycle None None I-DNA
genes None None I-DNA
in None None O
human None None I-cell_type
B None None I-cell_type
lymphocytes None None I-cell_type
. None None O

Here None None O
it None None O
is None None O
shown None None O
that None None O
ZEBRA None None I-protein
also None None O
behaves None None O
as None None O
a None None O
sequence-specific None None I-protein
transcriptional None None I-protein
activator None None I-protein
in None None O
Saccharomyces None None O
cerevisiae None None O
. None None O

Deletional None None O
mutagenesis None None O
defined None None O
three None None O
regions None None O
of None None O
ZEBRA None None I-protein
that None None O
participate None None O
in None None O
activation None None O
in None None O
S. None None O
cerevisiae None None O
. None None O

These None None O
regions None None O
are None None O
designated None None O
YI None None I-protein
( None None O
amino None None I-protein
acids None None I-protein
[ None None I-protein
aa None None I-protein
] None None I-protein
1 None None I-protein
to None None I-protein
25 None None I-protein
) None None O
, None None O
YII None None I-protein
( None None O
aa None None I-protein
51 None None I-protein
to None None I-protein
102 None None I-protein
) None None O
, None None O
and None None O
YIII None None I-protein
( None None O
aa None None I-protein
228 None None I-protein
to None None I-protein
245 None None I-protein
) None None O
. None None O

Two None None O
of None None O
the None None O
three None None O
regions None None O
of None None O
the None None O
native None None O
ZEBRA None None I-protein
protein None None I-protein
act None None O
together None None O
to None None O
mediate None None O
activation None None O
when None None O
assayed None None O
on None None O
ZEBRA None None I-protein
binding None None I-protein
sites None None I-protein
. None None O

However None None O
, None None O
when None None O
fused None None O
to None None O
the None None O
DNA None None I-protein
binding None None I-protein
domain None None I-protein
of None None O
GAL None None I-protein
4 None None O
and None None O
assayed None None O
on None None O
GAL4 None None I-protein
binding None None I-protein
sites None None I-protein
, None None O
regions None None I-protein
YII None None I-protein
and None None I-protein
YIII None None I-protein
were None None O
each None None O
sufficient None None O
to None None O
confer None None O
activation None None O
in None None O
S. None None O
cerevisiae None None O
. None None O

Regions None None O
of None None O
ZEBRA None None I-protein
which None None O
affected None None O
activation None None O
in None None O
S. None None O
cerevisiae None None O
were None None O
also None None O
required None None O
in None None O
human None None I-cell_type
B None None I-cell_type
lymphocytes None None I-cell_type
. None None O

The None None O
amino-terminal None None I-protein
region None None I-protein
of None None O
ZEBRA None None I-protein
( None None O
aa None None I-protein
1 None None I-protein
to None None I-protein
98 None None I-protein
) None None O
was None None O
required None None O
for None None O
activation None None O
both None None O
in None None O
S. None None O
cerevisiae None None O
and None None O
in None None O
human None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
; None None O
deletion None None O
of None None O
the None None O
carboxy-terminal None None I-protein
18 None None I-protein
aa None None I-protein
also None None O
significantly None None O
reduced None None O
activation None None O
in None None O
both None None O
cell None None O
types None None O
. None None O

Thus None None O
, None None O
the None None O
behavior None None O
of None None O
ZEBRA None None I-protein
in None None O
human None None I-cell_type
B None None I-cell_type
cells None None I-cell_type
and None None O
S. None None O
cerevisiae None None O
suggests None None O
that None None O
the None None O
protein None None O
contains None None O
universal None None I-protein
activation None None I-protein
motifs None None I-protein
that None None O
interact None None O
with None None O
conserved None None O
components None None O
of None None O
the None None O
transcription None None O
machinery None None O
. None None O

However None None O
, None None O
certain None None O
deletion None None I-protein
mutants None None I-protein
of None None O
ZEBRA None None I-protein
containing None None O
mutations None None O
in None None O
the None None O
N-terminal None None I-protein
region None None I-protein
exhibited None None O
discordant None None O
behaviors None None O
in None None O
S. None None O
cerevisiae None None O
and None None O
in None None O
B None None O
cells None None O
. None None O

For None None O
example None None O
, None None O
deletion None None O
of None None O
ZEBRA None None I-protein
aa None None I-protein
26 None None I-protein
to None None I-protein
51 None None I-protein
impaired None None O
activation None None O
to None None O
a None None O
great None None O
extent None None O
in None None O
B None None I-cell_type
cells None None I-cell_type
but None None O
had None None O
little None None O
or None None O
no None None O
effect None None O
in None None O
S. None None O
cerevisiae None None O
. None None O

The None None O
discordant None None O
mutants None None O
may None None O
reflect None None O
interactions None None O
with None None O
a None None O
variable None None I-protein
domain None None I-protein
of None None O
a None None O
conserved None None O
component None None O
or None None O
unique None None O
interactions None None O
with None None O
specialized None None O
components None None O
of None None O
the None None O
basal None None O
transcription None None O
apparatus None None O
in None None O
different None None O
cells None None O
. None None O

Functional None None O
interaction None None O
of None None O
the None None O
v-Rel None None I-protein
and None None I-protein
c-Rel None None I-protein
oncoproteins None None I-protein
with None None O
the None None O
TATA-binding None None I-protein
protein None None I-protein
and None None O
association None None O
with None None O
transcription None None I-protein
factor None None I-protein
IIB None None I-protein
. None None O

Rel None None I-protein
family None None I-protein
proteins None None I-protein
regulate None None O
the None None O
expression None None O
of None None O
genes None None O
linked None None O
to None None O
kappa None None O
B-binding None None O
motifs None None O
. None None O

Little None None O
is None None O
known None None O
, None None O
however None None O
, None None O
of None None O
the None None O
mechanism None None O
by None None O
which None None O
they None None O
enhance None None O
transcription None None O
. None None O

We None None O
have None None O
investigated None None O
the None None O
ability None None O
of None None O
the None None O
v-Rel None None I-protein
and None None I-protein
c-Rel None None I-protein
oncoproteins None None I-protein
to None None O
interact None None O
with None None O
components None None O
of None None O
the None None O
basal None None O
transcription None None O
machinery None None O
. None None O

Here None None O
we None None O
report None None O
that None None O
both None None O
the None None O
acidic None None O
transcription None None O
activation None None O
domain None None O
mapping None None O
to None None O
the None None O
unique None None O
C None None I-protein
terminus None None I-protein
of None None O
chicken None None I-protein
c-Rel None None I-protein
and None None O
the None None O
F9 None None I-protein
cell-specific None None I-protein
activation None None I-protein
region None None I-protein
common None None O
to None None O
both None None O
v-Rel None None I-protein
and None None O
c-Rel None None I-protein
interact None None O
with None None O
the None None O
TATA-binding None None I-protein
protein None None I-protein
( None None O
TBP None None I-protein
) None None O
and None None O
transcription None None I-protein
factor None None I-protein
IIB None None I-protein
( None None O
TFIIB None None I-protein
) None None O
in None None O
vitro None None O
and None None O
in None None O
vivo None None O
. None None O

We None None O
also None None O
demonstrate None None O
that None None O
TPB None None I-protein
interaction None None O
with None None O
Rel None None I-protein
activation None None I-protein
regions None None I-protein
leads None None O
to None None O
synergistic None None O
activation None None O
of None None O
transcription None None O
of None None O
a None None O
kappa None None I-DNA
B-linked None None I-DNA
reporter None None I-DNA
gene None None I-DNA
. None None O

Combined None None O
with None None O
the None None O
observation None None O
that None None O
the None None O
mouse None None I-protein
c-Rel None None I-protein
and None None I-protein
human None None I-protein
RelA None None I-protein
proteins None None I-protein
also None None O
interact None None O
with None None O
TBP None None I-protein
and None None O
TFIIB None None I-protein
in None None O
vitro None None O
, None None O
these None None O
results None None O
suggest None None O
that None None O
association None None O
with None None O
basal None None I-protein
transcription None None I-protein
factors None None I-protein
is None None O
important None None O
for None None O
the None None O
transcriptional None None O
activities None None O
of None None O
Rel None None I-protein
family None None I-protein
proteins None None I-protein
. None None O

p21ras None None I-protein
and None None O
calcineurin None None O
synergize None None O
to None None O
regulate None None O
the None None O
nuclear None None I-protein
factor None None I-protein
of None None O
activated None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

In None None O
T None None I-cell_type
lymphocytes None None I-cell_type
, None None O
triggering None None O
of None None O
the None None O
T None None I-protein
cell None None I-protein
receptor None None I-protein
( None None O
TCR None None I-protein
) None None O
induces None None O
several None None O
signaling None None O
cascades None None O
which None None O
ultimately None None O
synergize None None O
to None None O
induce None None O
the None None O
activity None None O
of None None O
the None None O
nuclear None None I-protein
factor None None I-protein
of None None O
activated None None O
T None None I-cell_type
cells None None I-cell_type
( None None O
NFAT None None I-cell_line
) None None O
, None None O
a None None O
DNA None None I-protein
binding None None I-protein
complex None None I-protein
critical None None O
to None None O
the None None O
inducibility None None O
and None None O
T None None O
cell None None O
specificity None None O
of None None O
the None None O
T None None I-protein
cell None None I-protein
growth None None I-protein
factor None None I-protein
interleukin None None B-protein
2 None None I-protein
. None None O

One None None O
immediate None None O
consequence None None O
of None None O
T None None O
cell None None O
activation None None O
via None None O
the None None O
TCR None None I-protein
is None None O
an None None O
increase None None O
in None None O
cytosolic None None O
calcium None None O
. None None O

Calcium None None O
signals None None O
are None None O
important None None O
for None None O
NFAT None None I-cell_line
induction None None O
, None None O
and None None O
recent None None O
studies None None O
have None None O
identified None None O
calcineurin None None I-protein
, None None O
a None None O
calcium-calmodulin None None I-protein
dependent None None I-protein
serine-threonine None None I-protein
phosphatase None None I-protein
, None None O
as None None O
a None None O
prominent None None O
component None None O
of None None O
the None None O
calcium None None O
signaling None None O
pathway None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

A None None O
second None None O
important None None O
molecule None None O
in None None O
TCR None None O
signal None None O
transduction None None O
is None None O
the None None O
guanine None None I-protein
nucleotide None None I-protein
binding None None I-protein
protein None None I-protein
, None None O
p21ras None None I-protein
, None None O
which None None O
is None None O
coupled None None O
to None None O
the None None O
TCR None None I-protein
by None None O
a None None O
protein None None I-protein
tyrosine None None I-protein
kinase None None I-protein
dependent None None O
mechanism None None O
. None None O

The None None O
experiments None None O
presented None None O
here None None O
show None None O
that None None O
expression None None O
by None None O
transfection None None O
of None None O
mutationally None None O
activated None None O
calcineurin None None I-protein
or None None O
activated None None O
p21ras None None I-protein
alone None None O
is None None O
insufficient None None O
for None None O
NFAT None None I-cell_type
transactivation None None O
. None None O

However None None O
, None None O
coexpression None None O
of None None O
the None None O
activated None None O
calcineurin None None O
with None None O
activated None None O
p21ras None None O
could None None O
mimic None None O
TCR None None O
signals None None O
in None None O
NFAT None None I-cell_type
induction None None O
. None None O

These None None O
data None None O
identify None None O
calcineurin None None I-protein
and None None O
p21ras None None I-protein
as None None O
cooperative None None O
partners None None O
in None None O
T None None I-cell_type
cell None None I-cell_type
activation None None O
. None None O

Expression None None O
of None None O
the None None O
chicken None None I-protein
GATA None None I-protein
factor None None I-protein
family None None I-protein
during None None O
early None None O
erythroid None None O
development None None O
and None None O
differentiation None None O
. None None O

The None None O
DNA None None O
motif None None O
WGATAR None None O
has None None O
been None None O
identified None None O
within None None O
transcriptional None None I-DNA
regulatory None None I-DNA
domains None None I-DNA
of None None O
globin None None I-DNA
and None None O
other None None O
erythroid-specific None None I-DNA
genes None None I-DNA
and None None O
the None None O
activator None None I-protein
proteins None None I-protein
that None None O
bind None None O
to None None O
this None None O
regulatory None None I-DNA
element None None I-DNA
, None None O
the None None O
GATA None None I-protein
factors None None I-protein
, None None O
belong None None O
to None None O
a None None O
multi-gene None None I-protein
family None None I-protein
that None None O
is None None O
expressed None None O
in None None O
chicken None None I-cell_type
erythroid None None I-cell_type
cells None None I-cell_type
. None None O

Here None None O
we None None O
show None None O
that None None O
, None None O
as None None O
in None None O
chickens None None O
, None None O
multiple None None O
members None None O
of None None O
the None None O
GATA None None I-protein
factor None None I-protein
family None None I-protein
are None None O
expressed None None O
in None None O
human None None I-cell_type
and None None I-cell_type
murine None None I-cell_type
erythroid None None I-cell_type
cells None None I-cell_type
. None None O

During None None O
the None None O
early None None O
stages None None O
of None None O
chicken None None O
embryogenesis None None O
( None None O
well None None O
before None None O
blood None None O
island None None O
formation None None O
) None None O
, None None O
each None None O
of None None O
the None None O
GATA None None I-protein
family None None I-protein
members None None I-protein
is None None O
transcribed None None O
with None None O
a None None O
unique None None O
temporal None None O
and None None O
spatial None None O
pattern None None O
. None None O

In None None O
the None None O
primitive None None I-cell_type
erythroid None None I-cell_type
lineage None None I-cell_type
, None None O
transcription None None O
of None None O
the None None O
embryonic None None I-DNA
epsilon-globin None None I-DNA
gene None None I-DNA
parallels None None O
GATA-1 None None O
expression None None O
while None None O
the None None O
switch None None O
to None None O
beta-globin None None O
transcription None None O
in None None O
definitive None None I-cell_type
erythroid None None I-cell_type
cells None None I-cell_type
is None None O
directly None None O
preceded None None O
by None None O
a None None O
pronounced None None O
increase None None O
in None None O
GATA-3 None None I-protein
accumulation None None O
. None None O

The None None O
timing None None O
and None None O
pattern None None O
of None None O
expression None None O
of None None O
these None None O
different None None O
mRNAs None None I-RNA
during None None O
avian None None O
erythroid None None O
development None None O
and None None O
differentiation None None O
suggests None None O
that None None O
temporally None None O
regulated None None O
changes None None O
in None None O
GATA None None I-protein
factor None None I-protein
expression None None O
are None None O
required None None O
for None None O
vertebrate None None O
hematopoiesis None None O
. None None O

Molecular None None O
regulation None None O
of None None O
human None None I-protein
interleukin None None I-protein
2 None None I-protein
and None None O
T-cell None None I-cell_type
function None None O
by None None O
interleukin None None I-protein
4 None None I-protein
. None None O

Distinct None None O
functional None None O
T-cell None None I-cell_type
subsets None None I-cell_type
, None None O
differing None None O
in None None O
the None None O
patterns None None O
of None None O
lymphokines None None I-protein
produced None None O
, None None O
regulate None None O
cell-mediated None None O
and None None O
humoral None None O
immune None None O
responses None None O
. None None O

The None None O
two None None O
major None None O
types None None O
and None None O
their None None O
principal None None O
products None None O
, None None O
interleukin None None I-protein
4 None None I-protein
and None None O
interferon None None I-protein
gamma None None I-protein
( None None O
IL-4 None None I-protein
and None None O
IFN-gamma None None I-protein
) None None O
, None None O
are None None O
reciprocally None None O
negatively None None O
interactive None None O
. None None O

To None None O
analyze None None O
the None None O
molecular None None O
mechanism None None O
of None None O
IL-4-mediated None None O
suppression None None O
of None None O
cell-mediated None None O
immunity None None O
we None None O
studied None None O
its None None O
effects None None O
on None None O
expression None None O
of None None O
interleukin None None I-protein
2 None None I-protein
( None None O
IL-2 None None I-protein
) None None O
and None None O
IFN-gamma None None I-protein
. None None O

IL-4 None None I-protein
pretreatment None None O
of None None O
Jurkat None None I-cell_type
cells None None I-cell_type
prior None None O
to None None O
stimulation None None O
resulted None None O
in None None O
a None None O
decrease None None O
in None None O
transcription None None O
of None None O
the None None O
IL2 None None I-DNA
gene None None I-DNA
. None None O

IL-4 None None I-protein
suppressed None None O
IL-2 None None O
and None None O
IFN-gamma None None O
mRNA None None O
levels None None O
in None None O
primary None None I-cell_type
human None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
, None None O
and None None O
addition None None O
of None None O
anti-CD28 None None I-protein
antibodies None None I-protein
relieved None None O
this None None O
suppression None None O
. None None O

Using None None O
enhancer-reporter None None I-DNA
constructs None None I-DNA
, None None O
IL-4 None None I-protein
specifically None None O
down-regulated None None O
the None None O
NFIL-2B None None I-DNA
element None None I-DNA
. None None O

Electrophoretic None None O
mobility None None O
shift None None O
assays None None O
using None None O
a None None O
DNA None None O
oligomer None None O
containing None None O
the None None O
NFIL-2B None None I-DNA
binding None None I-DNA
site None None I-DNA
indicated None None O
that None None O
IL-4 None None I-protein
inhibited None None O
the None None O
NFIL-2B None None I-protein
complex None None I-protein
and None None O
that None None O
the None None O
NFIL-2B None None I-protein
DNA None None I-protein
binding None None I-protein
factor None None I-protein
is None None O
distinct None None O
from None None O
AP- None None I-protein
1 None None O
. None None O

These None None O
results None None O
suggest None None O
that None None O
IL-4 None None I-protein
may None None O
regulate None None O
development None None O
and None None O
function None None O
of None None O
T-cell None None I-cell_type
subsets None None I-cell_type
involved None None O
in None None O
cell-mediated None None O
immunity None None O
in None None O
part None None O
by None None O
inhibiting None None I-protein
factors None None I-protein
required None None O
for None None O
transcription None None O
of None None O
the None None O
IL2 None None I-DNA
gene None None I-DNA

Immunochemical None None O
differences None None O
between None None O
glucocorticoid None None I-protein
receptors None None I-protein
from None None O
corticoid-sensitive None None I-cell_type
and None None I-cell_type
-resistant None None I-cell_type
malignant None None I-cell_type
lymphocytes None None I-cell_type
. None None O

We None None O
have None None O
explored None None O
the None None O
possibility None None O
of None None O
using None None O
antibodies None None I-protein
against None None O
purified None None O
rat None None O
liver None None O
glucocorticoid None None I-protein
receptors None None I-protein
to None None O
study None None O
the None None O
immunochemical None None O
properties None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
from None None O
murine None None I-cell_type
and None None I-cell_type
human None None I-cell_type
malignant None None I-cell_type
lymphocytes None None I-cell_type
. None None O

For None None O
this None None O
purpose None None O
, None None O
purified None None I-protein
immune None None I-protein
immunoglobulin None None I-protein
G None None I-protein
was None None O
covalently None None O
linked None None O
to None None O
Sepharose None None I-protein
CL-4B None None I-protein
. None None O

We None None O
then None None O
examined None None O
the None None O
ability None None O
of None None O
the None None O
affinity None None O
gel None None O
to None None O
recognize None None O
cytosolic None None I-protein
[ None None I-protein
3H None None I-protein
] None None I-protein
triamcinolone None None I-protein
acetonide-receptor None None I-protein
complexes None None I-protein
from None None O
the None None O
corticoid-sensitive None None I-cell_line
( None None I-cell_line
CS None None I-cell_line
) None None I-cell_line
and None None I-cell_line
-resistant None None I-cell_line
strains None None I-cell_line
of None None I-cell_line
mouse None None I-cell_line
lymphoma None None I-cell_line
P1798 None None I-cell_line
, None None O
from None None O
CS None None I-cell_type
lymphocytes None None I-cell_type
of None None O
patients None None O
with None None O
chronic None None O
lymphatic None None O
leukemia None None O
, None None O
and None None O
from None None O
a None None O
CS None None I-cell_line
clone None None I-cell_line
of None None O
human None None I-cell_type
leukemic None None I-cell_type
lymphoblasts None None I-cell_type
in None None O
tissue None None O
culture None None O
( None None O
CH6 None None I-cell_line
) None None O
. None None O

Mouse None None O
thymus None None O
was None None O
used None None O
as None None O
a None None O
source None None O
of None None O
glucocorticoid None None I-protein
receptor None None I-protein
from None None O
normal None None I-cell_type
CS None None I-cell_type
lymphocytes None None I-cell_type
. None None O

Whereas None None O
the None None O
immunoaffinity None None O
column None None O
retained None None O
70 None None O
to None None O
84 None None O
% None None O
of None None O
the None None O
58- None None O
to None None O
62-A None None O
( None None O
Stokes None None O
radius None None O
) None None O
[ None None I-protein
3H None None I-protein
] None None I-protein
triamcinolone None None I-protein
acetonide-receptor None None I-protein
complexes None None I-protein
characteristic None None O
of None None O
the None None O
CS None None I-cell_line
mouse None None I-cell_line
and None None I-cell_line
human None None I-cell_line
lymphocytes None None I-cell_line
, None None O
it None None O
failed None None O
to None None O
recognize None None O
the None None O
27- None None O
to None None O
28-A None None O
( None None O
Stokes None None O
radius None None O
) None None O
glucocorticoid None None I-protein
receptor None None I-protein
present None None O
in None None O
corticoid-resistant None None O
mouse None None I-cell_line
lymphoma None None I-cell_line
P1798 None None I-cell_line
cells None None I-cell_line
. None None O

Therefore None None O
, None None O
under None None O
appropriate None None O
experimental None None O
conditions None None O
, None None O
it None None O
was None None O
possible None None O
to None None O
demonstrate None None O
cross-reactivity None None O
between None None O
the None None O
antiserum None None O
against None None O
rat None None I-protein
liver None None I-protein
glucocorticoid None None I-protein
receptor None None I-protein
and None None O
the None None O
58- None None O
to None None O
62-A None None O
( None None O
Stokes None None O
radius None None O
) None None O
glucocorticoid None None I-protein
receptor None None I-protein
from None None O
species None None O
as None None O
diverse None None O
as None None O
mouse None None O
and None None O
humans None None O
. None None O

Heterogeneity None None O
of None None O
the None None O
in None None O
vitro None None O
responses None None O
to None None O
glucocorticoids None None O
in None None O
acute None None O
leukemia None None O
. None None O

In None None O
leukocyte None None I-cell_type
population None None I-cell_type
freshly None None O
isolated None None O
from None None O
the None None O
blood None None O
of None None O
26 None None O
patients None None O
with None None O
acute None None O
leukemia None None O
, None None O
we None None O
have None None O
measured None None O
several None None O
parameters None None O
including None None O
glucocorticoid None None I-protein
receptors None None I-protein
, None None O
nucleoside None None O
incorporation None None O
, None None O
percentage None None O
of None None O
cells None None O
in None None O
S None None O
phase None None O
, None None O
and None None O
steroid-induced None None O
cell None None O
lysis None None O
. None None O

In None None O
addition None None O
, None None O
in None None O
some None None O
cases None None O
, None None O
the None None O
short-term None None O
response None None O
to None None O
steroid None None O
therapy None None O
was None None O
determined None None O
. None None O

Although None None O
, None None O
in None None O
all None None O
the None None O
patients None None O
studied None None O
, None None O
leukocytes None None I-cell_type
were None None O
found None None O
to None None O
contain None None O
glucocorticoid None None I-protein
receptors None None I-protein
, None None O
we None None O
failed None None O
to None None O
demonstrate None None O
any None None O
correlation None None O
between None None O
the None None O
level None None O
of None None O
binding None None O
sites None None O
and None None O
the None None O
in None None O
vitro None None O
or None None O
in None None O
vivo None None O
response None None O
to None None O
glucocorticoids None None O
. None None O

This None None O
absence None None O
of None None O
correlation None None O
could None None O
be None None O
in None None O
part None None O
explained None None O
by None None O
the None None O
marked None None O
heterogeneity None None O
of None None O
the None None O
steroid None None O
response None None O
demonstrated None None O
in None None O
leukocyte None None O
subpopulations None None O
. None None O

It None None O
appears None None O
, None None O
however None None O
, None None O
that None None O
the None None O
degree None None O
of None None O
steroid None None O
action None None O
in None None O
vitro None None O
as None None O
well None None O
as None None O
the None None O
extent None None O
of None None O
spontaneous None None O
and None None O
dexamethasone-induced None None O
cell None None O
death None None O
may None None O
be None None O
related None None O
to None None O
the None None O
number None None O
of None None O
cells None None O
in None None O
the None None O
S None None O
phase None None O
of None None O
the None None O
cell None None O
cycle None None O
. None None O

Glucocorticoid None None I-protein
receptors None None I-protein
in None None O
cytosol None None O
and None None O
nuclear None None O
extract None None O
of None None O
human None None I-cell_type
leukocytes None None I-cell_type
. None None O

Cortisol None None O
binding None None O
by None None O
cytosol None None O
and None None O
0.4 None None O
M None None O
KCl None None O
extract None None O
of None None O
the None None O
nuclear None None O
fraction None None O
of None None O
human None None I-cell_type
leukocytes None None I-cell_type
were None None O
studied None None O
by None None O
gel None None O
chromatography None None O
and None None O
ion None None O
exchange None None O
filtration None None O
on None None O
DEAE None None O
cellulose None None O
. None None O

The None None O
cytoplasmic None None I-protein
cortisol None None I-protein
binding None None I-protein
protein None None I-protein
has None None O
a None None O
molecular None None O
weight None None O
95 None None O
000 None None O
and None None O
the None None O
soluble None None I-protein
nuclear None None I-protein
binding None None I-protein
protein None None I-protein
50 None None O
000 None None O
. None None O

The None None O
absence None None O
of None None O
the None None O
uptake None None O
of None None O
radioactive None None O
cortisol None None O
by None None O
isolated None None O
nuclei None None O
and None None O
the None None O
apparent None None O
requirement None None O
of None None O
the None None O
cytosol None None O
for None None O
glucocorticoid None None O
specific None None O
binding None None O
in None None O
nuclear None None O
receptor None None O
sites None None O
was None None O
observed None None O
. None None O

The None None O
association None None O
constant None None O
characterising None None O
the None None O
binding None None O
of None None O
cortisol None None O
to None None O
cytosol None None O
was None None O
KA None None O
= None None O
3.5 None None O
. None None O
10 None None O
( None None O
9 None None O
) None None O
l/mol None None O
. None None O

Corticosteroid-induced None None O
lymphopenia None None O
, None None O
immunosuppression None None O
, None None O
and None None O
body None None O
defense None None O
. None None O

The None None O
apparent None None O
paradox None None O
of None None O
heightened None None O
adrenal None None O
corticosteroid None None O
levels None None O
associated None None O
with None None O
reduction None None O
in None None O
the None None O
competence None None O
of None None O
the None None O
body None None O
's None None O
defensive None None O
apparatus None None O
to None None O
cope None None O
with None None O
exposure None None O
to None None O
new None None O
microbial None None I-protein
antigens None None I-protein
is None None O
considered None None O
. None None O

The None None O
question None None O
is None None O
asked None None O
how None None O
this None None O
lowered None None O
defensive None None O
capability None None O
, None None O
which None None O
occurs None None O
in None None O
the None None O
face None None O
of None None O
a None None O
threat None None O
to None None O
body None None O
integrity None None O
, None None O
is None None O
consistent None None O
with None None O
Cannon None None O
's None None O
principals None None O
of None None O
the None None O
`` None None O
wisdom None None O
of None None O
the None None O
body. None None O
'' None None O

The None None O
suggestion None None O
is None None O
offered None None O
that None None O
the None None O
immunologic None None O
response None None O
to None None O
self-antigens None None I-protein
exposed None None O
by None None O
disease None None O
or None None O
trauma None None O
may None None O
be None None O
suppressed None None O
by None None O
corticosteroid None None O
to None None O
offset None None O
the None None O
likelihood None None O
of None None O
autoimmune None None O
attack None None O
. None None O

Protein None None I-protein
tyrosine None None I-protein
kinase None None I-protein
activation None None O
is None None O
required None None O
for None None O
lipopolysaccharide None None O
induction None None O
of None None O
cytokines None None I-protein
in None None O
human None None I-cell_type
blood None None I-cell_type
monocytes None None I-cell_type
. None None O

Bacterial None None O
LPS None None O
induce None None O
production None None O
of None None O
cytokines None None I-protein
such None None O
as None None O
IL-1 None None I-protein
, None None O
IL-6 None None I-protein
, None None O
and None None O
TNF None None I-protein
in None None O
mononuclear None None I-cell_type
phagocytes None None I-cell_type
, None None O
and None None O
this None None O
represents None None O
a None None O
central None None O
component None None O
in None None O
the None None O
pathogenesis None None O
of None None O
septic None None O
shock None None O
syndrome None None O
. None None O

However None None O
, None None O
the None None O
mechanisms None None O
by None None O
which None None O
LPS None None O
activates None None O
these None None O
cells None None O
to None None O
express None None O
cytokines None None I-protein
are None None O
not None None O
completely None None O
characterized None None O
. None None O

The None None O
present None None O
study None None O
addressed None None O
the None None O
role None None O
of None None O
different None None O
protein None None I-protein
kinases None None I-protein
in None None O
the None None O
LPS None None O
induction None None O
of None None O
cytokines None None I-protein
. None None O

It None None O
is None None O
shown None None O
that None None O
LPS None None O
induced None None O
a None None O
12- None None O
to None None O
16-fold None None O
increase None None O
in None None O
IL-1 None None O
beta None None O
, None None O
IL-6 None None O
, None None O
and None None O
TNF-alpha None None O
mRNA None None O
levels None None O
, None None O
and None None O
this None None O
was None None O
completely None None O
or None None O
more None None O
than None None O
80 None None O
% None None O
blocked None None O
by None None O
the None None O
protein None None O
tyrosine None None O
kinase None None O
specific None None O
inhibitors None None O
herbimycin None None O
A None None O
and None None O
genistein None None O
at None None O
the None None O
concentrations None None O
of None None O
1.7 None None O
and None None O
37 None None O
microM None None O
, None None O
respectively None None O
. None None O

Protein None None I-protein
kinase None None I-protein
C None None I-protein
inhibition None None O
by None None O
staurosporine None None O
reduced None None O
LPS None None O
induction None None O
of None None O
TNF-alpha None None I-protein
, None None O
whereas None None O
it None None O
had None None O
no None None O
effects None None O
on None None O
IL-6 None None I-protein
and None None O
IL-1 None None O
beta None None O
. None None O

Inhibition None None O
of None None O
protein None None I-protein
kinase None None I-protein
A None None I-protein
by None None O
H89 None None O
reduced None None O
IL-6 None None I-RNA
mRNA None None I-RNA
levels None None O
but None None O
did None None O
not None None O
detectably None None O
change None None O
IL-1 None None O
beta None None O
or None None O
TNF-alpha None None O
mRNA None None O
levels None None O
. None None O

In None None O
contrast None None O
, None None O
LPS None None O
did None None O
not None None O
increase None None O
leukemia None None I-RNA
inhibitory None None I-RNA
factor None None I-RNA
mRNA None None I-RNA
, None None O
which None None O
was None None O
constitutively None None O
expressed None None O
and None None O
not None None O
significantly None None O
reduced None None O
by None None O
these None None O
inhibitors None None O
. None None O

In None None O
addition None None O
to None None O
cytokine None None I-RNA
mRNA None None I-RNA
levels None None O
, None None O
LPS-induced None None O
IL-6 None None O
protein None None O
synthesis None None O
and None None O
IL-6 None None O
bioactivity None None O
were None None O
also None None O
reduced None None O
to None None O
baseline None None O
levels None None O
by None None O
the None None O
PTK None None O
inhibitors None None O
herbimycin None None O
A None None O
and None None O
genistein None None O
. None None O

Both None None O
PTK None None O
inhibitors None None O
also None None O
reduced None None O
the None None O
LPS None None O
activation None None O
of None None O
nuclear None None I-protein
factor-kappa None None I-protein
B None None I-protein
( None None O
NF-kappa None None I-protein
B None None I-protein
) None None O
, None None O
which None None O
is None None O
a None None O
transcription None None I-protein
factor None None I-protein
involved None None O
in None None O
the None None O
expression None None O
of None None O
cytokine None None I-RNA
genes None None I-RNA
such None None O
as None None O
IL-6 None None I-DNA
and None None O
TNF-alpha None None I-DNA
. None None O

The None None O
activation None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
was None None O
also None None O
reduced None None O
by None None O
H89 None None O
, None None O
whereas None None O
staurosporine None None O
had None None O
no None None O
effect None None O
on None None O
this None None O
response None None O
. None None O

In None None O
summary None None O
, None None O
these None None O
findings None None O
suggest None None O
that None None O
protein None None I-protein
kinase None None I-protein
C None None I-protein
and None None O
protein None None I-protein
kinase None None I-protein
A None None I-protein
appear None None O
to None None O
have None None O
selective None None O
effects None None O
in None None O
the None None O
LPS None None O
induction None None O
of None None O
cytokines None None I-protein
, None None O
whereas None None O
PTK None None I-protein
is None None O
required None None O
for None None O
LPS None None O
induction None None O
of None None O
a None None O
broad None None O
spectrum None None O
of None None O
cytokines None None I-protein
and None None O
NF-kappa None None I-protein
B None None I-protein
activation None None O
in None None O
monocytes None None I-cell_type
. None None O

In None None O
vivo None None O
control None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
activation None None O
by None None O
I None None I-protein
kappa None None I-protein
B None None I-protein
alpha None None I-protein
. None None O

The None None O
transcription None None I-protein
factor None None I-protein
NF-kappa None None B-protein
B None None I-protein
is None None O
stored None None O
in None None O
the None None O
cytoplasm None None O
in None None O
complexes None None O
with None None O
the None None O
inhibitor None None I-protein
protein None None I-protein
I None None I-protein
kappa None None I-protein
B None None I-protein
alpha None None I-protein
. None None O

It None None O
has None None O
been None None O
shown None None O
in None None O
vitro None None O
that None None O
dissociation None None O
of None None O
I None None I-protein
kappa None None I-protein
B None None I-protein
alpha None None I-protein
from None None O
these None None O
complexes None None O
results None None O
in None None O
active None None I-protein
NF-kappa None None I-protein
B None None I-protein
. None None O

In None None O
this None None O
report None None O
we None None O
show None None O
that None None O
lipopolysaccharide None None O
( None None O
LPS None None O
) None None O
-induced None None O
activation None None O
of None None O
B None None I-cell_type
or None None I-cell_type
pre-B None None I-cell_type
cells None None I-cell_type
results None None O
in None None O
loss None None O
of None None O
I None None I-protein
kappa None None I-protein
B None None I-protein
alpha None None I-protein
from None None O
NF-kappa None None I-protein
B None None I-protein
complexes None None I-protein
in None None O
vivo None None O
. None None O

Many None None O
liberated None None O
NF-kappa None None I-protein
B None None I-protein
dimers None None I-protein
reached None None O
the None None O
nucleus None None O
, None None O
where None None O
increased None None O
c-rel None None I-protein
, None None O
p65 None None O
and None None O
p50 None None O
were None None O
detected None None O
by None None O
immunoblotting None None O
and None None O
by None None O
DNA None None O
binding None None O
assays None None O
. None None O

Some None None O
liberated None None I-protein
dimers None None I-protein
were None None O
retained None None O
in None None O
the None None O
cytoplasm None None O
, None None O
however None None O
, None None O
through None None O
binding None None O
to None None O
newly None None O
synthesized None None O
I None None I-protein
kappa None None I-protein
B None None I-protein
alpha None None I-protein
, None None O
a None None O
finding None None O
which None None O
strongly None None O
suggests None None O
( None None O
i None None O
) None None O
that None None O
the None None O
LPS-induced None None O
signal None None O
causes None None O
dissociation None None O
of None None O
complexes None None O
rather None None O
than None None O
preventing None None O
their None None O
association None None O
and None None O
( None None O
ii None None O
) None None O
that None None O
dissociation None None O
results None None O
from None None O
modification None None O
of None None O
I None None I-protein
kappa None None I-protein
B None None I-protein
alpha None None I-protein
and None None O
not None None O
of None None O
c-rel None None I-protein
or None None O
p65 None None I-protein
. None None O

No None None O
effect None None O
of None None O
LPS None None O
treatment None None O
was None None O
detected None None O
on None None O
p105 None None I-protein
or None None O
p100 None None I-protein
, None None O
which None None O
also None None O
retain None None O
rel None None I-protein
family None None I-protein
members None None I-protein
in None None O
the None None O
cytoplasm None None O
. None None O

Quite None None O
unexpectedly None None O
, None None O
we None None O
also None None O
found None None O
that None None O
in None None O
unstimulated None None I-cell_type
cells None None I-cell_type
there None None O
is None None O
a None None O
constant None None O
ongoing None None O
process None None O
of None None O
degradation None None O
and None None O
replacement None None O
of None None O
complexed None None I-protein
I None None I-protein
kappa None None I-protein
B None None I-protein
alpha None None I-protein
. None None O

We None None O
propose None None O
that None None O
this None None O
turnover None None O
results None None O
in None None O
the None None O
low None None O
level None None O
of None None O
active None None I-protein
NF-kappa None None I-protein
B None None I-protein
presumably None None O
necessary None None O
even None None O
in None None O
the None None O
unstimulated None None O
cell None None O
, None None O
and None None O
that None None O
the None None O
high None None O
rate None None O
of None None O
synthesis None None O
of None None O
I None None I-protein
kappa None None I-protein
B None None I-protein
alpha None None I-protein
provides None None O
the None None O
ability None None O
to None None O
turn None None O
off None None O
NF-kappa None None I-protein
B None None I-protein
activity None None O
rapidly None None O
as None None O
soon None None O
as None None O
the None None O
activating None None O
signal None None O
ceases None None O
. None None O

Identification None None O
of None None O
a None None O
killer None None I-DNA
cell-specific None None I-DNA
regulatory None None I-DNA
element None None I-DNA
of None None O
the None None O
mouse None None I-DNA
perforin None None I-DNA
gene None None I-DNA
: None None O
an None None O
Ets-binding None None O
site-homologous None None O
motif None None O
that None None O
interacts None None O
with None None O
Ets-related None None I-protein
proteins None None I-protein
. None None O

The None None O
gene None None O
encoding None None O
the None None O
cytolytic None None I-protein
protein None None I-protein
perforin None None B-protein
is None None O
selectively None None O
expressed None None O
by None None O
activated None None I-cell_type
killer None None I-cell_type
lymphocytes None None I-cell_type
. None None O

To None None O
understand None None O
the None None O
mechanisms None None O
underlying None None O
the None None O
cell-type-specific None None O
expression None None O
of None None O
this None None O
gene None None O
, None None O
we None None O
have None None O
characterized None None O
the None None O
regulatory None None O
functions None None O
and None None O
the None None O
DNA-protein None None O
interactions None None O
of None None O
the None None O
5'-flanking None None I-DNA
region None None I-DNA
of None None O
the None None O
mouse None None I-DNA
perforin None None I-DNA
gene None None I-DNA
( None None O
Pfp None None I-DNA
) None None O
. None None O

A None None O
region None None O
extending None None O
from None None O
residues None None I-DNA
+62 None None I-DNA
through None None I-DNA
-141 None None I-DNA
, None None O
which None None O
possesses None None O
the None None O
essential None None O
promoter None None O
activity None None O
, None None O
and None None O
regions None None O
further None None O
upstream None None O
, None None O
which None None O
are None None O
able None None O
to None None O
either None None O
enhance None None O
or None None O
suppress None None O
gene None None O
expression None None O
, None None O
were None None O
identified None None O
. None None O

The None None O
region None None O
between None None O
residues None None I-DNA
-411 None None I-DNA
and None None I-DNA
-566 None None I-DNA
was None None O
chosen None None O
for None None O
further None None O
characterization None None O
, None None O
since None None O
it None None O
contains None None O
an None None O
enhancer-like None None O
activity None None O
. None None O

We None None O
have None None O
identified None None O
a None None O
32-mer None None O
sequence None None O
( None None O
residues None None I-DNA
-491 None None I-DNA
to None None I-DNA
-522 None None I-DNA
) None None O
which None None O
appeared None None O
to None None O
be None None O
capable None None O
of None None O
enhancing None None O
gene None None O
expression None None O
in None None O
a None None O
killer None None O
cell-specific None None O
manner None None O
. None None O

Within None None O
this None None O
segment None None O
, None None O
a None None O
9-mer None None O
motif None None O
( None None O
5'-ACAGGAAGT-3 None None O
' None None O
, None None O
residues None None I-DNA
-505 None None I-DNA
to None None I-DNA
-497 None None I-DNA
; None None O
designated None None O
NF-P None None O
motif None None O
) None None O
, None None O
which None None O
is None None O
highly None None O
homologous None None O
to None None O
the None None O
Ets None None I-DNA
proto-oncoprotein-binding None None I-DNA
site None None I-DNA
, None None O
was None None O
found None None O
to None None O
interact None None O
with None None O
two None None O
proteins None None O
, None None O
NF-P1 None None I-protein
and None None O
NF-P2 None None I-protein
. None None O

NF-P2 None None I-protein
appears None None O
to None None O
be None None O
induced None None O
by None None O
reagents None None O
known None None O
to None None O
up-regulate None None O
the None None O
perforin None None O
message None None O
level None None O
and None None O
is None None O
present None None O
exclusively None None O
in None None O
killer None None I-cell_type
cells None None I-cell_type
. None None O

Electrophoretic None None O
mobility None None O
shift None None O
assay None None O
and None None O
UV None None O
cross-linking None None O
experiments None None O
revealed None None O
that None None O
NF-P1 None None I-protein
and None None O
NF-P2 None None I-protein
may None None O
possess None None O
common None None O
DNA-binding None None I-protein
subunits None None I-protein
. None None O

However None None O
, None None O
the None None O
larger None None O
native None None O
molecular None None O
mass None None O
of None None O
NF-P1 None None I-protein
suggests None None O
that None None O
NF-P1 None None I-protein
contains None None O
an None None O
additional None None O
non-DNA-binding None None I-protein
subunit None None I-protein
( None None O
s None None O
) None None O
. None None O

In None None O
view None None O
of None None O
the None None O
homology None None O
between None None O
the None None O
NF-P None None I-protein
motif None None I-protein
and None None O
other None None O
Ets None None I-protein
proto-oncoprotein-binding None None I-protein
sites None None I-protein
, None None O
it None None O
is None None O
postulated None None O
that None None O
NF-P1 None None I-protein
and None None O
NF-P2 None None I-protein
belong None None O
to None None O
the None None O
Ets None None I-protein
protein None None I-protein
family None None I-protein
. None None O

Results None None O
obtained None None O
from None None O
the None None O
binding None None O
competition None None O
assay None None O
, None None O
nevertheless None None O
, None None O
suggest None None O
that None None O
NF-P1 None None I-protein
and None None O
NF-P2 None None I-protein
are None None O
related None None O
to None None O
but None None O
distinct None None O
from None None O
Ets None None I-protein
proteins None None I-protein
, None None O
e.g. None None O
, None None O
Ets-1 None None I-protein
, None None O
Ets-2 None None I-protein
, None None O
and None None O
NF-AT/Elf-1 None None I-protein
, None None O
known None None O
to None None O
be None None O
expressed None None O
in None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
role None None O
of None None O
NF-kappa None None I-DNA
B1 None None I-DNA
( None None I-DNA
p50/p105 None None I-DNA
) None None I-DNA
gene None None I-DNA
expression None None O
in None None O
activation None None O
of None None O
human None None I-cell_type
blood None None I-cell_type
T-lymphocytes None None I-cell_type
via None None O
CD2 None None I-protein
and None None I-protein
CD28 None None I-protein
adhesion None None I-protein
molecules None None I-protein
. None None O

Stimulation None None O
of None None O
primary None None I-cell_type
human None None I-cell_type
T-lymphocytes None None I-cell_type
via None None O
CD2 None None I-protein
and None None I-protein
CD28 None None I-protein
adhesion None None I-protein
molecules None None I-protein
induces None None O
a None None O
long-lasting None None O
proliferation None None O
( None None O
> None None O
3 None None O
weeks None None O
) None None O
. None None O

This None None O
potent None None O
activation None None O
does None None O
not None None O
require None None O
accessory None None O
cells None None O
, None None O
such None None O
as None None O
monocytes None None I-cell_type
, None None O
but None None O
depends None None O
on None None O
persistent None None O
interleukin None None I-protein
2 None None I-protein
( None None O
IL-2 None None I-protein
) None None O
secretion None None O
and None None O
receptivity None None O
, None None O
which None None O
is None None O
associated None None O
with None None O
high None None O
and None None O
prolonged None None O
expression None None O
of None None O
the None None O
inducible None None O
CD25/IL-2 None None I-DNA
receptor None None I-DNA
alpha None None I-DNA
( None None I-DNA
IL-2R None None I-DNA
alpha None None I-DNA
) None None I-DNA
chain None None I-DNA
gene None None I-DNA
. None None O

The None None O
transcription None None I-protein
factor None None I-protein
NF-kappa None None I-protein
B None None I-protein
participates None None O
in None None O
the None None O
regulation None None O
of None None O
both None None O
IL-2 None None I-DNA
and None None I-DNA
IL-2R None None I-DNA
alpha None None I-DNA
genes None None I-DNA
, None None O
as None None O
well None None O
as None None O
multiple None None I-DNA
cellular None None I-DNA
genes None None I-DNA
involved None None O
in None None O
T-cell None None O
proliferation None None O
. None None O

To None None O
evaluate None None O
the None None O
role None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
in None None O
human None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
T-lymphocytes None None I-cell_type
, None None O
we None None O
previously None None O
analyzed None None O
the None None O
activation None None O
of None None O
NF-kappa None None I-protein
B-related None None I-protein
complexes None None I-protein
in None None O
response None None O
to None None O
CD2+CD28 None None O
costimulation None None O
. None None O

We None None O
demonstrated None None O
a None None O
long-term None None O
induction None None O
of None None O
p50/p65 None None I-protein
heterodimer None None I-protein
, None None O
a None None O
putative None None I-protein
p65/c-Rel None None I-protein
heterodimer None None I-protein
, None None O
and None None O
a None None O
constitutive None None O
nuclear None None O
expression None None O
of None None O
KBF1/p50 None None I-protein
homodimers None None I-protein
. None None I-protein

As None None O
the None None O
role None None O
of None None O
p50 None None I-protein
remains None None O
unclear None None O
, None None O
we None None O
focused None None O
our None None O
present None None O
study None None O
on None None O
NF-kappa None None I-protein
B1 None None I-protein
( None None O
p50/p105 None None I-protein
) None None O
gene None None O
regulation None None O
. None None O

Using None None O
electrophoretic None None O
mobility None None O
shift None None O
assays None None O
and None None O
Western None None O
and None None O
Northern None None O
blot None None O
analyses None None O
, None None O
we None None O
studied None None O
NF-kappa None None I-DNA
B1 None None I-DNA
gene None None I-DNA
expression None None O
during None None O
T-cell None None O
stimulation None None O
via None None O
CD2+CD28 None None I-protein
. None None O

We None None O
observed None None O
a None None O
transient None None O
4- None None O
to None None O
5-fold None None O
increase None None O
of None None O
NF-kappa None None O
B1 None None O
gene None None O
expression None None O
at None None O
both None None O
the None None O
mRNA None None O
and None None O
protein None None O
levels None None O
, None None O
lasting None None O
for None None O
at None None O
least None None O
24 None None O
h None None O
. None None O

p50 None None O
DNA-binding None None O
activity None None O
apparently None None O
stays None None O
highly None None O
controlled None None O
when None None O
p105 None None O
expression None None O
is None None O
enhanced None None O
by None None O
a None None O
physiological None None O
stimulus None None O
of None None O
peripheral None None I-cell_type
blood None None I-cell_type
T-cells None None I-cell_type
. None None O

Partial None None O
inhibition None None O
of None None O
p50 None None O
and None None O
p105 None None O
expression None None O
by None None O
NF-kappa None None I-protein
B1 None None I-protein
antisense None None O
oligonucleotides None None O
significantly None None O
reduced None None O
T-cell None None O
proliferation None None O
and None None O
CD25/IL-2R None None I-protein
alpha None None I-protein
cell None None O
surface None None O
expression None None O
. None None O

( None None O
ABSTRACT None None O
TRUNCATED None None O
AT None None O
250 None None O
WORDS None None O
) None None O

Vitamin None None I-protein
D None None I-protein
receptor None None I-protein
quantitation None None O
in None None O
human None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
in None None O
health None None O
and None None O
disease None None O
. None None O

Vitamin None None I-protein
D None None I-protein
receptor None None I-protein
( None None O
VDR None None O
) None None O
concentration None None O
was None None O
quantitated None None O
in None None O
human None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
mononuclear None None I-cell_type
cells None None I-cell_type
( None None O
PBMC None None I-cell_type
) None None O
from None None O
patients None None O
with None None O
absorptive None None O
hypercalciuria None None O
( None None O
AH None None O
) None None O
and None None O
patients None None O
with None None O
high None None O
1 None None O
, None None O
25 None None O
( None None O
OH None None O
) None None O
2D3 None None O
due None None O
to None None O
acquired None None O
or None None O
transient None None O
disease None None O
states None None O
and None None O
the None None O
results None None O
compared None None O
to None None O
those None None O
in None None O
normal None None O
subjects None None O
. None None O

VDR None None O
concentration None None O
in None None O
resting None None I-cell_type
cells None None I-cell_type
was None None O
not None None O
different None None O
between None None O
the None None O
three None None O
groups None None O
and None None O
represented None None O
constitutive None None O
receptor None None O
expression None None O
of None None O
monocytes None None I-cell_type
. None None O

Following None None O
activation None None O
with None None O
phytohemagglutinin None None I-protein
, None None O
patients None None I-cell_type
with None None O
hypercalcitriolemia None None O
demonstrated None None O
significantly None None O
greater None None O
VDR None None O
concentrations None None O
. None None O

Patients None None O
with None None O
AH None None O
demonstrated None None O
a None None O
normal None None O
value None None O
for None None O
the None None O
group None None O
, None None O
but None None O
6 None None O
patients None None O
had None None O
significantly None None O
greater None None O
concentrations None None O
of None None O
VDR None None I-protein
despite None None O
normal None None O
plasma None None O
1 None None O
, None None O
25 None None O
( None None O
OH None None O
) None None O
2D3 None None O
in None None O
four None None O
of None None O
the None None O
patients None None O
. None None O

Proliferation None None O
, None None O
as None None O
assessed None None O
from None None O
[ None None O
3H None None O
] None None O
thymidine None None O
incorporation None None O
was None None O
inversely None None O
correlated None None O
with None None O
serum None None O
1 None None O
, None None O
25 None None O
( None None O
OH None None O
) None None O
2D3 None None O
and None None O
was None None O
significant None None O
( None None O
R None None O
= None None O
-0.299 None None O
, None None O
p None None O
= None None O
0.048 None None O
) None None O
. None None O

Taken None None O
together None None O
, None None O
the None None O
results None None O
suggest None None O
that None None O
PBMC None None I-cell_type
provide None None O
a None None O
useful None None O
system None None O
for None None O
studying None None O
VDR None None I-protein
status None None O
in None None O
transient None None O
or None None O
acquired None None O
states None None O
of None None O
hypercalcitriolemia None None O
. None None O

Furthermore None None O
, None None O
the None None O
studies None None O
in None None O
patients None None O
with None None O
absorptive None None O
hypercalciuria None None O
disclosed None None O
it None None O
to None None O
be None None O
a None None O
heterogeneous None None O
disorder None None O
, None None O
characterized None None O
by None None O
both None None O
vitamin None None O
D-dependent None None O
and None None O
D-independent None None O
forms None None O
of None None O
receptor None None O
up-regulation None None O
. None None O

Reactive None None O
oxygen None None O
intermediates None None O
activate None None O
NF-kappa None None I-protein
B None None I-protein
in None None O
a None None O
tyrosine None None O
kinase-dependent None None O
mechanism None None O
and None None O
in None None O
combination None None O
with None None O
vanadate None None O
activate None None O
the None None O
p56lck None None I-protein
and None None I-protein
p59fyn None None I-protein
tyrosine None None I-protein
kinases None None I-protein
in None None O
human None None I-cell_type
lymphocytes None None I-cell_type
. None None O

We None None O
have None None O
previously None None O
observed None None O
that None None O
ionizing None None O
radiation None None O
induces None None O
tyrosine None None O
phosphorylation None None O
in None None O
human None None I-cell_type
B-lymphocyte None None I-cell_type
precursors None None I-cell_type
by None None O
stimulation None None O
of None None O
unidentified None None O
tyrosine None None I-protein
kinases None None I-protein
and None None O
this None None O
phosphorylation None None O
is None None O
substantially None None O
augmented None None O
by None None O
vanadate None None O
. None None O

Ionizing None None O
radiation None None O
generates None None O
reactive None None O
oxygen None None O
intermediates None None O
( None None O
ROI None None O
) None None O
. None None O

Because None None O
H2O2 None None O
is None None O
a None None O
potent None None O
ROI None None O
generator None None O
that None None O
readily None None O
crosses None None O
the None None O
plasma None None O
membrane None None O
, None None O
we None None O
used None None O
H2O2 None None O
to None None O
examine None None O
the None None O
effects None None O
of None None O
ROI None None O
on None None O
signal None None O
transduction None None O
. None None O

We None None O
now None None O
provide None None O
evidence None None O
that None None O
the None None O
tyrosine None None O
kinase None None O
inhibitor None None O
herbimycin None None O
A None None O
and None None O
the None None O
free None None O
radical None None O
scavenger None None O
N-acetyl-cysteine None None O
inhibit None None O
both None None O
radiation-induced None None O
and None None O
H2O2-induced None None O
activation None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
, None None O
indicating None None O
that None None O
activation None None O
triggered None None O
by None None O
ROI None None O
is None None O
dependent None None O
on None None O
tyrosine None None O
kinase None None O
activity None None O
. None None O

H2O2 None None O
was None None O
found None None O
to None None O
stimulate None None O
Ins-1 None None I-protein
, None None I-protein
4 None None I-protein
, None None I-protein
5-P3 None None I-protein
production None None O
in None None O
a None None O
tyrosine None None O
kinase-dependent None None O
manner None None O
and None None O
to None None O
induce None None O
calcium None None O
signals None None O
that None None O
were None None O
greatly None None O
augmented None None O
by None None O
vanadate None None O
. None None O

The None None O
synergistic None None O
induction None None O
of None None O
tyrosine None None O
phosphorylation None None O
by None None O
H2O2 None None O
plus None None O
vanadate None None O
included None None O
physiologically None None O
relevant None None O
proteins None None O
such None None O
as None None O
PLC None None I-protein
gamma None None I-protein
1 None None I-protein
. None None O

Although None None O
treatment None None O
of None None O
cells None None O
with None None O
H2O2 None None O
alone None None O
did None None O
not None None O
affect None None O
the None None O
activity None None O
of None None O
src None None I-protein
family None None I-protein
kinases None None I-protein
, None None O
treatment None None O
with None None O
H2O2 None None O
plus None None O
vanadate None None O
led None None O
to None None O
activation None None O
of None None O
the None None O
p56lck None None I-protein
and None None I-protein
p59fyn None None I-protein
tyrosine None None I-protein
kinases None None I-protein
. None None O

The None None O
combined None None O
inhibition None None O
of None None O
phosphatases None None I-protein
and None None O
activation None None O
of None None O
kinases None None I-protein
provides None None O
a None None O
potent None None O
mechanism None None O
for None None O
the None None O
synergistic None None O
effects None None O
of None None O
H2O2 None None O
plus None None O
vanadate None None O
. None None O

Induction None None O
of None None O
tyrosine None None O
phosphorylation None None O
by None None O
ROI None None O
may None None O
thus None None O
lead None None O
to None None O
many None None O
of None None O
the None None O
pleiotropic None None O
effects None None O
of None None O
ROI None None O
in None None O
lymphoid None None I-cell_type
cells None None I-cell_type
, None None O
including None None O
downstream None None O
activation None None O
of None None O
PLC None None I-protein
gamma None None I-protein
1 None None I-protein
and None None O
NF-kappa None None I-protein
B None None I-protein

Influence None None O
of None None O
sex None None I-protein
hormone None None I-protein
binding None None I-protein
globulin None None I-protein
and None None O
serum None None I-protein
albumin None None I-protein
on None None O
the None None O
conversion None None O
of None None O
androstenedione None None O
to None None O
testosterone None None O
by None None O
human None None I-cell_type
erythrocytes None None I-cell_type
. None None O

The None None O
influence None None O
of None None O
human None None I-protein
serum None None I-protein
albumin None None I-protein
and None None O
sex None None I-protein
hormone None None I-protein
binding None None I-protein
globulin None None I-protein
( None None O
SHBG None None I-protein
) None None O
on None None O
the None None O
enzymic None None O
conversion None None O
of None None O
androstenedione None None O
to None None O
testosterone None None O
in None None O
human None None I-cell_type
erythrocytes None None I-cell_type
was None None O
investigated None None O
in None None O
vitro None None O
. None None O

Total None None O
plasma None None O
and None None O
albumin None None I-protein
delayed None None O
the None None O
conversion None None O
rate None None O
of None None O
androstenedione None None O
, None None O
while None None O
SHBG None None I-protein
increased None None O
it None None O
markedly None None O
. None None O

The None None O
effect None None O
of None None O
SHBG None None I-protein
was None None O
largely None None O
abolished None None O
by None None O
heating None None O
to None None O
60 None None O
degrees None None O
C None None O
for None None O
1 None None O
h None None O
and None None O
by None None O
saturating None None O
its None None O
binding None None O
sites None None O
by None None O
DHT None None O
. None None O

The None None O
effect None None O
of None None O
both None None O
proteins None None O
was None None O
found None None O
to None None O
be None None O
related None None O
to None None O
their None None O
concentration None None O
. None None O

It None None O
appears None None O
that None None O
the None None O
binding None None O
sites None None O
of None None O
albumin None None I-protein
provide None None O
a None None O
mechanism None None O
for None None O
retarding None None O
androstenedione None None O
uptake None None O
by None None O
the None None O
erythrocytes None None I-cell_type
and None None O
that None None O
the None None O
high None None O
binding None None O
affinity None None O
of None None O
SHBG None None I-protein
for None None O
testosterone None None O
facilitates None None O
the None None O
diffusion None None O
of None None O
this None None O
steroid None None O
out None None O
of None None O
the None None O
cell None None O
and None None O
thus None None O
, None None O
displaces None None O
the None None O
chemical None None O
equilibrium None None O
within None None O
the None None O
cell None None O
. None None O

Glucocorticoids None None O
and None None O
lymphocytes None None I-cell_type
. None None O

I None None O
. None None O

Increased None None O
glucocorticoid None None I-protein
receptor None None I-protein
levels None None O
in None None O
antigen-stimulated None None I-cell_line
lymphocytes None None I-cell_line
. None None O

Recently None None O
a None None O
2- None None O
to None None O
3-fold None None O
increase None None O
in None None O
the None None O
number None None O
of None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
human None None I-cell_type
peripheral None None I-cell_type
lymphocytes None None I-cell_type
has None None O
been None None O
noted None None O
after None None O
in None None O
vitro None None O
mitogen None None O
stimulation None None O
. None None O

Here None None O
, None None O
we None None O
extend None None O
these None None O
observations None None O
to None None O
in None None O
vivo None None O
immunization None None O
. None None O

After None None O
unilateral None None O
immunization None None O
of None None O
adrenalectomized None None O
male None None O
rats None None O
, None None O
a None None O
50 None None O
% None None O
increase None None O
in None None O
glucocorticoid None None O
receptor None None O
sites None None O
per None None O
cell None None O
, None None O
determined None None O
by None None O
binding None None O
of None None O
dexamethasone None None O
, None None O
was None None O
observed None None O
in None None O
cell None None O
suspensions None None O
of None None O
homolateral None None O
lymph None None O
nodes None None O
over None None O
those None None O
from None None O
the None None O
contralateral None None O
nonimmunized None None O
side None None O
of None None O
the None None O
same None None O
animal None None O
. None None O

The None None O
association None None O
constant None None O
for None None O
dexamethasone None None O
was None None O
similar None None O
in None None O
both None None O
groups None None O
, None None O
as None None O
was None None O
the None None O
stereospecificity None None O
for None None O
various None None O
steroids None None O
, None None O
the None None O
time None None O
course None None O
of None None O
cytoplasmic None None O
and None None O
nuclear None None O
association None None O
, None None O
and None None O
cytoplasmic-to-nuclear None None O
translocation None None O
. None None O

Despite None None O
a None None O
50 None None O
% None None O
increase None None O
in None None O
the None None O
number None None O
of None None O
glucocorticoid None None O
receptor None None O
sites None None O
per None None O
cell None None O
, None None O
the None None O
cells None None O
from None None O
the None None O
homolateral None None O
and None None O
controlateral None None O
lymph None None O
nodes None None O
were None None O
equally None None O
sensitive None None O
to None None O
the None None O
inhibitory None None O
effects None None O
of None None O
dexamethasone None None O
, None None O
as None None O
determined None None O
by None None O
measurements None None O
of None None O
the None None O
incorporation None None O
of None None O
radiolabeled None None O
precursors None None O
of None None O
protein None None O
, None None O
RNA None None O
, None None O
and None None O
DNA None None O
, None None O
or None None O
measurements None None O
of None None O
in None None O
vitro None None O
cell None None O
survival None None O
. None None O

Glucocorticoid None None O
receptors None None O
and None None O
actions None None O
in None None O
rat None None I-cell_type
thymocytes None None I-cell_type
and None None O
immunologically None None O
stimulated None None O
human None None I-cell_type
peripheral None None I-cell_type
lymphocytes None None I-cell_type
. None None O

After None None O
reviewing None None O
briefly None None O
our None None O
earlier None None O
studies None None O
on None None O
glucocorticoid None None O
receptors None None O
and None None O
mechanisms None None O
in None None O
thymus None None I-cell_type
cells None None I-cell_type
, None None O
we None None O
have None None O
outlined None None O
results None None O
from None None O
the None None O
following None None O
two None None O
areas None None O
of None None O
current None None O
interest None None O
in None None O
our None None O
laboratories None None O
: None None O
the None None O
`` None None O
life-cycle None None O
'' None None O
of None None O
glucocorticoid None None O
receptors None None O
and None None O
complexes None None O
in None None O
thymus None None I-cell_type
cells None None I-cell_type
, None None O
and None None O
the None None O
levels None None O
of None None O
glucocorticoid None None O
receptors None None O
and None None O
sensitivity None None O
in None None O
immunologically None None I-cell_type
stimulated None None I-cell_type
human None None I-cell_type
peripheral None None I-cell_type
lymphocytes None None I-cell_type
. None None O

Several None None O
of None None O
our None None O
results None None O
on None None O
energetics None None O
and None None O
kinetics None None O
of None None O
hormone None None O
binding None None O
to None None O
glucocorticoid None None I-protein
receptors None None I-protein
in None None O
rat None None I-cell_type
thymus None None I-cell_type
cells None None I-cell_type
seem None None O
to None None O
require None None O
extension None None O
of None None O
the None None O
simplest None None O
model None None O
of None None O
hormone-receptor None None O
transformations None None O
in None None O
intact None None I-cell_type
cells None None I-cell_type
. None None O

ATP-depletion None None O
experiments None None O
suggest None None O
the None None O
existence None None O
of None None O
a None None O
nonbinding None None O
form None None O
of None None O
the None None O
receptor None None O
; None None O
`` None None O
chase None None O
'' None None O
experiments None None O
suggest None None O
reaction None None O
of None None O
hormone None None O
directly None None O
with None None O
nuclear-bound None None O
receptor None None O
; None None O
experiments None None O
on None None O
depletion None None O
and None None O
replenishment None None O
of None None O
cytoplasmic None None I-protein
receptor None None I-protein
using None None O
cortisol None None O
and None None O
dexamethasone None None O
suggest None None O
the None None O
existence None None O
of None None O
at None None O
least None None O
two None None O
subpopulations None None O
of None None O
nuclear-bound None None I-protein
hormone-receptor None None I-protein
complex None None I-protein
. None None O

We None None O
have None None O
found None None O
that None None O
mitogen None None O
or None None O
immunologic None None O
stimulation None None O
of None None O
human None None I-cell_type
peripheral None None I-cell_type
lymphocytes None None I-cell_type
in None None O
culture None None O
leads None None O
within None None O
24 None None O
h None None O
or None None O
so None None O
to None None O
a None None O
striking None None O
increase None None O
in None None O
the None None O
number None None O
of None None O
glucocorticoid None None I-protein
receptor None None I-protein
sites None None O
per None None O
cell None None O
. None None O

We None None O
believe None None O
this None None O
increase None None O
may None None O
be None None O
due None None O
to None None O
partial None None O
synchronization None None O
of None None O
the None None O
cell None None O
population None None O
in None None O
a None None O
phase None None O
of None None O
the None None O
cell None None O
cycle None None O
in None None O
which None None O
receptor None None O
content None None O
is None None O
high None None O
. None None O

Contrary None None O
to None None O
the None None O
widely None None O
held None None O
view None None O
that None None O
mitogen-stimulated None None I-cell_type
cells None None I-cell_type
become None None O
insensitive None None O
to None None O
glucocorticoids None None O
, None None O
our None None O
experiments None None O
show None None O
that None None O
with None None O
respect None None O
to None None O
inhibition None None O
of None None O
thymidine None None O
and None None O
uridine None None O
incorporation None None O
and None None O
glucose None None O
uptake None None O
, None None O
the None None O
cells None None O
are None None O
highly None None O
sensitive None None O
to None None O
dexamethasone None None O
at None None O
24 None None O
, None None O
48 None None O
, None None O
and None None O
72 None None O
h None None O
after None None O
stimulation None None O
with None None O
concanavalin None None I-protein
A None None I-protein
. None None O

Nuclear None None O
glucocorticoid None None O
binding None None O
in None None O
chronic None None I-cell_type
lymphatic None None I-cell_type
leukemia None None I-cell_type
lymphocytes None None I-cell_type
. None None O

A None None O
reliable None None O
procedure None None O
is None None O
described None None O
for None None O
isolating None None O
3H-triamcinolone None None I-protein
acetonide None None I-protein
( None None I-protein
3H-TA None None I-protein
) None None I-protein
receptor None None I-protein
complexes None None I-protein
from None None O
purified None None O
chronic None None O
lymphatic None None I-cell_type
leukemia None None I-cell_type
( None None I-cell_type
CLL None None I-cell_type
) None None I-cell_type
lymphocyte None None I-cell_type
nuclei None None O
, None None O
based None None O
on None None O
the None None O
use None None O
of None None O
carbobenzoxy-L-phenylalanine None None O
( None None O
CBZ-L-phe None None O
) None None O
to None None O
prevent None None O
breakdown None None O
of None None O
hormone-receptor None None I-protein
complexes None None I-protein
during None None O
extraction None None O
of None None O
nuclei None None O
with None None O
0.6M None None O
KCl None None O
. None None O

Using None None O
this None None O
method None None O
, None None O
specific None None O
nuclear None None O
glucocorticoid None None O
binding None None O
was None None O
demonstrated None None O
in None None O
14/14 None None O
patients None None O
with None None O
untreated None None O
CLL None None O
. None None O

No None None O
correlation None None O
was None None O
found None None O
between None None O
levels None None O
of None None O
nuclear-associated None None O
3H-TA None None O
and None None O
peripheral None None O
white None None O
blood None None O
cell None None O
count None None O
or None None O
rosetting None None O
ability None None O
of None None O
circulating None None I-cell_type
lymphocytes None None I-cell_type
. None None O

Multiple None None O
closely-linked None None O
NFAT/octamer None None I-DNA
and None None O
HMG None None I-DNA
I None None I-DNA
( None None I-DNA
Y None None I-DNA
) None None I-DNA
binding None None I-DNA
sites None None I-DNA
are None None O
part None None O
of None None O
the None None O
interleukin-4 None None O
promoter None None O
. None None O

We None None O
show None None O
here None None O
that None None O
the None None O
immediate None None I-DNA
upstream None None I-DNA
region None None I-DNA
( None None O
from None None O
position None None O
-12 None None O
to None None O
-270 None None O
) None None O
of None None O
the None None O
murine None None I-DNA
interleukin None None I-DNA
4 None None I-DNA
( None None I-DNA
Il-4 None None I-DNA
) None None I-DNA
gene None None I-DNA
harbors None None O
a None None O
strong None None O
cell-type None None O
specific None None O
transcriptional None None I-DNA
enhancer None None I-DNA
. None None O

In None None O
T None None I-cell_type
lymphoma None None I-cell_type
cells None None I-cell_type
, None None O
the None None O
activity None None O
of None None O
the None None O
Il-4 None None I-DNA
promoter/enhancer None None I-DNA
is None None O
stimulated None None O
by None None O
phorbol None None O
esters None None O
, None None O
Ca++ None None O
ionophores None None O
and None None O
agonists None None O
of None None O
protein None None I-protein
kinase None None I-protein
A None None I-protein
and None None O
inhibited None None O
by None None O
low None None O
doses None None O
of None None O
the None None O
immunosuppressant None None O
cyclosporin None None O
A None None O
. None None O

The None None O
Il-4 None None I-DNA
promoter/enhancer None None I-DNA
is None None O
transcriptionally None None O
inactive None None O
in None None O
B None None I-cell_type
lymphoma None None I-cell_type
cells None None I-cell_type
and None None O
HeLa None None I-cell_type
cells None None I-cell_type
. None None O

DNase None None O
I None None O
footprint None None O
protection None None O
experiments None None O
revealed None None O
six None None O
sites None None O
of None None O
the None None O
Il-4 None None I-DNA
promoter/enhancer None None I-DNA
to None None O
be None None O
bound None None O
by None None O
nuclear None None I-protein
proteins None None I-protein
from None None O
lymphoid None None I-cell_type
and None None I-cell_type
myeloid None None I-cell_type
cells None None I-cell_type
. None None O

Among None None O
them None None O
are None None O
four None None O
purine None None O
boxes None None O
which None None O
have None None O
been None None O
described None None O
to None None O
be None None O
important None None O
sequence None None O
motifs None None O
of None None O
the None None O
Il-2 None None I-DNA
promoter None None I-DNA
. None None O

They None None O
contain None None O
the None None O
motif None None O
GGAAA None None O
and None None O
are None None O
recognized None None O
by None None O
the None None O
inducible None None I-protein
and None None I-protein
cyclosporin None None I-protein
A-sensitive None None I-protein
transcription None None I-protein
factor None None I-protein
NFAT-1 None None I-protein
. None None O

Three None None O
of None None O
the None None O
Il-4 None None I-DNA
NFAT-1 None None I-DNA
sites None None I-DNA
are None None O
closely None None O
linked None None O
to None None O
weak None None O
binding None None O
sites None None O
of None None O
Octamer None None I-protein
factors None None I-protein
. None None O

Several None None O
purine None None O
boxes None None O
and None None O
an None None O
AT-rich None None I-DNA
protein-binding None None I-DNA
site None None I-DNA
of None None O
the None None O
Il-4 None None O
promoter None None O
are None None O
also None None O
recognized None None O
by None None O
the None None O
high None None I-protein
mobility None None I-protein
group None None I-protein
protein None None I-protein
HMG None None B-protein
I None None I-protein
( None None I-protein
Y None None I-protein
) None None O
. None None O

Whereas None None O
the None None O
binding None None O
of None None O
NFAT-1 None None I-protein
and None None O
Octamer None None I-protein
factors None None I-protein
enhance None None O
the None None O
activity None None O
of None None O
the None None O
Il-4 None None I-DNA
promoter None None I-DNA
, None None O
the None None O
binding None None O
of None None O
HMG None None O
I None None O
( None None O
Y None None O
) None None O
suppresses None None O
its None None O
activity None None O
and None None O
, None None O
therefore None None O
, None None O
appears None None O
to None None O
be None None O
involved None None O
in None None O
the None None O
suppression None None O
of None None O
Il-4 None None I-protein
transcription None None O
in None None O
resting None None I-cell_type
T None None I-cell_type
lymphocytes None None I-cell_type
. None None O

Reversibility None None O
of None None O
the None None O
differentiated None None O
state None None O
in None None O
somatic None None I-cell_type
cells None None I-cell_type
. None None O

Analysis None None O
of None None O
de None None O
novo None None O
gene None None O
activation None None O
in None None O
multinucleated None None I-cell_type
heterokaryons None None I-cell_type
has None None O
shown None None O
that None None O
the None None O
differentiated None None O
state None None O
, None None O
although None None O
stable None None O
, None None O
is None None O
not None None O
irreversible None None O
, None None O
and None None O
can None None O
be None None O
reprogrammed None None O
in None None O
the None None O
presence None None O
of None None O
appropriate None None O
combinations None None O
of None None O
trans-acting None None I-protein
regulatory None None I-protein
molecules None None I-protein
. None None O

These None None O
properties None None O
have None None O
been None None O
exploited None None O
to None None O
design None None O
strategies None None O
for None None O
identifying None None O
novel None None O
regulators None None O
of None None O
cellular None None O
differentiation None None O
. None None O

Phosphatidylcholine None None O
hydrolysis None None O
activates None None O
NF-kappa None None I-protein
B None None I-protein
and None None O
increases None None O
human None None O
immunodeficiency None None O
virus None None O
replication None None O
in None None O
human None None I-cell_type
monocytes None None I-cell_type
and None None O
T None None I-cell_type
lymphocytes None None I-cell_type
. None None O

We None None O
have None None O
tested None None O
whether None None O
breakdown None None O
of None None O
phosphatidylcholine None None O
( None None O
PC None None O
) None None O
initiated None None O
by None None O
exogenous None None O
addition None None O
of None None O
a None None O
PC-specific None None I-protein
phospholipase None None I-protein
C None None I-protein
( None None O
PC-PLC None None I-protein
) None None O
from None None O
Bacillus None None O
cereus None None O
or None None O
by None None O
endogenous None None O
overexpression None None O
of None None O
PC-PLC None None I-protein
induces None None O
functional None None O
activation None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
and None None O
increases None None O
human None None I-DNA
immunodeficiency None None I-DNA
virus None None I-DNA
( None None I-DNA
HIV None None I-DNA
) None None I-DNA
enhancer None None I-DNA
activity None None O
. None None O

PC-PLC-activated None None O
hydrolysis None None O
of None None O
PC None None O
was None None O
found None None O
to None None O
induce None None O
bona None None O
fide None None O
p50/p65 None None I-protein
NF-kappa None None I-protein
B None None I-protein
binding None None O
activity None None O
in None None O
three None None O
different None None O
cell None None I-cell_line
lines None None I-cell_line
of None None O
human None None O
or None None O
murine None None O
origin None None O
. None None O

No None None O
significant None None O
changes None None O
in None None O
the None None O
turnover None None O
of None None O
other None None O
cellular None None O
phospholipids None None O
were None None O
detected None None O
in None None O
PC-PLC-treated None None I-cell_line
cells None None I-cell_line
. None None O

Induction None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
by None None O
PC-PLC None None I-protein
did None None O
not None None O
depend None None O
on None None O
de None None O
novo None None O
synthesis None None O
of None None O
proteins None None O
or None None O
autocrine None None O
secretion None None O
of None None O
either None None O
tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
or None None O
interleukin None None I-protein
1 None None I-protein
. None None O

In None None O
human None None I-cell_line
monocytic None None I-cell_line
and None None I-cell_line
lymphoblastoid None None I-cell_line
T-cell None None I-cell_line
lines None None I-cell_line
, None None O
induction None None O
of None None O
NF-kappa None None I-protein
B None None I-protein
by None None O
PC-PLC None None I-protein
resulted None None O
in None None O
clear None None O
induction None None O
of None None O
luciferase None None I-protein
expression None None O
vectors None None O
placed None None O
under None None O
the None None O
control None None O
of None None O
synthetic None None I-DNA
kappa None None I-DNA
B None None I-DNA
enhancers None None I-DNA
or None None O
wild None None O
type None None O
, None None O
but None None O
not None None O
kappa None None O
B-mutated None None O
, None None O
HIV None None I-DNA
long None None I-DNA
terminal None None I-DNA
repeat None None I-DNA
constructs None None I-DNA
. None None O

HIV None None O
replication None None O
was None None O
increased None None O
by None None O
PC-PLC None None I-protein
in None None O
chronically None None O
infected None None O
monocytes None None I-cell_type
and None None O
T None None O
lymphocytes None None I-cell_type
. None None O

NF-kappa None None O
B None None O
activation None None O
promoted None None O
by None None O
addition None None O
of None None O
exogenous None None I-protein
PC-PLC None None I-protein
correlated None None O
with None None O
an None None O
intense None None O
production None None O
of None None O
diacylglycerol None None O
. None None O

However None None O
, None None O
addition None None O
of None None O
a None None O
phosphatidylinositol-specific None None I-protein
PLC None None I-protein
from None None O
B.cereus None None O
also None None O
induced None None O
diacylglycerol None None O
but None None O
did None None O
not None None O
activate None None O
kappa None None I-protein
B None None I-protein
enhancer-directed None None I-protein
vectors None None I-protein
. None None O

PC-PLC-induced None None O
NF-kappa None None O
B None None O
activation None None O
could None None O
not None None O
be None None O
blocked None None O
by None None O
a None None O
specific None None O
inhibitor None None O
of None None O
phorbol None None I-protein
ester-inducible None None I-protein
protein None None I-protein
kinases None None I-protein
C None None I-protein
. None None O

These None None O
results None None O
indicate None None O
that None None O
a None None O
cellular None None O
transduction None None O
pathway None None O
, None None O
dependent None None O
on None None O
specific None None O
PC None None O
breakdown None None O
, None None O
is None None O
functional None None O
in None None O
T None None I-cell_type
lymphocytes None None I-cell_type
and None None O
monocytes None None I-cell_type
and None None O
may None None O
be None None O
used None None O
by None None O
various None None O
transmembrane None None O
receptors None None O
to None None O
activate None None O
HIV None None O
transcription None None O
through None None O
NF-kappa None None O
B-dependent None None O
induction None None O
of None None O
the None None O
HIV None None I-DNA
enhancer None None I-DNA
. None None O

Novel None None O
mechanism None None O
for None None O
inhibition None None O
of None None O
human None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
by None None O
glucocorticoids None None O
. None None O

Glucocorticoids None None O
inhibit None None O
signal None None O
transduction None None O
through None None O
IL-2 None None I-protein
receptor None None I-protein
. None None O

Interaction None None O
of None None O
IL-2 None None I-protein
with None None O
its None None O
high None None I-protein
affinity None None I-protein
membrane None None I-protein
receptor None None I-protein
complex None None I-protein
( None None O
IL-2R None None I-protein
) None None O
present None None O
on None None O
activated None None O
T None None I-cell_type
lymphocytes None None I-cell_type
induces None None O
cell None None O
proliferation None None O
and None None O
mediates None None O
effector None None O
functions None None O
. None None O

Glucocorticoids None None O
inhibit None None O
IL-2 None None I-protein
production None None O
by None None O
inhibiting None None O
TCR-mediated None None O
signal None None O
transduction None None O
. None None O

We None None O
asked None None O
whether None None O
they None None O
also None None O
inhibit None None O
the None None O
action None None O
of None None O
IL-2 None None I-protein
by None None O
inhibiting None None O
signal None None O
transduction None None O
through None None O
IL-2R None None I-protein
. None None O

Human None None I-cell_type
peripheral None None I-cell_type
blood None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
, None None O
stimulated None None O
with None None O
PMA None None O
for None None O
48 None None O
h None None O
( None None O
PMA None None I-cell_line
blasts None None I-cell_line
) None None O
, None None O
were None None O
incubated None None O
with None None O
IL-2 None None I-protein
in None None O
the None None O
presence None None O
of None None O
incremental None None O
dosages None None O
of None None O
dexamethasone None None O
( None None O
Dex None None O
; None None O
10 None None O
( None None O
-5 None None O
) None None O
-10 None None O
( None None O
-9 None None O
) None None O
M None None O
) None None O
. None None O

Dex None None O
inhibited None None O
the None None O
IL-2-dependent None None O
proliferation None None O
of None None O
PMA None None I-cell_line
blasts None None I-cell_line
in None None O
a None None O
dose-dependent None None O
fashion None None O
( None None O
IC50 None None O
, None None O
5 None None O
x None None O
10 None None O
( None None O
-8 None None O
) None None O
M None None O
) None None O
. None None O

Cell None None O
surface None None O
expression None None O
of None None O
IL-2R None None I-protein
alpha- None None I-protein
and None None I-protein
beta-chains None None I-protein
as None None O
determined None None O
by None None O
immunofluorescence None None O
analysis None None O
was None None O
not None None O
affected None None O
by None None O
Dex None None O
. None None O

In None None O
addition None None O
, None None O
Scatchard None None O
plot None None O
analysis None None O
of None None O
125I-labeled None None I-protein
IL-2 None None I-protein
showed None None O
that None None O
Dex None None O
did None None O
not None None O
affect None None O
the None None O
binding None None O
of None None O
IL-2 None None I-protein
, None None O
thus None None O
suggesting None None O
that None None O
inhibition None None O
is None None O
due None None O
to None None O
a None None O
postreceptor None None O
effect None None O
. None None O

Inhibition None None O
of None None O
T None None O
cell None None O
proliferation None None O
by None None O
Dex None None O
was None None O
associated None None O
with None None O
decreased None None O
IL-2-dependent None None O
tyrosine None None O
phosphorylation None None O
of None None O
several None None O
intracellular None None I-protein
proteins None None I-protein
and None None O
decreased None None O
phosphorylation None None O
of None None O
the None None O
retinoblastoma None None I-protein
gene None None I-protein
product None None I-protein
Rb None None I-protein
, None None O
a None None O
protein None None O
essential None None O
for None None O
controlling None None O
the None None O
progression None None O
of None None O
cells None None O
through None None O
the None None O
cell None None O
cycle None None O
. None None O

IL-2-dependent None None O
IL-2R None None O
alpha None None O
expression None None O
in None None O
PMA None None I-cell_line
blasts None None I-cell_line
and None None O
NF-kB None None I-protein
induction None None O
in None None O
resting None None I-cell_type
human None None I-cell_type
T None None I-cell_type
cells None None I-cell_type
were None None O
also None None O
inhibited None None O
by None None O
Dex None None O
. None None O

These None None O
results None None O
demonstrate None None O
that None None O
glucocorticoids None None O
inhibit None None O
preactivated None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
by None None O
down-regulating None None O
signal None None O
transduction None None O
through None None O
IL-2R None None I-protein
. None None O

Chronic None None O
human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
infection None None O
stimulates None None O
distinct None None O
NF-kappa None None O
B/rel None None O
DNA None None O
binding None None O
activities None None O
in None None O
myelomonoblastic None None I-cell_type
cells None None I-cell_type
. None None O

The None None O
relationship None None O
between None None O
human None None O
immunodeficiency None None O
virus None None O
type None None O
1 None None O
( None None O
HIV-1 None None O
) None None O
infection None None O
and None None O
the None None O
induction None None O
of None None O
NF-kappa None None O
B None None O
binding None None O
activity None None O
was None None O
examined None None O
in None None O
a None None O
myeloid None None I-cell_line
cell None None I-cell_line
model None None I-cell_line
of None None O
HIV-1 None None O
infection None None O
derived None None O
from None None O
the None None O
PLB-985 None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
. None None O

Chronic None None O
infection None None O
of None None O
PLB-985 None None I-cell_line
cells None None I-cell_line
led None None O
to None None O
increased None None O
monocyte-specific None None O
surface None None O
marker None None O
expression None None O
, None None O
increased None None O
c-fms None None O
gene None None O
transcription None None O
, None None O
and None None O
morphological None None O
alterations None None O
consistent None None O
with None None O
differentiation None None O
along None None O
the None None O
monocytic None None O
pathway None None O
. None None O

PLB-IIIB None None I-cell_line
cells None None I-cell_line
displayed None None O
a None None O
constitutive None None O
NF-kappa None None O
B-like None None O
binding None None O
activity None None O
that None None O
was None None O
distinct None None O
from None None O
that None None O
induced None None O
by None None O
tumor None None I-protein
necrosis None None I-protein
factor None None I-protein
alpha None None I-protein
or None None O
phorbol None None O
12-myristate None None O
13-acetate None None O
treatment None None O
of None None O
the None None O
parental None None I-cell_line
PLB-985 None None I-cell_line
cell None None I-cell_line
line None None I-cell_line
. None None O

This None None O
unique None None O
DNA None None O
binding None None O
activity None None O
consisted None None O
of None None O
proteins None None O
of None None O
70 None None I-protein
, None None I-protein
90 None None I-protein
, None None I-protein
and None None I-protein
100 None None I-protein
kDa None None I-protein
with None None O
a None None O
high None None O
degree None None O
of None None O
binding None None O
specificity None None O
for None None O
the None None O
NF-kappa None None I-protein
B None None I-protein
site None None I-protein
within None None O
the None None O
PRDII None None I-protein
domain None None I-protein
of None None O
beta None None I-protein
interferon None None I-protein
. None None O

In None None O
this None None O
report None None O
, None None O
we None None O
characterize None None O
the None None O
nature None None O
of None None O
these None None O
proteins None None O
and None None O
demonstrate None None O
that None None O
binding None None O
of None None O
these None None O
proteins None None O
is None None O
also None None O
induced None None O
following None None O
Sendai None None O
paramyxovirus None None O
infection None None O
. None None O

The None None O
70-kDa None None I-protein
protein None None I-protein
corresponds None None O
to None None O
the None None O
NF-kappa None None I-protein
B None None I-protein
RelA None None I-protein
( None None I-protein
p65 None None I-protein
) None None I-protein
subunit None None I-protein
, None None O
which None None O
is None None O
activated None None O
in None None O
response None None O
to None None O
an None None O
acute None None O
paramyxovirus None None O
infection None None O
or None None O
a None None O
chronic None None O
HIV-1 None None O
infection None None O
. None None O

Virus None None O
infection None None O
does None None O
not None None O
appear None None O
to None None O
alter None None O
the None None O
amount None None O
of None None O
RelA None None I-protein
( None None O
p65 None None I-protein
) None None O
or None None O
NFKB1 None None I-protein
( None None O
p50 None None I-protein
) None None O
but None None O
rather None None O
affects None None O
the None None O
capacity None None O
of None None O
I None None I-protein
kappa None None I-protein
B None None I-protein
alpha None None I-protein
to None None O
sequester None None O
RelA None None I-protein
( None None I-protein
p65 None None I-protein
) None None I-protein
, None None O
therefore None None O
leading None None O
to None None O
constitutive None None O
levels None None O
of None None O
RelA None None O
DNA None None O
binding None None O
activity None None O
and None None O
to None None O
increased None None O
levels None None O
of None None O
NF-kappa None None O
B-dependent None None O
gene None None O
activity None None O
. None None O

The None None O
virally None None O
induced None None O
90- None None I-protein
to None None I-protein
100-kDa None None I-protein
proteins None None I-protein
have None None O
a None None O
distinct None None O
binding None None O
specificity None None O
for None None O
the None None O
PRDII None None I-DNA
domain None None I-DNA
and None None O
an None None O
AT-rich None None I-DNA
sequence None None I-DNA
but None None O
do None None O
not None None O
cross-react None None O
with None None O
NF-kappa None None O
B None None O
subunit-specific None None O
antisera None None O
directed None None O
against None None O
NFKB1 None None I-protein
( None None O
p105 None None I-protein
or None None O
p50 None None I-protein
) None None O
, None None O
NFKB2 None None I-protein
( None None O
p100 None None I-protein
or None None O
p52 None None I-protein
) None None O
, None None O
RelA None None I-protein
( None None O
p65 None None I-protein
) None None O
, None None O
or None None O
c-rel None None I-protein
. None None O

DNA None None O
binding None None O
of None None O
the None None O
90- None None I-protein
to None None I-protein
100-kDa None None I-protein
proteins None None I-protein
was None None O
not None None O
inhibited None None O
by None None O
recombinant None None I-protein
I None None I-protein
kappa None None I-protein
B None None I-protein
alpha/MAD-3 None None I-protein
and None None O
was None None O
resistant None None O
to None None O
tryptic None None O
digestion None None O
, None None O
suggesting None None O
that None None O
these None None O
proteins None None O
may None None O
not None None O
be None None O
NF-kappa None None I-protein
B None None I-protein
related None None I-protein
. None None O

Transient None None O
cotransfection None None O
experiments None None O
demonstrated None None O
that None None O
RelA None None O
and None None O
NFKB1 None None O
expression None None O
maximally None None O
stimulated None None O
HIV-1 None None I-DNA
LTR- None None I-DNA
and None None I-DNA
NF-kappa None None I-DNA
B-dependent None None I-DNA
reporter None None I-DNA
genes None None I-DNA
; None None O
differences None None O
in None None O
NF-kappa None None O
B-like None None O
binding None None O
activity None None O
were None None O
also None None O
reflected None None O
in None None O
higher None None O
constitutive None None O
levels None None O
of None None O
NF-kappa None None O
B-regulated None None O
gene None None O
expression None None O
in None None O
HIV-1-infected None None I-cell_line
myeloid None None I-cell_line
cells None None I-cell_line
. None None O

Presence None None O
of None None O
estrogen-binding None None O
sites None None O
on None None O
macrophage-like None None I-cell_type
synoviocytes None None I-cell_type
and None None O
CD8+ None None I-cell_line
, None None I-cell_line
CD29+ None None I-cell_line
, None None I-cell_line
CD45RO+ None None I-cell_line
T None None I-cell_line
lymphocytes None None I-cell_line
in None None O
normal None None O
and None None O
rheumatoid None None O
synovium None None O
. None None O

OBJECTIVE None None O
. None None O

To None None O
study None None O
the None None O
presence None None O
of None None O
estrogen-binding None None O
sites None None O
( None None O
EBS None None O
) None None O
in None None O
the None None O
synovial None None O
tissues None None O
of None None O
male None None O
and None None O
female None None O
patients None None O
with None None O
rheumatoid None None O
arthritis None None O
( None None O
RA None None O
) None None O
and None None O
in None None O
age- None None O
and None None O
sex-matched None None O
healthy None None O
controls None None O
. None None O

METHODS None None O
. None None O

Both None None O
type None None O
1 None None O
( None None O
high None None O
affinity None None O
, None None O
low None None O
binding None None O
capacity None None O
) None None O
and None None O
type None None O
2 None None O
( None None O
reduced None None O
affinity None None O
, None None O
higher None None O
binding None None O
capacity None None O
) None None O
EBS None None O
were None None O
investigated None None O
in None None O
both None None O
soluble None None O
and None None O
nuclear None None O
fractions None None O
of None None O
homogenized None None O
synovial None None O
tissue None None O
samples None None O
by None None O
a None None O
dextran-coated None None O
charcoal None None O
method None None O
. None None O

To None None O
determine None None O
what None None O
type None None O
of None None O
synovial None None I-cell_type
cell None None I-cell_type
was None None O
positive None None O
for None None O
EBS None None O
, None None O
cryosections None None O
of None None O
synovial None None O
tissues None None O
were None None O
immunostained None None O
with None None O
a None None O
specific None None O
monoclonal None None I-protein
anti-estrogen None None I-protein
receptor None None I-protein
antibody None None I-protein
( None None O
anti-ER None None I-protein
MAb None None I-protein
) None None O
using None None O
both None None O
immunofluorescence None None O
and None None O
immunoperoxidase None None O
techniques None None O
. None None O

Double None None O
immunostaining None None O
with None None O
the None None O
anti-ER None None I-protein
MAb None None I-protein
and None None O
with None None O
specific None None I-protein
MAb None None I-protein
to None None O
detect None None O
different None None O
macrophage None None I-protein
antigens None None I-protein
( None None O
Ber-MAC3 None None I-protein
, None None O
MAC387 None None I-protein
, None None O
CD68 None None I-protein
) None None O
and None None O
CD8+ None None I-cell_line
T None None I-cell_line
cell None None I-cell_line
subsets None None I-cell_line
( None None O
CD29+ None None I-cell_line
, None None O
CD45RO+ None None I-cell_line
and None None O
CD29- None None I-cell_line
, None None O
CD45RO- None None I-cell_line
) None None O
was None None O
performed None None O
. None None O

RESULTS None None O
. None None O

Higher None None O
affinity None None O
EBS None None O
were None None O
found None None O
mostly None None O
in None None O
nuclear None None O
cell None None O
fractions None None O
of None None O
either None None O
RA None None O
or None None O
control None None O
synovial None None O
tissues None None O
( None None O
28 None None O
of None None O
the None None O
33 None None O
) None None O
. None None O

These None None O
EBS None None O
were None None O
present None None O
to None None O
a None None O
lesser None None O
extent None None O
in None None O
soluble None None O
cell None None O
fractions None None O
( None None O
11 None None O
of None None O
the None None O
33 None None O
) None None O
. None None O

Immunostaining None None O
showed None None O
the None None O
estrogen None None I-cell_type
receptor-positive None None I-cell_type
cells None None I-cell_type
to None None O
be None None O
the None None O
macrophage-like None None I-cell_type
synoviocytes None None I-cell_type
and None None O
the None None O
CD8+ None None I-cell_line
, None None O
CD29+ None None I-cell_line
T None None I-cell_line
cells None None I-cell_line
both None None O
in None None O
RA None None O
and None None O
in None None O
control None None O
synovial None None O
tissues None None O
. None None O

Higher None None O
nuclear None None O
content None None O
of None None O
EBS None None O
was None None O
consistent None None O
with None None O
more None None O
intense None None O
nuclear None None O
staining None None O
of None None O
synoviocytes None None I-cell_type
and None None O
T None None I-cell_type
cells None None I-cell_type
. None None O

CONCLUSION None None O
. None None O

It None None O
is None None O
conceivable None None O
that None None O
the None None O
immunomodulatory None None O
activity None None O
exerted None None O
by None None O
estrogens None None O
is None None O
at None None O
least None None O
partly None None O
mediated None None O
through None None O
their None None O
interaction None None O
with None None O
EBS None None O
that None None O
are None None O
present None None O
on None None O
macrophage-like None None I-cell_type
synoviocytes None None I-cell_type
, None None O
functioning None None O
as None None O
antigen-processing None None I-cell_type
and None None I-cell_type
antigen-presenting None None I-cell_type
cells None None I-cell_type
, None None O
and None None O
on None None O
antigen-experienced None None I-cell_line
( None None I-cell_line
memory None None I-cell_line
) None None I-cell_line
CD8+ None None I-cell_line
T None None I-cell_line
lymphocytes None None I-cell_line
( None None O
CD29+ None None I-cell_line
, None None O
CD45RO+ None None I-cell_line
